

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number
WO 2004/053079 A2

(51) International Patent Classification⁷: C12N

City, CA 94539 (US). CHEN, Hwei-Mei [US/US]; 101
Lockwood Lane, Pleasant Hill, CA 94523 (US).

(21) International Application Number:
PCT/US2003/038855

(74) Agents: LICATA, Jane, Massey et al.; Licata & Tyrrell
P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(22) International Filing Date: 8 December 2003 (08.12.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/431,321 6 December 2002 (06.12.2002) US
60/431,301 6 December 2002 (06.12.2002) US
60/484,584 30 June 2003 (30.06.2003) US
60/518,607 7 November 2003 (07.11.2003) US

(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): DI-
ADEXUS, INC. [US/US]; 343 Oyster Point Boulevard,
South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): MACINA, Roberto,
A. [AR/US]; 4118 Crescendo Avenue, San Jose, CA 95136
(US). TURNER, Leah, R. [US/US]; 939 Rosette Court,
Sunnyvale, CA 94086 (US). SUN, Yongming [CN/US];
551 Shoal Circle, Redwood City, CA 94065 (US). LIU,
Shu-Hui [—/US]; 441 Cork Harbour Circle, #H, Redwood

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS, SPLICE VARIANTS AND METHODS RELATING TO OVARIAN SPECIFIC GENES AND PRO-
TEINS

(57) Abstract: The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic ovarian cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and non-cancerous disease states in ovarian, identifying ovarian tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered ovarian tissue for treatment and research.



WO 2004/053079 A2

COMPOSITIONS, SPLICE VARIANTS AND METHODS RELATING TO OVARIAN SPECIFIC GENES AND PROTEINS

5 INTRODUCTION

This application claims the benefit of priority from U.S. Provisional Patent Application Serial No. 60/431,321 filed December 6, 2002, U.S. Provisional Patent Application Serial No. 60/431,301 filed December 6, 2002, U.S. Provisional Patent Application Serial No. 60/484,584 filed June 30, 2003 and U.S. Provisional Patent Application Serial No. 60/518,607, filed November 7, 2003 which are herein incorporated by reference in their entireties.

FIELD OF THE INVENTION

The present invention relates to newly identified nucleic acids and polypeptides present in normal and neoplastic ovarian cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions comprising the nucleic acids, polypeptides, antibodies, post translational modifications (PTMs), variants, derivatives, agonists and antagonists thereto and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and/or non-cancerous disease states in ovarian, identifying ovarian tissue and monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, therapeutic molecules including but not limited to antibodies or antisense molecules, production of transgenic animals and cells, and production of engineered ovarian tissue for treatment and research.

BACKGROUND OF THE INVENTION

Cancer of the ovaries is the fourth-most common cause of cancer death in women in the United States, with more than 23,000 new cases and roughly 14,000 deaths predicted for the year 2001. Shridhar, V. *et al.*, *Cancer Res.* 61(15):5895-904 (2001); Memarzadeh, S. & Berek, J. S., *J. Reprod. Med.* 46(7):621-29 (2001). The incidence of ovarian cancer is of serious concern worldwide, with an estimated 191,000 new cases predicted annually. Runnebaum, I. B. & Stickeler, E., *J. Cancer Res. Clin. Oncol.* 127(2):73-79 (2001). These numbers continue to rise today. In the United States

alone, it is estimated there will be 25,400 new cases of ovarian cancer, and 14,300 deaths due to ovarian cancer in 2003. (American Cancer Society Website: cancer.org on the world wide web). Unfortunately, women with ovarian cancer are typically asymptomatic until the disease has metastasized. Because effective screening for ovarian cancer is not available, roughly 70% of women diagnosed have an advanced stage of the cancer with a five-year survival rate of ~25-30%. Memarzadeh, S. & Berek, J. S., *supra*; Nunns, D. *et al.*, *Obstet. Gynecol. Surv.* 55(12):746-51. Conversely, women diagnosed with early stage ovarian cancer enjoy considerably higher survival rates. Werness, B. A. & Eltabbakh, G. H., *Int'l. J. Gynecol. Pathol.* 20(1):48-63 (2001). Although our understanding of the etiology of ovarian cancer is incomplete, the results of extensive research in this area point to a combination of age, genetics, reproductive, and dietary/environmental factors. Age is a key risk factor in the development of ovarian cancer: while the risk for developing ovarian cancer before the age of 30 is slim, the incidence of ovarian cancer rises linearly between ages 30 to 50, increasing at a slower rate thereafter, with the highest incidence being among septagenarian women. Jeanne M. Schilder *et al.*, *Hereditary Ovarian Cancer: Clinical Syndromes and Management*, in *Ovarian Cancer* 182 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001).

With respect to genetic factors, a family history of ovarian cancer is the most significant risk factor in the development of the disease, with that risk depending on the number of affected family members, the degree of their relationship to the woman, and which particular first degree relatives are affected by the disease. *Id.* Mutations in several genes have been associated with ovarian cancer, including BRCA1 and BRCA2, both of which play a key role in the development of breast cancer, as well as hMSH2 and hMLH1, both of which are associated with hereditary non-polyposis colon cancer. Katherine Y. Look, *Epidemiology, Etiology, and Screening of Ovarian Cancer*, in *Ovarian Cancer* 169, 171-73 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001). BRCA1, located on chromosome 17, and BRCA2, located on chromosome 13, are tumor suppressor genes implicated in DNA repair; mutations in these genes are linked to roughly 10% of ovarian cancers. *Id.* at 171-72; Schilder *et al.*, *supra* at 185-86. hMSH2 and hMLH1 are associated with DNA mismatch repair, and are located on chromosomes 2 and 3, respectively; it has been reported that roughly 3% of hereditary ovarian carcinomas are due to mutations in these genes. Look, *supra* at 173; Schilder *et al.*, *supra* at 184, 188-89.

Reproductive factors have also been associated with an increased or reduced risk of ovarian cancer. Late menopause, nulliparity, and early age at menarche have all been linked with an elevated risk of ovarian cancer. Schilder *et al.*, *supra* at 182. One theory hypothesizes that these factors increase the number of ovulatory cycles over the course of a woman's life, leading to "incessant ovulation," which is thought to be the primary cause of mutations to the ovarian epithelium. *Id.*; Laura J. Havrilesky & Andrew Berchuck, *Molecular Alterations in Sporadic Ovarian Cancer*, in *Ovarian Cancer* 25 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001). The mutations may be explained by the fact that ovulation results in the destruction and repair of that epithelium, necessitating increased cell division, thereby increasing the possibility that an undetected mutation will occur. *Id.* Support for this theory may be found in the fact that pregnancy, lactation, and the use of oral contraceptives, all of which suppress ovulation, confer a protective effect with respect to developing ovarian cancer. *Id.*

Among dietary/environmental factors, there would appear to be an association between high intake of animal fat or red meat and ovarian cancer, while the antioxidant Vitamin A, which prevents free radical formation and also assists in maintaining normal cellular differentiation, may offer a protective effect. Look, *supra* at 169. Reports have also associated asbestos and hydrous magnesium trisilicate (talc), the latter of which may be present in diaphragms and sanitary napkins. *Id.* at 169-70.

Current screening procedures for ovarian cancer, while of some utility, are quite limited in their diagnostic ability, a problem that is particularly acute at early stages of cancer progression when the disease is typically asymptomatic yet is most readily treatable. Walter J. Burdette, *Cancer: Etiology, Diagnosis, and Treatment* 166 (1998); Memarzadeh & Berek, *supra*; Runnebaum & Stickeler, *supra*; Werness & Eltabbakh, *supra*. Commonly used screening tests include biannual rectovaginal pelvic examination, radioimmunoassay to detect the CA-125 serum tumor marker, and transvaginal ultrasonography. Burdette, *supra* at 166.

Pelvic examination has failed to yield adequate numbers of early diagnoses, and the other methods are not sufficiently accurate. *Id.* One study reported that only 15% of patients who suffered from ovarian cancer were diagnosed with the disease at the time of their pelvic examination. Look, *supra* at 174. Moreover, the CA-125 test is prone to giving false positives in pre-menopausal women and has been reported to be of low predictive value in post-menopausal women. *Id.* at 174-75. Although transvaginal

ultrasonography is now the preferred procedure for screening for ovarian cancer, it is unable to distinguish reliably between benign and malignant tumors, and also cannot locate primary peritoneal malignancies or ovarian cancer if the ovary size is normal. Schilder *et al.*, *supra* at 194-95. While genetic testing for mutations of the BRCA1, BRCA2, hMSH2, and hMLH1 genes is now available, these tests may be too costly for some patients and may also yield false negative or indeterminate results. Schilder *et al.*, *supra* at 191-94.

The staging of ovarian cancer, which is accomplished through surgical exploration, is crucial in determining the course of treatment and management of the disease. AJCC Cancer Staging Handbook 187 (Irvin D. Fleming *et al.* eds., 5th ed. 1998); Burdette, *supra* at 170; Memarzadeh & Berek, *supra*; Shridhar *et al.*, *supra*. Staging is performed by reference to the classification system developed by the International Federation of Gynecology and Obstetrics. David H. Moore, *Primary Surgical Management of Early Epithelial Ovarian Carcinoma*, in Ovarian Cancer 203 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001); Fleming *et al.* eds., *supra* at 188. Stage I ovarian cancer is characterized by tumor growth that is limited to the ovaries and is comprised of three substages. *Id.* In substage IA, tumor growth is limited to one ovary, there is no tumor on the external surface of the ovary, the ovarian capsule is intact, and no malignant cells are present in ascites or peritoneal washings. *Id.* Substage IB is identical to A1, except that tumor growth is limited to both ovaries. *Id.* Substage IC refers to the presence of tumor growth limited to one or both ovaries, and also includes one or more of the following characteristics: capsule rupture, tumor growth on the surface of one or both ovaries, and malignant cells present in ascites or peritoneal washings. *Id.*

Stage II ovarian cancer refers to tumor growth involving one or both ovaries, along with pelvic extension. *Id.* Substage IIA involves extension and/or implants on the uterus and/or fallopian tubes, with no malignant cells in the ascites or peritoneal washings, while substage IIB involves extension into other pelvic organs and tissues, again with no malignant cells in the ascites or peritoneal washings. *Id.* Substage IIC involves pelvic extension as in IIA or IIB, but with malignant cells in the ascites or peritoneal washings. *Id.*

Stage III ovarian cancer involves tumor growth in one or both ovaries, with peritoneal metastasis beyond the pelvis confirmed by microscope and/or metastasis in the regional lymph nodes. *Id.* Substage IIIA is characterized by microscopic peritoneal

metastasis outside the pelvis, with substage IIIB involving macroscopic peritoneal metastasis outside the pelvis 2 cm or less in greatest dimension. *Id.* Substage IIIC is identical to IIIB, except that the metastasis is greater than 2 cm in greatest dimension and may include regional lymph node metastasis. *Id.* Lastly, Stage IV refers to the presence
5 distant metastasis, excluding peritoneal metastasis. *Id.*

While surgical staging is currently the benchmark for assessing the management and treatment of ovarian cancer, it suffers from considerable drawbacks, including the invasiveness of the procedure, the potential for complications, as well as the potential for inaccuracy. Moore, *supra* at 206-208, 213. In view of these limitations, attention has
10 turned to developing alternative staging methodologies through understanding differential gene expression in various stages of ovarian cancer and by obtaining various biomarkers to help better assess the progression of the disease. Vartiainen, J. *et al.*, *Int'l J. Cancer*, 95(5):313-16 (2001); Shridhar *et al. supra*; Baekelandt, M. *et al.*, *J. Clin. Oncol.* 18(22):3775-81.

15 The treatment of ovarian cancer typically involves a multiprong attack, with surgical intervention serving as the foundation of treatment. Dennis S. Chi & William J. Hoskins, *Primary Surgical Management of Advanced Epithelial Ovarian Cancer*, in Ovarian Cancer 241 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001). For example, in the case of epithelial ovarian cancer, which accounts for ~90% of cases of
20 ovarian cancer, treatment typically consists of: (1) cytoreductive surgery, including total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and lymphadenectomy, followed by (2) adjuvant chemotherapy with paclitaxel and either cisplatin or carboplatin. Eltabbakh, G.H. & Awtrey, C.S., *Expert Op. Pharmacother.* 2(10):109-24. Despite a clinical response rate of 80% to the adjuvant therapy, most
25 patients experience tumor recurrence within three years of treatment. *Id.* Certain patients may undergo a second cytoreductive surgery and/or second-line chemotherapy. Memarzadeh & Berek, *supra*.

From the foregoing, it is clear that procedures used for detecting, diagnosing, monitoring, staging, prognosticating, and preventing the recurrence of ovarian cancer are
30 of critical importance to the outcome of the patient. Moreover, current procedures, while helpful in each of these analyses, are limited by their specificity, sensitivity, invasiveness, and/or their cost. As such, highly specific and sensitive procedures that would operate by

way of detecting novel markers in cells, tissues, or bodily fluids, with minimal invasiveness and at a reasonable cost, would be highly desirable.

Breast cancer, also referred to as mammary tumor cancer, is the second most common cancer among women, accounting for a third of the cancers diagnosed in the United States. One in nine women will develop breast cancer in her lifetime and about 192,000 new cases of breast cancer are diagnosed annually with about 42,000 deaths. Bevers, *Primary Prevention of Breast Cancer*, in *Breast Cancer*, 20-54 (Kelly K Hunt et al., ed., 2001); Kochanek *et al.*, 49 *Nat'l. Vital Statistics Reports* 1, 14 (2001). Breast cancer is extremely rare in women younger than 20 and is very rare in women under 30. The incidence of breast cancer rises with age and becomes significant by age 50. White Non-Hispanic women have the highest incidence rate for breast cancer and Korean women have the lowest. Increased prevalence of the genetic mutations BRCA1 and BRCA2 that promote breast and other cancers are found in Ashkenazi Jews. African American women have the highest mortality rate for breast cancer among these same groups (31 per 100,000), while Chinese women have the lowest at 11 per 100,000. Although men can get breast cancer, this is extremely rare. In the United States it is estimated there will be 212,600 new cases of breast cancer and 40,200 deaths due to breast cancer in 2003. (American Cancer Society Website: cancer.org on the world wide web). With the exception of those cases with associated genetic factors, precise causes of breast cancer are not known.

In the treatment of breast cancer, there is considerable emphasis on detection and risk assessment because early and accurate staging of breast cancer has a significant impact on survival. For example, breast cancer detected at an early stage (stage T0, discussed below) has a five-year survival rate of 92%. Conversely, if the cancer is not detected until a late stage (i.e., stage T4 (IV)), the five-year survival rate is reduced to 13%. *AJCC Cancer Staging Handbook* pp. 164-65 (Irvin D. Fleming *et al.* eds., 5th ed. 1998). Some detection techniques, such as mammography and biopsy, involve increased discomfort, expense, and/or radiation, and are only prescribed only to patients with an increased risk of breast cancer.

Current methods for predicting or detecting breast cancer risk are not optimal. One method for predicting the relative risk of breast cancer is by examining a patient's risk factors and pursuing aggressive diagnostic and treatment regiments for high risk patients. A patient's risk of breast cancer has been positively associated with increasing age,

nulliparity, family history of breast cancer, personal history of breast cancer, early menarche, late menopause, late age of first full term pregnancy, prior proliferative breast disease, irradiation of the breast at an early age and a personal history of malignancy.

Lifestyle factors such as fat consumption, alcohol consumption, education, and

5 socioeconomic status have also been associated with an increased incidence of breast cancer although a direct cause and effect relationship has not been established. While these risk factors are statistically significant, their weak association with breast cancer limited their usefulness. Most women who develop breast cancer have none of the risk factors listed above, other than the risk that comes with growing older. NIH Publication
10 No. 00-1556 (2000).

Current screening methods for detecting cancer, such as breast self exam, ultrasound, and mammography have drawbacks that reduce their effectiveness or prevent their widespread adoption. Breast self exams, while useful, are unreliable for the detection of breast cancer in the initial stages where the tumor is small and difficult to detect by
15 palpation. Ultrasound measurements require skilled operators at an increased expense. Mammography, while sensitive, is subject to over diagnosis in the detection of lesions that have questionable malignant potential. There is also the fear of the radiation used in mammography because prior chest radiation is a factor associated with an increase incidence of breast cancer.

20 At this time, there are no adequate methods of breast cancer prevention. The current methods of breast cancer prevention involve prophylactic mastectomy (mastectomy performed before cancer diagnosis) and chemoprevention (chemotherapy before cancer diagnosis) which are drastic measures that limit their adoption even among women with increased risk of breast cancer. Bevers, *supra*.

25 A number of genetic markers have been associated with breast cancer. Examples of these markers include carcinoembryonic antigen (CEA) (Mughal *et al.*, *JAMA* 249:1881 (1983)), MUC-1 (Frische and Liu, *J. Clin. Ligand* 22:320 (2000)), HER-2/neu (Haris *et al.*, *Proc.Am.Soc.Clin.Oncology* 15:A96 (1996)), uPA, PAI-1, LPA, LPC, RAK and BRCA (Esteva and Fritsche, *Serum and Tissue Markers for Breast Cancer*, in Breast
30 Cancer, 286-308 (2001)). These markers have problems with limited sensitivity, low correlation, and false negatives which limit their use for initial diagnosis. For example, while the BRCA1 gene mutation is useful as an indicator of an increased risk for breast cancer, it has limited use in cancer diagnosis because only 6.2 % of breast cancers are

BRCA1 positive. Malone *et al.*, *JAMA* 279:922 (1998). See also, Mewman *et al.*, *JAMA* 279:915 (1998) (correlation of only 3.3%).

There are four primary classifications of breast cancer varying by the site of origin and the extent of disease development.

- 5 I. Ductal carcinoma in situ (DCIS): Malignant transformation of ductal epithelial cells that remain in their normal position. DCIS is a purely localized disease, incapable of metastasis.
- II. Invasive ductal carcinoma (IDC): Malignancy of the ductal epithelial cells breaking through the basal membrane and into the supporting tissue of the breast.
- 10 IDC may eventually spread elsewhere in the body.
- III. Lobular carcinoma in situ (LCIS): Malignancy arising in a single lobule of the breast that fail to extend through the lobule wall, it generally remains localized.
- IV. Infiltrating lobular carcinoma (ILC): Malignancy arising in a single lobule of the breast and invading directly through the lobule wall into adjacent tissues.
- 15 By virtue of its invasion beyond the lobule wall, ILC may penetrate lymphatics and blood vessels and spread to distant sites.

For purpose of determining prognosis and treatment, these four breast cancer types have been staged according to the size of the primary tumor (T), the involvement of lymph nodes (N), and the presence of metastasis (M). Although DCIS by definition represents
20 localized stage I disease, the other forms of breast cancer may range from stage II to stage IV. There are additional prognostic factors that further serve to guide surgical and medical intervention. The most common ones are total number of lymph nodes involved, ER (estrogen receptor) status, Her2/neu receptor status and histologic grades.

Breast cancers are diagnosed into the appropriate stage categories recognizing that
25 different treatments are more effective for different stages of cancer. Stage TX indicates that primary tumor cannot be assessed (i.e., tumor was removed or breast tissue was removed). Stage T0 is characterized by abnormalities such as hyperplasia but with no evidence of primary tumor. Stage Tis is characterized by carcinoma in situ, intraductal carcinoma, lobular carcinoma in situ, or Paget's disease of the nipple with no tumor.
30 Stage T1 (I) is characterized as having a tumor of 2 cm or less in the greatest dimension. Within stage T1, Tmic indicates microinvasion of 0.1 cm or less, T1a indicates a tumor of between 0.1 to 0.5 cm, T1b indicates a tumor of between 0.5 to 1 cm, and T1c indicates tumors of between 1 cm to 2 cm. Stage T2 (II) is characterized by tumors from 2 cm to 5

cm in the greatest dimension. Tumors greater than 5 cm in size are classified as stage T3 (III). Stage T4 (IV) indicates a tumor of any size with extension to the chest wall or skin. Within stage T4, T4a indicates extension of the tumor to the chest wall, T4b indicates edema or ulceration of the skin of the breast or satellite skin nodules confined to the same breast, T4c indicates a combination of T4a and T4b, and T4d indicates inflammatory carcinoma. AJCC Cancer Staging Handbook pp. 159-70 (Irvin D. Fleming *et al.* eds., 5th ed. 1998). In addition to standard staging, breast tumors may be classified according to their estrogen receptor and progesterone receptor protein status. Fisher *et al.*, *Breast Cancer Research and Treatment* 7:147 (1986). Additional pathological status, such as HER2/neu status may also be useful. Thor *et al.*, *J.Nat'l.Cancer Inst.* 90:1346 (1998); Paik *et al.*, *J.Nat'l.Cancer Inst.* 90:1361 (1998); Hutchins *et al.*, *Proc. Am. Soc. Clin. Oncology* 17:A2 (1998).; and Simpson *et al.*, *J.Clin.Oncology* 18:2059 (2000).

In addition to the staging of the primary tumor, breast cancer metastases to regional lymph nodes may be staged. Stage NX indicates that the lymph nodes cannot be assessed (e.g., previously removed). Stage N0 indicates no regional lymph node metastasis. Stage N1 indicates metastasis to movable ipsilateral axillary lymph nodes. Stage N2 indicates metastasis to ipsilateral axillary lymph nodes fixed to one another or to other structures. Stage N3 indicates metastasis to ipsilateral internal mammary lymph nodes. *Id.*

Stage determination has potential prognostic value and provides criteria for designing optimal therapy. Simpson *et al.*, *J. Clin. Oncology* 18:2059 (2000). Generally, pathological staging of breast cancer is preferable to clinical staging because the former gives a more accurate prognosis. However, clinical staging would be preferred if it were as accurate as pathological staging because it does not depend on an invasive procedure to obtain tissue for pathological evaluation. Staging of breast cancer would be improved by detecting new markers in cells, tissues, or bodily fluids which could differentiate between different stages of invasion. Progress in this field will allow more rapid and reliable method for treating breast cancer patients.

Treatment of breast cancer is generally decided after an accurate staging of the primary tumor. Primary treatment options include breast conserving therapy (lumpectomy, breast irradiation, and surgical staging of the axilla), and modified radical mastectomy. Additional treatments include chemotherapy, regional irradiation, and, in extreme cases, terminating estrogen production by ovarian ablation.

Until recently, the customary treatment for all breast cancer was mastectomy. Fonseca *et al.*, *Annals of Internal Medicine* 127:1013 (1997). However, recent data indicate that less radical procedures may be equally effective, in terms of survival, for early stage breast cancer. Fisher *et al.*, *J. of Clinical Oncology* 16:441 (1998). The treatment options for a patient with early stage breast cancer (i.e., stage Tis) may be breast-sparing surgery followed by localized radiation therapy at the breast. Alternatively, mastectomy optionally coupled with radiation or breast reconstruction may be employed. These treatment methods are equally effective in the early stages of breast cancer.

Patients with stage I and stage II breast cancer require surgery with chemotherapy and/or hormonal therapy. Surgery is of limited use in stage III and stage IV patients. Thus, these patients are better candidates for chemotherapy and radiation therapy with surgery limited to biopsy to permit initial staging or subsequent restaging because cancer is rarely curative at this stage of the disease. AJCC Cancer Staging Handbook 84, 164-65 (Irvin D. Fleming *et al.* eds., 5th ed.1998).

In an effort to provide more treatment options to patients, efforts are underway to define an earlier stage of breast cancer with low recurrence which could be treated with lumpectomy without postoperative radiation treatment. While a number of attempts have been made to classify early stage breast cancer, no consensus recommendation on postoperative radiation treatment has been obtained from these studies. Page *et al.*, *Cancer* 75:1219 (1995); Fisher *et al.*, *Cancer* 75:1223 (1995); Silverstein *et al.*, *Cancer* 77:2267 (1996).

As discussed above, each of the methods for diagnosing and staging ovarian, and breast cancer is limited by the technology employed. Accordingly, there is need for sensitive molecular and cellular markers for the detection of ovarian, and breast cancer as well as pancreatic cancer. There is a need for molecular markers for the accurate staging, including clinical and pathological staging, of ovarian, pancreatic or breast cancers to optimize treatment methods. Finally, there is a need for sensitive molecular and cellular markers to monitor the progress of cancer treatments, including markers that can detect recurrence of ovarian, pancreatic or breast cancers following remission.

The present invention provides alternative methods of treating ovarian, pancreatic or breast cancer that overcome the limitations of conventional therapeutic methods as well as offer additional advantages that will be apparent from the detailed description below.

Growth and metastasis of solid tumors are also dependent on angiogenesis.

Folkman, J., 1986, *Cancer Research*, 46, 467-473; Folkman, J., 1989, *Journal of the National Cancer Institute*, 82, 4-6. It has been shown, for example, that tumors which
5 the growth of new capillary blood vessels. Once these new blood vessels become
embedded in the tumor, they provide a means for tumor cells to enter the circulation and
metastasize to distant sites such as liver, lung or bone. Weidner, N., *et al.*, 1991, *The New England Journal of Medicine*, 324(1), 1-8.

Angiogenesis, defined as the growth or sprouting of new blood vessels from
10 existing vessels, is a complex process that primarily occurs during embryonic
development. The process is distinct from vasculogenesis, in that the new endothelial cells
lining the vessel arise from proliferation of existing cells, rather than differentiating from
stem cells. The process is invasive and dependent upon proteolysis of the extracellular
matrix (ECM), migration of new endothelial cells, and synthesis of new matrix
15 components. Angiogenesis occurs during embryogenic development of the circulatory
system; however, in adult humans, angiogenesis only occurs as a response to a
pathological condition (except during the reproductive cycle in women).

Under normal physiological conditions in adults, angiogenesis takes place only in
very restricted situations such as hair growth and wounding healing. Auerbach, W. and
20 Auerbach, R., 1994, *Pharmacol Ther.* 63(3):265-311; Ribatti *et al.*, 1991, *Haematologica*
76(4):311-20; Risau, 1997, *Nature* 386(6626):671-4. Angiogenesis progresses by a
stimulus which results in the formation of a migrating column of endothelial cells.
Proteolytic activity is focused at the advancing tip of this "vascular sprout", which breaks
down the ECM sufficiently to permit the column of cells to infiltrate and migrate. Behind
25 the advancing front, the endothelial cells differentiate and begin to adhere to each other,
thus forming a new basement membrane. The cells then cease proliferation and finally
define a lumen for the new arteriole or capillary.

Unregulated angiogenesis has gradually been recognized to be responsible for a
wide range of disorders, including, but not limited to, cancer, cardiovascular disease,
30 rheumatoid arthritis, psoriasis and diabetic retinopathy. Folkman, 1995, *Nat Med* 1(1):27-
31; Isner, 1999, *Circulation* 99(13):1653-5; Koch, 1998, *Arthritis Rheum* 41(6):951-62;
Walsh, 1999, *Rheumatology (Oxford)* 38(2):103-12; Ware and Simons, 1997, *Nat Med*
3(2):158-64.

Of particular interest is the observation that angiogenesis is required by solid tumors for their growth and metastases. Folkman, 1986 *supra*; Folkman 1990, *J Natl. Cancer Inst.*, 82(1) 4-6; Folkman, 1992, *Semin Cancer Biol* 3(2):65-71; Zetter, 1998, *Annu Rev Med* 49:407-24. A tumor usually begins as a single aberrant cell which can proliferate
5 only to a size of a few cubic millimeters due to the distance from available capillary beds, and it can stay 'dormant' without further growth and dissemination for a long period of time. Some tumor cells then switch to the angiogenic phenotype to activate endothelial cells, which proliferate and mature into new capillary blood vessels. These newly formed blood vessels not only allow for continued growth of the primary tumor, but also for the
10 dissemination and recolonization of metastatic tumor cells. The precise mechanisms that control the angiogenic switch is not well understood, but it is believed that neovascularization of tumor mass results from the net balance of a multitude of angiogenesis stimulators and inhibitors Folkman, 1995, *supra*.

One of the most potent angiogenesis inhibitors is endostatin identified by O'Reilly
15 and Folkman. O'Reilly et al., 1997, *Cell* 88(2):277-85; O'Reilly et al., 1994, *Cell* 79(2):3 15-28. Its discovery was based on the phenomenon that certain primary tumors can inhibit the growth of distant metastases. O'Reilly and Folkman hypothesized that a primary tumor initiates angiogenesis by generating angiogenic stimulators in excess of inhibitors. However, angiogenic inhibitors, by virtue of their longer half life in the circulation, reach
20 the site of a secondary tumor in excess of the stimulators. The net result is the growth of primary tumor and inhibition of secondary tumor. Endostatin is one of a growing list of such angiogenesis inhibitors produced by primary tumors. It is a proteolytic fragment of a larger protein: endostatin is a 20 kDa fragment of collagen XVIII (amino acid H1132-K1315 in murine collagen XVIII). Endostatin has been shown to specifically inhibit
25 endothelial cell proliferation in vitro and block angiogenesis in vivo. More importantly, administration of endostatin to tumor-bearing mice leads to significant tumor regression, and no toxicity or drug resistance has been observed even after multiple treatment cycles. Boehm et al., 1997, *Nature* 390(6658):404-407. The fact that endostatin targets genetically stable endothelial cells and inhibits a variety of solid tumors makes it a very attractive
30 candidate for anticancer therapy. Fidler and Ellis, 1994, *Cell* 79(2):185-8; Gastl et al., 1997, *Oncology* 54(3):177-84; Hinsbergh et al., 1999, *Ann Oncol* 10 Suppl 4:60-3. In addition, angiogenesis inhibitors have been shown to be more effective when combined with radiation and chemotherapeutic agents. Klement, 2000, *J. Clin Invest*, 105(8) R15-

24. Browder, 2000, Cancer Res. 6-(7) 1878-86, Arap et al., 1998, Science 279(5349):377-80; Mauceri et al., 1998, Nature 394(6690):287-91.

SUMMARY OF THE INVENTION

5 The present invention solves many needs in the art by providing nucleic acid molecules, polypeptides and antibodies thereto, variants and derivatives of the nucleic acids and polypeptides, and agonists and antagonists thereto that may be used to identify, diagnose, monitor, stage, image and treat ovarian cancer and/or non-cancerous disease states in ovarian; identify and monitor ovarian tissue; and identify and design agonists and
10 antagonists of polypeptides of the invention. The invention also provides gene therapy, methods for producing transgenic animals and cells, and methods for producing engineered ovarian tissue for treatment and research.

 One aspect of the present invention relates to nucleic acid molecules that are specific to ovarian cells, ovarian tissue and/or the ovarian organ. These ovarian specific
15 nucleic acids (OSNAs) may be a naturally occurring cDNA, genomic DNA, RNA, or a fragment of one of these nucleic acids, or may be a non-naturally occurring nucleic acid molecule. If the OSNA is genomic DNA, then the OSNA is an ovarian specific gene (OSG). If the OSNA is RNA, then it is an ovarian specific transcript encoded by an OSG. Due to alternative splicing and transcriptional modification one OSG may encode for
20 multiple ovarian specific RNAs. In a preferred embodiment, the nucleic acid molecule encodes a polypeptide that is specific to ovarian. More preferred is a nucleic acid molecule that encodes a polypeptide comprising an amino acid sequence of SEQ ID NO: 129-295. In another preferred embodiment, the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO: 1-128. For the OSNA sequences listed herein,
25 DEX0455_001.nt.1 corresponds to SEQ ID NO: 1. For sequences with multiple splice variants, the parent sequence DEX0455_001.nt.1, will be followed by DEX0455_001.nt.2, etc. for each splice variant. The sequences of the corresponding peptides are listed as DEX0455_001.aa.1, etc. For the mapping of all of the nucleotides and peptides, see the table in the Example 1 section below.

30 This aspect of the present invention also relates to nucleic acid molecules that selectively hybridize or exhibit substantial sequence similarity to nucleic acid molecules encoding an Ovarian Specific Protein (OSP), or that selectively hybridize or exhibit

substantial sequence similarity to an OSNA. In one embodiment of the present invention the nucleic acid molecule comprises an allelic variant of a nucleic acid molecule encoding an OSP, or an allelic variant of an OSNA. In another embodiment, the nucleic acid molecule comprises a part of a nucleic acid sequence that encodes an OSP or a part of a nucleic acid sequence of an OSNA.

In addition, this aspect of the present invention relates to a nucleic acid molecule further comprising one or more expression control sequences controlling the transcription and/or translation of all or a part of an OSNA or the transcription and/or translation of a nucleic acid molecule that encodes all or a fragment of an OSP.

Another aspect of the present invention relates to vectors and/or host cells comprising a nucleic acid molecule of this invention. In a preferred embodiment, the nucleic acid molecule of the vector and/or host cell encodes all or a fragment of an OSP. In another preferred embodiment, the nucleic acid molecule of the vector and/or host cell comprises all or a part of an OSNA. Vectors and host cells of the present invention are useful in the recombinant production of polypeptides, particularly OSPs of the present invention.

Another aspect of the present invention relates to polypeptides encoded by a nucleic acid molecule of this invention. The polypeptide may comprise either a fragment or a full-length protein. In a preferred embodiment, the polypeptide is an OSP. However, this aspect of the present invention also relates to mutant proteins (muteins) of OSPs, fusion proteins of which a portion is an OSP, and proteins and polypeptides encoded by allelic variants of an OSNA as provided herein.

A further aspect of the present invention is a novel splice variant which encodes an amino acid sequence that provides a novel region to be targeted for the generation of reagents that can be used in the detection and/or treatment of cancer. The novel amino acid sequence may lead to a unique protein structure, protein subcellular localization, biochemical processing or function. This information can be used to directly or indirectly facilitate the generation of additional or novel therapeutics or diagnostics. The nucleotide sequence in this novel splice variant can be used as a nucleic acid probe for the diagnosis and/or treatment of cancer.

Another aspect of the present invention relates to antibodies and other binders that specifically bind to a polypeptide of the instant invention. Accordingly antibodies or binders of the present invention specifically bind to OSPs, muteins, fusion proteins, and/or

homologous proteins or polypeptides encoded by allelic variants of an OSNA as provided herein.

Another aspect of the present invention relates to agonists and antagonists of the nucleic acid molecules and polypeptides of this invention. The agonists and antagonists of the instant invention may be used to treat ovarian cancer and non-cancerous disease states in ovarian and to produce engineered ovarian tissue.

Another aspect of the present invention relates to methods for using the nucleic acid molecules to detect or amplify nucleic acid molecules that have similar or identical nucleic acid sequences compared to the nucleic acid molecules described herein. Such methods are useful in identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and/or non-cancerous disease states in ovarian. Such methods are also useful in identifying and/or monitoring ovarian tissue. In addition, measurement of levels of one or more of the nucleic acid molecules of this invention may be useful as a diagnostic as part of a panel in combination with known other markers, particularly those described in the ovarian cancer background section above.

Another aspect of the present invention relates to use of the nucleic acid molecules of this invention in gene therapy, for producing transgenic animals and cells, and for producing engineered ovarian tissue for treatment and research.

Another aspect of the present invention relates to methods for detecting polypeptides of this invention, preferably using antibodies thereto. Such methods are useful to identify, diagnose, monitor, stage, image and treat ovarian cancer and non-cancerous disease states in ovarian. In addition, measurement of levels of one or more of the polypeptides of this invention may be useful to identify, diagnose, monitor, stage, and/or image ovarian cancer in combination with known other markers, particularly those described in the ovarian cancer background section above. The polypeptides of the present invention can also be used to identify and/or monitor ovarian tissue, and to produce engineered ovarian tissue.

Yet another aspect of the present invention relates to a computer readable means of storing the nucleic acid and amino acid sequences of the invention. The records of the computer readable means can be accessed for reading and displaying of sequences for comparison, alignment and ordering of the sequences of the invention to other sequences. In addition, the computer records regarding the nucleic acid and/or amino acid sequences

and/or measurements of their levels may be used alone or in combination with other markers to diagnose ovarian related diseases.

BRIEF DESCRIPTION OF THE FIGURES

5 FIGURE 1 is a nucleotide sequence alignment which shows regions of similarity and difference between DEX0455_049.nt.5 (SEQ ID NO:96; EpCAM) and DEX0455_049.nt.1 (SEQ ID NO:92; Ovr232);

FIGURE 2 is an amino acid sequence alignment which shows regions of similarity and difference between DEX0455_049.aa.5 (SEQ ID NO:255; EpCAM) and
10 DEX0455_049.aa.1 (SEQ ID NO:251; Ovr232);

FIGURE 3 is a nucleotide sequence alignment which shows regions of similarity and difference between DEX0455_049.nt.5 (SEQ ID NO:96; EpCAM) and DEX0455_049.nt.2 (SEQ ID NO:93; Ovr232v1);

FIGURE 4 is an amino acid sequence alignment which shows regions of similarity
15 and difference between DEX0455_049.aa.5 (SEQ ID NO:255; EpCAM) and DEX0455_049.aa.2 (SEQ ID NO:252; Ovr232v1);

FIGURE 5 is a nucleotide sequence alignment which shows regions of similarity and difference between DEX0455_049.nt.5 (SEQ ID NO:96; EpCAM) and DEX0455_049.nt.3 (SEQ ID NO:94; Ovr232v2);

20 FIGURE 6 is an amino acid sequence alignment which shows regions of similarity and difference between DEX0455_049.aa.5 (SEQ ID NO:255; EpCAM) and DEX0455_049.aa.3 (SEQ ID NO:253; Ovr232v2);

FIGURE 7 is a nucleotide sequence alignment which shows regions of similarity and difference between DEX0455_049.nt.5 (SEQ ID NO:96; EpCAM) and
25 DEX0455_049.nt.4 (SEQ ID NO:95; Ovr232v3);

FIGURE 8 is an amino acid sequence alignment which shows regions of similarity and difference between DEX0455_049.aa.5 (SEQ ID NO:255; EpCAM) and DEX0455_049.aa.4 (SEQ ID NO:254; Ovr232v3);

FIGURE 9 is a nucleotide sequence alignment which shows regions of similarity
30 and difference between DEX0455_051.nt.1 (SEQ ID NO:98; Ovr107) and DEX0455_051.nt.2 (SEQ ID NO:99);

FIGURE 10 is an amino acid sequence alignment which shows regions of similarity and difference between DEX0455_051.aa.1 (SEQ ID NO:258; Ovr107) and DEX0455_051.aa.3 (SEQ ID NO:260);

FIGURE 11 is an amino acid sequence alignment which shows regions of similarity and difference between DEX0455_051.aa.1 (SEQ ID NO:258; Ovr107) and DEX0455_051.aa.2 (SEQ ID NO:259);

FIGURE 12 is a nucleotide sequence alignment which shows regions of similarity and difference between DEX0455_051.nt.1 (SEQ ID NO:98; Ovr107) and DEX0455_051.nt.3 (SEQ ID NO:100);

FIGURE 13 is a nucleotide sequence alignment which shows regions of similarity and difference between DEX0455_051.nt.1 (SEQ ID NO:98; Ovr107) and DEX0455_051.nt.4 (SEQ ID NO:101);

FIGURE 14 is a nucleotide sequence alignment which shows regions of similarity and difference between DEX0455_051.nt.1 (SEQ ID NO:98; Ovr107) and DEX0455_051.nt.5 (SEQ ID NO:102);

FIGURE 15 is a nucleotide sequence alignment which shows regions of similarity and difference between DEX0455_051.nt.1 (SEQ ID NO:98; Ovr107) and DEX0455_051.nt.6 (SEQ ID NO:103; Ovr107v4);

FIGURE 16 is a nucleotide sequence alignment which shows regions of similarity and difference between DEX0455_053.nt.1 (SEQ ID NO:108; Ovr110) and DEX0455_053.nt.2 (SEQ ID NO:109; Ovr110v1);

FIGURE 17 is an amino acid sequence alignment which shows regions of similarity and difference between DEX0455_053.aa.1 (SEQ ID NO:268; Ovr110) and DEX0455_053.aa.2 (SEQ ID NO:269);

FIGURE 18 is an amino acid sequence alignment which shows regions of similarity and difference between DEX0455_053.aa.1 (SEQ ID NO:268; Ovr110) and DEX0455_053.aa.3 (SEQ ID NO:270).

DETAILED DESCRIPTION OF THE INVENTION

Definitions and General Techniques

Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms

shall include pluralities and plural terms shall include the singular. Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those well known and commonly used in the art. The methods and techniques of the present invention are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. *See, e.g.*, Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1989) and Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 3d ed., Cold Spring Harbor Press (2001); Ausubel *et al.*, Current Protocols in Molecular Biology, Greene Publishing Associates (1992, and Supplements to 2000); Ausubel *et al.*, Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology – 4th Ed., Wiley & Sons (1999); Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1990); and Harlow and Lane, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1999).

Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

The following terms, unless otherwise indicated, shall be understood to have the following meanings:

A "nucleic acid molecule" of this invention refers to a polymeric form of nucleotides and includes both sense and antisense strands of RNA, cDNA, genomic DNA, and synthetic forms and mixed polymers of the above. A nucleotide refers to a ribonucleotide, deoxynucleotide or a modified form of either type of nucleotide. A "nucleic acid molecule" as used herein is synonymous with "nucleic acid" and "polynucleotide." The term "nucleic acid molecule" usually refers to a molecule of at least 10 bases in length, unless otherwise specified. The term includes single- and double-stranded forms of DNA. In addition, a polynucleotide may include either or both naturally

occurring and modified nucleotides linked together by naturally occurring and/or non-naturally occurring nucleotide linkages.

- Nucleotides are represented by single letter symbols in nucleic acid molecule sequences. The following table lists symbols identifying nucleotides or groups of nucleotides which may occupy the symbol position on a nucleic acid molecule. See
- 5 Nomenclature Committee of the International Union of Biochemistry (NC-IUB), Nomenclature for incompletely specified bases in nucleic acid sequences, Recommendations 1984., *Eur J Biochem.* 150(1):1-5 (1985).

Symbol	Meaning	Group/Origin of Designation	Complementary Symbol
a	a	Adenine	t/u
g	g	Guanine	c
c	c	Cytosine	g
t	t	Thymine	a
u	u	Uracil	a
r	g or a	puRine	y
y	t/u or c	pYrimidine	r
m	a or c	aMino	k
k	g or t/u	Keto	m
s	g or c	Strong interactions 3H-bonds	w
w	a or t/u	Weak interactions 2H-bonds	s
b	g or c or t/u	not a	v
d	a or g or t/u	not c	h
h	a or c or t/u	not g	d
v	a or g or c	not t, not u	b
n	a or g or c or t/u, unknown, or other	aNy	n

- 10 The nucleic acid molecules may be modified chemically or biochemically or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as uncharged linkages (*e.g.*, methyl phosphonates,
- 15 phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages (*e.g.*, phosphorothioates, phosphorodithioates, etc.), pendent moieties (*e.g.*, polypeptides), intercalators (*e.g.*, acridine, psoralen, etc.), chelators, alkylators, and modified linkages (*e.g.*, alpha anomeric nucleic acids, etc.) The term "nucleic acid molecule" also includes any topological conformation, including single-stranded, double-stranded, partially
- 20 duplexed, triplexed, hairpinned, circular and padlocked conformations. Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated

sequence via hydrogen bonding and other chemical interactions. Such molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.

A “gene” is defined as a nucleic acid molecule that comprises a nucleic acid
5 sequence that encodes a polypeptide and the expression control sequences that surround the nucleic acid sequence that encodes the polypeptide. For instance, a gene may comprise a promoter, one or more enhancers, a nucleic acid sequence that encodes a polypeptide, downstream regulatory sequences and, possibly, other nucleic acid sequences involved in regulation of the expression of an RNA. As is well known in the art,
10 eukaryotic genes usually contain both exons and introns. The term “exon” refers to a nucleic acid sequence found in genomic DNA that is bioinformatically predicted and/or experimentally confirmed to contribute contiguous sequence to a mature mRNA transcript. The term “intron” refers to a nucleic acid sequence found in genomic DNA that is predicted and/or confirmed to not contribute to a mature mRNA transcript, but rather to
15 be “spliced out” during processing of the transcript.

A nucleic acid molecule or polypeptide is “derived” from a particular species if the nucleic acid molecule or polypeptide has been isolated from the particular species, or if the nucleic acid molecule or polypeptide is homologous to a nucleic acid molecule or polypeptide isolated from a particular species.

20 An “isolated” or “substantially pure” nucleic acid or polynucleotide (*e.g.*, an RNA, DNA or a mixed polymer) is one which is substantially separated from other cellular components that naturally accompany the native polynucleotide in its natural host cell, *e.g.*, ribosomes, polymerases, or genomic sequences with which it is naturally associated. The term embraces a nucleic acid or polynucleotide that (1) has been removed from its
25 naturally occurring environment, (2) is not associated with all or a portion of a polynucleotide in which the “isolated polynucleotide” is found in nature, (3) is operatively linked to a polynucleotide which it is not linked to in nature, (4) does not occur in nature as part of a larger sequence or (5) includes nucleotides or internucleoside bonds that are not found in nature. The term “isolated” or “substantially pure” also can be used in
30 reference to recombinant or cloned DNA isolates, chemically synthesized polynucleotide analogs, or polynucleotide analogs that are biologically synthesized by heterologous systems. The term “isolated nucleic acid molecule” includes nucleic acid molecules that are integrated into a host cell chromosome at a heterologous site, recombinant fusions of a

native fragment to a heterologous sequence, recombinant vectors present as episomes or as integrated into a host cell chromosome.

A "part" of a nucleic acid molecule refers to a nucleic acid molecule that comprises a partial contiguous sequence of at least 10 bases of the reference nucleic acid molecule. Preferably, a part comprises at least 15 to 20 bases of a reference nucleic acid molecule. In theory, a nucleic acid sequence of 17 nucleotides is of sufficient length to occur at random less frequently than once in the three gigabase human genome, and thus provides a nucleic acid probe that can uniquely identify the reference sequence in a nucleic acid mixture of genomic complexity. A preferred part is one that comprises a nucleic acid sequence that can encode at least 6 contiguous amino acid sequences (fragments of at least 18 nucleotides) because they are useful in directing the expression or synthesis of peptides that are useful in mapping the epitopes of the polypeptide encoded by the reference nucleic acid. *See, e.g., Geysen et al., Proc. Natl. Acad. Sci. USA* 81:3998-4002 (1984); and U.S. Patent Nos. 4,708,871 and 5,595,915, the disclosures of which are incorporated herein by reference in their entireties. A part may also comprise at least 25, 30, 35 or 40 nucleotides of a reference nucleic acid molecule, or at least 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400 or 500 nucleotides of a reference nucleic acid molecule. A part of a nucleic acid molecule may comprise no other nucleic acid sequences. Alternatively, a part of a nucleic acid may comprise other nucleic acid sequences from other nucleic acid molecules.

The term "oligonucleotide" refers to a nucleic acid molecule generally comprising a length of 200 bases or fewer. The term often refers to single-stranded deoxyribonucleotides, but it can refer as well to single-or double-stranded ribonucleotides, RNA:DNA hybrids and double-stranded DNAs, among others. Preferably, oligonucleotides are 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19 or 20 bases in length. Other preferred oligonucleotides are 25, 30, 35, 40, 45, 50, 55 or 60 bases in length. Oligonucleotides may be single-stranded, *e.g.* for use as probes or primers, or may be double-stranded, *e.g.* for use in the construction of a mutant gene. Oligonucleotides of the invention can be either sense or antisense oligonucleotides. An oligonucleotide can be derivatized or modified as discussed above for nucleic acid molecules.

Oligonucleotides, such as single-stranded DNA probe oligonucleotides, often are synthesized by chemical methods, such as those implemented on automated

oligonucleotide synthesizers. However, oligonucleotides can be made by a variety of other methods, including in vitro recombinant DNA-mediated techniques and by expression of DNAs in cells and organisms. Initially, chemically synthesized DNAs typically are obtained without a 5' phosphate. The 5' ends of such oligonucleotides are not substrates for phosphodiester bond formation by ligation reactions that employ DNA ligases typically used to form recombinant DNA molecules. Where ligation of such oligonucleotides is desired, a phosphate can be added by standard techniques, such as those that employ a kinase and ATP. The 3' end of a chemically synthesized oligonucleotide generally has a free hydroxyl group and, in the presence of a ligase, such as T4 DNA ligase, readily will form a phosphodiester bond with a 5' phosphate of another polynucleotide, such as another oligonucleotide. As is well known, this reaction can be prevented selectively, where desired, by removing the 5' phosphates of the other polynucleotide(s) prior to ligation.

The term "naturally occurring nucleotide" referred to herein includes naturally occurring deoxyribonucleotides and ribonucleotides. The term "modified nucleotides" referred to herein includes nucleotides with modified or substituted sugar groups and the like. The term "nucleotide linkages" referred to herein includes nucleotide linkages such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate, phosphoroamidate, and the like. *See e.g.*, LaPlanche *et al. Nucl. Acids Res.* 14:9081-9093 (1986); Stein *et al. Nucl. Acids Res.* 16:3209-3221 (1988); Zon *et al. Anti-Cancer Drug Design* 6:539-568 (1991); Zon *et al.*, in Eckstein (ed.) Oligonucleotides and Analogues: A Practical Approach, pp. 87-108, Oxford University Press (1991); Uhlmann and Peyman *Chemical Reviews* 90:543 (1990), and U.S. Patent No. 5,151,510, the disclosure of which is hereby incorporated by reference in its entirety.

Unless specified otherwise, the left hand end of a polynucleotide sequence in sense orientation is the 5' end and the right hand end of the sequence is the 3' end. In addition, the left hand direction of a polynucleotide sequence in sense orientation is referred to as the 5' direction, while the right hand direction of the polynucleotide sequence is referred to as the 3' direction. Further, unless otherwise indicated, each nucleotide sequence is set forth herein as a sequence of deoxyribonucleotides. It is intended, however, that the given sequence be interpreted as would be appropriate to the polynucleotide composition: for

example, if the isolated nucleic acid is composed of RNA, the given sequence intends ribonucleotides, with uridine substituted for thymidine.

The term “allelic variant” refers to one of two or more alternative naturally occurring forms of a gene, wherein each gene possesses a unique nucleotide sequence. In
5 a preferred embodiment, different alleles of a given gene have similar or identical biological properties.

The term “percent sequence identity” in the context of nucleic acid sequences refers to the residues in two sequences which are the same when aligned for maximum correspondence. The length of sequence identity comparison may be over a stretch of at
10 least about nine nucleotides, usually at least about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 32 nucleotides, and preferably at least about 36 or more nucleotides. There are a number of different algorithms known in the art which can be used to measure nucleotide sequence identity. For instance, polynucleotide sequences can be compared using FASTA, Gap or
15 Bestfit, which are programs in Wisconsin Package Version 10.0, Genetics Computer Group (GCG), Madison, Wisconsin. FASTA, which includes, *e.g.*, the programs FASTA2 and FASTA3, provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson, *Methods Enzymol.* 183: 63-98 (1990); Pearson, *Methods Mol. Biol.* 132: 185-219 (2000); Pearson, *Methods Enzymol.*
20 266: 227-258 (1996); Pearson, *J. Mol. Biol.* 276: 71-84 (1998)). Unless otherwise specified, default parameters for a particular program or algorithm are used. For instance, percent sequence identity between nucleic acid sequences can be determined using FASTA with its default parameters (a word size of 6 and the NOPAM factor for the scoring matrix) or using Gap with its default parameters as provided in GCG Version 6.1.

25 A reference to a nucleic acid sequence encompasses its complement unless otherwise specified. Thus, a reference to a nucleic acid molecule having a particular sequence should be understood to encompass its complementary strand, with its complementary sequence. The complementary strand is also useful, *e.g.*, for antisense therapy, double-stranded RNA (dsRNA) inhibition (RNAi), combination of triplex and
30 antisense, hybridization probes and PCR primers.

In the molecular biology art, researchers use the terms “percent sequence identity”, “percent sequence similarity” and “percent sequence homology” interchangeably. In this

application, these terms shall have the same meaning with respect to nucleic acid sequences only.

The term “substantial similarity” or “substantial sequence similarity,” when referring to a nucleic acid or fragment thereof, indicates that, when optimally aligned with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 50%, more preferably 60% of the nucleotide bases, usually at least about 70%, more usually at least about 80%, preferably at least about 90%, and more preferably at least about 95-98% of the nucleotide bases, as measured by any well known algorithm of sequence identity, such as FASTA, BLAST or Gap, as discussed above.

Alternatively, substantial similarity exists between a first and second nucleic acid sequence when the first nucleic acid sequence or fragment thereof hybridizes to an antisense strand of the second nucleic acid, under selective hybridization conditions. Typically, selective hybridization will occur between the first nucleic acid sequence and an antisense strand of the second nucleic acid sequence when there is at least about 55% sequence identity between the first and second nucleic acid sequences—preferably at least about 65%, more preferably at least about 75%, and most preferably at least about 90%—over a stretch of at least about 14 nucleotides, more preferably at least 17 nucleotides, even more preferably at least 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 or 100 nucleotides.

Nucleic acid hybridization will be affected by such conditions as salt concentration, temperature, solvents, the base composition of the hybridizing species, length of the complementary regions, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art. “Stringent hybridization conditions” and “stringent wash conditions” in the context of nucleic acid hybridization experiments depend upon a number of different physical parameters. The most important parameters include temperature of hybridization, base composition of the nucleic acids, salt concentration and length of the nucleic acid. One having ordinary skill in the art knows how to vary these parameters to achieve a particular stringency of hybridization. In general, “stringent hybridization” is performed at about 25°C below the thermal melting point (T_m) for the specific DNA hybrid under a particular set of conditions. “Stringent washing” is performed at temperatures about 5°C lower than the T_m for the specific DNA hybrid under a particular set of conditions. The T_m is the

temperature at which 50% of the target sequence hybridizes to a perfectly matched probe. See Sambrook (1989), *supra*, p. 9.51.

The T_m for a particular DNA-DNA hybrid can be estimated by the formula:

$$T_m = 81.5^{\circ}\text{C} + 16.6 (\log_{10}[\text{Na}^+]) + 0.41 (\text{fraction G} + \text{C}) -$$

5 $0.63 (\% \text{ formamide}) - (600/l)$ where l is the length of the hybrid in base pairs.

The T_m for a particular RNA-RNA hybrid can be estimated by the formula:

$$T_m = 79.8^{\circ}\text{C} + 18.5 (\log_{10}[\text{Na}^+]) + 0.58 (\text{fraction G} + \text{C}) +$$

$$11.8 (\text{fraction G} + \text{C})^2 - 0.35 (\% \text{ formamide}) - (820/l).$$

The T_m for a particular RNA-DNA hybrid can be estimated by the formula:

10 $T_m = 79.8^{\circ}\text{C} + 18.5 (\log_{10}[\text{Na}^+]) + 0.58 (\text{fraction G} + \text{C}) +$

$$11.8 (\text{fraction G} + \text{C})^2 - 0.50 (\% \text{ formamide}) - (820/l).$$

In general, the T_m decreases by 1-1.5°C for each 1% of mismatch between two nucleic acid sequences. Thus, one having ordinary skill in the art can alter hybridization and/or washing conditions to obtain sequences that have higher or lower degrees of
 15 sequence identity to the target nucleic acid. For instance, to obtain hybridizing nucleic acids that contain up to 10% mismatch from the target nucleic acid sequence, 10-15°C would be subtracted from the calculated T_m of a perfectly matched hybrid, and then the hybridization and washing temperatures adjusted accordingly. Probe sequences may also hybridize specifically to duplex DNA under certain conditions to form triplex or other
 20 higher order DNA complexes. The preparation of such probes and suitable hybridization conditions are well known in the art.

An example of stringent hybridization conditions for hybridization of complementary nucleic acid sequences having more than 100 complementary residues on a filter in a Southern or Northern blot or for screening a library is 50% formamide/6X SSC
 25 at 42°C for at least ten hours and preferably overnight (approximately 16 hours). Another example of stringent hybridization conditions is 6X SSC at 68°C without formamide for at least ten hours and preferably overnight. An example of moderate stringency hybridization conditions is 6X SSC at 55°C without formamide for at least ten hours and preferably overnight. An example of low stringency hybridization conditions for
 30 hybridization of complementary nucleic acid sequences having more than 100 complementary residues on a filter in a Southern or northern blot or for screening a library is 6X SSC at 42°C for at least ten hours. Hybridization conditions to identify nucleic acid sequences that are similar but not identical can be identified by experimentally changing

the hybridization temperature from 68°C to 42°C while keeping the salt concentration constant (6X SSC), or keeping the hybridization temperature and salt concentration constant (e.g. 42°C and 6X SSC) and varying the formamide concentration from 50% to 0%. Hybridization buffers may also include blocking agents to lower background. These agents are well known in the art. *See* Sambrook *et al.* (1989), *supra*, pages 8.46 and 9.46-9.58. *See also* Ausubel (1992), *supra*, Ausubel (1999), *supra*, and Sambrook (2001), *supra*.

Wash conditions also can be altered to change stringency conditions. An example of stringent wash conditions is a 0.2x SSC wash at 65°C for 15 minutes (*see* Sambrook (1989), *supra*, for SSC buffer). Often the high stringency wash is preceded by a low stringency wash to remove excess probe. An exemplary medium stringency wash for duplex DNA of more than 100 base pairs is 1x SSC at 45°C for 15 minutes. An exemplary low stringency wash for such a duplex is 4x SSC at 40°C for 15 minutes. In general, signal-to-noise ratio of 2x or higher than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization.

As defined herein, nucleic acids that do not hybridize to each other under stringent conditions are still substantially similar to one another if they encode polypeptides that are substantially identical to each other. This occurs, for example, when a nucleic acid is created synthetically or recombinantly using a high codon degeneracy as permitted by the redundancy of the genetic code.

Hybridization conditions for nucleic acid molecules that are shorter than 100 nucleotides in length (e.g., for oligonucleotide probes) may be calculated by the formula:

$$T_m = 81.5^{\circ}\text{C} + 16.6(\log_{10}[\text{Na}^+]) + 0.41(\text{fraction G+C}) - (600/\text{N}),$$
 wherein N is change length and the $[\text{Na}^+]$ is 1 M or less. *See* Sambrook (1989), *supra*, p. 11.46. For hybridization of probes shorter than 100 nucleotides, hybridization is usually performed under stringent conditions (5-10°C below the T_m) using high concentrations (0.1-1.0 pmol/ml) of probe. *Id.* at p. 11.45. Determination of hybridization using mismatched probes, pools of degenerate probes or “guessmers,” as well as hybridization solutions and methods for empirically determining hybridization conditions are well known in the art. *See, e.g.,* Ausubel (1999), *supra*; Sambrook (1989), *supra*, pp. 11.45-11.57.

The term “digestion” or “digestion of DNA” refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA. The various restriction enzymes referred to herein are commercially available and their

reaction conditions, cofactors and other requirements for use are known and routine to the skilled artisan. For analytical purposes, typically, 1 µg of plasmid or DNA fragment is digested with about 2 units of enzyme in about 20 µl of reaction buffer. For the purpose of isolating DNA fragments for plasmid construction, typically 5 to 50 µg of DNA are
5 digested with 20 to 250 units of enzyme in proportionately larger volumes. Appropriate buffers and substrate amounts for particular restriction enzymes are described in standard laboratory manuals, such as those referenced below, and are specified by commercial suppliers. Incubation times of about 1 hour at 37°C are ordinarily used, but conditions may vary in accordance with standard procedures, the supplier's instructions and the
10 particulars of the reaction. After digestion, reactions may be analyzed, and fragments may be purified by electrophoresis through an agarose or polyacrylamide gel, using well known methods that are routine for those skilled in the art.

The term "ligation" refers to the process of forming phosphodiester bonds between two or more polynucleotides, which most often are double-stranded DNAs. Techniques
15 for ligation are well known to the art and protocols for ligation are described in standard laboratory manuals and references, such as, *e.g.*, Sambrook (1989), *supra*.

Genome-derived "single exon probes," are probes that comprise at least part of an exon ("reference exon") and can hybridize detectably under high stringency conditions to transcript-derived nucleic acids that include the reference exon but do not hybridize
20 detectably under high stringency conditions to nucleic acids that lack the reference exon. Single exon probes typically further comprise, contiguous to a first end of the exon portion, a first intronic and/or intergenic sequence that is identically contiguous to the exon in the genome, and may contain a second intronic and/or intergenic sequence that is identically contiguous to the exon in the genome. The minimum length of genome-
25 derived single exon probes is defined by the requirement that the exonic portion be of sufficient length to hybridize under high stringency conditions to transcript-derived nucleic acids, as discussed above. The maximum length of genome-derived single exon probes is defined by the requirement that the probes contain portions of no more than one exon. The single exon probes may contain priming sequences not found in contiguity with
30 the rest of the probe sequence in the genome, which priming sequences are useful for PCR and other amplification-based technologies. In another aspect, the invention is directed to single exon probes based on the OSNAs disclosed herein.

In one embodiment, the term “microarray” refers to a “nucleic acid microarray” having a substrate-bound plurality of nucleic acids, hybridization to each of the plurality of bound nucleic acids being separately detectable. The substrate can be solid or porous, planar or non-planar, unitary or distributed. Nucleic acid microarrays include all the devices so called in Schena (ed.), DNA Microarrays: A Practical Approach (Practical Approach Series), Oxford University Press (1999); *Nature Genet.* 21(1)(suppl.):1 - 60 (1999); Schena (ed.), Microarray Biochip: Tools and Technology, Eaton Publishing Company/BioTechniques Books Division (2000). Additionally, these nucleic acid microarrays include a substrate-bound plurality of nucleic acids in which the plurality of nucleic acids are disposed on a plurality of beads, rather than on a unitary planar substrate, as is described, *inter alia*, in Brenner *et al.*, *Proc. Natl. Acad. Sci. USA* 97(4):1665-1670 (2000). Examples of nucleic acid microarrays may be found in U.S. Patent Nos. 6,391,623, 6,383,754, 6,383,749, 6,380,377, 6,379,897, 6,376,191, 6,372,431, 6,351,712, 6,344,316, 6,316,193, 6,312,906, 6,309,828, 6,309,824, 6,306,643, 6,300,063, 6,287,850, 6,284,497, 6,284,465, 6,280,954, 6,262,216, 6,251,601, 6,245,518, 6,263,287, 6,251,601, 6,238,866, 6,228,575, 6,214,587, 6,203,989, 6,171,797, 6,103,474, 6,083,726, 6,054,274, 6,040,138, 6,083,726, 6,004,755, 6,001,309, 5,958,342, 5,952,180, 5,936,731, 5,843,655, 5,814,454, 5,837,196, 5,436,327, 5,412,087, and 5,405,783, the disclosures of which are incorporated herein by reference in their entirety.

In an alternative embodiment, a “microarray” may also refer to a “peptide microarray” or “protein microarray” having a substrate-bound collection or plurality of polypeptides, the binding to each of the plurality of bound polypeptides being separately detectable. Alternatively, the peptide microarray may have a plurality of binders, including but not limited to monoclonal antibodies, polyclonal antibodies, phage display binders, yeast 2 hybrid binders, and aptamers, which can specifically detect the binding of the polypeptides of this invention. The array may be based on autoantibody detection to the polypeptides of this invention, see Robinson *et al.*, *Nature Medicine* 8(3):295-301 (2002). Examples of peptide arrays may be found in WO 02/31463, WO 02/25288, WO 01/94946, WO 01/88162, WO 01/68671, WO 01/57259, WO 00/61806, WO 00/54046, WO 00/47774, WO 99/40434, WO 99/39210, and WO 97/42507 and U.S. Patent Nos. 6,268,210, 5,766,960, and 5,143,854, the disclosures of which are incorporated herein by reference in their entirety.

In addition, determination of the levels of the OSNA or OSP may be made in a multiplex manner using techniques described in WO 02/29109, WO 02/24959, WO 01/83502, WO01/73113, WO 01/59432, WO 01/57269, and WO 99/67641, the disclosures of which are incorporated herein by reference in their entireties.

5 The term “mutant”, “mutated”, or “mutation” when applied to nucleic acid sequences means that nucleotides in a nucleic acid sequence may be inserted, deleted or changed compared to a reference nucleic acid sequence. A single alteration may be made at a locus (a point mutation) or multiple nucleotides may be inserted, deleted or changed at a single locus. In addition, one or more alterations may be made at any number of loci
10 within a nucleic acid sequence. In a preferred embodiment of the present invention, the nucleic acid sequence is the wild type nucleic acid sequence encoding an OSP or is an OSNA. The nucleic acid sequence may be mutated by any method known in the art including those mutagenesis techniques described *infra*.

15 The term “error-prone PCR” refers to a process for performing PCR under conditions where the copying fidelity of the DNA polymerase is low, such that a high rate of point mutations is obtained along the entire length of the PCR product. *See, e.g.,* Leung *et al., Technique* 1: 11-15 (1989) and Caldwell *et al., PCR Methods Applic.* 2: 28-33 (1992).

20 The term “oligonucleotide-directed mutagenesis” refers to a process which enables the generation of site-specific mutations in any cloned DNA segment of interest. *See, e.g.,* Reidhaar-Olson *et al., Science* 241: 53-57 (1988).

25 The term “assembly PCR” refers to a process which involves the assembly of a PCR product from a mixture of small DNA fragments. A large number of different PCR reactions occur in parallel in the same vial, with the products of one reaction priming the products of another reaction.

30 The term “sexual PCR mutagenesis” or “DNA shuffling” refers to a method of error-prone PCR coupled with forced homologous recombination between DNA molecules of different but highly related DNA sequence *in vitro*, caused by random fragmentation of the DNA molecule based on sequence similarity, followed by fixation of the crossover by primer extension in an error-prone PCR reaction. *See, e.g.,* Stemmer, *Proc. Natl. Acad. Sci. U.S.A.* 91: 10747-10751 (1994). DNA shuffling can be carried out between several related genes (“Family shuffling”).

The term “*in vivo* mutagenesis” refers to a process of generating random mutations in any cloned DNA of interest which involves the propagation of the DNA in a strain of bacteria such as *E. coli* that carries mutations in one or more of the DNA repair pathways. These “mutator” strains have a higher random mutation rate than that of a wild-type parent. Propagating the DNA in a mutator strain will eventually generate random mutations within the DNA.

The term “cassette mutagenesis” refers to any process for replacing a small region of a double-stranded DNA molecule with a synthetic oligonucleotide “cassette” that differs from the native sequence. The oligonucleotide often contains completely and/or partially randomized native sequence.

The term “recursive ensemble mutagenesis” refers to an algorithm for protein engineering (protein mutagenesis) developed to produce diverse populations of phenotypically related mutants whose members differ in amino acid sequence. This method uses a feedback mechanism to control successive rounds of combinatorial cassette mutagenesis. See, e.g., Arkin *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 89: 7811-7815 (1992).

The term “exponential ensemble mutagenesis” refers to a process for generating combinatorial libraries with a high percentage of unique and functional mutants, wherein small groups of residues are randomized in parallel to identify, at each altered position, amino acids which lead to functional proteins. See, e.g., Delegrave *et al.*, *Biotechnology Research* 11: 1548-1552 (1993); Arnold, *Current Opinion in Biotechnology* 4: 450-455 (1993).

“Operatively linked” expression control sequences refers to a linkage in which the expression control sequence is either contiguous with the gene of interest to control the gene of interest, or acts in *trans* or at a distance to control the gene of interest.

The term “expression control sequence” as used herein refers to polynucleotide sequences which are necessary to affect the expression of coding sequences to which they are operatively linked. Expression control sequences are sequences which control the transcription, post-transcriptional events and translation of nucleic acid sequences. Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (e.g., ribosome binding sites); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. The nature

of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence. The term "control sequences" is intended to include, at a minimum, all components whose presence is essential for expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.

The term "vector," as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double-stranded DNA loop into which additional DNA segments may be ligated. Other vectors include cosmids, bacterial artificial chromosomes (BAC) and yeast artificial chromosomes (YAC). Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Viral vectors that infect bacterial cells are referred to as bacteriophages. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication). Other vectors can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, "expression vectors"). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" may be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include other forms of expression vectors that serve equivalent functions.

The term "recombinant host cell" (or simply "host cell"), as used herein, is intended to refer to a cell into which a recombinant expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein.

As used herein, the phrase "open reading frame" and the equivalent acronym "ORF" refers to that portion of a transcript-derived nucleic acid that can be translated in its

entirety into a sequence of contiguous amino acids. As so defined, an ORF has length, measured in nucleotides, exactly divisible by 3. As so defined, an ORF need not encode the entirety of a natural protein.

As used herein, the phrase "ORF-encoded peptide" refers to the predicted or actual translation of an ORF.

As used herein, the phrase "degenerate variant" of a reference nucleic acid sequence is meant to be inclusive of all nucleic acid sequences that can be directly translated, using the standard genetic code, to provide an amino acid sequence identical to that translated from the reference nucleic acid sequence.

The term "polypeptide" encompasses both naturally occurring and non-naturally occurring proteins and polypeptides, as well as polypeptide fragments and polypeptide mutants, derivatives and analogs thereof. A polypeptide may be monomeric or polymeric. Further, a polypeptide may comprise a number of different modules within a single polypeptide each of which has one or more distinct activities. A preferred polypeptide in accordance with the invention comprises an OSP encoded by a nucleic acid molecule of the instant invention, or a fragment, mutant, analog or derivative thereof.

The term "isolated protein" or "isolated polypeptide" is a protein or polypeptide that by virtue of its origin or source of derivation (1) is not associated with naturally associated components that accompany it in its native state, (2) is free of other proteins from the same species (3) is expressed by a cell from a different species, or (4) does not occur in nature. Thus, a polypeptide that is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be "isolated" from its naturally associated components. A polypeptide or protein may also be rendered substantially free of naturally associated components by isolation, using protein purification techniques well known in the art.

A protein or polypeptide is "substantially pure," "substantially homogeneous" or "substantially purified" when at least about 60% to 75% of a sample exhibits a single species of polypeptide. The polypeptide or protein may be monomeric or multimeric. A substantially pure polypeptide or protein will typically comprise about 50%, 60%, 70%, 80% or 90% W/W of a protein sample, more usually about 95%, and preferably will be over 99% pure. Protein purity or homogeneity may be determined by a number of means well known in the art, such as polyacrylamide gel electrophoresis of a protein sample, followed by visualizing a single polypeptide band upon staining the gel with a stain well

known in the art. For certain purposes, higher resolution may be provided by using HPLC or other means well known in the art for purification.

The term "fragment" when used herein with respect to polypeptides of the present invention refers to a polypeptide that has an amino-terminal and/or carboxy-terminal deletion compared to a full-length OSP. In a preferred embodiment, the fragment is a
5 contiguous sequence in which the amino acid sequence of the fragment is identical to the corresponding positions in the naturally occurring polypeptide. Fragments typically are at least 5, 6, 7, 8, 9 or 10 amino acids long, preferably at least 12, 14, 16 or 18 amino acids long, more preferably at least 20 amino acids long, more preferably at least 25, 30, 35, 40
10 or 45, amino acids, even more preferably at least 50 or 60 amino acids long, and even more preferably at least 70 amino acids long.

A "derivative" when used herein with respect to polypeptides of the present invention refers to a polypeptide which is substantially similar in primary structural sequence to an OSP but which includes, *e.g.*, *in vivo* or *in vitro* chemical and biochemical
15 modifications that are not found in the OSP. Such modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation,
20 formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.
25 Other modifications include, *e.g.*, labeling with radionuclides, and various enzymatic modifications, as will be readily appreciated by those skilled in the art. A variety of methods for labeling polypeptides and of substituents or labels useful for such purposes are well known in the art, and include radioactive isotopes such as ^{125}I , ^{32}P , ^{35}S , ^{14}C and ^3H , ligands which bind to labeled antiligands (*e.g.*, antibodies), fluorophores,
30 chemiluminescent agents, enzymes, and antiligands which can serve as specific binding pair members for a labeled ligand. The choice of label depends on the sensitivity required, ease of conjugation with the primer, stability requirements, and available instrumentation.

Methods for labeling polypeptides are well known in the art. *See* Ausubel (1992), *supra*; Ausubel (1999), *supra*.

The term "fusion protein" refers to polypeptides of the present invention coupled to a heterologous amino acid sequence. Fusion proteins are useful because they can be constructed to contain two or more desired functional elements from two or more different proteins. A fusion protein comprises at least 10 contiguous amino acids from a polypeptide of interest, more preferably at least 20 or 30 amino acids, even more preferably at least 40, 50 or 60 amino acids, yet more preferably at least 75, 100 or 125 amino acids. Fusion proteins can be produced recombinantly by constructing a nucleic acid sequence that encodes the polypeptide or a fragment thereof in frame with a nucleic acid sequence encoding a different protein or peptide and then expressing the fusion protein. Alternatively, a fusion protein can be produced chemically by crosslinking the polypeptide or a fragment thereof to another protein.

The term "analog" refers to both polypeptide analogs and non-peptide analogs. The term "polypeptide analog" as used herein refers to a polypeptide that is comprised of a segment of at least 25 amino acids that has substantial identity to a portion of an amino acid sequence but which contains non-natural amino acids or non-natural inter-residue bonds. In a preferred embodiment, the analog has the same or similar biological activity as the native polypeptide. Typically, polypeptide analogs comprise a conservative amino acid substitution (or insertion or deletion) with respect to the naturally occurring sequence. Analogs typically are at least 20 amino acids long, preferably at least 50 amino acids long or longer, and can often be as long as a full-length naturally occurring polypeptide.

The term "non-peptide analog" refers to a compound with properties that are analogous to those of a reference polypeptide. A non-peptide compound may also be termed a "peptide mimetic" or a "peptidomimetic." Such compounds are often developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to useful peptides may be used to produce an equivalent effect. Generally, peptidomimetics are structurally similar to a paradigm polypeptide (*i.e.*, a polypeptide that has a desired biochemical property or pharmacological activity), but have one or more peptide linkages optionally replaced by a linkage selected from the group consisting of: --CH₂NH--, --CH₂S--, --CH₂-CH₂--, --CH=CH--(cis and trans), --COCH₂--, --CH(OH)CH₂--, and --CH₂SO--, by methods well known in the art. Systematic

substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (*e.g.*, D-lysine in place of L-lysine) may also be used to generate more stable peptides. In addition, constrained peptides comprising a consensus sequence or a substantially identical consensus sequence variation may be generated by methods known
5 in the art (Rizo *et al.*, *Ann. Rev. Biochem.* 61:387-418 (1992)). For example, one may add internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.

The term "mutant" or "mutein" when referring to a polypeptide of the present invention relates to an amino acid sequence containing substitutions, insertions or
10 deletions of one or more amino acids compared to the amino acid sequence of an OSP. A mutein may have one or more amino acid point substitutions, in which a single amino acid at a position has been changed to another amino acid, one or more insertions and/or deletions, in which one or more amino acids are inserted or deleted, respectively, in the sequence of the naturally occurring protein, and/or truncations of the amino acid sequence
15 at either or both the amino or carboxy termini. Further, a mutein may have the same or different biological activity as the naturally occurring protein. For instance, a mutein may have an increased or decreased biological activity. A mutein has at least 50% sequence similarity to the wild type protein, preferred is 60% sequence similarity, more preferred is 70% sequence similarity. Even more preferred are muteins having 80%, 85% or 90%
20 sequence similarity to an OSP. In an even more preferred embodiment, a mutein exhibits 95% sequence identity, even more preferably 97%, even more preferably 98% and even more preferably 99%. Sequence similarity may be measured by any common sequence analysis algorithm, such as GAP or BESTFIT or other variation Smith-Waterman alignment. *See*, T. F. Smith and M. S. Waterman, *J. Mol. Biol.* 147:195-197 (1981) and
25 W.R. Pearson, *Genomics* 11:635-650 (1991).

Preferred amino acid substitutions are those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinity or enzymatic activity, and (5) confer or
30 modify other physicochemical or functional properties of such analogs. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in the naturally occurring sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular contacts. In a preferred embodiment, the amino acid substitutions are moderately conservative substitutions or

conservative substitutions. In a more preferred embodiment, the amino acid substitutions are conservative substitutions. A conservative amino acid substitution should not substantially change the structural characteristics of the parent sequence (*e.g.*, a replacement amino acid should not tend to disrupt a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterize the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in Creighton (ed.), Proteins, Structures and Molecular Principles, W. H. Freeman and Company (1984); Branden *et al.* (ed.), Introduction to Protein Structure, Garland Publishing (1991); Thornton *et al.*, *Nature* 354:105-106 (1991).

As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. See Golub *et al.* (eds.), Immunology - A Synthesis 2nd Ed., Sinauer Associates (1991). Stereoisomers (*e.g.*, D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as α -, α -disubstituted amino acids, N-alkyl amino acids, and other unconventional amino acids may also be suitable components for polypeptides of the present invention. Examples of unconventional amino acids include: 4-hydroxyproline, γ -carboxyglutamate, ϵ -N,N,N-trimethyllysine, ϵ -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, s-N-methylarginine, and other similar amino acids and imino acids (*e.g.*, 4-hydroxyproline). In the polypeptide notation used herein, the lefthand direction is the amino terminal direction and the right hand direction is the carboxy-terminal direction, in accordance with standard usage and convention.

By "homology" or "homologous" when referring to a polypeptide of the present invention it is meant polypeptides from different organisms with a similar sequence to the encoded amino acid sequence of an OSP and a similar biological activity or function. Although two polypeptides are said to be "homologous," this does not imply that there is necessarily an evolutionary relationship between the polypeptides. Instead, the term "homologous" is defined to mean that the two polypeptides have similar amino acid sequences and similar biological activities or functions. In a preferred embodiment, a homologous polypeptide is one that exhibits 50% sequence similarity to OSP, preferred is 60% sequence similarity, more preferred is 70% sequence similarity. Even more preferred are homologous polypeptides that exhibit 80%, 85% or 90% sequence similarity to an OSP. In yet a more preferred embodiment, a homologous polypeptide exhibits 95%, 97%, 98% or 99% sequence similarity.

When “sequence similarity” is used in reference to polypeptides, it is recognized that residue positions that are not identical often differ by conservative amino acid substitutions. In a preferred embodiment, a polypeptide that has “sequence similarity” comprises conservative or moderately conservative amino acid substitutions. A
5 “conservative amino acid substitution” is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (*e.g.*, charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a protein. In cases
10 where two or more amino acid sequences differ from each other by conservative substitutions, the percent sequence identity or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. *See, e.g.*, Pearson, *Methods Mol. Biol.* 24: 307-31 (1994).

For instance, the following six groups each contain amino acids that are
15 conservative substitutions for one another:

- 1) Serine (S), Threonine (T);
- 2) Aspartic Acid (D), Glutamic Acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 20 5) Isoleucine (I), Leucine (L), Methionine (M), Alanine (A), Valine (V), and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

Alternatively, a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet *et al.*, *Science* 256: 1443-45 (1992). A “moderately conservative” replacement is any change having a nonnegative
25 value in the PAM250 log-likelihood matrix.

Sequence similarity for polypeptides, which is also referred to as sequence identity, is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions. For
30 instance, GCG contains programs such as “Gap” and “Bestfit” which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of

organisms or between a wild type protein and a mutein thereof. *See, e.g.*, GCG Version 6.1. Other programs include FASTA, discussed *supra*.

A preferred algorithm when comparing a sequence of the invention to a database containing a large number of sequences from different organisms is the computer program
 5 BLAST, especially blastp or tblastn. *See, e.g.*, Altschul *et al.*, *J. Mol. Biol.* 215: 403-410 (1990); Altschul *et al.*, *Nucleic Acids Res.* 25:3389-402 (1997). Preferred parameters for blastp are:

	Expectation value:	10 (default)
	Filter:	seg (default)
10	Cost to open a gap:	11 (default)
	Cost to extend a gap:	1 (default)
	Max. alignments:	100 (default)
	Word size:	11 (default)
	No. of descriptions:	100 (default)
15	Penalty Matrix:	BLOSUM62

The length of polypeptide sequences compared for homology will generally be at least about 16 amino acid residues, usually at least about 20 residues, more usually at least about 24 residues, typically at least about 28 residues, and preferably more than about 35 residues. When searching a database containing sequences from a large number of
 20 different organisms, it is preferable to compare amino acid sequences.

Algorithms other than blastp for database searching using amino acid sequences are known in the art. For instance, polypeptide sequences can be compared using FASTA, a program in GCG Version 6.1. FASTA (*e.g.*, FASTA2 and FASTA3) provides alignments and percent sequence identity of the regions of the best overlap between the
 25 query and search sequences (Pearson (1990), *supra*; Pearson (2000), *supra*. For example, percent sequence identity between amino acid sequences can be determined using FASTA with its default or recommended parameters (a word size of 2 and the PAM250 scoring matrix), as provided in GCG Version 6.1.

An "antibody" refers to an intact immunoglobulin, or to an antigen-binding portion
 30 thereof that competes with the intact antibody for specific binding to a molecular species, *e.g.*, a polypeptide of the instant invention. Antigen-binding portions may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Antigen-binding portions include, *inter alia*, Fab, Fab', F(ab')₂, Fv, dAb, and

complementarity determining region (CDR) fragments, single-chain antibodies (scFv), chimeric antibodies, diabodies and polypeptides that contain at least a portion of an immunoglobulin that is sufficient to confer specific antigen binding to the polypeptide. A Fab fragment is a monovalent fragment consisting of the VL, VH, CL and CH1 domains; a F(ab')₂ fragment is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consists of the VH and CH1 domains; a Fv fragment consists of the VL and VH domains of a single arm of an antibody; and a dAb fragment consists of a VH domain. *See, e.g., Ward et al., Nature* 341: 544-546 (1989).

By "bind specifically" and "specific binding" as used herein it is meant the ability of the antibody to bind to a first molecular species in preference to binding to other molecular species with which the antibody and first molecular species are admixed. An antibody is said to "recognize" a first molecular species when it can bind specifically to that first molecular species.

A single-chain antibody (scFv) is an antibody in which VL and VH regions are paired to form a monovalent molecule via a synthetic linker that enables them to be made as a single protein chain. *See, e.g., Bird et al., Science* 242: 423-426 (1988); Huston et al., *Proc. Natl. Acad. Sci. USA* 85: 5879-5883 (1988). Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites. *See e.g., Holliger et al., Proc. Natl. Acad. Sci. USA* 90: 6444-6448 (1993); Poljak et al., *Structure* 2: 1121-1123 (1994). One or more CDRs may be incorporated into a molecule either covalently or noncovalently to make it an immunoadhesin. An immunoadhesin may incorporate the CDR(s) as part of a larger polypeptide chain, may covalently link the CDR(s) to another polypeptide chain, or may incorporate the CDR(s) noncovalently. The CDRs permit the immunoadhesin to specifically bind to a particular antigen of interest. A chimeric antibody is an antibody that contains one or more regions from one antibody and one or more regions from one or more other antibodies.

An antibody may have one or more binding sites. If there is more than one binding site, the binding sites may be identical to one another or may be different. For instance, a naturally occurring immunoglobulin has two identical binding sites, a single-chain

antibody or Fab fragment has one binding site, while a “bispecific” or “bifunctional” antibody has two different binding sites.

An “isolated antibody” is an antibody that (1) is not associated with naturally-associated components, including other naturally-associated antibodies, that accompany it in its native state, (2) is free of other proteins from the same species, (3) is expressed by a cell from a different species, or (4) does not occur in nature. It is known that purified proteins, including purified antibodies, may be stabilized with non-naturally-associated components. The non-naturally-associated component may be a protein, such as albumin (*e.g.*, BSA) or a chemical such as polyethylene glycol (PEG).

A “neutralizing antibody” or “an inhibitory antibody” is an antibody that inhibits the activity of a polypeptide or blocks the binding of a polypeptide to a ligand that normally binds to it. An “activating antibody” is an antibody that increases the activity of a polypeptide.

The term “epitope” includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics. An antibody is said to specifically bind an antigen when the dissociation constant is less than $1\ \mu\text{M}$, preferably less than $100\ \text{nM}$ and most preferably less than $10\ \text{nM}$.

The term “patient” includes human and veterinary subjects.

Throughout this specification and claims, the word “comprise,” or variations such as “comprises” or “comprising,” will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

The term “ovarian specific” refers to a nucleic acid molecule or polypeptide that is expressed predominantly in the ovarian as compared to other tissues in the body. In a preferred embodiment, a “ovarian specific” nucleic acid molecule or polypeptide is detected at a level that is 1.5-fold higher than any other tissue in the body. In a more preferred embodiment, the “ovarian specific” nucleic acid molecule or polypeptide is detected at a level that is 2-fold higher than any other tissue in the body, more preferably 5-fold higher, still more preferably at least 10-fold, 15-fold, 20-fold, 25-fold, 50-fold or 100-fold higher than any other tissue in the body. Nucleic acid molecule levels may be measured by nucleic acid hybridization, such as Northern blot hybridization, or

quantitative PCR. Polypeptide levels may be measured by any method known to accurately quantitate protein levels, such as Western blot analysis.

Nucleic Acid Molecules, Regulatory Sequences, Vectors, Host Cells and Recombinant Methods of Making Polypeptides

5 *Nucleic Acid Molecules*

One aspect of the invention provides isolated nucleic acid molecules that are specific to the ovarian or to ovarian cells or tissue or that are derived from such nucleic acid molecules. These isolated ovarian specific nucleic acids (OSNAs) may comprise cDNA genomic DNA, RNA, or a combination thereof, a fragment of one of these nucleic
10 acids, or may be a non-naturally occurring nucleic acid molecule. An OSNA may be derived from an animal. In a preferred embodiment, the OSNA is derived from a human or other mammal. In a more preferred embodiment, the OSNA is derived from a human or other primate. In an even more preferred embodiment, the OSNA is derived from a human.

15 In a preferred embodiment, the nucleic acid molecule encodes a polypeptide that is specific to ovarian, an ovarian-specific polypeptide (OSP). In a more preferred embodiment, the nucleic acid molecule encodes a polypeptide that comprises an amino acid sequence of SEQ ID NO: 129-295. In another highly preferred embodiment, the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO: 1-128.

20 Nucleotide sequences of the instantly-described nucleic acid molecules were determined by assembling several DNA molecules from either public or proprietary databases. Some of the underlying DNA sequences are the result, directly or indirectly, of at least one enzymatic polymerization reaction (*e.g.*, reverse transcription and/or polymerase chain reaction) using an automated sequencer (such as the MegaBACE™ 1000, Amersham
25 Biosciences, Sunnyvale, CA, USA).

Nucleic acid molecules of the present invention may also comprise sequences that selectively hybridize to a nucleic acid molecule encoding an OSNA or a complement or antisense thereof. The hybridizing nucleic acid molecule may or may not encode a polypeptide or may or may not encode an OSP. However, in a preferred embodiment, the
30 hybridizing nucleic acid molecule encodes an OSP. In a more preferred embodiment, the invention provides a nucleic acid molecule that selectively hybridizes to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule that encodes a polypeptide

comprising an amino acid sequence of SEQ ID NO: 129-295. In an even more preferred embodiment, the invention provides a nucleic acid molecule that selectively hybridizes to a nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO: 1-128 or the antisense sequence thereof. Preferably, the nucleic acid molecule selectively hybridizes to
5 a nucleic acid molecule or the antisense sequence of a nucleic acid molecule encoding an OSP under low stringency conditions. More preferably, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule encoding an OSP under moderate stringency conditions. Most preferably, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule or the antisense
10 sequence of a nucleic acid molecule encoding an OSP under high stringency conditions. In a preferred embodiment, the nucleic acid molecule hybridizes under low, moderate or high stringency conditions to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 129-295. In a more preferred embodiment, the nucleic acid molecule hybridizes
15 under low, moderate or high stringency conditions to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule comprising a nucleic acid sequence selected from SEQ ID NO: 1-128.

Nucleic acid molecules of the present invention may also comprise nucleic acid sequences that exhibit substantial sequence similarity to a nucleic acid encoding an OSP
20 or a complement of the encoding nucleic acid molecule. In this embodiment, it is preferred that the nucleic acid molecule exhibit substantial sequence similarity to a nucleic acid molecule encoding human OSP. More preferred is a nucleic acid molecule exhibiting substantial sequence similarity to a nucleic acid molecule encoding a polypeptide having an amino acid sequence of SEQ ID NO: 129-295. By substantial sequence similarity it is
25 meant a nucleic acid molecule having at least 60%, more preferably at least 70%, even more preferably at least 80% and even more preferably at least 85% sequence identity with a nucleic acid molecule encoding an OSP, such as a polypeptide having an amino acid sequence of SEQ ID NO: 129-295. In a more preferred embodiment, the similar nucleic acid molecule is one that has at least 90%, more preferably at least 95%, more
30 preferably at least 97%, even more preferably at least 98%, and still more preferably at least 99% sequence identity with a nucleic acid molecule encoding an OSP. Most preferred in this embodiment is a nucleic acid molecule that has at least 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with a nucleic acid molecule encoding an OSP.

The nucleic acid molecules of the present invention are also inclusive of those exhibiting substantial sequence similarity to an OSNA or its complement. In this embodiment, it is preferred that the nucleic acid molecule exhibit substantial sequence similarity to a nucleic acid molecule having a nucleic acid sequence of SEQ ID NO: 1-128. By substantial sequence similarity it is meant a nucleic acid molecule that has at least 60%, more preferably at least 70%, even more preferably at least 80% and even more preferably at least 85% sequence identity with an OSNA, such as one having a nucleic acid sequence of SEQ ID NO: 1-128. More preferred is a nucleic acid molecule that has at least 90%, more preferably at least 95%, more preferably at least 97%, even more preferably at least 98%, and still more preferably at least 99% sequence identity with an OSNA. Most preferred is a nucleic acid molecule that has at least 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with an OSNA.

Nucleic acid molecules that exhibit substantial sequence similarity are inclusive of sequences that exhibit sequence identity over their entire length to an OSNA or to a nucleic acid molecule encoding an OSP, as well as sequences that are similar over only a part of its length. In this case, the part is at least 50 nucleotides of the OSNA or the nucleic acid molecule encoding an OSP, preferably at least 100 nucleotides, more preferably at least 150 or 200 nucleotides, even more preferably at least 250 or 300 nucleotides, still more preferably at least 400 or 500 nucleotides.

The substantially similar nucleic acid molecule may be a naturally occurring one that is derived from another species, especially one derived from another primate, wherein the similar nucleic acid molecule encodes an amino acid sequence that exhibits significant sequence identity to that of SEQ ID NO: 129-295 or demonstrates significant sequence identity to the nucleotide sequence of SEQ ID NO: 1-128. The similar nucleic acid molecule may also be a naturally occurring nucleic acid molecule from a human, when the OSNA is a member of a gene family. The similar nucleic acid molecule may also be a naturally occurring nucleic acid molecule derived from a non-primate, mammalian species, including without limitation, domesticated species, *e.g.*, dog, cat, mouse, rat, rabbit, hamster, cow, horse and pig; and wild animals, *e.g.*, monkey, fox, lions, tigers, bears, giraffes, zebras, etc. The substantially similar nucleic acid molecule may also be a naturally occurring nucleic acid molecule derived from a non-mammalian species, such as birds or reptiles. The naturally occurring substantially similar nucleic acid molecule may be isolated directly from humans or other species. In another embodiment, the

substantially similar nucleic acid molecule may be one that is experimentally produced by random mutation of a nucleic acid molecule. In another embodiment, the substantially similar nucleic acid molecule may be one that is experimentally produced by directed mutation of an OSNA. In a preferred embodiment, the substantially similar nucleic acid molecule is an OSNA.

The nucleic acid molecules of the present invention are also inclusive of allelic variants of an OSNA or a nucleic acid encoding an OSP. For example, single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes and the sequence determined from one individual of a species may differ from other allelic forms present within the population. More than 1.4 million SNPs have already been identified in the human genome, International Human Genome Sequencing Consortium, *Nature* 409: 860-921 (2001) – Variants with small deletions and insertions of more than a single nucleotide are also found in the general population, and often do not alter the function of the protein. In addition, amino acid substitutions occur frequently among natural allelic variants, and often do not substantially change protein function.

In a preferred embodiment, the allelic variant is a variant of a gene, wherein the gene is transcribed into a mRNA that encodes an OSP. In a more preferred embodiment, the gene is transcribed into a mRNA that encodes an OSP comprising an amino acid sequence of SEQ ID NO: 129-295. In another preferred embodiment, the allelic variant is a variant of a gene, wherein the gene is transcribed into a mRNA that is an OSNA. In a more preferred embodiment, the gene is transcribed into a mRNA that comprises the nucleic acid sequence of SEQ ID NO: 1-128. Also preferred is that the allelic variant be a naturally occurring allelic variant in the species of interest, particularly human.

Nucleic acid molecules of the present invention are also inclusive of nucleic acid sequences comprising a part of a nucleic acid sequence of the instant invention. The part may or may not encode a polypeptide, and may or may not encode a polypeptide that is an OSP. In a preferred embodiment, the part encodes an OSP. In one embodiment, the nucleic acid molecule comprises a part of an OSNA. In another embodiment, the nucleic acid molecule comprises a part of a nucleic acid molecule that hybridizes or exhibits substantial sequence similarity to an OSNA. In another embodiment, the nucleic acid molecule comprises a part of a nucleic acid molecule that is an allelic variant of an OSNA. In yet another embodiment, the nucleic acid molecule comprises a part of a nucleic acid molecule that encodes an OSP. A part comprises at least 10 nucleotides, more preferably

at least 15, 17, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400 or 500 nucleotides. The maximum size of a nucleic acid part is one nucleotide shorter than the sequence of the nucleic acid molecule encoding the full-length protein.

5 Nucleic acid molecules of the present invention are also inclusive of nucleic acid sequences that encode fusion proteins, homologous proteins, polypeptide fragments, muteins and polypeptide analogs, as described *infra*.

10 Nucleic acid molecules of the present invention are also inclusive of nucleic acid sequences containing modifications of the native nucleic acid molecule. Examples of such modifications include, but are not limited to, nonnative internucleoside bonds, post-synthetic modifications or altered nucleotide analogues. One having ordinary skill in the art would recognize that the type of modification that may be made will depend upon the intended use of the nucleic acid molecule. For instance, when the nucleic acid molecule is used as a hybridization probe, the range of such modifications will be limited to those that permit sequence-discriminating base pairing of the resulting nucleic acid. When used to
15 direct expression of RNA or protein *in vitro* or *in vivo*, the range of such modifications will be limited to those that permit the nucleic acid to function properly as a polymerization substrate. When the isolated nucleic acid is used as a therapeutic agent, the modifications will be limited to those that do not confer toxicity upon the isolated nucleic acid.

20 Accordingly, in one embodiment, a nucleic acid molecule may include nucleotide analogues that incorporate labels that are directly detectable, such as radiolabels or fluorophores, or nucleotide analogues that incorporate labels that can be visualized in a subsequent reaction, such as biotin or various haptens. The labeled nucleic acid molecules are particularly useful as hybridization probes.

25 Common radiolabeled analogues include those labeled with ^{33}P , ^{32}P , and ^{35}S , such as α - ^{32}P -dATP, α - ^{32}P -dCTP, α - ^{32}P -dGTP, α - ^{32}P -dTTP, α - ^{32}P -3'dATP, α - ^{32}P -ATP, α - ^{32}P -CTP, α - ^{32}P -GTP, α - ^{32}P -UTP, α - ^{35}S -dATP, γ - ^{35}S -GTP, γ - ^{33}P -dATP, and the like.

30 Commercially available fluorescent nucleotide analogues readily incorporated into the nucleic acids of the present invention include Cy3-dCTP, Cy3-dUTP, Cy5-dCTP, Cy3-dUTP (Amersham Biosciences, Piscataway, New Jersey, USA), fluorescein-12-dUTP, tetramethylrhodamine-6-dUTP, Texas Red®-5-dUTP, Cascade Blue®-7-dUTP, BODIPY® FL-14-dUTP, BODIPY® TMR-14-dUTP, BODIPY® TR-14-dUTP, Rhodamine Green™-5-dUTP, Oregon Green® 488-5-dUTP, Texas Red®-12-dUTP,

BODIPY® 630/650-14-dUTP, BODIPY® 650/665-14-dUTP, Alexa Fluor® 488-5-dUTP, Alexa Fluor® 532-5-dUTP, Alexa Fluor® 568-5-dUTP, Alexa Fluor® 594-5-dUTP, Alexa Fluor® 546-14-dUTP, fluorescein-12-UTP, tetramethylrhodamine-6-UTP, Texas Red®-5-UTP, Cascade Blue®-7-UTP, BODIPY® FL-14-UTP, BODIPY® TMR-14-UTP, 5 BODIPY® TR-14-UTP, Rhodamine Green™-5-UTP, Alexa Fluor® 488-5-UTP, Alexa Fluor® 546-14-UTP (Molecular Probes, Inc. Eugene, OR, USA). One may also custom synthesize nucleotides having other fluorophores. *See Henegariu et al., Nature Biotechnol.* 18: 345-348 (2000).

Haptens that are commonly conjugated to nucleotides for subsequent labeling 10 include biotin (biotin-11-dUTP, Molecular Probes, Inc., Eugene, OR, USA; biotin-21-UTP, biotin-21-dUTP, Clontech Laboratories, Inc., Palo Alto, CA, USA), digoxigenin (DIG-11-dUTP, alkali labile, DIG-11-UTP, Roche Diagnostics Corp., Indianapolis, IN, USA), and dinitrophenyl (dinitrophenyl-11-dUTP, Molecular Probes, Inc., Eugene, OR, USA).

15 Nucleic acid molecules of the present invention can be labeled by incorporation of labeled nucleotide analogues into the nucleic acid. Such analogues can be incorporated by enzymatic polymerization, such as by nick translation, random priming, polymerase chain reaction (PCR), terminal transferase tailing, and end-filling of overhangs, for DNA 20 molecules, and *in vitro* transcription driven, *e.g.*, from phage promoters, such as T7, T3, and SP6, for RNA molecules. Commercial kits are readily available for each such labeling approach. Analogues can also be incorporated during automated solid phase chemical synthesis. Labels can also be incorporated after nucleic acid synthesis, with the 5' phosphate and 3' hydroxyl providing convenient sites for post-synthetic covalent attachment of detectable labels.

25 Other post-synthetic approaches also permit internal labeling of nucleic acids. For example, fluorophores can be attached using a cisplatin reagent that reacts with the N7 of guanine residues (and, to a lesser extent, adenine bases) in DNA, RNA, and Peptide Nucleic Acids (PNA) to provide a stable coordination complex between the nucleic acid and fluorophore label (Universal Linkage System) (available from Molecular Probes, Inc., 30 Eugene, OR, USA and Amersham Pharmacia Biotech, Piscataway, NJ, USA); *see Alers et al., Genes, Chromosomes & Cancer* 25: 301- 305 (1999); Jelsma *et al.*, *J. NIH Res.* 5: 82 (1994); Van Belkum *et al.*, *BioTechniques* 16: 148-153 (1994). Alternatively, nucleic acids can be labeled using a disulfide-containing linker (FastTag™ Reagent, Vector

Laboratories, Inc., Burlingame, CA, USA) that is photo- or thermally coupled to the target nucleic acid using aryl azide chemistry; after reduction, a free thiol is available for coupling to a hapten, fluorophore, sugar, affinity ligand, or other marker.

One or more independent or interacting labels can be incorporated into the nucleic acid molecules of the present invention. For example, both a fluorophore and a moiety that in proximity thereto acts to quench fluorescence can be included to report specific hybridization through release of fluorescence quenching or to report exonucleotidic excision. *See, e.g.,* Tyagi *et al.*, *Nature Biotechnol.* 14: 303-308 (1996); Tyagi *et al.*, *Nature Biotechnol.* 16: 49-53 (1998); Sokol *et al.*, *Proc. Natl. Acad. Sci. USA* 95: 11538-11543 (1998); Kostrikis *et al.*, *Science* 279: 1228-1229 (1998); Marras *et al.*, *Genet. Anal.* 14: 151-156 (1999); Holland *et al.*, *Proc. Natl. Acad. Sci. USA* 88: 7276-7280 (1991); Heid *et al.*, *Genome Res.* 6(10): 986-94 (1996); Kuimelis *et al.*, *Nucleic Acids Symp. Ser.* (37): 255-6 (1997); and U.S. Patent Nos. 5,846,726, 5,925,517, 5,925,517, 5,723,591 and 5,538,848, the disclosures of which are incorporated herein by reference in their entirety.

Nucleic acid molecules of the present invention may also be modified by altering one or more native phosphodiester internucleoside bonds to more nuclease-resistant, internucleoside bonds. *See* Hartmann *et al.* (eds.), Manual of Antisense Methodology: Perspectives in Antisense Science, Kluwer Law International (1999); Stein *et al.* (eds.), Applied Antisense Oligonucleotide Technology, Wiley-Liss (1998); Chadwick *et al.* (eds.), Oligonucleotides as Therapeutic Agents – Symposium No. 209, John Wiley & Son Ltd (1997). Such altered internucleoside bonds are often desired for techniques or for targeted gene correction, Gamper *et al.*, *Nucl. Acids Res.* 28(21): 4332-4339 (2000). For double-stranded RNA inhibition which may utilize either natural ds RNA or ds RNA modified in its, sugar, phosphate or base, *see* Hannon, *Nature* 418(11): 244-251 (2002); Fire *et al.* in WO 99/32619; Tuschl *et al.* in US2002/0086356; Kruetzer *et al.* in WO 00/44895, the disclosures of which are incorporated herein by reference in their entirety. For circular antisense, *see* Kool in U.S. Patent No. 5,426,180, the disclosure of which is incorporated herein by reference in its entirety.

Modified oligonucleotide backbones include, without limitation, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including

3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'.

5 Representative U.S. Patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Patent Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, the disclosures of
10 which are incorporated herein by reference in their entireties. In a preferred embodiment, the modified internucleoside linkages may be used for antisense techniques.

Other modified oligonucleotide backbones do not include a phosphorus atom, but have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or
15 more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino
20 backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts. Representative U.S. patents that teach the preparation of the above backbones include, but are not limited to, U.S. Patent Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086;
25 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437 and 5,677,439; the disclosures of which are incorporated herein by reference in their entireties.

In other preferred nucleic acid molecules, both the sugar and the internucleoside linkage are replaced with novel groups, such as peptide nucleic acids (PNA). In PNA
30 compounds, the phosphodiester backbone of the nucleic acid is replaced with an amide-containing backbone, in particular by repeating N-(2-aminoethyl) glycine units linked by amide bonds. Nucleobases are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone, typically by methylene carbonyl linkages. PNA can be

synthesized using a modified peptide synthesis protocol. PNA oligomers can be synthesized by both Fmoc and tBoc methods. Representative U.S. patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Patent Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference in its entirety. Automated PNA synthesis is readily achievable on commercial synthesizers (see, e.g., "PNA User's Guide," Rev. 2, February 1998, Perseptive Biosystems Part No. 60138, Applied Biosystems, Inc., Foster City, CA). PNA molecules are advantageous for a number of reasons. First, because the PNA backbone is uncharged, PNA/DNA and PNA/RNA duplexes have a higher thermal stability than is found in DNA/DNA and DNA/RNA duplexes. The T_m of a PNA/DNA or PNA/RNA duplex is generally 1°C higher per base pair than the T_m of the corresponding DNA/DNA or DNA/RNA duplex (in 100 mM NaCl). Second, PNA molecules can also form stable PNA/DNA complexes at low ionic strength, under conditions in which DNA/DNA duplex formation does not occur. Third, PNA also demonstrates greater specificity in binding to complementary DNA because a PNA/DNA mismatch is more destabilizing than DNA/DNA mismatch. A single mismatch in mixed a PNA/DNA 15-mer lowers the T_m by 8–20°C (15°C on average). In the corresponding DNA/DNA duplexes, a single mismatch lowers the T_m by 4–16°C (11°C on average). Because PNA probes can be significantly shorter than DNA probes, their specificity is greater. Fourth, PNA oligomers are resistant to degradation by enzymes, and the lifetime of these compounds is extended both *in vivo* and *in vitro* because nucleases and proteases do not recognize the PNA polyamide backbone with nucleobase sidechains. See, e.g., Ray *et al.*, *FASEB J.* 14(9): 1041-60 (2000); Nielsen *et al.*, *Pharmacol Toxicol.* 86(1): 3-7 (2000); Larsen *et al.*, *Biochim Biophys Acta.* 1489(1): 159-66 (1999); Nielsen, *Curr. Opin. Struct. Biol.* 9(3): 353-7 (1999), and Nielsen, *Curr. Opin. Biotechnol.* 10(1): 71-5 (1999).

Nucleic acid molecules may be modified compared to their native structure throughout the length of the nucleic acid molecule or can be localized to discrete portions thereof. As an example of the latter, chimeric nucleic acids can be synthesized that have discrete DNA and RNA domains and that can be used for targeted gene repair and modified PCR reactions, as further described in, Misra *et al.*, *Biochem.* 37: 1917-1925 (1998); and Finn *et al.*, *Nucl. Acids Res.* 24: 3357-3363 (1996), and U.S. Patent Nos. 5,760,012 and 5,731,181, the disclosures of which are incorporated herein by reference in their entireties.

Unless otherwise specified, nucleic acid molecules of the present invention can include any topological conformation appropriate to the desired use; the term thus explicitly comprehends, among others, single-stranded, double-stranded, triplexed, quadruplexed, partially double-stranded, partially-triplexed, partially-quadruplexed, 5 branched, hairpinned, circular, and padlocked conformations. Padlocked conformations and their utilities are further described in Banér *et al.*, *Curr. Opin. Biotechnol.* 12: 11-15 (2001); Escude *et al.*, *Proc. Natl. Acad. Sci. USA* 14: 96(19):10603-7 (1999); and Nilsson *et al.*, *Science* 265(5181): 2085-8 (1994). Triplexed and quadruplexed conformations, and their utilities, are reviewed in Praseuth *et al.*, *Biochim. Biophys. Acta.* 1489(1): 181-206 10 (1999); Fox, *Curr. Med. Chem.* 7(1): 17-37 (2000); Kochetkova *et al.*, *Methods Mol. Biol.* 130: 189-201 (2000); Chan *et al.*, *J. Mol. Med.* 75(4): 267-82 (1997); Rowley *et al.*, *Mol Med* 5(10): 693-700 (1999); Kool, *Annu Rev Biophys Biomol Struct.* 25: 1-28 (1996).

SNP Polymorphisms

Commonly, sequence differences between individuals involve differences in single 15 nucleotide positions. SNPs may account for 90% of human DNA polymorphism. Collins *et al.*, 8 *Genome Res.* 1229-31 (1998). SNPs include single base pair positions in genomic DNA at which different sequence alternatives (alleles) exist in a population. In addition, the least frequent allele generally must occur at a frequency of 1% or greater. DNA sequence variants with a reasonably high population frequency are observed 20 approximately every 1,000 nucleotide across the genome, with estimates as high as 1 SNP per 350 base pairs. Wang *et al.*, 280 *Science* 1077-82 (1998); Harding *et al.*, 60 *Am. J. Human Genet.* 772-89 (1997); Taillon-Miller *et al.*, 8 *Genome Res.* 748-54 (1998); Cargill *et al.*, 22 *Nat. Genet.* 231-38 (1999); and Semple *et al.*, 16 *Bioinform. Disc. Note* 735-38 (2000). The frequency of SNPs varies with the type and location of the change. In base 25 substitutions, two-thirds of the substitutions involve the C-T and G-A type. This variation in frequency can be related to 5-methylcytosine deamination reactions that occur frequently, particularly at CpG dinucleotides. Regarding location, SNPs occur at a much higher frequency in non-coding regions than in coding regions. Information on over one million variable sequences is already publicly available via the Internet and more such 30 markers are available from commercial providers of genetic information. Kwok and Gu, 5 *Med. Today* 538-53 (1999).

Several definitions of SNPs exist. See, e.g., Brooks, 235 *Gene* 177-86 (1999). As used herein, the term "single nucleotide polymorphism" or "SNP" includes all single base variants, thus including nucleotide insertions and deletions in addition to single nucleotide substitutions. There are two types of nucleotide substitutions. A transition is the replacement of one purine by another purine or one pyrimidine by another pyrimidine. A transversion is the replacement of a purine for a pyrimidine, or vice versa.

Numerous methods exist for detecting SNPs within a nucleotide sequence. A review of many of these methods can be found in Landegren *et al.*, 8 *Genome Res.* 769-76 (1998). For example, a SNP in a genomic sample can be detected by preparing a Reduced Complexity Genome (RCG) from the genomic sample, then analyzing the RCG for the presence or absence of a SNP. See, e.g., WO 00/18960 which is herein incorporated by reference in its entirety. Multiple SNPs in a population of target polynucleotides in parallel can be detected using, for example, the methods of WO 00/50869 which is herein incorporated by reference in its entirety. Other SNP detection methods include the methods of U.S. Pat. Nos. 6,297,018 and 6,322,980 which are herein incorporated by reference in their entirety. Furthermore, SNPs can be detected by restriction fragment length polymorphism (RFLP) analysis. See, e.g., U.S. Pat. Nos. 5,324,631; 5,645,995 which are herein incorporated by reference in their entirety. RFLP analysis of SNPs, however, is limited to cases where the SNP either creates or destroys a restriction enzyme cleavage site. SNPs can also be detected by direct sequencing of the nucleotide sequence of interest. In addition, numerous assays based on hybridization have also been developed to detect SNPs and mismatch distinction by polymerases and ligases. Several web sites provide information about SNPs including Ensembl on the World Wide Web at ensemble.org, Sanger Institute on the World Wide Web at sanger.ac.uk/genetics/exon/, National Center for Biotechnology Information (NCBI) on the World Wide Web at ncbi.nlm.nih.gov/SNP/, The SNP Consortium Ltd. on the World Wide Web at snp.cshl.org. The chromosomal locations for the compositions disclosed herein are provided below. In addition, one of ordinary skill in the art could use a BLAST against the genome or any of the databases cited above to find the chromosomal location. Another a preferred method to find the genomic coordinates and associated SNPs would be to use the BLAT tool (genome.ucsc.edu, Kent et al. 2001, The Human Genome Browser at UCSC, Genome Research 996-1006 or Kent 2002 BLAT —The BLAST -Like

Alignment Tool Genome Research, 1-9). All web sites above were accessed December 3, 2003.

RNA interference

RNA interference refers to the process of sequence-specific post transcriptional
5 gene silencing in animals mediated by short interfering RNAs (siRNA). Fire *et al.*, 1998, *Nature*, 391, 806. The corresponding process in plants is commonly referred to as post transcriptional gene silencing or RNA silencing and is also referred to as quelling in fungi. The process of post transcriptional gene silencing is thought to be an evolutionarily conserved cellular defense mechanism used to prevent the expression of foreign genes
10 which is commonly shared by diverse flora and phyla. Fire *et al.*, 1999, *Trends Genet.*, 15, 358. Such protection from foreign gene expression may have evolved in response to the production of double-stranded RNAs (dsRNA) derived from viral infection or the random integration of transposon elements into a host genome via a cellular response that specifically destroys homologous single-stranded RNA or viral genomic RNA. The
15 presence of dsRNA in cells triggers the RNAi response though a mechanism that has yet to be fully characterized. This mechanism appears to be different from the interferon response that results from dsRNA mediated activation of protein kinase PKR and 2',5'-oligoadenylate synthetase resulting in non-specific cleavage of mRNA by ribonuclease L.

The presence of long dsRNAs in cells stimulates the activity of a ribonuclease III
20 enzyme referred to as dicer. Dicer is involved in the processing of the dsRNA into short pieces of dsRNA known as short interfering RNAs (siRNA). Bernstein *et al.*, 2001, *Nature*, 409, 363. Short interfering RNAs derived from dicer activity are typically about 21-23 nucleotides in length and comprise about 19 base pair duplexes. Dicer has also been implicated in the excision of 21 and 22 nucleotide small temporal RNAs (stRNA) from
25 precursor RNA of conserved structure that are implicated in translational control. Hutvagner *et al.*, 2001, *Science*, 293, 834. The RNAi response also features an endonuclease complex containing a siRNA, commonly referred to as an RNA-induced silencing complex (RISC), which mediates cleavage of single-stranded RNA having sequence complementary to the antisense strand of the siRNA duplex. Cleavage of the
30 target RNA takes place in the middle of the region complementary to the antisense strand of the siRNA duplex. Elbashir *et al.*, 2001, *Genes Dev.*, 15, 188.

Short interfering RNA mediated RNAi has been studied in a variety of systems. Fire *et al.*, 1998, *Nature*, 391, 806, were the first to observe RNAi in *C. Elegans*. Wianny and Goetz, 1999, *Nature Cell Biol.*, 2, 70, describe RNAi mediated by dsRNA in mouse embryos. Hammond *et al.*, 2000, *Nature*, 404, 293, describe RNAi in *Drosophila* cells
5 transfected with dsRNA. Elbashir *et al.*, 2001, *Nature*, 411, 494, describe RNAi induced by introduction of duplexes of synthetic 21-nucleotide RNAs in cultured mammalian cells including human embryonic kidney and HeLa cells. Recent work in *Drosophila* embryonic lysates (Elbashir *et al.*, 2001, *EMBO J.*, 20, 6877) has revealed certain requirements for
10 siRNA length, structure, chemical composition, and sequence that are essential to mediate efficient RNAi activity. These studies have shown that 21 nucleotide siRNA duplexes are most active when containing two nucleotide 3'-overhangs. Furthermore, complete substitution of one or both siRNA strands with 2'-deoxy (2'-H) or 2'-O-methyl nucleotides abolishes RNAi activity, whereas substitution of the 3'-terminal siRNA overhang
nucleotides with deoxy nucleotides (2'-H) was shown to be tolerated. Single mismatch
15 sequences in the center of the siRNA duplex were also shown to abolish RNAi activity. In addition, these studies also indicate that the position of the cleavage site in the target RNA is defined by the 5'-end of the siRNA guide sequence rather than the 3'-end. Elbashir *et al.*, 2001, *EMBO J.*, 20, 6877. Other studies have indicated that a 5'-phosphate on the target-complementary strand of a siRNA duplex is required for siRNA activity and that
20 ATP is utilized to maintain the 5'-phosphate moiety on the siRNA. Nykanen *et al.*, 2001, *Cell*, 107, 309.

Studies have shown that replacing the 3'-overhanging segments of a 21-mer siRNA duplex having 2 nucleotide 3' overhangs with deoxyribonucleotides does not have an adverse effect on RNAi activity. Replacing up to 4 nucleotides on each end of the siRNA
25 with deoxyribonucleotides has been reported to be well tolerated whereas complete substitution with deoxyribonucleotides results in no RNAi activity. Elbashir *et al.*, 2001, *EMBO J.*, 20, 6877. In addition, Elbashir *et al.*, *supra*, also report that substitution of siRNA with 2'-O-methyl nucleotides completely abolishes RNAi activity. Li *et al.*, WO 00/44914, and Beach *et al.*, WO 01/68836 both suggest that siRNA "may include
30 modifications to either the phosphate-sugar back bone or the nucleoside to include at least one of a nitrogen or sulfur heteroatom", however neither application teaches to what extent these modifications are tolerated in siRNA molecules nor provides any examples of such modified siRNA. Kreutzer and Limmer, Canadian Patent Application No. 2,359,180, also

describe certain chemical modifications for use in dsRNA constructs in order to counteract activation of double-stranded RNA-dependent protein kinase PKR, specifically 2'-amino or 2'-O-methyl nucleotides, and nucleotides containing a 2'-O or 4'-C methylene bridge. However, Kreutzer and Limmer similarly fail to show to what extent these modifications are tolerated in siRNA molecules nor do they provide any examples of such modified siRNA.

Parrish et al., 2000, *Molecular Cell*, 6, 1977-1087, tested certain chemical modifications targeting the unc-22 gene in *C. elegans* using long (>25 nt) siRNA transcripts. The authors describe the introduction of thiophosphate residues into these siRNA transcripts by incorporating thiophosphate nucleotide analogs with T7 and T3 RNA polymerase and observed that "RNAs with two [phosphorothioate] modified bases also had substantial decreases in effectiveness as RNAi triggers; [phosphorothioate] modification of more than two residues greatly destabilized the RNAs in vitro and we were not able to assay interference activities." Parrish et al. at 1081. The authors also tested certain modifications at the 2'-position of the nucleotide sugar in the long siRNA transcripts and observed that substituting deoxynucleotides for ribonucleotides "produced a substantial decrease in interference activity", especially in the case of Uridine to Thymidine and/or Cytidine to deoxy-Cytidine substitutions. Parrish et al. In addition, the authors tested certain base modifications, including substituting 4-thiouracil, 5-bromouracil, 5-iodouracil, 3-(aminoallyl)uracil for uracil, and inosine for guanosine in sense and antisense strands of the siRNA, and found that whereas 4-thiouracil and 5-bromouracil were all well tolerated, inosine "produced a substantial decrease in interference activity" when incorporated in either strand. Incorporation of 5-iodouracil and 3-(aminoallyl)uracil in the antisense strand resulted in substantial decrease in RNAi activity as well.

Beach et al., WO 01/68836, describes specific methods for attenuating gene expression using endogenously derived dsRNA. Tuschl et al., WO 01/75164, describes a *Drosophila* in vitro RNAi system and the use of specific siRNA molecules for certain functional genomic and certain therapeutic applications; although Tuschl, 2001, *Chem. Biochem.*, 2, 239-245, doubts that RNAi can be used to cure genetic diseases or viral infection due "to the danger of activating interferon response". Li et al., WO 00/44914, describes the use of specific dsRNAs for use in attenuating the expression of certain target

genes. Zernicka-Goetz et al., WO 01/36646, describes certain methods for inhibiting the expression of particular genes in mammalian cells using certain dsRNA molecules. Fire et al., WO 99/32619, U.S. Patent No. 6,506,559, the contents of which are hereby incorporated by reference in their entirety, describes particular methods for introducing
5 certain dsRNA molecules into cells for use in inhibiting gene expression. Plaetinck et al., WO 00/01846, describes certain methods for identifying specific genes responsible for conferring a particular phenotype in a cell using specific dsRNA molecules. Mello et al., WO 01/29058, describes the identification of specific genes involved in dsRNA mediated RNAi. Deschamps Depaillette et al., International PCT Publication No. WO 99/07409,
10 describes specific compositions consisting of particular dsRNA molecules combined with certain anti-viral agents. Driscoll et al., International PCT Publication No. WO 01/49844, describes specific DNA constructs for use in facilitating gene silencing in targeted organisms. Parrish et al., 2000, Molecular Cell, 6, 1977-1087, describes specific chemically modified siRNA constructs targeting the unc-22 gene of *C. elegans*. Tuschl et al.,
15 International PCT Publication No. WO 02/44321, describe certain synthetic siRNA constructs.

Methods for Using Nucleic Acid Molecules as Probes and Primers

The isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize, and quantify hybridizing nucleic acids in, and
20 isolate hybridizing nucleic acids from, both genomic and transcript-derived nucleic acid samples. When free in solution, such probes are typically, but not invariably, detectably labeled; bound to a substrate, as in a microarray, such probes are typically, but not invariably unlabeled.

In one embodiment, the isolated nucleic acid molecules of the present invention
25 can be used as probes to detect and characterize gross alterations in the gene of an OSNA, such as deletions, insertions, translocations, and duplications of the OSNA genomic locus through fluorescence *in situ* hybridization (FISH) to chromosome spreads. See, e.g., Andreeff et al. (eds.), Introduction to Fluorescence In Situ Hybridization: Principles and Clinical Applications, John Wiley & Sons (1999). The isolated nucleic acid molecules of
30 the present invention can be used as probes to assess smaller genomic alterations using, e.g., Southern blot detection of restriction fragment length polymorphisms. The isolated nucleic acid molecules of the present invention can be used as probes to isolate genomic

clones that include a nucleic acid molecule of the present invention, which thereafter can be restriction mapped and sequenced to identify deletions, insertions, translocations, and substitutions (single nucleotide polymorphisms, SNPs) at the sequence level.

Alternatively, detection techniques such as molecular beacons may be used, see Kostrikis
5 *et al. Science* 279:1228-1229 (1998).

The isolated nucleic acid molecules of the present invention can also be used as probes to detect, characterize, and quantify OSNA in, and isolate OSNA from, transcript-derived nucleic acid samples. In one embodiment, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize by length,
10 and quantify mRNA by Northern blot of total or poly-A⁺- selected RNA samples. In another embodiment, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize by location, and quantify mRNA by *in situ* hybridization to tissue sections. *See, e.g.,* Schwarchzacher *et al.*, In Situ Hybridization, Springer-Verlag New York (2000). In another preferred embodiment, the
15 isolated nucleic acid molecules of the present invention can be used as hybridization probes to measure the representation of clones in a cDNA library or to isolate hybridizing nucleic acid molecules acids from cDNA libraries, permitting sequence level characterization of mRNAs that hybridize to OSNAs, including, without limitations, identification of deletions, insertions, substitutions, truncations, alternatively spliced forms
20 and single nucleotide polymorphisms. In yet another preferred embodiment, the nucleic acid molecules of the instant invention may be used in microarrays.

All of the aforementioned probe techniques are well within the skill in the art, and are described at greater length in standard texts such as Sambrook (2001), *supra*; Ausubel (1999), *supra*; and Walker *et al.* (eds.), The Nucleic Acids Protocols Handbook, Humana
25 Press (2000).

In another embodiment, a nucleic acid molecule of the invention may be used as a probe or primer to identify and/or amplify a second nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of the invention. In this embodiment, it is preferred that the probe or primer be derived from a nucleic acid molecule encoding an
30 OSP. More preferably, the probe or primer is derived from a nucleic acid molecule encoding a polypeptide having an amino acid sequence of SEQ ID NO: 129-295. Also preferred are probes or primers derived from an OSNA. More preferred are probes or

primers derived from a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-128.

In general, a probe or primer is at least 10 nucleotides in length, more preferably at least 12, more preferably at least 14 and even more preferably at least 16 or 17 nucleotides in length. In an even more preferred embodiment, the probe or primer is at least 18 nucleotides in length, even more preferably at least 20 nucleotides and even more preferably at least 22 nucleotides in length. Primers and probes may also be longer in length. For instance, a probe or primer may be 25 nucleotides in length, or may be 30, 40 or 50 nucleotides in length. Methods of performing nucleic acid hybridization using oligonucleotide probes are well known in the art. *See, e.g.,* Sambrook *et al.*, 1989, *supra*, Chapter 11 and pp. 11.31-11.32 and 11.40-11.44, which describes radiolabeling of short probes, and pp. 11.45-11.53, which describe hybridization conditions for oligonucleotide probes, including specific conditions for probe hybridization (pp. 11.50-11.51).

Methods of performing primer-directed amplification are also well known in the art. Methods for performing the polymerase chain reaction (PCR) are compiled, *inter alia*, in McPherson, PCR Basics: From Background to Bench, Springer Verlag (2000); Innis *et al.* (eds.), PCR Applications: Protocols for Functional Genomics, Academic Press (1999); Gelfand *et al.* (eds.), PCR Strategies, Academic Press (1998); Newton *et al.*, PCR, Springer-Verlag New York (1997); Burke (ed.), PCR: Essential Techniques, John Wiley & Son Ltd (1996); White (ed.), PCR Cloning Protocols: From Molecular Cloning to Genetic Engineering, Vol. 67, Humana Press (1996); and McPherson *et al.* (eds.), PCR 2: A Practical Approach, Oxford University Press, Inc. (1995). Methods for performing RT-PCR are collected, *e.g.*, in Siebert *et al.* (eds.), Gene Cloning and Analysis by RT-PCR, Eaton Publishing Company/Bio Techniques Books Division, 1998; and Siebert (ed.), PCR Technique: RT-PCR, Eaton Publishing Company/ BioTechniques Books (1995).

PCR and hybridization methods may be used to identify and/or isolate nucleic acid molecules of the present invention including allelic variants, homologous nucleic acid molecules and fragments. PCR and hybridization methods may also be used to identify, amplify and/or isolate nucleic acid molecules of the present invention that encode homologous proteins, analogs, fusion proteins or muteins of the invention. Nucleic acid primers as described herein can be used to prime amplification of nucleic acid molecules of the invention, using transcript-derived or genomic DNA as the template.

These nucleic acid primers can also be used, for example, to prime single base extension (SBE) for SNP detection (*See, e.g.*, U.S. Pat. No. 6,004,744, the disclosure of which is incorporated herein by reference in its entirety).

Isothermal amplification approaches, such as rolling circle amplification, are also
5 now well-described. *See, e.g.*, Schweitzer *et al.*, *Curr. Opin. Biotechnol.* 12(1): 21-7
(2001); International Patent publications WO 97/19193 and WO 00/15779, and U.S.
Patent Nos. 5,854,033 and 5,714,320, the disclosures of which are incorporated herein by
reference in their entireties. Rolling circle amplification can be combined with other
techniques to facilitate SNP detection. *See, e.g.*, Lizardi *et al.*, *Nature Genet.* 19(3):
10 225-32 (1998).

Nucleic acid molecules of the present invention may be bound to a substrate either
covalently or noncovalently. The substrate can be porous or solid, planar or non-planar,
unitary or distributed. The bound nucleic acid molecules may be used as hybridization
probes, and may be labeled or unlabeled. In a preferred embodiment, the bound nucleic
15 acid molecules are unlabeled.

In one embodiment, the nucleic acid molecule of the present invention is bound to
a porous substrate, *e.g.*, a membrane, typically comprising nitrocellulose, nylon, or
positively charged derivatized nylon. The nucleic acid molecule of the present invention
can be used to detect a hybridizing nucleic acid molecule that is present within a labeled
20 nucleic acid sample, *e.g.*, a sample of transcript-derived nucleic acids. In another
embodiment, the nucleic acid molecule is bound to a solid substrate, including, without
limitation, glass, amorphous silicon, crystalline silicon or plastics. Examples of plastics
include, without limitation, polymethylacrylic, polyethylene, polypropylene, polyacrylate,
polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene,
25 polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or
mixtures thereof. The solid substrate may be any shape, including rectangular, disk-like
and spherical. In a preferred embodiment, the solid substrate is a microscope slide or
slide-shaped substrate.

The nucleic acid molecule of the present invention can be attached covalently to a
30 surface of the support substrate or applied to a derivatized surface in a chaotropic agent
that facilitates denaturation and adherence by presumed noncovalent interactions, or some
combination thereof. The nucleic acid molecule of the present invention can be bound to a
substrate to which a plurality of other nucleic acids are concurrently bound, hybridization

to each of the plurality of bound nucleic acids being separately detectable. At low density, e.g. on a porous membrane, these substrate-bound collections are typically denominated macroarrays; at higher density, typically on a solid support, such as glass, these substrate bound collections of plural nucleic acids are colloquially termed microarrays. As used
5 herein, the term microarray includes arrays of all densities. It is, therefore, another aspect of the invention to provide microarrays that comprise one or more of the nucleic acid molecules of the present invention.

In yet another embodiment, the invention is directed to single exon probes based on the OSNAs disclosed herein.

10 *Expression Vectors, Host Cells and Recombinant Methods of Producing Polypeptides*

Another aspect of the present invention provides vectors that comprise one or more of the isolated nucleic acid molecules of the present invention, and host cells in which such vectors have been introduced.

15 The vectors can be used, *inter alia*, for propagating the nucleic acid molecules of the present invention in host cells (cloning vectors), for shuttling the nucleic acid molecules of the present invention between host cells derived from disparate organisms (shuttle vectors), for inserting the nucleic acid molecules of the present invention into host cell chromosomes (insertion vectors), for expressing sense or antisense RNA transcripts of
20 the nucleic acid molecules of the present invention *in vitro* or within a host cell, and for expressing polypeptides encoded by the nucleic acid molecules of the present invention, alone or as fusion proteins with heterologous polypeptides (expression vectors). Vectors are by now well known in the art, and are described, *inter alia*, in Jones *et al.* (eds.), Vectors: Cloning Applications: Essential Techniques (Essential Techniques Series), John
25 Wiley & Son Ltd. (1998); Jones *et al.* (eds.), Vectors: Expression Systems: Essential Techniques (Essential Techniques Series), John Wiley & Son Ltd. (1998); Gacesa *et al.*, Vectors: Essential Data, John Wiley & Sons Ltd. (1995); Cid-Arregui (eds.), Viral Vectors: Basic Science and Gene Therapy, Eaton Publishing Co. (2000); Sambrook (2001), *supra*; Ausubel (1999), *supra*. Furthermore, a variety of vectors are available
30 commercially. Use of existing vectors and modifications thereof are well within the skill in the art. Thus, only basic features need be described here.

Nucleic acid sequences may be expressed by operatively linking them to an expression control sequence in an appropriate expression vector and employing that expression vector to transform an appropriate unicellular host. Expression control sequences are sequences that control the transcription, post-transcriptional events and translation of nucleic acid sequences. Such operative linking of a nucleic acid sequence of this invention to an expression control sequence, of course, includes, if not already part of the nucleic acid sequence, the provision of a translation initiation codon, ATG or GTG, in the correct reading frame upstream of the nucleic acid sequence.

A wide variety of host/expression vector combinations may be employed in expressing the nucleic acid sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and synthetic nucleic acid sequences.

In one embodiment, prokaryotic cells may be used with an appropriate vector. Prokaryotic host cells are often used for cloning and expression. In a preferred embodiment, prokaryotic host cells include *E. coli*, *Pseudomonas*, *Bacillus* and *Streptomyces*. In a preferred embodiment, bacterial host cells are used to express the nucleic acid molecules of the instant invention. Useful expression vectors for bacterial hosts include bacterial plasmids, such as those from *E. coli*, *Bacillus* or *Streptomyces*, including pBluescript, pGEX-2T, pUC vectors, col E1, pCR1, pBR322, pMB9 and their derivatives, wider host range plasmids, such as RP4, phage DNAs, *e.g.*, the numerous derivatives of phage lambda, *e.g.*, NM989, λ GT10 and λ GT11, and other phages, *e.g.*, M13 and filamentous single-stranded phage DNA. Where *E. coli* is used as host, selectable markers are, analogously, chosen for selectivity in gram negative bacteria: *e.g.*, typical markers confer resistance to antibiotics, such as ampicillin, tetracycline, chloramphenicol, kanamycin, streptomycin and zeocin; auxotrophic markers can also be used.

In other embodiments, eukaryotic host cells, such as yeast, insect, mammalian or plant cells, may be used. Yeast cells, typically *S. cerevisiae*, are useful for eukaryotic genetic studies, due to the ease of targeting genetic changes by homologous recombination and the ability to easily complement genetic defects using recombinantly expressed proteins. Yeast cells are useful for identifying interacting protein components, *e.g.* through use of a two-hybrid system. In a preferred embodiment, yeast cells are useful for protein expression. Vectors of the present invention for use in yeast will typically, but not

invariably, contain an origin of replication suitable for use in yeast and a selectable marker that is functional in yeast. Yeast vectors include Yeast Integrating plasmids (*e.g.*, YIp5) and Yeast Replicating plasmids (the YRp and YEp series plasmids), Yeast Centromere plasmids (the YCp series plasmids), Yeast Artificial Chromosomes (YACs) which are
5 based on yeast linear plasmids, denoted YLp, pGPD-2, 2 μ plasmids and derivatives thereof, and improved shuttle vectors such as those described in Gietz *et al.*, *Gene*, 74: 527-34 (1988) (YIplac, YEplac and YCplac). Selectable markers in yeast vectors include a variety of auxotrophic markers, the most common of which are (in *Saccharomyces cerevisiae*) URA3, HIS3, LEU2, TRP1 and LYS2, which complement specific
10 auxotrophic mutations, such as *ura3-52*, *his3-D1*, *leu2-D1*, *trp1-D1* and *lys2-201*.

Insect cells may be chosen for high efficiency protein expression. Where the host cells are from *Spodoptera frugiperda*, *e.g.*, Sf9 and Sf21 cell lines, and expresSF™ cells (Protein Sciences Corp., Meriden, CT, USA), the vector replicative strategy is typically based upon the baculovirus life cycle. Typically, baculovirus transfer vectors are used to
15 replace the wild-type AcMNPV polyhedrin gene with a heterologous gene of interest. Sequences that flank the polyhedrin gene in the wild-type genome are positioned 5' and 3' of the expression cassette on the transfer vectors. Following co-transfection with AcMNPV DNA, a homologous recombination event occurs between these sequences resulting in a recombinant virus carrying the gene of interest and the polyhedrin or p10
20 promoter. Selection can be based upon visual screening for lacZ fusion activity.

The host cells may also be mammalian cells, which are particularly useful for expression of proteins intended as pharmaceutical agents, and for screening of potential agonists and antagonists of a protein or a physiological pathway. Mammalian vectors intended for autonomous extrachromosomal replication will typically include a viral
25 origin, such as the SV40 origin (for replication in cell lines expressing the large T-antigen, such as COS1 and COS7 cells), the papillomavirus origin, or the EBV origin for long term episomal replication (for use, *e.g.*, in 293-EBNA cells, which constitutively express the EBV EBNA-1 gene product and adenovirus E1A). Vectors intended for integration, and thus replication as part of the mammalian chromosome, can, but need not, include an
30 origin of replication functional in mammalian cells, such as the SV40 origin. Vectors based upon viruses, such as adenovirus, adeno-associated virus, vaccinia virus, and various mammalian retroviruses, will typically replicate according to the viral replicative strategy. Selectable markers for use in mammalian cells include, but are not limited to,

resistance to neomycin (G418), blasticidin, hygromycin and zeocin, and selection based upon the purine salvage pathway using HAT medium.

Expression in mammalian cells can be achieved using a variety of plasmids, including pSV2, pBC12BI, and p91023, as well as lytic virus vectors (*e.g.*, vaccinia virus, adeno virus, and baculovirus), episomal virus vectors (*e.g.*, bovine papillomavirus), and retroviral vectors (*e.g.*, murine retroviruses). Useful vectors for insect cells include baculoviral vectors and pVL 941.

Plant cells can also be used for expression, with the vector replicon typically derived from a plant virus (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) and selectable markers chosen for suitability in plants.

It is known that codon usage of different host cells may be different. For example, a plant cell and a human cell may exhibit a difference in codon preference for encoding a particular amino acid. As a result, human mRNA may not be efficiently translated in a plant, bacteria or insect host cell. Therefore, another embodiment of this invention is directed to codon optimization. The codons of the nucleic acid molecules of the invention may be modified to resemble, as much as possible, genes naturally contained within the host cell without altering the amino acid sequence encoded by the nucleic acid molecule.

Any of a wide variety of expression control sequences may be used in these vectors to express the nucleic acid molecules of this invention. Such useful expression control sequences include the expression control sequences associated with structural genes of the foregoing expression vectors. Expression control sequences that control transcription include, *e.g.*, promoters, enhancers and transcription termination sites. Expression control sequences in eukaryotic cells that control post-transcriptional events include splice donor and acceptor sites and sequences that modify the half-life of the transcribed RNA, *e.g.*, sequences that direct poly(A) addition or binding sites for RNA-binding proteins. Expression control sequences that control translation include ribosome binding sites, sequences which direct targeted expression of the polypeptide to or within particular cellular compartments, and sequences in the 5' and 3' untranslated regions that modify the rate or efficiency of translation.

Examples of useful expression control sequences for a prokaryote, *e.g.*, *E. coli*, will include a promoter, often a phage promoter, such as phage lambda pL promoter, the trc promoter, a hybrid derived from the trp and lac promoters, the bacteriophage T7 promoter (in *E. coli* cells engineered to express the T7 polymerase), the TAC or TRC

system, the major operator and promoter regions of phage lambda, the control regions of fd coat protein, and the araBAD operon. Prokaryotic expression vectors may further include transcription terminators, such as the aspA terminator, and elements that facilitate translation, such as a consensus ribosome binding site and translation termination codon,
5 Schomer *et al.*, *Proc. Natl. Acad. Sci. USA* 83: 8506-8510 (1986).

Expression control sequences for yeast cells, typically *S. cerevisiae*, will include a yeast promoter, such as the CYC1 promoter, the GAL1 promoter, the GAL10 promoter, ADH1 promoter, the promoters of the yeast α -mating system, or the GPD promoter, and will typically have elements that facilitate transcription termination, such as the
10 transcription termination signals from the CYC1 or ADH1 gene.

Expression vectors useful for expressing proteins in mammalian cells will include a promoter active in mammalian cells. These promoters include, but are not limited to, those derived from mammalian viruses, such as the enhancer-promoter sequences from the immediate early gene of the human cytomegalovirus (CMV), the enhancer-promoter
15 sequences from the Rous sarcoma virus long terminal repeat (RSV LTR), the enhancer-promoter from SV40 and the early and late promoters of adenovirus. Other expression control sequences include the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase. Other expression control sequences include those from the gene comprising the OSNA of interest. Often, expression is enhanced by
20 incorporation of polyadenylation sites, such as the late SV40 polyadenylation site and the polyadenylation signal and transcription termination sequences from the bovine growth hormone (BGH) gene, and ribosome binding sites. Furthermore, vectors can include introns, such as intron II of rabbit β -globin gene and the SV40 splice elements.

Preferred nucleic acid vectors also include a selectable or amplifiable marker gene
25 and means for amplifying the copy number of the gene of interest. Such marker genes are well known in the art. Nucleic acid vectors may also comprise stabilizing sequences (*e.g.*, ori- or ARS-like sequences and telomere-like sequences), or may alternatively be designed to favor directed or non-directed integration into the host cell genome. In a preferred embodiment, nucleic acid sequences of this invention are inserted in frame into an
30 expression vector that allows a high level expression of an RNA which encodes a protein comprising the encoded nucleic acid sequence of interest. Nucleic acid cloning and sequencing methods are well known to those of skill in the art and are described in an assortment of laboratory manuals, including Sambrook (1989), *supra*, Sambrook (2000),

supra; Ausubel (1992), *supra*; and Ausubel (1999), *supra*. Product information from manufacturers of biological, chemical and immunological reagents also provide useful information.

Expression vectors may be either constitutive or inducible. Inducible vectors
5 include either naturally inducible promoters, such as the *trc* promoter, which is regulated by the *lac* operon, and the *pL* promoter, which is regulated by tryptophan, the MMTV-LTR promoter, which is inducible by dexamethasone, or can contain synthetic promoters and/or additional elements that confer inducible control on adjacent promoters. Examples of inducible synthetic promoters are the hybrid *Plac/ara-1* promoter and the
10 *PLtetO-1* promoter. The *PLtetO-1* promoter takes advantage of the high expression levels from the *PL* promoter of phage lambda, but replaces the lambda repressor sites with two copies of operator 2 of the *Tn10* tetracycline resistance operon, causing this promoter to be tightly repressed by the Tet repressor protein and induced in response to tetracycline (Tc) and Tc derivatives such as anhydrotetracycline. Vectors may also be inducible
15 because they contain hormone response elements, such as the glucocorticoid response element (GRE) and the estrogen response element (ERE), which can confer hormone inducibility where vectors are used for expression in cells having the respective hormone receptors. To reduce background levels of expression, elements responsive to ecdysone, an insect hormone, can be used instead, with coexpression of the ecdysone receptor.

20 In one embodiment of the invention, expression vectors can be designed to fuse the expressed polypeptide to small protein tags that facilitate purification and/or visualization. Such tags include a polyhistidine tag that facilitates purification of the fusion protein by immobilized metal affinity chromatography, for example using NiNTA resin (Qiagen Inc., Valencia, CA, USA) or TALON™ resin (cobalt immobilized affinity chromatography
25 medium, Clontech Labs, Palo Alto, CA, USA). The fusion protein can include a chitin-binding tag and self-excising intein, permitting chitin-based purification with self-removal of the fused tag (IMPACT™ system, New England Biolabs, Inc., Beverly, MA, USA). Alternatively, the fusion protein can include a calmodulin-binding peptide tag, permitting purification by calmodulin affinity resin (Stratagene, La Jolla, CA, USA), or a specifically
30 excisable fragment of the biotin carboxylase carrier protein, permitting purification of *in vivo* biotinylated protein using an avidin resin and subsequent tag removal (Promega, Madison, WI, USA). As another useful alternative, the polypeptides of the present invention can be expressed as a fusion to glutathione-S-transferase, the affinity and

specificity of binding to glutathione permitting purification using glutathione affinity resins, such as Glutathione-Superflow Resin (Clontech Laboratories, Palo Alto, CA, USA), with subsequent elution with free glutathione. Other tags include, for example, the Xpress epitope, detectable by anti-Xpress antibody (Invitrogen, Carlsbad, CA, USA), a
5 myc tag, detectable by anti-myc tag antibody, the V5 epitope, detectable by anti-V5 antibody (Invitrogen, Carlsbad, CA, USA), FLAG® epitope, detectable by anti-FLAG® antibody (Stratagene, La Jolla, CA, USA), and the HA epitope, detectable by anti-HA antibody.

For secretion of expressed polypeptides, vectors can include appropriate sequences
10 that encode secretion signals, such as leader peptides. For example, the pSecTag2 vectors (Invitrogen, Carlsbad, CA, USA) are 5.2 kb mammalian expression vectors that carry the secretion signal from the V-J2-C region of the mouse Ig kappa-chain for efficient secretion of recombinant proteins from a variety of mammalian cell lines.

Expression vectors can also be designed to fuse proteins encoded by the
15 heterologous nucleic acid insert to polypeptides that are larger than purification and/or identification tags. Useful protein fusions include those that permit display of the encoded protein on the surface of a phage or cell, fusions to intrinsically fluorescent proteins, such as those that have a green fluorescent protein (GFP)-like chromophore, fusions to the IgG Fc region, and fusions for use in two hybrid systems.

20 Vectors for phage display fuse the encoded polypeptide to, *e.g.*, the gene III protein (pIII) or gene VIII protein (pVIII) for display on the surface of filamentous phage, such as M13. *See* Barbas *et al.*, Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001); Kay *et al.* (eds.), Phage Display of Peptides and Proteins: A Laboratory Manual, Academic Press, Inc., (1996); Abelson *et al.* (eds.), Combinatorial
25 Chemistry (Methods in Enzymology, Vol. 267) Academic Press (1996). Vectors for yeast display, *e.g.* the pYD1 yeast display vector (Invitrogen, Carlsbad, CA, USA), use the α -agglutinin yeast adhesion receptor to display recombinant protein on the surface of *S. cerevisiae*. Vectors for mammalian display, *e.g.*, the pDisplay™ vector (Invitrogen, Carlsbad, CA, USA), target recombinant proteins using an N-terminal cell surface
30 targeting signal and a C-terminal transmembrane anchoring domain of platelet derived growth factor receptor.

A wide variety of vectors now exist that fuse proteins encoded by heterologous nucleic acids to the chromophore of the substrate-independent, intrinsically fluorescent

green fluorescent protein from *Aequorea victoria* ("GFP") and its variants. The GFP-like chromophore can be selected from GFP-like chromophores found in naturally occurring proteins, such as *A. victoria* GFP (GenBank accession number AAA27721), *Renilla reniformis* GFP, FP583 (GenBank accession no. AF168419) (DsRed), FP593 (AF272711), FP483 (AF168420), FP484 (AF168424), FP595 (AF246709), FP486 (AF168421), FP538 (AF168423), and FP506 (AF168422), and need include only so much of the native protein as is needed to retain the chromophore's intrinsic fluorescence. Methods for determining the minimal domain required for fluorescence are known in the art. See Li *et al.*, *J. Biol. Chem.* 272: 28545-28549 (1997). Alternatively, the GFP-like chromophore can be selected from GFP-like chromophores modified from those found in nature. The methods for engineering such modified GFP-like chromophores and testing them for fluorescence activity, both alone and as part of protein fusions, are well known in the art. See Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996) and Palm *et al.*, *Methods Enzymol.* 302: 378-394 (1999). A variety of such modified chromophores are now commercially available and can readily be used in the fusion proteins of the present invention. These include EGFP ("enhanced GFP"), EBFP ("enhanced blue fluorescent protein"), BFP2, EYFP ("enhanced yellow fluorescent protein"), ECFP ("enhanced cyan fluorescent protein") or Citrine. EGFP (*see, e.g.* Cormack *et al.*, *Gene* 173: 33-38 (1996); U.S. Patent Nos. 6,090,919 and 5,804,387, the disclosures of which are incorporated herein by reference in their entireties) is found on a variety of vectors, both plasmid and viral, which are available commercially (Clontech Labs, Palo Alto, CA, USA); EBFP is optimized for expression in mammalian cells whereas BFP2, which retains the original jellyfish codons, can be expressed in bacteria (*see, e.g.* Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996) and Cormack *et al.*, *Gene* 173: 33-38 (1996)). Vectors containing these blue-shifted variants are available from Clontech Labs (Palo Alto, CA, USA). Vectors containing EYFP, ECFP (*see, e.g.* Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996); Miyawaki *et al.*, *Nature* 388: 882-887 (1997)) and Citrine (*see, e.g.* Heikal *et al.*, *Proc. Natl. Acad. Sci. USA* 97: 11996-12001 (2000)) are also available from Clontech Labs. The GFP-like chromophore can also be drawn from other modified GFPs, including those described in U.S. Patent Nos. 6,124,128; 6,096,865; 6,090,919; 6,066,476; 6,054,321; 6,027,881; 5,968,750; 5,874,304; 5,804,387; 5,777,079; 5,741,668; and 5,625,048, the disclosures of which are incorporated herein by reference in their entireties. See also Conn (ed.), Green Fluorescent Protein (Methods in Enzymology, Vol. 302), Academic Press, Inc. (1999); Yang, *et al.*, *J Biol Chem*, 273: 8212-6 (1998);

Bevis *et al.*, *Nature Biotechnology*, 20:83-7 (2002). The GFP-like chromophore of each of these GFP variants can usefully be included in the fusion proteins of the present invention.

5 Fusions to the IgG Fc region increase serum half-life of protein pharmaceutical products through interaction with the FcRn receptor (also denominated the FcRp receptor and the Brambell receptor, FcRb), further described in International Patent Application Nos. WO 97/43316, WO 97/34631, WO 96/32478, and WO 96/18412, the disclosures of which are incorporated herein by reference in their entireties.

10 For long-term, high-yield recombinant production of the polypeptides of the present invention, stable expression is preferred. Stable expression is readily achieved by integration into the host cell genome of vectors having selectable markers, followed by selection of these integrants. Vectors such as pUB6/V5-His A, B, and C (Invitrogen, Carlsbad, CA, USA) are designed for high-level stable expression of heterologous proteins in a wide range of mammalian tissue types and cell lines. pUB6/V5-His uses the
15 promoter/enhancer sequence from the human ubiquitin C gene to drive expression of recombinant proteins: expression levels in 293, CHO, and NIH3T3 cells are comparable to levels from the CMV and human EF-1a promoters. The bsd gene permits rapid selection of stably transfected mammalian cells with the potent antibiotic blasticidin.

20 Replication incompetent retroviral vectors, typically derived from Moloney murine leukemia virus, also are useful for creating stable transfectants having integrated provirus. The highly efficient transduction machinery of retroviruses, coupled with the availability of a variety of packaging cell lines such as RetroPack™ PT 67, EcoPack2™-293, AmphoPack-293, and GP2-293 cell lines (all available from Clontech Laboratories, Palo Alto, CA, USA) allow a wide host range to be infected with high efficiency; varying the
25 multiplicity of infection readily adjusts the copy number of the integrated provirus.

Of course, not all vectors and expression control sequences will function equally well to express the nucleic acid molecules of this invention. Neither will all hosts function equally well with the same expression system. However, one of skill in the art may make a selection among these vectors, expression control sequences and hosts without undue
30 experimentation and without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must be replicated in it. The vector's copy number, the ability to control that copy number, the ability to control integration, if any, and the expression of any other proteins encoded by the vector, such as

an antibiotic or other selection marker, should also be considered. The present invention further includes host cells comprising the vectors of the present invention, either present episomally within the cell or integrated, in whole or in part, into the host cell chromosome. Among other considerations, some of which are described above, a host cell strain may be
5 chosen for its ability to process the expressed polypeptide in the desired fashion. Such post-translational modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation, and it is an aspect of the present invention to provide OSPs with such post-translational modifications.

10 In selecting an expression control sequence, a variety of factors should also be considered. These include, for example, the relative strength of the sequence, its controllability, and its compatibility with the nucleic acid molecules of this invention, particularly with regard to potential secondary structures. Unicellular hosts should be selected by consideration of their compatibility with the chosen vector, the toxicity of the
15 product coded for by the nucleic acid sequences of this invention, their secretion characteristics, their ability to fold the polypeptide correctly, their fermentation or culture requirements, and the ease of purification from them of the products coded for by the nucleic acid molecules of this invention.

The recombinant nucleic acid molecules and more particularly, the expression
20 vectors of this invention may be used to express the polypeptides of this invention as recombinant polypeptides in a heterologous host cell. The polypeptides of this invention may be full-length or less than full-length polypeptide fragments recombinantly expressed from the nucleic acid molecules according to this invention. Such polypeptides include analogs, derivatives and muteins that may or may not have biological activity.

25 Vectors of the present invention will also often include elements that permit *in vitro* transcription of RNA from the inserted heterologous nucleic acid. Such vectors typically include a phage promoter, such as that from T7, T3, or SP6, flanking the nucleic acid insert. Often two different such promoters flank the inserted nucleic acid, permitting separate *in vitro* production of both sense and antisense strands.

30 Transformation and other methods of introducing nucleic acids into a host cell (*e.g.*, conjugation, protoplast transformation or fusion, transfection, electroporation, liposome delivery, membrane fusion techniques, high velocity DNA-coated pellets, viral infection and protoplast fusion) can be accomplished by a variety of methods which are

well known in the art (*See*, for instance, Ausubel, *supra*, and Sambrook *et al.*, *supra*). Bacterial, yeast, plant or mammalian cells are transformed or transfected with an expression vector, such as a plasmid, a cosmid, or the like, wherein the expression vector comprises the nucleic acid of interest. Alternatively, the cells may be infected by a viral
5 expression vector comprising the nucleic acid of interest. Depending upon the host cell, vector, and method of transformation used, transient or stable expression of the polypeptide will be constitutive or inducible. One having ordinary skill in the art will be able to decide whether to express a polypeptide transiently or stably, and whether to express the protein constitutively or inducibly.

10 A wide variety of unicellular host cells are useful in expressing the DNA sequences of this invention. These hosts may include well known eukaryotic and prokaryotic hosts, such as strains of, fungi, yeast, insect cells such as *Spodoptera frugiperda* (SF9), animal cells such as CHO, as well as plant cells in tissue culture. Representative examples of appropriate host cells include, but are not limited to, bacterial
15 cells, such as *E. coli*, *Caulobacter crescentus*, *Streptomyces* species, and *Salmonella typhimurium*; yeast cells, such as *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Pichia pastoris*, *Pichia methanolica*; insect cell lines, such as those from *Spodoptera frugiperda*, *e.g.*, Sf9 and Sf21 cell lines, and expresSF™ cells (Protein Sciences Corp., Meriden, CT, USA), *Drosophila* S2 cells, and *Trichoplusia ni* High Five® Cells
20 (Invitrogen, Carlsbad, CA, USA); and mammalian cells. Typical mammalian cells include BHK cells, BSC 1 cells, BSC 40 cells, BMT 10 cells, VERO cells, COS1 cells, COS7 cells, Chinese hamster ovary (CHO) cells, 3T3 cells, NIH 3T3 cells, 293 cells, HEPG2 cells, HeLa cells, L cells, MDCK cells, HEK293 cells, WI38 cells, murine ES cell lines (*e.g.*, from strains 129/SV, C57/BL6, DBA-1, 129/SVJ), K562 cells, Jurkat cells, and
25 BW5147 cells. Other mammalian cell lines are well known and readily available from the American Type Culture Collection (ATCC) (Manassas, VA, USA) and the National Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository at the Coriell Cell Repositories (Camden, NJ, USA). Cells or cell lines derived from ovarian are particularly preferred because they may provide a more native post-translational
30 processing. Particularly preferred are human ovarian cells.

Particular details of the transfection, expression and purification of recombinant proteins are well documented and are understood by those of skill in the art. Further details on the various technical aspects of each of the steps used in recombinant

production of foreign genes in bacterial cell expression systems can be found in a number of texts and laboratory manuals in the art. *See, e.g.,* Ausubel (1992), *supra*, Ausubel (1999), *supra*, Sambrook (1989), *supra*, and Sambrook (2001), *supra*.

5 Methods for introducing the vectors and nucleic acid molecules of the present invention into the host cells are well known in the art; the choice of technique will depend primarily upon the specific vector to be introduced and the host cell chosen.

Nucleic acid molecules and vectors may be introduced into prokaryotes, such as *E. coli*, in a number of ways. For instance, phage lambda vectors will typically be packaged using a packaging extract (*e.g.,* Gigapack® packaging extract, Stratagene, La Jolla, CA, USA), and the packaged virus used to infect *E. coli*.

10 Plasmid vectors will typically be introduced into chemically competent or electrocompetent bacterial cells. *E. coli* cells can be rendered chemically competent by treatment, *e.g.,* with CaCl_2 , or a solution of Mg^{2+} , Mn^{2+} , Ca^{2+} , Rb^+ or K^+ , dimethyl sulfoxide, dithiothreitol, and hexamine cobalt (III), Hanahan, *J. Mol. Biol.* 166(4):557-80 (1983), and vectors introduced by heat shock. A wide variety of chemically competent strains are also available commercially (*e.g.,* Epicurian Coli® XL10-Gold® Ultracompetent Cells (Stratagene, La Jolla, CA, USA); DH5α competent cells (Clontech Laboratories, Palo Alto, CA, USA); and TOP10 Chemically Competent *E. coli* Kit (Invitrogen, Carlsbad, CA, USA)). Bacterial cells can be rendered electrocompetent to
15 take up exogenous DNA by electroporation by various pre-pulse treatments; vectors are introduced by electroporation followed by subsequent outgrowth in selected media. An extensive series of protocols is provided by BioRad (Richmond, CA, USA).

Vectors can be introduced into yeast cells by spheroplasting, treatment with lithium salts, electroporation, or protoplast fusion. Spheroplasts are prepared by the action
25 of hydrolytic enzymes such as a snail-gut extract, usually denoted Glusulase or Zymolyase, or an enzyme from *Arthrobacter luteus* to remove portions of the cell wall in the presence of osmotic stabilizers, typically 1 M sorbitol. DNA is added to the spheroplasts, and the mixture is co-precipitated with a solution of polyethylene glycol (PEG) and Ca^{2+} . Subsequently, the cells are resuspended in a solution of sorbitol, mixed
30 with molten agar and then layered on the surface of a selective plate containing sorbitol.

For lithium-mediated transformation, yeast cells are treated with lithium acetate to permeabilize the cell wall, DNA is added and the cells are co-precipitated with PEG. The cells are exposed to a brief heat shock, washed free of PEG and lithium acetate, and

subsequently spread on plates containing ordinary selective medium. Increased frequencies of transformation are obtained by using specially-prepared single-stranded carrier DNA and certain organic solvents. Schiestl *et al.*, *Curr. Genet.* 16(5-6): 339-46 (1989).

5 For electroporation, freshly-grown yeast cultures are typically washed, suspended in an osmotic protectant, such as sorbitol, mixed with DNA, and the cell suspension pulsed in an electroporation device. Subsequently, the cells are spread on the surface of plates containing selective media. Becker *et al.*, *Methods Enzymol.* 194: 182-187 (1991). The efficiency of transformation by electroporation can be increased over 100-fold by
10 using PEG, single-stranded carrier DNA and cells that are in late log-phase of growth. Larger constructs, such as YACs, can be introduced by protoplast fusion.

Mammalian and insect cells can be directly infected by packaged viral vectors, or transfected by chemical or electrical means. For chemical transfection, DNA can be coprecipitated with CaPO_4 or introduced using liposomal and nonliposomal lipid-based
15 agents. Commercial kits are available for CaPO_4 transfection (CalPhos™ Mammalian Transfection Kit, Clontech Laboratories, Palo Alto, CA, USA), and lipid-mediated transfection can be practiced using commercial reagents, such as LIPOFECTAMINE™ 2000, LIPOFECTAMINE™ Reagent, CELLFECTIN® Reagent, and LIPOFECTIN® Reagent (Invitrogen, Carlsbad, CA, USA), DOTAP Liposomal Transfection Reagent,
20 FuGENE 6, X-tremeGENE Q2, DOSPER, (Roche Molecular Biochemicals, Indianapolis, IN USA), Effectene™, PolyFect®, Superfect® (Qiagen, Inc., Valencia, CA, USA). Protocols for electroporating mammalian cells can be found in, for example, ; Norton *et al.* (eds.), Gene Transfer Methods: Introducing DNA into Living Cells and Organisms, BioTechniques Books, Eaton Publishing Co. (2000). Other transfection techniques
25 include transfection by particle bombardment and microinjection. See, e.g., Cheng *et al.*, *Proc. Natl. Acad. Sci. USA* 90(10): 4455-9 (1993); Yang *et al.*, *Proc. Natl. Acad. Sci. USA* 87(24): 9568-72 (1990).

Production of the recombinantly produced proteins of the present invention can optionally be followed by purification.

30 Purification of recombinantly expressed proteins is now well within the skill in the art and thus need not be detailed here. See, e.g., Thorner *et al.* (eds.), Applications of Chimeric Genes and Hybrid Proteins, Part A: Gene Expression and Protein Purification (Methods in Enzymology, Vol. 326), Academic Press (2000); Harbin (ed.), Cloning, Gene

Expression and Protein Purification : Experimental Procedures and Process Rationale, Oxford Univ. Press (2001); Marshak *et al.*, Strategies for Protein Purification and Characterization: A Laboratory Course Manual, Cold Spring Harbor Laboratory Press (1996); and Roe (ed.), Protein Purification Applications, Oxford University Press (2001).

5 Briefly, however, if purification tags have been fused through use of an expression vector that appends such tags, purification can be effected, at least in part, by means appropriate to the tag, such as use of immobilized metal affinity chromatography for polyhistidine tags. Other techniques common in the art include ammonium sulfate fractionation, immunoprecipitation, fast protein liquid chromatography (FPLC), high
10 performance liquid chromatography (HPLC), and preparative gel electrophoresis.

Polypeptides, including Fragments Muteins, Homologous Proteins, Allelic Variants, Analogs and Derivatives

Another aspect of the invention relates to polypeptides encoded by the nucleic acid molecules described herein. In a preferred embodiment, the polypeptide is an ovarian
15 specific polypeptide (OSP). In an even more preferred embodiment, the polypeptide comprises an amino acid sequence of SEQ ID NO:129-295 or is derived from a polypeptide having the amino acid sequence of SEQ ID NO: 129-295. A polypeptide as defined herein may be produced recombinantly, as discussed *supra*, may be isolated from a cell that naturally expresses the protein, or may be chemically synthesized following the
20 teachings of the specification and using methods well known to those having ordinary skill in the art.

Polypeptides of the present invention may also comprise a part or fragment of an OSP. In a preferred embodiment, the fragment is derived from a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 129-295.
25 Polypeptides of the present invention comprising a part or fragment of an entire OSP may or may not be OSPs. For example, a full-length polypeptide may be ovarian-specific, while a fragment thereof may be found in other tissues as well as in ovarian. A polypeptide that is not an OSP, whether it is a fragment, analog, mutein, homologous protein or derivative, is nevertheless useful, especially for immunizing animals to prepare
30 anti-OSP antibodies. In a preferred embodiment, the part or fragment is an OSP. Methods of determining whether a polypeptide of the present invention is an OSP are described *infra*.

Polypeptides of the present invention comprising fragments of at least 6 contiguous amino acids are also useful in mapping B cell and T cell epitopes of the reference protein. *See, e.g., Geysen et al., Proc. Natl. Acad. Sci. USA* 81: 3998-4002 (1984) and U.S. Patent Nos. 4,708,871 and 5,595,915, the disclosures of which are
5 incorporated herein by reference in their entirety. Because the fragment need not itself be immunogenic, part of an immunodominant epitope, nor even recognized by native antibody, to be useful in such epitope mapping, all fragments of at least 6 amino acids of a polypeptide of the present invention have utility in such a study.

Polypeptides of the present invention comprising fragments of at least 8
10 contiguous amino acids, often at least 15 contiguous amino acids, are useful as immunogens for raising antibodies that recognize polypeptides of the present invention. *See, e.g., Lerner, Nature* 299: 592-596 (1982); Shinnick *et al., Annu. Rev. Microbiol.* 37: 425-46 (1983); Sutcliffe *et al., Science* 219: 660-6 (1983). As further described in the above-cited references, virtually all 8-mers, conjugated to a carrier, such as a protein,
15 prove immunogenic and are capable of eliciting antibody for the conjugated peptide; accordingly, all fragments of at least 8 amino acids of the polypeptides of the present invention have utility as immunogens.

Polypeptides comprising fragments of at least 8, 9, 10 or 12 contiguous amino acids are also useful as competitive inhibitors of binding of the entire polypeptide, or a
20 portion thereof, to antibodies (as in epitope mapping), and to natural binding partners, such as subunits in a multimeric complex or to receptors or ligands of the subject protein; this competitive inhibition permits identification and separation of molecules that bind specifically to the polypeptide of interest. *See* U.S. Patent Nos. 5,539,084 and 5,783,674, incorporated herein by reference in their entirety.

25 The polypeptide of the present invention thus preferably is at least 6 amino acids in length, typically at least 8, 9, 10 or 12 amino acids in length, and often at least 15 amino acids in length. Often, the polypeptide of the present invention is at least 20 amino acids in length, even 25 amino acids, 30 amino acids, 35 amino acids, or 50 amino acids or more in length. Of course, larger polypeptides having at least 75 amino acids, 100 amino acids,
30 or even 150 amino acids are also useful, and at times preferred.

One having ordinary skill in the art can produce fragments by truncating the nucleic acid molecule, *e.g.,* an OSNA, encoding the polypeptide and then expressing it recombinantly. Alternatively, one can produce a fragment by chemically synthesizing a

portion of the full-length polypeptide. One may also produce a fragment by enzymatically cleaving either a recombinant polypeptide or an isolated naturally occurring polypeptide. Methods of producing polypeptide fragments are well known in the art. *See, e.g.,* Sambrook (1989), *supra*; Sambrook (2001), *supra*; Ausubel (1992), *supra*; and Ausubel
5 (1999), *supra*. In one embodiment, a polypeptide comprising only a fragment, preferably a fragment of an OSP, may be produced by chemical or enzymatic cleavage of an OSP polypeptide. In a preferred embodiment, a polypeptide fragment is produced by expressing a nucleic acid molecule of the present invention encoding a fragment, preferably of an OSP, in a host cell.

10 Polypeptides of the present invention are also inclusive of mutants, fusion proteins, homologous proteins and allelic variants.

A mutant protein, or mutein, may have the same or different properties compared to a naturally occurring polypeptide and comprises at least one amino acid insertion, duplication, deletion, rearrangement or substitution compared to the amino acid sequence
15 of a native polypeptide. Small deletions and insertions can often be found that do not alter the function of a protein. Muteins may or may not be ovarian-specific. Preferably, the mutein is ovarian-specific. More preferably the mutein is a polypeptide that comprises at least one amino acid insertion, duplication, deletion, rearrangement or substitution compared to the amino acid sequence of SEQ ID NO: 129-295. Accordingly, in a
20 preferred embodiment, the mutein is one that exhibits at least 50% sequence identity, more preferably at least 60% sequence identity, even more preferably at least 70%, yet more preferably at least 80% sequence identity to an OSP comprising an amino acid sequence of SEQ ID NO: 129-295. In a yet more preferred embodiment, the mutein exhibits at least 85%, more preferably 90%, even more preferably 95% or 96%, and yet more preferably at
25 least 97%, 98%, 99% or 99.5% sequence identity to an OSP comprising an amino acid sequence of SEQ ID NO: 129-295.

A mutein may be produced by isolation from a naturally occurring mutant cell, tissue or organism. A mutein may be produced by isolation from a cell, tissue or organism that has been experimentally mutagenized. Alternatively, a mutein may be produced by
30 chemical manipulation of a polypeptide, such as by altering the amino acid residue to another amino acid residue using synthetic or semi-synthetic chemical techniques. In a preferred embodiment, a mutein is produced from a host cell comprising a mutated nucleic acid molecule compared to the naturally occurring nucleic acid molecule. For instance,

one may produce a mutein of a polypeptide by introducing one or more mutations into a nucleic acid molecule of the invention and then expressing it recombinantly. These mutations may be targeted, in which particular encoded amino acids are altered, or may be untargeted, in which random encoded amino acids within the polypeptide are altered.

5 Muteins with random amino acid alterations can be screened for a particular biological activity or property, particularly whether the polypeptide is ovarian-specific, as described below. Multiple random mutations can be introduced into the gene by methods well known to the art, *e.g.*, by error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, *in vivo* mutagenesis, cassette
10 mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis and site-specific mutagenesis. Methods of producing muteins with targeted or random amino acid alterations are well known in the art. *See, e.g.*, Sambrook (1989), *supra*; Sambrook (2001), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), as well as U.S. Patent No. 5,223,408, which is herein incorporated by reference in its entirety.

15 The invention also contemplates polypeptides that are homologous to a polypeptide of the invention. In a preferred embodiment, the polypeptide is homologous to an OSP. In an even more preferred embodiment, the polypeptide is homologous to an OSP selected from the group having an amino acid sequence of SEQ ID NO: 129-295. By homologous polypeptide it is meant one that exhibits significant sequence identity to an
20 OSP, preferably an OSP having an amino acid sequence of SEQ ID NO: 129-295. By significant sequence identity it is meant that the homologous polypeptide exhibits at least 50% sequence identity, more preferably at least 60% sequence identity, even more preferably at least 70%, yet more preferably at least 80% sequence identity to an OSP comprising an amino acid sequence of SEQ ID NO: 129-295. More preferred are
25 homologous polypeptides exhibiting at least 85%, more preferably 90%, even more preferably 95% or 96%, and yet more preferably at least 97% or 98% sequence identity to an OSP comprising an amino acid sequence of SEQ ID NO: 129-295. Most preferably, the homologous polypeptide exhibits at least 99%, more preferably 99.5%, even more preferably 99.6%, 99.7%, 99.8% or 99.9% sequence identity to an OSP comprising an
30 amino acid sequence of SEQ ID NO: 129-295. In a preferred embodiment, the amino acid substitutions of the homologous polypeptide are conservative amino acid substitutions as discussed *supra*.

Homologous polypeptides of the present invention also comprise polypeptide encoded by a nucleic acid molecule that selectively hybridizes to an OSNA or an antisense sequence thereof. In this embodiment, it is preferred that the homologous polypeptide be encoded by a nucleic acid molecule that hybridizes to an OSNA under low stringency, moderate stringency or high stringency conditions, as defined herein. More preferred is a homologous polypeptide encoded by a nucleic acid sequence which hybridizes to a OSNA selected from the group consisting of SEQ ID NO: 1-128 or a homologous polypeptide encoded by a nucleic acid molecule that hybridizes to a nucleic acid molecule that encodes an OSP, preferably an OSP of SEQ ID NO:129-295 under low stringency, moderate stringency or high stringency conditions, as defined herein.

Homologous polypeptides of the present invention may be naturally occurring and derived from another species, especially one derived from another primate, such as chimpanzee, gorilla, rhesus macaque, or baboon, wherein the homologous polypeptide comprises an amino acid sequence that exhibits significant sequence identity to that of SEQ ID NO: 129-295. The homologous polypeptide may also be a naturally occurring polypeptide from a human, when the OSP is a member of a family of polypeptides. The homologous polypeptide may also be a naturally occurring polypeptide derived from a non-primate, mammalian species, including without limitation, domesticated species, *e.g.*, dog, cat, mouse, rat, rabbit, guinea pig, hamster, cow, horse, goat or pig. The homologous polypeptide may also be a naturally occurring polypeptide derived from a non-mammalian species, such as birds or reptiles. The naturally occurring homologous protein may be isolated directly from humans or other species. Alternatively, the nucleic acid molecule encoding the naturally occurring homologous polypeptide may be isolated and used to express the homologous polypeptide recombinantly. The homologous polypeptide may also be one that is experimentally produced by random mutation of a nucleic acid molecule and subsequent expression of the nucleic acid molecule. Alternatively, the homologous polypeptide may be one that is experimentally produced by directed mutation of one or more codons to alter the encoded amino acid of an OSP. In a preferred embodiment, the homologous polypeptide encodes a polypeptide that is an OSP.

Relatedness of proteins can also be characterized using a second functional test, such as the ability of a first protein competitively to inhibit the binding of a second protein to an antibody. It is, therefore, another aspect of the present invention to provide isolated polypeptides not only identical in sequence to those described with particularity herein,

but also to provide isolated polypeptides ("cross-reactive proteins") that competitively inhibit the binding of antibodies to all or to a portion of the isolated polypeptides of the present invention. Such competitive inhibition can readily be determined using immunoassays well known in the art.

5 As discussed above, single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes, and the sequence determined from one individual of a species may differ from other allelic forms present within the population. Thus, polypeptides of the present invention are also inclusive of those encoded by an allelic variant of a nucleic acid molecule encoding an OSP. In this embodiment, it is preferred that the polypeptide be
10 encoded by an allelic variant of a gene that encodes a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO: 129-295. More preferred is that the polypeptide be encoded by an allelic variant of a gene that has the nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-128.

 Polypeptides of the present invention are also inclusive of derivative polypeptides
15 encoded by a nucleic acid molecule according to the instant invention. In this embodiment, it is preferred that the polypeptide be an OSP. Also preferred are derivative polypeptides having an amino acid sequence selected from the group consisting of SEQ ID NO: 129-295 and which has been acetylated, carboxylated, phosphorylated, glycosylated, ubiquitinated or post-translationally modified in another manner. In another
20 preferred embodiment, the derivative has been labeled with, *e.g.*, radioactive isotopes such as ^{125}I , ^{32}P , ^{35}S , and ^3H . In another preferred embodiment, the derivative has been labeled with fluorophores, chemiluminescent agents, enzymes, and antiligands that can serve as specific binding pair members for a labeled ligand.

 Polypeptide modifications are well known to those of skill and have been
25 described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as, for instance Creighton, Protein Structure and Molecular Properties, 2nd ed., W. H. Freeman and Company (1993). Many detailed reviews are
30 available on this subject, such as, for example, those provided by Wold, in Johnson (ed.), Posttranslational Covalent Modification of Proteins, pgs. 1-12, Academic Press (1983); Seifter *et al.*, *Meth. Enzymol.* 182: 626-646 (1990) and Rattan *et al.*, *Ann. N.Y. Acad. Sci.* 663: 48-62 (1992).

One may determine whether a polypeptide of the invention is likely to be post-translationally modified by analyzing the sequence of the polypeptide to determine if there are peptide motifs indicative of sites for post-translational modification. There are a number of computer programs that permit prediction of post-translational modifications.

5 See, e.g., expasy.org (accessed November 11, 2002) of the world wide web, which includes PSORT, for prediction of protein sorting signals and localization sites, SignalP, for prediction of signal peptide cleavage sites, MITOPROT and Predotar, for prediction of mitochondrial targeting sequences, NetOGlyc, for prediction of type O-glycosylation sites in mammalian proteins, big-PI Predictor and DGPI, for prediction of prenylation-anchor
10 and cleavage sites, and NetPhos, for prediction of Ser, Thr and Tyr phosphorylation sites in eukaryotic proteins. Other computer programs, such as those included in GCG, also may be used to determine post-translational modification peptide motifs.

General examples of types of post-translational modifications include, but are not limited to: (Z)-dehydrobutyrine; 1-chondroitin sulfate-L-aspartic acid ester; 1'-glycosyl-L-
15 tryptophan; 1'-phospho-L-histidine; 1-thioglycine; 2'-(S-L-cysteinyl)-L-histidine; 2'-[3-carboxamido (trimethylammonio)propyl]-L-histidine; 2'-alpha-mannosyl-L-tryptophan; 2-methyl-L-glutamine; 2-oxobutanoic acid; 2-pyrrolidone carboxylic acid; 3'-(1'-L-histidyl)-L-tyrosine; 3'-(8alpha-FAD)-L-histidine; 3'-(S-L-cysteinyl)-L-tyrosine; 3', 3'', 5'-triiodo-L-thyronine; 3'-4'-phospho-L-tyrosine; 3-hydroxy-L-proline; 3'-methyl-L-histidine; 3-
20 methyl-L-lanthionine; 3'-phospho-L-histidine; 4'-(L-tryptophan)-L-tryptophyl quinone; 42 N-cysteinyl-glycosylphosphatidylinositol ethanolamine; 43 -(T-L-histidyl)-L-tyrosine; 4-hydroxy-L-arginine; 4-hydroxy-L-lysine; 4-hydroxy-L-proline; 5'-(N6-L-lysine)-L-topaquinone; 5-hydroxy-L-lysine; 5-methyl-L-arginine; alpha-l-microglobulin-Ig alpha complex chromophore; bis-L-cysteinyl bis-L-histidino diiron disulfide; bis-L--cysteinyl-L-
25 N3'-histidino-L-serinyI tetrairon' tetrasulfide; chondroitin sulfate D-glucuronyl-D-galactosyl-D-galactosyl-D-xylosyl-L-serine; D-alanine; D-allo-isoleucine; D-asparagine; dehydroalanine; dehydrotyrosine; dermatan 4-sulfate D-glucuronyl-D-galactosyl-D-galactosyl-D-xylosyl-L-serine; D-glucuronyl-N-glycine; dipyrrolylmethanemethyl-L-cysteine; D-leucine; D-methionine; D-phenylalanine; D-serine; D-tryptophan; glycine
30 amide; glycine oxazolecarboxylic acid; glycine thiazolecarboxylic acid; heme P450-bis-L-cysteine-L-tyrosine; heme-bis-L-cysteine; hemediol-L-aspartyl ester-L-glutamyl ester; hemediol-L-aspartyl ester-L-glutamyl ester-L-methionine sulfonium; heme-L-cysteine; heme-L-histidine; heparan sulfate D-glucuronyl-D-galactosyl-D-galactosyl-D-xylosyl-L-

- serine; heme P450-bis-L-cysteine-L-lysine; hexakis-L-cysteinyl hexairon hexasulfide; keratan sulfate D-glucuronyl-D-galactosyl-D-galactosyl-D-xylosyl-L-threonine; L-oxoalanine- lactic acid; L-phenyllactic acid; l'-(8 α -FAD)-L-histidine; L-2'.4',5'-topaquinone; L-3',4'-dihydroxyphenylalanine; L-3'.4'.5'-trihydroxyphenylalanine; L-4'-bromophenylalanine; L-6'-bromotryptophan; L-alanine amide; L-alanyl imidazolinone glycine; L-allysine; L-arginine amide; L-asparagine amide; L-aspartic 4-phosphoric anhydride; L-aspartic acid 1-amide; L-beta-methylthioaspartic acid; L-bromohistidine; L-citrulline; L-cysteine amide; L-cysteine glutathione disulfide; L-cysteine methyl disulfide; L-cysteine methyl ester; L-cysteine oxazolecarboxylic acid; L-cysteine
- 10 oxazolinecarboxylic acid; L-cysteine persulfide; L-cysteine sulfenic acid; L-cysteine sulfinic acid; L-cysteine thiazolecarboxylic acid; L-cysteinyl homocitryl molybdenum-heptairon-nonasulfide; L-cysteinyl imidazolinone glycine; L-cysteinyl molybdopterin; L-cysteinyl molybdopterin guanine dinucleotide; L-cystine; L-erythro-beta-hydroxyasparagine; L-erythro-beta-hydroxyaspartic acid; L-gamma-carboxyglutamic acid;
- 15 L-glutamic acid 1-amide; L-glutamic acid 5-methyl ester; L-glutamine amide; L-glutamyl 5-glycerylphosphorylethanolamine; L-histidine amide; L-isoglutamyl-polyglutamic acid; L-isoglutamyl-polyglycine; L-isoleucine amide; L-lanthionine; L-leucine amide; L-lysine amide; L-lysine thiazolecarboxylic acid; L-lysinoalanine; L-methionine amide; L-methionine sulfone; L-phenylalanine thiazolecarboxylic acid; L-phenylalanine amide; L-proline amide; L-selenocysteine; L-selenocysteinyl molybdopterin guanine dinucleotide;
- 20 L-serine amide; L-serine thiazolecarboxylic acid; L-seryl imidazolinone glycine; L-T-bromophenylalanine; L-T-bromophenylalanine; L-threonine amide; L-thyroxine; L-tryptophan amide; L-tryptophyl quinone; L-tyrosine amide; L-valine amide; meso-lanthionine; N-(L-glutamyl)-L-tyrosine; N-(L-isoaspartyl)-glycine; N-(L-isoaspartyl)-L-cysteine; N,N,N-trimethyl-L-alanine; N,N-dimethyl-L-proline; N2-acetyl-L-lysine; N2-succinyl-L-tryptophan; N4-(ADP-ribosyl)-L-asparagine; N4-glycosyl-L-asparagine; N4-hydroxymethyl-L-asparagine; N4-methyl-L-asparagine; N5-methyl-L-glutamine; N6- 1 -carboxyethyl-L-lysine; N6-(4-amino hydroxybutyl)-L-lysine; N6-(L-isoglutamyl)-L-lysine; N6-(phospho-5'-adenosine)-L-lysine; N6-(phospho-5'-guanosine)-L-tyrosine;
- 30 N6,N6,N6-trimethyl-L-lysine; N6,N6-dimethyl-L-lysine; N6-acetyl-L-lysine; N6-biotinyl-L-lysine; N6-carboxy-L-lysine; N6-formyl-L-lysine; N6-glycyl-L-lysine; N6-lipoyl-L-lysine; N6-methyl-L-lysine; N6-methyl-N6-poly(N-methyl-propylamine)-L-lysine; N6-mureinyl-L-lysine; N6-myristoyl-L-lysine; N6-palmitoyl-L-lysine; N6-pyridoxal

- phosphate-L-lysine; N6-pyruvic acid 2-iminyl-L-lysine; N6-retinal-L-lysine; N-acetyl-glycine; N-acetyl-L-glutamine; N-acetyl-L-alanine; N-acetyl-L-aspartic acid; N-acetyl-L-cysteine; N-acetyl-L-glutamic acid; N-acetyl-L-isoleucine; N-acetyl-L-methionine; N-acetyl-L-proline; N-acetyl-L-serine; N-acetyl-L-threonine; N-acetyl-L-tyrosine; N-acetyl-L-valine; N-alanyl-glycosylphosphatidylinositoethanolamine; N-asparaginy-
 5 asparaginy-glycosylphosphatidylinositoethanolamine; N-aspartyl-glycosylphosphatidylinositoethanolamine; N-formylglycine; N-formyl-L-methionine; N-glycyl-glycosylphosphatidylinositoethanolamine; N-L-glutamyl-poly-L-glutamic acid; N-methylglycine; N-methyl-L-alanine; N-methyl-L-methionine; N-methyl-L-phenylalanine;
 10 N-myristoyl-glycine; N-palmitoyl-L-cysteine; N-pyruvic acid 2-iminyl-L-cysteine; N-pyruvic acid 2-iminyl-L-valine; N-seryl-glycosylphosphatidylinositoethanolamine; N-seryl-glycosyOSPhingolipidinositoethanolamine; O-(ADP-ribosyl)-L-serine; O-(phospho-5'-adenosine)-L-threonine; O-(phospho-5'-DNA)-L-serine; O-(phospho-5'-DNA)-L-threonine; O-(phospho-5'rRNA)-L-serine; O-(phosphoribosyl dephospho-coenzyme A)-L-serine;
 15 O-(sn-1-glycerophosphoryl)-L-serine; O4'-(8alpha-FAD)-L-tyrosine; O4'-(phospho-5'-adenosine)-L-tyrosine; O4'-(phospho-5'-DNA)-L-tyrosine; O4'-(phospho-5'-RNA)-L-tyrosine; O4'-(phospho-5'-uridine)-L-tyrosine; O4'-glycosyl-L-hydroxyproline; O4'-glycosyl-L-tyrosine; O4'-sulfo-L-tyrosine; O5-glycosyl-L-hydroxylysine; O-glycosyl-L-serine; O-glycosyl-L-threonine; omega-N-(ADP-ribosyl)-L-arginine; omega-N-omega-N'-
 20 dimethyl-L-arginine; omega-N-methyl-L-arginine; omega-N-omega-N-dimethyl-L-arginine; omega-N-phospho-L-arginine; O'octanoyl-L-serine; O-palmitoyl-L-serine; O-palmitoyl-L-threonine; O-phospho-L-serine; O-phospho-L-threonine; O-phosphopantetheine-L-serine; phycoerythrobilin-bis-L-cysteine; phycourobilin-bis-L-cysteine; pyrroloquinoline quinone; pyruvic acid; S hydroxycinnamyl-L-cysteine; S-(2-aminovinyl) methyl-D-cysteine; S-(2-aminovinyl)-D-cysteine; S-(6-FW-L-cysteine; S-(8alpha-FAD)-L-cysteine; S-(ADP-ribosyl)-L-cysteine; S-(L-isoglutamyl)-L-cysteine; S-12-hydroxyfarnesyl-L-cysteine; S-acetyl-L-cysteine; S-diacylglycerol-L-cysteine; S-diphytanylglycerol diether-L-cysteine; S-farnesyl-L-cysteine; S-geranylgeranyl-L-cysteine; S-glycosyl-L-cysteine; S-glycyl-L-cysteine; S-methyl-L-cysteine; S-nitrosyl-L-cysteine; S-palmitoyl-L-cysteine; S-phospho-L-cysteine; S-phycobiliviolin-L-cysteine; S-phycocyanobilin-L-cysteine; S-phycoerythrobilin-L-cysteine; S-phytochromobilin-L-cysteine; S-selenyl-L-cysteine; S-sulfo-L-cysteine; tetrakis-L-cysteinyl diiron disulfide; tetrakis-L-cysteinyl iron; tetrakis-L-cysteinyl tetrairon tetrasulfide; trans-2,3-cis 4-

dihydroxy-L-proline; tris-L-cysteinyl triiron tetrasulfide; tris-L-cysteinyl triiron trisulfide; tris-L-cysteinyl-L-aspartato tetrairon tetrasulfide; tris-L-cysteinyl-L-cysteine persulfido-bis-L-glutamato-L-histidino tetrairon disulfide trioxide; tris-L-cysteinyl-L-N3'-histidino tetrairon tetrasulfide; tris-L-cysteinyl-L-N1'-histidino tetrairon tetrasulfide; and tris-L-
 5 cysteinyl-L-serinyl tetrairon tetrasulfide.

Additional examples of PTMs may be found in web sites such as the Delta Mass database based on Krishna, R. G. and F. Wold (1998). Posttranslational Modifications. Proteins - Analysis and Design. R. H. Angeletti. San Diego, Academic Press. 1: 121-206; Methods in Enzymology, 193, J.A. McClosky (ed) (1990), pages 647-660; Methods in
 10 Protein Sequence Analysis edited by Kazutomo Imahori and Fumio Sakiyama, Plenum Press, (1993) "Post-translational modifications of proteins" R.G. Krishna and F. Wold pages 167-172; "GlycoSuiteDB: a new curated relational database of glycoprotein glycan structures and their biological sources" Cooper et al. Nucleic Acids Res. 29; 332-335 (2001) "O-GLYCBASE version 4.0: a revised database of O-glycosylated proteins" Gupta
 15 et al. Nucleic Acids Research, 27: 370-372 (1999); and "PhosphoBase, a database of phosphorylation sites: release 2.0.", Kreegipuu et al. Nucleic Acids Res 27(1):237-239 (1999) see also, WO 02/21139A2, the disclosure of which is incorporated herein by reference in its entirety.

Tumorigenesis is often accompanied by alterations in the post-translational
 20 modifications of proteins. Thus, in another embodiment, the invention provides polypeptides from cancerous cells or tissues that have altered post-translational modifications compared to the post-translational modifications of polypeptides from normal cells or tissues. A number of altered post-translational modifications are known. One common alteration is a change in phosphorylation state, wherein the polypeptide from
 25 the cancerous cell or tissue is hyperphosphorylated or hypophosphorylated compared to the polypeptide from a normal tissue, or wherein the polypeptide is phosphorylated on different residues than the polypeptide from a normal cell. Another common alteration is a change in glycosylation state, wherein the polypeptide from the cancerous cell or tissue has more or less glycosylation than the polypeptide from a normal tissue, and/or wherein
 30 the polypeptide from the cancerous cell or tissue has a different type of glycosylation than the polypeptide from a noncancerous cell or tissue. Changes in glycosylation may be critical because carbohydrate-protein and carbohydrate-carbohydrate interactions are important in cancer cell progression, dissemination and invasion. See, e.g., Barchi, *Curr.*

Pharm. Des. 6: 485-501 (2000), Verma, *Cancer Biochem. Biophys.* 14: 151-162 (1994) and Dennis et al., *Bioessays* 5: 412-421 (1999).

Another post-translational modification that may be altered in cancer cells is prenylation. Prenylation is the covalent attachment of a hydrophobic prenyl group (either farnesyl or geranylgeranyl) to a polypeptide. Prenylation is required for localizing a protein to a cell membrane and is often required for polypeptide function. For instance, the Ras superfamily of GTPase signalling proteins must be prenylated for function in a cell. See, e.g., Prendergast et al., *Semin. Cancer Biol.* 10: 443-452 (2000) and Khwaja et al., *Lancet* 355: 741-744 (2000).

Other post-translation modifications that may be altered in cancer cells include, without limitation, polypeptide methylation, acetylation, arginylation or racemization of amino acid residues. In these cases, the polypeptide from the cancerous cell may exhibit either increased or decreased amounts of the post-translational modification compared to the corresponding polypeptides from noncancerous cells.

Other polypeptide alterations in cancer cells include abnormal polypeptide cleavage of proteins and aberrant protein-protein interactions. Abnormal polypeptide cleavage may be cleavage of a polypeptide in a cancerous cell that does not usually occur in a normal cell, or a lack of cleavage in a cancerous cell, wherein the polypeptide is cleaved in a normal cell. Aberrant protein-protein interactions may be either covalent cross-linking or non-covalent binding between proteins that do not normally bind to each other. Alternatively, in a cancerous cell, a protein may fail to bind to another protein to which it is bound in a noncancerous cell. Alterations in cleavage or in protein-protein interactions may be due to over- or underproduction of a polypeptide in a cancerous cell compared to that in a normal cell, or may be due to alterations in post-translational modifications (see above) of one or more proteins in the cancerous cell. See, e.g., Henschen-Edman, *Ann. N.Y. Acad. Sci.* 936: 580-593 (2001).

Alterations in polypeptide post-translational modifications, as well as changes in polypeptide cleavage and protein-protein interactions, may be determined by any method known in the art. For instance, alterations in phosphorylation may be determined by using anti-phosphoserine, anti-phosphothreonine or anti-phosphotyrosine antibodies or by amino acid analysis. Glycosylation alterations may be determined using antibodies specific for different sugar residues, by carbohydrate sequencing, or by alterations in the size of the glycoprotein, which can be determined by, e.g., SDS polyacrylamide gel electrophoresis

(PAGE). Other alterations of post-translational modifications, such as prenylation, racemization, methylation, acetylation and arginylation, may be determined by chemical analysis, protein sequencing, amino acid analysis, or by using antibodies specific for the particular post-translational modifications. Changes in protein-protein interactions and in polypeptide cleavage may be analyzed by any method known in the art including, without limitation, non-denaturing PAGE (for non-covalent protein-protein interactions), SDS PAGE (for covalent protein-protein interactions and protein cleavage), chemical cleavage, protein sequencing or immunoassays.

In another embodiment, the invention provides polypeptides that have been post-translationally modified. In one embodiment, polypeptides may be modified enzymatically or chemically, by addition or removal of a post-translational modification. For example, a polypeptide may be glycosylated or deglycosylated enzymatically. Similarly, polypeptides may be phosphorylated using a purified kinase, such as a MAP kinase (e.g., p38, ERK, or JNK) or a tyrosine kinase (e.g., Src or erbB2). A polypeptide may also be modified through synthetic chemistry. Alternatively, one may isolate the polypeptide of interest from a cell or tissue that expresses the polypeptide with the desired post-translational modification. In another embodiment, a nucleic acid molecule encoding the polypeptide of interest is introduced into a host cell that is capable of post-translationally modifying the encoded polypeptide in the desired fashion. If the polypeptide does not contain a motif for a desired post-translational modification, one may alter the post-translational modification by mutating the nucleic acid sequence of a nucleic acid molecule encoding the polypeptide so that it contains a site for the desired post-translational modification. Amino acid sequences that may be post-translationally modified are known in the art. See, e.g., the programs described above on the website expasy.org of the world wide web. The nucleic acid molecule may also be introduced into a host cell that is capable of post-translationally modifying the encoded polypeptide. Similarly, one may delete sites that are post-translationally modified by either mutating the nucleic acid sequence so that the encoded polypeptide does not contain the post-translational modification motif, or by introducing the native nucleic acid molecule into a host cell that is not capable of post-translationally modifying the encoded polypeptide.

It will be appreciated, as is well known and as noted above, that polypeptides are not always entirely linear. For instance, polypeptides may be branched as a result of ubiquitination, and they may be circular, with or without branching, generally as a result

of posttranslation events, including natural processing events and events brought about by human manipulation which do not occur naturally. Circular, branched and branched circular polypeptides may be synthesized by non-translation natural processes and by entirely synthetic methods, as well. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. In fact, blockage of the amino or carboxyl group in a polypeptide, or both, by a covalent modification, is common in naturally occurring and synthetic polypeptides and such modifications may be present in polypeptides of the present invention, as well. For instance, the amino terminal residue of polypeptides made in *E. coli*, prior to proteolytic processing, almost invariably will be N-formylmethionine.

Useful post-synthetic (and post-translational) modifications include conjugation to detectable labels, such as fluorophores. A wide variety of amine-reactive and thiol-reactive fluorophore derivatives have been synthesized that react under nondenaturing conditions with N-terminal amino groups and epsilon amino groups of lysine residues, on the one hand, and with free thiol groups of cysteine residues, on the other.

Kits are available commercially that permit conjugation of proteins to a variety of amine-reactive or thiol-reactive fluorophores: Molecular Probes, Inc. (Eugene, OR, USA), *e.g.*, offers kits for conjugating proteins to Alexa Fluor 350, Alexa Fluor 430, Fluorescein-EX, Alexa Fluor 488, Oregon Green 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, and Texas Red-X.

A wide variety of other amine-reactive and thiol-reactive fluorophores are available commercially (Molecular Probes, Inc., Eugene, OR, USA), including Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR, USA).

The polypeptides of the present invention can also be conjugated to fluorophores, other proteins, and other macromolecules, using bifunctional linking reagents. Common

homobifunctional reagents include, *e.g.*, APG, AEDP, BASED, BMB, BMDB, BMH, BMOE, BM[PEO]3, BM[PEO]4, BS3, BSOCOES, DFDNB, DMA, DMP, DMS, DPDPB, DSG, DSP (Lomant's Reagent), DSS, DST, DTBP, DTME, DTSSP, EGS, HBVS, Sulfo-BSOCOES, Sulfo-DST, Sulfo-EGS (all available from Pierce, Rockford, IL, USA);

5 common heterobifunctional cross-linkers include ABH, AMAS, ANB-NOS, APDP, ASBA, BMPA, BMPH, BMPS, EDC, EMCA, EMCH, EMCS, KMUA, KMUH, GMBS, LC-SMCC, LC-SPDP, MBS, M2C2H, MPBH, MSA, NHS-ASA, PDPH, PMPI, SADP, SAED, SAND, SANPAH, SASD, SATP, SBAP, SFAD, SIA, SIAB, SMCC, SMPB, SMPH, SMPT, SPDP, Sulfo-EMCS, Sulfo-GMBS, Sulfo-HSAB, Sulfo-KMUS,

10 Sulfo-LC-SPDP, Sulfo-MBS, Sulfo-NHS-LC-ASA, Sulfo-SADP, Sulfo-SANPAH, Sulfo-SIAB, Sulfo-SMCC, Sulfo-SMPB, Sulfo-LC-SMPT, SVSB, TFCS (all available Pierce, Rockford, IL, USA).

Polypeptides of the present invention, including full length polypeptides, fragments and fusion proteins, can be conjugated, using such cross-linking reagents, to

15 fluorophores that are not amine- or thiol-reactive. Other labels that usefully can be conjugated to polypeptides of the present invention include radioactive labels, echosonographic contrast reagents, and MRI contrast agents.

Polypeptides of the present invention, including full length polypeptides, fragments and fusion proteins, can also usefully be conjugated using cross-linking agents

20 to carrier proteins, such as KLH, bovine thyroglobulin, and even bovine serum albumin (BSA), to increase immunogenicity for raising anti-OSP antibodies.

Polypeptides of the present invention, including full length polypeptides, fragments and fusion proteins, can also usefully be conjugated to polyethylene glycol (PEG); PEGylation increases the serum half life of proteins administered intravenously for

25 replacement therapy. Delgado *et al.*, *Crit. Rev. Ther. Drug Carrier Syst.* 9(3-4): 249-304 (1992); Scott *et al.*, *Curr. Pharm. Des.* 4(6): 423-38 (1998); DeSantis *et al.*, *Curr. Opin. Biotechnol.* 10(4): 324-30 (1999). PEG monomers can be attached to the protein directly or through a linker, with PEGylation using PEG monomers activated with tresyl chloride (2,2,2-trifluoroethanesulphonyl chloride) permitting direct attachment under mild

30 conditions.

Polypeptides of the present invention are also inclusive of analogs of a polypeptide encoded by a nucleic acid molecule according to the instant invention. In a preferred embodiment, this polypeptide is an OSP. In a more preferred embodiment, this

polypeptide is derived from a polypeptide having part or all of the amino acid sequence of SEQ ID NO: 129-295. Also preferred is an analog polypeptide comprising one or more substitutions of non-natural amino acids or non-native inter-residue bonds compared to the naturally occurring polypeptide. In one embodiment, the analog is structurally similar to an OSP, but one or more peptide linkages is replaced by a linkage selected from the group consisting of --CH₂NH--, --CH₂S--, --CH₂-CH₂--, --CH=CH--(cis and trans), --COCH₂--, --CH(OH)CH₂-- and --CH₂SO--. In another embodiment, the analog comprises substitution of one or more amino acids of an OSP with a D-amino acid of the same type or other non-natural amino acid in order to generate more stable peptides. D-amino acids can readily be incorporated during chemical peptide synthesis: peptides assembled from D-amino acids are more resistant to proteolytic attack; incorporation of D-amino acids can also be used to confer specific three-dimensional conformations on the peptide. Other amino acid analogues commonly added during chemical synthesis include ornithine, norleucine, phosphorylated amino acids (typically phosphoserine, phosphothreonine, phosphotyrosine), L-malonyltyrosine, a non-hydrolyzable analog of phosphotyrosine (*see, e.g., Kole et al., Biochem. Biophys. Res. Com.* 209: 817-821 (1995)), and various halogenated phenylalanine derivatives.

Non-natural amino acids can be incorporated during solid phase chemical synthesis or by recombinant techniques, although the former is typically more common. Solid phase chemical synthesis of peptides is well established in the art. Procedures are described, *inter alia*, in Chan *et al.* (eds.), Fmoc Solid Phase Peptide Synthesis: A Practical Approach (Practical Approach Series), Oxford Univ. Press (March 2000); Jones, Amino Acid and Peptide Synthesis (Oxford Chemistry Primers, No 7), Oxford Univ. Press (1992); and Bodanszky, Principles of Peptide Synthesis (Springer Laboratory), Springer Verlag (1993).

Amino acid analogues having detectable labels are also usefully incorporated during synthesis to provide derivatives and analogs. Biotin, for example can be added using biotinoyl-(9-fluorenylmethoxycarbonyl)-L-lysine (Fmoc biocytin) (Molecular Probes, Eugene, OR, USA). Biotin can also be added enzymatically by incorporation into a fusion protein of an *E. coli* BirA substrate peptide. The Fmoc and tBOC derivatives of dabcyL-L-lysine (Molecular Probes, Inc., Eugene, OR, USA) can be used to incorporate the dabcyL chromophore at selected sites in the peptide sequence during synthesis. The

aminonaphthalene derivative EDANS, the most common fluorophore for pairing with the dabcyI quencher in fluorescence resonance energy transfer (FRET) systems, can be introduced during automated synthesis of peptides by using EDANS-FMOC-L-glutamic acid or the corresponding *t*BOC derivative (both from Molecular Probes, Inc., Eugene, OR, USA). Tetramethylrhodamine fluorophores can be incorporated during automated FMOC synthesis of peptides using (FMOC)-TMR-L-lysine (Molecular Probes, Inc. Eugene, OR, USA).

Other useful amino acid analogues that can be incorporated during chemical synthesis include aspartic acid, glutamic acid, lysine, and tyrosine analogues having allyl side-chain protection (Applied Biosystems, Inc., Foster City, CA, USA); the allyl side chain permits synthesis of cyclic, branched-chain, sulfonated, glycosylated, and phosphorylated peptides.

A large number of other FMOC-protected non-natural amino acid analogues capable of incorporation during chemical synthesis are available commercially, including, *e.g.*, Fmoc-2-aminobicyclo[2.2.1]heptane-2-carboxylic acid, Fmoc-3-endo-aminobicyclo[2.2.1]heptane-2-endo-carboxylic acid, Fmoc-3-exo-aminobicyclo[2.2.1]heptane-2-exo-carboxylic acid, Fmoc-3-endo-amino-bicyclo[2.2.1]hept-5-ene-2-endo-carboxylic acid, Fmoc-3-exo-amino-bicyclo[2.2.1]hept-5-ene-2-exo-carboxylic acid, Fmoc-cis-2-amino-1-cyclohexanecarboxylic acid, Fmoc-trans-2-amino-1-cyclohexanecarboxylic acid, Fmoc-1-amino-1-cyclopentanecarboxylic acid, Fmoc-cis-2-amino-1-cyclopentanecarboxylic acid, Fmoc-1-amino-1-cyclopropanecarboxylic acid, Fmoc-D-2-amino-4-(ethylthio)butyric acid, Fmoc-L-2-amino-4-(ethylthio)butyric acid, Fmoc-L-buthionine, Fmoc-S-methyl-L-Cysteine, Fmoc-2-aminobenzoic acid (anthranillic acid), Fmoc-3-aminobenzoic acid, Fmoc-4-aminobenzoic acid, Fmoc-2-aminobenzophenone-2'-carboxylic acid, Fmoc-N-(4-aminobenzoyl)- β -alanine, Fmoc-2-amino-4,5-dimethoxybenzoic acid, Fmoc-4-aminohippuric acid, Fmoc-2-amino-3-hydroxybenzoic acid, Fmoc-2-amino-5-hydroxybenzoic acid, Fmoc-3-amino-4-hydroxybenzoic acid, Fmoc-4-amino-3-hydroxybenzoic acid, Fmoc-4-amino-2-hydroxybenzoic acid, Fmoc-5-amino-2-hydroxybenzoic acid, Fmoc-2-amino-3-methoxybenzoic acid, Fmoc-4-amino-3-methoxybenzoic acid, Fmoc-2-amino-3-methylbenzoic acid, Fmoc-2-amino-5-methylbenzoic acid, Fmoc-2-amino-6-methylbenzoic acid, Fmoc-3-amino-2-methylbenzoic acid, Fmoc-3-amino-4-methylbenzoic acid, Fmoc-4-amino-3-

methylbenzoic acid, Fmoc-3-amino-2-naphtoic acid, Fmoc-D,L-3-amino-3-phenylpropionic acid, Fmoc-L-Methyldopa, Fmoc-2-amino-4,6-dimethyl-3-pyridinecarboxylic acid, Fmoc-D,L-amino-2-thiophenacetic acid, Fmoc-4-(carboxymethyl)piperazine, Fmoc-4-carboxypiperazine, Fmoc-4-
5 (carboxymethyl)homopiperazine, Fmoc-4-phenyl-4-piperidinecarboxylic acid, Fmoc-L-1,2,3,4-tetrahydronorharman-3-carboxylic acid, Fmoc-L-thiazolidine-4-carboxylic acid, all available from The Peptide Laboratory (Richmond, CA, USA).

Non-natural residues can also be added biosynthetically by engineering a suppressor tRNA, typically one that recognizes the UAG stop codon, by chemical
10 aminoacylation with the desired unnatural amino acid. Conventional site-directed mutagenesis is used to introduce the chosen stop codon UAG at the site of interest in the protein gene. When the acylated suppressor tRNA and the mutant gene are combined in an *in vitro* transcription/translation system, the unnatural amino acid is incorporated in response to the UAG codon to give a protein containing that amino acid at the specified
15 position. Liu *et al.*, *Proc. Natl Acad. Sci. USA* 96(9): 4780-5 (1999); Wang *et al.*, *Science* 292(5516): 498-500 (2001).

Fusion Proteins

Another aspect of the present invention relates to the fusion of a polypeptide of the present invention to heterologous polypeptides. In a preferred embodiment, the
20 polypeptide of the present invention is an OSP. In a more preferred embodiment, the polypeptide of the present invention that is fused to a heterologous polypeptide which comprises part or all of the amino acid sequence of SEQ ID NO: 129-295, or is a mutein, homologous polypeptide, analog or derivative thereof. In an even more preferred embodiment, the fusion protein is encoded by a nucleic acid molecule comprising all or
25 part of the nucleic acid sequence of SEQ ID NO: 1-128, or comprises all or part of a nucleic acid sequence that selectively hybridizes or is homologous to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-128.

The fusion proteins of the present invention will include at least one fragment of a polypeptide of the present invention, which fragment is at least 6, typically at least 8, often
30 at least 15, and usefully at least 16, 17, 18, 19, or 20 amino acids long. The fragment of the polypeptide of the present to be included in the fusion can usefully be at least 25 amino acids long, at least 50 amino acids long, and can be at least 75, 100, or even 150

amino acids long. Fusions that include the entirety of a polypeptide of the present invention have particular utility.

The heterologous polypeptide included within the fusion protein of the present invention is at least 6 amino acids in length, often at least 8 amino acids in length, and preferably at least 15, 20, or 25 amino acids in length. Fusions that include larger polypeptides, such as the IgG Fc region, and even entire proteins (such as GFP chromophore-containing proteins) are particularly useful.

As described above in the description of vectors and expression vectors of the present invention, which discussion is incorporated here by reference in its entirety, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those designed to facilitate purification and/or visualization of recombinantly-expressed proteins. *See, e.g.*, Ausubel, Chapter 16, (1992), *supra*. Although purification tags can also be incorporated into fusions that are chemically synthesized, chemical synthesis typically provides sufficient purity that further purification by HPLC suffices; however, visualization tags as above described retain their utility even when the protein is produced by chemical synthesis, and when so included render the fusion proteins of the present invention useful as directly detectable markers of the presence of a polypeptide of the invention.

As also discussed above, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those that facilitate secretion of recombinantly expressed proteins into the periplasmic space or extracellular milieu for prokaryotic hosts or into the culture medium for eukaryotic cells through incorporation of secretion signals and/or leader sequences. For example, a His⁶ tagged protein can be purified on a Ni affinity column and a GST fusion protein can be purified on a glutathione affinity column. Similarly, a fusion protein comprising the Fc domain of IgG can be purified on a Protein A or Protein G column and a fusion protein comprising an epitope tag such as myc can be purified using an immunoaffinity column containing an anti-c-myc antibody. It is preferable that the epitope tag be separated from the protein encoded by the essential gene by an enzymatic cleavage site that can be cleaved after purification. See also the discussion of nucleic acid molecules encoding fusion proteins that may be expressed on the surface of a cell.

Other useful fusion proteins of the present invention include those that permit use of the polypeptide of the present invention as bait in a yeast two-hybrid system. *See*

Bartel *et al.* (eds.), The Yeast Two-Hybrid System, Oxford University Press (1997); Zhu *et al.*, Yeast Hybrid Technologies, Eaton Publishing (2000); Fields *et al.*, *Trends Genet.* 10(8): 286-92 (1994); Mendelsohn *et al.*, *Curr. Opin. Biotechnol.* 5(5): 482-6 (1994); Luban *et al.*, *Curr. Opin. Biotechnol.* 6(1): 59-64 (1995); Allen *et al.*, *Trends Biochem. Sci.* 20(12): 511-6 (1995); Drees, *Curr. Opin. Chem. Biol.* 3(1): 64-70 (1999); Topcu *et al.*, *Pharm. Res.* 17(9): 1049-55 (2000); Fashena *et al.*, *Gene* 250(1-2): 1-14 (2000); Colas *et al.*, *Nature* 380, 548-550 (1996); Norman, T. *et al.*, *Science* 285, 591-595 (1999); Fabbrizio *et al.*, *Oncogene* 18, 4357-4363 (1999); Xu *et al.*, *Proc Natl Acad Sci U S A.* 94, 12473-12478 (1997); Yang, *et al.*, *Nuc. Acids Res.* 23, 1152-1156 (1995); Kolonin *et al.*, *Proc Natl Acad Sci U S A* 95, 14266-14271 (1998); Cohen *et al.*, *Proc Natl Acad Sci U S A* 95, 14272-14277 (1998); Uetz, *et al.* *Nature* 403, 623-627(2000); Ito, *et al.*, *Proc Natl Acad Sci U S A* 98, 4569-4574 (2001). Typically, such fusion is to either *E. coli* LexA or yeast GAL4 DNA binding domains. Related bait plasmids are available that express the bait fused to a nuclear localization signal.

Other useful fusion proteins include those that permit display of the encoded polypeptide on the surface of a phage or cell, fusions to intrinsically fluorescent proteins, such as green fluorescent protein (GFP), and fusions to the IgG Fc region, as described above.

The polypeptides of the present invention can also usefully be fused to protein toxins, such as *Pseudomonas* exotoxin A, diphtheria toxin, shiga toxin A, anthrax toxin lethal factor, or ricin, in order to effect ablation of cells that bind or take up the proteins of the present invention.

Fusion partners include, *inter alia*, *myc*, hemagglutinin (HA), GST, immunoglobulins, β -galactosidase, biotin *trpE*, protein A, β -lactamase, α -amylase, maltose binding protein, alcohol dehydrogenase, polyhistidine (for example, six histidine at the amino and/or carboxyl terminus of the polypeptide), *lacZ*, green fluorescent protein (GFP), yeast α mating factor, GAL4 transcription activation or DNA binding domain, luciferase, and serum proteins such as ovalbumin, albumin and the constant domain of IgG. *See, e.g.*, Ausubel (1992), *supra* and Ausubel (1999), *supra*. Fusion proteins may also contain sites for specific enzymatic cleavage, such as a site that is recognized by enzymes such as Factor XIII, trypsin, pepsin, or any other enzyme known in the art. Fusion proteins will typically be made by either recombinant nucleic acid methods, as

described above, chemically synthesized using techniques well known in the art (*e.g.*, a Merrifield synthesis), or produced by chemical cross-linking.

Another advantage of fusion proteins is that the epitope tag can be used to bind the fusion protein to a plate or column through an affinity linkage for screening binding
5 proteins or other molecules that bind to the OSP.

As further described below, the polypeptides of the present invention can readily be used as specific immunogens to raise antibodies that specifically recognize polypeptides of the present invention including OSPs and their allelic variants and homologues. The antibodies, in turn, can be used, *inter alia*, specifically to assay for the
10 polypeptides of the present invention, particularly OSPs, *e.g.* by ELISA for detection of protein fluid samples, such as serum, by immunohistochemistry or laser scanning cytometry, for detection of protein in tissue samples, or by flow cytometry, for detection of intracellular protein in cell suspensions, for specific antibody-mediated isolation and/or purification of OSPs, as for example by immunoprecipitation, and for use as specific
15 agonists or antagonists of OSPs.

One may determine whether polypeptides of the present invention including OSPs, muteins, homologous proteins or allelic variants or fusion proteins of the present invention are functional by methods known in the art. For instance, residues that are tolerant of change while retaining function can be identified by altering the polypeptide at known
20 residues using methods known in the art, such as alanine scanning mutagenesis, Cunningham *et al.*, *Science* 244(4908): 1081-5 (1989); transposon linker scanning mutagenesis, Chen *et al.*, *Gene* 263(1-2): 39-48 (2001); combinations of homolog- and alanine-scanning mutagenesis, Jin *et al.*, *J. Mol. Biol.* 226(3): 851-65 (1992); and combinatorial alanine scanning, Weiss *et al.*, *Proc. Natl. Acad. Sci USA* 97(16): 8950-4
25 (2000), followed by functional assay. Transposon linker scanning kits are available commercially (New England Biolabs, Beverly, MA, USA, catalog. no. E7-102S; EZ::TN™ In-Frame Linker Insertion Kit, catalogue no. EZI04KN, (Epicentre Technologies Corporation, Madison, WI, USA).

Purification of the polypeptides or fusion proteins of the present invention is well
30 known and within the skill of one having ordinary skill in the art. *See, e.g.*, Scopes, Protein Purification, 2d ed. (1987). Purification of recombinantly expressed polypeptides is described above. Purification of chemically-synthesized peptides can readily be effected, *e.g.*, by HPLC.

Accordingly, it is an aspect of the present invention to provide the isolated polypeptides or fusion proteins of the present invention in pure or substantially pure form in the presence or absence of a stabilizing agent. Stabilizing agents include both proteinaceous and non-proteinaceous material and are well known in the art. Stabilizing agents, such as albumin and polyethylene glycol (PEG) are known and are commercially available.

Although high levels of purity are preferred when the isolated polypeptide or fusion protein of the present invention are used as therapeutic agents, such as in vaccines and replacement therapy, the isolated polypeptides of the present invention are also useful at lower purity. For example, partially purified polypeptides of the present invention can be used as immunogens to raise antibodies in laboratory animals.

In a preferred embodiment, the purified and substantially purified polypeptides of the present invention are in compositions that lack detectable ampholytes, acrylamide monomers, bis-acrylamide monomers, and polyacrylamide.

The polypeptides or fusion proteins of the present invention can usefully be attached to a substrate. The substrate can be porous or solid, planar or non-planar; the bond can be covalent or noncovalent. For example, the peptides of the invention may be stabilized by covalent linkage to albumin. See, U.S. Patent No. 5,876,969, the contents of which are hereby incorporated in its entirety.

The polypeptides or fusion proteins of the present invention can also be usefully bound to a porous substrate, commonly a membrane, typically comprising nitrocellulose, polyvinylidene fluoride (PVDF), or cationically derivatized, hydrophilic PVDF; so bound, the polypeptides or fusion proteins of the present invention can be used to detect and quantify antibodies, *e.g.* in serum, that bind specifically to the immobilized polypeptide or fusion protein of the present invention.

As another example, the polypeptides or fusion proteins of the present invention can usefully be bound to a substantially nonporous substrate, such as plastic, to detect and quantify antibodies, *e.g.* in serum, that bind specifically to the immobilized protein of the present invention. Such plastics include polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or mixtures thereof; when the assay is performed in a standard microtiter dish, the plastic is typically polystyrene.

The polypeptides and fusion proteins of the present invention can also be attached to a substrate suitable for use as a surface enhanced laser desorption ionization source; so attached, the polypeptide or fusion protein of the present invention is useful for binding and then detecting secondary proteins that bind with sufficient affinity or avidity to the surface-bound polypeptide or fusion protein to indicate biologic interaction there between. The polypeptides or fusion proteins of the present invention can also be attached to a substrate suitable for use in surface plasmon resonance detection; so attached, the polypeptide or fusion protein of the present invention is useful for binding and then detecting secondary proteins that bind with sufficient affinity or avidity to the surface-bound polypeptide or fusion protein to indicate biological interaction there between.

Alternative Transcripts

In another aspect, the present invention provides splice variants of genes and proteins encoded thereby. The identification of a novel splice variant which encodes an amino acid sequence with a novel region can be targeted for the generation of reagents for use in detection and/or treatment of cancer. The novel amino acid sequence may lead to a unique protein structure, protein subcellular localization, biochemical processing or function of the splice variant. This information can be used to directly or indirectly facilitate the generation of additional or novel therapeutics or diagnostics. The nucleotide sequence in this novel splice variant can be used as a nucleic acid probe for the diagnosis and/or treatment of cancer.

Specifically, the newly identified sequences may enable the production of new antibodies or compounds directed against the novel region for use as a therapeutic or diagnostic. Alternatively, the newly identified sequences may alter the biochemical or biological properties of the encoded protein in such a way as to enable the generation of improved or different therapeutics targeting this protein.

Antibodies

In another aspect, the invention provides antibodies, including fragments and derivatives thereof, that bind specifically to polypeptides encoded by the nucleic acid molecules of the invention. In a preferred embodiment, the antibodies are specific for a polypeptide that is an OSP, or a fragment, mutein, derivative, analog or fusion protein thereof. In a more preferred embodiment, the antibodies are specific for a polypeptide that

comprises SEQ ID NO: 129-295, or a fragment, mutein, derivative, analog or fusion protein thereof.

The antibodies of the present invention can be specific for linear epitopes, discontinuous epitopes, or conformational epitopes of such proteins or protein fragments, either as present on the protein in its native conformation or, in some cases, as present on the proteins as denatured, as, *e.g.*, by solubilization in SDS. New epitopes may also be due to a difference in post translational modifications (PTMs) in disease versus normal tissue. For example, a particular site on an OSP may be glycosylated in cancerous cells, but not glycosylated in normal cells or vice versa. In addition, alternative splice forms of an OSP may be indicative of cancer. Differential degradation of the C or N-terminus of an OSP may also be a marker or target for anticancer therapy. For example, an OSP may be N-terminal degraded in cancer cells exposing new epitopes to antibodies which may selectively bind for diagnostic or therapeutic uses.

As is well known in the art, the degree to which an antibody can discriminate among molecular species in a mixture will depend, in part, upon the conformational relatedness of the species in the mixture; typically, the antibodies of the present invention will discriminate over adventitious binding to non-OSP polypeptides by at least two-fold, more typically by at least 5-fold, typically by more than 10-fold, 25-fold, 50-fold, 75-fold, and often by more than 100-fold, and on occasion by more than 500-fold or 1000-fold. When used to detect the proteins or protein fragments of the present invention, the antibody of the present invention is sufficiently specific when it can be used to determine the presence of the polypeptide of the present invention in samples derived from human ovarian.

Typically, the affinity or avidity of an antibody (or antibody multimer, as in the case of an IgM pentamer) of the present invention for a protein or protein fragment of the present invention will be at least about 1×10^{-6} molar (M), typically at least about 5×10^{-7} M, 1×10^{-7} M, with affinities and avidities of at least 1×10^{-8} M, 5×10^{-9} M, 1×10^{-10} M and up to 1×10^{-13} M proving especially useful.

The antibodies of the present invention can be naturally occurring forms, such as IgG, IgM, IgD, IgE, IgY, and IgA, from any avian, reptilian, or mammalian species.

Human antibodies can, but will infrequently, be drawn directly from human donors or human cells. In such case, antibodies to the polypeptides of the present invention will typically have resulted from fortuitous immunization, such as autoimmune immunization,

with the polypeptide of the present invention. Such antibodies will typically, but will not invariably, be polyclonal. In addition, individual polyclonal antibodies may be isolated and cloned to generate monoclonals.

Human antibodies are more frequently obtained using transgenic animals that
5 express human immunoglobulin genes, which transgenic animals can be affirmatively immunized with the protein immunogen of the present invention. Human Ig-transgenic mice capable of producing human antibodies and methods of producing human antibodies therefrom upon specific immunization are described, *inter alia*, in U.S. Patent Nos. 6,162,963; 6,150,584; 6,114,598; 6,075,181; 5,939,598; 5,877,397; 5,874,299; 5,814,318;
10 5,789,650; 5,770,429; 5,661,016; 5,633,425; 5,625,126; 5,569,825; 5,545,807; 5,545,806, and 5,591,669, the disclosures of which are incorporated herein by reference in their entireties. Such antibodies are typically monoclonal, and are typically produced using techniques developed for production of murine antibodies.

Human antibodies are particularly useful, and often preferred, when the antibodies
15 of the present invention are to be administered to human beings as *in vivo* diagnostic or therapeutic agents, since recipient immune response to the administered antibody will often be substantially less than that occasioned by administration of an antibody derived from another species, such as mouse.

IgG, IgM, IgD, IgE, IgY, and IgA antibodies of the present invention are also
20 usefully obtained from other species, including mammals such as rodents (typically mouse, but also rat, guinea pig, and hamster), lagomorphs (typically rabbits), and also larger mammals, such as sheep, goats, cows, and horses; or egg laying birds or reptiles such as chickens or alligators. In such cases, as with the transgenic human-antibody-producing non-human mammals, fortuitous immunization is not required, and the non-
25 human mammal is typically affirmatively immunized, according to standard immunization protocols, with the polypeptide of the present invention. One form of avian antibodies may be generated using techniques described in WO 00/29444, published 25 May 2000, which is herein incorporated by reference in its entirety.

As discussed above, virtually all fragments of 8 or more contiguous amino acids of
30 a polypeptide of the present invention can be used effectively as immunogens when conjugated to a carrier, typically a protein such as bovine thyroglobulin, keyhole limpet hemocyanin, or bovine serum albumin, conveniently using a bifunctional linker such as those described elsewhere above, which discussion is incorporated by reference here.

Immunogenicity can also be conferred by fusion of the polypeptide of the present invention to other moieties. For example, polypeptides of the present invention can be produced by solid phase synthesis on a branched polylysine core matrix; these multiple antigenic peptides (MAPs) provide high purity, increased avidity, accurate chemical definition and improved safety in vaccine development. Tam *et al.*, *Proc. Natl. Acad. Sci. USA* 85: 5409-5413 (1988); Posnett *et al.*, *J. Biol. Chem.* 263: 1719-1725 (1988).

Protocols for immunizing non-human mammals or avian species are well-established in the art. See Harlow *et al.* (eds.), Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (1998); Coligan *et al.* (eds.), Current Protocols in Immunology, John Wiley & Sons, Inc. (2001); Zola, Monoclonal Antibodies: Preparation and Use of Monoclonal Antibodies and Engineered Antibody Derivatives (Basics: From Background to Bench), Springer Verlag (2000); Gross M, Speck *J.Dtsch. Tierarztl. Wochenschr.* 103: 417-422 (1996). Immunization protocols often include multiple immunizations, either with or without adjuvants such as Freund's complete adjuvant and Freund's incomplete adjuvant, and may include naked DNA immunization. Moss, *Semin. Immunol.* 2: 317-327 (1990).

Antibodies from non-human mammals and avian species can be polyclonal or monoclonal, with polyclonal antibodies having certain advantages in immunohistochemical detection of the polypeptides of the present invention and monoclonal antibodies having advantages in identifying and distinguishing particular epitopes of the polypeptides of the present invention. Antibodies from avian species may have particular advantage in detection of the polypeptides of the present invention, in human serum or tissues. Vikinge *et al.*, *Biosens. Bioelectron.* 13: 1257-1262 (1998). Following immunization, the antibodies of the present invention can be obtained using any art-accepted technique. Such techniques are well known in the art and are described in detail in references such as Coligan, *supra*; Zola, *supra*; Howard *et al.* (eds.), Basic Methods in Antibody Production and Characterization, CRC Press (2000); Harlow, *supra*; Davis (ed.), Monoclonal Antibody Protocols, Vol. 45, Humana Press (1995); Delves (ed.), Antibody Production: Essential Techniques, John Wiley & Son Ltd (1997); and Kenney, Antibody Solution: An Antibody Methods Manual, Chapman & Hall (1997).

Briefly, such techniques include, *inter alia*, production of monoclonal antibodies by hybridomas and expression of antibodies or fragments or derivatives thereof from host cells engineered to express immunoglobulin genes or fragments thereof. These two

methods of production are not mutually exclusive: genes encoding antibodies specific for the polypeptides of the present invention can be cloned from hybridomas and thereafter expressed in other host cells. Nor need the two necessarily be performed together: *e.g.*, genes encoding antibodies specific for the polypeptides of the present invention can be
5 cloned directly from B cells known to be specific for the desired protein, as further described in U.S. Patent No. 5,627,052, the disclosure of which is incorporated herein by reference in its entirety, or from antibody-displaying phage.

Recombinant expression in host cells is particularly useful when fragments or derivatives of the antibodies of the present invention are desired.

10 Host cells for recombinant antibody production of whole antibodies, antibody fragments, or antibody derivatives can be prokaryotic or eukaryotic.

Prokaryotic hosts are particularly useful for producing phage displayed antibodies of the present invention.

The technology of phage-displayed antibodies, in which antibody variable region
15 fragments are fused, for example, to the gene III protein (pIII) or gene VIII protein (pVIII) for display on the surface of filamentous phage, such as M13, is by now well-established. *See, e.g.*, Sidhu, *Curr. Opin. Biotechnol.* 11(6): 610-6 (2000); Griffiths *et al.*, *Curr. Opin. Biotechnol.* 9(1): 102-8 (1998); Hoogenboom *et al.*, *Immunotechnology*, 4(1): 1-20 (1998); Rader *et al.*, *Current Opinion in Biotechnology* 8: 503-508 (1997); Aujame *et al.*, *Human*
20 *Antibodies* 8: 155-168 (1997); Hoogenboom, *Trends in Biotechnol.* 15: 62-70 (1997); de Kruif *et al.*, 17: 453-455 (1996); Barbas *et al.*, *Trends in Biotechnol.* 14: 230-234 (1996); Winter *et al.*, *Ann. Rev. Immunol.* 433-455 (1994). Techniques and protocols required to generate, propagate, screen (pan), and use the antibody fragments from such libraries have recently been compiled. *See, e.g.*, Barbas (2001), *supra*; Kay, *supra*; and Abelson, *supra*.

25 Typically, phage-displayed antibody fragments are scFv fragments or Fab fragments; when desired, full length antibodies can be produced by cloning the variable regions from the displaying phage into a complete antibody and expressing the full length antibody in a further prokaryotic or a eukaryotic host cell. Eukaryotic cells are also useful for expression of the antibodies, antibody fragments, and antibody derivatives of the
30 present invention. For example, antibody fragments of the present invention can be produced in *Pichia pastoris* and in *Saccharomyces cerevisiae*. *See, e.g.*, Takahashi *et al.*, *Biosci. Biotechnol. Biochem.* 64(10): 2138-44 (2000); Freyre *et al.*, *J. Biotechnol.* 76(2-3):1 57-63 (2000); Fischer *et al.*, *Biotechnol. Appl. Biochem.* 30 (Pt 2): 117-20

(1999); Pennell *et al.*, *Res. Immunol.* 149(6): 599-603 (1998); Eldin *et al.*, *J. Immunol. Methods.* 201(1): 67-75 (1997);, Frenken *et al.*, *Res. Immunol.* 149(6): 589-99 (1998); and Shusta *et al.*, *Nature Biotechnol.* 16(8): 773-7 (1998).

Antibodies, including antibody fragments and derivatives, of the present invention
5 can also be produced in insect cells. *See, e.g.*, Li *et al.*, *Protein Expr. Purif.* 21(1): 121-8 (2001); Ailor *et al.*, *Biotechnol. Bioeng.* 58(2-3): 196-203 (1998); Hsu *et al.*, *Biotechnol. Prog.* 13(1): 96-104 (1997); Edelman *et al.*, *Immunology* 91(1): 13-9 (1997); and Nesbit *et al.*, *J. Immunol. Methods* 151(1-2): 201-8 (1992).

Antibodies and fragments and derivatives thereof of the present invention can also
10 be produced in plant cells, particularly maize or tobacco, Giddings *et al.*, *Nature Biotechnol.* 18(11): 1151-5 (2000); Gavilondo *et al.*, *Biotechniques* 29(1): 128-38 (2000); Fischer *et al.*, *J. Biol. Regul. Homeost. Agents* 14(2): 83-92 (2000); Fischer *et al.*, *Biotechnol. Appl. Biochem.* 30 (Pt 2): 113-6 (1999); Fischer *et al.*, *Biol. Chem.* 380(7-8): 825-39 (1999); Russell, *Curr. Top. Microbiol. Immunol.* 240: 119-38 (1999); and Ma *et al.*, *Plant Physiol.* 109(2): 341-6 (1995).
15

Antibodies, including antibody fragments and derivatives, of the present invention can also be produced in transgenic, non-human, mammalian milk. *See, e.g.* Pollock *et al.*, *J. Immunol Methods.* 231: 147-57 (1999); Young *et al.*, *Res. Immunol.* 149: 609-10 (1998); and Limonta *et al.*, *Immunotechnology* 1: 107-13 (1995).

20 Mammalian cells useful for recombinant expression of antibodies, antibody fragments, and antibody derivatives of the present invention include CHO cells, COS cells, 293 cells, and myeloma cells. Verma *et al.*, *J. Immunol. Methods* 216(1-2):165-81 (1998) review and compare bacterial, yeast, insect and mammalian expression systems for expression of antibodies. Antibodies of the present invention can also be prepared by cell
25 free translation, as further described in Merk *et al.*, *J. Biochem. (Tokyo)* 125(2): 328-33 (1999) and Ryabova *et al.*, *Nature Biotechnol.* 15(1): 79-84 (1997), and in the milk of transgenic animals, as further described in Pollock *et al.*, *J. Immunol. Methods* 231(1-2): 147-57 (1999).

The invention further provides antibody fragments that bind specifically to one or
30 more of the polypeptides of the present invention or to one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention, or the binding of which can be competitively inhibited by one or more of the polypeptides of the present invention or one or more of the polypeptides encoded by the isolated nucleic acid

molecules of the present invention. Among such useful fragments are Fab, Fab', Fv, F(ab)'₂, and single-chain Fv (scFv) fragments. Other useful fragments are described in Hudson, *Curr. Opin. Biotechnol.* 9(4): 395-402 (1998).

5 The present invention also relates to antibody derivatives that bind specifically to one or more of the polypeptides of the present invention, to one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention, or the binding of which can be competitively inhibited by one or more of the polypeptides of the present invention or one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention.

10 Among such useful derivatives are chimeric, primatized, and humanized antibodies; such derivatives are less immunogenic in human beings, and thus are more suitable for *in vivo* administration, than are unmodified antibodies from non-human mammalian species. Another useful method is PEGylation to increase the serum half life of the antibodies.

15 Chimeric antibodies typically include heavy and/or light chain variable regions (including both CDR and framework residues) of immunoglobulins of one species, typically mouse, fused to constant regions of another species, typically human. *See, e.g., Morrison et al., Proc. Natl. Acad. Sci USA* 81(21): 6851-5 (1984); Sharon *et al., Nature* 309(5966): 364-7 (1984); Takeda *et al., Nature* 314(6010): 452-4 (1985); and U.S. Patent
20 No. 5,807,715 the disclosure of which is incorporated herein by reference in its entirety. Primatized and humanized antibodies typically include heavy and/or light chain CDRs from a murine antibody grafted into a non-human primate or human antibody V region framework, usually further comprising a human constant region, Riechmann *et al., Nature* 332(6162): 323-7 (1988); Co *et al., Nature* 351(6326): 501-2 (1991); and U.S. Patent Nos.
25 6,054,297; 5,821,337; 5,770,196; 5,766,886; 5,821,123; 5,869,619; 6,180,377; 6,013,256; 5,693,761; and 6,180,370, the disclosures of which are incorporated herein by reference in their entireties. Other useful antibody derivatives of the invention include heteromeric antibody complexes and antibody fusions, such as diabodies (bispecific antibodies), single-chain diabodies, and intrabodies.

30 It is contemplated that the nucleic acids encoding the antibodies of the present invention can be operably joined to other nucleic acids forming a recombinant vector for cloning or for expression of the antibodies of the invention. Accordingly, the present invention includes any recombinant vector containing the coding sequences, or part

thereof, whether for eukaryotic transduction, transfection or gene therapy. Such vectors may be prepared using conventional molecular biology techniques, known to those with skill in the art, and would comprise DNA encoding sequences for the immunoglobulin V-regions including framework and CDRs or parts thereof, and a suitable promoter either
5 with or without a signal sequence for intracellular transport. Such vectors may be transduced or transfected into eukaryotic cells or used for gene therapy (Marasco et al., *Proc. Natl. Acad. Sci. (USA)* 90: 7889-7893 (1993); Duan et al., *Proc. Natl. Acad. Sci. (USA)* 91: 5075-5079 (1994), by conventional techniques, known to those with skill in the art.

10 The antibodies of the present invention, including fragments and derivatives thereof, can usefully be labeled. It is, therefore, another aspect of the present invention to provide labeled antibodies that bind specifically to one or more of the polypeptides of the present invention, to one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention, or the binding of which can be competitively inhibited
15 by one or more of the polypeptides of the present invention or one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention. The choice of label depends, in part, upon the desired use.

For example, when the antibodies of the present invention are used for immunohistochemical staining of tissue samples, the label can usefully be an enzyme that
20 catalyzes production and local deposition of a detectable product. Enzymes typically conjugated to antibodies to permit their immunohistochemical visualization are well known, and include alkaline phosphatase, β -galactosidase, glucose oxidase, horseradish peroxidase (HRP), and urease. Typical substrates for production and deposition of visually detectable products include o-nitrophenyl-beta-D-galactopyranoside (ONPG);
25 o-phenylenediamine dihydrochloride (OPD); p-nitrophenyl phosphate (PNPP); p-nitrophenyl-beta-D-galactopyranoside (PNPG); 3',3'-diaminobenzidine (DAB); 3-amino-9-ethylcarbazole (AEC); 4-chloro-1-naphthol (CN); 5-bromo-4-chloro-3-indolyl-phosphate (BCIP); ABTS®; BluoGal; iodonitrotetrazolium (INT); nitroblue tetrazolium chloride (NBT); phenazine methosulfate (PMS);
30 phenolphthalein monophosphate (PMP); tetramethyl benzidine (TMB); tetranitroblue tetrazolium (TNBT); X-Gal; X-Gluc; and X-Glucoside.

Other substrates can be used to produce products for local deposition that are luminescent. For example, in the presence of hydrogen peroxide (H₂O₂), horseradish

peroxidase (HRP) can catalyze the oxidation of cyclic diacylhydrazides, such as luminol. Immediately following the oxidation, the luminol is in an excited state (intermediate reaction product), which decays to the ground state by emitting light. Strong enhancement of the light emission is produced by enhancers, such as phenolic compounds. Advantages
5 include high sensitivity, high resolution, and rapid detection without radioactivity and requiring only small amounts of antibody. See, e.g., Thorpe *et al.*, *Methods Enzymol.* 133: 331-53 (1986); Kricka *et al.*, *J. Immunoassay* 17(1): 67-83 (1996); and Lundqvist *et al.*, *J. Biolumin. Chemilumin.* 10(6): 353-9 (1995). Kits for such enhanced chemiluminescent detection (ECL) are available commercially. The antibodies can also be labeled using
10 colloidal gold.

As another example, when the antibodies of the present invention are used, e.g., for flow cytometric detection, for scanning laser cytometric detection, or for fluorescent immunoassay, they can usefully be labeled with fluorophores. There are a wide variety of fluorophore labels that can usefully be attached to the antibodies of the present invention.
15 For flow cytometric applications, both for extracellular detection and for intracellular detection, common useful fluorophores can be fluorescein isothiocyanate (FITC), allophycocyanin (APC), R-phycoerythrin (PE), peridinin chlorophyll protein (PerCP), Texas Red, Cy3, Cy5, fluorescence resonance energy tandem fluorophores such as PerCP-Cy5.5, PE-Cy5, PE-Cy5.5, PE-Cy7, PE-Texas Red, and APC-Cy7.

Other fluorophores include, *inter alia*, Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY
25 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR, USA), and Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, all of
30 which are also useful for fluorescently labeling the antibodies of the present invention. For secondary detection using labeled avidin, streptavidin, captavidin or neutravidin, the antibodies of the present invention can usefully be labeled with biotin.

When the antibodies of the present invention are used, *e.g.*, for western blotting applications, they can usefully be labeled with radioisotopes, such as ^{33}P , ^{32}P , ^{35}S , ^3H , and ^{125}I . As another example, when the antibodies of the present invention are used for radioimmunoassay, the label can usefully be ^{228}Th , ^{227}Ac , ^{225}Ac , ^{223}Ra , ^{213}Bi , ^{212}Pb ,
 5 ^{212}Bi , ^{211}At , ^{203}Pb , ^{194}Os , ^{188}Re , ^{186}Re , ^{153}Sm , ^{149}Tb , ^{131}I , ^{125}I , ^{111}In , ^{105}Rh , $^{99\text{m}}\text{Tc}$, ^{97}Ru , ^{90}Y ,
 ^{90}Sr , ^{88}Y , ^{72}Se , ^{67}Cu , or ^{47}Sc .

As another example, when the antibodies of the present invention are to be used for *in vivo* diagnostic use, they can be rendered detectable by conjugation to MRI contrast agents, such as gadolinium diethylenetriaminepentaacetic acid (DTPA), Lauffer *et al.*,
 10 *Radiology* 207(2): 529-38 (1998), or by radioisotopic labeling.

As would be understood, use of the labels described above is not restricted to the application as for which they were mentioned.

The antibodies of the present invention, including fragments and derivatives thereof, can also be conjugated to toxins, in order to target the toxin's ablative action to
 15 cells that display and/or express the polypeptides of the present invention. Commonly, the antibody in such immunotoxins is conjugated to Pseudomonas exotoxin A, diphtheria toxin, shiga toxin A, anthrax toxin lethal factor, or ricin. *See* Hall (ed.), Immunotoxin Methods and Protocols (Methods in Molecular Biology, vol. 166), Humana Press (2000); and Frankel *et al.* (eds.), Clinical Applications of Immunotoxins, Springer-Verlag (1998).

20 The antibodies of the present invention can usefully be attached to a substrate, and it is, therefore, another aspect of the invention to provide antibodies that bind specifically to one or more of the polypeptides of the present invention, to one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention, or the binding of which can be competitively inhibited by one or more of the polypeptides of
 25 the present invention or one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention, attached to a substrate. Substrates can be porous or nonporous, planar or nonplanar. For example, the antibodies of the present invention can usefully be conjugated to filtration media, such as NHS-activated Sepharose or CNBr-activated Sepharose for purposes of immunoaffinity chromatography. For example, the
 30 antibodies of the present invention can usefully be attached to paramagnetic microspheres, typically by biotin-streptavidin interaction, which microsphere can then be used for isolation of cells that express or display the polypeptides of the present invention. As

another example, the antibodies of the present invention can usefully be attached to the surface of a microtiter plate for ELISA.

As noted above, the antibodies of the present invention can be produced in prokaryotic and eukaryotic cells. It is, therefore, another aspect of the present invention to
5 provide cells that express the antibodies of the present invention, including hybridoma cells, B cells, plasma cells, and host cells recombinantly modified to express the antibodies of the present invention.

In yet a further aspect, the present invention provides aptamers evolved to bind specifically to one or more of the OSPs of the present invention or to polypeptides
10 encoded by the OSNAs of the invention.

In sum, one of skill in the art, provided with the teachings of this invention, has available a variety of methods which may be used to alter the biological properties of the antibodies of this invention including methods which would increase or decrease the stability or half-life, immunogenicity, toxicity, affinity or yield of a given antibody
15 molecule, or to alter it in any other way that may render it more suitable for a particular application.

Transgenic Animals and Cells

In another aspect, the invention provides transgenic cells and non-human organisms comprising nucleic acid molecules of the invention. In a preferred
20 embodiment, the transgenic cells and non-human organisms comprise a nucleic acid molecule encoding an OSP. In a preferred embodiment, the OSP comprises an amino acid sequence selected from SEQ ID NO: 129-295, or a fragment, mutein, homologous protein or allelic variant thereof. In another preferred embodiment, the transgenic cells and non-human organism comprise an OSNA of the invention, preferably an OSNA comprising a
25 nucleotide sequence selected from the group consisting of SEQ ID NO: 1-128, or a part, substantially similar nucleic acid molecule, allelic variant or hybridizing nucleic acid molecule thereof.

In another embodiment, the transgenic cells and non-human organisms have a targeted disruption or replacement of the endogenous orthologue of the human OSG. The
30 transgenic cells can be embryonic stem cells or somatic cells. The transgenic non-human organisms can be chimeric, nonchimeric heterozygotes, and nonchimeric homozygotes. Methods of producing transgenic animals are well known in the art. *See, e.g., Hogan et*

al., Manipulating the Mouse Embryo: A Laboratory Manual, 2d ed., Cold Spring Harbor Press (1999); Jackson *et al.*, Mouse Genetics and Transgenics: A Practical Approach, Oxford University Press (2000); and Pinkert, Transgenic Animal Technology: A Laboratory Handbook, Academic Press (1999).

5 Any technique known in the art may be used to introduce a nucleic acid molecule of the invention into an animal to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection. (*see, e.g.*, Paterson *et al.*, *Appl. Microbiol. Biotechnol.* 40: 691-698 (1994); Carver *et al.*, *Biotechnology* 11: 1263-1270 (1993); Wright *et al.*, *Biotechnology* 9: 830-834 (1991); and U.S. Patent No. 10 4,873,191, herein incorporated by reference in its entirety); retrovirus-mediated gene transfer into germ lines, blastocysts or embryos (*see, e.g.*, Van der Putten *et al.*, *Proc. Natl. Acad. Sci., USA* 82: 6148-6152 (1985)); gene targeting in embryonic stem cells (*see, e.g.*, Thompson *et al.*, *Cell* 56: 313-321 (1989)); electroporation of cells or embryos (*see, e.g.*, Lo, 1983, *Mol. Cell. Biol.* 3: 1803-1814 (1983)); introduction using a gene gun (*see, e.g.*, Ulmer *et al.*, *Science* 259: 1745-49 (1993); introducing nucleic acid constructs into 15 embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (*see, e.g.*, Lavitrano *et al.*, *Cell* 57: 717-723 (1989)).

Other techniques include, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (*see, e.g.*, 20 Campell *et al.*, *Nature* 380: 64-66 (1996); Wilmut *et al.*, *Nature* 385: 810-813 (1997)). The present invention provides for transgenic animals that carry the transgene (*i.e.*, a nucleic acid molecule of the invention) in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.* *e.*, mosaic animals or chimeric animals.

The transgene may be integrated as a single transgene or as multiple copies, such 25 as in concatamers, *e. g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, *e.g.*, the teaching of Lasko *et al. et al.*, *Proc. Natl. Acad. Sci. USA* 89: 6232- 6236 (1992). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

30 Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the

transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, in situ hybridization analysis, and reverse transcriptase-PCR (RT-PCR). Samples of transgenic gene-expressing tissue may also be evaluated

- 5 immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than
10 one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA
15 analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of
20 the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Methods for creating a transgenic animal with a disruption of a targeted gene are also well known in the art. In general, a vector is designed to comprise some nucleotide
25 sequences homologous to the endogenous targeted gene. The vector is introduced into a cell so that it may integrate, via homologous recombination with chromosomal sequences, into the endogenous gene, thereby disrupting the function of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type. *See, e.g., Gu et al., Science* 265: 103-106
30 (1994). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. *See, e.g., Smithies et al., Nature* 317: 230-234 (1985); Thomas *et al., Cell* 51: 503-512 (1987); Thompson *et al., Cell* 5: 313-321 (1989).

In one embodiment, a mutant, non-functional nucleic acid molecule of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous nucleic acid sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable
5 marker, to transfect cells that express polypeptides of the invention in vivo. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications
10 to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene. *See, e.g.,* Thomas, *supra* and Thompson, *supra*. However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site in vivo using appropriate viral vectors that will be apparent to those of skill in the art.

15 In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (*e.g.*, knockouts) are administered to a patient in vivo. Such cells may be obtained from an animal or patient or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells,
20 blood cells (*e.g.*, lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered in vitro using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, *e.g.*, by transduction (using viral vectors, and preferably
25 vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.

The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve
30 expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, *e.g.*, in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, *e.g.*, genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. *See, e.g.*, U.S. Patent Nos. 5,399,349 and 5,460,959, each of which is
5 incorporated by reference herein in its entirety.

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of
10 components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with
15 aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Computer Readable Means

A further aspect of the invention is a computer readable means for storing the nucleic acid and amino acid sequences of the instant invention. In a preferred
20 embodiment, the invention provides a computer readable means for storing SEQ ID NO: 129-295 and SEQ ID NO: 1-128 as described herein, as the complete set of sequences or in any combination. The records of the computer readable means can be accessed for reading and display and for interface with a computer system for the application of programs allowing for the location of data upon a query for data meeting certain criteria,
25 the comparison of sequences, the alignment or ordering of sequences meeting a set of criteria, and the like.

The nucleic acid and amino acid sequences of the invention are particularly useful as components in databases useful for search analyses as well as in sequence analysis algorithms. As used herein, the terms "nucleic acid sequences of the invention" and
30 "amino acid sequences of the invention" mean any detectable chemical or physical characteristic of a polynucleotide or polypeptide of the invention that is or may be reduced to or stored in a computer readable form. These include, without limitation,

chromatographic scan data or peak data, photographic data or scan data therefrom, and mass spectrographic data.

This invention provides computer readable media having stored thereon sequences of the invention. A computer readable medium may comprise one or more of the
5 following: a nucleic acid sequence comprising a sequence of a nucleic acid sequence of the invention; an amino acid sequence comprising an amino acid sequence of the invention; a set of nucleic acid sequences wherein at least one of said sequences comprises the sequence of a nucleic acid sequence of the invention; a set of amino acid sequences wherein at least one of said sequences comprises the sequence of an amino acid sequence
10 of the invention; a data set representing a nucleic acid sequence comprising the sequence of one or more nucleic acid sequences of the invention; a data set representing a nucleic acid sequence encoding an amino acid sequence comprising the sequence of an amino acid sequence of the invention; a set of nucleic acid sequences wherein at least one of said sequences comprises the sequence of a nucleic acid sequence of the invention; a set of
15 amino acid sequences wherein at least one of said sequences comprises the sequence of an amino acid sequence of the invention; a data set representing a nucleic acid sequence comprising the sequence of a nucleic acid sequence of the invention; a data set representing a nucleic acid sequence encoding an amino acid sequence comprising the sequence of an amino acid sequence of the invention. The computer readable medium can
20 be any composition of matter used to store information or data, including, for example, commercially available floppy disks, tapes, hard drives, compact disks, and video disks.

Also provided by the invention are methods for the analysis of character sequences, particularly genetic sequences. Preferred methods of sequence analysis include, for example, methods of sequence homology analysis, such as identity and
25 similarity analysis, RNA structure analysis, sequence assembly, cladistic analysis, sequence motif analysis, open reading frame determination, nucleic acid base calling, and sequencing chromatogram peak analysis.

A computer-based method is provided for performing nucleic acid sequence identity or similarity identification. This method comprises the steps of providing a
30 nucleic acid sequence comprising the sequence of a nucleic acid of the invention in a computer readable medium; and comparing said nucleic acid sequence to at least one nucleic acid or amino acid sequence to identify sequence identity or similarity.

A computer-based method is also provided for performing amino acid homology identification, said method comprising the steps of: providing an amino acid sequence comprising the sequence of an amino acid of the invention in a computer readable medium; and comparing said amino acid sequence to at least one nucleic acid or an amino acid sequence to identify homology.

A computer-based method is still further provided for assembly of overlapping nucleic acid sequences into a single nucleic acid sequence, said method comprising the steps of: providing a first nucleic acid sequence comprising the sequence of a nucleic acid of the invention in a computer readable medium; and screening for at least one overlapping region between said first nucleic acid sequence and a second nucleic acid sequence. In addition, the invention includes a method of using patterns of expression associated with either the nucleic acids or proteins in a computer-based method to diagnose disease.

Diagnostic Methods for Ovarian Cancer

The present invention also relates to quantitative and qualitative diagnostic assays and methods for detecting, diagnosing, monitoring, staging and predicting cancers by comparing expression of an OSNA or an OSP in a human patient that has or may have ovarian cancer, or who is at risk of developing ovarian cancer, with the expression of an OSNA or an OSP in a normal human control. For purposes of the present invention, “expression of an OSNA” or “OSNA expression” means the quantity of OSNA mRNA that can be measured by any method known in the art or the level of transcription that can be measured by any method known in the art in a cell, tissue, organ or whole patient. Similarly, the term “expression of an OSP” or “OSP expression” means the amount of OSP that can be measured by any method known in the art or the level of translation of an OSNA that can be measured by any method known in the art.

The present invention provides methods for diagnosing ovarian cancer in a patient, by analyzing for changes in levels of OSNA or OSP in cells, tissues, organs or bodily fluids compared with levels of OSNA or OSP in cells, tissues, organs or bodily fluids of preferably the same type from a normal human control, wherein an increase, or decrease in certain cases, in levels of an OSNA or OSP in the patient versus the normal human control is associated with the presence of ovarian cancer or with a predilection to the disease. In another preferred embodiment, the present invention provides methods for diagnosing

ovarian cancer in a patient by analyzing changes in the structure of the mRNA of an OSG compared to the mRNA from a normal control. These changes include, without limitation, aberrant splicing, alterations in polyadenylation and/or alterations in 5' nucleotide capping. In yet another preferred embodiment, the present invention provides methods for
5 diagnosing ovarian cancer in a patient by analyzing changes in an OSP compared to an OSP from a normal patient. These changes include, *e.g.*, alterations, including post translational modifications such as glycosylation and/or phosphorylation of the OSP or changes in the subcellular OSP localization.

For purposes of the present invention, diagnosing means that OSNA or OSP levels
10 are used to determine the presence or absence of disease in a patient. As will be understood by those of skill in the art, measurement of other diagnostic parameters may be required for definitive diagnosis or determination of the appropriate treatment for the disease. The determination may be made by a clinician, a doctor, a testing laboratory, or a patient using an over the counter test. The patient may have symptoms of disease or may
15 be asymptomatic. In addition, the OSNA or OSP levels of the present invention may be used as screening marker to determine whether further tests or biopsies are warranted. In addition, the OSNA or OSP levels may be used to determine the vulnerability or susceptibility to disease.

In a preferred embodiment, the expression of an OSNA is measured by
20 determining the amount of a mRNA that encodes an amino acid sequence selected from SEQ ID NO: 129-295, a homolog, an allelic variant, or a fragment thereof. In a more preferred embodiment, the OSNA expression that is measured is the level of expression of an OSNA mRNA selected from SEQ ID NO: 1-128, or a hybridizing nucleic acid, homologous nucleic acid or allelic variant thereof, or a part of any of these nucleic acid
25 molecules. OSNA expression may be measured by any method known in the art, such as those described *supra*, including measuring mRNA expression by Northern blot, quantitative or qualitative reverse transcriptase PCR (RT-PCR), microarray, dot or slot blots or *in situ* hybridization. *See, e.g.*, Ausubel (1992), *supra*; Ausubel (1999), *supra*; Sambrook (1989), *supra*; and Sambrook (2001), *supra*. OSNA transcription may be
30 measured by any method known in the art including using a reporter gene hooked up to the promoter of an OSG of interest or doing nuclear run-off assays. Alterations in mRNA structure, *e.g.*, aberrant splicing variants, may be determined by any method known in the art, including, RT-PCR followed by sequencing or restriction analysis. As necessary,

OSNA expression may be compared to a known control, such as normal ovarian nucleic acid, to detect a change in expression.

In another preferred embodiment, the expression of an OSP is measured by determining the level of an OSP having an amino acid sequence selected from the group consisting of SEQ ID NO: 129-295, a homolog, an allelic variant, or a fragment thereof. Such levels are preferably determined in at least one of cells, tissues, organs and/or bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for diagnosing over- or underexpression of an OSNA or OSP compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of ovarian cancer. The expression level of an OSP may be determined by any method known in the art, such as those described *supra*. In a preferred embodiment, the OSP expression level may be determined by radioimmunoassays, competitive-binding assays, ELISA, Western blot, FACS, immunohistochemistry, immunoprecipitation, proteomic approaches: two-dimensional gel electrophoresis (2D electrophoresis) and non-gel-based approaches such as mass spectrometry or protein interaction profiling. *See, e.g., Harlow (1999), supra; Ausubel (1992), supra; and Ausubel (1999), supra.* Alterations in the OSP structure may be determined by any method known in the art, including, *e.g.,* using antibodies that specifically recognize phosphoserine, phosphothreonine or phosphotyrosine residues, two-dimensional polyacrylamide gel electrophoresis (2D PAGE) and/or chemical analysis of amino acid residues of the protein. *Id.*

In a preferred embodiment, a radioimmunoassay (RIA) or an ELISA is used. An antibody specific to an OSP is prepared if one is not already available. In a preferred embodiment, the antibody is a monoclonal antibody. The anti-OSP antibody is bound to a solid support and any free protein binding sites on the solid support are blocked with a protein such as bovine serum albumin. A sample of interest is incubated with the antibody on the solid support under conditions in which the OSP will bind to the anti-OSP antibody. The sample is removed, the solid support is washed to remove unbound material, and an anti-OSP antibody that is linked to a detectable reagent (a radioactive substance for RIA and an enzyme for ELISA) is added to the solid support and incubated under conditions in which binding of the OSP to the labeled antibody will occur. After binding, the unbound labeled antibody is removed by washing. For an ELISA, one or more substrates are added to produce a colored reaction product that is based upon the amount of an OSP in the

sample. For an RIA, the solid support is counted for radioactive decay signals by any method known in the art. Quantitative results for both RIA and ELISA typically are obtained by reference to a standard curve.

Other methods to measure OSP levels are known in the art. For instance, a
5 competition assay may be employed wherein an anti-OSP antibody is attached to a solid support and an allocated amount of a labeled OSP and a sample of interest are incubated with the solid support. The amount of labeled OSP attached to the solid support can be correlated to the quantity of an OSP in the sample.

Of the proteomic approaches, 2D PAGE is a well known technique. Isolation of
10 individual proteins from a sample such as serum is accomplished using sequential separation of proteins by isoelectric point and molecular weight. Typically, polypeptides are first separated by isoelectric point (the first dimension) and then separated by size using an electric current (the second dimension). In general, the second dimension is perpendicular to the first dimension. Because no two proteins with different sequences are
15 identical on the basis of both size and charge, the result of 2D PAGE is a roughly square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.

Expression levels of an OSNA can be determined by any method known in the art,
20 including PCR and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASBA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In
25 RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction.

Hybridization to specific DNA molecules (*e.g.*, oligonucleotides) arrayed on a solid support can be used to both detect the expression of and quantitate the level of
30 expression of one or more OSNAs of interest. In this approach, all or a portion of one or more OSNAs is fixed to a substrate. A sample of interest, which may comprise RNA, *e.g.*, total RNA or polyA-selected mRNA, or a complementary DNA (cDNA) copy of the RNA is incubated with the solid support under conditions in which hybridization will occur

between the DNA on the solid support and the nucleic acid molecules in the sample of interest. Hybridization between the substrate-bound DNA and the nucleic acid molecules in the sample can be detected and quantitated by several means, including, without limitation, radioactive labeling or fluorescent labeling of the nucleic acid molecule or a
5 secondary molecule designed to detect the hybrid.

The above tests can be carried out on samples derived from a variety of cells, bodily fluids and/or tissue extracts such as homogenates or solubilized tissue obtained from a patient. Tissue extracts are obtained routinely from tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva or any
10 other bodily secretion or derivative thereof. As used herein "blood" includes whole blood, plasma, serum, circulating epithelial cells, constituents, or any derivative of blood.

In addition to detection in bodily fluids, the proteins and nucleic acids of the invention are suitable to detection by cell capture technology. Whole cells may be captured by a variety of methods for example magnetic separation, such as described in U.S.
15 Patent Nos. 5,200,084; 5,186,827; 5,108,933; and 4,925,788, the disclosures of which are incorporated herein by reference in their entireties. Epithelial cells may be captured using such products as Dynabeads® or CELLection™ (DynaL Biotech, Oslo, Norway). Alternatively, fractions of blood may be captured, e.g., the buffy coat fraction (50mm cells isolated from 5ml of blood) containing epithelial cells. In addition, cancer cells may be
20 captured using the techniques described in WO 00/47998, the disclosure of which is incorporated herein by reference in its entirety. Once the cells are captured or concentrated, the proteins or nucleic acids are detected by the means described in the subject application. Alternatively, nucleic acids may be captured directly from blood samples, see U.S. Patent Nos. 6,156,504, 5,501,963; or WO 01/42504, the disclosures of
25 which are incorporated herein by reference in their entireties.

In a preferred embodiment, the specimen tested for expression of OSNA or OSP includes without limitation ovarian tissue, ovarian cells grown in cell culture, blood, serum, lymph node tissue, and lymphatic fluid. In another preferred embodiment, especially when metastasis of a primary ovarian cancer is known or suspected, specimens
30 include, without limitation, tissues from brain, bone, bone marrow, liver, lungs, colon, and adrenal glands. In general, the tissues may be sampled by biopsy, including, without limitation, needle biopsy, e.g., transthoracic needle aspiration, cervical mediastinoscopy,

endoscopic lymph node biopsy, video-assisted thoracoscopy, exploratory thoracotomy, bone marrow biopsy and bone marrow aspiration.

All the methods of the present invention may optionally include determining the expression levels of one or more other cancer markers in addition to determining the expression level of an OSNA or OSP. In many cases, the use of another cancer marker will decrease the likelihood of false positives or false negatives. In one embodiment, the one or more other cancer markers include other OSNAs or OSPs as disclosed herein. Other cancer markers useful in the present invention will depend on the cancer being tested and are known to those of skill in the art. In a preferred embodiment, at least one other cancer marker in addition to a particular OSNA or OSP is measured. In a more preferred embodiment, at least two other additional cancer markers are used. In an even more preferred embodiment, at least three, more preferably at least five, even more preferably at least ten additional cancer markers are used.

Diagnosing

In one aspect, the invention provides a method for determining the expression levels and/or structural alterations of one or more OSNA and/or OSP in a sample from a patient suspected of having ovarian cancer. In general, the method comprises the steps of obtaining the sample from the patient, determining the expression level or structural alterations of an OSNA and/or OSP and then ascertaining whether the patient has ovarian cancer from the expression level of the OSNA or OSP. In general, if high expression relative to a control of an OSNA or OSP is indicative of ovarian cancer, a diagnostic assay is considered positive if the level of expression of the OSNA or OSP is at least one and a half times higher, and more preferably are at least two times higher, still more preferably five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of an OSNA or OSP is indicative of ovarian cancer, a diagnostic assay is considered positive if the level of expression of the OSNA or OSP is at least one and a half times lower, and more preferably are at least two times lower, still more preferably five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control. The normal human control may be from a different patient or from uninvolved tissue of the same patient.

The present invention also provides a method of determining whether ovarian cancer has metastasized in a patient. One may identify whether the ovarian cancer has metastasized by measuring the expression levels and/or structural alterations of one or more OSNAs and/or OSPs in a variety of tissues. The presence of an OSNA or OSP in a tissue other than ovarian at levels higher than that of corresponding noncancerous tissue (e.g., the same tissue from another individual) is indicative of metastasis if high level expression of an OSNA or OSP is associated with ovarian cancer. Similarly, the presence of an OSNA or OSP in a tissue other than ovarian at levels lower than that of corresponding noncancerous tissue is indicative of metastasis if low level expression of an OSNA or OSP is associated with ovarian cancer. Further, the presence of a structurally altered OSNA or OSP that is associated with ovarian cancer is also indicative of metastasis.

In general, if high expression relative to a control of an OSNA or OSP is indicative of metastasis, an assay for metastasis is considered positive if the level of expression of the OSNA or OSP is at least one and a half times higher, and more preferably are at least two times higher, still more preferably five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of an OSNA or OSP is indicative of metastasis, an assay for metastasis is considered positive if the level of expression of the OSNA or OSP is at least one and a half times lower, and more preferably are at least two times lower, still more preferably five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control.

25 *Staging*

The invention also provides a method of staging ovarian cancer in a human patient. The method comprises identifying a human patient having ovarian cancer and analyzing cells, tissues or bodily fluids from such human patient for expression levels and/or structural alterations of one or more OSNAs or OSPs. First, one or more tumors from a variety of patients are staged according to procedures well known in the art, and the expression levels of one or more OSNAs or OSPs is determined for each stage to obtain a standard expression level for each OSNA and OSP. Then, the OSNA or OSP expression

levels of the OSNA or OSP are determined in a biological sample from a patient whose stage of cancer is not known. The OSNA or OSP expression levels from the patient are then compared to the standard expression level. By comparing the expression level of the OSNAs and OSPs from the patient to the standard expression levels, one may determine the stage of the tumor. The same procedure may be followed using structural alterations of an OSNA or OSP to determine the stage of a ovarian cancer.

Monitoring

Further provided is a method of monitoring ovarian cancer in a human patient. One may monitor a human patient to determine whether there has been metastasis and, if there has been, when metastasis began to occur. One may also monitor a human patient to determine whether a preneoplastic lesion has become cancerous. One may also monitor a human patient to determine whether a therapy, *e.g.*, chemotherapy, radiotherapy or surgery, has decreased or eliminated the ovarian cancer. The monitoring may determine if there has been a reoccurrence and, if so, determine its nature. The method comprises identifying a human patient that one wants to monitor for ovarian cancer, periodically analyzing cells, tissues or bodily fluids from such human patient for expression levels of one or more OSNAs or OSPs, and comparing the OSNA or OSP levels over time to those OSNA or OSP expression levels obtained previously. Patients may also be monitored by measuring one or more structural alterations in an OSNA or OSP that are associated with ovarian cancer.

If increased expression of an OSNA or OSP is associated with metastasis, treatment failure, or conversion of a preneoplastic lesion to a cancerous lesion, then detecting an increase in the expression level of an OSNA or OSP indicates that the tumor is metastasizing, that treatment has failed or that the lesion is cancerous, respectively. One having ordinary skill in the art would recognize that if this were the case, then a decreased expression level would be indicative of no metastasis, effective therapy or failure to progress to a neoplastic lesion. If decreased expression of an OSNA or OSP is associated with metastasis, treatment failure, or conversion of a preneoplastic lesion to a cancerous lesion, then detecting a decrease in the expression level of an OSNA or OSP indicates that the tumor is metastasizing, that treatment has failed or that the lesion is cancerous, respectively. In a preferred embodiment, the levels of OSNAs or OSPs are determined from the same cell type, tissue or bodily fluid as prior patient samples. Monitoring a

patient for onset of ovarian cancer metastasis is periodic and preferably is done on a quarterly basis, but may be done more or less frequently.

The methods described herein can further be utilized as prognostic assays to identify subjects having or at risk of developing a disease or disorder associated with increased or decreased expression levels of an OSNA and/or OSP. The present invention provides a method in which a test sample is obtained from a human patient and one or more OSNAs and/or OSPs are detected. The presence of higher (or lower) OSNA or OSP levels as compared to normal human controls is diagnostic for the human patient being at risk for developing cancer, particularly ovarian cancer. The effectiveness of therapeutic agents to decrease (or increase) expression or activity of one or more OSNAs and/or OSPs of the invention can also be monitored by analyzing levels of expression of the OSNAs and/or OSPs in a human patient in clinical trials or in *in vitro* screening assays such as in human cells. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the human patient or cells, as the case may be, to the agent being tested.

Detection of Genetic Lesions or Mutations

The methods of the present invention can also be used to detect genetic lesions or mutations in an OSG, thereby determining if a human with the genetic lesion is susceptible to developing ovarian cancer or to determine what genetic lesions are responsible, or are partly responsible, for a person's existing ovarian cancer. Genetic lesions can be detected, for example, by ascertaining the existence of a deletion, insertion and/or substitution of one or more nucleotides from the OSGs of this invention, a chromosomal rearrangement of an OSG, an aberrant modification of an OSG (such as of the methylation pattern of the genomic DNA), or allelic loss of an OSG. Methods to detect such lesions in the OSG of this invention are known to those having ordinary skill in the art following the teachings of the specification.

Methods of Detecting Noncancerous Ovarian Diseases

The present invention also provides methods for determining the expression levels and/or structural alterations of one or more OSNAs and/or OSPs in a sample from a patient suspected of having or known to have a noncancerous ovarian disease. In general, the method comprises the steps of obtaining a sample from the patient, determining the expression level or structural alterations of an OSNA and/or OSP, comparing the

expression level or structural alteration of the OSNA or OSP to a normal ovarian control, and then ascertaining whether the patient has a noncancerous ovarian disease. In general, if high expression relative to a control of an OSNA or OSP is indicative of a particular noncancerous ovarian disease, a diagnostic assay is considered positive if the level of expression of the OSNA or OSP is at least two times higher, and more preferably are at least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of an OSNA or OSP is indicative of a noncancerous ovarian disease, a diagnostic assay is considered positive if the level of expression of the OSNA or OSP is at least two times lower, more preferably are at least five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control. The normal human control may be from a different patient or from uninvolved tissue of the same patient.

One having ordinary skill in the art may determine whether an OSNA and/or OSP is associated with a particular noncancerous ovarian disease by obtaining ovarian tissue from a patient having a noncancerous ovarian disease of interest and determining which OSNAs and/or OSPs are expressed in the tissue at either a higher or a lower level than in normal ovarian tissue. In another embodiment, one may determine whether an OSNA or OSP exhibits structural alterations in a particular noncancerous ovarian disease state by obtaining ovarian tissue from a patient having a noncancerous ovarian disease of interest and determining the structural alterations in one or more OSNAs and/or OSPs relative to normal ovarian tissue.

Methods for Identifying Ovarian Tissue

In another aspect, the invention provides methods for identifying ovarian tissue. These methods are particularly useful in, *e.g.*, forensic science, ovarian cell differentiation and development, and in tissue engineering.

In one embodiment, the invention provides a method for determining whether a sample is ovarian tissue or has ovarian tissue-like characteristics. The method comprises the steps of providing a sample suspected of comprising ovarian tissue or having ovarian tissue-like characteristics, determining whether the sample expresses one or more OSNAs and/or OSPs, and, if the sample expresses one or more OSNAs and/or OSPs, concluding that the sample comprises ovarian tissue. In a preferred embodiment, the OSNA encodes

a polypeptide having an amino acid sequence selected from SEQ ID NO: 129-295, or a homolog, allelic variant or fragment thereof. In a more preferred embodiment, the OSNA has a nucleotide sequence selected from SEQ ID NO: 1-128, or a hybridizing nucleic acid, an allelic variant or a part thereof. Determining whether a sample expresses an OSNA can be accomplished by any method known in the art. Preferred methods include hybridization to microarrays, Northern blot hybridization, and quantitative or qualitative RT-PCR. In another preferred embodiment, the method can be practiced by determining whether an OSP is expressed. Determining whether a sample expresses an OSP can be accomplished by any method known in the art. Preferred methods include Western blot, ELISA, RIA and 2D PAGE. In one embodiment, the OSP has an amino acid sequence selected from SEQ ID NO: 129-295, or a homolog, allelic variant or fragment thereof. In another preferred embodiment, the expression of at least two OSNAs and/or OSPs is determined. In a more preferred embodiment, the expression of at least three, more preferably four and even more preferably five OSNAs and/or OSPs are determined.

In one embodiment, the method can be used to determine whether an unknown tissue is ovarian tissue. This is particularly useful in forensic science, in which small, damaged pieces of tissues that are not identifiable by microscopic or other means are recovered from a crime or accident scene. In another embodiment, the method can be used to determine whether a tissue is differentiating or developing into ovarian tissue. This is important in monitoring the effects of the addition of various agents to cell or tissue culture, *e.g.*, in producing new ovarian tissue by tissue engineering. These agents include, *e.g.*, growth and differentiation factors, extracellular matrix proteins and culture medium. Other factors that may be measured for effects on tissue development and differentiation include gene transfer into the cells or tissues, alterations in pH, aqueous:air interface and various other culture conditions.

Methods for Producing and Modifying Ovarian Tissue

In another aspect, the invention provides methods for producing engineered ovarian tissue or cells. In one embodiment, the method comprises the steps of providing cells, introducing an OSNA or an OSG into the cells, and growing the cells under conditions in which they exhibit one or more properties of ovarian tissue cells. In a preferred embodiment, the cells are pluripotent. As is well known in the art, normal ovarian tissue comprises a large number of different cell types. Thus, in one embodiment,

the engineered ovarian tissue or cells comprises one of these cell types. In another embodiment, the engineered ovarian tissue or cells comprises more than one ovarian cell type. Further, the culture conditions of the cells or tissue may require manipulation in order to achieve full differentiation and development of the ovarian cell tissue. Methods for manipulating culture conditions are well known in the art.

Nucleic acid molecules encoding one or more OSPs are introduced into cells, preferably pluripotent cells. In a preferred embodiment, the nucleic acid molecules encode OSPs having amino acid sequences selected from SEQ ID NO: 129-295, or homologous proteins, analogs, allelic variants or fragments thereof. In a more preferred embodiment, the nucleic acid molecules have a nucleotide sequence selected from SEQ ID NO: 1-128, or hybridizing nucleic acids, allelic variants or parts thereof. In another highly preferred embodiment, an OSG is introduced into the cells. Expression vectors and methods of introducing nucleic acid molecules into cells are well known in the art and are described in detail, *supra*.

Artificial ovarian tissue may be used to treat patients who have lost some or all of their ovarian function.

Pharmaceutical Compositions

In another aspect, the invention provides pharmaceutical compositions comprising the nucleic acid molecules, polypeptides, fusion proteins, antibodies, antibody derivatives, antibody fragments, agonists, antagonists, or inhibitors of the present invention. In a preferred embodiment, the pharmaceutical composition comprises an OSNA or part thereof. In a more preferred embodiment, the OSNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-128, a nucleic acid that hybridizes thereto, an allelic variant thereof, or a nucleic acid that has substantial sequence identity thereto. In another preferred embodiment, the pharmaceutical composition comprises an OSP or fragment thereof. In a more preferred embodiment, the pharmaceutical composition comprises an OSP having an amino acid sequence that is selected from the group consisting of SEQ ID NO: 129-295, a polypeptide that is homologous thereto, a fusion protein comprising all or a portion of the polypeptide, or an analog or derivative thereof. In another preferred embodiment, the pharmaceutical composition comprises an anti-OSP antibody, preferably an antibody that specifically binds to an OSP having an amino acid that is selected from the group consisting of SEQ ID NO: 129-295, or an antibody that

binds to a polypeptide that is homologous thereto, a fusion protein comprising all or a portion of the polypeptide, or an analog or derivative thereof.

Due to the association of angiogenesis with cancer vascularization there is great need of new markers and methods for diagnosing angiogenesis activity to identify
5 developing tumors and angiogenesis related diseases. Furthermore, great need is also present for new molecular targets useful in the treatment of angiogenesis and angiogenesis related diseases such as cancer. In addition known modulators of angiogenesis such as endostatin or vascular endothelial growth factor (VEGF). Use of the methods and compositions disclosed herein in combination with anti-angiogenesis drugs, drugs that
10 block the matrix breakdown (such as BMS-275291, Dalteparin (Fragmin®), Suramin), drugs that inhibit endothelial cells (2-methoxyestradiol (2-ME), CC-5013 (Thalidomide Analog), Combretastatin A4 Phosphate, LY317615 (Protein Kinase C Beta Inhibitor), Soy Isoflavone (Genistein; Soy Protein Isolate), Thalidomide), drugs that block activators of angiogenesis (AE-941 (Neovastat™; GW786034), Anti-VEGF Antibody (Bevacizumab; Avastin™), Interferon-alpha, PTK787/ZK 222584, VEGF-Trap, ZD6474), Drugs that
15 inhibit endothelial-specific integrin/survival signaling (EMD 121974, Anti-Anb3 Integrin Antibody (Medi-522; Vitaxin™)).

Such a composition typically contains from about 0.1 to 90% by weight of a therapeutic agent of the invention formulated in and/or with a pharmaceutically acceptable
20 carrier or excipient.

Pharmaceutical formulation is a well-established art that is further described in Gennaro (ed.), Remington: The Science and Practice of Pharmacy, 20th ed., Lippincott, Williams & Wilkins (2000); Ansel *et al.*, Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th ed., Lippincott Williams & Wilkins (1999); and Kibbe (ed.),
25 Handbook of Pharmaceutical Excipients American Pharmaceutical Association, 3rd ed. (2000) and thus need not be described in detail herein.

Briefly, formulation of the pharmaceutical compositions of the present invention will depend upon the route chosen for administration. The pharmaceutical compositions utilized in this invention can be administered by various routes including both enteral and
30 parenteral routes, including oral, intravenous, intramuscular, subcutaneous, inhalation, topical, sublingual, rectal, intra-arterial, intramedullary, intrathecal, intraventricular, transmucosal, transdermal, intranasal, intraperitoneal, intrapulmonary, and intrauterine.

Oral dosage forms can be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Solid formulations of the compositions for oral administration can contain suitable carriers or excipients, such as carbohydrate or protein fillers, such as sugars, including
5 lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, or microcrystalline cellulose; gums including arabic and tragacanth; proteins such as gelatin and collagen; inorganics, such as kaolin, calcium carbonate, dicalcium phosphate, sodium chloride; and other agents such as acacia and
10 alginic acid.

Agents that facilitate disintegration and/or solubilization can be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate, microcrystalline cellulose, cornstarch, sodium starch glycolate, and alginic acid.

Tablet binders that can be used include acacia, methylcellulose, sodium
15 carboxymethylcellulose, polyvinylpyrrolidone (Povidone™), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose.

Lubricants that can be used include magnesium stearates, stearic acid, silicone fluid, talc, waxes, oils, and colloidal silica.

Fillers, agents that facilitate disintegration and/or solubilization, tablet binders and
20 lubricants, including the aforementioned, can be used singly or in combination.

Solid oral dosage forms need not be uniform throughout. For example, dragee cores can be used in conjunction with suitable coatings, such as concentrated sugar solutions, which can also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic
25 solvents or solvent mixtures.

Oral dosage forms of the present invention include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally,
30 stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Additionally, dyestuffs or pigments can be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, *i.e.*, dosage.

Liquid formulations of the pharmaceutical compositions for oral (enteral) administration are prepared in water or other aqueous vehicles and can contain various
5 suspending agents such as methylcellulose, alginates, tragacanth, pectin, kelgin, carrageenan, acacia, polyvinylpyrrolidone, and polyvinyl alcohol. The liquid formulations can also include solutions, emulsions, syrups and elixirs containing, together with the active compound(s), wetting agents, sweeteners, and coloring and flavoring agents.

The pharmaceutical compositions of the present invention can also be formulated
10 for parenteral administration. Formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions.

For intravenous injection, water soluble versions of the compounds of the present invention are formulated in, or if provided as a lyophilate, mixed with, a physiologically acceptable fluid vehicle, such as 5% dextrose ("D5"), physiologically buffered saline,
15 0.9% saline, Hanks' solution, or Ringer's solution. Intravenous formulations may include carriers, excipients or stabilizers including, without limitation, calcium, human serum albumin, citrate, acetate, calcium chloride, carbonate, and other salts.

Intramuscular preparations, *e.g.* a sterile formulation of a suitable soluble salt form of the compounds of the present invention, can be dissolved and administered in a
20 pharmaceutical excipient such as Water-for-Injection, 0.9% saline, or 5% glucose solution. Alternatively, a suitable insoluble form of the compound can be prepared and administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, such as an ester of a long chain fatty acid (*e.g.*, ethyl oleate), fatty oils such as sesame oil, triglycerides, or liposomes.

25 Parenteral formulations of the compositions can contain various carriers such as vegetable oils, dimethylacetamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the like).

Aqueous injection suspensions can also contain substances that increase the
30 viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Non-lipid polycationic amino polymers can also be used for delivery. Optionally, the suspension can also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Pharmaceutical compositions of the present invention can also be formulated to permit injectable, long-term, deposition. Injectable depot forms may be made by forming microencapsulated matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in microemulsions that are compatible with body tissues.

The pharmaceutical compositions of the present invention can be administered topically. For topical use the compounds of the present invention can also be prepared in suitable forms to be applied to the skin, or mucus membranes of the nose and throat, and can take the form of lotions, creams, ointments, liquid sprays or inhalants, drops, tinctures, lozenges, or throat paints. Such topical formulations further can include chemical compounds such as dimethylsulfoxide (DMSO) to facilitate surface penetration of the active ingredient. In other transdermal formulations, typically in patch-delivered formulations, the pharmaceutically active compound is formulated with one or more skin penetrants, such as 2-N-methyl-pyrrolidone (NMP) or Azone. A topical semi-solid ointment formulation typically contains a concentration of the active ingredient from about 1 to 20%, *e.g.*, 5 to 10%, in a carrier such as a pharmaceutical cream base.

For application to the eyes or ears, the compounds of the present invention can be presented in liquid or semi-liquid form formulated in hydrophobic or hydrophilic bases as ointments, creams, lotions, paints or powders.

For rectal administration the compounds of the present invention can be administered in the form of suppositories admixed with conventional carriers such as cocoa butter, wax or other glyceride.

Inhalation formulations can also readily be formulated. For inhalation, various powder and liquid formulations can be prepared. For aerosol preparations, a sterile formulation of the compound or salt form of the compound may be used in inhalers, such as metered dose inhalers, and nebulizers. Aerosolized forms may be especially useful for treating respiratory disorders.

Alternatively, the compounds of the present invention can be in powder form for reconstitution in the appropriate pharmaceutically acceptable carrier at the time of delivery.

The pharmaceutically active compound in the pharmaceutical compositions of the present invention can be provided as the salt of a variety of acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms.

After pharmaceutical compositions have been prepared, they are packaged in an appropriate container and labeled for treatment of an indicated condition.

The active compound will be present in an amount effective to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

A "therapeutically effective dose" refers to that amount of active ingredient, for example OSP polypeptide, fusion protein, or fragments thereof, antibodies specific for OSP, agonists, antagonists or inhibitors of OSP, which ameliorates the signs or symptoms of the disease or prevent progression thereof; as would be understood in the medical arts, cure, although desired, is not required.

The therapeutically effective dose of the pharmaceutical agents of the present invention can be estimated initially by *in vitro* tests, such as cell culture assays, followed by assay in model animals, usually mice, rats, rabbits, dogs, or pigs. The animal model can also be used to determine an initial preferred concentration range and route of administration.

For example, the ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population) can be determined in one or more cell culture of animal model systems. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as LD50/ED50. Pharmaceutical compositions that exhibit large therapeutic indices are preferred.

The data obtained from cell culture assays and animal studies are used in formulating an initial dosage range for human use, and preferably provide a range of circulating concentrations that includes the ED50 with little or no toxicity. After administration, or between successive administrations, the circulating concentration of active agent varies within this range depending upon pharmacokinetic factors well known in the art, such as the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors specific to the subject requiring treatment. Factors that can be taken into account by the practitioner include the severity of the disease state, general health of the subject, age, weight, gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Where the therapeutic agent is a protein or antibody of the present invention, the therapeutic protein or antibody agent typically is administered at a daily dosage of 0.01 mg to 30 mg/kg of body weight of the patient (*e.g.*, 1mg/kg to 5 mg/kg). The pharmaceutical formulation can be administered in multiple doses per day, if desired, to achieve the total desired daily dose.

Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

Conventional methods, known to those of ordinary skill in the art of medicine, can be used to administer the pharmaceutical formulation(s) of the present invention to the patient. The pharmaceutical compositions of the present invention can be administered alone, or in combination with other therapeutic agents or interventions.

Therapeutic Methods

The present invention further provides methods of treating subjects having defects in a gene of the invention, *e.g.*, in expression, activity, distribution, localization, and/or solubility, which can manifest as a disorder of ovarian function. As used herein, "treating" includes all medically-acceptable types of therapeutic intervention, including palliation and prophylaxis (prevention) of disease. The term "treating" encompasses any improvement of a disease, including minor improvements. These methods are discussed below.

Gene Therapy and Vaccines

The isolated nucleic acids of the present invention can also be used to drive *in vivo* expression of the polypeptides of the present invention. *In vivo* expression can be driven from a vector, typically a viral vector, often a vector based upon a replication incompetent retrovirus, an adenovirus, or an adeno-associated virus (AAV), for the purpose of gene therapy. *In vivo* expression can also be driven from signals endogenous to the nucleic acid or from a vector, often a plasmid vector, such as pVAX1 (Invitrogen, Carlsbad, CA, USA), for purpose of “naked” nucleic acid vaccination, as further described in U.S. Patent Nos. 5,589,466; 5,679,647; 5,804,566; 5,830,877; 5,843,913; 5,880,104; 5,958,891; 5,985,847; 6,017,897; 6,110,898; 6,204,250, the disclosures of which are incorporated herein by reference in their entirety. For cancer therapy, it is preferred that the vector also be tumor-selective. *See, e.g., Doronin et al., J. Virol.* 75: 3314-24 (2001).

In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising a nucleic acid molecule of the present invention is administered. The nucleic acid molecule can be delivered in a vector that drives expression of an OSP, fusion protein, or fragment thereof, or without such vector. Nucleic acid compositions that can drive expression of an OSP are administered, for example, to complement a deficiency in the native OSP, or as DNA vaccines. Expression vectors derived from virus, replication deficient retroviruses, adenovirus, adeno-associated (AAV) virus, herpes virus, or vaccinia virus can be used as can plasmids. *See, e.g., Cid-Arregui, supra.* In a preferred embodiment, the nucleic acid molecule encodes an OSP having the amino acid sequence of SEQ ID NO: 129-295, or a fragment, fusion protein, allelic variant or homolog thereof.

In still other therapeutic methods of the present invention, pharmaceutical compositions comprising host cells that express an OSP, fusions, or fragments thereof can be administered. In such cases, the cells are typically autologous, so as to circumvent xenogeneic or allotypic rejection, and are administered to complement defects in OSP production or activity. In a preferred embodiment, the nucleic acid molecules in the cells encode an OSP having the amino acid sequence of SEQ ID NO: 129-295, or a fragment, fusion protein, allelic variant or homolog thereof.

Antisense Administration

Antisense nucleic acid compositions, or vectors that drive expression of an OSG antisense nucleic acid, are administered to downregulate transcription and/or translation of an OSG in circumstances in which excessive production, or production of aberrant protein, is the pathophysiologic basis of disease.

Antisense compositions useful in therapy can have a sequence that is complementary to coding or to noncoding regions of an OSG. For example, oligonucleotides derived from the transcription initiation site, *e.g.*, between positions -10 and +10 from the start site, are preferred.

Catalytic antisense compositions, such as ribozymes, that are capable of sequence-specific hybridization to OSG transcripts, are also useful in therapy. *See, e.g.*, Phylactou, *Adv. Drug Deliv. Rev.* 44(2-3): 97-108 (2000); Phylactou *et al.*, *Hum. Mol. Genet.* 7(10): 1649-53 (1998); Rossi, *Ciba Found. Symp.* 209: 195-204 (1997); and Sigurdsson *et al.*, *Trends Biotechnol.* 13(8): 286-9 (1995).

Other nucleic acids useful in the therapeutic methods of the present invention are those that are capable of triplex helix formation in or near the OSG genomic locus. Such triplexing oligonucleotides are able to inhibit transcription. *See, e.g.*, Intody *et al.*, *Nucleic Acids Res.* 28(21): 4283-90 (2000); and McGuffie *et al.*, *Cancer Res.* 60(14): 3790-9 (2000). Pharmaceutical compositions comprising such triplex forming oligos (TFOs) are administered in circumstances in which excessive production, or production of aberrant protein, is a pathophysiologic basis of disease.

In a preferred embodiment, the antisense molecule is derived from a nucleic acid molecule encoding an OSP, preferably an OSP comprising an amino acid sequence of SEQ ID NO: 129-295, or a fragment, allelic variant or homolog thereof. In a more preferred embodiment, the antisense molecule is derived from a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-128, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

Polypeptide Administration

In one embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising an OSP, a fusion protein, fragment, analog or derivative thereof is administered to a subject with a clinically-significant OSP defect.

Protein compositions are administered, for example, to complement a deficiency in native OSP. In other embodiments, protein compositions are administered as a vaccine to elicit a humoral and/or cellular immune response to OSP. The immune response can be used to modulate activity of OSP or, depending on the immunogen, to immunize against aberrant or aberrantly expressed forms, such as mutant or inappropriately expressed isoforms. In yet other embodiments, protein fusions having a toxic moiety are administered to ablate cells that aberrantly accumulate OSP.

In a preferred embodiment, the polypeptide administered is an OSP comprising an amino acid sequence of SEQ ID NO: 129-295, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the polypeptide is encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-128, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

Antibody, Agonist and Antagonist Administration

In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising an antibody (including fragment or derivative thereof) of the present invention is administered. As is well known, antibody compositions are administered, for example, to antagonize activity of OSP, or to target therapeutic agents to sites of OSP presence and/or accumulation. In a preferred embodiment, the antibody specifically binds to an OSP comprising an amino acid sequence of SEQ ID NO: 129-295, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the antibody specifically binds to an OSP encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-128, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

The present invention also provides methods for identifying modulators which bind to an OSP or have a modulatory effect on the expression or activity of an OSP. Modulators which decrease the expression or activity of OSP (antagonists) are believed to be useful in treating ovarian cancer. Such screening assays are known to those of skill in the art and include, without limitation, cell-based assays and cell-free assays. Small molecules predicted via computer imaging to specifically bind to regions of an OSP can also be designed, synthesized and tested for use in the imaging and treatment of ovarian cancer. Further, libraries of molecules can be screened for potential anticancer agents by

assessing the ability of the molecule to bind to the OSPs identified herein. Molecules identified in the library as being capable of binding to an OSP are key candidates for further evaluation for use in the treatment of ovarian cancer. In a preferred embodiment, these molecules will downregulate expression and/or activity of an OSP in cells.

5 In another embodiment of the therapeutic methods of the present invention, a pharmaceutical composition comprising a non-antibody antagonist of OSP is administered. Antagonists of OSP can be produced using methods generally known in the art. In particular, purified OSP can be used to screen libraries of pharmaceutical agents, often combinatorial libraries of small molecules, to identify those that specifically bind
10 and antagonize at least one activity of an OSP.

 In other embodiments a pharmaceutical composition comprising an agonist of an OSP is administered. Agonists can be identified using methods analogous to those used to identify antagonists.

 In a preferred embodiment, the antagonist or agonist specifically binds to and
15 antagonizes or agonizes, respectively, an OSP comprising an amino acid sequence of SEQ ID NO: 129-295, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the antagonist or agonist specifically binds to and antagonizes or agonizes, respectively, an OSP encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-128, or a part, allelic variant, substantially similar
20 or hybridizing nucleic acid thereof.

Targeting Ovarian Tissue

 The invention also provides a method in which a polypeptide of the invention, or an antibody thereto, is linked to a therapeutic agent such that it can be delivered to the
25 ovarian or to specific cells in the ovarian. In a preferred embodiment, an anti-OSP antibody is linked to a therapeutic agent and is administered to a patient in need of such therapeutic agent. The therapeutic agent may be a toxin, if ovarian tissue needs to be selectively destroyed. This would be useful for targeting and killing ovarian cancer cells. In another embodiment, the therapeutic agent may be a growth or differentiation factor,
30 which would be useful for promoting ovarian cell function.

 In another embodiment, an anti-OSP antibody may be linked to an imaging agent that can be detected using, *e.g.*, magnetic resonance imaging, CT or PET. This would be

useful for determining and monitoring ovarian function, identifying ovarian cancer tumors, and identifying noncancerous ovarian diseases.

EXAMPLES

Example 1a: Alternative Splice Variants

- 5 We identified gene transcripts using the Gencarta™ tools (Compugen Ltd., Tel Aviv, Israel) and a variety of public and proprietary databases. These splice variants are either sequences which differ from a previously defined sequence or new uses of known sequences. In general related variants are annotated as DEX0455_XXX.nt.1, DEX0455_XXX.nt.2, DEX0455_XXX.nt.3, etc. The variant DNA sequences encode
- 10 proteins which differ from a previously defined protein sequence. In relation to the nucleotide sequence naming convention, protein variants are annotated as DEX0455_XXX.aa.1, DEX0455_XXX.aa.2, etc., wherein transcript DEX0455_XXX.nt.1 encodes protein DEX0455_XXX.aa.1. A single transcript may encode a protein from an alternate Open Reading Fram (ORF) which is designated DEX0455_XXX.orf.1.
- 15 Additionally, multiple transcripts may encode for a single protein. In this case, DEX0455_XXX.nt.1 and DEX0455_XXX.nt.2 will both be associated with DEX0455_XXX.aa.1.

- The mapping of the nucleic acid ("NT") SEQ ID NO; DEX ID; chromosomal location (if known); open reading frame (ORF) location; amino acid ("AA") SEQ ID NO; AA DEX ID; are shown in the table below.
- 20

SEQ ID NO	DEX ID	Chromo Map	ORF Loc	SEQ ID NO	DEX ID
1	DEX0455_001.nt.1	X;47722965-47733965	1624-2937	129	DEX0455_001.orf.1
1	DEX0455_001.nt.1	X;47722965-47733965	322-1035	130	DEX0455_001.aa.1
2	DEX0455_002.nt.1	17q11.1	217-915	131	DEX0455_002.aa.1
3	DEX0455_003.nt.1	10p11.23	132-476	132	DEX0455_003.aa.1
4	DEX0455_004.nt.1	3q29	7357-7809	133	DEX0455_004.orf.1
4	DEX0455_004.nt.1	3q29	2974-5074	134	DEX0455_004.aa.1
5	DEX0455_004.nt.2	3q29	6201-6653	135	DEX0455_004.orf.2
5	DEX0455_004.nt.2	3q29	2968-5257	136	DEX0455_004.aa.2
6	DEX0455_005.nt.1	2q13	854-1267	137	DEX0455_005.aa.1
7	DEX0455_005.nt.2	2q13	853-1270	137	DEX0455_005.aa.1
8	DEX0455_006.nt.1	9q22.1	730-1266	138	DEX0455_006.aa.1
9	DEX0455_007.nt.1	19q13.41	1-882	139	DEX0455_007.orf.1

9	DEX0455_007.nt.1	19q13.41	1-885	140	DEX0455_007.aa.1
10	DEX0455_008.nt.1	4q27	869-1138	141	DEX0455_008.aa.1
11	DEX0455_009.nt.1	20p12.2	1-1123	142	DEX0455_009.aa.1
12	DEX0455_010.nt.1	Un_6;1484154-1498876	341-784	143	DEX0455_010.orf.1
12	DEX0455_010.nt.1	Un_6;1484154-1498876	151-370	144	DEX0455_010.aa.1
13	DEX0455_010.nt.2	Un_6;1484154-1498876	49-621	145	DEX0455_010.orf.2
13	DEX0455_010.nt.2	Un_6;1484154-1498876	151-490	146	DEX0455_010.aa.2
14	DEX0455_011.nt.1	19q13.31	1-384	147	DEX0455_011.aa.1
15	DEX0455_012.nt.1	1q32.1	207-974	148	DEX0455_012.aa.1
16	DEX0455_012.nt.2	1q32.1	102-851	149	DEX0455_012.orf.2
16	DEX0455_012.nt.2	1q32.1	206-1415	150	DEX0455_012.aa.2
17	DEX0455_013.nt.1	12p12.3	10-666	151	DEX0455_013.aa.1
18	DEX0455_013.nt.2	12p12.3	124-639	152	DEX0455_013.aa.2
19	DEX0455_014.nt.1	1q42.2	880-1866	153	DEX0455_014.orf.1
19	DEX0455_014.nt.1	1q42.2	82-1870	154	DEX0455_014.aa.1
20	DEX0455_015.nt.1	12q13.2	1-255	155	DEX0455_015.aa.1
21	DEX0455_016.nt.1	1p31.1	104-868	156	DEX0455_016.aa.1
22	DEX0455_017.nt.1	1p33	102-623	157	DEX0455_017.aa.1
23	DEX0455_018.nt.1	9q34.11	209-1270	158	DEX0455_018.aa.1
24	DEX0455_018.nt.2	9q34.11	682-2148	159	DEX0455_018.aa.2
25	DEX0455_019.nt.1	11q13.4	66-926	160	DEX0455_019.aa.1
26	DEX0455_020.nt.1	19p13.11	365-793	161	DEX0455_020.aa.1
27	DEX0455_020.nt.2	19p13.11	688-1035	162	DEX0455_020.orf.2
27	DEX0455_020.nt.2	19p13.11	474-678	163	DEX0455_020.aa.2
28	DEX0455_021.nt.1	1p36.11	175-486	164	DEX0455_021.orf.1
28	DEX0455_021.nt.1	1p36.11	1-250	165	DEX0455_021.aa.1
29	DEX0455_021.nt.2	1p36.11	190-1269	166	DEX0455_021.aa.2
30	DEX0455_021.nt.3	1p36.11	46-1173	167	DEX0455_021.orf.3
30	DEX0455_021.nt.3	1p36.11	189-1590	168	DEX0455_021.aa.3
31	DEX0455_021.nt.4	1p36.11	190-1173	169	DEX0455_021.aa.4
32	DEX0455_022.nt.1	19p13.12	109-642	170	DEX0455_022.aa.1
33	DEX0455_022.nt.2	19p13.12	70-492	171	DEX0455_022.orf.2
33	DEX0455_022.nt.2	19p13.12	108-675	172	DEX0455_022.aa.2
34	DEX0455_022.nt.3	19p13.12	91-324	173	DEX0455_022.aa.3
35	DEX0455_023.nt.1	7q11.21	609-956	174	DEX0455_023.aa.1
36	DEX0455_024.nt.1	2p13.3	486-1569	175	DEX0455_024.aa.1
37	DEX0455_024.nt.2	2p13.3	469-999	176	DEX0455_024.aa.2
38	DEX0455_025.nt.1	17q24.3	475-1614	177	DEX0455_025.aa.1
39	DEX0455_025.nt.2	17q24.3	328-1509	178	DEX0455_025.orf.2
39	DEX0455_025.nt.2	17q24.3	474-2514	179	DEX0455_025.aa.2
40	DEX0455_025.nt.3	17q24.3	474-1617	177	DEX0455_025.aa.1
41	DEX0455_025.nt.4	17q24.3	474-1617	177	DEX0455_025.aa.1
42	DEX0455_026.nt.1	2q32.2	3-218	180	DEX0455_026.orf.1
42	DEX0455_026.nt.1	2q32.2	1-236	181	DEX0455_026.aa.1

43	DEX0455_027.nt.1	2q24.3	986-1507	182	DEX0455_027.orf.1
43	DEX0455_027.nt.1	2q24.3	16-128	183	DEX0455_027.aa.1
44	DEX0455_028.nt.1	9p24.3	141-785	184	DEX0455_028.aa.1
45	DEX0455_029.nt.1	9q21.11	4134-4532	185	DEX0455_029.orf.1
45	DEX0455_029.nt.1	9q21.11	2985-5847	186	DEX0455_029.aa.1
46	DEX0455_029.nt.2	9q21.11	4562-5143	187	DEX0455_029.orf.2
46	DEX0455_029.nt.2	9q21.11	2962-5149	188	DEX0455_029.aa.2
47	DEX0455_030.nt.1	16p11.2	188-1123	189	DEX0455_030.aa.1
48	DEX0455_030.nt.2	16p11.2	82-627	190	DEX0455_030.aa.2
49	DEX0455_031.nt.1	12p13.31	135-1013	191	DEX0455_031.orf.1
49	DEX0455_031.nt.1	12p13.31	248-2156	192	DEX0455_031.aa.1
50	DEX0455_031.nt.2	12p13.31	248-749	193	DEX0455_031.aa.2
50	DEX0455_031.nt.2	12p13.31	1325-2239	194	DEX0455_031.orf.2
51	DEX0455_031.nt.3	12p13.31	1-582	195	DEX0455_031.aa.3
52	DEX0455_032.nt.1	7q31.1	39-761	196	DEX0455_032.aa.1
53	DEX0455_033.nt.1	1p34.1	161-943	197	DEX0455_033.aa.1
54	DEX0455_034.nt.1	15q21.1	197-1693	198	DEX0455_034.aa.1
55	DEX0455_034.nt.2	15q21.1	1-1497	198	DEX0455_034.aa.1
56	DEX0455_034.nt.3	15q21.1	197-1228	199	DEX0455_034.aa.3
57	DEX0455_034.nt.4	15q21.1	2-1438	200	DEX0455_034.aa.4
58	DEX0455_035.nt.1	10q22.1	102-464	201	DEX0455_035.aa.1
59	DEX0455_035.nt.2	10q22.1	755-1201	202	DEX0455_035.orf.2
59	DEX0455_035.nt.2	10q22.1	330-696	203	DEX0455_035.aa.2
60	DEX0455_035.nt.3	10q22.1	634-1080	204	DEX0455_035.orf.3
60	DEX0455_035.nt.3	10q22.1	269-575	205	DEX0455_035.aa.3
61	DEX0455_036.nt.1	19p13.2	86-370	206	DEX0455_036.orf.1
61	DEX0455_036.nt.1	19p13.2	58-389	207	DEX0455_036.aa.1
62	DEX0455_036.nt.2	19p13.2	295-4749	208	DEX0455_036.aa.2
63	DEX0455_036.nt.3	19p13.2	3-335	209	DEX0455_036.orf.3
63	DEX0455_036.nt.3	19p13.2	88-352	210	DEX0455_036.aa.3
64	DEX0455_036.nt.4	19p13.2	77-352	211	DEX0455_036.orf.4
64	DEX0455_036.nt.4	19p13.2	1-253	212	DEX0455_036.aa.4
65	DEX0455_037.nt.1	9	113-787	213	DEX0455_037.aa.1
66	DEX0455_037.nt.2	9	2-1048	214	DEX0455_037.orf.2
66	DEX0455_037.nt.2	9	112-1354	215	DEX0455_037.aa.2
67	DEX0455_037.nt.3	9	113-1342	216	DEX0455_037.aa.3
68	DEX0455_037.nt.4	9	2-410	217	DEX0455_037.aa.4
69	DEX0455_037.nt.5	9	3-452	218	DEX0455_037.aa.5
70	DEX0455_037.nt.6	9	113-784	219	DEX0455_037.aa.6
71	DEX0455_037.nt.7	9	113-1555	220	DEX0455_037.aa.7
72	DEX0455_038.nt.1	20p12.1	298-3561	221	DEX0455_038.aa.1
73	DEX0455_038.nt.2	20p12.1	298-3564	221	DEX0455_038.aa.1
74	DEX0455_038.nt.3	20p12.1	1-1320	222	DEX0455_038.orf.3
74	DEX0455_038.nt.3	20p12.1	298-1863	223	DEX0455_038.aa.3
75	DEX0455_039.nt.1	19q13.2	2-496	224	DEX0455_039.aa.1
76	DEX0455_039.nt.2	19q13.2	2-787	225	DEX0455_039.aa.2
77	DEX0455_040.nt.1	19q13.2	299-991	226	DEX0455_040.orf.1

77	DEX0455_040.nt.1	19q13.2	352-991	227	DEX0455_040.aa.1
78	DEX0455_040.nt.2	19q13.2	770-1495	228	DEX0455_040.aa.2
79	DEX0455_041.nt.1	20q11.23	54-212	229	DEX0455_041.orf.1
79	DEX0455_041.nt.1	20q11.23	7-138	230	DEX0455_041.aa.1
80	DEX0455_041.nt.2	20q11.23	11-208	231	DEX0455_041.orf.2
80	DEX0455_041.nt.2	20q11.23	1-107	232	DEX0455_041.aa.2
81	DEX0455_042.nt.1	4q22.1	90-437	233	DEX0455_042.orf.1
81	DEX0455_042.nt.1	4q22.1	70-439	234	DEX0455_042.aa.1
82	DEX0455_043.nt.1	1q42.12	511-768	235	DEX0455_043.orf.1
82	DEX0455_043.nt.1	1q42.12	1-93	236	DEX0455_043.aa.1
83	DEX0455_043.nt.2	1q42.12	413-787	237	DEX0455_043.orf.2
83	DEX0455_043.nt.2	1q42.12	1-93	236	DEX0455_043.aa.1
84	DEX0455_043.nt.3	1q42.12	1220-1531	238	DEX0455_043.orf.3
84	DEX0455_043.nt.3	1q42.12	1-93	236	DEX0455_043.aa.1
85	DEX0455_044.nt.1	17q25.3	445-627	239	DEX0455_044.aa.1
86	DEX0455_045.nt.1	16p12.3	1-579	240	DEX0455_045.orf.1
86	DEX0455_045.nt.1	16p12.3	1-492	241	DEX0455_045.aa.1
87	DEX0455_046.nt.1	17q21.32	709-1389	242	DEX0455_046.orf.1
87	DEX0455_046.nt.1	17q21.32	802-1389	243	DEX0455_046.aa.1
88	DEX0455_047.nt.1	8p23.1	2887-3195	244	DEX0455_047.orf.1
88	DEX0455_047.nt.1	8p23.1	136-334	245	DEX0455_047.aa.1
89	DEX0455_047.nt.2	8p23.1	1091-1399	246	DEX0455_047.orf.2
89	DEX0455_047.nt.2	8p23.1	19-102	247	DEX0455_047.aa.2
90	DEX0455_048.nt.1	X;150645762-150649651	84-545	248	DEX0455_048.aa.1
91	DEX0455_048.nt.2	X;150645762-150649651	286-813	249	DEX0455_048.orf.2
91	DEX0455_048.nt.2	X;150645762-150649651	1-817	250	DEX0455_048.aa.2
92	DEX0455_049.nt.1	2p21	1183-1986	251	DEX0455_049.aa.1
93	DEX0455_049.nt.2	2p21	378-1403	252	DEX0455_049.aa.2
94	DEX0455_049.nt.3	2p21	808-1527	253	DEX0455_049.aa.3
95	DEX0455_049.nt.4	2p21	1-1170	254	DEX0455_049.aa.4
96	DEX0455_049.nt.5	2p21	179-1120	255	DEX0455_049.aa.5
97	DEX0455_050.nt.1	7p22.1	186-551	256	DEX0455_050.orf.1
97	DEX0455_050.nt.1	7p22.1	1-149	257	DEX0455_050.aa.1
98	DEX0455_051.nt.1	19	1-1788	258	DEX0455_051.aa.1
99	DEX0455_051.nt.2	19	1-1224	259	DEX0455_051.aa.2
100	DEX0455_051.nt.3	19	1-1410	260	DEX0455_051.aa.3
101	DEX0455_051.nt.4	19	1-1224	259	DEX0455_051.aa.2
101	DEX0455_051.nt.4	19	1-1422	261	DEX0455_051.orf.4
102	DEX0455_051.nt.5	19	1-1224	259	DEX0455_051.aa.2
102	DEX0455_051.nt.5	19	1-1422	262	DEX0455_051.orf.5
103	DEX0455_051.nt.6	19	1-1224	259	DEX0455_051.aa.2
103	DEX0455_051.nt.6	19	1-1422	263	DEX0455_051.orf.6
104	DEX0455_052.nt.1	19	13-1422	264	DEX0455_052.aa.1
105	DEX0455_052.nt.2	19	13-1518	265	DEX0455_052.aa.2
106	DEX0455_052.nt.3	19	188-1831	266	DEX0455_052.aa.3

107	DEX0455_052.nt.4	19	100-930	267	DEX0455_052.aa.4
108	DEX0455_053.nt.1	1p12	1-846	268	DEX0455_053.aa.1
109	DEX0455_053.nt.2	1p12	1-177	269	DEX0455_053.aa.2
109	DEX0455_053.nt.2	1p12	253-1008	270	DEX0455_053.aa.3
110	DEX0455_054.nt.1	15q24.3	1218-1682	271	DEX0455_054.orf.1
110	DEX0455_054.nt.1	15q24.3	1038-1362	272	DEX0455_054.aa.1
111	DEX0455_054.nt.2	15q24.3	410-874	273	DEX0455_054.orf.2
111	DEX0455_054.nt.2	15q24.3	122-554	274	DEX0455_054.aa.2
112	DEX0455_055.nt.1	1	812-1570	275	DEX0455_055.aa.1
113	DEX0455_055.nt.2	1	388-1470	276	DEX0455_055.aa.2
114	DEX0455_055.nt.3	1p34.2	402-902	277	DEX0455_055.aa.3
115	DEX0455_056.nt.1	7q31.1	626-2533	278	DEX0455_056.orf.1
115	DEX0455_056.nt.1	7q31.1	670-3283	279	DEX0455_056.aa.1
116	DEX0455_056.nt.2	7q31.1	671-3043	280	DEX0455_056.aa.2
117	DEX0455_057.nt.1	1q21.3	146-511	281	DEX0455_057.orf.1
117	DEX0455_057.nt.1	1q21.3	1-513	282	DEX0455_057.aa.1
118	DEX0455_057.nt.2	1q21.3	405-681	283	DEX0455_057.aa.2
119	DEX0455_058.nt.1	1q42.12	1208-1405	284	DEX0455_058.orf.1
119	DEX0455_058.nt.1	1q42.12	315-513	285	DEX0455_058.aa.1
120	DEX0455_059.nt.1	19p13.11	294-1382	286	DEX0455_059.orf.1
120	DEX0455_059.nt.1	19p13.11	1-352	287	DEX0455_059.aa.1
121	DEX0455_059.nt.2	19p13.11	596-1093	288	DEX0455_059.orf.2
121	DEX0455_059.nt.2	19p13.11	1-352	287	DEX0455_059.aa.1
122	DEX0455_060.nt.1	21q21.1	3-623	289	DEX0455_060.aa.1
123	DEX0455_061.nt.1	10q11.21	1564-2619	290	DEX0455_061.aa.1
124	DEX0455_061.nt.2	10q11.21	2449-3231	291	DEX0455_061.aa.2
125	DEX0455_061.nt.3	10q11.21	2449-3255	292	DEX0455_061.aa.3
126	DEX0455_061.nt.4	10q11.21	1045-1443	293	DEX0455_061.aa.4
127	DEX0455_061.nt.5	10q11.21	842-1330	294	DEX0455_061.orf.5
127	DEX0455_061.nt.5	10q11.21	1740-2142	293	DEX0455_061.aa.4
128	DEX0455_062.nt.1	2p25.1	120-1592	295	DEX0455_062.aa.1

The polypeptides of the present invention were analyzed and the following attributes were identified; specifically, epitopes, post translational modifications, signal peptides and transmembrane domains. Antigenicity (Epitope) prediction was performed through the antigenic module in the EMBOSS package. Rice, P., EMBOSS: The European Molecular Biology Open Software Suite, *Trends in Genetics* 16(6): 276-277 (2000). The antigenic module predicts potentially antigenic regions of a protein sequence, using the method of Kolaskar and Tongaonkar. Kolaskar, AS and Tongaonkar, PC., A semi-empirical method for prediction of antigenic determinants on protein antigens, *FEBS Letters* 276: 172-174 (1990). Examples of post-translational modifications (PTMs) and other motifs of the OSPs of this invention are listed below. In addition, antibodies that specifically bind such post-translational modifications may be useful as a diagnostic or as

- therapeutic. The PTMs and other motifs were predicted by using the ProSite Dictionary of Proteins Sites and Patterns (Bairoch *et al.*, *Nucleic Acids Res.* 25(1):217-221 (1997)), the following motifs, including PTMs, were predicted for the OSPs of the invention. The signal peptides were detected by using the SignalP 2.0, *see* Nielsen *et al.*, *Protein Engineering* 12, 3-9 (1999). Prediction of transmembrane helices in proteins was performed by the application TMHMM 2.0, "currently the best performing transmembrane prediction program", according to authors (Krogh *et al.*, *Journal of Molecular Biology*, 305(3):567-580, (2001); Moller *et al.*, *Bioinformatics*, 17(7):646-653, (2001); Sonnhammer, *et al.*, *A hidden Markov model for predicting transmembrane helices in protein sequences* in Glasgow, *et al.* Ed. Proceedings of the Sixth International Conference on Intelligent Systems for Molecular Biology, pages 175-182, Menlo Park, CA, 1998. AAAI Press. The PSORT II program may also be used to predict cellular localizations. Horton *et al.*, *Intelligent Systems for Molecular Biology* 5: 147-152 (1997). The table below includes the following sequence annotations: Signal peptide presence; TM (number of membrane domain, topology in orientation and position); Amino acid location and antigenic index (location, AI score); PTM and other motifs (type, amino acid residue locations); and functional domains (type, amino acid residue locations).

DEX ID	Sig P	TMHMM	Antigenicity	PTM	Domains
DEX0455_001.orf.1	N	0 - 01-438;	333-345, 1.127; 155-162, 1.105; 184-208, 1.14; 231-239, 1.049; 56-63, 1.067; 170-176, 1.117; 38-47, 1.115; 75-81, 1.069; 108-119, 1.16; 305-311, 1.041; 273-283, 1.106; 241-256, 1.161; 4-36, 1.186;	CK2_PHOSPHO_SITE 104-107; PKC_PHOSPHO_SITE 284-286; CAMP_PHOSPHO_SITE 85-88; CK2_PHOSPHO_SITE 352-355; CK2_PHOSPHO_SITE 43-46; PKC_PHOSPHO_SITE 430-432; MYRISTYL 138-143; MYRISTYL 265-270; ASN_GLYCOSYLATION 167-170; PKC_PHOSPHO_SITE 216-218; MYRISTYL 260-265; TYR_PHOSPHO_SITE 200-206; MYRISTYL 179-184; PKC_PHOSPHO_SITE 84-86; PKC_PHOSPHO_SITE 153-155; PKC_PHOSPHO_SITE 163-165; CK2_PHOSPHO_SITE 284-287; MYRISTYL 267-272;	PRICHEXTENSIN 111-128; PRO_RICH_2 185-351; PRICHEXTENSIN 1-13; PRICHEXTENSIN 63-75; PRICHEXTENSIN 206-231; PRO_RICH_1 1-75;

			323- 329,1.094; 290- 302,1.123; 383- 435,1.147; 122- 131,1.09; 211- 217,1.039;		
DEX0455 _001.aa .1	N	0 - o1- 237;	164- 217,1.189; 14- 30,1.076; 79- 85,1.054; 64- 74,1.136; 148- 161,1.094; 89- 114,1.145; 116- 138,1.139; 43- 61,1.159; 33- 39,1.034; 4- 11,1.088;	MYRISTYL 194-199; MYRISTYL 5-10; PKC_PHOSPHO_SITE 88- 90; PKC_PHOSPHO_SITE 47- 49; CK2_PHOSPHO_SITE 41- 44; LEUCINE_ZIPPER 157- 178; MYRISTYL 198-203; PKC_PHOSPHO_SITE 29-31; MYRISTYL 187-192; PKC_PHOSPHO_SITE 235-237; CK2_PHOSPHO_SITE 205-208;	
DEX0455 _002.aa .1	N	0 - o1- 233;	174- 212,1.218; 88- 148,1.133; 153- 158,1.07; 67- 81,1.137; 46- 65,1.141; 9- 44,1.202;	CK2_PHOSPHO_SITE 159-162; MYRISTYL 139-144; MYRISTYL 112-117; MYRISTYL 83-88; ASN_GLYCOSYLATION 47-50; MYRISTYL 181-186; MYRISTYL 61-66;	TONB_DEPENDENT_ REC_1 1-49; GALAPTIN 165- 186; GLECT 103- 233; Gal- bind_lectin 104-233;
DEX0455 _003.aa .1	N	0 - o1- 115;	9- 18,1.083; 30- 51,1.14; 56- 82,1.155; 104- 111,1.084;	CAMP_PHOSPHO_SITE 21-24; CK2_PHOSPHO_SITE 24-27; MYRISTYL 57-62; PKC_PHOSPHO_SITE 32-34; CK2_PHOSPHO_SITE 43-46; MYRISTYL 25-30; PKC_PHOSPHO_SITE 4-6; AMIDATION 101-104; PKC_PHOSPHO_SITE 93-95; PKC_PHOSPHO_SITE 109-111; AMIDATION 4-7;	ARG_RICH 18- 104;
DEX0455 _004.or f.1	N	1 - o1- 54;tm5 5- 74:i75	112- 143,1.199; 5- 12,1.074; 40-	MYRISTYL 96-101; PKC_PHOSPHO_SITE 145-147; MYRISTYL 82-87; MYRISTYL 105-110; PKC_PHOSPHO_SITE 25-27; CK2 PHOSPHO SITE	

		-151;	104,1.27; 14- 37,1.097;	143-146;	
DEX0455 _004.aa .1	N	2 - 01- 594;tm 595- 617;i6 18- 666;tm 667- 689;o6 90- 699;	245- 261,1.17; 51- 68,1.161; 429- 437,1.15; 202- 222,1.139; 533- 553,1.095; 102- 115,1.182; 186- 193,1.076; 121- 140,1.245; 333- 341,1.129; 375- 383,1.117; 265- 319,1.148; 142- 174,1.138; 70- 98,1.151; 345- 354,1.089; 579- 588,1.236; 445- 458,1.242; 515- 531,1.129; 398- 405,1.098; 690- 696,1.182; 593- 617,1.232; 224- 243,1.183; 629- 688,1.194; 408- 413,1.058; 475- 512,1.147; 462- 473,1.227; 23- 34,1.175; 363- 369,1.038;	CK2_PHOSPHO_SITE 440-443; CK2_PHOSPHO_SITE 36-39; PKC_PHOSPHO_SITE 641-643; MYRISTYL 264-269; PKC_PHOSPHO_SITE 28-30; ASN_GLYCOSYLATION 471-474; ASN_GLYCOSYLATION 628-631; MYRISTYL 591-596; PKC_PHOSPHO_SITE 210-212; CAMP_PHOSPHO_SITE 15-18; ASN_GLYCOSYLATION 569-572; CK2_PHOSPHO_SITE 140-143; PKC_PHOSPHO_SITE 302-304; MYRISTYL 557-562; AMIDATION 19-22; ASN_GLYCOSYLATION 297-300; AMIDATION 197-200; CAMP_PHOSPHO_SITE 587-590; CK2_PHOSPHO_SITE 542-545; PKC_PHOSPHO_SITE 420-422; PKC_PHOSPHO_SITE 70-72; MYRISTYL 530-535; PKC_PHOSPHO_SITE 560-562; MYRISTYL 256-261; CAMP_PHOSPHO_SITE 16-19; MYRISTYL 625-630; PKC_PHOSPHO_SITE 527-529; MYRISTYL 93-98; PKC_PHOSPHO_SITE 19-21; PKC_PHOSPHO_SITE 514-516; TYR_PHOSPHO_SITE 149-155;	RIBOSOMAL_S2_1 245-256; LYS_RICH 9-22;
DEX0455 _004.or	N	1 - 01-	14- 37.1.097;	CK2_PHOSPHO_SITE 143-146; MYRISTYL 96-101;	

f.2		54;tm5 5- 74;i75 -151;	40- 104,1.27; 112- 143,1.199; 5- 12,1.074;	PKC_PHOSPHO_SITE 25-27; MYRISTYL 105-110; MYRISTYL 82-87; PKC_PHOSPHO_SITE 145-147;	
DEX0455 _004.aa N .2		9 - 01- 210;tm 211- 233;i2 34- 282;tm 283- 305;o3 06- 324;tm 325- 347;i3 48- 367;tm 368- 385;o3 86- 543;tm 544- 566;i5 67- 578;tm 579- 599;o6 00- 613;tm 614- 633;i6 34- 679;tm 680- 699;o7 00- 703;tm 704- 721;i7 22- 762;	713- 724,1.168; 19- 28,1.088; 131- 153,1.129; 746- 755,1.027; 209- 233,1.232; 604- 653,1.189; 78- 89,1.227; 484- 491,1.123; 402- 459,1.205; 497- 519,1.232; 367- 394,1.253; 195- 204,1.236; 91- 128,1.147; 657- 705,1.254; 245- 313,1.194; 577- 601,1.285; 555- 569,1.252; 523- 553,1.135; 737- 744,1.1; 61- 74,1.242; 156- 169,1.143; 45- 53,1.15; 323- 353,1.237; 472- 480,1.153;	PKC_PHOSPHO_SITE 257-259; MYRISTYL 14-19; MYRISTYL 173-178; CK2_PHOSPHO_SITE 676-679; PKC_PHOSPHO_SITE 620-622; PKC_PHOSPHO_SITE 143-145; ASN_GLYCOSYLATION 418-421; PKC_PHOSPHO_SITE 176-178; MYRISTYL 207-212; ASN_GLYCOSYLATION 87-90; CAMP_PHOSPHO_SITE 203-206; MYRISTYL 161-166; MYRISTYL 13-18; ASN_GLYCOSYLATION 493-496; MYRISTYL 691-696; TYR_PHOSPHO_SITE 755-761; PKC_PHOSPHO_SITE 676-678; MYRISTYL 241-246; ASN_GLYCOSYLATION 363-366; CK2_PHOSPHO_SITE 466-469; PKC_PHOSPHO_SITE 594-596; ASN_GLYCOSYLATION 312-315; ASN_GLYCOSYLATION 244-247; CK2_PHOSPHO_SITE 56-59; CK2_PHOSPHO_SITE 320-323; CK2_PHOSPHO_SITE 506-509; PKC_PHOSPHO_SITE 425-427; PKC_PHOSPHO_SITE 721-723; MYRISTYL 712-717; PKC_PHOSPHO_SITE 130-132; ASN_GLYCOSYLATION 185-188; PKC_PHOSPHO_SITE 506-508;	N4_MTASE 609- 614;
DEX0455 _005.aa N .1		0 - 01- 138;	19- 29,1.121; 125- 132,1.063; 4-9.1.045;	PKC_PHOSPHO_SITE 87-89; MYRISTYL 21-26; PKC_PHOSPHO_SITE 131-133; MYRISTYL 102-107; CK2 PHOSPHO SITE 38-41;	

			45- 61,1.116; 88- 107,1.22; 76- 85,1.064;	CK2_PHOSPHO_SITE 29-32;	
DEX0455 _006.aa .1	N	0 - 01- 179;	34- 45,1.149; 92- 99,1.162; 8- 14,1.034; 117- 135,1.172; 49- 61,1.175; 168- 176,1.097; 104- 110,1.069; 77- 85,1.119; 143- 155,1.15;	CAMP_PHOSPHO_SITE 62-65; CK2_PHOSPHO_SITE 110-113; AMIDATION 138-141; CK2_PHOSPHO_SITE 67-70; TYR_PHOSPHO_SITE 88-95; CK2_PHOSPHO_SITE 74-77; PKC_PHOSPHO_SITE 112-114; MYRISTYL 36-41; CAMP_PHOSPHO_SITE 127-130; CK2_PHOSPHO_SITE 106-109; MYRISTYL 133-138;	
DEX0455 _007.or f.1	N	0 - 01- 294;	4- 23,1.139; 194- 201,1.095; 133- 176,1.151; 39- 45,1.069; 58- 68,1.056; 244- 261,1.123; 78- 120,1.147;	PKC_PHOSPHO_SITE 24-26; CK2_PHOSPHO_SITE 71-74; MYRISTYL 231-236; CK2_PHOSPHO_SITE 203-206; PKC_PHOSPHO_SITE 270-272; PKC_PHOSPHO_SITE 131-133; CK2_PHOSPHO_SITE 189-192; MYRISTYL 278-283; CK2_PHOSPHO_SITE 24-27; MYRISTYL 201-206; MYRISTYL 266-271; MYRISTYL 120-125; CK2_PHOSPHO_SITE 56-59; CAMP_PHOSPHO_SITE 132-135;	
DEX0455 _007.aa .1	N	0 - 01- 294;	4- 23,1.139; 133- 176,1.151; 194- 201,1.095; 39- 45,1.069; 244- 261,1.123; 58- 68,1.056; 78- 120,1.147;	MYRISTYL 266-271; CAMP_PHOSPHO_SITE 132-135; PKC_PHOSPHO_SITE 131-133; MYRISTYL 278-283; CK2_PHOSPHO_SITE 24-27; MYRISTYL 120-125; CK2_PHOSPHO_SITE 189-192; MYRISTYL 201-206; CK2_PHOSPHO_SITE 71-74; PKC_PHOSPHO_SITE 270-272; CK2_PHOSPHO_SITE 203-206; MYRISTYL 231-236; PKC_PHOSPHO_SITE 24-26; CK2_PHOSPHO_SITE 56-59;	
DEX0455 _008.aa .1	N	0 - 01-90;	43- 78,1.171; 16- 37,1.092;	CK2_PHOSPHO_SITE 57-60; PKC_PHOSPHO_SITE 79-81; MYRISTYL 36-41; CAMP_PHOSPHO_SITE 81-84; PKC_PHOSPHO_SITE 12-14;	HORMA 14-72;
DEX0455	N	1 -	189-	MYRISTYL 335-340; MYRISTYL	LAMP 1 149-163;

_009.aa .1		o1- 328;tm 329- 351;i3 52- 373;	217,1.126; 139- 145,1.097; 258- 270,1.167; 38- 61,1.154; 272- 286,1.083; 156- 177,1.157; 73- 122,1.145; 231- 240,1.152; 289- 321,1.16; 328- 354,1.187; 4- 32,1.238; 247- 253,1.064;	83-88; PKC_PHOSPHO_SITE 241-243; ASN_GLYCOSYLATION 146-149; MYRISTYL 34-39; MYRISTYL 32-37; PKC_PHOSPHO_SITE 228-230; AMIDATION 51-54; PKC_PHOSPHO_SITE 4-6; CK2_PHOSPHO_SITE 195-198; ASN_GLYCOSYLATION 220-223; PKC_PHOSPHO_SITE 13-15; CK2_PHOSPHO_SITE 134-137;	LYSASSOCTDMP 139-163; LYSASSOCTDMP 267-281;
DEX0455 _010.or f.1	N	1 - o1- 109;tm 110- 132;i1 33- 148;	51- 57,1.138; 78- 98,1.159; 111- 132,1.193; 4- 41,1.243; 67- 75,1.122;	MYRISTYL 57-62; MYRISTYL 52-57; MYRISTYL 140-145;	IG_LIKE 8-112; IGc1 23-94; ig 21-86; IG_MHC 82-88;
DEX0455 _010.aa .1	N	0 - o1-72;	4- 12,1.148; 34- 44,1.09; 55- 69,1.084; 22- 28,1.112;	TYR_PHOSPHO_SITE 50-58; CK2_PHOSPHO_SITE 37-40; PKC_PHOSPHO_SITE 37-39;	sp_P13761_HB2J_ HUMAN 43-70;
DEX0455 _010.or f.2	Y	2 - o1- 14;tml 5- 37;i38 - 152;tm 153- 175;o1 76- 191;	94- 100,1.138; 4- 84,1.243; 154- 175,1.193; 121- 141,1.159; 110- 118,1.122;	MYRISTYL 24-29; MYRISTYL 95-100; MYRISTYL 100-105; MYRISTYL 183-188;	IGc1 66-137; ig 64-129; IG_MHC 125-131; IG_LIKE 51-155;
DEX0455 _010.aa .2	N	0 - o1- 112;	87- 103,1.09; 60- 66,1.138; 4- 50.1.243;	MYRISTYL 107-112; MYRISTYL 61-66; MYRISTYL 66-71; CK2_PHOSPHO_SITE 106-109; MYRISTYL 96-101;	IG_LIKE 17-112; IGc1 32-103; ig 30-95;

			76- 84,1.122;		
DEX0455 _011.aa .1	N	0 - 01- 128;	78- 97,1.118; 99- 115,1.098; 7- 33,1.125; 37- 43,1.08; 118- 125,1.159;	PKC_PHOSPHO_SITE 82-84; ASN_GLYCOSYLATION 48-51; CAMP_PHOSPHO_SITE 66-69; MYRISTYL 59-64; ASN_GLYCOSYLATION 58-61; CK2_PHOSPHO_SITE 34-37;	GALAPTIN 61-81; SUI1_1 115-122; GLECT 4-128; Gal-bind_lectin 1-128;
DEX0455 _012.aa .1	N	0 - 01- 256;	136- 143,1.08; 193- 199,1.037; 176- 189,1.099; 69- 82,1.102; 38- 45,1.131; 87- 93,1.067; 4-9,1.066; 100- 128,1.153; 26- 34,1.129; 236- 245,1.062;	CK2_PHOSPHO_SITE 20-23; CK2_PHOSPHO_SITE 215-218; MYRISTYL 202-207; CK2_PHOSPHO_SITE 132-135; CK2_PHOSPHO_SITE 131-134; MYRISTYL 200-205; CK2_PHOSPHO_SITE 93-96; MYRISTYL 53-58; CK2_PHOSPHO_SITE 88-91; MYRISTYL 182-187; CAMP_PHOSPHO_SITE 237-240; MYRISTYL 162-167; MYRISTYL 249-254; PKC_PHOSPHO_SITE 54-56; MYRISTYL 99-104;	SAM_PNT 48-132; SAM_PNT 48-132;
DEX0455 _012.or f.2	N	0 - 01- 250;	4-10,1.07; 104- 117,1.102; 240- 246,1.107; 135- 163,1.153; 16- 32,1.09; 61- 69,1.129; 228- 234,1.037; 73- 80,1.131; 122- 128,1.067; 171- 178,1.08; 37- 44,1.077; 211- 224,1.099;	CK2_PHOSPHO_SITE 166-169; MYRISTYL 1-6; MYRISTYL 134-139; MYRISTYL 217-222; MYRISTYL 197-202; CK2_PHOSPHO_SITE 167-170; MYRISTYL 88-93; CK2_PHOSPHO_SITE 238-241; PKC_PHOSPHO_SITE 89-91; CK2_PHOSPHO_SITE 128-131; PKC_PHOSPHO_SITE 11-13; MYRISTYL 28-33; MYRISTYL 22-27; CK2_PHOSPHO_SITE 123-126; MYRISTYL 33-38; MYRISTYL 235-240; CK2_PHOSPHO_SITE 55-58;	SAM_PNT 83-167; SAM_PNT 83-167;
DEX0455 _012.aa .2	N	0 - 01- 402;	176- 189,1.099; 38- 45,1.131;	AMIDATION 273-276; MYRISTYL 53-58; AMIDATION 377-380; CK2_PHOSPHO_SITE 246-249; MYRISTYL 99-104;	ETSDOMAIN 330- 348; ETSDOMAIN 349-367; ETSDOMAIN 304-

			288- 294,1.052; 26- 34,1.129; 69- 82,1.102; 205- 218,1.129; 100- 128,1.153; 136- 143,1.08; 311- 318,1.118; 4-9,1.066; 87- 93,1.067; 379- 385,1.088; 193- 199,1.037; 332- 346,1.091;	CK2_PHOSPHO_SITE 224-227; MYRISTYL 162-167; CK2_PHOSPHO_SITE 203-206; PKC_PHOSPHO_SITE 54-56; ASN_GLYCOSYLATION 388-391; CK2_PHOSPHO_SITE 213-216; CK2_PHOSPHO_SITE 88-91; MYRISTYL 182-187; ASN_GLYCOSYLATION 354-357; AMIDATION 293-296; CK2_PHOSPHO_SITE 20-23; CAMP_PHOSPHO_SITE 282-285; CK2_PHOSPHO_SITE 93-96; CAMP_PHOSPHO_SITE 350-353; CK2_PHOSPHO_SITE 132-135; MYRISTYL 233-238; CK2_PHOSPHO_SITE 131-134; MYRISTYL 200-205;	317; SAM_PNT 48-132; AT_hook 275-287; ETS_DOMAIN_3 304-386; SAM_PNT 48-132; HSF_ETS 314- 376; ETSDOMAIN 368-386; Ets 303-388; ETS 303-390;
DEX0455 _013.aa .1	N	0 - 01- 219;	38- 45,1.105; 183- 198,1.162; 129- 146,1.173; 154- 173,1.144; 93- 115,1.187; 4- 34,1.161; 50- 60,1.202;	CK2_PHOSPHO_SITE 37-40; MYRISTYL 49-54; ASN_GLYCOSYLATION 46-49; MYRISTYL 30-35; CK2_PHOSPHO_SITE 173-176; MYRISTYL 147-152; PKC_PHOSPHO_SITE 200-202; MYRISTYL 100-105; PKC_PHOSPHO_SITE 214-216;	
DEX0455 _013.aa .2	N	0 - 01- 172;	82- 99,1.173; 4- 10,1.154; 46- 68,1.187; 136- 151,1.162; 107- 126,1.144;	CK2_PHOSPHO_SITE 126-129; MYRISTYL 100-105; MYRISTYL 53-58; PKC_PHOSPHO_SITE 167-169; PKC_PHOSPHO_SITE 153-155;	
DEX0455 _014.or f.1	N	0 - 01- 329;	4- 10,1.104; 140- 146,1.062; 76- 82,1.057; 117- 125,1.126; 181- 192,1.181; 300- 307.1.103;	CK2_PHOSPHO_SITE 110-113; CK2_PHOSPHO_SITE 24-27; CAMP_PHOSPHO_SITE 198-201; PKC_PHOSPHO_SITE 95-97; PKC_PHOSPHO_SITE 308-310; CK2_PHOSPHO_SITE 156-159; AMIDATION 12-15; CK2_PHOSPHO_SITE 177-180; PKC_PHOSPHO_SITE 204-206; MYRISTYL 29-34; CK2_PHOSPHO_SITE 210-213; PKC PHOSPHO SITE 126-128;	EFh 204-232; EF_HAND_2_1 153-229; EF_HAND 213- 225; Calpain_III 1- 133; EF_HAND 243-255; efhand 204-232; EFh 234-262; calpain_III 5- 133; efhand

			162- 169,1.103; 314- 320,1.054; 52- 65,1.124; 197- 212,1.145; 235- 242,1.069; 32- 40,1.209; 96- 113,1.1; 224- 230,1.049; 18- 24,1.096; 255- 278,1.221; 290- 298,1.171;	CK2_PHOSPHO_SITE 150-153; CK2_PHOSPHO_SITE 251-254; PKC_PHOSPHO_SITE 24-26; ASN_GLYCOSYLATION 299-302; CK2_PHOSPHO_SITE 22-25; MYRISTYL 248-253;	234-262; EF_HAND_2_2 237-294;
DEX0455 _014.aa .1	0 - 01- 595;		21- 44,1.113; 556- 564,1.171; 49- 73,1.155; 75- 82,1.121; 179- 185,1.061; 284- 290,1.096; 342- 348,1.057; 117- 125,1.165; 103- 110,1.113; 566- 573,1.103; 259- 275,1.108; 428- 435,1.103; 188- 197,1.149; 86- 98,1.077; 318- 331,1.124; 447- 458,1.181; 132- 143,1.081; 4- 11,1.247; 362-	CK2_PHOSPHO_SITE 153-156; ASN_GLYCOSYLATION 143-146; PKC_PHOSPHO_SITE 290-292; CK2_PHOSPHO_SITE 200-203; MYRISTYL 189-194; CK2_PHOSPHO_SITE 288-291; CK2_PHOSPHO_SITE 290-293; CK2_PHOSPHO_SITE 517-520; CK2_PHOSPHO_SITE 250-253; ASN_GLYCOSYLATION 17-20; MYRISTYL 295-300; PKC_PHOSPHO_SITE 392-394; ASN_GLYCOSYLATION 248-251; ASN_GLYCOSYLATION 565-568; PKC_PHOSPHO_SITE 252-254; MYRISTYL 211-216; CK2_PHOSPHO_SITE 221-224; CK2_PHOSPHO_SITE 422-425; CAMP_PHOSPHO_SITE 464-467; MYRISTYL 164-169; MYRISTYL 144-149; CK2_PHOSPHO_SITE 114-117; CK2_PHOSPHO_SITE 47-50; PKC_PHOSPHO_SITE 114-116; MYRISTYL 45-50; PKC_PHOSPHO_SITE 470-472; PKC_PHOSPHO_SITE 227-229; CK2_PHOSPHO_SITE 19-22; PKC_PHOSPHO_SITE 361-363; CK2_PHOSPHO_SITE 376-379; CK2_PHOSPHO_SITE 476-479; MYRISTYL 514-519; PKC_PHOSPHO_SITE 574-576; CK2_PHOSPHO_SITE 443-446; CK2_PHOSPHO_SITE 416-419; CAMP_PHOSPHO_SITE 187-190; TYR_PHOSPHO_SITE 172-179;	Calpain_III 261-399; THIOL_PROTEASE_ CYS 53-64; EFh 470-498; CALPAIN 89-114; efhand 500-528; EF_HAND_2_1 419-495; Peptidase_C2 14-273; CYS_PROT_CALPAI N 32-273; CysPc 2-281; EF_HAND_2_2 503-560; CALPAIN 53-69; EFh 500-528; EF_HAND 509- 521; CALPAIN 29-51; EF_HAND 479-491; calpain_III 241-399; CALPAIN 365- 393; efhand 470-498; CALPAIN 119- 142;

			379,1.1; 209- 229,1.083; 490- 496,1.049; 298- 306,1.209; 521- 544,1.221; 580- 586,1.054; 463- 478,1.145; 501- 508,1.069; 383- 391,1.126; 406- 412,1.062;		
DEX0455 _015.aa .1	N	0 - 01-85;	63- 82,1.15; 20- 26,1.04; 4- 14,1.174; 35- 46,1.138;	CK2_PHOSPHO_SITE 42-45; PKC_PHOSPHO_SITE 35-37; CK2_PHOSPHO_SITE 81-84; CK2_PHOSPHO_SITE 19-22; PKC_PHOSPHO_SITE 68-70;	ER_TARGET 82-85;
DEX0455 _016.aa .1	N	0 - 01-255;	105- 110,1.047; 223- 241,1.155; 75- 81,1.064; 244- 252,1.167; 86- 94,1.048; 145- 151,1.048; 154- 171,1.113; 185- 202,1.095; 4- 12,1.094; 32- 44,1.04; 129- 138,1.113;	MYRISTYL 24-29; MYRISTYL 22-27; PKC_PHOSPHO_SITE 207-209; MYRISTYL 152-157; MYRISTYL 21-26; MYRISTYL 225-230; MYRISTYL 198-203; MYRISTYL 16-21; MYRISTYL 17-22; MYRISTYL 18-23; ASN_GLYCOSYLATION 82-85; MYRISTYL 13-18; MYRISTYL 20-25; MYRISTYL 46-51; MYRISTYL 26-31; MYRISTYL 19-24; MYRISTYL 50-55; PKC_PHOSPHO_SITE 159-161;	KH 189-240; GLY_RICH 13-26; KH 99-169; KH 184-239; KH_TYPE_1_1 100-164; KH 104-152; KH_TYPE_1_2 185-224;
DEX0455 _017.aa .1	N	0 - 01-174;	82- 95,1.136; 112- 129,1.149; 98- 110,1.124; 58- 65,1.171; 138- 155,1.209;	ASN_GLYCOSYLATION 29-32; MYRISTYL 104-109; PKC_PHOSPHO_SITE 166-168; ASN_GLYCOSYLATION 42-45; PKC_PHOSPHO_SITE 162-164; CK2_PHOSPHO_SITE 70-73; PKC_PHOSPHO_SITE 31-33; ASN_GLYCOSYLATION 72-75; MYRISTYL 105-110; CK2 PHOSPHO SITE 44-47;	TM4_2 16-124;

			4- 15,1.221; 34- 41,1.125;	MYRISTYL 34-39; MYRISTYL 112-117; ASN_GLYCOSYLATION 66-69; CK2_PHOSPHO_SITE 20-23;	
DEX0455 _018.aa .1	N	0 - o1- 354;	152- 174,1.101; 232- 240,1.163; 67- 74,1.098; 289- 311,1.168; 57- 63,1.087; 33- 44,1.198; 207- 225,1.149; 276- 282,1.104; 22- 28,1.058; 117- 150,1.291; 243- 265,1.125; 319- 338,1.116; 182- 199,1.136; 344- 350,1.079; 49- 55,1.112; 76- 110,1.213;	MYRISTYL 174-179; CK2_PHOSPHO_SITE 62-65; PKC_PHOSPHO_SITE 334-336; PKC_PHOSPHO_SITE 348-350; CK2_PHOSPHO_SITE 11-14; MYRISTYL 319-324; PKC_PHOSPHO_SITE 46-48; CK2_PHOSPHO_SITE 228-231; MYRISTYL 19-24; MYRISTYL 18-23; TYR_PHOSPHO_SITE 63-70;	PROTEIN_KINASE_ DOM 10-283; TYRKINASE 104- 117; S_TK_X 284-348; sp_Q9UM03_Q9UM0 3_HUMAN 37-283; S_TKc 37-283; TyrKc 38-277; PROTEIN_KINASE_ ST 145-157; TYRKINASE 139- 157; TYRKINASE 205-227; pkinase_C 284- 351; pkinase 31-283;
DEX0455 _018.aa .2	N	0 - o1- 489;	356- 363,1.123; 215- 226,1.053; 151- 169,1.163; 175- 195,1.157; 378- 390,1.189; 103- 122,1.165; 50- 59,1.127; 258- 276,1.096; 228- 252,1.133; 129- 134,1.041; 393- 422,1.174; 440-	CK2_PHOSPHO_SITE 135-138; PKC_PHOSPHO_SITE 60-62; PKC_PHOSPHO_SITE 434-436; PKC_PHOSPHO_SITE 206-208; MYRISTYL 442-447; PKC_PHOSPHO_SITE 45-47; CK2_PHOSPHO_SITE 307-310; PKC_PHOSPHO_SITE 453-455; LEUCINE_ZIPPER 50-71; PKC_PHOSPHO_SITE 205-207; CK2_PHOSPHO_SITE 164-167; LEUCINE_ZIPPER 222-243; ASN_GLYCOSYLATION 126-129; MYRISTYL 452-457; CK2_PHOSPHO_SITE 414-417; MYRISTYL 407-412; PKC_PHOSPHO_SITE 226-228; PKC_PHOSPHO_SITE 135-137; LEUCINE_ZIPPER 215-236;	HR1 105-181; HR1 182-255; HR1 18-90; HR1 18-90; REM_REPEAT_1 15-74; HR1 182- 255; REM_REPEAT_2 107-166; HR1 105-181; REM_REPEAT_3 175-239;

			457,1.171; 459- 483,1.218; 327- 343,1.235; 139- 147,1.103; 278- 307,1.151; 88- 94,1.072; 65- 83,1.135; 198- 206,1.174;		
DEX0455 _019.aa .1	Y	0 - o1- 287;	209- 234,1.163; 268- 274,1.108; 249- 254,1.037; 171- 180,1.184; 65- 73,1.106; 189- 197,1.098; 8- 21,1.242; 91- 102,1.114; 54- 60,1.089; 129- 136,1.123; 33- 40,1.121; 236- 244,1.078; 109- 127,1.096; 140- 154,1.114;	MYRISTYL 82-87; AMIDATION 102-105; MYRISTYL 214-219; PKC_PHOSPHO_SITE 26-28; ASN_GLYCOSYLATION 243-246; ASN_GLYCOSYLATION 163-166; PKC_PHOSPHO_SITE 238-240; PKC_PHOSPHO_SITE 193-195; MYRISTYL 247-252; CK2_PHOSPHO_SITE 218-221; PKC_PHOSPHO_SITE 165-167; ASN_GLYCOSYLATION 203-206; CK2_PHOSPHO_SITE 48-51; PKC_PHOSPHO_SITE 248-250;	Folate_rec 7- 287;
DEX0455 _020.aa .1	N	0 - o1- 143;	73- 79,1.044; 101- 120,1.206; 129- 140,1.111; 27- 32,1.039; 83- 93,1.128; 4- 18,1.179; 46- 67,1.134;	AMIDATION 25-28; CK2_PHOSPHO_SITE 99-102; MYRISTYL 126-131; MYRISTYL 79-84; PKC_PHOSPHO_SITE 71-73; MYRISTYL 119-124; MYRISTYL 75-80; PKC_PHOSPHO_SITE 72-74; ASN_GLYCOSYLATION 97-100; PKC_PHOSPHO_SITE 136-138; MYRISTYL 68-73;	
DEX0455 _020.or	N	0 - o1-	32- 64.1.153:	MYRISTYL 106-111; CK2 PHOSPHO SITE 34-37:	

f.2		116;	84- 90,1.128; 96- 102,1.085; 13- 21,1.109;	PKC_PHOSPHO_SITE 12-14; MYRISTYL 6-11; MYRISTYL 29-34; MYRISTYL 68-73; AMIDATION 61-64; PKC_PHOSPHO_SITE 78-80; MYRISTYL 92-97; CK2_PHOSPHO_SITE 25-28;	
DEX0455 _020.aa .2	N	0 - 01-67;	29- 46,1.092; 52- 64,1.187; 11- 21,1.128;	CK2_PHOSPHO_SITE 44-47; ASN_GLYCOSYLATION 25-28; MYRISTYL 7-12;	
DEX0455 _021.or f.1	N	0 - 01- 104;	86- 97,1.124; 4-9,1.11; 35- 71,1.171; 14- 22,1.095;	PKC_PHOSPHO_SITE 81-83; PKC_PHOSPHO_SITE 100-102; CAMP_PHOSPHO_SITE 33-36; PKC_PHOSPHO_SITE 32-34; MYRISTYL 10-15;	
DEX0455 _021.aa .1	N	0 - 01-82;	45- 51,1.09; 4- 11,1.131; 15- 23,1.096;		
DEX0455 _021.aa .2	N	0 - 01- 360;	112- 119,1.083; 209- 218,1.167; 121- 147,1.118; 179- 186,1.153; 73- 108,1.131; 290- 300,1.12; 169- 175,1.09; 46- 55,1.071; 309- 318,1.162; 4-10,1.11; 341- 347,1.071; 13- 34,1.181; 193- 199,1.098; 239- 267,1.186;	ASN_GLYCOSYLATION 108-111; MYRISTYL 203-208; AMIDATION 217-220; CK2_PHOSPHO_SITE 44-47; AMIDATION 325-328; PKC_PHOSPHO_SITE 48-50; CK2_PHOSPHO_SITE 18-21; CAMP_PHOSPHO_SITE 78-81; PKC_PHOSPHO_SITE 56-58; MYRISTYL 263-268; MYRISTYL 190-195;	Epimerase 5- 311; gale 4- 296;
DEX0455 _021.or f.3	N	0 - 01- 376;	24- 47,1.119; 241- 247,1.098; 94-	CK2_PHOSPHO_SITE 92-95; MYRISTYL 4-9; PKC_PHOSPHO_SITE 96-98; MYRISTYL 8-13; PKC PHOSPHO SITE 104-106;	gale 52-344; Epimerase 53- 359;

			103,1.071; 61- 82,1.181; 357- 366,1.162; 51- 58,1.11; 257- 266,1.167; 169- 195,1.118; 121- 156,1.131; 160- 167,1.083; 287- 315,1.186; 338- 348,1.12; 217- 223,1.09; 227- 234,1.153;	CAMP_PHOSPHO_SITE 126-129; MYRISTYL 238-243; CK2_PHOSPHO_SITE 66-69; MYRISTYL 9-14; AMIDATION 373-376; MYRISTYL 6-11; MYRISTYL 10-15; ASN_GLYCOSYLATION 156-159; AMIDATION 265-268; MYRISTYL 311-316; MYRISTYL 251-256;	
DEX0455 _021.aa .3	N	0 - o1- 466;	290- 300,1.12; 239- 267,1.186; 209- 218,1.167; 399- 417,1.182; 193- 199,1.098; 4-10,1.11; 121- 147,1.118; 46- 55,1.071; 112- 119,1.083; 337- 393,1.213; 13- 34,1.181; 309- 318,1.162; 73- 108,1.131; 169- 175,1.09; 422- 434,1.145; 179- 186,1.153;	PKC_PHOSPHO_SITE 48-50; MYRISTYL 203-208; AMIDATION 217-220; PKC_PHOSPHO_SITE 56-58; MYRISTYL 263-268; AMIDATION 325-328; PKC_PHOSPHO_SITE 399-401; PKC_PHOSPHO_SITE 372-374; MYRISTYL 359-364; MYRISTYL 190-195; ASN_GLYCOSYLATION 108-111; PKC_PHOSPHO_SITE 346-348; CK2_PHOSPHO_SITE 44-47; CAMP_PHOSPHO_SITE 78-81; CK2_PHOSPHO_SITE 18-21;	gale 4-462; Epimerase 5- 459;
DEX0455 _021.aa .4	N	0 - o1- 328;	112- 119,1.083; 239- 267,1.186; 193-	MYRISTYL 190-195; MYRISTYL 263-268; PKC_PHOSPHO_SITE 56-58; CK2_PHOSPHO_SITE 44-47; MYRISTYL 203-208; CK2 PHOSPHO SITE 18-21;	gale 4-296; Epimerase 5- 311;

			199,1.098; 169- 175,1.09; 309- 318,1.162; 73- 108,1.131; 209- 218,1.167; 290- 300,1.12; 121- 147,1.118; 13- 34,1.181; 46- 55,1.071; 179- 186,1.153; 4-10,1.11;	AMIDATION 217-220; ASN_GLYCOSYLATION 108-111; PKC_PHOSPHO_SITE 48-50; AMIDATION 325-328; CAMP_PHOSPHO_SITE 78-81;	
DEX0455 _022.aa .1	Y	1 - 11- 21;tm2 2- 44;o45 -178;	54- 73,1.132; 19- 46,1.26; 123- 135,1.041; 5- 12,1.131; 81- 101,1.08; 140- 149,1.16; 151- 157,1.051; 161- 171,1.056;	PKC_PHOSPHO_SITE 145-147; TYR_PHOSPHO_SITE 147-154; AMIDATION 173-176; CK2_PHOSPHO_SITE 4-7; ASN_GLYCOSYLATION 65-68; ASN_GLYCOSYLATION 92-95; PKC_PHOSPHO_SITE 45-47; CK2_PHOSPHO_SITE 156-159;	
DEX0455 _022.or f.2	Y	1 - o1- 34;tm3 5- 57;i58 -141;	32- 59,1.26; 67- 86,1.132; 4-9,1.102; 126- 138,1.071; 18- 25,1.131; 94- 114,1.08;	ASN_GLYCOSYLATION 78-81; PKC_PHOSPHO_SITE 58-60; PKC_PHOSPHO_SITE 7-9; CK2_PHOSPHO_SITE 17-20; ASN_GLYCOSYLATION 105-108;	
DEX0455 _022.aa .2	Y	1 - i1- 21;tm2 2- 44;o45 -188;	113- 128,1.071; 131- 144,1.136; 148- 157,1.16; 19- 46,1.26; 81- 101,1.08; 5- 12.1.131;	ASN_GLYCOSYLATION 92-95; ASN_GLYCOSYLATION 65-68; TYR_PHOSPHO_SITE 155-162; PKC_PHOSPHO_SITE 153-155; CK2_PHOSPHO_SITE 4-7; PKC_PHOSPHO_SITE 45-47; CK2_PHOSPHO_SITE 164-167;	

			169- 185,1.221; 159- 165,1.051; 54- 73,1.132;		
DEX0455 _022.aa .3	Y	0 - 01-78;	6-14,1.07; 48- 65,1.202; 70- 75,1.085;	MYRISTYL 48-53; MYRISTYL 34-39; MYRISTYL 14-19; MYRISTYL 27-32; MYRISTYL 6-11; PKC_PHOSPHO_SITE 68- 70; MYRISTYL 39-44; MYRISTYL 13-18; MYRISTYL 20-25;	GLY_RICH 5-48;
DEX0455 _023.aa .1	N	0 - 01- 116;	69- 80,1.147; 50- 61,1.08; 27- 37,1.085; 82- 89,1.049; 4-13,1.11;	PKC_PHOSPHO_SITE 57-59; CAMP_PHOSPHO_SITE 48-51; PKC_PHOSPHO_SITE 52-54; PKC_PHOSPHO_SITE 47-49; PKC_PHOSPHO_SITE 101-103; PKC_PHOSPHO_SITE 43-45; CK2_PHOSPHO_SITE 36-39; AMIDATION 39-42; PKC_PHOSPHO_SITE 97-99; CAMP_PHOSPHO_SITE 54-57;	
DEX0455 _024.aa .1	N	0 - 01- 360;	245- 252,1.15; 127- 136,1.145; 208- 215,1.12; 309- 317,1.126; 117- 124,1.107; 274- 284,1.206; 189- 197,1.193; 348- 357,1.265; 324- 340,1.091; 147- 157,1.162; 78- 85,1.168; 232- 240,1.187; 167- 172,1.042; 289- 295,1.073; 61- 70,1.189;	PKC_PHOSPHO_SITE 34-36; PKC_PHOSPHO_SITE 257-259; PKC_PHOSPHO_SITE 33-35; PKC_PHOSPHO_SITE 298-300; MYRISTYL 6-11; MYRISTYL 144-149; CK2_PHOSPHO_SITE 176-179; ASN_GLYCOSYLATION 286-289; PKC_PHOSPHO_SITE 22-24; CAMP_PHOSPHO_SITE 254-257; MYRISTYL 29-34; PKC_PHOSPHO_SITE 7-9; CK2_PHOSPHO_SITE 344-347; CK2_PHOSPHO_SITE 315-318; CK2_PHOSPHO_SITE 272-275; CAMP_PHOSPHO_SITE 163-166; CK2_PHOSPHO_SITE 71-74; MYRISTYL 303-308; CK2_PHOSPHO_SITE 158-161; PKC_PHOSPHO_SITE 264-266; CK2_PHOSPHO_SITE 73-76; CK2_PHOSPHO_SITE 257-260;	ANNEXINI 343- 356; sp_P09525_ANX4_ HUMAN 131-196; ANNEXINV 219- 245; annexin 212-280; ANNEXINV 343- 356; ANNEXINV 136-157; annexin 288- 355; ANNEXIN 109-125; sp_P08132_ANX4_ PIG 214-283; ANNEXIN 136- 157; sp_Q9NFS4_Q9NFS 4_GIALA 89-348; ANNEXIN 219- 245; ANNEXINV 299-325; ANNEXIN 72-124; ANNEXINI 299- 319; ANNEXINI 219-245; annexin 16-124; ANNEXIN 228- 280; ANNEXINI 136-157; annexin 129- 196; ANX 303- 355; ANNEXINV 69-91; ANX 144- 196; ANNEXINI 69-91;

					ANNEXINII 109-125; ANNEXIN 69-91; sp_P09525_ANX4_HUMAN 290-358; ANX 228-280; ANNEXINV 109-125; ANX 72-124; ANNEXIN 303-355; ANNEXINI 109-125; ANNEXINII 136-157; ANNEXINII 69-91; ANNEXINII 343-356; ANNEXIN 144-196; ANNEXINII 299-319; sp_P09525_ANX4_HUMAN 63-127; ANNEXIN 299-319; ANNEXINII 219-245; ANNEXIN 343-356;
DEX0455_024.aa .2	N	0 - 01- 177;	4- 14,1.157; 165- 174,1.265; 141- 157,1.091; 91- 101,1.206; 126- 134,1.126; 49- 57,1.187; 25- 32,1.12; 106- 112,1.073; 62- 69,1.15;	CK2_PHOSPHO_SITE 132-135; CK2_PHOSPHO_SITE 161-164; ASN_GLYCOSYLATION 103-106; MYRISTYL 120-125; CK2_PHOSPHO_SITE 89-92; CAMP_PHOSPHO_SITE 71-74; PKC_PHOSPHO_SITE 115-117; PKC_PHOSPHO_SITE 81-83; PKC_PHOSPHO_SITE 74-76; CK2_PHOSPHO_SITE 74-77;	ANNEXINIV 36-62; sp_P08132_ANX4_PIG 31-100; ANNEXINII 36-62; sp_P09525_ANX4_HUMAN 107-175; ANNEXINII 160-173; ANNEXINII 116-136; ANNEXIN 160-173; ANNEXINIV 160-173; annexin 29-97; ANNEXIN 120-172; ANX 45-97; ANNEXIN 36-62; ANX 120-172; ANNEXIN 45-97; ANNEXINIV 116-142; ANNEXIN 116-136; annexin 105-172;
DEX0455_025.aa .1	N	0 - 01- 380;	55- 61,1.085; 95- 102,1.121; 124- 165,1.203; 253- 265,1.112;	PKC_PHOSPHO_SITE 296-298; CK2_PHOSPHO_SITE 230-233; MYRISTYL 357-362; CK2_PHOSPHO_SITE 118-121; TYR_PHOSPHO_SITE 298-305; ASN_GLYCOSYLATION 51-54; PKC_PHOSPHO_SITE 358-360; CK2 PHOSPHO SITE 318-321;	

			280- 315,1.154; 201- 211,1.092; 323- 341,1.121; 25- 49,1.169; 350- 357,1.074; 362- 370,1.179; 9-15,1.13; 269- 278,1.061; 73- 90,1.133; 175- 185,1.225; 243- 250,1.061; 111- 121,1.127;	ASN_GLYCOSYLATION 344-347; MYRISTYL 55-60; PKC_PHOSPHO_SITE 349-351; MYRISTYL 224-229; CK2_PHOSPHO_SITE 169-172; PKC_PHOSPHO_SITE 71-73; CK2_PHOSPHO_SITE 352-355; CK2_PHOSPHO_SITE 308-311; CK2_PHOSPHO_SITE 228-231; PKC_PHOSPHO_SITE 68-70;	
DEX0455 _025.or f.2	Y	0 - 01- 394;	329- 364,1.154; 318- 327,1.061; 18- 31,1.139; 4-15,1.18; 104- 110,1.085; 122- 139,1.133; 302- 314,1.112; 250- 260,1.092; 74- 98,1.169; 372- 391,1.121; 292- 299,1.061; 173- 214,1.203; 36- 43,1.073; 160- 170,1.127; 144- 151,1.121; 224- 234,1.225; 58- 64,1.13;	PKC_PHOSPHO_SITE 45-47; CK2_PHOSPHO_SITE 35-38; TYR_PHOSPHO_SITE 347-354; MYRISTYL 104-109; PKC_PHOSPHO_SITE 117-119; PKC_PHOSPHO_SITE 120-122; CK2_PHOSPHO_SITE 357-360; CK2_PHOSPHO_SITE 218-221; PKC_PHOSPHO_SITE 15-17; CK2_PHOSPHO_SITE 279-282; MYRISTYL 273-278; CK2_PHOSPHO_SITE 277-280; ASN_GLYCOSYLATION 100-103; CK2_PHOSPHO_SITE 15-18; PKC_PHOSPHO_SITE 345-347; CK2_PHOSPHO_SITE 367-370; CK2_PHOSPHO_SITE 167-170;	
DEX0455 _025.aa 1.2	N	0 - 01- 679;	95- 102,1.121; 557-	PKC_PHOSPHO_SITE 652-654; PKC_PHOSPHO_SITE 296-298; TYR PHOSPHO SITE 298-305;	

			564,1.066; 111- 121,1.127; 9-15,1.13; 655- 665,1.082; 243- 250,1.061; 73- 90,1.133; 507- 513,1.056; 124- 165,1.203; 539- 548,1.107; 623- 630,1.089; 253- 265,1.112; 360- 365,1.048; 280- 315,1.154; 386- 392,1.069; 394- 416,1.152; 489- 499,1.139; 269- 278,1.061; 368- 384,1.143; 578- 589,1.155; 175- 185,1.225; 473- 482,1.179; 201- 211,1.092; 323- 355,1.122; 25- 49,1.169; 424- 465,1.143; 55- 61,1.085; 633- 639,1.052; 601- 618,1.106; 521- 528,1.118;	MYRISTYL 224-229; PKC_PHOSPHO_SITE 632-634; CK2_PHOSPHO_SITE 653-656; CK2_PHOSPHO_SITE 228-231; MYRISTYL 349-354; CK2_PHOSPHO_SITE 230-233; MYRISTYL 507-512; MYRISTYL 361-366; PKC_PHOSPHO_SITE 588-590; CK2_PHOSPHO_SITE 640-643; PKC_PHOSPHO_SITE 526-528; MYRISTYL 55-60; PKC_PHOSPHO_SITE 555-557; CK2_PHOSPHO_SITE 118-121; PKC_PHOSPHO_SITE 71-73; LEUCINE_ZIPPER 453-474; PKC_PHOSPHO_SITE 631-633; PKC_PHOSPHO_SITE 68-70; CK2_PHOSPHO_SITE 540-543; PKC_PHOSPHO_SITE 513-515; ASN_GLYCOSYLATION 51-54; MYRISTYL 674-679; CK2_PHOSPHO_SITE 318-321; CK2_PHOSPHO_SITE 308-311; CK2_PHOSPHO_SITE 169-172;	
DEX0455 _026.or f.1	N	0 - i1-72;		ASN_GLYCOSYLATION 46-49; CK2_PHOSPHO_SITE 62-65;	

DEX0455 _026.aa .1	N	0 - i1-77;	69- 74,1.113; 47- 54,1.103; 7- 34,1.196;	CK2_PHOSPHO_SITE 58-61; CK2_PHOSPHO_SITE 53-56;	
DEX0455 _027.or f.1	N	0 - o1- 174;	54- 76,1.16; 118- 139,1.134; 40- 52,1.162; 4- 20,1.164; 155- 171,1.137; 103- 113,1.167;	CK2_PHOSPHO_SITE 65-68; MYRISTYL 53-58; MYRISTYL 40-45; PKC_PHOSPHO_SITE 75-77; ASN_GLYCOSYLATION 93-96; CK2_PHOSPHO_SITE 171-174; CK2_PHOSPHO_SITE 114-117; CK2_PHOSPHO_SITE 83-86; MYRISTYL 152-157;	
DEX0455 _027.aa .1	N	0 - i1-36;	5- 28,1.145;		
DEX0455 _028.aa .1	N	0 - o1- 215;		MYRISTYL 144-149; CK2_PHOSPHO_SITE 30-33; PKC_PHOSPHO_SITE 111-113; PKC_PHOSPHO_SITE 68-70; CK2_PHOSPHO_SITE 111-114; MYRISTYL 52-57; CK2_PHOSPHO_SITE 167-170; CK2_PHOSPHO_SITE 28-31; GLYCOSAMINOGLYCAN 36-39; MYRISTYL 106-111; CK2_PHOSPHO_SITE 7-10; PKC_PHOSPHO_SITE 210-212; CK2_PHOSPHO_SITE 82-85;	cobW 41-214; ATP_GTP_A 49- 56;
DEX0455 _029.or f.1	Y	0 - o1- 133;	109- 124,1.141; 4- 18,1.154; 26- 79,1.144;	CK2_PHOSPHO_SITE 120-123;	
DEX0455 _029.aa .1	N	5 - i1- 20;tm2 1- 43;o44 - 55;tm5 6- 78;i79 - 188;tm 189- 211;o2 12- 265;tm 266- 288;i2 89-	589- 601,1.168; 141- 213,1.251; 4- 19,1.116; 84- 92,1.108; 810- 816,1.062; 787- 805,1.18; 292- 319,1.22; 818- 881,1.176; 914- 920.1.094;	CK2_PHOSPHO_SITE 503-506; PKC_PHOSPHO_SITE 546-548; CK2_PHOSPHO_SITE 714-717; ASN_GLYCOSYLATION 747-750; MYRISTYL 695-700; PKC_PHOSPHO_SITE 716-718; ASN_GLYCOSYLATION 51-54; MYRISTYL 651-656; PKC_PHOSPHO_SITE 351-353; ASN_GLYCOSYLATION 228-231; CK2_PHOSPHO_SITE 697-700; PKC_PHOSPHO_SITE 808-810; ASN_GLYCOSYLATION 782-785; CK2_PHOSPHO_SITE 904-907; PKC_PHOSPHO_SITE 622-624; PKC_PHOSPHO_SITE 904-906; TYR_PHOSPHO_SITE 297-303; PKC PHOSPHO SITE 755-757;	

		294;tm 295- 317;o3 18- 953;	121- 132,1.185; 721- 739,1.162; 531- 544,1.196; 655- 680,1.23; 52- 80,1.244; 348- 380,1.166; 388- 401,1.1; 700- 708,1.061; 609- 619,1.166; 753- 782,1.251; 321- 340,1.148; 551- 568,1.095; 884- 898,1.185; 570- 587,1.245; 924- 935,1.123; 691- 697,1.081; 255- 286,1.151; 409- 462,1.144; 99- 116,1.162; 492- 507,1.141; 21- 46,1.201; 243- 252,1.116; 512- 524,1.154; 624- 652,1.188;	PKC_PHOSPHO_SITE 784-786; PKC_PHOSPHO_SITE 317-319; PKC_PHOSPHO_SITE 2-4; PKC_PHOSPHO_SITE 879-881; CK2_PHOSPHO_SITE 546-549; PKC_PHOSPHO_SITE 332-334; PKC_PHOSPHO_SITE 835-837; MYRISTYL 130-135; CK2_PHOSPHO_SITE 936-939; PKC_PHOSPHO_SITE 139-141; CK2_PHOSPHO_SITE 934-937; ASN_GLYCOSYLATION 741-744; PKC_PHOSPHO_SITE 259-261; PKC_PHOSPHO_SITE 938-940; CK2_PHOSPHO_SITE 879-882; PKC_PHOSPHO_SITE 230-232; PKC_PHOSPHO_SITE 912-914; MYRISTYL 240-245; PKC_PHOSPHO_SITE 909-911; PKC_PHOSPHO_SITE 161-163;	
DEX0455 _029.or f.2	Y	0 - o1- 194;	26- 79,1.144; 165- 176,1.123; 125- 139,1.185; 109- 122,1.122; 4- 18,1.154; 155-	CK2_PHOSPHO_SITE 145-148; PKC_PHOSPHO_SITE 153-155; PKC_PHOSPHO_SITE 145-147; PKC_PHOSPHO_SITE 120-122; PKC_PHOSPHO_SITE 179-181; CK2_PHOSPHO_SITE 177-180; PKC_PHOSPHO_SITE 150-152; CK2_PHOSPHO_SITE 120-123; CK2_PHOSPHO_SITE 175-178;	cobW 1-176;

			161,1.094;		
			499- 531,1.166; 154- 160,1.051; 9- 27,1.196; 689- 695,1.094; 94- 120,1.182; 560- 613,1.144; 250- 283,1.185; 406- 437,1.151; 472- 491,1.148; 92- 699- 205,tm 710,1.123; 172- 197,1.201; 162- 170,1.116; 292- 364,1.251; 538- 552,1.1; 659- 673,1.185; 394- 403,1.116; 38- 69,1.174; 443- 470,1.22; 126- 152,1.243; 74- 83,1.196; 643- 656,1.122; 203- 243,1.244;	PKC_PHOSPHO_SITE 312-314; TYR_PHOSPHO_SITE 448-454; PKC_PHOSPHO_SITE 290-292; PKC_PHOSPHO_SITE 381-383; PKC_PHOSPHO_SITE 410-412; CK2_PHOSPHO_SITE 32-35; CK2_PHOSPHO_SITE 709-712; PKC_PHOSPHO_SITE 654-656; CK2_PHOSPHO_SITE 654-657; ASN_GLYCOSYLATION 379-382; ASN_GLYCOSYLATION 202-205; PKC_PHOSPHO_SITE 4-6; CK2_PHOSPHO_SITE 113-116; MYRISTYL 391-396; PKC_PHOSPHO_SITE 153-155; PKC_PHOSPHO_SITE 713-715; PKC_PHOSPHO_SITE 687-689; PKC_PHOSPHO_SITE 684-686; CK2_PHOSPHO_SITE 711-714; PKC_PHOSPHO_SITE 468-470; PKC_PHOSPHO_SITE 90-92; ASN_GLYCOSYLATION 120-123; PKC_PHOSPHO_SITE 502-504; MYRISTYL 281-286; CK2_PHOSPHO_SITE 679-682; PKC_PHOSPHO_SITE 483-485; PKC_PHOSPHO_SITE 679-681;	
DEX0455 _029.aa .2	N	6 - o1- 129;tm 130- 149;i1 50- 168;tm 169- 191;o1 92- 205;tm 206- 228;i2 29- 339;tm 340- 362;o3 63- 416;tm 417- 439;i4 40- 445;tm 446- 468;o4 69- 728;			cobW 458-710;
DEX0455 _030.aa .1	N	0 - o1- 312;	250- 278,1.145; 42- 55,1.148; 185- 198,1.08; 22- 40,1.148; 213- 225,1.123; 57- 71,1.09; 120- 175,1.145;	CK2_PHOSPHO_SITE 5-8; MYRISTYL 267-272; PKC_PHOSPHO_SITE 209-211; ASN_GLYCOSYLATION 250-253; CK2_PHOSPHO_SITE 198-201; MYRISTYL 166-171; MYRISTYL 113-118; TYR_PHOSPHO_SITE 141-149;	Metallophos 47- 242; STPHPHTASE 48-75; STPHPHTASE 145- 171; STPHPHTASE 230-250; STPHPHTASE 252- 268; STPHPHTASE 77-104; PP2Ac 20-290; STPHPHTASE 174- 201; PHOSPHO_ESTER 47-245;

			10- 20,1.094; 299- 309,1.17; 232- 243,1.157; 280- 289,1.066; 85- 105,1.201;		STPHPHTASE 110-134; sp_P33172_PPP4_HUMAN 7-290; SER_THR_PHOSPHATASE 111-116;
DEX0455 _030.aa .2	N	0 - o1- 182;	108- 118,1.128; 4- 12,1.114; 47- 67,1.252; 71- 81,1.118; 38-44,1.1; 149- 160,1.157; 91- 97,1.075; 167- 179,1.128; 18- 36,1.164; 130- 142,1.123;	PKC_PHOSPHO_SITE 126-128; PKC_PHOSPHO_SITE 95-97; CK2_PHOSPHO_SITE 53-56; CK2_PHOSPHO_SITE 116-119; MYRISTYL 83-88; ASN_GLYCOSYLATION 167-170;	STPHPHTASE 169-182; sp_P11084_PPP4_RABIT 104-182; STPHPHTASE 147-167; PP2Ac 33-182;
DEX0455 _031.or f.1	Y	0 - o1- 293;	161- 189,1.17; 150- 156,1.092; 285- 290,1.091; 12- 45,1.129; 89- 124,1.191; 249- 255,1.087; 203- 211,1.196; 231- 238,1.08; 47- 74,1.166; 262- 279,1.144; 220- 227,1.113; 132- 148,1.205;	ASN_GLYCOSYLATION 78-81; MYRISTYL 103-108; CK2_PHOSPHO_SITE 80-83; MYRISTYL 233-238; PKC_PHOSPHO_SITE 220-222; MYRISTYL 167-172; MYRISTYL 201-206; CK2_PHOSPHO_SITE 178-181; PKC_PHOSPHO_SITE 10-12; MYRISTYL 281-286; MYRISTYL 61-66; AMIDATION 16-19; PKC_PHOSPHO_SITE 247-249; PKC_PHOSPHO_SITE 156-158; CK2_PHOSPHO_SITE 125-128; CAMP_PHOSPHO_SITE 157-160; PKC_PHOSPHO_SITE 80-82; PKC_PHOSPHO_SITE 107-109; PKC_PHOSPHO_SITE 155-157; CK2_PHOSPHO_SITE 120-123; MYRISTYL 240-245; CAMP_PHOSPHO_SITE 18-21; TYR_PHOSPHO_SITE 82-89; CK2_PHOSPHO_SITE 227-230; CK2_PHOSPHO_SITE 190-193; ASN_GLYCOSYLATION 215-218;	TNFR_NGFR_1 121-164; TNFR_c6 81-118; TNFR_NGFR_2_2 120-162; CYS_RICH 96-186; TNFR 81-118; TNFR_c6 208-248; TNFR_NGFR_2_3 207-248; TNFR_NGFR_1 81-118; TNFR 121-162; TNFR 164-205; TNFR_c6 121-162; TNFR 208-248; TNFR_c6 164-194; TNFR_NGFR_2_1 80-118;
DEX0455 _031.aa .1	Y	1 - o1- 425;tm 426- 448;i4 49-	193- 200,1.08; 51- 86,1.191; 165- 173.1.196;	MYRISTYL 23-28; PKC_PHOSPHO_SITE 182-184; PKC_PHOSPHO_SITE 331-333; TYR_PHOSPHO_SITE 44-51; ASN_GLYCOSYLATION 177-180; CK2 PHOSPHO SITE 523-526;	TNFR_NGFR_1 43-80; TNFR_NGFR_2_3 169-210; TNFR_c6 43-80; CYS RICH 58-

		635;	614- 621,1.063; 182- 189,1.113; 427- 464,1.216; 112- 118,1.092; 268- 294,1.175; 211- 217,1.087; 344- 423,1.224; 296- 325,1.193; 247- 265,1.134; 472- 477,1.034; 482- 528,1.182; 596- 602,1.04; 224- 241,1.144; 123- 151,1.17; 575- 589,1.06; 538- 543,1.067; 9- 36,1.166; 560- 572,1.094; 94- 110,1.205;	MYRISTYL 547-552; PKC_PHOSPHO_SITE 209-211; MYRISTYL 65-70; MYRISTYL 552-557; PKC_PHOSPHO_SITE 118-120; AMIDATION 382- 385; MYRISTYL 195-200; CK2_PHOSPHO_SITE 87-90; PKC_PHOSPHO_SITE 623-625; MYRISTYL 202-207; MYRISTYL 411-416; MYRISTYL 376-381; MYRISTYL 286-291; CAMP_PHOSPHO_SITE 119-122; MYRISTYL 396-401; CK2_PHOSPHO_SITE 140-143; ASN_GLYCOSYLATION 40-43; CK2_PHOSPHO_SITE 42-45; PKC_PHOSPHO_SITE 321-323; MYRISTYL 243-248; CK2_PHOSPHO_SITE 152-155; PKC_PHOSPHO_SITE 42-44; CK2_PHOSPHO_SITE 82-85; MYRISTYL 163-168; MYRISTYL 619-624; MYRISTYL 129-134; PKC_PHOSPHO_SITE 117-119; CK2_PHOSPHO_SITE 189-192; PKC_PHOSPHO_SITE 69-71;	148; PRO_RICH 567-602; TNFR_NGFR_2_2 82-124; TNFR_NGFR_1 83- 126; TNFR 43- 80; TNFR_NGFR_2_1 42-80; TNFR 83- 124; TNFR_c6 83-124; TNFR 126-167; TNFR_c6 170- 210; TNFR 170- 210; TNFR_c6 126-156;
DEX0455 _031.aa .2	Y	0 - o1- 166;	112- 118,1.092; 123- 151,1.17; 51- 86,1.191; 94- 110,1.205; 9- 36,1.166;	PKC_PHOSPHO_SITE 161-163; MYRISTYL 65-70; PKC_PHOSPHO_SITE 117-119; CK2_PHOSPHO_SITE 87-90; MYRISTYL 129-134; CK2_PHOSPHO_SITE 42-45; CK2_PHOSPHO_SITE 82-85; PKC_PHOSPHO_SITE 42-44; ASN_GLYCOSYLATION 40-43; PKC_PHOSPHO_SITE 69-71; CK2_PHOSPHO_SITE 140-143; PKC_PHOSPHO_SITE 118-120; MYRISTYL 23-28; CAMP_PHOSPHO_SITE 119-122; TYR_PHOSPHO_SITE 44-51; CK2 PHOSPHO SITE 152-155;	TNFR_c6 43-80; TNFR 43-80; TNFR_NGFR_2_1 42-80; TNFR_NGFR_2_2 82-124; TNFR 83-124; TNFR 126-160; TNFR_NGFR_1 43- 80; TNFR_NGFR_1 83-126; TNFR_c6 126-156; TNFR_c6 83-124; CYS_RICH 58- 148;
DEX0455 _031.or f.2	N	1 - o1- 95;tm9 6- 118;i1	266- 272,1.04; 81- 87,1.087; 11-	PKC_PHOSPHO_SITE 293-295; PKC_PHOSPHO_SITE 5-7; MYRISTYL 72-77; MYRISTYL 65-70; PKC_PHOSPHO_SITE 52-54; MYRISTYL 33-38;	TNFR_NGFR_2 39- 80; PRO_RICH 237-272; TNFR 40-80;

		19-305;	29,1.128; 284- 291,1.063; 97- 134,1.216; 208- 213,1.067; 35- 43,1.196; 152- 198,1.182; 245- 259,1.06; 63- 70,1.08; 52- 59,1.113; 230- 242,1.094; 142- 147,1.034;	MYRISTYL 217-222; PKC_PHOSPHO_SITE 79-81; ASN_GLYCOSYLATION 47-50; MYRISTYL 289-294; CK2_PHOSPHO_SITE 59-62; CK2_PHOSPHO_SITE 193-196; MYRISTYL 222-227; MYRISTYL 1-6;	
DEX0455 _031.aa .3	Y	0 - o1- 194;	13- 25,1.182; 31- 36,1.034; 41- 87,1.182; 155- 161,1.04; 119- 131,1.094; 97- 102,1.067; 134- 148,1.06; 173- 180,1.063;	MYRISTYL 178-183; MYRISTYL 106-111; MYRISTYL 111-116; PKC_PHOSPHO_SITE 182-184; CAMP_PHOSPHO_SITE 9-12; CK2_PHOSPHO_SITE 82-85;	PRO_RICH 126-161;
DEX0455 _032.aa .1	N	0 - o1- 241;	42- 50,1.149; 84-96,1.1; 216- 238,1.152; 172- 179,1.085; 22- 32,1.209; 130- 141,1.11; 144- 168,1.133; 198- 204,1.108; 69- 78,1.125;	PKC_PHOSPHO_SITE 152-154; PKC_PHOSPHO_SITE 168-170; ASN_GLYCOSYLATION 39-42; CK2_PHOSPHO_SITE 206-209; CK2_PHOSPHO_SITE 204-207; PKC_PHOSPHO_SITE 112-114; ASN_GLYCOSYLATION 142-145; CK2_PHOSPHO_SITE 59-62; CK2_PHOSPHO_SITE 193-196; MYRISTYL 37-42; CK2_PHOSPHO_SITE 169-172; CK2_PHOSPHO_SITE 112-115; ASN_GLYCOSYLATION 104-107; CAMP_PHOSPHO_SITE 33-36; CK2_PHOSPHO_SITE 92-95;	
DEX0455 _033.aa .1	Y	5 - i1- 6;tm7- 29;o30 -	34- 40,1.091; 4- 32,1.218; 89-	PKC_PHOSPHO_SITE 248-250; MYRISTYL 53-58; MYRISTYL 161-166; MYRISTYL 104-109; MYRISTYL 139-144; MYRISTYL 183-188; MYRISTYL 159-164;	VACATPASE 149-175; ATP-synt_C 49-114; VACATPASE 176-199; VACATPASE

		48;tm4 9- 71;i72 - 90;tm9 1- 113;o1 14- 141;tm 142- 164;i1 65- 175;tm 176- 198;o1 99- 261;	113,1.207; 234- 258,1.182; 203- 232,1.183; 141- 167,1.258; 169- 201,1.2; 53- 74,1.179; 78- 84,1.057;	PKC_PHOSPHO_SITE 233-235; MYRISTYL 141-146; MYRISTYL 64-69; MYRISTYL 156-161; CK2_PHOSPHO_SITE 27-30; MYRISTYL 10-15; MYRISTYL 190-195; MYRISTYL 23-28; CK2_PHOSPHO_SITE 119-122; MYRISTYL 68-73; MYRISTYL 55-60; MYRISTYL 152-157;	65-89; ATP- synt_C 135-200;
DEX0455 _034.aaY .1	1 - i1- 11;tml 2- 34;o35 -499;	315- 320,1.032; 247- 254,1.118; 434- 444,1.138; 409- 419,1.088; 328- 355,1.171; 270- 283,1.163; 379- 385,1.079; 113- 132,1.192; 142- 152,1.084; 366- 372,1.056; 10- 33,1.215; 36- 53,1.085; 84- 105,1.209; 55- 67,1.131; 168- 183,1.161; 388- 403,1.136; 235- 243,1.176; 256- 262,1.043; 216- 227,1.151; 293- 303,1.148; 462- 486,1.137;	MYRISTYL 281-286; MYRISTYL 457-462; PKC_PHOSPHO_SITE 450-452; ASN_GLYCOSYLATION 235-238; ASN_GLYCOSYLATION 66-69; MYRISTYL 423-428; MYRISTYL 454-459; MYRISTYL 282-287; PKC_PHOSPHO_SITE 80-82; MYRISTYL 310-315; CK2_PHOSPHO_SITE 225-228; MYRISTYL 426-431; MYRISTYL 422-427; MYRISTYL 161-166; CK2_PHOSPHO_SITE 374-377; RGD 193-195; MYRISTYL 472- 477; MYRISTYL 212-217; MYRISTYL 29-34; MYRISTYL 313-318; MYRISTYL 482-487; MYRISTYL 43-48; PKC_PHOSPHO_SITE 242-244; PKC_PHOSPHO_SITE 440-442; PKC_PHOSPHO_SITE 490-492; PKC_PHOSPHO_SITE 148-150; CK2_PHOSPHO_SITE 350-353; MYRISTYL 494-499; PKC_PHOSPHO_SITE 253-255; CK2_PHOSPHO_SITE 74-77; MYRISTYL 285-290; PKC_PHOSPHO_SITE 386-388;	ldl_recept_a 333-371; Kunitz_BPTI 250-300; sp_Q99J04_Q99J0 4_MOUSE 250- 300; Kunitz_BPTI 391-441; LDLa 334-371; LDLRA_2 334- 370; LDLRA_1 347-369; BPTI_KUNITZ_2_2 391-441; BPTI_KUNITZ_1 419-437; BPTI_KUNITZ_1 278-296; BPTI_KUNITZ_2_1 250-300; BASICPTASE 275- 285; KU 389- 442; sp_Q99J04_Q99J0 4_MOUSE 391- 441; BASICPTASE 426-441; BASICPTASE 247- 261; KU 248- 301;	

DEX0455 _034.aa .3	Y	1 - i1- 11;tml 2- 34;o35 -344;	315- 320,1.032; 270- 283,1.163; 293- 303,1.148; 142- 152,1.084; 10- 33,1.215; 36- 53,1.085; 168- 183,1.161; 216- 227,1.151; 330- 341,1.103; 256- 262,1.043; 84- 105,1.209; 55- 67,1.131; 113- 132,1.192; 247- 254,1.118; 235- 243,1.176;	ASN_GLYCOSYLATION 235-238; MYRISTYL 285-290; CK2_PHOSPHO_SITE 74-77; PKC_PHOSPHO_SITE 242-244; MYRISTYL 282-287; CK2_PHOSPHO_SITE 225-228; MYRISTYL 281-286; PKC_PHOSPHO_SITE 253-255; MYRISTYL 43-48; RGD 193- 195; MYRISTYL 161-166; ASN_GLYCOSYLATION 66-69; PKC_PHOSPHO_SITE 148-150; MYRISTYL 212-217; MYRISTYL 313-318; MYRISTYL 29-34; PKC_PHOSPHO_SITE 80-82; MYRISTYL 310-315;	BPTI_KUNITZ_2 250-300; BASICPTASE 247- 261; sp_Q99J04_Q99J0 4_MOUSE 250- 300; KU 248- 301; BPTI_KUNITZ_1 278-296; BASICPTASE 275- 285; BASICPTASE 285-300; Kunitz_BPTI 250-300;
DEX0455 _034.aa .4	N	0 - o1- 479;	431- 437,1.056; 207- 217,1.084; 335- 348,1.163; 444- 450,1.079; 300- 308,1.176; 9-16,1.07; 101- 118,1.085; 380- 385,1.032; 54- 61,1.121; 120- 132,1.131; 233- 248,1.161; 312- 319,1.118; 75- 98,1.215; 178- 197,1.192; 466- 476.1.107;	CK2_PHOSPHO_SITE 439-442; MYRISTYL 94-99; CK2_PHOSPHO_SITE 290-293; PKC_PHOSPHO_SITE 451-453; MYRISTYL 226-231; MYRISTYL 277-282; PKC_PHOSPHO_SITE 307-309; MYRISTYL 462-467; MYRISTYL 378-383; CK2_PHOSPHO_SITE 415-418; MYRISTYL 350-355; PKC_PHOSPHO_SITE 213-215; ASN_GLYCOSYLATION 131-134; MYRISTYL 347-352; MYRISTYL 375-380; PKC_PHOSPHO_SITE 318-320; MYRISTYL 346-351; MYRISTYL 464-469; CK2_PHOSPHO_SITE 139-142; MYRISTYL 108-113; PKC_PHOSPHO_SITE 145-147; ASN_GLYCOSYLATION 300-303; RGD 258-260; AMIDATION 61- 64;	LDLRA_1 412- 434; KU 313- 366; LDLA 399- 436; BASICPTASE 340-350; BASICPTASE 312- 326; Kunitz_BPTI 315-365; sp_Q99J04_Q99J0 4_MOUSE 315- 365; BASICPTASE 350-365; ldl_recept_a 398-436; BPTI_KUNITZ_2 315-365; LDLRA_2 399- 435; BPTI_KUNITZ_1 343-361;

			393- 420,1.171; 281- 292,1.151; 321- 327,1.043; 149- 170,1.209; 457- 463,1.098; 358- 368,1.148; 37- 46,1.091;		
DEX0455 _035.aa .1	N	1 - i1- 92;tm9 3- 115;o1 16- 121;	81- 101,1.213; 103- 118,1.241; 54- 62,1.049;	MYRISTYL 54-59; MYRISTYL 40-45; PKC_PHOSPHO_SITE 119-121;	
DEX0455 _035.or f.2	N	1 - o1- 125;tm 126- 148;i1 49- 149;	21- 32,1.239; 111- 146,1.245; 57- 64,1.082; 69- 84,1.089; 4- 11,1.052; 86- 95,1.131; 34- 47,1.143;	PKC_PHOSPHO_SITE 30-32; MYRISTYL 46-51; MYRISTYL 45-50; MYRISTYL 7-12; MYRISTYL 49-54; PKC_PHOSPHO_SITE 53-55;	
DEX0455 _035.aa .2	N	1 - i1- 92;tm9 3- 115;o1 16- 121;	54- 62,1.049; 103- 118,1.241; 81- 101,1.213;	MYRISTYL 54-59; PKC_PHOSPHO_SITE 119-121; MYRISTYL 40-45;	
DEX0455 _035.or f.3	N	1 - o1- 125;tm 126- 148;i1 49- 149;	34- 47,1.143; 57- 64,1.082; 21- 32,1.239; 86- 95,1.131; 4- 11,1.052; 111- 146,1.245; 69- 84,1.089;	MYRISTYL 7-12; PKC_PHOSPHO_SITE 53-55; MYRISTYL 45-50; MYRISTYL 49-54; MYRISTYL 46-51; PKC_PHOSPHO_SITE 30-32;	
DEX0455 _035.aa	Y	1 - o1-	34- 42,1.049;	MYRISTYL 20-25; MYRISTYL 34-39; PKC PHOSPHO SITE	

.3		71;tm7 2- 94;i95 -101;	61- 81,1.213; 83- 98,1.241; 4- 12,1.132;	99-101;	
DEX0455 _036.or f.1	N	1 - o1- 40;tm4 1- 63;i64 -95;	39- 66,1.248; 76- 92,1.111; 15- 24,1.133;	TYR_PHOSPHO_SITE 68-75; PKC_PHOSPHO_SITE 66-68; MYRISTYL 61-66; CK2_PHOSPHO_SITE 87-90; PKC_PHOSPHO_SITE 65-67; ASN_GLYCOSYLATION 11-14; MYRISTYL 53-58;	
DEX0455 _036.aa .1	N	1 - o1- 54;tm5 5- 77;i78 -109;	53- 80,1.248; 4- 16,1.142; 29- 38,1.133; 90- 106,1.111;	TYR_PHOSPHO_SITE 82-89; MYRISTYL 75-80; CK2_PHOSPHO_SITE 101-104; PKC_PHOSPHO_SITE 80-82; MYRISTYL 67-72; ASN_GLYCOSYLATION 25-28; PKC_PHOSPHO_SITE 79-81; MYRISTYL 10-15;	G_PROTEIN_RECEP _F1_1 18-34;
DEX0455 _036.aa .2	N	0 - o1- 1485;	427- 433,1.051; 715- 725,1.093; 1161- 1180,1.113; ; 1009- 1017,1.062 ; 1369- 1374,1.054 ; 1428- 1480,1.146 ; 673- 683,1.16; 594- 600,1.049; 170- 199,1.136; 1388- 1401,1.161 ; 126- 132,1.062; 809- 823,1.119; 405- 413,1.091; 104- 110,1.07; 480- 511,1.148; 1405- 1417,1.159 ; 1356- 1366,1.086 ; 895- 901,1.051; 49- 61.1.148;	PKC_PHOSPHO_SITE 1000- 1002; MYRISTYL 191-196; CK2_PHOSPHO_SITE 440-443; ASN_GLYCOSYLATION 338-341; TYR_PHOSPHO_SITE 237-245; CK2_PHOSPHO_SITE 986-989; ASN_GLYCOSYLATION 806-809; PKC_PHOSPHO_SITE 1415- 1417; ASN_GLYCOSYLATION 1385-1388; MYRISTYL 35-40; PKC_PHOSPHO_SITE 837-839; ASN_GLYCOSYLATION 478-481; PKC_PHOSPHO_SITE 1148- 1150; CK2_PHOSPHO_SITE 82- 85; MYRISTYL 124-129; PKC_PHOSPHO_SITE 525-527; ASN_GLYCOSYLATION 457-460; MYRISTYL 436-441; PKC_PHOSPHO_SITE 318-320; CK2_PHOSPHO_SITE 550-553; CK2_PHOSPHO_SITE 1275- 1278; CK2_PHOSPHO_SITE 50- 53; CK2_PHOSPHO_SITE 362- 365; PKC_PHOSPHO_SITE 102- 104; CK2_PHOSPHO_SITE 674- 677; MYRISTYL 47-52; ASN_GLYCOSYLATION 790-793; ASN_GLYCOSYLATION 1235- 1238; ASN_GLYCOSYLATION 1365-1368; PKC_PHOSPHO_SITE 681-683; CK2_PHOSPHO_SITE 862-865; ASN_GLYCOSYLATION 1029- 1032; PKC_PHOSPHO_SITE 1038-1040; MYRISTYL 659- 664; ASN_GLYCOSYLATION 634-637; PKC_PHOSPHO_SITE 636-638; ASN_GLYCOSYLATION	SEA_1 757-823; SEA_2 913-979;

		73-	1081-1084; MYRISTYL 1126-	
		89,1.07;	1131; MYRISTYL 954-959;	
		114-	CK2_PHOSPHO_SITE 206-209;	
		121,1.085;	PKC_PHOSPHO_SITE 1103-	
		14-	1105; ASN_GLYCOSYLATION	
		43,1.136;	650-653; CK2_PHOSPHO_SITE	
		416-	518-521; PKC_PHOSPHO_SITE	
		422,1.032;	258-260; PKC_PHOSPHO_SITE	
		1195-	1097-1099;	
		1210,1.091	ASN_GLYCOSYLATION 1117-	
		; 873-	1120; MYRISTYL 983-988;	
		880,1.078;	ASN_GLYCOSYLATION 1101-	
		341-	1104; ASN_GLYCOSYLATION	
		355,1.139;	769-772; ASN_GLYCOSYLATION	
		1061-	301-304; MYRISTYL 503-508;	
		1081,1.165	ASN_GLYCOSYLATION 1018-	
		; 1051-	1021; ASN_GLYCOSYLATION	
		1059,1.101	322-325; ASN_GLYCOSYLATION	
		; 135-	925-928; PKC_PHOSPHO_SITE	
		145,1.171;	746-748; ASN_GLYCOSYLATION	
		572-	613-616; PKC_PHOSPHO_SITE	
		578,1.043;	948-950; PKC_PHOSPHO_SITE	
		537-	786-788; CK2_PHOSPHO_SITE	
		557,1.079;	830-833; PKC_PHOSPHO_SITE	
		603-	162-164; MYRISTYL 1255-	
		620,1.171;	1260; PKC_PHOSPHO_SITE	
		1341-	347-349; PKC_PHOSPHO_SITE	
		1351,1.091	882-884; PKC_PHOSPHO_SITE	
		; 742-	942-944; MYRISTYL 203-208;	
		747,1.017;	MYRISTYL 971-976;	
		1276-	PKC_PHOSPHO_SITE 324-326;	
		1305,1.178	ASN_GLYCOSYLATION 946-949;	
		; 1022-	PKC_PHOSPHO_SITE 792-794;	
		1027,1.076	CK2_PHOSPHO_SITE 1173-	
		; 853-	1176; PKC_PHOSPHO_SITE	
		869,1.079;	570-572; PKC_PHOSPHO_SITE	
		987-	733-735; PKC_PHOSPHO_SITE	
		998,1.127;	1268-1270; MYRISTYL 1227-	
		750-	1232; MYRISTYL 904-909;	
		756,1.049;	PKC_PHOSPHO_SITE 213-215;	
		1241-	PKC_PHOSPHO_SITE 1337-	
		1253,1.146	1339; PKC_PHOSPHO_SITE	
		; 260-	1231-1233;	
		266,1.074;	TYR_PHOSPHO_SITE 1002-	
		561-	1009; PKC_PHOSPHO_SITE	
		568,1.078;	168-170; MYRISTYL 815-820;	
		517-	ASN_GLYCOSYLATION 166-169;	
		527,1.127;	PKC_PHOSPHO_SITE 474-476;	
		583-	CK2_PHOSPHO_SITE 1425-	
		589,1.035;	1428; MYRISTYL 1426-1431;	
		1255-	CK2_PHOSPHO_SITE 1141-	
		1269,1.16;	1144; ASN_GLYCOSYLATION	
		437-	10-13; ASN_GLYCOSYLATION	
		443,1.069;	1214-1217;	
		361-	PKC_PHOSPHO_SITE 57-59;	
		374,1.127;	PKC_PHOSPHO_SITE 630-632;	
		649-	PKC_PHOSPHO_SITE 12-14;	
		667,1.12;	MYRISTYL 1422-1427;	
		1120-	PKC PHOSPHO SITE 1193-	

			1134,1.119 ; 759- 769,1.186; 1142- 1150,1.127 ; 1311- 1324,1.069 ; 448- 457,1.171; 205- 221,1.105; 1029- 1037,1.068 ; 529- 535,1.029; 950- 979,1.128; 229- 257,1.102; 904- 925,1.198; 271- 277,1.063; 697- 708,1.073; 326- 335,1.128; 1105- 1114,1.128 ; 794- 806,1.128; 93- 101,1.078; 385- 396,1.062; 829- 839,1.135; 1040- 1046,1.055 ; 884- 890,1.07; 1184- 1192,1.078 ; 638- 647,1.128; 282- 301,1.181;	1195; ASN_GLYCOSYLATION 145-148; PKC_PHOSPHO_SITE 6-8;	
DEX0455 _036.or f.3	N	1 - o1- 56;tm5 7- 79;i80 -111;		MYRISTYL 12-17; PKC_PHOSPHO_SITE 81-83; CK2_PHOSPHO_SITE 103-106; TYR_PHOSPHO_SITE 84-91; ASN_GLYCOSYLATION 11-14; PKC_PHOSPHO_SITE 82-84; MYRISTYL 69-74; MYRISTYL 11-16; ASN_GLYCOSYLATION 10-13; TYR_PHOSPHO_SITE 6- 12; MYRISTYL 77-82;	
DEX0455 036.aa	N	1 - o1-	8-16,1.19; 68-	MYRISTYL 53-58; TYR PHOSPHO SITE 60-67:	

.3		32;tm3 3- 55;i56 -87;	84,1.111; 31- 58,1.248;	CK2_PHOSPHO_SITE 79-82; PKC_PHOSPHO_SITE 58-60; MYRISTYL 45-50; PKC_PHOSPHO_SITE 57-59;	
DEX0455 _036.or f.4	N	0 - o1-92;	20- 29,1.064; 41- 53,1.181; 62- 72,1.212; 4- 10,1.151;	AMIDATION 34-37; PKC_PHOSPHO_SITE 51-53; MYRISTYL 56-61; PKC_PHOSPHO_SITE 88-90; PKC_PHOSPHO_SITE 62-64; MYRISTYL 61-66;	
DEX0455 _036.aa .4	N	1 - o1- 28;tm2 9- 51;i52 -83;	64- 80,1.111; 27- 54,1.248; 4- 13,1.104;	PKC_PHOSPHO_SITE 54-56; MYRISTYL 49-54; MYRISTYL 41-46; CK2_PHOSPHO_SITE 75-78; PKC_PHOSPHO_SITE 53-55; TYR_PHOSPHO_SITE 56-63;	
DEX0455 _037.aa .1	Y	0 - o1- 225;	199- 205,1.08; 60- 72,1.178; 150- 159,1.178; 161- 169,1.13; 116- 126,1.06; 181- 186,1.025; 45- 52,1.052; 8- 33,1.189; 210- 219,1.123; 137- 143,1.07; 94- 108,1.076;	MYRISTYL 124-129; CK2_PHOSPHO_SITE 154-157; PKC_PHOSPHO_SITE 189-191; PKC_PHOSPHO_SITE 106-108; CK2_PHOSPHO_SITE 109-112; MYRISTYL 129-134; ASN_GLYCOSYLATION 78-81; PKC_PHOSPHO_SITE 109-111; MYRISTYL 144-149; CK2_PHOSPHO_SITE 158-161; MYRISTYL 100-105; MYRISTYL 133-138; ASN_GLYCOSYLATION 51-54; MYRISTYL 76-81; MYRISTYL 148-153; PKC_PHOSPHO_SITE 218-220; MYRISTYL 47-52;	PGNDSYNTHASE 74-92; PGNDSYNTHASE 31-54; PGNDSYNTHASE 57-67; LIPOCALIN 33- 46; lipocalin 38-221;
DEX0455 _037.or f.2	N	0 - o1- 349;	294- 307,1.148; 108- 114,1.075; 200- 209,1.156; 320- 335,1.295; 263- 275,1.199; 15- 38,1.169; 246- 252,1.033; 6- 12,1.064; 87- 93.1.037;	PKC_PHOSPHO_SITE 215-217; PKC_PHOSPHO_SITE 173-175; MYRISTYL 185-190; AMIDATION 123-126; PKC_PHOSPHO_SITE 4-6; MYRISTYL 190-195; CAMP_PHOSPHO_SITE 228-231; PKC_PHOSPHO_SITE 179-181; MYRISTYL 223-228; MYRISTYL 116-121; PKC_PHOSPHO_SITE 83-85; PKC_PHOSPHO_SITE 226-228; CK2_PHOSPHO_SITE 256-259; PKC_PHOSPHO_SITE 120-122; AMIDATION 226- 229; PKC_PHOSPHO_SITE 243- 245; PKC_PHOSPHO_SITE 105- 107; MYRISTYL 283-288; MYRISTYL 287-292;	PRICHEXTENSN 247-263; PRICHEXTENSN 172-184; PRICHEXTENSN 339-349; PRICHEXTENSN 148-164;

			237- 242,1.056; 45- 70,1.189; 132- 149,1.075; 97- 102,1.067; 338- 346,1.088; 159- 172,1.15; 309- 315,1.106; 219- 225,1.098;	PKC_PHOSPHO_SITE 95-97; MYRISTYL 195-200; MYRISTYL 193-198; MYRISTYL 288-293; MYRISTYL 275-280; MYRISTYL 285-290; CAMP_PHOSPHO_SITE 1-4; MYRISTYL 99-104;	
DEX0455 _037.aa .2	Y	0 - 01- 413;	369- 374,1.025; 283- 295,1.178; 349- 357,1.13; 338- 347,1.178; 50- 56,1.037; 268- 275,1.052; 387- 393,1.08; 193- 201,1.082; 317- 332,1.076; 218- 224,1.049; 231- 240,1.065; 60- 65,1.067; 71- 77,1.075; 129- 135,1.033; 8- 33,1.189; 141- 148,1.121; 95- 113,1.107; 398- 407,1.123;	PKC_PHOSPHO_SITE 83-85; MYRISTYL 270-275; PKC_PHOSPHO_SITE 329-331; MYRISTYL 62-67; MYRISTYL 236-241; MYRISTYL 171-176; PKC_PHOSPHO_SITE 406-408; AMIDATION 256-259; MYRISTYL 154-159; MYRISTYL 168-173; AMIDATION 86-89; MYRISTYL 190-195; CK2_PHOSPHO_SITE 342-345; PKC_PHOSPHO_SITE 216-218; MYRISTYL 336-341; MYRISTYL 186-191; CK2_PHOSPHO_SITE 346-349; ASN_GLYCOSYLATION 301-304; PKC_PHOSPHO_SITE 162-164; CK2_PHOSPHO_SITE 177-180; MYRISTYL 256-261; MYRISTYL 323-328; ASN_GLYCOSYLATION 274-277; MYRISTYL 170-175; PKC_PHOSPHO_SITE 377-379; PKC_PHOSPHO_SITE 58-60; MYRISTYL 299-304; ASN_GLYCOSYLATION 226-229; MYRISTYL 79-84; PKC_PHOSPHO_SITE 46-48; PKC_PHOSPHO_SITE 68-70;	LIPOCALIN 256- 269; A1MCGLOBULIN 269-280; lipocalin 261- 409; MAJORURINARY 263-281; VNEBNERGLAND 300-312; PGNDSYNTHASE 368-382; VNEBNERGLAND 371-394; LIPOCALIN 343- 355; LIPOCALIN 260-272; VNEBNERGLAND 260-274; PGNDSYNTHASE 385-403; LIPOCALIN 371- 386; A1MCGLOBULIN 366-387; MAJORURINARY 393-410; A1MCGLOBULIN 394-413; PGNDSYNTHASE 280-290; MAJORURINARY 365-386; PGNDSYNTHASE 332-355; A1MCGLOBULIN 334-353; PGNDSYNTHASE 254-277; PGNDSYNTHASE 297-315;
DEX0455 _037.aa	Y	0 - 01-	95- 112.1.075;	MYRISTYL 304-309; MYRISTYL 251-256; MYRISTYL 336-341;	GLY_RICH 236- 395;

.3		410;	209- 215,1.033; 163- 172,1.156; 200- 205,1.056; 60- 65,1.067; 292- 298,1.068; 370- 376,1.106; 381- 396,1.295; 50- 56,1.037; 226- 238,1.199; 281- 288,1.078; 122- 135,1.15; 71- 77,1.075; 345- 351,1.103; 8- 33,1.189; 182- 188,1.098; 308- 317,1.074; 399- 407,1.088; 360- 368,1.106;	MYRISTYL 264-269; AMIDATION 285-288; MYRISTYL 148-153; CAMP_PHOSPHO_SITE 191-194; MYRISTYL 282-287; MYRISTYL 156-161; MYRISTYL 153-158; AMIDATION 189-192; PKC_PHOSPHO_SITE 189-191; MYRISTYL 250-255; PKC_PHOSPHO_SITE 136-138; PKC_PHOSPHO_SITE 142-144; MYRISTYL 299-304; AMIDATION 86-89; MYRISTYL 238-243; PKC_PHOSPHO_SITE 178-180; PKC_PHOSPHO_SITE 58-60; MYRISTYL 330-335; AMIDATION 339-342; MYRISTYL 79-84; PKC_PHOSPHO_SITE 68-70; MYRISTYL 186-191; MYRISTYL 318-323; PKC_PHOSPHO_SITE 206-208; CK2_PHOSPHO_SITE 219-222; MYRISTYL 322-327; MYRISTYL 274-279; PKC_PHOSPHO_SITE 83-85; MYRISTYL 248-253; MYRISTYL 246-251; PKC_PHOSPHO_SITE 46-48; MYRISTYL 158-163; MYRISTYL 326-331; MYRISTYL 62-67;	
DEX0455 _037.aa .4	Y	0 - 01- 135;	38- 44,1.052; 8- 36,1.181; 109- 115,1.08; 46- 89,1.223; 120- 129,1.123;	MYRISTYL 71-76; PKC_PHOSPHO_SITE 99-101; MYRISTYL 54-59; ASN_GLYCOSYLATION 93-96; MYRISTYL 21-26; PKC_PHOSPHO_SITE 128-130;	PGNDSYNTHASE 90-104; PGNDSYNTHASE 107-125;
DEX0455 _037.aa .5	N	0 - 01- 150;	110- 116,1.09; 11- 27,1.137; 75- 102,1.154; 137- 147,1.065; 47- 53,1.067; 38- 45,1.081;	MYRISTYL 62-67; MYRISTYL 51-56; ASN_GLYCOSYLATION 71-74; PKC_PHOSPHO_SITE 33-35; MYRISTYL 74-79; MYRISTYL 138-143; MYRISTYL 65-70; MYRISTYL 69-74; PKC_PHOSPHO_SITE 116-118; MYRISTYL 115-120; MYRISTYL 105-110; CK2_PHOSPHO_SITE 46-49;	
DEX0455	Y	0 -	149-	MYRISTYL 100-105; MYRISTYL	LIPOCALIN 33-

_037.aa .6		01- 224;	158,1.178; 137- 143,1.07; 209- 218,1.123; 116- 126,1.06; 198- 204,1.08; 45- 52,1.052; 94- 108,1.076; 160- 168,1.13; 8- 33,1.189; 60- 72,1.178; 180- 185,1.025;	147-152; PKC_PHOSPHO_SITE 188-190; MYRISTYL 47-52; ASN_GLYCOSYLATION 51-54; MYRISTYL 124-129; PKC_PHOSPHO_SITE 106-108; CK2_PHOSPHO_SITE 109-112; MYRISTYL 129-134; CK2_PHOSPHO_SITE 153-156; ASN_GLYCOSYLATION 78-81; MYRISTYL 133-138; PKC_PHOSPHO_SITE 109-111; CK2_PHOSPHO_SITE 157-160; MYRISTYL 76-81; PKC_PHOSPHO_SITE 217-219;	46; lipocalin 38-220; PGNDSYNTHASE 31-54; PGNDSYNTHASE 57-67; PGNDSYNTHASE 74-92;
DEX0455 _037.aa .7	Y	0 - 01- 481;	458- 464,1.07; 281- 288,1.078; 381- 393,1.178; 122- 135,1.15; 358- 364,1.026; 308- 317,1.074; 226- 238,1.199; 71- 77,1.075; 200- 205,1.056; 345- 351,1.103; 209- 215,1.033; 163- 172,1.156; 182- 188,1.098; 292- 298,1.068; 60- 65,1.067; 415- 429,1.076; 50- 56,1.037; 95- 112,1.075; 366- 373.1.052;	MYRISTYL 156-161; MYRISTYL 336-341; PKC_PHOSPHO_SITE 58-60; PKC_PHOSPHO_SITE 68-70; MYRISTYL 79-84; CK2_PHOSPHO_SITE 430-433; MYRISTYL 282-287; MYRISTYL 264-269; AMIDATION 285- 288; MYRISTYL 445-450; MYRISTYL 330-335; MYRISTYL 318-323; PKC_PHOSPHO_SITE 46-48; PKC_PHOSPHO_SITE 136-138; PKC_PHOSPHO_SITE 83-85; ASN_GLYCOSYLATION 399-402; MYRISTYL 186-191; MYRISTYL 450-455; MYRISTYL 299-304; MYRISTYL 421-426; CAMP_PHOSPHO_SITE 191-194; MYRISTYL 454-459; MYRISTYL 238-243; PKC_PHOSPHO_SITE 427-429; MYRISTYL 62-67; PKC_PHOSPHO_SITE 206-208; MYRISTYL 246-251; AMIDATION 86-89; MYRISTYL 274-279; PKC_PHOSPHO_SITE 189-191; MYRISTYL 397-402; MYRISTYL 368-373; MYRISTYL 468-473; MYRISTYL 158-163; PKC_PHOSPHO_SITE 142-144; MYRISTYL 148-153; ASN_GLYCOSYLATION 372-375; CK2_PHOSPHO_SITE 219-222; MYRISTYL 304-309; MYRISTYL 250-255; MYRISTYL 251-256; PKC_PHOSPHO_SITE 472-474; MYRISTYL 322-327; MYRISTYL 153-158; AMIDATION 339- 342; MYRISTYL 326-331; MYRISTYL 248-253;	LIPOCALIN 354- 367; PGNDSYNTHASE 395-413; PGNDSYNTHASE 352-375; GLY_RICH 236- 355; PGNDSYNTHASE 378-388;

			8- 33,1.189; 437- 447,1.06;	PKC_PHOSPHO_SITE 178-180; PKC_PHOSPHO_SITE 430-432; AMIDATION 189-192;	
DEX0455 _038.aa .1	N	1 - i1- 8;tm9- 31;o32 -1088;	605- 611,1.066; 944- 955,1.104; 810- 816,1.069; 542- 551,1.102; 674- 692,1.106; 879- 897,1.086; 765- 778,1.082; 1006- 1012,1.077; ; 518- 531,1.078; 856- 863,1.092; 462- 468,1.065; 174- 186,1.219; 1080- 1085,1.064; ; 822- 829,1.06; 144- 172,1.186; 565- 571,1.09; 841- 849,1.057; 712- 722,1.142; 731- 752,1.127; 130- 135,1.037; 661- 667,1.036; 89- 127,1.18; 1039- 1050,1.161; ; 904- 911,1.142; 957- 964,1.055; 1017- 1027,1.15; 973- 986,1.075; 915-	AMIDATION 268-271; CK2_PHOSPHO_SITE 423-426; AMIDATION 278-281; AMIDATION 288-291; PKC_PHOSPHO_SITE 750-752; CAMP_PHOSPHO_SITE 476-479; PKC_PHOSPHO_SITE 722-724; CK2_PHOSPHO_SITE 632-635; PKC_PHOSPHO_SITE 164-166; AMIDATION 248-251; PKC_PHOSPHO_SITE 209-211; AMIDATION 338-341; PKC_PHOSPHO_SITE 525-527; PKC_PHOSPHO_SITE 481-483; CK2_PHOSPHO_SITE 781-784; PKC_PHOSPHO_SITE 32-34; CK2_PHOSPHO_SITE 135-138; ASN_GLYCOSYLATION 931-934; CK2_PHOSPHO_SITE 998-1001; AMIDATION 228-231; AMIDATION 318-321; CK2_PHOSPHO_SITE 1059- 1062; AMIDATION 238-241; CK2_PHOSPHO_SITE 37-40; CK2_PHOSPHO_SITE 847-850; CK2_PHOSPHO_SITE 408-411; PKC_PHOSPHO_SITE 135-137; AMIDATION 308-311; AMIDATION 436-439; AMIDATION 396-399; PKC_PHOSPHO_SITE 539-541; AMIDATION 416-419; CK2_PHOSPHO_SITE 615-618; CK2_PHOSPHO_SITE 722-725; AMIDATION 426-429; PKC_PHOSPHO_SITE 615-617; MYRISTYL 186-191; AMIDATION 446-449; PKC_PHOSPHO_SITE 804-806; PKC_PHOSPHO_SITE 72-74; AMIDATION 368-371; CK2_PHOSPHO_SITE 775-778; CK2_PHOSPHO_SITE 561-564; CK2_PHOSPHO_SITE 828-831; AMIDATION 218-221; AMIDATION 376-379; PKC_PHOSPHO_SITE 902-904; MYRISTYL 189-194; CK2_PHOSPHO_SITE 32-35; CK2_PHOSPHO_SITE 664-667; ASN_GLYCOSYLATION 207-210; CK2_PHOSPHO_SITE 36-39; AMIDATION 386-389; AMIDATION 198-201; AMIDATION 328-331;	TROPOMYOSIN 622-639; TROPOMYOSIN 695-715; Rib_recp_KP_reg 33-176; LYS_RICH 47-82; TROPOMYOSIN 764-787; TROPOMYOSIN 831-856;

			930,1.17; 780- 793,1.075; 493- 510,1.135; 8- 31,1.182; 594- 602,1.136; 616- 631,1.118;	MYRISTYL 195-200; PKC_PHOSPHO_SITE 1070- 1072; AMIDATION 348-351; AMIDATION 258-261; ASN_GLYCOSYLATION 91-94; PKC_PHOSPHO_SITE 1027- 1029; MYRISTYL 1031-1036;	
DEX0455 _038.or f.3	N	1 - i1- 107;tm 108- 130;o1 31- 440;	49- 58,1.131; 243- 271,1.186; 188- 226,1.18; 107- 130,1.182; 16- 27,1.089; 64- 96,1.129; 229- 234,1.037; 273- 285,1.219;	PKC_PHOSPHO_SITE 263-265; AMIDATION 357-360; PKC_PHOSPHO_SITE 234-236; AMIDATION 297-300; AMIDATION 377-380; AMIDATION 327-330; CK2_PHOSPHO_SITE 136-139; CK2_PHOSPHO_SITE 234-237; PKC_PHOSPHO_SITE 308-310; AMIDATION 427-430; CK2_PHOSPHO_SITE 135-138; AMIDATION 317-320; AMIDATION 39-42; MYRISTYL 70-75; AMIDATION 347-350; AMIDATION 417-420; MYRISTYL 285-290; MYRISTYL 294-299; ASN_GLYCOSYLATION 190-193; MYRISTYL 7-12; CK2_PHOSPHO_SITE 131-134; AMIDATION 43-46; PKC_PHOSPHO_SITE 131-133; AMIDATION 367-370; PKC_PHOSPHO_SITE 32-34; AMIDATION 387-390; PKC_PHOSPHO_SITE 59-61; PKC_PHOSPHO_SITE 171-173; ASN_GLYCOSYLATION 306-309; AMIDATION 407-410; AMIDATION 337-340; MYRISTYL 288-293;	LYS_RICH 146- 181; Rib_recip_KP_reg 132-275;
DEX0455 _038.aa .3	Y	1 - i1- 8;tm9- 31;o32 -521;	174- 186,1.219; 415- 423,1.129; 130- 135,1.037; 396- 413,1.186; 8- 31,1.182; 144- 172,1.186; 339- 377,1.18; 455- 464,1.102; 507- 515.1.136;	ASN_GLYCOSYLATION 91-94; MYRISTYL 417-422; MYRISTYL 189-194; PKC_PHOSPHO_SITE 438-440; PKC_PHOSPHO_SITE 452-454; MYRISTYL 186-191; PKC_PHOSPHO_SITE 135-137; AMIDATION 228-231; PKC_PHOSPHO_SITE 209-211; AMIDATION 238-241; PKC_PHOSPHO_SITE 519-521; AMIDATION 198-201; PKC_PHOSPHO_SITE 164-166; CK2_PHOSPHO_SITE 32-35; AMIDATION 248-251; PKC_PHOSPHO_SITE 385-387; AMIDATION 258-261; MYRISTYL 195-200; CK2 PHOSPHO SITE 135-138;	Rib_recip_KP_reg 278-426; LYS_RICH 47-82; Rib_recip_KP_reg 33-176;

			478- 484,1.09; 431- 444,1.078; 380- 385,1.037; 89- 127,1.18;	AMIDATION 278-281; PKC_PHOSPHO_SITE 72-74; AMIDATION 308-311; CK2_PHOSPHO_SITE 474-477; CK2_PHOSPHO_SITE 413-416; AMIDATION 218-221; PKC_PHOSPHO_SITE 32-34; AMIDATION 318-321; CK2_PHOSPHO_SITE 385-388; AMIDATION 288-291; AMIDATION 268-271; CK2_PHOSPHO_SITE 37-40; AMIDATION 328-331; CK2_PHOSPHO_SITE 36-39; ASN GLYCOSYLATION 207-210;	
DEX0455 _039.aa .1	Y	0 - 01- 165;	53- 71,1.107; 74- 80,1.034; 86- 93,1.108; 6- 30,1.126; 34- 40,1.082; 125- 132,1.062;	PKC_PHOSPHO_SITE 72-74; MYRISTYL 41-46; MYRISTYL 78-83; CK2_PHOSPHO_SITE 110-113; AMIDATION 157- 160; PKC_PHOSPHO_SITE 3-5; CK2_PHOSPHO_SITE 121-124; MYRISTYL 76-81; CK2_PHOSPHO_SITE 117-120; CK2_PHOSPHO_SITE 119-122; CK2_PHOSPHO_SITE 32-35; AMIDATION 152-155; CK2_PHOSPHO_SITE 66-69; MYRISTYL 45-50;	LYS_RICH 141- 161;
DEX0455 _039.aa .2	N	0 - 01- 262;	103- 113,1.095; 74- 80,1.034; 210- 229,1.107; 6- 30,1.126; 118- 132,1.11; 86- 93,1.108; 53- 71,1.107; 139- 168,1.129; 174- 207,1.173; 34- 40,1.082;	MYRISTYL 76-81; AMIDATION 254-257; MYRISTYL 112-117; PKC_PHOSPHO_SITE 3-5; CK2_PHOSPHO_SITE 66-69; AMIDATION 249-252; MYRISTYL 41-46; MYRISTYL 173-178; MYRISTYL 45-50; PKC_PHOSPHO_SITE 72-74; CK2_PHOSPHO_SITE 32-35; MYRISTYL 78-83;	LYS_RICH 238- 258;
DEX0455 _040.or f.1	Y	0 - 01- 231;		CK2_PHOSPHO_SITE 51-54; MYRISTYL 88-93; CK2_PHOSPHO_SITE 98-101; RGD 219-221; PKC_PHOSPHO_SITE 223-225; CK2_PHOSPHO_SITE 108-111; MYRISTYL 91-96; PKC_PHOSPHO_SITE 190-192; MYRISTYL 183-188; MYRISTYL 212-217; MYRISTYL 42-47; MYRISTYL 204-209;	BPTI_KUNITZ_2_1 56-106; BASICPTASE 53- 67; BPTI_KUNITZ_1 179-197; KU 54- 107; BASICPTASE 91-106; sp_043291_SPT2_ HUMAN 56-106; sp_043291_SPT2

				ASN_GLYCOSYLATION 112-115; MYRISTYL 186-191; MYRISTYL 216-221; ASN_GLYCOSYLATION 75-78; MYRISTYL 24-29; MYRISTYL 182-187; PKC_PHOSPHO_SITE 119-121; MYRISTYL 87-92;	HUMAN 151-201; Kunitz_BPTI 151-201; KU 149-202; Kunitz_BPTI 56- 106; BASICPTASE 81-91; BPTI_KUNITZ_2_2 151-201; BPTI_KUNITZ_1 84-102;
DEX0455 _040.aa .1	Y	0 - 01- 213;	60- 70,1.189; 107- 113,1.087; 147- 153,1.047; 178- 188,1.133; 81- 91,1.13; 130- 136,1.11; 10- 28,1.181; 138- 145,1.083; 35- 47,1.25;	MYRISTYL 69-74; CK2_PHOSPHO_SITE 80-83; MYRISTYL 195-200; MYRISTYL 207-212; PKC_PHOSPHO_SITE 204-206; CK2_PHOSPHO_SITE 90-93; MYRISTYL 70-75; MYRISTYL 73-78; MYRISTYL 203-208; MYRISTYL 168-173; ASN_GLYCOSYLATION 94-97; ASN_GLYCOSYLATION 57-60; PKC_PHOSPHO_SITE 172-174; MYRISTYL 6-11; MYRISTYL 165-170; PKC_PHOSPHO_SITE 101-103; MYRISTYL 198-203; MYRISTYL 164-169; CK2_PHOSPHO_SITE 33-36; MYRISTYL 24-29;	KU 131-184; Kunitz_BPTI 38- 88; BASICPTASE 35-49; sp_O43291_SPT2_ HUMAN 133-183; BPTI_KUNITZ_1 66-84; BPTI_KUNITZ_2_2 133-183; BPTI_KUNITZ_1 161-179; BASICPTASE 73- 88; Kunitz_BPTI 133-183; BPTI_KUNITZ_2_1 38-88; KU 36- 89; sp_O43291_SPT2_ HUMAN 38-88; BASICPTASE 63- 73;
DEX0455 _040.aa .2	Y	0 - 01- 242;	35- 47,1.25; 107- 113,1.087; 201- 239,1.186; 178- 186,1.133; 130- 136,1.11; 138- 145,1.083; 189- 195,1.083; 10- 28,1.181; 81- 91,1.13; 60- 70,1.189; 147- 153,1.047;	MYRISTYL 73-78; MYRISTYL 6-11; MYRISTYL 168-173; ASN_GLYCOSYLATION 94-97; CK2_PHOSPHO_SITE 33-36; PKC_PHOSPHO_SITE 172-174; MYRISTYL 70-75; MYRISTYL 69-74; PKC_PHOSPHO_SITE 101-103; ASN_GLYCOSYLATION 57-60; CK2_PHOSPHO_SITE 214-217; CK2_PHOSPHO_SITE 90-93; MYRISTYL 164-169; MYRISTYL 24-29; CK2_PHOSPHO_SITE 80-83; MYRISTYL 165-170;	Kunitz_BPTI 38- 88; KU 131-184; BPTI_KUNITZ_2_2 133-183; sp_O43291_SPT2_ HUMAN 38-88; BPTI_KUNITZ_1 66-84; sp_O43291_SPT2_ HUMAN 133-183; BPTI_KUNITZ_2_1 38-88; BPTI_KUNITZ_1 161-179; Kunitz_BPTI 133-183; BASICPTASE 73- 88; BASICPTASE 63-73; KU 36- 89; BASICPTASE 35-49;
DEX0455 _041.or f.1	N	0 - 01-53;	16- 21,1.006; 4- 11,1.105;	PKC_PHOSPHO_SITE 21-23; PKC_PHOSPHO_SITE 42-44; PKC_PHOSPHO_SITE 20-22; MYRISTYL 7-12;	

DEX0455 _041.aa .1	N	0 - 01-43;	33- 38,1.046; 5- 20,1.129;	MYRISTYL 28-33; MYRISTYL 6-11; ASN_GLYCOSYLATION 32-35;	
DEX0455 _041.or f.2	N	0 - 01-66;	4- 17,1.129; 30- 35,1.046;	ASN_GLYCOSYLATION 29-32; MYRISTYL 25-30; PKC_PHOSPHO_SITE 55-57;	
DEX0455 _041.aa .2	Y	0 - 11-34;	6- 18,1.141; 25- 31,1.103;		
DEX0455 _042.or f.1	N	0 - 01- 116;		PKC_PHOSPHO_SITE 3-5; MYRISTYL 10-15; CK2_PHOSPHO_SITE 7-10; ASN_GLYCOSYLATION 75-78; AMIDATION 40-43; PKC_PHOSPHO_SITE 41-43; CK2_PHOSPHO_SITE 81-84; CK2_PHOSPHO_SITE 36-39; ASN_GLYCOSYLATION 34-37; CK2_PHOSPHO_SITE 72-75; TYR_PHOSPHO_SITE 51-59; CK2_PHOSPHO_SITE 93-96; ASN_GLYCOSYLATION 80-83; PKC_PHOSPHO_SITE 29-31; TYR_PHOSPHO_SITE 40-48; CK2_PHOSPHO_SITE 82-85; CK2_PHOSPHO_SITE 17-20; CK2_PHOSPHO_SITE 56-59; CAMP_PHOSPHO_SITE 69-72; CK2_PHOSPHO_SITE 71-74; CK2_PHOSPHO_SITE 112-115; CK2_PHOSPHO_SITE 76-79; CAMP_PHOSPHO_SITE 42-45; TYR_PHOSPHO_SITE 50-57; PKC_PHOSPHO_SITE 44-46; CK2_PHOSPHO_SITE 77-80; TYR_PHOSPHO_SITE 24-31; CAMP_PHOSPHO_SITE 4-7; PKC_PHOSPHO_SITE 113-115; PKC_PHOSPHO_SITE 71-73; TYR_PHOSPHO_SITE 35-41;	
DEX0455 _042.aa .1	N	0 - 01- 122;		MYRISTYL 8-13; CK2_PHOSPHO_SITE 87-90; PKC_PHOSPHO_SITE 9-11; CK2_PHOSPHO_SITE 99-102; PKC_PHOSPHO_SITE 47-49; AMIDATION 46-49; CK2_PHOSPHO_SITE 23-26; ASN_GLYCOSYLATION 40-43; TYR_PHOSPHO_SITE 30-37; CK2_PHOSPHO_SITE 88-91; MYRISTYL 16-21; PKC_PHOSPHO_SITE 35-37; CAMP_PHOSPHO_SITE 48-51; ASN_GLYCOSYLATION 7-10; PKC_PHOSPHO_SITE 87-89;	

				TYR_PHOSPHO_SITE 41-47; CK2_PHOSPHO_SITE 42-45;	
DEX0455 _043.or f.1	Y	0 - o1-86;	64- 72,1.133; 76- 83,1.14; 27- 38,1.086; 4- 20,1.192; 41- 50,1.137;	MYRISTYL 3-8; ASN_GLYCOSYLATION 60-63; PKC_PHOSPHO_SITE 29-31; MYRISTYL 64-69; MYRISTYL 56-61; MYRISTYL 61-66;	
DEX0455 _043.aa .1	N	0 - o1-30;	11- 26,1.155;	CK2_PHOSPHO_SITE 24-27;	
DEX0455 _043.or f.2	N	0 - o1- 125;		CK2_PHOSPHO_SITE 94-97; MYRISTYL 47-52; PKC_PHOSPHO_SITE 84-86; MYRISTYL 8-13; PKC PHOSPHO_SITE 77-79;	
DEX0455 _043.or f.3	N	0 - i1- 104;	89- 95,1.052; 59- 67,1.023; 10- 38,1.08;	PKC_PHOSPHO_SITE 42-44; CK2_PHOSPHO_SITE 34-37; MYRISTYL 9-14; PKC_PHOSPHO_SITE 45-47; PKC_PHOSPHO_SITE 3-5; ASN_GLYCOSYLATION 11-14;	
DEX0455 _044.aa .1	N	1 - i1- 31;tm3 2- 54;o55 -61;	14- 24,1.177; 29- 58,1.199;	MYRISTYL 27-32;	
DEX0455 _045.or f.1	N	0 - o1- 193;	178- 190,1.144; 135- 145,1.124; 121- 128,1.095; 70- 111,1.15; 25- 46,1.115; 51- 66,1.216;	AMIDATION 65-68; PKC_PHOSPHO_SITE 129-131; MYRISTYL 10-15; PKC_PHOSPHO_SITE 93-95; MYRISTYL 81-86; CAMP_PHOSPHO_SITE 175-178; AMIDATION 173-176; PKC_PHOSPHO_SITE 5-7; CAMP_PHOSPHO_SITE 110-113; MYRISTYL 83-88; CK2_PHOSPHO_SITE 167-170;	
DEX0455 _045.aa .1	N	0 - o1- 163;	25- 46,1.115; 121- 128,1.095; 51- 66,1.216; 135- 144,1.081; 70- 111,1.15;	CK2_PHOSPHO_SITE 149-152; AMIDATION 65-68; PKC_PHOSPHO_SITE 5-7; MYRISTYL 10-15; CAMP_PHOSPHO_SITE 146-149; MYRISTYL 81-86; PKC_PHOSPHO_SITE 93-95; CAMP_PHOSPHO_SITE 110-113; MYRISTYL 83-88; PKC PHOSPHO_SITE 129-131;	
DEX0455 _046.or f.1	N	0 - o1- 227;		MYRISTYL 115-120; PKC_PHOSPHO_SITE 3-5; MYRISTYL 97-102; MYRISTYL	

				133-138; CAMP_PHOSPHO_SITE 163-166; CK2_PHOSPHO_SITE 3-6; MYRISTYL 3-8;	
DEX0455 _046.aa .1	N	0 - o1- 198;	4- 11,1.144; 51- 59,1.107; 160- 184,1.151; 15- 25,1.11; 93- 99,1.11; 73- 85,1.118; 32- 40,1.076; 146- 153,1.088;	MYRISTYL 90-95; MYRISTYL 71-76; CK2_PHOSPHO_SITE 156-159; MYRISTYL 161-166; PKC_PHOSPHO_SITE 63-65; MYRISTYL 153-158; MYRISTYL 149-154; PKC_PHOSPHO_SITE 119-121; MYRISTYL 86-91; MYRISTYL 157-162; MYRISTYL 68-73; CAMP_PHOSPHO_SITE 120-123; MYRISTYL 104-109;	
DEX0455 _047.or f.1	N	0 - o1- 103;	66- 100,1.232; 23- 44,1.101; 10- 17,1.088;	AMIDATION 14-17; PKC_PHOSPHO_SITE 73-75; CK2_PHOSPHO_SITE 33-36; PKC_PHOSPHO_SITE 59-61; MYRISTYL 96-101;	
DEX0455 _047.aa .1	Y	0 - o1-65;	42- 48,1.073; 55- 62,1.119; 4- 30,1.142; 32- 40,1.122;	ASN_GLYCOSYLATION 32-35; CK2_PHOSPHO_SITE 23-26; ASN_GLYCOSYLATION 39-42; MYRISTYL 19-24;	
DEX0455 _047.or f.2	N	0 - o1- 103;	10- 17,1.088; 66- 100,1.232; 23- 44,1.101;	AMIDATION 14-17; CK2_PHOSPHO_SITE 33-36; MYRISTYL 96-101; PKC_PHOSPHO_SITE 73-75; PKC_PHOSPHO_SITE 59-61;	
DEX0455 _047.aa .2	N	0 - o1-27;			
DEX0455 _048.aa .1	Y	0 - o1- 154;	111- 117,1.077; 83- 97,1.104; 4- 60,1.197; 99- 107,1.051; 63- 78,1.095; 126- 151,1.156;	TYR_PHOSPHO_SITE 105-112; MYRISTYL 80-85; PKC_PHOSPHO_SITE 56-58; CK2_PHOSPHO_SITE 37-40; TYR_PHOSPHO_SITE 79-86;	
DEX0455 _048.or f.2	N	0 - o1- 176;	151- 173,1.203; 86- 100,1.104;	PKC_PHOSPHO_SITE 169-171; MYRISTYL 83-88; PKC_PHOSPHO_SITE 59-61; TYR PHOSPHO SITE 108-115;	

			114- 120,1.077; 129- 141,1.156; 102- 110,1.051; 66- 81,1.095; 4- 63,1.197;	CK2_PHOSPHO_SITE 40-43; TYR_PHOSPHO_SITE 82-89; CK2_PHOSPHO_SITE 24-27;	
DEX0455 _048.aa .2	N	0 - 01- 271;	39- 50,1.182; 4- 21,1.232; 181- 195,1.104; 98- 158,1.148; 246- 268,1.203; 161- 176,1.095; 197- 205,1.051; 66- 90,1.192; 224- 236,1.156; 209- 215,1.077; 57- 62,1.053;	TYR_PHOSPHO_SITE 203-210; PKC_PHOSPHO_SITE 154-156; PKC_PHOSPHO_SITE 34-36; RGD 26-28; PKC_PHOSPHO_SITE 264-266; ASN_GLYCOSYLATION 95-98; MYRISTYL 38-43; PKC_PHOSPHO_SITE 21-23; CK2_PHOSPHO_SITE 88-91; TYR_PHOSPHO_SITE 177-184; MYRISTYL 178-183; CK2_PHOSPHO_SITE 135-138; PKC_PHOSPHO_SITE 96-98; CK2_PHOSPHO_SITE 119-122;	
DEX0455 _049.aa .1	N	1 - 01- 219;tm 220- 242;i2 43- 268;	199- 209,1.147; 129- 139,1.104; 95- 105,1.087; 4- 24,1.212; 219- 244,1.317; 58- 63,1.099; 145- 153,1.156; 69- 76,1.121; 86- 93,1.085; 163- 172,1.122; 176- 182,1.056;	PKC_PHOSPHO_SITE 243-245; MYRISTYL 66-71; TYR_PHOSPHO_SITE 105-111; MYRISTYL 77-82; PKC_PHOSPHO_SITE 154-156; CK2_PHOSPHO_SITE 88-91; MYRISTYL 217-222; MYRISTYL 9-14; PKC_PHOSPHO_SITE 81- 83; ASN_GLYCOSYLATION 152- 155; PKC_PHOSPHO_SITE 115- 117; ASN_GLYCOSYLATION 28- 31; AMIDATION 32-35; MYRISTYL 29-34; PKC_PHOSPHO_SITE 125-127; MYRISTYL 57-62; CK2_PHOSPHO_SITE 81-84; CK2_PHOSPHO_SITE 157-160; PKC_PHOSPHO_SITE 90-92; MYRISTYL 40-45; ASN_GLYCOSYLATION 65-68; PKC_PHOSPHO_SITE 182-184;	THYROGLOBULIN_1 49-77; thyroglobulin_1 20-89; TY 50- 93;
DEX0455 _049.aa .2	N	1 - 01- 293;tm 294- 316;i3	237- 246,1.122; 52- 67,1.194; 169-	MYRISTYL 10-15; ASN_GLYCOSYLATION 139-142; MYRISTYL 291-296; TYR_PHOSPHO_SITE 179-185; MYRISTYL 29-34;	TY 124-167; thyroglobulin_1 94-163; THYROGLOBULIN_1 123-151;

		17-342;	179,1.087; 132- 137,1.099; 219- 227,1.156; 41- 50,1.059; 203- 213,1.104; 273- 283,1.147; 250- 256,1.056; 24- 29,1.038; 293- 318,1.317; 73- 98,1.193; 143- 150,1.121; 160- 167,1.085;	PKC_PHOSPHO_SITE 164-166; MYRISTYL 151-156; PKC_PHOSPHO_SITE 228-230; ASN_GLYCOSYLATION 25-28; CK2_PHOSPHO_SITE 231-234; MYRISTYL 32-37; MYRISTYL 140-145; CK2_PHOSPHO_SITE 155-158; PKC_PHOSPHO_SITE 317-319; MYRISTYL 103-108; PKC_PHOSPHO_SITE 155-157; PKC_PHOSPHO_SITE 256-258; MYRISTYL 114-119; ASN_GLYCOSYLATION 226-229; PKC_PHOSPHO_SITE 189-191; MYRISTYL 131-136; PKC_PHOSPHO_SITE 199-201; CK2_PHOSPHO_SITE 162-165; ASN_GLYCOSYLATION 102-105; AMIDATION 106-109; MYRISTYL 80-85;	
DEX0455_049.aa.3	Y	0 - 01- 240;	45- 70,1.193; 4- 22,1.166; 132- 139,1.085; 191- 199,1.156; 24- 39,1.194; 104- 109,1.099; 115- 122,1.121; 175- 185,1.104; 209- 216,1.122; 141- 151,1.087; 220- 237,1.155;	MYRISTYL 112-117; PKC_PHOSPHO_SITE 127-129; PKC_PHOSPHO_SITE 136-138; TYR_PHOSPHO_SITE 151-157; MYRISTYL 10-15; AMIDATION 78-81; ASN_GLYCOSYLATION 198-201; MYRISTYL 86-91; CK2_PHOSPHO_SITE 134-137; MYRISTYL 75-80; PKC_PHOSPHO_SITE 171-173; ASN_GLYCOSYLATION 74-77; PKC_PHOSPHO_SITE 200-202; MYRISTYL 123-128; MYRISTYL 52-57; MYRISTYL 103-108; CK2_PHOSPHO_SITE 127-130; CK2_PHOSPHO_SITE 203-206; PKC_PHOSPHO_SITE 161-163; ASN_GLYCOSYLATION 111-114;	thyroglobulin_1 66-135; TY 96- 139; THYROGLOBULIN_1 95-123;
DEX0455_049.aa.4	Y	1 - 01- 341;tm 342- 364;i3 65- 390;	191- 198,1.121; 251- 261,1.104; 4- 23,1.166; 217- 227,1.087; 321- 331,1.147; 298- 304,1.056; 341- 366.1.317;	PKC_PHOSPHO_SITE 212-214; CK2_PHOSPHO_SITE 203-206; AMIDATION 154-157; PKC_PHOSPHO_SITE 247-249; PKC_PHOSPHO_SITE 365-367; PKC_PHOSPHO_SITE 94-96; MYRISTYL 151-156; PKC_PHOSPHO_SITE 304-306; CK2_PHOSPHO_SITE 48-51; MYRISTYL 10-15; MYRISTYL 188-193; PKC_PHOSPHO_SITE 237-239; ASN_GLYCOSYLATION 150-153; MYRISTYL 179-184; TYR PHOSPHO SITE 227-233;	thyroglobulin_1 142-211; TY 172-215; THYROGLOBULIN_1 171-199;

			208- 215,1.085; 267- 275,1.156; 180- 185,1.099; 285- 294,1.122; 92- 115,1.194; 121- 146,1.193; 71- 77,1.09;	PKC_PHOSPHO_SITE 70-72; RGD 66-68; ASN_GLYCOSYLATION 274-277; PKC_PHOSPHO_SITE 203-205; MYRISTYL 39-44; AMIDATION 81-84; MYRISTYL 128-133; PKC_PHOSPHO_SITE 276-278; MYRISTYL 162-167; ASN_GLYCOSYLATION 187-190; MYRISTYL 199-204; CK2_PHOSPHO_SITE 210-213; MYRISTYL 339-344; CK2_PHOSPHO_SITE 279-282;	
DEX0455 _049.aa .5	Y	1 - 01- 265;tm 266- 288;i2 89- 314;	4- 22,1.166; 115- 122,1.133; 132- 139,1.085; 222- 228,1.056; 191- 199,1.156; 245- 255,1.147; 141- 151,1.087; 45- 70,1.193; 209- 218,1.122; 175- 185,1.104; 24- 39,1.194; 104- 109,1.099; 265- 290,1.317;	MYRISTYL 86-91; ASN_GLYCOSYLATION 198-201; PKC_PHOSPHO_SITE 127-129; PKC_PHOSPHO_SITE 228-230; MYRISTYL 75-80; MYRISTYL 52-57; MYRISTYL 103-108; CK2_PHOSPHO_SITE 127-130; PKC_PHOSPHO_SITE 289-291; PKC_PHOSPHO_SITE 200-202; TYR_PHOSPHO_SITE 151-157; MYRISTYL 123-128; CK2_PHOSPHO_SITE 203-206; PKC_PHOSPHO_SITE 136-138; ASN_GLYCOSYLATION 111-114; MYRISTYL 263-268; AMIDATION 78-81; CK2_PHOSPHO_SITE 134-137; ASN_GLYCOSYLATION 74-77; PKC_PHOSPHO_SITE 161-163; PKC_PHOSPHO_SITE 171-173; MYRISTYL 10-15; MYRISTYL 112-117;	thyroglobulin_1 66-135; TY 96- 139; THYROGLOBULIN_1 95-123;
DEX0455 _050.or f.1	Y	1 - i1- 11;tm1 2- 31;o32 -122; 45,1.137; 12- 34,1.192;	60- 71,1.212; 79- 93,1.103; 97- 119,1.218; 37- 45,1.137; 12- 34,1.192;	CK2_PHOSPHO_SITE 72-75; PKC_PHOSPHO_SITE 39-41; PKC_PHOSPHO_SITE 113-115; ASN_GLYCOSYLATION 2-5; CK2_PHOSPHO_SITE 4-7;	PHE_RICH 18-29;
DEX0455 _050.aa .1	Y	0 - 01-48;	9- 25,1.107; 40- 45,1.135;	PKC_PHOSPHO_SITE 4-6; CK2_PHOSPHO_SITE 31-34; MYRISTYL 16-21;	ACTINS_2 29-37;
DEX0455 _051.aa .1	N	0 - 01- 596;	130- 149,1.131; 509- 519,1.077;	TYR_PHOSPHO_SITE 182-189; PKC_PHOSPHO_SITE 463-465; PKC_PHOSPHO_SITE 167-169; MYRISTYL 459-464; MYRISTYL	PRO_RICH 407- 449; SH3 351- 410; SH3DOMAIN 368-383; SH3

			40- 45,1.041; 523- 540,1.153; 215- 230,1.13; 99- 105,1.045; 397- 422,1.135; 239- 258,1.127; 573- 579,1.113; 327- 334,1.141; 369- 383,1.122; 428- 443,1.091; 470- 477,1.104; 58- 76,1.133; 490- 496,1.055; 554- 568,1.178; 500- 506,1.046; 545- 551,1.071; 120- 128,1.127; 354- 361,1.134; 174- 182,1.075; 298- 304,1.052; 154- 160,1.084; 189- 205,1.127; 25- 31,1.047;	530-535; CK2_PHOSPHO_SITE 46-49; CAMP_PHOSPHO_SITE 65-68; CK2_PHOSPHO_SITE 295-298; CK2_PHOSPHO_SITE 106-109; PKC_PHOSPHO_SITE 241-243; MYRISTYL 524-529; PKC_PHOSPHO_SITE 371-373; MYRISTYL 506-511; CK2_PHOSPHO_SITE 549-552; CK2_PHOSPHO_SITE 12-15; CK2_PHOSPHO_SITE 463-466; CK2_PHOSPHO_SITE 13-16; ASN_GLYCOSYLATION 2-5; CK2_PHOSPHO_SITE 185-188; MYRISTYL 26-31; PKC_PHOSPHO_SITE 384-386; CK2_PHOSPHO_SITE 574-577; CK2_PHOSPHO_SITE 282-285; PKC_PHOSPHO_SITE 260-262; PKC_PHOSPHO_SITE 178-180; CK2_PHOSPHO_SITE 74-77; ASN_GLYCOSYLATION 231-234; MYRISTYL 79-84; PKC_PHOSPHO_SITE 68-70; CK2_PHOSPHO_SITE 260-263; PKC_PHOSPHO_SITE 33-35; ASN_GLYCOSYLATION 366-369; CK2_PHOSPHO_SITE 214-217; MYRISTYL 103-108; CK2_PHOSPHO_SITE 565-568; AMIDATION 163-166; CK2_PHOSPHO_SITE 269-272;	354-409; sp_Q9GZQ2_Q9GZQ 2_HUMAN 360- 403; SH3DOMAIN 354-364; SH3DOMAIN 396- 408; SH3 354- 408;
DEX0455 _051.aa .2	N	0 - 01- 408;	4- 41,1.232; 67- 83,1.127; 205- 212,1.141; 306- 321,1.091; 117- 136,1.127; 232- 239,1.134; 368-	PKC_PHOSPHO_SITE 401-403; CK2_PHOSPHO_SITE 341-344; CK2_PHOSPHO_SITE 63-66; ASN_GLYCOSYLATION 109-112; PKC_PHOSPHO_SITE 56-58; PKC_PHOSPHO_SITE 138-140; PKC_PHOSPHO_SITE 249-251; AMIDATION 401-404; PKC_PHOSPHO_SITE 119-121; PKC_PHOSPHO_SITE 262-264; CK2_PHOSPHO_SITE 138-141; ASN_GLYCOSYLATION 244-247; CK2 PHOSPHO SITE 147-150;	SH3DOMAIN 274- 286; SH3DOMAIN 246-261; SH3 232-286; PRICHEXTENSIN 165-182; PRICHEXTENSIN 50-62; PRO_RICH 285-327; sp_Q9GZQ2_Q9GZQ 2_HUMAN 238- 281; SH3 229- 288; SH3 232-

			374,1.055; 93- 108,1.13; 275- 300,1.135; 176- 182,1.052; 348- 355,1.104; 387- 397,1.077; 247- 261,1.122; 45- 60,1.079; 378- 384,1.046;	MYRISTYL 384-389; CK2_PHOSPHO_SITE 92-95; PKC_PHOSPHO_SITE 341-343; MYRISTYL 337-342; TYR_PHOSPHO_SITE 60-67; CK2_PHOSPHO_SITE 160-163; CK2_PHOSPHO_SITE 173-176;	287; SH3DOMAIN 232-242; PRICHEXTENSIN 308-320;
DEX0455 _051.aa .3	N	0 - o1- 470;	383- 393,1.077; 428- 442,1.178; 344- 351,1.104; 374- 380,1.046; 4- 37,1.232; 41- 56,1.079; 271- 296,1.135; 447- 453,1.113; 419- 425,1.071; 243- 257,1.122; 113- 132,1.127; 228- 235,1.134; 302- 317,1.091; 172- 178,1.052; 201- 208,1.141; 89- 104,1.13; 63- 79,1.127; 397- 414,1.153; 364- 370,1.055;	CK2_PHOSPHO_SITE 88-91; CK2_PHOSPHO_SITE 423-426; PKC_PHOSPHO_SITE 258-260; CK2_PHOSPHO_SITE 156-159; CK2_PHOSPHO_SITE 169-172; CK2_PHOSPHO_SITE 59-62; CK2_PHOSPHO_SITE 143-146; MYRISTYL 380-385; CK2_PHOSPHO_SITE 134-137; CK2_PHOSPHO_SITE 448-451; ASN_GLYCOSYLATION 105-108; PKC_PHOSPHO_SITE 134-136; PKC_PHOSPHO_SITE 52-54; CK2_PHOSPHO_SITE 439-442; CK2_PHOSPHO_SITE 337-340; PKC_PHOSPHO_SITE 115-117; MYRISTYL 398-403; PKC_PHOSPHO_SITE 337-339; MYRISTYL 404-409; TYR_PHOSPHO_SITE 56-63; ASN_GLYCOSYLATION 240-243; PKC_PHOSPHO_SITE 245-247; MYRISTYL 333-338;	sp_Q9GZQ2_Q9GZQ 2_HUMAN 234- 277; SH3 228- 283; PRICHEXTENSIN 304-316; SH3DOMAIN 228- 238; PRO_RICH 281-323; SH3 225-284; PRICHEXTENSIN 46-58; SH3DOMAIN 270- 282; SH3DOMAIN 242-257; SH3 228-282; PRICHEXTENSIN 161-178;
DEX0455 _051.or f.4	N	0 - o1- 474;	378- 384,1.046; 45- 60.1.079:	PKC_PHOSPHO_SITE 341-343; PKC_PHOSPHO_SITE 262-264; CK2_PHOSPHO_SITE 173-176; PKC PHOSPHO SITE 119-121:	PRO_RICH 285- 327; SH3 229- 288; PRICHEXTENSIN

			306- 321,1.091; 176- 182,1.052; 67- 83,1.127; 232- 239,1.134; 247- 261,1.122; 93- 108,1.13; 432- 446,1.178; 117- 136,1.127; 451- 457,1.113; 205- 212,1.141; 4- 41,1.232; 348- 355,1.104; 275- 300,1.135; 387- 397,1.077; 368- 374,1.055; 423- 429,1.071; 401- 418,1.153;	CK2_PHOSPHO_SITE 63-66; CK2_PHOSPHO_SITE 138-141; CK2_PHOSPHO_SITE 160-163; CK2_PHOSPHO_SITE 452-455; MYRISTYL 384-389; PKC_PHOSPHO_SITE 138-140; ASN_GLYCOSYLATION 109-112; CK2_PHOSPHO_SITE 427-430; TYR_PHOSPHO_SITE 60-67; PKC_PHOSPHO_SITE 249-251; CK2_PHOSPHO_SITE 341-344; MYRISTYL 402-407; CK2_PHOSPHO_SITE 147-150; MYRISTYL 408-413; CK2_PHOSPHO_SITE 443-446; PKC_PHOSPHO_SITE 56-58; MYRISTYL 337-342; CK2_PHOSPHO_SITE 92-95; ASN_GLYCOSYLATION 244-247;	165-182; SH3DOMAIN 274- 286; SH3DOMAIN 246-261; SH3DOMAIN 232- 242; PRICHEXTENSIN 308-320; PRICHEXTENSIN 50-62; sp_Q9GZQ2_Q9GZQ 2_HUMAN 238- 281; SH3 232- 287; SH3 232- 286;
DEX0455 _051.or f.5	N	0 - 01- 474;	306- 321,1.091; 93- 108,1.13; 232- 239,1.134; 423- 429,1.071; 451- 457,1.113; 247- 261,1.122; 432- 446,1.178; 348- 355,1.104; 401- 418,1.153; 368- 374,1.055; 45- 60,1.079; 275- 300,1.135; 387-	ASN_GLYCOSYLATION 244-247; PKC_PHOSPHO_SITE 249-251; CK2_PHOSPHO_SITE 341-344; CK2_PHOSPHO_SITE 443-446; MYRISTYL 402-407; PKC_PHOSPHO_SITE 119-121; PKC_PHOSPHO_SITE 56-58; CK2_PHOSPHO_SITE 160-163; PKC_PHOSPHO_SITE 138-140; CK2_PHOSPHO_SITE 63-66; MYRISTYL 337-342; TYR_PHOSPHO_SITE 60-67; CK2_PHOSPHO_SITE 92-95; CK2_PHOSPHO_SITE 173-176; MYRISTYL 408-413; ASN_GLYCOSYLATION 109-112; MYRISTYL 384-389; CK2_PHOSPHO_SITE 427-430; CK2_PHOSPHO_SITE 452-455; CK2_PHOSPHO_SITE 138-141; PKC_PHOSPHO_SITE 341-343; CK2_PHOSPHO_SITE 147-150; PKC_PHOSPHO_SITE 262-264;	PRO_RICH 285- 327; SH3 232- 287; PRICHEXTENSIN 308-320; SH3DOMAIN 246- 261; SH3DOMAIN 232-242; PRICHEXTENSIN 165-182; SH3 232-286; PRICHEXTENSIN 50-62; sp_Q9GZQ2_Q9GZQ 2_HUMAN 238- 281; SH3DOMAIN 274-286; SH3 229-288;

			397,1.077; 205- 212,1.141; 176- 182,1.052; 378- 384,1.046; 117- 136,1.127; 67- 83,1.127; 4- 41,1.232;		
DEX0455 _051.or f.6	N	0 - 01- 474;	368- 374,1.055; 205- 212,1.141; 348- 355,1.104; 93- 108,1.13; 275- 300,1.135; 45- 60,1.079; 176- 182,1.052; 401- 418,1.153; 378- 384,1.046; 67- 83,1.127; 117- 136,1.127; 387- 397,1.077; 4- 41,1.232; 232- 239,1.134; 306- 321,1.091; 423- 429,1.071; 432- 446,1.178; 451- 457,1.113; 247- 261,1.122;	CK2_PHOSPHO_SITE 443-446; CK2_PHOSPHO_SITE 452-455; PKC_PHOSPHO_SITE 56-58; MYRISTYL 408-413; CK2_PHOSPHO_SITE 63-66; MYRISTYL 402-407; CK2_PHOSPHO_SITE 147-150; MYRISTYL 384-389; TYR_PHOSPHO_SITE 60-67; ASN_GLYCOSYLATION 109-112; MYRISTYL 337-342; CK2_PHOSPHO_SITE 138-141; CK2_PHOSPHO_SITE 92-95; PKC_PHOSPHO_SITE 119-121; CK2_PHOSPHO_SITE 173-176; ASN_GLYCOSYLATION 244-247; PKC_PHOSPHO_SITE 249-251; CK2_PHOSPHO_SITE 160-163; PKC_PHOSPHO_SITE 138-140; PKC_PHOSPHO_SITE 341-343; PKC_PHOSPHO_SITE 262-264; CK2_PHOSPHO_SITE 341-344; CK2_PHOSPHO_SITE 427-430;	SH3 229-288; SH3DOMAIN 232- 242; SH3DOMAIN 246-261; PRICHEXTENSIN 308-320; sp_Q9GZQ2_Q9GZQ 2_HUMAN 238- 281; PRICHEXTENSIN 50-62; PRICHEXTENSIN 165-182; SH3 232-286; SH3DOMAIN 274- 286; PRO_RICH 285-327; SH3 232-287;
DEX0455 _052.aa .1	N	0 - 01- 470;	63- 79,1.127; 271- 296,1.135; 383- 393,1.077; 243- 257.1.122;	PKC_PHOSPHO_SITE 258-260; CK2_PHOSPHO_SITE 423-426; CK2_PHOSPHO_SITE 59-62; PKC_PHOSPHO_SITE 245-247; PKC_PHOSPHO_SITE 52-54; CK2_PHOSPHO_SITE 143-146; CK2_PHOSPHO_SITE 134-137; CK2 PHOSPHO SITE 88-91;	PRO_RICH 281- 323; PRICHEXTENSIN 161-178; SH3 228-283; PRICHEXTENSIN 304-316; SH3DOMAIN 270-

			4- 37,1.232; 89- 104,1.13; 374- 380,1.046; 41- 56,1.079; 397- 414,1.153; 364- 370,1.055; 419- 425,1.071; 302- 317,1.091; 172- 178,1.052; 447- 453,1.113; 228- 235,1.134; 344- 351,1.104; 201- 208,1.141; 113- 132,1.127; 428- 442,1.178;	PKC_PHOSPHO_SITE 134-136; ASN_GLYCOSYLATION 105-108; PKC_PHOSPHO_SITE 337-339; MYRISTYL 398-403; ASN_GLYCOSYLATION 240-243; TYR_PHOSPHO_SITE 56-63; MYRISTYL 333-338; CK2_PHOSPHO_SITE 439-442; MYRISTYL 380-385; PKC_PHOSPHO_SITE 115-117; CK2_PHOSPHO_SITE 337-340; CK2_PHOSPHO_SITE 448-451; MYRISTYL 404-409; CK2_PHOSPHO_SITE 169-172; CK2_PHOSPHO_SITE 156-159;	282; SH3DOMAIN 242-257; SH3 228-282; SH3DOMAIN 228- 238; PRICHEXTENSN 46-58; SH3 225- 284; sp_Q9GZQ2_Q9GZQ 2_HUMAN 234- 277;
DEX0455 _052.aa .2	N	0 - o1- 502;	479- 485,1.113; 260- 267,1.134; 223- 240,1.141; 406- 412,1.046; 303- 328,1.135; 376- 383,1.104; 451- 457,1.071; 415- 425,1.077; 275- 289,1.122; 4- 37,1.232; 334- 349,1.091; 63- 79,1.127; 113- 132,1.127; 396- 402,1.055; 172-	CK2_PHOSPHO_SITE 156-159; CK2_PHOSPHO_SITE 455-458; CK2_PHOSPHO_SITE 59-62; CK2_PHOSPHO_SITE 134-137; PKC_PHOSPHO_SITE 290-292; CK2_PHOSPHO_SITE 369-372; MYRISTYL 365-370; ASN_GLYCOSYLATION 105-108; ASN_GLYCOSYLATION 272-275; TYR_PHOSPHO_SITE 56-63; PKC_PHOSPHO_SITE 277-279; CK2_PHOSPHO_SITE 88-91; PKC_PHOSPHO_SITE 52-54; CK2_PHOSPHO_SITE 143-146; PKC_PHOSPHO_SITE 115-117; MYRISTYL 412-417; MYRISTYL 430-435; PKC_PHOSPHO_SITE 134-136; CK2_PHOSPHO_SITE 169-172; MYRISTYL 436-441; CK2_PHOSPHO_SITE 471-474; CK2_PHOSPHO_SITE 480-483; PKC_PHOSPHO_SITE 369-371;	SH3DOMAIN 302- 314; sp_Q9GZQ2_Q9GZQ 2_HUMAN 266- 309; SH3DOMAIN 274-289; SH3 257-316; SH3 260-314; SH3 260-315; SH3DOMAIN 260- 270; PRO_RICH 313-355;

			178,1.052; 429- 446,1.153; 89- 104,1.13; 460- 474,1.178; 41- 56,1.079;		
DEX0455 _052.aa .3	Y	0 - 01- 548;	4- 29,1.211; 79- 95,1.162; 56- 73,1.118; 495- 502,1.134; 510- 519,1.1; 167- 185,1.133; 239- 258,1.131; 263- 269,1.084; 99- 109,1.259; 208- 214,1.045; 407- 413,1.052; 298- 314,1.127; 134- 140,1.047; 324- 339,1.13; 42- 48,1.082; 149- 154,1.041; 348- 367,1.127; 525- 531,1.113; 283- 291,1.075; 113- 127,1.116; 458- 475,1.141; 229- 237,1.127;	PKC_PHOSPHO_SITE 512-514; MYRISTYL 135-140; ASN_GLYCOSYLATION 340-343; MYRISTYL 188-193; PKC_PHOSPHO_SITE 41-43; CK2_PHOSPHO_SITE 36-39; CK2_PHOSPHO_SITE 391-394; PKC_PHOSPHO_SITE 350-352; AMIDATION 1-4; CK2_PHOSPHO_SITE 294-297; PKC_PHOSPHO_SITE 276-278; MYRISTYL 212-217; CK2_PHOSPHO_SITE 183-186; PKC_PHOSPHO_SITE 287-289; ASN_GLYCOSYLATION 12-15; PKC_PHOSPHO_SITE 369-371; CK2_PHOSPHO_SITE 74-77; CK2_PHOSPHO_SITE 323-326; CK2_PHOSPHO_SITE 369-372; CAMP_PHOSPHO_SITE 174-177; CK2_PHOSPHO_SITE 68-71; TYR_PHOSPHO_SITE 291-298; AMIDATION 272-275; CK2_PHOSPHO_SITE 404-407; PKC_PHOSPHO_SITE 177-179; CK2_PHOSPHO_SITE 155-158; CK2_PHOSPHO_SITE 215-218; ASN_GLYCOSYLATION 507-510; CK2_PHOSPHO_SITE 526-529; CK2_PHOSPHO_SITE 378-381; PKC_PHOSPHO_SITE 142-144; MYRISTYL 121-126;	
DEX0455 _052.aa .4	Y	0 - 01- 277;	78- 103,1.135; 109- 124,1.091; 235- 249,1.178;	MYRISTYL 2-7; PKC_PHOSPHO_SITE 16-18; CK2_PHOSPHO_SITE 230-233; MYRISTYL 211-216; CK2_PHOSPHO_SITE 246-249; MYRISTYL 205-210;	SH3DOMAIN 77- 89; PRICHEXTENSN 170-195; PRICHEXTENSN 112-128: SH3

			254- 260,1.113; 4- 19,1.169; 151- 158,1.104; 181- 187,1.046; 204- 221,1.153; 190- 200,1.077; 50- 64,1.122; 226- 232,1.071; 35- 42,1.134; 171- 177,1.055;	CK2_PHOSPHO_SITE 255-258; CK2_PHOSPHO_SITE 144-147; PKC_PHOSPHO_SITE 65-67; MYRISTYL 140-145; PKC_PHOSPHO_SITE 144-146; ASN_GLYCOSYLATION 47-50; CK2_PHOSPHO_SITE 16-19; PKC_PHOSPHO_SITE 52-54; MYRISTYL 187-192;	35-89; PRICHEXTENSN 88-109; PRO_RICH 88- 130; SH3 32-91; SH3DOMAIN 35- 45; SH3 35-90; sp_Q9GZQ2_Q9GZQ 2_HUMAN 41-84; SH3DOMAIN 49- 64;
DEX0455 _053.aa .1	Y	1 - i1- 6;tm7- 29;o30 -282;	73- 83,1.16; 36- 45,1.103; 152- 160,1.069; 176- 186,1.162; 127- 134,1.125; 207- 217,1.215; 53- 59,1.066; 61- 71,1.119; 248- 279,1.179; 100- 123,1.136; 165- 171,1.06; 4- 30,1.146;	ASN_GLYCOSYLATION 112-115; CK2_PHOSPHO_SITE 91-94; ASN_GLYCOSYLATION 216-219; CK2_PHOSPHO_SITE 151-154; CAMP_PHOSPHO_SITE 246-249; ASN_GLYCOSYLATION 196-199; PKC_PHOSPHO_SITE 32-34; MYRISTYL 188-193; CK2_PHOSPHO_SITE 183-186; PKC_PHOSPHO_SITE 207-209; ASN_GLYCOSYLATION 190-193; ASN_GLYCOSYLATION 160-163; MYRISTYL 52-57; PKC_PHOSPHO_SITE 127-129; ASN_GLYCOSYLATION 205-208; CK2_PHOSPHO_SITE 241-244; PKC_PHOSPHO_SITE 134-136; CK2_PHOSPHO_SITE 197-200; PKC_PHOSPHO_SITE 165-167; PKC_PHOSPHO_SITE 114-116; ASN_GLYCOSYLATION 220-223; MYRISTYL 126-131;	IG_LIKE_2 153- 241; IG_LIKE_1 49-151;
DEX0455 _053.aa .2	Y	1 - i1- 6;tm7- 29;o30 -59;	4- 39,1.146; 41- 56,1.17;		
DEX0455 _053.aa .3	N	0 - o1- 252;	177- 187,1.215; 43- 53,1.16; 23-29,1.1; 122- 130,1.069; 146- 156,1.162; 218-	ASN_GLYCOSYLATION 166-169; PKC_PHOSPHO_SITE 177-179; PKC_PHOSPHO_SITE 97-99; CK2_PHOSPHO_SITE 153-156; PKC_PHOSPHO_SITE 104-106; ASN_GLYCOSYLATION 160-163; CK2_PHOSPHO_SITE 167-170; ASN_GLYCOSYLATION 186-189; CAMP_PHOSPHO_SITE 216-219; CK2 PHOSPHO SITE 61-64;	IG_LIKE_1 19- 121; ig 19-102; IG 11-116; IG_LIKE_2 123- 211;

			249,1.179; 6- 15,1.103; 70- 93,1.136; 97- 104,1.125; 135- 141,1.06; 31- 41,1.119;	ASN_GLYCOSYLATION 82-85; CK2_PHOSPHO_SITE 121-124; PKC_PHOSPHO_SITE 84-86; CK2_PHOSPHO_SITE 211-214; ASN_GLYCOSYLATION 190-193; MYRISTYL 158-163; ASN_GLYCOSYLATION 130-133; MYRISTYL 96-101; MYRISTYL 22-27; PKC_PHOSPHO_SITE 135-137; ASN_GLYCOSYLATION 175-178;	
DEX0455 _054.or f.1	N	0 - o1- 155;	6- 13,1.134; 145- 152,1.23; 34- 51,1.251; 53- 87,1.163; 21- 30,1.088; 99- 123,1.205;	CK2_PHOSPHO_SITE 72-75; PKC_PHOSPHO_SITE 67-69; AMIDATION 124-127; MYRISTYL 109-114; MYRISTYL 79-84; CK2_PHOSPHO_SITE 89-92;	PRO_RICH 51-70;
DEX0455 _054.aa .1	N	0 - o1- 107;	23- 31,1.113; 4-20,1.19; 61- 67,1.089; 36- 57,1.184; 81- 90,1.191;	PKC_PHOSPHO_SITE 100-102; MYRISTYL 94-99; PKC_PHOSPHO_SITE 35-37;	sp_P14786_KPY2_ HUMAN 12-105; PK_C 3-105;
DEX0455 _054.or f.2	N	0 - o1- 155;	99- 123,1.205; 6- 13,1.134; 53- 87,1.163; 145- 152,1.23; 34- 51,1.251; 21- 30,1.088;	AMIDATION 124-127; CK2_PHOSPHO_SITE 89-92; MYRISTYL 79-84; PKC_PHOSPHO_SITE 67-69; MYRISTYL 109-114; CK2_PHOSPHO_SITE 72-75;	PRO_RICH 51-70;
DEX0455 _054.aa .2	N	0 - o1- 143;	28- 45,1.179; 72- 93,1.184; 50- 56,1.095; 117- 126,1.191; 7-14,1.1; 97- 103,1.089; 59- 67,1.113;	MYRISTYL 27-32; PKC_PHOSPHO_SITE 32-34; PKC_PHOSPHO_SITE 136-138; PKC_PHOSPHO_SITE 71-73; MYRISTYL 130-135; PKC_PHOSPHO_SITE 46-48;	PK_C 21-141; sp_P11974_KPY1_ RABIT 1-141;
DEX0455	N	0 -		MYRISTYL 52-57;	

_055.aa .1		01- 253;		CK2_PHOSPHO_SITE 11-14; PKC_PHOSPHO_SITE 19-21; PKC_PHOSPHO_SITE 207-209; CK2_PHOSPHO_SITE 9-12; PKC_PHOSPHO_SITE 164-166; CK2_PHOSPHO_SITE 7-10; CAMP_PHOSPHO_SITE 131-134; PKC_PHOSPHO_SITE 130-132; PKC_PHOSPHO_SITE 245-247; CK2_PHOSPHO_SITE 243-246; AMIDATION 176-179; CK2_PHOSPHO_SITE 19-22;	
DEX0455 _055.aa .2	N	0 - 01- 361;	107- 114,1.114; 42- 52,1.147; 83- 97,1.14; 70- 76,1.055; 236- 242,1.115; 4- 11,1.148; 320- 326,1.056; 164- 186,1.208; 124- 135,1.132; 273- 278,1.03; 99- 105,1.047; 224- 230,1.064;	CAMP_PHOSPHO_SITE 18-21; CK2_PHOSPHO_SITE 12-15; AMIDATION 348-351; MYRISTYL 107-112; PKC_PHOSPHO_SITE 344-346; CAMP_PHOSPHO_SITE 186-189; MYRISTYL 311-316; CAMP_PHOSPHO_SITE 309-312; PKC_PHOSPHO_SITE 325-327; AMIDATION 231-234; CK2_PHOSPHO_SITE 62-65; MYRISTYL 22-27; CK2_PHOSPHO_SITE 66-69; ASN_GLYCOSYLATION 358-361; PKC_PHOSPHO_SITE 262-264; AMIDATION 306-309; PKC_PHOSPHO_SITE 16-18; CK2_PHOSPHO_SITE 74-77; PKC_PHOSPHO_SITE 185-187; PKC_PHOSPHO_SITE 219-221; PKC_PHOSPHO_SITE 74-76; CK2_PHOSPHO_SITE 319-322; AMIDATION 339-342; CK2_PHOSPHO_SITE 64-67; CAMP_PHOSPHO_SITE 341-344; PKC_PHOSPHO_SITE 293-295;	
DEX0455 _055.aa .3	N	0 - 11- 167;	28- 49,1.115; 126- 137,1.056; 68- 84,1.038; 4- 10,1.009; 12- 19,1.035; 60- 66,1.026;	AMIDATION 112-115; MYRISTYL 117-122; PKC_PHOSPHO_SITE 25-27; PKC_PHOSPHO_SITE 131-133; PKC_PHOSPHO_SITE 150-152; AMIDATION 145-148; CAMP_PHOSPHO_SITE 147-150; CK2_PHOSPHO_SITE 125-128; PKC_PHOSPHO_SITE 99-101; AMIDATION 37-40; CAMP_PHOSPHO_SITE 115-118; AMIDATION 154-157; PKC_PHOSPHO_SITE 68-70; ASN_GLYCOSYLATION 164-167;	
DEX0455 _056.or f.1	N	0 - 01- 636;	53- 59,1.147; 401- 411,1.092; 4- 10,1.067; 592-	ASN_GLYCOSYLATION 199-202; MYRISTYL 65-70; MYRISTYL 451-456; CK2_PHOSPHO_SITE 221-224; ASN_GLYCOSYLATION 454-457; CK2_PHOSPHO_SITE 574-577; CK2_PHOSPHO_SITE 115-118; MYRISTYL 531-536;	

			633,1.179; CK2_PHOSPHO_SITE 347-350; 218- CK2_PHOSPHO_SITE 137-140; 253,1.106; CK2_PHOSPHO_SITE 308-311; 474- CK2_PHOSPHO_SITE 301-304; 480,1.058; MYRISTYL 336-341; MYRISTYL 95- 154-159; PKC_PHOSPHO_SITE 136,1.207; 201-203; MYRISTYL 231-236; 440- CK2_PHOSPHO_SITE 525-528; 448,1.082; ASN_GLYCOSYLATION 415-418; 354- MYRISTYL 206-211; 372,1.185; PKC_PHOSPHO_SITE 565-567; 165- PKC_PHOSPHO_SITE 286-288; 203,1.177; TYR_PHOSPHO_SITE 351-357; 66- MYRISTYL 60-65; 74,1.083; TYR_PHOSPHO_SITE 421-428; 429- AMIDATION 20-23; 437,1.111; CK2_PHOSPHO_SITE 70-73; 142- MYRISTYL 63-68; 148,1.091; PKC_PHOSPHO_SITE 70-72; 153- CK2_PHOSPHO_SITE 293-296; 163,1.075; MYRISTYL 588-593; MYRISTYL 274- 51-56; CAMP_PHOSPHO_SITE 285,1.132; 23-26; ASN_GLYCOSYLATION 374- 548-551; CK2_PHOSPHO_SITE 386,1.187; 35-38; MYRISTYL 4-9; 578- MYRISTYL 11-16; 584,1.107; CK2_PHOSPHO_SITE 235-238; 530- CK2_PHOSPHO_SITE 286-289; 574,1.129; MYRISTYL 49-54; 460- 466,1.147; 76- 83,1.118; 490- 518,1.111; 259- 265,1.052; 290- 302,1.163; 309- 325,1.128;	
DEX0455 _056.aa .1	0 - 01- 870;		38- CK2_PHOSPHO_SITE 559-562; 44,1.147; CK2_PHOSPHO_SITE 122-125; 386- MYRISTYL 659-664; MYRISTYL 396,1.092; 36-41; MYRISTYL 34-39; 690- PKC_PHOSPHO_SITE 271-273; 699,1.137; CK2_PHOSPHO_SITE 510-513; 679- MYRISTYL 45-50; 688,1.065; TYR_PHOSPHO_SITE 406-413; 339- CK2_PHOSPHO_SITE 206-209; 357,1.185; MYRISTYL 834-839; 259- PKC_PHOSPHO_SITE 664-666; 270,1.132; CK2_PHOSPHO_SITE 332-335; 634- ASN_GLYCOSYLATION 533-536; 652,1.134; MYRISTYL 436-441; MYRISTYL 515- 139-144; MYRISTYL 191-196; 559,1.129; MYRISTYL 573-578; 51- PKC_PHOSPHO_SITE 550-552; 59.1.083; CK2 PHOSPHO SITE 220-223;	

			425- 433,1.082; 294- 310,1.128; 445- 451,1.147; 275- 287,1.163; 244- 250,1.052; 763- 796,1.144; 459- 465,1.058; 827- 844,1.127; 150- 188,1.177; 414- 422,1.111; 739- 754,1.163; 659- 664,1.038; 707- 723,1.101; 359- 371,1.187; 798- 805,1.037; 203- 238,1.106; 80- 121,1.207; 563- 569,1.107; 851- 867,1.148; 577- 629,1.179; 475- 503,1.111; 127- 133,1.091; 138- 148,1.075; 61- 68,1.118; 666- 676,1.164;	PKC_PHOSPHO_SITE 762-764; CK2_PHOSPHO_SITE 100-103; CK2_PHOSPHO_SITE 824-827; CK2_PHOSPHO_SITE 640-643; MYRISTYL 321-326; PKC_PHOSPHO_SITE 55-57; PKC_PHOSPHO_SITE 186-188; CK2_PHOSPHO_SITE 20-23; CK2_PHOSPHO_SITE 286-289; MYRISTYL 216-221; CK2_PHOSPHO_SITE 278-281; PKC_PHOSPHO_SITE 842-844; ASN_GLYCOSYLATION 184-187; CAMP_PHOSPHO_SITE 748-751; MYRISTYL 516-521; MYRISTYL 50-55; TYR_PHOSPHO_SITE 336-342; PKC_PHOSPHO_SITE 756-758; ASN_GLYCOSYLATION 439-442; ASN_GLYCOSYLATION 400-403; AMIDATION 5-8; PKC_PHOSPHO_SITE 824-826; CAMP_PHOSPHO_SITE 8-11; CK2_PHOSPHO_SITE 293-296; CK2_PHOSPHO_SITE 55-58; CK2_PHOSPHO_SITE 271-274; MYRISTYL 48-53;	
DEX0455 _056.aa .2	N	0 - 01- 791;	244- 250,1.052; 51- 59,1.083; 339- 357,1.185; 577- 619,1.179; 772-	CAMP_PHOSPHO_SITE 738-741; PKC_PHOSPHO_SITE 55-57; CK2_PHOSPHO_SITE 220-223; CK2_PHOSPHO_SITE 100-103; CK2_PHOSPHO_SITE 122-125; CK2_PHOSPHO_SITE 271-274; CK2_PHOSPHO_SITE 286-289; CAMP_PHOSPHO_SITE 8-11; PKC PHOSPHO SITE 654-656:	

			788,1.148; MYRISTYL 191-196; MYRISTYL 669- 516-521; CK2_PHOSPHO_SITE 678,1.065; 510-513; MYRISTYL 36-41; 138- PKC_PHOSPHO_SITE 763-765; 148,1.075; CK2_PHOSPHO_SITE 630-633; 656- MYRISTYL 321-326; 666,1.164; CK2_PHOSPHO_SITE 332-335; 294- PKC_PHOSPHO_SITE 271-273; 310,1.128; MYRISTYL 216-221; 475- PKC_PHOSPHO_SITE 186-188; 503,1.111; CK2_PHOSPHO_SITE 293-296; 515- MYRISTYL 139-144; 559,1.129; ASN_GLYCOSYLATION 439-442; 459- MYRISTYL 573-578; 465,1.058; AMIDATION 5-8; MYRISTYL 697- 50-55; PKC_PHOSPHO_SITE 713,1.101; 752-754; PKC_PHOSPHO_SITE 386- 550-552; ASN_GLYCOSYLATION 396,1.092; 533-536; TYR_PHOSPHO_SITE 624- 406-413; MYRISTYL 48-53; 642,1.134; PKC_PHOSPHO_SITE 746-748; 445- CK2_PHOSPHO_SITE 559-562; 451,1.147; ASN_GLYCOSYLATION 400-403; 127- MYRISTYL 34-39; MYRISTYL 133,1.091; 436-441; CK2_PHOSPHO_SITE 680- 278-281; CK2_PHOSPHO_SITE 689,1.137; 206-209; MYRISTYL 649-654; 38- CK2_PHOSPHO_SITE 20-23; 44,1.147; ASN_GLYCOSYLATION 184-187; 359- TYR_PHOSPHO_SITE 336-342; 371,1.187; MYRISTYL 755-760; 259- CK2_PHOSPHO_SITE 55-58; 270,1.132; MYRISTYL 45-50; 414- 422,1.111; 563- 569,1.107; 753- 765,1.127; 203- 238,1.106; 425- 433,1.082; 729- 744,1.163; 275- 287,1.163; 150- 188,1.177; 80- 121,1.207; 61- 68,1.118; 649- 654,1.038;	
DEX0455 _057.or f.1	N	0 - 01- 122;	97- PKC_PHOSPHO_SITE 3-5; 119,1.114; ASN_GLYCOSYLATION 48-51; 30- CK2_PHOSPHO_SITE 25-28; 41.1.138; PKC PHOSPHO SITE 27-29:	EF HAND_2 25- 101; S100_CABP 80-101; EFh 76- 104;

			4- 13,1.125;	CK2_PHOSPHO_SITE 23-26; PKC_PHOSPHO_SITE 118-120; MYRISTYL 103-108; CK2_PHOSPHO_SITE 12-15; CK2_PHOSPHO_SITE 86-89; CK2_PHOSPHO_SITE 52-55;	sp_P31949_S111_ HUMAN 25-94; S_100 27-70; efhand 76-104; sp_O93395_O9339 5_SALFO 44-98; EF HAND 85-97;
DEX0455 _057.aa .1	N	0 - 01- 170;	78- 89,1.138; 145- 167,1.114; 4-38,1.16;	ASN_GLYCOSYLATION 96-99; CK2_PHOSPHO_SITE 71-74; PKC_PHOSPHO_SITE 55-57; CK2_PHOSPHO_SITE 43-46; PKC_PHOSPHO_SITE 75-77; CK2_PHOSPHO_SITE 134-137; PKC_PHOSPHO_SITE 166-168; CK2_PHOSPHO_SITE 100-103; MYRISTYL 151-156; CK2_PHOSPHO_SITE 73-76; PKC_PHOSPHO_SITE 58-60; CK2_PHOSPHO_SITE 6-9;	sp_P31949_S111_ HUMAN 73-142; EF HAND 133- 145; S100_CABP 128-149; sp_O93395_O9339 5_SALFO 92-146; efhand 124-152; EFh 124-152; S_100 75-118; EF_HAND_2 73- 149;
DEX0455 _057.aa .2	N	0 - 01-91;	66- 88,1.114; 4- 11,1.134;	CK2_PHOSPHO_SITE 55-58; ASN_GLYCOSYLATION 17-20; PKC_PHOSPHO_SITE 87-89; CK2_PHOSPHO_SITE 21-24; MYRISTYL 72-77;	EFh 45-73; efhand 45-73; S100_CABP 49- 70; S_100 3-39; EF HAND 54-66; sp_P31949_S111_ HUMAN 9-63; EF_HAND_2 19- 70; sp_O93395_O9339 5_SALFO 13-67;
DEX0455 _058.or f.1	N	1 - 01- 14;tml 5- 37;i38 -66;	4- 25,1.178; 27- 63,1.191;	CK2_PHOSPHO_SITE 23-26; MYRISTYL 27-32;	
DEX0455 _058.aa .1	N	0 - 01-65;	24- 32,1.155; 36- 54,1.162; 14- 22,1.084;	TYR_PHOSPHO_SITE 12-18; ASN_GLYCOSYLATION 59-62; CK2_PHOSPHO_SITE 6-9;	
DEX0455 _059.or f.1	N	0 - 01- 363;	104- 122,1.145; 261- 268,1.085; 11- 21,1.113; 341- 351,1.191; 125- 159,1.118; 178- 212,1.171; 69- 77,1.128; 315- 330.1.192;	PKC_PHOSPHO_SITE 80-82; CK2_PHOSPHO_SITE 28-31; PKC_PHOSPHO_SITE 281-283; CAMP_PHOSPHO_SITE 105-108; MYRISTYL 47-52; CAMP_PHOSPHO_SITE 77-80; PKC_PHOSPHO_SITE 103-105; MYRISTYL 335-340; PKC_PHOSPHO_SITE 206-208; PKC_PHOSPHO_SITE 76-78; MYRISTYL 304-309; MYRISTYL 71-76; PKC_PHOSPHO_SITE 28-30; PKC_PHOSPHO_SITE 8- 10; CK2_PHOSPHO_SITE 17- 20; PKC_PHOSPHO_SITE 62- 64; CK2 PHOSPHO SITE 237-	

			270- 275,1.039; 235- 248,1.131; 281- 289,1.116; 353- 360,1.134; 85- 102,1.157; 295- 305,1.07; 225- 232,1.131;	240;	
DEX0455 _059.aa .1	N	0 - o1- 116;	38- 67,1.204; 28- 34,1.111; 12- 23,1.084; 71- 113,1.168;	PKC_PHOSPHO_SITE 25-27; PKC_PHOSPHO_SITE 58-60; AMIDATION 16-19; CK2_PHOSPHO_SITE 5-8; PKC_PHOSPHO_SITE 45-47;	
DEX0455 _059.or f.2	N	0 - o1- 166;	118- 133,1.192; 16- 26,1.124; 98- 108,1.07; 144- 154,1.191; 64- 71,1.085; 7- 13,1.026; 38- 51,1.131; 84- 92,1.116; 28- 35,1.122; 156- 163,1.134; 73- 78,1.039;	MYRISTYL 107-112; CK2_PHOSPHO_SITE 40-43; MYRISTYL 138-143; PKC_PHOSPHO_SITE 84-86;	
DEX0455 _060.aa .1	Y	0 - o1- 207;	115- 122,1.108; 149- 187,1.215; 193- 199,1.122; 4- 26,1.251; 138- 145,1.131; 43- 56,1.102; 87- 101,1.175;	MYRISTYL 76-81; AMIDATION 79-82; PKC_PHOSPHO_SITE 42-44; MYRISTYL 34-39; MYRISTYL 41-46; PKC_PHOSPHO_SITE 24-26; MYRISTYL 75-80;	BTG_1 124-144; ANTIPRLFBTG1 173-202; Anti_proliferat 83-207; BTG_2 170-189; btg1 83-190; ANTIPRLFBTG1 88-112; ANTIPRLFBTG1 113-142;

DEX0455 _061.aa .1	N	0 - o1- 352;	173- 179,1.031; 264- 290,1.129; 181- 187,1.04; 138- 148,1.114; 36- 68,1.256; 4-10,1.15; 108- 113,1.105; 230- 241,1.187; 120- 128,1.086; 249- 257,1.172; 344- 349,1.095; 14- 20,1.171; 208- 225,1.103; 333- 340,1.068; 81- 91,1.111; 292- 319,1.15;	MYRISTYL 57-62; CK2_PHOSPHO_SITE 22-25; MYRISTYL 133-138; CK2_PHOSPHO_SITE 150-153; PKC_PHOSPHO_SITE 178-180; ASN_GLYCOSYLATION 134-137; MYRISTYL 43-48; AMIDATION 10-13; CAMP_PHOSPHO_SITE 119-122; CK2_PHOSPHO_SITE 314-317; ASN_GLYCOSYLATION 225-228; TYR_PHOSPHO_SITE 263-269; PKC_PHOSPHO_SITE 331-333; CK2_PHOSPHO_SITE 170-173; MYRISTYL 217-222;	RA 203-293; RA_DOMAIN 205- 293; RA 203- 293;
DEX0455 _061.aa .2	N	0 - o1- 261;	230- 241,1.187; 108- 113,1.105; 173- 179,1.031; 208- 225,1.103; 36- 68,1.256; 81- 91,1.111; 249- 258,1.172; 138- 148,1.114; 120- 128,1.086; 4-10,1.15; 14- 20,1.171; 181- 187,1.04;	ASN_GLYCOSYLATION 134-137; MYRISTYL 43-48; CAMP_PHOSPHO_SITE 119-122; MYRISTYL 57-62; CK2_PHOSPHO_SITE 150-153; PKC_PHOSPHO_SITE 178-180; AMIDATION 10-13; CK2_PHOSPHO_SITE 22-25; MYRISTYL 217-222; ASN_GLYCOSYLATION 225-228; MYRISTYL 133-138; CK2_PHOSPHO_SITE 170-173;	RA 203-260; RA_DOMAIN 205- 261;
DEX0455 _061.aa .3	N	0 - o1- 269;	181- 187,1.04; 36- 68,1.256; 120-	CK2_PHOSPHO_SITE 22-25; CK2_PHOSPHO_SITE 258-261; MYRISTYL 133-138; CK2_PHOSPHO_SITE 170-173; CK2 PHOSPHO SITE 150-153;	RA 203-269; RA_DOMAIN 205- 269;

			128,1.086; 230- 241,1.187; 14- 20,1.171; 4-10,1.15; 173- 179,1.031; 108- 113,1.105; 81- 91,1.111; 138- 148,1.114; 208- 225,1.103; 249- 257,1.172;	ASN_GLYCOSYLATION 225-228; AMIDATION 10-13; MYRISTYL 217-222; ASN_GLYCOSYLATION 134-137; MYRISTYL 57-62; PKC_PHOSPHO_SITE 178-180; MYRISTYL 43-48; CAMP_PHOSPHO_SITE 119-122;	
DEX0455 _061.aa .4	Y	0 - 01- 133;	4- 31,1.159; 61- 129,1.207; 41- 58,1.181;	ASN_GLYCOSYLATION 51-54; PKC_PHOSPHO_SITE 77-79;	
DEX0455 _061.or f.5	N	0 - 01- 163;	92- 130,1.205; 56- 85,1.181; 147- 160,1.134; 4- 11,1.118; 32- 52,1.22;	CK2_PHOSPHO_SITE 51-54; MYRISTYL 17-22; PKC_PHOSPHO_SITE 5-7; CK2_PHOSPHO_SITE 47-50; MYRISTYL 143-148; MYRISTYL 144-149; MYRISTYL 139-144;	
DEX0455 _062.aa .1	Y	0 - 01- 491;	395- 401,1.032; 180- 196,1.118; 403- 409,1.077; 121- 138,1.121; 214- 232,1.143; 4- 31,1.234; 431- 463,1.191; 259- 269,1.1; 86- 103,1.07; 292- 308,1.304; 465- 481,1.149; 69-84,1.2; 159- 165.1.052;	CK2_PHOSPHO_SITE 22-25; MYRISTYL 140-145; CK2_PHOSPHO_SITE 290-293; CK2_PHOSPHO_SITE 315-318; CK2_PHOSPHO_SITE 343-346; PKC_PHOSPHO_SITE 157-159; MYRISTYL 422-427; CK2_PHOSPHO_SITE 257-260; MYRISTYL 454-459; CK2_PHOSPHO_SITE 405-408; PKC_PHOSPHO_SITE 100-102; CK2_PHOSPHO_SITE 158-161; CK2_PHOSPHO_SITE 248-251; MYRISTYL 401-406; CK2_PHOSPHO_SITE 375-378; MYRISTYL 90-95; PKC_PHOSPHO_SITE 464-466; PKC_PHOSPHO_SITE 106-108; MYRISTYL 116-121; PKC_PHOSPHO_SITE 158-160; MYRISTYL 105-110; PKC_PHOSPHO_SITE 148-150; MYRISTYL 79-84; MYRISTYL 19-24; MYRISTYL 458-463; MYRISTYL 144-149;	thioered 24-132; THIOREDOXIN 47- 65; pdi_dom 165-269; THIOREDOXIN 189-198; THIOREDOXIN 46- 54; THIOREDOXIN_2_2 161-284; THIOREDOXIN 233-244; THIOREDOXIN_2_1 26-137; thioered 159-270; pdi_dom 30-131; THIOREDOXIN 182-200;

			38- 61, 1.134; 201- 207, 1.072; 275- 281, 1.087; 369- 375, 1.067; 422- 429, 1.117; 316- 326, 1.166; 172- 178, 1.087;	PKC_PHOSPHO_SITE 239-241; MYRISTYL 7-12; CK2_PHOSPHO_SITE 23-26;	
--	--	--	---	--	--

Example 1b: Sequence Alignment Support

Alignments between previously identified sequences and splice variant sequences are performed to confirm unique portions of splice variant nucleic acid and amino acid sequences. The alignments are done using the Needle program in the European Molecular Biology Open Software Suite (EMBOSS) version 2.2.0 available at www.emboss.org from EMBnet (<http://www.embnnet.org>). Default settings are used unless otherwise noted. The Needle program in EMBOSS implements the Needleman-Wunsch algorithm. Needleman, S. B., Wunsch, C. D., *J. Mol. Biol.* 48:443-453 (1970).

It is well known to those skilled in the art that implication of alignment algorithms by various programs may result in minor changes in the generated output. These changes include but are not limited to: alignment scores (percent identity, similarity, and gap), display of nonaligned flanking sequence regions, and number assignment to residues. These minor changes in the output of an alignment do not alter the physical characteristics of the sequences or the differences between the sequences, e.g. regions of homology, insertions, or deletions.

Example 1c: RT-PCR Analysis

To detect the presence and tissue distribution of a particular splice variant Reverse Transcription-Polymerase Chain Reaction (RT-PCR) is performed using cDNA generated from a panel of tissue RNAs. See, e.g., Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1989) and; Kawasaki ES *et al.*, *PNAS* 85(15):5698 (1988). Total RNA is extracted from a variety of tissues and first strand cDNA is prepared with reverse transcriptase (RT). Each panel includes 23 cDNAs from five cancer types (lung, ovary, breast, colon, and prostate) and normal samples of

testis, placenta and fetal brain. Each cancer set is composed of three cancer cDNAs from different donors and one normal pooled sample. Using a standard enzyme kit from BD Bioscience Clontech (Mountain View, CA), the target transcript is detected with sequence-specific primers designed to only amplify the particular splice variant. The PCR reaction is run on the GeneAmp PCR system 9700 (Applied Biosystem, Foster City, CA) thermocycler under optimal conditions. One of ordinary skill can design appropriate primers and determine optimal conditions. The amplified product is resolved on an agarose gel to detect a band of equivalent size to the predicted RT-PCR product. A band indicated the presence of the splice variant in a sample. The relation of the amplified product to the splice variant was subsequently confirmed by DNA sequencing.

After subcloning, all positively screened clones are sequence verified. The DNA sequence verification results show the splice variant contains the predicted sequence differences in comparison with the reference sequence.

Results for RT-PCR analysis in the table below include the sequence DEX ID, Lead Name, Cancer Tissue(s) the transcript was detected in, Normal Tissue(s) the transcript was detected in, the predicted length of the RT-PCR product, and the confirmed Length of the RT-PCR product.

DEX ID	Lead Name	Cancer Tissue(s)	Normal Tissue(s)	Predicted Length	Confirmed Length
DEX0455_019.nt.1	Ovr224	Lung, Ovary, Colon, Prostate	Placenta, Fetal brain	334bp	334bp
DEX0455_034.nt.1, DEX0455_034.nt.2	Ovr223	Lung, Ovary, Breast, Colon		448bp	894bp (exon insertion)
DEX0455_034.nt.3	Ovr223v1	Lung, Ovary, Breast, Colon, Prostate	Lung, Breast, Colon, Prostate, Placenta	385bp	385bp
DEX0455_034.nt.4	Ovr223v2	Lung, Ovary, Breast, Colon, Prostate	Lung, Breast, Colon, Prostate, Placenta	491bp	491bp
DEX0455_037.nt.6	Ovr229	Ovary, Prostate	Prostate	390bp	387bp
DEX0455_037.nt.7	Ovr227	Prostate	Placenta	257bp	256bp
DEX0455_049.nt.1	Ovr232	Lung, Ovary, Breast, Colon	Breast	134bp	134bp

DEX0455_049.nt.2	Ovr232v1	Lung, Ovary, Breast, Colon, Prostate	Ovary, Breast	345bp	345bp
DEX0455_049.nt.3	Ovr232v2	Lung, Ovary, Breast, Colon, Prostate	Lung, Ovary, Breast, Colon, Prostate	334bp	334bp
DEX0455_049.nt.4	Ovr232v3	Colon	Breast	254bp	254bp
DEX0455_053.nt.2	Ovr110V1	Ovary, Breast, Prostate	Breast	383bp	383bp

RT-PCR results confirm the presence SEQ ID NO: 1-128 in biologic samples and distinguish between related transcripts.

Example 1d: Secretion Assay

- 5 To determine if a protein encoded by a splice variant is secreted from cells a secretion assay is preformed. A pcDNA3.1 clone containing the gene transcript which encodes the variant protein is transfected into 293T cells using the Superfect transfection reagent (Qiagen, Valencia CA). Transfected cells are incubated for 28 hours before the media is collected and immediately spun down to remove any detached cells. The
- 10 adherent cells are solubilized with lysis buffer (1% NP40, 10mM sodium phosphate pH7.0, and 0.15M NaCl). The lysed cells are collected and spun down and the supernatant extracted as cell lysate. Western immunoblot is carried out in the following manner: 15µl of the cell lysate and media are run on 4-12% NuPage Bis-Tris gel (Invitrogen, Carlsbad CA), and blotted onto a PVDF membrane (Invitrogen, Carlsbad
- 15 CA). The blot is incubated with a polyclonal primary antibody which binds to the variant protein (Imgenex, San Diego CA) and polyclonal goat anti-rabbit-peroxidase secondary antibody (Sigma-Aldrich, St. Louis MO). The blot is developed with the ECL Plus chemiluminescent detection reagent (Amersham BioSciences, Piscataway NJ).

- 20 Secretion assay results are indicative of SEQ ID NO: 129-295 being a diagnostic marker and/or therapeutic target for cancer.

Example 2a: Gene Expression Analysis

Custom Microarray Experiment - Cancer

Custom oligonucleotide microarrays were provided by Agilent Technologies, Inc. (Palo Alto, CA). The microarrays were fabricated by Agilent using their technology for

the *in-situ* synthesis of 60mer oligonucleotides (Hughes, et al. 2001, Nature Biotechnology 19:342-347). The 60mer microarray probes were designed by Agilent, from gene sequences provided by diaDexus, using Agilent proprietary algorithms. Whenever possible two different 60mers were designed for each gene of interest.

5 All microarray experiments were two-color experiments and were preformed using Agilent-recommended protocols and reagents. Briefly, each microarray was hybridized with cRNAs synthesized from RNA (total RNA for ovarian and prostate, polyA+ RNA for lung, breast and colon samples), isolated from cancer and normal tissues, labeled with fluorescent dyes Cyanine3 (Cy3) or Cyanine5 (Cy5) (NEN Life Science Products, Inc.,
10 Boston, MA) using a linear amplification method (Agilent). In each experiment the experimental sample was RNA isolated from cancer tissue from a single individual and the reference sample was a pool of RNA isolated from normal tissues of the same organ as the cancerous tissue (*i.e.* normal ovarian tissue in experiments with ovarian cancer samples). Hybridizations were carried out at 60°C, overnight using Agilent *in-situ*
15 hybridization buffer. Following washing, arrays were scanned with a GenePix 4000B Microarray Scanner (Axon Instruments, Inc., Union City, CA). The resulting images were analyzed with GenePix Pro 3.0 Microarray Acquisition and Analysis Software (Axon).

Data normalization and expression profiling were done with Expressionist software from GeneData Inc. (Daly City, CA/Basel, Switzerland). Gene expression
20 analysis was performed using only experiments that met certain quality criteria. The quality criteria that experiments must meet are a combination of evaluations performed by the Expressionist software and evaluations performed manually using raw and normalized data. To evaluate raw data quality, detection limits (the mean signal for a replicated negative control + 2 Standard Deviations (SD)) for each channel were calculated. The
25 detection limit is a measure of non-specific hybridization. Acceptable detection limits were defined for each dye (<80 for Cy5 and <150 for Cy3). Arrays with poor detection limits in one or both channels were not analyzed and the experiments were repeated. To evaluate normalized data quality, positive control elements included in the array were utilized. These array features should have a mean ratio of 1 (no differential expression).
30 If these features have a mean ratio of greater than 1.5-fold up or down, the experiments were not analyzed further and were repeated. In addition to traditional scatter plots demonstrating the distribution of signal in each experiment, the Expressionist software also has minimum thresholding criteria that employ user defined parameters to identify

quality data. These thresholds include two distinct quality measurements: 1) minimum area percentage, which is a measure of the integrity of each spot and 2) signal to noise ratio, which ensures that the signal being measured is significantly above any background (nonspecific) signal present. Only those features that met the threshold criteria were included in the filtering and analyses carried out by Expressionist. The thresholding settings employed require a minimum area percentage of 60% [(% pixels > background + 2SD)-(% pixels saturated)], and a minimum signal to noise ratio of 2.0 in both channels. By these criteria, very low expressors, saturated features and spots with abnormally high local background were not included in analysis.

Relative expression data was collected from Expressionist based on filtering and clustering analyses. Up-regulated genes were identified using criteria for the percentage of experiments in which the gene is up-regulated by at least 2-fold. In general, up-regulation in ~30% of samples tested was used as a cutoff for filtering.

Two microarray experiments were performed for each normal and cancer tissue pair. The tissue specific Array Chip for each cancer tissue is a unique microarray specific to that tissue and cancer. The Multi-Cancer Array Chip is a universal microarray that was hybridized with samples from each of the cancers (ovarian, breast, colon, lung, and prostate). See the description below for the experiments specific to the different cancers.

Microarray Experiments and Data Tables

OVARIAN CANCER CHIPS

For ovarian cancer two different chip designs were evaluated with overlapping sets of a total of 19 samples, comparing the expression patterns of ovarian cancer derived total RNA to total RNA isolated from a pool of 9 normal ovarian tissues. For the Multi-Cancer Array Chip, all 19 samples (14 invasive carcinomas, 5 low malignant potential samples) were analyzed and for the Ovarian Array Chip, a subset of 17 of these samples (13 invasive carcinomas, 4 low malignant potential samples) were assessed.

The results for the statistically significant up-regulated genes on the Ovarian Array Chip are shown in Table 1. The results for the Multi-Cancer Array Chip are shown in Table 2. The first two columns of each table contain information about the sequence itself (DEX ID, Oligo Name), the next columns show the results obtained for all ("ALL") ovarian cancer samples, invasive carcinomas ("INV") and low malignant potential ("LMP") samples. '%up' indicates the percentage of all experiments in which up-

regulation of at least 2-fold was observed (n=19 for the Multi-Cancer Array Chip, n=17 for the Ovarian Array Chip), '%valid up' indicates the percentage of experiments with valid expression values in which up-regulation of at least 2-fold was observed.

Table 1.

DEX ID	Oligo Name	Ovr ALL %up n=17	Ovr ALL %valid up n=17	Ovr INV %up n=13	Ovr INV %valid up n=13	Ovr LMP %up n=4	Ovr LMP %valid up n=4
DEX0455_001.nt.1	34930.01	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455_001.nt.1	34930.02	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455_002.nt.1	21553.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_002.nt.1	21553.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_002.nt.1	21577.01	17.6	20.0	15.4	16.7	25.0	33.3
DEX0455_002.nt.1	21577.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_003.nt.1	17466.01	11.8	11.8	7.7	7.7	25.0	25.0
DEX0455_003.nt.1	17466.02	11.8	11.8	7.7	7.7	25.0	25.0
DEX0455_005.nt.1	20619.01	23.5	25.0	23.1	23.1	25.0	33.3
DEX0455_005.nt.1	20619.02	17.6	20.0	15.4	16.7	25.0	33.3
DEX0455_005.nt.1	24874.01	23.5	25.0	23.1	25.0	25.0	25.0
DEX0455_005.nt.1	24874.02	29.4	31.2	23.1	25.0	50.0	50.0
DEX0455_005.nt.2	20619.01	23.5	25.0	23.1	23.1	25.0	33.3
DEX0455_005.nt.2	20619.02	17.6	20.0	15.4	16.7	25.0	33.3
DEX0455_005.nt.2	24874.01	23.5	25.0	23.1	25.0	25.0	25.0
DEX0455_005.nt.2	24874.02	29.4	31.2	23.1	25.0	50.0	50.0
DEX0455_007.nt.1	30109.01	41.2	46.7	30.8	33.3	75.0	100.0
DEX0455_007.nt.1	30109.02	35.3	40.0	23.1	27.3	75.0	75.0
DEX0455_008.nt.1	18508.01	23.5	44.4	30.8	44.4	0.0	0.0
DEX0455_008.nt.1	18508.02	17.6	23.1	23.1	30.0	0.0	0.0
DEX0455_008.nt.1	22387.01	35.3	54.5	46.2	66.7	0.0	0.0
DEX0455_008.nt.1	22387.02	41.2	43.8	53.8	58.3	0.0	0.0
DEX0455_009.nt.1	19720.01	47.1	47.1	38.5	38.5	75.0	75.0
DEX0455_009.nt.1	19720.02	52.9	52.9	46.2	46.2	75.0	75.0
DEX0455_010.nt.1	20627.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_010.nt.1	20627.02	23.5	25.0	23.1	25.0	25.0	25.0
DEX0455_010.nt.1	21675.01	11.8	11.8	15.4	15.4	0.0	0.0
DEX0455_010.nt.1	21675.02	11.8	11.8	15.4	15.4	0.0	0.0
DEX0455_010.nt.2	21675.01	11.8	11.8	15.4	15.4	0.0	0.0
DEX0455_010.nt.2	21675.02	11.8	11.8	15.4	15.4	0.0	0.0
DEX0455_013.nt.1	9838.01	35.3	42.9	38.5	45.5	25.0	33.3
DEX0455_013.nt.1	9838.02	35.3	37.5	38.5	38.5	25.0	33.3
DEX0455_013.nt.2	9838.01	35.3	42.9	38.5	45.5	25.0	33.3
DEX0455_013.nt.2	9838.02	35.3	37.5	38.5	38.5	25.0	33.3
DEX0455_014.nt.1	10624.01	17.6	50.0	15.4	50.0	25.0	50.0
DEX0455_014.nt.1	10624.02	17.6	50.0	7.7	33.3	50.0	66.7
DEX0455_014.nt.1	14604.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_014.nt.1	14604.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_015.nt.1	19518.01	29.4	29.4	38.5	38.5	0.0	0.0
DEX0455_015.nt.1	19518.02	29.4	29.4	38.5	38.5	0.0	0.0
DEX0455_016.nt.1	23734.01	5.9	6.2	7.7	7.7	0.0	0.0
DEX0455_016.nt.1	23734.02	11.8	11.8	15.4	15.4	0.0	0.0
DEX0455_018.nt.1	21571.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_018.nt.1	21571.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_018.nt.1	21575.01	41.2	41.2	46.2	46.2	25.0	25.0
DEX0455_018.nt.1	21575.02	41.2	41.2	46.2	46.2	25.0	25.0
DEX0455_018.nt.1	21609.01	0.0	0.0	0.0	0.0	0.0	0.0

DEX0455 018.nt.1	21609.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455 018.nt.2	21575.01	41.2	41.2	46.2	46.2	25.0	25.0
DEX0455 018.nt.2	21575.02	41.2	41.2	46.2	46.2	25.0	25.0
DEX0455 019.nt.1	20669.01	35.3	42.9	46.2	50.0	0.0	0.0
DEX0455 019.nt.1	20669.02	35.3	46.2	46.2	50.0	0.0	0.0
DEX0455 021.nt.1	21433.01	64.7	64.7	61.5	61.5	75.0	75.0
DEX0455 021.nt.1	21433.02	64.7	64.7	61.5	61.5	75.0	75.0
DEX0455 021.nt.1	21469.01	70.6	70.6	61.5	61.5	100.0	100.0
DEX0455 021.nt.1	21469.02	82.4	82.4	76.9	76.9	100.0	100.0
DEX0455 021.nt.1	21475.01	58.8	58.8	53.8	53.8	75.0	75.0
DEX0455 021.nt.1	21475.02	52.9	52.9	53.8	53.8	50.0	50.0
DEX0455 021.nt.1	23780.01	47.1	47.1	46.2	46.2	50.0	50.0
DEX0455 021.nt.1	23780.02	41.2	50.0	46.2	54.5	25.0	33.3
DEX0455 021.nt.2	21433.01	64.7	64.7	61.5	61.5	75.0	75.0
DEX0455 021.nt.2	21433.02	64.7	64.7	61.5	61.5	75.0	75.0
DEX0455 021.nt.2	21469.01	70.6	70.6	61.5	61.5	100.0	100.0
DEX0455 021.nt.2	21469.02	82.4	82.4	76.9	76.9	100.0	100.0
DEX0455 021.nt.2	21475.01	58.8	58.8	53.8	53.8	75.0	75.0
DEX0455 021.nt.2	21475.02	52.9	52.9	53.8	53.8	50.0	50.0
DEX0455 021.nt.2	23780.01	47.1	47.1	46.2	46.2	50.0	50.0
DEX0455 021.nt.2	23780.02	41.2	50.0	46.2	54.5	25.0	33.3
DEX0455 021.nt.3	21433.01	64.7	64.7	61.5	61.5	75.0	75.0
DEX0455 021.nt.3	21433.02	64.7	64.7	61.5	61.5	75.0	75.0
DEX0455 021.nt.3	21469.01	70.6	70.6	61.5	61.5	100.0	100.0
DEX0455 021.nt.3	21469.02	82.4	82.4	76.9	76.9	100.0	100.0
DEX0455 021.nt.3	21475.01	58.8	58.8	53.8	53.8	75.0	75.0
DEX0455 021.nt.3	21475.02	52.9	52.9	53.8	53.8	50.0	50.0
DEX0455 021.nt.3	23780.01	47.1	47.1	46.2	46.2	50.0	50.0
DEX0455 021.nt.3	23780.02	41.2	50.0	46.2	54.5	25.0	33.3
DEX0455 021.nt.4	21433.01	64.7	64.7	61.5	61.5	75.0	75.0
DEX0455 021.nt.4	21433.02	64.7	64.7	61.5	61.5	75.0	75.0
DEX0455 021.nt.4	21469.01	70.6	70.6	61.5	61.5	100.0	100.0
DEX0455 021.nt.4	21469.02	82.4	82.4	76.9	76.9	100.0	100.0
DEX0455 021.nt.4	21475.01	58.8	58.8	53.8	53.8	75.0	75.0
DEX0455 021.nt.4	21475.02	52.9	52.9	53.8	53.8	50.0	50.0
DEX0455 021.nt.4	23780.01	47.1	47.1	46.2	46.2	50.0	50.0
DEX0455 021.nt.4	23780.02	41.2	50.0	46.2	54.5	25.0	33.3
DEX0455 022.nt.1	9920.01	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455 022.nt.1	9920.02	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455 022.nt.1	20299.01	17.6	18.8	23.1	25.0	0.0	0.0
DEX0455 022.nt.1	20299.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455 022.nt.1	20311.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455 022.nt.1	20311.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455 022.nt.1	20317.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455 022.nt.1	20317.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455 022.nt.2	9920.01	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455 022.nt.2	9920.02	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455 022.nt.2	20299.01	17.6	18.8	23.1	25.0	0.0	0.0
DEX0455 022.nt.2	20299.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455 022.nt.2	20311.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455 022.nt.2	20311.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455 022.nt.2	20317.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455 022.nt.2	20317.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455 022.nt.3	9920.01	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455 022.nt.3	9920.02	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455 022.nt.3	20311.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455 022.nt.3	20311.02	17.6	17.6	23.1	23.1	0.0	0.0

DEX0455 022.nt.3	20317.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455 022.nt.3	20317.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455 023.nt.1	16187.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455 023.nt.1	16187.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455 023.nt.1	16374.01	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455 023.nt.1	16374.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455 023.nt.1	16378.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455 023.nt.1	16378.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455 024.nt.1	12149.01	52.9	52.9	46.2	46.2	75.0	75.0
DEX0455 024.nt.1	12149.02	47.1	47.1	38.5	38.5	75.0	75.0
DEX0455 024.nt.1	21487.01	5.9	6.7	7.7	8.3	0.0	0.0
DEX0455 024.nt.1	21487.02	17.6	18.8	15.4	16.7	25.0	25.0
DEX0455 024.nt.1	21507.01	29.4	29.4	23.1	23.1	50.0	50.0
DEX0455 024.nt.1	21507.02	29.4	31.2	23.1	25.0	50.0	50.0
DEX0455 024.nt.1	21547.01	47.1	47.1	46.2	46.2	50.0	50.0
DEX0455 024.nt.1	21547.02	41.2	41.2	38.5	38.5	50.0	50.0
DEX0455 024.nt.2	12149.01	52.9	52.9	46.2	46.2	75.0	75.0
DEX0455 024.nt.2	12149.02	47.1	47.1	38.5	38.5	75.0	75.0
DEX0455 024.nt.2	21507.01	29.4	29.4	23.1	23.1	50.0	50.0
DEX0455 024.nt.2	21507.02	29.4	31.2	23.1	25.0	50.0	50.0
DEX0455 024.nt.2	21547.01	47.1	47.1	46.2	46.2	50.0	50.0
DEX0455 024.nt.2	21547.02	41.2	41.2	38.5	38.5	50.0	50.0
DEX0455 025.nt.1	12167.01	17.6	18.8	23.1	23.1	0.0	0.0
DEX0455 025.nt.1	12167.02	11.8	11.8	15.4	15.4	0.0	0.0
DEX0455 025.nt.1	16956.01	5.9	5.9	7.7	7.7	0.0	0.0
DEX0455 025.nt.1	16956.02	5.9	5.9	7.7	7.7	0.0	0.0
DEX0455 025.nt.1	16958.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455 025.nt.1	16958.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455 025.nt.1	16964.01	5.9	5.9	7.7	7.7	0.0	0.0
DEX0455 025.nt.1	16964.02	5.9	5.9	7.7	7.7	0.0	0.0
DEX0455 025.nt.1	19010.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455 025.nt.1	19010.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455 025.nt.2	12167.01	17.6	18.8	23.1	23.1	0.0	0.0
DEX0455 025.nt.2	12167.02	11.8	11.8	15.4	15.4	0.0	0.0
DEX0455 025.nt.2	16956.01	5.9	5.9	7.7	7.7	0.0	0.0
DEX0455 025.nt.2	16956.02	5.9	5.9	7.7	7.7	0.0	0.0
DEX0455 025.nt.2	16958.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455 025.nt.2	16958.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455 025.nt.2	16964.01	5.9	5.9	7.7	7.7	0.0	0.0
DEX0455 025.nt.2	16964.02	5.9	5.9	7.7	7.7	0.0	0.0
DEX0455 025.nt.2	19010.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455 025.nt.2	19010.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455 025.nt.3	12167.01	17.6	18.8	23.1	23.1	0.0	0.0
DEX0455 025.nt.3	12167.02	11.8	11.8	15.4	15.4	0.0	0.0
DEX0455 025.nt.3	16958.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455 025.nt.3	16958.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455 025.nt.3	19010.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455 025.nt.3	19010.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455 025.nt.4	12167.01	17.6	18.8	23.1	23.1	0.0	0.0
DEX0455 025.nt.4	12167.02	11.8	11.8	15.4	15.4	0.0	0.0
DEX0455 025.nt.4	16956.01	5.9	5.9	7.7	7.7	0.0	0.0
DEX0455 025.nt.4	16956.02	5.9	5.9	7.7	7.7	0.0	0.0
DEX0455 025.nt.4	16958.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455 025.nt.4	16958.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455 025.nt.4	16964.01	5.9	5.9	7.7	7.7	0.0	0.0
DEX0455 025.nt.4	16964.02	5.9	5.9	7.7	7.7	0.0	0.0
DEX0455 025.nt.4	19010.01	0.0	0.0	0.0	0.0	0.0	0.0

DEX0455_025.nt.4	19010.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_027.nt.1	21549.01	29.4	31.2	23.1	25.0	50.0	50.0
DEX0455_027.nt.1	21549.02	29.4	31.2	23.1	25.0	50.0	50.0
DEX0455_029.nt.1	17430.01	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455_029.nt.1	17430.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_029.nt.1	17448.01	11.8	11.8	15.4	15.4	0.0	0.0
DEX0455_029.nt.1	17448.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_029.nt.1	22113.01	11.8	25.0	15.4	28.6	0.0	0.0
DEX0455_029.nt.1	22113.02	11.8	20.0	15.4	25.0	0.0	0.0
DEX0455_029.nt.1	23386.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_029.nt.1	23386.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_029.nt.1	23400.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_029.nt.1	23400.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_029.nt.2	17424.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_029.nt.2	17424.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_029.nt.2	17430.01	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455_029.nt.2	17430.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_029.nt.2	17448.01	11.8	11.8	15.4	15.4	0.0	0.0
DEX0455_029.nt.2	17448.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_029.nt.2	22113.01	11.8	25.0	15.4	28.6	0.0	0.0
DEX0455_029.nt.2	22113.02	11.8	20.0	15.4	25.0	0.0	0.0
DEX0455_029.nt.2	23386.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_029.nt.2	23386.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_029.nt.2	23400.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_029.nt.2	23400.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_030.nt.1	11613.01	11.8	11.8	15.4	15.4	0.0	0.0
DEX0455_030.nt.1	11613.02	11.8	13.3	15.4	16.7	0.0	0.0
DEX0455_030.nt.1	17204.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_030.nt.1	17204.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_030.nt.1	17262.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_030.nt.1	17262.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_030.nt.1	17278.01	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455_030.nt.1	17278.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_030.nt.2	11613.01	11.8	11.8	15.4	15.4	0.0	0.0
DEX0455_030.nt.2	11613.02	11.8	13.3	15.4	16.7	0.0	0.0
DEX0455_030.nt.2	17204.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_030.nt.2	17204.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_030.nt.2	17262.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_030.nt.2	17262.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_030.nt.2	17274.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_030.nt.2	17274.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_030.nt.2	17278.01	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455_030.nt.2	17278.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_031.nt.1	20773.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_031.nt.1	20773.02	23.5	25.0	30.8	33.3	0.0	0.0
DEX0455_031.nt.2	20773.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_031.nt.2	20773.02	23.5	25.0	30.8	33.3	0.0	0.0
DEX0455_031.nt.3	20773.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_031.nt.3	20773.02	23.5	25.0	30.8	33.3	0.0	0.0
DEX0455_032.nt.1	11585.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_032.nt.1	11585.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_032.nt.1	18556.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_032.nt.1	18556.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_034.nt.1	10722.01	82.4	82.4	84.6	84.6	75.0	75.0
DEX0455_034.nt.1	10722.02	76.5	81.2	84.6	84.6	50.0	66.7
DEX0455_034.nt.1	21401.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_034.nt.1	21401.02	5.9	6.7	7.7	8.3	0.0	0.0

DEX0455 034.nt.1	21421.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455 034.nt.1	21421.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455 035.nt.1	103385.01	58.8	58.8	76.9	76.9	0.0	0.0
DEX0455 035.nt.1	103385.02	58.8	58.8	76.9	76.9	0.0	0.0
DEX0455 035.nt.2	103385.01	58.8	58.8	76.9	76.9	0.0	0.0
DEX0455 035.nt.2	103385.02	58.8	58.8	76.9	76.9	0.0	0.0
DEX0455 035.nt.3	103385.01	58.8	58.8	76.9	76.9	0.0	0.0
DEX0455 035.nt.3	103385.02	58.8	58.8	76.9	76.9	0.0	0.0
DEX0455 036.nt.1	92327.01	52.9	56.2	61.5	66.7	25.0	25.0
DEX0455 036.nt.1	92327.02	52.9	52.9	61.5	61.5	25.0	25.0
DEX0455 036.nt.2	92327.01	52.9	56.2	61.5	66.7	25.0	25.0
DEX0455 036.nt.2	92327.02	52.9	52.9	61.5	61.5	25.0	25.0
DEX0455 036.nt.3	92327.01	52.9	56.2	61.5	66.7	25.0	25.0
DEX0455 036.nt.3	92327.02	52.9	52.9	61.5	61.5	25.0	25.0
DEX0455 036.nt.4	92327.01	52.9	56.2	61.5	66.7	25.0	25.0
DEX0455 036.nt.4	92327.02	52.9	52.9	61.5	61.5	25.0	25.0
DEX0455 037.nt.1	11575.01	52.9	52.9	53.8	53.8	50.0	50.0
DEX0455 037.nt.1	11575.02	52.9	52.9	53.8	53.8	50.0	50.0
DEX0455 037.nt.1	17486.01	47.1	47.1	46.2	46.2	50.0	50.0
DEX0455 037.nt.1	17486.02	47.1	47.1	46.2	46.2	50.0	50.0
DEX0455 037.nt.1	17490.01	52.9	52.9	53.8	53.8	50.0	50.0
DEX0455 037.nt.1	17490.02	58.8	58.8	53.8	53.8	75.0	75.0
DEX0455 037.nt.2	11575.01	52.9	52.9	53.8	53.8	50.0	50.0
DEX0455 037.nt.2	11575.02	52.9	52.9	53.8	53.8	50.0	50.0
DEX0455 037.nt.2	17486.01	47.1	47.1	46.2	46.2	50.0	50.0
DEX0455 037.nt.2	17486.02	47.1	47.1	46.2	46.2	50.0	50.0
DEX0455 037.nt.2	17490.01	52.9	52.9	53.8	53.8	50.0	50.0
DEX0455 037.nt.2	17490.02	58.8	58.8	53.8	53.8	75.0	75.0
DEX0455 037.nt.3	11575.01	52.9	52.9	53.8	53.8	50.0	50.0
DEX0455 037.nt.3	11575.02	52.9	52.9	53.8	53.8	50.0	50.0
DEX0455 037.nt.3	17486.01	47.1	47.1	46.2	46.2	50.0	50.0
DEX0455 037.nt.3	17486.02	47.1	47.1	46.2	46.2	50.0	50.0
DEX0455 037.nt.3	17490.01	52.9	52.9	53.8	53.8	50.0	50.0
DEX0455 037.nt.3	17490.02	58.8	58.8	53.8	53.8	75.0	75.0
DEX0455 037.nt.4	11575.01	52.9	52.9	53.8	53.8	50.0	50.0
DEX0455 037.nt.4	11575.02	52.9	52.9	53.8	53.8	50.0	50.0
DEX0455 037.nt.4	17486.01	47.1	47.1	46.2	46.2	50.0	50.0
DEX0455 037.nt.4	17486.02	47.1	47.1	46.2	46.2	50.0	50.0
DEX0455 037.nt.4	17490.01	52.9	52.9	53.8	53.8	50.0	50.0
DEX0455 037.nt.4	17490.02	58.8	58.8	53.8	53.8	75.0	75.0
DEX0455 037.nt.5	11575.01	52.9	52.9	53.8	53.8	50.0	50.0
DEX0455 037.nt.5	11575.02	52.9	52.9	53.8	53.8	50.0	50.0
DEX0455 037.nt.5	17486.01	47.1	47.1	46.2	46.2	50.0	50.0
DEX0455 037.nt.5	17486.02	47.1	47.1	46.2	46.2	50.0	50.0
DEX0455 037.nt.5	17490.01	52.9	52.9	53.8	53.8	50.0	50.0
DEX0455 037.nt.5	17490.02	58.8	58.8	53.8	53.8	75.0	75.0
DEX0455 039.nt.1	21505.01	94.1	94.1	92.3	92.3	100.0	100.0
DEX0455 039.nt.1	21505.02	94.1	94.1	92.3	92.3	100.0	100.0
DEX0455 039.nt.2	11527.01	88.2	88.2	84.6	84.6	100.0	100.0
DEX0455 039.nt.2	11527.02	88.2	88.2	84.6	84.6	100.0	100.0
DEX0455 040.nt.1	21489.01	11.8	11.8	15.4	15.4	0.0	0.0
DEX0455 040.nt.1	21489.02	17.6	18.8	23.1	23.1	0.0	0.0
DEX0455 040.nt.1	21501.01	47.1	50.0	61.5	61.5	0.0	0.0
DEX0455 040.nt.1	21501.02	41.2	41.2	53.8	53.8	0.0	0.0
DEX0455 040.nt.1	21511.01	47.1	47.1	61.5	61.5	0.0	0.0
DEX0455 040.nt.1	21511.02	47.1	47.1	53.8	53.8	25.0	25.0
DEX0455 040.nt.2	21489.01	11.8	11.8	15.4	15.4	0.0	0.0

DEX0455	040.nt.2	21489.02	17.6	18.8	23.1	23.1	0.0	0.0
DEX0455	040.nt.2	21501.01	47.1	50.0	61.5	61.5	0.0	0.0
DEX0455	040.nt.2	21501.02	41.2	41.2	53.8	53.8	0.0	0.0
DEX0455	040.nt.2	21511.01	47.1	47.1	61.5	61.5	0.0	0.0
DEX0455	040.nt.2	21511.02	47.1	47.1	53.8	53.8	25.0	25.0
DEX0455	041.nt.1	12155.01	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455	041.nt.1	12155.02	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455	041.nt.1	16980.01	29.4	29.4	38.5	38.5	0.0	0.0
DEX0455	041.nt.1	16980.02	29.4	29.4	38.5	38.5	0.0	0.0
DEX0455	041.nt.2	12155.01	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455	041.nt.2	12155.02	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455	042.nt.1	18214.01	94.1	94.1	92.3	92.3	100.0	100.0
DEX0455	042.nt.1	18214.02	88.2	93.8	84.6	91.7	100.0	100.0
DEX0455	043.nt.1	14656.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455	043.nt.1	14656.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455	043.nt.3	14656.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455	043.nt.3	14656.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455	045.nt.1	36013.01	23.5	23.5	7.7	7.7	75.0	75.0
DEX0455	045.nt.1	36013.02	11.8	11.8	0.0	0.0	50.0	50.0
DEX0455	046.nt.1	17314.01	23.5	26.7	15.4	16.7	50.0	66.7
DEX0455	046.nt.1	17314.02	23.5	26.7	15.4	16.7	50.0	66.7
DEX0455	049.nt.1	11511.01	94.1	100.0	92.3	100.0	100.0	100.0
DEX0455	049.nt.1	11511.02	88.2	100.0	84.6	100.0	100.0	100.0
DEX0455	049.nt.2	11511.01	94.1	100.0	92.3	100.0	100.0	100.0
DEX0455	049.nt.2	11511.02	88.2	100.0	84.6	100.0	100.0	100.0
DEX0455	049.nt.4	11511.01	94.1	100.0	92.3	100.0	100.0	100.0
DEX0455	049.nt.4	11511.02	88.2	100.0	84.6	100.0	100.0	100.0
DEX0455	049.nt.5	11511.01	94.1	100.0	92.3	100.0	100.0	100.0
DEX0455	049.nt.5	11511.02	88.2	100.0	84.6	100.0	100.0	100.0
DEX0455	050.nt.1	23378.01	11.8	18.2	15.4	20.0	0.0	0.0
DEX0455	050.nt.1	23378.02	17.6	23.1	7.7	9.1	50.0	100.0
DEX0455	052.nt.1	91971.01	94.1	94.1	92.3	92.3	100.0	100.0
DEX0455	052.nt.1	91971.02	94.1	94.1	92.3	92.3	100.0	100.0
DEX0455	055.nt.1	11273.01	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455	055.nt.1	11273.02	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455	055.nt.1	20541.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455	055.nt.1	20541.02	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455	055.nt.2	11273.01	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455	055.nt.2	11273.02	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455	055.nt.2	20541.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455	055.nt.2	20541.02	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455	055.nt.3	11273.01	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455	055.nt.3	11273.02	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455	055.nt.3	20541.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455	055.nt.3	20541.02	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455	056.nt.1	18520.01	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455	056.nt.1	18520.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455	056.nt.1	22734.01	5.9	5.9	7.7	7.7	0.0	0.0
DEX0455	056.nt.1	22734.02	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455	056.nt.1	23444.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455	056.nt.1	23444.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455	056.nt.2	18520.01	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455	056.nt.2	18520.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455	056.nt.2	22734.01	5.9	5.9	7.7	7.7	0.0	0.0
DEX0455	056.nt.2	22734.02	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455	056.nt.2	23444.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455	056.nt.2	23444.02	0.0	0.0	0.0	0.0	0.0	0.0

DEX0455_057.nt.1	24524.01	70.6	70.6	69.2	69.2	75.0	75.0
DEX0455_057.nt.1	24524.02	70.6	70.6	69.2	69.2	75.0	75.0
DEX0455_057.nt.2	24524.01	70.6	70.6	69.2	69.2	75.0	75.0
DEX0455_057.nt.2	24524.02	70.6	70.6	69.2	69.2	75.0	75.0
DEX0455_058.nt.1	14656.01	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_058.nt.1	14656.02	17.6	17.6	23.1	23.1	0.0	0.0
DEX0455_059.nt.1	11469.01	47.1	47.1	61.5	61.5	0.0	0.0
DEX0455_059.nt.1	11469.02	52.9	52.9	61.5	61.5	25.0	25.0
DEX0455_059.nt.1	17370.01	5.9	25.0	7.7	25.0	0.0	0.0
DEX0455_059.nt.1	17370.02	5.9	25.0	7.7	25.0	0.0	0.0
DEX0455_059.nt.1	17372.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_059.nt.1	17372.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_059.nt.2	11469.01	47.1	47.1	61.5	61.5	0.0	0.0
DEX0455_059.nt.2	11469.02	52.9	52.9	61.5	61.5	25.0	25.0
DEX0455_059.nt.2	17372.01	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_059.nt.2	17372.02	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_060.nt.1	10372.01	35.3	35.3	46.2	46.2	0.0	0.0
DEX0455_060.nt.1	10372.02	35.3	35.3	46.2	46.2	0.0	0.0
DEX0455_060.nt.1	18582.01	23.5	23.5	30.8	30.8	0.0	0.0
DEX0455_060.nt.1	18582.02	29.4	29.4	38.5	38.5	0.0	0.0
DEX0455_061.nt.1	96523.01	23.5	23.5	15.4	15.4	50.0	50.0
DEX0455_061.nt.1	96523.02	17.6	17.6	7.7	7.7	50.0	50.0
DEX0455_061.nt.1	103529.01	23.5	25.0	15.4	16.7	50.0	50.0
DEX0455_061.nt.1	103529.02	23.5	23.5	15.4	15.4	50.0	50.0
DEX0455_061.nt.2	96523.01	23.5	23.5	15.4	15.4	50.0	50.0
DEX0455_061.nt.2	96523.02	17.6	17.6	7.7	7.7	50.0	50.0
DEX0455_061.nt.2	103529.01	23.5	25.0	15.4	16.7	50.0	50.0
DEX0455_061.nt.2	103529.02	23.5	23.5	15.4	15.4	50.0	50.0
DEX0455_061.nt.3	96523.01	23.5	23.5	15.4	15.4	50.0	50.0
DEX0455_061.nt.3	96523.02	17.6	17.6	7.7	7.7	50.0	50.0
DEX0455_061.nt.3	103529.01	23.5	25.0	15.4	16.7	50.0	50.0
DEX0455_061.nt.3	103529.02	23.5	23.5	15.4	15.4	50.0	50.0
DEX0455_061.nt.4	96523.01	23.5	23.5	15.4	15.4	50.0	50.0
DEX0455_061.nt.4	96523.02	17.6	17.6	7.7	7.7	50.0	50.0
DEX0455_061.nt.4	103529.01	23.5	25.0	15.4	16.7	50.0	50.0
DEX0455_061.nt.4	103529.02	23.5	23.5	15.4	15.4	50.0	50.0
DEX0455_061.nt.5	96523.01	23.5	23.5	15.4	15.4	50.0	50.0
DEX0455_061.nt.5	96523.02	17.6	17.6	7.7	7.7	50.0	50.0
DEX0455_061.nt.5	103529.01	23.5	25.0	15.4	16.7	50.0	50.0
DEX0455_061.nt.5	103529.02	23.5	23.5	15.4	15.4	50.0	50.0
DEX0455_062.nt.1	17464.01	29.4	29.4	38.5	38.5	0.0	0.0
DEX0455_062.nt.1	17464.02	29.4	29.4	38.5	38.5	0.0	0.0
DEX0455_062.nt.1	18094.01	52.9	52.9	69.2	69.2	0.0	0.0
DEX0455_062.nt.1	18094.02	52.9	52.9	69.2	69.2	0.0	0.0

Table 2.

DEX ID	Oligo Name	Ovr Multi-Cancer ALL %up n=19	Ovr Multi-Cancer ALL %valid up n=19	Ovr Multi-Cancer INV %up n=14	Ovr Multi-Cancer INV %valid up n=14	Ovr Multi-Cancer LMP %up n=5	Ovr Multi-Cancer LMP %valid up n=5
DEX0455_002.nt.1	79699.1	10.5	10.5	14.3	14.3	0.0	0.0
DEX0455_002.nt.1	79700.0	10.5	10.5	14.3	14.3	0.0	0.0
DEX0455_002.nt.1	79700.1	26.3	26.3	21.4	21.4	40.0	40.0
DEX0455_004.nt.1	96339.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	96339.1	0.0	0.0	0.0	0.0	0.0	0.0

DEX0455_004.nt.1	96340.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	96340.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105991.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105991.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105992.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105992.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105996.0	21.1	21.1	28.6	28.6	0.0	0.0
DEX0455_004.nt.1	105996.1	21.1	21.1	28.6	28.6	0.0	0.0
DEX0455_004.nt.2	96339.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	96339.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	96340.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	96340.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105991.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105991.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105992.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105992.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105996.0	21.1	21.1	28.6	28.6	0.0	0.0
DEX0455_004.nt.2	105996.1	21.1	21.1	28.6	28.6	0.0	0.0
DEX0455_011.nt.1	35317.0	31.6	42.9	14.3	20.0	80.0	100.0
DEX0455_011.nt.1	35317.1	31.6	35.3	14.3	15.4	80.0	100.0
DEX0455_012.nt.1	34334.0	89.5	89.5	85.7	85.7	100.0	100.0
DEX0455_012.nt.1	34334.1	84.2	88.9	85.7	85.7	80.0	100.0
DEX0455_012.nt.1	34335.0	94.7	100.0	92.9	100.0	100.0	100.0
DEX0455_012.nt.1	34335.1	89.5	100.0	92.9	100.0	80.0	100.0
DEX0455_012.nt.2	34334.0	89.5	89.5	85.7	85.7	100.0	100.0
DEX0455_012.nt.2	34334.1	84.2	88.9	85.7	85.7	80.0	100.0
DEX0455_012.nt.2	34335.0	94.7	100.0	92.9	100.0	100.0	100.0
DEX0455_012.nt.2	34335.1	89.5	100.0	92.9	100.0	80.0	100.0
DEX0455_017.nt.1	36482.0	31.6	42.9	28.6	40.0	40.0	50.0
DEX0455_017.nt.1	36482.1	31.6	50.0	28.6	44.4	40.0	66.7
DEX0455_033.nt.1	2023.0	21.1	23.5	28.6	30.8	0.0	0.0
DEX0455_033.nt.1	5327.0	15.8	16.7	21.4	21.4	0.0	0.0
DEX0455_033.nt.1	5328.0	10.5	11.1	14.3	14.3	0.0	0.0
DEX0455_035.nt.1	78519.0	42.1	47.1	57.1	57.1	0.0	0.0
DEX0455_035.nt.1	78519.1	47.4	52.9	64.3	69.2	0.0	0.0
DEX0455_035.nt.1	78520.0	36.8	38.9	50.0	50.0	0.0	0.0
DEX0455_035.nt.1	78520.1	42.1	44.4	57.1	57.1	0.0	0.0
DEX0455_035.nt.2	78519.0	42.1	47.1	57.1	57.1	0.0	0.0
DEX0455_035.nt.2	78519.1	47.4	52.9	64.3	69.2	0.0	0.0
DEX0455_035.nt.2	78520.0	36.8	38.9	50.0	50.0	0.0	0.0
DEX0455_035.nt.2	78520.1	42.1	44.4	57.1	57.1	0.0	0.0
DEX0455_035.nt.3	78519.0	42.1	47.1	57.1	57.1	0.0	0.0
DEX0455_035.nt.3	78519.1	47.4	52.9	64.3	69.2	0.0	0.0
DEX0455_035.nt.3	78520.0	36.8	38.9	50.0	50.0	0.0	0.0
DEX0455_035.nt.3	78520.1	42.1	44.4	57.1	57.1	0.0	0.0
DEX0455_038.nt.1	23542.0	5.3	5.6	7.1	7.7	0.0	0.0
DEX0455_038.nt.1	23542.1	10.5	10.5	14.3	14.3	0.0	0.0
DEX0455_038.nt.1	23543.0	15.8	16.7	14.3	15.4	20.0	20.0
DEX0455_038.nt.1	23543.1	21.1	21.1	21.4	21.4	20.0	20.0
DEX0455_038.nt.2	23542.0	5.3	5.6	7.1	7.7	0.0	0.0
DEX0455_038.nt.2	23542.1	10.5	10.5	14.3	14.3	0.0	0.0
DEX0455_038.nt.2	23543.0	15.8	16.7	14.3	15.4	20.0	20.0
DEX0455_038.nt.2	23543.1	21.1	21.1	21.4	21.4	20.0	20.0
DEX0455_038.nt.3	23542.0	5.3	5.6	7.1	7.7	0.0	0.0
DEX0455_038.nt.3	23542.1	10.5	10.5	14.3	14.3	0.0	0.0
DEX0455_038.nt.3	23543.0	15.8	16.7	14.3	15.4	20.0	20.0
DEX0455_038.nt.3	23543.1	21.1	21.1	21.4	21.4	20.0	20.0

DEX0455	047.nt.1	96212.0	10.5	11.8	14.3	15.4	0.0	0.0
DEX0455	047.nt.1	96212.1	5.3	5.9	7.1	7.7	0.0	0.0
DEX0455	047.nt.1	105764.0	10.5	12.5	14.3	15.4	0.0	0.0
DEX0455	047.nt.1	105764.1	15.8	16.7	14.3	15.4	20.0	20.0
DEX0455	047.nt.1	105767.0	15.8	15.8	14.3	14.3	20.0	20.0
DEX0455	047.nt.1	105767.1	15.8	15.8	14.3	14.3	20.0	20.0
DEX0455	047.nt.1	105768.0	15.8	15.8	14.3	14.3	20.0	20.0
DEX0455	047.nt.1	105768.1	21.1	22.2	21.4	23.1	20.0	20.0
DEX0455	047.nt.2	96212.0	10.5	11.8	14.3	15.4	0.0	0.0
DEX0455	047.nt.2	96212.1	5.3	5.9	7.1	7.7	0.0	0.0
DEX0455	047.nt.2	105764.0	10.5	12.5	14.3	15.4	0.0	0.0
DEX0455	047.nt.2	105764.1	15.8	16.7	14.3	15.4	20.0	20.0
DEX0455	047.nt.2	105767.0	15.8	15.8	14.3	14.3	20.0	20.0
DEX0455	047.nt.2	105767.1	15.8	15.8	14.3	14.3	20.0	20.0
DEX0455	047.nt.2	105768.0	15.8	15.8	14.3	14.3	20.0	20.0
DEX0455	047.nt.2	105768.1	21.1	22.2	21.4	23.1	20.0	20.0
DEX0455	048.nt.1	1168.0	10.5	10.5	14.3	14.3	0.0	0.0
DEX0455	048.nt.2	1175.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455	050.nt.1	23378.0	5.3	5.3	7.1	7.1	0.0	0.0
DEX0455	050.nt.1	23378.1	5.3	5.3	7.1	7.1	0.0	0.0
DEX0455	050.nt.1	23379.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455	050.nt.1	23379.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455	050.nt.1	42007.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455	050.nt.1	42007.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455	050.nt.1	42007.2	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455	050.nt.1	42008.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455	050.nt.1	42008.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455	050.nt.1	42008.2	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455	061.nt.1	78508.0	21.1	21.1	21.4	21.4	20.0	20.0
DEX0455	061.nt.1	78508.1	21.1	21.1	21.4	21.4	20.0	20.0
DEX0455	061.nt.2	78508.0	21.1	21.1	21.4	21.4	20.0	20.0
DEX0455	061.nt.2	78508.1	21.1	21.1	21.4	21.4	20.0	20.0
DEX0455	061.nt.3	78508.0	21.1	21.1	21.4	21.4	20.0	20.0
DEX0455	061.nt.3	78508.1	21.1	21.1	21.4	21.4	20.0	20.0
DEX0455	061.nt.4	78508.0	21.1	21.1	21.4	21.4	20.0	20.0
DEX0455	061.nt.4	78508.1	21.1	21.1	21.4	21.4	20.0	20.0
DEX0455	061.nt.5	78508.0	21.1	21.1	21.4	21.4	20.0	20.0
DEX0455	061.nt.5	78508.1	21.1	21.1	21.4	21.4	20.0	20.0

BREAST CANCER CHIPS

For breast cancer two different chip designs were evaluated with overlapping sets of a total of 36 samples, comparing the expression patterns of breast cancer derived polyA⁺ RNA to polyA⁺ RNA isolated from a pool of 10 normal breast tissues. For the Breast Array Chip, all 36 samples (9 stage I cancers, 23 stage II cancers, 4 stage III cancers) were analyzed. These samples also represented 10 Grade1/2 and 26 Grade 3 cancers. The histopathologic grades for cancer are classified as follows: GX, cannot be assessed; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; and G4, undifferentiated. AJCC Cancer Staging Handbook, pp. 9, (5th Ed, 1998). Samples were further grouped based on the expression patterns of the known breast cancer

associated genes Her2 and ER α (10 HER2 up, 26 HER2 not up, 20 ER up and 16 ER not up) and for the Multi-Cancer Array Chip, a subset of 20 of these samples (9 stage I cancers, 8 stage II cancers, 3 stage III cancers) were assessed.

The results for the statistically significant up-regulated genes on the Breast Array Chip are shown in Tables 3 and 4. The results for the statistically significant up-regulated genes on the Multi-Cancer Array Chip are shown in Table 5. The first two columns of each table contain information about the sequence itself (Seq ID, Oligo Name), the next columns show the results obtained for all ("ALL") breast cancer samples, cancers corresponding to stage I ("ST1"), stages II and III ("ST2,3"), grades 1 and 2 ("GR1,2"), grade 3 ("GR3"), cancers exhibiting up-regulation of Her2 ("HER2up") or ER α ("ERup") or those not exhibiting up-regulation of Her2 ("NOT HER2up") or ER α ("NOT ERup"). '%up' indicates the percentage of all experiments in which up-regulation of at least 2-fold was observed (n=36 for Colon Array Chip, n=20 for the Multi-Cancer Array Chip), '%valid up' indicates the percentage of experiments with valid expression values in which up-regulation of at least 2-fold was observed.

Table 3.

DEX ID	Oligo Name	Mam ALL %up n=36	Mam ALL % valid up n=36	Mam ST1 %up n=9	Mam ST1 % valid up n=9	Mam ST2, 3 %up n=27	Mam ST2, 3 % valid up n=27	Mam GR1, 2 %up n=10	Mam GR1, 2 % valid up n=10	Mam GR3 %up n=26	Mam GR3 % valid up n=26
DEX0455_010.nt.1	32151.0	22.2	22.2	44.4	44.4	14.8	14.8	10.0	10.0	26.9	26.9
DEX0455_017.nt.1	28221.0	2.8	3.1	0.0	0.0	3.7	4.3	0.0	0.0	3.8	4.5
DEX0455_022.nt.1	23280.0	11.1	11.8	11.1	11.1	11.1	12.0	10.0	10.0	11.5	12.5
DEX0455_035.nt.3	21143.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_035.nt.3	21144.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_041.nt.1	16998.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_046.nt.1	19072.0	11.1	11.4	0.0	0.0	14.8	15.4	20.0	20.0	7.7	8.0
DEX0455_050.nt.1	22136.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23378.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23378.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23379.0	5.6	5.7	0.0	0.0	7.4	7.7	0.0	0.0	7.7	8.0
DEX0455_050.nt.1	23379.2	5.6	5.7	0.0	0.0	7.4	7.7	0.0	0.0	7.7	8.0

DEX0455_050.nt.1	29736.0	2.8	2.8	0.0	0.0	3.7	3.7	0.0	0.0	3.8	3.8
DEX0455_054.nt.1	19799.0	8.3	8.3	0.0	0.0	11.1	11.1	0.0	0.0	11.5	11.5
DEX0455_055.nt.1	12731.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_055.nt.1	12732.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_055.nt.2	12731.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_055.nt.2	12732.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_055.nt.3	12731.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_055.nt.3	12732.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Table 4.

DEX ID	Oligo Name	Mam HER2up %up n=10	Mam HER2up %valid up n=10	Mam NOT HER2up %up n=26	Mam NOT HER2up %valid up n=26	Mam ERup %up n=20	Mam ERup %valid up n=20	Mam NOT ERup %up n=16	Mam NOT ERup %valid up n=16
DEX0455_010.nt.1	32151.0	20.0	20.0	23.1	23.1	10.0	10.0	37.5	37.5
DEX0455_017.nt.1	28221.0	10.0	11.1	0.0	0.0	0.0	0.0	6.2	8.3
DEX0455_022.nt.1	23280.0	20.0	20.0	7.7	8.3	10.0	11.1	12.5	12.5
DEX0455_035.nt.3	21143.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_035.nt.3	21144.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_041.nt.1	16998.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_046.nt.1	19072.0	20.0	20.0	7.7	8.0	15.0	15.0	6.2	6.7
DEX0455_050.nt.1	22136.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23378.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23378.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23379.0	0.0	0.0	7.7	8.0	0.0	0.0	12.5	13.3
DEX0455_050.nt.1	23379.2	0.0	0.0	7.7	8.0	0.0	0.0	12.5	13.3
DEX0455_050.nt.1	29736.0	0.0	0.0	3.8	3.8	0.0	0.0	6.2	6.2
DEX0455_054.nt.1	19799.0	10.0	10.0	7.7	7.7	10.0	10.0	6.2	6.2
DEX0455_055.nt.1	12731.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_055.nt.1	12732.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_055.nt.2	12731.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_055.nt.2	12732.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_055.nt.3	12731.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_055.nt.3	12732.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Table 5.

DEX ID	Oligo Name	Mam Multi-Cancer ALL %up n=20	Mam Multi-Cancer ALL %valid up n=20	Mam Multi-Cancer ST1 %up n=9	Mam Multi-Cancer ST1 %valid up n=9	Mam Multi-Cancer ST2,3 %up n=11	Mam Multi-Cancer ST2,3 %valid up n=11
DEX0455_002.nt.1	79699.1	20.0	20.0	44.4	44.4	0.0	0.0
DEX0455_002.nt.1	79700.0	10.0	10.0	22.2	22.2	0.0	0.0
DEX0455_002.nt.1	79700.1	15.0	15.0	33.3	33.3	0.0	0.0
DEX0455_004.nt.1	96339.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	96339.1	0.0	0.0	0.0	0.0	0.0	0.0

DEX0455_004.nt.1	96340.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	96340.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105991.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105991.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105992.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105992.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105996.0	15.0	15.0	11.1	11.1	18.2	18.2
DEX0455_004.nt.1	105996.1	15.0	15.0	11.1	11.1	18.2	18.2
DEX0455_004.nt.2	96339.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	96339.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	96340.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	96340.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105991.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105991.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105992.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105992.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105996.0	15.0	15.0	11.1	11.1	18.2	18.2
DEX0455_004.nt.2	105996.1	15.0	15.0	11.1	11.1	18.2	18.2
DEX0455_011.nt.1	35317.0	5.0	7.1	11.1	20.0	0.0	0.0
DEX0455_011.nt.1	35317.1	5.0	7.1	11.1	20.0	0.0	0.0
DEX0455_012.nt.1	34334.0	5.0	5.0	0.0	0.0	9.1	9.1
DEX0455_012.nt.1	34334.1	5.0	5.0	0.0	0.0	9.1	9.1
DEX0455_012.nt.1	34335.0	5.0	5.0	0.0	0.0	9.1	9.1
DEX0455_012.nt.1	34335.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_012.nt.2	34334.0	5.0	5.0	0.0	0.0	9.1	9.1
DEX0455_012.nt.2	34334.1	5.0	5.0	0.0	0.0	9.1	9.1
DEX0455_012.nt.2	34335.0	5.0	5.0	0.0	0.0	9.1	9.1
DEX0455_012.nt.2	34335.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_017.nt.1	36482.0	10.0	10.0	11.1	11.1	9.1	9.1
DEX0455_017.nt.1	36482.1	10.0	10.0	11.1	11.1	9.1	9.1
DEX0455_033.nt.1	2023.0	10.0	10.0	0.0	0.0	18.2	18.2
DEX0455_033.nt.1	5327.0	10.0	10.0	0.0	0.0	18.2	18.2
DEX0455_033.nt.1	5328.0	10.0	10.0	0.0	0.0	18.2	18.2
DEX0455_035.nt.1	78519.0	50.0	50.0	66.7	66.7	36.4	36.4
DEX0455_035.nt.1	78519.1	40.0	40.0	66.7	66.7	18.2	18.2
DEX0455_035.nt.1	78520.0	20.0	20.0	33.3	33.3	9.1	9.1
DEX0455_035.nt.1	78520.1	20.0	20.0	33.3	33.3	9.1	9.1
DEX0455_035.nt.2	78519.0	50.0	50.0	66.7	66.7	36.4	36.4
DEX0455_035.nt.2	78519.1	40.0	40.0	66.7	66.7	18.2	18.2
DEX0455_035.nt.2	78520.0	20.0	20.0	33.3	33.3	9.1	9.1
DEX0455_035.nt.2	78520.1	20.0	20.0	33.3	33.3	9.1	9.1
DEX0455_035.nt.3	78519.0	50.0	50.0	66.7	66.7	36.4	36.4
DEX0455_035.nt.3	78519.1	40.0	40.0	66.7	66.7	18.2	18.2
DEX0455_035.nt.3	78520.0	20.0	20.0	33.3	33.3	9.1	9.1
DEX0455_035.nt.3	78520.1	20.0	20.0	33.3	33.3	9.1	9.1
DEX0455_038.nt.1	23542.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	23542.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	23543.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	23543.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	23542.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	23542.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	23543.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	23543.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.3	23542.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.3	23542.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.3	23543.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.3	23543.1	0.0	0.0	0.0	0.0	0.0	0.0

DEX0455_047.nt.1	96212.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	96212.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	105764.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	105764.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	105767.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	105767.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	105768.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	105768.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	96212.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	96212.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	105764.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	105764.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	105767.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	105767.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	105768.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	105768.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_048.nt.1	1168.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_048.nt.2	1175.0	5.0	5.0	0.0	0.0	9.1	9.1
DEX0455_050.nt.1	23378.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23378.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23379.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23379.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42007.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42007.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42007.2	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42008.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42008.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42008.2	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_061.nt.1	78508.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_061.nt.1	78508.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_061.nt.2	78508.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_061.nt.2	78508.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_061.nt.3	78508.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_061.nt.3	78508.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_061.nt.4	78508.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_061.nt.4	78508.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_061.nt.5	78508.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_061.nt.5	78508.1	0.0	0.0	0.0	0.0	0.0	0.0

COLON CANCER CHIPS

For colon cancer two different chip designs were evaluated with overlapping sets of a total of 38 samples, comparing the expression patterns of colon cancer derived polyA+ RNA to polyA+ RNA isolated from a pool of 7 normal colon tissues. For the Colon Array Chip all 38 samples (23 Ascending colon carcinomas and 15 Rectosigmoidal carcinomas including: 5 stage I cancers, 15 stage II cancers, 15 stage III and 2 stage IV cancers, as well as 28 Grade1/2 and 10 Grade 3 cancers) were analyzed. The histopathologic grades for cancer are classified as follows: GX, cannot be assessed; G1, well differentiated; G2, Moderately differentiated; G3, poorly differentiated; and G4, undifferentiated. AJCC Cancer Staging Handbook, 5th Edition, 1998, page 9. For the Colon Array Chip analysis, samples were further divided into groups based on the

expression pattern of the known colon cancer associated gene Thymidilate Synthase (TS) (13 TS up 25 TS not up). The association of TS with advanced colorectal cancer is well documented. Paradiso *et al.*, *Br J Cancer* 82(3):560-7 (2000); Etienne *et al.*, *J Clin Oncol.* 20(12):2832-43 (2002); Aschele *et al.* *Clin Cancer Res.* 6(12):4797-802 (2000).

5 For the Multi-Cancer Array Chip a subset of 27 of these samples (14 Ascending colon carcinomas and 13 Rectosigmoidal carcinomas including: 3 stage I cancers, 9 stage II cancers, 13 stage III and 2 stage IV cancers) were assessed.

The results for the statistically significant up-regulated genes on the Colon Array Chip are shown in Tables 6 and 7. The results for the statistically significant up-regulated genes on the Multi-Cancer Array Chip are shown in Table 8.

The first two columns of each table contain information about the sequence itself (Seq ID, Oligo Name), the next columns show the results obtained for all (“ALL”) the colon samples, ascending colon carcinomas (“ASC”), Rectosigmoidal carcinomas (“RS”), cancers corresponding to stages I and II (“ST1,2”), stages III and IV (“ST3,4”), grades 1 and 2 (“GR1,2”), grade 3 (“GR3”), cancers exhibiting up-regulation of the TS gene (“TSup”) or those not exhibiting up-regulation of the TS gene (“NOT TSup”). ‘%up’ indicates the percentage of all experiments in which up-regulation of at least 2-fold was observed n=38 for the Colon Array Chip (n=27 for the Multi-Cancer Array Chip), ‘%valid up’ indicates the percentage of experiments with valid expression values in which up-regulation of at least 2-fold was observed.

Table 6.

[illegible]

DEX0455- 012.nt.2	34335.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 012.nt.2	34343.0	5.3	5.7	4.3	4.5	6.7	7.7	0.0	0.0	11.1	12.5
DEX0455- 012.nt.2	34368.0	7.9	7.9	8.7	8.7	6.7	6.7	5.0	5.0	11.1	11.1
DEX0455- 012.nt.2	34369.0	7.9	7.9	8.7	8.7	6.7	6.7	5.0	5.0	11.1	11.1
DEX0455- 017.nt.1	21032.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 024.nt.1	17957.0	5.3	5.3	4.3	4.3	6.7	6.7	0.0	0.0	11.1	11.1
DEX0455- 028.nt.1	30821.0	2.6	2.6	0.0	0.0	6.7	6.7	5.0	5.0	0.0	0.0
DEX0455- 028.nt.1	41120.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 029.nt.1	30820.0	2.6	2.6	0.0	0.0	6.7	6.7	5.0	5.0	0.0	0.0
DEX0455- 029.nt.1	30821.0	2.6	2.6	0.0	0.0	6.7	6.7	5.0	5.0	0.0	0.0
DEX0455- 029.nt.1	30824.0	7.9	7.9	8.7	8.7	6.7	6.7	10.0	10.0	5.6	5.6
DEX0455- 029.nt.1	30869.0	18.4	18.4	17.4	17.4	20.0	20.0	15.0	15.0	22.2	22.2
DEX0455- 029.nt.1	41117.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 029.nt.1	41120.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 029.nt.1	41151.0	10.5	10.5	13.0	13.0	6.7	6.7	15.0	15.0	5.6	5.6
DEX0455- 029.nt.1	41152.0	2.6	2.6	0.0	0.0	6.7	6.7	5.0	5.0	0.0	0.0
DEX0455- 029.nt.2	30820.0	2.6	2.6	0.0	0.0	6.7	6.7	5.0	5.0	0.0	0.0
DEX0455- 029.nt.2	30821.0	2.6	2.6	0.0	0.0	6.7	6.7	5.0	5.0	0.0	0.0
DEX0455- 029.nt.2	30824.0	7.9	7.9	8.7	8.7	6.7	6.7	10.0	10.0	5.6	5.6
DEX0455- 029.nt.2	30922.0	10.5	10.5	13.0	13.0	6.7	6.7	15.0	15.0	5.6	5.6
DEX0455- 029.nt.2	41117.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 029.nt.2	41120.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 029.nt.2	41151.0	10.5	10.5	13.0	13.0	6.7	6.7	15.0	15.0	5.6	5.6
DEX0455- 029.nt.2	41152.0	2.6	2.6	0.0	0.0	6.7	6.7	5.0	5.0	0.0	0.0
DEX0455- 034.nt.1	16423.0	2.6	3.1	0.0	0.0	6.7	9.1	0.0	0.0	5.6	6.2
DEX0455- 049.nt.1	36902.0	2.6	2.6	4.3	4.3	0.0	0.0	0.0	0.0	5.6	5.6
DEX0455- 049.nt.2	36901.0	5.3	5.3	4.3	4.3	6.7	6.7	0.0	0.0	11.1	11.1
DEX0455- 049.nt.2	36902.0	2.6	2.6	4.3	4.3	0.0	0.0	0.0	0.0	5.6	5.6
DEX0455- 049.nt.3	36901.0	5.3	5.3	4.3	4.3	6.7	6.7	0.0	0.0	11.1	11.1

DEX0455_049.nt.3	36902.0	2.6	2.6	4.3	4.3	0.0	0.0	0.0	0.0	5.6	5.6
DEX0455_049.nt.4	36901.0	5.3	5.3	4.3	4.3	6.7	6.7	0.0	0.0	11.1	11.1
DEX0455_049.nt.4	36902.0	2.6	2.6	4.3	4.3	0.0	0.0	0.0	0.0	5.6	5.6
DEX0455_049.nt.5	36901.0	5.3	5.3	4.3	4.3	6.7	6.7	0.0	0.0	11.1	11.1
DEX0455_049.nt.5	36902.0	2.6	2.6	4.3	4.3	0.0	0.0	0.0	0.0	5.6	5.6
DEX0455_050.nt.1	23378.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23378.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23379.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23379.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_061.nt.1	19803.0	2.6	2.6	4.3	4.3	0.0	0.0	0.0	0.0	5.6	5.6
DEX0455_061.nt.1	19804.0	5.3	5.3	4.3	4.3	6.7	6.7	0.0	0.0	11.1	11.1
DEX0455_061.nt.2	19803.0	2.6	2.6	4.3	4.3	0.0	0.0	0.0	0.0	5.6	5.6
DEX0455_061.nt.2	19804.0	5.3	5.3	4.3	4.3	6.7	6.7	0.0	0.0	11.1	11.1
DEX0455_061.nt.3	19803.0	2.6	2.6	4.3	4.3	0.0	0.0	0.0	0.0	5.6	5.6
DEX0455_061.nt.3	19804.0	5.3	5.3	4.3	4.3	6.7	6.7	0.0	0.0	11.1	11.1
DEX0455_061.nt.4	19803.0	2.6	2.6	4.3	4.3	0.0	0.0	0.0	0.0	5.6	5.6
DEX0455_061.nt.4	19804.0	5.3	5.3	4.3	4.3	6.7	6.7	0.0	0.0	11.1	11.1
DEX0455_061.nt.5	19803.0	2.6	2.6	4.3	4.3	0.0	0.0	0.0	0.0	5.6	5.6
DEX0455_061.nt.5	19804.0	5.3	5.3	4.3	4.3	6.7	6.7	0.0	0.0	11.1	11.1

Table 7.

DEX ID	Oligo Name	Cln GR1,2 %up n=28	Cln GR1,2 %valid up n=28	Cln GR3 %up n=10	Cln GR3 %valid up n=10	Cln TS %up n=13	Cln TS %valid up n=13	Cln NOT TS %up n=25	Cln NOT TS %valid up n=25
DEX0455_010.nt.1	37415.0	46.4	46.4	70.0	70.0	46.2	46.2	56.0	56.0
DEX0455_011.nt.1	35317.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_012.nt.1	34334.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_012.nt.1	34335.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_012.nt.1	34343.0	3.6	3.7	10.0	12.5	15.4	15.4	0.0	0.0
DEX0455_012.nt.1	34368.0	7.1	7.1	10.0	10.0	15.4	15.4	4.0	4.0
DEX0455_012.nt.1	34369.0	7.1	7.1	10.0	10.0	15.4	15.4	4.0	4.0
DEX0455_012.nt.2	34334.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_012.nt.2	34335.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_012.nt.2	34343.0	3.6	3.7	10.0	12.5	15.4	15.4	0.0	0.0
DEX0455_012.nt.2	34368.0	7.1	7.1	10.0	10.0	15.4	15.4	4.0	4.0
DEX0455_012.nt.2	34369.0	7.1	7.1	10.0	10.0	15.4	15.4	4.0	4.0

DEX0455_017.nt.1	21032.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_024.nt.1	17957.0	7.1	7.1	0.0	0.0	7.7	7.7	4.0	4.0
DEX0455_028.nt.1	30821.0	3.6	3.6	0.0	0.0	7.7	7.7	0.0	0.0
DEX0455_028.nt.1	41120.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_029.nt.1	30820.0	3.6	3.6	0.0	0.0	7.7	7.7	0.0	0.0
DEX0455_029.nt.1	30821.0	3.6	3.6	0.0	0.0	7.7	7.7	0.0	0.0
DEX0455_029.nt.1	30824.0	10.7	10.7	0.0	0.0	15.4	15.4	4.0	4.0
DEX0455_029.nt.1	30869.0	17.9	17.9	20.0	20.0	30.8	30.8	12.0	12.0
DEX0455_029.nt.1	41117.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_029.nt.1	41120.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_029.nt.1	41151.0	14.3	14.3	0.0	0.0	15.4	15.4	8.0	8.0
DEX0455_029.nt.1	41152.0	3.6	3.6	0.0	0.0	7.7	7.7	0.0	0.0
DEX0455_029.nt.2	30820.0	3.6	3.6	0.0	0.0	7.7	7.7	0.0	0.0
DEX0455_029.nt.2	30821.0	3.6	3.6	0.0	0.0	7.7	7.7	0.0	0.0
DEX0455_029.nt.2	30824.0	10.7	10.7	0.0	0.0	15.4	15.4	4.0	4.0
DEX0455_029.nt.2	30922.0	14.3	14.3	0.0	0.0	15.4	15.4	8.0	8.0
DEX0455_029.nt.2	41117.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_029.nt.2	41120.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_029.nt.2	41151.0	14.3	14.3	0.0	0.0	15.4	15.4	8.0	8.0
DEX0455_029.nt.2	41152.0	3.6	3.6	0.0	0.0	7.7	7.7	0.0	0.0
DEX0455_034.nt.1	16423.0	0.0	0.0	10.0	12.5	7.7	8.3	0.0	0.0
DEX0455_049.nt.1	36902.0	3.6	3.6	0.0	0.0	7.7	7.7	0.0	0.0
DEX0455_049.nt.2	36901.0	3.6	3.6	10.0	10.0	15.4	15.4	0.0	0.0
DEX0455_049.nt.2	36902.0	3.6	3.6	0.0	0.0	7.7	7.7	0.0	0.0
DEX0455_049.nt.3	36901.0	3.6	3.6	10.0	10.0	15.4	15.4	0.0	0.0
DEX0455_049.nt.3	36902.0	3.6	3.6	0.0	0.0	7.7	7.7	0.0	0.0
DEX0455_049.nt.4	36901.0	3.6	3.6	10.0	10.0	15.4	15.4	0.0	0.0
DEX0455_049.nt.4	36902.0	3.6	3.6	0.0	0.0	7.7	7.7	0.0	0.0
DEX0455_049.nt.5	36901.0	3.6	3.6	10.0	10.0	15.4	15.4	0.0	0.0
DEX0455_049.nt.5	36902.0	3.6	3.6	0.0	0.0	7.7	7.7	0.0	0.0
DEX0455_050.nt.1	23378.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23378.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23379.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23379.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_061.nt.1	19803.0	0.0	0.0	10.0	10.0	0.0	0.0	4.0	4.0
DEX0455_061.nt.1	19804.0	0.0	0.0	20.0	20.0	7.7	7.7	4.0	4.0
DEX0455_061.nt.2	19803.0	0.0	0.0	10.0	10.0	0.0	0.0	4.0	4.0
DEX0455_061.nt.2	19804.0	0.0	0.0	20.0	20.0	7.7	7.7	4.0	4.0
DEX0455_061.nt.3	19803.0	0.0	0.0	10.0	10.0	0.0	0.0	4.0	4.0
DEX0455_061.nt.3	19804.0	0.0	0.0	20.0	20.0	7.7	7.7	4.0	4.0
DEX0455_061.nt.4	19803.0	0.0	0.0	10.0	10.0	0.0	0.0	4.0	4.0
DEX0455_061.nt.4	19804.0	0.0	0.0	20.0	20.0	7.7	7.7	4.0	4.0
DEX0455_061.nt.5	19803.0	0.0	0.0	10.0	10.0	0.0	0.0	4.0	4.0
DEX0455_061.nt.5	19804.0	0.0	0.0	20.0	20.0	7.7	7.7	4.0	4.0

Table 8.

DEX ID	Oligo Name	Cln Multi-Cancer ALL %up n=27	Cln Multi-Cancer ALL %valid up n=27	Cln Multi-Cancer ASC %up n=14	Cln Multi-Cancer ASC %valid up n=14	Cln Multi-Cancer RS %up n=13	Cln Multi-Cancer RS %valid up n=13
DEX0455_002.nt.1	79699.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_002.nt.1	79700.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_002.nt.1	79700.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	96339.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	96339.1	7.4	33.3	14.3	66.7	0.0	0.0

DEX0455_004.nt.1	96340.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	96340.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105991.0	3.7	20.0	7.1	50.0	0.0	0.0
DEX0455_004.nt.1	105991.1	3.7	25.0	7.1	33.3	0.0	0.0
DEX0455_004.nt.1	105992.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105992.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105996.0	3.7	3.7	7.1	7.1	0.0	0.0
DEX0455_004.nt.1	105996.1	7.4	7.4	7.1	7.1	7.7	7.7
DEX0455_004.nt.2	96339.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	96339.1	7.4	33.3	14.3	66.7	0.0	0.0
DEX0455_004.nt.2	96340.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	96340.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105991.0	3.7	20.0	7.1	50.0	0.0	0.0
DEX0455_004.nt.2	105991.1	3.7	25.0	7.1	33.3	0.0	0.0
DEX0455_004.nt.2	105992.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105992.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105996.0	3.7	3.7	7.1	7.1	0.0	0.0
DEX0455_004.nt.2	105996.1	7.4	7.4	7.1	7.1	7.7	7.7
DEX0455_011.nt.1	35317.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_011.nt.1	35317.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_012.nt.1	34334.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_012.nt.1	34334.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_012.nt.1	34335.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_012.nt.1	34335.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_012.nt.2	34334.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_012.nt.2	34334.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_012.nt.2	34335.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_012.nt.2	34335.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_017.nt.1	36482.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_017.nt.1	36482.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_033.nt.1	2023.0	7.4	7.4	14.3	14.3	0.0	0.0
DEX0455_033.nt.1	5327.0	3.7	3.8	7.1	7.7	0.0	0.0
DEX0455_033.nt.1	5328.0	3.7	3.7	7.1	7.1	0.0	0.0
DEX0455_035.nt.1	78519.0	51.9	51.9	50.0	50.0	53.8	53.8
DEX0455_035.nt.1	78519.1	44.4	46.2	42.9	46.2	46.2	46.2
DEX0455_035.nt.1	78520.0	33.3	33.3	42.9	42.9	23.1	23.1
DEX0455_035.nt.1	78520.1	33.3	33.3	42.9	42.9	23.1	23.1
DEX0455_035.nt.2	78519.0	51.9	51.9	50.0	50.0	53.8	53.8
DEX0455_035.nt.2	78519.1	44.4	46.2	42.9	46.2	46.2	46.2
DEX0455_035.nt.2	78520.0	33.3	33.3	42.9	42.9	23.1	23.1
DEX0455_035.nt.2	78520.1	33.3	33.3	42.9	42.9	23.1	23.1
DEX0455_035.nt.3	78519.0	51.9	51.9	50.0	50.0	53.8	53.8
DEX0455_035.nt.3	78519.1	44.4	46.2	42.9	46.2	46.2	46.2
DEX0455_035.nt.3	78520.0	33.3	33.3	42.9	42.9	23.1	23.1
DEX0455_035.nt.3	78520.1	33.3	33.3	42.9	42.9	23.1	23.1
DEX0455_038.nt.1	23542.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	23542.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	23543.0	3.7	3.7	0.0	0.0	7.7	7.7
DEX0455_038.nt.1	23543.1	3.7	3.7	0.0	0.0	7.7	7.7
DEX0455_038.nt.2	23542.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	23542.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	23543.0	3.7	3.7	0.0	0.0	7.7	7.7
DEX0455_038.nt.2	23543.1	3.7	3.7	0.0	0.0	7.7	7.7
DEX0455_038.nt.3	23542.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.3	23542.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.3	23543.0	3.7	3.7	0.0	0.0	7.7	7.7
DEX0455_038.nt.3	23543.1	3.7	3.7	0.0	0.0	7.7	7.7

DEX0455_047.nt.1	96212.0	7.4	7.4	14.3	14.3	0.0	0.0
DEX0455_047.nt.1	96212.1	7.4	7.4	14.3	14.3	0.0	0.0
DEX0455_047.nt.1	105764.0	7.4	8.0	14.3	14.3	0.0	0.0
DEX0455_047.nt.1	105764.1	7.4	7.4	14.3	14.3	0.0	0.0
DEX0455_047.nt.1	105767.0	3.7	3.7	7.1	7.1	0.0	0.0
DEX0455_047.nt.1	105767.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	105768.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	105768.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	96212.0	7.4	7.4	14.3	14.3	0.0	0.0
DEX0455_047.nt.2	96212.1	7.4	7.4	14.3	14.3	0.0	0.0
DEX0455_047.nt.2	105764.0	7.4	8.0	14.3	14.3	0.0	0.0
DEX0455_047.nt.2	105764.1	7.4	7.4	14.3	14.3	0.0	0.0
DEX0455_047.nt.2	105767.0	3.7	3.7	7.1	7.1	0.0	0.0
DEX0455_047.nt.2	105767.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	105768.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	105768.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_048.nt.1	1168.0	3.7	3.7	0.0	0.0	7.7	7.7
DEX0455_048.nt.2	1175.0	3.7	4.0	7.1	7.7	0.0	0.0
DEX0455_050.nt.1	23378.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23378.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23379.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23379.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42007.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42007.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42007.2	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42008.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42008.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42008.2	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_061.nt.1	78508.0	7.4	7.4	7.1	7.1	7.7	7.7
DEX0455_061.nt.1	78508.1	7.4	7.4	7.1	7.1	7.7	7.7
DEX0455_061.nt.2	78508.0	7.4	7.4	7.1	7.1	7.7	7.7
DEX0455_061.nt.2	78508.1	7.4	7.4	7.1	7.1	7.7	7.7
DEX0455_061.nt.3	78508.0	7.4	7.4	7.1	7.1	7.7	7.7
DEX0455_061.nt.3	78508.1	7.4	7.4	7.1	7.1	7.7	7.7
DEX0455_061.nt.4	78508.0	7.4	7.4	7.1	7.1	7.7	7.7
DEX0455_061.nt.4	78508.1	7.4	7.4	7.1	7.1	7.7	7.7
DEX0455_061.nt.5	78508.0	7.4	7.4	7.1	7.1	7.7	7.7
DEX0455_061.nt.5	78508.1	7.4	7.4	7.1	7.1	7.7	7.7

LUNG CANCER CHIPS

For lung cancer two different chip designs were evaluated with overlapping sets of a total of 29 samples, comparing the expression patterns of lung cancer derived polyA+ RNA to polyA+ RNA isolated from a pool of 12 normal lung tissues. For the Lung Array

5 Chip all 29 samples (15 squamous cell carcinomas and 14 adenocarcinomas including 14 stage I and 15 stage II/III cancers) were analyzed and for the Multi-Cancer Array Chip a subset of 22 of these samples (10 squamous cell carcinomas, 12 adenocarcinomas) were assessed.

The results for the statistically significant up-regulated genes on the Lung Array

10 Chip are shown in Table 9. The results for the statistically significant up-regulated genes on the Multi-Cancer Array Chip are shown in Table 10. The first two columns of each

table contain information about the sequence itself (DEX ID, Oligo Name), the next columns show the results obtained for all ("ALL") lung cancer samples, squamous cell carcinomas ("SQ"), adenocarcinomas ("AD"), or cancers corresponding to stage I ("ST1"), or stages II and III ("ST2,3"). '%up' indicates the percentage of all experiments in which up-regulation of at least 2-fold was observed (n=29 for Lung Array Chip, n=22 for Multi-Cancer Array Chip), '%valid up' indicates the percentage of experiments with valid expression values in which up-regulation of at least 2-fold was observed.

Table 9.

DEX ID	Oligo Name	Lng ALL %up n=29	Lng ALL % valid up n=29	Lng SQ %up n=15	Lng SQ % valid up n=15	Lng AD %up n=14	Lng AD % valid up n=14	Lng ST1 %up n=14	Lng ST1 % valid up n=14	Lng ST2,3 %up n=15	Lng ST2,3 % valid up n=15
DEX0455_010.nt.1	791.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_010.nt.1	2720.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_010.nt.1	2721.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_010.nt.2	791.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_010.nt.2	2720.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_010.nt.2	2721.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_032.nt.1	2688.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_032.nt.1	2689.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_032.nt.1	5313.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_033.nt.1	2006.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_033.nt.1	2007.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_033.nt.1	2022.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_033.nt.1	2032.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_042.nt.1	889.0	93.1	93.1	100.0	100.0	85.7	85.7	92.9	92.9	93.3	93.3
DEX0455_048.nt.1	1009.0	3.4	3.4	6.7	6.7	0.0	0.0	0.0	0.0	6.7	6.7
DEX0455_048.nt.1	1010.0	6.9	6.9	13.3	13.3	0.0	0.0	0.0	0.0	13.3	13.3
DEX0455_048.nt.1	1011.0	6.9	6.9	13.3	13.3	0.0	0.0	7.1	7.1	6.7	6.7
DEX0455_048.nt.1	1169.0	3.4	3.4	6.7	6.7	0.0	0.0	0.0	0.0	6.7	6.7
DEX0455_048.nt.2	1009.0	3.4	3.4	6.7	6.7	0.0	0.0	0.0	0.0	6.7	6.7

DEX0455- 048.nt.2	1010.0	6.9	6.9	13.3	13.3	0.0	0.0	0.0	0.0	13.3	13.3
DEX0455- 048.nt.2	1011.0	6.9	6.9	13.3	13.3	0.0	0.0	7.1	7.1	6.7	6.7
DEX0455- 048.nt.2	1169.0	3.4	3.4	6.7	6.7	0.0	0.0	0.0	0.0	6.7	6.7
DEX0455- 048.nt.2	1174.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 050.nt.1	7815.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 050.nt.1	23378.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 050.nt.1	23378.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 050.nt.1	42007.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 050.nt.1	42008.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 056.nt.1	1582.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 056.nt.1	1583.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 056.nt.1	2661.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 056.nt.1	3143.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 056.nt.1	3160.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 056.nt.1	3161.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 056.nt.1	3164.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 056.nt.1	3165.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 056.nt.2	1582.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 056.nt.2	1583.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 056.nt.2	2661.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 056.nt.2	3160.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 056.nt.2	3161.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 056.nt.2	3164.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 056.nt.2	3165.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 057.nt.1	7612.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 057.nt.1	7613.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 057.nt.2	7612.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455- 057.nt.2	7613.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Table 10.

DEX ID	Oligo Name	Lng Multi-Cancer ALL %up n=22	Lng Multi-Cancer ALL %valid up n=22	Lng Multi-Cancer SQ %up n=10	Lng Multi-Cancer SQ %valid up n=10	Lng Multi-Cancer AD %up n=12	Lng Multi-Cancer AD %valid up n=12
DEX0455_002.nt.1	79699.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_002.nt.1	79700.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_002.nt.1	79700.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	96339.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	96339.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	96340.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	96340.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105991.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105991.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105992.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105992.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105996.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105996.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	96339.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	96339.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	96340.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	96340.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105991.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105991.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105992.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105992.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105996.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105996.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_011.nt.1	35317.0	9.1	13.3	0.0	0.0	16.7	18.2
DEX0455_011.nt.1	35317.1	9.1	13.3	0.0	0.0	16.7	18.2
DEX0455_012.nt.1	34334.0	13.6	13.6	10.0	10.0	16.7	16.7
DEX0455_012.nt.1	34334.1	13.6	13.6	10.0	10.0	16.7	16.7
DEX0455_012.nt.1	34335.0	13.6	13.6	10.0	10.0	16.7	16.7
DEX0455_012.nt.1	34335.1	13.6	13.6	10.0	10.0	16.7	16.7
DEX0455_012.nt.2	34334.0	13.6	13.6	10.0	10.0	16.7	16.7
DEX0455_012.nt.2	34334.1	13.6	13.6	10.0	10.0	16.7	16.7
DEX0455_012.nt.2	34335.0	13.6	13.6	10.0	10.0	16.7	16.7
DEX0455_012.nt.2	34335.1	13.6	13.6	10.0	10.0	16.7	16.7
DEX0455_017.nt.1	36482.0	4.5	4.5	0.0	0.0	8.3	8.3
DEX0455_017.nt.1	36482.1	4.5	4.5	0.0	0.0	8.3	8.3
DEX0455_033.nt.1	2023.0	4.5	4.5	10.0	10.0	0.0	0.0
DEX0455_033.nt.1	5327.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_033.nt.1	5328.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_035.nt.1	78519.0	50.0	50.0	40.0	40.0	58.3	58.3
DEX0455_035.nt.1	78519.1	50.0	50.0	40.0	40.0	58.3	58.3
DEX0455_035.nt.1	78520.0	40.9	40.9	30.0	30.0	50.0	50.0
DEX0455_035.nt.1	78520.1	45.5	45.5	40.0	40.0	50.0	50.0
DEX0455_035.nt.2	78519.0	50.0	50.0	40.0	40.0	58.3	58.3
DEX0455_035.nt.2	78519.1	50.0	50.0	40.0	40.0	58.3	58.3
DEX0455_035.nt.2	78520.0	40.9	40.9	30.0	30.0	50.0	50.0
DEX0455_035.nt.2	78520.1	45.5	45.5	40.0	40.0	50.0	50.0
DEX0455_035.nt.3	78519.0	50.0	50.0	40.0	40.0	58.3	58.3
DEX0455_035.nt.3	78519.1	50.0	50.0	40.0	40.0	58.3	58.3
DEX0455_035.nt.3	78520.0	40.9	40.9	30.0	30.0	50.0	50.0
DEX0455_035.nt.3	78520.1	45.5	45.5	40.0	40.0	50.0	50.0
DEX0455_038.nt.1	23542.0	4.5	4.5	0.0	0.0	8.3	8.3
DEX0455_038.nt.1	23542.1	9.1	9.1	0.0	0.0	16.7	16.7

DEX0455_038.nt.1	23543.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	23543.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	23542.0	4.5	4.5	0.0	0.0	8.3	8.3
DEX0455_038.nt.2	23542.1	9.1	9.1	0.0	0.0	16.7	16.7
DEX0455_038.nt.2	23543.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	23543.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.3	23542.0	4.5	4.5	0.0	0.0	8.3	8.3
DEX0455_038.nt.3	23542.1	9.1	9.1	0.0	0.0	16.7	16.7
DEX0455_038.nt.3	23543.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.3	23543.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	96212.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	96212.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	105764.0	4.5	5.0	10.0	12.5	0.0	0.0
DEX0455_047.nt.1	105764.1	4.5	5.0	10.0	11.1	0.0	0.0
DEX0455_047.nt.1	105767.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	105767.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	105768.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	105768.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	96212.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	96212.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	105764.0	4.5	5.0	10.0	12.5	0.0	0.0
DEX0455_047.nt.2	105764.1	4.5	5.0	10.0	11.1	0.0	0.0
DEX0455_047.nt.2	105767.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	105767.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	105768.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	105768.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_048.nt.1	1168.0	4.5	4.5	10.0	10.0	0.0	0.0
DEX0455_048.nt.2	1175.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23378.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23378.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23379.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23379.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42007.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42007.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42007.2	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42008.0	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42008.1	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42008.2	0.0	0.0	0.0	0.0	0.0	0.0
DEX0455_061.nt.1	78508.0	31.8	31.8	30.0	30.0	33.3	33.3
DEX0455_061.nt.1	78508.1	31.8	31.8	20.0	20.0	41.7	41.7
DEX0455_061.nt.2	78508.0	31.8	31.8	30.0	30.0	33.3	33.3
DEX0455_061.nt.2	78508.1	31.8	31.8	20.0	20.0	41.7	41.7
DEX0455_061.nt.3	78508.0	31.8	31.8	30.0	30.0	33.3	33.3
DEX0455_061.nt.3	78508.1	31.8	31.8	20.0	20.0	41.7	41.7
DEX0455_061.nt.4	78508.0	31.8	31.8	30.0	30.0	33.3	33.3
DEX0455_061.nt.4	78508.1	31.8	31.8	20.0	20.0	41.7	41.7
DEX0455_061.nt.5	78508.0	31.8	31.8	30.0	30.0	33.3	33.3
DEX0455_061.nt.5	78508.1	31.8	31.8	20.0	20.0	41.7	41.7

PROSTATE CANCER

For prostate cancer three different chip designs were evaluated with overlapping sets of a total of 29 samples, comparing the expression patterns of prostate cancer or

5 benign disease derived total RNA to total RNA isolated from a pool of 35 normal prostate tissues. For the Prostate1 Array and Prostate2 Array Chips all 29 samples (17 prostate

cancer samples, 12 non-malignant disease samples) were analyzed. For the Multi-Cancer Array Chip a subset of 28 of these samples (16 prostate cancer samples, 12 non-malignant disease samples) were analyzed.

The results for the statistically significant up-regulated genes on the Prostate1 Array Chip and the Prostate2 Array Chip are shown in Table 11. The results for the statistically significant up-regulated genes on the Multi-Cancer Array Chip are shown in Table 12. The first two columns of each table contain information about the sequence itself (DEX ID, Oligo Name), the next columns show the results obtained for prostate cancer samples ("CAN") or non-malignant disease samples ("DIS"). '%up' indicates the percentage of all experiments in which up-regulation of at least 2-fold was observed (n=29 for the Prostate2 Array Chip and the Multi-Cancer Array Chip), '%valid up' indicates the percentage of experiments with valid expression values in which up-regulation of at least 2-fold was observed.

Table 11.

DEX ID	Oligo Name	Pro CAN %up n=17	Pro CAN %valid up n=17	Pro DIS %up n=12	Pro DIS %valid up n=12
DEX0455_010.nt.1	28129.01	0.0	0.0	0.0	0.0
DEX0455_010.nt.1	28129.02	0.0	0.0	8.3	8.3
DEX0455_010.nt.2	28129.01	0.0	0.0	0.0	0.0
DEX0455_010.nt.2	28129.02	0.0	0.0	8.3	8.3
DEX0455_023.nt.1	8770.01	0.0	0.0	0.0	0.0
DEX0455_023.nt.1	8770.02	0.0	0.0	0.0	0.0
DEX0455_023.nt.1	8770.03	0.0	0.0	0.0	0.0
DEX0455_034.nt.1	26867.01	0.0	0.0	0.0	0.0
DEX0455_034.nt.1	26867.02	0.0	0.0	0.0	0.0
DEX0455_034.nt.1	32554.01	0.0	0.0	0.0	0.0
DEX0455_034.nt.1	32554.02	5.9	5.9	8.3	8.3
DEX0455_034.nt.1	32554.03	5.9	7.1	0.0	0.0
DEX0455_034.nt.1	32558.01	0.0	0.0	0.0	0.0
DEX0455_034.nt.1	32558.02	0.0	0.0	0.0	0.0
DEX0455_034.nt.1	32558.03	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	23492.01	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	23492.02	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	23542.01	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	23542.02	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	23546.01	5.9	33.3	0.0	0.0
DEX0455_038.nt.1	23546.02	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	24418.01	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	24418.02	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	24422.01	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	24422.02	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	27965.01	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	27965.02	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	28535.01	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	28535.02	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	23492.01	0.0	0.0	0.0	0.0

DEX0455_038.nt.2	23492.02	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	23542.01	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	23542.02	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	23684.01	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	23684.02	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	24418.01	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	24418.02	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	27965.01	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	27965.02	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	28535.01	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	28535.02	0.0	0.0	0.0	0.0
DEX0455_038.nt.3	23492.01	0.0	0.0	0.0	0.0
DEX0455_038.nt.3	23492.02	0.0	0.0	0.0	0.0
DEX0455_038.nt.3	23542.01	0.0	0.0	0.0	0.0
DEX0455_038.nt.3	23542.02	0.0	0.0	0.0	0.0
DEX0455_038.nt.3	27965.01	0.0	0.0	0.0	0.0
DEX0455_038.nt.3	27965.02	0.0	0.0	0.0	0.0
DEX0455_038.nt.3	28535.01	0.0	0.0	0.0	0.0
DEX0455_038.nt.3	28535.02	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23378.01	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23378.02	5.9	11.1	0.0	0.0
DEX0455_057.nt.1	33332.01	0.0	0.0	0.0	0.0
DEX0455_057.nt.1	33332.02	0.0	0.0	0.0	0.0
DEX0455_057.nt.2	33332.01	0.0	0.0	0.0	0.0
DEX0455_057.nt.2	33332.02	0.0	0.0	0.0	0.0

Table 12.

DEX ID	Oligo Name	Pro Multi-Cancer CAN %up n=16	Pro Multi-Cancer CAN %valid up n=16	Pro Multi-Cancer DIS %up n=12	Pro Multi-Cancer DIS %valid up n=12
DEX0455_002.nt.1	79699.1	0.0	0.0	0.0	0.0
DEX0455_002.nt.1	79700.0	0.0	0.0	0.0	0.0
DEX0455_002.nt.1	79700.1	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	96339.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	96339.1	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	96340.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	96340.1	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105991.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105991.1	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105992.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105992.1	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105996.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.1	105996.1	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	96339.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	96339.1	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	96340.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	96340.1	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105991.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105991.1	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105992.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105992.1	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105996.0	0.0	0.0	0.0	0.0
DEX0455_004.nt.2	105996.1	0.0	0.0	0.0	0.0
DEX0455_011.nt.1	35317.0	0.0	0.0	0.0	0.0
DEX0455_011.nt.1	35317.1	0.0	0.0	0.0	0.0
DEX0455_012.nt.1	34334.0	17.6	18.8	0.0	0.0

DEX0455_012.nt.1	34334.1	23.5	25.0	0.0	0.0
DEX0455_012.nt.1	34335.0	23.5	26.7	8.3	8.3
DEX0455_012.nt.1	34335.1	17.6	18.8	0.0	0.0
DEX0455_012.nt.2	34334.0	17.6	18.8	0.0	0.0
DEX0455_012.nt.2	34334.1	23.5	25.0	0.0	0.0
DEX0455_012.nt.2	34335.0	23.5	26.7	8.3	8.3
DEX0455_012.nt.2	34335.1	17.6	18.8	0.0	0.0
DEX0455_017.nt.1	36482.0	5.9	6.7	0.0	0.0
DEX0455_017.nt.1	36482.1	5.9	6.2	0.0	0.0
DEX0455_033.nt.1	2023.0	0.0	0.0	0.0	0.0
DEX0455_033.nt.1	5327.0	0.0	0.0	0.0	0.0
DEX0455_033.nt.1	5328.0	0.0	0.0	0.0	0.0
DEX0455_035.nt.1	78519.0	0.0	0.0	0.0	0.0
DEX0455_035.nt.1	78519.1	0.0	0.0	0.0	0.0
DEX0455_035.nt.1	78520.0	0.0	0.0	0.0	0.0
DEX0455_035.nt.1	78520.1	0.0	0.0	0.0	0.0
DEX0455_035.nt.2	78519.0	0.0	0.0	0.0	0.0
DEX0455_035.nt.2	78519.1	0.0	0.0	0.0	0.0
DEX0455_035.nt.2	78520.0	0.0	0.0	0.0	0.0
DEX0455_035.nt.2	78520.1	0.0	0.0	0.0	0.0
DEX0455_035.nt.3	78519.0	0.0	0.0	0.0	0.0
DEX0455_035.nt.3	78519.1	0.0	0.0	0.0	0.0
DEX0455_035.nt.3	78520.0	0.0	0.0	0.0	0.0
DEX0455_035.nt.3	78520.1	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	23542.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	23542.1	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	23543.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.1	23543.1	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	23542.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	23542.1	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	23543.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.2	23543.1	0.0	0.0	0.0	0.0
DEX0455_038.nt.3	23542.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.3	23542.1	0.0	0.0	0.0	0.0
DEX0455_038.nt.3	23543.0	0.0	0.0	0.0	0.0
DEX0455_038.nt.3	23543.1	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	96212.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	96212.1	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	105764.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	105764.1	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	105767.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	105767.1	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	105768.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.1	105768.1	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	96212.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	96212.1	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	105764.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	105764.1	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	105767.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	105767.1	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	105768.0	0.0	0.0	0.0	0.0
DEX0455_047.nt.2	105768.1	0.0	0.0	0.0	0.0
DEX0455_048.nt.1	1168.0	0.0	0.0	8.3	8.3
DEX0455_048.nt.2	1175.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23378.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23378.1	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	23379.0	0.0	0.0	0.0	0.0

DEX0455_050.nt.1	23379.1	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42007.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42007.1	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42007.2	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42008.0	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42008.1	0.0	0.0	0.0	0.0
DEX0455_050.nt.1	42008.2	0.0	0.0	0.0	0.0
DEX0455_061.nt.1	78508.0	0.0	0.0	0.0	0.0
DEX0455_061.nt.1	78508.1	0.0	0.0	0.0	0.0
DEX0455_061.nt.2	78508.0	0.0	0.0	0.0	0.0
DEX0455_061.nt.2	78508.1	0.0	0.0	0.0	0.0
DEX0455_061.nt.3	78508.0	0.0	0.0	0.0	0.0
DEX0455_061.nt.3	78508.1	0.0	0.0	0.0	0.0
DEX0455_061.nt.4	78508.0	0.0	0.0	0.0	0.0
DEX0455_061.nt.4	78508.1	0.0	0.0	0.0	0.0
DEX0455_061.nt.5	78508.0	0.0	0.0	0.0	0.0
DEX0455_061.nt.5	78508.1	0.0	0.0	0.0	0.0

SEQ ID NO: 1-128 was up-regulated on various tissue microarrays. Accordingly, nucleotide SEQ ID NO: 1-128 or the encoded protein SEQ ID NO: 129-295 may be used as a cancer therapeutic and/or diagnostic target for the tissues in which expression is shown.

The following table lists the location (Oligo Location) where the microarray oligos (Oligo ID) map on the transcripts (DEX ID) of the present invention. Each Oligo ID may have been printed multiple times on a single chip as replicates. The Oligo Name is an exemplary replicate (e.g. 1000.01) for the Oligo ID (e.g. 1000), and data from other replicates (e.g. 1000.02, 1000.03) may be reported. Additionally, the Array (Chip Name) that each oligo and oligo replicates were printed on is included.

DEX NT ID	Oligo ID	Oligo Name	Chip Name	Oligo Location
DEX0455_001.nt.1	34930	34930.01	Ovarian array	4736-4795
DEX0455_002.nt.1	21577	21577.02	Ovarian array	198-257
DEX0455_002.nt.1	79699	79699.0	Multi-Cancer array	1430-1489
DEX0455_002.nt.1	21553	21553.01	Ovarian array	513-572
DEX0455_002.nt.1	79700	79700.0	Multi-Cancer array	1429-1488
DEX0455_003.nt.1	17466	17466.02	Ovarian array	1075-1134
DEX0455_004.nt.1	96340	96340.0	Multi-Cancer array	6807-6866
DEX0455_004.nt.1	96339	96339.0	Multi-Cancer array	6906-6965
DEX0455_004.nt.1	105991	105991.0	Multi-Cancer array	6906-6965
DEX0455_004.nt.1	105992	105992.0	Multi-Cancer array	6807-6866
DEX0455_004.nt.1	105996	105996.0	Multi-Cancer array	8462-8521
DEX0455_004.nt.2	96340	96340.0	Multi-Cancer array	5651-5710
DEX0455_004.nt.2	105991	105991.0	Multi-Cancer array	5750-5809
DEX0455_004.nt.2	105992	105992.0	Multi-Cancer array	5651-5710
DEX0455_004.nt.2	105996	105996.0	Multi-Cancer array	7306-7365

DEX0455_004.nt.2	96339	96339.0	Multi-Cancer array	5750-5809
DEX0455_005.nt.1	24874	24874.01	Ovarian array	475-534
DEX0455_005.nt.1	20619	20619.02	Ovarian array	472-531
DEX0455_005.nt.2	24874	24874.01	Ovarian array	475-534
DEX0455_007.nt.1	30109	30109.01	Ovarian array	982-1041
DEX0455_008.nt.1	22387	22387.01	Ovarian array	1666-1725
DEX0455_008.nt.1	18508	18508.02	Ovarian array	1193-1252
DEX0455_009.nt.1	9720	9720.02	Ovarian array	1745-1804
DEX0455_010.nt.1	2721	2721.0	Lung array	501-560
DEX0455_010.nt.1	37415	37415.0	Colon array	1040-1099
DEX0455_010.nt.1	32151	32151.0	Breast array	748-807
DEX0455_010.nt.1	2720	2720.0	Lung array	542-601
DEX0455_010.nt.1	21675	21675.02	Ovarian array	965-1024
DEX0455_010.nt.1	20627	20627.02	Ovarian array	250-309
DEX0455_010.nt.1	28129	28129.02	Prostate1 array	964-1023
DEX0455_010.nt.1	791	791.0	Lung array	1045-1104
DEX0455_010.nt.2	2720	2720.0	Lung array	379-438
DEX0455_010.nt.2	32151	32151.0	Breast array	585-644
DEX0455_010.nt.2	28129	28129.02	Prostate1 array	801-860
DEX0455_010.nt.2	37415	37415.0	Colon array	877-936
DEX0455_010.nt.2	21675	21675.02	Ovarian array	802-861
DEX0455_010.nt.2	791	791.0	Lung array	882-941
DEX0455_010.nt.2	2721	2721.0	Lung array	338-397
DEX0455_011.nt.1	35317	35317.0	Colon array	398-457
DEX0455_012.nt.1	34368	34368.0	Colon array	2484-2543
DEX0455_012.nt.1	34369	34369.0	Colon array	2441-2500
DEX0455_012.nt.1	34334	34334.0	Colon array	3108-3167
DEX0455_012.nt.1	34343	34343.0	Colon array	472-531
DEX0455_012.nt.1	34335	34335.0	Colon array	3022-3081
DEX0455_012.nt.2	34334	34334.0	Colon array	2527-2586
DEX0455_012.nt.2	34343	34343.0	Colon array	472-531
DEX0455_012.nt.2	34369	34369.0	Colon array	1860-1919
DEX0455_012.nt.2	34335	34335.0	Colon array	2441-2500
DEX0455_012.nt.2	34368	34368.0	Colon array	1903-1962
DEX0455_013.nt.1	9838	9838.02	Ovarian array	1304-1363
DEX0455_014.nt.1	10624	10624.02	Ovarian array	1832-1891
DEX0455_014.nt.1	14604	14604.01	Ovarian array	925-984
DEX0455_015.nt.1	19518	19518.01	Ovarian array	277-336
DEX0455_016.nt.1	23734	23734.02	Ovarian array	531-590
DEX0455_017.nt.1	28221	28221.0	Breast array	679-738
DEX0455_017.nt.1	21032	21032.0	Colon array	314-373
DEX0455_017.nt.1	36482	36482.0	Multi-Cancer array	314-373
DEX0455_018.nt.1	21575	21575.01	Ovarian array	1516-1575
DEX0455_018.nt.1	21571	21571.02	Ovarian array	623-682
DEX0455_018.nt.1	21609	21609.02	Ovarian array	933-992
DEX0455_018.nt.2	21575	21575.01	Ovarian array	2287-2346
DEX0455_019.nt.1	20669	20669.01	Ovarian array	615-674

DEX0455_021.nt.1	23780	23780.01	Ovarian array	517-576
DEX0455_021.nt.1	21469	21469.02	Ovarian array	430-489
DEX0455_021.nt.1	21433	21433.01	Ovarian array	518-577
DEX0455_021.nt.1	21475	21475.01	Ovarian array	517-576
DEX0455_021.nt.2	21469	21469.02	Ovarian array	1528-1587
DEX0455_021.nt.2	21475	21475.01	Ovarian array	1615-1674
DEX0455_021.nt.2	21433	21433.01	Ovarian array	1616-1675
DEX0455_021.nt.2	23780	23780.01	Ovarian array	1615-1674
DEX0455_021.nt.3	21433	21433.01	Ovarian array	1859-1918
DEX0455_021.nt.3	21475	21475.01	Ovarian array	1858-1917
DEX0455_021.nt.3	21469	21469.02	Ovarian array	1771-1830
DEX0455_021.nt.3	23780	23780.01	Ovarian array	1858-1917
DEX0455_021.nt.4	21469	21469.02	Ovarian array	1914-1973
DEX0455_021.nt.4	21475	21475.01	Ovarian array	2001-2060
DEX0455_021.nt.4	21433	21433.01	Ovarian array	2002-2061
DEX0455_022.nt.1	9920	9920.02	Ovarian array	1022-1081
DEX0455_022.nt.1	20311	20311.01	Ovarian array	718-777
DEX0455_022.nt.1	20299	20299.01	Ovarian array	529-588
DEX0455_022.nt.1	23280	23280.0	Breast array	427-486
DEX0455_022.nt.1	20317	20317.02	Ovarian array	718-777
DEX0455_022.nt.2	9920	9920.02	Ovarian array	1016-1075
DEX0455_022.nt.2	20311	20311.01	Ovarian array	712-771
DEX0455_022.nt.2	20317	20317.02	Ovarian array	712-771
DEX0455_022.nt.2	20299	20299.01	Ovarian array	552-611
DEX0455_022.nt.3	9920	9920.02	Ovarian array	613-672
DEX0455_022.nt.3	20317	20317.02	Ovarian array	309-368
DEX0455_022.nt.3	20311	20311.01	Ovarian array	309-368
DEX0455_023.nt.1	16374	16374.02	Ovarian array	2119-2178
DEX0455_023.nt.1	8770	8770.03	Prostate2 array	1897-1956
DEX0455_023.nt.1	16378	16378.01	Ovarian array	937-996
DEX0455_023.nt.1	16187	16187.01	Ovarian array	666-725
DEX0455_024.nt.1	21507	21507.01	Ovarian array	2357-2416
DEX0455_024.nt.1	21487	21487.01	Ovarian array	796-855
DEX0455_024.nt.1	12149	12149.01	Ovarian array	2439-2498
DEX0455_024.nt.1	21547	21547.02	Ovarian array	1555-1614
DEX0455_024.nt.1	17957	17957.0	Colon array	2002-2061
DEX0455_024.nt.2	21507	21507.01	Ovarian array	1790-1849
DEX0455_024.nt.2	12149	12149.01	Ovarian array	1872-1931
DEX0455_024.nt.2	21547	21547.02	Ovarian array	988-1047
DEX0455_024.nt.2	17957	17957.0	Colon array	1435-1494
DEX0455_025.nt.1	12167	12167.01	Ovarian array	475-534
DEX0455_025.nt.1	16964	16964.02	Ovarian array	3509-3568
DEX0455_025.nt.1	16956	16956.02	Ovarian array	3533-3592
DEX0455_025.nt.1	16958	16958.01	Ovarian array	808-867
DEX0455_025.nt.1	19010	19010.01	Ovarian array	1260-1319
DEX0455_025.nt.2	12167	12167.01	Ovarian array	475-534
DEX0455_025.nt.2	16964	16964.02	Ovarian array	2465-2524

DEX0455_025.nt.2	16956	16956.02	Ovarian array	2489-2548
DEX0455_025.nt.2	16958	16958.01	Ovarian array	808-867
DEX0455_025.nt.2	19010	19010.01	Ovarian array	1260-1319
DEX0455_025.nt.3	12167	12167.01	Ovarian array	475-534
DEX0455_025.nt.3	19010	19010.01	Ovarian array	1260-1319
DEX0455_025.nt.3	16958	16958.01	Ovarian array	808-867
DEX0455_025.nt.4	19010	19010.01	Ovarian array	1260-1319
DEX0455_025.nt.4	16956	16956.02	Ovarian array	2167-2226
DEX0455_025.nt.4	16964	16964.02	Ovarian array	2143-2202
DEX0455_025.nt.4	12167	12167.01	Ovarian array	475-534
DEX0455_027.nt.1	21549	21549.01	Ovarian array	1483-1542
DEX0455_028.nt.1	41120	41120.0	Colon array	477-536
DEX0455_028.nt.1	30821	30821.0	Colon array	673-732
DEX0455_029.nt.1	41151	41151.0	Colon array	2429-2488
DEX0455_029.nt.1	22113	22113.01	Ovarian array	3222-3281
DEX0455_029.nt.1	30869	30869.0	Colon array	5572-5631
DEX0455_029.nt.1	41120	41120.0	Colon array	1984-2043
DEX0455_029.nt.1	23386	23386.01	Ovarian array	2429-2488
DEX0455_029.nt.1	30820	30820.0	Colon array	2388-2447
DEX0455_029.nt.1	41117	41117.0	Colon array	2296-2355
DEX0455_029.nt.1	30821	30821.0	Colon array	2348-2407
DEX0455_029.nt.1	23400	23400.02	Ovarian array	2296-2355
DEX0455_029.nt.1	41152	41152.0	Colon array	2372-2431
DEX0455_029.nt.1	17430	17430.02	Ovarian array	2388-2447
DEX0455_029.nt.1	30824	30824.0	Colon array	5798-5857
DEX0455_029.nt.1	17448	17448.01	Ovarian array	5798-5857
DEX0455_029.nt.2	41120	41120.0	Colon array	2412-2471
DEX0455_029.nt.2	17430	17430.02	Ovarian array	2816-2875
DEX0455_029.nt.2	23386	23386.01	Ovarian array	2857-2916
DEX0455_029.nt.2	30824	30824.0	Colon array	5101-5160
DEX0455_029.nt.2	17424	17424.01	Ovarian array	4880-4939
DEX0455_029.nt.2	30922	30922.0	Colon array	4880-4939
DEX0455_029.nt.2	23400	23400.02	Ovarian array	2724-2783
DEX0455_029.nt.2	41152	41152.0	Colon array	2800-2859
DEX0455_029.nt.2	30820	30820.0	Colon array	2816-2875
DEX0455_029.nt.2	22113	22113.01	Ovarian array	3650-3709
DEX0455_029.nt.2	41117	41117.0	Colon array	2724-2783
DEX0455_029.nt.2	41151	41151.0	Colon array	2857-2916
DEX0455_029.nt.2	30821	30821.0	Colon array	2776-2835
DEX0455_029.nt.2	17448	17448.01	Ovarian array	5101-5160
DEX0455_030.nt.1	17204	17204.02	Ovarian array	1225-1284
DEX0455_030.nt.1	17262	17262.02	Ovarian array	1011-1070
DEX0455_030.nt.1	17278	17278.02	Ovarian array	991-1050
DEX0455_030.nt.1	11613	11613.01	Ovarian array	1011-1070
DEX0455_030.nt.2	17274	17274.02	Ovarian array	696-755
DEX0455_030.nt.2	17204	17204.02	Ovarian array	984-1043
DEX0455_030.nt.2	17278	17278.02	Ovarian array	713-772

DEX0455_030.nt.2	17262	17262.02	Ovarian array	733-792
DEX0455_031.nt.1	20773	20773.02	Ovarian array	2724-2783
DEX0455_032.nt.1	2688	2688.0	Lung array	952-1011
DEX0455_032.nt.1	11585	11585.01	Ovarian array	1342-1401
DEX0455_032.nt.1	2689	2689.0	Lung array	910-969
DEX0455_032.nt.1	18556	18556.02	Ovarian array	952-1011
DEX0455_032.nt.1	5313	5313.0	Lung array	1342-1401
DEX0455_033.nt.1	5328	5328.0	Multi-Cancer array	402-461
DEX0455_033.nt.1	2006	2006.0	Lung array	402-461
DEX0455_033.nt.1	2022	2022.0	Lung array	482-541
DEX0455_033.nt.1	2032	2032.0	Lung array	290-349
DEX0455_033.nt.1	2007	2007.0	Lung array	361-420
DEX0455_033.nt.1	5327	5327.0	Multi-Cancer array	442-501
DEX0455_033.nt.1	2023	2023.0	Multi-Cancer array	442-501
DEX0455_034.nt.1	10722	10722.02	Ovarian array	2454-2513
DEX0455_034.nt.1	32554	32554.02	Prostate2 array	1815-1874
DEX0455_034.nt.1	21421	21421.02	Ovarian array	1815-1874
DEX0455_034.nt.1	32558	32558.01	Prostate2 array	1053-1112
DEX0455_034.nt.1	16423	16423.0	Colon array	885-944
DEX0455_034.nt.1	21401	21401.02	Ovarian array	1053-1112
DEX0455_034.nt.1	26867	26867.01	Prostate1 array	2454-2513
DEX0455_035.nt.1	78519	78519.0	Multi-Cancer array	923-982
DEX0455_035.nt.1	78520	78520.0	Multi-Cancer array	857-916
DEX0455_035.nt.1	103385	103385.01	Ovarian array	926-985
DEX0455_035.nt.2	78519	78519.0	Multi-Cancer array	1152-1211
DEX0455_035.nt.2	103385	103385.01	Ovarian array	1155-1214
DEX0455_035.nt.2	78520	78520.0	Multi-Cancer array	1086-1145
DEX0455_035.nt.3	103385	103385.01	Ovarian array	1034-1093
DEX0455_035.nt.3	78519	78519.0	Multi-Cancer array	1031-1090
DEX0455_035.nt.3	78520	78520.0	Multi-Cancer array	965-1024
DEX0455_035.nt.3	21144	21144.0	Breast array	126-185
DEX0455_035.nt.3	21143	21143.0	Breast array	212-271
DEX0455_036.nt.1	92327	92327.01	Ovarian array	177-236
DEX0455_037.nt.1	17490	17490.01	Ovarian array	894-953
DEX0455_037.nt.1	11575	11575.01	Ovarian array	892-951
DEX0455_037.nt.1	17486	17486.01	Ovarian array	887-946
DEX0455_037.nt.2	17490	17490.01	Ovarian array	1459-1518
DEX0455_037.nt.2	11575	11575.01	Ovarian array	1457-1516
DEX0455_037.nt.3	17490	17490.01	Ovarian array	2399-2458
DEX0455_037.nt.3	11575	11575.01	Ovarian array	2397-2456
DEX0455_037.nt.3	17486	17486.01	Ovarian array	2392-2451
DEX0455_037.nt.4	17490	17490.01	Ovarian array	515-574
DEX0455_037.nt.4	17486	17486.01	Ovarian array	508-567
DEX0455_037.nt.4	11575	11575.01	Ovarian array	513-572
DEX0455_037.nt.5	17486	17486.01	Ovarian array	571-630
DEX0455_037.nt.5	17490	17490.01	Ovarian array	578-637
DEX0455_037.nt.5	11575	11575.01	Ovarian array	576-635

DEX0455_038.nt.1	23543	23543.0	Multi-Cancer array	5011-5070
DEX0455_038.nt.1	23492	23492.02	Prostate1 array	5433-5492
DEX0455_038.nt.1	23546	23546.01	Prostate1 array	3874-3933
DEX0455_038.nt.1	24422	24422.01	Prostate1 array	3874-3933
DEX0455_038.nt.1	23542	23542.0	Multi-Cancer array	5118-5177
DEX0455_038.nt.1	24418	24418.01	Prostate1 array	2859-2918
DEX0455_038.nt.1	27965	27965.01	Prostate1 array	1956-2015
DEX0455_038.nt.1	28535	28535.01	Prostate1 array	5154-5213
DEX0455_038.nt.2	27965	27965.01	Prostate1 array	1956-2015
DEX0455_038.nt.2	23543	23543.0	Multi-Cancer array	4443-4502
DEX0455_038.nt.2	28535	28535.01	Prostate1 array	4586-4645
DEX0455_038.nt.2	23492	23492.02	Prostate1 array	4865-4924
DEX0455_038.nt.2	24418	24418.01	Prostate1 array	2859-2918
DEX0455_038.nt.2	23542	23542.0	Multi-Cancer array	4550-4609
DEX0455_038.nt.2	23684	23684.02	Prostate1 array	3719-3778
DEX0455_038.nt.3	23543	23543.0	Multi-Cancer array	2528-2587
DEX0455_038.nt.3	23492	23492.02	Prostate1 array	2950-3009
DEX0455_038.nt.3	23542	23542.0	Multi-Cancer array	2635-2694
DEX0455_038.nt.3	27965	27965.01	Prostate1 array	1693-1752
DEX0455_038.nt.3	28535	28535.01	Prostate1 array	2671-2730
DEX0455_039.nt.1	21505	21505.02	Ovarian array	355-414
DEX0455_039.nt.2	11527	11527.01	Ovarian array	467-526
DEX0455_040.nt.1	21489	21489.02	Ovarian array	281-340
DEX0455_040.nt.1	21501	21501.02	Ovarian array	772-831
DEX0455_040.nt.1	21511	21511.01	Ovarian array	586-645
DEX0455_040.nt.2	21489	21489.02	Ovarian array	698-757
DEX0455_040.nt.2	21511	21511.01	Ovarian array	1003-1062
DEX0455_040.nt.2	21501	21501.02	Ovarian array	1189-1248
DEX0455_041.nt.1	16980	16980.01	Ovarian array	125-184
DEX0455_041.nt.1	16998	16998.0	Breast array	125-184
DEX0455_041.nt.1	12155	12155.01	Ovarian array	309-368
DEX0455_042.nt.1	889	889.0	Lung array	346-405
DEX0455_042.nt.1	18214	18214.02	Ovarian array	346-405
DEX0455_043.nt.1	14656	14656.02	Ovarian array	463-522
DEX0455_045.nt.1	36013	36013.01	Ovarian array	382-441
DEX0455_046.nt.1	17314	17314.01	Ovarian array	614-673
DEX0455_046.nt.1	19072	19072.0	Breast array	614-673
DEX0455_047.nt.1	105768	105768.0	Multi-Cancer array	3274-3333
DEX0455_047.nt.1	96212	96212.0	Multi-Cancer array	2703-2762
DEX0455_047.nt.1	105767	105767.0	Multi-Cancer array	3314-3373
DEX0455_047.nt.1	105764	105764.0	Multi-Cancer array	2703-2762
DEX0455_047.nt.2	105768	105768.0	Multi-Cancer array	1478-1537
DEX0455_047.nt.2	105767	105767.0	Multi-Cancer array	1518-1577
DEX0455_047.nt.2	96212	96212.0	Multi-Cancer array	907-966
DEX0455_048.nt.1	1169	1169.0	Lung array	175-234
DEX0455_048.nt.1	1011	1011.0	Lung array	202-261
DEX0455_048.nt.1	1009	1009.0	Lung array	192-251

DEX0455_048.nt.1	1010	1010.0	Lung array	242-301
DEX0455_048.nt.1	1168	1168.0	Multi-Cancer array	180-239
DEX0455_048.nt.2	1169	1169.0	Lung array	386-445
DEX0455_048.nt.2	1011	1011.0	Lung array	413-472
DEX0455_048.nt.2	1009	1009.0	Lung array	403-462
DEX0455_048.nt.2	1175	1175.0	Multi-Cancer array	254-313
DEX0455_048.nt.2	1168	1168.0	Multi-Cancer array	391-450
DEX0455_048.nt.2	1174	1174.0	Lung array	259-318
DEX0455_048.nt.2	1010	1010.0	Lung array	453-512
DEX0455_049.nt.1	11511	11511.02	Ovarian array	2111-2170
DEX0455_049.nt.1	36902	36902.0	Colon array	928-987
DEX0455_049.nt.2	36901	36901.0	Colon array	621-680
DEX0455_049.nt.2	11511	11511.02	Ovarian array	1528-1587
DEX0455_049.nt.2	36902	36902.0	Colon array	582-641
DEX0455_049.nt.3	36901	36901.0	Colon array	967-1026
DEX0455_049.nt.4	11511	11511.02	Ovarian array	2102-2161
DEX0455_049.nt.4	36902	36902.0	Colon array	1156-1215
DEX0455_049.nt.4	36901	36901.0	Colon array	1195-1254
DEX0455_049.nt.5	36902	36902.0	Colon array	299-358
DEX0455_049.nt.5	11511	11511.02	Ovarian array	1245-1304
DEX0455_050.nt.1	29736	29736.0	Breast array	171-230
DEX0455_050.nt.1	7815	7815.0	Lung array	385-444
DEX0455_050.nt.1	23378	23378.0	Breast array	684-743
DEX0455_050.nt.1	42008	42008.0	Multi-Cancer array	329-388
DEX0455_050.nt.1	42007	42007.0	Multi-Cancer array	329-388
DEX0455_050.nt.1	22136	22136.0	Breast array	636-695
DEX0455_050.nt.1	23379	23379.0	Breast array	385-444
DEX0455_052.nt.1	91971	91971.01	Ovarian array	1686-1745
DEX0455_054.nt.1	19799	19799.0	Breast array	1918-1977
DEX0455_055.nt.1	20541	20541.01	Ovarian array	1705-1764
DEX0455_055.nt.1	12731	12731.0	Breast array	1601-1660
DEX0455_055.nt.1	12732	12732.0	Breast array	1395-1454
DEX0455_055.nt.1	11273	11273.02	Ovarian array	1815-1874
DEX0455_055.nt.2	20541	20541.01	Ovarian array	1403-1462
DEX0455_055.nt.2	12731	12731.0	Breast array	1299-1358
DEX0455_055.nt.2	12732	12732.0	Breast array	1136-1195
DEX0455_055.nt.2	11273	11273.02	Ovarian array	1513-1572
DEX0455_055.nt.3	12732	12732.0	Breast array	568-627
DEX0455_055.nt.3	12731	12731.0	Breast array	731-790
DEX0455_055.nt.3	20541	20541.01	Ovarian array	835-894
DEX0455_056.nt.1	23444	23444.01	Ovarian array	2588-2647
DEX0455_056.nt.1	3161	3161.0	Lung array	2547-2606
DEX0455_056.nt.1	3164	3164.0	Lung array	3317-3376
DEX0455_056.nt.1	3160	3160.0	Lung array	2588-2647
DEX0455_056.nt.1	3165	3165.0	Lung array	3277-3336
DEX0455_056.nt.1	1583	1583.0	Lung array	3277-3336
DEX0455_056.nt.1	18520	18520.02	Ovarian array	3317-3376

DEX0455_056.nt.1	3143	3143.0	Lung array	3107-3166
DEX0455_056.nt.1	1582	1582.0	Lung array	3317-3376
DEX0455_056.nt.1	22734	22734.02	Ovarian array	3317-3376
DEX0455_056.nt.1	2661	2661.0	Lung array	3523-3582
DEX0455_056.nt.2	23444	23444.01	Ovarian array	2559-2618
DEX0455_056.nt.2	2661	2661.0	Lung array	3287-3346
DEX0455_056.nt.2	3161	3161.0	Lung array	2518-2577
DEX0455_056.nt.2	1582	1582.0	Lung array	3081-3140
DEX0455_056.nt.2	22734	22734.02	Ovarian array	3081-3140
DEX0455_056.nt.2	3160	3160.0	Lung array	2559-2618
DEX0455_056.nt.2	18520	18520.02	Ovarian array	3081-3140
DEX0455_056.nt.2	3165	3165.0	Lung array	3041-3100
DEX0455_056.nt.2	1583	1583.0	Lung array	3041-3100
DEX0455_056.nt.2	3164	3164.0	Lung array	3081-3140
DEX0455_057.nt.1	7613	7613.0	Lung array	292-351
DEX0455_057.nt.1	33332	33332.02	Prostate1 array	600-659
DEX0455_057.nt.1	7612	7612.0	Lung array	381-440
DEX0455_057.nt.1	24524	24524.02	Ovarian array	600-659
DEX0455_057.nt.2	7613	7613.0	Lung array	458-517
DEX0455_057.nt.2	7612	7612.0	Lung array	547-606
DEX0455_057.nt.2	33332	33332.02	Prostate1 array	766-825
DEX0455_058.nt.1	14656	14656.02	Ovarian array	555-614
DEX0455_059.nt.1	17372	17372.01	Ovarian array	1778-1837
DEX0455_059.nt.1	11469	11469.02	Ovarian array	424-483
DEX0455_059.nt.1	17370	17370.01	Ovarian array	957-1016
DEX0455_059.nt.2	17372	17372.01	Ovarian array	1489-1548
DEX0455_059.nt.2	11469	11469.02	Ovarian array	424-483
DEX0455_060.nt.1	10372	10372.01	Ovarian array	1201-1260
DEX0455_060.nt.1	18582	18582.01	Ovarian array	672-731
DEX0455_061.nt.1	78508	78508.0	Multi-Cancer array	3736-3795
DEX0455_061.nt.1	103529	103529.01	Ovarian array	3740-3799
DEX0455_061.nt.1	19803	19803.0	Colon array	3736-3795
DEX0455_061.nt.1	96523	96523.02	Ovarian array	3740-3799
DEX0455_061.nt.1	19804	19804.0	Colon array	3684-3743
DEX0455_061.nt.2	19803	19803.0	Colon array	4690-4749
DEX0455_061.nt.2	78508	78508.0	Multi-Cancer array	4690-4749
DEX0455_061.nt.2	19804	19804.0	Colon array	4638-4697
DEX0455_061.nt.2	103529	103529.01	Ovarian array	4694-4753
DEX0455_061.nt.2	96523	96523.02	Ovarian array	4694-4753
DEX0455_061.nt.3	19803	19803.0	Colon array	4556-4615
DEX0455_061.nt.3	78508	78508.0	Multi-Cancer array	4556-4615
DEX0455_061.nt.3	103529	103529.01	Ovarian array	4560-4619
DEX0455_061.nt.3	19804	19804.0	Colon array	4504-4563
DEX0455_061.nt.3	96523	96523.02	Ovarian array	4560-4619
DEX0455_061.nt.4	103529	103529.01	Ovarian array	1702-1761
DEX0455_061.nt.4	19804	19804.0	Colon array	1646-1705
DEX0455_061.nt.4	78508	78508.0	Multi-Cancer array	1698-1757

DEX0455 061.nt.4	19803	19803.0	Colon array	1698-1757
DEX0455 061.nt.4	96523	96523.02	Ovarian array	1702-1761
DEX0455 061.nt.5	78508	78508.0	Multi-Cancer array	2394-2453
DEX0455 061.nt.5	103529	103529.01	Ovarian array	2398-2457
DEX0455 061.nt.5	19803	19803.0	Colon array	2394-2453
DEX0455 061.nt.5	19804	19804.0	Colon array	2342-2401
DEX0455 061.nt.5	96523	96523.02	Ovarian array	2398-2457
DEX0455 062.nt.1	18094	18094.01	Ovarian array	914-973
DEX0455 062.nt.1	17464	17464.02	Ovarian array	1167-1226

Example 2b: Relative Quantitation of Gene Expression

Real-Time quantitative PCR with fluorescent Taqman[®] probes is a quantitation detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman[®]) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA). Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ATPase, or 18S ribosomal RNA (rRNA) is used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained using the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

The tissue distribution and the level of the target gene are evaluated for every sample in normal and cancer tissues. Total RNA is extracted from normal tissues, cancer tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA is prepared with reverse transcriptase and the polymerase chain reaction is done using primers and Taqman[®] probes specific to each target gene. The results are analyzed using the ABI PRISM 7700 Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.

One of ordinary skill can design appropriate primers. The relative levels of expression of the OSNA versus normal tissues and other cancer tissues can then be

determined. All the values are compared to the calibrator. Normal RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

The relative levels of expression of the OSNA in pairs of matched samples may also be determined. A matched pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. All the values are compared to the calibrator.

In the analysis of matching samples, the OSNAs show a high degree of tissue specificity for the tissue of interest. These results confirm the tissue specificity results obtained with normal pooled samples. Further, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual are compared. This comparison provides an indication of specificity for the cancer state (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent).

Information on the samples tested in the QPCR experiments below include the Sample ID (Smpl ID), Organ, Tissue Type (Tiss Type), Diagnosis (DIAG), Disease Detail, and Stage or Grade (STG or GRD) in following table.

Sample ID	ORGAN	TISS TYPE	DIAGNOSIS	DISEASE DETAIL	STAGE OR GRADE
A084	Ovary	CAN	Mucinous borderline tumor		
A084	Ovary	NAT	NAT		
G010	Ovary	CAN	Adenocarcinoma	Adenocarcinoma	Stage III
G010	Ovary	NAT		NAT	
G021	Ovary	CAN	Carcinoma	St. IIIC, poorly diff.	Stage-IIIC, poorly diff.
G021	Ovary	NAT		NAT	
1157	Ovary	CAN		malignant tumor	
7730	Ovary	CAN	Papillary adenocarcinoma	serous papillary adenocarcinoma	metastatic
8140	Ovary	CAN		Papillary Serous Adenocarcinoma	Stage IV
C360	Ovary	CAN	Adenocarcinoma	endometrioid adenocarcinoma	
10050	Ovary	CAN		papillary serous and endometrioid ovarian carcinoma, concurrent metastatic breast cancer	3
10400	Ovary	CAN		papillary serous adeno, metastatic	

1050	Ovary	CAN		Papillary Serous Carcinoma with Focal Mucinous Differentiation	Stage IC G0; T1cN0M0
130X	Ovary	CAN		Ovarian cancer	
7180	Ovary	CAN	Adenocarcinoma	malignant tumor	IIIC
A1B	Ovary	CAN	Adenocarcinoma	CA	
988Z	Ovary	CAN		papillary serous adenocarcinoma	poorly diff, FIGO IIIC
4510	Ovary	NRM		Normal Tissue	
247A	Ovary	NRM		NL	
35GA	Ovary	NRM		NL	
C087	Ovary	NRM		NL	
C109	Ovary	NRM		NL	
206I	Ovary	NRM		NL	
5150	Ovary	NRM		Normal	
18GA	Ovary	NRM		NL	
3370	Ovary	NRM		Normal	
1230	Ovary	NRM		Normal	
C177	Ovary	NRM		several fluid filled cysts	
40G	Ovary	NRM		NL	
C004	Ovary	NRM		NL	
030B	Urinary Bladder	CAN	Carcinoma	invasive Carcinoma, poorly differentiated	Stage III, Grade 3
030B	Urinary Bladder	NAT		NAT	
TR17	Urinary Bladder	CAN	Carcinoma	transitional cell carcinoma	Stage II/Grade III
TR17	Urinary Bladder	NAT		NAT	
520B	Urinary Bladder	CAN	Sarcomatoid transitional cell carcinoma	Sarcomatoid transitional cell carcinoma	
520B	Urinary Bladder	NAT		NAT	
401C	Colon	CAN	Adenocarcinoma	Adenocarcinoma of ascending colon and cecum	Stage III
401C	Colon	NAT		NAT	
AS43	Colon	CAN	Adenocarcinoma	malignant	
AS43	Colon	NAT	Adenocarcinoma	NAT	
AS98	Colon	CAN	Adenocarcinoma	Moderately to poorly differentiated adenocarcinoma	Duke's C
AS98	Colon	NAT		NAT	
CM12	Colon	CAN		T	Stage D
CM12	Colon	NAT	Adenocarcinoma	Nat	
DC19	Colon	CAN		T	Stage B
DC19	Colon	NAT		NL	
RC01	Colon	CAN	Cancer		Stage IV
RC01	Colon	NAT		NAT	

RS53	Colon	CAN	Adenocarcinoma	moderately differentiated adenocarcinoma	
RS53	Colon	NAT	Adenocarcinoma	NAT	
SG27	Colon	CAN		malig	Stage B
SG27	Colon	NAT		NAT	
TX01	Colon	CAN	Adenocarcinoma	Moderately differentiated adenocarcinoma of cecum	Stage II; T3NoMo
TX01	Colon	NAT		NAT	
KS52	Cervix	CAN	Squamous cell carcinoma	Keratinizing Squamous Cell Carcinoma	IIIB, well diff. G1; T3bNxM0
KS52	Cervix	NAT		NAT	
NK23	Cervix	CAN		Nonkeratinizing Large Cell	FIGO IIIB, undiff. G4; T3bNxM0
NK23	Cervix	NAT		NAT	
NKS54	Cervix	CAN	Squamous cell carcinoma	Nonkeratinizing Squamous Cell Carcinoma	IIB, mod diff. G2; T2bNxM0
NKS54	Cervix	NAT		NAT	
NKS55	Cervix	CAN	Squamous cell carcinoma	Nonkeratinizing Squamous Cell Carcinoma	IIIB, Mod diff. G2; T3bNxM0
NKS55	Cervix	NAT		NAT	
NKS81	Cervix	CAN	Squamous cell carcinoma	large cell nonkeratinizing sq carc, IIB, moderately diff	IIB
NKS81	Cervix	NAT		NAT	
NKS25	Cervix	CAN			
NKS25	Cervix	NAT		NAT	
NKS18	Cervix	CAN	Squamous cell carcinoma	Nonkeratinizing squamous cell carcinoma	GII
NKS18	Cervix	NAT		NAT	
10479	Endometrium	CAN		malignant mixed mullerian tumor	T?, Nx, M1
10479	Endometrium	NAT		NAT	
28XA	Endometrium	CAN	Endometrial adenocarcinoma	malignant	II/III
28XA	Endometrium	NAT		NAT	II/III
8XA	Endometrium	CAN	mod. diff, invasive, squamous differentiation, FIGO-II		
8XA	Endometrium	NAT		NAT	
106XD	Kidney	CAN	Renal cell carcinoma	renal cell carcinoma, clear cell, localized	3
106XD	Kidney	NAT		NL	

107XD	Kidney	CAN	Renal cell carcinoma	renal cell carcinoma, clear cell, with metastatic	G III
107XD	Kidney	NAT		NL	
109XD	Kidney	CAN		Malignant	G III
109XD	Kidney	NAT		NL	
10XD	Kidney	CAN	Renal cell carcinoma	renal cell carcinoma, clear cell, localized, grade 2-3	3
10XD	Kidney	NAT		NL	
22K	Kidney	CAN	Renal cell carcinoma	Renal cell carcinoma	G2, Mod. Diff.
22K	Kidney	NAT		NAT	
12XD	Kidney	CAN	Renal cell carcinoma	Left renal cell carcinoma	
12XD	Kidney	NAT		NAT	
15XA	Liver	CAN		Sarcoma, Retroperitoneal Tumor	Grade-2
15XA	Liver	NAT		CA	St. I, G4
174L	Liver	CAN	Hepatocellular carcinoma	Moderate to well differentiated hepatocellular carcinoma	
174L	Liver	NAT	Hepatocellular carcinoma	NAT	
187L	Liver	CAN	Adenocarcinoma	Metastatic Adenocarcinoma	Liver (Gallbladder)
187L	Liver	NAT		NAT	
205L	Lung	CAN	Adenocarcinoma	poorly differentiated adenocarcinoma	T2, N1, Mx
205L	Lung	NAT		NAT	
315L	Lung	CAN	Squamous cell carcinoma		
315L	Lung	NAT	Adenocarcinoma	NAT	
507L	Lung	CAN	Bronchioloalveolar carcinoma	bronchioalveolar carcinoma	Stage IB, G1, well diff.
507L	Lung	NAT		NAT	
528L	Lung	CAN	Adenocarcinoma	Adenocarcinoma	St. IV, T2N0 M1, infiltrating poorly diff.
528L	Lung	NAT		NAT	
8837L	Lung	CAN	Squamous cell carcinoma	Squamous cell carcinoma	T2, N0, M0
8837L	Lung	NAT		NAT	
AC11	Lung	CAN	Adenocarcinoma	poorly differentiated adenocarcinoma	T2, N2, M1
AC11	Lung	NAT		NAT	
AC39	Lung	CAN	Adenocarcinoma	intermediate grade adnecarcinoma	T2, N2, Mx
AC39	Lung	NAT		NAT	

SQ80	Lung	CAN	Squamous cell carcinoma	poorly differentiated squamous cell carcinoma	T1, N1, M0
SQ80	Lung	NAT		NAT	
SQ81	Lung	CAN	Squamous cell carcinoma	poorly differentiated squamous carcinoma	T3, N1, Mx
SQ81	Lung	NAT		NAT	
19DN	Mammary	CAN	Invasive ductal carcinoma	Invasive ductal carcinoma	G3, Stage IIA; T2N0M0
19DN	Mammary	NAT		NAT	
42DN	Mammary	CAN	Invasive ductal carcinoma	Invasive Ductal Carcinoma	T3aN1M0 IIIA, G3
42DN	Mammary	NAT		NAT	
517	Mammary	CAN	Infiltrating ductal carcinoma	Infiltrating ductal carcinoma	St. IIA, G3
517	Mammary	NAT		NAT	
781M	Mammary	CAN	Invasive ductal carcinoma		Architectural grade-3/3, Nuclear grade-3/3
781M	Mammary	NAT		NAT	
869M	Mammary	CAN	Invasive carcinoma	Invasive Carcinoma	Stage IIA G1; T2NoMo
869M	Mammary	NAT		NAT	
976M	Mammary	CAN	Invasive ductal carcinoma	Invasive Ductal Carcinoma	T2N1M0 (Stage 2B Grade 2-3)
976M	Mammary	NAT		NAT	
S570	Mammary	CAN	Carcinoma	Carcinoma	Stage IIA; T1N1Mo
S570	Mammary	NAT		NAT	
S699	Mammary	CAN	Invasive lobular carcinoma	Invasive Lobular Carcinoma	Stage IIB G1; T2N1Mo
S699	Mammary	NAT		NAT	
S997	Mammary	CAN	Invasive ductal carcinoma	Invasive Ductal Carcinoma	Stage IIB G3; T2N1Mo
S997	Mammary	NAT		NAT	
71XL	Pancreas	CAN		villous adenoma with paneth cell metaplasia	localized
71XL	Pancreas	NAT		NL	
82XP	Pancreas	CAN		serious cystadenoma	
82XP	Pancreas	NAT		NL	
92X	Pancreas	CAN	Ductal adenocarcinoma	ductal adenocarcinoma	mod to focally poorly diff.
92X	Pancreas	NAT		NL	
77X	Pancreas	CAN	Hepatic adenoma	Hepatic adenoma	
77X	Pancreas	NAT		NL	
23B	Prostate	CAN		Prostate tumor	Gleason's 3+4

23B	Prostate	NAT		NAT	
65XB	Prostate	CAN	Adenocarcinoma	adenocarcinom	3+4=7
65XB	Prostate	NAT		NL	
675P	Prostate	CAN	Adenocarcinoma	adenocarcinoma	
675P	Prostate	NAT		Normal	
84XB	Prostate	CAN	Adenocarcinoma	adenocarcinom	2+3
84XB	Prostate	NAT		NL	
958P	Prostate	CAN	Adenocarcinoma	Adenocarcinoma	T2C, NO, MX
958P	Prostate	NAT		Normal	
263C	Prostate	BPH		BPH	
276P	Prostate	BPH		BPH	
767B	Prostate	BPH		prostate BPH	
855P	Prostate	BPH		BPH	
10R	Prostate	PROS T		active chronic prostatitis	T0, N0, M0
20R	Prostate	PROS T		PROSTATITIS	
287S	Skin	CAN	Squamous cell carcinoma	Invasive Keratinizing Squamous Cell Carcinoma	Moderately Differenti ated
287S	Skin	NAT		NAT	
39A	Skin	CAN		CA	St. II
39A	Skin	NAT		CA	St. II
669S	Skin	CAN	Melanoma	Nodular malignant melanoma	
669S	Skin	NAT		NAT	
171S	Small Intestine	CAN	Adenocarcinoma	Moderately differentiated Adenocarcinoma, invasive	
171S	Small Intestine	NAT		NAT	
20SM	Small Intestine	CAN	Adenocarcinoma	Adenocarcinoma, metastatic to lung & liver	St. IV, poorly diff.
20SM	Small Intestine	NAT		NAT	
H89	Small Intestine	CAN	Adenocarcinoma	Adenocarcinoma	80% tumor, 50% necrosis, moderately differenti ated, G2- 3; T3N1MX
H89	Small Intestine	NAT	Adenocarcinoma	NAT	
261S	Stomach	CAN	Signet-ring cell carcinoma	Signet-ring cell carcinoma	Stage IIIA, T3N1M0
261S	Stomach	NAT		NAT	
288S	Stomach	CAN	Adenocarcinoma	Infiltrating Adneocarcinoma	Moderately Differenti ated
288S	Stomach	NAT		NAT	

AC93 or 509L	Stomach	CAN	Adenocarcinoma	Adenocarcinoma	St. IV, G4, T4N3M0, poorly diff.
AC93 or 509L	Stomach	NAT		NAT	
88S	Stomach	CAN	Adenocarcinoma	Mucinous adenocarcinoma	T3N1M0, St. IIIA
88S	Stomach	NAT		NAT	
143N	Thyroid Gland	CAN	Follicular carcinoma	Follicular Carcinoma	
143N	Thyroid Gland	NAT		NAT	
270T	Thyroid Gland	CAN		CA	
270T	Thyroid Gland	NAT		NAT	
56T	Thyroid Gland	CAN	Papillary carcinoma	Papillary Carcinoma	St. III; T4N1M0
56T	Thyroid Gland	NAT		NAT	
39X	Testes	CAN		CA	
39X	Testes	NAT		NAT	
647T	Testes	CAN	Teratocarcinoma	Teratocarcinoma	Stage IA
647T	Testes	NAT	Teratocarcinoma	NAT	
663T	Testes	CAN	Teratocarcinoma	Teratocarcinoma	
663T	Testes	NAT		NAT	
135XO	Uterus	CAN		Uterus normal	
135XO	Uterus	NAT		Uterus tumor	
85XU	Uterus	CAN		endometrial carcinoma	I
85XU	Uterus	NAT		NL	
B1	Blood	NRM		Normal	
B3	Blood	NRM		Normal	
B5	Blood	NRM		Normal	
B6	Blood	NRM		Normal	
B11	Blood	NRM		Normal	
982B	Blood	NRM		Normal	
B69	Blood	NRM		Normal	
B72	Blood	NRM		Normal	
B73	Blood	NRM		Normal	
B75	Blood	NRM		Normal	
48AD	Adrenal Gland	NRM		Normal	
10BR	Brain	NRM		Normal	
01CL	Colon	NRM		Normal	
06CV	Cervix	NRM		Normal	
01ES	Esophagus	NRM		Normal	
46HR	Heart	NRM		Normal	
00HR	Human Reference	CAN	CAN	Cancer pool	
55KD	Kidney	NRM		Normal	
89LV	Liver	NRM		Normal	
90LN	Lung	NRM		Normal	
01MA	Mammary	NRM		Normal	

84MU	Skeletal Muscle	NRM		Normal	
3APV	Ovary	NRM		Normal	
04PA	Pancreas	NRM		Normal	
59PL	Placenta	NRM		Normal	
09PR	Prostate	NRM		Normal	
21RC	Rectum	NRM		Normal	
59SM	Small Intestine	NRM		Normal	
7GSP	Spleen	NRM		Normal	
09ST	Stomach	NRM		Normal	
4GTS	Testes	NRM		Normal	
99TM	Thymus Gland	NRM		Normal	
16TR	Trachea	NRM		Normal	
57UT	Uterus	NRM		Normal	

DEX0455_019.nt.1 (Ovr224)

The relative expression level of Ovr224 in various tissue samples is included below. Tissue samples include 68 pairs of matching samples, 10 non matched cancer samples, and 39 normal samples, all from various tissues annotated in the table. A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. Of the normal samples 4 were blood samples which measured the expression levels in blood cells. Additionally, 2 prostatitis, and 4 Benign Prostatic Hyperplasia (BPH) samples are included. All the values are compared to ovarian cancer sample OVR7730 (calibrator).

The table below contains the relative expression level values for the sample as compared to the calibrator. The table includes the Sample ID, and expression level values for the following samples: Cancer (CAN), Normal Adjacent Tissue (NAT), Normal Tissue (NRM), Benign Prostatic Hyperplasia (BPH), and Prostatitis (PROST).

Sample ID	CAN	NAT	NRM	BPH	PROST
OVRA084	0.01	0.00			
OVRG010	0.00	0.06			
OVRG021	0.03	0.03			
OVR1157	0.36				
OVR7730	1.00				
OVR8140	0.02				
OVRC360	0.02				
OVR10050	0.35				
OVR10400	0.10				
OVR1050	0.00				
OVR130X	0.44				
OVR7180	0.02				
OVRA1B	0.04				

OVR247A			0.00		
OVR35GA			0.00		
OVR087			0.00		
OVR109			0.00		
OVR206I			0.00		
OVR515O			0.00		
OVR18GA			0.00		
OVR337O			0.00		
OVR123O			0.00		
OVR177			0.02		
OVR40G			0.00		
OVR004			0.00		
BLD030B	0.00	0.00			
BLDTR17	0.00	0.03			
CLN401C	0.00	0.00			
CLNAS98	0.02	0.00			
CLNCM12	0.00	0.02			
CLNDC19	0.02	0.00			
CLNRC01	0.00	0.01			
CLNRS53	0.14	0.00			
CLNSG27	0.00	0.00			
CLNTX01	0.00	0.00			
CVXKS52	0.00	0.03			
CVXNK23	0.01	0.00			
CVXNKS54	0.00	0.25			
CVXNKS55	0.06	0.17			
CVXNKS81	0.87	0.00			
ENDO10479	0.03	0.00			
ENDO28XA	0.00	0.00			
ENDO8XA	0.02	0.00			
KID106XD	0.00	0.08			
KID107XD	0.00	0.07			
KID109XD	0.06	0.37			
KID10XD	0.00	0.02			
KID22K	0.00	0.00			
LNG205L	0.00	0.33			
LNG315L	0.00	0.53			
LNG507L	0.21	0.43			
LNG528L	0.00	2.39			
LNG8837L	0.02	0.13			
LNGAC11	0.32	0.23			
LNGSQ80	0.00	0.00			
LVR187L	0.00	0.04			
MAM19DN	0.00	0.00			
MAM42DN	0.13	0.00			
MAM517	0.62	0.00			
MAM781M	0.00	0.00			

MAM869M	0.00	0.42			
MAM976M	0.00	0.00			
MAMS570	0.00	0.00			
MAMS699	0.00	0.00			
MAMS997	0.00	0.00			
PAN71XL	0.01	0.04			
PAN82XP	0.01	0.00			
PAN92X	0.00	0.00			
PRO23B	0.02	0.03			
PRO65XB	0.01	0.02			
PRO675P	0.07	0.00			
PRO84XB	0.02	0.09			
PRO958P	0.00	0.04			
PRO263C				0.00	
PRO276P				0.00	
PRO767B				0.04	
PRO855P				0.00	
PRO10R					0.00
PRO20R					0.00
SKN287S	0.00	0.00			
SKN39A	0.62	0.73			
SKN669S	0.02	0.00			
SMINT171S	0.00	0.00			
SMINT20SM	0.04	0.00			
SMINTH89	0.01	0.00			
STO261S	0.00	0.00			
STO288S	0.00	0.03			
STO88S	0.04	0.03			
THRD143N	0.00	0.04			
THRD270T	0.05	0.03			
THRD56T	0.44	0.05			
TST39X	0.00	0.33			
TST647T	0.02	0.07			
TST663T	0.05	0.01			
UTR135XO	0.05	0.00			
UTR85XU	0.03	0.00			
BLOB1			9.03		
BLOB3			0.71		
BLOB6			5.37		
BLOB11			3.85		
BLO982B			0.93		
ADR48AD			0.00		
BRN10BR			0.00		
CLN01CL			0.00		
ESO01ES			0.22		
HRT46HR			0.00		
HUMREF00HR	0.00				

KID55KD			0.03		
LVR89LV			0.00		
LNG90LN			0.01		
MAM01MA			0.00		
MSL84MU			0.00		
OVR3APV			0.01		
PAN04PA			0.00		
PLA59PL			0.00		
PRO09PR			0.00		
REC21RC			0.00		
SMINT59SM			0.01		
SPL7GSP			0.63		
STO09ST			0.00		
THYM99TM			0.00		
TRA16TR			0.00		
TST4GTS			0.03		
UTR57UT			0.00		

Note: 0.00= Negative or Not Detected

The sensitivity for Ovr224 expression was calculated for the cancer samples versus normal samples. The sensitivity value indicates the percentage of cancer samples that show levels of Ovr224 at least 2 fold higher than the normal tissue or the corresponding normal adjacent form the same patient.

This specificity is an indication of the level of ovary tissue specific expression of the transcript compared to all the other tissue types tested in our assay. Thus, these experiments indicate Ovr224 being useful as an ovarian cancer diagnostic marker and/or therapeutic target.

Sensitivity and specificity data is reported in the table below.

	CLN	LNG	MAM	OV R	PRO
Sensitivity, Up vs. NAT	44%	0%	22%	0%	20%
Sensitivity, Down vs. NAT	22%	56%	11%	0%	40%
Sensitivity, Up vs. NRM	44%	33%	22%	92%	80%
Sensitivity, Down vs. NRM	0%	44%	0%	0%	0%
Specificity	47.03%	54.59%	45.41%	56%	52.41%

Altogether, the tissue specificity, plus the mRNA differential expression in the samples tested are believed to make Ovr224 a good marker for diagnosing, monitoring, staging, imaging and/or treating ovarian cancer.

Primers used for QPCR Expression Analysis of Ovr224 are as follows:

(Ovr224_forward): TCCTCAAGGGCCCTCCCCAG (SEQ ID NO:296)

(Ovr224_reverse): CCACAGCCATCTCCTCCATATTCTG (SEQ ID NO:297)

(Ovr224_probe): AAGTGTTCTCTGGATGACCTACCTGG (SEQ ID NO:298)

5

DEX0455_031.nt.2 (Cln257)

The relative expression level of Cln257 in various tissue samples is included below.

Tissue samples include 78 pairs of matching samples, 6 non matched cancer samples, and 35 normal samples, all from various tissues annotated in the table. A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. Of the normal samples 5 were blood samples which measured the expression levels in blood cells. Additionally, 2 prostatitis, and 4 Benign Prostatic Hyperplasia (BPH) samples are included. All the values are compared to normal colon sample CLN01CL (calibrator).

15

The table below contains the relative expression level values for the sample as compared to the calibrator. The table includes the Sample ID, and expression level values for the following samples: Cancer (CAN), Normal Adjacent Tissue (NAT), Normal Tissue (NRM), Benign Prostatic Hyperplasia (BPH), and Prostatitis (PROST).

Sample ID	CAN	NAT	NRM	BPH	PROST
CLNAS12	5.55	10.39			
CLNAS46	6.28	3.22			
CLNB34	1.78	3.88			
CLNC9XR	2.76	3.35			
CLNCM67	2.91	2.44			
CLNTX89	6.56	5.08			
CLNAS43	27.92	6.39			
CLNAS98	6.93	5.42			
CLNRS53	8.04	6.77			
CLNRC01	9.91	2.51			
CLNSG27	4.56	7.39			
CLNDC19	3.97	3.84			
CLN401C	7.09	4.98			
CLNCM12	3.28	6.25			
CLNTX01	16.34	8.61			
BLD030B	2.29	2.59			
BLD520B	12.82	14.74			
BLDTR17	10.50	5.28			
CVXKS52	12.36	17.89			

CVXNK23	12.42	62.77			
CVXNKS54	24.16	13.33			
CVXNKS55	15.58	17.45			
CVXNKS81	84.82	132.51			
ENDO10479	15.86	25.40			
ENDO28XA	12.96	13.04			
ENDO8XA	12.25	3.60			
KID106XD	0.32	1.89			
KID107XD	29.14	4.27			
KID109XD	8.21	5.31			
KID10XD	5.61	0.84			
KID22K	2.84	1.47			
LNG205L	8.83	9.05			
LNG315L	16.63	28.85			
LNG507L	13.87	27.96			
LNG528L	20.05	27.89			
LNG8837L	16.21	10.02			
LNGAC11	15.21	14.83			
LNGAC39	49.00	16.41			
LNGSQ80	18.40	11.35			
LNGSQ81	7.80	54.12			
LVR15XA	9.04	2.93			
LVR174L	4.08	6.13			
LVR187L	3.52	3.60			
MAM19DN	14.68	14.78			
MAM42DN	12.41	26.01			
MAM517	133.69	12.41			
MAM781M	23.89	12.22			
MAM869M	7.84	17.28			
MAM976M	39.22	32.92			
MAMS570	21.06	26.04			
MAMS699	6.70	0.00			
MAMS997	11.37	13.47			
OVRG021	9.65	18.53			
OVR1005O	36.75				
OVR1040O	14.88				
OVR105O	8.82				
OVR130X	32.30				
OVR718O	22.87				
OVRA1B	15.50				
OVR123O			16.94		
OVR18GA			13.92		
OVR206I			15.98		

OVR337O			13.2 8		
OVR40G			20.2 3		
OVR515O			26.9 7		
OVR004			54.2 1		
OVR0177			6.97		
PAN71XL	9.65	8.64			
PAN82XP	7.20	24.22			
PAN92X	8.74	26.55			
PRO23B	13.10	14.00			
PRO65XB	6.20	10.57			
PRO675P	20.64	27.15			
PRO84XB	10.46	10.35			
PRO958P	11.48	10.47			
PRO263C				35.8 7	
PRO276P				7.20	
PRO767B				17.0 9	
PRO855P				8.27	
PRO10R					16.9 2
PRO20R					15.2 7
SKN287S	8.51	9.87			
SKN39A	12.75	8.64			
SKN669S	8.95	23.59			
SMINT171S	9.57	15.19			
SMINT20SM	30.83	12.12			
SMINTH89	10.91	10.48			
STO261S	16.09	3.67			
STO288S	8.76	3.43			
STO88S	14.77	4.27			
THRD143N	6.43	17.06			
THRD270T	25.28	27.05			
THRD56T	12.28	9.55			
TST39X	7.03	1.37			
TST647T	4.87	5.35			
TST663T	10.23	3.49			
UTR135XO	10.47	13.31			
UTR85XU	25.28	27.08			
BLOB1			82.9 9		
BLOB3			15.8 4		

BLOB6			81.3 1		
BLOB11			12.6 8		
BLO982B			3.82		
ADR48AD			1.96		
HUMREF00H R	0.94				
BRN10BR			0.00		
CLN01CL			1.00		
ESO01ES			4.70		
HRT46HR			0.59		
KID55KD			0.58		
LVR89LV			1.93		
LNG90LN			3.14		
MAM01MA			6.01		
MSL84MU			0.21		
OVR3APV			5.62		
PAN04PA			3.59		
PLA59PL			5.14		
PRO09PR			3.40		
REC21RC			8.88		
SMINT59SM			3.09		
SPL7GSP			3.91		
STO09ST			2.19		
THYM99TM			4.39		
TRA16TR			6.32		
TST4GTS			1.10		
UTR57UT			14.3 6		

0.00= Negative or Not Detected

The sensitivity for Cln257 expression was calculated for the cancer samples versus normal samples. The sensitivity value indicates the percentage of cancer samples that show levels of Cln257 at least 2 fold higher than the normal tissue or the corresponding normal adjacent form the same patient.

This specificity is an indication of the level of colon tissue specific expression of the transcript compared to all the other tissue types tested in our assay. Thus, these experiments indicate Cln257 being useful as an colon cancer diagnostic marker and/or therapeutic target.

Sensitivity and specificity data is reported in the table below.

	CLN	LNG	MAM	OVR	PRO
Sensitivity, Up vs. NAT	13%	11%	22%	0%	0%

Sensitivity, Down vs. NAT	7%	22%	22%	0%	0%
Sensitivity, Up vs. NRM	93%	100%	67%	29%	80%
Sensitivity, Down vs. NRM	0%	0%	0%	0%	0%
Specificity	3.47%	6.49%	5.95%	6.42%	5.35%

Altogether, the tissue specificity, plus the mRNA differential expression in the samples tested are believed to make Cln257 a good marker for diagnosing, monitoring, staging, imaging and/or treating colon cancer.

- 5 Primers used for QPCR Expression Analysis of Cln257 are as follows:
 (Cln257_forward): CTGAAGCCGAGCTCAAAGGT (SEQ ID NO:299)
 (Cln257_reverse): CCCTGCTCCCACTTGAGATC (SEQ ID NO:300)
 (Cln257_probe): TGTGAAAAGGAGGCTGGGTGCCAG (SEQ ID NO:301)

10 DEX0455_034.nt.1 and DEX0455_034.nt.2 (Ovr223)

The relative expression level of Ovr223 in various tissue samples is included below. Tissue samples include 75 pairs of matching samples, 11 non matched cancer samples, and 39 normal samples, all from various tissues annotated in the table. A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. Of the normal samples 4 were blood samples which measured the expression levels in blood cells. Additionally, 2 prostatitis, and 4 Benign Prostatic Hyperplasia (BPH) samples are included. All the values are compared to ovarian cancer sample OVR773O (calibrator).

- 15 The table below contains the relative expression level values for the sample as compared to the calibrator. The table includes the Sample ID, and expression level values for the following samples: Cancer (CAN), Normal Adjacent Tissue (NAT), Normal Tissue (NRM), Benign Prostatic Hyperplasia (BPH), and Prostatitis (PROST).

Sample ID	CAN	NAT	NRM	BPH	PROST
OVRA084	0.12	0.05			
OVRG010	0.04	0.24			
OVRG021	0.16	0.05			
OVR1157	0.32				
OVR773O	1.00				
OVR814O	0.06				
OVRC360	0.00				
OVR1005O	0.75				

OVR10400	0.97				
OVR1050	0.80				
OVR130X	2.15				
OVR7180	0.80				
OVRA1B	1.90				
OVR247A			0.00		
OVR35GA			0.03		
OVR087			0.06		
OVR0109			0.04		
OVR206I			0.00		
OVR5150			0.00		
OVR18GA			0.12		
OVR3370			0.00		
OVR1230			0.00		
OVR0177			0.03		
OVR40G			0.02		
OVR004			0.00		
BLD030B	0.00	0.00			
BLD520B	0.74	0.02			
BLDTR17	0.00	0.11			
CLN401C	0.40	0.35			
CLNAS43	1.05	0.16			
CLNAS98	0.16	0.25			
CLNCM12	0.21	0.31			
CLNDC19	0.47	0.17			
CLNRC01	0.31	0.31			
CLNRS53	0.18	1.03			
CLNSG27	0.00	0.29			
CLNTX01	0.36	0.25			
CVXKS52	0.00	0.74			
CVXNK23	0.68	2.29			
CVXNKS54	1.18	2.21			
CVXNKS55	0.92	0.82			
CVXNKS81	1.72				
ENDO10479	0.48	1.16			
ENDO28XA	1.17	0.25			
ENDO8XA	0.52	0.13			
KID106XD	0.05	0.05			
KID107XD	0.00	0.21			
KID109XD	0.14	0.61			
KID10XD	0.00	0.06			
KID22K	0.21	0.10			
LNG205L	0.23	0.00			
LNG315L	0.15	2.19			
LNG507L	0.37	0.82			
LNG528L	2.95	0.60			
LNG8837L	0.45	0.70			

LNGAC11	0.17	0.54			
LNGAC39	1.86	0.23			
LNGSQ80	0.82	0.00			
LNGSQ81	1.06	0.69			
LVR174L	0.00	0.00			
LVR187L	0.00	0.29			
MAM19DN	1.16	0.87			
MAM42DN	0.60	0.00			
MAM517	7.70	0.00			
MAM781M	0.41	0.74			
MAM869M	0.58	0.00			
MAM976M	1.01	0.42			
MAMS570	2.29	4.07			
MAMS699	0.39	0.00			
MAMS997	1.33	0.86			
PAN71XL	0.44	0.77			
PAN82XP	0.10	7.85			
PAN92X	0.49	0.81			
PRO23B	0.15	0.19			
PRO65XB	0.20	0.52			
PRO675P	0.43	0.32			
PRO84XB	0.43	0.45			
PRO958P	0.46	0.52			
PRO263C				0.00	
PRO276P				0.13	
PRO767B				0.48	
PRO855P				0.28	
PRO10R					0.34
PRO20R					0.95
SKN287S	0.49	0.46			
SKN39A	0.00	0.16			
SKN669S	0.38	2.09			
SMINT171S	0.70	0.51			
SMINT20SM	0.83	0.31			
SMINTH89	0.43	1.27			
STO261S	1.61	0.52			
STO288S	0.39	0.16			
STO88S	0.00	0.18			
THRD143N	0.25	0.45			
THRD270T	0.95	2.10			
THRD56T	2.62	0.23			
TST39X	0.47	0.90			
TST647T	0.38	0.16			
TST663T	0.30	0.02			
UTR135XO	0.09	0.30			
UTR85XU	1.07	0.59			
BLOB1			0.00		

BLOB6			0.00		
BLOB11			0.95		
BLO982B			0.00		
ADR48AD			0.00		
BRN10BR			0.00		
CLN01CL			0.04		
CVX1ACV			7.20		
ESO01ES			0.56		
HRT46HR			0.00		
HUMREF00HR	0.00				
KID55KD			0.01		
LVR89LV			0.00		
LNG90LN			0.26		
MAM01MA			0.10		
MSL84MU			0.00		
OVR3APV			0.03		
PAN04PA			0.11		
PLA59PL			0.33		
PRO09PR			0.27		
REC21RC			0.18		
SMINT59SM			0.09		
SPL7GSP			0.06		
STO09ST			0.21		
THYM99TM			0.00		
TRA16TR			0.69		
TST4GTS			0.00		
UTR57UT			0.14		

0.00= Negative or Not Detected

The sensitivity for Ovr223 expression was calculated for the cancer samples versus normal samples. The sensitivity value indicates the percentage of cancer samples that show levels of Ovr223 at least 2 fold higher than the normal tissue or the corresponding normal adjacent form the same patient.

This specificity is an indication of the level of ovary tissue specific expression of the transcript compared to all the other tissue types tested in our assay. Thus, these experiments indicate Ovr223 being useful as an ovarian cancer diagnostic marker and/or therapeutic target.

Sensitivity and specificity data is reported in the table below.

	CLN	LNG	MAM	OVR	PRO
Sensitivity, Up vs. NAT	22%	44%	56%	0%	0%
Sensitivity, Down vs. NAT	22%	33%	0%	0%	20%
Sensitivity, Up vs. NRM	89%	44%	100%	85%	0%

256

Sensitivity, Down vs. NRM	11%	0%	0%	8%	0%
Specificity	24.32%	25.41%	30.81%	22.86%	25.67%

Altogether, the tissue specificity, plus the mRNA differential expression in the samples tested are believed to make Ovr223 a good marker for diagnosing, monitoring, staging, imaging and/or treating ovarian cancer.

- 5 Additionally, the tissue specificity, plus the mRNA differential expression in the samples tested may make Ovr223 a good marker for diagnosing, monitoring, staging, imaging and/or treating breast cancer.

Primers used for QPCR Expression Analysis of Ovr223 are as follows:

(Ovr223_forward): AGTGAGAGGGTGGGCATGTATG (SEQ ID NO:302)

- 10 (Ovr223_reverse): TACTCCAGGCGCTCTGAGGAT (SEQ ID NO:303)

(Ovr223_probe): TTAGCCAGTGGCCTCCACTCTGTCCC (SEQ ID NO:304)

DEX0455_034.nt.4 (Ovr223v2)

- 15 The relative expression level of Ovr223v2 in various tissue samples is included below. Tissue samples include 74 pairs of matching samples, 11 non matched cancer samples, and 39 normal samples, all from various tissues annotated in the table. A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. Of the normal samples 4 were blood samples which measured the expression levels in blood cells. Additionally, 2 prostatitis, and 4 Benign Prostatic Hyperplasia (BPH) samples are included. All the values are compared to normal pancreas sample PAN04PA (calibrator).

- 20 The table below contains the relative expression level values for the sample as compared to the calibrator. The table includes the Sample ID, and expression level values for the following samples: Cancer (CAN), Normal Adjacent Tissue (NAT), Normal Tissue (NRM), Benign Prostatic Hyperplasia (BPH), and Prostatitis (PROST).

Sample ID	CAN	NAT	NRM	BPH	PROST
OVRA084	0.25	0.00			
OVRG010	4.93				
OVRG021	0.40	0.06			
OVR1157	3.69				
OVR7730	7.06				
OVR988Z	1.93				
OVR360	0.34				

OVR10050	2.85				
OVR10400	3.20				
OVR1050	3.02				
OVR130X	1.84				
OVR7180	2.15				
OVRA1B	7.99				
OVR247A			0.44		
OVR35GA			0.21		
OVRC087			0.23		
OVRC109			0.20		
OVR206I			0.11		
OVR5150			0.12		
OVR18GA			0.07		
OVR3370			0.20		
OVR1230			0.93		
OVRC177			0.10		
OVR40G			0.05		
OVR4510			0.32		
BLD030B	0.20	1.10			
BLD520B	2.00	0.18			
BLDTR17	0.39	1.04			
CLN401C	0.85	1.23			
CLNAS43	2.68	0.16			
CLNAS98	0.61	0.35			
CLNCM12	0.61	0.80			
CLNDC19	1.94	1.18			
CLNRC01	0.46	0.42			
CLNRS53	0.54	1.26			
CLNSG27	0.61	0.65			
CLNTX01	1.62	0.59			
CVXKS52	3.54	4.98			
CVXNKS55	7.35	4.40			
CVXNKS25	4.23	4.81			
CVXNKS18	1.26	3.88			
CVXNKS54	3.00	1.47			
ENDO10479	3.07	0.37			
ENDO28XA	4.24	0.69			
ENDO8XA	0.31	3.57			
KID106XD	0.11	0.33			
KID12XD	0.27	2.13			
KID10XD	0.10	0.21			
KID22K	0.60	0.28			
KID107XD	0.16	0.44			
LNG205L	0.81	1.09			
LNG315L	0.89	2.02			
LNG507L	1.16	1.68			
LNG528L	9.15	1.43			

LNG8837L	1.46	1.65			
LNGAC11	0.86	1.78			
LNGAC39	6.93	1.66			
LNGSQ80	1.13	0.32			
LNGSQ81	1.95	1.13			
LVR15XA	0.01	0.03			
LVR174L	0.00	0.01			
LVR187L	0.00	2.35			
MAM19DN	3.52	3.45			
MAM42DN	0.83	1.62			
MAM517	10.39	3.02			
MAM781M	1.80	0.34			
MAM869M	1.85	0.13			
MAM976M	4.08	0.67			
MAMS570	2.43	4.41			
MAMS699	1.16	1.50			
MAMS997	1.20	1.39			
PAN71XL	1.91	1.83			
PAN77X	0.00	0.02			
PAN92X	3.25	0.25			
PRO10R					2.41
PRO20R					1.07
PRO23B	1.32	1.17			
PRO263C				1.30	
PRO276P				0.88	
PRO65XB	0.87	1.60			
PRO675P	1.50	0.69			
PRO767B				4.10	
PRO84XB	1.41	1.13			
PRO855P				1.16	
PRO958P	2.49	2.56			
SKN287S	0.76	0.57			
SKN39A	0.25	0.20			
SKN669S	0.60	1.12			
SMINT171S	1.06	2.38			
SMINT20SM	3.20	1.14			
SMINTH89	1.92	1.80			
STO261S	3.86	0.75			
STO288S	1.00	0.23			
STOAC93	0.66	2.01			
STO88S	2.57	0.20			
THRD143N	1.77	1.15			
THRD270T	2.23	2.56			
THRD56T	3.02	0.40			
TST39X	0.80	0.77			
TST647T	1.15	0.43			
TST663T	0.55	0.05			

UTR135XO	0.58	0.52			
UTR85XU	2.70	1.49			
BLOB3			0.19		
BLOB11			0.93		
BLO69			0.10		
BLO72			0.06		
BLO73			0.13		
ADR48AD			0.15		
BRN10BR			0.00		
CLN01CL			1.03		
CVX06CV			0.48		
ESO01ES			3.34		
HRT46HR			0.01		
HUMREF00HR	0.08				
KID55KD			0.27		
LVR89LV			0.03		
LNG90LN			3.99		
MAM01MA			2.38		
MSL84MU			0.00		
OVR3APV			0.13		
PAN04PA			1.00		
PRO09PR			3.27		
REC21RC			2.01		
SMINT59SM			0.55		
SPL7GSP			0.46		
STO09ST			0.98		
THYM99TM			0.54		
TRA16TR			3.04		
TST4GTS			0.10		
UTR57UT			0.43		

0.00= Negative or Not Detected

The sensitivity for Ovr223v2 expression was calculated for the cancer samples versus normal samples. The sensitivity value indicates the percentage of cancer samples that show levels of Ovr223v2 at least 2 fold higher than the normal tissue or the corresponding normal adjacent form the same patient.

This specificity is an indication of the level of ovary tissue specific expression of the transcript compared to all the other tissue types tested in our assay. Thus, these experiments indicate Ovr223v2 being useful as an ovarian cancer diagnostic marker and/or therapeutic target.

Sensitivity and specificity data is reported in the table below.

	CLN	LNG	MAM	OVR	PRO
Sensitivity, Up vs. NAT	22%	33%	44%	0%	20%

Sensitivity, Down vs. NAT	11%	22%	0%	0%	0%
Sensitivity, Up vs. NRM	11%	11%	11%	85%	0%
Sensitivity, Down vs. NRM	11%	78%	22%	0%	80%
Specificity	8.06%	12.9%	16.67%	19.77%	14.89%

Altogether, the tissue specificity, plus the mRNA differential expression in the samples tested are believed to make Ovr223v2 a good marker for diagnosing, monitoring, staging, imaging and/or treating ovarian cancer.

- 5 Primers used for QPCR Expression Analysis of Ovr223v2 are as follows:
 (Ovr223v2_forward): TCCAGATGGCTCAGCTTCTTC (SEQ ID NO:305)
 (Ovr223v2_reverse): GAAGGTGTTTCGGAGAATGAGTGA (SEQ ID NO:306)
 (Ovr223v2_probe): TTTCTTCTGTGGCTCTGTGTTTCCAGGC (SEQ ID NO:307)

10

DEX0455_037.nt.6 (Ovr229)

- The relative expression level of Ovr229 in various tissue samples is included below. Tissue samples include 74 pairs of matching samples, 10 non matched cancer samples, and 40 normal samples, all from various tissues annotated in the table. A matching pair is
- 15 formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. Of the normal samples 5 were blood samples which measured the expression levels in blood cells. Additionally, 2 prostatitis, and 4 Benign Prostatic Hyperplasia (BPH) samples are included. All the values are compared to normal prostate sample PRO09PR (calibrator).

- 20 The table below contains the relative expression level values for the sample as compared to the calibrator. The table includes the Sample ID, and expression level values for the following samples: Cancer (CAN), Normal Adjacent Tissue (NAT), Normal Tissue (NRM), Benign Prostatic Hyperplasia (BPH), and Prostatitis (PROST).

Sample ID	CAN	NAT	NRM	BPH	PROST
OVRA084	0.01	0.00			
OVRG010	0.36	0.00			
OVRG021	0.39	0.09			
OVR1157	0.00				
OVR773O	0.31				
OVR988Z	1.25				
OVR360	1.64				

OVR1005O	0.47				
OVR1040O	1.49				
OVR105O	0.33				
OVR130X	0.00				
OVR718O	0.42				
OVRA1B	0.27				
OVR247A			0.00		
OVR35GA			0.05		
OVRC087			0.40		
OVRC109			0.00		
OVR206I			0.12		
OVR515O			0.42		
OVR18GA			0.00		
OVR337O			0.00		
OVR123O			0.00		
OVRC177			0.22		
OVR40G			0.00		
OVR451O			0.00		
BLD030B	0.04	0.14			
BLD520B	0.00	0.23			
BLDTR17	0.37	0.19			
CLN401C	0.04	0.04			
CLNAS43	0.10	0.14			
CLNAS98	0.00	0.00			
CLNCM12	0.11	0.12			
CLNDC19	0.00	0.09			
CLNRC01	0.01	0.02			
CLNRS53	0.00	0.00			
CLNSG27	0.08	0.31			
CLNTX01	0.00	0.24			
CVXKS52	0.00	0.35			
CVXNKS55	0.03	0.25			
CVXNKS25	1.68	0.25			
CVXNKS18	0.00	0.06			
CVXNKS54	0.00	1.22			
ENDO10479	0.13	0.35			
ENDO28XA	0.18	0.54			
ENDO8XA	0.00	0.05			
KID106XD	0.00	0.02			
KID12XD	0.01	0.37			
KID10XD	0.00	0.01			
KID22K	0.02	0.06			
KID107XD	0.00	0.02			
LNG205L	0.01	1.04			
LNG315L	0.14	1.69			
LNG507L	0.48	3.36			
LNG528L	0.00	0.71			

LNG8837L	0.12	1.08			
LNGAC11	0.10	0.20			
LNGAC39	0.52	2.65			
LNGSQ80	0.16	2.29			
LNGSQ81	0.23	2.01			
LVR15XA	0.00	0.03			
LVR174L	0.00	0.02			
LVR187L	0.00	0.00			
MAM19DN	0.00	0.28			
MAM42DN	0.17	0.00			
MAM517	2.59	0.00			
MAM781M	0.00	0.00			
MAM869M	0.05	0.74			
MAM976M	0.26	0.00			
MAMS570	0.00	0.00			
MAMS699	0.28	0.89			
MAMS997	0.13	0.23			
PAN71XL	0.06	0.09			
PAN77X	0.00	0.05			
PAN92X	0.27	0.00			
PRO10R					1.00
PRO20R					8.84
PRO23B	1.11	1.14			
PRO263C				1.16	
PRO276P				0.93	
PRO65XB	0.14	0.85			
PRO675P	0.42	0.51			
PRO767B				0.88	
PRO84XB	0.15	3.51			
PRO855P				2.76	
PRO958P	0.76	2.69			
SKN287S	0.22	2.01			
SKN39A	0.16	0.00			
SKN669S	0.40	0.00			
SMINT171S	0.02	0.04			
SMINT20SM	0.07	0.15			
SMINTH89	0.05	0.00			
STO261S	0.00	0.11			
STO288S	0.02	0.12			
STOAC93	0.23	0.05			
THRD143N	0.00	0.27			
THRD270T	0.09	0.07			
THRD56T	0.00	0.00			
TST39X	0.00	8.21			
TST647T	0.19	9.27			
TST663T	0.14	10.16			
UTR135XO	0.58	0.35			

UTR85XU	0.00	0.99			
BLOB3			0.00		
BLOB11			0.00		
BLO69			0.00		
BLO72			0.17		
BLO73			0.00		
ADR48AD			0.00		
BRN10BR			2.25		
CLN01CL			0.10		
CVX06CV			2.46		
ESO01ES			0.00		
HRT46HR			0.88		
HUMREF00HR	0.00				
KID55KD			0.02		
LVR89LV			0.03		
LNG90LN			0.03		
MAM01MA			0.02		
MSL84MU			0.02		
OVR3APV			0.08		
PAN04PA			0.29		
PLA59PL			1.46		
PRO09PR			1.00		
REC21RC			0.67		
SMINT59SM			0.04		
SPL7GSP			0.80		
STO09ST			0.10		
THYM99TM			0.46		
TRA16TR			0.15		
TST4GTS			12.18		
UTR57UT			1.54		

0.00= Negative or Not Detected

The sensitivity for Ovr229 expression was calculated for the cancer samples versus normal samples. The sensitivity value indicates the percentage of cancer samples that show levels of Ovr229 at least 2 fold higher than the normal tissue or the corresponding normal adjacent form the same patient.

This specificity is an indication of the level of ovary tissue specific expression of the transcript compared to all the other tissue types tested in our assay. Thus, these experiments indicate Ovr229 being useful as an ovarian cancer diagnostic marker and/or therapeutic target.

Sensitivity and specificity data is reported in the table below.

	CLN	LNG	MAM	OVR	PRO
Sensitivity, Up vs. NAT	0%	0%	33%	0%	0%

Sensitivity, Down vs. NAT	44%	100%	33%	0%	60%
Sensitivity, Up vs. NRM	0%	78%	67%	85%	0%
Sensitivity, Down vs. NRM	67%	22%	33%	0%	60%
Specificity	26.06%	31.38%	28.19%	35.96%	42.11%

Altogether, the tissue specificity, plus the mRNA differential expression in the samples tested are believed to make Ovr229 a good marker for diagnosing, monitoring, staging, imaging and/or treating ovarian cancer.

- 5 Primers used for QPCR Expression Analysis of Ovr229 are as follows:
 (Ovr229_forward): CCTGCCGCGGAGATCCAT (SEQ ID NO:308)
 (Ovr229_reverse): GCAGCGCGTACTGGTCGTA (SEQ ID NO:309)
 (Ovr229_probe): CCTACTCCGTGTCAGTGGTGGAG (SEQ ID NO:310)

10 DEX0455_037.nt.7 (Ovr227)

- The relative expression level of Ovr227 in various tissue samples is included below. Tissue samples include 74 pairs of matching samples, 10 non matched cancer samples, and 39 normal samples, all from various tissues annotated in the table. A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the
 15 normal adjacent sample for that same tissue from the same individual. Of the normal samples 5 were blood samples which measured the expression levels in blood cells. Additionally, 2 prostatitis, and 4 Benign Prostatic Hyperplasia (BPH) samples are included. All the values are compared to prostate normal sample PRO09PR (calibrator).

- The table below contains the relative expression level values for the sample as
 20 compared to the calibrator. The table includes the Sample ID, and expression level values for the following samples: Cancer (CAN), Normal Adjacent Tissue (NAT), Normal Tissue (NRM), Benign Prostatic Hyperplasia (BPH), and Prostatitis (PROST).

Sample ID	CAN	NAT	NRM	BPH	PROST
OVRA084	1.31	0.24			
OVRG010	1.65	0.75			
OVRG021	0.87	0.00			
OVR1157	0.85				
OVR7730	0.21				
OVR8140	0.24				
OVR360	0.58				
OVR10050	0.33				

OVR1040O	0.11				
OVR105O	0.12				
OVR130X	0.15				
OVR718O	0.32				
OVRA1B	0.11				
OVR247A			0.40		
OVR35GA			0.06		
OVRC087			0.16		
OVRC109			0.08		
OVR206I			0.00		
OVR515O			0.63		
OVR18GA			0.00		
OVR337O			0.00		
OVR123O			0.00		
OVRC177			0.03		
OVR40G			0.02		
OVRC004			0.00		
BLD030B	0.02	0.00			
BLD520B	0.00	0.06			
BLDTR17	0.00	0.00			
CLN401C	0.02	0.04			
CLNAS43	0.00	0.00			
CLNAS98	0.00	0.09			
CLNCM12	0.06	0.05			
CLNDC19	0.04	0.10			
CLNRC01	0.00	0.00			
CLNRS53	0.18	0.40			
CLNSG27	0.00	0.28			
CLNTX01	0.58	0.00			
CVXKS52	0.00	0.49			
CVXNK23	0.00	0.00			
CVXNKS54	1.12	2.58			
CVXNKS55	0.01	0.00			
CVXNKS81	0.00	0.00			
ENDO10479	0.00	2.93			
ENDO28XA	0.76	0.52			
ENDO8XA	0.03	0.00			
KID106XD	0.00	0.00			
KID107XD	0.00	0.04			
KID109XD	0.00	0.00			
KID10XD	0.21	0.02			
KID22K	0.01	0.02			
LNG205L	0.00	0.35			
LNG315L	0.33	1.50			
LNG507L	0.24	2.81			
LNG528L	0.00	0.42			
LNG8837L	0.18	1.12			

LNGAC11	0.20	0.04			
LNGAC39	0.59	1.37			
LNGSQ80	1.38	1.09			
LNGSQ81	0.65	1.59			
LVR15XA	0.00	0.02			
LVR174L	0.00	0.01			
LVR187L	0.00	0.09			
MAM19DN	0.00	0.07			
MAM42DN	0.16	0.00			
MAM517	0.00	0.00			
MAM781M	0.00	0.24			
MAM869M	0.00	0.00			
MAM976M	0.12	0.00			
MAMS570	0.00	0.00			
MAMS699	0.53	0.00			
MAMS997	0.20	0.11			
PAN71XL	0.00	0.03			
PAN82XP	0.00	0.00			
PAN92X	0.10	0.78			
PRO23B	0.35	0.20			
PRO65XB	0.05	0.61			
PRO675P	0.22	0.40			
PRO84XB	0.12	1.68			
PRO958P	0.18	0.31			
PRO263C				0.32	
PRO276P				0.21	
PRO767B				0.69	
PRO855P				0.29	
PRO10R					0.38
PRO20R					1.35
SKN287S	0.00	2.19			
SKN39A	0.17	0.00			
SKN669S	0.14	0.12			
SMINT171S	0.39	0.15			
SMINT20SM	0.06	0.07			
SMINTH89	0.01	0.00			
STO261S	0.60	0.18			
STO288S	0.03	0.04			
STO88S	0.00	0.07			
THRD143N	0.01	0.04			
THRD270T	0.03	0.03			
THRD56T	0.00	0.14			
TST39X	0.00	1.74			
TST647T	0.02	3.30			
TST663T	0.05	0.68			
UTR135XO	0.22	0.17			
UTR85XU	0.12	0.19			

BLOB1			7.89		
BLOB3			0.00		
BLOB6			0.00		
BLOB11			0.07		
BLO982B			2.25		
ADR48AD			0.00		
BRN10BR			1.02		
CLN01CL			0.00		
ESO01ES			0.25		
HRT46HR			0.10		
HUMREF00HR	0.00				
KID55KD			0.01		
LVR89LV			0.02		
LNG90LN			0.11		
MAM01MA			0.00		
MSL84MU			0.07		
OVR3APV			0.02		
PAN04PA			0.20		
PLA59PL			0.42		
PRO09PR			1.00		
REC21RC			0.28		
SMINT59SM			0.01		
SPL7GSP			1.33		
STO09ST			0.02		
THYM99TM			0.38		
TRA16TR			0.10		
TST4GTS			2.47		
UTR57UT			0.43		

0.00= Negative or Not Detected

The sensitivity for Ovr227 expression was calculated for the cancer samples versus normal samples. The sensitivity value indicates the percentage of cancer samples that show levels of Ovr227 at least 2 fold higher than the normal tissue or the corresponding normal adjacent form the same patient.

This specificity is an indication of the level of ovary tissue specific expression of the transcript compared to all the other tissue types tested in our assay. Thus, these experiments indicate Ovr227 being useful as an ovarian cancer diagnostic marker and/or therapeutic target.

Sensitivity and specificity data is reported in the table below.

	CLN	LNG	MAM	OVR	PRO
Sensitivity, Up vs. NAT	11%	11%	33%	0%	0%
Sensitivity, Down vs. NAT	67%	78%	22%	0%	40%

Sensitivity, Up vs. NRM	56%	56%	44%	100%	0%
Sensitivity, Down vs. NRM	0%	22%	0%	0%	100%
Specificity	28.11%	40.54%	25.41%	42.86%	39.04%

Altogether, the tissue specificity, plus the mRNA differential expression in the samples tested are believed to make Ovr227 a good marker for diagnosing, monitoring, staging, imaging and/or treating ovarian cancer.

- 5 Primers used for QPCR Expression Analysis of Ovr227 are as follows:
 (Ovr227_forward): AGAGGCGCCCCCGCAGGTA (SEQ ID NO:311)
 (Ovr227_reverse): CCCGGAGCCAGCTCGAGTT (SEQ ID NO:312)
 (Ovr227_probe): CAGGAAGTGC GGCGAGCGACCC (SEQ ID NO:313)

10 DEX0455_040.nt.2 (Ovr218)

 The relative expression level of Ovr218 in various tissue samples is included below. Tissue samples include 75 pairs of matching samples, 10 non matched cancer samples, and 41 normal samples, all from various tissues annotated in the table. A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the
 15 normal adjacent sample for that same tissue from the same individual. Of the normal samples 6 were blood samples which measured the expression levels in blood cells. Additionally, 2 prostatitis, and 4 Benign Prostatic Hyperplasia (BPH) samples are included. All the values are compared to cancer pool reference HUMREF00HR (calibrator).

 The table below contains the relative expression level values for the sample as
 20 compared to the calibrator. The table includes the Sample ID, and expression level values for the following samples: Cancer (CAN), Normal Adjacent Tissue (NAT), Normal Tissue (NRM), Benign Prostatic Hyperplasia (BPH), and Prostatitis (PROST).

Sample ID	CAN	NAT	NRM	BPH	PROST
OVRA084	0.46	0.17			
OVRG010	1.55	3.95			
OVRG021	6.74	6.08			
OVR1157	4.90				
OVR7730	8.80				
OVR8140	3.90				
OVR0360	1.37				
OVR10050	19.92				
OVR10400	20.35				
OVR1050	5.63				

OVR130X	19.60				
OVR7180	55.03				
OVRA1B	34.34				
OVR247A			1.35		
OVR35GA			2.50		
OVRC087			0.98		
OVRC109			0.23		
OVR206I			3.37		
OVR5150			1.42		
OVR18GA			1.49		
OVR3370			3.54		
OVR1230			3.29		
OVRC177			3.49		
OVR40G			1.62		
OVRC004			9.36		
BLD030B	3.36	0.72			
BLD520B	3.23	2.25			
BLDTR17	1.08	1.89			
CLN401C	3.90	3.01			
CLNAS43	4.55	1.92			
CLNAS98	3.44	2.33			
CLNCM12	3.07	3.22			
CLNDC19	7.72	2.05			
CLNRC01	1.80	2.17			
CLNRS53	2.59	3.02			
CLNSG27	2.69	4.49			
CLNTX01	5.68	5.10			
CVXKS52	9.10	10.59			
CVXNK23	9.81	41.11			
CVXNKS54	20.97	12.22			
CVXNKS55	37.01	21.89			
CVXNKS81	17.75	35.18			
ENDO10479	13.27	1.33			
ENDO28XA	13.53	4.98			
ENDO8XA	0.34	0.58			
KID106XD	0.28	0.70			
KID107XD	5.01	2.27			
KID109XD	7.16	4.83			
KID10XD	1.34	0.46			
KID22K	2.79	0.65			
LNG205L	1.40	4.10			
LNG315L	8.68	8.32			
LNG507L	6.50	4.85			
LNG528L	9.26	4.03			
LNG8837L	4.36	5.37			
LNGAC11	2.50	4.70			
LNGAC39	16.03	4.63			

LNGSQ80	3.70	0.84			
LNGSQ81	14.10	7.33			
LVR15XA	0.05	0.03			
LVR174L	0.15	0.12			
LVR187L	0.00	9.89			
MAM19DN	17.32	17.15			
MAM42DN	15.00	9.52			
MAM517	66.52	6.34			
MAM781M	4.45	3.02			
MAM869M	9.21	1.73			
MAM976M	28.64	3.82			
MAMS570	22.00	25.62			
MAMS699	5.42	5.54			
MAMS997	10.63	7.95			
PAN71XL	5.56	5.74			
PAN82XP	2.41	26.35			
PAN92X	52.91	6.82			
PRO23B	7.13	7.97			
PRO65XB	5.61	6.99			
PRO675P	7.00	4.30			
PRO84XB	7.18	6.80			
PRO958P	6.32	4.35			
PRO263C				6.28	
PRO276P				4.78	
PRO767B				10.75	
PRO855P				5.51	
PRO10R					9.97
PRO20R					8.32
SKN287S	6.30	6.42			
SKN39A	4.04	1.83			
SKN669S	6.16	19.67			
SMINT171S	11.57	8.96			
SMINT20SM	10.72	4.23			
SMINTH89	5.77	4.77			
STO261S	8.85	2.39			
STO288S	2.33	1.18			
STO509L	5.78	10.86			
STO88S	4.07	1.01			
THRD143N	8.25	15.21			
THRD270T	10.97	7.35			
THRD56T	9.88	11.23			
TST39X	9.41	4.59			
TST647T	11.31	1.05			
TST663T	7.35	2.94			
UTR135XO	2.34	5.62			
UTR85XU	17.13	6.68			
BLOB1			7.23		

BLOB3			3.50		
BLOB5			122.49		
BLOB6			9.34		
BLOB11			5.44		
BLO982B			14.78		
ADR48AD			0.61		
BRN10BR			0.99		
CLN01CL			0.51		
CVX1ACV			14.89		
ESO01ES			5.63		
HRT46HR			0.00		
HUMREF00HR	1.00				
KID55KD			0.29		
LVR89LV			0.05		
LNG90LN			2.25		
MAM01MA			1.00		
MSL84MU			0.00		
OVR3APV			0.93		
PAN04PA			2.42		
PLA59PL			3.63		
PRO09PR			3.03		
REC21RC			2.74		
SMINT59SM			2.21		
SPL7GSP			1.19		
STO09ST			0.87		
THYM99TM			5.68		
TRA16TR			8.67		
TST4GTS			9.06		
UTR57UT			1.93		

0.00= Negative or Not Detected

The sensitivity for Ovr218 expression was calculated for the cancer samples versus normal samples. The sensitivity value indicates the percentage of cancer samples that show levels of Ovr218 at least 2 fold higher than the normal tissue or the corresponding normal adjacent form the same patient.

This specificity is an indication of the level of ovary tissue specific expression of the transcript compared to all the other tissue types tested in our assay. Thus, these experiments indicate Ovr218 being useful as an ovarian cancer diagnostic marker and/or therapeutic target.

Sensitivity and specificity data is reported in the table below.

	CLN	LNG	MAM	OVR	PRO
Sensitivity, Up vs. NAT	22%	33%	33%	0%	0%

Sensitivity, Down vs. NAT	0%	11%	0%	0%	0%
Sensitivity, Up vs. NRM	100%	56%	100%	77%	80%
Sensitivity, Down vs. NRM	0%	0%	0%	8%	0%
Specificity	6.88%	9.52%	20.63%	8.94%	9.95%

Altogether, the tissue specificity, plus the mRNA differential expression in the samples tested are believed to make Ovr218 a good marker for diagnosing, monitoring, staging, imaging and/or treating ovarian cancer.

- 5 Additionally, the tissue specificity, plus the mRNA differential expression in the samples tested may make Ovr218 a good marker for diagnosing, monitoring, staging, imaging and/or treating breast cancer.

Primers used for QPCR Expression Analysis of Ovr218 are as follows:

(Ovr218_forward): TGCCCAGCTGTGGTTTACATTA (SEQ ID NO:314)

- 10 (Ovr218_reverse): CACCACCTCGCCATTCTCA (SEQ ID NO:315)

(Ovr218_probe): TTCACTGTGAACATCATCTTGGCA (SEQ ID NO:316)

DEX0455_049.nt.1 (Ovr232)

The relative expression level of Ovr232 in various tissue samples is included below.

- 15 Tissue samples include 73 pairs of matching samples, 10 non matched cancer samples, and 36 normal samples, all from various tissues annotated in the table. A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. Of the normal samples 4 were blood samples which measured the expression levels in blood cells.
- 20 Additionally, 2 prostatitis, and 4 Benign Prostatic Hyperplasia (BPH) samples are included. All the values are compared to ovarian cancer sample OVRA084 (calibrator).

- The table below contains the relative expression level values for the sample as compared to the calibrator. The table includes the Sample ID, and expression level values for the following samples: Cancer (CAN), Normal Adjacent Tissue (NAT), Normal Tissue (NRM), Benign Prostatic Hyperplasia (BPH), and Prostatitis (PROST).
- 25

Sample ID	CAN	NAT	NRM	BPH	PROST
OVRA084	1.00	0.10			
OVRG010	0.01	0.31			
OVRG021	0.39	0.02			
OVR1157	2.79				

OVR773O	1.14				
OVR814O	0.37				
OVR360	0.00				
OVR1005O	5.91				
OVR1040O	5.77				
OVR105O	1.68				
OVR130X	1.08				
OVR718O	0.55				
OVR1B	4.48				
OVR247A			0.00		
OVR35GA			0.00		
OVR3087			0.00		
OVR109			0.00		
OVR206I			0.03		
OVR515O			0.00		
OVR18GA			0.00		
OVR123O			0.00		
OVR177			0.02		
OVR40G			0.00		
OVR3004			0.00		
BLD030B	0.26	0.00			
BLD520B	0.13	0.02			
BLDTR17	0.24	0.25			
CLN401C	3.46	2.62			
CLNAS43	4.08	1.49			
CLNAS98	1.19	5.27			
CLNCM12	2.46	7.45			
CLNDC19	9.09	1.85			
CLNRC01	2.55	3.52			
CLNRS53	1.38	9.36			
CLNSG27	4.28	3.65			
CLNTX01	3.83	4.54			
CVXKS52	0.15	0.12			
CVXNK23	0.13	0.00			
CVXNKS54	0.59	0.54			
CVXNKS55	0.58	0.15			
CVXNKS81	0.25	0.61			
ENDO10479	6.19	1.01			
ENDO28XA	6.03	0.82			
ENDO8XA	0.40	1.67			
KID106XD	0.02	0.24			
KID107XD	0.10	0.34			
KID109XD	0.07	0.59			
KID10XD	0.00	0.15			
KID22K	0.05	0.14			
LNG205L	0.08	1.91			
LNG315L	1.42	0.43			

LNG507L	0.96	0.87			
LNG528L	9.39	0.92			
LNG8837L	1.08	0.45			
LNGAC11	0.28	1.23			
LNGAC39	13.19	0.76			
LNGSQ80	2.02	0.86			
LNGSQ81	2.19	0.67			
LVR15XA	0.00	0.01			
LVR174L	0.00	0.01			
LVR187L	0.00	10.06			
MAM19DN	0.46	0.85			
MAM42DN	0.71	0.74			
MAM517	3.27	0.33			
MAM781M	1.52	0.34			
MAM976M	0.83	0.37			
MAMS570	0.35	1.02			
MAMS699	0.28	0.39			
MAMS997	1.23	0.52			
PAN71XL	6.96	4.45			
PAN82XP	0.15	2.74			
PAN92X	2.89	0.00			
PRO23B	0.23	0.12			
PRO65XB	0.24	0.50			
PRO675P	0.40	0.21			
PRO84XB	0.45	0.30			
PRO958P	0.22	0.21			
PRO263C				0.27	
PRO276P				0.12	
PRO767B				0.24	
PRO855P				0.21	
PRO10R					0.18
PRO20R					0.44
SKN287S	0.38	0.11			
SKN39A	0.00	0.00			
SKN669S	0.03	0.08			
SMINT171S	3.18	4.30			
SMINT20SM	8.08	5.63			
SMINTH89	8.24	3.50			
STO261S	6.10	2.42			
STO288S	5.52	0.23			
STO88S	2.64	0.14			
THRD143N	1.00	5.56			
THRD270T	8.64	11.30			
THRD56T	3.91	1.96			
TST39X	0.42	0.56			
TST647T	4.38	0.11			
TST663T	2.81	0.13			

UTR135XO	0.40	0.48			
UTR85XU	3.06	1.79			
BLOB3			0.31		
BLOB6			0.00		
BLOB11			0.00		
BLO982B			0.00		
ADR48AD			0.00		
BRN10BR			0.07		
CLN01CL			0.57		
ESO01ES			0.00		
HUMREF00HR	0.17				
KID55KD			0.05		
LVR89LV			0.00		
LNG90LN			2.56		
MAM01MA			0.13		
MSL84MU			0.00		
OVR3APV			0.00		
PAN04PA			0.09		
PLA59PL			0.00		
PRO09PR			0.30		
REC21RC			4.27		
SMINT59SM			0.97		
SPL7GSP			0.03		
STO09ST			0.09		
THYM99TM			0.04		
TRA16TR			0.43		
TST4GTS			0.11		
UTR57UT			0.07		

0.00= Negative or Not Detected

The sensitivity for Ovr232 expression was calculated for the cancer samples versus normal samples. The sensitivity value indicates the percentage of cancer samples that show levels of Ovr232 at least 2 fold higher than the normal tissue or the corresponding normal adjacent form the same patient.

This specificity is an indication of the level of ovary tissue specific expression of the transcript compared to all the other tissue types tested in our assay. Thus, these experiments indicate Ovr232 being useful as an ovarian cancer diagnostic marker and/or therapeutic target.

Sensitivity and specificity data is reported in the table below.

	CLN	LNG	MAM	OVR	PRO
Sensitivity, Up vs. NAT	22%	67%	44%	0%	0%
Sensitivity, Down vs. NAT	33%	22%	11%	0%	20%

Sensitivity, Up vs. NRM	100%	22%	100%	92%	0%
Sensitivity, Down vs. NRM	0%	44%	0%	8%	0%
Specificity	50.82%	33.88%	22.95%	21.84%	19.46%

Altogether, the tissue specificity, plus the mRNA differential expression in the samples tested are believed to make Ovr232 a good marker for diagnosing, monitoring, staging, imaging and/or treating ovarian cancer.

- 5 Primers used for QPCR Expression Analysis of Ovr232 are as follows:
 (Ovr232_forward): GCTCAAAGCGTGAGTAAATATCCT (SEQ ID NO:317)
 (Ovr232_reverse): CCACACTTACTTTGTAACATGATTCAGA (SEQ ID NO:318)
 (Ovr232_probe): TTTGACTTAATACTTCTTTAATTGATGTGCCTTGAGTTGG
 10 (SEQ ID NO:319)

DEX0455 049.nt.2 (Ovr232v1)

- The relative expression level of Ovr232v1 in various tissue samples is included below. Tissue samples include 75 pairs of matching samples, 10 non matched cancer
 15 samples, and 40 normal samples, all from various tissues annotated in the table. A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. Of the normal samples 5 were blood samples which measured the expression levels in blood cells. Additionally, 2 prostatitis, and 4 Benign Prostatic Hyperplasia (BPH) samples are
 20 included. All the values are compared to normal colon sample CLN01CL (calibrator).

The table below contains the relative expression level values for the sample as compared to the calibrator. The table includes the Sample ID, and expression level values for the following samples: Cancer (CAN), Normal Adjacent Tissue (NAT), Normal Tissue (NRM), Benign Prostatic Hyperplasia (BPH), and Prostatitis (PROST).

Sample ID	CAN	NAT	NRM	BPH	PROST
OVRA084	0.02	0.67			
OVRG010	0.00	0.00			
OVRG021	0.10	0.00			
OVR1157	0.00				
OVR773O	0.00				
OVR988Z	0.00				
OVRC360	0.00				

OVR10050	0.42				
OVR10400	0.53				
OVR1050	0.09				
OVR130X	0.53				
OVR7180	0.25				
OVRA1B	0.26				
OVR247A			0.00		
OVR35GA			0.05		
OVRC087			0.00		
OVRC109			0.00		
OVR206I			0.00		
OVR5150			0.00		
OVR18GA			0.00		
OVR3370			0.00		
OVR1230			0.38		
OVRC177			0.01		
OVR40G			0.00		
OVR4510			0.00		
BLD030B	0.06	0.09			
BLD520B	0.20	0.03			
BLDTR17	0.46	0.01			
CLN401C	0.18	0.22			
CLNAS43	0.39	0.21			
CLNAS98	0.31	0.47			
CLNCM12	0.10	0.20			
CLNDC19	0.40	0.07			
CLNRC01	0.27	0.13			
CLNRS53	0.15	0.33			
CLNSG27	0.17	0.25			
CLNTX01	0.13	0.20			
CVXKS52	0.00	0.00			
CVXNKS55	0.00	0.12			
CVXNKS25	0.85	0.00			
CVXNKS18	0.00	0.00			
CVXNKS54	0.00	0.00			
ENDO10479	0.13	0.00			
ENDO28XA	0.32	0.12			
ENDO8XA	0.07	0.40			
KID106XD	0.05	0.10			
KID12XD	0.04	0.12			
KID10XD	0.05	0.05			
KID22K	0.02	0.03			
KID107XD	0.00	0.04			
LNG205L	0.00	0.26			
LNG315L	0.38	0.00			
LNG507L	0.20	0.00			
LNG528L	0.37	0.37			

LNG8837L	0.10	0.06			
LNGAC11	0.03	0.06			
LNGAC39	0.58	0.63			
LNGSQ80	0.21	0.19			
LNGSQ81	0.15	0.00			
LVR15XA	0.00	0.00			
LVR174L	0.00	0.00			
LVR187L	0.00	0.37			
MAM19DN	0.12	0.25			
MAM42DN	0.44	0.64			
MAM517	0.25	0.00			
MAM781M	0.24	0.67			
MAM869M	0.04	0.00			
MAM976M	0.22	0.00			
MAMS570	0.00	0.47			
MAMS699	0.00	0.00			
MAMS997	0.11	0.04			
PAN71XL	1.10	0.31			
PAN77X	0.00	0.00			
PAN92X	0.19	0.00			
PRO10R					0.00
PRO20R					0.20
PRO23B	0.17	0.10			
PRO263C				0.54	
PRO276P				0.27	
PRO65XB	0.17	0.11			
PRO675P	0.47	0.85			
PRO767B				0.10	
PRO84XB	0.12	0.13			
PRO855P				0.08	
PRO958P	0.15	0.12			
SKN287S	0.10	0.00			
SKN39A	0.06	0.00			
SKN669S	0.00	0.51			
SMINT171S	0.38	0.67			
SMINT20SM	0.23	0.40			
SMINTH89	0.14	0.31			
STO261S	0.69	0.24			
STO288S	0.36	0.17			
STOAC93	0.00	0.00			
STO88S	0.00	0.17			
THRD143N	0.15	0.25			
THRD270T	0.37	0.28			
THRD56T	0.34	0.45			
TST39X	0.20	0.43			
TST647T	0.59	0.41			
TST663T	0.33	0.25			

UTR135XO	0.19	0.13			
UTR85XU	1.42	0.14			
BLOB3			0.00		
BLOB11			0.00		
BLO69			0.00		
BLO72			0.00		
BLO73			0.00		
ADR48AD			0.00		
BRN10BR			0.00		
CLN01CL			0.12		
CVX06CV			0.00		
ESO01ES			0.00		
HRT46HR			0.00		
HUMREF00HR	0.08				
KID55KD			0.02		
LVR89LV			0.00		
LNG90LN			1.00		
MAM01MA			0.10		
MSL84MU			0.00		
OVR3APV			0.03		
PAN04PA			0.17		
PLA59PL			0.00		
PRO09PR			0.00		
REC21RC			0.36		
SMINT59SM			0.13		
SPL7GSP			0.09		
STO09ST			0.39		
THYM99TM			0.00		
TRA16TR			0.09		
TST4GTS			0.50		
UTR57UT			0.15		

0.00= Negative or Not Detected

The sensitivity for Ovr232v1 expression was calculated for the cancer samples versus normal samples. The sensitivity value indicates the percentage of cancer samples that show levels of Ovr232v1 at least 2 fold higher than the normal tissue or the corresponding normal adjacent form the same patient.

This specificity is an indication of the level of ovary tissue specific expression of the transcript compared to all the other tissue types tested in our assay. Thus, these experiments indicate Ovr232v1 being useful as an ovarian cancer diagnostic marker and/or therapeutic target.

Sensitivity and specificity data is reported in the table below.

	CLN	LNG	MAM	OVR	PRO
--	-----	-----	-----	-----	-----

Sensitivity, Up vs. NAT	22%	33%	44%	0%	0%
Sensitivity, Down vs. NAT	22%	22%	33%	0%	0%
Sensitivity, Up vs. NRM	44%	0%	44%	62%	100%
Sensitivity, Down vs. NRM	0%	89%	33%	0%	0%
Specificity	36.7%	34.57%	32.45%	28.65%	35.26%

Altogether, the tissue specificity, plus the mRNA differential expression in the samples tested are believed to make Ovr232v1 a good marker for diagnosing, monitoring, staging, imaging and/or treating ovarian cancer.

- 5 Primers used for QPCR Expression Analysis of Ovr232v1 are as follows:
 (Ovr232v1_forward): GGCGGTGACTCATCAACGA (SEQ ID NO:320)
 (Ovr232v1_reverse): CATTGACGATTATTATTACAAAGCA (SEQ ID NO:321)
 (Ovr232v1_probe): GCGGCCAGAGAATGTGTCTGTGAAAAC (SEQ ID NO:322)
- 10

DEX0455_049.nt.3 (Ovr232v2)

- The relative expression level of Ovr232v2 in various tissue samples is included below. Tissue samples include 72 pairs of matching samples, 12 non matched cancer samples, and 37 normal samples, all from various tissues annotated in the table. A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. Of the normal samples 5 were blood samples which measured the expression levels in blood cells. Additionally, 2 prostatitis, and 4 Benign Prostatic Hyperplasia (BPH) samples are included. All the values are compared to normal spleen sample SPL7GSP (calibrator).
- 15
- 20

The table below contains the relative expression level values for the sample as compared to the calibrator. The table includes the Sample ID, and expression level values for the following samples: Cancer (CAN), Normal Adjacent Tissue (NAT), Normal Tissue (NRM), Benign Prostatic Hyperplasia (BPH), and Prostatitis (PROST).

Sample ID	CAN	NAT	NRM	BPH	PROST
OVRA084	20.82	1.47			
OVRG010	7.06	0.00			
OVRG021	2.01	0.55			
OVR1157	17.09				

OVR7730	31.56				
OVR988Z	17.68				
OVR360	0.00				
OVR10050	20.28				
OVR10400	29.36				
OVR1050	15.24				
OVR130X	10.08				
OVR7180	12.73				
OVR1B	34.60				
OVR247A			0.00		
OVR35GA			0.11		
OVR087			0.00		
OVR109			0.00		
OVR206I			0.43		
OVR5150			1.11		
OVR18GA			0.00		
OVR1230			3.47		
OVR177			0.08		
OVR40G			0.06		
BLD030B	6.81	0.00			
BLD520B	4.04	0.57			
BLDTR17	3.89	2.17			
CLN401C	22.89	17.80			
CLNAS43	72.65	16.04			
CLNAS98	15.32	35.15			
CLNCM12	17.48	29.75			
CLNDC19	81.83	20.01			
CLNRC01	20.30	18.70			
CLNRS53	17.98	55.34			
CLNSG27	59.40	41.80			
CLNTX01	30.45	37.83			
CVXKS52	3.47	2.77			
CVXNKS55	12.43	2.43			
CVXNKS18	0.00	0.54			
CVXNKS54	13.64	2.13			
ENDO10479	95.97	4.22			
ENDO28XA	39.72	8.50			
ENDO8XA	3.02	11.79			
KID106XD	0.18	1.97			
KID12XD	1.46	10.05			
KID10XD	0.35	1.92			
KID22K	0.65	1.57			
KID107XD	4.13	2.74			
LNG205L	3.09	13.46			
LNG315L	18.48	9.39			
LNG507L	15.67	4.96			
LNG528L	78.28	10.67			

LNG8837L	14.25	6.13			
LNGAC11	7.45	16.04			
LNGAC39	151.52	5.87			
LNGSQ80	27.78	24.91			
LNGSQ81	9.10	5.92			
LVR15XA	0.27	0.09			
LVR174L	0.00	0.23			
LVR187L	0.00	85.59			
MAM19DN	7.21	18.30			
MAM42DN	29.31	5.38			
MAM517	13.24	1.54			
MAM781M	26.05	0.95			
MAM869M	4.02	0.00			
MAM976M	13.42	2.33			
MAMS570	4.31	5.78			
MAMS699	1.12	4.34			
MAMS997	13.01	5.21			
PAN71XL	64.87	58.75			
PAN77X	0.00	0.00			
PAN92X	26.90	0.00			
PRO10R					2.57
PRO20R					5.10
PRO23B	3.74	3.66			
PRO263C				3.92	
PRO276P				1.99	
PRO65XB	3.35	4.51			
PRO675P	8.17	1.15			
PRO767B				10.45	
PRO84XB	5.75	3.97			
PRO855P				3.29	
PRO958P	2.91	5.35			
SKN287S	5.73	0.91			
SKN39A	0.00				
SKN669S	0.13	2.14			
SMINT171S	56.03	62.72			
SMINT20SM	106.47	33.80			
SMINTH89	96.97	40.02			
STO261S	118.64	19.05			
STO288S	47.55	4.07			
STOAC93	67.18	64.23			
STO88S	79.32				
THRD143N	14.71	30.26			
THRD270T	43.65	40.86			
THRD56T	23.82	8.72			
TST39X	6.89	5.65			
TST647T	30.28	3.55			
TST663T	23.55	1.69			

UTR135XO	2.75	5.63			
UTR85XU	32.07	28.53			
BLOB3			2.60		
BLOB11			0.00		
BLO69			0.00		
BLO72			0.34		
BLO73			0.00		
ADR48AD			0.00		
BRN10BR			0.47		
CLN01CL			24.82		
ESO01ES			0.00		
HRT46HR			0.00		
HUMREF00HR	4.31				
KID55KD			2.28		
LVR89LV			0.02		
LNG90LN			10.08		
MAM01MA			1.17		
MSL84MU			0.00		
OVR3APV			0.02		
PAN04PA			0.61		
PLA59PL			0.00		
PRO09PR			8.47		
REC21RC			95.94		
SMINT59SM			16.37		
SPL7GSP			1.00		
STO09ST			2.19		
THYM99TM			0.83		
TRA16TR			6.78		
TST4GTS			1.57		
UTR57UT			2.24		

0.00= Negative or Not Detected

The sensitivity for Ovr232v2 expression was calculated for the cancer samples versus normal samples. The sensitivity value indicates the percentage of cancer samples that show levels of Ovr232v2 at least 2 fold higher than the normal tissue or the corresponding normal adjacent form the same patient.

This specificity is an indication of the level of ovary tissue specific expression of the transcript compared to all the other tissue types tested in our assay. Thus, these experiments indicate Ovr232v2 being useful as an ovarian cancer diagnostic marker and/or therapeutic target.

Sensitivity and specificity data is reported in the table below.

	CLN	LNG	MAM	OVR	PRO
Sensitivity, Up vs. NAT	22%	44%	67%	0%	20%

Sensitivity, Down vs. NAT	22%	22%	22%	0%	0%
Sensitivity, Up vs. NRM	33%	33%	89%	92%	0%
Sensitivity, Down vs. NRM	0%	11%	0%	8%	60%
Specificity	36.46%	29.28%	25.41%	24.28%	19.13%

Altogether, the tissue specificity, plus the mRNA differential expression in the samples tested are believed to make Ovr232v2 a good marker for diagnosing, monitoring, staging, imaging and/or treating ovarian cancer.

- 5 Primers used for QPCR Expression Analysis of Ovr232v2 are as follows:
 (Ovr232v2_forward): CCTTTTATCCACTTACAGATCAACCA (SEQ ID NO:323)
 (Ovr232v2_reverse): ACAAGCAAGATGCATGTGAGTGA (SEQ ID NO:324)
 (Ovr232v2_probe): ATGGTTCGCTGCTGCCGTT (SEQ ID NO:325)

10 DEX0455_049.nt.4 (Ovr232v3)

- The relative expression level of Ovr232v3 in various tissue samples is included below. Tissue samples include 75 pairs of matching samples, 10 non matched cancer samples, and 39 normal samples, all from various tissues annotated in the table. A matching pair is formed by mRNA from the cancer sample for a particular tissue and
 15 mRNA from the normal adjacent sample for that same tissue from the same individual. Of the normal samples 5 were blood samples which measured the expression levels in blood cells. Additionally, 2 prostatitis, and 4 Benign Prostatic Hyperplasia (BPH) samples are included. All the values are compared to normal lung sample LNG90LN (calibrator).

- The table below contains the relative expression level values for the sample as
 20 compared to the calibrator. The table includes the Sample ID, and expression level values for the following samples: Cancer (CAN), Normal Adjacent Tissue (NAT), Normal Tissue (NRM), Benign Prostatic Hyperplasia (BPH), and Prostatitis (PROST).

Sample ID	CAN	NAT	NRM	BPH	PROST
OVRA084	0.00	0.00			
OVRG010	0.07	0.00			
OVRG021	0.00	0.00			
OVR1157	0.01				
OVR7730	0.00				
OVR988Z	0.00				
OVR360	0.00				
OVR10050	0.52				

OVR10400	0.55				
OVR1050	0.25				
OVR130X	0.00				
OVR7180	0.29				
OVR101B	0.22				
OVR247A			0.00		
OVR0087			0.00		
OVR0109			0.00		
OVR206I			0.00		
OVR5150			0.00		
OVR18GA			0.00		
OVR3370			0.00		
OVR1230			0.00		
OVR0177			0.00		
OVR40G			0.00		
OVR4510			0.00		
BLD030B	0.12	0.00			
BLD520B	0.00	0.00			
BLDTR17	0.00	0.02			
CLN401C	0.57	0.24			
CLNAS43	1.60	0.00			
CLNAS98	0.86	0.00			
CLNCM12	0.06	0.06			
CLNDC19	0.47	0.03			
CLNRC01	0.12	0.12			
CLNRS53	0.00	0.00			
CLNSG27	1.08	0.00			
CLNTX01	0.00	0.41			
CVXKS52	0.00	0.00			
CVXNKS55	0.00	0.00			
CVXNKS25	0.00	0.00			
CVXNKS18	0.00	0.00			
CVXNKS54	0.00	0.00			
ENDO10479	0.30	0.00			
ENDO28XA	0.19	0.00			
ENDO8XA	0.00	0.46			
KID106XD	0.00	0.00			
KID12XD	0.00	0.00			
KID10XD	0.00	0.04			
KID22K	0.00	0.02			
KID107XD	0.00	0.12			
LNG205L	0.00	0.68			
LNG315L	0.00	0.00			
LNG507L	0.00	0.00			
LNG528L	1.50	0.00			
LNG8837L	0.96	0.81			
LNGAC11	0.03	0.00			

LNGAC39	0.35	1.20			
LNGSQ80	0.87	0.00			
LNGSQ81	0.65	0.00			
LVR15XA	0.10	0.00			
LVR174L	0.00	0.00			
LVR187L	0.00	0.38			
MAM19DN	0.00	0.00			
MAM42DN	0.00	0.07			
MAM517	0.00	0.00			
MAM781M	0.00	0.00			
MAM869M	0.00	0.00			
MAM976M	0.00	0.00			
MAMS570	0.00	0.00			
MAMS699	0.00	0.00			
MAMS997	0.05	0.21			
PAN71XL	0.00	0.64			
PAN77X	0.00	0.00			
PAN92X	0.19	0.00			
PRO10R					0.00
PRO20R					0.00
PRO23B	0.04	0.00			
PRO263C				0.00	
PRO276P				0.00	
PRO65XB	0.09	0.00			
PRO675P	0.68	0.00			
PRO767B				0.09	
PRO84XB	0.00	0.00			
PRO855P				0.01	
PRO958P	0.00	0.00			
SKN287S	0.06	0.00			
SKN39A	0.00	0.00			
SKN669S	0.00	0.00			
SMINT171S	0.03	0.00			
SMINT20SM	0.55	0.24			
SMINTH89	0.00	0.47			
STO261S	1.03	0.00			
STO288S	0.54	0.00			
STOAC93	0.00	2.29			
STO88S	0.00	0.00			
THRD143N	0.51	2.00			
THRD270T	0.49	0.97			
THRD56T	0.79	0.00			
TST39X	0.00	0.00			
TST647T	0.52	0.59			
TST663T	0.40	0.46			
UTR135XO	0.00	0.00			
UTR85XU	0.77	0.29			

BLOB3			0.00		
BLOB11			0.00		
BLO69			0.00		
BLO72			0.00		
BLO73			0.00		
ADR48AD			0.00		
BRN10BR			0.00		
CLN01CL			0.03		
CVX06CV			0.00		
ESO01ES			0.00		
HRT46HR			0.00		
HUMREF00HR	0.00				
KID55KD			0.01		
LVR89LV			0.00		
LNG90LN			1.00		
MAM01MA			0.06		
MSL84MU			0.00		
OVR3APV			0.01		
PAN04PA			0.00		
PLA59PL			0.00		
PRO09PR			0.00		
REC21RC			1.27		
SMINT59SM			0.00		
SPL7GSP			0.00		
STO09ST			0.00		
THYM99TM			0.00		
TRA16TR			0.00		
TST4GTS			1.21		
UTR57UT			0.00		

0.00= Negative or Not Detected

The sensitivity for Ovr232v3 expression was calculated for the cancer samples versus normal samples. The sensitivity value indicates the percentage of cancer samples that show levels of Ovr232v3 at least 2 fold higher than the normal tissue or the corresponding normal adjacent form the same patient.

This specificity is an indication of the level of ovary tissue specific expression of the transcript compared to all the other tissue types tested in our assay. Thus, these experiments indicate Ovr232v3 being useful as an ovarian cancer diagnostic marker and/or therapeutic target.

Sensitivity and specificity data is reported in the table below.

	CLN	LNG	MAM	OVR	PRO
Sensitivity, Up vs. NAT	56%	44%	0%	0%	60%

Sensitivity, Down vs. NAT	11%	22%	22%	0%	0%
Sensitivity, Up vs. NRM	78%	0%	0%	62%	60%
Sensitivity, Down vs. NRM	22%	56%	89%	0%	0%
Specificity	72.73 %	70.59 %	61.5 %	62.36 %	63.49 %

Altogether, the tissue specificity, plus the mRNA differential expression in the samples tested are believed to make Ovr232v3 a good marker for diagnosing, monitoring, staging, imaging and/or treating ovarian cancer.

- 5 Primers used for QPCR Expression Analysis of Ovr232v3 are as follows:
 (Ovr232v3_forward): CCTCACTTCGCAGCTTTGCT (SEQ ID NO:326)
 (Ovr232v3_reverse): CTGGCATTGACGATTATTATTCACA (SEQ ID NO:327)
 (Ovr232v3_probe): CTGTGAAACTACAAGCTGGCCGTAAACTGCT (SEQ ID NO:328)

10

DEX0455_052.nt.2 (Ovr107v1)

- The relative expression level of Ovr107v1 in various tissue samples is included below. Tissue samples include 69 pairs of matching samples, 14 non matched cancer samples, and 33 normal samples, all from various tissues annotated in the table. A
 15 matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. Of the normal samples 2 were blood samples which measured the expression levels in blood cells. Additionally, 2 prostatitis, and 4 Benign Prostatic Hyperplasia (BPH) samples are included. All the values are compared to prostate normal sample PRO09PR (calibrator).

- 20 The table below contains the relative expression level values for the sample as compared to the calibrator. The table includes the Sample ID, and expression level values for the following samples: Cancer (CAN), Normal Adjacent Tissue (NAT), Normal Tissue (NRM), Benign Prostatic Hyperplasia (BPH), and Prostatitis (PROST).

Sample ID	CAN	NAT	NRM	BPH	PROST
OVRA084	1.11	0.00			
OVRG010	0.00	6.59			
OVRG021	0.36	0.35			
OVR1157	3.79				
OVR7730	7.68				
OVR8140	1.90				
OVRC360	0.00				

OVR10050	4.09				
OVR10400	3.29				
OVR1050	4.05				
OVR130X	0.00				
OVR7180	0.84				
OVRA1B	3.99				
OVR247A			0.12		
OVR35GA			0.14		
OVRC087			0.06		
OVRC109			0.22		
OVR206I			0.42		
OVR5150			0.00		
OVR18GA			0.00		
OVRC177			0.02		
OVR40G			0.00		
BLD030B	0.79	0.00			
BLD520B	0.10	0.12			
BLDTR17	2.53	1.19			
CLN401C	0.26	0.44			
CLNAS43	4.02	1.01			
CLNAS98	1.42	0.50			
CLNCM12	1.48	0.45			
CLNDC19	2.32	0.79			
CLNRC01	0.33	0.15			
CLNRS53	0.31	0.88			
CLNSG27	2.00	1.15			
CLNTX01	0.00	0.00			
CVXKS52	1.77	3.80			
CVXNK23	1.76				
CVXNKS54	2.77	3.22			
CVXNKS55	6.45	9.73			
CVXNKS81	2.00				
ENDO10479	5.01	1.45			
ENDO28XA	5.66	0.29			
ENDO8XA	0.85	0.18			
KID106XD	0.00	0.61			
KID107XD	0.44	1.12			
KID109XD	2.85	0.99			
KID10XD	0.00	0.09			
KID22K	0.32	0.03			
LNG205L	0.26	1.68			
LNG315L	0.44	0.44			
LNG507L	0.24	0.00			
LNG528L	0.19	0.17			
LNG8837L	1.07	0.62			
LNGAC11	0.63	0.30			
LNGAC39	1.29	1.24			

LNGSQ80	1.39	0.25			
LNGSQ81	1.23	0.56			
LVR15XA	0.00	0.04			
LVR174L	0.00	0.02			
LVR187L	0.25	0.86			
MAM19DN	1.91	1.04			
MAM42DN	0.36	0.00			
MAM517		0.00			
MAM781M	0.00	0.53			
MAM869M	1.40	1.23			
MAM976M	2.55	0.00			
MAMS570	0.00	1.69			
MAMS699	1.35	0.00			
MAMS997	2.41	1.23			
PAN71XL	0.72	0.00			
PAN82XP	0.71				
PAN92X	5.33				
PRO23B	1.06	0.93			
PRO65XB	0.61	0.70			
PRO675P	0.57	0.48			
PRO84XB	0.62	0.75			
PRO958P	1.10	1.03			
PRO263C				1.38	
PRO276P				0.66	
PRO767B				2.26	
PRO855P				0.76	
PRO10R					0.26
PRO20R					0.36
SKN287S	2.27	0.00			
SKN39A	0.54	0.00			
SKN669S	0.52	6.42			
SMINT171S	1.91	0.09			
SMINT20SM	3.08	1.13			
SMINTH89	1.92	1.28			
STO261S	1.20	0.35			
STO288S	0.14	0.29			
STO88S	0.58	0.00			
THRD143N	1.09	6.12			
THRD270T	5.60	6.15			
THRD56T	2.63	2.16			
TST39X	0.58	0.29			
TST647T	0.41	0.03			
TST663T	0.95	0.07			
UTR135XO	0.63	1.00			
UTR85XU	0.00	0.19			
BLOB3			0.35		
BLOB11			0.00		

ADR48AD			0.00		
BRN10BR			0.00		
CLN01CL			0.79		
ESO01ES			1.69		
HRT46HR			0.00		
HUMREF00HR	0.67				
KID55KD			0.17		
LVR89LV			0.00		
LNG90LN			0.36		
MAM01MA			0.55		
MSL84MU			0.00		
OVR3APV			0.33		
PAN04PA			0.24		
PLA59PL			5.67		
PRO09PR			1.00		
REC21RC			0.51		
SMINT59SM			0.12		
SPL7GSP			0.08		
STO09ST			2.33		
THYM99TM			0.20		
TRA16TR			2.37		
TST4GTS			0.33		
UTR57UT			0.32		

Note: 0.00= Negative or Not Detected

The sensitivity for Ovr107v1 expression was calculated for the cancer samples versus normal samples. The sensitivity value indicates the percentage of cancer samples that show levels of Ovr107v1 at least 2 fold higher than the normal tissue or the corresponding normal adjacent form the same patient.

This specificity is an indication of the level of ovary tissue specific expression of the transcript compared to all the other tissue types tested in our assay. Thus, these experiments indicate Ovr107v1 being useful as an ovarian cancer diagnostic marker and/or therapeutic target.

Sensitivity and specificity data is reported in the table below.

	CLN	LNG	MAM	OVR	PRO
Sensitivity, Up vs. NAT	56%	44%	38%	0%	0%
Sensitivity, Down vs. NAT	11%	11%	25%	0%	0%
Sensitivity, Up vs. NRM	33%	44%	63%	77%	0%
Sensitivity, Down vs. NRM	44%	0%	25%	23%	0%
Specificity	25.86%	21.26%	22.86%	25.15%	21.59%

Altogether, the tissue specificity, plus the mRNA differential expression in the samples tested are believed to make Ovr107v1 a good marker for diagnosing, monitoring, staging, imaging and/or treating ovarian cancer.

- 5 Primers used for QPCR Expression Analysis of Ovr107v1 are as follows:
 (Ovr107v1_forward): CGCCTGACCCGACTGTCTTA (SEQ ID NO:329)
 (Ovr107v1_reverse): GCTCAGATTCTGGCTCCAAGTCT (SEQ ID NO:330)
 (Ovr107v1_probe): CCTACAGCAAAGCGCCCCCA (SEQ ID NO:331)

10 DEX0455_052.nt.4 (Ovr107v3)

- The relative expression level of Ovr107v3 in various tissue samples is included below. Tissue samples include 73 pairs of matching samples, 11 non matched cancer samples, and 37 normal samples, all from various tissues annotated in the table. A matching pair is formed by mRNA from the cancer sample for a particular tissue and
 15 mRNA from the normal adjacent sample for that same tissue from the same individual. Of the normal samples 4 were blood samples which measured the expression levels in blood cells. Additionally, 2 prostatitis, and 4 Benign Prostatic Hyperplasia (BPH) samples are included. All the values are compared to ovarian cancer sample OVR8140 (calibrator).

- The table below contains the relative expression level values for the sample as
 20 compared to the calibrator. The table includes the Sample ID, and expression level values for the following samples: Cancer (CAN), Normal Adjacent Tissue (NAT), Normal Tissue (NRM), Benign Prostatic Hyperplasia (BPH), and Prostatitis (PROST).

Sample	CAN	NAT	NRM	BPH	PROST
OVRA084	0.32	0.10			
OVRG010	0.01	4.12			
OVRG021	0.17	0.04			
OVR1157	2.88				
OVR7730	6.48				
OVR8140	1.00				
OVRC360	0.11				
OVR10050	1.56				
OVR10400	1.09				
OVR1050	0.68				
OVR130X	1.17				
OVR7180	0.79				
OVRA1B	1.43				
OVR247A			0.06		
OVR35GA			0.03		

OVR087			0.03		
OVR109			0.01		
OVR206I			0.08		
OVR5150			0.09		
OVR18GA			0.03		
OVR3370			0.00		
OVR1230			0.00		
OVR177			0.04		
OVR40G			0.05		
BLD030B	0.16	0.00			
BLD520B	0.09	0.03			
BLDTR17	0.06	0.16			
CLN401C	0.09	0.10			
CLNAS43	0.24	0.03			
CLNAS98	0.14	0.11			
CLNCM12	0.05	0.11			
CLNDC19	0.40	0.14			
CLNRC01	0.05	0.07			
CLNRS53	0.06	0.16			
CLNSG27	0.11	0.12			
CLNTX01	0.07	0.02			
CVXKS52	0.50	1.56			
CVXNK23	0.51	2.02			
CVXNKS54	0.56	0.93			
CVXNKS55	1.32	3.28			
CVXNKS81	0.55	1.16			
ENDO10479	1.12	0.12			
ENDO28XA	1.33	0.11			
ENDO8XA	0.30	0.07			
KID106XD	0.01	0.03			
KID107XD	0.03	0.13			
KID109XD	0.25	0.04			
KID10XD	0.02	0.01			
KID22K	0.07	0.03			
LNG205L	0.03	0.05			
LNG315L	0.03	0.08			
LNG507L	0.58	0.07			
LNG528L	0.29	0.06			
LNG8837L	0.09	0.17			
LNGAC11	0.14	0.15			
LNGAC39	0.50	0.08			
LNGSQ80	0.18	0.22			
LNGSQ81	0.07	0.16			
LVR15XA	0.00	0.01			
LVR174L	0.01	0.01			
LVR187L	0.01	0.19			
MAM19DN	0.62	0.28			

MAM42DN	0.57	0.37			
MAM517	2.06	0.15			
MAM781M	0.07	0.06			
MAM869M	0.67	0.11			
MAM976M	0.60	0.16			
MAMS570	0.72	0.76			
MAMS699	0.10	0.46			
MAMS997	0.18	0.34			
PAN71XL	0.09	0.02			
PAN82XP	0.12				
PAN92X	2.58	0.00			
PRO23B	0.23	0.27			
PRO65XB	0.22	0.25			
PRO675P	0.40	0.19			
PRO84XB	0.34	0.42			
PRO958P	0.38	0.22			
PRO263C				0.30	
PRO276P				0.24	
PRO767B				0.93	
PRO855P				0.44	
PRO10R					0.32
PRO20R					0.19
SKN287S	0.86	0.00			
SKN39A	0.03	0.00			
SKN669S	0.12	0.40			
SMINT171S	0.21	0.04			
SMINT20SM	2.32	0.40			
SMINTH89	0.51	0.05			
STO261S	0.65	0.05			
STO288S	0.08	0.03			
STO88S	0.15	0.07			
THRD143N	0.09	0.73			
THRD270T	1.23	1.14			
THRD56T	0.64	0.18			
TST39X	0.07	0.02			
TST647T	0.11	0.01			
TST663T	0.12	0.03			
UTR135XO	0.13	0.27			
UTR85XU	0.15	0.09			
BLOB3			0.00		
BLOB6			0.69		
BLOB11			0.02		
BLO982B			0.10		
ADR48AD			0.02		
BRN10BR			0.01		
CLN01CL			0.05		
ESO01ES			0.93		

295

HRT46HR			0.00		
HUMREF00HR	0.09				
KID55KD			0.05		
LVR89LV			0.00		
LNG90LN			0.04		
MAM01MA			0.15		
MSL84MU			0.01		
OVR3APV			0.07		
PAN04PA			0.10		
PLA59PL			0.82		
PRO09PR			0.50		
REC21RC			0.26		
SMINT59SM			0.03		
SPL7GSP			0.03		
STO09ST			1.10		
THYM99TM			0.02		
TRA16TR			0.32		
TST4GTS			0.01		
UTR57UT			0.08		

Note: 0.00= Negative or Not Detected

The sensitivity for Ovr107v3 expression was calculated for the cancer samples versus normal samples. The sensitivity value indicates the percentage of cancer samples that show levels of Ovr107v3 at least 2 fold higher than the normal tissue or the corresponding normal adjacent form the same patient.

This specificity is an indication of the level of ovary tissue specific expression of the transcript compared to all the other tissue types tested in our assay. Thus, these experiments indicate Ovr107v3 being useful as an ovarian cancer diagnostic marker and/or therapeutic target.

Sensitivity and specificity data is reported in the table below.

	CLN	LNG	MAM	OVR	PRO
Sensitivity, Up vs. NAT	33%	33%	44%	0%	20%
Sensitivity, Down vs. NAT	22%	22%	11%	0%	0%
Sensitivity, Up vs. NRM	44%	67%	67%	92%	0%
Sensitivity, Down vs. NRM	0%	0%	11%	8%	40%
Specificity	8.79%	10.44%	33.52%	43.35%	21.74%

Altogether, the tissue specificity, plus the mRNA differential expression in the samples tested are believed to make Ovr107v3 a good marker for diagnosing, monitoring, staging, imaging and/or treating ovarian cancer.

Primers used for QPCR Expression Analysis of Ovr107v3 are as follows:

(Ovr107v3_forward): CCTGCAGCCCAGAGCAAT (SEQ ID NO:332)

(Ovr107v3_reverse): GCTCAGATTCTGGCTCCAAGTC (SEQ ID NO:333)

(Ovr107v3_probe): ATCTCCAACCCTCCCGCTTCT (SEQ ID NO:334)

5

DEX0455_051.nt.6 (Ovr107v4)

The relative expression level of Ovr107v4 in various tissue samples is included below. Tissue samples include 69 pairs of matching samples, 15 non matched cancer samples, and 34 normal samples, all from various tissues annotated in the table. A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. Of the normal samples 2 were blood samples which measured the expression levels in blood cells. Additionally, 2 prostatitis, and 4 Benign Prostatic Hyperplasia (BPH) samples are included. All the values are compared to breast normal sample MAM01MA (calibrator).

15

The table below contains the relative expression level values for the sample as compared to the calibrator. The table includes the Sample ID, and expression level values for the following samples: Cancer (CAN), Normal Adjacent Tissue (NAT), Normal Tissue (NRM), Benign Prostatic Hyperplasia (BPH), and Prostatitis (PROT).

Sample ID	CAN	NAT	NRM	BPH	PROT
OVRA084	1.03	0.60			
OVRG010	0.43	1.15			
OVRG021	0.72	1.63			
OVR1157	0.00				
OVR7730	2.63				
OVR8140	1.26				
OVR360	0.46				
OVR10050	13.92				
OVR10400	6.00				
OVR1050	6.04				
OVR7180	4.15				
OVRA1B	3.67				
OVR247A			0.55		
OVR35GA			1.06		
OVR087			0.35		
OVR109			0.43		
OVR206I			0.93		
OVR5150			2.17		
OVR18GA			1.17		

OVRC177			0.68		
OVR40G			1.89		
OVRC004			0.00		
BLD030B	0.77	0.00			
BLD520B	2.75	0.88			
BLDTR17	0.70	2.67			
CLN401C	0.78	1.03			
CLNAS43	2.36	0.77			
CLNAS98	1.73	1.27			
CLNCM12	0.67	0.61			
CLNDC19	1.46	0.43			
CLNRC01	0.12	0.36			
CLNRS53	0.36	2.08			
CLNSG27	0.48	2.08			
CLNTX01	0.72	0.56			
CVXKS52	1.32	10.88			
CVXNK23	2.75				
CVXNKS54	1.33	10.06			
CVXNKS55	9.56	20.77			
CVXNKS81	3.27				
ENDO10479	3.77	4.17			
ENDO28XA	5.41	4.55			
ENDO8XA	1.21	1.31			
KID106XD	0.27	0.12			
KID107XD	0.60	0.45			
KID109XD	2.94	0.76			
KID10XD	0.18	0.28			
KID22K	0.80	0.15			
LNG205L	0.46	1.80			
LNG315L	0.37	2.06			
LNG507L	1.43				
LNG528L	1.26	0.85			
LNG8837L	0.86	1.74			
LNGAC11	0.77	1.37			
LNGAC39	1.28	1.22			
LNGSQ80	1.34	2.91			
LNGSQ81	0.95	1.01			
LVR15XA	0.05	0.06			
LVR174L	0.10	0.05			
LVR187L	0.00	0.86			
MAM19DN	1.31	3.79			
MAM42DN	1.98	3.48			
MAM517	3.35	0.00			
MAM781M	0.57	0.51			
MAM869M	2.29	1.06			
MAM976M	3.78	2.13			
MAMS570	2.14	3.13			

MAMS699	0.58	4.99			
MAMS997	2.72	1.84			
PAN71XL	0.76	0.24			
PAN82XP	1.49				
PAN92X	4.92				
PRO23B	0.87	1.01			
PRO65XB	0.62	0.72			
PRO675P	1.19	2.30			
PRO84XB	0.99	2.38			
PRO958P	1.31	1.39			
PRO263C				1.64	
PRO276P				0.60	
PRO767B				3.10	
PRO855P				0.92	
PRO10R					1.33
PRO20R					2.41
SKN287S	5.46	0.65			
SKN39A	2.56	0.22			
SKN669S	6.12	9.44			
SMINT171S	1.39	0.62			
SMINT20SM	7.46	2.59			
SMINTH89	0.97	0.16			
STO261S	4.97	3.16			
STO288S	0.23	0.40			
STO88S	3.10	0.38			
THRD143N	0.70	5.66			
THRD270T	11.59	12.76			
THRD56T	4.61	1.92			
TST39X	0.91	0.00			
TST647T	1.42	0.29			
TST663T	1.42	0.37			
UTR135XO	3.28	4.02			
UTR85XU	1.51	2.11			
BLOB3			0.25		
BLOB11			0.92		
ADR48AD			0.00		
BRN10BR			0.00		
CLN01CL			0.22		
ESO01ES			7.88		
HRT46HR			0.06		
HUMREF00HR	0.49				
KID55KD			0.10		
LVR89LV			0.03		
LNG90LN			0.26		
MAM01MA			1.00		
MSL84MU			0.06		
OVR3APV			1.02		

PAN04PA			0.14		
PLA59PL			2.01		
PRO09PR			0.57		
REC21RC			1.21		
SMINT59SM			0.11		
SPL7GSP			0.26		
STO09ST			1.56		
THYM99TM			0.20		
TRA16TR			1.45		
TST4GTS			0.19		
UTR57UT			1.28		

0.00= Negative or no expression

The sensitivity for Ovr107v4 expression was calculated for the cancer samples versus normal samples. The sensitivity value indicates the percentage of cancer samples that show levels of Ovr107v4 at least 2 fold higher than the normal tissue or the corresponding normal adjacent form the same patient.

This specificity is an indication of the level of ovary tissue specific expression of the transcript compared to all the other tissue types tested in our assay. Thus, these experiments indicate Ovr107v4 being useful as an ovarian cancer diagnostic marker and/or therapeutic target.

Sensitivity and specificity data is reported in the table below.

	CLN	LN G	MAM	OVR	PRO
Sensitivity, Up vs. NAT	22%	0%	22%	0%	0%
Sensitivity, Down vs. NAT	33%	50 %	22%	0%	20%
Sensitivity, Up vs. NRM	78%	78 %	56%	50%	40%
Sensitivity, Down vs. NRM	0%	0%	0%	25%	0%
Specificity	8.05 %	8%	13.79 %	13.17 %	7.95 %

Altogether, the tissue specificity, plus the mRNA differential expression in the samples tested are believed to make Ovr107v4 a good marker for diagnosing, monitoring, staging, imaging and/or treating ovarian cancer.

Primers used for QPCR Expression Analysis of Ovr107v4 are as follows:

(Ovr107v4_forward): GGAGCCCTGAGCATTGTAATATG (SEQ ID NO:335)

(Ovr107v4_reverse): CCCTGGTAGCCGGGTAGAG (SEQ ID NO:336)

(Ovr107v4_probe): CAGATGGTGTGCCAACTGCTGT (SEQ ID NO:337)

DEX0455_053.nt.2 (Ovr110v1)

The relative expression level of Ovr110v1 in various tissue samples is included below. Tissue samples include 74 pairs of matching samples, 11 non matched cancer
 5 samples, and 39 normal samples, all from various tissues annotated in the table. A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. Of the normal samples 5 were blood samples which measured the expression levels in blood
 10 cells. Additionally, 2 prostatitis, and 4 Benign Prostatic Hyperplasia (BPH) samples are included. All the values are compared to breast normal sample MAM01MA (calibrator).

The table below contains the relative expression level values for the sample as compared to the calibrator. The table includes the Sample ID, and expression level values for the following samples: Cancer (CAN), Normal Adjacent Tissue (NAT), Normal Tissue (NRM), Benign Prostatic Hyperplasia (BPH), and Prostatitis (PROST).

Sample ID	CAN	NAT	NRM	BPH	PROST
OVRA084	0.00	0.00			
OVRG010	0.00	0.00			
OVRG021	0.00	0.00			
OVR1157	4.92				
OVR7730	4.23				
OVRC360	0.00				
OVR10050	0.00				
OVR10400	0.11				
OVR1050	0.00				
OVR130X	0.00				
OVR7180	0.33				
OVRA1B	0.07				
OVRA35GA			0.00		
OVRC087			0.00		
OVRC109			0.00		
OVR206I			0.00		
OVR5150			0.00		
OVR18GA			0.00		
OVR3370			0.00		
OVR1230			0.00		
OVRC177			0.00		
OVR40G			0.00		
OVR4510			0.00		
BLD030B	0.00	0.53			
BLD520B	0.00	0.00			
BLDTR17	0.00	0.03			

CLN401C	0.00	0.00			
CLNAS43	0.00	0.00			
CLNAS98	0.00	0.00			
CLNCM12	0.00	0.00			
CLNDC19	0.00	0.00			
CLNRC01	0.00	0.00			
CLNRS53	0.00	0.00			
CLNSG27	0.00	0.00			
CLNTX01	0.00	0.00			
CVXKS52	0.00	0.00			
CVXNKS55	0.03	0.00			
CVXNKS25	0.00	0.29			
CVXNKS18	0.00	0.00			
CVXNKS54	0.00	0.00			
ENDO10479	0.10	0.00			
ENDO28XA	0.78	0.00			
ENDO8XA	0.00	0.01			
KID106XD	0.00	0.00			
KID12XD	0.01	0.15			
KID10XD	0.00	0.00			
KID22K	0.00	0.01			
KID107XD	0.00	0.01			
LNG205L	0.00	0.00			
LNG315L	0.00	0.00			
LNG507L	0.00	0.00			
LNG528L	0.00	0.00			
LNG8837L	0.21	0.00			
LNGAC11	0.01	0.00			
LNGAC39	0.00	0.00			
LNGSQ80	0.00	0.00			
LNGSQ81	0.08	0.00			
LVR15XA	0.00	0.00			
LVR174L	0.00	0.00			
LVR187L	0.00	0.03			
MAM19DN	0.36	1.23			
MAM42DN	0.09	0.00			
MAM517	0.00	0.00			
MAM781M	0.47	0.00			
MAM869M	0.46	0.00			
MAM976M	0.22	0.00			
MAMS570	0.55	0.45			
MAMS699	0.22	1.06			
MAMS997	0.73	0.21			
PAN71XL	0.00	0.00			
PAN77X	0.00				
PAN92X	0.00	0.00			
PRO10R					0.00

PRO20R					0.00
PRO23B	0.00	0.00			
PRO263C				0.00	
PRO276P				0.01	
PRO65XB	0.01	0.01			
PRO675P	0.00	0.00			
PRO767B				0.35	
PRO84XB	0.00	0.08			
PRO855P				0.00	
PRO958P	0.03	0.03			
SKN287S	0.00	0.00			
SKN39A	0.00	0.00			
SKN669S	0.00	0.00			
SMINT171S	0.00	0.00			
SMINT20SM	0.00	0.00			
SMINTH89	0.00	0.00			
STO261S	0.00	0.00			
STO288S	0.00	0.00			
STOAC93	0.00	0.00			
STO88S	0.00	0.00			
THRD143N	0.00	0.00			
THRD270T	0.00	0.00			
THRD56T	0.00	0.00			
TST39X	0.84	0.00			
TST647T	0.00	0.00			
TST663T	0.04	0.00			
UTR135XO	0.00	0.00			
UTR85XU	0.00	0.03			
BLOB3			0.00		
BLOB11			0.00		
BLO69			0.00		
BLO72			0.00		
BLO73			0.00		
ADR48AD			0.00		
BRN10BR			0.00		
CLN01CL			0.00		
CVX06CV			0.00		
ESO01ES			0.00		
HRT46HR			0.00		
HUMREF00HR	0.00				
KID55KD			0.00		
LVR89LV			0.00		
LNG90LN			0.00		
MAM01MA			1.00		
MSL84MU			0.00		
OVR3APV			0.00		
PAN04PA			0.00		

PLA59PL			0.00		
PRO09PR			0.51		
REC21RC			0.00		
SMINT59SM			0.00		
SPL7GSP			0.00		
STO09ST			0.00		
THYM99TM			0.00		
TRA16TR			0.15		
TST4GTS			0.15		
UTR57UT			0.00		

0.00= Negative or no expression

The sensitivity for Ovr110v1 expression was calculated for the cancer samples versus normal samples. The sensitivity value indicates the percentage of cancer samples that show levels of Ovr110v1 at least 2 fold higher than the normal tissue or the corresponding normal adjacent form the same patient.

This specificity is an indication of the level of ovary tissue specific expression of the transcript compared to all the other tissue types tested in our assay. Thus, these experiments indicate Ovr110v1 being useful as an ovarian cancer diagnostic marker and/or therapeutic target.

Sensitivity and specificity data is reported in the table below.

	CLN	LNG	MAM	OVR	PRO
Sensitivity, Up vs. NAT	0%	33%	56%	0%	0%
Sensitivity, Down vs. NAT	0%	0%	22%	0%	20%
Sensitivity, Up vs. NRM	0%	33%	0%	42%	0%
Sensitivity, Down vs. NRM	0%	0%	78%	0%	100%
Specificity	74.73 %	76.34 %	89.78 %	76.27 %	79.26 %

Altogether, the tissue specificity, plus the mRNA differential expression in the samples tested are believed to make Ovr110v1 a good marker for diagnosing, monitoring, staging, imaging and/or treating ovarian cancer.

Additionally, the tissue specificity, plus the mRNA differential expression in the samples tested may make Ovr110v1 a good marker for diagnosing, monitoring, staging, imaging and/or treating lung cancer.

Primers used for QPCR Expression Analysis of Ovr110v1 are as follows:

(Ovr110v1_forward): TCATTGGCTTTGGTATTTCAGAAG (SEQ ID NO:338)

(Ovr110v1_reverse): GTTCAGGAAGCAAAGATCAATGC (SEQ ID NO:339)

(Ovr110v1_probe): AGCAATGAAGGGTTTGGTTGTAGAAG (SEQ ID NO:340)

Conclusions

Altogether, the high level of tissue specificity, plus the mRNA overexpression in
5 matched samples tested are indicative of SEQ ID NO: 1-128 being a diagnostic marker
and/or a therapeutic target for cancer.

Example 3: Protein Expression

The OSNA is amplified by polymerase chain reaction (PCR) and the amplified
DNA fragment encoding the OSNA is subcloned in pET-21d for expression in E. coli. In
10 addition to the OSNA coding sequence, codons for two amino acids, Met-Ala, flanking the
NH₂-terminus of the coding sequence of OSNA, and six histidines, flanking the
COOH-terminus of the coding sequence of OSNA, are incorporated to serve as initiating
Met/restriction site and purification tag, respectively.

An over-expressed protein band of the appropriate molecular weight may be
15 observed on a Coomassie blue stained polyacrylamide gel. This protein band is confirmed
by Western blot analysis using monoclonal antibody against 6X Histidine tag.

Large-scale purification of OSP is achieved using cell paste generated from 6-liter
bacterial cultures, and purified using immobilized metal affinity chromatography (IMAC).
Soluble fractions that are separated from total cell lysate were incubated with a nickel
20 chelating resin. The column is packed and washed with five column volumes of wash
buffer. OSP is eluted stepwise with various concentration imidazole buffers.

Example 4: Fusion Proteins

The human Fc portion of the IgG molecule can be PCR amplified, using primers
that span the 5' and 3' ends of the sequence described below. These primers also should
25 have convenient restriction enzyme sites that will facilitate cloning into an expression
vector, preferably a mammalian expression vector. For example, if pC4 (Accession No.
209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note
that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc
portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the
30 present invention, isolated by the PCR protocol described in Example 2, is ligated into this
BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a
fusion protein will not be produced. If the naturally occurring signal sequence is used to

produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. *See, e.g.*, WO 96/34891.

Example 5: Production of an Antibody from a Polypeptide

5 In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential
10 amino acids, about 1,000 U/ml of penicillin, and about 100, µg/ml of streptomycin. The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP20), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT
15 medium, and then cloned by limiting dilution as described by Wands *et al.*, *Gastroenterology* 80: 225-232 (1981).

 The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide. Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step
20 procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened
25 to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

Example 6: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

30 RNA is isolated from individual patients or from a family of individuals that have a phenotype of interest. cDNA is then generated from these RNA samples using protocols

known in the art. *See*, Sambrook (2001), *supra*. The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO: 1-128.

Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky *et al.*,
5 *Science* 252(5006): 706-9 (1991). *See also* Sidransky *et al.*, *Science* 278(5340): 1054-9 (1997).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons are also determined and genomic PCR products
10 analyzed to confirm the results. PCR products harboring suspected mutations are then cloned and sequenced to validate the results of the direct sequencing. PCR products is cloned into T-tailed vectors as described in Holton *et al.*, *Nucleic Acids Res.*, 19: 1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

15 Genomic rearrangements may also be determined. Genomic clones are nick-translated with digoxigenin deoxyuridine 5' triphosphate (Boehringer Mannheim), and FISH is performed as described in Johnson *et al.*, *Methods Cell Biol.* 35: 73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

20 Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C-and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. Johnson (1991). Image collection, analysis and
25 chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

30 **Example 7: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample**

Antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a

final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described above. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced. The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial
5 dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbound polypeptide. Next, 50 µl of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbound conjugate. 75 µl of
10 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution are added to each well and incubated 1 hour at room temperature.

The reaction is measured by a microtiter plate reader. A standard curve is prepared, using serial dilutions of a control sample, and polypeptide concentrations are plotted on the X-axis (log scale) and fluorescence or absorbance on the Y-axis (linear
15 scale). The concentration of the polypeptide in the sample is calculated using the standard curve.

Example 8: Formulating a Polypeptide

The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the
20 individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of secreted
25 polypeptide administered parenterally per dose will be in the range of about 1, µg/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1
30 µg/kg/hour to about 50 mg/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the

interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, 5 topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and 10 intraarticular injection and infusion.

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semipermeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained-release matrices include polylactides (U. S. Pat. No.3,773,919, EP 58,481, the contents of 15 which are hereby incorporated by reference herein in their entirety), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22: 547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15: 167-277 (1981), and R. Langer, Chem. Tech. 12: 98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988). Sustained-release 20 compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE Epstein et al., Proc. Natl. Acad. Sci. USA 82: 3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77: 4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324, the 25 contents of which are hereby incorporated by reference herein in their entirety. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is 30 formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.

For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides. Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably, the carrier is a parenteral carrier, more preferably, a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e. g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1 % (w/v) aqueous polypeptide solution, and the resulting mixture

is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container (s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

Example 9: Method of Treating Decreased Levels of the Polypeptide

It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided above.

Example 10: Method of Treating Increased Levels of the Polypeptide

Antisense or RNAi technology are used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided above.

Example 11: Method of Treatment Using Gene Therapy

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e. g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks. pMV-7 (Kirschmeier, P. T. et al., DNA, 7: 219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 3. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB 101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+aml2 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing

the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media.

5 If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

10 The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

Example 12: Method of Treatment Using Gene Therapy-In Vivo

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences
15 into an animal to increase or decrease the expression of the polypeptide.

The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, Tabata H. *et al. Cardiovasc. Res.* 35 (3): 470-479 (1997); Chao J
20 *et al. Pharmacol. Res.* 35 (6): 517-522 (1997); Wolff J. A. *Neuromuscul. Disord.* 7 (5): 314-318 (1997), Schwartz B. *et al. Gene Ther.* 3 (5): 405-411 (1996); and Tsurumi Y. *et al. Circulation* 94 (12): 3281-3290 (1996); W0 90/11092, W0 98/11779; U. S. Patent No. 5,693,622; 5,705,151; 5,580,859, the contents of which are hereby incorporated by reference herein in their entirety.

25 The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, ovarian, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

30 The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be

delivered in liposome formulations (such as those taught in Felgner P. L. *et al. Ann. NY Acad. Sci.* 772: 126-139 (1995) and Abdallah B. *et al. Biol. Cell* 85 (1): 1-7 (1995)) which can be prepared by methods well known to those skilled in the art.

5 The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-
10 replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, ovarian, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach,
15 intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by
20 the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or
25 less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. In vivo muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 µg/kg body weight to about 50 mg/kg body
30 weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined

by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to ovarians
5 or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle in vivo is determined as follows. Suitable template DNA for production of mRNA coding for
10 polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by
15 intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin
20 is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different
25 mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice.

The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

30 **Example 13: Transgenic Animals**

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea

pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, e. g., baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

5 Any technique known in the art may be used to introduce the transgene (I. e., polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., *Appl. Microbiol. Biotechnol.* 40: 691-698 (1994); Carver et al., *Biotechnology* 11: 1263-1270 (1993); Wright et al., *Biotechnology* 9: 830-834 (1991); and
10 U. S. Pat. No. 4,873,191, the contents of which is hereby incorporated by reference herein in its entirety); retrovirus mediated gene transfer into germ lines (Van der Putten et al., *Proc. Natl. Acad. Sci., USA* 82: 6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., *Cell* 56: 313-321 (1989)); electroporation of cells or embryos (Lo, 1983, *Mol Cell. Biol.* 3: 1803-1814 (1983)); introduction of the
15 polynucleotides of the invention using a gene gun (see, e. g., Ulmer et al., *Science* 259: 1745 (1993); introducing nucleic acid constructs into embryonic pleuripotent stem cells and transferring the stem cells back into the blastocyst; and sperm mediated gene transfer (Lavitrano et al., *Cell* 57: 717-723 (1989). For a review of such techniques, see Gordon, "Transgenic Animals," *Intl. Rev. Cytol.* 115: 171-229 (1989).

20 Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., *Nature* 380: 64-66 (1996); Wilmut et al., *Nature* 385: 810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in
25 all their cells, as well as animals which carry the transgene in some, but not all their cells, I. e., mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, e.g., head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al.,
30 *Proc. Natl. Acad. Sci. USA* 89: 6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting

is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene
5 may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., *Science* 265: 103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

10 Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques
15 which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, in situ hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

20 Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because
25 of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is
30 appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant

expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Example 14: Knock-Out Animals

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (E. g., see Smithies et al., *Nature* 317: 230-234 (1985); Thomas & Capecchi, *Cell* 51: 503512 (1987); Thompson et al., *Cell* 5: 313-321 (1989)) Alternatively, RNAi technology may be used. For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention in vivo. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e. g., see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However, this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site in vivo using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e. g., knockouts) are administered to a patient in vivo. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e. g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered in vitro using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or

transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.

The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve
5 expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e. g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e. g., genetically engineered fibroblasts can be implanted as part of a skin graft;
10 genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U. S. Patent No. 5,399,349; and Mulligan & Wilson, U. S. Patent No. 5,460,959, the contents of which are hereby incorporated by reference herein in their entirety).

When the cells to be administered are non-autologous or non-MHC compatible
15 cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

20 Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

25 While preferred illustrative embodiments of the present invention are described, one skilled in the art will appreciate that the present invention can be practiced by other than the described embodiments, which are presented for purposes of illustration only and not by way of limitation. The present invention is limited only by the claims that follow.

We claim:

1. An isolated nucleic acid molecule comprising:
 - (a) a nucleic acid molecule comprising a nucleic acid sequence that encodes an amino acid sequence of SEQ ID NO: 129-295;
 - 5 (b) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-128;
 - (c) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (a) or (b); or
 - (d) a nucleic acid molecule having at least 95% sequence identity to the nucleic acid molecule of (a) or (b).
- 10 2. The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is a cDNA.
- 15 3. The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is genomic DNA.
4. The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is an RNA.
- 20 5. The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is a mammalian nucleic acid molecule.
6. The nucleic acid molecule according to claim 5, wherein the nucleic acid molecule is a human nucleic acid molecule.
- 25 7. A method for determining the presence of an ovarian specific nucleic acid (OSNA) in a sample, comprising the steps of:
 - (a) contacting the sample with the nucleic acid molecule of SEQ ID NO: 1-128 under conditions in which the nucleic acid molecule will selectively hybridize to an ovarian specific nucleic acid; and
- 30

- (b) detecting hybridization of the nucleic acid molecule to an OSNA in the sample, wherein the detection of the hybridization indicates the presence of an OSNA in the sample.
- 5 8. A vector comprising the nucleic acid molecule of claim 1.
9. A host cell comprising the vector according to claim 8.
- 10 10. A method for producing a polypeptide encoded by the nucleic acid molecule according to claim 1, comprising the steps of:
- (a) providing a host cell comprising the nucleic acid molecule operably linked to one or more expression control sequences, and
- (b) incubating the host cell under conditions in which the polypeptide is produced.
- 15 11. A polypeptide encoded by the nucleic acid molecule according to claim 1.
12. An isolated polypeptide selected from the group consisting of:
- 20 (a) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 129-295 ; or
- (b) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-128.
- 25 13. An antibody or fragment thereof that specifically binds to:
- (a) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 129-295 ; or
- (b) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-128.
- 30 14. A method for determining the presence of an ovarian specific protein in a sample, comprising the steps of:

- (a) contacting the sample with a suitable reagent under conditions in which the reagent will selectively interact with the ovarian specific protein comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 129-295; and
- 5 (b) detecting the interaction of the reagent with an ovarian specific protein in the sample, wherein the detection of binding indicates the presence of an ovarian specific protein in the sample.
15. A method for diagnosing or monitoring the presence and metastases of ovarian cancer in a patient, comprising the steps of:
- 10 (a) determining an amount of:
- (i) a nucleic acid molecule comprising a nucleic acid sequence that encodes an amino acid sequence of SEQ ID NO: 129-295;
- (ii) a nucleic acid molecule comprising a nucleic acid sequence of SEQ
15 ID NO: 1-128;
- (iii) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (i) or (ii);
- (iv) a nucleic acid molecule having at least 95% sequence identity to the nucleic acid molecule of (i) or (ii);
- 20 (v) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 129-295 ; or
- (vi) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-128
25 and;
- (b) comparing the amount of the determined nucleic acid molecule or the polypeptide in the sample of the patient to the amount of the ovarian specific marker in a normal control; wherein a difference in the amount of the nucleic acid molecule or the polypeptide in the sample compared to the amount of the nucleic
30 acid molecule or the polypeptide in the normal control is associated with the presence of ovarian cancer.

16. A kit for detecting a risk of cancer or presence of cancer in a patient, said kit comprising a means for determining the presence of:

- (a) a nucleic acid molecule comprising a nucleic acid sequence that encodes an amino acid sequence of SEQ ID NO: 129-295;
- 5 (b) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-128;
- (c) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (a) or (b); or
- (d) a nucleic acid molecule having at least 95% sequence identity to the nucleic acid molecule of (a) or (b); or
- 10 (e) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 129-295 ; or
- (f) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule
- 15 comprising a nucleic acid sequence of SEQ ID NO: 1-128.

17. A method of treating a patient with ovarian cancer, comprising the step of administering a composition consisting of:

- (a) a nucleic acid molecule comprising a nucleic acid sequence that encodes an amino acid sequence of SEQ ID NO: 129-295;
- 20 (b) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-128;
- (c) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (a) or (b);
- 25 (d) a nucleic acid molecule having at least 95% sequence identity to the nucleic acid molecule of (a) or (b);
- (e) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 129-295 ; or
- (f) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule
- 30 comprising a nucleic acid sequence of SEQ ID NO: 1-128;

to a patient in need thereof, wherein said administration induces an immune response against the ovarian cancer cell expressing the nucleic acid molecule or polypeptide.

18. A vaccine comprising the polypeptide or the nucleic acid encoding the polypeptide of claim 12.

FIGURE 1

EpCAM_nt	1		0
Ovr232_nt	1	CAGATCTCAATTATCTAATTGCAATTGCAACGAGAACCAAAGCAGGGGAG	50
EpCAM_nt	1		0
Ovr232_nt	51	CAGAGACAAACAATTTCTGAGGTAACCAGATGGCTTTATTAACTCAAGTT	100
EpCAM_nt	1		0
Ovr232_nt	101	CTCACCTAAAATTGCCCTCAAGAATCCTGTGGGAATGGGTTGCAGTGGTG	150
EpCAM_nt	1		0
Ovr232_nt	151	TGGCCCTGGATTACACAACCGACAGAGCTTCTGAATTCTGAGTGATCTGTA	200
EpCAM_nt	1		0
Ovr232_nt	201	CACAAACACACCTCTGCCTGGGTTACACGCCTCCACGTTCTCTATCCAG	250
EpCAM_nt	1		0
Ovr232_nt	251	TTCCCGCACCCCTTCCCCCAGGCCCATTTCTTCAAGGCTTCAGAGCAGCG	300
EpCAM_nt	1		0
Ovr232_nt	301	CTCCTCCGGTTAAAAGGAAGTCTCAGCACAGAATCTTCAAACCTCCTCGG	350
EpCAM_nt	1		0
Ovr232_nt	351	AGGCCACCAAAGATCCCTAACGCCGCCATGGAGACGAAGCACCTGGGGCG	400
EpCAM_nt	1		0
Ovr232_nt	401	GGGCGGAGCGGGGCGCGGGGCCACACCTGTGGAGAGGGCCGCGCCCCA	450
EpCAM_nt	1		0
Ovr232_nt	451	ACTGCAGCGCCGGGGCTGGGGGAGGGGAGCCTACTCACTCCCCCAACTCC	500
EpCAM_nt	1		0
Ovr232_nt	501	CGGGCGGTGACTCATCAACGAGCACCAGCGGCCAGAGGTGAGCAGTCCCG	550
EpCAM_nt	1		0
Ovr232_nt	551	GGAAGGGGCCGAGAGGCGGGGCCGAGGTCGGGCAGGTGTGCGCTCCGC	600
EpCAM_nt	1	CGGCGAGCGAGCACCTTCGAC	21
Ovr232_nt	601	CCCCCGCGCGCACAGAGCGCTAGTCCTTCGGCGAGCGAGCACCTTCGAC	650
EpCAM_nt	22	GCGGTCCGGGGACCCCCCTCGTCTGCTGTCTCCCGACGCGGACCCGCGTGC	71
Ovr232_nt	651	GCGGTCCGGGGACCCCCCTCGTCTGCTGTCTCCCGACGCGGACCCGCGTGC	700
EpCAM_nt	72	CCCAGGCCTCGCGCTGCCCGCCGGCTCCTCGTGTCCCACTCCCGGCGCA	121
Ovr232_nt	701	CCCAGGCCTCGCGCTGCCCGCCGGCTCCTCGTGTCCCACTCCCGGCGCA	750

FIGURE 1 (continued)

EpCAM_nt	122	CGCCCTCCCGCGAGTCCCGGGCCCCCTCCCGCGCCCCCTCTTCTCGGCGCGC	171
Ovr232_nt	751	CGCCCTCCCGCGAGTCCCGGGCCCCCTCCCGCGCCCCCTCTTCTCGGCGCGC	800
EpCAM_nt	172	GCGCAGCATGGCGCCCCCGCAGGTCTCGCGTTCTGGGCTTCTGCTTGCCG	221
Ovr232_nt	801	GCGCAGCATGGCGCCCCCGCAGGTCTCGCGTTCTGGGCTTCTGCTTGCCG	850
EpCAM_nt	222	CGGCGACGGCGACTTTTGCCGCAGCTCAGGAAGAATGTGTCTGTGAAAAAC	271
Ovr232_nt	851	CGGCGACGGCGACTTTTGCCGCAGCTCAGGAAGAATGTGTCTGTGAAAAAC	900
EpCAM_nt	272	TACAAGCTGGCCGTAAACTGCTTTGTGAATAATAATCGTCAATGCCAGTG	321
Ovr232_nt	901	TACAAGCTGGCCGTAAACTGCTTTGTGAATAATAATCGTCAATGCCAGTG	950
EpCAM_nt	322	TACTTCAGTTGGTGACAAAATACTGTCAATTTGCTCAAAGC-----	362
Ovr232_nt	951	TACTTCAGTTGGTGACAAAATACTGTCAATTTGCTCAAAGCGTGAGTAAA	1000
EpCAM_nt	363	-----	362
Ovr232_nt	1001	ATATCCTAATTACCTGTAAGCTTTATTTTGACTTAATACTTCTTTAATTG	1050
EpCAM_nt	363	-----	362
Ovr232_nt	1051	ATGTGCCTTGAGTTGGAAAGAGTTTTATTGGCTTAAATCTGAATCATGTT	1100
EpCAM_nt	363	-----	362
Ovr232_nt	1101	ACAAAGTAAGTGTGGGAACACATAAATTTCAAATAATCTTTGACCCTGGA	1150
EpCAM_nt	363	-----	362
Ovr232_nt	1151	ACTTTAGAGTTAATTTTTTTTTTTTCCCGTAATCATGAAATCAGTTATTTTT	1200
EpCAM_nt	363	-----TGGCTGCCAAATGTTTGGTGAT	384
Ovr232_nt	1201	CAGTTTGGCATTAAAGGTTTCTTTTTTCAGTGGCTGCCAAATGTTTGGTGAT	1250
EpCAM_nt	385	GAAGGCAGAAATGAATGGCTCAAACTTGGGAGAAGAGCAAAACCTGAAG	434
Ovr232_nt	1251	GAAGGCAGAAATGAATGGCTCAAACTTGGGAGAAGAGCAAAACCTGAAG	1300
EpCAM_nt	435	GGGCCCTCCAGAACAATGATGGGCTTTATGATCCTGACTGCGATGAGAGC	484
Ovr232_nt	1301	GGGCCCTCCAGAACAATGATGGGCTTTATGATCCTGACTGCGATGAGAGC	1350
EpCAM_nt	485	GGGCTCTTTAAGGCCAAGCAGTGCAACGGCACCTCCACGTGCTGGTGTGT	534
Ovr232_nt	1351	GGGCTCTTTAAGGCCAAGCAGTGCAACGGCACCTCCATGTGCTGGTGTGT	1400
EpCAM_nt	535	GAACACTGCTGGGGTCAGAAGAACAGACAAGGACACTGAAATAACCTGCT	584
Ovr232_nt	1401	GAACACTGCTGGGGTCAGAAGAACAGACAAGGACACTGAAATAACCTGCT	1450
EpCAM_nt	585	CTGAGCGAGTGAGAACCCTACTGGATCATCATTGAACTAAAACACAAAGCA	634
Ovr232_nt	1451	CTGAGCGAGTGAGAACCCTACTGGATCATCATTGAACTAAAACACAAAGCA	1500

FIGURE 1 (continued)

EpCAM_nt	635	AGAGAAAAACCTTATGATAGTAAAAGTTTGCGGACTGCACTTCAGAAGGA	684
Ovr232_nt	1501	AGAGAAAAACCTTATGATAGTAAAAGTTTGCGGACTGCACTTCAGAAGGA	1550
EpCAM_nt	685	GATCACAACGCGTTATCAACTGGATCCAAAATTTATCACGAGTATTTTGT	734
Ovr232_nt	1551	GATCACAACGCGTTATCAACTGGATCCAAAATTTATCACGAGTATTTTGT	1600
EpCAM_nt	735	ATGAGAATAATGTTATCACTATTGATCTGGTTCAAAATTCTTCTCAAAAA	784
Ovr232_nt	1601	ATGAGAATAATGTTATCACTATTGATCTGGTTCAAAATTCTTCTCAAAAA	1650
EpCAM_nt	785	ACTCAGAATGATGTGGACATAGCTGATGTGGCTTATTATTTTGAAAAAGA	834
Ovr232_nt	1651	ACTCAGAATGATGTGGACATAGCTGATGTGGCTTATTATTTTGAAAAAGA	1700
EpCAM_nt	835	TGTTAAAGGTGAATCCTTGTTTCATTCTAAGAAAATGGACCTGACAGTAA	884
Ovr232_nt	1701	TGTTAAAGGTGAATCCTTGTTTCATTCTAAGAAAATGGACCTGACAGTAA	1750
EpCAM_nt	885	ATGGGGAACAACCTGGATCTGGATCCTGGTCAAACCTTTAATTTATTATGTT	934
Ovr232_nt	1751	ATGGGGAACAACCTGGATCTGGATCCTGGTCAAACCTTTAATTTATTATGTT	1800
EpCAM_nt	935	GATGAAAAAGCACCTGAATTCTCAATGCAGGGTCTAAAAGCTGGTGTAT	984
Ovr232_nt	1801	GATGAAAAAGCACCTGAATTCTCAATGCAGGGTCTAAAAGCTGGTGTAT	1850
EpCAM_nt	985	TGCTGTTATTGTGGTTGTGGTGATAGCAGTTGTTGCTGGAATTGTTGTGC	1034
Ovr232_nt	1851	TGCTGTTATTGTGGTTGTGGTGATAGCAGTTGTTGCTGGAATTGTTGTGC	1900
EpCAM_nt	1035	TGGTTATTTCCAGAAAAGAAGAGAATGGCAAAGTATGAGAAGGCTGAGATA	1084
Ovr232_nt	1901	TGGTTATTTCCAGAAAAGAAGAGAATGGCAAAGTATGAGAAGGCTGAGATA	1950
EpCAM_nt	1085	AAGGAGATGGGTGAGATGCATAGGGAACCTCAATGCATAACTATATAATTT	1134
Ovr232_nt	1951	AAGGAGATGGGTGAGATGCATAGGGAACCTCAATGCATAACTATATAATTT	2000
EpCAM_nt	1135	GAAGATTATAGAAGAAGGGAAATAGCAAATGGACACAAAATTACAAATGTG	1184
Ovr232_nt	2001	GAAGATTATAGAAGAAGGGAAATAGCAAATGGACACAAAATTACAAATGTG	2050
EpCAM_nt	1185	TGTGCGTGGGACGAAGACATCTTTGAAGGTCATGAGTTTGTTAGTTTAAAC	1234
Ovr232_nt	2051	TGTGCGTGGGACGAAGACATCTTTGAAGGTCATGAGTTTGTTAGTTTAAAC	2100
EpCAM_nt	1235	ATCATATATTTGTAATAGTGAAACCTGTACTCAAAATATAAGCAGCTTGA	1284
Ovr232_nt	2101	ATCATATATTTGTAATAGTGAAACCTGTACTCAAAATATAAGCAGCTTGA	2150
EpCAM_nt	1285	AACTGGCTTTACCAATCTTGAAATTTGACCACAAGTGCTTATATATGCA	1334
Ovr232_nt	2151	AACTGGCTTTACCAATCTTGAAATTTGACCACAAGTGCTTATATATGCA	2200
EpCAM_nt	1335	GATCTAATGTAAAATCCAGAACTTGGACTCCATCGTTAAAATTATTTATG	1384
Ovr232_nt	2201	GATCTAATGTAAAATCCAGAACTTGGACTCCATCGTTAAAATTATTTATG	2250

FIGURE 1 (continued)

EpCAM_nt	1385	TGTAACATTCAAATGTGTGCATTAAATATGCTTCCACAGTAAAAATCTGAA	1434
Ovr232_nt	2251	TGTAACATTCAAATGTGTGCATTAAATATGCTTCCACAGTAAAAATCTGAA	2300
EpCAM_nt	1435	AAACTGATTGTGATTGAAAGCTGCCTTTCTATTTACTTGAGTCTTGATAC	1484
Ovr232_nt	2301	AAACTGATTGTGATTGAAAGCTGCCTTTCTATTTACTTGAGTCTTGATAC	2350
EpCAM_nt	1485	ATACATACTTTTTTATGAGCTATGAAATAAAACATTTTAAACTG	1528
Ovr232_nt	2351	ATACATACTTTTTTATGAGCTATGAAATAAAACATTTTAAACTGAA	2396

FIGURE 2

EpCAM_aa	1	MAPPQVLAFGLLLAAATATFAAAQEECV	CENYKLAVNCFVNNNRQCQCTS	50
Ovr232_aa	1	 MKS	4
EpCAM_aa	51	VGAQNTVICS	KLAACKLVMKAEMNGSKLGRRAKPEGALQNN	DGLYDPDCD 100
Ovr232_aa	5	IFQFGIKVSFS	VAAKCLVMKAEMNGSKLGRRAKPEGALQNN	DGLYDPDCD 54
EpCAM_aa	101	ESGLFKAKQCNGT	STCWCVNTAGVRRTDKDTEITCSERV	RTYWIIEELKH 150
Ovr232_aa	55	ESGLFKAKQCNGT	SMCWCVNTAGVRRTDKDTEITCSERV	RTYWIIEELKH 104
EpCAM_aa	151	KAREKPYDSKSL	R TALQKEITTRYQLDPKFITSILYENNV	ITIDL VQNSS 200
Ovr232_aa	105	KAREKPYDSKSL	R TALQKEITTRYQLDPKFITSILYENNV	ITIDL VQNSS 154
EpCAM_aa	201	QKTQNDVDIAD	VAYYFEKDVKGESLFHSSKMDLTVNGE	QLDLDPGQTLIY 250
Ovr232_aa	155	QKTQNDVDIAD	VAYYFEKDVKGESLFHSSKMDLTVNGE	QLDLDPGQTLIY 204
EpCAM_aa	251	YVDEKAPEFSM	QGLKAGVIAVIVVVVIAVVAGIVVL	VISRKKRMAYEKA 300
Ovr232_aa	205	YVDEKAPEFSM	QGLKAGVIAVIVVVVIAVVAGIVVL	VISRKKRMAYEKA 254
EpCAM_aa	301	EIKEMGEMHREL	NA	314
Ovr232_aa	255	EIKEMGEMHREL	NA	268

FIGURE 3

EpCAM_nt	1		0
Ovr232V1_nt	1	CAGATCTCAATTATCTAATTGCAATTGCAACGAGAACCAAAGCAGGGGAG	50
EpCAM_nt	1		0
Ovr232V1_nt	51	CAGAGACAAACAATTTCTGAGGTAACCAGATGGCTTTATTA ACTCAAGTT	100
EpCAM_nt	1		0
Ovr232V1_nt	101	CTCACCTAAAATTGCCCTCAAGAATCCTGTGGGAATGGGTTGCAGTGGTG	150
EpCAM_nt	1		0
Ovr232V1_nt	151	TGGCCCTGGATT CACAACCGACAGAGCTTCTGAATCTGAGTGATCTGTA	200
EpCAM_nt	1		0
Ovr232V1_nt	201	CACAAACACACCTCTGCCTGGGTTACACGCCTCCACGTTCTCTATCCAG	250
EpCAM_nt	1		0
Ovr232V1_nt	251	TTCCCGCACCCCTTCCCCCAGGCCCATTTCTTCAAGGCTTCAGAGCAGCG	300
EpCAM_nt	1		0
Ovr232V1_nt	301	CTCCTCCGGTTAAAAGGAAGTCTCAGCACAGAATCTTCAAACCTCCTCGG	350
EpCAM_nt	1		0
Ovr232V1_nt	351	AGGCCACCAAAGATCCCTAACGCCGCCATGGAGACGAAGCACCTGGGGCG	400
EpCAM_nt	1		0
Ovr232V1_nt	401	GGGCGGAGCGGGGCGCGGGGCCACACCTGTGGAGAGGGCCGCGCCCCA	450
EpCAM_nt	1		0
Ovr232V1_nt	451	ACTGCAGCGCCGGGGCTGGGGGAGGGGAGCCTACTCACTCCCCCAACTCC	500
EpCAM_nt	1	CGGCGAGCGAGCACCTTCGACG	22
Ovr232V1_nt	501	CGGGCGGTGACTCATCAACGAGCACCAGCGGCCAG-----	535
EpCAM_nt	23	CGGTCCGGGGACCCCTCGTCGCTGTCTCCCGACGCGGACCCGCGTGCC	72
Ovr232V1_nt	536	-----	535
EpCAM_nt	73	CCAGGCCTCGCGCTGCCCCGGCCGGCTCCTCGTGTCCCACTCCCGGCGCAC	122
Ovr232V1_nt	536	-----	535
EpCAM_nt	123	GCCCTCCCGCGAGTCCCGGGCCCCCTCCCGCGCCCCCTTCTCTCGGCGCGCG	172
Ovr232V1_nt	536	-----	535
EpCAM_nt	173	CGCAGCATGGCGCCCCCGCAGGTCCTCGCGTTCGGGGCTTCTGCTTGCCGC	222
Ovr232V1_nt	536	-----	535

FIGURE 3 (continued)

EpCAM_nt	223	GGCGACGGCGACTTTTGGCCGAGCTCAGGAAGAATGTGTCTGTGAAAACT	272
Ovr232V1_nt	536	-----AGAAATGTGTCTGTGAAAACT	555
EpCAM_nt	273	ACAAGCTGGCCGTAAACTGCTTTGTGAATAATAATCGTCAATGCCAGTGT	322
Ovr232V1_nt	556	ACAAGCTGGCCGTAAACTGCTTTGTGAATAATAATCGTCAATGCCAGTGT	605
EpCAM_nt	323	ACTTCAGTTGGTGCACAAAATACTGTCATTTGCTCAAAGCTGGCTGCCAA	372
Ovr232V1_nt	606	ACTTCAGTTGGTGCACAAAATACTGTCATTTGCTCAAAGCTGGCTGCCAA	655
EpCAM_nt	373	ATGTTTGGTGATGAAGGCAGAAATGAATGGCTCAAACTTGGGAGAAGAG	422
Ovr232V1_nt	656	ATGTTTGGTGATGAAGGCAGAAATGAATGGCTCAAACTTGGGAGAAGAG	705
EpCAM_nt	423	CAAACCTGAAGGGGCCCTCCAGAACAATGATGGGCTTTATGATCCTGAC	472
Ovr232V1_nt	706	CAAACCTGAAGGGGCCCTCCAGAACAATGATGGGCTTTATGATCCTGAC	755
EpCAM_nt	473	TGCGATGAGAGCGGGCTCTTTAAGGCCAAGCAGTGCAACGGCACCTCCAC	522
Ovr232V1_nt	756	TGCGATGAGAGCGGGCTCTTTAAGGCCAAGCAGTGCAACGGCACCTCCAT	805
EpCAM_nt	523	GTGCTGGTGTGTGAACACTGCTGGGGTCAGAAGAACAGACAAGGACACTG	572
Ovr232V1_nt	806	GTGCTGGTGTGTGAACACTGCTGGGGTCAGAAGAACAGACAAGGACACTG	855
EpCAM_nt	573	AAATAACCTGCTCTGAGCGAGTGAGAACCTACTGGATCATCATTGAACTA	622
Ovr232V1_nt	856	AAATAACCTGCTCTGAGCGAGTGAGAACCTACTGGATCATCATTGAACTA	905
EpCAM_nt	623	AAACACAAAGCAAGAGAAAAACCTTATGATAGTAAAAGTTTGCGGACTGC	672
Ovr232V1_nt	906	AAACACAAAGCAAGAGAAAAACCTTATGATAGTAAAAGTTTGCGGACTGC	955
EpCAM_nt	673	ACTTCAGAAGGAGATCACACGCGTTATCAACTGGATCCAAAATTTATCA	722
Ovr232V1_nt	956	ACTTCAGAAGGAGATCACACGCGTTATCAACTGGATCCAAAATTTATCA	1005
EpCAM_nt	723	CGAGTATTTTGTATGAGAATAATGTTATCACTATTGATCTGGTTCAAAAT	772
Ovr232V1_nt	1006	CGAGTATTTTGTATGAGAATAATGTTATCACTATTGATCTGGTTCAAAAT	1055
EpCAM_nt	773	TCTTCTCAAAAAACTCAGAATGATGTGGACATAGCTGATGTGGCTTATTA	822
Ovr232V1_nt	1056	TCTTCTCAAAAAACTCAGAATGATGTGGACATAGCTGATGTGGCTTATTA	1105
EpCAM_nt	823	TTTTGAAAAAGATGTTAAAGGTGAATCCTTGTTTCATTCTAAGAAAATGG	872
Ovr232V1_nt	1106	TTTTGAAAAAGATGTTAAAGGTGAATCCTTGTTTCATTCTAAGAAAATGG	1155
EpCAM_nt	873	ACCTGACAGTAAATGGGGAACAACCTGGATCTGGATCCTGGTCAAACCTTA	922
Ovr232V1_nt	1156	ACCTGACAGTAAATGGGGAACAACCTGGATCTGGATCCTGGTCAAACCTTA	1205
EpCAM_nt	923	ATTTATTATGTTGATGAAAAAGCACCTGAATTCTCAATGCAGGGTCTAAA	972
Ovr232V1_nt	1206	ATTTATTATGTTGATGAAAAAGCACCTGAATTCTCAATGCAGGGTCTAAA	1255

FIGURE 3 (continued)

EpCAM_nt	973	AGCTGGTGTATTGCTGTTATTGTGGTTGTGGTGATAGCAGTTGTTGCTG	1022
Ovr232V1_nt	1256	AGCTGGTGTATTGCTGTTATTGTGGTTGTGGTGATAGCAGTTGTTGCTG	1305
EpCAM_nt	1023	GAATTGTTGTGCTGGTTATTTCCAGAAAGAAGAGAATGGCAAAGTATGAG	1072
Ovr232V1_nt	1306	GAATTGTTGTGCTGGTTATTTCCAGAAAGAAGAGAATGGCAAAGTATGAG	1355
EpCAM_nt	1073	AAGGCTGAGATAAAGGAGATGGGTGAGATGCATAGGGAAGTCAATGCATA	1122
Ovr232V1_nt	1356	AAGGCTGAGATAAAGGAGATGGGTGAGATGCATAGGGAAGTCAATGCATA	1405
EpCAM_nt	1123	ACTATATAATTTGAAGATTATAGAAGAAGGGAAATAGCAAATGGACACAA	1172
Ovr232V1_nt	1406	ACTATATAATTTGAAGATTATAGAAGAAGGGAAATAGCAAATGGACACAA	1455
EpCAM_nt	1173	ATTACAAATGTGTGTGCGTGGGACGAAGACATCTTTGAAGGTCATGAGTT	1222
Ovr232V1_nt	1456	ATTACAAATGTGTGTGCGTGGGACGAAGACATCTTTGAAGGTCATGAGTT	1505
EpCAM_nt	1223	TGTTAGTTTAAACATCATATATTTGTAATAGTGAAACCTGTACTCAAATA	1272
Ovr232V1_nt	1506	TGTTAGTTTAAACATCATATATTTGTAATAGTGAAACCTGTACTCAAATA	1555
EpCAM_nt	1273	TAAGCAGCTTGAAACTGGCTTTACCAATCTTGAAATTTGACCACAAGTGT	1322
Ovr232V1_nt	1556	TAAGCAGCTTGAAACTGGCTTTACCAATCTTGAAATTTGACCACAAGTGT	1605
EpCAM_nt	1323	CTTATATATGCAGATCTAATGTAAATCCAGAACTTGGACTCCATCGTTA	1372
Ovr232V1_nt	1606	CTTATATATGCAGATCTAATGTAAATCCAGAACTTGGACTCCATCGTTA	1655
EpCAM_nt	1373	AAATTATTTATGTGTAAACATTCAAATGTGTGCATTAAATATGCTTCCACA	1422
Ovr232V1_nt	1656	AAATTATTTATGTGTAAACATTCAAATGTGTGCATTAAATATGCTTCCACA	1705
EpCAM_nt	1423	GTAAAACTGAAAACTGATTTGTGATTGAAAGCTGCCTTTCTATTTACT	1472
Ovr232V1_nt	1706	GTAAAACTGAAAACTGATTTGTGATTGAAAGCTGCCTTTCTATTTACT	1755
EpCAM_nt	1473	TGAGTCTTGACATACATACTTTTTTATGAGCTATGAAATAAAACATTTT	1522
Ovr232V1_nt	1756	TGAGTCTTGACATACATACTTTTTTATGAGCTATGAAATAAAACATTTT	1805
EpCAM_nt	1523	AAACTG	1528
Ovr232V1_nt	1806	AAACTGAA	1813

FIGURE 4

EpCAM_aa	1	MAPPQVLAFLGLLLAAATATFAA	22
		
Ovr232V1_aa	1	METKHLGRGGAGRAGPHLWRGPRPNCSAGAGGGEPHSPNSRAVTHQRAP	50
EpCAM_aa	23	AQEECVCENYKLAVNCFVNNNRQCQCTSVGAQNTVICSKLAAKCLVMKAE	72
		
Ovr232V1_aa	51	AARECVCENYKLAVNCFVNNNRQCQCTSVGAQNTVICSKLAAKCLVMKAE	100
EpCAM_aa	73	MNGSKLGRRRAKPEGALQNNNDGLYDPDCDESGLFKAKQCNGTSTCWCVNTA	122
		
Ovr232V1_aa	101	MNGSKLGRRRAKPEGALQNNNDGLYDPDCDESGLFKAKQCNGTSMCWCVNTA	150
EpCAM_aa	123	GVRRTDKDTEITCSEVRVTYWIIIECLKHKAREKPYDSKSLRTALQKEITT	172
		
Ovr232V1_aa	151	GVRRTDKDTEITCSEVRVTYWIIIECLKHKAREKPYDSKSLRTALQKEITT	200
EpCAM_aa	173	RYQLDPKFITSILYENNVITIDLQNSSQKTQNDVDIADVAYYFEKDVKG	222
		
Ovr232V1_aa	201	RYQLDPKFITSILYENNVITIDLQNSSQKTQNDVDIADVAYYFEKDVKG	250
EpCAM_aa	223	ESLFHSHKMDLTVNGEQLDLDPGQTLIIYYVDEKAPEFSMQGLKAGVIAVI	272
		
Ovr232V1_aa	251	ESLFHSHKMDLTVNGEQLDLDPGQTLIIYYVDEKAPEFSMQGLKAGVIAVI	300
EpCAM_aa	273	VVVVIAVVAGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA	314
		
Ovr232V1_aa	301	VVVVIAVVAGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA	342

FIGURE 5

EpCAM_nt	1		0
Ovr232V2_nt	1	CAGATCTCAATTATCTAATTGCAATTGCAACGAGAACCAAAGCAGGGGAG	0
EpCAM_nt	1		0
Ovr232V2_nt	51	CAGAGACAAACAATTTCTGAGGTAACCAGATGGCTTTATTAACCTCAAGTT	100
EpCAM_nt	1		0
Ovr232V2_nt	101	CTCACCTAAAATTGCCCTCAAGAATCCTGTGGGAATGGGTTGCAGTGGTG	150
EpCAM_nt	1		0
Ovr232V2_nt	151	TGGCCCTGGATTACACAACCGACAGAGCTTCTGAATTCTGAGTGATCTGTA	200
EpCAM_nt	1		0
Ovr232V2_nt	201	CACAAACACACCTCTGCCTGGGTTACACGCCTCCACGTTCTCTATCCAG	250
EpCAM_nt	1		0
Ovr232V2_nt	251	TTCCCGCACCTTCCCCCAGGCCCATTCCTTCAAGGCTTCAGAGCAGCG	300
EpCAM_nt	1		0
Ovr232V2_nt	301	CTCCTCCGGTTAAAAGGAAGTCTCAGCACAGAATCTTCAAACCTCCTCGG	350
EpCAM_nt	1		0
Ovr232V2_nt	351	AGGCCACCAAAGATCCCTAACGCCGCCATGGAGACGAAGCACCTGGGGCG	400
EpCAM_nt	1		0
Ovr232V2_nt	401	GGGCGGAGCGGGGCGCGGGGCCACACCTGTGGAGAGGGCCGCGCCCCA	450
EpCAM_nt	1		0
Ovr232V2_nt	451	ACTGCAGCGCCGGGGCTGGGGGAGGGGAGCCTACTCACTCCCCAACTCC	500
EpCAM_nt	1		0
Ovr232V2_nt	501	CGGGCGGTGACTCATCAACGAGCACCAGCGGCCAGAGGTGAGCAGTCCCG	550
EpCAM_nt	1		0
Ovr232V2_nt	551	GGAAGGGGCCGAGAGGGCGGGGCCAGGTCGGGCAGGTGTGCGCTCCGC	600
EpCAM_nt	1	CGGCGAGCGAGCACCTTCGAC	21
Ovr232V2_nt	601	CCCGCCGCGCGCACAGAGCGCTAGTCCTTCGGCGAGCGAGCACCTTCGAC	650
EpCAM_nt	22	GCGGTCCGGGGACCCCCCTCGTCGCTGTCTCCCGACGCGGACCCGCGTGC	71
Ovr232V2_nt	651	GCGGTCCGGGGACCCCCCTCGTCGCTGTCTCCCGACGCGGACCCGCGTGC	700
EpCAM_nt	72	CCCAGGCCTCGCGCTGCCCGGCCGGCTCCTCGTGTCCCACTCCCGGCGCA	21
Ovr232V2_nt	701	CCCAGGCCTCGCGCTGCCCGGCCGGCTCCTCGTGTCCCACTCCCGGCGCA	750

FIGURE 5 (continued)

EpCAM_nt	122	CGCCCTCCCGCGAGTCCCGGGCCCCCTCCCGCGCCCCCTCTTCTCGGCGCGC	171
Ovr232V2_nt	751	CGCCCTCCCGCGAGTCCCGGGCCCCCTCCCGCGCCCCCTCTTCTCGGCGCGC	800
EpCAM_nt	172	GCGCAGCATGGCGCCCCCGCAGGTCCCTCGCGTTCGGGCTTCTGCTTGCCG	221
Ovr232V2_nt	801	GCGCAGCATGGCGCCCCCGCAGGTCCCTCGCGTTCGGGCTTCTGCTTGCCG	850
EpCAM_nt	222	CGGCGACGGCGACTTTTGCCGCGAGCTCAGGAAGAAATGTGTCTGTGAAAAAC	271
Ovr232V2_nt	851	CGGCGACGGCGACTTTTGCCGCGAGCTCAGGAAGAAATGTGTCTGTGAAAAAC	900
EpCAM_nt	272	TACAAGCTGGCCGTAAACTGCTTTGTGAATAATAATCGTCAATGCCAGTG	321
Ovr232V2_nt	901	TACAAGCTGGCCGTAAACTGCTTTGTGAATAATAATCGTCAATGCCAGTG	950
EpCAM_nt	322	TACTTCAGTTGGTGCACAAAATACTGTCAATTGCTCAAAGCTGGCTGCCA	371
Ovr232V2_nt	951	TACTTCAGTTGGTGCACAAAATACTGTCAATTGCTCAAAGCTGGCTGCCA	1000
EpCAM_nt	372	AATGTTTGGTGATGAAGGCAGAAATGAATGGCTCAAAACTTGGGAGAAGA	421
Ovr232V2_nt	1001	AATGTTTGGTGATGAAGGCAGAAATGAATGGCTCAAAACTTGGGAGAAGA	1050
EpCAM_nt	422	GCAAAACCTGAAGGGGCCCTCCAGAACAATGATGGGCTTTATGATCCTGA	471
Ovr232V2_nt	1051	GCAAAACCTGAAGGGGCCCTCCAGAACAATGATGGGCTTTATGATCCTGA	1100
EpCAM_nt	472	CTGCGATGAGAGCGGGCTCTTTAAGGCCAAGCAGTGCAACGGCACCTCCA	521
Ovr232V2_nt	1101	CTGCGATGAGAGCGGGCTCTTTAAGGCCAAGCAGTGCAACGGCACCTCCA	1150
EpCAM_nt	522	CGTGCTGGTGTGTGAACACTGCTGGGGTCAGAAGAACAGACAAGGACACT	571
Ovr232V2_nt	1151	TGTGCTGGTGTGTGAACACTGCTGGGGTCAGAAGAACAGACAAGGACACT	1200
EpCAM_nt	572	GAAATAACCTGCTCTGAGCGAGTGAGAACCTACTGGATCATCATTGAACT	621
Ovr232V2_nt	1201	GAAATAACCTGCTCTGAGCGAGTGAGAACCTACTGGATCATCATTGAACT	1250
EpCAM_nt	622	AAAACACAAAGCAAGAGAAAAACCTTATGATAGTAAAAGTTTGCGGACTG	671
Ovr232V2_nt	1251	AAAACACAAAGCAAGAGAAAAACCTTATGATAGTAAAAGTTTGCGGACTG	1300
EpCAM_nt	672	CACTTCAGAAGGAGATCACAAACGCGTTATCAACTGGATCCAAAATTTATC	721
Ovr232V2_nt	1301	CACTTCAGAAGGAGATCACAAACGCGTTATCAACTGGATCCAAAATTTATC	1350
EpCAM_nt	722	ACGAGTATTTTGTATGAGAATAATGTTATCACTATTGATCTGGTTCAAAA	771
Ovr232V2_nt	1351	ACGAGTATTTTGTATGAGAATAATGTTATCACTATTGATCTGGTTCAAAA	1400
EpCAM_nt	772	TTCTTCTCAAAAAACTCAGAATGATGTGGACATAGCTGATGTGGCTTATT	821
Ovr232V2_nt	1401	TTCTTCTCAAAAAACTCAGAATGATGTGGACATAGCTGATGTGGCTTATT	1450
EpCAM_nt	822	ATTTTGAAAAAGATGTTAAAGGTGAATCCTTGTTTCATTCTAAGAAAAATG	871
Ovr232V2_nt	1451	ATTTTGAAAAAGATGATGTGAGTATCATCTTCTTTATTCCTGTGTTTCAGG	1500

FIGURE 5 (continued)

EpCAM_nt	872	GACCTGACAGTAAATGGGGAACAACTGGATCTGGATCCTGGTCAAACTTT	921
Ovr232V2_nt	1501	AATGTAGTCTATCATGCCTCAATGAATTAAATATATTTTCATCACCTTTTT	1550
EpCAM_nt	922	AATTTATTATGTTGATGAAAAAGCACCTGAATTCTCAATGCAGGGTCTAA	971
Ovr232V2_nt	1551	ATCCACTTACAGATCAACCAAATGGTTCGCTGCTGCCGTAAATTTTGTCC	1600
EpCAM_nt	972	AAGCTGGTGTTATTGCTGTTATTGTGGTTGTGGTGATAGCAGTTGTTGCT	1021
Ovr232V2_nt	1601	TCCCTGTCACTCACATGCATCTTGCTTGTTTGTATATTTATGCCTCTTAT	1650
EpCAM_nt	1022	GGAATTGTTGTGCTGGTTATTTCCAGAAAGAAGAGAATGGCAAAGTATGA	1071
Ovr232V2_nt	1651	CAAATTGTTCTGCCTAAATATCTCCCCTCTTTCTTATAATTCTTATTTA	1700
EpCAM_nt	1072	GAAGGCTGAGATAAAGGAGATGGGTGAGATGCATAGGGAACCTCAATGCAT	1121
Ovr232V2_nt	1701	TTATCTACTTGGTGTTACTTAGTTTGTGCATATATGCTCCCCTATG---	1747
EpCAM_nt	1122	AACATATATAATTTGAAGATTATAGAAGAAGGGAAATAGCAAATGGACACA	1171
Ovr232V2_nt	1748	ATATTTATAATTTACACAAATAAAAGTCTGTTAAAAAAGACTGTAAGTGA	1797
EpCAM_nt	1172	AATTACAAATGTGTGTGCGTGGGACGAAGACATCTTTGAAGGTCATGAGT	1221
Ovr232V2_nt	1798	TATGATTAAAAATATTTTGTGAAACTTTAATATATTATAGTGAGGT	1843
EpCAM_nt	1222	TTGTTAGTTTAAACATCATATATTTGTAATAGTGAAACCTGTACTCAAAAT	1271
Ovr232V2_nt	1844		1843
EpCAM_nt	1272	ATAAGCAGCTTGAAACTGGCTTTACCAATCTTGAAATTTGACCACAAGTG	1321
Ovr232V2_nt	1844		1843
EpCAM_nt	1322	TCTTATATATATGCAGATCTAATGTAAAATCCAGAACTTGGACTCCATCGTT	1371
Ovr232V2_nt	1844		1843
EpCAM_nt	1372	AAAATTATTTATGTGTAACATTCAAATGTGTGCATTAAATATGCTTCCAC	1421
Ovr232V2_nt	1844		1843
EpCAM_nt	1422	AGTAAAATCTGAAAACTGATTTGTGATTGAAAGCTGCCTTTCTATTTAC	1471
Ovr232V2_nt	1844		1843
EpCAM_nt	1472	TTGAGTCTTGTTACATACATACTTTTTTATGAGCTATGAAATAAACATTT	1521
Ovr232V2_nt	1844		1843
EpCAM_nt	1522	TAAACTG	1528
Ovr232V2_nt	1844		1843

FIGURE 6

EpCAM_aa	1	MAPPQVLAFGLLLAAATATFAAAQEECV	CENYKLAVNCFVNNNRQCQCTS	50
Ovr232V2_aa	1	MAPPQVLAFGLLLAAATATFAAAQEECV	CENYKLAVNCFVNNNRQCQCTS	50
EpCAM_aa	51	VGAQNTVICS	KLAAKCLVMKAEMNGSKLGRRAKPEGALQNN	100
Ovr232V2_aa	51	VGAQNTVICS	KLAAKCLVMKAEMNGSKLGRRAKPEGALQNN	100
EpCAM_aa	101	ESGLFKAKQCNGTSTCWCVN	TAGVRRTDKDTEITCSE	150
Ovr232V2_aa	101	ESGLFKAKQCNGTSMCWCVN	TAGVRRTDKDTEITCSE	150
EpCAM_aa	151	KAREKPYDSKSLRTALQKEITTRYQLDPKFITSILYENNVITIDL	VQNSS	200
Ovr232V2_aa	151	KAREKPYDSKSLRTALQKEITTRYQLDPKFITSILYENNVITIDL	VQNSS	200
EpCAM_aa	201	QKTQNDVDIADVAYYFEKDVKGESLFHSHKKMDLTVNGEQ	LDLDPGQTLIY	250
Ovr232V2_aa	201	QKTQNDVDIADVAYYFEKDDVSIIFFIPVFRNVVYHASMN		240
EpCAM_aa	251	YVDEKAPEFSMQGLKAGVIAVIVVVVIAVVAGIVVLVISRKKRMAKYEKA		300
Ovr232V2_aa	241			240
EpCAM_aa	301	EIKEMGEMHRELNA		314
Ovr232V2_aa	241			240

FIGURE 7

EpCAM_nt	1		0
Ovr232V3_nt	1	CAGATCTCAATTATCTAATTGCAATTGCAACGAGAACCAAAGCAGGGGAG	50
EpCAM_nt	1		0
Ovr232V3_nt	51	CAGAGACAAACAATTTCTGAGGTAACCAGATGGCTTTATTAAGTCAAGTT	100
EpCAM_nt	1		0
Ovr232V3_nt	101	CTCACCTAAAATTGCCCTCAAGAATCCTGTGGGAATGGGTTCAGTGGTG	150
EpCAM_nt	1		0
Ovr232V3_nt	151	TGGCCCTGGATTCAACAACGACAGAGCTTCTGAATTCTGAGTGATCTGTA	200
EpCAM_nt	1		0
Ovr232V3_nt	201	CACAAACACACCTCTGCCTGGGTTACACGCCTCCACGTTCTCTATCCAG	50
EpCAM_nt	1		0
Ovr232V3_nt	251	TTCCCGCACCTTCCCCCAGGCCCCATTCTTCAAGGCTTCAGAGCAGCG	300
EpCAM_nt	1		0
Ovr232V3_nt	301	CTCCTCCGGTTAAAAGGAAGTCTCAGCACAGAATCTTCAAACCTCTCTCGG	350
EpCAM_nt	1		0
Ovr232V3_nt	351	AGGCCACCAAAGATCCCTAACGCCGCCATGGAGACGAAGCACCTGGGGCG	400
EpCAM_nt	1		0
Ovr232V3_nt	401	GGGCGGAGCGGGGCGCGGGGCCACACCTGTGGAGAGGGCCGCGCCCCA	450
EpCAM_nt	1		0
Ovr232V3_nt	451	ACTGCAGCGCCGGGGCTGGGGGAGGGGAGCCTACTCACTCCCCAACTCC	500
EpCAM_nt	1		0
Ovr232V3_nt	501	CGGGCGGTGACTCATCAACGAGCACCAGCGGCCAGAGGTGAGCAGTCCCG	550
EpCAM_nt	1		0
Ovr232V3_nt	551	GGAAGGGGCCGAGAGGCGGGGCCGCCAGGTTCGGGCAGGTGTGCGCTCCGC	600
EpCAM_nt	1	CGGCGAGCGAGCACCTTCGAC	21
Ovr232V3_nt	601	CCCCCGCGCGCACAGAGCGCTAGTCCTTCGGCGAGCGAGCACCTTCGAC	650
EpCAM_nt	22	GCGGTCCGGGGACCCCTCGTCGCTGTCTCCCGACGCGGACCCGCGTGC	71
Ovr232V3_nt	651	GCGGTCCGGGGACCCCTCGTCGCTGTCTCCCGACGCGGACCCGCGTGC	700
EpCAM_nt	72	CCCAGGCCTCGCGCTGCCCGGCCGGCTCCTCGTGTCCCACTCCCGGCGCA	121
Ovr232V3_nt	701	CCCAGGCCTCGCGCTGCCCGGCCGGCTCCTCGTGTCCCACTCCCGGCGCA	750

FIGURE 7 (continued)

EpCAM_nt	122	CGCCCTCCCGCGAGTCCCGGGCCCCCTCCCGCGCCCCCTCTTCTCGGCGCGC	171
Ovr232V3_nt	751	CGCCCTCCCGCGAGTCCCGGGCCCCCTCCCGCGCCCCCTCTTCTCGGCGCGC	800
EpCAM_nt	172	GCGCAGCATGGCGCCCCCGCAGGTCCTCGCGTTCGGGCTTCTGCTTGCCG	221
Ovr232V3_nt	801	GCGCAGCATGGCGCCCCCGCAGGTCCTCGCGTTCGGGCTTCTGCTTGCCG	850
EpCAM_nt	222	CGGCGACGGCGACTTTTGCCGAGCTCAGGAA-----	253
Ovr232V3_nt	851	CGGCGACGGCGACTTTTGCCGAGCTCAGGAAGGTGAGGCGCGGATTGGA	900
EpCAM_nt	254	-----	253
Ovr232V3_nt	901	GCAGAGTTGTGGAGCTGGGCTGGGCTGGGGGGCAGCGGCCCCCGGCCCTC	950
EpCAM_nt	254	-----	253
Ovr232V3_nt	951	GGCCCCCGAAACGGGCATAATAGGGAGGGGACCAAGAGGCCGCGCTTTCC	1000
EpCAM_nt	254	-----	253
Ovr232V3_nt	1001	AGCGTGGAGACCGGACGGTGCGGCCGTGCTCCGGCTCAGGCCCTCCGCGC	1050
EpCAM_nt	254	-----	253
Ovr232V3_nt	1051	GGTAGGAAACGGCGAGGGCCGTCCCGGGAGCAGCCTCACTTCGCAGCTT	1100
EpCAM_nt	254	-----GAATGTGTCTGTGAAAACTACAAGCTGGCCGTAAACTGCT	293
Ovr232V3_nt	1101	TGCTCGCCTTGAATGTGTCTGTGAAAACTACAAGCTGGCCGTAAACTGCT	1150
EpCAM_nt	294	TTGTGAATAATAATCGTCAATGCCAGTGTACTTCAGTTGGTGCACAAAAT	343
Ovr232V3_nt	1151	TTGTGAATAATAATCGTCAATGCCAGTGTACTTCAGTTGGTGCACAAAAT	1200
EpCAM_nt	344	ACTGTCATTTGCTCAAAGCTGGCTGCCAAATGTTTGGTGATGAAGGCAGA	393
Ovr232V3_nt	1201	ACTGTCATTTGCTCAAAGCTGGCTGCCAAATGTTTGGTGATGAAGGCAGA	1250
EpCAM_nt	394	AATGAATGGCTCAAAACTTGGGAGAAGAGCAAAACCTGAAGGGGCCCTCC	443
Ovr232V3_nt	1251	AATGAATGGCTCAAAACTTGGGAGAAGAGCAAAACCTGAAGGGGCCCTCC	1300
EpCAM_nt	444	AGAACAATGATGGGCTTTATGATCCTGACTGCGATGAGAGCGGGCTCTTT	493
Ovr232V3_nt	1301	AGAACAATGATGGGCTTTATGATCCTGACTGCGATGAGAGCGGGCTCTTT	1350
EpCAM_nt	494	AAGGCCAAGCAGTGCAACGGCACCTCCACGTGCTGGTGTGTGAACACTGC	543
Ovr232V3_nt	1351	AAGGCCAAGCAGTGCAACGGCACCTCCATGTGCTGGTGTGTGAACACTGC	1400
EpCAM_nt	544	TGGGGTCAGAAGAACAGACAAGGACACTGAAATAACCTGCTCTGAGCGAG	593
Ovr232V3_nt	1401	TGGGGTCAGAAGAACAGACAAGGACACTGAAATAACCTGCTCTGAGCGAG	1450
EpCAM_nt	594	TGAGAACCTACTGGATCATCATTTGAACTAAAACACAAAGCAAGAGAAAAA	643
Ovr232V3_nt	1451	TGAGAACCTACTGGATCATCATTTGAACTAAAACACAAAGCAAGAGAAAAA	1500

FIGURE 7 (continued)

EpCAM_nt	644	CCTTATGATAGTAAAAGTTTGC GGACTGCACTTCAGAAGGAGATCACAAC	693
Ovr232V3_nt	1501	CCTTATGATAGTAAAAGTTTGC GGACTGCACTTCAGAAGGAGATCACAAC	1550
EpCAM_nt	694	GCGTTATCAACTGGATCCAAAATTTATCACGAGTATTTTGTATGAGAATA	743
Ovr232V3_nt	1551	GCGTTATCAACTGGATCCAAAATTTATCACGAGTATTTTGTATGAGAATA	1600
EpCAM_nt	744	ATGTTTACTACTATTGATCTGGTTCAAATTCCTTCTCAAAAACTCAGAAT	793
Ovr232V3_nt	1601	ATGTTTACTACTATTGATCTGGTTCAAATTCCTTCTCAAAAACTCAGAAT	1650
EpCAM_nt	794	GATGTGGACATAGCTGATGTGGCTTATTATTTTGAAAAAGATGTTAAAGG	843
Ovr232V3_nt	1651	GATGTGGACATAGCTGATGTGGCTTATTATTTTGAAAAAGATGTTAAAGG	1700
EpCAM_nt	844	TGAATCCTTGTTTCATTCTAAGAAAATGGACCTGACAGTAAATGGGGAAC	893
Ovr232V3_nt	1701	TGAATCCTTGTTTCATTCTAAGAAAATGGACCTGACAGTAAATGGGGAAC	1750
EpCAM_nt	894	AACTGGATCTGGATCCTGGTCAAACCTTTAATTTATTATGTTGATGAAAAA	943
Ovr232V3_nt	1751	AACTGGATCTGGATCCTGGTCAAACCTTTAATTTATTATGTTGATGAAAAA	1800
EpCAM_nt	944	GCACCTGAATTCTCAATGCAGGGTCTAAAAGCTGGTGTTATTGCTGTTAT	993
Ovr232V3_nt	1801	GCACCTGAATTCTCAATGCAGGGTCTAAAAGCTGGTGTTATTGCTGTTAT	1850
EpCAM_nt	994	TGTGGTTGTGGTGATAGCAGTTGTTGCTGGAATTGTTGTGCTGGTTATTT	1043
Ovr232V3_nt	1851	TGTGGTTGTGGTGATAGCAGTTGTTGCTGGAATTGTTGTGCTGGTTATTT	1900
EpCAM_nt	1044	CCAGAAAGAAGAGAATGGCAAAGTATGAGAAGGCTGAGATAAAGGAGATG	1093
Ovr232V3_nt	1901	CCAGAAAGAAGAGAATGGCAAAGTATGAGAAGGCTGAGATAAAGGAGATG	1950
EpCAM_nt	1094	GGTGAGATGCATAGGGAACCTCAATGCATAACTATATAATTTGAAGATTAT	1143
Ovr232V3_nt	1951	GGTGAGATGCATAGGGAACCTCAATGCATAACTATATAATTTGAAGATTAT	2000
EpCAM_nt	1144	AGAAGAAGGGAAATAGCAAATGGACACAAATTACAAATGTGTGTGCGTGG	1193
Ovr232V3_nt	2001	AGAAGAAGGGAAATAGCAAATGGACACAAATTACAAATGTGTGTGCGTGG	2050
EpCAM_nt	1194	GACGAAGACATCTTTGAAGGTCATGAGTTTGTTAGTTTAAACATCATATAT	1243
Ovr232V3_nt	2051	GACGAAGACATCTTTGAAGGTCATGAGTTTGTTAGTTTAAACATCATATAT	2100
EpCAM_nt	1244	TTGTAATAGTGAAACCTGTACTCAAAATATAAGCAGCTTGAAACTGGCTT	1293
Ovr232V3_nt	2101	TTGTAATAGTGAAACCTGTACTCAAAATATAAGCAGCTTGAAACTGGCTT	2150
EpCAM_nt	1294	TACCAATCTTGAAATTTGACCACAAGTGTCTTATATATGCAGATCTAATG	1343
Ovr232V3_nt	2151	TACCAATCTTGAAATTTGACCACAAGTGTCTTATATATGCAGATCTAATG	2200
EpCAM_nt	1344	TAAAATCCAGAACTTGGACTCCATCGTTAAAATTATTTATGTGTAACATT	1393
Ovr232V3_nt	2201	TAAAATCCAGAACTTGGACTCCATCGTTAAAATTATTTATGTGTAACATT	2250

FIGURE 7 (continued)

EpCAM_nt	1394	CAAATGTGTGCATTAAATATGCTTCCACAGTAAAATCTGAAAACTGATT	1443
Ovr232V3_nt	2251	CAAATGTGTGCATTAAATATGCTTCCACAGTAAAATCTGAAAACTGATT	2300
EpCAM_nt	1444	TGTGATTGAAAGCTGCCTTTCTATTTACTTGAGTCTTGTACATACATACT	1493
Ovr232V3_nt	2301	TGTGATTGAAAGCTGCCTTTCTATTTACTTGAGTCTTGTACATACATACT	2350
EpCAM_nt	1494	TTTTTATGAGCTATGAAATAAAACATTTTAACTG	1528
Ovr232V3_nt	2351	TTTTTATGAGCTATGAAATAAAACATTTTAACTGAA	2387

FIGURE 8

EpCAM_aa	1	MAPPQVLAFGLLLAAATATFAAAQE-----	25
Ovr232V3_aa	1	MAPPQVLAFGLLLAAATATFAAAQEGEARIGAKLWSWAGLGGNGPRPSAP	50
EpCAM_aa	26	-----	25
Ovr232V3_aa	51	ETGIIGRGPRGRAFQRGDRTVRPCSGSGPPRGRKRRGPSRGAASLRSFAR	100
EpCAM_aa	26	-ECVCENYKLAVNCFVNNNRQCQCTSVGAQNTVICSKLAACKLVMKAEMN	74
Ovr232V3_aa	101	LECVENYKLAVNCFVNNNRQCQCTSVGAQNTVICSKLAACKLVMKAEMN	150
EpCAM_aa	75	GSKLGRRRAKPEGALQNNDGLYDPDCDESGLFKAKQCNGTSTCWCVNNTAGV	124
Ovr232V3_aa	151	GSKLGRRRAKPEGALQNNDGLYDPDCDESGLFKAKQCNGTSMCWCVNNTAGV	200
EpCAM_aa	125	RRTDKDTEITCSEVRVRYWIIIELKHKAREKPYDSKSLRTALQKEITTRY	174
Ovr232V3_aa	201	RRTDKDTEITCSEVRVRYWIIIELKHKAREKPYDSKSLRTALQKEITTRY	250
EpCAM_aa	175	QLDPKFITSILYENNVITIDLQNSSQKTQNDVDIADVAYYFEKDVKGES	224
Ovr232V3_aa	251	QLDPKFITSILYENNVITIDLQNSSQKTQNDVDIADVAYYFEKDVKGES	300
EpCAM_aa	225	LFHSHKMDLTVNGEQDLDPGQTLIYYVDEKAPEFSMQGLKAGVIAVIVV	274
Ovr232V3_aa	301	LFHSHKMDLTVNGEQDLDPGQTLIYYVDEKAPEFSMQGLKAGVIAVIVV	350
EpCAM_aa	275	VVIAVVAGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA	314
Ovr232V3_aa	351	VVIAVVAGIVVLVISRKKRMAKYEKAEIKEMGEMHRELNA	390

FIGURE 9

Ovr107	1	AGAGCAAGGAAGGGCAGGGGACCTGGGAAGGAAGTTCTGGAAGGCAGTGG	50
455_051.nt.2	1		0
Ovr107	51	GGTTTGAGATTGGACCCAGGGTCAAGATAGAACATGAAGGTGGGATGAGG	100
455_051.nt.2	1		0
Ovr107	101	ACATGAACAGAACATGGCCAAGAAGGATCTGGGGGAGCAGCCAGGACGAG	150
455_051.nt.2	1		0
Ovr107	151	GCGGAGCTGATCCGAGAGGACATCCAGGGGGCTCTGCACAATTACCGCTC	200
455_051.nt.2	1		0
Ovr107	201	GGGCCGCGGGGAGCGCAGGGCGGCGGCGCTCAGGGCCACGCAGGAGGAGT	250
455_051.nt.2	1		0
Ovr107	251	TGCAGCGCGACCGCTCGCCCGCGCTGAGACCCCGCCCCTGCAGCGCCGC	300
455_051.nt.2	1		0
Ovr107	301	CCGTCAGTCCGCGCAGTGATCAGCACCGTAGAGCGGGGCGGGGCCGCGG	350
455_051.nt.2	1		0
Ovr107	351	ACGACCCAGGCGAAGCCCATTCCCGAGGCAGAGGAGGCGCAGAGGCCTG	400
455_051.nt.2	1		0
Ovr107	401	AGCCGGTGGGGACCTCGAGCAA-----CGCTGACTC----GGC-CTCC	438
455_051.nt.2	1	<div style="display: flex; align-items: center;"> <div style="flex: 1;"> <div style="display: flex; justify-content: space-between;"> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> </div> <div>GATCTCTTCCAAATGTCCCGCT--CTCCCCAGGCTCTCC</div> </div> </div>	38
Ovr107	439	CCGGACCTGGGTCC-----CCGGGGTCTGACCTGGCGGTTCTGCA	479
455_051.nt.2	39	<div style="display: flex; align-items: center;"> <div style="flex: 1;"> <div style="display: flex; justify-content: space-between;"> <div> </div> <div> </div> <div> . </div> <div> </div> <div> </div> </div> <div>CC-----TCCCGCCACTTGCCAGGG--CTGACCT-----CA</div> </div> </div>	67
Ovr107	480	-GGCGGAGCGGGAAGTGGACATCCTGAACCACGTGTTTCGACGACGTAGAG	528
455_051.nt.2	68	<div style="display: flex; align-items: center;"> <div style="flex: 1;"> <div style="display: flex; justify-content: space-between;"> <div>. </div> <div> </div> <div> . .. </div> </div> <div>CCGC-----CAT-CTTAACGGGTGTCC-----</div> </div> </div>	89
Ovr107	529	AGCTTTGTATCGAGGCTGCAGAAGTCGGCGGAGGCGGCCAGGGTGCTGGA	578
455_051.nt.2	90	<div style="display: flex; align-items: center;"> <div style="flex: 1;"> <div style="display: flex; justify-content: space-between;"> <div> . . </div> <div> </div> <div> . </div> <div> </div> <div> </div> </div> <div>ACCTCTCT-----CTGC-----CTGCC-TGGTGCTGGC</div> </div> </div>	116
Ovr107	579	GCACCGGGAACGCGGCCGAGGAGCCGGCGCCGGGCGGCT----GGGGAG	624
455_051.nt.2	117	<div style="display: flex; align-items: center;"> <div style="flex: 1;"> <div style="display: flex; justify-content: space-between;"> <div>. </div> <div> . . </div> <div>. </div> <div> </div> <div>. . </div> </div> <div>CC-----CGCGTCCCCA-TCGCC-GCGCCCGTCTGCTCCCTCAGAG</div> </div> </div>	156
Ovr107	625	GGCTTGCTGACGCTGCGGGCCAAGCCGCCCTCGGAGGCCGAGTACACCGA	674
455_051.nt.2	157	<div style="display: flex; align-items: center;"> <div style="flex: 1;"> <div style="display: flex; justify-content: space-between;"> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> </div> <div>GGCTTGCTGACGCTGCGGGCCAAGCCGCCCTCGGAGGCCGAGTACACCGA</div> </div> </div>	206
Ovr107	675	CGTGCTGCAGAAGATCAAGTACGCCTTCAGCCTGCTGGCCCCGGCTGCGCG	724
455_051.nt.2	207	<div style="display: flex; align-items: center;"> <div style="flex: 1;"> <div style="display: flex; justify-content: space-between;"> <div> </div> <div> </div> <div> </div> <div> </div> <div> </div> </div> <div>CGTGCTGCAGAAGATCAAGTACGCCTTCAGCCTGCTGGCCCCGGCTGCGCG</div> </div> </div>	256

FIGURE 9 (continued)

Ovr107	725	GCAACATCGCCGACCCCTCCTCTCCGGAGCTGTTGCACTTCCTTTTCGGG	774
455_051.nt.2	257	GCAACATCGCCGACCCCTCCTCTCCGGAGCTGTTGCACTTCCTTTTCGGG	306
Ovr107	775	CCTCTGCAGATGATTGTGAACACGTCGGGGGGGCGGAGTTCGCGAGCAG	824
455_051.nt.2	307	CCTCTGCAGATGATTGTGAACACGTCGGGGGGGCGGAGTTCGCGAGCAG	356
Ovr107	825	TGTGCGGCGGCCGCATCTGACATCGGATGCCGTGGCGCTGCTGCGGGACA	874
455_051.nt.2	357	TGTGCGGCGGCCGCATCTGACATCGGATGCCGTGGCGCTGCTGCGGGACA	406
Ovr107	875	ACGTCACTCCACGTGAAAACGAGCTCTGGACCTCGCTGGGGGACTCGTGG	924
455_051.nt.2	407	ACGTCACTCCACGTGAAAACGAGCTCTGGACCTCGCTGGGGGACTCGTGG	456
Ovr107	925	ACCCGCCCCGGGCTGGAGCTGTCCCCGGAGGAGGGACCCCATACAGACC	974
455_051.nt.2	457	ACCCGCCCCGGGCTGGAGCTGTCCCCGGAGGAGGGACCCCATACAGACC	506
Ovr107	975	CGAGTTCTTCAGCGGCTGGGAGCCGCCGGTCACTGACCCGCAGAGCCGCG	1024
455_051.nt.2	507	CGAGTTCTTCAGCGGCTGGGAGCCGCCGGTCACTGACCCGCAGAGCCGCG	556
Ovr107	1025	CCTGGGAGGACCCAGTTGAGAAACAGCTACAGCACGAGCGGAGGCGCCGG	1074
455_051.nt.2	557	CCTGGGAGGACCCAGTTGAGAAACAGCTACAGCACGAGCGGAGGCGCCGG	606
Ovr107	1075	CAGCAAAGCGCCCCCAGGTCGCTGTCAATGGTCACCGAGACTTGGAGCC	1124
455_051.nt.2	607	CAGCAAAGCGCCCCCAGGTCGCTGTCAATGGTCACCGAGACTTGGAGCC	656
Ovr107	1125	AGAATCTGAGCCTCAGCTGGAGTCAGAGACAGCAGGAAAATGGGTCTCTGT	1174
455_051.nt.2	657	AGAATCTGAGCCTCAGCTGGAGTCAGAGACAGCAGGAAAATGGGTCTCTGT	706
Ovr107	1175	GTAATTATGACTTCCAGGCCCGCAACAGCAGTGAGCTGTCCGGTCAAGCAG	1224
455_051.nt.2	707	GTAATTATGACTTCCAGGCCCGCAACAGCAGTGAGCTGTCCGGTCAAGCAG	756
Ovr107	1225	CGGGACGTACTGGAGGTCCTGGATGACAGTCGTAAGTGGTGGAAGGTTTCG	1274
455_051.nt.2	757	CGGGACGTACTGGAGGTCCTGGATGACAGTCGTAAGTGGTGGAAGGTTTCG	806
Ovr107	1275	GGACCCAGCGGGGCGAGGAGGATATGTGCCCTACAACATCCTGACACCCT	1324
455_051.nt.2	807	GGACCCAGCGGGGCGAGGAGGATATGTGCCCTACAACATCCTGACACCCT	856
Ovr107	1325	ACCCCGGACCCCGGCTGCACCACAGCCAAAGCCCTGCCCCGAGCCTGAAC	1374
455_051.nt.2	857	ACCCCGGACCCCGGCTGCACCACAGCCAAAGCCCTGCCCCGAGCCTGAAC	906
Ovr107	1375	AGCACTCCTCCTCCACCACCAGCCCCAGCCCCGGCCCCACCTCCAGCTCT	1424
455_051.nt.2	907	AGCACTCCTCCTCCACCACCAGCCCCAGCCCCGGCCCCACCTCCAGCTCT	956
Ovr107	1425	GGCTCGGCCCCGCTGGGACAGGCCCGCTGGGACAGCTGCGATAGCCTCA	1474
455_051.nt.2	957	GGCTCGGCCCCGCTGGGACAGGCCCGCTGGGACAGCTGCGATAGCCTCA	1006

FIGURE 9 (continued)

```

Ovr107      1475  ACGGCTTGGACCCCAGCGAGAAGGAGAAATTCTCCAGATGCTCATCGTC 1524
               |||
455_051.nt. 21007 ACGGCTTGGACCCCAGCGAGAAGGAGAAATTCTCCAGATGCTCATCGTC 1056
               |||

Ovr107      1525  AACGAGGAACGTCAGGCGCGCCTGGCCCAGGGCCGCTCGGGACCGAGCCG 1574
               |||
455_051.nt.2 1057  AACGAGGAACGTCAGGCGCGCCTGGCCCAGGGCCGCTCGGGACCGAGCCG 1106
               |||

Ovr107      1575  CGCAGTCCCAGGGCCCCGCGCCCCGGAACCGCAGCTCAGCCCGGGCTCGG 1624
               |||
455_051.nt.2 1107  CGCAGTCCCAGGGCCCCGCGCCCCGGAACCGCAGCTCAGCCCGGGCTCGG 1156
               |||

Ovr107      1625  ACGCCTCCGAGGTCCGCGCCTGGCTGCAGGCCAAGGGCTTTAGCTCCGGG 1674
               |||
455_051.nt.2 1157  ACGCCTCCGAGGTCCGCGCCTGGCTGCAGGCCAAGGGCTTTAGCTCCG-- 1204
               |||

Ovr107      1675  ACCGTGGACGCGCTGGGTGTGCTGACCGGGGCGCAGCTTTTCTCGCTGCA 1724
               |||
455_051.nt.2 1205  ----- 1204
               |||

Ovr107      1725  GAGGGAGGAGCTGCGGGCGGTGAGCCCCGAGGAGGGGGCACGTGTGTACA 1774
               |||.|||
455_051.nt.2 1205  GAAGGAGGAGCTGCGGGCGGTGAGCCCCGAGGAGGGGGCACGTGTGTACA 1254
               |||.|||

Ovr107      1775  GCCAGGTCACCGTGCAGCGCTCGCTGCTGGAGGACAAAGAGAAAGTGTCA 1824
               |||
455_051.nt.2 1255  GCCAGGTCACCGTGCAGCGCTCGCTGCTGGAGGACAAAGAGAAAGTGTCA 1304
               |||

Ovr107      1825  GAGCTGGAGGCAGTGATGGAGAAGCAAAAGAAGAAGGTGGAAGGCGAGGT 1874
               |||
455_051.nt.2 1305  GAGCTGGAGGCAGTGATGGAGAAGCAAAAGAAGAAGGTGGAAGGCGAGGT 1354
               |||

Ovr107      1875  GGAAATGGAGGTCATTTGACCTGCCAGGCGCCCTTCGCAAAGAGTGACGA 1924
               |||
455_051.nt.2 1355  GGAAATGGAGGTCATTTGACCTGCCAGGCGCCCTTCGCAAAGAGTGACGA 1404
               |||

Ovr107      1925  GGCCCCGTGGGAGAACGGACTCCTCAGACTCTCCCCAATAGCGGAAGTCG 1974
               |||
455_051.nt.2 1405  GGCCCCGTGGGAGAACGGACTCCTCAGACTCTCCCCAATAGCGGAAGTCG 1454
               |||

Ovr107      1975  ATCTTCTGAAGGATGGCCAATCTGCTCCGGCCCTGGTCTTCCCCCATCCC 2024
               |||
455_051.nt.2 1455  ATCTTCTGAAGGATGGCCAATCTGCTCCGGCCCTGGTCTTCCCCCATCCC 1504
               |||

Ovr107      2025  GGTGGACAGACTTAACGATCCTTGCTGCAGTCCCTCCGGAGAGGATCTGG 2074
               |||
455_051.nt.2 1505  GGTGGACAGACTTAACGATCCTTGCTGCAGTCCCTCCGGAGAGGATCTGG 1554
               |||

Ovr107      2075  ACTGGCTGGGAGTGGGGAGGGCGTGGAGACAGTCTACGGAAAGCGCTAGC 2124
               |||
455_051.nt.2 1555  ACTGGCTGGGAGTGGGGAGGGCGTGGAGACAGTCTACGGAAAGCGCTAGC 1604
               |||

Ovr107      2125  AGACCCCGAGAGGGTGCAGTGGAGCCCTGAGCATTGTAATATGCGGCC 2174
               |||
455_051.nt.2 1605  AGACCCCGAGAGGGTGCAGTGGAGCCCTGAGCATTGTAATATGCGGCC 1654
               |||

Ovr107      2175  AGCCTATAAACAGCCTCCGTGCTTAGCAAAAAAAAAAAAAAAAAAAAA 2221
               |||.
455_051.nt.2 1655  AGCCTATAAACAGCCTCCGTGCTTAGCAG 1683
               |||.

```

FIGURE 10

[illegible]

[illegible]

[illegible]

FIGURE 12 (continued)

Ovr107	725	GCAACATCGCCGACCCCTCCTCTCCGGAGCTGTTGCAC'TTC'TTTCGGG	774
455_051.nt.3	257	GCAACATCGCCGACCCCTCCTCTCCGGAGCTGTTGCAC'TTC'TTTCGGG	306
Ovr107	775	CCTCTGCAGATGATTGTGAACACGTCGGGGGGGCGGAGTTCGCGAGCAG	824
455_051.nt.3	307	CCTCTGCAGATGATTGTGAACACGTCGGGGGGGCGGAGTTCGCGAGCAG	356
Ovr107	825	TGTGCGGCGGCCGCATCTGACATCGGATGCCGTGGCGCTGCTGCGGGACA	874
455_051.nt.3	357	TGTGCGGCGGCCGCATCTGACATCGGATGCCGTGGCGCTGCTGCGGGACA	406
Ovr107	875	ACGTCAC'TCCACGTGAAAACGAGCTCTGGACCTCGCTGGGGGACTCGTGG	924
455_051.nt.3	407	ACGTCAC'TCCACGTGAAAACGAGCTCTGGACCTCGCTGGGGGACTCGTGG	456
Ovr107	925	ACCCGCCCCGGGCTGGAGCTGTCCCCGGAGGAGGGACCCCCATACAGACC	974
455_051.nt.3	457	ACCCGCCCCGGGCTGGAGCTGTCCCCGGAGGAGGGACCCCCATACAGACC	506
Ovr107	975	CGAGTTCTTCAGCGGCTGGGAGCCGCCGGTCACTGACCCGCAGAGCCGCG	024
455_051.nt.3	507	CGAGTTCTTCAGCGGCTGGGAGCCGCCGGTCACTGACCCGCAGAGCCGCG	556
Ovr107	1025	CCTGGGAGGACCCAGTTGAGAAACAGCTACAGCACGAGCGGAGGCGCCGG	1074
455_051.nt.3	557	CCTGGGAGGACCCAGTTGAGAAACAGCTACAGCACGAGCGGAGGCGCCGG	606
Ovr107	1075	CAGCAAAGCGCCCCCAGGTCGCTGTCAATGGTCACCGAGACTTGGAGCC	1124
455_051.nt.3	607	CAGCAAAGCGCCCCCAGGTCGCTGTCAATGGTCACCGAGACTTGGAGCC	656
Ovr107	1125	AGAATCTGAGCCTCAGCTGGAGTCAGAGACAGCAGGAAAATGGGTCTCTGT	1174
455_051.nt.3	657	AGAATCTGAGCCTCAGCTGGAGTCAGAGACAGCAGGAAAATGGGTCTCTGT	706
Ovr107	1175	GTAATTATGACTTCCAGGCCCGCAACAGCAGTGAGCTGTCCGGTCAAGCAG	1224
455_051.nt.3	707	GTAATTATGACTTCCAGGCCCGCAACAGCAGTGAGCTGTCCGGTCAAGCAG	756
Ovr107	1225	CGGGACGTACTGGAGGTCCTGGATGACAGTCGTAAGTGGTGGAAAGGTTTCG	1274
455_051.nt.3	757	CGGGACGTACTGGAGGTCCTGGATGACAGTCGTAAGTGGTGGAAAGGTTTCG	806
Ovr107	1275	GGACCCAGCGGGGCAGGAGGGATATGTGCCCTACAACATCCTGACACCCT	1324
455_051.nt.3	807	GGACCCAGCGGGGCAGGAGGGATATGTGCCCTACAACATCCTGACACCCT	856
Ovr107	1325	ACCCCGGACCCCGGCTGCACCACAGCCAAAGCCCTGCCCGCAGCCTGAAC	374
455_051.nt.3	857	ACCCCGGACCCCGGCTGCACCACAGCCAAAGCCCTGCCCGCAGCCTGAAC	906
Ovr107	1375	AGCACTCCTCCTCCACCACCAGCCCCAGCCCCGGCCCCACCTCCAGCTCT	1424
455_051.nt.3	907	AGCACTCCTCCTCCACCACCAGCCCCAGCCCCGGCCCCACCTCCAGCTCT	956
Ovr107	1425	GGCTCGGCCCCGCTGGGACAGGCCCCGCTGGGACAGCTGCGATAGCCTCA	1474
455_051.nt.3	957	GGCTCGGCCCCGCTGGGACAGGCCCCGCTGGGACAGCTGCGATAGCCTCA	1006

FIGURE 12 (continued)

Ovr107	1475	ACGGCTTGGACCCCAGCGAGAAGGAGAAATTCTCCCAGATGCTCATCGTC	1524
455_051.nt.3	1007	ACGGCTTGGACCCCAGCGAGAAGGAGAAATTCTCCCAGATGCTCATCGTC	1056
Ovr107	1525	AACGAGGAACTGCAGGCGCGCCTGGCCCAGGGCCGCTCGGGACCGAGCCG	1574
455_051.nt.3	1057	AACGAGGAACTGCAGGCGCGCCTGGCCCAGGGCCGCTCGGGACCGAGCCG	1106
Ovr107	1575	CGCAGTCCCAGGGCCCCGCGCCCCGGAACCGCAGCTCAGCCCGGGCTCGG	1624
455_051.nt.3	1107	CGCAGTCCCAGGGCCCCGCGCCCCGGAACCGCAGCTCAGCCCGGGCTCGG	1156
Ovr107	1625	ACGCCTCCGAGGTCCGCGCCTGGCTGCAGGCCAAGGGCTTTAGCTCCGGG	1674
455_051.nt.3	1157	ACGCCTCCGAGGTCCGCGCCTGGCTGCAGGCCAAGGGCTTTAGCTCCGGG	1206
Ovr107	1675	ACCGTGGACGCGCTGGGTGTGCTGACCGGGGCGCAGCTTTTCTCGCTGCA	1724
455_051.nt.3	1207	ACCGTGGACGCGCTGGGTGTGCTGACCGGGGCGCAGCTTTTCTCGCTGCA	1256
Ovr107	1725	GAGGGAGGAGCTGCGGGCGGTGAGCCCCGAGGAGGGGGCACGTGTGTACA	1774
		.	
455_051.nt.3	1257	GAAGGAGGAGCTGCGGGCGGTGAGCCCCGAGGAGGGGGCACGTGTGTACA	1306
Ovr107	1775	GCCAGGTCACCGTGCAGCGCTCGCTGCTGGAGGACAAAGAGAAAGTGTCA	1824
455_051.nt.3	1307	GCCAGGTCACCGTGCAGCGCTCGCTGCTGGAGGACAAAGAGAAAGTGTCA	1356
Ovr107	1825	GAGCTGGAGGCAGTGATGGAGAAGCAAAAGAAGAAGGTGGAAGGCGAGGT	1874
455_051.nt.3	1357	GAGCTGGAGGCAGTGATGGAGAAGCAAAAGAAGAAGGTGGAAGGCGAGGT	1406
Ovr107	1875	GGAAATGGAGGTCAATTTGACCTGCCAGGCGCCCTTCGCAAAGAGTGACGA	1924
455_051.nt.3	1407	GGAAATGGAGGTCAATTTGACCTGCCAGGCGCCCTTCGCAAAGAGTGACGA	1456
Ovr107	1925	GGCCCCGTGGGAGAACGGACTCCTCAGACTCTCCCCAATAGCGGAAGTCG	1974
455_051.nt.3	1457	GGCCCCGTGGGAGAACGGACTCCTCAGACTCTCCCCAATAGCGGAAGTCG	1506
Ovr107	1975	ATCTTCTGAAGGATGGCCAATCTGCTCCGGCCCTGGTCTTCCCCCATCCC	2024
455_051.nt.3	1507	ATCTTCTGAAGGATGGCCAATCTGCTCCGGCCCTGGTCTTCCCCCATCCC	1556
Ovr107	2025	GGTGGACAGACTTAACGATCCTTGCTGCAGTCCCTCCGGAGAGGATCTGG	2074
455_051.nt.3	1557	GGTGGACAGACTTAACGATCCTTGCTGCAGTCCCTCCGGAGAGGATCTGG	1606
Ovr107	2075	ACTGGCTGGGAGTGGGGAGGGCGTGGAGACAGTCTACGGAAAGCGCTAGC	2124
455_051.nt.3	1607	ACTGGCTGGGAGTGGGGAGGGCGTGGAGACAGTCTACGGAAAGCGCTAGC	1656
Ovr107	2125	AGACCCCCGAGAGGGTGCAGTGGAGCCCTGAGCATTGTAATATGCGGCCC	2174
455_051.nt.3	1657	AGACCCCCGAGAGGGTGCAGTGGAGCCCTGAGCATTGTAATATGCGGCCC	1706
Ovr107	2175	AGCCTATAAACAGCCTCCGTGCTTAGCAAAAAAAAAAAAAAAAAAAAAA	2221
		.	
455_051.nt.3	1707	AGCCTATAAACAGCCTCCGTGCTTAGCAG	1735

Ovr107	1	AGAGCAAGGAAGGGCAGGGGACCTGGGAAGGAAGTTCTGGAAGGCAGTGG	50
455_051.nt.4	1		0
Ovr107	51	GGTTTGAGATTGGACCCAGGGTCAAGATAGAACATGAAGGTGGGATGAGG	100
455_051.nt.4	1		0
Ovr107	101	ACATGAACAGAACATGGCCAAGAAGGATCTGGGGGAGCAGCCAGGACGAG	150
455_051.nt.4	1		0
Ovr107	151	GCGGAGCTGATCCGAGAGGACATCCAGGGGGCTCTGCACAATTACCGCTC	200
455_051.nt.4	1		0
Ovr107	201	GGGCCGCGGGGAGCGCAGGGCGGCGGCGCTCAGGGCCACGCAGGAGGAGT	250
455_051.nt.4	1		0
Ovr107	251	TGCAGCGCGACCGCTCGCCCCCGCTGAGACCCCGCCCTGCAGCGCCGC	300
455_051.nt.4	1		0
Ovr107	301	CCGTCAGTCCGCGCAGTGATCAGCACCGTAGAGCGGGGCGGGGCCGCGG	350
455_051.nt.4	1		0
Ovr107	351	ACGACCCCAGGCGAAGCCCATTTCCCGAGGCAGAGGAGGCGCAGAGGCCTG	400
455_051.nt.4	1		0
Ovr107	401	AGCCGGTGGGGACCTCGAGCAA-----CGCTGACTC----GGC-CTCC	438
455_051.nt.4	1 GATCTCTTCCAAATGTCCCCGCT--CTCCCCAGGCTCTCC	38
Ovr107	439	CCGGACCTGGGTCC-----CCGGGGTCTCTGACCTGGCGGTTCTGCA	79
455_051.nt.4	39	. CC-----TCCCGCCACTTGCCAGGG--CTGACCT-----CA	67
Ovr107	480	-GGCGGAGCGGGAAGTGACATCTGAACCACGTGTTTCGACGACGTAGAG	28
455_051.nt.4	68 CCGC-----CAT-CTTAACCGGGTGTCC-----	89
Ovr107	529	AGCTTTGTATCGAGGCTGCAGAAGTCGGCGGAGGCGGCCAGGGTGCTGGA	78
455_051.nt.4	90 ACCTCTCT-----CTGC-----CTGCC-TGGTGCTGGC	16
Ovr107	579	GCACCGGGAACGCGGCCGCAGGAGCCGGCGCCGGGCGGCT----GGGGAG	24
455_051.nt.4	117 CC-----CGCGTCCCA-TCGCC-GCGCCCGTCTGTCTCCCCTCAGAG	156
Ovr107	625	GGCTTGCTGACGCTGCGGGCCAAGCCGCCCTCGGAGGCCGAGTACACCGA	674
455_051.nt.4	157	 GGCTTGCTGACGCTGCGGGCCAAGCCGCCCTCGGAGGCCGAGTACACCGA	206
Ovr107	675	CGTGCTGCAGAAGATCAAGTACGCCTTCAGCCTGCTGGCCCCGGCTGCGCG	724
455_051.nt.4	207	 CGTGCTGCAGAAGATCAAGTACGCCTTCAGCCTGCTGGCCCCGGCTGCGCG	256

FIGURE 13 (continued)

Ovr107	725	GCAACATCGCCGACCCCTCCTCTCCGGAGCTGTTGCACTTCCTTTTCGGG	774
455_051.nt.4	257	GCAACATCGCCGACCCCTCCTCTCCGGAGCTGTTGCACTTCCTTTTCGGG	306
Ovr107	775	CCTCTGCAGATGATTGTGAACACGTCGGGGGGCCGGAGTTCGCGAGCA	824
455_051.nt.4	307	CCTCTGCAGATGATTGTGAACACGTCGGGGGGCCGGAGTTCGCGAGCAG	356
Ovr107	825	TGTGCGGCGGCCGCATCTGACATCGGATGCCGTGGCGCTGCTGCGGGACA	874
455_051.nt.4	357	TGTGCGGCGGCCGCATCTGACATCGGATGCCGTGGCGCTGCTGCGGGACA	406
Ovr107	875	ACGTCACTCCACGTGAAAACGAGCTCTGGACCTCGCTGGGGGACTCGTGG	924
455_051.nt.4	407	ACGTCACTCCACGTGAAAACGAGCTCTGGACCTCGCTGGGGGACTCGTGG	456
Ovr107	925	ACCCGCCCCGGGCTGGAGCTGTCCCCGGAGGAGGGACCCCCATACAGACC	974
455_051.nt.4	457	ACCCGCCCCGGGCTGGAGCTGTCCCCGGAGGAGGGACCCCCATACAGACC	506
Ovr107	975	CGAGTTCTTCAGCGGCTGGGAGCCGCCGGTCACTGACCCGCAGAGCCGCG	1024
455_051.nt.4	507	CGAGTTCTTCAGCGGCTGGGAGCCGCCGGTCACTGACCCGCAGAGCCGCG	556
Ovr107	1025	CCTGGGAGGACCCAGTTGAGAAACAGCTACAGCACGAGCGGAGGCGCCGG	1074
455_051.nt.4	557	CCTGGGAGGACCCAGTTGAGAAACAGCTACAGCACGAGCGGAGGCGCCGG	606
Ovr107	1075	CAGCAAAGCGCCCCCAGGTCGCTGTCAATGGTCACCGAGACTTGGAGCC	1124
455_051.nt.4	607	CAGCAAAGCGCCCCCAGGTCGCTGTCAATGGTCACCGAGACTTGGAGCC	656
Ovr107	1125	AGAATCTGAGCCTCAGCTGGAGTCAGAGACAGCAGGAAAATGGGTCTGT	1174
455_051.nt.4	657	AGAATCTGAGCCTCAGCTGGAGTCAGAGACAGCAGGAAAATGGGTCTGT	706
Ovr107	1175	GTAATTATGACTTCCAGGCCCGCAACAGCAGTGAGCTGTCTGGTCAAGCAG	224
455_051.nt.4	707	GTAATTATGACTTCCAGGCCCGCAACAGCAGTGAGCTGTCTGGTCAAGCAG	756
Ovr107	1225	CGGGACGTACTGGAGGTCCTGGATGACAGTCGTAAGTGGTGGAAGGTTTCG	1274
455_051.nt.4	757	CGGGACGTACTGGAGGTCCTGGATGACAGTCGTAAGTGGTGGAAGGTTTCG	806
Ovr107	1275	GGACCCAGCGGGGCAGGAGGGATATGTGCCCTACAACATCCTGACACCT	1324
455_051.nt.4	807	GGACCCAGCGGGGCAGGAGGGATATGTGCCCTACAACATCCTGACACCT	856
Ovr107	1325	ACCCCGGACCCCGGCTGCACCACAGCCAAAGCCCTGCCCCGACGCTGAAC	1374
455_051.nt.4	857	ACCCCGGACCCCGGCTGCACCACAGCCAAAGCCCTGCCCCGACGCTGAAC	906
Ovr107	1375	AGCACTCCTCCTCCACCACCAGCCCCAGCCCCGGCCCCACCTCCAGCTCT	1424
455_051.nt.4	907	AGCACTCCTCCTCCACCACCAGCCCCAGCCCCGGCCCCACCTCCAGCTCT	956
Ovr107	1425	GGCTCGGCCCCGCTGGGACAGGCCCCGCTGGGACAGCTGCGATAGCCTCA	1474
455_051.nt.4	957	GGCTCGGCCCCGCTGGGACAGGCCCCGCTGGGACAGCTGCGATAGCCTCA	1006

FIGURE 13 (continued)

```

Ovr107      1475  ACGGCTTGGACCCAGCGAGAAGGAGAAATTCTCCCAGATGCTCATCGTC 1524
               |||
455_051.nt.4 1007  ACGGCTTGGACCCAGCGAGAAGGAGAAATTCTCCCAGATGCTCATCGTC 1056
               |||

Ovr107      1525  AACGAGGAACTGCAGGCGCGCCTGGCCCAGGGCCGCTCGGGACCGAGCCG 1574
               |||
455_051.nt.4 1057  AACGAGGAACTGCAGGCGCGCCTGGCCCAGGGCCGCTCGGGACCGAGCCG 1106
               |||

Ovr107      1575  CGCAGTCCCAGGGCCCCGCGCCCCGGAACCGCAGCTCAGCCCCGGGCTCGG 1624
               |||
455_051.nt.4 1107  CGCAGTCCCAGGGCCCCGCGCCCCGGAACCGCAGCTCAGCCCCGGGCTCGG 1156
               |||

Ovr107      1625  ACGCCTCCGAGGTCCGCGCCTGGCTGCAGGCCAAGGGCTTTAGCTCCGGG 1674
               |||
455_051.nt.4 1157  ACGCCTCCGAGGTCCGCGCCTGGCTGCAGGCCAAGGGCTTTAGCTCCGGG 1206
               |||

Ovr107      1675  ACCGTGGACGCGCTGGGTGTGCTGACCGGGGCGCAGCTTTTCTCGCTGCA 1724
               |||
455_051.nt.4 1207  ACCGTGGACGCGCTGGGTGTGCTGACCGGGGCGCAGCTTTTCTCGCTGCA 1256
               |||

Ovr107      1725  GAGGGAGGAGCTGCGGGCGGTGAGCCCCGAGGAGGGGGCACGTGTGTACA 1774
               |||.|||
455_051.nt.4 1257  GAAGGAGGAGCTGCGGGCGGTGAGCCCCGAGGAGGGGGCACGTGTGTACA 1306
               |||.|||

Ovr107      1775  GCCAGGTCACCGTGCAGCGCTCGCTGCTGGAGGACAAAGAGAAAGTGTC 1824
               |||
455_051.nt.4 1307  GCCAGGTCACCGTGCAGCGCTCGCTGCTGGAGGACAAAGAGAAAGTGTC 1356
               |||

Ovr107      1825  GAGCTGGAGGCAGTGATGGAGAAGCAAAAGAAGAAGGTGGAAGGCGAGGT 1874
               |||
455_051.nt.4 1357  GAGCTGGAGGCAGTGATGGAGAAGCAAAAGAAGAAGGTGGAAGGCGAGGT 1406
               |||

Ovr107      1875  GGAAATGGAGGTCATTTGACCTGCCAGGCGCCCTTCGCAAAGAGTGACGA 1924
               |||
455_051.nt.4 1407  GGAAATGGAGGTCATTTGACCTGCCAGGCGCCCTTCGCAAAGAGTGACGA 1456
               |||

Ovr107      1925  GGCCCCGTGGGAGAACGGACTCCTCAGACTCTCCCCAATAGCGGAAGTCG 1974
               |||
455_051.nt.4 1457  GGCCCCGTGGGAGAACGGACTCCTCAGACTCTCCCCAATAGCGGAAGTCG 1506
               |||

Ovr107      1975  ATCTTCTGAAGGATGGCCAATCTGCTCCGGCCCTGGTCTTCCCCCATCCC 2024
               |||
455_051.nt.4 1507  ATCTTCTGAAGGATGGCCAATCTGCTCCGGCCCTGGTCTTCCCCCATCCC 1556
               |||

Ovr107      2025  GGTGGACAGACTTAACGATCCTTGCTGCAGTCCCTCCGGAGAGGATCTGG 2074
               |||
455_051.nt.4 1557  GGTGGACAGACTTAACGATCCTTGCTGCAGTCCCTCCGGAGAGGATCTGG 1606
               |||

Ovr107      2075  ACTGGCTGGGAGTGGGGAGGGCGTGGAGACAGTCTACGGAAGCGCTAGC 2124
               |||
455_051.nt.4 1607  ACTGGCTGGGAGTGGGGAGGGCGTGGAGACAGTCTACGGAAGCGCTAGC 1656
               |||

Ovr107      2125  AGACCCCCGAGAGGGTGCAGTGGAGCCCTGAGCATTGTAATATGCGGCCC 2174
               |||
455_051.nt.4 1657  AGACCCCCGAGAGGGTGCAGTGGAGCCCTGAGCATTGTAATATGCGGCCC 1706
               |||

Ovr107      2175  AGCCTATAAACAGCCTCCGTGCTTAGCAAAAAAAAAAAAAAAAAAAAAA 2221
               |||
455_051.nt.4 1707  AGCCTATAAACAGCCTCCGTGCTTAGCAAAAAAAAAAAAAAAAAAAAAA 1756
               |||

```

FIGURE 13 (continued)

Ovr107	2222		2221
455_051.nt.4	1757	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACATACAAAAAATAAAAGA	1806
Ovr107	2222		2221
455_051.nt.4	1807	ATAGTCAACAAACAAAATAAGAACTATAGATAATATAAAAAATGAAAATA	1856
Ovr107	2222		2221
455_051.nt.4	1857	AAAAAGAGATGGGGTGGGGCCCTTGTCCTTACTCTCTCCCTCTGGAGTGG	1906
Ovr107	2222		2221
455_051.nt.4	1907	GCACACTATATTATTTTCGCCCTCCCCCTCTTTTTTTGTATGAGAGGGCTC	1956
Ovr107	2222		2221
455_051.nt.4	1957	TTTTA	1961

Ovr107	1	AGAGCAAGGAAGGGCAGGGGACCTGGGAAGGAAGTTCTTGGAAAGGCAGTG	50
455_051.nt.5	1		0
Ovr107	51	GGTTTGAGATTGGACCCAGGGTCAAGATAGAACATGAAGGTGGGATGAGG	100
455_051.nt.5	1		0
Ovr107	101	ACATGAACAGAACATGGCCAAGAAGGATCTGGGGGAGCAGCCAGGACGAG	150
455_051.nt.5	1		0
Ovr107	151	GCGGAGCTGATCCGAGAGGACATCCAGGGGGCTCTGCACAATTACCGCTC	200
455_051.nt.5	1		0
Ovr107	201	GGGCCGCGGGGAGCGCAGGGCGGCGGCTCAGGGCCACGCAGGAGGAGT	250
455_051.nt.5	1		0
Ovr107	251	TGCAGCGCGACCGCTCGCCCCCGCTGAGACCCCGCCCCTGCAGCGCCGC	300
455_051.nt.5	1		0
Ovr107	301	CCGTCAGTCCGCGCAGTGATCAGCACCGTAGAGCGGGGCGGGGCCGCGG	50
455_051.nt.5	1		0
Ovr107	351	ACGACCCCGAGCGAAGCCCATTCCTCGAGGCAGAGGAGGCGCAGAGGCCTG	400
455_051.nt.5	1		0
Ovr107	401	AGCCGGTGGGGACCTCGAGCAA-----CGCTGACTC----GGC-CTCC	438
455_051.nt.5	1	. GATCTCTTCCAAATGTCCCGCT--CTCCCCAGGCTCTCC	38
Ovr107	439	CCGGACCTGGGTCC-----CCGGGGTCCTGACCTGGCGGTTCTGCA	79
455_051.nt.5	39	CC-----TCCCGCCACTTGCCAGGG--CTGACCT-----CA	67
Ovr107	480	-GGCGGAGCGGGAAGTGGACATCCTGAACCACGTGTTTCGACGACGTAGAG	528
455_051.nt.5	68	. CCGC-----CAT-CTTAACCGGGTGTCC-----	89
Ovr107	529	AGCTTTGTATCGAGGCTGCAGAAGTCGGCGGAGGCGGCCAGGGTGCTGGA	578
455_051.nt.5	90 ACCTCTCT-----CTGC-----CTGCC-TGGTGCTGGC	16
Ovr107	579	GCACCGGGAACGCGGCCGAGGAGCCGGCGCCGGGCGGCT---GGGGAG	624
455_051.nt.5	117	. CC-----CGCGTCCCA-TCGCC-GCGCCCGTCTGCTCCCTCAGAG	156
Ovr107	625	GGCTTGCTGACGCTGCGGGCCAAGCCGCCCTCGGAGGCCAGTACACCGA	674
455_051.nt.5	157	 GGCTTGCTGACGCTGCGGGCCAAGCCGCCCTCGGAGGCCAGTACACCGA	206
Ovr107	675	CGTGCTGCAGAAGATCAAGTACGCCTTCAGCCTGCTGGCCCCGGCTGCGCG	724
455_051.nt.5	207	 CGTGCTGCAGAAGATCAAGTACGCCTTCAGCCTGCTGGCCCCGGCTGCGCG	256

FIGURE 14 (continued)

Ovr107	725	GCAACATCGCCGACCCCTCCTCTCCGGAGCTGTTGCACTTCCTTTTCGGG	774
455_051.nt.5	257	GCAACATCGCCGACCCCTCCTCTCCGGAGCTGTTGCACTTCCTTTTCGGG	306
Ovr107	775	CCTCTGCAGATGATTGTGAACACGTCGGGGGGCCGGAGTTTCGCGAGCAG	824
455_051.nt.5	307	CCTCTGCAGATGATTGTGAACACGTCGGGGGGCCGGAGTTTCGCGAGCAG	356
Ovr107	825	TGTGCGGCGGCCGCATCTGACATCGGATGCCGTGGCGCTGCTGCGGGACA	874
455_051.nt.5	357	TGTGCGGCGGCCGCATCTGACATCGGATGCCGTGGCGCTGCTGCGGGACA	406
Ovr107	875	ACGTCACTCCACGTGAAAACGAGCTCTGGACCTCGCTGGGGGACTCGTGG	924
455_051.nt.5	407	ACGTCACTCCACGTGAAAACGAGCTCTGGACCTCGCTGGGGGACTCGTGG	456
Ovr107	925	ACCCGCCCCGGGCTGGAGCTGTCCCCGGAGGAGGGACCCCCATACAGACC	974
455_051.nt.5	457	ACCCGCCCCGGGCTGGAGCTGTCCCCGGAGGAGGGACCCCCATACAGACC	506
Ovr107	975	CGAGTTCTTCAGCGGCTGGGAGCCCGGCTCACTGACCCGCAGAGCCGCG	024
455_051.nt.5	507	CGAGTTCTTCAGCGGCTGGGAGCCCGGCTCACTGACCCGCAGAGCCGCG	556
Ovr107	1025	CCTGGGAGGACCCAGTTGAGAAACAGCTACAGCACGAGCGGAGGCGCCGG	1074
455_051.nt.5	557	CCTGGGAGGACCCAGTTGAGAAACAGCTACAGCACGAGCGGAGGCGCCGG	606
Ovr107	1075	CAGCAAAGCGCCCCCAGGTCGCTGTCAATGGTCACCGAGACTTGGAGCC	1124
455_051.nt.5	607	CAGCAAAGCGCCCCCAGGTCGCTGTCAATGGTCACCGAGACTTGGAGCC	656
Ovr107	1125	AGAATCTGAGCCTCAGCTGGAGTCAGAGACAGCAGGAAAATGGGTCCTGT	1174
455_051.nt.5	657	AGAATCTGAGCCTCAGCTGGAGTCAGAGACAGCAGGAAAATGGGTCCTGT	706
Ovr107	1175	GTAATTATGACTTCCAGGCCCCGCAACAGCAGTGAGCTGTGGTCAAGCAG	1224
455_051.nt.5	707	GTAATTATGACTTCCAGGCCCCGCAACAGCAGTGAGCTGTGGTCAAGCAG	756
Ovr107	1225	CGGGACGTACTGGAGGTCCTGGATGACAGTCGTAAGTGGTGGAAAGGTTTCG	1274
455_051.nt.5	757	CGGGACGTACTGGAGGTCCTGGATGACAGTCGTAAGTGGTGGAAAGGTTTCG	806
Ovr107	1275	GGACCCAGCGGGGCGAGGGGATATGTGCCCTACAACATCCTGACACCCCT	1324
455_051.nt.5	807	GGACCCAGCGGGGCGAGGGGATATGTGCCCTACAACATCCTGACACCCCT	856
Ovr107	1325	ACCCCGGACCCCGGCTGCACCACAGCCAAAGCCCTGCCCGCAGCCTGAAC	1374
455_051.nt.5	857	ACCCCGGACCCCGGCTGCACCACAGCCAAAGCCCTGCCCGCAGCCTGAAC	906
Ovr107	1375	AGCACTCCTCCTCCACCACCAGCCCCAGCCCCGGCCCCACCTCCAGCTCT	1424
455_051.nt.5	907	AGCACTCCTCCTCCACCACCAGCCCCAGCCCCGGCCCCACCTCCAGCTCT	956
Ovr107	1425	GGCTCGGCCCCGCTGGGACAGGCCCCGCTGGGACAGCTGCGATAGCCTCA	1474
455_051.nt.5	957	GGCTCGGCCCCGCTGGGACAGGCCCCGCTGGGACAGCTGCGATAGCCTCA	1006

FIGURE 14 (continued)

Ovr107	1475	ACGGCTTGGACCCCAGCGAGAAGGAGAAATTCTCCAGATGCTCATCGTC	1524
455_051.nt.5	1007	ACGGCTTGGACCCCAGCGAGAAGGAGAAATTCTCCAGATGCTCATCGTC	1056
Ovr107	1525	AACGAGGAACTGCAGGCGCGCCTGGCCCAGGGCCGCTCGGGACCGAGCCG	1574
455_051.nt.5	1057	AACGAGGAACTGCAGGCGCGCCTGGCCCAGGGCCGCTCGGGACCGAGCCG	1106
Ovr107	1575	CGCAGTCCCAGGGCCCCGCGCCCCGGAACCGCAGCTCAGCCCCGGGCTCGG	1624
455_051.nt.5	1107	CGCAGTCCCAGGGCCCCGCGCCCCGGAACCGCAGCTCAGCCCCGGGCTCGG	1156
Ovr107	1625	ACGCCTCCGAGGTCCGCGCCTGGCTGCAGGCCAAGGGCTTTAGCTCCGGG	1674
455_051.nt.5	1157	ACGCCTCCGAGGTCCGCGCCTGGCTGCAGGCCAAGGGCTTTAGCTCCGGG	1206
Ovr107	1675	ACCGTGGACGCGCTGGGTGTGCTGACCGGGGCGCAGCTTTTCTCGCTGCA	1724
455_051.nt.5	1207	ACCGTGGACGCGCTGGGTGTGCTGACCGGGGCGCAGCTTTTCTCGCTGCA	1256
Ovr107	1725	GAGGGAGGAGCTGCGGGCGGTGAGCCCCGAGGAGGGGGCACGTGTGTACA	1774
		.	
455_051.nt.5	1257	GAAGGAGGAGCTGCGGGCGGTGAGCCCCGAGGAGGGGGCACGTGTGTACA	1306
Ovr107	1775	GCCAGGTCAACCGTGCAGCGCTCGCTGCTGGAGGACAAAGAGAAAGTGTCA	1824
455_051.nt.5	1307	GCCAGGTCAACCGTGCAGCGCTCGCTGCTGGAGGACAAAGAGAAAGTGTCA	1356
Ovr107	1825	GAGCTGGAGGCAGTGATGGAGAAGCAAAAGAAGAAGGTGGAAGGCGAGGT	1874
455_051.nt.5	1357	GAGCTGGAGGCAGTGATGGAGAAGCAAAAGAAGAAGGTGGAAGGCGAGGT	1406
Ovr107	1875	GGAAATGGAGGTCATTTGACCTGCCAGGCGCCCTTCGCAAAGAGTGACGA	1924
455_051.nt.5	1407	GGAAATGGAGGTCATTTGACCTGCCAGGCGCCCTTCGCAAAGAGTGACGA	1456
Ovr107	1925	GGCCCCGTGGGAGAACGGACTCCTCAGACTCTCCCCAATAGCGGAAGTCG	1974
455_051.nt.5	1457	GGCCCCGTGGGAGAACGGACTCCTCAGACTCTCCCCAATAGCGGAAGTCG	1506
Ovr107	1975	ATCTTCTGAAGGATGGCCAATCTGCTCCGGCCCTGGTCTTCCCCCATCCC	2024
455_051.nt.5	1507	ATCTTCTGAAGGATGGCCAATCTGCTCCGGCCCTGGTCTTCCCCCATCCC	1556
Ovr107	2025	GGTGGACAGACTTAACGATCCTTGCTGCAGTCCCTCCGGAGAGGATCTGG	2074
455_051.nt.5	1557	GGTGGACAGACTTAACGATCCTTGCTGCAGTCCCTCCGGAGAGGATCTGG	1606
Ovr107	2075	ACTGGCTGGGAGTGGGGAGGGCGTGAGACAGTCTACGGAAGCGCTAGC	2124
455_051.nt.5	1607	ACTGGCTGGGAGTGGGGAGGGCGTGAGACAGTCTACGGAAGCGCTAGC	1656
Ovr107	2125	AGACCCCCGAGAGGGTGCAGTGGAGCCCTGAGCATTGTAATATGCGGCC	2174
455_051.nt.5	1657	AGACCCCCGAGAGGGTGCAGTGGAGCCCTGAGCATTGTAATATGCGGCC	1706
Ovr107	2175	AGCCTATAAACAGCCTCCGTGCTTAGCAAAAAAAAAAAAAA-----	2215
		
455_051.nt.5	1707	AGCCTATAAACAGCCTCCGTGCTTAGCAGAAAAASAAAACACATCAACCC	1756

FIGURE 14 (continued)

Ovr107	2216	AAAAAA		2221
		.		
455_051.nt.5	1757	AACAAACGTTTGGGGTATTCCATGGCCAATACCGTTGTTCCCGTGTGTGA	1806	
Ovr107	2222			2221
455_051.nt.5	1807	ACATTGTTATTTTCAGCTCACATTTCCCACAGTATTGGAACAACACATCAT	1856	
Ovr107	2222			2221
455_051.nt.5	1857	ACCACACACACACAGAACCAATCGAGATATATAAACCCAATGCACACTCA	1906	
Ovr107	2222			2221
455_051.nt.5	1907	AACACCTAAT		1916

Ovr107		1 AGAGCAAGGAAGGGCAGGGGACCTGGGAAGGAAGTTCTTGAAGGCAGTG	50
455_051.nt.6	1		0
Ovr107	51 GGT TTGAGATTGGACC CAGGGTC AAGATAGA ACATGAAGGTGGG ATGAGG	100	
455_051.nt.6	1		0
Ovr107	101 ACATGAACAGA ACATGGCCAAGAAGGATCTGGGGGAGCAGCCAGGACGAG	50	
455_051.nt.6	1		0
Ovr107	151 GCGGAGCTGATCCGAGAGGACATCCAGGGGGCTCTGCACAATTACCGCTC	200	
455_051.nt.6	1		0
Ovr107	201 GGGCCGCGGGGAGCGCAGGGCGGCGGCTCAGGGCCACGCAGGAGGAGT	250	
455_051.nt.6	1		0
Ovr107	251 TGCAGCGCGACCGCTCGCCC GCCGTGAGACCCCCGCCCTGCAGCGCCGC	300	
455_051.nt.6	1		0
Ovr107	301 CCGTCAGTCCGCGCAGTGATCAGCACCGTAGAGCGGGGCGGGGCCGCGG	350	
455_051.nt.6	1		0
Ovr107	351 ACGACCC CAGGCGAAGCCCATTC CCAGGCAGAGGAGGCGCAGAGGCCTG	400	
455_051.nt.6	1		0
Ovr107	401 AGCCGGTGGGGACCTCGAGCAA-----CGCTGACTC----GGC-CTCC	438	
455_051.nt.6	1	GATCTCTTCCAAATGTCCCCGCT--CTCCC CAGGCTCTCC	38
Ovr107	439 CCGGACCTGGGTCC-----CCGGGGTCTTGACCTGGCGGTTCTGCA	479	
455_051.nt.6	39 CC-----TCCCGCCACTTGCCAGGG--CTGACCT-----CA	67	
Ovr107	480 -GGCGGAGCGGGAAGTGGACATCTTGA ACCACGTGTT CGACGACGTAGAG	528	
455_051.nt.6	68 CCGC-----CAT-CTTAACCGGGTGTCC-----	89	
Ovr107	529 AGCTTTGTATCGAGGCTGCAGAAGTCGGCGGAGGCGGCCAGGGTGCTGGA	578	
455_051.nt.6	90 ACCTCTCT-----CTGC-----CTGCC-TGGTGTCTGGC	116	
Ovr107	579 GCACCGGGAACGCGGCCGAGGAGCCGCGCGGGCGGCT---GGGGAG	624	
455_051.nt.6	117 CC-----CGCGTCCCA-TCGCC-GCGCCCGTCTGTCTCCCTCAGAG	156	
Ovr107	625 GGCTTGCTGACGCTGCGGGCCAAGCCGCCCTCGGAGGCCGAGTACACCGA	674	
455_051.nt.6	157 GGCTTGCTGACGCTGCGGGCCAAGCCGCCCTCGGAGGCCGAGTACACCGA	206	
Ovr107	675 CGTGCTGCAGAAGATCAAGTACGCCTTCAGCCTGCTGGCCCCGGCTGCGCG	724	
455_051.nt.6	207 CGTGCTGCAGAAGATCAAGTACGCCTTCAGCCTGCTGGCCCCGGCTGCGCG	256	

FIGURE 15 (continued)

Ovr107	725	GCAACATCGCCGACCCCTCCTCTCCGGAGCTGTTGCACTTCCTTTTCGGG	774
455_051.nt.6	257	GCAACATCGCCGACCCCTCCTCTCCGGAGCTGTTGCACTTCCTTTTCGGG	306
Ovr107	775	CCTCTGCAGATGATTGTGAACACGTCGGGGGGGCGGAGTTTCGCGAGCAG	824
455_051.nt.6	307	CCTCTGCAGATGATTGTGAACACGTCGGGGGGGCGGAGTTTCGCGAGCAG	356
Ovr107	825	TGTGCGGCGGCCGCATCTGACATCGGATGCCGTGGCGCTGCTGCGGGACA	874
455_051.nt.6	357	TGTGCGGCGGCCGCATCTGACATCGGATGCCGTGGCGCTGCTGCGGGACA	406
Ovr107	875	ACGTCACTCCACGTGAAAACGAGCTCTGGACCTCGCTGGGGGACTCGTGG	924
455_051.nt.6	407	ACGTCACTCCACGTGAAAACGAGCTCTGGACCTCGCTGGGGGACTCGTGG	456
Ovr107	925	ACCCGCCCCGGGCTGGAGCTGTCCCCGGAGGAGGGACCCCCATACAGACC	974
455_051.nt.6	457	ACCCGCCCCGGGCTGGAGCTGTCCCCGGAGGAGGGACCCCCATACAGACC	506
Ovr107	975	CGAGTTCTTCAGCGGCTGGGAGCCGCCGGTCACTGACCCGCAGAGCCGCG	1024
455_051.nt.6	507	CGAGTTCTTCAGCGGCTGGGAGCCGCCGGTCACTGACCCGCAGAGCCGCG	556
Ovr107	1025	CCTGGGAGGACCCAGTTGAGAAACAGCTACAGCACGAGCGGAGGCGCCGG	1074
455_051.nt.6	557	CCTGGGAGGACCCAGTTGAGAAACAGCTACAGCACGAGCGGAGGCGCCGG	606
Ovr107	1075	CAGCAAAGCGCCCCCAGGTCGCTGTCAATGGTCACCGAGACTTGGAGCC	1124
455_051.nt.6	607	CAGCAAAGCGCCCCCAGGTCGCTGTCAATGGTCACCGAGACTTGGAGCC	656
Ovr107	1125	AGAATCTGAGCCTCAGCTGGAGTCAGAGACAGCAGGAAAATGGGTCTCTGT	1174
455_051.nt.6	657	AGAATCTGAGCCTCAGCTGGAGTCAGAGACAGCAGGAAAATGGGTCTCTGT	706
Ovr107	1175	GTAATTATGACTTCCAGGCCCGCAACAGCAGTGAGCTGTCCGGTCAAGCAG	1224
455_051.nt.6	707	GTAATTATGACTTCCAGGCCCGCAACAGCAGTGAGCTGTCCGGTCAAGCAG	756
Ovr107	1225	CGGGACGTACTGGAGGTCCTGGATGACAGTCGTAAGTGGTGAAGGTTTCG	1274
455_051.nt.6	757	CGGGACGTACTGGAGGTCCTGGATGACAGTCGTAAGTGGTGAAGGTTTCG	806
Ovr107	1275	GGACCCAGCGGGGCGAGGAGGATATGTGCCCTACAACATCCTGACACCCT	1324
455_051.nt.6	807	GGACCCAGCGGGGCGAGGAGGATATGTGCCCTACAACATCCTGACACCCT	856
Ovr107	1325	ACCCCGGACCCCGGCTGCACCACAGCCAAAGCCCTGCCCAGCCTGAAC	1374
455_051.nt.6	857	ACCCCGGACCCCGGCTGCACCACAGCCAAAGCCCTGCCCAGCCTGAAC	906
Ovr107	1375	AGCACTCCTCCTCCACCACCAGCCCCAGCCCCGGCCCCACCTCCAGCTCT	1424
455_051.nt.6	907	AGCACTCCTCCTCCACCACCAGCCCCAGCCCCGGCCCCACCTCCAGCTCT	956
Ovr107	1425	GGCTCGGCCCGCTGGGACAGGCCCGCTGGGACAGCTGCGATAGCCTCA	1474
455_051.nt.6	957	GGCTCGGCCCGCTGGGACAGGCCCGCTGGGACAGCTGCGATAGCCTCA	1006

FIGURE 15 (continued)

```

Ovr107      1475  ACGGCTTGGACCCAGCGAGAAGGAGAAATTCTCCAGATGCTCATCGTC 1524
              |||
455_051.nt.6 1007  ACGGCTTGGACCCAGCGAGAAGGAGAAATTCTCCAGATGCTCATCGTC 1056
              |||

Ovr107      1525  AACGAGGAACTGCAGGCGCGCCTGGCCCAGGGCCGCTCGGGACCGAGCCG 1574
              |||
455_051.nt.6 1057  AACGAGGAACTGCAGGCGCGCCTGGCCCAGGGCCGCTCGGGACCGAGCCG 1106
              |||

Ovr107      1575  CGCAGTCCCAGGGCCCCGCGCCCCGGAACCGCAGCTCAGCCCAGGGCTCGG 1624
              |||
455_051.nt.6 1107  CGCAGTCCCAGGGCCCCGCGCCCCGGAACCGCAGCTCAGCCCAGGGCTCGG 1156
              |||

Ovr107      1625  ACGCCTCCGAGGTCCGCGCCTGGCTGCAGGCCAAGGGCTTTAGCTCCGGG 1674
              |||
455_051.nt.6 1157  ACGCCTCCGAGGTCCGCGCCTGGCTGCAGGCCAAGGGCTTTAGCTCCGGG 1206
              |||

Ovr107      1675  ACCGTGGACGCGCTGGGTGTGCTGACCGGGGCGCAGCTTTTCTCGCTGCA 1724
              |||
455_051.nt.6 1207  ACCGTGGACGCGCTGGGTGTGCTGACCGGGGCGCAGCTTTTCTCGCTGCA 1256
              |||

Ovr107      1725  GAGGGAGGAGCTGCGGGCGGTGAGCCCCGAGGAGGGGGCACGTGTGTACA 1774
              ||.
455_051.nt.6 1257  GAAGGAGGAGCTGCGGGCGGTGAGCCCCGAGGAGGGGGCACGTGTGTACA 1306
              |||

Ovr107      1775  GCCAGGTCACCGTGCAGCGCTCGCTGCTGGAGGACAAAGAGAAAGTGTCA 1824
              |||
455_051.nt.6 1307  GCCAGGTCACCGTGCAGCGCTCGCTGCTGGAGGACAAAGAGAAAGTGTCA 1356
              |||

Ovr107      1825  GAGCTGGAGGCAGTGATGGAGAAGCAAAAGAAGAAGGTGGAAGGCGAGGT 1874
              |||
455_051.nt.6 1357  GAGCTGGAGGCAGTGATGGAGAAGCAAAAGAAGAAGGTGGAAGGCGAGGT 1406
              |||

Ovr107      1875  GGAAATGGAGGTCATTTGACCTGCCAGGCGCCCTTCGCAAAGAGTGACGA 1924
              |||
455_051.nt.6 1407  GGAAATGGAGGTCATTTGACCTGCCAGGCGCCCTTCGCAAAGAGTGACGA 1456
              |||

Ovr107      1925  GGCCCCGTGGGAGAACGGACTCCTCAGACTCTCCCCAATAGCGGAAGTCG 1974
              |||
455_051.nt.6 1457  GGCCCCGTGGGAGAACGGACTCCTCAGACTCTCCCCAATAGCGGAAGTCG 1506
              |||

Ovr107      1975  ATCTTCTGAAGGATGGCCAATCTGCTCCGGCCCTGGTCTTCCCCCATCCC 2024
              |||
455_051.nt.6 1507  ATCTTCTGAAGGATGGCCAATCTGCTCCGGCCCTGGTCTTCCCCCATCCC 1556
              |||

Ovr107      2025  GGTGGACAGACTTAACGATCCTTGCTGCAGTCCCTCCGGAGAGGATCTGG 2074
              |||
455_051.nt.6 1557  GGTGGACAGACTTAACGATCCTTGCTGCAGTCCCTCCGGAGAGGATCTGG 1606
              |||

Ovr107      2075  ACTGGCTGGGAGTGGGGAGGGCGTGGAGACAGTCTACGGAAGCGCTAGC 2124
              |||
455_051.nt.6 1607  ACTGGCTGGGAGTGGGGAGGGCGTGGAGACAGTCTACGGAAGCGCTAGC 1656
              |||

Ovr107      2125  AGACCCCCGAGAGGGTGCAGTGGAGCCCTGAGCATTGTAATATGCGGCCC 2174
              |||
455_051.nt.6 1657  AGACCCCCGAGAGGGTGCAGTGGAGCCCTGAGCATTGTAATATGCGGCCC 1706
              |||

Ovr107      2175  AGCCTATAAACAGCCTCCGTGCTTAGCAAAAAAAAAAAAAAAAAAAAAA 2221
              |||.
455_051.nt.6 1707  AGCCTATAAACAGCCTCCGTGCTTAGCAG 1735

```

FIGURE 16

Ovr110	1	GAGTCACCAAGGAAGGCAGCGGCAGCTCCACTCAGCCAGTACCCAGA	47
Ovr110v1	1	TGTGAGTCACCAAGGAAGGCAGCGGCA-CTCCACTCAGCCAGTACCCAGA	49
Ovr110	48	TACGCTGGGAACCTTCCCCAGCCATGGCTTCCCTGGGGCAGATCCTCTTC	97
Ovr110v1	50	TACGCTGGGAACCTTCCCCAGCCATGGCTTCCCTGGGGCAGATCCTCTTC	99
Ovr110	98	TGGAGCATAATTAGCATCATCATTATTCTGGCTGGAGCAATTGCACTCAT	147
Ovr110v1	100	TGGAGCATAATTAGCATCATCATTATTCTGGCTGGAGCAATTGCACTCAT	149
Ovr110	148	CATTGGCTTTGGTATTT-----	164
Ovr110v1	150	CATTGGCTTTGGTATTTTCAGAACTCTCTGTCTGGCTTTTCAGCAATGAAGG	199
Ovr110	165	-----	164
Ovr110v1	200	GTTTGGTTGTAGAAGTTCCAAGGCTTCCCTTAGCATTGATCTTTGCTTCC	249
Ovr110	165	-----CAGGGAGACACTCCATCACAGTCACTACTGTGCGCTCAGCTGG	207
Ovr110v1	250	TGAACTGCAGGGAGACACTCCATCACAGTCACTACTGTGCGCTCAGCTGG	299
Ovr110	208	GAACATTGGGGAGGATGGAATCCAGAGCTGCACTTTTGAACCTGACATCA	257
Ovr110v1	300	GAACATTGGGGAGGATGGAATCCTGAGCTGCACTTTTGAACCTGACATCA	349
Ovr110	258	AACTTTCTGATATCGTGATACAATGGCTGAAGGAAGGTGTTTTAGGCTTG	307
Ovr110v1	350	AACTTTCTGATATCGTGATACAATGGCTGAAGGAAGGTGTTTTAGGCTTG	399
Ovr110	308	GTCCATGAGTTCAAAGAAGGCAAAGATGAGCTGTCGGAGCAGGATGAAAT	357
Ovr110v1	400	GTCCATGAGTTCAAAGAAGGCAAAGATGAGCTGTCGGAGCAGGATGAAAT	449
Ovr110	358	GTTTCAGAGGCCGGACAGCAGTGTGCTGATCAAGTGATAGTTGGCAATG	407
Ovr110v1	450	GTTTCAGAGGCCGGACAGCAGTGTGCTGATCAAGTGATAGTTGGCAATG	499
Ovr110	408	CCTCTTTGCGGCTGAAAAACGTGCAACTCACAGATGCTGGCACCTACAAA	457
Ovr110v1	500	CCTCTTTGCGGCTGAAAAACGTGCAACTCACAGATGCTGGCACCTACAAA	549
Ovr110	458	TGTTATATCATCACTTCTAAAGGCAAGGGGAATGCTAACCTTGAGTATAA	507
Ovr110v1	550	TGTTATATCATCACTTCTAAAGGCAAGGGGAATGCTAACCTTGAGTATAA	599
Ovr110	508	AACTGGAGCCTTCAGCATGCCGGAAGTGAATGTGGACTATAATGCCAGCT	557
Ovr110v1	600	AACTGGAGCCTTCAGCATGCCGGAAGTGAATGTGGACTATAATGCCAGCT	649
Ovr110	558	CAGAGACCTTGCGGTGTGAGGCTCCCCGATGGTTCCCCAGCCCACAGTG	607
Ovr110v1	650	CAGAGACCTTGCGGTGTGAGGCTCCCCGATGGTTCCCCAGCCCACAGTG	699
Ovr110	608	GTCTGGGCATCCCAAGTTGACCAGGGAGCCAACTTCTCGGAAGTCTCCAA	657
Ovr110v1	700	GTCTGGGCATCCCAAGTTGACCAGGGAGCCAACTTCTCGGAAGTCTCCAA	749

FIGURE 16 (continued)

Ovr110	658	TACCAGCTTTGAGCTGAACTCTGAGAATGTGACCATGAAGGTTGTGTCTG	707
Ovr110v1	750	TACCAGCTTTGAGCTGAACTCTGAGAATGTGACCATGAAGGTTGTGTCTG	799
Ovr110	708	TGCTCTACAATGTTACGATCAACAACACATACTCCTGTATGATTGAAAAT	757
Ovr110v1	800	TGCTCTACAATGTTACGATCAACAACACATACTCCTGTATGATTGAAAAT	849
Ovr110	758	GACATTGCCAAAGCAACAGGGGATATCAAAGTGACAGAATCGGAGATCAA	807
Ovr110v1	850	GACATTGCCAAAGCAACAGGGGATATCAAAGTGACAGAATCGGAGATCAA	899
Ovr110	808	AAGGCGGAGTCACCTACAGCTGCTAAACTCAAAGGCTTCTCTGTGTGTCT	857
Ovr110v1	900	AAGGCGGAGTCACCTACAGCTGCTAAACTCAAAGGCTTCTCTGTGTGTCT	949
Ovr110	858	CTTCTTTCTTTGCCATCAGCTGGGCACTTCTGCCTCTCAGCCCTTACCTG	907
Ovr110v1	950	CTTCTTTCTTTGCCATCAGCTGGGCACTTCTGCCTCTCAGCCCTTACCTG	999
Ovr110	908	ATGCTAAAATAATGTGCCTCGGCCACAAAAAGCATGCAAAGTCATTGTT	957
Ovr110v1	1000	TGCTAAAATAATGTGCCTTGGGCCACAAAAAGCATGCAAAGTCATTGTT	1049
Ovr110	958	ACAACAGGGATCTACAGAACTATTTACCACCAGATATGACCTAGTTTTA	1007
Ovr110v1	1050	ACAACAGGGATCTACAGAACTATTTACCACCAGATATGACCTAGTTTTA	1099
Ovr110	1008	TATTTCTGGGAGGAAATGAATTCATATCTAGAAGTCTGGAGTGAGCAAAC	1057
Ovr110v1	1100	TATTTCTGGGAGGAAATGAATTCATATCTAGAAGTCTGGAGTGAGCAAAC	1149
Ovr110	1058	AAGAGCAAGAAACAAAAAGAAGCCAAAAGCAGAAGGCTCCAATATGAACA	1107
Ovr110v1	1150	AAGAGCAAGAAACAAAAAGAAGCCAAAAGCAGAAGGCTCCAATATGAACA	1199
Ovr110	1108	AGATAAATCTATCTTCAAAGACATATTAGAAGTTGGGAAAATAATTCATG	1157
Ovr110v1	1200	AGATAAATCTATCTTCAAAGACATATTAGAAGTTGGGAAAATAATTCATG	1249
Ovr110	1158	TGAACTAGA-----	1166
Ovr110v1	1250	TGAACTAGACAAGTGTGTGAAGAGTGATAAGTAAAATGCACGTGGAGACA	1299
Ovr110	1167	-----	1166
Ovr110v1	1300	AGTGCATCCCCAGATCTCAGGGACCTCCCCCTGCCTGTCACCTGGGGAGT	1349
Ovr110	1167	-----	1166
Ovr110v1	1350	GAGAGGACAGGATAGTGCATGTTCTTTGTCTCTGAATTTTAGTTATATG	1399
Ovr110	1167	-----	1166
Ovr110v1	1400	TGCTGTAATGTTGCTCTGAGGAAGCCCCTGGAAAGTCTATCCCAACATAT	1449
Ovr110	1167	-----	1166
Ovr110v1	1450	CCACATCTTATATTCCACAAATTAAGCTGTAGTATGTACCCTAAGACGCT	1499

FIGURE 16 (continued)

Ovr110	1167	-----	1166
Ovr110v1	1500	GCTAATTGACTGCCACTTCGCAACTCAGGGGCGGCTGCATTTTAGTAATG	1549
Ovr110	1167	-----	1166
Ovr110v1	1550	GGTCAAATGATTCACTTTTATGATGCTTCCAAAGGTGCCTTGGCTTCTC	1599
Ovr110	1167	-----	1166
Ovr110v1	1600	TTCCCAACTGACAAATGCCAAAGTTGAGAAAAATGATCATAATTTAGCA	1649
Ovr110	1167	-----	1166
Ovr110v1	1650	TAAACAGAGCAGTCGCGGACACCGATTTTATAAATAAACTGAGCACCTTC	1699
Ovr110	1167	-----	1166
Ovr110v1	1700	TTTTTAAACAAACAAATGCGGGTTTATTTCTCAGATGATGTTTCATCCGTG	1749
Ovr110	1167	-----	1166
Ovr110v1	1750	AATGGTCCAGGGAAGGACCTTTCACCTTGACTATATGGCATTATGTCATC	1799
Ovr110	1167	-----	1166
Ovr110v1	1800	ACAAGCTCTGAGGCTTCTCCTTTCCATCCTGCGTGGACAGCTAAGACCTC	1849
Ovr110	1167	-----	1166
Ovr110v1	1850	AGTTTTCAATAGCATCTAGAGCAGTGGGACTCAGCTGGGGTGATTTCGCC	1899
Ovr110	1167	-----	1166
Ovr110v1	1900	CCCCATCTCCGGGGGAATGTCTGAAGACAATTTTGGTTACCTCAATGAGG	1949
Ovr110	1167	-----	1166
Ovr110v1	1950	GAGTGGAGGAGGATACAGTGCTACTACCAACTAGTGGATAAAGGCCAGGG	1999
Ovr110	1167	-----	1166
Ovr110v1	2000	ATGCTGCTCAACCTCCTACCATGTACAGGACGTCTCCCCATTACAACCTAC	2049
Ovr110	1167	-----GTCAACTGTGTCTAGGGCTAAGAAACCTGGTTTGTGAGT	1204
Ovr110v1	2050	CCAATCCGAAGTGTCAACTGTGTCTAGGACTAAGAAACCTGGTTTGTGAGT	2099
Ovr110	1205	AGAAAAGGGCCTGGAAAGAGGGGAGCCAACAAATCTGTCTGCTTCCTCAC	1254
Ovr110v1	2100	AGAAAAGGGCCTGGAAAGAGGGGAGCCAACAAATCTGTCTGCTTCCTCAC	2149
Ovr110	1255	ATTAGTCATTGGCAAATAAGCATTCTGTCTCTTTGGCTGCTGCCTCAGCA	1304
Ovr110v1	2150	ATTAGTCATTGGCAAATAAGCATTCTGTCTCTTTGGCTGCTGCCTCAGCA	2199
Ovr110	1305	CAGAGAGCCAGAAGCTCTATCGGGCACCAGGATAACATCTCTCAGTGAACA	1354
Ovr110v1	2200	CAGAGAGCCAGAAGCTCTATCGGGCACCAGGATAACATCTCTCAGTGAACA	2249

FIGURE 16 (continued)

Ovr110	1355	GAGTTGACAAGGCCTATGGGAAATGCCTGATGGGATTATCTTCAGCTTGT	1404
Ovr110v1	2250	GAGTTGACAAGGCCTATGGGAAATGCCTGATGGGATTATCTTCAGCTTGT	2299
Ovr110	1405	TGAGCTTCTAAGTTTCTTTCCCTTCATTCTACCCTGCAAGCCAAGTTCTG	1454
Ovr110v1	2300	TGAGCTTCTAAGTTTCTTTCCCTTCATTCTACCCTGCAAGCCAAGTTCTG	2349
Ovr110	1455	TAAGAGAAATGCCTGAGTTCTAGCTCAGGTTTCTTACTCTGAATTTAGA	1504
Ovr110v1	2350	TAAGAGAAATGCCTGAGTTCTAGCTCAGGTTTCTTACTCTGAATTTAGA	2399
Ovr110	1505	TCTCCAGACCCTGCCTGGCCACAATTCAAATTAAGGCAACAAACATATAC	1554
Ovr110v1	2400	TCTCCAGACCCTTCCTGGCCACAATTCAAATTAAGGCAACAAACATATAC	2449
Ovr110	1555	CTTCCATGAAGCACACACAGACTTTTGAAAGCAAGGACAATGACTGCTTG	1604
Ovr110v1	2450	CTTCCATGAAGCACACACAGACTTTTGAAAGCAAGGACAATGACTGCTTG	2499
Ovr110	1605	AATTGAGGCCTTGAGGAATGAAGCTTTGAAGGAAAAGAATACTTTGTTTC	1654
Ovr110v1	2500	AATTGAGGCCTTGAGGAATGAAGCTTTGAAGGAAAAGAATACTTTGTTTC	2549
Ovr110	1655	CAGCCCCCTTCCCACACTCTTCATGTGTTAACCCTGCCTTCCTGGACCT	1704
Ovr110v1	2550	CAGCCCCCTTCCCACACTCTTCATGTGTTAACCCTGCCTTCCTGGACCT	2599
Ovr110	1705	TGGAGCCACGGTGACTGTATTACATGTTGTTATAGAAAAGTGAATTTTAGA	1754
Ovr110v1	2600	TGGAGCCACGGTGACTGTATTACATGTTGTTATAGAAAAGTGAATTTTAGA	2649
Ovr110	1755	GTTCTGATCGTTCAAGAGAATGATTAAATATACATTTCTTAAAAAAAAA	1804
Ovr110v1	2650	GTTCTGATCGTTCAAGAGAATGATTAAATATACATTTCTTA	2690
Ovr110	1805	AAAAAA	1811
Ovr110v1	2691		2690

FIGURE 17

Ovr110	1	MASLGQILFWSIISIIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGE	50
455_053.aa.2	1	MASLGQILFWSIISIIIIILAGAIALIIGFGIS---EVS VWLSAMKGLVVE	47
Ovr110	51	DGIQSCTFEPDIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGR	100
	 :.. ...	
455_053.aa.2	48	-----VPRLP LALIFAS	59
Ovr110	101	TAVFADQVIVGNASLRLKNVQLTDAGTYKCYIITSKGKGNANLEYKTGAF	150
455_053.aa.2	60		59
Ovr110	151	SMPEVNV DYNASSETLRCEAPRWF PQPTV VWASQVDQGANFSEVSNTSFE	200
455_053.aa.2	60		59
Ovr110	201	LNSENVTMKVVS VLYNVTINNTYSCMIENDIAKATGDIKVT ESEIKRRSH	250
455_053.aa.2	60		59
Ovr110	251	LQLLNSKASLCVSSFFAISWALLPLSPYLM LK	282
455_053.aa.2	60		59

FIGURE 18

Ovr110	1	MASLGQILFWSIIISIIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGE	50
455_053.aa.3	1	.: TAGRHSITVTTVASAGNIGE	20
Ovr110	51	DGIQSCTFEPDIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGR	100
455_053.aa.3	21	. DGILSCTFEPDIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGR	70
Ovr110	101	TAVFADQVIVGNASLRLKNVQLTDAGTYKCYIITSKGKGNANLEYKTGAF	150
455_053.aa.3	71	 TAVFADQVIVGNASLRLKNVQLTDAGTYKCYIITSKGKGNANLEYKTGAF	120
Ovr110	151	SMPEVNVDYNASSETLRCEAPRWFPQPTVVWASQVDQGANFSEVSNTSFE	200
455_053.aa.3	121	 SMPEVNVDYNASSETLRCEAPRWFPQPTVVWASQVDQGANFSEVSNTSFE	170
Ovr110	201	LNSENVMTKVVSVLVNTINNTYSCMIENDIAKATGDIKVTESEIKRRSH	250
455_053.aa.3	171	 LNSENVMTKVVSVLVNTINNTYSCMIENDIAKATGDIKVTESEIKRRSH	220
Ovr110	251	LQLLNSKASLCVSSFFAISWALLPLSPYLMLK	282
455_053.aa.3	221	 LQLLNSKASLCVSSFFAISWALLPLSPYLMLK	252

1

SEQUENCE LISTING

<110> diaDexus, Inc.
Macina, Roberto
Turner, Leah
Sun, Yongming
Liu, Shu-Hui
Chen, Huei-Mei

<120> Compositions, Splice Variants and Methods Relating to Ovarian Specific Genes and Proteins

<130> DEX-0455

<150> US 60/431,321
<151> 2002-12-06

<150> US 60/431,301
<151> 2002-12-06

<150> US 60/484,584
<151> 2003-06-30

<150> US 60/518,607
<151> 2003-11-07

<160> 340

<170> PatentIn version 3.1

<210> 1
<211> 4798
<212> DNA
<213> Homo sapien

<400> 1
ggsasgwggc caaggcatct gccactgctg ctgactgcc a ctaccagccg gagccagggc 60
ctggctcgaga caactatctt tgaggtatct gaggctaccc cacagcactc tctggcattg 120
gcaagactcg tggctgtgac ccatgggcct ctgaggagggc gttgtaagtc cgcccagctc 180
cccacttgct gtgctctcac tcaatgcgaa gggaaaccaag gtaccagggc caagtgggtc 240
cagacatcca cacggattct gaaagggcag gtcaagcaga ctttgtccag ccatcagcca 300
cggcctctcg acagcaccaa gatggaagtc aaaggtcagc tgatcagctc tcctaccttc 360
aatgccccag ctgccctgtt cggagaggct gccccccagg tgaagtcaga gcgtctgcgg 420
gggctgcttg accggcagcg gaccctgcag gaggccctga gcctgaaact tcaggagctc 480
cgcaaagtgt gtctccagga ggcggagctg actggccagc tgccccctga gtgcccacta 540
gagcctgggtg aacggcccca gttgggtccgc cggcggcccc ccacagcccg cgcctaccct 600
ccaccgcacc ccaaccaagc acaccactcc ttgtgccttg ctgaggagct ggctcttgag 660
gccctggaac gcgaggtgtc agtgcaacag cagatcgcg cggccgcccc ccgcctggcc 720
ttggccccctg atctgagcac cgagcagcgc cggcgccggc gccaggtcca ggcagatgca 780

ctgaggaggc	tgcattgagct	agaggagcag	ctcaggggatg	tccggggccc	ccttggcctc	840
ccagtgtctcc	cgttgcccca	gccactgcc	ctgtccacgg	ggtcagtgat	caccacccag	900
ggagtctgcc	tgggcatgcg	tcttgctcag	ctcagccaag	gtgagcatcc	cctggtgagg	960
gtgggagagt	ggacactggc	aaatggacgt	ggtagggctg	ggatgggtga	ctggccgggtg	1020
aaaaccggga	ggtaggcaca	actcaagtgg	cccaaccctg	gagaagagtt	gcgacaaact	1080
ggcttaccgg	aaaggacaaa	ctgtggggga	ctgatgaata	tctgccagga	cagtcaggaa	1140
ccaaactggg	gtggtcttgg	gctctggtaa	aagcagattc	ttgggacagg	aacaggatga	1200
ggcggaaaact	ggccagaagg	tggcccaagt	agaggtgccc	accagtggt	gtaagggggc	1260
agcaccacagg	cctgggagtg	agaggccac	ttctccccct	ctcacctgta	gaggacgtag	1320
ttctgcactc	agagagcagc	tccctctcag	agtctggggc	cagccatgac	aacggtgagg	1380
actcctatcc	cccaaacctg	ccccgactc	ctacgtccct	ttagcccatc	ccctttattc	1440
atccgaccac	atcctgcatg	atcagcccat	cctttgatgc	ccagcccctc	ctgtgctgct	1500
tcagcttctc	cttagccatg	ctccatcttc	ctatgggtcc	cccatcttct	tagcctcacc	1560
ccaccccagc	cccacagccc	cagaacctac	ttgtcagcct	tagttcctcc	tcagcctgct	1620
taacctgtcc	cagcactttg	cccctcccca	tggccttgcc	cccagcctg	tctgcccc	1680
tctggggccc	cctcattgaa	ttctatccca	cttgtctctc	tccactcaga	ggagccccat	1740
ggctgtttct	ctctggcgga	gcgcccctca	ccacccaagg	cttgggacca	gctgcgggca	1800
gtatctgggg	ggagccctga	gcggcgaaac	ccatggaaac	cacctccatc	agatctttat	1860
ggggatctga	agagccggcg	gaactctgtg	gccagcccca	ccagcccccac	acgtctgctg	1920
cccaggagtg	cctccagttt	tgagggcgga	agtgtgcctg	ccacccctgt	cctcaccggg	1980
ggcgtggcc	cccagctctg	caaacctgaa	ggccttcatt	ctcgtcagtg	gtccggcagc	2040
caggactccc	agatgggctt	ccccggggcg	gaccctgcct	ccgatcgcg	ctccctcttc	2100
gtagctcgca	cccgccgcag	caacagttct	gaggccctgc	tgggtggaccg	ggccgctggt	2160
gggggagctg	gctccccgcc	tgccctctg	gctccctctg	cctctggccc	cccagtctgc	2220
aagagcagtg	aggtgctgta	tgagcgcccc	caaccaaccc	ctgccttctc	ctcccgacaca	2280
gcaggcccc	cagacccctc	ccgggcccgc	cggcctagct	cagctgcccc	tgcctccga	2340
ggtgcccc	ggctcccacc	tgtgtgtgga	gacttctctc	tggactattc	cttggaccgg	2400
ggcctgcccc	gcagtggcg	tggaacaggc	tggggggagc	tgcgcctgc	agctgaggtc	2460
ccaggacccc	tctcccgcg	ggatgggctc	ctcaccatgc	tccccggccc	accacctgtg	2520
tatgcagctg	acagcaacag	ccccctctc	cgcaccaagg	acccccacac	ccgtgccacc	2580

cgcactaagc cctgtggcct gccccagag gctgccgaag gccctgaggt gcatccaaac	2640
cctctgctgt ggatgcccc acccaccgt atccctcgg ctggtgaacg cagtggccac	2700
aagaacctgg ctctggaggg gctgcgggac tggtagatcc ggaactcggg actggctgcg	2760
gggccccagc gccggcctgt gctcccttcc gtggggccgc cacaccacc cttcctccat	2820
gcccgtctgt atgaggtggg ccaggcgctg tacggggccc ccagccaggc gccactccca	2880
cactcgagga gtttcacggc gccccctgtc tctggcaggt atggggggtg cttttactga	2940
tgggtagggg tctcgtaagg cagatggcga agatatccag gccagggagt ggctagtcac	3000
gatagctaata gaattggacc atgaggaaac tagctgctgt gatggcacag ggtcactcta	3060
ctgcacatga cctgcattag tccatggggc cctggtggag gggatcttgg gcactggtag	3120
cagcaattct ttatcaagtt ataggctgaa gatgagcctt gaagccaggg tgccgggagg	3180
aagggaacatc tcatgcccct tgctgttttc ttcctttttt ctccatgcc cagagcctga	3240
aagtgtgtc ctgtgcctgc ctccacctct ttaacgagcc tcttttctt tctttttctg	3300
tgtcttgtct gtcttttctt cttcttgtct tcccgcctt gtctccgga ttctgtctac	3360
cccttctaaa gatactacgc ggacttctct tatcccccg agctgagcgc tcgtttaagt	3420
gacctgacgc tagaggggga gcagtcctcc agttctgaca ccagacccc ggggacactg	3480
gtctgacccc ttctgatatg tcccttggtg gcctgggcac gattccaatc tggggagcac	3540
acagctgacc tcgctgggccc ctggggtgtg gttgctctca gtctgagca gagtgcgcca	3600
acctaattct ccaaggcccc tggtccccc taggcccagg aaggtgtctg acacctgct	3660
tcttctctca cactgtgctg gggactgggg gccctcagct agcttaaaag aggggggatg	3720
atgtcatggg gacccaagc cccttctctc atttatgttt acagttgtga cttagggtatt	3780
cactgtcttc ctccaacact aggcgtttta caaaaggga actgtgatct catctgggtg	3840
ggttcattcc tgttcccatg cccaaccagg ttccattcag gaaccacctc cataaaatgg	3900
accatatcgg gtctcagggc cathtagggc agccaggaga ctccggtgtg aacagaaatc	3960
cctgccacgc atgccaggg cagttggggc agtgggctct ctgccacac ttggaaggac	4020
tgcagtctgg gtgggatgcc tgaaagagcc caacccccctc tgtgcccattg gcctctgccc	4080
tgaccacccc cagttagggg gccccacagg aggggcaccc ggtagatgcc agtgaaatcc	4140
tcaggggagg tctgcctgaa agagcccaac cccctctgtg cccatggcct ctgccctgac	4200
cacccccagt caggaggccc cacaggaggg gcacccggta gatgccagtg aaatcctcag	4260
gtgaggtctg cctacggggc acggggccact caccactcac accttccttg gctttccttc	4320
cacctttttt tttttctcga gacggagtct tgctctgtca ccaggctgga gtgcagcggc	4380
gcaatctcag ctactgcaa cctctgcctc ctgggttctc ctgcctcacc ctcccgagta	4440

gctgggatta caggcacacg ccacccatgcc cggctaattt ttgtattctt agtagagaca 4500
 aggtttcacc atattggcca ggctggtctt gaactcttga cctcgtgatc tgcccgcctt 4560
 ggccctcccaa agtgctggga ttacagccgt gagccactgc acccagcccc aatccaccac 4620
 tttttaagca aaccacaca agttgtgttt tctatgatac ctgtctgtga ttttcggagc 4680
 tgggggttcc cctaccccct tttcctggcg ttaagctttt ctttttatac cagtggatct 4740
 ggaccaaga cattaccac actggaaggg gatttgtata ataaatgtgt aaactgaa 4798

<210> 2
 <211> 1494
 <212> DNA
 <213> Homo sapien

<400> 2
 aggcgccgag gccctcctgt gcctgtcact ggcaataatc catgccacag aagactattt 60
 gctttccctg ggccctaggtt tgctgtgaac tttcagactg gcttcagtgg aaatgacatt 120
 gccttccact tcaaccctcg gtttgaagat ggaggggtacg tgggtgtgcaa cacgaggcag 180
 aacggaagct gggggcccga ggagaggaag acacacatgc ctttccagaa ggggatgccc 240
 tttgacctct gcttcctggg gcagagctca gatttcaagg tgatggtgaa cgggatcctc 300
 ttctgtgcagt acttccaccg cgtgcccttc caccgtgtgg acaccatctc cgtcaatggc 360
 tctgtgcagc tgtcctacat cagcttccag cctcccggcg tgtggcctgc caaccggct 420
 ccattatccc agacagtcac ccacacagtgc cagagcgccc ctggacagat gttctctact 480
 cccgccatcc cacctatgat gtacccccac cccgcctatc cgatgccttt catcaccacc 540
 attctgggag ggctgtaccc atccaagtcc atcctcctgt caggcactgt cctgcccagt 600
 gctcagaggt tccacatcaa cctgtgctct ggggaaccaca tcgccttcca cctgaacccc 660
 cgttttgatg agaatgctgt ggtccgcaac acccagatcg acaactcctg ggggtctgag 720
 gagcgaagtc tgccccgaaa aatgcccttc gtccgtggcc agagcttctc agtgtggatc 780
 ttgtgtgaag ctcactgcct caagggtggc gtggatggtc agcacctgtt tgaatactac 840
 catcgctga ggaacctgcc caccatcaac agactggaag tggggggcga catccagctg 900
 acccatgtgc agacataggc ggcttcctgg ccctggggcc gggggctggg gtgtggggca 960
 gtctgggtcc tctcatcatc cccacttccc aggcccagcc tttccaaccc tgccctgggat 1020
 ctgggcttta atgcagaggc catgtccttg tctggtcctg cttctggcta cagccaccct 1080
 ggaacggaga aggcagctga cggggattgc cttcctcagc cgcagcagca cctggggctc 1140
 cagctgctgg aatcctacca tcccaggagg caggcacagc caggagagg ggaggagtgg 1200
 gcagtgaaga tgaagcccca tgctcagtc cctcccatcc cccacgcagc tccaccccag 1260

tcccaagcca	ccagctgtct	gctcctgggtg	ggaggtggcc	tcctcagccc	ctcctctctg	1320
acctttaacc	tcactctcac	cttgccacctg	gcaccaaccc	ttcacccttc	ctggaaagca	1380
ggcctgatgg	cttcccactg	gcctccacca	cctgaccaga	gtgttctctt	cagaggactg	1440
gctcctttcc	cagtgtcctt	aaaataaaga	aatgaaaatg	cttggtggca	catt	1494

<210> 3
 <211> 1691
 <212> DNA
 <213> Homo sapien

<400> 3	
cgggcgccca	gagggcaa
gagggcgccg	gggggtggcg
gtggggggga	gacgcggaat
60	
ttcccagcgc	gggggctctg
gcttaccctg	caaccgggca
gtctctttct	gtttacggag
120	
agaaagggga	aatggaaaag
tcggggaggc	ggtggctggc
gtccgctgcg	cgcgccctgg
180	
gcaggctcag	acgccgtgag
tcaggggcag	agcagggcgg
tctgagcgtg	cgggcgacgc
240	
gggtctcact	cgtccgctcc
gctctggact	gcgcgccacg
ctctgggggtc	cggcgccctg
300	
gttcctgctt	ctgccgctgc
cgccgcccga	tcccagtggc
cggcgctgct	cggctccac
360	
aggcctgcag	ccagcatcgc
accgaacctt	cggggggccg
cggctggagc	gctcggccgg
420	
cgtgggagcg	ccaaggccgc
agatgcaatc	ttcttaccgc
gaagaagcca	ggggaatagg
480	
tagccacatc	ttgtttgcag
ataagaaagg	aagctaacgc
agtatctgca	aagccaggag
540	
tctgactcag	tacttttctc
actcatgcat	acaaagcagc
taaaaatgac	acagcttatt
600	
taccatgccc	ctgacactgc
actgagcact	ttatgagctt
gaactctgtt	aatcctcacg
660	
accacctcat	gagactctcc
agaaagagca	acagtaatgg
agtacatgag	cactggaagt
720	
gacaataaag	aagagattga
tttattaatt	aaacatttaa
atgtgtctga	tgtaatagac
780	
attatggaaa	atctttatgc
aagtgaagag	ccagcagttt
atgaaccag	tctaatagacc
840	
atgtgtcaag	acagtaatca
aaacgatgag	cgttctaagt
ctctgctgct	tagtggccaa
900	
gaggtacat	ggttgtcatc
agtcagatat	ggaactgtgg
aggatttgct	tgtttttgca
960	
aaccatatat	ccaacactgc
aaagcatttt	tatggacaac
gaccacagga	atctggaatt
1020	
ttattaaaca	tgggtacgtt
ctttccgata	agttgggtgc
tatgtgctca	gctttcctac
1080	
tgcagcttca	tttaatgcag
agtgggtgtt	gaatttggct
tagatgggct	ggcaggcatg
1140	
attttaaaaa	atgtaatcat
cagtaagaag	tacttccatg
ttaaagatgc	aaaaaaaaaa
1200	
gtcttcatta	aaatttctat
ttaaagattc	ttgatcatat
tttagtagta	tttctacaaa
1260	
taggtaatta	agaagaatgt
atgtgggccc	ggcgcagggg
ctcacgcctg	taatccgcgc
1320	
acttggagag	gccgaggtgg
gtggatcact	tgaggtcagc
aattagagac	cagtctggcc
1380	

aacatggtga aaccccgctct ctactaaaaa tacaaaatta gcctggcatg gtggcgggcg 1440
 cctgtaattc cagctacctg ggaggctgag gcacgagaat cccttgaacc tgggaggtgg 1500
 aggttgtgat gagccgagat cacaccactg cactccagcc tgtgtgactg agtgagactc 1560
 tgtctcaaca acaacaaaga agaatgtatt ttaatttaac agttcactaa aaagttttatt 1620
 catcagttat gcagaaaaga aaggcttaat gagactcctt cgtctgagag ggggaataaac 1680
 actttgtcac t 1691

<210> 4
 <211> 8772
 <212> DNA
 <213> Homo sapien

<400> 4
 accaaactga agtgaagga taagacctct cctgctgcta gtactaggag aggtcttatt 60
 cttacacttc agtttggtca ccagattatg taaggataag acctctocta gtactagcag 120
 caggaattgt gtgttccagt aagtgggtctc ttgcacggca cttttttggg atcaaagtgt 180
 aacgttactc cccagactct tcgggcaaag gaatggctag attcagagta agaacaaccc 240
 tccctttttt gtaagtcccc gtgttttagca gggagaagaa attctctaac atgggttttg 300
 ttttgttgtg ttcttcatgt ggaaatgtcg ctttaacaaaa tatccaggct tttgtttacg 360
 tggaaaaagc atcccttgta atgattgctc atcatactta aaaacctttt tcaaaggatt 420
 ttcattgtcc cagctataag gactatttcc atgacatgtg ttattggcag aatgagtgtt 480
 aaatatggag catatagcat ggggtgactt tcattgtcct aacctgagac agttttcctt 540
 attactctgt attgatcctg ctagtccaag aatggacatg aagtgaacct atcgtggtga 600
 ctgggatagg aagggtgctt ctatttttgc cagcacagca tattagtcc tttggagccc 660
 tccattgtct gagtctgcag tgatctgtag gaaggcagct ggtcaataat catgtagtac 720
 aatggcttgg aattgtaacc actatggta ttgattgtcc tgtgttgttt caggcatact 780
 taggtatgtc cctggggaaa aagaaaacca ttcagctgag agttgctaac catgtttctt 840
 tgggttagaaa taatggttca ttttttgccc ctggttgga tagtctctaa aaggctctgg 900
 tgactgaatt gaacatgagt ccgcatgctg ttttctttca aaaggtatca aaacggaaag 960
 cctctctaag gggaagacct ttcaactcca ttcagaagac aacatttagt aaggaggatg 1020
 gcggagggtta ctagtaattt tcagatgtct tgggcttttt ctgccaacaa aacccaaaat 1080
 caaattagag ttggtgaaag ctttcttcag tgtttttaga agaggccatc ttgaatctgt 1140
 agaataccat ttacacatca acttcacct atgtcattt cgtattttga gcttaaatgg 1200
 agtcctctga agggggggta gtcgtgattc tgggtggcaaa actagaactt ttaacttgta 1260

aaatgaaaaa	tattaaatgg	acctttttgt	cagttgagga	tttagattga	ttcttttatc	1320
tgaggagcgt	atgttcctca	gatgttgctg	agagaccttt	aggttttcat	ctactttaag	1380
attgctctct	tggcaattag	gggatttggt	aaaagaagaa	aaaaagatgc	catgtgttgc	1440
tagtacacag	ttataggata	tggtttctaa	tggttgaatt	ttgaggaact	ctccctaaag	1500
aatgagtttt	atatctcttc	aaggaaatca	tggaaaaatc	tgtttattct	tcagtgagtc	1560
cttttgaatt	aatgttctta	aatttttttc	taagtctgtg	taagtgccta	tgtataagta	1620
tataattgta	taaatattta	taaatatatt	tatataatta	cggtttcatt	tctaccttga	1680
gtcaaagttc	tgtctttaga	ttggtgactg	agtaatactt	acactttggt	gttttttctt	1740
aggttcttga	ggcttactta	actagcagct	tctgatttat	tgagtgaaag	atggttttca	1800
tgtaatttcc	tcagttgcat	ctctgaactt	ggataacata	cttgccgttt	gaaaaataga	1860
gctgtatact	gtcaaagggt	cactggaggg	taaaacatth	gttggttagta	gacaagctca	1920
gaaatccaaa	aattcmggga	gggcacaggg	taagaagaga	ggtttgctca	gctttgtgct	1980
ctgatggcac	ccatctgtac	tccagcaaag	tcatagctga	agcccaaata	gctcaaacgt	2040
gtgaagtcaa	tcatttttcc	tatagggctc	tgtttccttt	tctttacctt	ctagcttctc	2100
ttgataaaac	agttgggaga	actgccaacg	tgttcatcag	tgagaggggt	tggttctttc	2160
cgatatgttc	agcacgtgca	tattcattta	tgagaaacca	aagtaacttc	ttcaactcgg	2220
gttactgtgg	gatgattaag	tagatataaa	gtgatttaaa	agacagcatg	gtactttcac	2280
tcagcttaac	atgcagctgg	gatgtctaca	atacaagatg	tggtggggtt	tattttatth	2340
tattttgagg	caggagtgtg	attatcttag	ggttgatata	aaggcccatg	ggaagagtta	2400
cggattgtac	atgggaagaa	tccataagga	gtattgcctt	gctcaagaat	ttaatccgct	2460
gacagtatgc	ttcttccagt	ttgccttact	tcctctgcaa	gtttctttgc	tccttagggc	2520
agaggtttta	ttgaatagat	taaatgaggt	cagtaagatt	agttaaaaat	agtcattcct	2580
tgtgggtggt	ggacacagct	tgaaaggagt	gtttaaaaaa	aaaaagctag	ggaggaaaag	2640
aacaagaaa	atagacttcg	agagtgataa	gagaaaaata	caggagagatg	gaatggaaac	2700
taccaggaag	gocgggcgcg	gtggctcatg	cctgtaatcc	caacactttg	ggaggcggag	2760
gtgggcagat	cacctaaggt	caggagatcg	aggccagcct	gagcaacatg	gtgaaacccc	2820
gtcttacta	aaaatacaaa	aattacctgg	gtgtgggtgg	gtgcacctgt	aatcccagct	2880
actcagaggc	tgaggcaggg	gaatggcttg	aacctgggag	gcagaggttg	cagtgcagca	2940
agatcgcacc	attacactcc	agcctgggcg	acaaagcgac	actccatctc	aaatttaaaa	3000
aaaaaaaaaa	agaagaagaa	gaaaactagt	gggaaaaaag	tgagaggaat	acttttttga	3060

aattggtatc	ggaaggaact	ggagaagaga	aaacaacagt	gccaaatgag	aaaagaacag	3120
gaaacttaat	actaattggc	atgcaccaga	tacttttgtg	tacatttgcc	tcttcaatct	3180
cccgaagaat	cgtacaaaat	gtatactttc	ttcccatggt	aagaaaacag	gtatagagaa	3240
cttattcagg	actcatagct	agtgagtggc	aaatcagaat	tggaatccag	agtccatgct	3300
gtggtctcct	tcagcaagag	aatcaagcta	cccagatgat	tctcttctca	ttgtttggct	3360
ttgtaaagtg	tcacttagtt	ttgttcccat	aaatatagag	gaagtagttg	ggtaaagtt	3420
gtgggatttg	cactatgcct	atacattttt	atttatgcc	ttattttgag	aggctgatta	3480
ttgctttttt	aaaatgatgc	actggtgaag	atgtgaaagt	aaaattgcc	cgtggcatta	3540
tttgccaaga	ataaatgaaa	agggtaaaa	aacaattttt	tcttttttta	aacatttttc	3600
agaaaagata	caattacott	ttttaatagg	tgagcgccac	cacgcccggc	taatttttgc	3660
attttttagta	gagacagggt	ttcaccatgt	tggccaggat	ggtctcgatc	tcttgatctc	3720
gtgttccgcc	cacctcggcc	tcctaaagtg	ctgggattac	aggcatgagc	cactgcgccc	3780
gatctacaat	tctgttttct	gtgtcccatc	cataccagat	tattgaacct	tctgtgtgta	3840
tgtttttaaa	tcttgatat	aattctactt	ccttgactta	caagtcaaca	attagctatt	3900
gagttcttta	tagaagttgg	aagtattttg	aaatctgaga	tctaattcct	ggccgggccc	3960
ggtggctcat	gcctgtaatc	ccaatatttt	gggaggccga	ggtgggtgga	tcacctgagg	4020
ttgggagttc	gagatcagcc	tggccaacat	ggtgaaacct	catctctact	gaaaaataca	4080
aaaattagcc	aggcatggtg	gctgtctgta	atcccagcta	atggggaggc	tgaggcacia	4140
gaatctcttg	aacctgggag	gaggagggtg	cagtgcgccc	agatcacacc	actgcactcc	4200
atcctgggca	atggagcgag	actctgtctc	aaaaaataat	aaataagata	tgattcctgc	4260
ctgttttatc	cagttagaga	gacacactac	acatgaaata	attggagagc	atgtaaattg	4320
ttacctatta	gttcaaactt	agaaaaagg	aagaatatgt	tttagttagc	aaagtcttaa	4380
acaagactga	agtggcaagc	actgtagctc	acgttttctt	ttgactcacc	tttttcttta	4440
gctccacctt	ttgtaacttc	tagatttggg	gcatgaagtt	ctgccactaa	ggcataacca	4500
gtacccaagt	aggaaaggat	tattgatccc	tggagtaaag	attcctagct	tgccggggtc	4560
tcactattga	tccccoggag	taaagattcc	tagctcgag	gaatcttact	tgacacttta	4620
gggaaaaatac	cagaggggagc	cactagcaac	cgaaaaatga	aggaaagatt	taatttctct	4680
accaggttac	aaatccaatg	catagtatag	tatatgttat	atgcagaaag	ggcactggag	4740
gtgtgagagc	cctttgggta	acagctctgc	tagttgttac	cttcacactt	ctctttcttc	4800
ttaatctctg	gtttctcgtc	tgaaaaatga	gataattgga	ctagattaat	agttctcagc	4860
cttttctaga	acaacaaatt	agattatctc	tgaagtcctt	ttccaaaatt	tcattgcttc	4920

agtctctccc	cgtgattgcg	tattatccct	aggctaatta	aaagtgtgct	ggttaatcag	4980
tttctttact	tttttttctc	tctttttttt	attctgtgtt	caggtatcat	ttgaccaaca	5040
acttgctctt	aatcttactg	cgatgactga	aatctccaaa	gaggagagta	tagtagttat	5100
aggtctagta	ataataatct	tgtaaacaat	tcattatttt	ttaaaactta	atgctgtgtg	5160
cctaatacgt	gttgagtatg	actaaaatgt	aatgagAAC	caaatatgac	actaacgctg	5220
gcactaaaatt	ttatttttac	ttgtgtactt	aaagtacttt	actggcctgt	tgggaaattg	5280
atttgtataa	gattcacacc	tggttttggc	agaaacagct	ttttaaagat	acaattaggc	5340
tgacttaaaa	atgtttttta	ttccacagaa	tgtatcttta	ttatgtcatt	cttaccgtct	5400
ctctgccttt	tttgaccatc	atgtaactac	gcagtagtaa	atcatggggg	gcaggctgat	5460
gaattagtag	tctttgtaaa	actaaaatgt	aatgagcata	ggaagagaca	gctcttctgg	5520
tgaacatggc	agttttccgg	taataccagc	cttgatgaat	aggctaaaga	cagctgtgta	5580
ctatggacat	tcaacttcac	tggattgcct	ggcttagctt	ttcagttatt	gtcttgccgt	5640
gaaacatggg	gttgcaactgt	acacatttta	gaatagtggc	aagaatgttc	tttagaactg	5700
cagataaacc	aacagagaat	accataccaa	tatatcggtt	tctcctgtta	catagagatt	5760
tggatatttca	gtgatgggta	tggtttttga	ctcacctgtg	tgtcagtcct	gctagagaga	5820
cagtatagaa	tcaagaattt	cttgatgtct	ttttaaaaat	agagattata	atggccttgc	5880
tagttgtcct	gtgaagtgac	agacccttaa	ttagaaatct	tttaatcctg	ctttccattt	5940
tacttctcca	ccatttattt	ttaacattca	ttctctgaaa	atagtatatga	tttttagtgt	6000
aattggctat	gtttaagaaa	ttccatttca	aagtcttaat	atgtaacaat	cttcattttt	6060
tataaaaattg	aaggacattt	ttgaggcaaa	cttactttta	tagctcattt	tctccctagt	6120
taaggagaat	tctctgggtt	catatagaga	atggctagct	ctgtgatacc	ccaccctctt	6180
tgtggcctac	cagttgctgt	tgtgttgctt	aaaattgcag	atattctcat	aaacatgatg	6240
atttttggca	caggcctttc	tttgctattg	atttcaaaaat	aaagttgggc	aatccaattt	6300
gaactacttt	aataaacata	athtagcatt	cctgtaatga	gaaagtattt	tcaaaagata	6360
accagattta	tttctaggat	tagagatggc	aaataccaat	gatagtattt	ttcccaagag	6420
caatcacaga	ttaatctata	aatatgagaa	gtcgcattat	tgtacttaat	tctttggcaa	6480
caaacagcaa	gtttttattg	tttaattgta	tttctctctc	agagatcaca	atactctggg	6540
tatttttatat	cccttctaaa	ggtcatttgg	gttttcaaat	gggaagaata	gtcaagctaa	6600
gctggactaa	acctaagtaa	tattttttct	catcaaaaga	agttattaat	ctaactgggt	6660
tagcatgagt	cattcatttt	ttagacatga	taaatgggaa	acatatcaaa	tcattagata	6720

aattctgacc	tggaattgaa	ttcccccttt	cttaaaatct	ttttaatttg	cttttttcat	6780
agactcagta	tggaactcct	aactgataag	ggagagattc	ttgatctgga	accgttccct	6840
gccattctcc	ttttttctct	ctgtctaggt	agctggttcc	atagtgcccg	tcacgagggg	6900
ccatttcagt	ttgatgacat	tagactgctt	acactcagct	ggatgccttg	ctgtttgcag	6960
caacatgatt	ttacagtatg	ctttttctca	agctttgcat	tcttaatgga	gatatcaaat	7020
ggtgtaattc	caaatataaa	tatgtttatg	acactaatca	tatgctttta	acaataactt	7080
tttgataact	tattgccctg	taagttaaag	cttacacgga	gtgactgttg	ccatcagaaa	7140
atcccccttc	acctgctaga	gagagtgaag	gtagtgcgtg	gcctccactt	ttcagttaac	7200
gagtagcaag	cttctagtag	gggctgctta	tctgaccocat	gtggggctct	gggccttggt	7260
actttcctgg	gttcgtccct	tcagctggaa	aggctgttga	aaacacttgc	caggaaacag	7320
taaagctgtg	agagaatcct	ctagtcttag	atatagagaa	atgagtacca	gttgatgcta	7380
acacgatact	tagactttga	ggggcttcca	tccaagcttt	ggcatgaatc	tgtagacac	7440
ggttttcttc	actcctctga	taatcttttt	ttccagaatg	gttttttggt	gtgtgtgttg	7500
ttaacaaatt	ctaaacatcc	agtgttactt	tttgttttgt	ttgttttggt	ttgttttggt	7560
ttgttttggt	tgcccttcag	gaaagtcctt	tttcgagtag	gtattgattg	ttccctggaa	7620
actctcagca	gtgtctgtgc	aggctctgtg	catgctttgt	atgagttcgg	cttgaacaat	7680
gcatttgaag	tcacctggga	tgtccagttc	tggcatgtct	tcattgattg	tgtttttaaa	7740
catgtttcat	gtttcatgtc	attttccaaa	cctcacttta	catcttactc	agagaagtta	7800
atcaaggaat	gaaatttcta	gggggatagg	gatgatgagg	gtgggttggg	ggccttgagt	7860
aagtcaactt	gggggtatttg	ctttaaagtg	ttttctaaag	cagttcctaa	cagtatttag	7920
agattccctg	ggatgtttgt	ggctcaactt	attctggaca	aagtgtgtgt	gggggtggtc	7980
ttactgagat	ttgcattcct	aatgcaggac	aggctctaaa	tttcatctgt	actctaaatt	8040
tgtgattgaa	tccaagaaga	taacagagac	agtgtcctct	ttgtaatggt	tctggcaagt	8100
gctccctaaa	atgcacatcg	aattctgttt	tctgggcctt	ttctccaatg	gtgctaggag	8160
ataccgttga	tttctgcagc	tcttctcagt	ggtgggaaga	agtctttggg	attgttgagc	8220
aaggggcagc	tggaccatcc	actaaatttt	ttgtttcaag	acacattaga	gaccctcctg	8280
tatatctagt	aagtcataat	aaaggtgctt	gggaaagcct	taaatttgaa	gacacatgga	8340
ggcggtagaa	aattaaactt	gtaagaggag	aaaaacatgc	cattaggtaa	cgcagagtgt	8400
taactactgg	ctaagactca	atggaacttc	cacttgctct	aaaaccaggg	aagggagtgg	8460
gacgataagt	cttttgaaga	catcagctca	ctgtgctgag	agagggacca	aactcaagga	8520
aacctctgat	ctatacattc	aactgctgca	tttttttata	aatacatgta	aatgtcctgt	8580

tgtaatat	gatcttgg	ataaaaaa	aaacttttca	gtagaaaaa	aacaaaaaa	8640
aaaaaat	tggtggcc	gccaagaag	ttcaaccaca	tgtgtgggg	cgccccagg	8700
gaaggaa	tgcaagtg	aagaaccgg	cagaagggg	gtttcccaa	aaacgcgcg	8760
gcgcgcg	gtttga					8772

<210> 5
 <211> 7616
 <212> DNA
 <213> Homo sapien

<400> 5						
ttctggtggc	aaaactagaa	tcacgactac	cccccttca	gaggactcca	tttaaggggg	60
ggtagtcgtg	attctggtgg	caaaactaga	acttttaact	tgtaaaatga	aaaatattaa	120
atggaccttt	ttgtcagttg	aggatttaga	ttgattcttt	tatctgagga	gcgtatgttc	180
ctcagatgtt	gcgtagagac	ctttaggttt	tcactacttt	taagattgct	ctcttggcaa	240
ttaggggatt	tgggaaaaga	agaaaaaaag	atgccatgtg	ttgctagtac	acagttatag	300
gatatggttt	ctaattggtt	aattttgagg	aactctccct	aaagaatgag	ttttatatct	360
cctcaaggaa	atcatggaaa	aatctgttta	ttcttcagtg	agtccttttg	aattaatgtt	420
cttaaat	tttctaagtc	tgtgtaagt	cttatgtata	agtatataat	tgtataaata	480
tttataaata	tatttatata	attacggttt	catttctacc	ttgagtcaaa	gttctgtctt	540
tagattggtg	actgagtaat	acttacactt	tggtgttttt	tcttaggttc	ttgaggctta	600
cttaactagc	agcttctgat	ttattgagtg	aaagatgggt	ttcatgttaa	ttcctcagtt	660
gcactctctga	acttggataa	catacttgcc	gtttgaaaaa	tagagctgta	tactgtcaaa	720
ggtgcactgg	agggtaaaac	atttgttggg	agtagacaag	ctcagaaatc	caaaaattcm	780
gggagggcac	agggtaaaga	gagagggttg	ctcagctttg	tgctctgatg	gcacccatct	840
gtactccagc	aaagtcatag	ctgaagccca	aatcgctcaa	acgtgtgaag	tcaatcattt	900
ttcctatagg	gctctgtttc	cttttcttta	ccttctagct	tctcttgata	aaacagttgg	960
gagaactgcc	aacgtgttca	tcagtgaag	ggtgtggttc	tttccgatat	gttcagcacg	1020
tgcatattca	tttatgagaa	accaaagtaa	cttcttcaac	tgggttact	gtgggatgat	1080
taagtagata	taaagtgatt	taaaagacag	catggtactt	tcaactcagct	taacatgcag	1140
ctgggatgtc	tacaatacaa	gatgtggtgg	gttttat	attttat	gaggcaggag	1200
tgtaattatc	ttagggttga	tataaaggcc	catgggaaga	gttacggatt	gtacatggga	1260
agaatccata	aggagtattg	ccttgctcaa	gaatttaatc	cgctgacagt	atgcttcttc	1320
cagtttgcct	tacttctct	gcaagtttct	ttgctcctta	gggcagaggt	tttattgaat	1380

agattaaatg aggtcagtaa gattagttaa aaatagtcac	tccttgtggg	tgttggacac	1440
agcttgaaag gagtgtttaa aaaaaaaaaag	ctagggagga	aaagaacaag aaagatagac	1500
ttcgagagtg ataagagaaa aatacaggga	gatggaatgg	aaactaccag gaaggccggg	1560
cgcggtggct catgcctgta atcccaacac	tttgggaggc	ggagggtggc agatcaccta	1620
aggtcaggag atcgaggcca gcctgagcaa	catggtgaaa	ccccgtctct actaaaaata	1680
caaaaattac ctgggtgtgg tggcgtgcac	ctgtaatccc	agctactcag aggctgaggc	1740
aggggaatgg cttgaacctg ggaggcagag	gttgacgtga	gccaagatcg caccattaca	1800
ctccagcctg ggcgacaaaag cgacactcca	tctcaaattt	aaaaaaaaa aaaaagaaga	1860
agaagaaaac tagtgggaaa aaagtgagag	gaatactttt	ttgaaattgg tatcggaagg	1920
aactggagaa gagaaaacaa cagtgcctaa	tgagaaaaga	acaggaaact taataactaat	1980
tggcatgcac cagatacttt tgtgtacatt	tgctctttca	atctcccgaa gaatcgtaca	2040
aaatgtatac tttcttccca tgttaagaaa	acaggtatag	agaacttatt caggactcat	2100
agctagttag tggcaaatca gaattggaat	ccagagtcca	tgtgtgtggc tccttcagca	2160
agagaatcaa gctaccacaga tgattctctt	ctcattgttt	ggctttgtaa agtgtcactt	2220
agttttgttc ccataaatat agaggaagta	gttgggttaa	agttgtggga tttgcactat	2280
gcctatacat ttttatttat gccattattt	tgagaggctg	attattgctt ttttaaatg	2340
atgcactggg gaagatgtga aagtaaaatt	gccacgtggc	attatttgcc aagaataaat	2400
gaaaagggtg aaaaaacaat tttttctttt	tttaaacatt	tttcagaaaa gatacaatta	2460
ccttttttaa taggtgagcg ccaccacgcc	cggtctaattt	ttgcattttt agtagagaca	2520
gggtttcacc atgttggcca ggatggctct	gatctcttga	tctcgtgttc cgcccacctc	2580
ggcctcctaa agtgctggga ttacaggcat	gagccactgc	gcccgatcta caattctgtt	2640
ttctgtgtcc catccatacc agattattga	accctctgtg	tgtatgtttt taaatcttgt	2700
atataattct acttcttga cttacaagtc	aacaattagc	tattgagttc tttatagaag	2760
ttggaagtat tttgaaatct gagatcta	atctggccgg	gcgcgggtggc tcatgcctgt	2820
aatcccaata ttttgggagg ccgagggtgg	tggtacacct	gagggttggga gttcgagatc	2880
agcctggcca acatgggtgaa accccatctc	tactgaaaaa	tacaaaaatt agccaggcat	2940
ggtggctgtc tgtaatccca gctaattggg	aggctgaggc	acaagaatct cttgaacctg	3000
ggaggcggag gttgcagtga gccgagatca	caccactgca	ctccatcctg ggcaatggag	3060
cgagactctg tctcaaaaaa taataaataa	gatatgattc	ctgcctgttt tatccagtta	3120
gagagacaca ctacacatga aataattgga	gagcatgtaa	atgtttacct attagttcaa	3180

acttagaaaa	agggagaagaat	atgttttagt	tagcaaagtc	ttaaacaaga	ctgaagtggc	3240
aagcactgta	gctcacgttt	tcttttgact	cacctttttc	tttagctcca	ccttttgtaa	3300
cttctagatt	tggggcatga	agttctgcc	ctaaggcata	accagtaccc	aagtaggaaa	3360
ggattattga	tccctggagt	aaagattcct	agcttgcggg	gatctcacta	ttgatccccc	3420
ggagtaaaga	ttcctagctc	gcaggaatct	tacttgcaca	cttagggaaa	ataccagagg	3480
gagccactag	caaccgaaaa	atgaaggaaa	gatttaattt	ctctaccag	gtacaaatcc	3540
aatgcatagt	atagtatatg	ttatatgcag	aaagggcact	ggaggtgtga	gagccctttg	3600
ggtaacagct	ctgctagttg	ttaccttcac	acttctcttt	cttcttaatc	tctggtttct	3660
cgtctgaaaa	atgagataat	tggactagat	taatagttct	cagccttttc	tagaacaaca	3720
aattagatta	tctctgaagt	ccttttccaa	aatttcatgc	ttccagtctc	ccccgtgat	3780
tgcgtattat	ccctaggcta	attaaaagtg	tgctggttaa	tcagtttctt	tacttttttt	3840
tctctctttt	ttttattctg	tgttcaggta	tcatttgacc	aacaacttgc	tcttaatctt	3900
actgcatga	ctgaaatctc	caaagaggag	agtatagtag	ttataggtct	agtaataata	3960
atcttgtaaa	caattcatta	ttttttaaaa	cttaatgctg	tgtgcctaata	cagtgttgag	4020
tatgactaaa	atgtaaata	gaaccaaata	tgacactaac	gctggcacta	aattttattt	4080
ttacttgtgt	acttaaagta	ctttactggc	ctgttgggaa	attgatttgt	ataagattca	4140
cacctggttt	tggcagaaac	agctttttta	agatacaatt	aggctgactt	aaaaatgttt	4200
tttattccac	agaatgtatc	tttattatgt	cattcttacc	gtctctctgc	cttttttgac	4260
catcatgtaa	ctacgcagta	gtaaatcatg	gggtgcaggc	tgatgaatta	gtagtctttg	4320
taaaactaaa	atgtaataag	cataggaaga	gacagctctt	ctggtgaaca	tggcagtttt	4380
ccggtataac	cagccttgat	gaataggcta	aagacagctg	tgtactatgg	acattcaact	4440
tcactggatt	gcctggctta	gcttttcagt	tattgtcttg	ccgtgaaaca	tgggtgttga	4500
ctgtacacat	tttagaatag	tggcaagaat	gttctttaga	actgcagata	acccaacaga	4560
gaataccata	ccaatatatc	ggtttctcct	gttacataga	gatttggtat	ttcagtgatg	4620
gttatggttt	ttgactcacc	tgtgtgtcag	tcctgctaga	gagacagtat	agaatcaaga	4680
atttcttgat	gtctttttta	aaatagagat	tataatggcc	ttgctagttg	tcctgtgaag	4740
tgacagaccc	ttaattagaa	atcttttaat	cctgctttcc	attttaacttc	tccaccattt	4800
atttttaaca	ttcattctct	gaaaatagtt	atgattttta	gtgtaattgg	ctatgtttta	4860
gaaattccat	ttcaaagtct	taatatgtaa	caatcttcat	tttttataaa	attgaaggac	4920
atttttgagg	caaacttact	tttatagctc	attttctccc	tagttaagga	gaattctctg	4980
gtttcatata	gagaatggct	agctctgtga	tacccacccc	tctttgtggc	ctaccagttg	5040

ctgttgtgtt gcttaaaatt gcagatattc tcataaacat gatgattttt ggcacaggcc	5100
tttctttgct attgatttca aaataaagtt gggcaatcca atttgaacta ctttaataaa	5160
cataatttag cattcctgta atgagaaagt attttcaaaa gataaccaga tttattttcta	5220
ggattagaga tggcaaatac caatgatagt atttttccca agagcaatca cagattaatc	5280
tataaatatg agaagtcgca ttattgtact taattctttg gcaacaaaca gcaagttttt	5340
attgtttaat tgtattttct ctctagagat cacaatactc tgggtatttt atatcccttc	5400
taaagggtcat ttgggttttc aaatgggaag aatagtcaag ctaagctgga ctaaaccctaa	5460
gtaatatttt ttctcatcaa aagaagttat taatctaact gggttagcat gagtcattca	5520
tttttttagac atgataaatg ggaaacatat caaatcatta gataaattct gacctggaat	5580
tgaattcccc ctttcttaaa atctttttta tttgcttttt tcatagactc agtatggaac	5640
tcttaactga taaggagag attcttgatc tgggaaccgtt ccctgccatt ctcttttttt	5700
ctctctgtct aggtagctgg ttccatagtg cccgtcacga ggggtccattt cagtttgatg	5760
acattagact gcttacactc agctggatgc cttgctgttt gcagcaacat gattttacag	5820
tatgcttttc tcaaagcttt gcattcttaa tggagatatc aaatggtgta attccaaata	5880
taaatatgtt tatgacacta atcatatgct ttttaacaata actttttgat aacttattgc	5940
cctgtaagtt aaaccttaca cggagtgact gttgccatca gaaaatcccc ttccacctgc	6000
tagagagagt gaaagtagtg cgtggcctcc acttttcagt taacgagtag caagcttcta	6060
gtaggggctg cttatctgac ccatgtgggg tcttgggcct tgttactttc ctgggttcgt	6120
cccttcagct ggaaaggctg ttgaaaacac ttgccaggaa acagtaaagc tgtgagagaa	6180
tcttctagtc ttagatatag agaaatgagt accagttgat gctaacacga tacttagact	6240
ttgaggggct tccatccaag ctttggcatg aatctgttag acacggtttt cttcactcct	6300
ctgataatct ttttttccag aatgggtttt tgttgttgtt gttgttaaca aattctaaac	6360
atccagtgtt actttttgtt ttgtttgttt tgttttgttt tgttttgttt tgtttgccct	6420
tcaggaaagt cctttttcga gtaggtattg attgttcctt ggaaactctc agcagtgtct	6480
gtgcaggctc tgtgcatgct ttgtatgagt tcggcttgaa caatgcattt gaagtcacct	6540
gggatgtcca gttctggcat gtcttcattg attgtgtttt taaacatgtt tcatgtttca	6600
tgtcattttc caaacctcac ttacatctt actcagagaa gttaatcaag gaatgaaatt	6660
tctaggggga tagggatgat gaggggtgggt tgggggcttg agtgaagtca acttggggta	6720
tttgctttaa agtgttttct aaagcagttc ctaacagtat ttagagattc cctgggatgt	6780
ttgtggctca acttattctg gacaaagtgt gtgtgggggt ggtcttactg agatttgcac	6840

15

tcttaatgca ggacaggctc taaatttcat ctgtactcta aatttgtgat tgaatccaag 6900
 aagataacag agacagtgct cctggtgttaa tgtttctggc aagtgtctcc taaaatgcac 6960
 atcgaattct gttttctggg ccttttctcc aatgggtgcta ggagataccg ttgatttctg 7020
 cagctcttct cagtgggtggg aagaagtctt tgggattgtt gagcaagggg cagctggacc 7080
 atccactaaa ttttttgtt caagacacat tagagaccct cctgtatatc tagtaagtca 7140
 taataaagggt gcttgggaaa gccttaaatt tgaagacaca tggaggcggg agaaaattaa 7200
 acttgtaaga ggagaaaaac atgccattag gtaacgcaga gttgtaacta ctggctaaga 7260
 ctcaatggaa cttccacttg ctctaaaacc agggaaggga gtgggacgat aagtcttttg 7320
 aagacatcag ctactgtgc tgagagaggg accaaactca aggaaacctc tgatctatac 7380
 attcaactgc tgcatttttt tataaatata tgtaaatgtc ctggtgtaat atttgatctt 7440
 ggaaataaaa acaaaaactt ttcagtagaa aaaaaacaaa aaaaaaaaaa tttkgggggc 7500
 cggcgccaag aagtttcaac cacatgtgtg gggccggccc aggtgaagga aatggcaagt 7560
 ggccaagaac cggccagaag gggggtttcc caaaaaacgc gcgggcgcgc gtttga 7616

<210> 6
 <211> 1921
 <212> DNA
 <213> Homo sapien

<400> 6
 gacctctcct catctgtgca tggatgagtg gccgactttg gagcccaggc tgttacttcc 60
 tgggtctggtg gtgaatcctc catagtctga gagtaagatc cttgatactg gctcagcatg 120
 gaacatctgg cacacagtat gcaactgagga aatacttgtt ggaataatca gtgaatcata 180
 gatgaaaact taaccttgga attaatattg agactgctca gaggaagaga atgggagaca 240
 aaggacctgg tgattagacc cccaagacac tgggctgtct gcttgtgtct cgggtggaac 300
 aggcccagcg agagtcttta gggccagaac tcaagaattt attgagccct tgttctagggc 360
 acttgggatt caccagtata caatggagac aaaaatccct gccctggagc agcttacatt 420
 ctagcatggc aaacaggcag taaacagccc attctggctg ctgtattgag aagagaatgt 480
 ggtggacaga tatagaagca tggaaacctg atagggctat tgcaatcact cagaaaagag 540
 gcgatggcag cttggacctg ttggaagcag tagagtgtt ccaggaggga gaaaggacct 600
 gaagggttaat ttgatcacca atggccaatg atgtaatcag ttatgcctat gtaatgaagc 660
 ttccgtaaaa accaaaagga ttgggtttga ttgagcttct ggatagctaa acatgtggaa 720
 gttcctggag gatgggtggc ctaaacaggg ttaccagaaa atttaaagtt acgccagtca 780
 ctccattct attgctgaga gaaaatacag agcgggtgaag agcttacagt cgggtgagca 840

16

agatacgcgc ccaatgttag ctaatgatgt aaggcatcaa caagaaatgt ggggggttcag 900
 gaaagtggaa ggtgggggtcg tccaaagcct gggaaagtct tcagttgaag gcgagacaga 960
 tgggactatt agtgagtttc gagagatcca acgcctcgcc gccttcgctt cttttttgtc 1020
 tcacgccccca cccttgaacg cggggcgccct tttgaccccg ccgccgcgcc gtagaccgcg 1080
 ctgcacgcgc gcggcagcca tggcggatgt gtcagagagg aactgcagt tgtccgtgct 1140
 agtagccttc gcttctggag tactcctggg ctggcaggcg aaccgactgc ggaggcgcta 1200
 cttggactgg aggaaaagga ggctgcagga caagctggcg gcgacgcaga agaagctgga 1260
 cctggcctga gactctgcgc cttccgcccc attctgtccc cctcatggcc accttgccat 1320
 gtccgcgcgc gagccccggt ccgcccggcg ccagaaccag gcttgccaca cagtccccgc 1380
 ctgccatggc cggctcttcc tggagtgttg cttgttgaag atgcatatag actaccggaa 1440
 agaaatgact tcttcttgca ctttatgaat caattttatt tttaaaataa aaaaattaaa 1500
 catcaaaaaa aaaaaaaaaa acaaaaaaaa aaaaaaggaa aaaagaaaaa aaaaaaaaaa 1560
 aagaaacaag acaaaaacag agagcggcaa aaaaagaaca cagagaggag acacacaaag 1620
 acgaacaaac cacgagaaag agcgaccaag aagcgacaaa aaaaaagaaa agaggaggca 1680
 cagaaacaac cgcgaggaaa aagaacaaca gcagaccgag agcgcccgga gcgggaaaac 1740
 acacacgaag tgaggacaga gaagacgaca gccggacaca aacaaaaaga aaggaaaaga 1800
 gacacgagcg gagggcgaca caaaaaacaa aagacagaac aaacgacgcg aagacacccg 1860
 agacaaaagc gaccaggaga gagaagcgaa cgagcgccca ccccgacaac acaagacaag 1920
 a 1921

<210> 7
 <211> 1469
 <212> DNA
 <213> Homo sapien

<400> 7
 gacctctcct catctgtgca tggatgagtg gccgactttg gagcccaggc tgttacttcc 60
 tggctctggtg gtgaatcctc catagtctga gagtaagatc cttgatactg gctcagcatg 120
 gaacatctgg cacacagtat gcaactgagga aatacttggtt ggaataatca gtgaatcata 180
 gatgaaaact taaccttgga attaatatg agactgctca gaggaagaga atgggagaca 240
 aaggacctgg tgattagacc cccaagacac tgggctgtct gcttgtgtct cgggtggaac 300
 aggccagcg agagtcttta gggccagaac tcaagaattt attgagccct tgttctaggc 360
 acttgggatt caccagtata caatggagac aaaaatccct gccctggagc agcttacatt 420
 ctagcatggc aaacaggcag taaacagccc attctggctg ctgtattgag aagagaatgt 480

17

```

ggtggacaga tatagaagca tggaaacctg atagggctat tgcaatcact cagaaaagag 540
gcgatggcag cttggacctg ttggaagcag tagagtgctt ccagggagga gaaaggacct 600
gaagggttaat ttgatcacca atggccaatg atgtaatcag ttatgcctat gtaatgaagc 660
ttccgtaaaa accaaaagga ttgggtttga ttgagcttct ggatagctaa acatgtggaa 720
gttcctggag gatgggtggc ctaaacaggg ttaccagaaa atttaaagtt acgccagtca 780
ctccattct attgctgaga gaaaatacag agcggtgaa agcttacagt cgggtgagca 840
agatacgccc ccaatgttag ctaatgatgt aaggcatcaa caagaaatgt ggggggttcag 900
gaaagtggaa ggtggggctg tccaaagcct gggaaagtct tcagttgaag gcgagacaga 960
tgggactatt agtgagtttc gagagatcca acgcctcgcc gccttcgctt cttttttgtc 1020
tcacgccccca cccttgaacg cgcggcgcct tttagacccg ccgcgcgcgc gtagaccgcg 1080
ctgcacgccc gcggcagcca tggcggatgt gtcagagagg aactgcagt tgtccgtgct 1140
agtagccttc gcttctggag tactcctggg ctggcaggcg aaccgactgc ggaggcgcta 1200
cttggactgg aggaaaagga ggctgcagga caagctggcg gcgacgcaga agaagctgga 1260
cctggcctga gactctgcgc cttccgcccc attctgagcc ccggtccgcc ggcgccaga 1320
accaggcttg ccacacagtc cccgcctgcc atggccggct cttcctggag tgttgcttgt 1380
tgaagatgca tatagactac cggaaagaaa tgacttcttc ttgcacttta tgaatcaatt 1440
ttattttttaa aataaaaaaa ttaaacatc 1469

```

```

<210> 8
<211> 1268
<212> DNA
<213> Homo sapien

```

```

<400> 8
ttcctgggtgg tgatgggtgtg cacttttatt caactggtct caagtcagtg tacaggtaag 60
ccctggctgc ctccaccac tcccaggag accaaaagcc ttcatacatc tcaagttgga 120
ggacaaagga agggagaggg gtggagggac agaaaggaag aggaaggatg gaggaaggaa 180
aaaggaggag aagcaaacgg ggggggctgc ccttgcctct gagaacctgc tacactgtct 240
cctttggtag cagcctgcc ctgtgcctct aacctacacg tgacttgggt caaataaaac 300
ttccaggagg atccaaacct gaaggacagt gggaaaccca gaatgcactt tgaggcttct 360
ctagcagtgg acgagcgcct gtcttcttag tccctgaccc tggatcttct tgaaggctct 420
ctcatcacc agctgccagg gaacctggct gccctgaag cagctcacac tgggtctgtc 480
cctctgcagc accacccatg ctgcccctca gctcttcccg ctgctctcac tctgaacac 540
ttaaggagat ggcaggggag gagctgccga accagaggag caccacac actgccaaca 600

```

18

gggcttgacc	caggagcggg	ggcttgaaaa	gctccagctc	cgttttttaga	ggaagaagaa	660
tgccggatta	caacacagca	ccagcaatct	ggatattcgt	tccttggtg	ttctttaacc	720
agccaggaaa	tgccctgtgc	aagggtgga	ggcctggggc	tgagactcc	caatctcaat	780
gggcacccca	gggctgagcc	acctgagggc	actgggggtt	tccattttca	aacgggaatc	840
ctagcagctt	ccctgctccc	acctgcggaa	gaggagacac	ttttgtacat	tctgactttc	900
tgagacagg	taaaaaggcg	tacacagacc	tttggggatg	aaagagaaac	taaaactgaa	960
ccaagtgtac	aggttacagc	gtcacagtca	aggcacctaa	cagaccctac	ttactgtttg	1020
ttcttaaaaca	tgaatgactg	cagatccctg	ccagagacgg	taagtgaaaa	aacagctacc	1080
tcctattttc	tttacgtatt	tcccatcaaa	cgctgtctt	gggttgggtt	agaattaca	1140
gaaggtaaac	ggagtcaatt	ccaagtcact	caagcaattt	tctgtgtgaa	gagagaacaa	1200
gacaaaagcc	aaccacaaca	gcaaaaccca	aagcctcgt	tacgccttct	atggcaatca	1260
aacacgcc						1268

<210> 9
 <211> 1328
 <212> DNA
 <213> Homo sapien

ataagtgtct	taacttgggc	tgtcttcact	ccacccctcc	cgagtaggta	cttcagttgt	60
gcccattcta	cagacaggga	agctgaggct	ggagaggtca	ggactcgcct	gaggtcctac	120
ggtctcccct	gggacctggc	tgaggatggg	ggccgggctg	ggccctcagg	gttgagact	180
ctgaccccct	actccccgac	cccagcttc	acgtggagtg	acgcacgcct	gcaccgaggc	240
ctggtgaccc	tgctgactgg	tgaaattgtt	gacgccttca	gccttgagtt	ccggacgctg	300
tacgcggcct	cctgcccgt	cccacctgcg	cccccccaga	aacctcgggt	cataggtggc	360
ctgcagcggg	gcgcagcct	gcaccgcgtg	tcccgccgcc	gctccgtggc	ccccgcgtcg	420
cctccgccgc	ctgacggccc	gctggccac	cgctggccg	cctgccgcgt	ctcccctgct	480
accccggggc	cggcactcag	tgacattcta	aggagtgtgc	agcgcgcccg	gacccccagc	540
ggccccccgg	cccgcccag	ccgtccatg	tgggacctaa	gccgcctgtc	ccagctgtct	600
ggctccagtg	atggggacaa	cgagctcaag	aaatcctggg	gctccaagga	cactccagcc	660
aaggctctga	tgaggcagcg	gggactgga	ggaggccct	ggggggaagt	ggactcccga	720
cctccgtggg	gcggtgccct	gcccctgccc	ccgcgccacc	gcctccgcta	tctgtcccca	780
gcccgaaggc	ggttcggtgg	ggatgctaca	ttcaaacttc	aagagcccag	aggcgtcagg	840
ccgtcagact	gggccccccg	ggcaggactt	ggggggcaac	cctgaacagg	agcccaagcc	900

19

aaatctgctg	gcccacccaa	ggagcagtgc	cggacaactg	tgggtcaga	gcctctgcc	960
tcaatgccct	gccttggaca	aggcttctgg	cctcggcgtc	tgtcaagcag	aagggatggt	1020
tgtcacttgt	tctgcaactt	gggccgggag	tgggtggctca	tgctgtaat	ccctgcactt	1080
tgggaggcta	aggtgggagg	gttgcttaag	gccaggagtt	ggagaccagc	ctgggcaaca	1140
tagtgagacc	ccatctctac	aattaaaaaa	acaaattagt	tgggtgtggt	ggcgacgcc	1200
tgtggtccca	gctacgcagg	aggctgaggt	gggaggatcc	ctcgagctca	ggaggtggag	1260
gcagcagtga	gccaagatca	tgcccttgca	ctccagcctg	ggcaacacag	tgagaggcca	1320
tctcttta						1328

<210> 10
 <211> 2061
 <212> DNA
 <213> Homo sapien

<400> 10	
cccttttcaa	tgaaaagtca
ctgagcttgg	tgagtcaaga
ttcactgaaa	tattcttcca
60	
tgttgatggg	cctcttttgg
gaggtgacct	tattcctgtc
ctgcccccta	aggggtgggca
120	
gggtggacag	aacgcagcct
ggacttccgg	acgcagcccc
ctaccgcccc	ggactcgcct
180	
acctctctgg	cctctgagga
gggccctaag	cccaggacag
acgtggaaaa	agggcagtaa
240	
aaaggatgca	gttcttctct
ttaatcccta	acccaatttc
tggggaaaag	ctgcgttccc
300	
acacagaagg	cgaaccctgt
aaagctgtgg	cttggtctgcc
gcgacgcag	tcgctttacg
360	
aattcccaaa	gcatctagcg
gaagtttaga	ccgttcacta
ggggtcacat	gggccacttc
420	
gcgagcagct	ggcgaacagt
tcctttcagt	ttgaaagtat
ctttgaaact	cggaaattgt
480	
gctccttggg	ctttcagttc
ataagcctag	agagtggcta
ctgaaattgg	aatcgatc
540	
ttcttccttc	ggccccaaact
agtagaccac	gaccagaaga
cacatcctaa	cctacaccta
600	
ccgtagtgtc	acacccggca
cagcgcgacc	aggtccacca
actgcgcctg	cgcgaaccgg
660	
ccgctccgc	gacatcacag
gaaggctgag	agaaagggca
gggtccccgct	gcgtggggct
720	
gggcttaaag	gctcgtcgcg
cctgcgcaaa	ggacctgacg
acgtgctgcg	tcgttacttt
780	
tgaaacgctt	ggcggggaag
tgctgttggg	gccgctgtgg
ttgctgtccg	cggagtggaa
840	
gcgcgtgctt	ttgtttgtgt
ccctggccat	ggcgtctgcag
ctctcccggg	agcagggaaat
900	
cacctgcgc	gggagcgccg
aaatcgtggc	cagattcttc
tcattcggca	tcaacagcat
960	
tttatatcag	cgtggcataat
atccatctga	aacctttact
cagatgcaga	aatacggact
1020	
caccttgctt	gtaactactg
atcttgagct	cataaaatac
ctaaataatg	tgggtggaaca
1080	
actgaaagtg	caccagaga
aaagtctcag	aaagctatcc
aggatgaaat	ccgttcagtg
1140	

20

```

atcagacaga tcacagctac ggtgacattt ctgccactgt tggaagtttc ttgttcattt 1200
gatctgctga tttatacaga caaagatttg gttgtacctg aaaaatggga agagtcggga 1260
ccacagttta ttaccaattc tgaggaagtc cgccttcgtt catttactac tacaatccac 1320
aaagtaaata gcatggtggc ctacaaaatt cctgtcaatg actgaggatg acatgaggaa 1380
aataatgtaa ttgtaatttt gaaatgtggt tttcctgaaa tcaggtcata tatagttgat 1440
atgttttatt tcattgggta atttttacat ggagaaaacc aaaatgatac ttactgaact 1500
gtgtgtaatt gttcctttta tttttttggt acctatttga cttaccatgg agttaacatc 1560
atgaatttat tgcacattgt tcaaaaggaa ccaggagggt tttttgtcaa cattgtgatg 1620
tatattcctt tgaagatagt aactgtagat ggaaaaactt gtgctataaa gctagatgct 1680
ttcctaaatc agatgttttg gtcaagtagt ttgactcagt ataggtaggg agatatttaa 1740
gtataaaata caacaaagga agtctaaata ttcagaatct ttgttaaggt cctgaaagta 1800
actcataatc tataaacaat gaaatattgc tgtatagctc cttttgacct tcatttcatg 1860
tatagttttc cctattgaat cagtttccaa ttatttgact ttaatttatg taacttgaac 1920
ctatgaagca atggatattt gtactgttta atgttctgtg atacagaact cttaaaaatg 1980
ttttttcatg tgttttataa aatcaagttt taagtgaag tgaggaaata aagttaagtt 2040
tgttttaaat ttgtcttaaa a                                     2061

```

```

<210> 11
<211> 1826
<212> DNA
<213> Homo sapien

```

```

<400> 11
tcgaaymgta accgttcgta cgagaatcgc tgtcctctcc ttgcgggccgc agtgtggtgg 60
aattcttttc cgacacgtag tagtactgac gcttgggaac ggccctgggccc agaatctcga 120
tctggcgagc gttcaggccc atgcggcggg acagggccgc cgtgtcctca tccctggcgt 180
aaatattcgg caggaaaatc ttggtcgcgg tcgattccac gatcacgtcc aggatgccgc 240
tgttggcggc gtcggacagg ctctgcgttg ccatcagcac aaggcagttg gccttacgca 300
gcaccttgag ccattccctg atcttcgcgc ggaatgccgg gtggccgagc atcaaccagg 360
cttcgtccag gatgatgacg gccgccagtg tgggtggaatt ctaaccctga aaaagatata 420
tttgtggtgc gggaaaatgg gacgacgtgt ctcatggcag agtttgcagc caaatttatt 480
gtaccttatg atgtgtgggc cagcaactac gtatgatctga tcacagaaca ggccgatatc 540
gcattgaccc ggggagctga ggtgaagggc cgctgtggcc acagccagtc ggagctgcaa 600
gtgttctggg tggatcgcgc atatgcactc aaaatgctct ttgtaaagga aagccacaac 660

```

21

atgtccaagg gacctgaggg gacttggagg ctgagcaaag tgcagtttgt ctacgactcc	720
tcggaagaaaa cccacttcaa agacgcagtc agtgctggga agcacacagc caactcgcac	780
cacctctctg ccttggtcac ccccgctggg aagtcctatg agtgtcaagc tcaacaaacc	840
atttacttgg cctctagtga tccgcagaag acgggtcacca tgatcctgtc tgcgggtccac	900
atccaacctt ttgacattat ctcagatttt gtcttcagtg aagagcataa atgcccagtg	960
gatgagcggg agcaactgga agaaaccttg cccctgattt tggggctcat cttgggcctc	1020
gtcatcatgg taacactcgc gatttaccac gtccaccaca aaatgactgc caaccagggtg	1080
cagatccctc gggacagatc ccagtataag cacatgggct agaggccgtt aggcaggcac	1140
cccctattcc tgctcccca actggatcag gtagaacaac aaaagcactt ttccatcttg	1200
tacacgagat acaccaacat agctacaatc aaacaggcct gggatatctga ggcttgcttg	1260
gcttgtgtcc atgcttaaac ccacggaagg gggagactct ttcggatttg tagggtgaaa	1320
tggcaattat tctctccatg ctggggagga ggggaggagg gtctcagaca gctttcgtgc	1380
tcattggtggc ttggctttga ctctccaaag agcaataaat gccacttgga gctgtatctg	1440
gccccaaagt ttagggattg aaaacatgct tctttgagga ggaaaccctt ttaggttcag	1500
aagaatatgg ggtgctttgc tcccttggac acagctggct tctcctatac agttgtcaat	1560
gcacacagaa tacaacctca tgctccctgc agcaagaccc ctgaaagtga ttcatgcttc	1620
tggctggcat tctgcatgtt tagtgattgt cttgggaatg tttcactgct acccgcatcc	1680
agcgactgca gcaccagaaa acgactaatg taactatgca gagttgtttg gacttcttcc	1740
tgtgccaggt ccaagtcggg ggacctgaag aatcaatctg tgtgagtctg tttttcaaaa	1800
tgaaataaaa cacactattc tctggc	1826

<210> 12

<211> 1106

<212> DNA

<213> Homo sapien

<400> 12

ataatttgga atgtgggtgg agaggggatc atagttctcc ctgagtgaga ctcacctgct	60
cctctggccc ctggtcctgt cctgttctcc agcatgggtgt gtctgaagct ccctggaggg	120
tcttgcattg cagctctgac agtgacactg atgggtgctga gctccccact ggctttggct	180
ggggacaccc aaccacgttt cttgtggcag gataagtatg agtgtcattt cttcaacggg	240
acggagcggg tgcggttcct ggaaagagtc atctataacc aagaggagtt cgtgcgcttc	300
gacagcgacg tgggggagta ccgggcggtg acggagctag ggccggcctgt cgcgatcca	360
tcttgagggt actgtgtatc ctgccaagac tcagccccctg cagcaccaca acctcctggt	420

22

ctgctctgtg agtgggtttct atccaggcag cattgaagtc aggtgggttcc ggaacggcca 480
 ggaagagaag gctgggggtgg tgtccacagg cctgatccag aatggagact ggaccttcca 540
 gaccctgggtg atgctggaaa cagttcctcg gagtggagaa gtttacacct gccaaagtga 600
 gcaccaagt gtgatgagcc ctctcacagt ggaatggaga gcacgggtctg aatctgcaca 660
 gagcaagatg ctgagtggag tcgggggctt tgtgctgggc ctgctcttcc ttggggccgg 720
 gtgtttcatc tacttcagga atcagaaaagg aactcttgga cttcagccaa caggattcct 780
 gagctgaagt gaagatgacc acattcaagg aaaaaccttc tgcccagct ttgcaggatg 840
 aaacacttcc ccgcttggtc ctcatcttc cacaagagag acctttctcc ggacctggtt 900
 gctactggtt cagcaactct gcagaaaatg tcctcccctg tggtgcctc agctcatgcc 960
 tttggcctga agtcccagca ttgatggcag cccctcatct tccaagtttt gtgctccct 1020
 ttacctaacg cttcctgcct cccatgcac tgtactcctc ctgtgccaca aacacattac 1080
 attattaaat gtttctcaaa catgga 1106

<210> 13
 <211> 943
 <212> DNA
 <213> Homo sapien

<400> 13
 ataatttggga atgtgggtgg agaggggatc atagttctcc ctgagtgaga ctacctgct 60
 cctctggccc ctggtcctgt cctgttctcc agcatgggtgt gtctgaagct ccctggaggc 120
 tcctgcatgg cagctctgac agtgacactg atgggtgctga gctccccact ggctttggct 180
 ggggacaccc aactccatcc tgaggtgact gtgtatcctg ccaagactca gccctgcag 240
 caccacaacc tcctgggtctg ctctgtgagt ggtttctatc caggcagcat tgaagtcagg 300
 tggttccgga acggccagga agagaaggct ggggtgggtgt ccacaggcct gatccagaat 360
 ggagactgga ccttcagac cctggtgatg ctggaaacag ttctcggag tggagaagtt 420
 tacacctgcc aagtggagca cccaagtgtg atgagccctc tcacagtgga atggagagca 480
 cggcttgaat ctgcacagag caagatgctg agtggagtcg ggggctttgt gctgggcctg 540
 ctcttccttg gggccgggtt gttcatctac ttcaggaatc agaaaggaca ctctggactt 600
 cagccaacag gattcctgag ctgaagtga gatgaccaca ttcaaggaaa aaccttctgc 660
 ccagctttg caggatgaaa cacttccccg cttggctctc attcttcac aagagagacc 720
 tttctccgga cctgggttgc actggttcag caactctgca gaaaatgtcc tccctgtgg 780
 ctgcctcagc tcatgccttt ggccgaagt cccagcattg atggcagccc ctcatcttcc 840
 aagttttgtg ctccccctta cctaacgctt cctgcctccc atgcatctgt actcctcctg 900

23

tgccacaaaac acattacatt attaaatggt tctcaaakat gga 943

<210> 14
 <211> 487
 <212> DNA
 <213> Homo sapien

<400> 14
 ggattcagag gtccagccca ctggcctctt cccactggac tccatctgac tccccatcc 60
 ctctctgtcc ccagctttgc tatcaacttc aaggtgggct cctcagggga catagctctg 120
 cacattaatc cccgcatggg caacgggtacc gtggtccgga acagccttct gaatggctcg 180
 tggggatccg aggagaagaa gatcaccac aaccattttg gtcccgga gttctttgat 240
 ctgtccattc gctgtggctt ggatcgcttc aaggtttacg ccaatggcca gcacctcttt 300
 gactttgccc atcgctctc ggccttcag aggggtggaca cattggaaat ccagggtgat 360
 gtcaccttgt cctatgtcca gatctaactc attcctgggg ccataactca tgggaaaaca 420
 gaattatccc ctaggactcc tttctaagcc cctaataaaa tgtctgaggg tgtctcatga 480
 aaaaaaa 487

<210> 15
 <211> 3870
 <212> DNA
 <213> Homo sapien

<400> 15
 catccaatga gacaccagct caggttactg caggggacac actataaagc cctgagctca 60
 gggaggagct ccctccaggc tctatattta gagccgggta ggggagcgca gcggccagat 120
 acctcagcgc tacctggcgg aactggattt ctctcccgcc tgccggcctg cctgccacag 180
 ccggactccg ccaactccgt agcctcatgg ctgcaacctg tgagattagc aacattttta 240
 gcaactactt cagtgcgatg tacagctcgg aggactccac cctggcctct gttccccctg 300
 ctgccacctt tggggccgat gacttggtac tgaccctgag caacccccag atgtcattgg 360
 agggtagaga gaaggccagc tggttggggg aacagcccca gttctggctg aagacgcagg 420
 ttctggactg gatcagctac caagtggaga agaacaagta cgacgcaagc gccattgact 480
 tctcacgatg tgacatggat ggcgccaccc tctgcaattg tgcccttgag gagctgcgtc 540
 tgggtctttg gctctgggg gaccaactcc atgcccagct gcgagacctc acttccagct 600
 cttctgatga gctcagttgg atcattgagc tgctggagaa ggatggcatg gccttccagg 660
 aggccctaga ccagggccc ttgaccagg gcagcccctt tgcccaggag ctgctggagc 720
 acggtcagca agccagcccc taccaccccg gcagctgtgg cgcaggagcc ccctcccctg 780
 gcagctctga cgtctccacc gcagggactg gtgcttctcg gagctccac tcctcagact 840

ccggtggaag tgacgtggac ctggatccca ctgatggcaa gctcttcccc agcggtagagt	900
cgagggaggt ccccaagagg gcgtcccatt tagcaatgca cagggggccc ggctcttcct	960
gcagcctttt cctgtagagg ggctactctc cctaactccc ctcttgcccc tccttgacct	1020
tccaccaccg tccccacaga tggttttcgt gactgcaaga aggggggatcc caagcacggg	1080
aagcggaaac gagggccggc ccgaaagctg agcaaagagt actgggactg tctcgagggc	1140
aagaagagca agcacgggtga gctccggggg cacgtgggtc ctccctgcgc cgggctgagc	1200
ggcttcctgg ggcactgcgg gttgttgca gttatcccttc tcccgttttc tctggcctcc	1260
gcatggcctt tggtaaggct gtgcacaagc tgggggctct atgggtatcg tcaccacctt	1320
attgcagagc ctggccttgg ggtcctggag aggaggagga aataaggctc ccagtgggag	1380
gctcatggta ccagagtcct gtccactgac tccagtgtcc tgtccactga ctccagttct	1440
ctctgcactt ggccactgtc ctgccctctg ggacaccctc aatgtgagga ggcagctggg	1500
gggtcttagg tgggctgagg agaaaagcag tcaactgcagt acccgcacag agggcactgc	1560
ggggctctct gagaggcttg ctgcatgctg tggccaagtc agcagtgcac tggggcgggc	1620
agggctggct ggccttgggt gagaggggac acctggatgg caaactgatg gaggctggcc	1680
ttgcagcgcc cagaggcacc cacctgtggg agttcatccg ggacatcctc atccaccg	1740
agctcaacga gggcctcatg aagtgggaga atcggcatga aggcgtcttc aagtctctgc	1800
gctccgaggc tgtggcccaa ctatggggcc aaaagaaaaa gaacagcaac atgacctacg	1860
agaagctgag ccgggcatg aggtactact acaaacggga gatcctggaa cgggtggatg	1920
gccggcgact cgtctacaag tttggcaaaa actcaagcgg ctggaaggag gaagaggttc	1980
tccagagtgc gaactgaggg ttggaactat acccgggacc aaactcacgg accactcgag	2040
gcctgcaaac ctctctggga ggacaggcag gccagatggc ccctccactg gggaatgctc	2100
ccagctgtgc tgtggagaga agctgatgtt ttggtgtatt gtcagccatc gtctggggac	2160
toggagacta tggcctcgcc tccccaccct cctcttgga ttacaagccc tggggtttga	2220
agctgacttt atagctgcaa gtgtatctcc ttttatctgg tgctcctca aaccagttct	2280
cagacactaa atgcagacaa caccttcctc ctgcagacac ctggactgag ccaaggaggc	2340
ctggggaggc cctaggggag caccgtgatg gagaggacag agcaggggct ccagcacctt	2400
ctttctggac tggcgttcac ctccctgctc agtgcttggg ctccacgggc aggggtcaga	2460
gcactcccta atttatgtgc tatataaata tgtcagatgt acatagagat ctattttttc	2520
taaaacattc ccctccccac tcctctccca cagagtgtct gactgttcca ggccctccag	2580
tgggctgatg ctgggaccct taggatgggg ctcccagctc ctttctcctg tgaatggagg	2640

25

cagagacctc caataaagtg ccttctgggc tttttctaac ctttgtctta gctacctgtg 2700
 tactgaaatt tgggcctttg gatcgaatat ggtcaagagg ttggagggga ggaaaatgaa 2760
 ggtctaccag gctgaggggtg agggcaaagg ctgacgaaga ggggagttac agatttcctg 2820
 tagcaggtgt gggcttacag acacatggac tgggctggga ggcgagcaaa ggaagcagct 2880
 gagactgttg gagaacgctt acaagacttc atgcaagcaa ggacatgaac tcagaacact 2940
 gaggtcagaa gcatcctgct gtcatgacac cgctcgagtg accttgacct tgaccaagtc 3000
 tgtcctgttt aggactgatt tttcctatta ggctaggggtt tggacctgat gttctcaaga 3060
 tgtctagaat tgcattggctg gccttggtga atagatgggtt ttgcattcca gccaaagtgtg 3120
 ctgtaaaactg tataatctgta atatgaatcc cagcttttga gtctgacaaa atcagagtta 3180
 ggatcttgta aaggaaaaaa aaaaaaaca aaacaaaatg gagatgagta cttgctgaga 3240
 aagaatgagg gaaggagttg gcatttggtg aaagtatagt ctttttctct ttttttttta 3300
 attgcaactt ttactttaga tttaggaggt cgtgcgcagg tttgttacat gggatatattg 3360
 tgtgatgctg agcttgggat gcgaatgatc ctgtcaccca ggtagtgagt atagcaccca 3420
 gtgaaactgt agtctcatgc caggcactgt gctagccac tctggctcat ttaatcctct 3480
 cctaagaaga gaggagacac agcgtcccca tttgacagat gcagaaagag gttccacagg 3540
 tgtgccttga ttctgtccta aaaccgtttc ccggaagctt ttcttggtgt gggcgcttct 3600
 aacctaatacc tcaatcgatt ccagaactat tactctgttt ccacagtgat actgtgtcta 3660
 ggttttaggg aggacagttc attgatgtta cttaagaatg ctttccagggt ggaaagttcc 3720
 ttaagtttga ggcttcaa atccatacagc acattaaaat cccattcatg agtttgaaat 3780
 actgctctgt tgtcttgaa ataccaatca gattgttggc tgaagtgatg tggataaaga 3840
 agggatctta gaaaaactaa agcttgtgtg 3870

<210> 16

<211> 3289

<212> DNA

<213> Homo sapien

<400> 16

catccaatga gacaccagct cagggttactg caggggacac actataaagc cctgagctca 60
 gggaggagct ccctccaggc tctatatatta gagccgggta ggggagcgca gcggccagat 120
 acctcagcgc tacctggcgg aactggattt ctctcccgcc tgccggcctg cctgccacag 180
 cgggactccg ccactccggg agcctcatgg ctgcaacctg tgagattagc aacattttta 240
 gcaactactt cagtgcgatg tacagctcgg aggactccac cctggcctct gttccccctg 300
 ctgccacctt tggggccgat gacttggtac tgaccctgag caacccccag atgtcattgg 360

agggtacaga	gaaggccagc	tgggtggggg	aacagcccca	gttctggtcg	aagacgcagg	420
ttctggactg	gatcagctac	caagtggaga	agaacaagta	cgacgcaagc	gccattgact	480
tctcacgatg	tgacatggat	ggcgccaccc	tctgcaattg	tgccttgag	gagctgogtc	540
tggctctttg	gcctctgggg	gaccaactcc	atgccagct	gcgagacctc	acttccagct	600
cttctgatga	gctcagttgg	atcattgagc	tgctggagaa	ggatggcatg	gccttccagg	660
aggccctaga	cccaggggccc	tttgaccagg	gcagcccctt	tgcccaggag	ctgctggacg	720
acggctcagca	agccagcccc	taccaccccg	gcagctgtgg	cgcaggagcc	ccctcccctg	780
gcagctctga	cgtctccacc	gcaggaacag	gaacaggctg	ggaagtgtgt	cctgagagcc	840
agcagcgtgg	ttgagcagag	ggtgggcccg	caggggactt	actctgacct	cgcccccccg	900
actggtgctt	ctcgagctc	ccactcctca	gactccggtg	gaagtgacgt	ggacctggat	960
cccactgatg	gcaagctctt	ccccagcgat	ggttttcgtg	actgcaagaa	gggggatccc	1020
aagcacggga	agcggaaacg	aggccggccc	cgaaagctga	gcaaagagta	ctgggactgt	1080
ctcgagggca	agaagagcaa	gcacgcgccc	agaggcaccc	acctgtggga	gttcatccgg	1140
gacatcctca	tccacccgga	gctcaacgag	ggcctcatga	agtgggagaa	tcggcatgaa	1200
ggcgtcttca	agttcctgcg	ctccgaggct	gtggcccaac	tatggggcca	aaagaaaaag	1260
aacagcaaca	tgacctacga	gaagctgagc	cgggccatga	ggtactacta	caaacgggag	1320
atcctggaac	gggtggatgg	ccggcgactc	gtctacaagt	ttggcaaaaa	ctcaagcggc	1380
tggaaggagg	aagaggttct	ccagagtcgg	aactgagggt	tggaactata	cccgggacca	1440
aactcacgga	ccactcgagg	cctgcaaac	ttcctgggag	gacaggcagg	ccagatggcc	1500
cctccactgg	ggaatgctcc	cagctgtgct	gtggagagaa	gctgatgttt	tgggtgtattg	1560
tcagccatcg	tcctgggact	cggagactat	ggcctcgct	ccccaccctc	ctcttggaat	1620
tacaagccct	ggggtttgaa	gctgacttta	tagctgcaag	tgtatctcct	tttatctggt	1680
gcctcctcaa	accagctctc	agacactaaa	tgacagacaac	accttcctcc	tgcagacacc	1740
tggactgagc	caaggaggcc	tggggaggcc	ctaggggagc	accgtgatgg	agaggacaga	1800
gcaggggctc	cagcaccttc	tttctggact	ggcgttcacc	tcctgctca	gtgcttgggc	1860
tccacgggca	ggggtcagag	cactccctaa	tttatgtgct	atataaatat	gtcagatgta	1920
catagagatc	tattttttct	aaaacattcc	cctccccact	cctctcccac	agagtgtctg	1980
actgttccag	gcctccagt	gggctgatgc	tgggaccctt	aggatggggc	tcccagctcc	2040
tttctcctgt	gaatggaggc	agagacctcc	aataaagtgc	cttctgggct	ttttctaacc	2100
tttgtcttag	ctacctgtgt	actgaaatth	gggccttttg	atcgaatatg	gtcaagagggt	2160
tggaggggag	gaaaatgaag	gtctaccagg	ctgagggtga	gggcaaaggc	tgacgaagag	2220

```

gggagttaca gatttcctgt agcaggtgtg ggcttacaga cacatggact gggctgggag 2280
gcgagcaaag gaagcagctg agactgttgg agaacgctta caagacttca tgcaagcaag 2340
gacatgaact cagaacactg aggtcagaag catcctgctg tcatgacacc gctcgagtga 2400
ccttgacctt gaccaagtct gtccctgttta ggactgattt ttcctattag gctagggttt 2460
ggacctgatg ttctcaagat gtctagaatt gcatggctgg ccttgtggaa tagatgggtt 2520
tgcatccag ccaagtgtgc tgtaaactgt atatctgtaa tatgaatccc agcttttgag 2580
tctgacaaaa tcagagttag gatccttgtaa aggaaaaaaa aaaaaaaca aaaaaatgg 2640
agatgagtac ttgctgagaa agaatgaggg aaggagttgg catttggtga aagtatagtc 2700
ttttctctt ttttttttaa ttgcaacttt tacttttagat ttaggaggtc gtgcgcaggt 2760
ttgttacatg ggtatattgt gtgatgctga gcttgggatg cgaatgatcc tgtcaccag 2820
gtagtgagta tagcaccag tgaaactgta gtctcatgcc aggcactgtg ctagccact 2880
ctggctcatt taatcctctc ctaagaagag aggagacaca gcgtcccat ttgacagatg 2940
cagaaagagg ttccacaggt gtgccttgat tctgtcctaa aaccgtttcc cggaagcttt 3000
tcctgggtgtg ggcgttcta acctaactc caatcgattc cagaactatt actctgtttc 3060
cacagtgata ctgtgtctag gttttaggga ggacagttca ttgatgttac ttaagaatgc 3120
tttccaggtg gaaagttcct taagtttgag gcttcaaatt ccatacagca cattaaaatc 3180
ccattcatga gtttgaaata ctgctctgtt gtcttgaaa taccaatcag attgttggt 3240
gaagtgatgt ggataaagaa gggatcctag aaaaactaaa gcttggtgtg 3289

```

<210> 17

<211> 1390

<212> DNA

<213> Homo sapien

<400> 17

```

aattcaagaa tgtcactgcc agttaaact gaattgttag gggatttaga aataccagca 60
gtgcccatac tccatagcat ggtgcaaaaa tcccaggcg tgtcatttgg gatcagcact 120
gattctgagg ttctgacaca ctacaacatc actgggaaca ccatctgcct ctttcgcctg 180
gtagacaatg aacaactgaa ttagaggac gaagacattg aaagcattga tgccaccaa 240
ttgagccgtt tcattgagat caacagcctc cacatggtga cagagtaca ccctgtgact 300
gtgattgggt tattcaacag cgtaattcag attcatctcc tcctgataat gaacaaggcc 360
tcccagagt atgaagagaa catgcacaga taccagaagg cagccaagct cttccagggg 420
aagattctct ttattctggt ggacagtgg atgaaagaaa atgggaagg gatatcattt 480
ttcaaactaa aggagtctca actgccagct ttggcaattt accagactct agatgacgag 540

```



```

tgggatacac tgcccacagc agaagtttcc gtagagcatg tgcaaaactt ttgtgatgga      600
ttcctaagtg gaaaattggt gaaagaaaat cgtgaatcag aaggaaagac tccaaagggtg      660
gaactctgac ttctccttgg aactacatat ggccaagtat ctactttatg caaagtaaaa      720
aggcacaact caaatctcag agacactaaa caacaggatc actaggcctg ccaaccacac      780
acacacgcac gtgcacacac gcacgcacgc gtgcacacac acacgcgcac acacacacac      840
acacacacag agcttcattt cctgtcttaa aatctcgttt tctcttcttc cttcttttaa      900
atttcatatc ctactccct atccaatttc cttcttatcg tgcattcata ctctgtaagc      960
ccatctgtaa cacacctaga tcaaggcttt aagagactca ctgtgatgcc tctatgaaag     1020
agaggcattc ctagagaaaag attgttccaa tttgtcattt aatatcaagt ttgtatactg     1080
cacatgactt acacacaaca tagttcctgc tcttttaagg ttacctaagg gttgaaactc     1140
taccttcttt cataagcaca tgtccgtctc tgactcagga tcaaaaacca aaggatgggt     1200
ttaaacacct ttgtgaaatt gtctttttgc cagaagttaa aggctgtctc caagtccctg     1260
aactcagcag aaatagacca tgtgaaaact ccatgcttgg ttagcatctc caactcccta     1320
tgtaaataca caacctgcat aataaataaa aggcaatcat gttataggag aaggctggca     1380
tctctttgca                                     1390

```

```

<210> 18
<211> 1363
<212> DNA
<213> Homo sapien

```

```

<400> 18
accagaccta ggaattccta gaaaaatagt caggaagcat ttagacacat caaatgttaa      60
acgagtcctg attatgatga taatgatgat gattttggtg gttgcaatag caaagcctta     120
agtatgaagg agacgtgcca gctggaaata caggtagaca atgaacaact gaatttagag     180
gacgaagaca ttgaaagcat tgatgccacc aaattgagcc gtttcattga gatcaacagc     240
ctccacatgg tgacagagta caaccctgtg actgtgattg ggttattcaa cagcgtaatt     300
cagattcatc tcctcctgat aatgaacaag gcctccccag agtatgaaga gaacatgcac     360
agataccaga aggcagccaa gctcttcocag gggaagattc tctttattct ggtggacagt     420
ggtatgaaag aaaatgggaa ggtgatatca tttttcaaac taaaggagtc tcaactgccca     480
gctttggcaa ttaccagac tctagatgac gagtgggata cactgccac agcagaagtt     540
tcogtagagc atgtgcaaaa cttttgtgat ggattcctaa gtggaaaatt gttgaaagaa     600
aatcgtgaat cagaaggaaa gactccaaag gtggaactct gacttctcct tggaactaca     660
tatggccaag tatctacttt atgcaaagta aaaaggcaca actcaaactc cagagacact     720

```

```

aaacaacagg atcactaggc ctgccaacca cacacacacg cacgtgcaca cacgcacgca      780
cgcgtgcaca cacacacgcg cacacacaca cacacacaca cagagcttca tttcctgtct      840
taaaatctcg ttttctcttc ttcttctttt taaatttcat atcctcactc cctatccaat      900
ttccttctta tcgtgcattc atactctgta agcccatctg taacacacct agatcaaggc      960
tttaagagac tcactgtgat gcctctatga aagagaggca ttcttagaga aagattgttc     1020
caatttgtca tttaatatca agtttgtata ctgcacatga cttacacaca acatagtacc     1080
tgctctttta aggttaccta agggttgaaa ctctaccttc tttcataagc acatgtccgt     1140
ctctgactca ggatcaaaaa ccaaaggatg gttttaaaca cctttgtgaa attgtctttt     1200
tgccagaagt taaaggctgt ctccaagtcc ctgaactcag cagaaataga ccatgtgaaa     1260
actccatgct tggtttagcat ctccaactcc ctatgtaaata caacaacctg cataataaat     1320
aaaaggcaat catgttatag gagaaggctg gcctctcttt gca                          1363

```

```

<210> 19
<211> 2382
<212> DNA
<213> Homo sapien

```

```

<400> 19
gcctcccctg ctgactgctg tagctagcct tgccccatcc cacccttcc ctctccatcc      60
tcgctctttt ctctcctggt ttatggtttg tctcttcctc aaatgcaatt tgcaaaactc     120
tcctgaacga aacaacagct tctgggaggt ggtggcagct gcaggcacag tggcgccgtg     180
ggaaatcgtg aaaaaccagc aattcattct tggaggggccc accaggactg atatctgccca     240
gggagagctg ggagactgct ggctattagc cgccatcgcc tcccttacgc ttaatcaaaa     300
agcactggcc agagtcatcc cccaggacca aagctttggc cctgggttatg ccgggatatt     360
ccatttccag ttctggcagc acagtgagtg gctggacgtg gtgatcgatg accgcctgcc     420
caccttcagg gaccgcttgg ttttcctcca ctctgccgac cacaatgagt tctggagcgc     480
cttgctggaa aaagcctacg ccaagctaaa tgggagctat gaagctctga agggaggcag     540
cgccatcgag gccatggaag acttcaccgg ggggtgtggca gagaccttcc aaactaaaga     600
ggcccccgag aacttctatg agattctaga gaaggctttg aagagaggct ccctgctggg     660
ctgcttcatt gataccagaa gtgctgcaga atctgaggcc cggacgccgt ttggctttat     720
taagggatcat gcctacagtg taacgggaat tgaccaggta agcttccgag gccagagaat     780
cgagctcatc cgaatccgga acccttgggg ccaggtttag tggaaagggt cgtggagcga     840
caggatggca tttaaggact tcaaggccca ctttgataaa gtggagatct gcaacctcac     900
tcccgatgcc ctggaggaag acgcatcca caaataaaat tgtctctgac tgagaaagat     960

```

gaggggacagg aggagtgtag tttccttgta gccctgatgc agaaagatag aaggaaactc 1020
 aagagatttg gtgccaatgt gctgacaatc ggctatgcca tttatgagtg ccctgacaaa 1080
 gacgaacacc tgaacaaaga cttcttcaga taccacgctt ctggggccag aagcaagacg 1140
 ttcatacaacc tgagagaagt ctccgaccgg ttcaagctgc cccctgggga gtacatcctg 1200
 attcccagca cttttgagcc ccaccaggaa gctgatttct gtctgagaat cttttcagag 1260
 aaaaaagcca ttaccggga tatggatgga aatgtagaca ttgaccttc tgagcctcca 1320
 aagccaactc cacctgacca ggagacagag gaggagcagc ggtttcgggc tctgtttgaa 1380
 caagtcgctg gtgaggacat ggaggtgaca gcagaggaac ttgagtatgt tttaaatgct 1440
 gtgctgcaaa agaaaaagga catcaaattc aagaagctaa gcctgatctc ctgtaaaaac 1500
 atcatttccc tgatggacac cagcggcaat gggaagctgg agtttgatga attcaaagtg 1560
 ttctgggaca agctgaagca gtggattaac cttttccttc ggtttgatgc tgacaagtcc 1620
 ggcacatgt ctacctatga actacggact gcaactgaaag ctgcaggctt tcagctgagc 1680
 agccacctcc tgcagctgat tgtgctcagg tatgctgatg aggagctcca gctggacttc 1740
 gatgaactcc tcaactgcct ggtccggctg gagaatgcga gccgggtgtt ccaggctctc 1800
 agtacaaaga acaaggagtt cattcatctc aatataaatg agttcatcca tttgacaatg 1860
 aacatctgag gctgccttgt agagatgcag cctgccacgc tgaatcttgg cttctggacc 1920
 ttgaccttca gaacttctct tgggtgtggaa ccattacgcc cagggttcac tcccctctca 1980
 tcgtccggcc ttctcccttc atcttgatct gggaagaatg aaatgaactc agctacactc 2040
 tctgattttg tgctactcct ttgtaaagtc actgccttaa gggggctgat ggcgccacct 2100
 gtgccttaca tccagggttc ggcatcacta gctttccac actctacttt ccttatttcc 2160
 ttocatlaag aattactcag agttctaacg cacagaatcc tgacttccat gtagctccag 2220
 tcattgtgat cagacatcct ttataaaaca tgtttttata aatgtgtatg tggaataaga 2280
 tgaggaggaa aaggagttag gtcataatct agcatttctg catcataagt gtgcttcctt 2340
 atcaggggaag acatcaggta gttccgataa ttggacaaga gt 2382

<210> 20
 <211> 377
 <212> DNA
 <213> Homo sapien

<400> 20
 gcccttagcg tggctcgggc cgaggtacgt gtagtgggccc ggaatggaga atccagtga 60
 ctggacctac aaggcatccg aatcgactca gatattagcg gcacctcaa gtttgctgt 120
 gagagcattg tggaggaata cgaggatgaa ctattgaat tcttttcccg agaggctgac 180

aatgttaaag acaaactttg cagtaagcga acagatcttt gtgaccatgc cctgcacata 240
 tcgcatgatg agctatgaac cactggagca gcccacactg gcttgatgga tcacccccag 300
 gaggggaaaa tgggtggcaat gccttttata tattatgttt ttactgaaat taactgaaaa 360
 aatatgaaac caaaagt 377

<210> 21
 <211> 1056
 <212> DNA
 <213> Homo sapien

<400> 21
 ggtaatagag cttcgacttc gacggccgcc attttctttc tttcttagct gttagctgag 60
 aggaagtctc tgaacaggcg gcagcggctc ttatagtgca accatggcag actattcaac 120
 agtgccctccc ccctcttctg gtcagctgg tggcgggtggg ggccggcggg gtggtggagg 180
 agttaacgac gctttcaaag atgcactgca gagagcccg cagattgcag caaaaattgg 240
 aggtgatgca gggacatcac tgaattcaaa tgactatggt tatggggggac aaaaaagacc 300
 tttagaagat ggagatcaac cagatgctaa gaaagttgct cctcaaaatg actcttttgg 360
 aacacagtta ccaccgatgc atcagcagca aagcagatct gtaatgacag aagaatacaa 420
 agttccagat ggaatggttg gattcataat tggcagagga ggtgaacaga tctcacgcat 480
 acaacaggaa tctggatgca aaatacagat agctcctgac agtgggtggc ttccagaaag 540
 gtccctgtatg ttaactggaa cacctgaatc tgtccagtca gcaaacggg tactggacca 600
 gattgttgaa aaaggaagac cagctcctgg cttccatcat ggcgatggac cgggaaatgc 660
 agttcaagaa atcatgattc cagctagcaa ggcaggatta gtcattggaa aagggggaga 720
 aactattaaa cagcttcagg aacgggctgg agttaaaatg gttatgattc aagacggggg 780
 agcggccgcc gcggccgtat ttttcacatc catcataagg ttggcattca ataaggaaaa 840
 agttctaact ccagtattaa attgtacata aatcccaaat gttcttaaag aacactcagg 900
 gacatgtttg ttgcctggca ttggtaatga aagggtgggt tttgaaactt gaaatttcac 960
 cattgggtttt tttcctatca tttctgcata tccagcaaaa ggaatctcat gttgactcct 1020
 ggcagagttc agtggcttca gtctgtctat ctgcgg 1056

<210> 22
 <211> 772
 <212> DNA
 <213> Homo sapien

<400> 22
 acaaagttaa atttcaacac attctctatg ctagtgtgac aaaagcagcc ccataatttg 60

32

```

gttttttattg ttgaccttta caggatgaag gagacaccac aatggctgag cacttcctga 120
cgttgctgggt agtgacctgcc atcaagaaaag attatgggtc ccaggaagac ttcactcaag 180
tgtggaacac caccatgaaa gggctcaagt gctgtggctt caccaactat acggattttg 240
aggactcacc ctacttcaaa gagaacagtg cctttccccc attctgttgc aatgacaacg 300
tcaccaacac agccaatgaa acctgcacca agcaaaaggc tcacgaccaa aaagtagagg 360
gttgcttcaa tcagcttttg tatgacatcc gaactaatgc agtcaccgtg ggtggtgtgg 420
cagctggaat tgggggcctc gagctggctg ccatgattgt gtccatgtat ctgtacctgc 480
ccggggggcc agcgtggctg cggccgaggt acagcgacag cgtcggcagg gtcagcttcc 540
ccagcctgggt ctgcttcctg atgcggcttg aagccatggc aaagaccttc cgcaactctc 600
taaggatgga aaaggactct acctgacaga aatggagtgg atgagcctgg tcatgtctgg 660
ttgccaggag gagcaagcaa agtcagcagg acatgaagtt gtattaaatg gacttcgtga 720
ttttgttttg cactaaagtt tctgtgattt aacaattaaa ttctgttagc ac 772

```

```

<210> 23
<211> 1594
<212> DNA
<213> Homo sapien

```

```

<400> 23
gggctttttc gagcccatag gtcgggacag cccaggactg ggcattgggag gcttggagtg 60
gctctgggta gggggccagc cagtgccta ggggacttca tataccctct ctccctttgc 120
aggaaacccc ctcggttca ggacttccgc tgcttagctg tgctgggccc gggacacttt 180
gggaaggtag tgggctgaag agggtggtat gggacaggat tgggggcctc atcacatgag 240
ccgggaggac ctgatctgtg ggggcggtaa aggtccctg gtctggcca cctggagcac 300
aacctctctc tggccccagg tcctcctggg ccagttcaag gggacaggga aatactacgc 360
catcaaagca ctgaagaagc aggaggtgct cagccgggac gagatagaga gcctgtactg 420
cgagaagcgg atcctggagg ctgtgggctg cacagggcac cctttcctgc tctccctcct 480
tgctgcttc cagacctca gccatgcctg ctttgtgact gagtttgtgc ctggtggtga 540
cctcatgatg cagatccacg aggatgtctt ccccgagccc caggcccgtc tctacgtggc 600
ttgtgttgct ctggggctgc agttcttaca cgagaagaag atcatttaca gggacctgaa 660
gttgataaac cttctgctgg atgccaggg attcctgaag atcgcagact ttggactctg 720
caaggaaggg atcggcttcg gggaccggac tagcaccttc tgtggcacc cggagttcct 780
ggctcccag gtgctgacct aggaggcata cacacgggct gtggactggg gggggctggg 840
tgtgctgctc tacgagatgc tgggtgggtga gtgcccgttc ccaggggaca cagaggaaga 900

```

33

```

gggtgtttgac tgcatacgtca acatggacgc cccctacccc ggctttctgt cgggtgcaagg      960
gcttgagttc attcagaagc tcctccagaa gtgcccggag aagcgccctcg gggcaggtga      1020
gcaggatgcc gaggagatca aggtccagcc attcttcagg accaccaact ggcaagccct      1080
gctcgcccgcc accatccagc cccctctcgt gcctaccctg tgtggccctg cggacctgog      1140
ctactttgag ggcgagttca cagggtcgcc gcctgccctg accccacctg cccccacag      1200
cctcctcact gcccgcacaac aggcgcctt ccgggacttc gactttgtgt cagagcgatt      1260
cctggaaccc tgagggcatc tcctggcacc tctgtcccct tccccacag actgttagag      1320
cctctgctcg ttcacccgtg cgccctgcct ggaggtccag gccttgctgg gtactttctga      1380
gcccttggga ttcaaagtgg cagccatggg gccactgttg tgggctttgc tcagtgtcac      1440
tgggcaaagt gtgtcccttc cccctccagc tcgcccctct ctacctccca gcgagacctg      1500
gccagaaaag ggtgccgcag caaggagtga tatggtttgt ctttttaaga ctggacttgc      1560
tttatattaa atttgtaaaa gtgaaaaaaaa aaag                                1594

```

```

<210> 24
<211> 2365
<212> DNA
<213> Homo sapien

```

```

<400> 24
accgcacctg gcctagtata cattcttgta gtgactaata tctagtctgg gccaacct      60
ccgaggagag agacaatttt ggattagccc acattacacc aacaacgtgc gagacaaaga      120
gagacttgag gggcttggtc gaggaggccc agcgcgcttag aggcgggagc caggttgtag      180
agggggtcaa agttagagga ggcggccagc tccaccggct gcacccggct gggcgacccg      240
gcaaccttca gggggcgctg tttcccctac cctgtcccct aactggccgg ctcccgcggg      300
cgcgcgggcg ggaaggccag aggacctggg cgcgggcgat gtgcctcctg agcgtccaaa      360
ccgggggtga ggcgcggtca cggccagcgg gaaccgcagg cgccgaagcc cgggtactgg      420
gccagaatc ccgcggaatt ttggatccga gggaggcgct ggggcgcggg acctcgggcg      480
tgggggtccc ggcgctggat cggcgcgga cggaggcggc gctggtcccg cgggcccagcg      540
ggtctcggga gggggcgccc gatccgcgct ctccggcgcc gcttcccggg aagtttcaag      600
tttgaaagtc ctggcgagag gtctgcggtc tccgggaccg gagtggctga gaggagggcc      660
ccaagcggcc ggagcggcgc catggaggag ggggcgcccgc ggcagcctgg gccgagccag      720
tggcccccag aggatgagaa ggaggtgatc cgccggggcca tccagaaaga gctgaagatc      780
aaggaggggg tggagaacct gcggcgcgct gccacagacc gccgccactt gggccatgtg      840
cagcagctgc tgcggtcctc caaccgcccgc ctggagcagc tgcattggcg gctgcgggag      900

```

34

```

ctgcacgccc gaatcctgct gcccgccctt gggcctggcc cagctgagcc tgtggcctca    960
ggaccccggc cgtgggcaga gcagctcagg gctcggcacc tagaggctct cggaggcag    1020
ctgcatgtgg agctgaaggt gaagcagggg gctgagaaca tgaccacac gtgcgccagt    1080
ggcaccacca aggagaggaa gctcctggca gctgcccagc agatgctgcg ggacagccag    1140
ctgaaggtgg ccctgctgcg gatgaagatc agcagcctgg aggccagtgg gtccccggag    1200
ccagggcctg agctgctggc ggaggagcta cagcatcgac tgcacgttga ggcagctgtg    1260
gctgagggcg ccaagaacgt ggtgaaactg cttagtagcc ggagaacaca ggaccgcaag    1320
gcactggctg agggccaggc ccagctacag gagtcccttc agaaactgga cctcctgctc    1380
ctggccttgg agcagctgct ggagcaactg cctcctgccc accctttgct cagcagagtg    1440
acccgagagt tgcgggctgc ggtgcctgga tacccccagc cttcaggggc acctgtgaag    1500
cccaccgccc taacaggggc actgcaggtc cgcctcctgg gctgtgaaca gttgctgaca    1560
gccgtgcctg ggcgctcccc agcgcccgca ctggccagca gccctccga gggctggctt    1620
cggaccaagg ccaagcacca gcgtggccga ggcgagcttg ccagcgaggt gctggctgtg    1680
ctaaaggtgg acaaccgtgt tgtggggcag acgggctggg ggaggtggc cgaacagtcc    1740
tgggaccaga ctttgtcat cccactggag cgagcccgtg agctggagat tggggtacac    1800
tggggggact ggcggcagct atgtggcgtg gccttcctga gacttgagga ctccctggac    1860
aatgcctgtc accaactgtc cctcagcctg gtaccgcagg gactgctttt tgcccagggtg    1920
accttctgct atcctgtcat tgagaggcgg ccccggtgc agaggcagga acgcatcttc    1980
tctaaacgca gaggccgctt tccgggactt cgactttgtg tcagagcgat tcctggaacc    2040
ctgagggcat ctctggcac ctctgtcccc ttccccaca gactgttaga gcctctgctc    2100
gttcacccgt gcgcctgcc tggaggtcca ggccttgctg ggtacttctg agcccttggg    2160
attcaaagtg gcagccatgg ggccactgtt gtgggctttg ctcagtgtca ctgggcaaag    2220
tgtgtccctt cccctccag ctgcctctct tctacctccc agcgagacct ggcccagaaa    2280
gggtgccgca gcaaggagtg atatggtttg tctttttaag actggacttg ctttatatta    2340
aatttgtaaa agtgaaaaaa aaaag                                     2365

```

<210> 25

<211> 988

<212> DNA

<213> Homo sapien

<400> 25

```

gagcaagctg gtgtcagagc ctggacctac agcgctgttg gtggaggtcc tgccctccagg    60

```

```

aatagatgga catggcctgg cagatgatgc agctgctgct tctggctttg gtgactgctg    120

```

35

```

cggggagtgcc ccagcccagg agtgcgcggg ccaggacgga cctgctcaat gtctgcatga 180
acgccaaagca ccacaagaca cagcccagcc ccgaggacga gctgtatggc caggtggggag 240
ctcctcaagg gccctcccca ggaagtgttc ctctggatga cctacctggg gcagaggagc 300
cagaatatgg aggagatggc tgtggtgggg agagacttag tcctgtgtct tccccacca 360
gtgcagtccc tggaagaaga atgcctgctg cacggccagc accagccagg agctgcacaa 420
ggacacctcc cgcctgtaca actttaactg ggatcactgt ggtaagatgg aaccacctg 480
caagcgccac tttatccagg acagctgtct ctgagtgtct acccaacctg ggccctgga 540
tccggcaggt caaccagagc tggcgcaaag agcgattct gaacgtgcc ctgtgcaaag 600
aggactgtga gcgctgggtg gaggactgtc gcacctcta cacctgcaa agcaactggc 660
acaaggctg gaattggacc tcagggatta atgagtgtcc ggccggggcc ctctgcagca 720
cctttgagtc ctacttcccc actccagccg cctttgtga aggcctctgg agccactcct 780
tcaaggtcag caactatagt cgagggagcg gccgctgcat ccagatgtgg tttgactcag 840
cccagggcaa cccaatgag gaggtggcca agttctatgc tgcggccatg aatgctgggg 900
ccccgtctcg tgggattatt gattcctgat ccaagaaggg tcctctgggg ttcttccaac 960
aacctattct aatagacaaa tccacatg 988

```

<210> 26

<211> 1591

<212> DNA

<213> Homo sapien

<400> 26

```

ccaagccac gcggttccgg gtccaagat ttggctccaa gagctattcg cagagaaaca 60
gcctcgaca aaaagccacc gccccgaaa ccgcgggaa atctgtttcc tgtgaaaggc 120
ctggcctccg ggcatggcg gttccctga tcctctctcc caaatTTTcc ggcaggggat 180
tgatcgaggc gacatttagg actgggggtg gcgaggaggt ggcggttctc gtccaagtt 240
acaggtagg acgttcaggc caaggcgtag ccaagatcgc gccgccctgt agcttgagga 300
ggcgccggga ttcgaaccaa ggctgtgccc aatcctaagc cctgcgaggt cttgtggaac 360
cgacatgacc cactctttgg tttgtccaga gacagtgagc agggtagatt cagtgtgaa 420
tcgcaacact cggcagtttg gaaaaaaaca tcttttcgac caggatgagg agacatgttg 480
gaactcagac cagggcccct ccagtggtg gacgctggag tttcccagc tcatcgtgt 540
ctcccagctg cagatccagt ttcagggtg cttctccagt cgcgggggct gcctggaagg 600
ttcacagggc actcaggctc tccacaagat tgtagatttc tacctgagg acaacaactc 660
gcttcaggat atcctgcccc tgcttctggg gtgggtggtc tgtgcctctg gaagctttgg 720

```


36

```

actcacccaa acccgaatgg gaaccctgat gtgtgatcctt gaacacgtga cctctaggac      780
tccacttttt ctgtaaaatg gtgctgatga ccacctgttc tgtgtgagag gcttagaggg      840
acctgcagct tccccagggt gccacatcg gtggagtgtg agctgggtct ggaaggggtg      900
ggggcctgcg ggtgggaaac cagaaatcac cagtttcctt tgactgcca cgctcacaca      960
ctttcccat accagctgct gaagtggacc ggctgaaggt gacgtttgag gatgccactg     1020
acttttttgg ccgtgtggtc atctaccacc tgggggtgct tggggagaag gtgtgagacc     1080
tctaggggct gtctcctcca ggaagccctc cgggaagcac agcaaagtcc ctcatctctgc     1140
acagaagggt tattggttcc tcttggaag ggtccctcc caccacctgt ccagaagctg     1200
cctttgaagt cagttctggg tttcccagc tctggctgac cattttgttc cctgagtgtc     1260
tgagtcccg caggcggtt cactcagggt cagcgggcac caggttgtct tgggaagagct     1320
tgaggatgtg gttctcgatc acctgttgca ctgagatggg gcagggaata gcgtgggctg     1380
tgagcttgaa tcgggagtgg ggtggaggca caggccaacc tgcgctctcc ccttagggga     1440
caaacaggga cccttcgaga gacctgcatt acagagcaaa gctgggagaa ccgaggactc     1500
accccaggaa cctcaacttc ccctaagttt gtaaaaatgc actttttag cttttcagaa     1560
ttaatataaa aatatttcct accaagcaaa a                                  1591

```

```

<210> 27
<211> 1193
<212> DNA
<213> Homo sapien

```

```

<400> 27
ccaagccac gcggttcccg gtcccaagat ttggctccaa gagctattcg cagagaaaca      60
gcctcgcaca aaaagccacc gccccgaaa cccgcgggaa atctgtttcc tgtgaaaggc     120
ctggcctccg ggcattggcg gtttcctga tctctctcc caaattttcc ggcaggggat     180
tgatcgaggc gacatttagg actggggtgg gcgaggaggt ggcggttctc gtcccaagtt     240
acaggtaggg acgttcaggc caaggcgtag ccaagatcgc gccgccctgt agcttgagga     300
ggcgccggga ttcgaaccaa ggctgtgcc aatcctaagc cctgcgaggt cttgtggaac     360
cgacatgacc cactctttgg tttgtccaga gacagtgagc aggttgagtt cagtgtgaa     420
tcgcaacact cggcagtttg gaaaaaaca tcttttcgac caggatgagg agacatgttg     480
gaactcagac caggttcaca gggcactcag gctctccaca agattgtaga tttctaccct     540
gaggacaaca actcgcttca gactttcccc ataccagctg ctgaagtggg ccggctgaag     600
gtgacgtttg aggatgccac tgactttttt ggccgtgtgg tcatctacca cctgcgggtg     660
cttggggaga aggtgtgaga cctctagggg ctgtctctc caggaagccc tccgggaagc     720

```

37

```

acagcaaagt ccctcattct gcacagaagg tttattgggt cctcttggga aggggtccct 780
cccaccacct gtccagaagc tgcctttgaa gtcagttctg ggtttcccca gctctggctg 840
accattttgt tccctgagtg tctgagtcct ggcaggcggc ttcactcagg gtcagcgggc 900
accagggtgc tctggaagag cttgaggatg tggttctcga tcacctgttg cactgagatg 960
gggcagggaa aagcgtgggc tgtgagcttg aatcgggagt ggggtggagg cacaggccaa 1020
cctgcgctct ccccttaggg gacaaacagg gacccttgca gagacctgca ttacagagca 1080
aagctgggag aaccgaggac tacccccagg aacctcaact tcccctaagt ttgtaaaaat 1140
gcacttttgt agcttttcag aattaatata aaaatatttc ctaccaagca aaa 1193

```

```

<210> 28
<211> 598
<212> DNA
<213> Homo sapien

```

```

<400> 28
acaggtgccc atgcctctgg ctgcattggg gaggatcccc agggcatacc ctgccccttg 60
atgaggccca cccacgggt ggttgtacca acccttacgg caagtccaag ttcttcatcg 120
aggaaatgat ccgggacctg tgccaggcag acaaggggtg gacagcagcc ttagggctgg 180
acaggatgtg tgaggatctc tggcgctggc agaagcagaa tccttcaggc tttggcacgc 240
aagcctgagg accctcccct accaaggacc aggaaaagca gcagctgcct gctctccagc 300
ctctggcagg aactcagggc cctggagctg ctggggccaa gccaaaggcct cccctacctc 360
aaaccccagc tgggcccgtc tagcccacca ggcattgagg caagggtcc actgaccagg 420
aggccgaggt ctctaactct tatcttcac aggggtccaag agttcatcag gacccccaaag 480
agtgagttag ggggcaaggc tctggcacia aacctcctcc tcccaggcac tcatttatat 540
tgctctgaaa gagctttcca aagtatttaa aaataaaaac aagttttctt aactggg 598

```

```

<210> 29
<211> 1696
<212> DNA
<213> Homo sapien

```

```

<400> 29
cgtggagggg cggggtcggg gccggagtgg gccgtcagca cttaaagggc ccgaggctcg 60
ggcgtaggag gcggtgcctc tgcagcaagc gtggggcgcg ggaacccgag caggactctc 120
cagtccctag tcaccttgga caaagaagtg tggatcctca gattccatct tttccaactc 180
caaggtgcca tggcagagaa ggtgctggta acaggtgggg ctggctacat tggcagccac 240
acgggtgctg agctgctgga ggctggctac ttgcctgtgg tcatcgataa cttccataat 300
gccttccgtg gagggggctc cctgcctgag agcctgcggc gggtcagga gctgacaggc 360

```

cgctctgtgg agtttgagga gatggacatt ttggaccagg gagccctaca gcgtctcttc 420
 aaaaagtaca gctttatggc ggtcatccac tttgcggggc tcaaggccgt gggcgagtcg 480
 gtgcagaagc ctctggatta ttacagagtt aacctgaccg ggaccatcca gcttctggag 540
 atcatgaagg cccacggggg gaagaacctg gtgttcagca gctcagccac tgtgtacggg 600
 aacccccagt acctgcccct tgatgaggcc cccccacgg gtggttgtac caacccttac 660
 ggcaagtcca agttcttcat cgaggaaatg atccgggacc tgtgccaggc agacaagact 720
 tggaacgcag tgctgctgcg ctatttcaac cccacagggtg cccatgcctc tggctgcatt 780
 ggtgaggatc cccaggggcat acccaacaac ctcatgcctt atgtctccca ggtggcgatc 840
 gggcgacggg aggccctgaa tgtctttggc aatgactatg acacagagga tggcacaggc 900
 gtccgggatt acatccatgt cgtggatctg gccaaaggcc acattgcagc cttaaggaag 960
 ctgaaagaac agtgtggctg ccgggtagga agagaaggga gaagtgaggg aggggagggga 1020
 ccagatccag gcagagcggc ccagaggcgt ggtcagtcca gcccgctcca taaacctgt 1080
 tctccgtggg ccagatctac aacctgggca cgggcacagg ctattcagtg ctgcagatgg 1140
 tccaggctat ggagaaggcc tctgggaaga agatcccgtc caagggtgtg gcacggcggg 1200
 aaggatgatgt ggcagcctgt tacgccaacc ccagcctggc ccaagaggag ctgggggtgga 1260
 cagcagcctt agggctggac aggatgtgtg aggatctctg gcgctggcag aagcagaatc 1320
 cttcaggctt tggcacgcaa gcctgaggac cctcccctac caaggaccag gaaaagcagc 1380
 agctgcctgc tctccagcct ctggcaggaa ctcaggggcc tggagctgct ggggccaaagc 1440
 caaggcctcc cctacctcaa accccagctg ggcccgtta gccaccagg catgaggcca 1500
 agggctccac tgaccaggag gccgagggtc ctaactctta tcttccacag ggtccaagag 1560
 ttcatcagga cccccaagag tgagtgaggg ggcaaggctc tggcacaaaa cctcctcctc 1620
 ccaggcactc atttatattg ctctgaaaga gctttccaaa gtatttataaa ataaaaacaa 1680
 gttttcttac actggg 1696

<210> 30
 <211> 1939
 <212> DNA
 <213> Homo sapien

<400> 30
 cgtggagggg cgggggtcggg gccggagtgg gccgtcagca cttaaagggc ccgcggtcgc 60
 ggcgtaggag gcggtgcctc tgcagcaagc gtggggcgcg ggaaccgcag caggactctc 120
 cagtcctcag tcaccttgga caaagaagtg tggatcctca gattccatct tttccaactc 180
 caagggtgcca tggcagagaa ggtgctggta acagggtggg ctggctacat tggcagccac 240

acggtgctgg agctgctgga ggctggctac ttgcctgtgg tcatcgataa cttccataat 300
 gccttccgtg gagggggctc cctgcctgag agcctgcggc gggccagga gctgacaggc 360
 cgctctgtgg agtttgagga gatggacatt ttggaccagg gagccctaca gcgtctcttc 420
 aaaaagtaca gctttatggc ggtcatccac ttgcggggc tcaaggccgt gggcgagtgc 480
 gtgcagaagc ctctggatta ttacagagtt aacctgaccg ggaccatcca gcttctggag 540
 atcatgaagg ccacaggggt gaagaacctg gtgttcagca gctcagccac tgtgtacggg 600
 aacccccagt acctgcccct tgatgaggcc caccacagg gtggttgtag caacccttac 660
 ggcaagtcca agttcttcat cgaggaaatg atccgggacc tgtgccaggc agacaagact 720
 tggaacgcag tgctgctgcg ctatttcaac ccacaggtg cccatgcctc tggctgcatt 780
 ggtgaggatc ccagggcat acccaacaac ctcatgcctt atgtctcca ggtggcgatc 840
 gggcgacggg aggccctgaa tgtctttggc aatgactatg acacagagga tggcacaggc 900
 gtccgggatt acatccatgt cgtggatctg gccaaaggcc acattgcagc cttaaaggaag 960
 ctgaaagaac agtgtggctg ccgggtagga agagaaggga gaagtgaggg aggggaggga 1020
 ccagatccag gcagagcggc ccagaggcgt ggtcagtcca gcccgctcca taaacctgt 1080
 tctccgtggg ccagatctac aacctgggca cgggcacagg ctattcagtg ctgcagatgg 1140
 tccaggctat ggagaaggcc tctgggaaga aggtaggccc cccacccca cccacctcac 1200
 ccacctcacc ccaccagct ctcagcaaca gagcagcttt ggcccttccc actcacctct 1260
 ctggagggta cctggcactg ccagttctcc tcagcctgcc tagcaccggg tgccctgcggg 1320
 ccagccgctg ctctgcactt ctgcttctta aagacctggc cagcagctgg gccaggggcg 1380
 gctcagctaa gctccaacta cctcctgtct tgcagatccc gtacaagggtg gtggcacggc 1440
 gggaagggtg tgtggcagcc tgttacgcca acccagcct ggcccaagag gagctggggc 1500
 ggacagcagc cttagggctg gacaggatgt gtgaggatct ctggcgctgg cagaagcaga 1560
 atccttcagg ctttggcacg caagcctgag gacctcccc taccaaggac caggaaaagc 1620
 agcagctgcc tgctctccag cctctggcag gaactcaggc ccctggagct gctggggcca 1680
 agccaaggcc tcccctacct caaacccag ctggggccgc ttagcccacc aggcagagg 1740
 ccaagggctc cactgaccag gaggccgagg tctctaactc ttatcttcca cagggtccaa 1800
 gagttcatca ggacccccaa gagtgagtga gggggcaagg ctctggcaca aaacctctc 1860
 ctcccaggca ctcatctata ttgctctgaa agagctttcc aaagtattta aaaataaaaa 1920
 caagttttct tacactggg 1939

40

<211> 2082
 <212> DNA
 <213> Homo sapien

<400> 31
 cgtggagggg cgggggcggg gccggagtg gccgtcagca cttaaagggc ccgcggtcgc 60
 ggcgtaggag gcggtgcctc tgcagcaagc gtggggcgcg ggaacccgag caggactctc 120
 cagtcctcag tcaccttgga caaagaagtg tggatcctca gattccatct tttccaactc 180
 caagggtgcca tggcagagaa ggtgctggta acagggtggg ctggctacat tggcagccac 240
 acgggtgctg agctgctgga ggctggctac ttgcctgtgg tcatcgataa cttccataat 300
 gccttccgtg gaggggggctc cctgcctgag agcctgcggc ggggtccagga gctgacaggc 360
 cgctctgtgg agtttgagga gatggacatt ttggaccagg gagccctaca gcgtctcttc 420
 aaaaagtaca gctttatggc ggtcatccac tttgcggggc tcaaggccgt gggcgagtcg 480
 gtgcagaagc ctctggatta ttacagagtt aacctgaccg ggaccatcca gcttctggag 540
 atcatgaagg ccacacgggt gaagaacctg gtgttcagca gctcagccac tgtgtacggg 600
 aacccccagt acctgcccct tgatgaggcc caccacacgg gtggttgtag caacccttac 660
 ggcaagtcca agttcttcat cgaggaaatg atccgggacc tgtgccaggc agacaagact 720
 tggaacgcag tgctgctgcg ctatttcaac ccacaggtg cccatgcctc tggctgcatt 780
 ggtgaggatc ccaggggcat acccaacaac ctcatgcctt atgtctccca ggtggcgatc 840
 gggcgacggg aggccctgaa tgtctttggc aatgactatg acacagagga tggcacaggc 900
 gtccgggatt acatccatgt cgtggatctg gccaaaggcc acattgcagc cttaaggaag 960
 ctgaaagaac agtgtggctg ccgggtagga agagaaggga gaagtgaggg aggggaggga 1020
 ccagatccag gcagagcggc ccagaggcgt ggtcagcca gcccgctcca taaaccctgt 1080
 tctccgtggg ccagatctac aacctgggca cgggcacagg ctattcagtg ctgcagatgg 1140
 tccaggctat ggagaaggcc tctgggaaga aggtaggccc cccacccca cccacctcac 1200
 ccacctcacc ccaccagct ctcagcaaca gagcagcttt ggcccttccc actcacctct 1260
 ctggagggta cctggcactg ccagtcctcc tcagcctgcc tagcaccogg tgctgcggg 1320
 ccagccgctg ctctgcactt ctgcttctta aagacctggc cagcagctgg gccagggccg 1380
 gctcagctaa gctccaacta cctcctgtct tgcagatccc gtacaagggt gtggcacggc 1440
 gggaagggtga tgtggcagcc tgttacgcca accccagcct ggcccaagag gagctggggc 1500
 ggacagcagc cttagggctg gacaggatgt gtgagtgtg gcctgacccc tgcagttagg 1560
 ggccaggaggg gggctaaatc agatctgggc atgcccaccc agggcgggct gtgggggtggg 1620
 ggaggctctg cattccaccg tgggccctga gcacacacct cgccgtgttg cagggtgagga 1680

41

tctctggcgc tggcagaagc agaatccttc aggcctttggc acgcaagcct gaggaccctc 1740
 ccctaccaag gaccaggaaa agcagcagct gcctgctctc cagcctctgg caggaactca 1800
 gggccctgga gctgctgggg ccaagccaag gcctccccta cctcaaacc cagctgggcc 1860
 cgcttagccc accaggcatg aggcccaagg ctccactgac caggaggccg aggtctctaa 1920
 ctcttatctt ccacagggtc caagagttca tcaggacccc caagagtgag tgagggggca 1980
 aggctctggc acaaaacctc ctccctccag gcactcattt atattgctct gaaagagctt 2040
 tccaaagtat ttaaaaataa aaacaagttt tcttacctg gg 2082

<210> 32
 <211> 1081
 <212> DNA
 <213> Homo sapien

<400> 32
 ctattggtca ggacgtttcc tatgctaata aaggggtggc ccgtagaaga ttccagcacc 60
 ctcccctaac tccaggccag actcctttca gctaaagggg agatctggat ggcactctact 120
 tcgtatgact attgcagagt gcccatggaa gacggggata agcgtgttaa gcttctgctg 180
 gggataggaa ttctgggtgt cctgatcatc gtgattctgg gggtgccctt gattatcttc 240
 accatcaagg ccaacagcga ggcctgccgg gacggccttc gggcagtgat ggagtgtcgc 300
 aatgtcacc atctcctgca acaagagctg accgaggccc agaagggctt tcaggatgtg 360
 gaggcccagg ccgccacctg caaccacact gtgatggccc taatggcttc cctggatgca 420
 gagaaggccc aaggacaaaa gaaagtggag gagcttgagg gagagatcac tacattaaac 480
 cataagcttc aggacgcgtc tgcagaggtg gagcgactga gaagagaaaa ccaggtctta 540
 agcgtgagaa tcgcggaaca gaagtactac ccagctccc aggactccag ctccgctgcg 600
 gcgccccagc agcacaatca gcagctgggg cgccgcagct gctgattgtg ctgctgggcc 660
 tcagcgctct gctgcagtga gatcccagga agctggcaca tcttgggaagg tccgtcctgc 720
 tcggcttttc gcttgaacat tcccttgatc tcatcagttc tgagcgggtc atggggcaac 780
 acggttagcg gggagagcac ggggtagccg gagaagggcc tctggagcag gtctggaggg 840
 gccatggggc agtcctgggt gtggggacac agtcgggttg acccagggct gtctccctcc 900
 agagcctccc tccggacaat gagtcccccc tcttgtctcc caccctgaga ttgggcatgg 960
 ggtgcggtgt ggggggcatg tgctgcctgt tgttatgggt tttttttgcg ggggggggtg 1020
 cttttttctg gggctcttga gctccaaaaa ataaacactt cctttgaggg agagcacacc 1080
 t 1081

<210> 33

42

<211> 1075
 <212> DNA
 <213> Homo sapien

<400> 33
 ctattggtca ggacgtttcc tatgctaata aaggggtggc ccgtagaaga ttccagcacc 60
 ctcccctaac tccaggccag actcctttca gctaaagggg agatctggat ggcactact 120
 tcgtatgact attgcagagt gcccatggaa gacggggata agcgctgtaa gcttctgctg 180
 gggataggaa ttctggtgct cctgatcatc gtgattctgg ggtgcccctt gattatcttc 240
 accatcaagg ccaacagcga ggcctgccgg gacggccttc gggcagtgat ggagtgtcgc 300
 aatgtcacc atctcctgca acaagagctg accgaggccc agaagggtt tcaggatgtg 360
 gaggcccagg ccgccacctg caaccacact gtgatggccc taatggcttc cctggatgca 420
 gagaaggccc aaggacaaaa gaaagtggag gagcttgagg tcactacatt aaaccataag 480
 cttcaggacg cttaagacct ggttttctct tctcagtcgc tccacctctg cagacgcgtc 540
 tgagaagaga aaaccaggtc ttaagcgtga gaatcgcgga caagaagtac taccacagct 600
 cccaggactc cagctccgct gcggcgcccc agctgctgat tgtgctgctg ggcctcagcg 660
 ctctgctgca gtgagatccc aggaagctgg cacatcttgg aaggctccgtc ctgctcggct 720
 tttcgcttga acattccctt gatctcatca gttctgagcg ggtcatgggg caacacgggt 780
 agcggggaga gcacggggta gccggagaag ggcctctgga gcaggctctgg aggggccatg 840
 gggcagtcct ggggtgtggg acacagtcgg gttgaccag ggtgtctcc ctccagagcc 900
 tccctccgga caatgagtcc cccctcttgt ctcccacct gagattgggc atggggtgcg 960
 gtgtgggggg catgtgctgc ctgttggtat ggggtttttt tgcggggggg gttgcttttt 1020
 tctggggtct ttgagctcca aaaaataaac acttcctttg agggagagca cacct 1075

<210> 34
 <211> 672
 <212> DNA
 <213> Homo sapien

<400> 34
 ctccgaagtc tagagagaga ggctgcaggg gaagggactg ggcgcagagg tgaggggcct 60
 tggggaagga gggagaatcc agtgagaagg atgccctgga tcgggggcgg gctgatagct 120
 gtatggggcg gggctatcaa tgggggcggg tctatcgatg gaggggaggg gcttatggat 180
 ggggtggggcg ggtctagcga tgggggcggg gcttggggcc gggcttgagg cggggccagt 240
 gcctgtgcc tccagtctgc cctgagtcct tcttctggtc ctttaggcac atcttggaag 300
 gtccgtcctg ctgggctttt cgcttgaaca ttcccttgat ctcatcagtt ctgagcgggt 360
 catggggcaa cacgggttagc ggggagagca cggggtagcc ggagaagggc ctctggagca 420

ggtctggagg ggccatgggg cagtcctggg tgtggggaca cagtcgggtt gacccagggc 480
 tgtctccctc cagagcctcc ctccggacaa tgagtcccc ctcttgtctc ccaccctgag 540
 attgggcatg ggggtgcggtg tggggggcat gtgctgcctg ttgttatggg ttttttttgc 600
 ggggggggtt gcttttttct ggggtctttg agctccaaaa aataaacact tcctttgagg 660
 gagagcacac ct 672

<210> 35
 <211> 2184
 <212> DNA
 <213> Homo sapien

<400> 35
 aggcagacgg gaacctgaga ctttgtccaa acctcggctg gaaggctggc cttggcactc 60
 ggcgtcttag ctagtggatt tatcgatta agactgtact tgggcctttt tcatgatgac 120
 ttgggtctca atccttggag cagctgaaag aacagctcgg gccacctgtg gatgcacca 180
 caatgaaatc agaggccacg tgaggtttgc aaggcagagt ggctgcagt ttttaactcg 240
 gcactatggc aatgcagacc caaaccaatt gtgccagttc tttgctgggt ggcaaagtgt 300
 tttcaggctt gtggtcactc ctgatttctg tttggaagca cagttctctc tctaaggaga 360
 atggaaactt ggaaaggcct gtaaaatcgg aaagcctgta aaaggccgta gaggggagat 420
 gtataaaaat gtacggtcac ccatgtttta ggggttgacc gggagcgggg cgaggaggag 480
 ggtgggtatg aggcggtagc ggaccgcgga gtcgagacct acccgaacga cgcgggcgag 540
 cggggctttg gacgccggtg gagacgcagg cgagggtgct tgtaaaatat tacaggcata 600
 ctttgagat gttatgggtt tggttccaca tcaactgcaat aaaactccag cgggaggaag 660
 aagaggcctt tgccagcagt cagagcagcc aaggggcca atccctcata ttctccaagt 720
 ttgaaggaaa gaaaaccaac aagaagacc gcaagggttac cacagtgaag aaatcttcag 780
 tacgtcttcc agggtcggat caaagaagga tattgaaatg gattccaggc gtgtgcctcg 840
 agacaagctg gcctgcatca ccaagtgcag caagcacatc ttgatgcca tcaagatcac 900
 ctagaacgag ctggcgctcag cagatgactt cctccccacc ctcatctaca ttgttttgaa 960
 gggcaacccc catgccttca gtctaataatc cagtatatca cgcgcttctg caatccaagc 1020
 cgactgatga ctggagagga tggctactat ttcaccaatc tggtgagtaa gtgagttctt 1080
 ggcgttggtg agaaggacta ggaagggtgt ggttttgggg atgtgatagg tcactcaggc 1140
 ccatgacagg tgaatgcttc tgtgtgagaa ggcagcacgg ctgaggaagc tcactttgca 1200
 tcaggagca caaggaccag gccgtacaga cactccgcct cccgcactt gatcagagat 1260
 tgtgtttatc ctacagaaac agatgacatg tgttgggcat cactcccccac ggtcctgggt 1320


```

agaagagtcc ttcacttggc agggcctttt caaccaatga ataaggcaaa ttatatataa 1380
gttaataatg ccatttcgaa ccgagacaga tggcagctaa atgaagttta attaaagaat 1440
gagcgcgggg cccttttcat tgggtactgc atctacttcg accgcaaaag acgaagtgc 1500
cccaacttca agaacaggct tcgagaacga agaaagaaac agaagcttgc caaggagaga 1560
gctgggcttt ccaagttacc tgaccttaaa gatgctgaag ctgttcagaa gttcttcctt 1620
gaagaaatac agcttgggtga agagttacta gctcaagggtg aatatgagaa gggcgtagac 1680
catctgacaa atggaattgc tgtgtgtgga cagccacagc agttactgca ggccttacag 1740
caaactcttc caccactagt gttccagatg cttttgacta agtcccaac aattagagaa 1800
ttctaagtgc tcagagcttg gctgaagatg atgtggaatg agaaacaaat gttaacataa 1860
taaaatctca gttaaaaata tttaaaaaat tcttggtagt tgagcagctc tgggggaata 1920
agggcaaata tccttggtat gaactacact gaaatctacc aaagttaatg tttactttgt 1980
gtaggtccat ttgtctattt tatttatttt tcccagtga aagtgtattt tgatagagaa 2040
cttttcattt tataaataca ctatgagtta ctgaaaattc atatcatgga tttcatttat 2100
tcctgaaaca tagttaaaat gtacatatga catggcttat gttaaaaata cccagtgcctc 2160
agttttgaaa gataggcaca aaaa 2184

```

```

<210> 36
<211> 2515
<212> DNA
<213> Homo sapien

```

```

<400> 36
ctggcgaggt ggcccgggct cggccctccg aggggtgtgga gcgcccggga aacgggaccc 60
caagaatcca actgctccca ccctgcgcgg ccaggagcgg ggctggcgat actggggaca 120
ctgtccaatc cgggcagggg gcgaggccgg gggaccgggc gggcctgggg agcaggcacg 180
tgtggagggc ggacccgcgc ggggtcgagg cctgcctctc cgagagctcc tggcgcggcc 240
gtcccggccc ggggccccag gtgcgcttcc cctagagagg gattttccgg tctcgtgggc 300
agaggaacaa ccaggaactt gggctcagtc tccacccac agtggggcgg atccgtcccg 360
gataagaccc gctgtctggc cctgagtagg gtgtgacctc cgcagccgca gaggaggagc 420
gcagcccggc ctgaagaac ttctgcttgg gtggctgaac tctgatcttg acctagagtc 480
atggccatgg caaccaaagg aggtactgtc aaagctgctt caggattcaa tgccatggaa 540
gatgccaga ccctgaggaa ggccatgaaa gggctgcac aaacaacgag gaaacagaag 600
attcaccaaa catttatgaa cagccagctg ttataaagac aagggaacca tctgaaaaat 660
cagaataaag tctccttggt aaagctgctg caagaaacag gcaccgatga agacgccatt 720

```

attagcgtcc ttgcctaccg caacaccgcc cagcgccagg agatcaggac agcctacaag	780
agcaccatcg gcagggactt gatagacgac ctgaagtcag aactgagtgg caacttcgag	840
caggtgattg tggggatgat gacgcccacg gtgctgtatg acgtgcaaga gctgcgaagg	900
gccatgaagg gagccggcac tgatgagggc tgcctaattg agatcctggc ctcccggacc	960
cctgaggaga tccggcgcat aagccaaacc taccagcagc aatatggacg gagccttgaa	1020
gatgacattc gctctgacac atcgttcatg ttccagcgag tgctgggtgtc tctgtcagct	1080
ggtgggaggg atgaaggaaa ttatctggac gatgctctcg tgagacagga tgcccaggac	1140
ctgtatgagg ctggagagaa gaaatggggg acagatgagg tgaaatttct aactgttctc	1200
tgttcccga accgaaatca cctgttgcac gtgtttgatg aatacaaaag gatatcacag	1260
aaggatattg aacagagtat taaatctgaa acatctggta gctttgaaga tgctctgctg	1320
gctatagtaa agtgcatgag gaacaaatct gcatattttg ctgaaaagct ctataaatcg	1380
atgaagggct tgggcaccga tgataacacc ctcatcagag tgatgggttc tgcagcagaa	1440
attgacatgt tggatatccg ggcacacttc aagagactct atggaaagtc tctgtactcg	1500
ttcatcaagg gtgacacatc tggagactac aggaaagtac tgcttggtct ctgtggagga	1560
gatgattaaa ataaaaatcc cagaaggaca ggaggattct caacactttg aattttttta	1620
acttcatttt tctacactgc tattatcatt atctcagaat gcttatttcc aattaaaacg	1680
cctacagctg cctcctagaa tatagactgt ctgtattatt attcacctat aattagtcac	1740
tatgatgctt taaagctgta cttgcatttc aaagcttata agatataaat ggagatttta	1800
aagtagaaat aaatatgtat tccatgtttt taaaagatta ctttctactt tgtgtttcac	1860
agacattgaa tatattaaat tattccatat tttcttttca gtgaaaaatt ttttaaattg	1920
aagactgttc taaaatcact tttttcccta atccaatttt tagagtggct agtagtttct	1980
tcatttgaaa ttgtaagcat ccggtcagta agaatgccca tccagttttc tatatttcat	2040
agtcaaagcc ttgaaagcat ctacaaatct ctttttttag gttttgtcca tagcatcagt	2100
tgatccttac taagtttttc atgggagact tccttcatca catcttatgt tgaaatcact	2160
ttctgtagtc aaagtatacc aaaaccaatt tatctgaact aaattctaaa gtatgggtat	2220
acaaaccata tacatctggc taccaaaccat aaatgctgaa cattccatat tattatagtt	2280
aatgtcttaa tccagcttgc aagtgaatgg aaaaaaaaaat aagcttcaaa ctaggtattc	2340
tgggaatgat gtaatgctct gaatttagta tgatataaag aaaacttttt tgtgctaaaa	2400
atacttttta aaatcaattt tgttgattgt agtaatttct atttgactg tgcctttcaa	2460
ctccagaaac attctgaaga tgtacttggc ttttaattaaa aagttcactt tgtaa	2515

<210> 37
 <211> 1948
 <212> DNA
 <213> Homo sapien

<400> 37
 aagattcaag gtcttgctat gtttcccagg ccagctcttc acaggtgcc a tcttagctca 60
 ctgccttgaa ctcttgacct caagacatcc tcccacctca gcctcgagta gctggaacta 120
 catgcacatc ccgacccccct tttggcagag gttgatcaat gtagatttgc cagttaggaa 180
 ggcatgagtc agctgggaag acacaggaga gtgggtggtt gggggaggcc aggagatagt 240
 ggagggagct gtccttggga agcttctcct gctattggca gaggcactca tgcaacgtta 300
 gggggccacac tgaggctcag ccctctaggc acacatcaga gccattgtaa taatgcgagc 360
 gcatttagag gacgtctgtc ctccctccct gggctgaag ctccaattct tgtggtattt 420
 tgtctcatta ctctagacct gctatcttaa tgggtgtccc agatcttcat gtatactctc 480
 gaattatttt ttatttggtt ttctcatcct cagggtggga gggatgaagg aaattatctg 540
 gacgatgctc tcgtgagaca ggatgccag gacctgtatg aggctggaga gaagaaatgg 600
 gggacagatg aggtgaaatt tctaactgtt ctctgttccc ggaaccgaaa tcacctgttg 660
 catgtgtttg atgaatacaa aaggatatca cagaaggata ttgaacagag tattaatctt 720
 gaaacatctg gtagctttga agatgctctg ctggctatag taaagtgc at gaggaacaaa 780
 tctgcataatt ttgctgaaaa gctctataaa tcgatgaagg gcttgggcac cgatgataac 840
 accctcatca gagtgatggt ttctcgagca gaaattgaca tgttggatat ccgggcacac 900
 ttcaagagac tctatggaaa gtctctgtac tcgttcatca agggtgacac atctggagac 960
 tacaggaaaag tactgcttgt tctctgtgga ggagatgatt aaaataaaaa tcccagaagg 1020
 acaggaggat tctcaacact ttgaattttt ttaacttcat ttttctacac tgctattatc 1080
 attatctcag aatgcttatt tccaattaaa acgcctacag ctgcctccta gaatatagac 1140
 tgtctgtatt attattcacc tataattagt cattatgatg ctttaaagct gtacttgc at 1200
 ttcaaagctt ataagatata aatggagatt ttaaagtaga aataaatatg tattccatgt 1260
 ttttaaaaga ttactttcta ctttgtgttt cacagacatt gaatatatta aattattcca 1320
 tattttcttt tcagtgaaaa attttttaaa tgggaagactg ttctaaaatc acttttttcc 1380
 ctaatccaat ttttagagtg gctagtagtt tcttcatttg aaattgtaag catccggtca 1440
 gtaagaatgc ccatccagtt ttctatattt catagtcaaa gccttgaaag catctacaaa 1500
 tctctttttt taggttttgt ccatagcatc agttgatcct tactaagttt ttcattggag 1560
 acttccttca tcacatctta tgttgaaatc actttctgta gtcaaagtat accaaaacca 1620

47

atttatctga actaaattct aaagtatggt tatacaaacc atatacatct ggttaccaaa 1680
 cataaatgct gaacattcca tattattata gttaatgtct taatccagct tgcaagtga 1740
 tggaaaaaaa aataagcttc aaactaggta ttctgggaat gatgtaatgc tctgaattta 1800
 gtatgatata aagaaaactt ttttgtgcta aaaatacttt ttaaaatcaa ttttgttgat 1860
 tgtagtaatt tctatttgca ctgtgccttt caactccaga aacattctga agatgtactt 1920
 ggatttaatt aaaaagttca ctttgtaa 1948

<210> 38
 <211> 3633
 <212> DNA
 <213> Homo sapien

<400> 38
 gaaaaaaaaa aaaaaaaaaa acaaaaaaca aaaaatacat cacaataaga ggccgaatgt 60
 aaataaagac gagggacgca gaggggtggc cgtggctgag aggagacagc gccgcagcac 120
 tgagggtttg ggcttgacagg cgctgcagga gacgccagg cgaggtcttg tctgcagacc 180
 agctctgagc gggaggcctg agcgggaagc attggcgctc gagcgacttc taggagcctg 240
 gggttcggcg ctatggagga gctcgatggc gagccaacag tcaactgtaag ggtaccccga 300
 acaggccttg tcgtccttgc gggttgagaa ctgcgtctgc ttagttactt caggccttgc 360
 tgcttcccta gtggtcgcga ggcgctcgtc cccttccctc gactcagttg ccacttttcc 420
 ggaggtcgca gtgttaacga gttgattcca ggcgtgaatt ccaagaagaa ccaaagtgtat 480
 tttgactggg gtccagggga gatgctggta tgtgaaacct ccttcaacaa aaaagaaaaa 540
 tcagagatgg tgccaagttg cccctttatc tatatcatcc gtaaggatgt agatgtttac 600
 tctcaaactc tgagaaaact cttcaatgaa tcccatggaa tctttctggg cctccagaga 660
 attgacgaag agttgactgg aaaatccaga aaatctcaat tggttcgagt gagtaaaaaac 720
 taccgatcag tcatcagagc atgtatggag gaaatgcacc aggttgcaat tgctgctaaa 780
 gatccagcca atggccgcca gttcagcagc caggctctcca ttttgtcagc aatggagctc 840
 atctggaacc tgtgtgagat tctttttatt gaagtggccc cagctggccc tctcctcctc 900
 catctccttg actgggtccg gctccatgtg tgcgaggtgg acagtttgtc gccagatggt 960
 ctgggcagtg agaatccaag caaacatgac agcttctgga acttggtgac catcttggtg 1020
 ctgcagggcc ggctggatga ggcccgacag atgctctcca aggaagccga tgccagcccc 1080
 gcctctgcag gcatatgccg aatcatgggg gacctgatga ggacaatgcc cattcttagt 1140
 cctgggaaca cccagacact gacagagctg gagctgaagt ggcagcactg gcacgaggaa 1200
 tgtgagcggg acctccagga cagcacattc gccaccagcc ctcacctgga gtctctcttg 1260

aagattatgc	tgggagacga	agctgccttg	ttagagcaga	aggaacttct	gagtaattgg	1320
tatcatttcc	tagtgactcg	gctcttgtag	tccaatccca	cagtaaaacc	cattgatctg	1380
cactactatg	cccagtcacg	cctggacctg	tttctgggag	gtgagagcag	cccagaaccc	1440
ctggacaaca	tcttggtggc	agcctttgag	tttgacatcc	atcaagtaat	caaagagtgc	1500
aggaataaaa	cagatttgag	cagaagaagt	ctggtggatg	cagggagtat	aaaaggggaa	1560
agcatcctgc	tgtttccagt	ggcagaagag	aaagagaagt	accatgaaga	ggggtgaaca	1620
acatcactct	cgtgccggac	acagacaagg	aatgattagg	cttgacgtcc	cccagtctca	1680
gcctctctcc	actctcacia	gcaggaaggg	atctgagctc	tgtagtgagg	aaatcttgga	1740
gtttgcattt	ctctgatcac	gaggctacct	cctatcctgt	tttgaaagag	gaacagaaaa	1800
gcagagcttg	tcccaggaat	tgtgaaatgg	gctgcaatgt	cttcagaggc	agtagcagtt	1860
ttaggaagtg	tgccctcctg	cctctgggga	aagggtgaat	tggggtcttg	tgggcacttg	1920
ttttctcatg	ggatgtatca	gtcagaccca	tgcacagtcc	tgggcggcag	ggaagtgtgt	1980
ctctttctgg	acttgagcca	gtgagctggt	ggcatgcctt	tttaaaggca	ttagaaaaaa	2040
ggtttctttc	ttttttttcc	tttctgttcc	acaccacctt	catatgaaca	tggagaaggg	2100
aggtttctaa	gtgggcccct	gatttactcc	tatgtcaata	atcgtgccag	accctaaggg	2160
gcagaaaagg	cagccagggg	atcctgactc	agaggctgta	gttcgtcagc	cctgctaaag	2220
ggccaggggt	ttgtctctca	gtgcctgggt	gggcatgctt	gactgctaac	cccttagctg	2280
aaaggagatg	gcaggagtcc	tccacagggg	cccttcttcc	ctcctggctt	acagcttcct	2340
ctgaagacgg	gccagtctct	tgtgtctctg	caagaggaaa	cagctggggg	gcacttcact	2400
gggagttggg	caagatgtcg	gcagtttctc	gggtcccttc	aagtctccca	aaagtatcga	2460
gctaaaagag	gtgacaagtc	ttccttcaat	aaccaagaag	agttccagct	taatgtctgc	2520
tgaatctaga	atcttctgac	ttgtattttg	gccagccca	caatcttgga	tgcaggggtgc	2580
agcagtgttt	acaaacctca	caccccatct	ccagaatagc	aggtagaggc	actggagctt	2640
tgattactcc	agagccccc	acaagcaaga	tggggcctgg	catcgccctg	agcaactggg	2700
ggtttgtggc	ccacctgaca	gacctgctgg	accactgcaa	gctcctccag	tcacacaacc	2760
tctatttcgg	ttccaacatg	agagagttcc	tcctgctgga	gtacgcctcg	ggactgtttg	2820
ctcatcccag	cctgtggcag	ctgggggtcg	attactttga	ttactgcccc	gagctggggc	2880
gagtctccct	ggagctgcac	attgagcgga	tacctctgaa	caccgagcag	aaagccctga	2940
aggtgctgcg	gatctgtgag	cagcggcaga	tgactgaaca	agttcgcagc	atgtgtgaaga	3000
tcttagccat	gaaagccgtc	cgcaacaatc	gcctgggttc	tgcctctctc	tggagcatcc	3060
gtgctaagga	tgcgcctttt	gccacgctcg	tgtcagacag	gttcctcagg	gattactgtg	3120

49

```

agcgaggctg cttttctgat ttggatctca ttgacaacct ggggccagcc atgatgctca 3180
gtgaccgact gacattcctg ggaaagtatc gcgagttcca ccgtatgtac ggggagaagc 3240
gttttgccga cgcagcttct ctccctctgt ccttgatgac gtctcggatt gcccctcggt 3300
ctttctggat gactctgctg acagatgcct tgcccctttt ggaacagaaa caggtgattt 3360
tctcagcaga acagacttat gagttgatgc ggtgtctgga ggacttgacg tcaagaagac 3420
ctgtgcatgg agaactctgat accgagcagc tccaggatga tgacatagag accaccaagg 3480
tggaatgct gagactttct ctggcacgaa atcttgctcg ggcaattata agagaaggct 3540
cactggaagg ttcctgagaa ctgcttcaat gtggtatctt tgtatggcaa tgtatataga 3600
ttttttaaaa gaataaatgt tgttttgcaa atg 3633

```

```

<210> 39
<211> 2589
<212> DNA
<213> Homo sapien

```

```

<400> 39
gaaaaaaaaa aagaaaaaaaa acaaaaaaca aaaaatacat cacaataaga ggccgaatgt 60
aaataaagac gagggacgca gaggggtggc cgtggctgag aggagacagc gccgcagcac 120
tgaggggttg ggcttgcagg cgctgcagga gacgccagg cggagtcttg tctgcagcc 180
agctctgagc gggaggcctg agcgggaagc attggcgtcc gagcgacttc taggagcctg 240
gggttcggcg ctatggagga gctcgatggc gagccaacag tcaactgtaag ggtaccccga 300
acaggcttgc tcgtccttgc gggttgagaa ctgctctgct ttagttaact caggcttgtc 360
tgcttcctta gtggctcgca ggcgctcgtc cccttccttc gactcagttg ccacttttcc 420
ggaggtcgca gtgttaacga gttgattcca ggcgtgaatt ccaagaagaa ccaaagtgtat 480
tttgactggg gtccagggga gatgctggta tgtgaaacct ccttcaaca aaaagaaaaa 540
tcagagatgg tgccaagttg cccctttatc tatatcatcc gtaaggatgt agatgtttac 600
tctcaaactc tgagaaaact cttcaatgaa tcccatggaa tctttctggg cctccagaga 660
attgacgaag agttgactgg aaaatccaga aaatctcaat tggttcgagt gagtaaaaac 720
taccgatcag tcatcagagc atgtatggag gaaatgcacc aggttgcaat tgctgctaaa 780
gatccagcca atggccgcca gttcagcagc caggtctcca ttttgtcagc aatggagctc 840
atctggaacc tgtgtgagat tctttttatt gaagtggccc cagctggccc tctcctctc 900
catctccttg actgggtccg gctccatgtg tgcgaggtgg acagtttgtc ggcagatgtt 960
ctgggcagtg agaatccaag caaacatgac agcttctgga acttggtgac catcttggtg 1020
ctgcagggcc ggctggatga ggcccgacag atgctctcca aggaagccga tgccagcccc 1080

```

gcctctgcag gcatatgccg aatcatgggg gacctgatga ggacaatgcc cattcttagt 1140
 cctgggaaca ccagacact gacagagctg gagctgaagt ggcagcactg gcacgaggaa 1200
 tgtgagcggg acctccagga cagcacattc gccaccagcc ctcacctgga gtctctcttg 1260
 aagattatgc tgggagacga agctgccttg ttagagcaga aggaacttct gagtaattgg 1320
 tatcatttcc tagtgactcg gctcttgtag tccaatccca cagtaaaacc cattgatctg 1380
 cactactatg ccagtgccag cctggacctg tttctgggag gtgagagcag ccagaacccc 1440
 ctggacaaca tcttggtggc agcctttgag tttgacatcc atcaagtaat caaagagtgc 1500
 agcttcctct gaagacgggc cagttccttg ctgtctggca agaggaaaca gctgggggtgc 1560
 acttcactgg gagttgggca agatgtcggc agtttcctgg tgcccttcaa gtcctccaaa 1620
 agtatcgagc taaaagcatc gccctgagca actggtggtt tgtggccac ctgacagacc 1680
 tgctggacca ctgcaagctc ctccagtcac acaacctcta tttcggttcc aacatgagag 1740
 agttcctcct gctggagtac gcctcgggac tgtttgctca tcccagcctg tggcagctgg 1800
 gggtcgatta ctttgattac tgccccgagc tgggccgagt ctccctggag ctgcacattg 1860
 agcggatacc tctgaacacc gagcagaaaag ccctgaaggt gctgcggatc tgtgagcagc 1920
 ggcagatgac tgaacaagtt cgcagcattt gtaagatctt agccatgaaa gccgtccgca 1980
 acaatcgctt gggttctgcc ctctcttgga gcatccgtgc taaggatgcc gcctttgcca 2040
 cgctcgtgtc agacaggttc ctccaggatt actgtgagcg aggetgcttt tctgatttgg 2100
 atctcattga caacctgggg ccagccatga tgctcagtga ccgactgaca ttctgggaa 2160
 agtatcgca gttccaccgt atgtacgggg agaagcgttt tgccgacgca gcttctctcc 2220
 ttctgtcctt gatgacgtct cggattgccc ctcggtcttt ctggatgact ctgctgacag 2280
 atgccttgcc ccttttgga cagaaacagg tgattttctc agcagaacag acttatgagt 2340
 tgatgcggtg tctggaggac ttgacgtcaa gaagacctgt gcatggagaa tctgataccg 2400
 agcagctcca ggatgatgac atagagacca ccaaggtgga aatgctgaga ctttctctgg 2460
 cacgaaatct tgctcgggca attataagag aaggctcact ggaagggtcc tgagaactgc 2520
 ttcaatgtgg tatctttgta tggcaatgta tatagatttt ttaaaagaat aaatgttgtt 2580
 ttgcaaattg 2589

<210> 40
 <211> 2695
 <212> DNA
 <213> Homo sapien

<400> 40
 gaaaaaaaaa aagaaaaaaaa acaaaaaaca aaaaatacat cacaataaga ggccgaatgt 60

aaataaagac	gagggacgca	gaggggtggc	cgtggctgag	aggagacagc	gccgcagcac	120
tgaggggtttg	ggcttgacagg	cgctgcagga	gacgcccagg	cggagtcttg	tctgcagacc	180
agctctgagc	gggaggcctg	agcgggaagc	attggcgctcc	gagcgacttc	taggagcctg	240
gggttcggcg	ctatggagga	gctcgatggc	gagccaacag	tcaactgtaag	ggtacccccga	300
acaggcttgc	tcgtccttgc	gggttgagaa	ctgcgtctgc	ttagttaactt	caggcttgtc	360
tgcttcccta	gtggtcgcga	ggcgctcgtc	cccttccctc	gactcagttg	ccacttttcc	420
ggaggtcgca	gtgttaacga	gttgattcca	ggcgtgaatt	ccaagaagaa	ccaaatgtat	480
tttgactggg	gtccagggga	gatgctggta	tgtgaaacct	ccttcaacaa	aaaagaaaaa	540
tcagagatgg	tgccaagttg	ccccctttatc	tatatcatcc	gtaaggatgt	agatgtttac	600
tctcaaactct	tgagaaaact	cttcaatgaa	tcccatggaa	tctttctggg	cctccagaga	660
attgacgaag	agttgactgg	aaaatccaga	aaatctcaat	tggttcgagt	gagtaaaaac	720
taccgatcag	tcacagagc	atgtatggag	gaaatgcacc	aggttgcaat	tgctgctaaa	780
gatccagcca	atggccgcca	gttcagcagc	caggtctcca	ttttgtcagc	aatggagctc	840
atctggaacc	tgtgtgagat	tctttttatt	gaagtggccc	cagctggccc	tctcctcctc	900
catctccttg	actgggtccg	gctccatgtg	tgcgagggtg	acagtttgct	ggcagatgtt	960
ctgggcagtg	agaatccaag	caaacatgac	agcttctgga	acttggtgac	catcttggtg	1020
ctgcagggcc	ggctggatga	ggcccgacag	atgctctcca	aggaagccga	tgccagcccc	1080
gcctctgcag	gcataatgcc	aatcatgggg	gacctgatga	ggacaatgcc	cattcttagt	1140
cctgggaaca	cccagacact	gacagagctg	gagctgaagt	ggcagcactg	gcacgaggaa	1200
tgtgagcggg	acctccagga	cagcacattc	gccaccagcc	ctcacctgga	gtctctcttg	1260
aagattatgc	tgggagacga	agctgccttg	ttagagcaga	aggaacttct	gagtaattgg	1320
tatcatttcc	tagtgactcg	gctcttgtag	tccaatccca	cagtaaaacc	cattgatctg	1380
cactactatg	cccagtcag	cctggacctg	tttctgggag	gtgagagcag	cccagaaccc	1440
ctggacaaca	tcttggtggc	agcctttgag	tttgacatcc	atcaagtaat	caaagagtgc	1500
aggaataaaa	cagatttgag	cagaagaagt	ctgttggtatg	cagggagtat	aaaaggggaa	1560
agcatcctgc	tgtttccagt	ggcagaagag	aaagagaagt	accatgaaga	ggggtgaaca	1620
acatcactct	cgtgccggac	acagacaagg	aatgattagg	cttgacgtcc	cccagtctca	1680
gcctctctcc	actctcacia	gcaggaagg	atctgagctc	tgtagtgagg	aaatcttgga	1740
gtttgcattt	ctctgatcac	gaggctacct	cctatcctgt	tttgaaagag	gaacagaaaa	1800
gcagagcttg	tcccaggaat	tgtgaaatgg	gctgcaatgt	cttcagaggc	agtagcagtt	1860

52

ttaggaagtg	tgccctcctg	cctctgggga	aaggttgaat	tggggtcttg	tgggcacttg	1920
ttttctcatg	ggatgtatca	gtcagacca	tgcacagttc	tgggcggcag	ggaagtgtgt	1980
ctctttctgg	acttgagcca	gtgagctgtt	ggcatgcctt	tttaaaggca	ttagaaaaaa	2040
ggtttctttc	ttttttttcc	tttctgttcc	acaccacctt	catatgaaca	tggagaaggg	2100
aggtttctaa	gtgggcccct	gatttactcc	tatgtcaata	atcgtgccag	accctaaggg	2160
gcagaaaagg	cagccagggg	atcctgactc	agaggctgta	gttcgtcagc	cctgctaaag	2220
ggccaggggt	ttgtctctca	gtgcctgggt	gggcatgctt	gactgctaac	cccttagctg	2280
aaaggagatg	gcaggagtcc	tccacagggg	cccttcttcc	ctcctggctt	acagcttcct	2340
ctgaagacgg	gccagttcct	tgctgtctgg	caagaggaaa	cagctggggg	gcacttcact	2400
gggagttggg	caagatgtcg	gcagtttctc	ggtgcccttc	aagtcctcca	aaagtatcga	2460
gctaaaagca	tcgccctgag	caactgggtg	tttgtggccc	acctgacaga	cctgctggac	2520
cactgcaagc	tcctccagtc	acacaacctc	tatttcggtt	ccaacatgag	agagttcctc	2580
ctgctggagt	acgcctcggg	actgtttgct	catcccagrc	ctgtggctgc	ctgggggtcc	2640
ggctgtctgg	tactagcttt	ttcataccgg	cgccctcgcg	gggccctttt	acgcg	2695

<210> 41
 <211> 2267
 <212> DNA
 <213> Homo sapien

<400> 41	
gaaaaaaaaa	aagaaaaaaaa acaaaaaaca aaaaatacat cacaataaga ggccgaatgt 60
aaataaagac	gagggacgca gaggggtggc cgtggctgag aggagacagc gccgcagcac 120
tgagggtttg	ggcttgacagg cgctgcagga gacgcccagg cggagtcttg tctcgacagc 180
agctctgagc	gggaggcctg agcgggaagc attggcgtcc gagcgacttc taggagcctg 240
gggttcggcg	ctatggagga gctcgatggc gagccaacag tcaactgtaag ggtaccccga 300
acaggcttgc	tcgtccttgc ggggtgagaa ctgcgtctgc ttagttactt caggcttgtc 360
tgcttcccta	gtggtcgcga ggcgctcgtc cccttccctc gactcagttg ccacttttcc 420
ggaggtcgca	gtgttaacga gttgattcca ggcgtgaatt ccaagaagaa ccaaatgtat 480
tttgactggg	gtccagggga gatgctggta tgtgaaacct ccttcaacaa aaaagaaaaa 540
tcagagatgg	tgccaagttg cccctttatc tatatcatcc gtaaggatgt agatgtttac 600
tctcaaactc	tgagaaaact cttcaatgaa tcccatggaa tctttctggg cctccagaga 660
attgacgaag	agttgactgg aaaatccaga aaatctcaat tggttcgagt gagtaaaaac 720
taccgatcag	tcatacagagc atgtatggag gaaatgcacc aggttgcaat tgctgctaaa 780

53

```

gatccagcca atggccgcca gttcagcagc caggtctcca ttttgtcagc aatggagctc      840
atctggaacc tgtgtgagat tttttttatt gaagtggccc cagctggccc tctcctcctc      900
catctccttg actgggtccg gctccatgtg tgcgaggtgg acagtttgtc ggcagatggt      960
ctgggagctg agaatccaag caaacatgac agcttctgga acttggtgac catcttggtg     1020
ctgcagggcc ggctggatga ggcccgacag atgctctcca aggaagccga tgccagcccc     1080
gcctctgcag gcatatgccg aatcatgggg gacctgatga ggacaatgcc cattcttagt     1140
cctgggaaca cccagacact gacagagctg gagctgaagt ggcagcactg gcacgaggaa     1200
tgtgagcggg acctccagga cagcacattc gccaccagcc ctcacctgga gtctctcttg     1260
aagattatgc tgggagacga agctgccttg ttagagcaga aggaacttct gagtaattgg     1320
tatcatttcc tagtgactcg gctcttgtag tccaatccca cagtaaaacc cattgatctg     1380
cactactatg cccagtccag cctggacctg tttctgggag gtgagagcag cccagaaccc     1440
ctggacaaca tcttggtggc agcctttgag ttgacatcc atcaagtaat caaagagtgc     1500
aggaataaaa cagatttgag cagaagaagt ctgttggaat cagggagtat aaaaggggaa     1560
agcatcctgc tgtttccagt ggcagaagag aaagagaagt accatgaaga ggggtgaaca     1620
acatcactct cgtgccggac acagacaagg aatgattagg cttgcagtcc cccagtctca     1680
gcctctctcc actctcacia gcaggaaggg atctgagctc tgttagtggg aaatcttgga     1740
gtttgcattt ctctgatcac gaggctacct cctatcctgt tttgaaagag gaacagaaaa     1800
gcagagcttg tcccaggaat tgtgaaatgg gctgcaatgt cttcagaggc agtagcagtt     1860
ttaggaagtg tgccctcctg cctctgggga aaggttgaat tggggtcttg tgggcacttg     1920
ttttctcatg ggatgtatca gtcagacca tgacagttc tgggcggcag ggaagtgtgt     1980
ctctttctgg acttgagcca gtgagctgtt ggcattgcct tttaaaggca ttagaaaaaa     2040
ggtttctttc ttttttttcc tttcctgttc acaccacctt catatgaacg atgatgacat     2100
agagaccacc aaggtggaaa tgctgagact ttctctggca cgaaatcttg ctcgggcaat     2160
tataagagaa ggctcactgg aaggttcctg agaactgctt caatgtggta tctttgtatg     2220
gcaatgtata tagatTTTTT aaaagaataa atgttgTTTT gcaaatg                     2267

```

<210> 42
 <211> 415
 <212> DNA
 <213> Homo sapien

```

<400> 42
ctcgatgtaa cccccgacg tcttcacaaa ttaaatttca acacattctc tatgctagtg      60
tgacaaagca gcccataat ttggttttta ttgttgacct ttacaggatg aaggaggaga     120

```

54

atccccctgtg gcatroccaat gaatctttct ggtggggaca gctgacgagg ccacgcgggc	180
agagatccag atccgaatcg aggccaacga ggccctgggtg aaggccctgg agtaggcgga	240
catgtgttat ctacytcaag gtaacaagag tatgtggcaa acatatacca cccatagtgc	300
ttcacaaatg cacttctatt tagccagcgt ttattgtagt aaactattct taatagaagt	360
gcattttgtg aagcacacct cggccgcgac cacatccatc aactgogcc gctcg	415

<210> 43
 <211> 1805
 <212> DNA
 <213> Homo sapien

<400> 43	
acgtgcatgt tgaatcaatg caagagcgaa atggttgctg tgaaatccct ttaagaaact	60
acattattca agtaatgaaa atcactcagt tctacttcca gagaagaact gatgagaaag	120
gtctttaaca gtaattgaat ggaacaagaa gatagtatct ttctgggact gtgtgtctcc	180
tttggctctc tccctcctt cctgtcactg ttgcatacgg tggtttctgc aatggctgat	240
ccagtttgcc acattccact ccggctgctg tttctctgag attttcttga gtttttatca	300
aaccaatccc cagataaatc acaattgctc tagaacacca gccctcaggg taacatgtta	360
gaaattagct tgaaacccctc aattttgagg gtttcccatg actttttaaa cgttgcctt	420
cagtgtagcc ccttgctcct aaggaaagat ttattttcaa aatagttttc aaatggatgc	480
tcttctgtga tggagctaaa aaggaattat ttccatatta attaatgatg aattgaggat	540
gcctaagtat gaaatggaag acggttgat atttctctca aatgtctctg aaaatgaagt	600
gatgattatc attaacaaca atgtgataag aaattaatat aatttaaagc agcaagaaca	660
aaatccttct ttccgatagc tggggatttg gaaacttggc cctgctcaat gctgctgcta	720
cttcttgtgt cactatgaac ccacttttg gcctctctga gtctcaggta cccccacg	780
attagactac aaggccttat accgctctga cattaccagt caataactgt acaacagagt	840
ctaagggaat ctttttatct ctttgcagaa aacatgataa tattatttta attatttga	900
aatgcaggct tattatgcat gtgtttaaac aaagaaaatg tagcgtttct attaaatctt	960
tggattaaat atggttgtgt aatgaagtaa atgtcatgtg tatacactta acattctaaa	1020
aatttgtttc ttttaactta gaaaattcat agaaatgggt ttcatgtatg aaaaaagaat	1080
agccatatgg ggctggctct atggaggata cgtttcatca ctggcccttg catctggaac	1140
tggctctttc aaatgtggta tagcagtggc tccagtctcc agctgggaat attacgcgtc	1200
tgtctacaca gagagattca tgggtctccc aacaaaggat gataatcttg agcactataa	1260
gaattcaact gtgatggcaa gagcagaata tttcagaaat gtagactatc ttctcatcca	1320

55

```

cggaacagca gatgataatg tgcactttca aaactcagca cagattgcta aagctctggg 1380
taatgcacaa gtggattttcc aggcaatgtg gtactctgac cagaaccacg gcttatccgg 1440
cctgtccacg aaccacttat acaccacat gaccacttc ctaaagcagt gtttctcttt 1500
gtcagactaa aaacgatgca gatgcaagcc tgtatcagaa tctgaaaacc ttatataaac 1560
ccctcagaca gtttgcttat tttatTTTTT atgttgtaaa atgctagtat aaacaaacaa 1620
attaatgttg ttctaaaggc tgttaaaaaa aagatgagga ctcagaagtt caagctaaat 1680
attgtttaca ttttctggta ctctgtgaaa gaagagaaaa gggagtcatg ctttttgctt 1740
tggacacagt gttttatcac ctgttcattt gaagaaaaat aataaagtca gaagttcaag 1800
tgcta 1805

```

```

<210> 44
<211> 806
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (760)..(760)
<223> n=a, c, g or t

```

```

<220>
<221> misc_feature
<222> (772)..(772)
<223> n=a, c, g or t

```

```

<220>
<221> misc_feature
<222> (803)..(803)
<223> n=a, c, g or t

```

```

<400> 44
cgggcgggat cagcgagcgt cgcgatgtga tgacgtcagg ccccgacag gccgggagtg 60
gcgtgctggg cgtgcgcggc tgcggtacgg cgtgttggtc ccagcggttc agctgaggta 120
gggacgtgct gtaggcgga atgttaccgg ctgttggtc tgcggatgag gaggaggatc 180
ctgcggagga ggattgtcct gaattgggtc ccattgagac gacgcaaagc gaggaggagg 240
aaaagtctgg cctcggcgcc aagatcccag tcacaattat caccgggtat ttaggtgctg 300
ggaagacaac acttctgaac tatatTTTga cagagcaaca tagtaaaaga gtagcgggtca 360
ttttaaatga atttggggaa ggaagtgcgc tggagaaatc cttagctgtc agccaagggtg 420
gagagctcta tgaagagtgg ctggaactta gaaacggttg cctctgctgt tcagtgaagg 480
acagtggcct tagagctatt gagaatttga tgcaaaagaa ggggaaattt gattacatac 540

```

56

tgtagagac cactggatta gcagaccctg gtgcagtggc ttctatgttt tgggttgatg	600
ctgaattagg gaggatatt tatcttgatg gtatcataac tattgtggat tcaaaatatg	660
gattaaaaca tttaacagaa gagaaacctg atggccttat caatgaagct actagacaag	720
ttgctttggc agaaattggg cccccccca attttttttn ccctttttcc cnaaaatttt	780
tttttttaaa aaaaattttt ttnaaa	806

<210> 45
 <211> 6351
 <212> DNA
 <213> Homo sapien

<400> 45	
aaaaagaaaa aattgtcact gggtatcctt caggataaaa aattacaatt aaaattgtaa	60
tggtataacc ttccattctt tcccctatga attaaaactt ttttttttaa cgagactaaa	120
aatcaagtt gataaaatct atgccctgtg ggaactgggt aggtcaggct acccactcca	180
gatttccagc aggctggcct cagctctacc tacagccagt agcttattaa ggctctaggc	240
gccagtgaac ctttcagaca ggtggttagt gcgccctaag gactctccgc agcgtcgctc	300
aggttcacag aacacgcca ggggcgtgtc cagctgtcgt cggggagagc ccacctcccc	360
gggggggtgtg gctaagggaac gaggcagttc tcgtccagag ccaggtaat ccgggcggga	420
tcagctagcg tcgcgatgtg atgacgtcag gccccggcca ggccgggagt ggcgtgctgg	480
gcgtgcgcgg ctgcggtacg gcgtgttggg cccagcgggt cagctgaggt agggacgtgc	540
tgtaggccgg aatgttaccg gctgttgat ctgtggatga ggaagaggat cctgcggagg	600
aggattgtcc tgaattgggt cccattgaga cgacgcaaag cgaggaggag gaaaagtctg	660
gcctcggcgc caagatccca gtcacaatta tcaccgggta ttaggtgct gggaagacaa	720
cacttctgaa ctatattttg acagagcaac atagtaaaag agtagcggtc attttaaattg	780
aatctgggga aggaagtgcg ctggagaaat ccttagctgt cagccaaggt ggagagctct	840
atgaagagtg gctggaactt agaaacgggt gcctctgctg ttcagtgaag tgaggaatgt	900
gtttactgtg tacatgggtt actagaaatg tttattgatt atatttccag ctttaatttt	960
cttgagtaat ttaactgaat ttacacagtt tgcttcattg tattttcaaa caaatagaaa	1020
ataaacttat taggaagcat tttcttaaag tgtttcttgc tgtcttttct atctgctcta	1080
atgttttggg ctttttattg agtttttatt gcttttgatg tcagggtta tttaatctct	1140
agtgcataag agtctcatat gtaaaaaatg attattctga atttaattctg tcattgggtca	1200
tacttctaag tgttcaacct tataaaaaat aaatgactat caaaaaagaa aaaccttaca	1260
ttatgttcta gtagttaagt ttccaaggac agtgatcact agtctaccat agaccctaga	1320

agagttaccc aacacatagt agcactcaaa tatttgttga atgaattata aaaatgacta	1380
cttgtattgt taattttgtg tattctagtg aattaaatct cttcggcatc atttactccc	1440
ttaggtattht gacttttgtgt caaatgtttt ggcaaggata aaattataac agactttctt	1500
gaacaaccaa aatgtaatct attaaggatt ttccttcact tttgataaaa taagaaaaaa	1560
ggaatttaaa accttgcac ctaatgtaaa atagaattat atgggtgttt atatcagtgt	1620
cccttttagct attatattaa actactatag ttaataaatt ttatcattat tttgtatgtt	1680
ggtttttaaa aatttcataa agctataaaa agataacttg tcagataaag tttcctctgc	1740
ttttaatttt aataaagtat tattatgtat atgatttctt tttacctatt atatatatgc	1800
atctattgtt ttctcactgg taaatatggg acagacattt tgttagaagg ttagaagtga	1860
gttaaatttt cacattccta aggatacttt tgtctcgggt tgttgaatac attttaaagt	1920
gtttataata atcacttcaa aatatttagg taattaaactg taaattatgt tttgggtattc	1980
tccagggaca atggccttag agctattgag aatttgatgc aaaagaagg gaaatttgat	2040
gacatactgt tagagaccac tggattagca gaccctggta tcataactat tgtggattca	2100
aaatatggat taaaagtga ataccactaa aggcagaaga gaatgaaatc atcccacca	2160
ctgaccctgt cccaatctga gcatatggat agggcccaa gcagcaaaga attggacaac	2220
ttaaaatgac agctctctat tctgaggact tgacaccctg gctactgaca ttgttctttt	2280
cagttctaca aatgtgacag catttaatgc aatagaagca atgaatgaag ttaccagag	2340
aagcatttaa cagaagagaa acctgatggc cttatcaatg aagctactag gcaagttgct	2400
ttggcagata tcattctcat taataaaaca gacttgggtc cagaagaaga tgtaaagaaa	2460
ttaagaacga cacttagatc cataaatgga ctaggacaaa tcttagaaac acaaagatca	2520
aggctcagca gctgatagac tcagcaacag gcagccagga gctctgaggc tcacagctgg	2580
cagtctagtt ccaactcagtc tctacttgag aaattctttc tttggaagta cagcagaggc	2640
cttaggtgag tggcttgtct gctatggcag agattagagg tgctgacaga ctgccataag	2700
tattaggcag taacagcagc agctgcttat atgcatgtga acagctgggg aattaatttg	2760
gtatgcatte tcaggagcca ctcatctgct ggcagaggta gcagaagaat gcccttagtg	2820
taagtccctc acaaccatac accaaatgtg ctccctgcgt ttcaaattcc attgtagaga	2880
gtctctgata atctcactta taccatgagc cattcctcag tatctgtcct cttcctgtta	2940
gtgttctaca attcctttct ccttaatttt tctccgcttt acaaaatgtc acacagacaa	3000
gtgcatgata cttaaacaag cttttaaaaa taatgctcat aaatagcttt gggttctgtca	3060
taatattcgt atttataaac attttaagtc aattctcttc ttttattttc atttcagaaa	3120
tatccatgtc ctgaataaaa gttgtgtctt gattagttta ttatgtaaca atttagtgtg	3180

tttgacat	ttt	ctaact	tttta	tttcta	acat	ttgcttt	tatt	atagaaca	aat	aaacat	gcag	3240	
tgattgatt	tt	cttact	ttc	aagtgg	atga	gtgagca	agt	gactaaa	atc	ttctgt	gaat	3300	
tcttcagt	gt	atgggt	gcttg	ccaatg	catc	tgagaat	cta	gggact	tttct	gaaatag	tac	3360	
ttccttg	cta	tgaggact	ga	agttgg	atta	gaatcct	tttt	caatga	agat	cagatgt	cct	3420	
gagtaga	att	cttact	tattg	ggtcct	gaat	cttatatt	taa	atattct	ctc	aaattc	ccttg	3480	
agccacc	gcg	cccagc	ctgt	cctctg	tgat	tttctg	gggt	tatgtt	aaaa	ttataac	tca	3540	
atcaccag	tc	tttataa	aatt	tgcttt	tttta	tatttta	aaacc	aaaccta	aatg	ctaattg	tga	3600	
tatgttatt	tt	attctc	acct	gatttg	aatc	attggatt	tca	attaaat	gag	tttaatt	tac	3660	
attaaata	aat	tctaag	agaa	ataatg	tcta	ttcggat	gggt	gggaatt	tttc	tttctac	atg	3720	
cagcccc	att	ctgaat	gaat	gaaatc	aaat	cacgtga	cga	tcaggg	tcct	agagta	actt	3780	
aatatttt	gt	acattg	gtta	tttgact	cct	cattttt	tata	ttacat	gtta	tatcaag	gga	3840	
gggggtat	aa	aagaa	taca	aaaattg	cag	aggatat	ctgg	aatgtac	cta	tttgtt	aatt	3900	
ctatttg	tca	tttcttt	gggt	ttcatc	tttt	gagtaata	aag	ctgcttg	gaa	aagttt	ctgt	3960	
tctttag	ctg	atttttt	tagc	tataaaa	atg	tatttgaaa	a	gctcata	aat	ttcagg	attg	4020	
aaaagata	aat	tgaaag	ttta	aaaaaaa	acct	aattcatt	ga	agtaata	aacc	aaataat	tttt	4080	
caatcttg	at	tcaact	gtga	ttcaa	atctt	acaccatt	tg	cccact	tcta	tgaatt	tttat	4140	
gtataaaa	att	ttttaag	agt	cagagt	tttt	ttttcttg	at	taattg	gatg	tatttc	acag	4200	
aattttcc	aac	tgctcac	gtt	agtttt	cttc	cttttag	agt	tgatct	ctct	aatgtat	tag	4260	
atcttcat	gc	ctttgat	agt	ctctctg	gaa	taagttt	gca	gaaaaa	actt	cagcat	gtgc	4320	
caggaac	aca	acctcac	ctt	gatcag	agta	ttgttaca	aat	cacattt	gac	gtaccag	gaa	4380	
atgcaa	agga	agaacat	ctt	aatatg	ttta	ttcaga	atct	tctgtg	ggga	aagaat	gtga	4440	
gaaaca	agga	caatcact	gc	atggag	gtca	taaggct	gaa	ggtacag	ttt	actgtt	gcag	4500	
acttttg	gac	aaagt	ccttt	tcttg	gctgt	tataaaa	act	atatttg	ggt	ttaaac	agaa	4560	
acactg	ggtt	tagtaca	aat	catctt	tgtc	tactttc	att	tttctt	tatt	attttc	atga	4620	
ctgaaa	agga	gctttg	gaaa	tacttg	cata	aggcttg	att	tatttg	caca	actttc	ttta	4680	
gggttg	cagc	tagaaca	aaac	ctgtgt	gctt	tgaaat	gtta	ccttct	gctc	tctgtt	ccca	4740	
agtacag	aga	aataat	gttg	caa	atctc	ac	ttctg	ctgaa	cattat	gctt	cctgat	gcat	4800
ttagcag	aca	ctaaac	at	gttg	tact	ct	aaacaa	agtt	acaaag	gact	agaaga	at	4860
ttgttct	gta	tttagaa	acc	cactcac	att	acttgat	att	tgggtat	ttta	agtc	atgaaa	4920	
ggtat	ttct	ctagga	agca	gtgatt	ctaa	agtgtat	gct	taaccag	tca	gttgag	tgtc	4980	

59

tactcttgtg tgttcacaag tgtgcacaaa gtttttggta aattaagaat attatttcaa 5040
 ataaattaat ttcatcccca taggagccag tttatcagat aattcgtttc tcatttctgc 5100
 aaatcaatac acaatgagct catattccag ataaatataa tagtttttct ttatttcaac 5160
 attgttcatt gattgcaacc catttctaaa acaaattatt taatataacc aaactccttt 5220
 aacttctcaa cttttcccac taaaactgtg aaacattata taaaatcttt aatcaatagg 5280
 atatgatata tatttcatca ttttgtttca ggttttgggt gtgataaata aactgaaaa 5340
 accatcctaa tatatgtatt aactttatca ttagaaaagg ggattgttca aaaaaaatc 5400
 aatacacaga aacctttttt gaaaattaaa aacattaaga aacttcttgt aattcacaaa 5460
 taattggaat taagtaattt tctcagctta agagtgtgta ttttttaagt gaatatcagt 5520
 aattaatcca ttaacattga tgctctatct ctgcttttaa gtttgaactg aggctgatta 5580
 atgttcagtc aattctcctt tgagcaggat tgggtgtcaat caaagacaaa tcacaacaag 5640
 tgattgtcca ggggtgtccat gagctctatg atctggagga gactccagtg agctggaagg 5700
 atgacactga gagaacaaat cgattggctc tcattggcag aaatttagat aaggatatcc 5760
 ttaaacagct gtttatagct actgtgacag aaacagaaaa gcagtggaca acacatttca 5820
 aagaagatca agtttgtaca taacactaga ggcatttctt atcaaaagga ttggataata 5880
 aaaataagtt tctactgggt atatttcaag catttattta ttactttagt tacgaattcc 5940
 aatatacttt aaaatgggtat ttgttttaca gcatacataa aatgtagcaa atcagtactg 6000
 taaaacattt aacattcata caattatata taatatcctt ttttttaaag aatggatttt 6060
 cacaaaaata tcttttgaaa ttggcttttg agtttacata tactgaacat gaaagtttat 6120
 aataatgatg atacaacttt caacattgtc attttttctt agaacttcag ctgattgcag 6180
 agatataatg attacattgt tattaaattt ttttaacaca agtaagtgtc accattttat 6240
 gacatgaaat aaaagggtat gactgttaaa aaaaaaaatg gcctcttggc cctacggtgg 6300
 gtctcggccc ttcctttatg ggggtattca tgacctctc cttgccccgc a 6351

<210> 46
 <211> 5654
 <212> DNA
 <213> Homo sapien

<400> 46
 cgcaatcagt attttcatac atatttaaaa ttttccatcc atacaaagggt tgctaacata 60
 tttattttaa attttaaaaa taattttata tgctcttgt aaccagtaat aggatgcaaa 120
 gttttttttt aaggtaacat tgctcctctt cccccattgt ctctgtcatc tatagtactc 180
 cctgaggtag ttcatgttat tgcaagggtg tgtatcatca caaacatatt gcttccacat 240

60

acatatatca gcatacatat atatatatga gcacatatatta atatatgccc atgcacatac	300
aagcatgttt ttgttaattt ttactgaaat ggaatcatac tacataactta tgaacaaatt	360
gcttcttttca ccttatatca cttataattg ttattctaca aatcagtaca tataaaaaat	420
acataatttac atatgtaata ctctatcttt ctgttataat tttctgcatg cacatgtatg	480
catatacata tattcataaa cataaaactt aatctaaaacg ggattttttt ttgggggggt	540
gatatggttt ggctgtgtcc ccacccaaat ctcatcttga attcccatgt gttgtggggg	600
gacccggttg gaggtaattg aattatgggg gcaggtcttt cctgtgctgt tcttgggata	660
gtgaaaaagt ctcacaagat ctgatggttt taaaaagggtg agtttccctg cataatctct	720
cttctcctgt ctggttccat gtgagatgtg ccttttgcct tccgccatga ttgtgaggcc	780
tccccagcca tgcggacccg cccatagggtg gaagggactt gccttgtctc ggatgagact	840
ttggactttg gactgtggac ttttgagtta acactgaaat gaattaatgc tgaaatgaat	900
taagactttg ggagacgggt gagaagccat gactcatttt aaaatgtgag acatgccttt	960
caccttctgc catgattgtg aggcctctcc agccatgtgg aactgtgaac acacagtgtt	1020
catccctca ggaggacaca gcttttgagg taccatcttg gaagcagaga ccagccctca	1080
ctagacacaa acttcctggc acgttgattt tggacttcat agcctctaga actgtgctgg	1140
gaagacaaca cttctgaact atattttgac agagcaacat agtaaaagag tagcggtcac	1200
tttaaatgaa tctggggaag gaagtgcgct ggagaaatcc ttagctgtca gccaaagggtg	1260
agagctctat gaagagtggc tggaaacttag aaacggttgc ctctgctgtt cagtgaagtg	1320
aggaatgtgt ttactgtgta catggtttac tagaaatgtt tattgattat atttccagct	1380
ttaattttct tgagtaattt aactgaattt acacagtttg cttcattgta ttttcaaaca	1440
aatagaaaat aaacttatta ggaagcattt tcttaaagtg tttcttgctg tcttttctat	1500
ctgctctaata gttttggtcc ttttattgag tttttattgc ttttgatgtc agggcttatt	1560
taatctctag tgcataaaag tctcatatgt aaaaaatgat tattctgaat ttaatctgtc	1620
attggtcata cttctaagtg ttcaacctta taaaaaataa atgactatca aaaaagaaaa	1680
accttacatt atgttctagt agttaagttt ccaaggacag tgatcactag tctaccatag	1740
accttagaag agttacccaa cacatagtag cactcaaata tttgttgaat gaattataaa	1800
aatgactact tgtattgtta attttgtgta ttctagtga ttaaatctct tcggcatcat	1860
ttactccctt aggtatttga ctttgtgtca aatgttttgg caaggataaa attataacag	1920
actttcttga acaacaaaaa tgtaatctat taaggatttt ccttcacttt tgataaaaata	1980
agaaaaagg aatttaaaac cttgcatcct aatgtaaaat agaattatat ggtgtttaat	2040
atcagtgctc ctttagctat tatattaaac tactatagtt aataaatttt atcattattt	2100

tgtatgttgg	tttttaaaaa	tttcataaaag	ctataaaaaag	atacttggtc	agataaaagtt	2160
tcctctgctt	ttaatttttaa	taaagtatta	ttatgtatat	gatttctttt	tacctattat	2220
atatatgcat	ctattgtttt	ctcactggta	aatatgggac	agacattttg	ttagaaggtt	2280
agaagtgagt	taaattttca	cattcctaag	gatacttttg	tctcgggttg	ttgaatacat	2340
tttaaagtgt	ttataataat	cacttcaaaa	tatttaggta	attaactgta	aattatgttt	2400
tggatttctc	cagggacaat	ggccttagag	ctattgagaa	tttgatgcaa	aagaagggga	2460
aatttgatga	catactgtta	gagaccactg	gattagcaga	ccctgggtatc	ataactattg	2520
tggattcaaa	atatggatta	aaagtgaaat	accactaaag	gcagaagaga	atgaaatcat	2580
ccccccact	gaccggttcc	caatctgagc	atatggatag	ggcccaaagc	agcaaagaat	2640
tggacaactt	aaaatgacag	ctctctattc	tgaggacttg	acacccgggc	tactgacatt	2700
gttcttttca	gttctacaaa	tgtgacagca	tttaatgcaa	tagaagcaat	gaatgaagtt	2760
accagagaa	gcatttaaca	gaagagaaac	ctgatggcct	tatcaatgaa	gctactaggc	2820
aagttgcttt	ggcagatatc	attctcatta	ataaaacaga	cttgggttcca	gaagaagatg	2880
taaagaaatt	aagaacgaca	cttagatcca	taaatggact	aggacaaatc	ttagaaacac	2940
aaagatcaag	gctcagcagc	tgatagactc	agcaacaggc	agccaggagc	tctgaggctc	3000
acagctggca	gtctagttcc	actcagtctc	tacttgagaa	attctttctt	tggaggtaca	3060
gcagaggcct	taggtgagtg	gcttgtctgc	tatggcagag	attagagggtg	ctgacagact	3120
gccataagta	ttaggcagta	acagcagcag	ctgcttatat	gcatgtgaac	agctggggaa	3180
ttaattttggt	atgcattctc	aggagccact	catctgctgg	cagaggtagc	agaagaatgc	3240
ccttagtgta	agtcctctac	aaccatacac	caaatgtgct	ccctgcgttt	caaattccat	3300
tgtagagagt	ctctgataat	ctcacttata	ccatgagcca	ttcctcagta	tctgtcctct	3360
tcctgttagt	gttctacaat	tcctttctcc	ttaatttttc	tccgctttac	aaaatgtcac	3420
acagacaagt	gcatgatact	taaacaagct	tttaaaaaata	atgctcataa	atagctttgg	3480
ttctgtcata	atattcgat	ttataaacat	tttaagtcaa	ttctcttctt	ttattttcat	3540
ttcagaaata	tccatgtcct	gaataaaaagt	tgtgtcttga	ttagtttatt	atgtaacaat	3600
ttagtgtgtt	tgacatttct	aacttttatt	tctaacattt	gctttattat	agaacaataa	3660
acatgcagtg	attgattttt	cttacttcaa	gtggatgagt	gagcaagtga	ctaaaatctt	3720
ctgtgaattc	ttcagtgtat	ggtgcttgcc	aatgcatctg	agaatctagg	gactttctga	3780
aatagtactt	ccttgctatg	aggactgaag	ttggattaga	atccttttca	atgaagatca	3840
gatgtcctga	gtagaattct	tactattggg	tcctgaatct	tatattaaat	attctctcaa	3900

attccttgag ccaccgcgcc cagcctgtcc tctgtgattt tctgggctta tgttaaaatt	3960
ataactcaat caccagtctt tataaatttg cttttttata tttaaacc aaacctaagct	4020
aattgtgata tgttatttat tctcacctga tttgaatcat tggattcaat taaatgagtt	4080
taattatcat taaataattc taagagaaat aatgtctatt cggatgggtgg gaattttctt	4140
tctacatgca gccccattct gaatgaatga aatcaaatac cgtgacgac agggtcctag	4200
agtaacttaa tattttgtac attgggtatt tgactcctca tttttatatt acatgttata	4260
tcaagggagg ggggtataaaa gaaatacaaaa aattgcagag gtatctggaa tgtacctatt	4320
tgttaattct atttgtcatt tctttgggtt catcttttga gtaataagct gcttggaaaa	4380
gtttctgttc tttagctgat tttttagcta taaaaatgta tttgaaaagc tcataaattt	4440
caggattgaa aagataattg aaagttaaaa aaaaaccta ttcattgaag taataaccaa	4500
ataattttca atcttgattc aactgtgatt caaatcttac accatttgcc cacttctatg	4560
aattttatgt ataaaatttt ttaagagtca gagttttttt ttcttgatta attggatgta	4620
tttcacagaa tttccaactg ctacgcttag ttttcttctt tttagagttg atctctctaa	4680
tgtattagat ctcatgcct ttgatagtct ctctggaata agtttgacaga aaaaacttca	4740
gcatgtgcc ggaacacaa ctcaccttga tcagagtatt gttacaatca catttgacgt	4800
accaggaaat gcaaaggaag aacatcttaa tatgtttatt cagaatcttc tgtgggaaaa	4860
gaatgtgaga aacaaggaca atcactgcat ggaggtcata aggctgaagg gattgggtgc	4920
aatcaaagac aaatcacaa aagtgattgt ccagggtgtc catgagctct atgatctgga	4980
ggagactcca gtgagctgga aggatgacac tgagagaaca aatcgattgg tcctcattgg	5040
cagaaattta gataaggata tccttaaaaca gctgtttata gctactgtga cagaaacaga	5100
aaagcagtgg acaacacatt tcaaagaaga tcaagtttgt acataaact agaggcattt	5160
cttatcaaaa ggattggata ataaaaataa gtttctactg ggtatatttc aagcatttat	5220
ttattacttt agttacgaat tccaatatac tttaaaatgg tatttgtttt acagcataca	5280
taaaatgtag caaatcagta ctgtaaaaca tttaacattc atacaattat atataatatc	5340
ctttttttta aagaatggta tttcacaaaa atatcttttg aaattggctt tggagtttac	5400
atatactgaa catgaaagtt tataataatg atgatacaac tttcaacatt gtcatttttt	5460
cttagaactt cagctgattg cagagatata atgattacat tgttattaaa tttttttaac	5520
acaagtaagt gtcaccattt tatgacatga aataaaagg ttagactgtt aaaaaaaaaa	5580
atggcctctt ggccctacgg tgggtctcgg cccttccttt atgggggtat tcatgaccct	5640
ctccttgccc cgca	5654

<210> 47
 <211> 1678
 <212> DNA
 <213> Homo sapien

<400> 47
 agcggcctttg cttccgcggc ggggccggaa gtaggagcgg cggcggcggc ggcggcggcg 60
 gtcgaaagcg gaggtaaaga gggaggcagg gagccggaga gccggaaccg gagtgcgagc 120
 ggcggagacc cctgtgcggc gcggaggggg cggcggcccc gactctgacc cgcgccgggg 180
 gtggggccatg gcggagatca gcgacctgga cgggcagatc gagcagctgc gtcgctgcga 240
 gctcatcaag gagagcgaag tcaaggccct gtgcgctaag gccagagaga tcttggtaga 300
 ggagagcaac gtgcagaggg tggactcgcc agtcacagtg tgcggcgaca tccatggaca 360
 attctatgac ctcaaagagc tgttcagagt aggtggcgac gtccctgaga ccaactacct 420
 cttcatgggg gactttgtgg accgtggctt ctatagcgtc gaaacgttcc tctgtctgct 480
 ggcaacttaag gttcgctatc ctgatcgcat cacactgac cggggcaacc atgagagtcg 540
 ccagatcacg caggtctatg gcttctacga tgagtgcctg cgcaagtacg gctcggtgac 600
 tgtgtggcgc tactgcactg agatctttga ctacctcagc ctgtcagcca tcatcgatgg 660
 caagatcttc tgcgtgcacg ggggcctctc cccctccatc cagaccctgg atcagattcg 720
 gacaatcgac cgaaagcaag aggtgcctca tgatggggcc atgtgtgacc tcctctggctc 780
 tgaccacagaa gacaccacag gctggggcgt gagccccga ggagccggct acctatattg 840
 cagtgcagtg gtggcccagt tcaacgcagc caatgacatt gacatgatct gccgtgocca 900
 ccaactggtg atggaagggt acaagtggca cttcaatgag acggtgctca ctgtgtggctc 960
 ggcacccaac tactgctacc gctgtgggaa tgtggcagcc atcttgagc tggacgagca 1020
 tctccagaaa gatttcatca tctttgaggc tgctcccaa gagacacggg gcaaccccg 1080
 cgggccctg cccctccaa cccttctggc cctcgcacca ctgtgactct gccatcttcc 1140
 tcagacggag gctgggcgtg ggggggggct gtcctggctc tgctgtcccc caagaggggtg 1200
 cttcgagggg gaggacttct ctggagaggc ctggagacct agctccatgt tcctcctcct 1260
 ctctcccccac ttgaaccatg aagtttccaa taatTTTTTT ttctTTTTTT ccttctTTTT 1320
 tctgtttgtt tttagataaa aattttgaga aaaaaaatga aaaaattcta ataaaagaag 1380
 aaaaatggtt tttgggtttg tgccagactt ggttggaat gcacaggggt gctggcctgg 1440
 gacctggggg ggacgtcagg gccttgactg cctcagggcc ccgacctgcc aagagggcca 1500
 ggctcaggcc agtcagcttg ccagggcct ccaggggccc ctgcctgctg gcttccccag 1560
 ccctagggag agggctctgt tctcatgggc agccttatct tattaacagc atacacacac 1620
 aggcacacac agaatcacag gattctgatt tctccatttt cctgaagagg agatgggc 1678

<210> 48
 <211> 1437
 <212> DNA
 <213> Homo sapien

<400> 48
 catcacagcc acacacaagc acacgaggcc tctgctccat cacagccaca cacatacaga 60
 cacacacatg cagacacaca catgcagccg ctgctccaca gtcactccgg acctccctgt 120
 gacaacacag ggtgcccttc tgtctctggg agtgccctt tcaactcttat gtgctgtttg 180
 gacggggatt gtatgatcac tgtgattatg agggggcccc aggcatggg cgttctttct 240
 cctctggagc ttatctgccc ctacatttgc tgtcctggtc cccgccatcc cacagaccat 300
 attcaggccc catgctctgg tcccacgggc ctctggtgga cttggggagg ggccaggctg 360
 ctcaccctca aggggcagcg ctggcagcca gagaagcctg aggacatccc tctccatccc 420
 tccctttccg catcagacac cacaggctgg ggcgtgagcc cccgaggagc cggctaccta 480
 tttggcagtg acgtggtggc ccagttcaac gcagccaatg acattgacat gatctgccgt 540
 gccaccaaac tggatgatga aggttacaag tggcacttca atgagacggt gctcactgtg 600
 tggtcggcac ccaactactg ctaccggtga gccggctggg ccgggctggg atgggcgggc 660
 atctgagccg agctgctcct gaccctgctg ccccgccctc cagctgtggg aatgtggcag 720
 ccatcttgga gctggacgag catctccaga aagatttcat catctttgag gctgctcccc 780
 aagagacacg gggcatcccc tccaagaagc ccgtggccga ctacttcctg tgaccccgcc 840
 cggcccctgc cccctccaac ccttctggcc ctgcaccac tgtgactctg ccatcttctc 900
 cagacggagg ctgggcgtgg gggggggctg tcctggctct gctgtcccc aagaggggtg 960
 ttcgaggggtg aggacttctc tggagaggcc tggagacctg gctccatgtt cctcctcctc 1020
 tctccccact tgaacatga agtttccaat aatttttttt tctttttttc cttctttttt 1080
 ctgtttgttt ttagataaaa attttgagaa aaaaaatgaa aaaattctaa taaaagaaga 1140
 aaaatggttt ttgggtttgt gccagacttg gttgggaatg cacagggttg ctggcctggg 1200
 acctggggtg gacgtcaggg ccttgactgc ctgaggcccc cgacctgcca agagggccag 1260
 gctcaggcca gtcagcttgc ccagggcctc caggggcgcg tgccctgctg cttccccagc 1320
 cctagggaga gggctctgtt ctcatgggca gccttatctt attaacagca tacacacaca 1380
 ggcacacaca gaatcacagg attctgattt ctccattttc ctgaagagga gatgggc 1437

<210> 49
 <211> 2785
 <212> DNA
 <213> Homo sapien

<400> 49
 ccggcctggc tcccagcgct ccctgtcccc gccccgcggc cagctcgctc cactcccaact 60
 tcctgagctc cgccgtggga gccctggagg cccggcctgg ccgctcccgg ccctgggggtg 120
 cacatcgggc ctgagtcccg tcccaggctc tgggctcggg cagccgcccgc caccgctgcc 180
 caggacgtcg ggccctcctgc ctctctccca ggcccccaag ttgctggccg cctggccgag 240
 tggccgccaat gctcctgcct tgggccacct ctgcccccg cctggcctgg gggcctctgg 300
 tgctggggcct ctccgggctc ctggcagcat cgcagcccca ggcggtgcct ccatatgcgt 360
 cggagaacca gacctgcagg gaccaggaaa aggaatacta tgagccccag caccgcatct 420
 gctgctcccg ctgcccgcga ggacacctatg tctcagctaa atgtagccgc atccgggaca 480
 cagtttgtgc cacatgtgcc gagaattcct acaacgagca ctggaactac ctgaccatct 540
 gccagctgtg ccgcccctgt gaccagtgga tgggcctcga ggagattgcc cctgcacaa 600
 gcaaacggaa gaccagtgcc cgctgccagc cgggaatgtt ctgtgctgcc tgggccctcg 660
 agtgtacaca ctgcgagcta ctttctgact gccgcctgg cactgaagcc gagctcaaag 720
 atgaagttgg gaagggtaac aaccactgcg tcccctgcaa ggcagggcac ttccagaata 780
 cctcctcccc cagcgcccg cgcagcccc acaccaggtg tgagaaccaa ggtctggtgg 840
 aggcagctcc aggcactgcc cagtccgaca caacctgcaa aaatccatta gagccactgc 900
 cccagagat gtcagaacct gccctgagca aggggggtgga gaacttgcaa gccctgctct 960
 accaggcggc cacaggcagt tccgaagcaa gtttccttac tctctcacc ctgtaaacac 1020
 cccacaggt acaggtacag cagggaacc ctagctctc tacagcagcc cctctgtaca 1080
 atggctgagg ccacagaaat gtggctctag cctgtgtctg tttaactc caagtccac 1140
 ccttccttac tgtctccaa tccacttcc agacctgaa aatcaactgc ctaagctccc 1200
 atcctgcaca cacaagcctg cccaatcctg gtctctgagc aggagggcac ccacaccacc 1260
 cccaaacatg cccatccatg atacagtctc tcctggctgc caagaggtcc tcaagtccaa 1320
 cttagtctcc cttctctata acccaaggga agtttctctc attctgcctt taggagctgc 1380
 attgtgtcta gaaggaaaa agctgctccc ttttctctgt ctgggttgcc cagggatctg 1440
 gaaagctctt cttctctc cctccctctg cccttcttgg ggctgtgatc accctcctgt 1500
 ctgctgtcct ggcaggaacc atgctgatgc tggccgttct gctgccactg gccttcttct 1560
 tgctccttgc caccgtcttc tcctgcatct ggaagagcca cccttctctc tgcaggaaac 1620
 tgggatcgct gctcaagagg cgtccgcagg gagagggacc caatcctgta gctggaagct 1680
 gggagcctcc gaaggcccat ccatacttcc ctgacttggg acagccactg ctacccatct 1740
 ctggagatgt ttcccagta tccactgggc tccccgcagc ccagttttg gaggcagggg 1800

tgccgcaaca gcagagtcct ctggacctga ccagggagcc gcagttggaa cccggggagc 1860
 agagccaggt ggcccacggt accaatggca ttcatgtcac cggcgggtct atgactatca 1920
 ctggcaacat ctacatctac aatggaccag tactgggggg accaccgggt cctggagacc 1980
 tcccagctac ccccgaacct ccatacccca ttcccgaaga gggggaccct ggccctcccg 2040
 ggctctctac accccaccag gaagatggca aggcttggca cctagcggag acagagcact 2100
 gtggtgccac accctctaac aggggcccac ggaaccaatt tatcacccat gactgacgga 2160
 gtctgagaaa aggcagaaga agggggggcac aagggcacct tctcccttga ggctgccctg 2220
 cccacgtggg attcacaggg gcctgagtag ggcccgggga agcagagccc taagggatta 2280
 aggtcagac acctctgaga gcaggtgggc actggctggg tacggtgccc tccacaggac 2340
 tctccctact gcctgagcaa acctgaggcc tcccggcaga cccaccacc cctggggct 2400
 gctcagcctc aggcacggac agggcacatg ataccaactg ctgcccacta cggcacgccc 2460
 caccggagca cggcacggag ggagccgcca cacggtcacc tgcaaggacg tcacggggccc 2520
 ctctaaagga ttcggtgtgc tcatcccaa gcttcagaga ccctttggg ttccacactt 2580
 cacgtggact gaggtagacc ctgcatgaag atgaaattat agggaggacg ctccctccct 2640
 cccctcctag aggagaggaa agggagtcat taacaactag ggggttgggt aggattccta 2700
 ggtatgggga agagttttgg aaggggagga aaatggcaag tgtatttata ttgtaaccac 2760
 atgcaaataa aaagaatggg accta 2785

<210> 50
 <211> 2871
 <212> DNA
 <213> Homo sapien

<400> 50
 ccggcctggc tcccagcgt cctgtcccc gcccgcggc cagctcgct cactcccaact 60
 tcctgagctc cgccgtggga gccctggagg ccggcctgg ccgctcccgg cctgggggtg 120
 cacatoggcc ctgagtccc tcccaggctc tgggctcggg cagccgccgc caccgctgcc 180
 caggacgtcg ggctcctgc cttcctccca ggccccacg ttgctggccg cctggccgag 240
 tggccgccat gctcctgcct tgggccacct ctgcccccg cctggcctgg gggcctctgg 300
 tgctgggcct cttcgggctc ctggcagcat cgcagcccca ggcggtgcct ccatatgcgt 360
 cggagaacca gacctgcagg gaccaggaaa aggaatacta tgagccccag caccgcatct 420
 gctgctcccg ctgcccgcga ggcacctatg tctcagctaa atgtagccgc atccgggaca 480
 cagtttgtgc cacatgtgcc gagaattcct acaacgagca ctggaactac ctgaccatct 540
 gccagctgtg ccgccctgt gaccagtgga tgggcctcga ggagattgcc cctgcacaa 600

gcaaacggaa gaccagtgcc cgctgccagc cggaatgtt ctgtgctgcc tgggccctcg	660
agtgtacaca ctgcgagcta ctttctgact gcccgctgg cactgaagcc gagctcaaag	720
gtcagaggtc cctgaggggc tggatgtgaa aaggaggctg ggtgccaggg atctcaagtg	780
ggagcaggga atatggtact gtgtccacgg cgacccccca gatccttggc ttaaaattcc	840
tcttctcatt ccatgcagag gctcacagaa gggttctgga gggacatgga actgggacag	900
gtgcagggga cacaggaggt ggttcttctc agtactggga agcttgggca aaatggtagg	960
cagtaggccg ggtgtggtgg cccacgcctg taatcccagc actttgggag gccgaggtgg	1020
gcggatcacg aggtcaggag atcgagacca tcctggctaa cacagtgaac ccccgctctc	1080
actaaaaata caaaaaatta gccgggcgtg gtggtgggag cctgtatccc agctactcgg	1140
gaggctgagg caggagaatg gcgtgaactt gggaggcgga gcttgacagt agccgagatc	1200
gcgccactgc actccagcct gggcgacaga gcaagactcc gtctcaaaaa aaaaaaaaaa	1260
aaaggcagca aagcagagct tgggaaaggc gagagctacg caatgggggtg gatgggcatc	1320
ctgaggctta aaggaaactc acaggccggc aaaggggccc tcccttttgc ccattcaccc	1380
tggctggcct gcctttctct tgccagatga agttgggaag ggtaacaacc actgcgtccc	1440
ctgcaaggca gggcacttcc agaatacctc ctccccagc gcccgctgcc agccccacac	1500
cagggtgtgag aaccaaggct tgggtggaggc agctccaggc actgcccagt ccgacacaac	1560
ctgcaaaaat ccattagagc cactgcccc agagatgtca ggaaccatgc tgatgctggc	1620
cgttctgctg cactggcct tctttctgct ccttgccacc gtcttctcct gcattctggaa	1680
gagccaccct tctctctgca ggaaactggg atcgctgctc aagaggcgct cgcagggaga	1740
gggacccaat cctgtagctg gaagctggga gcctccgaag gcccatccat acttccctga	1800
cttgggtacag cactgctac ccatttctgg agatgtttcc ccagtatcca ctgggctccc	1860
cgcagcccca gttttggagg caggggtgcc gcaacagcag agtcctctgg acctgaccag	1920
ggagccgcag ttggaaccgc gggagcagag ccagggtggc cacggtacca atggcattca	1980
tgtcaocggc gggctctatga ctatcactgg caacatctac atctacaatg gaccagtact	2040
ggggggacca ccgggtcctg gagacctccc agctaccccc gaacctccat accccattcc	2100
cgaagagggg gaccctggcc ctcccggtct ctctacaccc caccaggaag atggcaaggc	2160
ttggcaccta gcggagacag agcactgtgg tgccacaccc tctaacaggg gcccaaggaa	2220
ccaatttatc acccatgact gacggagtct gagaaaaggc agaagaaggg gggcacaagg	2280
gcaccttctc ccttgaggct gccctgcccc cgtgggatcc acaggggcct gagtagggcc	2340
cggggaagca gagccctaag ggattaaggc tcagacacct ctgagagcag gtgggcactg	2400

68

gctgggtacg	gtgccctcca	caggactctc	cctactgcct	gagcaaacct	gaggcctccc	2460
ggcagaccca	cccaccccct	ggggctgctc	agcctcaggc	acggacaggg	cacatgatac	2520
caactgctgc	ccactacggc	acgccgcacc	ggagcacggc	accgagggag	ccgccacacg	2580
gtcacctgca	aggacgtcac	gggcccctct	aaaggattcg	tggtgctcat	ccccaagctt	2640
cagagaccct	ttggggttcc	acacttcacg	tggactgagg	tagaccctgc	atgaagatga	2700
aattataggg	aggacgtccc	ttccctcccc	tcctagagga	gaggaaaggg	agtcattaac	2760
aactaggggg	ttgggtagga	ttcctaggtg	tggggaagag	ttttggaagg	ggaggaaaaat	2820
ggcaagtgtg	tttatattgt	aaccacatgc	aaataaaaag	aatgggacct	a	2871

<210> 51
 <211> 1214
 <212> DNA
 <213> Homo sapien

<400> 51	
aagaagaggg	agggagggag agagaaaaaa gggctctgggg ccctcatcat tgtttgggtc 60
tccatctctt	tcctgcaggg agagggaccc aatcctgtag ctggaagctg ggagcctccg 120
aaggcccatc	catacttccc tgacttggtg cagccactgc taccatttc tggagatgtt 180
tccccagtat	ccactgggct ccccgagcc ccagttttgg aggcaggggt gccgcaacag 240
cagagtccct	tggaacctgac caggagccg cagttggaac ccggggagca gagccaggtg 300
gcccacggta	ccaatggcat tcatgtcacc ggcggtgcta tgactatcac tggcaacatc 360
tacatctaca	atggaccagt actgggggga ccaccgggtc ctggagacct ccagctacc 420
cccgaacctc	catacccat tcccgaagag ggggacctg gccctcccgg gctctctaca 480
ccccaccagg	aagatggcaa ggcttggcac ctagcggaga cagagcactg tggtgccaca 540
ccctctaaca	ggggcccaag gaaccaatct atcaccatg actgacggag tctgagaaaa 600
ggcagaagaa	ggggggcaca agggcacctt ctcccttgag gctgccctgc ccacgtggga 660
ttcacagggg	cctgagtagg gcccggggaa gcagagccct aagggattaa ggctcagaca 720
cctctgagag	caggtgggca ctggctgggt acggtgccct ccacaggact ctccctactg 780
cctgagcaaa	cctgaggcct cccggcagac ccacccaccc cctggggctg ctcagcctca 840
ggcacggaca	gggcacatga taccaactgc tgcccactac ggcacgccgc accggagcac 900
ggcacccagg	gagccgccac acggtcacct gcaaggacgt cacgggcccc tctaaaggat 960
togtgggtg	ctcatcccaag cttcagagac cctttggggg tccacacttc acgtggactg 1020
aggtagaccc	tgcatgaaga tgaaattata gggaggacgc tccttccctc ccctcctaga 1080
ggagaggaaa	gggagtcatt aacaactagg ggggtgggta ggattcctag gtatggggaa 1140

69

gagtttttgggaggaggaggaa aatggcaagt gtattttatat tgtaaccaca tgcaaataaa 1200
aagaatggga ccta 1214

<210> 52
<211> 4667
<212> DNA
<213> Homo sapien

<400> 52
tgggggggagg ggggaagacga agcttgaaag acttggtaat ggcgacgggt ttgtcagagc 60
accataacat ggtgtgggaa gtgaagacaa atcagatgcc taatgcagta cagaaactcc 120
tgttgggtgat ggacaagaga gcctcaggaa tgaatgactc attggagttg ctgcagtgtgta 180
atgagaattht gccatcttca cctggatata actcctgtga tgaacacatg gagcttgatg 240
accttcctga acttcaggca gttcaaagtgt atcctaccca atctggcatg taccagctga 300
gttcagatgt ttcacatcaa gaatacccaa gatcatcttg gaacccaaat acctcagaca 360
taccagaaac tacttaccgt gaaaatgagg tggactggct aacagaattg gcaaatatcg 420
cgaccagtcc acaaagtcca ctgatgcagt gctcatttta caatagatca tctcctgtac 480
acatcatagc cactagcaaa agtttacatt cctatgcacg cctccacca gtgtcctctt 540
cttcgaagag tgaaccagcc ttccctcatc accattggaa ggaggaaaca ccagtaagac 600
acgaaagggc aaatagttag tcagaatctg gcattttctg catgtcctcc ctgtcagatg 660
atgatgattt gggatgggtgc aattcctggc cttcaactgt ctggcactgt tttttgaaag 720
ctatgacttc acacctatgg attcttctgc agtttatgtg ttaagtagta tggctcgcca 780
gcgtcggtgca tctttgtctt gtggaggacc tgggtgggtcaa gactttgcaa gatctggatt 840
cagtaaaaaac tgtgggtcac ctggatcatc acagctctct tccaattctt tgtatgctaa 900
agctgtcaaa aaccacagct cagggactgt gagtgccact tctcctaata agtgcaaaag 960
accaatgaat gccttcatgc tttttgcaa aaaatacaga gttgaatata ctcatatgta 1020
tccagggaaa gataacaggt aaaaatagtgt ataattctga ttacaataaa tgagtaaacac 1080
ttcaatacgg ttcattggtaa ctggaatagt taagtaaaact tattctttaa tagcttttat 1140
tcaactctta ggttgacttt tttgtttgtt tttgagacgg agtctcgctg tgtcacccaa 1200
gctggagttc agtggtacga tctcagctca ctgcaacctc cgccttcag gttcaaagcc 1260
ataagtgtga tccttgggtga cagggtggaag aaaatgaaga atgaagagag aagaatgtac 1320
acattagaag caaaggcttt ggctgaagaa cagaaacggt taaatcctga ctgttggaag 1380
aggaaaagaa ccaattcagt atgtttcaat aaatagtgtt taaaattatc ttgccttata 1440
cgtgcagggtg tactggcatg ttggagcagt tgttacaacc ttaagaggt tgtgttgatg 1500

ctgtctctag	catttttata	cttcaaaacc	taataatggt	atcacatcat	catataaaga	1560
ctgcctttcc	tcaaggggtca	tttactctca	tagcatggca	agtcgaaatc	tcaggcaaac	1620
ttcaaaagaa	tgtttggtct	aaacattgag	ttggaaaaat	aattttggaa	tgcagtgttt	1680
ctagttgggt	tgaaagataa	gcattattaa	tccattaata	tcacagtaga	aaattttctct	1740
aataattttg	ggattgtctc	aacagctttt	tttccttaat	tgggtgaggga	ccaataaggc	1800
tggagggtgt	ggggtatggt	agctgtcatt	catggggact	tgtgccattg	gcacagaatt	1860
tctagattga	aaaatttcaa	ggaggagaag	aaataggccc	aggaatgggtg	gcaaaacaagt	1920
ctatatgata	agctatcttg	gatagacttg	tttcttataa	cttttccatt	actaaactag	1980
catcttttag	gttcagcgtt	tttagattaa	ttgcaaaaaa	attacatgtg	atatagtggg	2040
gtcaatttga	agtatcattg	aaagatgaag	ggaagatatc	aatattttta	tagtagggagg	2100
gctggccaaa	gatgttttaa	attcattgtg	tacatgtgcc	tgtttcttag	taaaatgcag	2160
gtcatatctg	tttaaatttt	tcacaatttc	tttaaaaaata	gtggtcagtc	agtagtcaga	2220
tgagaggggtg	gctgaactga	attttggcag	ttcttggtta	atrtagaatt	tcatgtgttc	2280
ggacttttcc	tgtatccctt	ttctgttcat	cctagtcaat	gtcttatcat	tgcatacatt	2340
ttctggatgc	ttgagccatc	agatatcagc	tagcttttta	aaatcacctt	taagaagca	2400
gtatttttcta	atagtaaatt	tataaacatc	ttatacatct	tagcttttcat	atataggatt	2460
actatgtatt	gatttgtaaa	cattcactga	gtttaatttt	atrtccacag	ggctcacaac	2520
aacattaaac	caggatgctt	atgttcttaa	gtctatatatt	gcatatacat	tgactcttga	2580
tggaaagact	taagaagatc	aagggtctcac	catttgtcct	caattcgtgt	gaccataaga	2640
tactgatagc	attgagtctt	gaaatgattt	aataatatga	gtgaggattt	gctttctcca	2700
ttagagcatt	aagctaaaac	tatcaacatt	ttaaaccaa	ttgccttatt	tttcttccaa	2760
acttcatata	tgtctatcag	gtaataatag	gcttgaaaat	tgatatcctg	tggtgctaaa	2820
gtacagtaga	aagagaggag	aagtgtatac	atgttttatt	ttaaattgta	cgaaagggga	2880
atrtaaaaaa	tatgtaactg	ctgtttatac	attggctcct	tactgcttat	taatctgtat	2940
tgtacacatg	atgaaatgaa	gcagaagctg	ggagtgggcc	tttcctctag	taaccaccac	3000
atggctcagc	atctgtgcca	aacataggcg	ctcctagtct	ggtcagtgcc	aagaggctac	3060
cagaacatgg	ggcaggtggc	tggtgttggt	gtcccagcct	aagagccacc	tgctgcagtt	3120
accatggcat	gctgagttga	tgccaccagg	ggcagcagcc	atccgttatt	atrtccaatg	3180
gagacctagc	ccaggccaag	gtaaagttag	ttaatagcat	tgggatatag	tactgttaat	3240
ggtgctatta	acaaacagtc	aacaccattg	tatrttttta	cttcgtgttc	tgtatctcct	3300
cagccatgta	tcttaaatat	atrttgtcat	cataatcttt	atgggtggggg	cagactttgc	3360

71

```

acttactgca gtgcaacact tgcactttaa ttttcctcca actgtctaaa attagagcaa 3420
atacattggc aatacagctg cttttgctct gagctacaat catggctttt catgttactt 3480
accaagtggg gtttctgggt aggaatcaca gctgtaaaat tgatttcagt tcatcacact 3540
tcttcatgat gttgccccta aattttgcac actataattct tgtatattat ttcaaataaa 3600
tggaaaaaaa agttgcttat ctctgacgtc tactgattga ttgattgatt gattaatctt 3660
ggctgaatth tatttatgag ttctcagaat aacagggttca ggagatgaga tggaaaacat 3720
aaggcaaat cctaacactg ctaattagga ggctgctgat aggattttta aaattaaaaa 3780
caatgttaat agtggaaaca gagccatcag aaaataagga cttagattat ctactattta 3840
tagagaattg ctatacaata aaaatthtta tttttcacgt ggcattthttg ttacacgggt 3900
aaacagccca aagggtctgct ttaataaca tgacaaagt taacaaaagc cttgctthtat 3960
ttaagatcc agtatgacat acttaaaaag gccatttaac cttgtatctt agcttgggat 4020
gtgccagtgg ttctcaact ttgttgtcta ttggaatcat tttggggatt tttttthttt 4080
taatagtggg gtctgtcagg ctcccactcc tagacatgtt aattaatgtg gagtgcaagt 4140
tgggcatcag gattthtaaa aaatcccctg gtgattggta tgaatgtgca gccaaatthg 4200
gaaaccactg agctacatgc ttatttagtg aagaaggcag ggttggggga agcagggtac 4260
atgttataac ttgatcatat ccctthtaaa gaagtgggga ctttgggttt atgtacccat 4320
aggaggactt ggttatggat gggaaagaca ttttagcctt gtacaaaaat ctgaaagagg 4380
aaaacatctt tctggaaaaa tcagggtccat ggaattgaaa ggtggtgata actcaacatt 4440
ttttatgcta aagtataagt gctaaagagg taaataaacg tcgataggaa ataccgaaca 4500
atcaattaca ttctthaaat agtagatagt agcagtcctt tggagtatgt gtttaactgc 4560
caactatgaa tgggttagca caaagtggag atgaacaaag atttcatgtc attactgaag 4620
agcagacata gcctthtgaa gcagctgaac cattatggga taaactg 4667

```

```

<210> 53
<211> 1829
<212> DNA
<213> Homo sapien

```

```

<400> 53
gcgcggggaa ccggcgtggg gtcacgtggg accggcgcat cacgtgggag agttaggtga 60
cgctgcgggg cgggcggaca gactgcggga cggacgggtg acgctgggac gcgtttgtag 120
ctccggcccc gccgttccga ccccgccgc cgtcgccgcc atgacggggc tagcactgct 180
ctactccggg gtcttcgtgg ccttctgggc ctgcgcgctg gccgtgggag tctgtacac 240
cattthtgat ttgggcttcc gctthtgatg ggcattgggt ctgacggaga ctgcgccctt 300

```

```

catgtggtcc aacctgggca ttggcctagc tatctccctg tctgtggttg gggcagcctg      360
gggcatctat attaccggct cctccatcat tgggtggagga gtgaaggccc ccaggatcaa      420
gaccaagaac ctggtcagca tcatcttctg tgaggctgtg gccatctacg gcatcatcat      480
ggcaattgtc attagcaaca tggctgagcc tttcagtgcc acagacccca aggccatcgg      540
ccatcggaac taccatgcag gctactccat gtttggggct ggcctcaccg taggcctgtc      600
taacctcttc tgtggagtct gcgtgggcat cgtgggcagt ggggctgccc tggccgatgc      660
tcagaacccc agcctctttg taaagattct catcgtggag atctttggca gcgccattgg      720
cctctttggg gtcacgtcgc caattcttca ggtgatgaat ccccttggga agcctctgtg      780
tccttgtccc caacctagcc ttacctcct tctggagaag ctgaagtgtc ctccctctct      840
acctataact atagattccc ccaaacagct tccacctcct catttccatc ttctggtttt      900
ctcctacagg ggctctctat ttttgtctct gatttgggtg cactgacaac agccctgttc      960
tttttccccc ctttctaata cgttgtatct gtatagcact tagtcctccc tctttctgtt     1020
ctctcatttt atctgccatg cttttcatgt ctccagtctg tatttgtgat ctagactaga     1080
atggaatttt gtctgtctat atcagtctgt catggtgtgt ttgactgtct ctcgagctta     1140
tgtgtatctc cctctcacat gcctgtcagt aggacaccat tgtctaaatt gtgtgtgtct     1200
agtctgtctg acagtgtgtg agtttgtgac taaggatcag cctgagggtc tgagtgtgac     1260
tgtgggtgct tgactgagtt gattcttagt gactagcttt atccatatgc cacttctctc     1320
cgtctgtccc acagcgtaac tctgtggttg tctgtccctg tctgccttgt ctgtcacagt     1380
gtgtccatcc tggtagtca tatactctct gtggtctgtc catccaacca tgtgctagat     1440
gtcatcttct atcatttgtc actgccttac ctattcctct gtccctgcct gatttctcct     1500
gttctttttt tgcaacctcc agagtgaaga tgggtgacta gatgatatgt gtgggtgggg     1560
cogtgcctca cttttattta ttgctgggtt tctctgggaca gctggagctg tgtcccttag     1620
cctttcagag gcttgggtgt cagggccctc cctgcactcc cctcttgctg cgtgttgatt     1680
tggaggcact gcagtccagg ccgagtcctc agtgcgggga gcaggctgct gctgctgact     1740
ctgtgcagct gcgcacctgt gtccccacc tccacctca acccatcttc ctagtgtttg     1800
tgaaataaac ttggtatttg tctgggtca                                     1829

```

```

<210> 54
<211> 2679
<212> DNA
<213> Homo sapien

```

```

<400> 54
cagaaaccag ggggagaagg cggccgagcc ccagctctcc gagcaccggg tcggaagccg      60

```

cgacccgagc	cgcgccaggaa	gctgggaccg	gaacctcggc	ggacccggcc	ccacccaact	120
cacctgcgca	ggtcaccagc	accctcgga	cccagaggcc	cgcgctctga	aggtgacccc	180
cctggggagg	aaggcgatgg	cccctgcgag	gacgatggcc	cgcgcccgc	tcgccccggc	240
cggcatccct	gccgtcgcc	tgtggcttct	gtgcacgctc	ggcctccagg	gcacccaggc	300
cgggccaccg	cccgcgccc	ctgggctgcc	cgcgggagcc	gactgcctga	acagctttac	360
cgcgggggtg	cctggcttcg	tgtgggacac	caacgcctcg	gtcagcaacg	gagctacctt	420
cctggagtc	cccaccgtgc	gccggggctg	ggactgcgtg	cgcgccctgt	gcaccaccca	480
gaactgcaac	ttggcgctag	tggagctgca	gcccgaaccg	ggggaggacg	ccatcgccgc	540
ctgcttcctc	atcaactgcc	tctacgagca	gaacttcgtg	tgcaagttcg	cgcacaggga	600
gggcttcctc	aactacctca	cgagggaagt	gtaccgctcc	taccgccagc	tgccggaccca	660
gggctttgga	gggtctggga	tccccaaggc	ctgggcaggc	atagacttga	aggtacaacc	720
ccaggaaccc	ctgggtgctga	aggatgtgga	aaacacagat	tggcgccctac	tgccgggtga	780
cacggatgtc	agggtagaga	ggaaagaccc	aaaccagggtg	gaactgtggg	gactcaagga	840
aggcacctac	ctgttccagc	tgacagtgc	tagctcagac	caccagagg	acacggccaa	900
cgtcacagtc	actgtgctgt	ccaccaagca	gacagaagac	tactgcctcg	catccaacaa	960
ggtgggtcgc	tgccggggct	ctttcccacg	ctggtactat	gacccacgg	agcagatctg	1020
caagagtttc	gtttatggag	gctgcttggg	caacaagaac	aactaccttc	gggaagaaga	1080
gtgcattcta	gcctgtcggg	gtgtgcaagg	tgggcctttg	agaggcagct	ctggggctca	1140
ggcgactttc	ccccagggcc	cctccatgga	aaggcgccat	ccagtgtgct	ctggcacctg	1200
tcagcccacc	cagttccgct	gcagcaatgg	ctgctgcctc	gacagtttcc	tggagtgtga	1260
cgcaccccc	aactgccccg	acgcctccga	cagggtgcc	tgtgaaaaat	acacgagtgg	1320
ctttgacgag	ctccagcgca	tccatttccc	cagtgacaaa	gggcactgcg	tggacctgcc	1380
agacacagga	ctctgcaagg	agagcatccc	gcgctgggtac	tacaacctct	tcagcgaaca	1440
ctgcgcccgc	tttacctatg	gtggttggtta	tggcaacaag	aacaactttg	aggaagagca	1500
gcagtgcctc	gagtcttgct	gcggcatctc	cagtgagtgg	gccagtgaga	gggtgggcat	1560
gtatggggga	aggcttagcc	agtggcctcc	actctgtccc	caggcctttg	ggagtcaccc	1620
ctccatcctc	agagcgccctg	gagtaggagt	gggagaggat	gccagtgtga	ggtctggggc	1680
actggggagc	agctgagtct	ctgagccctc	agtactgact	ggtctttccc	ctcatcatctc	1740
tgcagagaag	gatgtgtttg	gcctgaggcg	ggaaatcccc	attcccagca	caggctctgt	1800
ggagatggct	gtcgcagtgt	tcctgggtcat	ctgcattgtg	gtggtggtag	ccatcttggg	1860

74

```

ttactgcttc ttcaagaacc agagaaagga cttccacgga caccaccacc acccaccacc 1920
caccctgcc agctccactg tctccactac cgaggacacg gagcacctgg tctataacca 1980
caccacccgg cccctctgag cctgggtctc accggctctc acctggccct gcttcctgct 2040
tgccaaggca gaggcctggg ctgggaaaaa ctttggaacc agactcttgc ctgtttccca 2100
ggccactgt gcctcagaga ccagggtcc agccctctt ggagaagtct cagctaagct 2160
cacgtcctga gaaagctcaa aggtttggaa ggagcagaaa acccttgggc cagaagtacc 2220
agactagatg gacctgcctg cataggagtt tggaggaagt tggagttttg tttcctctgt 2280
tcaaagctgc ctgtccctac cccatggtgc taggaagagg agtggggtgg tgtcagaccc 2340
tggaggcccc aaccctgtcc tcccgagctc ctcttccatg ctgtgcgccc agggctggga 2400
ggaaggactt ccctgtgtag tttgtgctgt aaagagttgc tttttgttta tttaatgctg 2460
tggcatgggt gaagaggagg ggaagaggcc tgtttggcct ctctgtctc tcttcctctt 2520
ccccaagat tgagctctct gcccttgatc agccccaccc tggcctagac cagcagacag 2580
agccaggaga ggctcagctg cattccgcag cccccacccc caaggttctc caacatcaca 2640
gccagccca cccactgggt aataaaagtg gtttgtgga 2679

```

```

<210> 55
<211> 3125
<212> DNA
<213> Homo sapien

```

```

<400> 55
cagaaaccag ggggagaagg cggccgagcc ccagctctcc gagcaccggg tcggaagccg 60
cgacccgagc cgcgcaggaa gctgggaccg gaacctcggc ggaccgggcc ccaccaact 120
cacctgcgca ggtcaccagc accctcgga cccagaggcc cgcgctctga aggtgacccc 180
cctggggagg aaggcgatgg cccctgcgag gacgatggcc cgcgcccgcc tcgccccggc 240
cggcacccct gccgtgcct tgtggcttct gtgcacgctc ggcctccagg gcacccaggc 300
cgggccaccg cccgcgcccc ctgggctgcc cgcgggagcc gactgcctga acagctttac 360
cgccggggtg cctggcttcg tgctggacac caacgcctcg gtcagcaacg gagctacctt 420
cctggagtcc ccacccgtgc gccggggctg ggactgcgtg cgcgcctgct gcaccacca 480
gaactgcaac ttggcgctag tggagctgca gcccgaccgc ggggaggacg ccatcgccgc 540
ctgcttcctc atcaactgcc tctacgagca gaacttcgtg tgcaagtctg cgcccaggga 600
gggcttcctc aactacctca cgagggaagt gtaccgctcc taccgccagc tgcggaccca 660
gggctttgga gggctctgga tccccaggc ctgggcaggc atagacttga aggtacaacc 720
ccaggaaccc ctggtgctga aggatgtgga aaacacagat tggcgcctac tgcggggtga 780

```

75

cacggatgtc	agggtagaga	ggaaagaccc	aaaccagggtg	gaactgtggg	gactcaagga	840
aggcacctac	ctgttccagc	tgacagtgc	tagctcagac	caccagagg	acacggccaa	900
cgtcacagtc	actgtgctgt	ccaccaagca	gacagaagac	tactgcctcg	catccaacaa	960
ggtgggtcgc	tgccggggct	ctttcccacg	ctggtactat	gacccacgg	agcagatctg	1020
caagagtttc	gtttatggag	gctgcttggg	caacaagaac	aactaccttc	gggaagaaga	1080
gtgcattcta	gcctgtcggg	gtgtgcaagg	tgggcctttg	agaggcagct	ctggggctca	1140
ggcgactttc	ccccagggcc	cctccatgga	aaggcgccat	ccagtgtgct	ctggcacctg	1200
tcagcccacc	cagttccgct	gcagcaatgg	ctgctgcac	gacagtttcc	tggagtgtga	1260
cgacaccccc	aactgccccg	acgcctccga	cgaggctgcc	tgtgaaaaat	acacgagtgg	1320
ctttgacgag	ctccagcgca	tccatttccc	cagtgcacaa	gggcactgcg	tggacctgcc	1380
agacacagga	ctctgcaagg	agagcatccc	gcgctggtac	tacaaccctt	tcagcgaaca	1440
ctgcgcccgc	tttacctatg	gtggttggtta	tggcaacaag	aacaactttg	aggaagagca	1500
gcagtgcctc	gagtcttgtc	gcggcatctc	cagtgcagtg	gccagtgcga	gggtgggcat	1560
gtatggggga	aggcttagcc	agtggcctcc	actctgtccc	caggcctttg	ggagtcaccc	1620
ctccatcctc	agagcgctg	gagtaggagt	gggagaggat	gccagtgtga	ggtctggggc	1680
actggggagc	agctgagtct	ctgagccctc	agtactgact	ggtctttccc	ctcatcatte	1740
tgcaggtaag	ccctgatctg	tcctgtaact	gaggtagca	tgtaggatc	aactcacgga	1800
tcaactccac	ctgttgtagc	agcctaacct	gtgttgagaa	ggatgccaag	gtggcctata	1860
gagacagagt	accgtaatca	aatggggatg	cctgccacac	acgagggagg	gagtacagta	1920
aagtgcgtgc	cgatgtctgt	cagcagcgtc	ccaggcttcc	cccaagttaa	ctgcaaggag	1980
agcgacttga	gctgagacct	gaggcccaac	agagttcctc	tgagctcctg	gacagagctg	2040
ttcagctgtt	catatgtggg	aggctctgag	cgggtgccca	tgtccttcca	tacctggcat	2100
ccatttgact	tggctctctc	catagattgg	gggtgggtgt	cagaaccagg	caggccctgg	2160
gagcccctta	ttctaccctt	tcttccccca	gagaaggatg	tgtttggcct	gaggcgggaa	2220
atccccattc	ccagcacagg	ctctgtggag	atggctgtcg	cagtgttcc	ggtcatctgc	2280
attgtgggtg	tggtagccat	cttgggttac	tgcttcttca	agaaccagag	aaaggacttc	2340
cacggacacc	accaccaccc	accaccaccc	cctgccagct	ccactgtctc	cactaccgag	2400
gacacggagc	acctggtcta	taaccacacc	acccggcccc	tctgagcctg	ggtctcaccg	2460
gctctcacct	ggccctgctt	cctgcttgcc	aaggcagagg	cctgggctgg	gaaaaacttt	2520
ggaaccagac	tcttgctgtg	ttcccaggcc	cactgtgcct	cagagaccag	ggctccagcc	2580
cctcttgagg	aagtctcagc	taagctcacg	tcctgagaaa	gctcaaaggt	ttggaaggag	2640

cagaaaaccc ttggggccaga agtaccagac tagatggacc tgccctgcata ggagtttggg 2700
 ggaagttgga gttttgtttc ctctgttcaa agctgcctgt ccctacccca tgggtgctagg 2760
 aagaggagtg ggggtggtgtc agaccctgga ggccccaacc ctgtcctccc gagtcctctc 2820
 tccatgctgt ggcgccaggg ctgggaggaa ggacttccct gtgtagtttg tgctgtaaag 2880
 agttgctttt tgtttattta atgctgtggc atgggtgaag aggaggggaa gaggcctgtt 2940
 tggcctctct gtccctctct cctcttcccc caagattgag ctctctgccc ttgatcagcc 3000
 ccaccctggc ctagaccagc agacagagcc aggagaggct cagctgcatt ccgcagcccc 3060
 ccccccaag gttctccaac atcacagccc agcccaccca ctgggtaata aaagtggttt 3120
 gtgga 3125

<210> 56
 <211> 2774
 <212> DNA
 <213> Homo sapien

<400> 56
 cagaaaccag ggggagaagg cggccgagcc ccagctctcc gagcaccggg tcggaagccg 60
 cgacccgagc cgcgcaggaa gctgggaccg gaacctcggc ggacccggcc ccacccaact 120
 cacctgcgca ggtcaccagc accctcgga cccagaggcc cgcgctctga aggtgacccc 180
 cctggggagg aaggcgatgg ccctgcgag gacgatggcc cgcgcccgc tcgccccggc 240
 cggcatccct gccgtgcct tgtggcttct gtgcacgctc ggctccagg gcaccaggc 300
 cggggccacc cccgcgccc ctgggctgcc cgcgggagcc gactgcctga acagctttac 360
 cgccgggggtg cctggcttcg tgctggacac caacgcctcg gtcagcaacg gagctacctt 420
 cctggagtcc ccaccgtgc gccggggctg ggactgcgtg cgcgcctgct gcaccaccca 480
 gaactgcaac ttggcgctag tggagctgca gcccgaccgc ggggaggacg ccatcgccgc 540
 ctgcttcttc atcaactgcc tctacgagca gaacttcgtg tgcaagttcg cgcacaggga 600
 gggcttcctc aactacctca cgagggaagt gtaccgctcc taccgccagc tgcggaccca 660
 gggcttttga gggctctggga tccccaaagg ctgggcaggc atagacttga aggtacaacc 720
 ccaggaaccc ctgggtgctga aggatgtgga aaacacagat tggcgcctac tgcggggtga 780
 cacggatgtc agggtagaga ggaaagaccc aaaccagggt gaactgtggg gactcaagga 840
 aggcacctac ctgttccagc tgacagtgac tagctcagac caccagagg acacggccaa 900
 cgtcacagtc actgtgctgt ccaccaagca gacagaagac tactgcctcg catccaacaa 960
 ggtgggtcgc tgccggggct ctttcccacg ctggtactat gacccacagg agcagatctg 1020
 caagagtttc gtttatggag gctgcttggg caacaagaac aactaccttc gggagaaga 1080

```

gtgcattcta gcctgtcggg gtgtgcaagg tgggcctttg agaggcagct ctggggctca 1140
ggcgactttc cccaggggcc cctccatgga aaggcgccat ccaggtgggc tttactcccc 1200
tccccatccc ccatccccac cacatctcta gccatatca tccctatgcc cctaagcagc 1260
ctgcctttga ccaagccatt cctcccctca gagtttgtgg aaggaccaca aacatcccc 1320
cccttccagc ccagcatcgt cctatgagga tctgcccagt ttgcgtgggg caggagtggg 1380
gttgggtggaa aggggaatggg ggatgtgctg tgtctgggca gagagggccca agtagaagggt 1440
gggcccctggg cacttgttct ttgcttgagc ctgacctccc ctccaccctg cctgtgctct 1500
ggcacctgtc agcccaccca gttccgctgc agcaatggct gctgcatcga cagtttcctg 1560
gagtgtgacg acacccccaa ctgccccgac gcctccgacg aggctgcctg tgaaaaatac 1620
acgagtgggt ttgacgagct ccagcgcac cttttcccca gtgacaaagg gactgctgtg 1680
gacctgccag acacaggact ctgcaaggag agcatccgcg gctggtacta caacccttc 1740
agcgaacact gcgcccgtt tacctatggg ggttggtatg gcaacaagaa caactttgag 1800
gaagagcagc agtgcctcga gtcttgctgc ggcacatcca agaaggatgt gtttggcctg 1860
aggcgggaaa tccccattcc cagcacaggc tctgtggaga tggctgtcgc agtgttcctg 1920
gtcatctgca ttgtgggtgt ggtagccatc ttgggttact gcttcttcaa gaaccagaga 1980
aaggacttcc acggacacca ccaccaccca ccaccaccc ctgccagctc cactgtctcc 2040
actaccgagg acacggagca cctgggtctat aaccacacca cccggccctt ctgagcctgg 2100
gtctcaccgg ctctcacctg gccctgcttc ctgcttgcca aggagaggc ctgggctggg 2160
aaaaactttg gaaccagact cttgcctgtt tcccaggccc actgtgcctc agagaccagg 2220
gctccagccc ctcttgagga agtctcagct aagctcacgt cctgagaaaag ctcaaagggt 2280
tggaaggagc agaaaaccct tgggccagaa gtaccagact agatggacct gcctgcatag 2340
gagtttgag gaagttggag ttttgtttcc tctgttcaaa gctgcctgtc cctaccccat 2400
ggtgctagga agaggagtgg ggtgggtgtc gacctggag gcccacccc tgtcctcccg 2460
agctcctctt ccatgctgtg cggccagggc tgggaggaag gacttccctg tgtagtttgt 2520
gctgtaaaga gttgcttttt gtttatattaa tgctgtggca tgggtgaaga ggaggggaag 2580
aggcctgttt ggctctctg tctctctctt ctcttcccc aagattgagc tctctgccct 2640
tgatcagccc caccctggcc tagaccagca gacagagcca ggagaggctc agctgcattc 2700
cgcagcccc accccaagg ttctccaaca tcacagccca gcccaccac tgggtaataa 2760
aagtggtttg tgga 2774

```

<211> 1779
 <212> DNA
 <213> Homo sapien

<400> 57
 cagaaaccag ggggagaagg cggccgagcc ccagctctcc gagcaccggg tcggaagccg 60
 cgacccgagc cgcgcaggaa gctgggaccg gaacctcggc ggacccggcc ccacccaact 120
 cacctgcgca ggtcaccagc accctcgga cccagaggcc cgcgctctga aggtgacccc 180
 cctggggagg aaggcgatgg cccctgcgag gacgatggcc cgcgcccgcc tcgccccggc 240
 cggcatccct gccgtcgctt tgtggcttct gtgcacgctc ggcctccagg gcacccaggc 300
 cgggccaccg cccgcgcccc ctgggctgcc cgcgggagcc gactgcctga acagctttac 360
 cgccgggggtg cctggcttcg tgtgggacac caacgcctcg gtcagcaacg gagctacctt 420
 cctggagtcc cccaccgtgc gccggggctg ggactgcgtg cgcgctgtct gcaccaccca 480
 gaactgcaac ttggcgctag tggagctgca gcccgaccgc ggggaggacg ccatcgccgc 540
 ctgcttcctc atcaactgcc tctacgagca gaacttcgtg tgcaagttcg cgcccaggga 600
 gggcttcctc aactacctca cgaggggaagt gtaccgctcc taccgccagc tgcggaccca 660
 gggcttttga gggctctgga tccccaggc ctgggcaggc atagacttga aggtacaacc 720
 ccaggaaccc ctgggtgctga aggatgtgga aaacacagat tggcgcttac tgcgggggtga 780
 cacggatgtc agggtagaga ggaaagaccc aaaccagggtg gaactgtggg gactcaagga 840
 aggcacctac ctgttccagc tgacagtgc tagctcagac caccagagg acacggccaa 900
 cgtcacagtc actgtgctgt ccaccaagca gacagaagac tactgcctcg catccaacaa 960
 ggtgggtcgc tgccggggct ctttccacg ctggtactat gacccacgg agcagatctg 1020
 caagagtttc gtttatggag gctgcttggg caacaagaac aactaccttc gggaagaaga 1080
 gtgcattcta gcctgtcggg gtgtgcaagg tgggcctttg agaggcagct ctggggctca 1140
 ggcgactttc cccaggggcc cctccatgga aaggcgccat ccagtgtgct ctggcacctg 1200
 tcagcccacc cagttccgct gcagcaatgg ctgctgcctc gacagtttcc tggagtgtga 1260
 cgacaccccc aactgccccg acgcctccga cgaggctgcc tgtgaaaaat acacgagtgg 1320
 ctttgacgag ctccagcgca tccatttccc cagtgacaaa ggtgagatcc tccccagggtg 1380
 ccctggatca gggcagacgc tgacactgcc atcctcacta tttccatcca gcagtgcctg 1440
 aggggcctgc tgggtgtacg ggcctgtggg caciaagagc cagggtgggc tccccgttct 1500
 ccagatggct cagcttcttc cctggctggc tcttgggctt tcttctgtgg ctctgtgttt 1560
 tccaggcatc actcattctc cgaacacctt cataacttca gccatgtcca ccacatattg 1620
 ctgagatctt atttacttaa tcagttactt tttaaatgta atatattaaa aagggaacttt 1680

79

cacatcacta ccataaatgg gaagccacta ttacttgcca aacattgaaa aacaacacaa 1740
 ataaatataa taaaacagta agtttttagct tgccaggcg 1779

<210> 58
 <211> 1004
 <212> DNA
 <213> Homo sapien

<400> 58
 ggtgggagga aaccgcctgg agccgccggg agtggacgcc gccgaggccc ggagtcgcgc 60
 ctgcagggtgc agcccatcag ggaccacag cgctggggag gatgggtgcgg atcttggcca 120
 atggggaaat cgtgcaggat gacgaccccc gagtgaggac cactaccag ccaccaagag 180
 gtagcattcc tcgacagagc ttcttcaata gggggccatgg tgctcccca gggggtcctg 240
 gcccccgcca gcagcaggca ggtgccaggc tgggtgctgc tcagtcccc ttcaatgacc 300
 tcaaccggca gctggtgaac atgggctttc cgcagtggca tctcggcaac catgctgtgg 360
 agccggtgac ctccatcctg ctctctctcc tgctcatgat gcttgggtgtt cgtggcctcc 420
 tcctgggttg ccttgtctac ctggtgtccc acctgagtca gcggtgacct ctgagggctg 480
 ataggggttg gtttgttgag agggacttgc tgggccttgg tgtgagagca ggcatatttg 540
 gaggggatct ggtggtgcct tgaaggatatg atcagagagg ggaccacagg tgtgtgttcc 600
 ccctttgtgt taagcgtgag gcagagggag acgttagtcc agcatttcca aagtgtgggt 660
 ggggtccgttg gttcccgaga tacttttagg tggtatgggg cctgcattaa gtggcacaaa 720
 atcagagcaa gaaagcgatg cccttcccaa ttctctcaat ccttttatgc cgagaagatc 780
 tcagctggat gccaacatgt tccgatgcct gtggaagaca tgccgacgtc tcctctgcct 840
 agggagcagg acttgggctt agggcagggtg gaaaaaattc cagacttttt tagcactgtt 900
 tttgttttaa tggatatatt ttattggcta ctttattgtt taggacaagt ggtagtggca 960
 ttctatttat tgtgacctt tcaataaata gatttaagta aaaa 1004

<210> 59
 <211> 1233
 <212> DNA
 <213> Homo sapien

<400> 59
 ggtgggagga aaccgcctgg agccgccggg agtggacgcc gccgaggccc ggagtcgcgc 60
 ctgcagacac agcatctact cagcgtgggt cacctctgtg aacatcactg actgcaagcc 120
 tccctcaatt tctggtaaatt ttttcccttc aagctttttg aggtcagggg gaaaatcctc 180
 cacagatctt cacgagtctg gtcccagatc actaacagct aaagggtttg tgggtggggag 240
 aacttctgtg ccaattgggt tccattagcc tgcccacct gaccacacaa tgcagggtgca 300

80

```

gcccatcagg gacccacagc gcctgggagg atggtgcgga tcttggccaa tggggaaatc   360
gtgcaggatg acgacccccg agtgaggacc actaccacagc caccaagagg tagcattcct   420
cgacagagct tcttcaatag gggccatggg gctccccag ggggtcctgg ccccgccag   480
cagcaggcag gtgccaggct ggggtgctgct cagtccccct tcaatgacct caaccggcag   540
ctggtgaaca tgggctttcc gcagtggcat ctcggaacc atgctgtgga gccggtgacc   600
tccatcctgc tctcttctct gctcatgatg cttgggtgttc gtggcctcct cctgggtggc   660
cttgtctacc tgggtgtcca cctgagtcag cggtagacct tgagggctga taggggtggg   720
tttggtgaga gggacttgct gggccttggg gtgagagcag gcatatttgg aggggatctg   780
gtggtgcctt gaaggatatga tcagagaggg gaccacaggt gtgtgtttcc cctttgtgtt   840
aagcgtgagg cagagggaga cgttagtcca gcatttccaa agtgtgggtg ggtccgttgg   900
ttcccagatg acttttaggt ggtatggggc ctgcattaag tggcacaaaa tcagagcaag   960
aaagcgatgc ctttcccaat tctctcaatc cttttatgcc gagaagatct cagctggatg  1020
ccaacatggt ccgatgcctg tggagacat gccgacgtct cctctgccta gggagcagga  1080
cttgggctta gggcagggtg aaaaaattcc agactttttt agcactgttt ttgttttaat  1140
ggtatatattt tattggctac tttattgttt aggacaagtg gtagtggcat tctatttatt  1200
gtgacctttt caataaatag atttaagtaa aaa                               1233

```

```

<210> 60
<211> 1112
<212> DNA
<213> Homo sapien

```

```

<400> 60
ggagtgatga tgagtattaa aaatgctggc cctagagcca tgccctgtag tccaacctgc   60
ctcaaccact tctctctcc tctgtcctgg gcctgatgtg aggaatatag actggcatgt   120
tctgtgctct gagagcttgt gacttggttg ttgggattct tatgggtggc atgggggatt   180
gctgagaaag gaggtgtga ccctgggtgg ctgtaggaag ggcaggatgc agcctagaga   240
ggttgattcc tggcagggtc ctcaacccaa tgattcattc atctctctct gtcttcacat   300
tccagagctt cttcaatagg ggccatggtg ccccccagg gggtcctggc ccccgccagc   360
agcaggcagg tgccaggctg ggtgctgctc agtccccctt caatgacctc aaccggcagc   420
tgggtgaacat gggctttccg cagtggcatc tcggcaacca tgctgtggag ccggtgacct   480
ccatcctgct cctcttcctg ctcatgatgc ttgggtgttcg tggcctcctc ctggttggcc   540
ttgtctacct ggtgtccac ctgagtcagc ggtgacctct gagggctgat aggggtgggt   600
ttgttgagag ggacttgctg ggccttgggtg tgagagcagg catatttggg ggggatctgg   660

```

81

```

tggtgccttg aaggtatgat cagagagggg accacaggtg tgtgtttccc ctttgtgtta 720
agcgtgaggg agagggagac gttagtccag catttccaaa gtgtgggtgg gtccgttggg 780
tcccagagata ctttttaggtg gtatggggcc tgcattaagt ggcacaaaat cagagcaaga 840
aagcgatgcc cttcccaatt ctctcaatcc ttttatgccg agaagatctc agctggatgc 900
caacatgttc cgatgcctgt ggaagacatg ccgacgtctc ctctgcctag ggagcaggac 960
ttgggcttag ggcaggtgga aaaaattcca gactttttta gcactgtttt tgttttaatg 1020
gtatatTTTT attggctact ttattgttta ggacaagtgg tagtggcatt ctatttattg 1080
tgaccttttc aataaataga ttttaagtaaa aa 1112

```

```

<210> 61
<211> 478
<212> DNA
<213> Homo sapien

```

```

<400> 61
gaaaaaagag gaaagaaaga aaaagggaga atgwtratac tataggcact ggttctctaa 60
tgcattgctcg agcggcgagc tgtgatggat cgcccgggca ggtaccagc tgcagaactt 120
caccctggac aggagcagtg tccttgtgga tgggtattct cccaacagaa atgagccctt 180
aactgggaat tctgaccttc ctttctgggc tgtcatctc atcggcttgg caggactcct 240
gggactcatc acatgcctga tctgcggtgt cctggtgacc acccgccggc ggaagaagga 300
aggagaatac aacgtccagc aacagtgcc aggctactac cagtacacac tagacctgga 360
ggatctgcaa tgactggaac ttgccgtgct ctgggggtgc tttccccag ccagggtcca 420
aagaagcttg gctggggcag aaataaacca tattggtcgg taaaaaaact ctgagcct 478

```

```

<210> 62
<211> 5650
<212> DNA
<213> Homo sapien

```

```

<400> 62
cgcgttgatc ccatcggacc tggactggac agagagcggc tatactggga gctgagccag 60
ctgaccaaca gcatcacaga gctgggaccc tacaccctgg atagggacag tctctatgtc 120
aatggcttca acccttggag ctctgtgcca accaccagca ctctggggac ctccacagtg 180
cacctggcaa cctctgggac tccatcctcc ctgcctggcc acacagcccc tgtccctctc 240
ttgataccat tcaccctcaa ctttaccatc accaacctgc attatgaaga aaacatgcaa 300
caccctgggt ccaggaagtt caacaccacg gagaggggtc tgcagggtct gctcaagccc 360
ttgttcaaga gcaccagcgt tggccctctg tactctggct gcaggctgac cttgctcaga 420

```

cctgagaaac	atggggcagc	cactggagtg	gacgccatct	gcaccctccg	ccttgatccc	480
actggctcctg	gactggacag	agagcgggcta	tactgggagc	tgagccagct	gaccaacagc	540
gttacagagc	tgggccccta	caccctggac	agggacagtc	tctatgtcaa	tggcttcacc	600
catcggagct	ctgtgccaac	caccagtatt	cctgggacct	ctgcagtgca	cctggaaacc	660
tctgggactc	cagcctccct	ccctggccac	acagcccctg	gccctctcct	gggtgccattc	720
accctcaact	tcactatcac	caacctgcag	tatgaggagg	acatgcgtca	ccctgggttcc	780
aggaagttca	acaccacgga	gagagtctctg	cagggctctgc	tcaagccctt	gttcaagagc	840
accagtgttg	gccctctgta	ctctggctgc	agactgacct	tgctcaggcc	tgaaaaacgt	900
ggggcagcca	ccggcgtgga	caccatctgc	actcaccgcc	ttgaccctct	aaaccttgga	960
ctggacagag	agcagctata	ctgggagctg	agcaaaactga	cccgtggcat	catcgagctg	1020
ggccccctacc	tcctggacag	aggcagtctc	tatgtcaatg	gtttcaccca	tcggaaacttt	1080
gtgcccataca	ccagcactcc	tgggacctcc	acagtacacc	taggaacctc	tgaaactcca	1140
tcctccctac	ctagacccat	agtgcctggc	cctctcctgg	tgccattcac	cctcaacttc	1200
accatcacca	acttgacagta	tgaggaggcc	atgcgacacc	ctggctccag	gaagttcaat	1260
accacggaga	gggtcctaca	gggtctgctc	aggcccttgt	tcaagaatac	cagtatcggc	1320
cctctgtact	ccagctgcag	actgaccttg	ctcaggccag	agaaggacaa	ggcagccacc	1380
agagtggatg	ccatctgtac	ccaccaccct	gaccctcaaa	gccctggact	gaacagagag	1440
cagctgtact	gggagctgag	ccagctgacc	cacggcatca	ctgagctggg	cccctacacc	1500
ctggacaggg	acagtctcta	tgtcgatggg	ttcactcatt	ggagcccat	accaaccacc	1560
agcactcctg	ggacctccat	agtgaacctg	ggaacctctg	ggatcccacc	ttccctccct	1620
gaaactacag	ccaccggccc	tctcctgggtg	ccattcacac	tcaacttcac	catcactaac	1680
ctacagtatg	aggagaacat	gggtcaccct	ggctccagga	agttcaacat	cacggagagt	1740
gttctgcagg	gtctgtcaa	gcccttggtc	aagagcacca	gtgttgcccc	tctgtattct	1800
ggctgcagac	tgaccttgct	caggcctgag	aaggacggag	tagccaccag	agtggacgcc	1860
atctgcaccc	accgccctga	ccccaaaatc	cctgggctag	acagacagca	gctatactgg	1920
gagctgagcc	agctgaccca	cagcatcact	gagctgggac	cctacaccct	ggatagggac	1980
agtctctatg	tcaatggttt	caccacgcgg	agctctgtgc	ccaccaccag	cactcctggg	2040
actttcacag	tacagccgga	aacctctgag	actccatcat	ccctccctgg	ccccacagcc	2100
actggccctg	tcctgtctgc	attcaccctc	aattttacca	tcattaacct	gcagtatgag	2160
gaggacatgc	atcgccctgg	ctccaggaag	ttcaacacca	cggagagggg	ccttcagggg	2220
ctgcttatgc	ccttggttaa	gaacaccagt	gtcagctctc	tgtactctgg	ttgcagactg	2280

accttgctca	ggcctgagaa	ggatggggca	gccaccagag	tggatgctgt	ctgcacccat	2340
cgtcctgacc	ccaaaagccc	tggactggac	agagagcggc	tgtactggaa	gctgagccag	2400
ctgaccacag	gcatcactga	gctgggcccc	tacaccctgg	acaggcacag	tctctatgtc	2460
aatggtttca	cccatcagag	ctctatgaog	accaccagaa	ctcctgatac	ctccacaatg	2520
cacctggcaa	cctcgagaac	tccagcctcc	ctgtctggac	ctacgaccgc	cagccctctc	2580
ctggtgctat	tcacaattaa	cttcaccato	actaacctgc	ggtatgagga	gaacatgcat	2640
cacctgggct	ctagaaagtt	taacaccacg	gagagagtcc	ttcagggctc	gctcaggcct	2700
gtgttcaaga	acaccagtgt	tggccctctg	tactctggct	gcagactgac	cttgctcagg	2760
ccaagaagg	atggggcagc	caccaaagtg	gatgccatct	gcacctaccg	ccctgatccc	2820
aaaagccctg	gactggacag	agagcagcta	tactgggagc	tgagccagct	aaccacagc	2880
atcactgagc	tgggccccta	cacctgggac	agggacagtc	tctatgtcaa	tggtttcaca	2940
cagcggagct	ctgtgccac	cactagcatt	cctgggaccc	ccacagtgga	cctgggaaca	3000
tctgggactc	cagtttctaa	acctgggtccc	tcggctgcca	gccctctcct	ggtgctattc	3060
actctcaact	tcaccatcac	caacctgcgg	tatgaggaga	acatgcagca	ccctgggtcc	3120
aggaagttca	acaccacgga	gagggtcctt	cagggcctgc	tcaggtcctc	gttcaagagc	3180
accagtgttg	gccctctgta	ctctgggtgc	agactgactt	tgctcaggcc	tgaaaaggat	3240
gggacagcca	ctggagtgga	tgccatctgc	accaccacc	ctgaccccaa	aagccctagg	3300
ctggacagag	agcagctgta	ttgggagctg	agccagctga	cccacaatat	cactgagctg	3360
ggccccatg	ccctggacaa	cgacagcctc	tttgtcaatg	gtttcactca	tcggagctct	3420
gtgtccacca	ccagcactcc	tgggaccccc	acagtgtatc	tgggagcatc	taagactcca	3480
gcctcgatat	ttggcccttc	agctgccagc	catctcctga	tactattcac	cctcaacttc	3540
accatcacta	acctgcggta	tgaggagaac	atgtggcctg	gctccaggaa	gttcaacact	3600
acagagaggg	tccttcaggg	cctgctaagg	cccttgttca	agaacaccag	tggtggccct	3660
ctgtactctg	gctgcaggct	gaccttgctc	aggccagaga	aagatgggga	agccaccgga	3720
gtggatgcca	tctgcaccca	cgcctctgac	cccacaggcc	ctgggctgga	cagagagcag	3780
ctgtatttgg	agctgagcca	gctgaccac	agcatcactg	agctgggccc	ctacacactg	3840
gacagggaca	gtctctatgt	caatggtttc	acccatcgga	gctctgtacc	caccaccagc	3900
accggggtgg	tcagcgagga	gccattcaca	ctgaacttca	ccatcaacaa	cctgcgctac	3960
atggcggaca	tgggccaacc	cggctccctc	aagttcaaca	tcacagacaa	cgatcatgaag	4020
cacctgctca	gtcctttgtt	ccagaggagc	agcctgggtg	cacggtacac	aggctgcagg	4080

84

```

gtcatcgcac taaggtctgt gaagaacggt gctgagacac ggggtggacct cctctgcacc 4140
tacctgcagc ccctcagcgg ccaggtctg cctatcaagc aggtgttcca tgagctgagc 4200
cagcagaccc atggcatcac ccggtgggc ccctactctc tggacaaaga cagcctctac 4260
cttaacggtt acaatgaacc tggtcagat gagcctccta caactcccaa gccagccacc 4320
acattcctgc ctctctgtc agaagccaca acagccatgg ggtaccacct gaagaccctc 4380
aactcaact tcaccatctc caatctccag tattcaccag atatgggcaa gggctcagct 4440
acattcaact ccaccgaggg ggtccttcag cacctgtcga gacccttggt ccagaagagc 4500
agcatgggccc ccttctactt gggttgcaa ctgatctccc tcaggcctga gaaggatggg 4560
gcagccactg gtgtggacac cacctgcacc taccacctg accctgtggg ccccgggctg 4620
gacatacagc agctttactg ggagctgagt cagctgaccc atggtgtcac ccaactgggc 4680
ttctatgtcc tggacagggg tagcctcttc atcaatggtc accacactct acaaaggcag 4740
tcaactacat gacacattcc gcttctgcct ggtcaccaac ttgacgatgg actccgtgtt 4800
ggtcactgtc aaggcattgt tctctccaa tttggacccc agcctgggtg agcaagtctt 4860
tctagataag accctgaatg cctcattcca ttggctgggc tccacctacc agttgggtga 4920
catccatgtg acagaaatgg agtcatcagt ttatcaacca acaagcagct ccagcaccca 4980
gcacttctac ctgaatttca ccatcaccaa cctaccatat tcccaggaca aagcccagcc 5040
aggcaccacc aattaccaga ggaacaaaag gaatattgag gatgcgctca accaactctt 5100
ccgaaacagc agcatcaaga gttatTTTTT tgactgtcaa gtttcaacat tcaggtctgt 5160
ccccaacagg caccacaccg ggggtggact cctgtgtaac ttctcgccac tggctcggag 5220
agtagacaga gttgccatct atgaggaatt tctgcggatg acccgccggg caggtaccca 5280
gctgcagaac ttcaccctgg acaggagcag tgccttctgt gatgggtatt ctcccaacag 5340
aatgagccc ttaactggga attctgacct tcccttctgg gctgtcatcc tcatcggctt 5400
ggcaggactc ctgggactca tcacatgcct gatctgcggt gtcttggtga ccaccgccc 5460
gcggaagaag gaaggagaat acaacgtcca gcaacagtgc ccaggctact accagtcaca 5520
cctagacctg gaggatctgc aatgactgga acttgccggt gcctggggtg cctttccccc 5580
agccagggtc caaagaagct tggctggggc agaaataaac catattgggtc ggtaaaaaaa 5640
ctctgagcct 5650

```

```

<210> 63
<211> 443
<212> DNA
<213> Homo sapien
<400> 63

```

85

```

gaaaaaagag gaaagaaaga aaaagggaga atgwtratac tataggcact ggttctctaa      60
tgcattgctcg agcggcgagcag tgtgatggat cgccggggcag gtgtgtcctt gtggatgggt      120
attctdccaac cagaaatgag cccttaactg ggaattctga ccttcccttc tgggctgtca      180
tcctcatcgg cttggcagga ctctggggac tcatcacatg cctgatctgc ggtgtcctgg      240
tgaccacccg ccggcggaag aaggaaggag aatacaacgt ccagcaacag tgcccaggct      300
actaccagtc acacctagac ctggaggatc tgcaatgact ggaacttgcc ggtgcctggg      360
gtgcctttcc ccagccagg gtccaaagaa gcttgggtgg ggcagaaata aaccatattg      420
gtcggtaaaa aaactctgag cct                                          443

```

```

<210> 64
<211> 359
<212> DNA
<213> Homo sapien

```

```

<400> 64
catgcaccct ccaggtatctt ctttcatttc tagggatctt tcccaacaga aatgagccct      60
taactgggaa ttctgacctt cccttctggg ctgtcatcct catcggtctg gcaggactcc      120
tgggactcat cacatgcctg atctgcgggtg tcctggtgac caccgcggcg cggaagaagg      180
aaggagaata caacgtccag caacagtgc caggctacta ccagtcacac ctagacctgg      240
aggatctgca atgactggaa cttgccgggtg cctgggggtgc ctttccccca gccagggtcc      300
aaagaagctt ggctggggca gaaataaacc atattggtcg gtaaaaaaac tctgagcct      359

```

```

<210> 65
<211> 954
<212> DNA
<213> Homo sapien

```

```

<400> 65
gcggcgccac agctcccgca gctcctgctc tgggtccgct cgcccgccac acctccctcg      60
ctctcccaca ccactggcac caggccccgg acaccgctc tgctgcagga gaatggctac      120
tcatcacacg ctgtggatgg gactggccct gctgggggtg ctgggcgacc tgcaggcagc      180
accggaggcc caggctctcg tgcagcccaa cttccagcag gacaagttcc tggggcgctg      240
gttcagcgcg ggcctcgctt ccaactcgag ctgggtccgg gagaagaagg cggcggtgtc      300
catgtgcaag tctgtggtgg cccctgccac ggatggtggc ctcaacctga cctccacctt      360
cctcaggaaa aaccagtgtg agaccgaac catgctgctg cagcccgagg ggtccctcgg      420
ctcctacagc taccggagtc cccgtgagtg gggcctccac cggccccctg ggcccagcct      480
gggggagaca cttgccggga cgactctggg ccagccccct gccgcggaga tccatggggg      540
gggaggtgac tggggcagca cctactccgt gtcagtgggtg gagaccgact acgaccagta      600

```

cgcgctgctg tacagccagg gcagcaaggg ccctggcgag gacttccgca tggccaacct 660
 ctacagccga acccagaccc ccagggtga gttaaaggag aaattcaccg ccttctgcaa 720
 ggccagggc ttacagagg ataccattgt cttcctgccc caaacgata agtgcagac 780
 ggaacaatag gactccccag ggctgaagct gggatcccgg ccagccagg gacccccacg 840
 ctctggatgt ctctgctctg ttcttcccc gagcccctgc cccggctccc cgccaaagca 900
 cccctgcca ctggggcttc atcctgcaca ataaactccg gaagcaagtc agta 954

<210> 66

<211> 1519

<212> DNA

<213> Homo sapien

<400> 66

gggggggcac agtcccga gctcctgctc tgggtccgct cggcccggac acctccctcg 60
 ctctcccaca cactggcac cagggcccgg acaccgctc tgctgcagga gaatggctac 120
 tcatcacacg ctgtggatgg gactggccct gctgggggtg ctgggcgacc tgcaggcagc 180
 accggaggcc caggtctccg tgcagcccaa cttccagcag gacaaggatga ggggctttcc 240
 tgcgtcatcc ccaagggcta caggaccctg tcaggggaag ggactttcc ggctgggtct 300
 tccccctggg aggagtgagc gaagtccgc agtgccgggc agtgccggcc agggactgag 360
 cgggcgcgca ggaaggaggc tgggtagccg cccgaggagg ctgcccgcga gaagccctcc 420
 ctgggcaccg cgtcccgtct cccctgatgg gccacgcaga caccgggcca cacacgcgcc 480
 cagccagcc agacacgtcc acccctgtgg gcacgcgacc ccagaggac acacgagcgc 540
 acgttccaca cctgggtgcc aggacacggg cgggtggggc acagggatgg cgacaaacac 600
 tccgtgcgcg gtgggggttg ggaggacgc gcaccgcaca gacagccggc gacgcgcgct 660
 ctgcccggg agtgcctcg ggaagcgcg gagcgcgggt cccgcgcggc cgcgcccctc 720
 cctggcgtcg aggagaacct cagcggctcc cagagctgag ccgaagacct gccccgatcc 780
 ccgccaggaa tgcgacgtcc tctgcgcgcc gctgtatggg ccaggcgctc agccagggca 840
 cagaatcggg accggggggc gagggggcca agctggctgg tgggcggcgt gcgaggttcc 900
 tggggcgctg gttcagcgcg ggcctcgct ccaactcgag ctggctccgg gagaagaagg 960
 cggcgttgct catgtgcaag tctgtggtgg cccctgccac ggatgggtgg ctcaacctga 1020
 cctccacctt cctcaggaaa aaccagtgtg agaccgaac catgctgctg cagcccgcgg 1080
 ggtccctcgg ctctacagc taccggagtc cccactgggg cagcacctac tccgtgtcag 1140
 tgggtggagc cgactacgac cagtacgcgc tgctgtacag ccagggcagc aagggccctg 1200
 gcgaggactt ccgcatggcc accctctaca gccgaacca gacccccagg gctgaggtaa 1260

87

aggagaaatt caccgccttc tgcaaggccc agggcttcac agaggatacc attgtcttcc 1320
 tgccccaac cgataagtgc atgacggaac aataggactc ccagggtg aagctgggat 1380
 ccggccagc caggtgaccc ccacgtctctg gatgtctctg ctctgttctt tccccgagcc 1440
 cctgccccgg ctccccgcca aagcaccctt gccactcgg gcttcatcct gcacaataaa 1500
 ctccggaagc aagtcagta 1519

<210> 67
 <211> 2459
 <212> DNA
 <213> Homo sapien

<400> 67
 ggggcccac agtcccgc gctcctgctc tggctccgct cggcccggac acctccctcg 60
 ctctcccaca ccactggcac caggccccgg acaccgcctc tgctgcagga gaatggctac 120
 tcatcacacg ctgtggatgg gactggccct gctgggggtg ctgggcgacc tgcaggcagc 180
 accggaggcc caggtctccg tgcagcccaa ctccagcag gacaagggtga ggggctttcc 240
 tgcgtcatcc ccaagggtta caggaccctg tcagggggaag ggcactttcc ggctgggtct 300
 tccccctggg aggagtgagc gaagtccgc agtgccgggc agtgccggcc agggactgag 360
 cgggcccgcga ggaaggaggc tgggtagccg cccgaggagg ctgcccgcga gaagccctcc 420
 ctgggcaccg cgtcccgtct cccctgatgg gccacgcaga caccgggcca cacacgcgcc 480
 cacgccagcc agacacgtcc acccctgtgg gcacgcgacc ccagaggac acacgagcgc 540
 acgttccaca cctgggtgcc aggacacggg cgggtggggc acagggatgg cgacaaacac 600
 tccgtgcgcg gtgggggttg ggagggacgc gcaccgcaca gacagccggc gacgcgcgct 660
 ctgcccggg agtgctcgg ggaagcgccg gagcgcggt ccccgcgccg cgcgcccctc 720
 cctggcgtcg aggagaacct cagcggctcg cagagctgag ccgaagacct gcccgatcc 780
 ccgccaggaa tgcgacgtcc tctgcgccc gctgtatggg ccaggcgctc agccagggca 840
 cagaatcggg accgggggcg gaggggccga agctggctgg tgggcggcgt gcgagggtga 900
 gggactgtcc tcgggagggg cgtggccaga cgggggtgct ggggtgtcagg ggcgtggcca 960
 gctcctgggg cggagatgtg aggggcgggg tcatctcctg gggcggggat tgaggggcgg 1020
 gggtcagttc ctggggcggg gcgtgagggg cgtggctgct cgggggatgt ggcgtggggg 1080
 cggggccggg ttggagaccg gaggagtaga cggcagaggc gccccgcag gtaggcgcag 1140
 gtgggtccgg agggctcctg ccgacgcggg tgggggtcgc tcgcccgagt ttcttggggc 1200
 gctggttcag cgcgggcctc gcctccaact cgagctggct ccgggagaag aaggcggcgt 1260
 tgtccatgtg caagtctgtg gtggcccctg ccacggatgg tggcctcaac ctgacctcca 1320

ccttcctcag gaaaaaccag tgtgagaccc gaaccatgct gctgcagccc gcgggggtccc 1380
 tcggctccta cagctaccgg agtccccgtg agtggggcct ccaccggccc cctggggccca 1440
 gcctggggggc gacacttgcc gggacgaactc tgggccagcc ccctgccgcg gagatccatg 1500
 ggggtgggagg tgatggctgc cccaccagcg tcagaggcaa aggccaggcc tgggcgtgac 1560
 taccatgca caagtgttag ggacagagag acccttcctc caggggggtg gatcctctct 1620
 ggagcccacc attgtcttgt caggcccctt ccctgccctc tggagttttc cccacataag 1680
 cagcccccca agggccctcc atatgcctcc tcccaattct cctcccagg acccaggggt 1740
 ttctcactc ccacctgggg aatggctccc acggggaaac ctcttcactt ccggttctgg 1800
 cagcgacttc tgcggctgca ccaggaatcc tggttttctg agcctggctc ccccagattc 1860
 tggtttgggg acaggggtca caggctgtgc aggcgagagc agggcactgg ctggagagca 1920
 gccgggtggg ggagcatccc gggccagccg aggggctgag tgccccaaa gccacaggt 1980
 gcaccccttc cctgaagcag aggtgaggtt tggggggctg agtccccgac agggttgtct 2040
 cttgggttcc cagactgggg cagcacctac tccgtgtcag tgggtggagac cgactacgac 2100
 cagtacgcgc tgctgtacag ccagggcagc aagggccctg gcgaggactt ccgcatggcc 2160
 accctctaca gccgaacca gacccccagg gctgagttaa aggagaaatt caccgccttc 2220
 tgcaaggccc agggcttcac agaggatacc attgtcttcc tgccccaaac cgataagtgc 2280
 atgacggaac aataggactc cccagggctg aagctgggat cccggccagc caggtgacct 2340
 ccacgctctg gatgtctctg ctctgttctt tccccgagcc cctgccccgg ctccccgcca 2400
 aagcaccctt gccactcgg gcttcctctt gcacaataaa ctccggaagc aagtcagta 2459

<210> 68

<211> 575

<212> DNA

<213> Homo sapien

<400> 68

caatggcagc cggcccaatg gcagccgtag ccgtgcgggc cgcaocggtt agtcgccctg 60
 gccggcctcg tcacagggat acccaccac catcccaggg totacaacat ccacagccgg 120
 accgtcaccc gctatcctgc caactctatc gtggtcgtag gaggtgttcc tgtctgcagg 180
 gttgggggtgc tggaggactg cttcaccttc ctgggcatct tcttggccat catcctcttc 240
 cgcattgggc cggctgccat tgggcaatgg cagccgcccc atggcagccg aaccagacc 300
 cccagggctg agttaagga gaaattcacc gccttctgca agggccaggg cttcacagag 360
 gataccattg tcttcttgcc ccaaaccgat aagtgcata cggaacaata ggactcccca 420
 gggctgaagc tgggatcccg gccagccagg tgacccccac gctctggatg tctctgctct 480

89

gttccttccc cgagccctg ccccggtcc ccgccaagc acccctgcc actcgggctt 540
 catcctgcac aataaactcc ggaagcaagt cagta 575

<210> 69
 <211> 638
 <212> DNA
 <213> Homo sapien

<400> 69
 ccgccctgct cgaggcctgg gccagggaca gaggggtgag tgttcaagtc agaacctccc 60
 tcccgcagcc ccttcatgag gagccccctc catgggggac atggagacca ggcccccact 120
 ctgtgccagg cccagcagc tcccaggatg tggggcttca gcctgggtggg gggcataggg 180
 tagaggggtgc ccatggggga tacaggggaa ccaaccatac tgggctcagg cacagcctcc 240
 taggggtgga cagcctgctc ttggcagagg tggagaaaga ccctctcttt gtttccagtg 300
 cccagggaga ggtgggaggt gatgggggat ctgtgcagtt tgggggctca gtcaagacga 360
 gctctgcgtt acgggaggaa caggaagccc agtgggaaaa ttggcctaag tctggggttc 420
 tgacgacagc ccctggcttc tttcttggca gataagtga tgacggaaca ataggactcc 480
 ccagggctga agctgggatc ccggccagcc aggtgacccc cacgctctgg atgtctctgc 540
 tctgttcctt ccccgagccc ctgccccggc tccccgcaa agcaccctg cccactcggg 600
 cttcatcctg cacaataaac tccggaagca agtcagta 638

<210> 70
 <211> 951
 <212> DNA
 <213> Homo sapien

<400> 70
 gcggcggcac agctcccga gctcctgctc tgggtccgct cgccccggac acctccctcg 60
 ctctcccaca ccactggcac caggccccgg acaccgctc tgctgcagga gaatggctac 120
 tcatcacacg ctgtggatgg gactggccct gctgggggtg ctggggcgacc tgcaggcagc 180
 accggaggcc caggtctccg tgcagcccaa cttccagcag gacaagtcc tggggcgctg 240
 gttcagcgcg ggctcgct ccaactcgag ctgggtccgg gagaagaagg cggcgttgtc 300
 catgtgcaag tctgtgggtg cccctgccac ggatggtggc ctcaacctga cctccacctt 360
 cctcaggaaa aaccagtgtg agaccgaac catgctgctg cagcccgcg ggtccctcgg 420
 ctctacagc taccggagt cccgtgagt gggcctccac cgccccctg ggcccagcct 480
 gggggcgaca cttgccggga cgactctggg ccagccccct gcgcgggaga tccatgggggt 540
 gggagactgg ggcagcacct actccgtgtc agtgggtggag accgactacg accagtacgc 600

90

gctgctgtac agccagggca gcaagggccc tggcgaggac ttccgcatgg ccaccctcta	660
cagccgaacc cagaccccca gggctgagtt aaaggagaaa ttcaccgcct tctgcaaggc	720
ccagggcttc acagaggata ccattgtctt cctgccccaa accgataagt gcatgacgga	780
acaataggac tccccagggc tgaagctggg atccccggca gccaggtgac cccacgctc	840
tggatgtctc tgctctgttc cttccccgag cccctgcccc ggctccccgc caaagcacc	900
ctgccactc gggcttcac ctcgacaata aactccggaa gcaagtcagt a	951

<210> 71

<211> 2458

<212> DNA

<213> Homo sapien

<400> 71

gcggcggcac agctcccgca gctcctgctc tgggtccgcct cggccccggac acctccctcg	60
ctctcccaca ccaactggcac caggccccgg acaccgcctc tgctgcagga gaatggctac	120
tcatcacacg ctgtggatgg gactggccct gctgggggtg ctgggcgacc tgcaggcagc	180
accggaggcc caggtctccg tgcagccaa cttccagcag gacaaggtga ggggctttcc	240
tgcgtcatcc ccaagggcta caggaccctg tcaggggaag ggcactttcc ggctgggtct	300
tccccctggg aggagtgagc gaagtccgc agtgccgggc agtgccggcc agggactgag	360
cgggcgcgca ggaaggaggc tgggtagccg cccgaggagg ctgccgcga gaagccctcc	420
ctgggcaccg cgtcccgctc cccctgatgg gccacgcaga caccgggcca cacacgcgcc	480
cacgccagcc agacacgtcc acccctgtgg gcacgcgacc cccagaggac acacgagcgc	540
acgttccaca cctgggtgcc aggacacggg cgggtggggc acagggatgg cgacaaacac	600
tccgtgcgcg gtgggggttg ggaggacgc gcaccgcaca gacagccggc gacgcgcgct	660
ctcgcccggg agctgctcgg ggaagcgccg gagcgcggt ccccgcgccg cgcgcccctc	720
cctggcgtcg aggagaacct cagcggctcc cagagctgag ccgaagacct gccccgatcc	780
ccgccaggaa tgcgacgtcc tctgccgcc gctgtatggg ccaggcgctc agccagggca	840
cagaatcggg accgggggcg gaggggcca agctggctgg tgggcggcgt gcgagggtga	900
gggactgtcc tggggagggg cgtggccaga cgggggtgct ggggtgtcagg ggcgtggcca	960
gctcctgggg cggagatgtg aggggcgggg tcatctcctg gggcggggat tgaggggcgg	1020
gggtcagttc ctggggcggg gcgtgagggg cgtggctgct cgggggattg ggcgtggggg	1080
cggggccggg ttggagaccg gaggagtaga cggcagaggc gccccgcag gtaggcgcag	1140
gtgggtccgg agggctcctg ccgacgcggg tgggggtcgc tcgccgcagt tcctggggcg	1200
ctgggtcagc gcgggcctcg cctccaactc gagctggctc cgggagaaga aggcggcgtt	1260

91

gtccatgtgc aagtctgtgg tggccctgc cacggatggt ggctcaacc tgacctccac 1320
 ctctctcagg aaaaaccagt gtgagaccgc aaccatgctg ctgcagcccg cgggggtccct 1380
 cggctcctac agctaccgga gtccccgtga gtggggcctc caccggcccc ctggggccag 1440
 cctgggggcg acacttgccg ggacgactct gggccagccc cctgccgcgg agatccatgg 1500
 ggtgggaggt gatggctgcc ccaccagcgt cagaggcaaa ggccaggcct gggcgtgact 1560
 acccatgcac aagtgttagg gacagagaga cccttcctcc agggggttgg atcctctctg 1620
 gagcccacca ttgtcttgtc agggcccttc cctgccctct ggagttttcc ccacataagc 1680
 agcccccaa ggccctcca tatgcctcct cccaattctc ctcccagga ccagggggtt 1740
 tcctcactcc cacctgggga atggctccca cggggaaacc tcttcacttc cggttctggc 1800
 agcgacttct gcggctgcac caggaatcct ggttttctga gcctggctcc ccagattct 1860
 ggtttgggga cagggttcac aggtgtgca ggcgagagca gggcactggc tggagagcag 1920
 cggggtgggg gagcatcccg ggccagccga ggggctgagt gccccaaag ccacaggtg 1980
 cacccttcc ctgaagcaga ggtgaggttt ggggggctga gtccccgaca ggttggtctc 2040
 ttgggttccc agactggggc agcacctact ccgtgtcagt ggtggagacc gactacgacc 2100
 agtacgcgct gctgtacagc cagggcagca agggccctgg cgaggacttc cgcattggcca 2160
 ccctctacag ccgaaccag accccagggt ctgagttaaa ggagaaattc accgccttct 2220
 gcaaggccca gggcttcaca gaggatacca ttgtcttccg gccccaaacc gataagtgc 2280
 tgacggaaca ataggactcc ccagggtga agctgggatc ccggccagcc aggtgacccc 2340
 cacgctctgg atgtctctgc ttgttctctt ccccgagccc ctgcccggc tcccgccta 2400
 agcaccctg ccactcggg cttcatcctg cacaataaac tccggaagca agtcagta 2458

<210> 72

<211> 5495

<212> DNA

<213> Homo sapien

<400> 72

cgggtgggga aggcaggagg cggcgatccc ggcgaggggg gccgttcgcc agctctgagg 60
 cagaaagtgc cagactcca cagcgcgca cgcagccagc gagcggccgg agcggacggc 120
 agacggggcg ggcggcgtca gggtcgcagc gtctacagct gctcgggggc ggtttcttgg 180
 cggaggcttg gccggctcct ctctccggc tccgcggcgg ctgogaaggc ggcggctcct 240
 gccctctgc tttccctctc gcgtctctgg ctgcaggtga aaggaaagca agccaggatg 300
 gatatttacg aactcaaac cttgggggtt gtggtctttg gaggattcat ggttgtttct 360
 gccattggca tcttctgggt gtcgactttc tccatgaagg aaacgtcata tgaagaagcc 420

ctagccaacc	agcgcaagga	gatggcgaaa	actcaccacc	agaaagtcga	gaagaaaaag	480
aaggagaaaa	cagtggagaa	gaaaggaaaag	accaagaaaa	aggaagagaa	acctaattggg	540
aagatacctg	atcatgatcc	agcccccaat	gtgactgtcc	tccttcgaga	accagtgcgg	600
gctcctgctg	tggctgtggc	tccaacccca	gtgcagcccc	ccattatcgt	tgtcctgttc	660
gccacagttc	cagccatgcc	ccaggagaag	ctggcctcct	cccccaagga	caaaaaagaag	720
aaggagaaaa	aagtggcaaa	agtggaacca	gctgtcagct	ctgtagtgaa	ttccatccag	780
gttctcactt	cgaaggctgc	catcttggaa	actgctccca	aggaggtgcc	gatggtggtg	840
gtgccccag	tgggtgccaa	gggcaacaca	ccagccactg	gcactactca	gggcaaaaag	900
gcggagggga	ctcagaatca	aagcaaaaag	gctgaaggag	ccccaaacca	gggcagaaag	960
gcagagggga	ccccaaacca	gggcaaaaag	acagagggga	ccccaaacca	agggaaaaag	1020
gcagagggga	ccccaaacca	aggcaaaaag	gcagaaggaa	ccccaaacca	aggcaaaaag	1080
gcggaggggg	cccagaacca	gggtaaaaag	gtagatacaa	ccccaaacca	ggggaaaaag	1140
gtggaggggg	ccccaaacca	gggcagaaaag	gccgaggggg	ctcagaacca	ggccaaaaag	1200
gtagaagggg	cccagaacca	gggcaaaaag	gcagaggggg	cccagaatca	gggcaaaaag	1260
ggagaggggg	cccagaacca	gggcaagaag	gctgaggggg	cccagaacca	gggcaagaag	1320
gccgaggggg	ctcagaacca	gggcaaaaag	gccgagggag	cccagaacca	gggccaaaaa	1380
ggagagggag	cccagaatca	gggtaaaaag	acagaagggg	ctcagggcaa	aaaggcagaa	1440
aggagtccca	accaaggcaa	aaaaggagag	ggagctccca	tccagggcaa	aaaggcagat	1500
tcggttgcta	atcagggcac	aaaggtagag	ggtattacaa	accaggggaa	aaaagcagaa	1560
gggtccccca	gtgaaggcaa	aaaggcagaa	gggtccccca	accaaggcaa	aaaggcagac	1620
gcagctgcca	atcagggtaa	aaagacagag	tcagcttctg	tccagggcag	aaatacagat	1680
gtggcccaga	gccagagggc	accaaagcaa	gaggctcctg	ccaagaagaa	gtctgggttca	1740
aagaaaaaag	gtgagcctgg	gccccagat	gccgacggcc	ctctctacct	cccctacaag	1800
acgctggtct	ccacgggttg	gagcatggtg	ttcaacgagg	gcgaggccca	gcggctcatc	1860
gagatcctgt	ctgagaaggc	tggcatcatt	caggacacct	ggcacaaggc	cactcagaag	1920
ggtgaccctg	tggcgattct	gaaacgccag	ctggaagaga	aggaaaaact	gctggccaca	1980
gaacaggaag	atgcggctgt	cgccaagagc	aaactgaggg	agctcaacaa	ggagatggca	2040
gcagaaaagg	ccaaagcagc	agccggggag	gccaaagtga	aaaagcagct	ggtggcccgg	2100
gagcaggaga	tcacggctgt	gcaggcacgc	atgcaggcca	gctaccggga	gcacgtgaag	2160
gaggtgcagc	agctgcaggg	caagatccgg	actcttcagg	agcagctgga	gaatggcccc	2220
aacacgcagc	tggcccgctt	gcagcaggag	aactccatcc	tgcgggatgc	cttgaaccag	2280

gccacgagcc	aggtggagag	caagcagaac	gcagagctgg	ccaagcttcg	gcaggagctc	2340
agcaaggtca	gcaaagagct	ggtggagaag	tcagaggctg	tgcggaaga	tgagcagcag	2400
cggaaagctc	tggaagccaa	ggcagctgcc	ttcgagaagc	aggtcctgca	gctgcaggcg	2460
tcccacaggg	agagtgagga	ggccctgcag	aagcgcttg	acgaggtcag	ccgggagctg	2520
tgccacacgc	agagcagcca	cgccagcctc	cgggcggatg	ccgagaaggc	ccaggagcaa	2580
cagcagcaga	tggccgagct	gcacagcaag	ttacagtcct	ccgaggcgga	ggtgcgcagc	2640
aaatgcgagg	agctgagtg	cctccacggg	cagctccagg	aggccagggc	ggagaactcc	2700
cagctcacag	agagaatccg	ttccattgag	gccctgctgg	aggcgggcca	ggcgcgggat	2760
gcccaggacg	tccaggccag	ccaggcgagg	gctgaccagc	agcagactcg	cctcaaggag	2820
ctggagtccc	aggtgtcggg	tctggagaag	gaggccatcg	agctcaggga	ggccgtcgag	2880
cagcagaaa	tgaagaacaa	tgacctccgg	gagaagaact	ggaaggccat	ggaggcactg	2940
gccacggccg	agcaggcctg	caaggagaag	ctgactccc	tgaccagggc	caaggaggaa	3000
tcggagaagc	agctctgtct	gattgaggcg	cagaccatgg	aggccctgct	ggctctgctc	3060
ccagaactct	ctgtcttggc	acaacagaat	tacaccgagt	ggctgcagga	tctcaaagag	3120
aaaggcccca	cgctgctgaa	gcacccgcc	gctcccgcgg	agccctcctc	ggacctggcc	3180
tccaagtga	gggaggccga	ggagacgcag	agcacactgc	aggccgagtg	tgaccagtac	3240
cgcagcatcc	tggcggagac	ggagggcattg	ctcagagacc	tgagaagag	cgtggaggag	3300
gaggagcagg	tgtggagggg	caagggtggc	gccgcagagg	aggagctcca	gaaggatat	3360
gcagccctgc	ctgcctcccg	gcgccgtgga	gcacatgaag	cccaggggag	agttgacagg	3420
attgtctctg	tcacctgtga	gactcgtgtg	tctcggtggg	gcttttccac	gacaccctat	3480
gaagcacagt	tgcgggatga	cagctcagtc	cgtcctccag	gaggcccccg	cctaggaaga	3540
cactgccaga	tggcgccagg	gtgaccgtcc	cagctgggcg	gagtgggcac	ccccggggct	3600
tcctaagttg	ggtcagtccc	gctcgggtcc	tagcatggcc	tcggaaggag	acacccccag	3660
gtgctcgtgt	ctgacggagc	cttccccctg	ctttgtagtc	cggggtcaca	gtgaagcatc	3720
tcgaagagat	tgtagagaag	ctaaaaggag	aacttgaaag	ttcggaaccag	gtatgtgctc	3780
tgctcagaga	actctttctc	ttgtcccggg	agcctctttg	aaagtgacgt	taatgcagag	3840
gacacttcac	tgatttcttc	ctcatggacc	gtgtgcctta	agagaggcat	tctctctcaa	3900
gccaaaggat	cttgctccatc	ctgtttttcc	ttaatgagag	acattgacta	cctcagagga	3960
ccctgagacc	cagccacggg	ccctgtgcag	acctgcccag	ccctggtgaa	cagggtctct	4020
gccacggcct	tcacagtcaa	ggtggcccca	ctgccccctt	cagacgccac	agggagccct	4080

94

```

ggagaaggta cccttggtac ctgcttttgc aagtaaactct aagagcatgt cagtccccag 4140
gagtgcccggt gtgcagcctg ccacttttcg taaggggttc tcttgccggt gactagtttc 4200
tcgtttgctt ggtagctggt gggcctcagg gatctcccga gaggcctcac ctatcccagg 4260
gccagcctgc tccctgaggt gagtgcctt tgagcagagg ctgctggcgc atgcgtgtgc 4320
gtgtctgtgc atctgtccgt gagggagcac acgttgcat tggaggcaga gctggaaaag 4380
cacatggcgg ccgccagcgc cgagtgcag aactacgcca aggaggtggc agggctgagg 4440
caactttctc tagaatctca atctcagctc gatgccgcca agagcgaagc ccagaaacag 4500
agcgatgagc ttgccttggt caggcagcag ttgagtgaat tgaagagcca cgtagaggat 4560
ggtgacatag ctggggcccc agcttctctc ccagaggcgc cccagccga gcaggacccc 4620
gttcagctga agacgcagct ggagtggaca gaagccatcc tggaggatga gcagacacag 4680
cggcagaagc tcacggccga gtttgaggag gctcagacct cggcatgtcg gttacaagaa 4740
gaattggaga agctccgcac agccggcccc ctagagtctt cagaaacaga ggaggcctca 4800
cagctgaagg agagactaga aaaagagaag aagttaacaa gtgacctggg gcgcgcgcgc 4860
acgagactgc aggagcttct gaagacgacc caggagcagc tggcaaggga gaaggacacg 4920
gtgaagaagc tgcaggaaca gctggaaaag gcagaggacg gcagcagctc aaaggagggc 4980
acctctgtct gagtttctc tttggaaaaa gaagttactg ttcaacttac caaatgcct 5040
tacacattcc ttacaaataa accaaccaac ctacacagcg ttatccaggc ccaacttccg 5100
gtactccgag agaagccatg agagacaagt ctcttagagc cacagaagta gaccttccag 5160
agccccagtt tgtaaatgaa cctgtgtcac atttgataaa cactatcctg gggcgcagccc 5220
cgggccaccg ccgagtgcag ccaaagccct ggttgactct gacagccccg tgggtgtgtg 5280
ggaggccggg cgctctgggg tctgtctgtc agtgcaatcg tttagtgttt tttcagtggg 5340
gcggggcggg aagcgggtgg gaccgggcag ccagttctca aaggctgtgg ggccgactgg 5400
aggccacagc ccctcaccct tagacgttgc caaccagaac tgacgtgtga cctcctgggt 5460
gttgatgcca ttaaaaccaa cgttggtgcc cgggtg 5495

```

```

<210> 73
<211> 4927
<212> DNA
<213> Homo sapien

```

```

<400> 73
cgggtgggga aggcaggagg cggcgatccc ggcggagggg gccgttcgcc agctctgagg 60
cagaaagtgc cacgactcca cacgcgcgca cgcagccagc gagcggccgg agcggacggc 120
agacggggcg ggccggtca gggtcgcagc gtctacagct gtcggggg gcgttctctgg 180

```

cggaggcttg gccggctcct ctctcccggc tccgcggcgg ctgcgaaggc ggcggctcct	240
gccctctcgc tttccctctc gcgtctctgg ctgcagggtga aaggaaagca agccaggatg	300
gatatttacg acactcaaac cttggggggtt gtggctctttg gaggattcat ggttggttct	360
gccattggca tcttcctggg gtgcactttc tccatgaagg aaacgtcata tgaagaagcc	420
ctagccaacc agcgcaagga gatggcgaaa actcaccacc agaaagtcga gaagaaaaag	480
aaggagaaaa cagtggagaa gaaaggaaag accaagaaaa aggaagagaa acctaattggg	540
aagatacctg atcatgatcc agcccccaat gtgactgtcc tccttcgaga accagtgcgg	600
gctcctgctg tggctgtggc tccaacccca gtgcagcccc ccattatcgt tgctcctgtc	660
gccacagttc cagccatgcc ccaggagaag ctggcctcct cccccaagga caaaaagaag	720
aaggagaaaa aagtggcaaa agtggaaacca gctgtcagct ctgtagtga tccatccag	780
gttctcactt cgaaggctgc catcttgga actgctcca aggaggtgcc gatgggtggtg	840
gtgccccag tgggtgccaa gggcaacaca ccagccactg gcactactca gggcaaaaag	900
gcgaggggga ctcagaatca aagcaaaaag gctgaaggag ccccaaacca gggcagaaag	960
gcagagggaa ccccaaacca gggcaaaaag acagagggaa ccccaaacca agggaaaaag	1020
gcagagggaa ccccaaacca aggcaaaaag gcagaaggaa ccccaaacca aggcaaaaag	1080
gcgagggggg ccagaacca gggtaaaaag gtagatacaa ccccaaacca ggggaaaaag	1140
gtggaggggg ccccaaacca gggcagaaag gccgaggggg ctcagaacca ggccaaaaag	1200
gtagaagggg ccagaacca gggcaaaaag gcagaggggg ccagaatca gggcaaaaag	1260
ggagaggggg ccagaacca gggcaagaag gctgaggggg ccagaacca gggcaagaag	1320
gccgaggggg ctcagaacca gggcaaaaag gccgagggag ccagaacca gggccaaaaa	1380
ggagagggag ccagaatca gggtaaaaag acagaagggg ctcagggcaa aaaggcagaa	1440
aggagtccca accaaggcaa aaaaggagag ggagctccca tccagggcaa aaaggcagat	1500
tcggttgcta atcagggcac aaaggtagag ggtattacaa accaggggaa aaaagcagaa	1560
gggtcccca gtgaaggcaa aaaggcagaa ggggtcccca accaaggcaa aaaggcagac	1620
gcagctgcca atcagggtaa aaagacagag tcagcttctg tccagggcag aaatacagat	1680
gtggcccaga gccagaggc accaaagcaa gaggctcctg ccaagaagaa gtctggttca	1740
aagaaaaaag gtgagcctgg gccccagat gccgacggcc ctctctacct ccctacaag	1800
acgctggtct ccacgggttg gagcatggtg ttcaacgagg gcgaggccca gcggtcatc	1860
gagatcctgt ctgagaaggc tggcatcatt caggacacct ggcacaaggc cactcagaag	1920
ggtgaccctg tggcgattct gaaacgccag ctggaagaga aggaaaaact gctggccaca	1980
gaacaggaag atgcggtgtg cgccaagagc aaactgaggg agctcaacaa ggagatggca	2040

gcagaaaagg	ccaaagcagc	agccggggag	gccaaagtga	aaaagcagct	gggtggcccgg	2100
gagcaggaga	tcacggctgt	gcaggcacgc	atgcaggcca	gctaccggga	gcacgtgaag	2160
gaggtgcagc	agctgcaggg	caagatccgg	actcttcagg	agcagctgga	gaatggcccc	2220
aacacgcagc	tggcccgctt	gcagcaggag	aactccatcc	tgccgggatgc	cttgaaccag	2280
gccacgagcc	aggtggagag	caagcagaac	gcagagctgg	ccaagcttcg	gcaggagctc	2340
agcaaggtca	gcaaagagct	gggtggagaag	tcagaggctg	tgccggcaaga	tgagcagcag	2400
cggaaagctc	tggaagccaa	ggcagctgcc	ttcgagaagc	aggtcctgca	gctgcaggcg	2460
tcccacaggg	agagtgagga	ggccctgcag	aagcgcctgg	acgaggtcag	ccgggagctg	2520
tgccacacgc	agagcagcca	cgccagcctc	cgggcgggatg	ccgagaaggc	ccaggagcaa	2580
cagcagcaga	tggccgagct	gcacagcaag	ttacagtcct	ccgaggcgga	gggtgcgcagc	2640
aaatgcgagg	agctgagtgg	cctccacggg	cagctccagg	aggccagggc	ggagaactcc	2700
cagctcacag	agagaatccg	ttccattgag	gccctgctgg	aggcgggcca	ggcgcgggat	2760
gcccaggacg	tccaggccag	ccaggcggag	gctgaccagc	agcagactcg	cctcaaggag	2820
ctggagtccc	aggtgtcggg	tctggagaag	gaggccatcg	agctcaggga	ggccgtcgag	2880
cagcagaaaag	tgaagaacaa	tgacctccgg	gagaagaact	ggaaggccat	ggaggcactg	2940
gccacggccg	agcaggcctg	caaggagaag	ctgcactccc	tgacccaggc	caaggaggaa	3000
tcggagaagc	agctctgtct	gattgaggcg	cagaccatgg	aggccctgct	ggctctgctc	3060
ccagaactct	ctgtcttggc	acaacagaat	tacaccgagt	ggctgcagga	tctcaaagag	3120
aaaggcccca	cgctgctgaa	gcacccgcc	gctcccgcgg	agccctcctc	ggacctggcc	3180
tccaagttga	gggaggccga	ggagacgcag	agcacactgc	aggccgagtg	tgaccagtac	3240
cgcagcatcc	tggcggagac	ggagggcag	ctcagagacc	tgagaagag	cgtggaggag	3300
gaggagcagg	tgtggagggc	caaggtgggc	gccgcagagg	aggagctcca	gaaggtatat	3360
gcagccctgc	ctgcctcccg	gcgccgtgga	gcacatgaag	cccaggggag	agttgacagg	3420
attgtctctg	tcacctgtga	gactcgtgtg	tctcgggtgg	gcttttccac	gacaccctat	3480
gaagcacagt	tgccgggatga	cagctcagtc	cgtcctccag	gagggccccc	cctaggaaga	3540
cactgccaga	tggcgccagg	gtgaccgtcc	cagctgggcg	gagtgggcac	ccccggggct	3600
tcctaagttg	ggtcagtccc	gctcgggtcc	tagcatggcc	tcggaaggag	acacccccag	3660
gtgctcgtgt	ctgacggagc	cttccccttg	ctttgtagtc	ccgggtcaca	gtgaagcatc	3720
tcgaagagat	tgtagagaag	ctaaaaggag	aacttgaaag	ttcggaccag	gtgaggagac	3780
acacgttgca	tttggaggca	gagctggaaa	agcacatggc	ggccgccagc	gccgagtgcc	3840

97

```

agaactacgc caaggaggtg gcagggctga ggcaacttct cctagaatct caatctcagc 3900
tcgatgccgc caagagcgaa gccagaaaac agagcgatga gcttgccctg gtcaggcagc 3960
agttgagtga aatgaagagc cacgtagagg atggtgacat agctggggcc ccagcttcct 4020
ccccagaggc gccccagcc gagcaggacc ccgttcagct gaagacgcag ctggagtggg 4080
cagaagccat cctggaggat gagcagacac agcggcagaa gctcacggcc gagtttgagg 4140
aggctcagac ctcgcatgt cggttacaag aagaattgga gaagctccgc acagccggcc 4200
ccctagagtc ttcagaaaca gaggaggcct cacagctgaa ggagagacta gaaaaagaga 4260
agaagttaac aagtgacctg gggcgcgccg ccacgagact gcaggagctt ctgaagacga 4320
cccaggagca gctggcaagg gagaaggaca cggatgaaga gctgcaggaa cagctggaaa 4380
aggcagagga cggcagcagc tcaaaggagg gcacctctgt ctgagtttcc tctttggaaa 4440
aagaagttac tgttcaactt accaaaatgc cttacacatt ccttacaaat aaaccaacca 4500
acctacacag cgttatccag gcccaacttc cgttactccg agagaagcca tgagagacaa 4560
gtctcttaga gccacagaag tagaccttcc agagccccag tttgtaaatg aacctgtgtc 4620
acatttgata aacactatcc tgggcgcagc cccgggccac cgccgagtga cgccaaagcc 4680
ctgggtgact ctgacagccc cgtgggtgtg tgggaggccg ggcgctctgg ggtctgtctg 4740
tcagtgcaat cgtttagtgt tttttcagtg gggcggggcg ggaagcgggt gggaccgggc 4800
agccagttct caaaggctgt ggggccgact ggaggccaca gcccctcacc cctagacgtt 4860
gccaaccaga actgacgtgt gacctcctgg gtgttgatgc cattaaaacc aacgttggtg 4920
cccggtg 4927

```

<210> 74
 <211> 3012
 <212> DNA
 <213> Homo sapien

```

<400> 74
ggggtgggga aggcaggagg cggcgatccc ggcggagggg gccgttcgcc agctctgagg 60
cagaaagtgc cacgactcca cacgcgcgca cgcagccagc gagcggccgg agcggacggc 120
agacggggcg ggcggcgta gggtcgcagc gtctacagct gctcgggggc ggtttcttgg 180
cggaggcttg gccggctcct ctctcccggc tccgcggcgg ctgcgaaggc ggcggctcct 240
gccctctcgc tttccctctc gcgtctctgg ctgcaggtga aaggaaagca agccaggatg 300
gatatttacg aactcaaac cttggggggt gtggtctttg gaggattcat ggttgtttct 360
gccattggca tcttcctggt gtcgactttc tccatgaagg aaacgtcata tgaagaagcc 420
ctagccaacc agcgcaagga gatggcgaaa actcaccacc agaaagtcga gaagaaaaag 480

```

aaggagaaaa	cagtggagaa	gaaaggaaa	accaagaaaa	aggaagagaa	acctaattggg	540
aagatacctg	atcatgatcc	agcccccaat	gtgactgtcc	tccttcgaga	accagtgcgg	600
gctcctgctg	tggtgtggc	tccaacccca	gtgcagcccc	ccattatcgt	tgctcctgtc	660
gccacagttc	cagccatgcc	ccaggagaag	ctggcctcct	cccccaagga	caaaaagaag	720
aaggagaaaa	aagtggcaaa	agtggaacca	gctgtcagct	ctgtagtgaa	ttccatccag	780
gttctcactt	cgaaggctgc	catcttgaa	actgtccca	aggaggtgcc	gatgggtggtg	840
gtgccccag	tgggtgcaa	gggcaacaca	ccagccactg	gcactactca	gggcaaaaag	900
gcggagggga	ctcagaatca	aagcaaaaag	gctgaaggag	cccccaccca	gggcagaaaag	960
gcagagggaa	cccccaccca	gggcaaaaag	acagagggaa	cccccaccca	agggaaaaag	1020
gcagagggaa	cccccaccca	aggcaaaaag	gcagaaggaa	cccccaccca	aggcaaaaag	1080
gcggaggggg	cccagaacca	gggtaaaaag	gtagatacaa	cccccaccca	ggggaaaaag	1140
gtggaggggg	ccccaaccca	gggcagaaaag	gccgaggggg	ctcagaacca	ggccaaaaag	1200
gtagaagggg	cccagaacca	gggcaaaaag	gcagaggggg	cccagaatca	gggcaaaaag	1260
ggagaggggg	cccagaacca	gggcaagaag	gctgaggggg	cccagaacca	gcccccaatg	1320
tgactgtcct	ccttcgagaa	ccagtgcggg	ctcctgtgtg	ggctgtgggt	ccaacccag	1380
tgcagcccc	cattatcggt	gctcctgtcg	ccacagttcc	agccatgccc	caggagaagc	1440
tggcctcctc	ccccaggac	aaaaagaaga	aggagaaaaa	cgtggccaaa	gtggaaccag	1500
ctgtcagctc	tgtagtgaat	tccatccagg	ttctcacttc	gaaggctgcc	aggttgggag	1560
catggtgttc	aacgagggcg	aggcccagcg	gctcatcgag	atcctgtctg	agaaggctgg	1620
catcattcag	gacacctggc	acaaggccac	tcagaagggg	gacctgtggg	cgattctgaa	1680
acgccagctg	gaagagaagg	aaaaactgct	ggccacagaa	caggaagatg	cggctgtcgc	1740
caagagcaaa	ctgagggagc	tcaacaagga	gatggcagca	gaaaaggcca	aagcagcagc	1800
cggggaggcc	aaagtgaaaa	agcagctggt	ggcccgggag	caggagatca	cggctgtgag	1860
ggagcacacg	ttgcatttgg	aggcagagct	ggaaaagcac	atggcggccg	ccagcgccga	1920
gtgccagaac	tacgccaaag	aggtggcagg	gctgaggcaa	cttctcctag	aatctcaatc	1980
tcagctcgat	gccgccaaag	gcgaagccca	gaaacagagc	gatgagcttg	ccctggctcag	2040
gcagcagttg	agtgaaatga	agagccacgt	agaggatggg	gacatagctg	gggccccagc	2100
ttcctcccca	gaggcgcccc	cagccgagca	ggaccccggt	cagctgaaga	cgcagctgga	2160
gtggacagaa	gccatcctgg	aggatgagca	gacacagcgg	cagaagctca	cggccgagtt	2220
tgaggaggct	cagacctcgg	catgtcgggt	acaagaagaa	ttggagaagc	tccgcacagc	2280
cggcccccta	gagtcttcag	aaacagagga	ggcctcacag	ctgaaggaga	gactagaaaa	2340

99

```

agagaagaag ttaacaagtg acctggggcg cgccgccacg agactgcagg agcttctgaa 2400
gacgacccag gagcagctgg caagggagaa ggacacggtg aagaagctgc aggaacagct 2460
ggaaaaggca gaggacggca gcagctcaaa ggagggcacc tctgtctgag tttcctcttt 2520
ggaaaaagaa gttactgttc aacttaccaa aatgccttac acattcctta caaataaacc 2580
aaccaaccta cacagcgtta tccaggccca acttccggtg ctccgagaga agccatgaga 2640
gacaagtctc ttagagccac agaagtagac cttccagagc ccagtttgt aaatgaacct 2700
gtgtcacatt tgataaacac tatcctgggc gcagccccgg gccaccgccg agtgacgcca 2760
aagccctggt tgactctgac agccccgtgg gtgtgtggga ggccgggcgc tctggggtct 2820
gtctgtcagt gcaatcgttt agtggttttt cagtggggcg gggcgggaag cgggtgggac 2880
cgggcagcca gttctcaaag gctgtggggc cgactggagg ccacagcccc taccacctag 2940
acgttgccaa ccagaactga cgtgtgacct cctgggtgtt gatgccatta aaaccaacgt 3000
tggtgcccgg tg 3012

```

<210> 75
 <211> 541
 <212> DNA
 <213> Homo sapien

```

<400> 75
gggcaggtct cagcgctcct cccctgctc cgctcctctg cagggcccag gcgcccttgg 60
ccttaggacc caacttctct taccgccatg gagttcgacc tgggagcagg tgagctcctg 120
gggagtgtgg actggagggtg cagggggccc gactcaagcc cagaagctgc ctgcaccaac 180
cacccaactt ctctccacag ccctggagcc cacctcccag aagcccgggtg tgggggcggg 240
ccacggggga gatcccaagc tcagtcccca caaagttcag ggccggtcgg aggcaggggc 300
aggtccgggt ccaaagcaag gacaccacag ctcttccgac tccagcagca gctccagcga 360
ttcggacacg gatgtgaagt ccacgctgc tggctccaag cagcacgaga gcatcccggg 420
caaggccaag aagcccaaag tgaagaagaa ggagaagggc aagaaggaga agggcaagaa 480
gaaggaggct cccactgaa gggccctgga cagggtcat taaaccttcc tctctgcctt 540
c 541

```

<210> 76
 <211> 832
 <212> DNA
 <213> Homo sapien

```

<400> 76
gggcaggtct cagcgctcct cccctgctc cgctcctctg cagggcccag gcgcccttgg 60

```


100

```

ccttaggacc caacttctct taccgccatg gagttcgacc tgggagcagg tgagctcctg      120
gggagtgtgg actggagggt cagggggccg gactcaagcc cagaagctgc ctgcaccaac      180
cacccaactt ctctccacag ccctggagcc cacctcccag aagcccggtg tgggggcggg      240
ccacggggga gatcccaagc tcagtcccca caaagttcag ggccgggtcg aggcagggggc      300
aggtccgggt ccaaaggtaa gtgcctcat caccggctgc ggagggggcg gaaggctggg      360
gttgcccctg accccagggt cctgccttag gcctccaact tcagggggct gggtaagggg      420
cgccgcctca ctgcgcacc tccatccagc aaggacacca cagctcttcc gactccagca      480
gcagctccag cgattcggac acggatgtga aggtaagggg ctctcgccag cgtccccaag      540
cacgtgccct gcaccccaga gaggcgtccc cgcactgggg ctggcgggga gggcgcgggg      600
agtgtcccc ctgtctcgct tccagcccag aaccatctct tctctcccat ccctgccctc      660
ggccccacag tcccacgctg ctggctccaa gcagcacgag agcatcccgg gcaaggccaa      720
gaagcccaaa gtgaagaaga aggagaaggg caagaaggag aagggcaaga agaaggaggc      780
tccccactga agggccctgg acagggtca ttaaaccctc ctctctgcct tc              832

```

```

<210> 77
<211> 991
<212> DNA
<213> Homo sapien

```

```

<400> 77
aaaattaggc taggtacgag gcytgggtgt aatcggccga ggcgagcgac ctccgcgcgt      60
tgggagggtgt agcgcggtct tgaacgcgct gagggccggt gagtgtcgca ggcggcgagg      120
gcgcgagtga ggagcagacc caggcatcgc gcgcgagaa ggccggggcgt cccacactg      180
aagggtccgga aaggcgactt ccgggggctt tggcacctgg cggaccctcc cggagcgctcg      240
gcacctgaac gcgaggcgct ccattgcgcg tgcgcgttga ggggcttccc gcacctgatc      300
gcgagacccc aacggctggg ggcgtcgctt gcgcgtctcg gctgagctgg ccatggcgca      360
gctgtgcggg ctgaggcgga gccgggcgtt tctgcacctg ctgggatcgc tgctcctctc      420
tggggtcctg gcggccgacc gagaacgcag catccacgac ttctgcctgg tgtcgaagg      480
gggtgggcaga tgccgggcct ccatgcctag gtggtggtac aatgtcactg acggatcctg      540
ccagctgttt gtgtatgggg gctgtgacgg aaacagcaat aattacctga ccaaggagga      600
gtgcctcaag aaatgtgcca ctgtcacaga gaatgccacg ggtgacctgg ccaccagcag      660
gaatgcagcg gattcctctg tccaagtgc tccagaagg caggattctg aagaccactc      720
cagcgatatg ttcaactatg aagaatactg caccgccaac gcagtcactg ggccttgccg      780
tgcacacctc ccacgctggg actttgacgt ggagaggaac tcctgcaata acttcatcta      840

```

101

tggaggctgc	cggggcaata	agaacagcta	ccgctctgag	gaggcctgca	tgctccgctg	900
cttccagggg	aayytcccgg	csctkgkcca	rgggggggccg	gggggaggcc	cgcgggggga	960
cccctcgggg	cgcccagggg	acagaaccgg	g			991

<210> 78

<211> 1675

<212> DNA

<213> Homo sapien

<400> 78

ccaccgctgg	gtccccagca	ttaagccctg	gagcatgagc	ccagtgaact	ttgaaattca	60
ggaaggaatt	cacaggaaag	ctgcggcgag	gcgggcagaa	aaccacaggc	ttccaagaaa	120
cgcggtgtctg	ccgccccctc	ctcccaccct	gaggccagtc	ctagagcgaa	ggccctcctc	180
cgacgtcgtc	accaagccca	aggggaaggg	ggcaggtgct	cagcgggcag	acgccccgcc	240
ccgccccgcc	aggttctgtt	gggggagagg	cccgcgcaag	ccccgcctct	tccccggcac	300
caggggaggg	cccaggtgag	cccagggccg	gggagcggcc	gcgcaggtgc	ctgccctttg	360
cgcctgcgcc	cagctcgccc	tgccctagcca	ggtgcgcccc	gccccctgcc	tgccccggcca	420
ccttcgggag	ccgcttccaa	taggcgttcg	ccattggctc	tggcgacctc	cgcgcggttg	480
gaggtgtagc	gcggctctga	acgcgctgag	ggccgttgag	tgtcgcaggc	ggcgagggcg	540
cgagtgagga	gcagacccag	gcctcgcgcg	ccgagaaggc	cgggcgtccc	cacactgaag	600
gtccggaaaag	gcgacttccg	ggggcttttg	cacctggcgg	accctcccgg	agcgtcggca	660
cctgaacgcg	aggcgctcca	ttgcgcgtgc	gcgttgaggg	gcttcccgca	cctgatcgcg	720
agaccccaac	ggctgggtgg	gtcgccctgc	cgtctcggct	gagctggcca	tggcgagct	780
gtgcgggctg	aggcggagcc	gggcgtttct	cgccctgctg	ggatcgctgc	tcctctctgg	840
ggtcctggcg	gccgaccgag	aacgcagcat	ccacgacttc	tgccctgggt	cgaagggtgt	900
gggcagatgc	cgggcctcca	tgccctaggtg	gtggtacaat	gtcactgacg	gatcctgcc	960
gctgtttgtg	tatgggggct	gtgacggaaa	cagcaataat	tacctgacca	aggaggagt	1020
cctcaagaaa	tgtgccactg	tcacagagaa	tgccacgggt	gacctggcca	ccagcaggaa	1080
tgcagcggat	tcctctgtcc	caagtgtccc	cagaaggcag	gattctgaag	accactccag	1140
cgatatgttc	aactatgaag	aatactgcac	cgccaacgca	gtcactgggc	cttgccgtgc	1200
atccttccca	cgctgggtact	ttgacgtgga	gaggaaactcc	tgcaataact	tcacttatgg	1260
aggctgcggg	ggcaataaga	acagctaccg	ctctgaggag	gcctgcatgc	tcgctgctt	1320
ccgccagcag	gagaatccct	ccctgccccct	tggtctaaaag	ggtaagtggc	cccttaccct	1380
cctcctgcc	tcagcctgcc	tcctcccttc	cttgactgag	ctcagccctg	cccagctgtg	1440

102

gtttacatta tccttcactg tgaacatcat cttggcagaa agtcatgttt ctgcgtgaga 1500
 atggcgaggt ggtggtttgt cccaccgttc agtgtacaca gttggggctg gagtgagtca 1560
 gtcacaaggc aggccctgcc caggcggcgt gggtgactgg ggatgaggtc ttcctgttga 1620
 gcatttgagg actgctgcac acgggcctga ggctggcctg aggtgtggag ggagc 1675

<210> 79
 <211> 432
 <212> DNA
 <213> Homo sapien

<400> 79
 agtgtgatgg atcgcccgcc cgggcaggta cctggccatc ttgggcagtg tgacgtttct 60
 ggctggcaat cggatgctgg cccagcaggc agtcaagaga acagcacatt agttccagaa 120
 gaaagatgga aattctgaaa actgaatgtc aagaaaagga gtcaagaaca attcacagta 180
 tgagaagaaa aatggaaaaa aaaaacttta tttaaaaaag aaaaaagtcc agattgtagt 240
 tatacttttg cttgtttttc agtttcccca acacacagca gatacctggg gagctcagat 300
 agtctctttc tctgacactg tgtaagaagc tgtgaatatt cctaacttac ccagatgttg 360
 cttttgaaaa gttgaaatgt gtaattgttt tggaataaag agggtaacaa taggaaaaaa 420
 aaaaacaaaa aa 432

<210> 80
 <211> 428
 <212> DNA
 <213> Homo sapien

<400> 80
 tgatggatag gtcgcggccg aggtacctgg ccatcttggg cagtgtgacg tttctggctg 60
 gcaatcggat gctggcccag caggcagtca agagaacagc acattagttc cagaagaaag 120
 atgggaaatt ctgaaaactg aatgtcaaga aaaggagtca agaacaattc acagtatgag 180
 aagaaaaatg gaaaaaaaaa actttattta aaaaagaaaa aagtccagat tgtagttata 240
 cttttgcttg tttttcagtt tccccaacac acagcagata cctgggtgagc tcagatagtc 300
 tctttctctg aactgtgta agaagctgtg aatattccta acttaccag atgttgcttt 360
 tgaaaagtgt aaatgtgtaa ttgttttgga ataaagaggg taacaatagg aaaaaaaaaa 420
 acaaaaaa 428

<210> 81
 <211> 846
 <212> DNA
 <213> Homo sapien

<220>

<221> misc_feature
<222> (66)..(66)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (96)..(96)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (6)..(6)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (100)..(100)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (118)..(118)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (120)..(120)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (180)..(180)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (191)..(191)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (205)..(206)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (211)..(212)
<223> n=a, c, g or t

<220>
<221> misc_feature

104

<222> (330)..(330)
 <223> n=a, c, g or t

<220>
 <221> misc_feature
 <222> (844)..(844)
 <223> n=a, c, g or t

<400> 81
 aaaatntaag aaggttcgca gacctgacat ccagtaccct gatgcaacag acgaggacat 60
 cacctnacac atggaaagcg aggagttgaa tggtnatan aaggccatcc ccgttgcn cn 120
 aggacctgaa cgcgcttct gattgggaca gccgtgggaa ggacagttat gaaacgagan 180
 agctggatga naagagtgc t gaaannaaaa nnaaaaagma gtccagatta tataagcgga 240
 aagctaata t gtagagcaaw gagcakrcg atgtgattga tagwmaggaa ctkkcm aag 300
 rmagccgtga akycmacagc catgaatkkn acagcmakga agatatgctg gtkgtagacg 360
 ccaaaagtaa ggaagaagaw aaacacctga aatttcgtat atctcatgaa ttagatagtg 420
 catcttctga gktcaattaa aaggagtaat aaaatacaat ttctcacttt gcatttagtc 480
 aaaagaaaa atgctttata gcaaaatgaa agagaacatg aaatgcttct ttctcagttt 540
 attggttgaa tgtgtatcta tttgagtctg gaaataactg atgtgtttga taattagttt 600
 agtttgtggc ttcatggaaa ctccctgtaa actaaaagct tcagggttat gtctatgttc 660
 attctataga agaaatgcaa actatcactg tattttaata tttgttatto tctcatgaat 720
 agaaatttat gtagacgcaa acaaaatact ttaccact tmaaagagr atataacatt 780
 ttatgwcact ataatctttt kttttttaak ttagtgtata ttttattgtg attatctttt 840
 tgtntg 846

<210> 82
 <211> 806
 <212> DNA
 <213> Homo sapien

<400> 82
 aagagtggta tcaacgcaga gkgccatta cggccggggg ccgccatctt ggggctgctg 60
 ggactcgcgt cggttggcga ctcccgacg taggtagttt gttggg ccg gttctgaggc 120
 cttgyttctc ttacttttc cactctaggc cacgatgccg cagtaccaga cctgggagga 180
 gttcagccgc gctgccgaga agctttacct cgctgacct atgaaggcac gtgtggttct 240
 caaatatagg cattctgatg ggaacttgtg tgtgttaaag taacagatga ttagttgtg 300
 ttggtgtata aaacagacca agctcaagat gtaaagaaga ttgagaaatt ccacagtcaa 360
 ctaatgcgac ttatggtagc caaaggaagc ccgcaatgtt accatggaaa actgagttaa 420

105

```

tggtttgaaa tgaagacttt gtcgtgtact tagggaagta aatatctttt gaattagaga      480
aagtgttggg acagaaagta ctttatgtaa ctaagtgggc tggtcagaag cttagaggtc      540
atTTTTgtaa ttttcttttt aaattacttt agagagctag ggatgcaa atgtttcagtt      600
agaaagcctt tatttacttt gtggaaattg aacaagaaat gcatctgtct tagaaactgg      660
agattattga tgtaggtaa cacatgtaat ggttctctgt gcaattgtgt ctcagtattt      720
ggaaatgaga tttacggaaa accatttttt aaattagtca tgcttcttta atgacctag      780
tgtacacttg gtgatcaggt ttggga                                           806

```

```

<210> 83
<211> 2606
<212> DNA
<213> Homo sapien

```

```

<400> 83
aagagtggta tcaacgcaga gkgccatta cgccggggg ccgccatctt ggggctgctg      60
ggactcgcgt cggttggcga ctccgggacg taggtagttt gttgggcccg gttctgaggc      120
cttgyttctc tttacttttc cactctaggg cacgatgccg cagtaccaga cctgggagga      180
gttcagccgc gctgccgaga agctttacct cgctgacct atgaaggcac gtgtggttct      240
caaatatagg cattctgatg ggaacttggt tgtgttaaag taacagatga tttagttaga      300
cagtgtcttg ctctatgtgc tccaggctgc agtgtagtgg cttgatcatg gctcactgca      360
atcctcgacc tcctgggctc aagcggctct cttgcttcag cctcctgaat agcagagact      420
rcagcgggta gctgggatta caggcacctg ccaccacacc cagctaattt ttatatctct      480
agtagagaca gggtttcacc atgttggcca ggctggtttc gaactgctga tctgggtggc      540
cgctgcctc ggctcccag agtgctggga ttacaggcgt aagccaccac gcctggccaa      600
gaaaatcaag atttacctgg wttatgtgtt gaccagctat acacagagaa ttctagattt      660
tktttctaaaa attattatca aaccssaat ttcaccagta gaaaaagaga tcttaagatt      720
tctgtgtttt tttttccagc ataactcagt tacttatggc tgggagaaaa tatgtagga      780
gataatctaa tacctaattc gaaggragaa aatatcta atctaagctt gagttcttct      840
yatymgacca tagcaggstt taacatttwa catTTTTcar aagcttctaa wagacytcat      900
tcartTTTTt gccmcagcag kggcatttaa atmactgrct ttamarccat gaatygtgg      960
aggsttggaa acttgagtca atttcctag tacsacctcc aaggcagaac tagcagcaaa     1020
acagtggtag gaaaaactct caaaatttta ccaatctgt atgtttctct acattgtcag     1080
tatctagttc ttatatagtc tcacatcatg tcacttctaa caatttcctg acagtgttgg     1140
tgtataaaac agaccaagct caagatgtaa agaagattga gaaattccac agtcaactaa     1200

```

106

```

tgcgacttat ggtagccaaa ggaagcccg c aatgttacca tggaaaactg agtgaatggt 1260
ttgaaatgaa gactttgtcg tgtacttagg gaagtaaata tcttttgaat tagagaaagt 1320
gttggggacag aaagtacttt atgtaactaa tctttctgac atcccactta gttacataaa 1380
gtacttttctg taactaagtg ggctgttcag aagcttagag gtcatttttg taattttctt 1440
tttaaattac tttagagagc tagggatgca aatgttttca gttagaaagc ctttattttac 1500
tttgtggaaa ttgaacaaga aatgcatctg tcttagaaac tggagattat tgatgttagg 1560
taacacatgt aattgtttct ctggcaaatt wgtatcagta atttgaaaat gagatattag 1620
gaaaaacaat tcttcttaaa tttagtcat ctttctttca acacagcaac atatcaaag 1680
taacccatat tagtccagat ccatgtatta tggagcatac aaatgtatgc tgtagtgacc 1740
aataaatcat aacatatggt aattggcact taactccaca ccactagtat gcacttgttc 1800
atacactact gtgtacctaa ttatagtata cgcagtgtag tctcaattaa taatctgaaa 1860
cgtaacttag tggcctaaac aagtatgcaa tagaacttat tctaccacat atcaaacact 1920
accatgcaa aactactaca cgggggatac acgcaacaca actacaagac aatagaccag 1980
aacgcaacga ggcactatag gacaaaacat aagtcacaca caccaacgac acacgaaacc 2040
ccccacacac gcaataacta gaccactgat acggacactg gcggaacctg actggaaatc 2100
cacaagatcg accaaatata tcgggaaccc gccacaccga aacccaaaat tagacaaggc 2160
aaaaatcaca gcaacgacac caataaataa gaagcccaac actagacaca caagaaaccc 2220
cccaccaaac cggcgaccaa tgccaatata ccagcaaacg cacaccaagg acaaaaaaag 2280
acacgaatga cacaaaaccg tcccagggga aaaaaacaca aacagaacac aaaaaaaaca 2340
caagaaacac acaacactaa aagcccacaa aaacgcaaca aaacaaagaa aacaaagcaa 2400
aaacaaaaac ggcaacccca ctggcaacac aaacagaaca aaaatgagac aaagttcacg 2460
aagagctaag agagagaaaa gcaaagcaca ggggaacatg gaacagaccc acatacagt 2520
caaacaggga cggcaacaaa cacaaaaaga acaagaacga gcaccgagaa gcacacccta 2580
aagaaaagca aaaagaaaac agaaca 2606

```

```

<210> 84
<211> 1850
<212> DNA
<213> Homo sapien

```

```

<400> 84
aagagtggta tcaacgcaga gkgcccatc cggccggggg ccgcatctt ggggctgctg 60
ggactcgcgt cggttggcga ctccgggacg taggtagttt gttgggcccg gttctgaggg 120
cttgyttctc tttacttttc cactctaggg cacgatgccg cagtaccaga cctgggagga 180

```

107

```

gttcagccgc gctgccgaga agctttacct cgctgaccct atgaaggcac gtgtgggttct 240
caaatatagg cattctgatg ggaacttgtg tgtgttaaag taacagatga tttagttaga 300
cagtgtcttg ctctatgtgc tccaggctgc agtgcaagtgg cttgatcatg gctcactgca 360
atcctcgacc tcctgggctc aagcggctct cttgcttcag cctcctgaat agcagagact 420
rcagggtgtg gtgtataaaa cagaccaagc tcaagatgta aagaagattg agaaattcca 480
cagtcaacta atgcgactta tggtagccaa aggaagcccg caatgttacc atggaaaact 540
gagtgaatgg tttgaaatga agactttgtc gtgtacttag ggaagtaa atcttttgaa 600
ttagagaaaag tgttgggaca gaaagtactt tatgtaacta agtgggctgt tcagaagctt 660
agaggtcatt tttgtaattt tcttttttaa ttactttaga gagctaggga tgcaaagtgt 720
ttcagttaga aagcctttat ttactttgtg gaaattgaac aagaaatgca tctgtcttag 780
aaactggaga ttattgatgt taggtaacac atgtaattgt ttctctggca aattwgtatc 840
agtaatttga aaatgagata ttaggaaaaa caattcttct taaatttagt tcatcttct 900
ttcaacacag caacatatca aatgtaaccc atattagtcc agatccatgt attatggagc 960
atacaaatgt atgctgtagt gaccaataaa tcataacata tggtaattgg cacttaactc 1020
cacaccacta gtatgcactt gttcatacac tactgtgtac ctaattatag tatacgcagt 1080
gtagtctcaa ttaataatct gaaacgtaac ttagtggcct aaacaagtat gcaatagaac 1140
ttattctacc acatatcaaa cactacccat gcaaaaactac tacacggggg atacacgcaa 1200
cacaactaca agacaataga ccagaacgca acgaggcact ataggacaaa acataagtca 1260
cacacaccaa cgacacacga aacccccac acacgcaata actagaccac tgatacggac 1320
actggcggaa cctgactgga aatccacaag atcgacaaa tacatcgga acccgccaca 1380
ccgaaaccca aaattagaca aggcaaaaat cacagcaacg acaccaataa ataagaagcc 1440
caacactaga cacacaagaa aacccccacc aaacggcgga ccaatgccaa tacaccagca 1500
aacgcacacc aaggacaaaa aaagacacga atgacacaaa accgtccga gggaaaaaaa 1560
cacaaacaga acacaaaaaa aacacaagaa acacacaaca ctaaaagccc aaaaaacgc 1620
aacaaaacaa agaaaacaaa gcaaaaacaa aaacggcaac cccactggca acacaaacag 1680
aacaaaaatg agacaaagtt cacgaagagc taagagagag aaaagcaaag cacagggaac 1740
catggaacag acccacatac agtgcaaaac gggacggcaa caaacacaaa aagaacaaga 1800
acgagcaccg agaagcacac cctaaagaaa agcaaaaaga aacagaaca 1850

```

<210> 85
<211> 924
<212> DNA

108

<213> Homo sapien

<400> 85

```

gcagggcttc cactacaccc ccacgtggcg agcgccatcc aagaccttgt gttcaggcag      60
aggctgggtc gggcccccac ctgcctgggc ctggccctct aagccccctt gggctccctc      120
gctgctctct gtggtgaagc ctgtgttgc ggtggagctt tagccagggt agtgcagcca      180
ggttaagttt ctccagggtg ccaaggggac agctgcacgg agtaaaaagg caagtggaag      240
gatgtggggc agaagggcaa gcacaataaa gctgaaattc accactagca aaacatcctc      300
agagtcaaaa gagccaagcc tgaatcagcg ttgctctttc acagcccaag ggtgaccoga      360
aaacgccccat cctgggcagc cttcctcgac tggcagggac tcaagggccg gaagtgcgag      420
gtggcctgtc caggctgtgc cagcatgcac cagggcaggg agcattctgc ccaaactatt      480
gactcggact acctgctcac agtctgcaga aggcacgctg gcggcctcaa gcggggctgc      540
atcctgcttc cttctcttgc tgggtatggc attagcagct tcccattcat cggatatgag      600
gtctacagca gcatctacca aaacctctga tgtagctccc tgttgaaaca cgacccccct      660
cagacagggc agggctgtgc accccacwgc acagctccag tagactcgca aagacccac      720
ctcagggggc acctcctctt gggaaggccc aggcagggac acccacatgt gggcactgac      780
cagcttccca gcaccgtctg cctccagggc ccatgggcag gaggggtgtg gaagacgaag      840
aagcagctcc tgcagmcgtg caggacaagt ccacgtaaga ggagaactgc ccacaccaga      900
ggcggcagca ctgccaggct cacg                                         924

```

<210> 86

<211> 847

<212> DNA

<213> Homo sapien

<400> 86

```

agcggagggg tcacctccg ctccacaggg tcggcagcag ggcggggcct ccggaagctc      60
cgccccacgc tttcccgggg cgcctgcgac gtgggcccga gcgtctggaa gctccgcccg      120
tcgcactgta ggtcggccg aggcgcacga ggtatttttc acgctccgcc cctctgcagg      180
ctaaagtgcg tgggcgggaa ggggtgggca ggggtgccatc tggctccgcc cttctcctgt      240
ggtgtggggc aggcggcggc ttccctcctc tgcagcagcc acaggctcca ctctgatcct      300
tctcccgcg catggatcct tctcccgcg cgtggatcct tctcccgcaa tctcgtgcg      360
cgtccccagt cagtaccgc agcctccga cgcacccgct ggctccaagc ctccctaccc      420
caggtttcct ggctaagaga gagacagagg gagagagggg ggaagacgag agaacaggca      480
atgggaggtg atggtgagag cttattggaa cagacaagag ggaggaaacc cacattcctt      540
cattccccat ccattcattt atggccttat gtattccatt gaatcttcac agctctagaa      600

```

109

```

aaaagtgtgc tacaattatt ccctttatta catgaggtca ctgaggcaca gttaaagaaa      660
atttgccagc aggcacagtg ggtcactccg gtaattcgca gaactttgag aagggggagg      720
aaggtggatc cattgaagcc caggaagttg gagaccaggt ctgggcaaca atggggggaga      780
ccccgtttct acaaaaactt aggcaaaatt agcaaaactgg ttcacacttg tagtcccagg      840
gtattca                                          847

```

```

<210> 87
<211> 1389
<212> DNA
<213> Homo sapien

```

```

<400> 87
cttcgggcct aaccacaaga ggcatgtctg gttccgagag agcatgaccg attggattcc      60
agttcgagta tgccgcctag ggctccgata ctgccgatgt ggcctatcca gctgaaccttt      120
ctgcgcctga tgtccactgg aggcctccca ggacatcacc taccactgca agaacagcgt      180
ggcctacatg gaccagcaga ctggcaacct caagaaggcc tgctcctcca gggctcaacg      240
agatcgagat ccgcgccgag ggcaacagcc gcttcacctc cagcgtcact gtcgatggct      300
gcacgagtca caccggagcc tggggcaaga cagtgattga atacaaaacc accaagacct      360
ccgcctgcc catcatcgat gtggccccct tggacgttgg tgcccagac caggaattcg      420
gcttcgacgt tggcctgtc tgcttctgt aaactccctc catcccaacc tggctccctc      480
ccaccaacc aactttcccc ccaaccggga aacagacaag caacccaaac tgaacccct      540
caaaagccaa aaaatgggag acaatttcac atggactttg gaaaatatTT ttttctttg      600
cattcatctc tcaaacttag tttttatctt tgaccaaccg aacatgacca aaaacaaaa      660
gtgcattcaa ccttaccaa aaaaaawww wamamaarga ttawttaatt ttttttsmam      720
aaggaagctg ggccccctgg cttgaaaacc catgcggggg taggtccctt ttggcccgtg      780
gggtttttga aacccaatg gcgtgccctt tcgagctcct tttctcaaaa cccccctggg      840
ggccttcccc tccactcctt cccaaattct ggtctcccca gaagacacag ggaaacattg      900
tttggctctg ccagcaaata aagggcaatg ctcaaacacc catggggggc ccaacccttc      960
agcccgctcg tgcccgcaa agaacccaa ggccctgggg gacatggggc tcgcttcaga      1020
gttgccaaaa aaagccttgt gccaaatcag ggggcctccc aaggggctct gttgaaaaca      1080
ttgtcccta cggatgatg gaggggggtc aatgccgggg ggaagccacc aaggcccat      1140
caacggggat tccagaagga gcagccagca aggggccac ggctacgaaa taaccgccga      1200
gaaaccaccg gttgggcgga accgcgtgtc aaataccctt gggtgcccgc aaggggacggg      1260
gaccggcgca gagcatggtg ctgtacttgg tgttactggt gtgcgcggaa aaaatacccc      1320

```

110

ggcctgggtcc tggaggtgcc ccgcgacaaa ttgactgcgg cgggaatgaa gacagatgaa 1380
 ggaccccat 1389

<210> 88
 <211> 3429
 <212> DNA
 <213> Homo sapien

<400> 88
 ctgtagtgat ctgaggatcc cttcgattgg tgtgggaact tattgggtgct ctgagtagag 60
 ggcctgatga ggttgacagt aatgattgaa agaggcattt gagtgattca cagtactaat 120
 gcgggttctc ggccctatgt tgccaccagc aactgcacag ctctgtctgt ttgacccaag 180
 agcagtagct ggtctgtaca ttcccttgta tgatcataag ttgcccgcca atcgaatcga 240
 tttgcgtgga caacttaact tataacattt taagtaaaat catgcatttt aggcagacag 300
 acatctcact ttttagtata tttccttct tctagaggat tatttgggtgt gtgtctgcgt 360
 gtgaccgtgt gtgtttattg aaaggaaaca gttccgtgtt tagagttttg ggttgttagt 420
 tagagggtcta gttaagctat aaaattacag tggaataagt gatgacagcc agttagtaca 480
 gttccctctt atagctgaac tgagcttaac acaccaacag aaatgtttgg caaatagact 540
 gctaaaatga ctctttcctt tgtggggaca taagttgcct gacatttaca tgtttataat 600
 gagtcctgga agtagaaatg aaaatatgtg cagaaaatag atttctatca tcacttcctt 660
 ttcttattga gggtagcatt gtccagtacg tttttgtcat ctctgtgctt tcttgttgctc 720
 caccataca ggaagaatgt tggtgaaaag cacagaaacc agtgacgttt gtggctgtgg 780
 aatttocatg gagaaaagag agcatctgaa cacctggacc atcttttgca cctggcagac 840
 cctctgcact caccacagcg tgttctgtga acttgagtga caacgcgtgc ttgcaggggtg 900
 ctttttggat gactggggaa gaggtgggga ggggggtggtg gggggaagca tggacgagaa 960
 catggagcaa atgttttaca acctgaacct cagaactgtg atcctccaag gagcgcgcta 1020
 cttgaagaaa agaaaaaaaa aaaaaaaagt cgaatggctt ctgagggatt ttgttttccg 1080
 tgcacatata agccatagtt acagtacagg tggcagtatt tagagcactc agatttcagt 1140
 tctgttaaata gtgaaagagg gatcgactga cgttcattgc tgttcataa ctagtgtaaa 1200
 atatgtatat gtttatcttt atttttataa tatgcaaata catttaaatt tatacagttt 1260
 gaagcttcta gcgttagttc aactgggtg caatattctg catgagaact gtgccaagat 1320
 ggggctgatt tcttatttta gtataagact tttttgtttt ttctttattc tttaatcctc 1380
 ttcacattaa aaaaaaaaaa tctctctgtt agcccatgga ttaagtgttg gttcatagag 1440
 attgccaata atcagaaaga accttaaatg tgcatttaag acagtgtccc ttcccttctt 1500

ttcaatgaag gtccctgcct atataaatca tctggcacgc tgggtgggaaa tcctttgctc	1560
ttccaacgtg ttattagtgc tgggcagaga tggggcacac tcaggggcca aagaggacaa	1620
aaagtccatg caaaacttga gtcttttaat ggcttaagat aatcaggagt cagttctgaa	1680
tcttacaaag tgctctgctt aataagtacc ttacttagca gagcactttg caaacatatt	1740
acttattagc agagctcttt gtagaccttc cacatctggc tgtcagatct taaggttgtg	1800
aatttaggct ccagttatat tcactggaga gcataatccc acacgggtta ttataaata	1860
cagagcctct gattggacgg tctcctgcca agaactagta atacccttgt tttaaaatct	1920
tcacaaggta aaacttaaaa agccaaccaa acaaattgct ctccattcta cttttaattg	1980
ggccaaacag catatgctac agtagtaaca tgtttttcgg agagtgtaaa aaactctgtt	2040
tacatttgcc tcctccgtgg gttgatcgaa aatgtataaa actgactgct tctcgccagc	2100
ctcagacaag aagagtgagt tgctggtact cgctactctt ttacttcttt tgtaaagtat	2160
tgactcttgg aaggctacag tatacaaagt ctcaacatgt tttttaaaag aaataaggag	2220
caagcgactg ccctgctaga aatcacaaac cgatttttgt agaataattt gtgccccagg	2280
cattaatttc actgactcca gaacctgcag ttcagagaat gatttcttat gatgataaaa	2340
atcgaatggg atcagacgat gtttgcatth ttttaataact tgaataggac acctcaagtt	2400
tgagatttca ttttctttta gaacacagtc acaagattaa tctggtgaat ccttttgtca	2460
cagttctcgt gtgtgtgtgc gcgtctccgt gtgtgtgtgt gtgcatgtgt gtaaaactga	2520
atggtcacat ttaattgctt tttggaccat tgaatagttg ggaagtaaga attttttaat	2580
tggcatgaga cggttcctca actgttaaat taaccaactt tgacctgtct ttagaaaaag	2640
gcttatttgt atgattttgg gctaactccc cggggaccat attaaatgac aaaaatgctc	2700
ctttgggtga cacaccctac aaagtatttg ctgttacgaa cataaacgcc cacattctta	2760
atatctaata tttttgacca gtgatgtttt atgctgtcat ctgaacccta gagaagcagt	2820
gtcagaggaa accttggtgt cacatgtgtc ttagcaaaaag ggttaccatg atcgagggtc	2880
atgtgaccaa aagatgctcc agagaagctt gagaatttgt ttcaagttgg gaggagggtt	2940
ggagatacaa aaatcactct gctctacagg actcttcagc tgtctatgca agaaattccg	3000
ttttctcttt cagcacctgg aaagacacag cagcccaccg aggcgatagg tgattcacta	3060
agcacaagag gaatgttttc taagcaaggc gtcccttgcc tctcaaacia atgcctcca	3120
agtttgtag ggtttctatt cctgcaactt gtggtatcaa aaccacttcc tggattgtc	3180
aaagcactgc caaaataaat gtttttcccc cttctaagaa aaaaaaatg acagtgtctc	3240
tatttgacac ttgtgtattg gactctcttt tgaatgaata aaaaggaaaa ggggtttggt	3300

112

gtaattcctg atgggggtgcg tgttggtttt catgccatgg tttgtgaatt ttaattgtgg 3360
 tttcccatTT cgttggttga actgggcaga aattaaaaaa gaaaaatcaa taaaaataca 3420
 aagaaatgg 3429

<210> 89
 <211> 1633
 <212> DNA
 <213> Homo sapien

<400> 89
 atcaatgaac ccgcaatcat gaaacttctg acaccaccag gagctgactc acacctgaac 60
 agtacaccgt cgaagcttcg acggtctcct gccagaact agtaataccc ttgtttttaa 120
 atcttcacaa ggtaaaactt aaaaagccaa ccaaacaat tgctctccat tctactttta 180
 attggggcaa acagcatatg ctacagtagt aacatgtttt tccgagagtg taaaaactc 240
 tgtttacatt tgctctctcc gtgggttgat cgaaaatgta taaaactgac tgcttctcgc 300
 cagcctcaga caagaagagt gagttgctgg tactcgctac tcttttactt cttttgtaaa 360
 gtattgactc ttggaaggct acagtataca aagtctcaac atgtttttta aaagaataa 420
 ggagcaagcg actgccctgc tagaaatcac aaaccgattt ttgtagaata ttttgtgccc 480
 caggcattaa tttcactgac tccagaacct gcagttcaga gaatgatttc ttatgatgat 540
 aaaaatcgaa tgggatcaga cgatgtttgc atttttttta tacttgaata ggacacctca 600
 agtttgagat ttcattttct tttagaacac agtcacaaga ttaatctggg gaatcctttt 660
 gtcacagttc tcgtgtgtgt gtgcgcgtct ccgtgtgtgt gtgtgtgcat gtgtgtaaaa 720
 ctgaatgggc acattttaatt gcttttttga ccattgaata gttgggaagt aagaattttt 780
 taattggcat gagacggttc ctcaactggt aaattaacca actttgacct gtcttttagaa 840
 aaaggcttat ttgtatgatt ttgggctaac tccccgggga ccatattaaa tgacaaaaat 900
 gctccttttg gtgacacacc ctacaaagta tttgctgtta cgaacataaa cgccacatt 960
 cttaatatct aatatttttg accagtgatg ttttatgctg tcacttgaac cctagagaag 1020
 cagtgtcaga ggaaaccttg gtgtcacatg tgtcttagca aaagggttac catgatcgag 1080
 ggtcatgtga ccaaaagatg ctccagagaa gcttgagaat ttgtttcaag ttgggaggag 1140
 ggttgagat acaaaaatca ctctgctcta caggactctt cagctgtcta tgcaagaaat 1200
 tccgttttct ctttcagcac ctggaaagac acagcagccc accgaggcga taggtgattc 1260
 actaagcaca agaggaatgt tttctaagca aggcgtccct tgctctcaa acaaatgccc 1320
 tccaagtttg ttagggtttc tattcctgca acttggtgta tcaaaaccac ttcttggaat 1380
 tgtcaaagca ctgcaaaaat aaatgttttt ccccttcta agaaaaaaaa aatgacagtg 1440

113

ctcatatttg acacttgtgt attggactct cttttgaatg aataaaaagg aaaaggggtt 1500
 tgggtgtaatt cctgatgggg tgcgtgttgt ttttcatgcc atggtttgtg aattttaatt 1560
 gtggtttccc atttcgttgt tgtaactggg cagaaattaa aaaagaaaaa tcaataaaaa 1620
 tacaagaaa tgg 1633

<210> 90
 <211> 857
 <212> DNA
 <213> Homo sapien

<400> 90
 tgccacttac gcgtcgctct tcctcgtttg cccctcgtgt tcatgggagc tcgttttctt 60
 ttctcttagg cagagaagag gcgatggcgg cgatggcatc tctcggcgcc ctggcgctgc 120
 tcctgctgtc cagcctctcc cgctgctcag ccgaggcctg cctggagccc cagatcacc 180
 ctctactacta caccattct gacgtgtca tttccactga gaccgtcttc attgtggaga 240
 tctccctgac atgcaagaac aggtccaga acatggctct ctatgctgac gtcggtggaa 300
 aacaattccc tgtcactcga ggccaggatg tggggcggtta tcagggtgtcc tggagcctgg 360
 accacaagag cgcccacgca ggacactatg aggttagatt ctctgacgag gagtcctaca 420
 gcctctcag gaaggctcag aggaataacg aggacatttc catcatccc cctctgttta 480
 cagtcagcgt ggaccatcgg gtgagtggcc tgggtccctcc tccttttttg ggttggtggg 540
 ctgagtgaag gttatcctct ccacagcccc agctctgctg ctgggccgtg attggccagc 600
 atgtcttggg tcccctggcg gaaggtgacc agggctggct ggtctgctca cctgtactcc 660
 cctgagctgg ctgtgatct cttttttttc agggcacttg gaacgggccc tgggtgtcca 720
 ctgaggtgct ggctgcggcg atcggccttg tgatctacta cttggccttc agtgccaaga 780
 gccacatcca ggctgaggg cggcacccca gccctgcct tgcttccttc aataaacatc 840
 acaggacctg ggactgc 857

<210> 91
 <211> 876
 <212> DNA
 <213> Homo sapien

<400> 91
 tgccacttac gcgtcgctct tcctcgtttg cccctcgtgt tcatgggagc tcgttttctt 60
 ttctcttagg cagagaagag gcgatggcgg cgatggcatc tctcggcgcc ctggcgctgc 120
 tcctgctgtc cagcctctcc cgctgctcag gaaacgctgg ggccagtctt caccctctgt 180
 caactggccg ggggcagaga ccttttctct catcttgaaa gcccagtgct attgcctgcc 240
 tgcagccccc acccccgatg tctctgctga ggatgccttc agtaactcgt ccaggccgtt 300

114

```

tgtggctctg aattgaggct ggctggccc cggggcctcc gtgtcatagg tccaagtgtt 360
gccgaggcct gcctggagcc ccagatcacc ccttcctact acaccacttc tgacgctgtc 420
atctccactg agaccgtctt cattgtggag atctccctga catgcaagaa cagggtccag 480
aacatggctc tctatgctga cgtcgggtga aaacaattcc ctgtcactcg aggccaggat 540
gtggggcggt atcagggtgtc ctggagcctg gaccacaaga gcgccacgc aggcacctat 600
gaggtttagat tcttcgacga ggagtcctac agcctcctca ggaaggctca gaggaataac 660
gaggacattt ccatcatccc gcctctgttt acagtacgag tggaccatcg gggcacttgg 720
aacggggcct ggggtgtccac tgagggtgctg gctgcggcga tcggccttgt gatctactac 780
ttggccttca gtgcgaagag ccacatccag gcctgagggc ggcaccccag ccctgccctt 840
gcttccttca ataaacatca caggacctgg gactgc 876

```

```

<210> 92
<211> 2396
<212> DNA
<213> Homo sapien

```

```

<400> 92
cagatctcaa ttatctaatt gcaattgcaa cgagaaccaa agcaggggag cagagacaaa 60
caattttctga ggtaaccaga tggctttatt aactcaagtt ctcacctaaa attgccctca 120
agaatcctgt gggaatgggt tgcaagtgggt tggccctgga ttcacaaccg acagagcttc 180
tgaattctga gtgatctgta cacaacacac cctctgcctg gggtacacgc ctccacgttc 240
ctctatccag ttcccgccacc cttcccccca ggccccatcc ttcaaggctt cagagcagcg 300
ctcctccggt taaaaggaag tctcagcaca gaatcttcaa acctcctcgg aggccaccaa 360
agatccctaa cgccgccatg gagacgaagc acctggggcg gggcgagcg gggcgcgcg 420
gccacacact gtggagaggg ccgcgccccca actgcagcgc cggggctggg ggaggggagc 480
ctactcactc cccaactcc cgggcggtga ctcatcaacg agcaccagcg gccagaggtg 540
agcagtcccg ggaagggggc gagaggcggg gcgcgcaggt cgggcaggtg tgcgtccgc 600
ccgcgcgcgc gcacagagcg ctagtccctc ggcgagcgag caccttcgac gcggtccggg 660
gacccccctc tcgctgtcct ccgcagcggg acccgcgctg ccaggcctc gcgctgccc 720
gcgggtcct cgtgtccac tcccggcgca cgccctcccg cgagtcccg gccctcccg 780
cgccctctt ctggcgcggc gcgcagcatg gcgccccgc aggtcctcgc gttcgggctt 840
ctgcttgccg cggcgacggc gacttttgcc gcagctcagg aagaatgtgt ctgtgaaaac 900
tacaagctgg ccgtaaaactg ctttgtgaat aataatcgtc aatgccagtg tacttcagtt 960
ggtgcacaaa atactgtcat ttgctcaaag cgtgagtaaa atactcctaat tacctgtaag 1020

```

115

ctttatatttg acttaatact tctttaattg atgtgccttg agttggaaag agttttattg 1080
 gcttaaactct gaatcatggt acaaagtaag tgtgggaaca cataaatttc aaataatctt 1140
 tgaccttgga acttttagagt taattttttt tttcccgtaa tcatgaaatc agttattttt 1200
 cagtttggca ttaagggttc tttttcagtg gctgccaaat gtttgggtgat gaaggcagaa 1260
 atgaatggct caaaacttgg gagaagagca aaacctgaag gggccctcca gaacaatgat 1320
 gggcttttatg atcctgactg cgatgagagc gggctcttta aggccaagca gtgcaacggc 1380
 acctccatgt gctgggtgtg gaacactgct ggggtcagaa gaacagacaa ggacactgaa 1440
 ataacctgct ctgagcgagt gagaacctac tggatcatca ttgaactaaa acacaaagca 1500
 agagaaaaac cttatgatag taaaagtttg cggactgcac ttcagaagga gatcacaacg 1560
 cgttatcaac tggatccaaa atttatcacg agtattttgt atgagaataa tgttatcact 1620
 attgatctgg ttcaaaattc ttctcaaaaa actcagaatg atgtggacat agctgatgtg 1680
 gcttattatt ttgaaaaaga tgttaaagggt gaatccttgt ttcattctaa gaaaatggac 1740
 ctgacagtaa atggggaaca actggatctg gatcctggtc aaactttaat ttattatggt 1800
 gatgaaaaag cacctgaatt ctcaatgcag ggtctaaaag ctggtgttat tgctgttatt 1860
 gtggttgttg tgatagcagt tgttgctgga attgttgtgc tggttatttc cagaaagaag 1920
 agaatggcaa agtatgagaa ggctgagata aaggagatgg gtgagatgca tagggaactc 1980
 aatgcataac tatataattt gaagattata gaagaaggga aatagcaaat ggacacaaat 2040
 tacaaatgtg tgtgctggg acgaagacat ctttgaagggt catgagtttg ttagtttaac 2100
 atcatatatt tgtaatagtg aaacctgtac tcaaaatata agcagcttga aactggcttt 2160
 accaatcttg aaatttgacc acaagtgtct tatatatgca gatctaattg aaaatccaga 2220
 acttggactc catcgtaaa attatttatg tgtaacattc aaatgtgtgc attaaatatg 2280
 cttccacagt aaaatctgaa aaactgattt gtgattgaaa gctgcctttc tatttacttg 2340
 agtcttgtac atacatactt ttttatgagc tatgaaataa aacattttaa actgaa 2396

<210> 93
 <211> 1813
 <212> DNA
 <213> Homo sapien

<400> 93
 cagatctcaa ttatctaatt gcaattgcaa cgagaaccaa agcaggggag cagagacaaa 60
 caatttctga ggtaaccaga tggctttatt aactcaagtt ctcacctaaa attgccttca 120
 agaatcctgt gggaatgggt tgcagtgggt tggccctgga ttcacaaccg acagagcttc 180
 tgaattctga gtgatctgta cacaaacaca cctctgcctg gggttacogc ctccacgttc 240

116

```

ctctatccag ttcccgccacc cttcccccca ggccccattc ttcaaggctt cagagcagcg      300
ctcctccggt taaaaggaag tctcagcaca gaatcttcaa acctcctcgg aggccaccaa      360
agatccctaa cgccgccatg gagacgaagc acctggggcg gggcggagcg gggcgcgcg      420
gcccacacct gtggagaggg ccgcgcccca actgcagcgc cggggctggg ggaggggagc      480
ctactcactc cccaactcc cgggcggtga ctcatcaacg agcaccagcg gccagagaat      540
gtgtctgtga aaactacaag ctggccgtaa actgctttgt gaataataat cgtcaatgcc      600
agtgtacttc agttgggtga caaaatactg tcatttgcgc aaagctggct gccaaatgtt      660
tggtgatgaa ggcagaaatg aatggctcaa aacttgggag aagagcaaaa cctgaagggg      720
ccctccagaa caatgatggg ctttatgatc ctgactgcga tgagagcggg ctctttaagg      780
ccaagcagtg caacggcacc tccatgtgct ggtgtgtgaa cactgctggg gtcagaagaa      840
cagacaagga cactgaaata acctgctctg agcgagtga aacctactgg atcatcattg      900
aactaaaaca caaagcaaga gaaaaacctt atgatagtaa aagtttgcg actgcacttc      960
agaaggagat cacaacgcgt tatcaactgg atccaaaatt tatcacgagt attttgtatg     1020
agaataatgt tatcactatt gatctggttc aaaattcttc tcaaaaaact cagaatgatg     1080
tggacatagc tgatgtggct tattattttg aaaaagatgt taaagggtgaa tccttgtttc     1140
attctaagaa aatggacctg acagtaaatt ggggaacaact ggatctggat cctggtaaaa     1200
ctttaattta ttatgttgat gaaaaagcac ctgaattctc aatgcagggg ctaaaagctg     1260
gtgttattgc tgttattgtg gttgtggtga tagcagttgt tgctggaatt gttgtgctgg     1320
ttatttccag aaagaagaga atggcaaagt atgagaaggc tgagataaag gagatgggtg     1380
agatgcatag ggaactcaat gcataactat ataatttgaa gattatagaa gaagggaat      1440
agcaaatgga cacaattac aaatgtgtgt gcgtgggacg aagacatctt tgaagggtcat     1500
gagtttgtaa gtttaacatc atatatttgt aatagtgaac cctgtactca aaatataagc     1560
agcttgaaac tggctttacc aatcttgaaa tttgaccaca agtgtcttat atatgcagat     1620
ctaattgtaa atccagaact tggactccat cgttaaaatt atttatgtgt aacattcaaa     1680
tgtgtgcatt aaatatgctt ccacagtaaa atctgaaaaa ctgatttgtg attgaaagct     1740
gcctttctat ttacttgagt cttgtacata catacttttt tatgagctat gaaataaaac     1800
attttaaact gaa                                     1813

```

```

<210> 94
<211> 1843
<212> DNA
<213> Homo sapien

```

117

<400> 94
 cagatctcaa ttatctaatt gcaattgcaa cgagaaccaa agcaggggag cagagacaaa 60
 caatttctga ggtaaccaga tggctttatt aactcaagtt ctcacctaaa attgccctca 120
 agaatcctgt gggaatgggt tgcatgggtg tggccctgga ttcacaaccg acagagcttc 180
 tgaattctga gtgatctgta cacaaacaca cctctgcctg gggttacacgc ctccacgttc 240
 ctctatccag ttcccgccacc cttcccccca ggccccattc ttcaaggctt cagagcagcg 300
 ctctctccgt taaaaggaag tctcagcaca gaatcttcaa acctcctcgg aggccaccaa 360
 agatccctaa cgccgccatg gagacgaagc acctggggcg gggcgaggcg gggcgcgcg 420
 gcccacacct gtggagaggg ccgcccccca actgcagcgc cggggctggg ggaggggagc 480
 ctactcactc ccccaactcc cggcggggtga ctcatcaacg agcaccagcg gccagaggtg 540
 agcagtcccg ggaagggggc gagaggcggg gccgccaggt cgggcaggtg tgcgtccgc 600
 ccgcccgcgc gcacagagcg ctagtcttcc ggcgagcgag caccttcgac gcggtccggg 660
 gacccccctg tcgctgtcct cccgacgcgg acccgcggtg cccaggcctc gcgctgcccg 720
 gccggctcct cgtgtccac tcccggcgca cgccctcccg cgagtcccg gccctcccg 780
 cgccctctt ctggcgcggc gcgcagcatg gcgccccgc aggtcctcgc gttcgggctt 840
 ctgcttgccg cggcgacggc gacttttgcc gcagctcagg aagaatgtgt ctgtgaaaac 900
 tacaagctgg ccgtaaactg ctttgtgaat aataatcgtc aatgccagtg tacttcagtt 960
 ggtgcacaaa atactgtcat ttgctcaaag ctggctgcc aatgtttggg gatgaaggca 1020
 gaaatgaatg gctcaaaact tgggagaaga gcaaaacctg aaggggccct ccagaacaat 1080
 gatgggcttt atgatcctga ctgcgatgag agcgggctct ttaaggccaa gcagtgcac 1140
 ggcacctcca tgtgctgggt tgtgaacact gctgggggtc gaagaacaga caaggacact 1200
 gaaataacct gctctgagcg agtgagaacc tactggatca tcattgaact aaaacacaaa 1260
 gcaagagaaa aaccttatga tagtaaaagt ttgcggactg cacttcagaa ggagatcaca 1320
 acgcgttato aactggatcc aaaatttato acgagtatct tgtatgagaa taatgttato 1380
 actattgato tggttcaaaa ttcttctcaa aaaactcaga atgatgtgga catagctgat 1440
 gtggcttatt attttgaaaa agatgatgtg agtatcatct tctttattcc tgtgttcagg 1500
 aatgtagtct atcatgcctc aatgaattaa atatatctca tcaccttttt atccacttac 1560
 agatcaacca aatgggttcgc tgctgccgtt aattttgtcc tccctgtcac tcacatgcat 1620
 cttgcttggt tgtatattta tgcctcttat caaattgttc tgcctaaaaat atctccctc 1680
 tttcttataa ttcttattta ttatctactt ggtgggttact tagtttgtgc atatatgctc 1740
 ccctatgata ttataatctt acacaaataa aagtctgtta aaaaagactg taactgatat 1800

118

gattaaaata ttttgttgaa actttaatat attatagtga ggt 1843

<210> 95

<211> 2387

<212> DNA

<213> Homo sapien

<400> 95

cagatctcaa ttatctaatt gcaattgcaa cgagaaccaa agcaggggag cagagacaaa 60

caattttctga ggtaaccaga tggcttttatt aactcaagtt ctcacctaaa attgccctca 120

agaatcctgt gggaatgggt tgcagtgggtg tggccctgga ttcacaaccg acagagcttc 180

tgaattctga gtgatctgta cacaacaca cctctgcctg ggttacacgc ctccacgttc 240

ctctatccag ttcccgccacc cttcccccca ggccccattc ttcaaggctt cagagcagcg 300

ctcctccggt taaaaggaag tctcagcaca gaatcttcaa acctcctcgg aggccaccaa 360

agatccctaa cgccgccatg gagacgaagc acctggggcg gggcgagcg gggcgcgcg 420

gcccacacct gtggagaggg ccgcgccccca actgcagcgc cggggctggg ggaggggagc 480

ctactcactc cccaactcc cggcgcggtga ctcatcaacg agcaccagcg gccagaggtg 540

agcagtcccg ggaagggggc gagaggcggg gccgccaggt cgggcaggtg tgcgctccgc 600

cccgcgcgcg gcacagagcg ctagtcttcc ggcgagcgag caccttcgac gcggtccggg 660

gacccccctcg tcgctgtcct cccgacgcgg acccgcggtgc cccaggcctc gcgctgcccg 720

gccggctcct cgtgtccac tcccggcgca cgccctcccg cgagtcccg gcccctcccg 780

cgccccctct ctcggcgcgc gcgcagcatg gcgccccgc aggtcctcgc gttcgggctt 840

ctgcttgccg cggcgacggc gacttttgcc gcagctcagg aagggtgaggc gcggattgga 900

gcagagttgt ggagctgggc tgggctgggg ggcagcgggc cccggccctc ggccccgaa 960

acgggcataa tagggagggg accaagaggc cgcgctttcc agcgtggaga ccggacgggtg 1020

cggccgtgct ccggctcagg ccctccgcgc ggtaggaaac ggcgagggcc gtcccgggga 1080

gcagcctcac ttgcagctt tgctcgctt gaatgtgtct gtgaaaacta caagctggcc 1140

gtaaactgct ttgtgaataa taatcgtcaa tgccagtgtg cttcagttgg tgcacaaaat 1200

actgtcatth gctcaaagct ggctgccaaa tgtttggtga tgaaggcaga aatgaatggc 1260

tcaaaacttg ggagaagagc aaaacctgaa ggggcccctc agaacaatga tgggctttat 1320

gatcctgact gcgatgagag cgggctcttt aaggccaagc agtgcaacgg cacctccatg 1380

tgctggtgtg tgaacactgc tggggtcaga agaacagaca aggacactga aataacctgc 1440

tctgagcgag tgagaaccta ctggatcatc attgaaacta aacacaaagc aagagaaaaa 1500

ccttatgata gtaaaagttt gcggactgca cttcagaagg agatcacaac gcgttatcaa 1560

119

```

ctggatccaa aatttatcac gagtattttg tatgagaata atgttatcac tattgatctg 1620
gttcaaaatt cttctcaaaa aactcagaat gatgtggaca tagctgatgt ggcttattat 1680
tttgaaaaag atgttaaagg tgaatccttg tttcattcta agaaaatgga cctgacagta 1740
aatggggaac aactggatct ggatcctggg caaactttaa tttattatgt tgatgaaaaa 1800
gcacctgaat tctcaatgca ggggtctaaaa gctgggtgta ttgctgttat tgtggttgtg 1860
gtgatagcag ttgttgctgg aattgttgtg ctgggtatatt ccagaaagaa gagaatggca 1920
aagtatgaga aggctgagat aaaggagatg ggtgagatgc ataggggaact caatgcataa 1980
ctatataatt tgaagattat agaagaaggg aaatagcaaa tggacacaaa ttacaaatgt 2040
gtgtgcgtgg gacgaagaca tctttgaagg tcatgagttt gttagtttaa catcatatat 2100
ttgtaatagt gaaacctgta ctcaaaatat aagcagcttg aaactggctt taccaatctt 2160
gaaatttgac cacaagtgtc ttatatatgc agatctaata taaaatccag aacttggact 2220
ccatcgtaa aattatttat gtgtaacatt caaatgtgtg cattaaatat gctccacag 2280
taaaatctga aaaactgatt tgtgattgaa agctgccttt ctatttactt gagtcttgta 2340
catacatact tttttatgag ctatgaaata aaacatttta aactgaa 2387

```

```

<210> 96
<211> 1528
<212> DNA
<213> Homo sapien

```

```

<400> 96
cggcgagcga gcaccttcga cgcggtccgg ggacccccctc gtcgctgtcc tcccgaacgcg 60
gacccgcgtg cccagggcct cgcgctgccc ggccgggctcc tcgtgtccca ctcccggcgc 120
acgcctctcc gcgagtcctg ggcctctccc gcgcctctct tctcggcgcg cgcgcagcat 180
ggcgcccccg caggctctcg cgttcgggct tctgcttgcc gcggcgacgg cgacttttgc 240
cgcagctcag gaagaatgtg tctgtgaaaa ctacaagctg gccgtaaaact gctttgtgaa 300
taataatcgt caatgccagt gtacttcagt tgggtgcacaa aatactgtca tttgctcaaa 360
gctggctgcc aaatgtttgg tgatgaaggc agaaatgaat ggctcaaaac ttgggagaag 420
agcaaaacct gaagggggccc tccagaacaa tgatgggctt tatgatcctg actgogatga 480
gagcgggctc tttaaggcca agcagtgcaa cggcacctcc acgtgctggg gtgtgaacac 540
tgctgggggtc agaagaacag acaaggacac tgaaataacc tgctctgagc gagtgagaac 600
ctactggatc atcattgaac taaaacacaa agcaagagaa aaaccttatg atagtaaaag 660
tttgcggaact gcacttcaga aggagatcac aacgcgttat caactggatc caaaatttat 720
cacgagtatt ttgtatgaga ataatgttat cactattgat ctgggttcaa attcttctca 780

```

120

```

aaaaactcag aatgatgtgg acatagctga tgtggcttat tattttgaaa aagatgttaa      840
aggtgaatcc ttgtttcatt ctaagaaaat ggacctgaca gtaaattggg aacaactgga      900
tctggatcct ggtcaaaactt taatttatta tgttgatgaa aaagcacctg aattctcaat      960
gcaggggtcta aaagctgggtg ttattgctgt tattgtgggt gtggtgatag cagttgttgc    1020
tggaattggt gtgctgggta tttccagaaa gaagagaatg gcaaagtatg agaaggctga    1080
gataaaggag atgggtgaga tgcataggga actcaatgca taactatata atttgaagat    1140
tatagaagaa gggaaatagc aaatggacac aaattacaaa tgtgtgtgcg tgggacgaag    1200
acatctttga aggtcatgag tttgttagtt taacatcata tatttgtaat agtgaaacct    1260
gtactcaaaa tataagcagc ttgaaactgg ctttaccaat cttgaaattt gaccacaagt    1320
gtcttatata tgcagatcta atgtaaaatc cagaacttgg actccatcgt taaaattatt    1380
tatgtgtaac attcaaatgt gtgcattaaa tatgcttcca cagtaaaatc tgaaaaactg    1440
atgtgtgatt gaaagctgcc tttctattta cttgagtcct gtacatacat acttttttat    1500
gagctatgaa ataaaacatt ttaaactg                                     1528

```

```

<210> 97
<211> 748
<212> DNA
<213> Homo sapien

```

```

<400> 97
tcgccctttc gagcggcgcc cgggcaggta ctccgtgtgg atcggcggct ccatcctggc      60
ctcgtgtgcc accttccagc agatgtggat cagcaagcag gagtatgacg agtccggccc    120
ctccatcgtc caccgcaaat gcttctaggc ggactatgac ttagttgcgt tacacccttt    180
cttgacaaaa cctaacttgc gcagaaaaca agatgagatt ggcatggctt tatttgtttt    240
ttttgttttg ttttggtttt tttttttttt ttggcttgac tcaggattta aaaactggaa    300
cgggtgaaggc gacagcagtc ggttggagcg agcatcccc aaagttcaca atgtggccga    360
ggactttgat tgcacattgt tgttttttta atagtcattc caaatatgag atgcgttggt    420
acaggaagtc ccttgccatc ctaaaagcca cccacttct ctctaaggag aatggcccag    480
tcctctccca agtccacaca ggggagggtga tagcattgct ttcgtgtaaa ttatgtaatg    540
caaaattttt ttaatcttcg ccttaatact tttttatttt gttttatttt gaatgatgag    600
ccttcgtgcc ccccttccc ccttttttgt cccccaactt gagatgtatg aaggcttttg    660
gtctccctgg gagtgggtgg aggcagccag ggcttacctg tacactgact tgagaccagt    720
tgaataaaaag tgcacacctt aaaaatga                                     748

```

```

<210> 98

```

121

<211> 2221
 <212> DNA
 <213> Homo sapien

<400> 98
 agagcaagga agggcagggg acctgggaag gaagttctgg aaggcagtgg ggtttgagat 60
 tggacccagg gtcaagatag aacatgaagg tgggatgagg acatgaacag aacatggcca 120
 agaaggatct gggggagcag ccaggacgag gcgagactga tccgagagga catccagggg 180
 gctctgcaca attaccgctc gggccgcggg gagcgcaggg cggcggcgct cagggccacg 240
 caggaggagt tgcagcgcga ccgctcgccc gccgctgaga ccccgcccct gcagcgcgc 300
 ccgtcagtcg gcgcagtgat cagcaccgta gagcggggcg cgggcccggg acgaccccag 360
 gcgaagccca ttcccagggc agaggaggcg cagaggcctg agccgggtggg gacctcgagc 420
 aacgctgact cggcctcccc ggacctgggt ccccggggtc ctgacctggc ggttctgcag 480
 gcgagcgagg aagtggacat cctgaaccac gtgttcgacg acgtagagag ctttgtatcg 540
 aggctgcaga agtcggcgga ggcggccagg gtgctggagc accgggaacg cggccgcagg 600
 agccggcgcc gggcggtggg ggagggttg ctgacgctgc gggccaagcc gccctcgag 660
 gccgagtaca ccgacgtgct gcagaagatc aagtacgcct tcagcctgct ggcccggctg 720
 cgcggcaaca tcgccgaccc ctctctctcg gagctgttgc acttcctttt cgggcctctg 780
 cagatgattg tgaacacgtc gggggggccg gagttcgcg gacgtgtgcg gcggccgcat 840
 ctgacatcgg atgccgtggc gctgctgcgg gacaacgtca ctccacgtga aaacgagctc 900
 tggacctcgc tgggggactc gtggaccgc cccgggctgg agctgtcccc ggaggaggga 960
 ccccatatac gacccgagtt cttcagcggc tgggagccgc cggtcactga cccgcagagc 1020
 cgcgcctggg aggaccaggt tgagaaacag ctacagcacg agcggaggcg ccggcagcaa 1080
 agcgcctccc aggtcgctgt caatggtcac cgagacttgg agccagaatc tgagcctcag 1140
 ctggagtcag agacagcagg aaaatgggtc ctgtgtaatt atgacttcca ggcccgaac 1200
 agcagtgagc tgtcgggtcaa gcagcgggac gtactggagg tcctggatga cagtcgtaag 1260
 tgggtggaagg ttcgggaccc agcggggcag gagggatatg tgccctacaa catcctgaca 1320
 ccctaccccg gaccccggtt gcaccacagc caaagccctg cccgcagcct gaacagcact 1380
 cctcctccac caccagcccc agccccggcc ccacctccag ctctggctcg gccccgctgg 1440
 gacaggcccc gctgggacag ctgcgatagc ctcaacggct tggacccag cgagaaggag 1500
 aaatttctcc agatgctcat cgtcaacgag gaactgcagg cgcgcctggc ccagggccgc 1560
 tcgggaccga gccgcgcagt cccagggccc cgcgccccgg aaccgcagct cagccccggc 1620
 tcggacgcct ccgaggtccg cgcctggctg caggccaagg gctttagctc cgggaccgtg 1680

122

```

gacgcgctgg gtgtgctgac cggggcgag cttttctcgc tgcagagggg ggagctgcgg 1740
gcggtgagcc ccgaggaggg ggcacgtgtg tacagccagg tcaccgtgca gcgctcgctg 1800
ctggaggaca aagagaaagt gtcagagctg gaggcagtga tggagaagca aaagaagaag 1860
gtggaaggcg aggtggaaat ggaggtcatt tgacctgcca ggcgcccttc gcaaagagtg 1920
acgaggcccc gtgggagAAC ggactcctca gactctcccc aatagcggaa gtcgatcttc 1980
tgaaggatgg ccaatctgct ccggccctgg tcttccccca tcccgggtga cagacttaac 2040
gatccttgct gcagtccttc cggagaggat ctggactggc tgggagtggg gagggcgctg 2100
agacagtcta cggaaagcgc tagcagaccc ccgagagggg gcagtggagc cctgagcatt 2160
gtaatatgcg gccagccta taaacagcct ccgtgcttag caaaaaaaaa aaaaaaaaaa 2220
a 2221

```

```

<210> 99
<211> 1683
<212> DNA
<213> Homo sapien

```

```

<400> 99
gatctcttcc aaatgtcccc gctctcccca ggctctcccc tcccgccact tgccagggtt 60
gacctaccg ccatcttaac cgggtgtcca cctctctctg cctgcctggt gctggccccg 120
cgtccccatc gccgcgcccg tctgctcccc tcagaggggt tgctgacgct gcgggccaaag 180
ccgccctcgg aggccgagta caccgacgtg ctgcagaaga tcaagtacgc cttcagcctg 240
ctggccccggc tgcgcggcaa catcgccgac ccctcctctc cggagctgtt gcaacttctt 300
ttcggggctc tgcagatgat tgtgaacacg tccggggggc cggagtctgc gagcagtgtg 360
cggcggccgc atctgacatc ggatgccgtg gcgctgctgc gggacaacgt cactccacgt 420
gaaaacgagc tctggacctc gctgggggac tctgggacct gcccgggct ggagctgtcc 480
ccggaggagg gacccccata cagacccgag ttcttcagcg gctgggagcc gccggtcact 540
gaccgcgaga gccgcgcctg ggaggaccca gttgagaaac agctacagca cgagcggagg 600
cgccggcagc aaagcgcccc ccaggtcgct gtcaatggtc accgagactt ggagccagaa 660
tctgagcctc agctggagtc agagacagca ggaaaatggg tcctgtgtaa ttatgacttc 720
caggccccga acagcagtga gctgtcggtc aagcagcggg acgtactgga ggtcctggat 780
gacagtcgta agtgggtgaa ggttcgggac ccagcggggc aggagggata tgtgccctac 840
aacatcctga caccctaccc cggacccccg ctgcaccaca gccaaaagccc tgccgcgagc 900
ctgaacagca ctctcctcc accaccagcc ccagccccgg cccacctcc agctctggct 960
cggccccgct gggacaggcc ccgtgggac agctgcgata gcctcaacgg cttggacccc 1020

```

123

```

agcgagaagg agaaattctc ccagatgctc atcgtcaacg aggaactgca ggcgcgcctg 1080
gccaggggcc gctcgggacc gagccgcgca gtcccagggc cccgcgcccc ggaaccgcag 1140
ctcagcccgg gctcggacgc ctccgaggtc cgcgcctggc tgcaggccaa gggctttagc 1200
tccggaagga ggagctgcgg gcggtgagcc ccgaggaggg ggcacgtgtg tacagccagg 1260
tcaccgtgca gcgctcgctg ctggaggaca aagagaaagt gtcagagctg gaggcagtga 1320
tggagaagca aaagaagaag gtggaaggcg aggtggaaat ggaggtcatt tgacctgcca 1380
ggcgcccttc gcaaagagtg acgaggcccc gtgggagaac ggactcctca gactctcccc 1440
aatagcggaa gtcgatcttc tgaaggatgg ccaatctgct ccggccctgg tcttccccca 1500
tcccggtgga cagacttaac gatccttgct gcagtccctc cggagaggat ctggactggc 1560
tgggagtggg gagggcgtag agacagtcta cggaaagcgc tagcagaccc ccgagagggg 1620
gcagtggagc cctgagcatt gtaatatgcg gccagccta taaacagcct ccgtgcttag 1680
cag 1683

```

```

<210> 100
<211> 1735
<212> DNA
<213> Homo sapien

```

```

<400> 100
gatctcttcc aaatgtcccc gctctcccca ggctctcccc tcccgcact tgccagggct 60
gacctaccg ccactttaac cgggtgtcca cctctctctg cctgcctggg gctggccccg 120
cgtccccatc gccgcgcccg tctgctcccc tcagagggct tgctgacgct gcgggccaag 180
ccgcctcgg aggcgagta caccgacgtg ctgcagaaga tcaagtacgc cttcagcctg 240
ctggcccggc tgcgcggcaa catcgccgac ccctcctctc eggagctgtt gcacttcctt 300
ttcgggcctc tgcagatgat tgtgaacacg tcgggggggc cggagttcgc gagcagtgtg 360
cggcggccgc atctgacatc ggatgccgtg gcgctgctgc gggacaacgt cactccacgt 420
gaaaacgagc tctggacctc gctgggggac tcgtggacct gccccgggct ggagctgtcc 480
ccggaggagg gacccccata cagacccgag ttcttcagcg gctgggagcc gccggtcact 540
gaccgcgaga gccgcgcctg ggaggaccca gttgagaaac agctacagca cgagcggagg 600
cgccggcagc aaagcgcccc ccaggtcgct gtcaatggtc accgagactt ggagccagaa 660
tctgagcctc agctggagtc agagacagca ggaaaatggg tcctgtgtaa ttatgacttc 720
caggcccgca acagcagtga gctgtcggtc aagcagcggg acgtactgga ggtcctggat 780
gacagtcgta agtgggtgaa ggttcgggac ccagcggggc aggagggata tgtgccctac 840
aacatcctga caccctaccc cggaccccg gctgcaccaca gccaaagccc tgcccgcagc 900

```


124

ctgaacagca	ctcctcctcc	accaccagcc	ccagccccgg	ccccacctcc	agctctggct	960
cggccccgct	gggacaggcc	ccgctgggac	agctgcgata	gcctcaacgg	cttggacccc	1020
agcgagaagg	agaaattctc	ccagatgctc	atcgtcaacg	aggaactgca	ggcgcgcctg	1080
gcccagggcc	gctcgggacc	gagccgcgca	gtcccagggc	cccgcgcccc	ggaaccgcag	1140
ctcagccccg	gctcggacgc	ctccgaggtc	cgcgcctggc	tgcaggccaa	gggctttagc	1200
tccgggaccg	tggacgcgct	gggtgtgctg	accggggcgc	agcttttctc	gctgcagaag	1260
gaggagctgc	gggcgggtgag	ccccgaggag	ggggcacgtg	tgtacagcca	ggtcaccgtg	1320
cagcgctcgc	tgctggagga	caaagagaaa	gtgtcagagc	tggaggcagt	gatggagaag	1380
caaaagaaga	aggtggaagg	cgaggtggaa	atggagggtca	tttgacctgc	caggcgcctt	1440
tcgcaaagag	tgacgaggcc	ccgtgggaga	acggactcct	cagactctcc	ccaatagcgg	1500
aagtcgatct	tctgaaggat	ggccaatctg	ctccggccct	ggtcttcccc	catcccggtg	1560
gacagactta	acgatccttg	ctgcagtccc	tccggagagg	atctggactg	gctgggagtg	1620
gggagggcgt	ggagacagtc	tacggaaaagc	gctagcagac	ccccgagagg	gtgcagtggg	1680
gccttgagca	ttgtaatatg	cggcccagcc	tataaacagc	ctccgtgctt	agcag	1735

<210> 101

<211> 1961

<212> DNA

<213> Homo sapien

<400> 101

gatctcttcc	aaatgtcccc	gctctcccca	ggctctcccc	tcccgccact	tgccagggct	60
gacctcaccg	ccatcttaac	cgggtgtcca	cctctctctg	cctgcctggt	gctggccccg	120
cgtccccatc	gccgcgcccc	tctgctcccc	tcagagggct	tgctgacgct	gcggggccaag	180
ccgccctcgg	aggccgagta	caccgacgtg	ctgcagaaga	tcaagtacgc	cttcagcctg	240
ctggcccggc	tgcgcgccaa	catcgccgac	ccctcctctc	cggagctgtt	gcacttcctt	300
ttcggggcctc	tgcagatgat	tgtgaacacg	tcgggggggc	cggagttcgc	gagcagtgtg	360
cggcgggcgc	atctgacatc	ggatgcctg	gcgctgctgc	gggacaacgt	cactccacgt	420
gaaaacgagc	tctggacctc	gctggggggac	tcgtggaccc	gccccgggct	ggagctgtcc	480
ccggaggagg	gacccccata	cagacccgag	ttcttcagcg	gctgggagcc	gccggtcact	540
gacccgcaga	gccgcgcctg	ggaggaccca	gttgagaaac	agctacagca	cgagcggagg	600
cgccggcagc	aaagcgcccc	ccaggtcgct	gtcaatggtc	accgagactt	ggagccagaa	660
tctgagcctc	agctggagtc	agagacagca	ggaaaatggg	tcctgtgtaa	ttatgacttc	720
caggccccga	acagcagtga	gctgtcggtc	aagcagcggg	acgtactgga	ggtcctggat	780

125

gacagtcgta agtgggtggaa ggttcggggac ccagcggggc aggagggata tgtgccctac 840
 aacatcctga caccctaccc cggacccccg ctgcaccaca gccaaagccc tgcccgcagc 900
 ctgaacagca ctccctctcc accaccagcc ccagcccccg cccacacctc agctctggct 960
 cggccccgct gggacaggcc ccgctgggac agctgcgata gcctcaacgg cttggacccc 1020
 agcgagaagg agaaattctc ccagatgctc atcgtcaacg aggaactgca ggcgcgcctg 1080
 gcccagggcc gctcgggacc gagccgcgca gtcccagggc cccgcgcccc ggaaccgcag 1140
 ctcagccccg gctcggacgc ctccgaggtc cgcgcctggc tgcaggccaa gggctttagc 1200
 tccgggaccg tggacgcgct ggggtgtgctg accggggcgc agcttttctc gctgcagaag 1260
 gaggagctgc gggcgggtgag ccccgaggag ggggcacgtg tgtacagcca ggtcacctg 1320
 cagcgcctgc tgctggagga caaagagaaa gtgtcagagc tggaggcagt gatggagaag 1380
 caaaagaaga aggtggaagg cgaggtggaa atggaggtca tttgacctgc caggcgcctc 1440
 tcgcaaagag tgacgaggcc ccgtgggaga acggactcct cagactctcc ccaatagcgg 1500
 aagtcgatct tctgaaggat ggccaatctg ctccggccct ggtcttcccc catcccggtg 1560
 gacagactta acgatccttg ctgcagtccc tccggagagg atctggactg gctgggagtg 1620
 gggagggcgt ggagacagtc tacggaaagc gctagcagac ccccgagagg gtgcagtgga 1680
 gccctgagca ttgtaatatg cggcccagcc tataaacagc ctccgtgctt agcagaaaaa 1740
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaca taaaaaaat 1800
 aaaagaatag tcaacaaaca aaataagaaa ctatagataa tataaaaatg aaaataaaaa 1860
 agagatgggg tggggccctt gtctttactc tctccctctg gagtgggcac actatattat 1920
 ttccgcccctc ccctcttttt ttgtatgaga gggctctttt a 1961

<210> 102

<211> 1916

<212> DNA

<213> Homo sapien

<400> 102

gatctcttcc aaatgtcccc gctctcccca ggctctcccc tcccgccact tgccagggct 60
 gacctcaccg ccatcttaac cgggtgtcca cctctctctg cctgcctggg gctggccccg 120
 cgtccccatc gccgcgcccc tctgctcccc tcagagggct tgctgacgct gcggggccaag 180
 ccgcctctcg aggccgagta caccgacgtg ctgcagaaga tcaagtacgc cttcagcctg 240
 ctggcccggc tgcgcggcaa catcgccgac ccctcctctc cggagctgtt gcacttcctt 300
 ttccgggcctc tgcagatgat tgtgaacacg tcgggggggc cggagtctgc gagcagtgtg 360
 cggcggccgc atctgacatc ggatgccgtg gcgctgctgc gggacaacgt cactccacgt 420

126

gaaaacgagc tctggacctc gctggggggac tctgtggaccc gccccgggct ggagctgtcc 480
 ccggaggagg gacccccata cagacccgag ttcttcagcg gctgggagcc gccggtcact 540
 gacccgcaga gccgcgcctg ggaggaccca gttgagaaac agctacagca cgagcggagg 600
 cgccggcagc aaagcgcccc ccaggtcgct gtcaatggtc accgagactt ggagccagaa 660
 tctgagcctc agctggagtc agagacagca ggaaaatggg tcctgtgtaa ttatgacttc 720
 caggcccgca acagcagtga gctgtcggtc aagcagcggg acgtactgga ggtcctggat 780
 gacagtcgta agtgggtgaa ggttcggggac ccagcggggc aggagggata tgtgccctac 840
 aacatcctga caccctaccc cggacccccg ctgcaccaca gccaaagccc tgcccgagc 900
 ctgaacagca ctctcctcc accaccagcc ccagccccgg cccacctcc agctctggct 960
 cggccccgct gggacaggcc ccgctgggac agctgcgata gcctcaacgg cttggacccc 1020
 agcgagaagg agaaattctc ccagatgctc atcgtcaacg aggaactgca ggcgcgctg 1080
 gccacgggcc gctcgggacc gagccgcgca gtcccagggc cccgcgcccc ggaaccgcag 1140
 ctacgcccgg gctcggacgc ctccgaggtc cgcgcctggc tgcaggccaa gggcttttagc 1200
 tccgggaccg tggacgcgct ggggtgtgctg accggggcgc agcttttctc gctgcagaag 1260
 gaggagctgc gggcggtgag ccccgaggag ggggcacgtg tgtacagcca ggtcacctg 1320
 cagcgctcgc tgctggagga caaagagaaa gtgtcagagc tggaggcagt gatggagaag 1380
 caaaagaaga aggtggaagg cgaggtggaa atggaggtca tttgacctgc caggcgccct 1440
 tcgcaaagag tgacgaggcc ccgtgggaga acggactcct cagactctcc ccaatagcgg 1500
 aagtcgatct tctgaaggat ggccaatctg ctccggccct ggtcttcccc catcccggtg 1560
 gacagactta acgatccttg ctgcagtccc tccggagagg atctggactg gctgggagtg 1620
 gggagggcgt ggagacagtc tacggaaagc gctagcagac ccccgagagg gtgcagtgga 1680
 gccctgagca ttgtaatatg cggcccagcc tataaacagc ctccgtgctt agcagaaaaa 1740
 saaaacacat caaccaaca aacgtttggg gtattccatg gccaataccg ttgttcccgt 1800
 gtgtgaacat tgttatttca gctcacattt ccacagtat tggaacaaca catcatacca 1860
 cacacacaca gaaccaatcg agatatataa acccaatgca cactcaaaca cctaata 1916

<210> 103
 <211> 1735
 <212> DNA
 <213> Homo sapien

<400> 103
 gatctcttcc aaatgtcccc gctctcccca ggctctcccc tcccgccact tgccagggct 60
 gacctcaccg ccatcttaac cgggtgtcca cctctctctg cctgcctggg gctggccccg 120

127

```

cgccccatc gccgcgcccg tctgctcccc tcagagggct tgctgacgct gcgggccaag    180
ccgccctcgg aggcgcgagta caccgacgtg ctgcagaaga tcaagtacgc cttcagcctg    240
ctggcccggc tgcgcgggcaa catcgccgac cctcctcttc cggagctgtt gcacttcctt    300
ttcgggcctc tgcagatgat tgtgaacacg tcgggggggc cggagttcgc gagcagtgtg    360
cggcgggcgc atctgacatc ggatgccgtg gcgctgctgc gggacaacgt cactccacgt    420
gaaaacgagc tctggacctc gctgggggac tcgtggaccc gcccggggct ggagctgtcc    480
ccggaggagg gacccccata cagacccgag ttcttcagcg gctgggagcc gccggtcact    540
gaccgcgaga gccgcgcctg ggaggacca gttgagaaac agctacagca cgagcggagg    600
cgccggcagc aaagcgcccc ccaggtcgct gtcaatggtc accgagactt ggagccagaa    660
tctgagcctc agctggagtc agagacagca ggaaaatggg tcctgtgtaa ttatgacttc    720
caggcccgca acagcagtga gctgtcggtc aagcagcggg acgtactgga ggtcctggat    780
gacagtcgta agtgggtggaa gggtcgggac ccagcggggc aggagggata tgtgccctac    840
aacatcctga caccctaccc cggacccccg ctgcaccaca gccaaagccc tgccgcgagc    900
ctgaacagca ctctcctccc accaccagcc ccagccccgg cccacacctc agctctggct    960
cggccccgct gggacaggcc ccgctgggac agctgcgata gcctcaacgg cttggacccc   1020
agcgagaagg agaaattctc ccagatgctc atcgtcaacg aggaactgca ggcgcgctg   1080
gcccagggcc gctcgggacc gagccgcgca gtcccagggc cccgcgcccc ggaaccgcag   1140
ctcagcccgg gctcggacgc ctccgaggtc cgcgcctggc tgcaggccaa gggcttttagc   1200
tccgggaccg tggacgcgct ggggtgtgctg accggggcgc agcttttctc gctgcagaag   1260
gaggagctgc gggcggtgag ccccgaggag ggggcacgtg tgtacagcca ggtcaccgtg   1320
cagcgctcgc tgctggagga caaagagaaa gtgtcagagc tggaggcagt gatggagaag   1380
caaaagaaga aggtggaagg cgaggtggaa atggagggtca tttgacctgc caggcgccct   1440
tcgcaaagag tgacgaggcc ccgtgggaga acggactcct cagactctcc ccaatagcgg   1500
aagtcgatct tctgaaggat ggccaatctg ctccggccct ggtcttcccc catcccgggtg   1560
gacagactta acgatccttg ctgcagtccc tccggagagg atctggactg gctgggagtg   1620
gggagggcgt ggagacagtc tacggaaagc gctagcagac ccccgagagg gtgcagtgga   1680
gccctgagca ttgtaatatg cggcccagcc tataaacagc ctccgtgctt agcag       1735

```

```

<210> 104
<211> 1821
<212> DNA
<213> Homo sapien
<400> 104

```

128

gatctcttcc aaatgtcccc gctctcccca ggctctcccc tcccgccact tgccagggct	60
gacctcaccg ccatcttaac cgggtgtcca cctctctctg cctgcctggg gctggccccg	120
egtccccatc gcgcgcgcgc tctgctcccc tcagaggggt tgctgacgct gcgggccaag	180
ccgccctcgg aggcgcagta caccgacgtg ctgcagaaga tcaagtacgc cttcagcctg	240
ctggcccggc tgcgcggcaa catcgccgac ccctcctctc cggagctggt gcacttcctt	300
ttcgggcctc tgcagatgat tgtgaacacg tcgggggggc cggagtctgc gagcagtgtg	360
cggcggccgc atctgacatc ggatgccgtg gcgctgctgc gggacaacgt cactccacgt	420
gaaaacgagc tctggacctc gctgggggac tcgtggaccc gcccggggct ggagctgtcc	480
ccggaggagg gacccccata cagaccgcag ttcttcagcg gctgggagcc gccggtcact	540
gaccgcgaga gccgcgcctg ggaggacca gttgagaaac agctacagca cgagcggagg	600
cgccggcagc aaagcgcccc ccaggctcgt gtcaatggtc accgagactt ggagccagaa	660
tctgagcctc agctggagtc agagacagca ggaaaatggg tcctgtgtaa ttatgacttc	720
caggcccgca acagcagtga gctgtcggtc aagcagcggg acgtactgga ggtcctggat	780
gacagtcgta agtgggtgaa ggttcgggac ccagcggggc aggagggata tgtgccctac	840
aacatcctga caccctaccc cggaccccg gctgcaccaca gccaaagccc tgcccgcagc	900
ctgaacagca ctctcctcc accaccagcc ccagcccg cccacctcc agctctgggt	960
cggccccgct gggacaggcc ccgctgggac agctgcgata gcctcaacgg cttggacccc	1020
agcgagaagg agaaattctc ccagatgctc atcgtcaacg aggaactgca ggcgcgcctg	1080
gccaggggcc gctcgggacc gagccgcgca gtcccagggc cccgcgcccc ggaaccgcag	1140
ctcagcccg gctcggacgc ctccgaggtc cgcgcctggc tgcaggccaa gggctttagc	1200
tccgggaccg tggacgcgct ggggtgtgctg accgggggcg agcttttctc gctgcagaag	1260
gaggagctgc gggcgggtgag ccccgaggag ggggcacgtg tgtacagcca ggtcacctg	1320
cagcgctcgc tgctggagga caaagagaaa gtgtcagagc tggaggcagt gatggagaag	1380
caaaagaaga aggtggaagg cgaggtggaa atggaggtca tttgacctgc caggcgccct	1440
tcgcaaagag tgacgaggcc ccgtgggaga acggactcct cagactctcc ccaatagcgg	1500
aagtcgatct tctgaaggat ggccaatctg ctccggccct ggtcttcccc catcccggtg	1560
gacagactta acgatccttg ctgcagtccc tccggagagg atctggactg gctgggagtg	1620
gggagggcgt ggagacagtc tacggaaagc gctagcagac ccccgagagg gtgcagtgga	1680
gccctgagca ttgtaatatg cggcccagcc tataaacagc ctccgtgctt agcagatggg	1740
gtgccaaactg ctgtcctcta cccggctacc agggggctca gaaacctgcc cctcgaccca	1800
gtcacagcct catggaacct g	1821

<210> 105
 <211> 1831
 <212> DNA
 <213> Homo sapien

<400> 105
 gatctcttcc aaatgtcccc gctctcccca ggctctcccc tcccgccact tgccagggct 60
 gacctcaccg ccatcttaac cgggtgtcca cctctctctg cctgcctggg gctggccccg 120
 cgtccccatc gcgcgcgccg tctgctcccc tcagaggggt tgctgacgct gcggggccaag 180
 ccgcccctcg aggccgagta caccgacgtg ctgcagaaga tcaagtacgc cttcagcctg 240
 ctggcccggc tgccgggcaa catcgccgac ccctcctctc cggagctgtt gcacttcctt 300
 ttcgggcctc tgcagatgat tgtgaacacg tcgggggggc cggagttcgc gagcagtgtg 360
 cggcggccgc atctgacatc ggatgccgtg gcgctgctgc gggacaacgt cactccacgt 420
 gaaaacgagc tctggacctc gctgggggac tcgtggacct gccccgggct ggagctgtcc 480
 ccggaggagg gacccccata cagacccgag ttcttcagcg gctgggagcc gccggtcact 540
 gaccgcgaga gccgcgcctg ggaggacca gttgagaaac agctacagca cgagcggagg 600
 cgccggcagg tgaccaagc gacacagcag ggccgaggct gggaagtccg ggggcgcggc 660
 cggtcgcctt ggcgccgctt gaccgcactg tcttacttcc tacagcaaag cgcgccccag 720
 gtcgctgtca atggtcaccg agacttgag ccagaatctg agcctcagct ggagtcagag 780
 acagcaggaa aatgggtcct gtgtaattat gacttcagag cccgcaacag cagtgaagctg 840
 tcggtcaagc agcgggacgt actggaggtc ctggatgaca gtcgtaagtg gtggaagggt 900
 cgggacccag cggggcagga gggatatgtg ccctacaaca tcctgacacc ctaccccgga 960
 ccccggtgc accacagcca aagccctgcc cgcagcctga acagcactcc tcctccacca 1020
 ccagccccag ccccgcccc acctccagct ctggctcggc cccgctggga caggcccccgc 1080
 tgggacagct gcgatagcct caacggcttg gaccccagcg agaaggagaa attctcccag 1140
 atgctcatcg tcaacgagga actgcaggcg cgctggccc agggccgctc gggaccgagc 1200
 cgcgcagtc cagggccccc cgccccggaa ccgcagctca gcccgggctc ggacgcctcc 1260
 gaggtccgcg cctggctgca ggccaagggc tttagctccg ggaccgtgga cgcgctgggt 1320
 gtgctgaccg gggcgcagct tttctcgctg cagaaggagg agctgcgggc ggtgagcccc 1380
 gaggaggggg cacgtgtgta cagccaggtc accgtgcagc gctcgctgct ggaggacaaa 1440
 gagaaagtgt cagagctgga ggcaagtatg gagaagcaaa agaagaaggt ggaaggcgag 1500
 gtggaaatgg aggtcatttg acctgccagg cgcccttcgc aaagagtac gagggcccg 1560
 gggagaacgg actcctcaga ctctcccaa tagcggaagt cgatcttctg aaggatggcc 1620

130

aatctgctcc ggccctggtc ttcccccatc ccggtggaca gacttaacga tccttgctgc 1680
 agtccctccg gagaggatct ggactggctg ggagtgggga gggcgtggag acagtctacg 1740
 gaaagcgcta gcagaccccc gagaggggtgc agtggagccc tgagcattgt aatatgcggc 1800
 ccagcctata aacagcctcc gtgcttagca g 1831

<210> 106
 <211> 2144
 <212> DNA
 <213> Homo sapien

<400> 106
 ggcacgaggc cagaacaccc ctatcttcta ggattgacac tggctgtcaa actcatcctt 60
 caaggtgatt cctggcctgc cctcctcctc caggcagcct gtctcctcc tccaggcagc 120
 ctgtcctgac cctcagcagc ctctcctggc cttggcagag cccctcgtgt cctcccttgc 180
 agcacgcctg ggaagaaagg ccatcgtcct cgccattgct aacaccagcc ttgcgtttcc 240
 tctttgccag cacctgggtga cgttctgcct ggggtgaggac gatggcgtgc ataccgtgga 300
 ggatgcctcc aggaagtggc ccgtcatgga tagccagggc cgagtctggg cacaggagat 360
 gctgctgcga gtgtctcccg accatgtcac gctgctcgac ccggcctcca aggaggagct 420
 ggagtgcgtac ccaactgggcg ccacgtgcg ctgtgacgcg gtgatgccac ccggcaggag 480
 ccgctcgttg ctgctgctcg tgtgccagga acccgagcgc gcgcagcccg acgtgcactt 540
 cttccagggc ctgcgcctcg gggcgagct gatccgagag gacatycagg gggctctgca 600
 caattaccgc tcgggcccgcg gggagcgcag ggcggcggcg ctcagggcca cgcaggagga 660
 gttgcagcgc gaccgctcgc ccgcgctga gaccccgccc ctgcagcgc gcccgtcagt 720
 ccgcgcagtg atcagcaccc tagagcgggg cgcgggccgc ggacgacccc aggcgaagcc 780
 cattcccgag gcagaggagg cgagaggcc tgagccgggtg gggacctga gcaacgtga 840
 ctcggcctcc ccggacctgg gtccccgggg tcttgacctg gcggttctgc aggcggagcg 900
 ggaagtggac atcctgaacc acgtgttcga cgacgtagag agctttgtat cgaggctgca 960
 gaagtgcggc gagggcgcca ggggtgctgga gcacccggga cgcgcccgca ggagccggcg 1020
 ccgggcccgt ggggagggct tgctgacgct gcggggccaag ccgccctcgg aggccagta 1080
 caccgacgtg ctgcagaaga tcaagtacgc cttcagcctg ctggcccggc tgcgcggcaa 1140
 catcgccgac ccctcctctc cggagctgtt gcaacttctt ttccggcctc tgcagatgat 1200
 tgtgaacacg tcggggggggc cggagttcgc gagcagtgtg cggcgccgc atctgacatc 1260
 ggatgcctg gcgctgctgc gggacaacgt cactccacgt gaaaacgagc tctggacctc 1320
 gctggggggac tcgtggacct gccccgggct ggagctgtcc ccggaggagg gacccccata 1380

131

cagacccgag ttcttcagcg gctgggagcc gccggtcact gacccgcaga gccgcgcctg 1440
 ggaggaccca gttgagaaac agctacagca cgagcggagg cgccggcagg tgacccaagc 1500
 gacacagcag ggccgaggct gggaagtccg ggggcgcggc cggtcgcctt ggccccgcct 1560
 gacccgactg tcttacttcc tacagcaaag cccccccag gtcgctgtca atggtcaccg 1620
 agacttggag ccagaatctg agcctcagct ggagtcagag acagcaggaa aatgggtcct 1680
 gtgtaattat gacttccagg cccgcaacag cagtgaactg tcgggtcaagc agcgggacgt 1740
 actggaggac aaagagaaag tgtcagagct ggaggcagtg atggagaagc aaaagaagaa 1800
 ggtggaaggc gaggtggaaa tggaggtcat ttgacctgcc aggcgcctt cgcaaagagt 1860
 gacgaggccc cgtgggagaa cggactcctc agactctccc caatagcggg agtcgatctt 1920
 ctgaaggatg gccaatctgc tccggccctg gtcttcccc atcccgggtg acagacttaa 1980
 cgatccttgc tgcagtcctt ccggagagga tctggactgg ctgggagtgg ggagggcgtg 2040
 gagacagtct acggaaagcg ctagcagacc cccgagaggg tgcagtggag ccctgagcat 2100
 tgtaatatgc ggcccagcct ataaacagcc tccgtgctta gcag 2144

<210> 107

<211> 1243

<212> DNA

<213> Homo sapien

<400> 107

cttgtttcaa atttctatta acagtattaa cccggccctt gctgtgcccc cagcttgggt 60
 ctaaccccag ctacaccag caccctgcag ccagagcaa tggggctggc tgcctcctta 120
 tctccaaccc tcccgcttct cctcagtcac cgagacttgg agccagaatc tgagcctcag 180
 ctggagtcag agacagcagg aaaatgggtc ctgtgtaatt atgacttcca ggccccgaac 240
 agcagtgagc tgtcgggtcaa gcagcgggac gtactggagg tcctggatga cagtcgtaag 300
 tgggtggaagg ttcgggaccc agcggggcag gagggatatg tgccctacaa catcctgaca 360
 ccctaccccg gaccccggtt gcaccacagc caaagccctg cccgcagcct gaacagcaact 420
 cctcctccac caccagcccc agccccggcc ccacctccag ctctgggtcg gccccgctgg 480
 gacaggcccc gctgggacag ctgcgatagc ctcaacggct tggaccccag cgagaaggag 540
 aaattctccc agatgctcat cgtcaacgag gaactgcagg cgcgcctggc ccagggccgc 600
 tcgggaccga gccgcgcagt cccagggccc cgcgccccgg aaccgcagct cagccccggc 660
 tcggacgcct ccgaggtccg cgcttggtg caggccaagg gctttagctc cgggaccgtg 720
 gacgcgctgg gtgtgctgac cggggcgcag cttttctcgc tgcagaagga ggagctgcgg 780
 gcggtgagcc ccgaggaggg ggcacgtgtg tacagccagg tcaccgtgca gcgctogctg 840

132

```

ctggaggaca aagagaaagt gtcagagctg gaggcagtga tggagaagca aaagaagaag    900
gtggaaggcg aggtggaaat ggaggtcatt tgacctgccca ggcgcccttc gcaaagagtg    960
acgaggcccc gtgggagAAC ggactcctca gactctcccc aatagcggaa gtcgatcttc    1020
tgaaggatgg ccaatctgct ccggccctgg tcttccccca tcccggtgga cagacttaac    1080
gatccttgct gcagtccttc cggagaggat ctggactggc tgggagtggg gagggcgtgg    1140
agacagtcta cggaaagcgc tagcagacccc ccgagagggt gcagtggagc cctgagcatt    1200
gtaatatgcg gccagccta taaacagcct ccgtgcttag cag                                1243

```

```

<210> 108
<211> 1811
<212> DNA
<213> Homo sapien

```

```

<400> 108
gagtcaccaa ggaaggcagc ggcagctcca ctccagccagt acccagatac gctgggaacc    60
ttccccagcc atggcttccc tggggcagat cctcttctgg agcataatta gcatcatcat    120
tattctggct ggagcaattg cactcatcat tggctttggt atttcaggga gacactccat    180
cacagtcact actgtcgctt cagctgggaa cattggggag gatggaatcc agagctgcac    240
ttttgaacct gacatcaaac tttctgatat cgtgatacaa tggctgaagg aagggtgttt    300
aggcttggtc catgagttca aagaaggcaa agatgagctg tcggagcagg atgaaatgtt    360
cagaggccgg acagcagtgt ttgctgatca agtgatagtt ggcaatgcct ctttgccgct    420
gaaaaacgtg caactcacag atgctggcac ctacaaatgt tatatcatca cttctaaagg    480
caaggggaat gctaaccttg agtataaaac tggagccttc agcatgccgg aagtgaatgt    540
ggactataat gccagctcag agaccttgcg gtgtgaggct ccccgatggt tccccagcc    600
cacagtggtc tgggcatccc aagttgacca gggagccaac ttctcggaag tctccaatac    660
cagctttgag ctgaactctg agaatgtgac catgaagggt gtgtctgtgc tctacaatgt    720
tacgatcaac aacacatact cctgtatgat tgaaaatgac attgccaaag caacagggga    780
tatcaaagtg acagaatcgg agatcaaaag gcggagtcac ctacagctgc taaactcaaa    840
ggcttctctg tgtgtctctt ctttctttgc catcagctgg gcaacttctgc ctctcagccc    900
ttacctgatg ctaaaataat gtgcctcggc cacaaaaaag catgcaaagt cattgttaca    960
acagggatct acagaactat ttcaccacca gatatgacct agttttatat ttctgggagg    1020
aaatgaattc atatctagaa gtctggagtg agcaaacaag agcaagaaac aaaaagaagc    1080
caaaagcaga aggctccaat atgaacaaga taaatctatc ttcaaagaca tattagaagt    1140
tgggaaaata attcatgtga actagagtca actgtgtcag ggctaagaaa ccctggtttt    1200

```

133

```

gagtagaaaaa gggcctggaa agaggggagc caacaaatct gtctgcttcc tcacattagt 1260
cattggcaaa taagcattct gtctcttttg ctgctgcctc agcacagaga gccagaactc 1320
tatcgggcac caggataaca tctctcagtg aacagagttg acaaggccta tgggaaatgc 1380
ctgatgggat tatcttcagc ttgttgagct tctaagtttc tttcccttca ttctaccctg 1440
caagccaagt tctgtaagag aaatgcctga gttctagctc aggttttctt actctgaatt 1500
tagatctcca gacctgcct ggccacaatt caaatgaagg caacaaacat ataccttcca 1560
tgaagcacac acagactttt gaaagcaagg acaatgactg cttgaattga ggccttgagg 1620
aatgaagctt tgaaggaaaa gaatactttg tttccagccc ccttcccaca ctcttcatgt 1680
gttaaccact gccttcctgg accttgagc cacggtgact gtattacatg ttgttataga 1740
aaactgattt tagagttctg atcgttcaag agaatgatta aatatacatt tcctaaaaaa 1800
aaaaaaaaa a 1811

```

```

<210> 109
<211> 2690
<212> DNA
<213> Homo sapien

```

```

<400> 109
tgtgagtcac caaggaaggc agcggcactc cactcagcca gtaccagat acgctgggaa 60
ccttccccag ccatggcttc cctggggcag atcctcttct ggagcataat tagcatcatc 120
attattcttg ctggagcaat tgcactcatc attggctttg gtatttcaga agtctctgtc 180
tggttttcag caatgaaggg tttggttgta gaagttccaa ggcttccctt agcattgatc 240
tttgcttcct gaactgcagg gagacactcc atcacagtca ctactgtcgc ctgagctggg 300
aacattgggg aggatggaat cctgagctgc acttttgaac ctgacatcaa actttctgat 360
atcgtagtac aatggctgaa ggaagggtgt ttaggcttgg tccatgagtt caaagaaggc 420
aaagatgagc tgtcggagca ggatgaaatg ttcagaggcc ggacagcagt gtttgctgat 480
caagtgatag ttggcaatgc ctctttgcgg ctgaaaaacg tgcaactcac agatgctggc 540
acctacaaat gttatatcat cacttctaaa ggcaagggga atgctaacct tgagtataaa 600
actggagcct tcagcatgcc ggaagtgaat gtggactata atgccagctc agagaccttg 660
cgggtgtgagg ctccccgatg gttccccag cccacagtgg tctgggcatc ccaagttgac 720
cagggagcca acttctcgga agtctccaat accagctttg agctgaactc tgagaatgtg 780
accatgaagg ttgtgtctgt gctctacaat gttacgatca acaacacata ctctgtatg 840
attgaaaatg acattgccaa agcaacaggg gatatcaaag tgacagaatc ggagatcaaa 900
aggcggagtc acctacagct gctaaactca aaggcttctc tgtgtgtctc ttctttcttt 960

```

134

```

gccatcagct gggcacttct gcctctcagc ccttacctga tgctaaaata atgtgccttg 1020
gccacaaaaa agcatgcaaa gtcattgtta caacagggat ctacagaact atttcaccac 1080
cagatatgac ctagttttat atttctggga ggaaatgaat tcatatctag aagtctggag 1140
tgagcaaaca agagcaagaa aaaaaagaa gccaaaagca gaaggctcca atatgaacaa 1200
gataaatcta tcttcaaaga catattagaa gttgggaaaa taattcatgt gaactagaca 1260
agtgtgttaa gagtgataag taaaatgcac gtggagacaa gtgcatcccc agatctcagg 1320
gacctcccc tgctgtcac ctggggagtg agaggacagg atagtgcatt ttctttgtct 1380
ctgaattttt agttatatgt gctgtaatgt tgctctgagg aagcccctgg aaagtctatc 1440
ccaacatata cacatcttat attccacaaa ttaagctgta gtatgtacct taagacgctg 1500
ctaattgact gccacttcgc aactcagggg cggtgcatt ttagtaatgg gtcaaagat 1560
tcacttttta tgatgcttcc aaagggtgct tggcttctct tccaactga caaatgccaa 1620
agttgagaaa aatgatcata attttagcat aaacagagca gtcggcgaca ccgattttat 1680
aaataaactg agcaccttct ttttaacaa acaaatgcgg gtttatttct cagatgatgt 1740
tcatccgtga atgggtccagg gaaggacctt tcaccttgac tatatggcat tatgtcatca 1800
caagctctga ggcttctcct ttccatcctg cgtggacagc taagacctca gttttcaata 1860
gcatctagag cagtgggact cagctggggg gatttcgccc cccatctccg ggggaatgtc 1920
tgaagacaat tttggttacc tcaatgaggg agtggaggag gatacagtgc tactaccaac 1980
tagtggataa aggccaggga tgctgctcaa cctcctacca tgtacaggac gtctcccat 2040
tacaactacc caatccgaag tgtcaactgt gtcaggacta agaaaccctg gttttgagta 2100
gaaaagggcc tggaaagagg ggagccaaca aatctgtctg cttcctcaca ttagtcattg 2160
gcaaataagc attctgtctc tttggctgct gcctcagcac agagagccag aactctatcg 2220
ggcaccagga taacatctct cagtgaacag agttgacaag gcctatggga aatgcctgat 2280
gggattatct tcagcttggt gagcttctaa gtttctttcc cttcattcta ccctgcaagc 2340
caagttctgt aagagaaatg cctgagttct agctcagggt ttcttactct gaatttagat 2400
ctccagacct ttctggcca caattcaaat taaggcaaca aacatatacc ttccatgaag 2460
cacacacaga cttttgaaag caaggacaat gactgcttga attgaggcct tgaggaatga 2520
agctttgaag gaaaagaata ctttgtttcc agcccccttc ccacactctt catgtgttaa 2580
ccactgcctt cctggacctt ggagccacgg tgactgtatt acatgttggt atagaaaact 2640
gatttttagag ttctgatcgt tcaagagaat gattaaatat acatttccta 2690

```

<210> 110

135

<211> 1982

<212> DNA

<213> Homo sapien

<400> 110

gagaaccagg acacaagctc tgtgcagatg ccctcagcag agggctccag cctcccactc	60
ttggctgaac agctccaacc cgtaggggtg acctttctta aaaggctccag ttcttgctgt	120
ttggctatatt taagctctag tcttctgggg ttctactcag ctggctcctgg cttcagcaat	180
tgcttccctc tgaaggcctt gcatagaggc caagcgtgaa gtgcagggac ttctctgctg	240
tgatgtggct taagtttccc tgacacctgt tgagtgtcct cataacttcc cttctggtgc	300
ccctccccag ctcttgagac acagctgcag ctacaagtgt gcagtgtcag tgttcaagaa	360
agtgcctggc agaggggctt tagaagggtc ccctgccttc caaaggagct ttggcaggca	420
gagctgctcc tgcagcaaca ctcccatttc ctgttcttgc ctgctgagta gcacctagat	480
ttctaagcct catctagata ctgagatttg attctggggc ttatagccc agttgctggg	540
actgtttcag gagctagggg ccatgtgggg caggagagg gcacaaaagt agagaagcct	600
gatgttgatt cccagggggc tggtcagctc tgctactgct ccttgagat gtcaagagtc	660
agggtgctagt cacgtgctgc ttggcttgtc actgtcattg gcagcgagag gaatgggtgc	720
tggtagacatt gggccagggc tgctctctctg tgtcagagtt cagggtgtag gagggttct	780
gccaaccatg ggctgtgtgg ggtaagtggg tgaggctgat cttgctgggt caagtgatc	840
ctgagccctt ggctgtgga atgggggtag agggcaaatg gtaacctagc atgctgtggg	900
ggatatagga tgaggggctg cccgagcctc gggaggggtc ctaggagca gatgttgaa	960
aggccagagc cctcagtgag ctggatgaga gggtagctg ttgaacgcc ctgagggtac	1020
ttctggggc ctggtgtaat ggtctcttct gtatgtccc catccatct caggctctgt	1080
caccaggtgg ccagataccg cccacgtgc ccatcattg ctgtgaccg gaatccccag	1140
acagctctgc agggccacct gtaccgtggc atcttccctg tgctgtgcaa ggaccagtc	1200
caggaggcct gggctgagga cgtggacctc cgggtgaact ttgccatgaa tgttggaag	1260
gcccagggtc tcttcaagaa gggagatgtg gtcattgtgc tgaccgatg gcgccctggc	1320
tccggcttca ccaacaccat gcgtgttggt cctgtgccgt gatggacccc agagcccctc	1380
ctccagcccc tgtcccacc ccttccccca gccatccat taggccagca acgctttag	1440
aactcactct gggctgtaac gtggcactgg taggttggga caccaggga gaagatcaac	1500
gcctcactga aacatggctg tgtttgcagc ctgctctagt gggacagccc agagcctggc	1560
tgccatcat gtggccccac ccaatcaagg gaagaaggag gaatgctgga ctggaggccc	1620
ctggagccag atggcaagag ggtgacagct tccttccctg tgtgtactct gtccagttcc	1680

136

tttagaaaa atggatgccc agaggactcc caaccctggc ttgggggtcaa gaaacagcca 1740
 gcaagagtta ggggccttag ggcactgggc tgttggtcca ttgaagccga ctctggccct 1800
 ggcccttact tgcttctcta gctctctagg cctctccagt ttgcacctgt cccaccctc 1860
 cactcagctg tcctgcagca aacactccac cctccacctt ccattttccc ccactactgc 1920
 agcacctcca ggccgtgtgc tatagagcct acctgtatgt caataaaca cagctgaagc 1980
 ac 1982

<210> 111
 <211> 1174
 <212> DNA
 <213> Homo sapien

<400> 111
 ctctgataaa ttccccattc tgtcttccca tgtgttgtgt ctcgtttttt tcctcctcct 60
 tcctctttcc ttgccccctc ttcccctaaa ccttacagat agctcgtgag gctgaggcag 120
 ccatgttcca ccgcaagctg tttgaagaac ttgtgcgagc ctcaagtcac tccacagacc 180
 tcatggaagc catggccatg ggcagcgtgg aggccttctta taagtgttta gcagcagctt 240
 tgatagttct gacggagtct ggcaggtctg ctaccaggt ggccagatac cggccacgtg 300
 ccccatcat tgctgtgacc cggaatcccc agacagctcg tcaggccac ctgtaccgtg 360
 gcatcttccc tgtgctgtgc aaggacccag tcaggaggc ctgggctgag gacgtggacc 420
 tcggggtgaa ctttgccatg aatgttgga aggcccgagg cttcttcaag aaggagatg 480
 tggtcattgt gctgaccgga tggcgccctg gctccggctt caccaacacc atgcgtgttg 540
 ttctgtgcc gtgatggacc ccagagcccc tcctccagcc cctgtccac ccccttcccc 600
 cagcccatcc attaggccag caacgcttgt agaactcact ctgggctgta acgtggcact 660
 ggtaggttg gacaccagg aagaagatca acgcctcact gaaacatggc tgtgtttgca 720
 gcctgctcta gtgggacagc ccagagcctg gctgcccac atgtggcccc acccaatcaa 780
 gggaagaagg aggaatgctg gactggaggc ccctggagcc agatggcaag agggtgacag 840
 cttcctttcc tgtgtgtact ctgtccagtt cctttagaaa aaatggatgc ccagaggact 900
 cccaaccctg gcttggggtc aagaaacagc cagcaagagt taggggcctt agggcactgg 960
 gctgttgttc cattgaagcc gactctggcc ctggccctta cttgcttctc tagctctcta 1020
 ggcccttcca gtttgacact gtccccaccc tccactcagc tgcctgcag caaacactcc 1080
 accctccacc ttccattttc cccactact gcagcacctc caggcctgtt gctatagagc 1140
 ctacctgtat gtcaataaac aacagctgaa gcac 1174

<210> 112

137

<211> 1909
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1528)..(1528)
 <223> n=a, c, g or t

<220>
 <221> misc_feature
 <222> (1538)..(1538)
 <223> n=a, c, g or t

<220>
 <221> misc_feature
 <222> (1545)..(1545)
 <223> n=a, c, g or t

<400> 112
 ctgtgacttc gttgggtctga aaatgcttgc acagtattgt gtccagaatt gggttccttcc 60
 ggtggggttct tgggtctcact gacttcaaga atgaagccac ggacccttgc gtcacaagca 120
 cctcttcggc aaagcccacc tccctctctc gcttgattcc ccggccatcc ttatcaaaga 180
 ccttccagggt gaacaggcag ccattctcag cagcagtcag caggaactga tcatcaaaga 240
 atctcgctct gttgcccagg ctggagtgtg gtgggtgcgat ctcggtctac tgaaacctcc 300
 gcctcccagg ttcaagcgat tctcctgcct cagtctcccg agtagctggg actacagtga 360
 tttcctgaag gaaatataat gatctgttca tcgaagtaga agatattgtt ggccacgtgg 420
 gatcgaagac caaaaacatg cagcgtctga gctaccacgg ctgacatgat cccccgccaa 480
 acagttctgc tgaagaccaa gaccacgcat gtatccagag gcgctacctg tagggatcct 540
 aagcaacccg gacactttca aacgccgtag cggttcctat agcaacgaca aaccggaagt 600
 atggtttgcc gccggaagcg gaagtccaa tcaaaagttg agcagtagct gtgagttgct 660
 ggcgctggag cgattcgggtg gcacgtggag ccacggcggtg ggagtagggg gctgaaggca 720
 ggcagcagcg gccagggccg ccctctgcta gccgcttggg tctcgggata ccccgtttct 780
 tcctgtaggt gtgggacgtg cgtgcggcga gatggacact cccccgctct cggattcggg 840
 gtcggaatcc gatgaatccc ttgtcacaga cagagagttg caggatgcgt tttcccaggg 900
 gcttctgaag ccaggcctca atgtcgtgct agagggggccg aagaaggccg tgaacgacgt 960
 gaatggcctg aagcaatgtt tggcagaatt caagcgggat ctggaatggg ttgaaaggct 1020
 cgatgtgaca ctgggtccg taccggagat cgggtgatct gaggcgccag cacctcagaa 1080
 caaggaccag aaagctgttg atccagaaga cgacttccag cgagagatga gtttctatcg 1140

138

```

ccaagccag gccgcagtgc ttgcagtctt accccgcctc catcagctca aagtccttac 1200
gaagcgaccc actgattatt ttgcggaaat ggccaaatct gatctgcaga tgcagaagat 1260
tcgacagaag ctgcagacta aacaggctgc catggagagg tctgaaaaag ctaagcaact 1320
gcgagcactt aggaaatacg ggaagaaggt gcaaacggag gttcttcaga agaggcagca 1380
ggagaaagcc catatgatga atgctattaa gaaatatcag aaaggcttct ctgataaact 1440
ggatttcctt gagggagatc agaaacctct ggacagcgc aagaaggcag gagccaaagg 1500
ccagcagatg aggaagggcc caacgggncc ccaacggnaa atttntgaaa aggggaaagg 1560
ggcccagtgc taaacgacgg tataaaaacc agaagtttg ttttggtgga aagaagaaag 1620
gctcaaagtg gaacactcgg gagagctatg atgatgtatc tagcttcagg gccaaagacag 1680
ctcatggcag aggcctcaag aggcctggca agaaagggtc aaataagaga cctggaaaac 1740
gaacaagaga gaagatgaag aacagaacac actaaatagc atctttgaat acaaagaacc 1800
aagaaaaagg aatgaagact cgcaatttca cgacacactt tgatcccttc tgttggtgtc 1860
atgttgtaaa catttctttc aataaactaa agaaaaatta ttaaaggaa 1909

```

```

<210> 113
<211> 1607
<212> DNA
<213> Homo sapien

```

```

<400> 113
ctgtgacttc gttggtctga aaatgcttgc acagtattgt gtccagaatt ggttccttcc 60
ggtgggttct tggctcact gacttcaaga atgaagccac ggacccttgc gtcacaagca 120
cctcttcggc aaagcccacc tccctctctc gcttgattcc ccggccatcc ttatcaaaga 180
ccttccaggt tcaagcgatt ctctgcctc agtctccga gtagctggga ctacagtgat 240
ttcctgaagg aaatataatg atctgttcat cgaagtagaa gatattgttg gccacgtggg 300
atcgaagacc aaaaacatgc agcgtctgag ctaccacggc tgacatgatc tcccgcacaa 360
cagttctgct gaagaccaag accacgcag tatccagagg cgctacctgt agggatccta 420
agcaaccogg acactttcaa acgccgtagc ggttcctata gcaacgacaa accggaagta 480
tggtttgccg ccggaagcgg aagtcccaat caaaagttga gcagtagctg tgtgggacgt 540
gcgtgcccgg agatggacac tccccgctc tcggattcgg agtcggaatc cgatgaatcc 600
cttgtcacag acagagagtt gcaggatgcg ttttcccgag ggcttctgaa gccaggcctc 660
aatgtcgtgc tagaggggcc gaagaaggcc gtgaacgacg tgaatggcct gaagcaatgt 720
ttggcagaat tcaagcggga tctggaatgg gttgaaaggc tcgatgtgac actgggtccg 780
gtaccggaga tcggtggatc tgaggcgcca gcacctcaga acaaggacca gaaagctgtt 840

```

139

```

gatccagaag acgacttcca gcgagagatg agtttctatc gccaaagccca ggccgcagtg      900
cttgcagttc taccgccctt ccatcagctc aaagtcccta cgaagcgacc cactgattat      960
tttgcggaag tggccaaatc tgatctgcag atgcagaaga ttcgacagaa gctgcagact    1020
aaacaggctg ccatggagag gtctgaaaaa gctaagcaac tgcgagcact taggaaatac    1080
gggaagaagg tgcaaacgga ggttcttcag aagaggcagc aggagaaagc ccatatgatg    1140
aatgctatta agaaatatca gaaaggcttc tctgataaac tggatttcct tgaggagat      1200
cagaaacctc tggcacagcg caagaaggca ggagccaaag gccagcagat gaggaagggg    1260
cccagtgcta aacgacggta taaaaaccag aagtttggtt ttggtggaaa gaagaaaggc    1320
tcaaagtgga aactcggga gagctatgat gatgtatcta gcttcggggc caagacagct    1380
catggcagag gcctcaagag gcctggcaag aaagggtcaa ataagagacc tggaaaacga    1440
acaagagaga agatgaagaa cagaacacac taaatagcat ctttgaatac aaagaaccaa    1500
gaaaaaggaa tgaagactcg caatttcacg acacactttg atcccttctg ttggtgtcat    1560
gttgtaaaca tttctttcaa taaactaaag aaaaattatt aaaggaa                    1607

```

```

<210> 114
<211> 1039
<212> DNA
<213> Homo sapien

```

```

<400> 114
tgtggaattg ctttagtaat tacataagaa tccataatcg acattcgttt gtgttaatgg      60
gtacctttag agtagtcatt ctcttaaaact attttttagca acaccctcc cctttttaaa    120
aactagtata cggctacatt tcttttagat actaaatcag tgagacagtt tttgtttggt    180
tgttcttgct aatggagggtc agattttgag agtccttctg agcttgata actcatgatt    240
ggcggtgaaa aggaacgtaa ggcctcctcc ttcacctcat tacacatttt gtcctacgat    300
tctcagccta tcgccaagcc caggccgcag tgcttgcagt cttacccgc ctccatcagc    360
tcaaagtccc tacgaagcga cccactgatt attttgcgga aatggccaaa tctgatctgc    420
agatgcagaa gattcgacag aagctgcaga ctaaacaggc tgccatggag aggtctgaaa    480
aagctaagca actgcgagca cttaggaaat acgggaagaa ggtgcaaacg gaggttcttc    540
agaagaggca gcaggagaaa gcccatatga tgaatgctat taagaaatat cagaaaggct    600
tctctgataa actggatttc cttgaggag atcagaaacc tctggcacag cgcaagaagg    660
caggagccaa aggccagcag atgaggaagg ggccagtg ctaaagcagc tataaaaaacc    720
agaagtttgg ttttggtgga aagaagaaag gctcaaagtg gaacactcgg gagagctatg    780
atgatgtatc tagcttccgg gccaaagacag ctcatggcag aggcctcaag aggcctggca    840

```


140

agaaaggggtc aaataagaga cctggaaaac gaacaagaga gaagatgaag aacagaacac 900
 actaaatagc atctttgaat acaaagaacc aagaaaaagg aatgaagact cgcaatttca 960
 cgacacactt tgatcccttc tgttggtgtc atgttgtaaa catttctttc aataaactaa 1020
 agaaaaatta ttaaaggaa 1039

<210> 115
 <211> 4254
 <212> DNA
 <213> Homo sapien

<400> 115
 tcaatactgt tagttgagat gtggaccatc tatcagtttg taattaagaa aaagtctggc 60
 acgtgactga aactgaggaa gaagtagaaa aggcaaaagg tcaaaggctct catgggaagg 120
 aaggagggta gagacagtga gttttatttg tccttttatg gttcagactt ctttcttcat 180
 cgactctccc taattctctt cactgttcat cccagcaac ttttcttccc aagcatttcc 240
 tgcgggcttt tattacccca ggagtgccaa tcaaggcgtg gaacagataa agctgtgtag 300
 caactaacgc gtgactcttg tgagtgtgga gggcaaacga agctccctga aacctccgct 360
 ctgctctcct gccttacgcc gcgcggcccc tgttctgagg tttaatactt gcttcacaga 420
 taagcgctgc ggccacgttc cggtgccac cttctccttg gctagggcac gacgccagcc 480
 cagggggcgc ggccctgagc tgctgcgaga gacagctgaa agcgccggcc cgacggcctt 540
 ggctccctcg gtgcgctggg cgcagagcac tcggaccctg ggcgcccact gctcgagtac 600
 ctgcgcggct cctagccagg cttagcccag gcgcgggctg agagtcagtt cgccaggtgg 660
 gcctggagcc atgggctggg tgggcgggcg gcgcgggat tctgcgtcac cacctgggcg 720
 gagccgttct gctgctgacg acatcaacct ggcacctgcc aacatggaag gtggcggcgg 780
 cagcgtcgct gtagctggcc tcggagctcg aggcctctgga gcggctgcag ctacagtccg 840
 ggaacttctg caggacgggt gttatagtga ctttttaaac gaagactttg atgtaaagac 900
 ttatacttct caatctattc atcaagctgt aattgctgaa caactagcaa aacttgccca 960
 aggaatcagt cagttggaca gagaactaca cttacagggtt gttgcaagac atgaagattt 1020
 actggcaciaa gcaactggga ttgagtcgtt ggaagggtgtt cttcagatga tgcagacgag 1080
 aattggggct ttacaggag ctgttgatag gataaaagca aaaattgttg aaccatacaa 1140
 taagatagtt gcccgactg cacaactagc aagacttcag gttgcctgtg atttgcttcg 1200
 gaggattatt cgtatcttga atctcagtaa gagactccaa ggacaactgc aagggggaag 1260
 tagagagata acaaaagctg ctgagagtct caatgaactt gattatcttt ctcaagggaat 1320
 agatctttct ggaatagaag tgatagaaaa tgatctactt tttattgcaa gagcccgact 1380

141

tgaagtggaa aatcaagcta agcgctact agagcagggg ttggagactc agaatccaac	1440
tcaagtcgga acagctcttc aggttttcta taatcttggg actttgaagg atactattac	1500
cagtgttgtg gatggatatt gtgctacttt agaagaaaat atcaacagtg cattagacat	1560
aaaagttttg actcagcctt cccagtcagc tgtgagaggg ggacctggac gatctaccat	1620
gccaaaccca ggaaatactg cagctttgcg tgcctcactc tggaccaata tggagaaact	1680
tatggatcat atttatgctg tttgtggaca ggtacaacat ctacaaaaag tattggccaa	1740
gaagagagat cctgtttctc acatttgttt cattgaagaa atagttaagg atggacaacc	1800
ggaaattttc tacacatttt ggaattcagt tactcaggca ctttcttctc aatttcatat	1860
ggcaacaaac tcttcgatgt ttttgaagca ggcatttgaa ggagaatacc ctaaattatt	1920
acgtctttat aatgacttat ggaagcgtct tcaacaatac agtcagcata tccaagggaa	1980
ttttaatgca agtggaacta cagacctcta tgttgaccta caacacatgg aagatgatgc	2040
acaagatata ttcataccaa aaaagccaga ttatgatcca gaaaaggctt tgaaagactc	2100
actacaaccc tatgaggctg cttatctatc aaaatcctta tctcgactct tcgatcctat	2160
caacttggtt tttccccggg gtggtcgtaa tcctccttcc tctgatgaac ttgatggtat	2220
tattaaaact atagcaagtg aactaaatgt tgctgctggt gatacaaacc tcacattagc	2280
tgtgtcaaaa aatgtggcaa agaccatcca gttatacagt gtaaaatcag agcagcttct	2340
ctccacacaa ggagatgcaa gtcaggatgat tgggcctctt actgaaggac agagaagaaa	2400
tgtggcagta gtgaattcat tgtataagtt gcaccaatca gtaacaaagg ttgtttccag	2460
tcagagctca tttccactgg cagctgagca aactataatt tcagctctaa aggatctgca	2520
gtacagtgtt gaatagaact ggctattcat gctcttatgg aaaatgctgt gcaaccctta	2580
ctcacttctg tgggagatgc tatagaggcc ataatcatca ccatgcatca agaagacttt	2640
tctgggtcat tatccagctc aggaaaacct gatgttcctt gttctctgta catgaaggag	2700
ctacaagggt tcattgccag agttatgagt gactatttta aacactttga atgcttggat	2760
tttgtctttg acaacactga ggctattgcc caaagagctg ttgaactttt tatccgccat	2820
gccagtctca taagacctct tgggtgaaggt gggaaaatgc gacttgctgc tgattttgca	2880
cagatggagt tggctgtggg tccattctgt agacgagtat ctgatttagg aaagtccat	2940
cggatgctga gatcattcag acctctgctc ttccaggcaa gtgaacatgt agccagtagt	3000
cctgcattgg gggatgtgat tccgttcagc atcattatc agtttttgtt cacgagagca	3060
cccgtgaac tgaaatctcc tttccagagg gcagagtggg cccacacacg cttctctcag	3120
tggctggatg accatccatc tgaaaaggac aggcctcctc tcatcagggg agccctggaa	3180
gcttatgttc aatcagtgag aagtagagaa ggcaagaat ttgcaccagt ttatcccata	3240

142

atgggttcagc	tgcttcaaaa	ggctatgtct	gctcttcagt	aatgacatga	aatctttggt	3300
catctccact	ttgtgctaac	ccattcatag	ttggcagtta	aacacatact	ccaaaagact	3360
gctactatct	actattttaa	gaatgtaatt	gattgttcgg	tatttcctat	cgacgtttat	3420
ttacctcttt	agcacttata	cttttagcata	aaaaatggtg	agttatcacc	acctttcaat	3480
tccatggacc	tgatttttcc	agaaagatgt	tttctctctt	cagatttttg	tacaaggcta	3540
aaatgtcttt	cccatccata	accaagtcct	cctatgggta	cataaaccca	aagtccccac	3600
ttctttttaa	gggatatgat	caagttataa	catgtaccct	gcttccccca	accctgcctt	3660
cttcactaaa	taagcatgta	gctcagtggg	ttccaaatct	ggctgcacat	tcataccaat	3720
caccagggga	ttttttttaa	atcctgatgc	ccaacttgca	ctccacatta	attaacatgt	3780
ctaggagtgg	gagcctgaca	gacaccacta	ttaaaaaaaa	aaaaaaaaatc	cccaaatga	3840
ttccaataga	caacaaagtt	gaggaaccac	tggcacatcc	caagctaaga	tacaagggtta	3900
aatggccttt	ttaagtatgt	catactggat	ctttaataaa	agcaaggctt	ttgttacact	3960
ttgtcatggt	attaaaagca	gacctttggg	ctgtttaacc	gtgtaacaaa	aatgccacgt	4020
gaaaaataaa	aatttttatt	gtatagcaat	tctctataaa	tagtagataa	tctaagtcct	4080
tattttctga	tggctcttgt	tccactatta	acattgtttt	taatttttaa	aatcctatca	4140
gcagcctcct	aattagcagt	gttaggaatt	tgcttatgt	tttccatctc	atctcctgaa	4200
cctgttattc	tgagaactca	taaataaaat	tcagccaaga	ttaatcaatc	aatc	4254

<210> 116
 <211> 4018
 <212> DNA
 <213> Homo sapien

<400> 116	
tcaatactgt	tagttgagat
gtggaccatc	tatcagtttg
taattaagaa	aaagtctggc
60	
acgtgactga	aactgaggaa
gaagtagaaa	aggcaaaagg
tcaaaggctc	catgggaagg
120	
aaggagggta	gagacagtga
gttttattgg	tccttttatg
gttcagaactt	ccttcttcat
180	
cgactctccc	taattctctt
cactgttcat	ccccagcaac
ttttcttccc	aagcatttcc
240	
tgcgggcttt	tattacccca
ggagtgccaa	tcaaggcgtg
gaacagataa	agctgtgtag
300	
caactaacgc	gtgactcttg
tgagtgtgga	gggcaaacga
agctccctga	aacctccgct
360	
ctgctctcct	gccttacgcc
gcgcggcccc	tgttctgagg
tttaataactt	gcttcacaga
420	
taagcgtgc	ggccaacgtc
cgggtgccac	cttctccttg
gctagggcac	gacgccagcc
480	
cagggggcgc	ggccctgagc
tgctgcgaga	gacagctgaa
agcgccggcc	cgacggcctt
540	
ggctccctcg	gtgcgctggg
cgcagagcac	tcggaccctg
ggcgcccact	gctcgagtac
600	

143

ctgcgcggct	cctagccagg	cttagcccag	gcgcgggctg	agagtcagtt	cgccaggtgg	660
gcctggagcc	atgggctggg	tgggcgggcg	gcgcgggat	tctgcgtcac	cacctgggcg	720
gagccgttct	gctgctgacg	acatcaaccc	ggcacctgcc	aacatggaag	gtggcggcgg	780
cagcgctcgt	gtagctggcc	tcggagctcg	aggctctgga	gcggctgcag	ctacagtccg	840
ggaacttctg	caggacgggt	gttatagtga	ctttttaaac	gaagactttg	atgtaaagac	900
ttatacttct	caatctattc	atcaagctgt	aattgctgaa	caactagcaa	aacttgccca	960
aggaatcagt	cagttggaca	gagaactaca	cttacagggt	gttgcaagac	atgaagattt	1020
actggcacia	gcaactggga	ttgagtcgtt	ggaagggtgt	cttcagatga	tgcagacgag	1080
aattggggct	ttacagggag	ctgttgatag	gataaaagca	aaaattgttg	aaccatacaa	1140
taagatagtt	gcccggactg	cacaactagc	aagacttcag	gttgctgtg	atttgcttcg	1200
gaggattatt	cgtatcttga	atctcagtaa	gagactccaa	ggacaactgc	aagggggaag	1260
tagagagata	acaaaagctg	ctcagagctc	caatgaactt	gattatcttt	ctcaaggaat	1320
agatctttct	ggaatagaag	tgatagaaaa	tgatctactt	tttattgcaa	gagcccgact	1380
tgaagtggaa	aatcaagcta	agcgcctact	agagcagggt	ttggagactc	agaatccaac	1440
tcaagtcgga	acagctcttc	aggttttcta	taatcttgga	actttgaagg	atactattac	1500
cagtgttggt	gatggatatt	gtgctacttt	agaagaaaat	atcaacagtg	cattagacat	1560
aaaagttttg	actcagcctt	cccagtcagc	tgtgagaggg	ggacctggac	gatctaccat	1620
gccaaaccca	ggaaatactg	cagctttgcg	tgctcactc	tggaccaata	tggagaaact	1680
tatggatcat	atztatgctg	tttgtggaca	ggtacaacat	ctacaaaaag	tattggccaa	1740
gaagagagat	cctgtttctc	acatttgttt	cattgaagaa	atagttaagg	atggacaacc	1800
ggaaattttc	tacacatttt	ggaattcagt	tactcaggca	ctttcttctc	aatttcatat	1860
ggcaacaaac	tcttcgatgt	ttttgaagca	ggcatttgaa	ggagaatacc	ctaaattatt	1920
acgtctttat	aatgacttat	ggaagcgtct	tcaacaatac	agtcagcata	tccaagggaa	1980
ttttaatgca	agtggaaact	cagacctcta	tgttgacctc	caacacatgg	aagatgatgc	2040
acaagatata	ttcataccia	aaaagccaga	ttatgatcca	gaaaaggctt	tgaaagactc	2100
actacaaccc	tatgaggctg	cttatctatc	aaaatcctta	tctcgactct	tcgatcctat	2160
caacttggtt	tttcccccg	gtggtcgtaa	tcctccttcc	tctgatgaac	ttgatggtat	2220
tattaaaact	atagcaagtg	aactaaatgt	tgctgctgtt	gatacaaacc	tcacattagc	2280
tgtgtcaaaa	aatgtggcaa	agaccatcca	gttatacagt	gtaaaatcag	agcagcttct	2340
ctccacacaa	ggagatgcaa	gtcagggtgat	tgggcctctt	actgaaggac	agagaagaaa	2400

144

tgtggcagta	gtgaattcat	tgtataagtt	gcaccaatca	gtaacaaagg	ttgtttccag	2460
tcagagctca	ttcccactgg	cagctgagca	aactataatt	tcagctctaa	aggctattca	2520
tgctcttatg	gaaaatgctg	tgcaaccott	actcacttct	gtgggagatg	ctatagaggc	2580
cataatcatc	accatgcatc	aagaagactt	ttctgggtca	ttatccagct	caggaaaacc	2640
tgatgttcct	tgttctctgt	acatgaagga	gctacaaggt	ttcattgcca	gagttatgag	2700
tgactatfff	aaacactttg	aatgcttggg	ttttgtcttt	gacaacactg	aggctattgc	2760
ccaaagagct	ggtgaacttt	ttatccgcc	tgccagtctc	ataagacctc	ttggtgaagg	2820
tgggaaaatg	cgacttgctg	ctgattttgc	acagatggag	ttggctgtgg	gtccattctg	2880
tagacgagta	tctgatttag	gaaagtccta	tcggatgctg	agatcattca	ggggagccct	2940
ggaagcttat	gttcaatcag	tgagaagtag	agaaggcaaa	gaatttgcac	cagtttatcc	3000
cataatgggt	cagctgcttc	aaaaggctat	gtctgctctt	cagtaatgac	atgaaatctt	3060
tgttcatctc	cactttgtgc	taaccatttc	atagttggca	gttaaacaca	tactccaaaa	3120
gactgctact	atctactatt	ttaagaatgt	aattgattgt	tcggtatctc	ctatcgacgt	3180
ttatttacct	cttttagcact	tatacttttag	cataaaaaat	gttgagttat	caccaccttt	3240
caattccatg	gacctgattt	ttccagaaag	atgttttcct	ctttcagatt	tttgtacaag	3300
gctaaaatgt	ctttcccatc	cataaccaag	tcctcctatg	ggtacataaa	cccaaagtcc	3360
ccacttcttt	taaagggata	tgatcaagtt	ataacatgta	ccctgcttcc	cccaaccctg	3420
ccttcttcac	taaataagca	tgtagctcag	tggtttccaa	atttggtgc	acattcatac	3480
caatcaccag	gggatttttt	taaaatcctg	atgcccaact	tgcaactccac	attaattaac	3540
atgtctagga	gtgggagcct	gacagacacc	actattaaaa	aaaaaaaaaa	aatccccaaa	3600
atgattccaa	tagacaacaa	agttgaggaa	ccactggcac	atcccaagct	aagatacaag	3660
gttaaatggc	ctttttaagt	atgtcatact	ggatctttta	ataaagcaag	gcttttggtta	3720
cactttgtca	tgttattaaa	agcagacctt	tggtgtgttt	aaccgtgtta	caaaaatgcc	3780
acgtgaaaaa	taaaaatttt	tattgtatag	caattctcta	taaatagtag	ataatctaag	3840
tccttatfff	ctgatggctc	ttgttccact	attaacattg	tttttaattt	ttaaaatcct	3900
atcagcagcc	tcctaattag	cagtgttagg	aatttgccct	atgttttcca	tctcatctcc	3960
tgaacctggt	attctgagaa	ctcataaata	aaattcagcc	aagattaatc	aatcaatc	4018

<210> 117

<211> 893

<212> DNA

<213> Homo sapien

<400> 117

145

```

cacaggccca gcagcacaca ctgtgatctt caacctgctt tatttgtttc aagtttgccg      60
tttaaaaggc aacttgctct agaaggcat ttgctttcct ctcttcctct agacacaccc      120
acaaaaacac aaggagaggc cctgaaaagt aactggaaag tcacagaccg ttctggcaag      180
tggagttgat gagaaacagg caaaaatctc cagccctaca gagactgagc ggtgcatcga      240
gtccctgatt gctgtcttcc agaagtatgc tggaaaggat ggttataact acactctctc      300
caagacagag ttcctaagct tcatgaatac agaactagct gccttcacaa agaaccagaa      360
ggaccctggt gtccttgacc gcatgatgaa gaaactggac accaacagtg atggtcagct      420
agattttctca gaattttcta atctgattgg tggcctagct atggcttgcc atgactcctt      480
cctcaaggct gtcccttccc agaagcggac ctgaggaccc cttggccctg gccttcaaac      540
ccacccctt tccttcagc ctttctgtca tcatctccac agcccaccca tccctgagc      600
acactaacca cctcatgcag gccccacctg ccaatagtaa taaagcaatg tcactttttt      660
aaaacatgaa aaaaaaaaaa smacaamaca accaamasaa acatttgcg ggggcctggc      720
gccacaaag aagccttcca acccaaccg gtgcgccgcg gggcccgat ggtaagtaaa      780
ccgtggcaac cggccaagg aaaccggcc agacaaggcg gggcccca aaanaagccc      840
ggggacgcgc ctgccacaa ggctcggccc ggcccacggg gccggagcgt aac      893

```

```

<210> 118
<211> 896
<212> DNA
<213> Homo sapien

```

```

<400> 118
ttcgatgtgg gacagagcac aagctccgag tcactcgggc gttgttatag ctagagcttc      60
attccttaaa tccagccagg gaactgggaa gccttacttt ttctttcaag atcaaataca      120
ggtgtgtggc agagataggt gtaaaattga cacgcacttt taagctgaaa cttagactt      180
ctatgatctt ttggacttag gggtccttg aggttggagc cccatcctct aggagggccc      240
cattgtgtat ttccctgggtg agtctggggt gtggcctctg ggggtcactc tgcatgggca      300
ggcctggccc agttgggctg aggcagtttt ggggtcggct gcctctgtgt ggggtgcctgg      360
ttatcctctg agcccacaat cgaaaaggca gctagtctct tattcatgaa gcttaggaac      420
tctgtctgaa gtatgctgga aaggatgggt ataactacac tctctccaag acagagttcc      480
taagcttcat gaatacagaa ctagctgcct tcacaaagaa ccagaaggac cctggtgtcc      540
ttgaccgcat gatgaagaaa ctggacacca acagtgatgg tcagctagat ttctcagaat      600
ttcttaatct gattgggtggc ctagctatgg cttgccatga ctcttcctc aaggctgtcc      660
cttcccagaa gcggacctga ggacccttg gccctggcct tcaaaccac ccccttctc      720

```

146

tccagccttt	ctgtcatcat	ctccacagcc	cacccatccc	ctgagcacac	taaccacctc	780
atgcaggccc	cacctgcaa	tagtaataaa	gcaatgtcac	ttttttaaaa	catgaactat	840
cggcaggtgg	ggcctgcatg	agcatgtgga	taacccccgg	ggcgccgtgg	caccag	896

<210> 119

<211> 1617

<212> DNA

<213> Homo sapien

<400> 119

cagacataaa	catctcacca	ggtcgggtgt	aacctttccc	acggtaactt	ctaggcctaa	60
aattttctct	ctgttttttt	tttttccaag	aaaaccacaa	aacttttctt	aaagttaga	120
ttactgattt	tagacctctt	ttcttttctc	atctaagtat	ttaaggatag	aaacttcccc	180
ttaagcggat	cagcgctgat	ccgcttaagg	gggggctgct	gggactcgcg	tcggttggcg	240
actcccgga	gtaggtagtt	tgttggggcg	ggttctgagg	ccttgcttct	ctttactttt	300
ccactctagg	ccacgatgcc	gcagtaccag	acctgggagg	agttcagccg	cgctgccgag	360
aagctttacc	tcgctgaccc	tatgaaggca	cgtgtggttc	tcaaataatag	gcattctgat	420
gggaacttgt	gtgttaaagt	aacagatgat	ttagtttaat	gcgacttatg	gtagccaagg	480
aagcccgcaa	tgttaccatg	gaaactgagt	gaatggtttg	aatgaagac	tttgtcgtgt	540
acttaggaag	taaatatctt	ttgaattaga	gaaagtgttg	ggacagaaag	tactttatgt	600
aactaagtgg	gctgttcaga	agcttagagg	tcattttttg	taattttctt	tttaattact	660
ttagagagct	agggatgcaa	atgttttcag	ttägaagcc	tttatttact	tttggaatt	720
gaacaagaaa	tgcatctgtc	ttagaaactg	gagattatth	gatgttaggt	aaaacatgta	780
attgtttctc	tggcaaattt	gtatcagtaa	tttgaaaatg	agatattagg	aaaaaccaat	840
tcttcttaaa	tttagttcat	ctttctttta	aagaacatta	aatgtaacca	ttttgtcaga	900
tccatgtatt	ttggagcata	aatgtatgc	tgttgtgacc	aataaatata	aatatggta	960
attggaatta	actccacacc	atagtatgca	ttgttatata	tactgtgtac	ctaattatgt	1020
atagcagtgt	agtctcaatt	atatctgaaa	gtaattgtga	ctaacaagta	tgctttgcct	1080
tatttocaca	tttaaactac	ctgttaatat	aagggatttg	tagtatcagc	ttgttgagca	1140
atgactttga	atctagtttt	cagtgatcag	aagcagcagt	tatttgagtg	tatgaatgga	1200
atgatgatca	ctgtgctata	atgtactgaa	accaccatat	tacagaaata	tttactacat	1260
attttccatc	tgtagtttct	cagaagggtc	atggattagt	ttgaactgtc	aatccttgc	1320
atacttctgt	gacaccctg	cccatthtct	gtctttaatt	aaccaagggtg	ttagggtgtga	1380
ctgtcacaac	tgttatgttt	tccagtaaac	tagaagtacg	atatttgata	attatatttg	1440

147

tatttcacca cctaaatgta atgttgattc ctcaagaatg aaatgaaggc actacattga 1500
aatatgtttt gtataaattt gtcattgtga acagcatttt agcatggtaa gttcccttag 1560
ctatatgaat tttggcatgt ttcagagaga tcagtaaata aaatattaga taaaata 1617

<210> 120

<211> 1916

<212> DNA

<213> Homo sapien

<400> 120

atgccaggc tcattctttt atgaaagtca caattcacac tttttgcttg gtaggaaata 60
tttttatatt aattctgaaa agctacaaaa gtgcattttt acaaacttag gggaagttga 120
ggttcctggg gtgagtcctc gggtctccca gctttgctct gtaatgcagg tctctgcaag 180
ggtcctgtt tgtccctaa ggggagagcg caggttgcc tgtgcctcca cccactccc 240
gattcaagct cacagcccac cttttccctg ccccatctca gtgcaacagg tgatcgagaa 300
ccacatcctc aagctcttcc agagcaacct ggtgccgct gaccctgagt gaaggccgcc 360
tgccggggac tcagacactc aggaacaaa atggtcagcc agagctgggg aaaccagaa 420
ctgacttcaa aggcagcttc tggacaggtg gtgggagggg acccttccca agaggaacca 480
ataaaccttc tgtgcagaat gagggacttt gctgtgcttc ccggagggct tcctggagga 540
gacagcccct agaggtctca caccttctcc ccaagcacc gcaggtggta gatgaccaca 600
cggccaaaaa agtcagtggc atcctcaaac gtcaccttca gccggtccac ttcagcagct 660
ggtatgggga aagtgtgagc gtgggcagtc aagggaact ggtgatttct ggtttccac 720
ccgcaggccc ccacccttc cagaccagc tcacactcca ccgatgtggg caacctgggg 780
aagctgcagg tcctctaaag cctctcacac agaacaggtg gtcacagca ccattttaca 840
gaaaaagtgg agtcctagag gtcacgtgtt caagatcaca catcagggtt cccattcggg 900
tttgggtgag tccaaagctt ccagaggcac agaccacca cccagaagc aggggcagga 960
tatctgaagc gagttgttgt cctcagggtg gaaatctaca atcttgtgga gagcctgagt 1020
gcctgtgaa ccttcagcag agaaaggcaa tgagtgtctg gggtagcccc tggaaccct 1080
gccaccagg gccttctagt accttcagg cagccccggc gactggagaa gccaccctga 1140
aactggatct gcagctggga gacacggatg agctggggaa actccagcgt caccactgg 1200
gaggggccct ggaagcagac agggaaactg aggcgaagc tcaactgcagg cacagagccc 1260
tgctatgcct gtctcattca catagtctt ggaatggagg ggaagaagga aattcggcac 1320
atgttccttt cctggtcgaa aagatgtttt tttccaaact gccgagtgtt gcgattcagc 1380
actgaactca ccctggaggc accaggatca aggcgaagag aggggctgag accagctctc 1440

148

```

agctccgcgg agggcctgac cccagatct gtccactgag ggctcgaccc caggcttagg 1500
gcctcgccac tgcctgtccc cacagactct tacctgctca ctgtctctgg acaaacaaaa 1560
gagtggttca tgtcggttcc acaagacctc gcagggctta ggattgggca cagccttggg 1620
tcgaatcccg gcgcctcctc aagctacagg gcggcgcgat cttggctaag ccttggcctg 1680
aacgtcctca cctgtaactt gggacgagaa ccgccactcc ctgccccacc ccagtcctaa 1740
atgtcgctc gatcaatccc ctgccggaat atttgggaga gaggatcagg gaaaccgcca 1800
atgcccggag gccaggcctt tcacaggaaa cagatttccc gcgggtttcg ggggcgggtg 1860
ctttttgtgc gaggtgttt ctctgcgaat agctcttga gccaaatctt gggacc 1916

```

```

<210> 121
<211> 1627
<212> DNA
<213> Homo sapien

```

```

<400> 121
atgccaggc tcatcttttc atgaaagtca caattcacac tttttgcttg gtaggaaata 60
tttttatatt aattctgaaa agctacaaaa gtgcattttt acaaacttag gggaagttga 120
ggttcctggg gtgagtcctc ggttctccca gctttgctct gtaatgcagg tctctgcaag 180
ggtccctggt tgtcccttaa ggggagagcg caggttggcc tgtgcctcca cccactccc 240
gattcaagct cacagcccac cttttccctg cccatctca gtgcaacagg tgatcgagaa 300
ccacatcctc aagctcttcc agagcaacct ggtgcccgct gacctgagt gaaggccgcc 360
tgccggggac tcagacactc agggaacaaa atggtcagcc agagctgggg aaaccagaa 420
ctgacttcaa aggcagcttc tggacaggtg gtgggagggg acccttccca agaggaacca 480
ataaaccttc tgtgcagaat gagggacttt gctgtgcttc ccggagggct tcctggagga 540
gacagccct agaggtctca caccttctcc ccaagcacc gcagggtgta gatgaccaca 600
cggccaaaaa agtcagtggc atcctcaaac gtcaccttca gccggtccac ttcagcagct 660
ggtatgggga aagtctgaag cgagttgttg tcctcagggg agaaatctac aatcttgttg 720
agagcctgag tgccctgtga accttcagca gagaaaggca atgagtgtct ggggtgaccc 780
ctggaacccc tgccaccag gcccttctag taccttcag gcagccccgg cgaactggaga 840
agccaccctg aaactggatc tgcagctggg agacacggat gagctgggga aactccagcg 900
tcaccactg ggagggggcc tggaaagcaga cagggaact gaggcgaag ctactgcag 960
gcacagagcc ctgctatgcc tgtctcatc acatagttct tggaatggag ggaagaagg 1020
aaattcggca catgttcctt tcctggtcga aaagatgttt tttccaaac tgccgagtgt 1080
tgcgattcag cactgaactc accctggagg caccaggatc aaggcgaaga gaggggctga 1140

```

149

```

gaccagctct cagctccgcg gagggcctga cccccagatc tgtccactga gggctcgacc 1200
ccaggcttag ggccctcgcca ctgcctgtcc ccacagactc ttacctgctc actgtctctg 1260
gacaaaccaa agagtgggtc atgtcgggtc cacaagacct cgcagggctt aggattgggc 1320
acagccttgg ttgaatccc ggccgctcct caagctacag ggccggcgga tcttggctac 1380
gccttggcct gaacgtcctc acctgtaact tgggacgaga accgccactc cctcgcccac 1440
cccagtcta aatgtcgctc cgatcaatcc cctgccggaa aatttgggag agaggatcag 1500
ggaaaccgcc aatgcccgga ggccaggcct ttcacaggaa acagatttcc cgccgggtttc 1560
gggggcggtg gctttttgtg cgaggctgtt tctctgcgaa tagctcttgg agccaaatct 1620
tgggacc 1627

```

```

<210> 122
<211> 1368
<212> DNA
<213> Homo sapien

```

```

<400> 122
ccgcgagccc cctgcgcgcc gctttggggc tgcgctcact cgtgtgcgcg ctgctccgcc 60
cgccagtcct ctcaacgcgc gcttggccgc ccgacgacgc gggagccgca cgcgccggac 120
gaggctcgct gcgctccctg ttgccagcg cgggcccggt gaggcggagc cctcagttcc 180
cggccaggac acggtctggg ccgccgaatc tccggccgaa gagcggcggc ggcagcggcg 240
ggaaaaaaat gaagaatgaa attgctgccg ttgtcttctt tttcacaagg ctagttcgaa 300
aacaatgataa gttgaaaaaa gaggcagttg agaggtttgc tgagaaattg accctaatac 360
ttcaagaaaa atataaaaat cactggatat cagaaaaacc atcgaaagga caggcctaca 420
gatgtattcg tgtcaataaa tttcagagag ttgatcctga tgcctgaaa gcctgtgaaa 480
acagctgcat cttgtatagt gacctgggct tgccaaagga gctcactctc tgggtggacc 540
catgtgaggt gtgctgtcgg tatggagaga aaaacaatgc attcattgtt gccagctttg 600
aaaataaaga tgaaggttac ctctgattat cattcaggat cctcttcttc agatgaagaa 660
acaagtaagg aaatggaagt gaaacccaat ttcagaactt atatttccac ctcttccaat 720
gtggcaccct ttgccagaa aaaagccagg aatgtatcga gggaatggcc atcagaatca 780
ctatcctcct cctgttccat ttggttatcc aaatcaggga agaaaaata aaccatatcg 840
cccaattcca gtgacatggg tacctcctcc tggaatgcat tgtgaccgga atcactggat 900
taatcctcac atgttagcac ctcaactaact tcgtttttga ttgtgttggg gtcattgtga 960
gaaaaaggta gaataaacct tactacacat taaaagttaa aagttcttac taatagtagt 1020
gaagttagat gggccaaacc atcaaactta tttttataga agttattgag aataatcttt 1080

```

150

cttaaaaaat atatgcactt tagatattga tatagtttga gaaattttat taaagttagt 1140
 caagtgccta agtttttaaat attggacttg agtatattata tattgtgcat caactctgtt 1200
 ggatacgaga aactgtaga agtggacgat ttgttctagc acctttgaga atttacttta 1260
 tggagcgtat gtaagttatt tatatacaag gaaatctatt ttatgtcgtt gtttaagaga 1320
 attgtgtgaa atcatgtagt tgcaaataaa aaatagtttg aggcatga 1368

<210> 123
 <211> 4007
 <212> DNA
 <213> Homo sapien

<400> 123
 ctggccccga gcagctgaag cctgggggtca gcaggcgctg cgggcgcagc tccgggtgcaa 60
 gcgaggacac gacacatgca gtggcttctg gactgcgcga tgactggacg caagtaactt 120
 ctaggtctgc agacaagagg aagagaagat gaaggaagac tgtctgccga gttctcacgt 180
 gcccatcagt gacagcaagt ccattcagaa gtaagccttg gtgtgcaggt tgggcggggg 240
 agtcttcaca ttgccatcc ccctcatcct gggcagcctt taggtggagg ggttctgagc 300
 acttgttcag agatctgatg ggggtgccctg ggggacagtg atgggggtgct tctttttgag 360
 cctgtccaat aggggatccc caagctacac atgaccatgg ctgggaggca tgggcaatag 420
 aaaagagggt ccagatggca ggcactttat acgaaatagg tgtgtacagg gcctcattat 480
 aacttttaca ttgattgcat gttgacaaat agtaatttag atatattgag ttcaataaaa 540
 tgtgttatta atgctaattt cacctgtttc attttccct ctgtattagg ccattcttgt 600
 gttgctataa agaaatacct gaagctgggt aatttacaaa gaaaagagat ttagttggct 660
 cacggttctg gaggctttac aagaagtgtg gtgctggcat ctgctcggct tccagggagg 720
 cctcaaggag cctccagtca tgttgaagg cgaacgggga gcaggcactt cacatggcga 780
 aagcaggagc aagagagagg gagtggaggg tgggtgccaca cactttttaa tgaccagacc 840
 tcgtgtgaac tcagagcaaa agctcactta tcaccacggg gatggcccaa gccactcatg 900
 agggatctgc tcccatgatc caaacacctc ccacctggcc ccacctcaa cactgggaat 960
 tacaattcca catgagattt ggggtggggac acacatccaa accatatcac ctccataacat 1020
 gtactagaag attgaaatta ccagtgtggc tcacatccca cgtctgctgg cccacagacc 1080
 ccacagagcc cagcttgggt tcaggcagct gtccaggcct ccccttcctc caacattagc 1140
 cagggtctg gctttccctt cggaaggga gacagcgttg agggaaagt gcttactgca 1200
 gacttcaggc ccttactcac agggccatca ccttcactg cgcctttgga aagtcagggt 1260
 ggggaagaag caggcaccoc tcagggtggc ccgcagcagc cacagcaggc cttgtaggaa 1320

151

gtgatatggg gaaaagcaag aggctgtaca atgccaaaag caagtccagg gcattttactg	1380
tgaggaagca acgcaggtgg agggcagggg ggcctgccagg gccttacctg tgatagtga	1440
agtgtcggca ccctggacat cctggaccag acgcaggcct gtcccgtgag tctcgcctcc	1500
tcctcagccc gaccccatg ccccccacca gggccatgtg cagaaccatc cgggtgcatt	1560
gcgatggcag tctggtctcc tctggttatg cctggccggc gagaaggggtg ctgtcacact	1620
cctgttataa atgaggaaac agaggccagg gaagccaaag gccagaagct gaggccctgc	1680
cacaccctag gagtacatgt gtgtctttcc ctttttaggt cggagctctt aggctgctg	1740
aaaacctaca actgctacca tgagggaag agcttcacag tgagacaccg tgaggaagaa	1800
gggactctga tcatcgaggg gctcctcaac attgcctggg ggctgaggcg gcccatccgg	1860
ctgcagatgc aggatgaccg ggagcagggtg cacctcccct ccacctcatg gatgccaga	1920
cggcctagct gccctctaaa ggagccatcg cccagaacg ggaacatcac agcccagggg	1980
ccaagcattc agccagtga caaggctgag agttccacag acagctcggg gccctggag	2040
gaggcagagg agggcccca gctgatgcgg accaagagcg acgccagttg catgagccag	2100
aggaggcca agtgccgcgc ccccggtgag gccagcgca tccggcgaca ccggttctct	2160
atcaacggcc acttctataa tcataagacc tccgtgttta ctccagccta tggatccgtg	2220
accaatgtga gggtaaacag caccatgaca accctgcagg tgcacacct gctgctgaac	2280
aaatttaggg tggaagatgg cccagtgag ttcgcactct acatcgttca cgagtctggg	2340
gagcggacaa aattaaaaga ctgcgagtag ccgctgattt ccagaatcct gcatgggcca	2400
tgtgagaaga tcgccaggat cttcctgatg gaagctgact tgggcgtgga agtccccat	2460
gaagtcgctc agtacattaa gtttgaaatg ccggtgctgg acagttttgt tgaaaaatta	2520
aaagaagagg aagaaagaga aataatcaaa ctgaccatga agttccaagc cctgcgtctg	2580
acgatgctgc agcgctgga gcagctgggtg gaggccaagt aactggccaa cacctgcctc	2640
ttccaaagtc cccagcagtg gcagggtgac actgagccct ggttgctggc cccggccggt	2700
cacattgact gatggccacc gcctgacgaa tcgagtgcct gtgtgtctac ctctctgaag	2760
cctgagcacc atgattccca cagccagctc ttgggtccaa gatgagcacc cacaggaagc	2820
cgaccaggc ctgaggggccc aggaacttgc tgggtcagat ctgtgtggcc agccctgtcc	2880
acaccatgcc tctcctgcac tggagagcag tgctggccca gccctgcgg cttaggcttc	2940
atctgcttgc acattgcctg tcccagagcc cctgtgggtc cacaagcccc tgtcctcttc	3000
cttcatatga gattcttgtc tgccctcata tcacgctgcc ccacaggaat gctgctggga	3060
aaagcagggc ctgccagcag gtatgagatc tagcctgctt tcagccatca ccttgccaca	3120
gtgtccccgg cttctaagcc tccaatatca ccctgtgagc ctgcacagc tcagccccaa	3180

152

cacagaggtg agaccaggaa taaggccaca agtatctcac tttctctgca gaaatcaatc 3240
 tttacttcat cagagagacc taaagcgatt cttacaagga gcttgctgca agaaacacgg 3300
 tcattcaatc acattgagga ggggtccacat ggcattgaga gggtgctgcc cgctcaatgc 3360
 ccagcagcag ctctggaagg cagtgtctcag ccccatcacc actgtcccgt ggatgcctgt 3420
 gtacctcttg ccttttctgg gcttgcggtt ctctcctcta gtgggtgggg atgactttca 3480
 atgactttca atacttcccc tgaaggaaga atgataagga gaaatgtctg ttttgaggaa 3540
 agggccttga attccccaga tactgaacaa tttgtgtttg tgactgatgg agaatttcag 3600
 gaatgaatga gaaagccttt gcgaaactat gcaacagttt acatcagtca tgtgaagtat 3660
 ttgtctaaaa cagagcaaac tgaagaccaa attattctcc tgttgaggtc cgtggatggc 3720
 agatttaaag ggaagaacca caaaggcttg caaagatagg agaggctcca tctctaattgc 3780
 atgtagaagc tccttacggg tgcccatcaa gagcatagct tggaagccac catgctgtgc 3840
 ggaactgcgt cagggcaaat gtcacagcag gatttcccca acccagctcc atcatcacag 3900
 acacagagag ctgcagggga ggctgcccc ctgttttgtc gactctgccc tcctctggca 3960
 gcatagatcc ttaggtgctc aataaagggtg tgctgtattg aactgaa 4007

<210> 124
 <211> 4961
 <212> DNA
 <213> Homo sapien

<400> 124
 taggaggcct tgataagagt ccttggccac attgacatgg gggagagaga ggaacaggaa 60
 gctgtgcaga tgccaacagg ttcgagaaag ctctgggtgga tttactgtcc gtgaaagaaa 120
 cctggggagg gcaggagcgg ctccctcaaac caatcaaggc tgtgtgtgga aagagggaat 180
 agtatgtgtg tggaacagtg tgtgtgaacc gcgtgtgtgt ggatccacta atgatcctgt 240
 gggccttgaga ttaccttgtt gcacagacga ggaaggaag gtttgggagt ttaagtcact 300
 gcccgatgc aatatagaga aggtactaag agaccagaat caggggtcca aatgcttgtg 360
 ctggaacagt ggcttttctg cttacttgcg ggtaatcttg ggcaaagtgc ttaagctctt 420
 gtccctgtct tctcatctgt aaaatgggaa tatgggtgata ctcacctcac aatatcgttg 480
 tagggactgg aggagataac tcagagaaga tgccaacat ttacagcaca tagggaacac 540
 agtgccgact aaccactgc caggacagcc agtgatgggc cactgcctgg ctgagcggga 600
 aggcaggaga gaggccagg gtagctctgg aggattgcag gagcaaccga ggcagaagcc 660
 agtagtcagg ctgtccctgc caaggggaagg gagcatgtga tctaaaatgc ttaggagatg 720
 gatctggatt cctggggatt atggagagtc ttctggggtg ggcggtgaa aggaccagtg 780

tcactggctc agcatgacct tgcccaacca aggcagcttg actgacatgt ggccatgtgg	840
gtctgggcca gacctttca gccgcagcca ccttgtgcca aggcgggtgtg atgccaaggg	900
cgacgggtgc tgtgccaggg ctgcgggtgt tgggtgctgc actggccggc actcctctgg	960
ctcacctgtc tgtccacct tccttgtctt cccagcaagt aacttctagg tctgcagaca	1020
agaggaagag aagatgaagg aagactgtct gccgagttct cacgtgcccc tcagtgcag	1080
caagtccatt cagaagtaag ccttgggtgtg cagggtgggc gggggagtct tcacatttgc	1140
catccccctc atcctgggca gccttttaggt ggaggggttc tgagcacttg ttcagagatc	1200
tgatgggggtg ccctggggga cagtgatggg gtgcttcttt ttgagcctgt ccaatagggg	1260
atccccaaagc tacacatgac catggctggg aggcattgggc aatagaaaag aggcctccaga	1320
tggcaggcac tttatacgaa ataggtgtgt acagggcctc attataactt ttacattgat	1380
tgcattgtga caaatagtaa tttagatata ttgagttcaa taaaatgtgt tattaatgct	1440
aatttcacct gtttcatttt ccctctgta ttaggccatt cttgtgttgc tataaagaaa	1500
tacctgaagc tgggtaattt acaaagaaaa gagatttagt tggctcacgg ttctggaggc	1560
tttacaagaa gtgtgggtgct ggcatctgct cggtctccag ggaggcctca aggagcctcc	1620
agtcattgtg gaaggcgaac ggggagcagg cacttcacat ggcgaaagca ggagcaagag	1680
agagggagtg gaggggtgtg ccacacactt ttaaatagacc agacctcgtg tgaactcaga	1740
gcaaaagctc acttatcacc acggggatgg cccaagccac tcatgaggga tctgctccca	1800
tgatccaaac acctcccacc tggccccacc tccaacactg ggaattacaa ttccacatga	1860
gatttggtgtg gggacacaca tccaaacctat atcacctcct aacatgtact agaagattga	1920
aattaccagt gtggctcaca tcccacgtct gctggcccca cagccccaca gagcccagct	1980
tgggttcagg cagctgtcca ggcctcccct tcctccaaca ttagccaggg ctgtggcttt	2040
cccttcggga agggagacag cgttgaggga aagtggctta ctgcagactt cagggcctta	2100
ctcacagggc catcaccttc cactgcgcct ttggaaagtc aggggtggga agaagcaggc	2160
acccctcagg gtggcccga gcagccacag caggccttgt aggaagtgat atggggaaaa	2220
gcaagaggct gtacaatgcc aaaagcaagt ccagggcatt tactgtgagg aagcaacgca	2280
ggtggagggc agggaggctg ccagggcctt acctgtgata gtgaaagtgt cggcacccctg	2340
gacatcctgg accagacgca ggcctgtccc gtgagtctcg cctcctcctc agcccagccc	2400
ccatgcccc caccagggcc atgtgcagaa ccatccgggt gcattgcgat ggcagtctgg	2460
tctcctctgg ttatgcctgg ccggcgagaa ggggtgctgtc aactcctgt taaaaatgag	2520
gaaacagagg ccagggaagc caaaggccag aagctgaggc cctgccacac cctaggagta	2580

154

catgtgtgtc	tttccctttt	taggtcggag	ctcttaggcc	tgctgaaaac	ctacaactgc	2640
taccatgagg	gcaagagctt	ccagctgaga	caccgtgagg	aagaagggaac	tctgatcatc	2700
gaggggctcc	tcaacattgc	ctgggggctg	aggcggccca	tccggctgca	gatgcaggat	2760
gaccgggagc	aggtgcacct	cccctccacc	tcatggatgc	ccagacggcc	tagctgccct	2820
ctaaaggagc	catcgcccca	gaacgggaac	atcacagccc	agggggccaag	cattcagcca	2880
gtgcacaagg	ctgagagttc	cacagacagc	tgggggcccc	tggaggaggc	agaggaggcc	2940
ccccagctga	tggcgaccaa	gagcgacgcc	agttgcatga	gccagaggag	gccccagtgc	3000
cgcgcccccg	gtgaggccca	gcgcattccg	cgacaccggt	tctctatcaa	cggccacttc	3060
tacaatcata	agacctccgt	gtttactcca	gcctatggat	ccgtgaccaa	tgtgagggtc	3120
aacagcacca	tgacaacctt	gcagggtgtc	accctgctgc	tgaacaaatt	taggggtggaa	3180
gatggcccca	gtgagtctgc	actctacatc	gttcacgagt	ctgggggatt	ctgaaggaga	3240
atcccaccaa	gctataggaa	gcctccctct	ccgcctcttc	cagagaaatg	gatggagcgg	3300
acaaaattaa	aagactgcga	gtaccgctg	atctccagaa	tcttgcattg	gccatgtgag	3360
aagatcgcca	ggatcttctt	gatggaagct	gacttgggct	tgggaagtcc	ccatgaagtc	3420
gctcagtaca	ttaagtttga	aatgccggtg	ctggacagtt	ttgttgaaaa	attaaaagaa	3480
gaggaagaaa	gagaaataat	caaactgacc	atgaagttcc	aagccctgcg	tctgacgatg	3540
ctgcagcgcc	tggagcagct	ggtggaggcc	aagtaactgg	ccaacacctg	cctcttccaa	3600
agtccccagc	agtggcaggt	gtacactgag	ccctggttgc	tggccccggc	cggtcacatt	3660
gactgatggc	caccgcctga	cgaatcgagt	gcctgtgtgt	ctacctctct	gaagcctgag	3720
caccatgatt	cccacagcca	gctcttggct	ccaagatgag	caccacagg	aagccgacct	3780
aggcctgagg	ggccaggaac	ttgctgggtc	agatctgtgt	ggccagccct	gtccacacca	3840
tgctctctct	gcactggaga	gcagtgtgtg	cccagcccct	gcggcttagg	cttcatctgc	3900
ttgcacattg	cctgtcccag	agcccctgtg	ggtccacaag	cccctgtcct	cttccttcat	3960
atgagattct	tgtctgccct	catatcacgc	tgccccacag	gaatgctgct	gggaaaagca	4020
gggcctgcca	gcaggatatga	gatctagcct	gctttcagcc	atcaccttgc	cacagtgtcc	4080
ccggcttcta	agcctccaat	atcacccctgt	gagcctcgca	cagctcagcc	ccaacacaga	4140
ggtgagacca	ggaataaggc	cacaagtatc	tcactttctc	tgcagaaatc	aatctttact	4200
tcacagagag	gacctaaagc	gattcttaca	aggagcttgc	tgcaagaaac	acgggtcatc	4260
aatcacattg	aggagggtcc	acatggcatt	gagaggggtg	tgcccgctca	atgcccagca	4320
gcagctctgg	aaggcagtgc	tcagcccat	caccactgtc	ccgtggatgc	ctgtgtacct	4380
cttgcccttt	ctgggcttgc	gtttctctcc	tctagtgggt	ggggatgact	ttcaatgact	4440

155

```

ttcaatactt cccctgaagg aagaatgata aggagaaatg tctgttttga ggaaagggct 4500
ttgaattccc cagatactga acaatttgtg tttgtgactg atggagaatt tcaggaatga 4560
atgagaaaagc ctttgcgaaa ctatgcaaca gtttacatca gtcattgtgaa gtatttgtct 4620
aaaacagagc aaactgaaga ccaaattatt ctctgttga ggtccgtgga tggcagattt 4680
aaagggaaga accacaaagg cttgcaaaga taggagagggc tccatctcta atgcatgtag 4740
aagctcctta cgggtgcccc tcaagagcat agcttggaag ccaccatgct gtgcggaact 4800
gcgtcagggc aaatgtcaca gcaggatttc cccaaccag ctccatcatc acagacacag 4860
agagctgcag gggaggcctg cccactgttt tgtcgactct gccctcctct ggcagcatag 4920
atccttaggt gctcaataaa ggtgtgctgt attgaactga a 4961

```

```

<210> 125
<211> 4827
<212> DNA
<213> Homo sapien

```

```

<400> 125
taggaggcct tgataagagt ccttggccac attgacatgg gggagagaga ggaacaggaa 60
gctgtgcaga tgccaacagg ttcgagaaag ctctgggtgga tttactgtcc gtgaaagaaa 120
cctggggagg gcaggagcgg ctctcaaac caatcaaggc tgtgtgtgga aagagggaaat 180
agtatgtgtg tggaacagtg tgtgtgaacc gcgtgtgtgt ggatccacta atgatcctgt 240
gggcttgaga ttaccttggt gcacagacga ggaaaggaag gtttgggagt ttaagtcaact 300
gcccgatgac aatatagaga aggtactaag agaccagaat caggggtcca aatgcttgtg 360
ctggaacagt ggcttttctg cttacttgct ggtaatcttg ggcaaagtgc ttaagctctt 420
gtccctgtct tctcatctgt aaaatgggaa tatggtgata ctcacctcac aatatcgttg 480
tagggactgg aggagataac tcagagaaga tgccaacat ttacagcaca tagggaacac 540
agtgccgact aaccactgc caggacagcc agtgatgggc cactgcctgg ctgagcggga 600
aggcaggaga gaggcccagg gtagctctgg aggattgcag gagcaaccga ggcagaagcc 660
agtagtcagg ctgtccctgc caagggaagg gagcatgtga tctaaaatgc ttaggagatg 720
gatctggatt cctggggatt atggagagtc ttctgggggtg ggcggctgaa aggaccagtg 780
tcaactggctc agcatgacct tgcccaacca aggcagcttg actgacatgt ggccatgtgg 840
gtctgggcca gacctttca gccgcagcca ccttgtgcca aggcgggtgtg atgccaaggc 900
cgacggtgtc tgtgccaggg ctgcgggtgt tgggtgctgc actggccggc actcctctgg 960
ctcacctgtc tgtccacctt tccttgtctt ccagcaagt aacttctagg tctgcagaca 1020
agaggaagag aagatgaagg aagactgtct gccgagttct cacgtgcccc tcagtgcacag 1080

```


caagtccatt	cagaagtaag	ccttggtgtg	caggttgggc	gggggagtct	tcacatttgc	1140
catccccctc	atcctgggca	gccttttaggt	ggaggggttc	tgagcacttg	ttcagagatc	1200
tgatgggggtg	ccctggggga	cagtgatggg	gtgcttcttt	ttgagcctgt	ccaatagggg	1260
atccccaagc	tacacatgac	catggctggg	aggcatgggc	aatagaaaag	aggctccaga	1320
tggcaggcac	tttatacgaa	ataggtgtgt	acagggcctc	attataactt	ttacattgat	1380
tgcatgttga	caaatagtaa	tttagatata	ttgagttcaa	taaaatgtgt	tattaatgct	1440
aatttcacct	gtttcatttt	cccctctgta	ttaggccatt	cttgtgttgc	tataaagaaa	1500
tacctgaagc	tgggtaattt	acaaagaaaa	gagatttagt	tggctcacgg	ttctggaggc	1560
tttacaagaa	gtgtggtgct	ggcatctgct	cggtctccag	ggaggcctca	aggagcctcc	1620
agtcatgttg	gaaggcgaac	ggggagcagg	cacttcacat	ggcgaaagca	ggagcaagag	1680
agagggagtg	gagggtggtg	ccacacactt	ttaaatagacc	agacctcgtg	tgaactcaga	1740
gcaaaaagctc	acttatcacc	acggggatgg	cccaagccac	tcatagagga	tctgctccca	1800
tgatccaaac	acctcccacc	tggccccacc	tccaacactg	ggaattacaa	ttccacatga	1860
gatttgggtg	gggacacaca	tccaaaccat	atcacctcct	aacatgtact	agaagattga	1920
aattaccagt	gtggctcaca	tcccacgtct	gctggcccca	cagccccaca	gagcccagct	1980
tgggttcagg	cagctgtcca	ggcctcccct	tcctccaaca	ttagccaggg	ctgtggcttt	2040
cccttcggga	agggagacag	cgttgaggga	aagtggctta	ctgcagactt	cagggcctta	2100
ctcacagggc	catcaccttc	cactgcgctt	ttggaaagtc	aggggtgggga	agaagcaggc	2160
accctcagg	gtggcccgcg	gcagccacag	caggccttgt	aggaagtgat	atggggaaaa	2220
gcaagaggct	gtacaatgcc	aaaagcaagt	ccagggcatt	tactgtgagg	aagcaacgca	2280
ggtggagggc	agggaggctg	ccagggcctt	acctgtgata	gtgaaagtgt	cggcaccttg	2340
gacatcctgg	accagacgca	ggcctgtccc	gtgagtctcg	cctcctcctc	agcccgaccc	2400
ccatgcccc	caccagggcc	atgtgcagaa	ccatccgggt	gcattgcat	ggcagtctgg	2460
tctcctctgg	ttatgcctgg	ccggcgagaa	gggtgctgtc	acactcctgt	tacaaatgag	2520
gaaacagagg	ccagggaagc	caaaggccag	aagctgaggc	cctgccacac	cctaggagta	2580
catgtgtgtc	tttccctttt	taggtcggag	ctcttaggcc	tgctgaaaac	ctacaactgc	2640
taccatgagg	gcaagagctt	ccagctgaga	caccgtgagg	aagaaggac	tctgatcatc	2700
gaggggctcc	tcaacattgc	ctgggggctg	aggcggccca	tccggctgca	gatgcaggat	2760
gaccgggagc	aggtgcacct	cccctccacc	tcattggatgc	ccagacggcc	tagctgccct	2820
ctaaaggagc	catcgcccca	gaacgggaac	atcacagccc	aggggccaag	cattcagcca	2880

157

gtgcacaagg	ctgagagttc	cacagacagc	tcgggggcccc	tggaggaggc	agaggaggcc	2940
ccccagctga	tgcggaccaa	gagcgacgcc	agttgcatga	gccagaggag	gccccagtgc	3000
cgcgcccccg	gtgaggccca	gcgcatccgg	cgacaccggc	tctctatcaa	cggccacttc	3060
tacaatcata	agacctccgt	gtttactcca	gcctatggat	ccgtgaccaa	tgtgagggtc	3120
aacagcacca	tgacaaccct	gcagggtgctc	accctgctgc	tgaacaaatt	tagggtggaa	3180
gatggcccca	gtgagttcgc	actctacatc	gttcacgagt	ctggggaaga	tcgccaggat	3240
cttcctgatg	gaagctgact	tgggcgtgga	agtcccccat	gaagtcgctc	agtacattaa	3300
gtttgaaatg	ccgggtgctgg	acagttttgt	tgaaaaatta	aaagaagagg	aagaaagaga	3360
aataatcaaa	ctgaccatga	agttccaagc	cctgcgtctg	acgatgctgc	agcgcctgga	3420
gcagctggtg	gaggccaagt	aactggccaa	cacctgcctc	ttccaaagtc	cccagcagtg	3480
gcagggtgtac	actgagccct	ggttgctggc	cccggccggc	cacattgact	gatggccacc	3540
gcctgacgaa	tcgagtgcct	gtgtgtctac	ctctctgaag	cctgagcacc	atgattccca	3600
cagccagctc	ttggctccaa	gatgagcacc	cacaggaagc	cgacccaggc	ctgagggggcc	3660
aggaacttgc	tgggtcagat	ctgtgtggcc	agccctgtcc	acaccatgcc	tctcctgcac	3720
tggagagcag	tgctggccca	gcccctgcgg	cttaggcttc	atctgcttgc	acattgcctg	3780
tcccagagcc	cctgtgggtc	cacaagcccc	tgtcctcttc	cttcatatga	gattcttgtc	3840
tgccctcata	tcacgctgcc	ccacaggaat	gctgctggga	aaagcagggc	ctgccagcag	3900
gtatgagatc	tagcctgctt	tcagccatca	ccttgccaca	gtgtccccgg	cttctaagcc	3960
tccaatatca	ccctgtgagc	ctcgcacagc	tcagccccaa	cacagagggtg	agaccaggaa	4020
taaggccaca	agtatctcac	tttctctgca	gaaatcaatc	tttacttcat	cagagagacc	4080
taaagcgatt	cttacaagga	gcttgctgca	agaaacacgg	tcattcaatc	acattgagga	4140
gggtccacat	ggcattgaga	gggtgctgcc	cgctcaatgc	ccagcagcag	ctctggaagg	4200
cagtgtcag	ccccatcacc	actgtcccgt	ggatgcctgt	gtacctcttg	ccttttcttg	4260
gcttgcgttt	ctctcctcta	gtgggtgggg	atgactttca	atgactttca	atacttcccc	4320
tgaaggaaga	atgataagga	gaaatgtctg	ttttgaggaa	agggctttga	attccccaga	4380
tactgaacaa	tttgtgtttg	tgactgatgg	agaatttcag	gaatgaatga	gaaagccttt	4440
gcgaaactat	gcaacagttt	acatcagtca	tgtgaagtat	ttgtctaaaa	cagagcaaac	4500
tgaagaccaa	attattctcc	tgttgaggtc	cgtggatggc	agatttaaag	ggaagaacca	4560
caaaggcttg	caaagatagg	agaggctcca	tctctaatac	atgtagaagc	tccttacggg	4620
tgcccatcaa	gagcatagct	tgggaagccac	catgctgtgc	ggaactgcgt	cagggcaaat	4680
gtcacagcag	gatttcccca	accagctcc	atcatcacag	acacagagag	ctgcagggga	4740

158

ggcctgcca ctgttttgtc gactctgcc tctctggca gcatagatcc ttaggtgctc 4800
 aataaagggtg tgctgtattg aactgaa 4827

<210> 126
 <211> 1969
 <212> DNA
 <213> Homo sapien

<400> 126
 gggcttcagt ttccggacgt gctgtgcagg ttcctctggg gccctctcca ggctgaggag 60
 gggctcgggt tgtctctggg gattaactcc atcattgcct agagagggac gggggcacac 120
 cttgacaaat ttatgtcctg ctttttggca aataggggag ggcaaagagc ctcaattgta 180
 tcttcttctt ctcaattgcc agccgctcca cttaatcctt atgccaaagt ggcatgctg 240
 ggggcccctgt tctgcctccc ttctgcatga gcaggaatct ctcaaggcag cgctgttagc 300
 gagagcggac aaaattaaaa gactgcgagt acccgctgat ttccagaatc ctgcatgggc 360
 catgtgagaa gatcgccagg atcttcctga tggagctga cttgggctg gaagtcccc 420
 atgaagtgc tcagtacatt aagtttgaat tgccgggtgct ggacagtttt gttgaaaaat 480
 taaaagaaga ggaagaaaga gaaataatca aactgacat gaagttccaa gccctgcgtc 540
 tgacgatgct gcagcgcctg gagcagctgg tggaggccaa gtaactggcc aacacctgcc 600
 tcttccaaag tccccagcag tggcaggtgt aactgagcc ctggttgctg gccccggccg 660
 gtcacattga ctgatggcca ccgcctgacg aatcgagtgc ctgtgtgtct acctctctga 720
 agcctgagca ccatgattcc cacagccagc tcttggctcc aagatgagca cccacaggaa 780
 gccgaccag gcctgagggg ccaggaactt gctgggtcag atctgtgtgg ccagcccctgt 840
 ccacaccatg cctctcctgc actggagagc agtgctggcc cagcccctgc ggcttaggct 900
 tcatctgctt gcacattgcc tgtcccagag cccctgtggg tccacaagcc cctgtcctct 960
 tccttcatat gagattcttg tctgccctca tatcacgctg cccacagga atgctgctgg 1020
 gaaaagcagg gcctgccagc aggtatgaga tctagcctgc tttcagccat caccttgcca 1080
 cagtgtcccc ggcttctaag cctccaatat caccctgtga gcctcgaca gctcagcccc 1140
 aacacagagg tgagaccagg aataaggcca caagtatctc actttctctg cagaaatcaa 1200
 tctttacttc atcagagaga cctaaagcga ttcttacaag gagcttgctg caagaaacac 1260
 ggtcattcaa tcacattgag gagggccac atggcattga gaggtgctg ccgctcaat 1320
 gccagcagc agctctggaa ggcagtgtc agcccatca cactgtccc gtggatgcct 1380
 gtgtacctct tgccttttct gggcttgcgt ttctctctc tagtgggtgg ggatgacttt 1440
 caatgacttt caatacttcc cctgaaggaa gaatgataag gagaaatgtc tgttttgagg 1500

159

```

aaagggcttt gaattcccca gatactgaac aatttgtgtt tgtgactgat ggagaatttc 1560
aggaatgaat gagaaagcct ttgcgaaact atgcaacagt ttacatcagt catgtgaagt 1620
at ttgtctaa aacagagcaa actgaagacc aaattattct cctgttgagg tccgtggatg 1680
gcagatttaa agggagaagc cacaaggct tgcaaagata ggagaggctc catctcta 1740
gcatgtagaa gctccttacg ggtgcccac aagagcatag cttggaagcc accatgctgt 1800
gcggaactgc gtcagggcaa atgtcacagc aggattttccc caaccagct ccatcatcac 1860
agacacagag agctgcaggg gaggcctgcc cactgttttg tgcactctgc cctcctctgg 1920
cagcatagat ccttaggtgc tcaataaagg tgtgctgtat tgaactgaa 1969

```

```

<210> 127
<211> 2665
<212> DNA
<213> Homo sapien

```

```

<400> 127
gggtctgcaa gcacagcacc agtgccggct gggagggtctc tctcctccat gggcaccagt 60
accctggtag ggggaaggcct gctaacccta gctccccagc atcacctctt gggccctgc 120
tcgggtattgc caccacgctg gggtagacagc ttgccaaaac agtgggacac agccccgatc 180
acccatccag tcttggcatc ctcaccagcg caggcatgag ctgcagaaca cctggcagga 240
aagtcaggca ggaacccaag tgggcgctgg gtcaagcttc tgagttctgc tgggtgatgtg 300
gctccaagga gcaggcatgc tgaggcagac ttggcctgat tagggccttt tgccttagtg 360
ggaattctga gccttcccca aagtggcaga tgctggaact cccagcctca gccgatgttt 420
tcagggtgcag agggctagtt caatgaaaag gtgagcaggt ctcacctgcc agctcctggg 480
gacaccacgc cagggtccgg atgcatgagt tagccaggct gtagtcccaa tgacgtctcc 540
ccctcagcaa agtgaagtgt ggtccaggac ttgtggaggg caccacacca gggctggtgg 600
ggaggcagct aggaaggaaa gggcaggagc tcaactgagag ggcctggggg gtgtggggaa 660
aggatggatg ttagcctctg gttgaatgac ccgtggaaaag ccacatcctc cacaggctcc 720
tgtctgtgca gccagacccc aaacaggcag aggagaccaa agtcagaggg aatcttccat 780
tctgcagtca gtcctgacct cgtaagattt gagagctgaa agggatctgg ggggcaacta 840
gtgggtccac tcaacgtaca gagtggacgc tgaggcccag cacaaggaag gttgccgcat 900
agggttatggc agaattctgg ctgaaacatg ggcttcccga tctctgctct accgccctgt 960
ccactccagt gtgctgttgt ctgtattaga gtctgcaata gaaatgacaa cactctgctc 1020
tgatgctctg tgcagtccac agcctggttt gactgcacct catgaggcgc aggccacagc 1080
cttccccctc cttggcagag gagagatgag gctgctgcag ggatctcctg agctggccat 1140

```

160

```

ctgcagggtcc cttgctctgc tgcccacctc cctgccctgt ctggcctcag tgagtcctct 1200
tggcgatgtc tccctccagg ttccaagccc tgcgtctgac gatgctgcag cgctgggagc 1260
agctggtgga ggccaagtaa ctggccaaca cctgcctctt ccaaagtccc cagcagtggc 1320
aggtgtacac tgagccctgg ttgctggccc cgcccggtca cattgactga tggccaccgc 1380
ctgacgaatc gaggcctgt gtgtctacct ctctgaagcc tgagcaccat gattcccaca 1440
gccagctctt ggctccaaga tgagcaccca caggaagccg acccaggcct gaggggcccag 1500
gaacttgctg ggctcagatct gtgtggccag ccctgtccac accatgcctc tctgactg 1560
gagagcagtg ctggcccagc ccctgcggct taggcttcat ctgcttgac attgcctgtc 1620
ccagagcccc tgtgggtcca caagcccctg tctcttctc tcatatgaga ttcttgtctg 1680
ccctcatatc acgctgcccc acaggaatgc tgctgggaaa agcagggcct gccagcaggt 1740
atgagatcta gcctgctttc agccatcacc ttgccacagt gtccccggct tctaagcctc 1800
caatatcacc ctgtgagcct cgcacagctc agccccaaca cagaggtag accaggaata 1860
agggccacaag tatctcactt tctctgcaga aatcaatctt tacttcatca gagagaccta 1920
aagcgattct tacaaggagc ttgctgcaag aaacacggtc attcaatcac attgaggagg 1980
gtccacatgg cattgagagg gtgctgcccg ctcaatgcc agcagcagct ctggaaggca 2040
gtgctcagcc ccatcaccac tgtcccgtag atgcctgtgt acctcttgcc ttttctgggc 2100
ttgcgtttct ctctctagt ggggtgggat gactttcaat gactttcaat acttcccctg 2160
aaggaagaat gataaggaga aatgtctgtt ttgaggaaag ggctttgaat tccccagata 2220
ctgaacaatt tgtgtttgtg actgatggag aatttcagga atgaatgaga aagcctttgc 2280
gaaactatgc aacagtttac atcagtcatg tgaagtattt gtctaaaaca gagcaaactg 2340
aagaccaaatt tattctcctg ttgagggtccg tggatggcag atttaaaggg aagaaccaca 2400
aaggcttgca aagataggag aggcctccat tctaattgat gtagaagctc cttacgggtg 2460
cccatcaaga gcatagcttg gaagccacca tgctgtgcgg aactgcgtca gggcaaattg 2520
cacagcagga tttccccaac ccagctccat catcacagac acagagagct gcaggggagg 2580
cctgcccact gttttgtcga ctctgcctc ctctggcagc atagatcctt aggtgctcaa 2640
taaagggtgtg ctgtattgaa ctgaa 2665

```

<210> 128

<211> 1835

<212> DNA

<213> Homo sapien

<400> 128

```

gcccctcgga ccaccggact ggccctggggc gggacgtggg cgcgggggcg cggcgtgcgg 60

```

161

cacgctgcag ggctgaagcg gcggcggcgg tggggactgc acgtagcccc ggcctcggca	120
tggctctcct ggtgctcggt ctggtgagct gtaccttctt tctggcagtg aatggtctgt	180
attcctctag tgatgatgtg atcgaattaa ctccatcgaa tttcaaccga gaagttattc	240
agagtgatag tttgtggctt gtagaattct atgctccatg gtgtgggtcac tgtcaaagat	300
taacaccaga atggaagaaa gcagcaactg cattaaaaga tgttgtcaaa gttggtgcag	360
ttgatgcaga taagcatcat tccctaggag gtcagtatgg tgttcaggga tttcctacca	420
ttaagatfff tggatccaac aaaaacagac cagaagatta ccaagggtggc agaactggtg	480
aagccattgt agatgctgcg ctgagtgtc tgcgccagct cgtgaaggat cgcctcgggg	540
gacggagcgg aggatacagt tctggaaaac aaggcagaag tgatagttca agtaagaagg	600
atgtgattga gctgacagac gacagctttg ataagaatgt tctggacagt gaagatgttt	660
ggatggttga gttctatgct ccttggtgtg gacactgcaa aaacctagag ccagagtggg	720
ctgccgcagc ttcagaagta aaagagcaga cgaaaggaaa agtgaaactg gcagctgtgg	780
atgctacagt caatcagggt ctggcctccc gatacgggat tagaggattt cctacaatca	840
agatatttca gaaaggcgag tctcctgtgg attatgacgg tgggcggaca agatccgaca	900
tcgtgtcccc ggcccttgat ttgttttctg ataacgcccc acctcctgag ctgcttgaga	960
ttatcaacga ggacattgcc aagaggacgt gtgaggagca ccagctctgt gttgtggctg	1020
tgtgccccca tatccttgat actggagctg caggcagaaa ttcttatctg gaagttcttc	1080
tgaagtggc agacaaatac aaaaagaaaa tgtgggggtg gctgtggaca gaagctggag	1140
cccagtctga acttgagacc gcgttgggga ttggagggtt tgggtacccc gccatggccg	1200
ccatcaatgc acgcaagatg aaatttgctc tgctaaaagg ctcccttcagt gagcaaggca	1260
tcaacgagtt tctcaggag ctctcttttg ggcgtggctc cacggcacct gtaggaggcg	1320
gggctttccc taccatcgtt gagagagagc cttgggacgg cagggatggc gaggagtgcc	1380
cgggagggaa gctgtgcggg cagcagtcct ggtttactct cttgagcctg tgcattctctg	1440
cacctggagt caagtccttc ccatcagacc tcagccctgg tgcacccgtg ggccttttaa	1500
gaggttcttc tctgaagacc ctcatcttc cttatcacia gtttaagtgc tgcattggcat	1560
ttgatactct tgacagccaa gatacatttc agtagtaagg ttgctttcct gattattacc	1620
ttaaagtga catttaacct ggaattcatt tactttatct tagaaaaata gaaaatgata	1680
gctttgaaat tagcacttat ttctgtactg ttgtgtccca ccctcctcaa aaggacacgt	1740
tcaagtggct tccagtgtta aaatggtgag tgatgtgat ttgaaatggt tcacctgagt	1800
tctgagcttt tccatccgta taatcatagg tacga	1835

162

<210> 129
 <211> 438
 <212> PRT
 <213> Homo sapien

<400> 129

Pro Val Pro Ala Leu Cys Pro Ser Pro Trp Pro Cys Pro Pro Ala Cys
 1 5 10 15

Pro Ala Pro Ser Gly Pro Pro Ser Leu Asn Ser Ile Pro Leu Ala Leu
 20 25 30

Phe His Ser Glu Glu Pro His Gly Cys Phe Ser Leu Ala Glu Arg Pro
 35 40 45

Ser Pro Pro Lys Ala Trp Asp Gln Leu Arg Ala Val Ser Gly Gly Ser
 50 55 60

Pro Glu Arg Arg Thr Pro Trp Lys Pro Pro Pro Ser Asp Leu Tyr Gly
 65 70 75 80

Asp Leu Lys Ser Arg Arg Asn Ser Val Ala Ser Pro Thr Ser Pro Thr
 85 90 95

Arg Ser Leu Pro Arg Ser Ala Ser Ser Phe Glu Gly Arg Ser Val Pro
 100 105 110

Ala Thr Pro Val Leu Thr Arg Gly Ala Gly Pro Gln Leu Cys Lys Pro
 115 120 125

Glu Gly Leu His Ser Arg Gln Trp Ser Gly Ser Gln Asp Ser Gln Met
 130 135 140

Gly Phe Pro Arg Ala Asp Pro Ala Ser Asp Arg Ala Ser Leu Phe Val
 145 150 155 160

Ala Arg Thr Arg Arg Ser Asn Ser Ser Glu Ala Leu Leu Val Asp Arg
 165 170 175

Ala Ala Gly Gly Gly Ala Gly Ser Pro Pro Ala Pro Leu Ala Pro Ser
 180 185 190

Ala Ser Gly Pro Pro Val Cys Lys Ser Ser Glu Val Leu Tyr Glu Arg
 195 200 205

Pro Gln Pro Thr Pro Ala Phe Ser Ser Arg Thr Ala Gly Pro Pro Asp

163

210		215		220
Pro Pro Arg Ala Ala Arg Pro Ser Ser Ala Ala Pro Ala Ser Arg Gly				
225		230		235 240
Ala Pro Arg Leu Pro Pro Val Cys Gly Asp Phe Leu Leu Asp Tyr Ser				
	245		250	255
Leu Asp Arg Gly Leu Pro Arg Ser Gly Gly Gly Thr Gly Trp Gly Glu				
	260		265	270
Leu Pro Pro Ala Ala Glu Val Pro Gly Pro Leu Ser Arg Arg Asp Gly				
	275		280	285
Leu Leu Thr Met Leu Pro Gly Pro Pro Pro Val Tyr Ala Ala Asp Ser				
	290		295	300
Asn Ser Pro Leu Leu Arg Thr Lys Asp Pro His Thr Arg Ala Thr Arg				
	305	310		315 320
Thr Lys Pro Cys Gly Leu Pro Pro Glu Ala Ala Glu Gly Pro Glu Val				
	325		330	335
His Pro Asn Pro Leu Leu Trp Met Pro Pro Pro Thr Arg Ile Pro Ser				
	340		345	350
Ala Gly Glu Arg Ser Gly His Lys Asn Leu Ala Leu Glu Gly Leu Arg				
	355		360	365
Asp Trp Tyr Ile Arg Asn Ser Gly Leu Ala Ala Gly Pro Gln Arg Arg				
	370	375		380
Pro Val Leu Pro Ser Val Gly Pro Pro His Pro Pro Phe Leu His Ala				
	385	390		395 400
Arg Cys Tyr Glu Val Gly Gln Ala Leu Tyr Gly Ala Pro Ser Gln Ala				
	405		410	415
Pro Leu Pro His Ser Arg Ser Phe Thr Ala Pro Pro Val Ser Gly Arg				
	420		425	430
Tyr Gly Gly Cys Phe Tyr				
	435			

<210> 130

<211> 237

164

<212> PRT

<213> Homo sapien

<400> 130

Met	Glu	Val	Lys	Gly	Gln	Leu	Ile	Ser	Ser	Pro	Thr	Phe	Asn	Ala	Pro
1				5					10					15	

Ala	Ala	Leu	Phe	Gly	Glu	Ala	Ala	Pro	Gln	Val	Lys	Ser	Glu	Arg	Leu
			20					25					30		

Arg	Gly	Leu	Leu	Asp	Arg	Gln	Arg	Thr	Leu	Gln	Glu	Ala	Leu	Ser	Leu
		35					40					45			

Lys	Leu	Gln	Glu	Leu	Arg	Lys	Val	Cys	Leu	Gln	Glu	Ala	Glu	Leu	Thr
	50					55					60				

Gly	Gln	Leu	Pro	Pro	Glu	Cys	Pro	Leu	Glu	Pro	Gly	Glu	Arg	Pro	Gln
65					70					75					80

Leu	Val	Arg	Arg	Arg	Pro	Pro	Thr	Ala	Arg	Ala	Tyr	Pro	Pro	Pro	His
				85					90						95

Pro	Asn	Gln	Ala	His	His	Ser	Leu	Cys	Pro	Ala	Glu	Glu	Leu	Ala	Leu
			100					105						110	

Glu	Ala	Leu	Glu	Arg	Glu	Val	Ser	Val	Gln	Gln	Gln	Ile	Ala	Ala	Ala
		115					120					125			

Ala	Arg	Arg	Leu	Ala	Leu	Ala	Pro	Asp	Leu	Ser	Thr	Glu	Gln	Arg	Arg
	130					135					140				

Arg	Arg	Arg	Gln	Val	Gln	Ala	Asp	Ala	Leu	Arg	Arg	Leu	His	Glu	Leu
145					150					155					160

Glu	Glu	Gln	Leu	Arg	Asp	Val	Arg	Ala	Arg	Leu	Gly	Leu	Pro	Val	Leu
				165					170					175	

Pro	Leu	Pro	Gln	Pro	Leu	Pro	Leu	Ser	Thr	Gly	Ser	Val	Ile	Thr	Thr
			180					185					190		

Gln	Gly	Val	Cys	Leu	Gly	Met	Arg	Leu	Ala	Gln	Leu	Ser	Gln	Gly	Glu
		195					200						205		

His	Pro	Leu	Val	Arg	Val	Gly	Glu	Trp	Thr	Leu	Ala	Asn	Gly	Arg	Gly
	210					215					220				

165

Arg Ala Gly Met Gly Asp Trp Pro Val Lys Thr Gly Arg
 225 230 235

<210> 131
 <211> 233
 <212> PRT
 <213> Homo sapien

<400> 131

Met Pro Phe Gln Lys Gly Met Pro Phe Asp Leu Cys Phe Leu Val Gln
 1 5 10 15

Ser Ser Asp Phe Lys Val Met Val Asn Gly Ile Leu Phe Val Gln Tyr
 20 25 30

Phe His Arg Val Pro Phe His Arg Val Asp Thr Ile Ser Val Asn Gly
 35 40 45

Ser Val Gln Leu Ser Tyr Ile Ser Phe Gln Pro Pro Gly Val Trp Pro
 50 55 60

Ala Asn Pro Ala Pro Ile Thr Gln Thr Val Ile His Thr Val Gln Ser
 65 70 75 80

Ala Pro Gly Gln Met Phe Ser Thr Pro Ala Ile Pro Pro Met Met Tyr
 85 90 95

Pro His Pro Ala Tyr Pro Met Pro Phe Ile Thr Thr Ile Leu Gly Gly
 100 105 110

Leu Tyr Pro Ser Lys Ser Ile Leu Leu Ser Gly Thr Val Leu Pro Ser
 115 120 125

Ala Gln Arg Phe His Ile Asn Leu Cys Ser Gly Asn His Ile Ala Phe
 130 135 140

His Leu Asn Pro Arg Phe Asp Glu Asn Ala Val Val Arg Asn Thr Gln
 145 150 155 160

Ile Asp Asn Ser Trp Gly Ser Glu Glu Arg Ser Leu Pro Arg Lys Met
 165 170 175

Pro Phe Val Arg Gly Gln Ser Phe Ser Val Trp Ile Leu Cys Glu Ala
 180 185 190

His Cys Leu Lys Val Ala Val Asp Gly Gln His Leu Phe Glu Tyr Tyr
 195 200 205

166

His Arg Leu Arg Asn Leu Pro Thr Ile Asn Arg Leu Glu Val Gly Gly
 210 215 220

Asp Ile Gln Leu Thr His Val Gln Thr
 225 230

<210> 132
 <211> 115
 <212> PRT
 <213> Homo sapien

<400> 132

Met Glu Lys Ser Gly Arg Arg Trp Leu Ala Ser Ala Ala Pro Pro Leu
 1 5 10 15

Gly Arg Leu Arg Arg Arg Glu Ser Gly Ala Glu Gln Gly Gly Leu Ser
 20 25 30

Val Arg Ala Thr Arg Val Ser Leu Val Arg Ser Ala Leu Asp Cys Ala
 35 40 45

Pro Arg Ser Gly Val Arg Arg Pro Gly Ser Cys Phe Cys Arg Cys Arg
 50 55 60

Arg Arg Ile Pro Val Ala Arg Arg Ala Arg Leu Pro Gln Ala Cys Ser
 65 70 75 80

Gln His Arg Thr Glu Pro Ser Gly Gly Arg Gly Trp Ser Ala Arg Pro
 85 90 95

Ala Trp Glu Arg Gln Gly Arg Arg Cys Asn Leu Leu Thr Ala Lys Lys
 100 105 110

Pro Gly Glu
 115

<210> 133
 <211> 151
 <212> PRT
 <213> Homo sapien

<400> 133

Arg Asn Glu Tyr Gln Leu Met Leu Thr Arg Tyr Leu Asp Phe Glu Gly
 1 5 10 15

Leu Pro Ser Lys Leu Trp His Glu Ser Val Arg His Gly Phe Leu His

167

20

25

30

Ser Ser Asp Asn Leu Phe Phe Gln Asn Gly Phe Leu Leu Leu Leu Leu
 35 40 45

Leu Thr Asn Ser Lys His Pro Val Leu Leu Phe Val Leu Phe Val Leu
 50 55 60

Phe Cys Phe Val Leu Phe Cys Leu Pro Phe Arg Lys Val Leu Phe Arg
 65 70 75 80

Val Gly Ile Asp Cys Ser Leu Glu Thr Leu Ser Ser Val Cys Ala Gly
 85 90 95

Ser Val His Ala Leu Tyr Glu Phe Gly Leu Asn Asn Ala Phe Glu Val
 100 105 110

Thr Trp Asp Val Gln Phe Trp His Val Phe Ile Asp Cys Val Phe Lys
 115 120 125

His Val Ser Cys Phe Met Ser Phe Ser Lys Pro His Phe Thr Ser Tyr
 130 135 140

Ser Glu Lys Leu Ile Lys Glu
 145 150

<210> 134
 <211> 699
 <212> PRT
 <213> Homo sapien

<400> 134

Met Arg His Ser Ile Ser Asn Leu Lys Lys Lys Lys Lys Lys Lys Lys
 1 5 10 15

Lys Thr Ser Gly Lys Lys Val Arg Gly Ile Leu Ser Leu Lys Leu Val
 20 25 30

Ser Glu Gly Thr Gly Glu Glu Lys Thr Thr Val Pro Asn Glu Lys Arg
 35 40 45

Thr Gly Asn Leu Ile Leu Ile Gly Met His Gln Ile Leu Leu Cys Thr
 50 55 60

Phe Ala Ser Ser Ile Ser Arg Arg Ile Val Gln Asn Val Tyr Phe Leu
 65 70 75 80

168

Pro Met Leu Arg Lys Gln Val Tyr Arg Thr Tyr Ser Gly Leu Ile Ala
 85 90 95

Ser Glu Trp Gln Ile Arg Ile Gly Ile Gln Ser Pro Cys Cys Gly Leu
 100 105 110

Leu Gln Gln Glu Asn Gln Ala Thr Gln Met Ile Leu Phe Ser Leu Phe
 115 120 125

Gly Phe Val Lys Cys His Leu Val Leu Phe Pro Ser Asn Ile Glu Glu
 130 135 140

Val Val Gly Leu Lys Leu Trp Asp Leu His Tyr Ala Tyr Thr Phe Leu
 145 150 155 160

Phe Met Pro Leu Phe Arg Glu Ala Asp Tyr Cys Phe Phe Lys Met Met
 165 170 175

His Trp Arg Arg Cys Glu Ser Lys Ile Ala Thr Trp His Tyr Leu Pro
 180 185 190

Arg Ile Asn Glu Lys Gly Lys Lys Thr Ile Phe Ser Phe Phe Lys His
 195 200 205

Phe Ser Glu Lys Ile Gln Leu Pro Phe Leu Ile Gly Glu Arg His His
 210 215 220

Ala Arg Leu Ile Phe Ala Phe Leu Val Glu Thr Gly Phe His His Val
 225 230 235 240

Gly Gln Asp Gly Leu Asp Leu Leu Ile Ser Cys Ser Ala His Leu Gly
 245 250 255

Leu Leu Ser Ala Gly Ile Thr Gly Met Ser His Cys Ala Arg Ser Thr
 260 265 270

Ile Leu Phe Ser Val Ser His Pro Tyr Gln Ile Ile Glu Pro Ser Val
 275 280 285

Cys Met Phe Leu Asn Leu Val Tyr Asn Ser Thr Ser Leu Thr Tyr Lys
 290 295 300

Ser Thr Ile Ser Tyr Glu Phe Phe Ile Glu Val Gly Ser Ile Leu Lys
 305 310 315 320

169

Trp Thr Glu Asn Leu Ile Pro Gly Arg Ala Arg Trp Leu Met Pro Val
 325 330 335

Ile Pro Tyr Phe Gly Arg Pro Arg Trp Val Asp His Leu Arg Leu Gly
 340 345 350

Val Arg Asp Gln Pro Gly Gln His Gly Glu Thr Pro Ser Leu Leu Lys
 355 360 365

Asn Thr Lys Ile Ser Gln Ala Trp Trp Leu Ser Val Ile Pro Ala Asn
 370 375 380

Gly Glu Ala Glu Ala Gln Glu Ser Leu Glu Pro Glu Glu Ala Glu Val
 385 390 395 400

Ala Val Ser Arg Asp His Thr Thr Ala Leu His Pro Gly Gln Trp Ser
 405 410 415

Glu Thr Leu Ser Gln Lys Ile Ile Asn Glu Asp Met Ile Pro Ala Cys
 420 425 430

Phe Ile Gln Leu Glu Arg His Thr Thr His Glu Ile Ile Gly Glu His
 435 440 445

Val Asn Val Tyr Leu Leu Val Gln Leu Arg Lys Arg Glu Glu Tyr Val
 450 455 460

Leu Val Ser Lys Val Leu Asn Lys Thr Glu Val Ala Ser Thr Val Ala
 465 470 475 480

His Val Phe Phe Gly Leu Thr Phe Phe Phe Ser Ser Thr Phe Cys Asn
 485 490 495

Phe Tyr Asp Leu Gly His Glu Val Leu Pro Leu Arg His Asn Gln Tyr
 500 505 510

Pro Ser Arg Lys Gly Leu Leu Ile Pro Gly Val Lys Ile Pro Ser Leu
 515 520 525

Arg Gly Ser His Tyr Gly Ser Pro Gly Val Lys Ile Pro Ser Ser Gln
 530 535 540

Glu Ser Tyr Leu Gln His Leu Gly Lys Ile Pro Glu Gly Ala Thr Ser
 545 550 555 560

Asn Arg Lys Met Lys Glu Arg Phe Asn Phe Ser Thr Gln Val Thr Asn

170

565

570

575

Pro Met His Ser Ile Val Tyr Val Ile Cys Arg Lys Gly Thr Gly Gly
 580 585 590

Val Arg Ala Leu Trp Val Thr Ala Leu Leu Val Val Thr Phe Thr Leu
 595 600 605

Leu Phe Leu Leu Asn Leu Trp Phe Ser Arg Leu Lys Asn Glu Ile Ile
 610 615 620

Gly Gln Ile Asn Ser Ser Gln Pro Phe Leu Glu Gln Gln Ile Arg Leu
 625 630 635 640

Ser Leu Lys Ser Phe Ser Lys Ile Ser Cys Phe Gln Ser Leu Pro Val
 645 650 655

Ile Ala Ile Ile Pro Arg Leu Ile Lys Ser Val Leu Val Asn Gln Phe
 660 665 670

Leu Tyr Phe Phe Phe Leu Ser Phe Phe Tyr Ser Val Phe Arg Tyr His
 675 680 685

Leu Thr Asn Asn Leu Leu Leu Ile Leu Leu Arg
 690 695

<210> 135

<211> 151

<212> PRT

<213> Homo sapien

<400> 135

Arg Asn Glu Tyr Gln Leu Met Leu Thr Arg Tyr Leu Asp Phe Glu Gly
 1 5 10 15

Leu Pro Ser Lys Leu Trp His Glu Ser Val Arg His Gly Phe Leu His
 20 25 30

Ser Ser Asp Asn Leu Phe Phe Gln Asn Gly Phe Leu Leu Leu Leu Leu
 35 40 45

Leu Thr Asn Ser Lys His Pro Val Leu Leu Phe Val Leu Phe Val Leu
 50 55 60

Phe Cys Phe Val Leu Phe Cys Leu Pro Phe Arg Lys Val Leu Phe Arg
 65 70 75 80

171

Val Gly Ile Asp Cys Ser Leu Glu Thr Leu Ser Ser Val Cys Ala Gly
 85 90 95

Ser Val His Ala Leu Tyr Glu Phe Gly Leu Asn Asn Ala Phe Glu Val
 100 105 110

Thr Trp Asp Val Gln Phe Trp His Val Phe Ile Asp Cys Val Phe Lys
 115 120 125

His Val Ser Cys Phe Met Ser Phe Ser Lys Pro His Phe Thr Ser Tyr
 130 135 140

Ser Glu Lys Leu Ile Lys Glu
 145 150

<210> 136
 <211> 762
 <212> PRT
 <213> Homo sapien

<400> 136

Met Gly Arg Leu Arg His Lys Asn Leu Leu Asn Leu Gly Gly Gly Gly
 1 5 10 15

Cys Ser Glu Pro Arg Ser His His Cys Thr Pro Ser Trp Ala Met Glu
 20 25 30

Arg Asp Ser Val Ser Lys Asn Asn Lys Glu Asp Met Ile Pro Ala Cys
 35 40 45

Phe Ile Gln Leu Glu Arg His Thr Thr His Glu Ile Ile Gly Glu His
 50 55 60

Val Asn Val Tyr Leu Leu Val Gln Leu Arg Lys Arg Glu Glu Tyr Val
 65 70 75 80

Leu Val Ser Lys Val Leu Asn Lys Thr Glu Val Ala Ser Thr Val Ala
 85 90 95

His Val Phe Phe Gly Leu Thr Phe Phe Phe Ser Ser Thr Phe Cys Asn
 100 105 110

Phe Tyr Asp Leu Gly His Glu Val Leu Pro Leu Arg His Asn Gln Tyr
 115 120 125

Pro Ser Arg Lys Gly Leu Leu Ile Pro Gly Val Lys Ile Pro Ser Leu

172

130		135		140
Arg Gly Ser His Tyr Val Ile Pro Arg Ser Lys Asp Ser Tyr Leu Ala				
145		150		155
				160
Gly Ile Leu Leu Ala His Leu Gly Lys Ile Pro Glu Gly Ala Thr Ser				
		165		170
				175
Asn Arg Lys Met Lys Glu Arg Phe Asn Phe Ser Thr Gln Val Thr Asn				
		180		185
				190
Pro Met His Ser Ile Val Tyr Val Ile Cys Arg Lys Gly Thr Gly Gly				
		195		200
				205
Val Arg Ala Leu Trp Val Thr Ala Leu Leu Val Val Thr Phe Thr Leu				
		210		215
				220
Leu Phe Leu Leu Asn Leu Trp Phe Ser Arg Leu Lys Asn Glu Ile Ile				
		225		230
				235
				240
Gly Gln Ile Asn Ser Ser Gln Pro Phe Leu Glu Gln Gln Ile Arg Leu				
		245		250
				255
Ser Leu Lys Ser Phe Ser Lys Ile Ser Cys Phe Gln Ser Leu Pro Val				
		260		265
				270
Ile Ala Ile Ile Pro Arg Leu Ile Lys Ser Val Leu Val Asn Gln Phe				
		275		280
				285
Leu Tyr Phe Phe Phe Leu Ser Phe Phe Tyr Ser Val Phe Gln Val Ser				
		290		295
				300
Phe Asp Gln Gln Leu Ala Leu Asn Leu Thr Ala Met Thr Glu Ile Ser				
		305		310
				315
				320
Lys Glu Glu Ser Ile Val Val Ile Gly Leu Val Ile Ile Ile Leu Lys				
		325		330
				335
Thr Ile His Tyr Phe Leu Lys Leu Asn Ala Val Cys Leu Ile Ser Val				
		340		345
				350
Glu Tyr Asp Lys Asn Val Asn Glu Lys Pro Asn Met Thr Leu Thr Leu				
		355		360
				365
Ala Leu Asn Phe Ile Phe Thr Cys Val Leu Lys Val Leu Tyr Trp Pro				
		370		375
				380

173

Val Gly Lys Leu Ile Cys Ile Arg Phe Thr Pro Gly Phe Gly Arg Asn
 385 390 395 400

Ser Phe Leu Lys Ile Gln Leu Ala Asp Leu Lys Met Phe Phe Ile Pro
 405 410 415

Gln Asn Val Ser Leu Leu Cys His Ser Tyr Arg Leu Ser Ala Phe Phe
 420 425 430

Asp His His Val Asn Tyr Ala Val Val Asn His Gly Val Gln Ala Asp
 435 440 445

Glu Leu Val Val Phe Val Lys Gln Asn Val Met Ser Ile Gly Arg Asp
 450 455 460

Ser Ser Ser Gly Glu His Gly Ser Phe Pro Val Ile Pro Ala Leu Met
 465 470 475 480

Asn Arg Leu Lys Thr Ala Val Tyr Tyr Gly Gln Phe Asn Phe Thr Gly
 485 490 495

Leu Pro Gly Leu Ala Phe Gln Leu Leu Ser Cys Arg Glu Thr Trp Cys
 500 505 510

Cys Thr Val His Ile Leu Glu Lys Trp Gln Glu Cys Ser Leu Glu Leu
 515 520 525

Gln Ile Thr Gln Gln Arg Ile Pro Tyr Gln Tyr Ile Gly Phe Ser Cys
 530 535 540

Tyr Ile Glu Ile Trp Tyr Phe Ser Asp Gly Tyr Gly Phe Cys Leu Thr
 545 550 555 560

Cys Val Ser Val Leu Leu Glu Arg Gln Tyr Arg Ile Lys Asn Phe Leu
 565 570 575

Met Ser Phe Leu Lys Ile Glu Ile Ile Met Ala Leu Leu Val Val Leu
 580 585 590

Cys Ser Asp Arg Pro Leu Ile Lys Lys Ser Phe Asn Pro Ala Phe His
 595 600 605

Phe Thr Ser Pro Pro Phe Ile Phe Asn Ile His Ser Leu Lys Ile Val
 610 615 620

174

Met Ile Phe Ser Val Ile Gly Tyr Val Lys Lys Phe His Phe Lys Val
625 630 635 640

Leu Ile Cys Asn Asn Leu His Phe Leu Leu Asn Trp Arg Thr Phe Leu
645 650 655

Arg Gln Thr Tyr Phe Tyr Glu Leu Ile Phe Ser Leu Val Lys Glu Asn
660 665 670

Ser Leu Val Ser Tyr Arg Glu Trp Leu Ala Leu Cys Ile Pro His Pro
675 680 685

Leu Cys Gly Leu Pro Val Ala Val Val Leu Leu Lys Ile Ala Asp Ile
690 695 700

Leu Ile Asn Met Met Ile Phe Gly Thr Gly Leu Ser Leu Leu Leu Ile
705 710 715 720

Ser Asn Lys Val Gly Gln Ser Asn Leu Asn Tyr Phe Asn Lys His Asn
725 730 735

Leu Ala Phe Leu Tyr Met Arg Lys Tyr Phe Gln Lys Ile Thr Arg Phe
740 745 750

Ile Ser Arg Ile Arg Asp Gly Lys Tyr Gln
755 760

<210> 137
<211> 138
<212> PRT
<213> Homo sapien

<400> 137

Met Leu Ala Asn Asp Val Arg His Gln Gln Glu Met Trp Gly Phe Arg
1 5 10 15

Lys Val Glu Gly Gly Val Val Gln Ser Leu Gly Lys Ser Ser Val Glu
20 25 30

Gly Glu Thr Asp Gly Thr Ile Ser Glu Phe Arg Glu Ile Gln Arg Leu
35 40 45

Ala Ala Phe Ala Ser Phe Leu Ser His Ala Pro Pro Leu Asn Ala Arg
50 55 60

Arg Leu Leu Thr Pro Pro Pro Arg Arg Arg Pro Arg Cys Thr Pro Ala

65	175										75	80				
Ala	Ala	Met	Ala	Asp	Val	Ser	Glu	Arg	Thr	Leu	Gln	Leu	Ser	Val	Leu	
			85						90					95		
Val	Ala	Phe	Ala	Ser	Gly	Val	Leu	Leu	Gly	Trp	Gln	Ala	Asn	Arg	Leu	
			100					105					110			
Arg	Arg	Arg	Tyr	Leu	Asp	Trp	Arg	Lys	Arg	Arg	Leu	Gln	Asp	Lys	Leu	
		115					120					125				
Ala	Ala	Thr	Gln	Lys	Lys	Leu	Asp	Leu	Ala							
	130					135										
<210>	138															
<211>	179															
<212>	PRT															
<213>	Homo sapien															
<400>	138															
Met	Pro	Cys	Ala	Arg	Ala	Gly	Gly	Leu	Gly	Leu	Gln	Thr	Pro	Asn	Leu	
1				5					10					15		
Asn	Gly	His	Pro	Arg	Ala	Glu	Pro	Pro	Glu	Gly	Thr	Gly	Gly	Phe	His	
			20					25					30			
Phe	Gln	Thr	Gly	Ile	Leu	Ala	Ala	Ser	Leu	Leu	Pro	Pro	Ala	Glu	Glu	
		35					40					45				
Glu	Thr	Leu	Leu	Tyr	Ile	Leu	Thr	Phe	Cys	Arg	Gln	Val	Lys	Arg	Arg	
	50					55					60					
Thr	Gln	Thr	Phe	Gly	Asp	Glu	Arg	Glu	Thr	Lys	Thr	Glu	Pro	Ser	Val	
65					70					75					80	
Gln	Val	Thr	Ala	Ser	Gln	Ser	Arg	His	Leu	Thr	Asp	Pro	Thr	Tyr	Cys	
				85					90					95		
Leu	Phe	Leu	Asn	Met	Asn	Asp	Cys	Arg	Ser	Leu	Pro	Glu	Thr	Val	Ser	
			100					105					110			
Glu	Lys	Thr	Ala	Thr	Ser	Tyr	Phe	Leu	Tyr	Val	Phe	Pro	Ile	Lys	Arg	
		115					120					125				
Leu	Ser	Trp	Val	Gly	Leu	Arg	Ile	Thr	Glu	Gly	Lys	Arg	Ser	Gln	Phe	
	130					135					140					

176

Gln Val Thr Gln Ala Ile Phe Cys Val Lys Arg Glu Gln Asp Lys Ser
 145 150 155 160

Gln Pro Gln Gln Gln Asn Pro Lys Pro Pro Leu Arg Leu Leu Trp Gln
 165 170 175

Ser Asn Thr

<210> 139
 <211> 294
 <212> PRT
 <213> Homo sapien

<400> 139

Ile Ser Val Leu Thr Trp Ala Val Phe Thr Pro Pro Leu Pro Ser Arg
 1 5 10 15

Tyr Phe Ser Cys Ala His Ser Thr Asp Arg Glu Ala Glu Ala Gly Glu
 20 25 30

Val Arg Thr Arg Leu Arg Ser Tyr Gly Leu Pro Trp Asp Leu Ala Glu
 35 40 45

Asp Gly Gly Arg Ala Gly Pro Ser Gly Leu Glu Thr Leu Thr Pro Tyr
 50 55 60

Ser Pro Thr Pro Ser Phe Thr Trp Ser Asp Ala Arg Leu His Arg Gly
 65 70 75 80

Leu Val Thr Leu Leu Thr Gly Glu Ile Val Asp Ala Phe Ser Leu Glu
 85 90 95

Phe Arg Thr Leu Tyr Ala Ala Ser Cys Pro Leu Pro Pro Ala Pro Pro
 100 105 110

Gln Lys Pro Ser Val Ile Gly Gly Leu Gln Arg Gly Arg Ser Leu His
 115 120 125

Arg Val Ser Arg Arg Arg Ser Val Ala Pro Ala Ser Pro Pro Pro Pro
 130 135 140

Asp Gly Pro Leu Ala His Arg Leu Ala Ala Cys Arg Val Ser Pro Ala
 145 150 155 160

Thr Pro Gly Pro Ala Leu Ser Asp Ile Leu Arg Ser Val Gln Arg Ala

177

165 170 175

Arg Thr Pro Ser Gly Pro Pro Ala Arg Pro Ser Arg Ser Met Trp Asp
 180 185 190

Leu Ser Arg Leu Ser Gln Leu Ser Gly Ser Ser Asp Gly Asp Asn Glu
 195 200 205

Leu Lys Lys Ser Trp Gly Ser Lys Asp Thr Pro Ala Lys Ala Leu Met
 210 215 220

Arg Gln Arg Gly Thr Gly Gly Gly Pro Trp Gly Glu Val Asp Ser Arg
 225 230 235 240

Pro Pro Trp Gly Gly Ala Leu Pro Leu Pro Pro Ala His Arg Leu Arg
 245 250 255

Tyr Leu Ser Pro Ala Arg Arg Arg Phe Gly Gly Asp Ala Thr Phe Lys
 260 265 270

Leu Gln Glu Pro Arg Gly Val Arg Pro Ser Asp Trp Ala Pro Arg Ala
 275 280 285

Gly Leu Gly Gly Gln Pro
 290

<210> 140
 <211> 294
 <212> PRT
 <213> Homo sapien

<400> 140

Ile Ser Val Leu Thr Trp Ala Val Phe Thr Pro Pro Leu Pro Ser Arg
 1 5 10 15

Tyr Phe Ser Cys Ala His Ser Thr Asp Arg Glu Ala Glu Ala Gly Glu
 20 25 30

Val Arg Thr Arg Leu Arg Ser Tyr Gly Leu Pro Trp Asp Leu Ala Glu
 35 40 45

Asp Gly Gly Arg Ala Gly Pro Ser Gly Leu Glu Thr Leu Thr Pro Tyr
 50 55 60

Ser Pro Thr Pro Ser Phe Thr Trp Ser Asp Ala Arg Leu His Arg Gly
 65 70 75 80

[illegible]

```
<210> 141
<211> 90
<212> PRT
<213> Homo sapien
```

179

<400> 141

Met Ala Leu Gln Leu Ser Arg Glu Gln Gly Ile Thr Leu Arg Gly Ser
 1 5 10 15

Ala Glu Ile Val Ala Glu Phe Phe Ser Phe Gly Ile Asn Ser Ile Leu
 20 25 30

Tyr Gln Arg Gly Ile Tyr Pro Ser Glu Thr Phe Thr Arg Val Gln Lys
 35 40 45

Tyr Gly Leu Thr Leu Leu Val Thr Thr Asp Leu Glu Leu Ile Lys Tyr
 50 55 60

Leu Asn Asn Val Val Glu Gln Leu Lys Val His Pro Glu Lys Ser Leu
 65 70 75 80

Arg Lys Leu Ser Arg Met Lys Ser Val Gln
 85 90

<210> 142

<211> 373

<212> PRT

<213> Homo sapien

<400> 142

Arg Thr Val Thr Val Arg Thr Arg Ile Ala Val Leu Ser Leu Arg Pro
 1 5 10 15

Gln Cys Gly Gly Ile Leu Phe Arg His Val Val Val Leu Thr Leu Gly
 20 25 30

Asn Gly Leu Gly Gln Asn Leu Asp Leu Ala Ser Val Gln Ala His Ala
 35 40 45

Ala Val Gln Gly Arg Arg Val Leu Ile Pro Gly Val Asn Ile Arg Gln
 50 55 60

Glu Asn Leu Gly Arg Gly Arg Phe His Asp His Val Gln Asp Ala Ala
 65 70 75 80

Val Gly Gly Val Gly Gln Ala Leu Arg Cys His Gln His Lys Ala Val
 85 90 95

Gly Leu Thr Gln His Leu Glu Pro Phe Pro Asp Leu Arg Ala Glu Cys
 100 105 110

180

Arg	Val	Ala	Glu	His	Gln	Pro	Gly	Phe	Val	Gln	Asp	Asp	Glu	Arg	Pro
	115						120					125			
Pro	Val	Trp	Trp	Asn	Ser	Asn	Pro	Glu	Lys	Asp	Ile	Phe	Val	Val	Arg
	130					135					140				
Glu	Asn	Gly	Thr	Thr	Cys	Leu	Met	Ala	Glu	Phe	Ala	Ala	Lys	Phe	Ile
145					150					155					160
Val	Pro	Tyr	Asp	Val	Trp	Ala	Ser	Asn	Tyr	Val	Asp	Leu	Ile	Thr	Glu
				165					170					175	
Gln	Ala	Asp	Ile	Ala	Leu	Thr	Arg	Gly	Ala	Glu	Val	Lys	Gly	Arg	Cys
			180					185					190		
Gly	His	Ser	Gln	Ser	Glu	Leu	Gln	Val	Phe	Trp	Val	Asp	Arg	Ala	Tyr
		195					200					205			
Ala	Leu	Lys	Met	Leu	Phe	Val	Lys	Glu	Ser	His	Asn	Met	Ser	Lys	Gly
	210					215					220				
Pro	Glu	Ala	Thr	Trp	Arg	Leu	Ser	Lys	Val	Gln	Phe	Val	Tyr	Asp	Ser
225					230					235					240
Ser	Glu	Lys	Thr	His	Phe	Lys	Asp	Ala	Val	Ser	Ala	Gly	Lys	His	Thr
				245					250					255	
Ala	Asn	Ser	His	His	Leu	Ser	Ala	Leu	Val	Thr	Pro	Ala	Gly	Lys	Ser
			260					265					270		
Tyr	Glu	Cys	Gln	Ala	Gln	Gln	Thr	Ile	Ser	Leu	Ala	Ser	Ser	Asp	Pro
		275					280					285			
Gln	Lys	Thr	Val	Thr	Met	Ile	Leu	Ser	Ala	Val	His	Ile	Gln	Pro	Phe
	290					295					300				
Asp	Ile	Ile	Ser	Asp	Phe	Val	Phe	Ser	Glu	Glu	His	Lys	Cys	Pro	Val
305					310					315				320	
Asp	Glu	Arg	Glu	Gln	Leu	Glu	Glu	Thr	Leu	Pro	Leu	Ile	Leu	Gly	Leu
				325					330					335	
Ile	Leu	Gly	Leu	Val	Ile	Met	Val	Thr	Leu	Ala	Ile	Tyr	His	Val	His
			340					345					350		

181

His Lys Met Thr Ala Asn Gln Val Gln Ile Pro Arg Asp Arg Ser Gln
 355 360 365

Tyr Lys His Met Gly
 370

<210> 143
 <211> 148
 <212> PRT
 <213> Homo sapien

<400> 143

Gly Gly Leu Ser Pro Ile His Pro Glu Val Thr Val Tyr Pro Ala Lys
 1 5 10 15

Thr Gln Pro Leu Gln His His Asn Leu Leu Val Cys Ser Val Ser Gly
 20 25 30

Phe Tyr Pro Gly Ser Ile Glu Val Arg Trp Phe Arg Asn Gly Gln Glu
 35 40 45

Glu Lys Ala Gly Val Val Ser Thr Gly Leu Ile Gln Asn Gly Asp Trp
 50 55 60

Thr Phe Gln Thr Leu Val Met Leu Glu Thr Val Pro Arg Ser Gly Glu
 65 70 75 80

Val Tyr Thr Cys Gln Val Glu His Pro Ser Val Met Ser Pro Leu Thr
 85 90 95

Val Glu Trp Arg Ala Arg Ser Glu Ser Ala Gln Ser Lys Met Leu Ser
 100 105 110

Gly Val Gly Gly Phe Val Leu Gly Leu Leu Phe Leu Gly Ala Gly Leu
 115 120 125

Phe Ile Tyr Phe Arg Asn Gln Lys Gly His Ser Gly Leu Gln Pro Thr
 130 135 140

Gly Phe Leu Ser
 145

<210> 144
 <211> 72
 <212> PRT
 <213> Homo sapien

<400> 144

182

Met Val Leu Ser Ser Pro Leu Ala Leu Ala Gly Asp Thr Gln Pro Arg
 1 5 10 15

Phe Leu Trp Gln Asp Lys Tyr Gly Val Ser Phe Leu Gln Arg Asp Gly
 20 25 30

Ala Gly Ala Val Ser Trp Lys Glu Cys Ile Tyr Asn Gln Glu Glu Phe
 35 40 45

Val Arg Phe Asp Ser Asp Val Gly Glu Tyr Arg Ala Val Thr Glu Leu
 50 55 60

Gly Arg Pro Val Ala Asp Pro Ser
 65 70

<210> 145

<211> 191

<212> PRT

<213> Homo sapien

<400> 145

Asp Ser Pro Ala Pro Leu Ala Pro Gly Pro Val Leu Phe Ser Ser Met
 1 5 10 15

Val Cys Leu Lys Leu Pro Gly Gly Ser Cys Met Ala Ala Leu Thr Val
 20 25 30

Thr Leu Met Val Leu Ser Ser Pro Leu Ala Leu Ala Gly Asp Thr Gln
 35 40 45

Leu His Pro Glu Val Thr Val Tyr Pro Ala Lys Thr Gln Pro Leu Gln
 50 55 60

His His Asn Leu Leu Val Cys Ser Val Ser Gly Phe Tyr Pro Gly Ser
 65 70 75 80

Ile Glu Val Arg Trp Phe Arg Asn Gly Gln Glu Glu Lys Ala Gly Val
 85 90 95

Val Ser Thr Gly Leu Ile Gln Asn Gly Asp Trp Thr Phe Gln Thr Leu
 100 105 110

Val Met Leu Glu Thr Val Pro Arg Ser Gly Glu Val Tyr Thr Cys Gln
 115 120 125

Val Glu His Pro Ser Val Met Ser Pro Leu Thr Val Glu Trp Arg Ala

183

130 135 140
 Arg Ser Glu Ser Ala Gln Ser Lys Met Leu Ser Gly Val Gly Gly Phe
 145 150 155 160
 Val Leu Gly Leu Leu Phe Leu Gly Ala Gly Leu Phe Ile Tyr Phe Arg
 165 170 175
 Asn Gln Lys Gly His Ser Gly Leu Gln Pro Thr Gly Phe Leu Ser
 180 185 190

 <210> 146
 <211> 112
 <212> PRT
 <213> Homo sapien

 <400> 146
 Met Val Leu Ser Ser Pro Leu Ala Leu Ala Gly Asp Thr Gln Leu His
 1 5 10 15
 Pro Glu Val Thr Val Tyr Pro Ala Lys Thr Gln Pro Leu Gln His His
 20 25 30
 Asn Leu Leu Val Cys Ser Val Ser Gly Phe Tyr Pro Gly Ser Ile Glu
 35 40 45
 Val Arg Trp Phe Arg Asn Gly Gln Glu Glu Lys Ala Gly Val Val Ser
 50 55 60
 Thr Gly Leu Ile Gln Asn Gly Asp Trp Thr Phe Gln Thr Leu Val Met
 65 70 75 80
 Leu Glu Thr Val Pro Arg Ser Gly Glu Val Tyr Thr Cys Gln Gly Gly
 85 90 95
 Ala Pro Lys Cys Asp Glu Pro Ser His Ser Gly Met Glu Ser Thr Val
 100 105 110

 <210> 147
 <211> 128
 <212> PRT
 <213> Homo sapien

 <400> 147
 Gly Phe Arg Gly Pro Ala His Trp Pro Leu Pro Thr Gly Leu His Leu
 1 5 10 15

184

Thr Pro Pro Ser Leu Ser Val Pro Ser Phe Ala Ile Asn Phe Lys Val
 20 25 30

Gly Ser Ser Gly Asp Ile Ala Leu His Ile Asn Pro Arg Met Gly Asn
 35 40 45

Gly Thr Val Val Arg Asn Ser Leu Leu Asn Gly Ser Trp Gly Ser Glu
 50 55 60

Glu Lys Lys Ile Thr His Asn Pro Phe Gly Pro Gly Gln Phe Phe Asp
 65 70 75 80

Leu Ser Ile Arg Cys Gly Leu Asp Arg Phe Lys Val Tyr Ala Asn Gly
 85 90 95

Gln His Leu Phe Asp Phe Ala His Arg Leu Ser Ala Phe Gln Arg Val
 100 105 110

Asp Thr Leu Glu Ile Gln Gly Asp Val Thr Leu Ser Tyr Val Gln Ile
 115 120 125

<210> 148

<211> 256

<212> PRT

<213> Homo sapien

<400> 148

Met Ala Ala Thr Cys Glu Ile Ser Asn Ile Phe Ser Asn Tyr Phe Ser
 1 5 10 15

Ala Met Tyr Ser Ser Glu Asp Ser Thr Leu Ala Ser Val Pro Pro Ala
 20 25 30

Ala Thr Phe Gly Ala Asp Asp Leu Val Leu Thr Leu Ser Asn Pro Gln
 35 40 45

Met Ser Leu Glu Gly Thr Glu Lys Ala Ser Trp Leu Gly Glu Gln Pro
 50 55 60

Gln Phe Trp Ser Lys Thr Gln Val Leu Asp Trp Ile Ser Tyr Gln Val
 65 70 75 80

Glu Lys Asn Lys Tyr Asp Ala Ser Ala Ile Asp Phe Ser Arg Cys Asp
 85 90 95

Met Asp Gly Ala Thr Leu Cys Asn Cys Ala Leu Glu Glu Leu Arg Leu
 100 105 110

185

Val Phe Gly Pro Leu Gly Asp Gln Leu His Ala Gln Leu Arg Asp Leu
 115 120 125

Thr Ser Ser Ser Ser Asp Glu Leu Ser Trp Ile Ile Glu Leu Leu Glu
 130 135 140

Lys Asp Gly Met Ala Phe Gln Glu Ala Leu Asp Pro Gly Pro Phe Asp
 145 150 155 160

Gln Gly Ser Pro Phe Ala Gln Glu Leu Leu Asp Asp Gly Gln Gln Ala
 165 170 175

Ser Pro Tyr His Pro Gly Ser Cys Gly Ala Gly Ala Pro Ser Pro Gly
 180 185 190

Ser Ser Asp Val Ser Thr Ala Gly Thr Gly Ala Ser Arg Ser Ser His
 195 200 205

Ser Ser Asp Ser Gly Gly Ser Asp Val Asp Leu Asp Pro Thr Asp Gly
 210 215 220

Lys Leu Phe Pro Ser Gly Glu Ser Arg Glu Val Pro Lys Arg Ala Ser
 225 230 235 240

His Leu Ala Met His Arg Gly Pro Gly Ser Ser Cys Ser Leu Phe Leu
 245 250 255

<210> 149

<211> 250

<212> PRT

<213> Homo sapien

<400> 149

Gly Ser Ala Ala Ala Arg Tyr Leu Ser Ala Thr Trp Arg Asn Trp Ile
 1 5 10 15

Ser Leu Pro Pro Ala Gly Leu Pro Ala Thr Ala Gly Leu Arg His Ser
 20 25 30

Gly Ser Leu Met Ala Ala Thr Cys Glu Ile Ser Asn Ile Phe Ser Asn
 35 40 45

Tyr Phe Ser Ala Met Tyr Ser Ser Glu Asp Ser Thr Leu Ala Ser Val
 50 55 60

186

Pro Pro Ala Ala Thr Phe Gly Ala Asp Asp Leu Val Leu Thr Leu Ser
65 70 75 80

Asn Pro Gln Met Ser Leu Glu Gly Thr Glu Lys Ala Ser Trp Leu Gly
85 90 95

Glu Gln Pro Gln Phe Trp Ser Lys Thr Gln Val Leu Asp Trp Ile Ser
100 105 110

Tyr Gln Val Glu Lys Asn Lys Tyr Asp Ala Ser Ala Ile Asp Phe Ser
115 120 125

Arg Cys Asp Met Asp Gly Ala Thr Leu Cys Asn Cys Ala Leu Glu Glu
130 135 140

Leu Arg Leu Val Phe Gly Pro Leu Gly Asp Gln Leu His Ala Gln Leu
145 150 155 160

Arg Asp Leu Thr Ser Ser Ser Ser Asp Glu Leu Ser Trp Ile Ile Glu
165 170 175

Leu Leu Glu Lys Asp Gly Met Ala Phe Gln Glu Ala Leu Asp Pro Gly
180 185 190

Pro Phe Asp Gln Gly Ser Pro Phe Ala Gln Glu Leu Leu Asp Asp Gly
195 200 205

Gln Gln Ala Ser Pro Tyr His Pro Gly Ser Cys Gly Ala Gly Ala Pro
210 215 220

Ser Pro Gly Ser Ser Asp Val Ser Thr Ala Gly Thr Gly Thr Gly Trp
225 230 235 240

Glu Val Cys Pro Glu Ser Gln Gln Arg Gly
245 250

<210> 150

<211> 402

<212> PRT

<213> Homo sapien

<400> 150

Met Ala Ala Thr Cys Glu Ile Ser Asn Ile Phe Ser Asn Tyr Phe Ser
1 5 10 15

Ala Met Tyr Ser Ser Glu Asp Ser Thr Leu Ala Ser Val Pro Pro Ala
20 25 30

187

Ala Thr Phe Gly Ala Asp Asp Leu Val Leu Thr Leu Ser Asn Pro Gln
35 40 45

Met Ser Leu Glu Gly Thr Glu Lys Ala Ser Trp Leu Gly Glu Gln Pro
50 55 60

Gln Phe Trp Ser Lys Thr Gln Val Leu Asp Trp Ile Ser Tyr Gln Val
65 70 75 80

Glu Lys Asn Lys Tyr Asp Ala Ser Ala Ile Asp Phe Ser Arg Cys Asp
85 90 95

Met Asp Gly Ala Thr Leu Cys Asn Cys Ala Leu Glu Glu Leu Arg Leu
100 105 110

Val Phe Gly Pro Leu Gly Asp Gln Leu His Ala Gln Leu Arg Asp Leu
115 120 125

Thr Ser Ser Ser Ser Asp Glu Leu Ser Trp Ile Ile Glu Leu Leu Glu
130 135 140

Lys Asp Gly Met Ala Phe Gln Glu Ala Leu Asp Pro Gly Pro Phe Asp
145 150 155 160

Gln Gly Ser Pro Phe Ala Gln Glu Leu Leu Asp Asp Gly Gln Gln Ala
165 170 175

Ser Pro Tyr His Pro Gly Ser Cys Gly Ala Gly Ala Pro Ser Pro Gly
180 185 190

Ser Ser Asp Val Ser Thr Ala Gly Thr Gly Thr Gly Trp Glu Val Cys
195 200 205

Pro Glu Ser Arg Ser Val Val Glu Gln Arg Val Gly Arg Gln Gly Thr
210 215 220

Tyr Ser Asp Pro Ala Pro Arg Thr Gly Ala Ser Arg Ser Ser His Ser
225 230 235 240

Ser Asp Ser Gly Gly Ser Asp Val Asp Leu Asp Pro Thr Asp Gly Lys
245 250 255

Leu Phe Pro Ser Asp Gly Phe Arg Asp Cys Lys Lys Gly Asp Pro Lys
260 265 270

188

His Gly Lys Arg Lys Arg Gly Arg Pro Arg Lys Leu Ser Lys Glu Tyr
 275 280 285

Trp Asp Cys Leu Glu Gly Lys Lys Ser Lys His Ala Pro Arg Gly Thr
 290 295 300

His Leu Trp Glu Phe Ile Arg Asp Ile Leu Ile His Pro Glu Leu Asn
 305 310 315 320

Glu Gly Leu Met Lys Trp Glu Asn Arg His Glu Gly Val Phe Lys Phe
 325 330 335

Leu Arg Ser Glu Ala Val Ala Gln Leu Trp Gly Gln Lys Lys Lys Asn
 340 345 350

Ser Asn Met Thr Tyr Glu Lys Leu Ser Arg Ala Met Arg Tyr Tyr Tyr
 355 360 365

Lys Arg Glu Ile Leu Glu Arg Val Asp Gly Arg Arg Leu Val Tyr Lys
 370 375 380

Phe Gly Lys Asn Ser Ser Gly Trp Lys Glu Glu Glu Val Leu Gln Ser
 385 390 395 400

Arg Asn

<210> 151
 <211> 219
 <212> PRT
 <213> Homo sapien

<400> 151

Met Ser Leu Pro Val Lys Pro Glu Leu Leu Gly Asp Leu Glu Ile Pro
 1 5 10 15

Ala Val Pro Ile Leu His Ser Met Val Gln Lys Phe Pro Gly Val Ser
 20 25 30

Phe Gly Ile Ser Thr Asp Ser Glu Val Leu Thr His Tyr Asn Ile Thr
 35 40 45

Gly Asn Thr Ile Cys Leu Phe Arg Leu Val Asp Asn Glu Gln Leu Asn
 50 55 60

Leu Glu Asp Glu Asp Ile Glu Ser Ile Asp Ala Thr Lys Leu Ser Arg

189																
65	70										75				80	
Phe	Ile	Glu	Ile	Asn	Ser	Leu	His	Met	Val	Thr	Glu	Tyr	Asn	Pro	Val	
				85					90					95		
Thr	Val	Ile	Gly	Leu	Phe	Asn	Ser	Val	Ile	Gln	Ile	His	Leu	Leu	Leu	
			100					105					110			
Ile	Met	Asn	Lys	Ala	Ser	Pro	Glu	Tyr	Glu	Glu	Asn	Met	His	Arg	Tyr	
		115					120					125				
Gln	Lys	Ala	Ala	Lys	Leu	Phe	Gln	Gly	Lys	Ile	Leu	Phe	Ile	Leu	Val	
	130					135					140					
Asp	Ser	Gly	Met	Lys	Glu	Asn	Gly	Lys	Val	Ile	Ser	Phe	Phe	Lys	Leu	
145					150					155					160	
Lys	Glu	Ser	Gln	Leu	Pro	Ala	Leu	Ala	Ile	Tyr	Gln	Thr	Leu	Asp	Asp	
				165					170					175		
Glu	Trp	Asp	Thr	Leu	Pro	Thr	Ala	Glu	Val	Ser	Val	Glu	His	Val	Gln	
			180					185					190			
Asn	Phe	Cys	Asp	Gly	Phe	Leu	Ser	Gly	Lys	Leu	Leu	Lys	Glu	Asn	Arg	
		195					200					205				
Glu	Ser	Glu	Gly	Lys	Thr	Pro	Lys	Val	Glu	Leu						
	210					215										
<210>	152															
<211>	172															
<212>	PRT															
<213>	Homo sapien															
<400>	152															
Met	Lys	Glu	Thr	Cys	Gln	Leu	Glu	Ile	Gln	Val	Asp	Asn	Glu	Gln	Leu	
1				5					10					15		
Asn	Leu	Glu	Asp	Glu	Asp	Ile	Glu	Ser	Ile	Asp	Ala	Thr	Lys	Leu	Ser	
			20					25					30			
Arg	Phe	Ile	Glu	Ile	Asn	Ser	Leu	His	Met	Val	Thr	Glu	Tyr	Asn	Pro	
	35						40					45				
Val	Thr	Val	Ile	Gly	Leu	Phe	Asn	Ser	Val	Ile	Gln	Ile	His	Leu	Leu	
	50					55					60					

190

Leu Ile Met Asn Lys Ala Ser Pro Glu Tyr Glu Glu Asn Met His Arg
 65 70 75 80

Tyr Gln Lys Ala Ala Lys Leu Phe Gln Gly Lys Ile Leu Phe Ile Leu
 85 90 95

Val Asp Ser Gly Met Lys Glu Asn Gly Lys Val Ile Ser Phe Phe Lys
 100 105 110

Leu Lys Glu Ser Gln Leu Pro Ala Leu Ala Ile Tyr Gln Thr Leu Asp
 115 120 125

Asp Glu Trp Asp Thr Leu Pro Thr Ala Glu Val Ser Val Glu His Val
 130 135 140

Gln Asn Phe Cys Asp Gly Phe Leu Ser Gly Lys Leu Leu Lys Glu Asn
 145 150 155 160

Arg Glu Ser Glu Gly Lys Thr Pro Lys Val Glu Leu
 165 170

<210> 153

<211> 329

<212> PRT

<213> Homo sapien

<400> 153

Ser Gly Asp Leu Gln Pro His Ser Arg Cys Pro Gly Gly Arg Arg Asp
 1 5 10 15

Pro Gln Ile Lys Leu Ser Leu Thr Glu Lys Asp Glu Gly Gln Glu Glu
 20 25 30

Cys Ser Phe Leu Val Ala Leu Met Gln Lys Asp Arg Arg Lys Leu Lys
 35 40 45

Arg Phe Gly Ala Asn Val Leu Thr Ile Gly Tyr Ala Ile Tyr Glu Cys
 50 55 60

Pro Asp Lys Asp Glu His Leu Asn Lys Asp Phe Phe Arg Tyr His Ala
 65 70 75 80

Ser Arg Ala Arg Ser Lys Thr Phe Ile Asn Leu Arg Glu Val Ser Asp
 85 90 95

Arg Phe Lys Leu Pro Pro Gly Glu Tyr Ile Leu Ile Pro Ser Thr Phe

191

100	105	110
Glu Pro His Gln Glu Ala Asp Phe Cys Leu Arg Ile Phe Ser Glu Lys 115 120 125		
Lys Ala Ile Thr Arg Asp Met Asp Gly Asn Val Asp Ile Asp Leu Pro 130 135 140		
Glu Pro Pro Lys Pro Thr Pro Pro Asp Gln Glu Thr Glu Glu Glu Gln 145 150 155 160		
Arg Phe Arg Ala Leu Phe Glu Gln Val Ala Gly Glu Asp Met Glu Val 165 170 175		
Thr Ala Glu Glu Leu Glu Tyr Val Leu Asn Ala Val Leu Gln Lys Lys 180 185 190		
Lys Asp Ile Lys Phe Lys Lys Leu Ser Leu Ile Ser Cys Lys Asn Ile 195 200 205		
Ile Ser Leu Met Asp Thr Ser Gly Asn Gly Lys Leu Glu Phe Asp Glu 210 215 220		
Phe Lys Val Phe Trp Asp Lys Leu Lys Gln Trp Ile Asn Leu Phe Leu 225 230 235 240		
Arg Phe Asp Ala Asp Lys Ser Gly Thr Met Ser Thr Tyr Glu Leu Arg 245 250 255		
Thr Ala Leu Lys Ala Ala Gly Phe Gln Leu Ser Ser His Leu Leu Gln 260 265 270		
Leu Ile Val Leu Arg Tyr Ala Asp Glu Glu Leu Gln Leu Asp Phe Asp 275 280 285		
Asp Phe Leu Asn Cys Leu Val Arg Leu Glu Asn Ala Ser Arg Val Phe 290 295 300		
Gln Ala Leu Ser Thr Lys Asn Lys Glu Phe Ile His Leu Asn Ile Asn 305 310 315 320		
Glu Phe Ile His Leu Thr Met Asn Ile 325		
 <210> 154 <211> 595		

192

<212> PRT

<213> Homo sapien

<400> 154

Met Val Cys Leu Phe Leu Lys Cys Asn Leu Gln Asn Ser Pro Glu Arg
 1 5 10 15

Asn Asn Ser Phe Trp Glu Val Val Ala Ala Ala Gly Thr Val Ala Pro
 20 25 30

Trp Glu Ile Val Lys Asn Pro Glu Phe Ile Leu Gly Gly Ala Thr Arg
 35 40 45

Thr Asp Ile Cys Gln Gly Glu Leu Gly Asp Cys Trp Leu Leu Ala Ala
 50 55 60

Ile Ala Ser Leu Thr Leu Asn Gln Lys Ala Leu Ala Arg Val Ile Pro
 65 70 75 80

Gln Asp Gln Ser Phe Gly Pro Gly Tyr Ala Gly Ile Phe His Phe Gln
 85 90 95

Phe Trp Gln His Ser Glu Trp Leu Asp Val Val Ile Asp Asp Arg Leu
 100 105 110

Pro Thr Phe Arg Asp Arg Leu Val Phe Leu His Ser Ala Asp His Asn
 115 120 125

Glu Phe Trp Ser Ala Leu Leu Glu Lys Ala Tyr Ala Lys Leu Asn Gly
 130 135 140

Ser Tyr Glu Ala Leu Lys Gly Gly Ser Ala Ile Glu Ala Met Glu Asp
 145 150 155 160

Phe Thr Gly Gly Val Ala Glu Thr Phe Gln Thr Lys Glu Ala Pro Glu
 165 170 175

Asn Phe Tyr Glu Ile Leu Glu Lys Ala Leu Lys Arg Gly Ser Leu Leu
 180 185 190

Gly Cys Phe Ile Asp Thr Arg Ser Ala Ala Glu Ser Glu Ala Arg Thr
 195 200 205

Pro Phe Gly Leu Ile Lys Gly His Ala Tyr Ser Val Thr Gly Ile Asp
 210 215 220

193

Gln Val Ser Phe Arg Gly Gln Arg Ile Glu Leu Ile Arg Ile Arg Asn
 225 230 235 240

Pro Trp Gly Gln Val Glu Trp Asn Gly Ser Trp Ser Asp Arg Met Ala
 245 250 255

Phe Lys Asp Phe Lys Ala His Phe Asp Lys Val Glu Ile Cys Asn Leu
 260 265 270

Thr Pro Asp Ala Leu Glu Glu Asp Ala Asp Pro Gln Ile Lys Leu Ser
 275 280 285

Leu Thr Glu Lys Asp Glu Gly Gln Glu Glu Cys Ser Phe Leu Val Ala
 290 295 300

Leu Met Gln Lys Asp Arg Arg Lys Leu Lys Arg Phe Gly Ala Asn Val
 305 310 315 320

Leu Thr Ile Gly Tyr Ala Ile Tyr Glu Cys Pro Asp Lys Asp Glu His
 325 330 335

Leu Asn Lys Asp Phe Phe Arg Tyr His Ala Ser Arg Ala Arg Ser Lys
 340 345 350

Thr Phe Ile Asn Leu Arg Glu Val Ser Asp Arg Phe Lys Leu Pro Pro
 355 360 365

Gly Glu Tyr Ile Leu Ile Pro Ser Thr Phe Glu Pro His Gln Glu Ala
 370 375 380

Asp Phe Cys Leu Arg Ile Phe Ser Glu Lys Lys Ala Ile Thr Arg Asp
 385 390 395 400

Met Asp Gly Asn Val Asp Ile Asp Leu Pro Glu Pro Pro Lys Pro Thr
 405 410 415

Pro Pro Asp Gln Glu Thr Glu Glu Glu Gln Arg Phe Arg Ala Leu Phe
 420 425 430

Glu Gln Val Ala Gly Glu Asp Met Glu Val Thr Ala Glu Glu Leu Glu
 435 440 445

Tyr Val Leu Asn Ala Val Leu Gln Lys Lys Lys Asp Ile Lys Phe Lys
 450 455 460

Lys Leu Ser Leu Ile Ser Cys Lys Asn Ile Ile Ser Leu Met Asp Thr

465	470										475					480				
Ser	Gly	Asn	Gly	Lys	Leu	Glu	Phe	Asp	Glu	Phe	Lys	Val	Phe	Trp	Asp					
				485					490					495						
Lys	Leu	Lys	Gln	Trp	Ile	Asn	Leu	Phe	Leu	Arg	Phe	Asp	Ala	Asp	Lys					
			500					505					510							
Ser	Gly	Thr	Met	Ser	Thr	Tyr	Glu	Leu	Arg	Thr	Ala	Leu	Lys	Ala	Ala					
		515					520					525								
Gly	Phe	Gln	Leu	Ser	Ser	His	Leu	Leu	Gln	Leu	Ile	Val	Leu	Arg	Tyr					
	530					535					540									
Ala	Asp	Glu	Glu	Leu	Gln	Leu	Asp	Phe	Asp	Asp	Phe	Leu	Asn	Cys	Leu					
545					550					555					560					
Val	Arg	Leu	Glu	Asn	Ala	Ser	Arg	Val	Phe	Gln	Ala	Leu	Ser	Thr	Lys					
				565					570					575						
Asn	Lys	Glu	Phe	Ile	His	Leu	Asn	Ile	Asn	Glu	Phe	Ile	His	Leu	Thr					
			580					585					590							
Met	Asn	Ile																		
		595																		
<210>	155																			
<211>	85																			
<212>	PRT																			
<213>	Homo sapien																			
<400>	155																			
Ala	Leu	Ser	Val	Val	Ala	Ala	Glu	Val	Arg	Val	Val	Gly	Arg	Asn	Gly					
1				5					10					15						
Glu	Ser	Ser	Glu	Leu	Asp	Leu	Gln	Gly	Ile	Arg	Ile	Asp	Ser	Asp	Ile					
			20					25					30							
Ser	Gly	Thr	Leu	Lys	Phe	Ala	Cys	Glu	Ser	Ile	Val	Glu	Glu	Tyr	Glu					
		35					40					45								
Asp	Glu	Leu	Ile	Glu	Phe	Phe	Ser	Arg	Glu	Ala	Asp	Asn	Val	Lys	Asp					
	50					55					60									
Lys	Leu	Cys	Ser	Lys	Arg	Thr	Asp	Leu	Cys	Asp	His	Ala	Leu	His	Ile					
65					70					75					80					

195

Ser His Asp Glu Leu
85

<210> 156
<211> 255
<212> PRT
<213> Homo sapien

<400> 156

Met Ala Asp Tyr Ser Thr Val Pro Pro Pro Ser Ser Gly Ser Ala Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Val Asn Asp Ala Phe Lys
20 25 30

Asp Ala Leu Gln Arg Ala Arg Gln Ile Ala Ala Lys Ile Gly Gly Asp
35 40 45

Ala Gly Thr Ser Leu Asn Ser Asn Asp Tyr Gly Tyr Gly Gly Gln Lys
50 55 60

Arg Pro Leu Glu Asp Gly Asp Gln Pro Asp Ala Lys Lys Val Ala Pro
65 70 75 80

Gln Asn Asp Ser Phe Gly Thr Gln Leu Pro Pro Met His Gln Gln Gln
85 90 95

Ser Arg Ser Val Met Thr Glu Glu Tyr Lys Val Pro Asp Gly Met Val
100 105 110

Gly Phe Ile Ile Gly Arg Gly Gly Glu Gln Ile Ser Arg Ile Gln Gln
115 120 125

Glu Ser Gly Cys Lys Ile Gln Ile Ala Pro Asp Ser Gly Gly Leu Pro
130 135 140

Glu Arg Ser Cys Met Leu Thr Gly Thr Pro Glu Ser Val Gln Ser Ala
145 150 155 160

Lys Arg Leu Leu Asp Gln Ile Val Glu Lys Gly Arg Pro Ala Pro Gly
165 170 175

Phe His His Gly Asp Gly Pro Gly Asn Ala Val Gln Glu Ile Met Ile
180 185 190

Pro Ala Ser Lys Ala Gly Leu Val Ile Gly Lys Gly Gly Glu Thr Ile

196

195

200

205

Lys Gln Leu Gln Glu Arg Ala Gly Val Lys Met Val Met Ile Gln Asp
 210 215 220

Gly Val Ala Ala Ala Ala Val Phe Phe Thr Ser Ile Ile Arg Leu
 225 230 235 240

Ala Phe Asn Lys Glu Lys Val Leu Thr Pro Val Leu Asn Cys Thr
 245 250 255

<210> 157

<211> 174

<212> PRT

<213> Homo sapien

<400> 157

Met Ala Glu His Phe Leu Thr Leu Leu Val Val Pro Ala Ile Lys Lys
 1 5 10 15

Asp Tyr Gly Ser Gln Glu Asp Phe Thr Gln Val Trp Asn Thr Thr Met
 20 25 30

Lys Gly Leu Lys Cys Cys Gly Phe Thr Asn Tyr Thr Asp Phe Glu Asp
 35 40 45

Ser Pro Tyr Phe Lys Glu Asn Ser Ala Phe Pro Pro Phe Cys Cys Asn
 50 55 60

Asp Asn Val Thr Asn Thr Ala Asn Glu Thr Cys Thr Lys Gln Lys Ala
 65 70 75 80

His Asp Gln Lys Val Glu Gly Cys Phe Asn Gln Leu Leu Tyr Asp Ile
 85 90 95

Arg Thr Asn Ala Val Thr Val Gly Gly Val Ala Ala Gly Ile Gly Gly
 100 105 110

Leu Glu Leu Ala Ala Met Ile Val Ser Met Tyr Leu Tyr Leu Pro Gly
 115 120 125

Arg Pro Ala Trp Ser Arg Pro Arg Tyr Ser Asp Ser Val Gly Arg Val
 130 135 140

Ser Phe Pro Ser Leu Val Cys Phe Leu Met Arg Leu Glu Ala Met Ala
 145 150 155 160

197

Lys Thr Phe Arg Asn Ser Leu Arg Met Glu Lys Asp Ser Thr
 165 170

<210> 158
 <211> 354
 <212> PRT
 <213> Homo sapien
 <400> 158

Met Gly Gln Asp Trp Gly Pro His His Met Ser Arg Glu Asp Leu Ile
 1 5 10 15

Cys Gly Gly Gly Lys Gly Ser Leu Val Trp Pro Thr Trp Ser Thr Thr
 20 25 30

Ser Leu Trp Pro Gln Val Leu Leu Val Gln Phe Lys Gly Thr Gly Lys
 35 40 45

Tyr Tyr Ala Ile Lys Ala Leu Lys Lys Gln Glu Val Leu Ser Arg Asp
 50 55 60

Glu Ile Glu Ser Leu Tyr Cys Glu Lys Arg Ile Leu Glu Ala Val Gly
 65 70 75 80

Cys Thr Gly His Pro Phe Leu Leu Ser Leu Leu Ala Cys Phe Gln Thr
 85 90 95

Ser Ser His Ala Cys Phe Val Thr Glu Phe Val Pro Gly Gly Asp Leu
 100 105 110

Met Met Gln Ile His Glu Asp Val Phe Pro Glu Pro Gln Ala Arg Phe
 115 120 125

Tyr Val Ala Cys Val Val Leu Gly Leu Gln Phe Leu His Glu Lys Lys
 130 135 140

Ile Ile Tyr Arg Asp Leu Lys Leu Asp Asn Leu Leu Leu Asp Ala Gln
 145 150 155 160

Gly Phe Leu Lys Ile Ala Asp Phe Gly Leu Cys Lys Glu Gly Ile Gly
 165 170 175

Phe Gly Asp Arg Thr Ser Thr Phe Cys Gly Thr Pro Glu Phe Leu Ala
 180 185 190

Pro Glu Val Leu Thr Gln Glu Ala Tyr Thr Arg Ala Val Asp Trp Trp

198

195

200

205

Gly Leu Gly Val Leu Leu Tyr Glu Met Leu Val Gly Glu Cys Pro Phe
 210 215 220

Pro Gly Asp Thr Glu Glu Glu Val Phe Asp Cys Ile Val Asn Met Asp
 225 230 235 240

Ala Pro Tyr Pro Gly Phe Leu Ser Val Gln Gly Leu Glu Phe Ile Gln
 245 250 255

Lys Leu Leu Gln Lys Cys Pro Glu Lys Arg Leu Gly Ala Gly Glu Gln
 260 265 270

Asp Ala Glu Glu Ile Lys Val Gln Pro Phe Phe Arg Thr Thr Asn Trp
 275 280 285

Gln Ala Leu Leu Ala Arg Thr Ile Gln Pro Pro Phe Val Pro Thr Leu
 290 295 300

Cys Gly Pro Ala Asp Leu Arg Tyr Phe Glu Gly Glu Phe Thr Gly Leu
 305 310 315 320

Pro Pro Ala Leu Thr Pro Pro Ala Pro His Ser Leu Leu Thr Ala Arg
 325 330 335

Gln Gln Ala Ala Phe Arg Asp Phe Asp Phe Val Ser Glu Arg Phe Leu
 340 345 350

Glu Pro

<210> 159

<211> 489

<212> PRT

<213> Homo sapien

<400> 159

Met Glu Glu Gly Ala Pro Arg Gln Pro Gly Pro Ser Gln Trp Pro Pro
 1 5 10 15

Glu Asp Glu Lys Glu Val Ile Arg Arg Ala Ile Gln Lys Glu Leu Lys
 20 25 30

Ile Lys Glu Gly Val Glu Asn Leu Arg Arg Val Ala Thr Asp Arg Arg
 35 40 45

199

His Leu Gly His Val Gln Gln Leu Leu Arg Ser Ser Asn Arg Arg Leu
 50 55 60

Glu Gln Leu His Gly Glu Leu Arg Glu Leu His Ala Arg Ile Leu Leu
 65 70 75 80

Pro Gly Pro Gly Pro Gly Pro Ala Glu Pro Val Ala Ser Gly Pro Arg
 85 90 95

Pro Trp Ala Glu Gln Leu Arg Ala Arg His Leu Glu Ala Leu Arg Arg
 100 105 110

Gln Leu His Val Glu Leu Lys Val Lys Gln Gly Ala Glu Asn Met Thr
 115 120 125

His Thr Cys Ala Ser Gly Thr Pro Lys Glu Arg Lys Leu Leu Ala Ala
 130 135 140

Ala Gln Gln Met Leu Arg Asp Ser Gln Leu Lys Val Ala Leu Leu Arg
 145 150 155 160

Met Lys Ile Ser Ser Leu Glu Ala Ser Gly Ser Pro Glu Pro Gly Pro
 165 170 175

Glu Leu Leu Ala Glu Glu Leu Gln His Arg Leu His Val Glu Ala Ala
 180 185 190

Val Ala Glu Gly Ala Lys Asn Val Val Lys Leu Leu Ser Ser Arg Arg
 195 200 205

Thr Gln Asp Arg Lys Ala Leu Ala Glu Ala Gln Ala Gln Leu Gln Glu
 210 215 220

Ser Ser Gln Lys Leu Asp Leu Leu Arg Leu Ala Leu Glu Gln Leu Leu
 225 230 235 240

Glu Gln Leu Pro Pro Ala His Pro Leu Arg Ser Arg Val Thr Arg Glu
 245 250 255

Leu Arg Ala Ala Val Pro Gly Tyr Pro Gln Pro Ser Gly Thr Pro Val
 260 265 270

Lys Pro Thr Ala Leu Thr Gly Thr Leu Gln Val Arg Leu Leu Gly Cys
 275 280 285

200

Glu Gln Leu Leu Thr Ala Val Pro Gly Arg Ser Pro Ala Ala Ala Leu
 290 295 300

Ala Ser Ser Pro Ser Glu Gly Trp Leu Arg Thr Lys Ala Lys His Gln
 305 310 315 320

Arg Gly Arg Gly Glu Leu Ala Ser Glu Val Leu Ala Val Leu Lys Val
 325 330 335

Asp Asn Arg Val Val Gly Gln Thr Gly Trp Gly Gln Val Ala Glu Gln
 340 345 350

Ser Trp Asp Gln Thr Phe Val Ile Pro Leu Glu Arg Ala Arg Glu Leu
 355 360 365

Glu Ile Gly Val His Trp Arg Asp Trp Arg Gln Leu Cys Gly Val Ala
 370 375 380

Phe Leu Arg Leu Glu Asp Phe Leu Asp Asn Ala Cys His Gln Leu Ser
 385 390 395 400

Leu Ser Leu Val Pro Gln Gly Leu Leu Phe Ala Gln Val Thr Phe Cys
 405 410 415

Asp Pro Val Ile Glu Arg Arg Pro Arg Leu Gln Arg Gln Glu Arg Ile
 420 425 430

Phe Ser Lys Arg Arg Gly Arg Leu Pro Gly Leu Arg Leu Cys Val Arg
 435 440 445

Ala Ile Pro Gly Thr Leu Arg Ala Ser Pro Gly Thr Ser Val Pro Phe
 450 455 460

Pro His Arg Leu Leu Glu Pro Leu Leu Val His Pro Cys Ala Leu Pro
 465 470 475 480

Gly Gly Pro Gly Leu Ala Gly Tyr Phe
 485

<210> 160

<211> 287

<212> PRT

<213> Homo sapien

<400> 160

Met Asp Met Ala Trp Gln Met Met Gln Leu Leu Leu Leu Ala Leu Val
 1 5 10 15

201

Thr Ala Ala Gly Ser Ala Gln Pro Arg Ser Ala Arg Ala Arg Thr Asp
 20 25 30

Leu Leu Asn Val Cys Met Asn Ala Lys His His Lys Thr Gln Pro Ser
 35 40 45

Pro Glu Asp Glu Leu Tyr Gly Gln Val Gly Ala Pro Gln Gly Pro Ser
 50 55 60

Pro Gly Ser Val Pro Leu Asp Asp Leu Pro Gly Ala Glu Glu Pro Glu
 65 70 75 80

Tyr Gly Gly Asp Gly Cys Gly Gly Glu Arg Leu Ser Pro Val Ser Ser
 85 90 95

Pro Pro Ser Ala Val Pro Gly Arg Arg Met Pro Ala Ala Arg Pro Ala
 100 105 110

Pro Ala Arg Ser Cys Thr Arg Thr Pro Pro Ala Cys Thr Thr Leu Thr
 115 120 125

Gly Ile Thr Val Val Arg Trp Asn Pro Pro Ala Ser Ala Thr Leu Ser
 130 135 140

Arg Thr Ala Val Ser Glu Cys Ser Pro Asn Leu Gly Pro Trp Ile Arg
 145 150 155 160

Gln Val Asn Gln Ser Trp Arg Lys Glu Arg Ile Leu Asn Val Pro Leu
 165 170 175

Cys Lys Glu Asp Cys Glu Arg Trp Trp Glu Asp Cys Arg Thr Ser Tyr
 180 185 190

Thr Cys Lys Ser Asn Trp His Lys Gly Trp Asn Trp Thr Ser Gly Ile
 195 200 205

Asn Glu Cys Pro Ala Gly Ala Leu Cys Ser Thr Phe Glu Ser Tyr Phe
 210 215 220

Pro Thr Pro Ala Ala Leu Cys Glu Gly Leu Trp Ser His Ser Phe Lys
 225 230 235 240

Val Ser Asn Tyr Ser Arg Gly Ser Gly Arg Cys Ile Gln Met Trp Phe
 245 250 255

202

Asp Ser Ala Gln Gly Asn Pro Asn Glu Glu Val Ala Lys Phe Tyr Ala
 260 265 270

Ala Ala Met Asn Ala Gly Ala Pro Ser Arg Gly Ile Ile Asp Ser
 275 280 285

<210> 161
 <211> 143
 <212> PRT
 <213> Homo sapien

<400> 161

Met Thr His Ser Leu Val Cys Pro Glu Thr Val Ser Arg Val Ser Ser
 1 5 10 15

Val Leu Asn Arg Asn Thr Arg Gln Phe Gly Lys Lys His Leu Phe Asp
 20 25 30

Gln Asp Glu Glu Thr Cys Trp Asn Ser Asp Gln Gly Pro Ser Gln Trp
 35 40 45

Val Thr Leu Glu Phe Pro Gln Leu Ile Arg Val Ser Gln Leu Gln Ile
 50 55 60

Gln Phe Gln Gly Gly Phe Ser Ser Arg Arg Gly Cys Leu Glu Gly Ser
 65 70 75 80

Gln Gly Thr Gln Ala Leu His Lys Ile Val Asp Phe Tyr Pro Glu Asp
 85 90 95

Asn Asn Ser Leu Gln Asp Ile Leu Pro Leu Leu Leu Gly Trp Val Val
 100 105 110

Cys Ala Ser Gly Ser Phe Gly Leu Thr Gln Thr Arg Met Gly Thr Leu
 115 120 125

Met Cys Asp Leu Glu His Val Thr Ser Arg Thr Pro Leu Phe Leu
 130 135 140

<210> 162
 <211> 116
 <212> PRT
 <213> Homo sapien

<400> 162

Gly Leu Ser Pro Pro Gly Ser Pro Pro Gly Ser Thr Ala Lys Ser Leu
 1 5 10 15

203

Ile Leu His Arg Arg Phe Ile Gly Ser Ser Trp Glu Gly Ser Pro Pro
 20 25 30

Thr Thr Cys Pro Glu Ala Ala Phe Glu Val Ser Ser Gly Phe Pro Gln
 35 40 45

Leu Trp Leu Thr Ile Leu Phe Pro Glu Cys Leu Ser Pro Gly Arg Arg
 50 55 60

Leu His Ser Gly Ser Ala Gly Thr Arg Leu Leu Trp Lys Ser Leu Arg
 65 70 75 80

Met Trp Phe Ser Ile Thr Cys Cys Thr Glu Met Gly Gln Gly Lys Ala
 85 90 95

Trp Ala Val Ser Leu Asn Arg Glu Trp Gly Gly Gly Thr Gly Gln Pro
 100 105 110

Ala Leu Ser Pro
 115

<210> 163
 <211> 67
 <212> PRT
 <213> Homo sapien

<400> 163

Met Leu Glu Leu Arg Pro Gly Ser Gln Gly Thr Gln Ala Leu His Lys
 1 5 10 15

Ile Val Asp Phe Tyr Pro Glu Asp Asn Asn Ser Leu Gln Thr Phe Pro
 20 25 30

Ile Pro Ala Ala Glu Val Asp Arg Leu Lys Val Thr Phe Glu Asp Ala
 35 40 45

Thr Asp Phe Phe Gly Arg Val Val Ile Tyr His Leu Arg Val Leu Gly
 50 55 60

Glu Lys Val
 65

<210> 164
 <211> 104
 <212> PRT
 <213> Homo sapien

204

<400> 164

Gly Trp Thr Gly Cys Val Arg Ile Ser Gly Ala Gly Arg Ser Arg Ile
 1 5 10 15

Leu Gln Ala Leu Ala Arg Lys Pro Glu Asp Pro Pro Leu Pro Arg Thr
 20 25 30

Arg Lys Ser Ser Ser Cys Leu Leu Ser Ser Leu Trp Gln Glu Leu Arg
 35 40 45

Ala Leu Glu Leu Leu Gly Pro Ser Gln Gly Leu Pro Tyr Leu Lys Pro
 50 55 60

Gln Leu Gly Pro Leu Ser Pro Pro Gly Met Arg Pro Arg Ala Pro Leu
 65 70 75 80

Thr Arg Arg Pro Arg Ser Leu Thr Leu Ile Phe His Arg Val Gln Glu
 85 90 95

Phe Ile Arg Thr Pro Lys Ser Glu
 100

<210> 165

<211> 82

<212> PRT

<213> Homo sapien

<400> 165

Gln Val Pro His Ala Ser Gly Cys Ile Gly Glu Asp Pro Gln Gly Ile
 1 5 10 15

Pro Leu Pro Leu Asp Glu Ala His Pro Thr Gly Gly Cys Thr Asn Pro
 20 25 30

Tyr Gly Lys Ser Lys Phe Phe Ile Glu Glu Met Ile Arg Asp Leu Cys
 35 40 45

Gln Ala Asp Lys Gly Trp Thr Ala Ala Leu Gly Leu Asp Arg Met Cys
 50 55 60

Glu Asp Leu Trp Arg Trp Gln Lys Gln Asn Pro Ser Gly Phe Gly Thr
 65 70 75 80

Gln Ala

205

<210> 166
 <211> 360
 <212> PRT
 <213> Homo sapien

<400> 166

Met Ala Glu Lys Val Leu Val Thr Gly Gly Ala Gly Tyr Ile Gly Ser
 1 5 10 15

His Thr Val Leu Glu Leu Leu Glu Ala Gly Tyr Leu Pro Val Val Ile
 20 25 30

Asp Asn Phe His Asn Ala Phe Arg Gly Gly Gly Ser Leu Pro Glu Ser
 35 40 45

Leu Arg Arg Val Gln Glu Leu Thr Gly Arg Ser Val Glu Phe Glu Glu
 50 55 60

Met Asp Ile Leu Asp Gln Gly Ala Leu Gln Arg Leu Phe Lys Lys Tyr
 65 70 75 80

Ser Phe Met Ala Val Ile His Phe Ala Gly Leu Lys Ala Val Gly Glu
 85 90 95

Ser Val Gln Lys Pro Leu Asp Tyr Tyr Arg Val Asn Leu Thr Gly Thr
 100 105 110

Ile Gln Leu Leu Glu Ile Met Lys Ala His Gly Val Lys Asn Leu Val
 115 120 125

Phe Ser Ser Ser Ala Thr Val Tyr Gly Asn Pro Gln Tyr Leu Pro Leu
 130 135 140

Asp Glu Ala His Pro Thr Gly Gly Cys Thr Asn Pro Tyr Gly Lys Ser
 145 150 155 160

Lys Phe Phe Ile Glu Glu Met Ile Arg Asp Leu Cys Gln Ala Asp Lys
 165 170 175

Thr Trp Asn Ala Val Leu Leu Arg Tyr Phe Asn Pro Thr Gly Ala His
 180 185 190

Ala Ser Gly Cys Ile Gly Glu Asp Pro Gln Gly Ile Pro Asn Asn Leu
 195 200 205

Met Pro Tyr Val Ser Gln Val Ala Ile Gly Arg Arg Glu Ala Leu Asn

206

210

215

220

Val Phe Gly Asn Asp Tyr Asp Thr Glu Asp Gly Thr Gly Val Arg Asp
 225 230 235 240

Tyr Ile His Val Val Asp Leu Ala Lys Gly His Ile Ala Ala Leu Arg
 245 250 255

Lys Leu Lys Glu Gln Cys Gly Cys Arg Val Gly Arg Glu Gly Arg Ser
 260 265 270

Glu Gly Gly Glu Gly Pro Asp Pro Gly Arg Ala Ala Gln Arg Arg Gly
 275 280 285

Gln Ser Ser Pro Leu His Lys Pro Cys Ser Pro Trp Ala Arg Ser Thr
 290 295 300

Thr Trp Ala Arg Ala Gln Ala Ile Gln Cys Cys Arg Trp Ser Arg Leu
 305 310 315 320

Trp Arg Arg Pro Leu Gly Arg Arg Ser Arg Thr Arg Trp Trp His Gly
 325 330 335

Gly Lys Val Met Trp Gln Pro Val Thr Pro Thr Pro Ala Trp Pro Lys
 340 345 350

Arg Ser Trp Gly Gly Gln Gln Pro
 355 360

<210> 167

<211> 376

<212> PRT

<213> Homo sapien

<400> 167

Arg Ala Arg Gly Ser Gly Val Gly Gly Gly Ala Ser Ala Ala Ser Val
 1 5 10 15

Gly Arg Gly Asn Pro Ser Arg Thr Leu Gln Ser Ser Val Thr Leu Asp
 20 25 30

Lys Glu Val Trp Ile Leu Arg Phe His Leu Phe Gln Leu Gln Gly Ala
 35 40 45

Met Ala Glu Lys Val Leu Val Thr Gly Gly Ala Gly Tyr Ile Gly Ser
 50 55 60

207

His Thr Val Leu Glu Leu Leu Glu Ala Gly Tyr Leu Pro Val Val Ile
 65 70 75 80

Asp Asn Phe His Asn Ala Phe Arg Gly Gly Gly Ser Leu Pro Glu Ser
 85 90 95

Leu Arg Arg Val Gln Glu Leu Thr Gly Arg Ser Val Glu Phe Glu Glu
 100 105 110

Met Asp Ile Leu Asp Gln Gly Ala Leu Gln Arg Leu Phe Lys Lys Tyr
 115 120 125

Ser Phe Met Ala Val Ile His Phe Ala Gly Leu Lys Ala Val Gly Glu
 130 135 140

Ser Val Gln Lys Pro Leu Asp Tyr Tyr Arg Val Asn Leu Thr Gly Thr
 145 150 155 160

Ile Gln Leu Leu Glu Ile Met Lys Ala His Gly Val Lys Asn Leu Val
 165 170 175

Phe Ser Ser Ser Ala Thr Val Tyr Gly Asn Pro Gln Tyr Leu Pro Leu
 180 185 190

Asp Glu Ala His Pro Thr Gly Gly Cys Thr Asn Pro Tyr Gly Lys Ser
 195 200 205

Lys Phe Phe Ile Glu Glu Met Ile Arg Asp Leu Cys Gln Ala Asp Lys
 210 215 220

Thr Trp Asn Ala Val Leu Leu Arg Tyr Phe Asn Pro Thr Gly Ala His
 225 230 235 240

Ala Ser Gly Cys Ile Gly Glu Asp Pro Gln Gly Ile Pro Asn Asn Leu
 245 250 255

Met Pro Tyr Val Ser Gln Val Ala Ile Gly Arg Arg Glu Ala Leu Asn
 260 265 270

Val Phe Gly Asn Asp Tyr Asp Thr Glu Asp Gly Thr Gly Val Arg Asp
 275 280 285

Tyr Ile His Val Val Asp Leu Ala Lys Gly His Ile Ala Ala Leu Arg
 290 295 300

208

Lys Leu Lys Glu Gln Cys Gly Cys Arg Val Gly Arg Glu Gly Arg Ser
 305 310 315 320

Glu Gly Gly Glu Gly Pro Asp Pro Gly Arg Ala Ala Gln Arg Arg Gly
 325 330 335

Gln Ser Ser Pro Leu His Lys Pro Cys Ser Pro Trp Ala Arg Ser Thr
 340 345 350

Thr Trp Ala Arg Ala Gln Ala Ile Gln Cys Cys Arg Trp Ser Arg Leu
 355 360 365

Trp Arg Arg Pro Leu Gly Arg Arg
 370 375

<210> 168
 <211> 466
 <212> PRT
 <213> Homo sapien

<400> 168

Met Ala Glu Lys Val Leu Val Thr Gly Gly Ala Gly Tyr Ile Gly Ser
 1 5 10 15

His Thr Val Leu Glu Leu Leu Glu Ala Gly Tyr Leu Pro Val Val Ile
 20 25 30

Asp Asn Phe His Asn Ala Phe Arg Gly Gly Gly Ser Leu Pro Glu Ser
 35 40 45

Leu Arg Arg Val Gln Glu Leu Thr Gly Arg Ser Val Glu Phe Glu Glu
 50 55 60

Met Asp Ile Leu Asp Gln Gly Ala Leu Gln Arg Leu Phe Lys Lys Tyr
 65 70 75 80

Ser Phe Met Ala Val Ile His Phe Ala Gly Leu Lys Ala Val Gly Glu
 85 90 95

Ser Val Gln Lys Pro Leu Asp Tyr Tyr Arg Val Asn Leu Thr Gly Thr
 100 105 110

Ile Gln Leu Leu Glu Ile Met Lys Ala His Gly Val Lys Asn Leu Val
 115 120 125

Phe Ser Ser Ser Ala Thr Val Tyr Gly Asn Pro Gln Tyr Leu Pro Leu
 130 135 140

209

Asp Glu Ala His Pro Thr Gly Gly Cys Thr Asn Pro Tyr Gly Lys Ser
 145 150 155 160

Lys Phe Phe Ile Glu Glu Met Ile Arg Asp Leu Cys Gln Ala Asp Lys
 165 170 175

Thr Trp Asn Ala Val Leu Leu Arg Tyr Phe Asn Pro Thr Gly Ala His
 180 185 190

Ala Ser Gly Cys Ile Gly Glu Asp Pro Gln Gly Ile Pro Asn Asn Leu
 195 200 205

Met Pro Tyr Val Ser Gln Val Ala Ile Gly Arg Arg Glu Ala Leu Asn
 210 215 220

Val Phe Gly Asn Asp Tyr Asp Thr Glu Asp Gly Thr Gly Val Arg Asp
 225 230 235 240

Tyr Ile His Val Val Asp Leu Ala Lys Gly His Ile Ala Ala Leu Arg
 245 250 255

Lys Leu Lys Glu Gln Cys Gly Cys Arg Val Gly Arg Glu Gly Arg Ser
 260 265 270

Glu Gly Gly Glu Gly Pro Asp Pro Gly Arg Ala Ala Gln Arg Arg Gly
 275 280 285

Gln Ser Ser Pro Leu His Lys Pro Cys Ser Pro Trp Ala Arg Ser Thr
 290 295 300

Thr Trp Ala Arg Ala Gln Ala Ile Gln Cys Cys Arg Trp Ser Arg Leu
 305 310 315 320

Trp Arg Arg Pro Leu Gly Arg Arg Ser Gly Pro Pro Thr Pro Pro Thr
 325 330 335

Ser Pro Thr Ser Pro His Pro Ala Leu Ser Asn Arg Ala Ala Leu Ala
 340 345 350

Leu Pro Thr His Leu Ser Gly Gly Tyr Leu Ala Leu Pro Ser Leu Leu
 355 360 365

Ser Leu Pro Ser Thr Arg Cys Leu Arg Ala Ser Arg Cys Ser Ala Leu
 370 375 380

210

Leu Leu Leu Lys Asp Leu Ala Ser Ser Trp Ala Arg Ala Gly Ser Ala
 385 390 395 400

Lys Leu Gln Leu Pro Pro Val Leu Gln Ile Pro Tyr Lys Val Val Ala
 405 410 415

Arg Arg Glu Gly Asp Val Ala Ala Cys Tyr Ala Asn Pro Ser Leu Ala
 420 425 430

Gln Glu Glu Leu Gly Trp Thr Ala Ala Leu Gly Leu Asp Arg Met Cys
 435 440 445

Glu Asp Leu Trp Arg Trp Gln Lys Gln Asn Pro Ser Gly Phe Gly Thr
 450 455 460

Gln Ala
 465

<210> 169
 <211> 328
 <212> PRT
 <213> Homo sapien

<400> 169

Met Ala Glu Lys Val Leu Val Thr Gly Gly Ala Gly Tyr Ile Gly Ser
 1 5 10 15

His Thr Val Leu Glu Leu Leu Glu Ala Gly Tyr Leu Pro Val Val Ile
 20 25 30

Asp Asn Phe His Asn Ala Phe Arg Gly Gly Gly Ser Leu Pro Glu Ser
 35 40 45

Leu Arg Arg Val Gln Glu Leu Thr Gly Arg Ser Val Glu Phe Glu Glu
 50 55 60

Met Asp Ile Leu Asp Gln Gly Ala Leu Gln Arg Leu Phe Lys Lys Tyr
 65 70 75 80

Ser Phe Met Ala Val Ile His Phe Ala Gly Leu Lys Ala Val Gly Glu
 85 90 95

Ser Val Gln Lys Pro Leu Asp Tyr Tyr Arg Val Asn Leu Thr Gly Thr
 100 105 110

Ile Gln Leu Leu Glu Ile Met Lys Ala His Gly Val Lys Asn Leu Val

211

115		120		125
Phe Ser Ser Ser Ala Thr Val Tyr Gly Asn Pro Gln Tyr Leu Pro Leu				
130		135		140
Asp Glu Ala His Pro Thr Gly Gly Cys Thr Asn Pro Tyr Gly Lys Ser				
145		150	155	160
Lys Phe Phe Ile Glu Glu Met Ile Arg Asp Leu Cys Gln Ala Asp Lys				
	165		170	175
Thr Trp Asn Ala Val Leu Leu Arg Tyr Phe Asn Pro Thr Gly Ala His				
	180		185	190
Ala Ser Gly Cys Ile Gly Glu Asp Pro Gln Gly Ile Pro Asn Asn Leu				
	195	200	205	
Met Pro Tyr Val Ser Gln Val Ala Ile Gly Arg Arg Glu Ala Leu Asn				
	210	215	220	
Val Phe Gly Asn Asp Tyr Asp Thr Glu Asp Gly Thr Gly Val Arg Asp				
225		230	235	240
Tyr Ile His Val Val Asp Leu Ala Lys Gly His Ile Ala Ala Leu Arg				
	245	250		255
Lys Leu Lys Glu Gln Cys Gly Cys Arg Val Gly Arg Glu Gly Arg Ser				
	260	265		270
Glu Gly Gly Glu Gly Pro Asp Pro Gly Arg Ala Ala Gln Arg Arg Gly				
	275	280		285
Gln Ser Ser Pro Leu His Lys Pro Cys Ser Pro Trp Ala Arg Ser Thr				
	290	295	300	
Thr Trp Ala Arg Ala Gln Ala Ile Gln Cys Cys Arg Trp Ser Arg Leu				
305		310	315	320
Trp Arg Arg Pro Leu Gly Arg Arg				
	325			

<210> 170

<211> 178

<212> PRT

<213> Homo sapien

<400> 170

212

Met Ala Ser Thr Ser Tyr Asp Tyr Cys Arg Val Pro Met Glu Asp Gly
 1 5 10 15
 Asp Lys Arg Cys Lys Leu Leu Leu Gly Ile Gly Ile Leu Val Leu Leu
 20 25 30
 Ile Ile Val Ile Leu Gly Val Pro Leu Ile Ile Phe Thr Ile Lys Ala
 35 40 45
 Asn Ser Glu Ala Cys Arg Asp Gly Leu Arg Ala Val Met Glu Cys Arg
 50 55 60
 Asn Val Thr His Leu Leu Gln Gln Glu Leu Thr Glu Ala Gln Lys Gly
 65 70 75 80
 Phe Gln Asp Val Glu Ala Gln Ala Ala Thr Cys Asn His Thr Val Met
 85 90 95
 Ala Leu Met Ala Ser Leu Asp Ala Glu Lys Ala Gln Gly Gln Lys Lys
 100 105 110
 Val Glu Glu Leu Glu Gly Glu Ile Thr Thr Leu Asn His Lys Leu Gln
 115 120 125
 Asp Ala Ser Ala Glu Val Glu Arg Leu Arg Arg Glu Asn Gln Val Leu
 130 135 140
 Ser Val Arg Ile Ala Asp Lys Lys Tyr Tyr Pro Ser Ser Gln Asp Ser
 145 150 155 160
 Ser Ser Ala Ala Ala Pro Gln Gln His Asn Gln Gln Leu Gly Arg Arg
 165 170 175
 Ser Cys

<210> 171
 <211> 141
 <212> PRT
 <213> Homo sapien

<400> 171

Leu Gln Ala Arg Leu Leu Ser Ala Lys Gly Glu Ile Trp Met Ala Ser
 1 5 10 15

Thr Ser Tyr Asp Tyr Cys Arg Val Pro Met Glu Asp Gly Asp Lys Arg

213

20

25

30

Cys Lys Leu Leu Leu Gly Ile Gly Ile Leu Val Leu Leu Ile Ile Val
 35 40 45

Ile Leu Gly Val Pro Leu Ile Ile Phe Thr Ile Lys Ala Asn Ser Glu
 50 55 60

Ala Cys Arg Asp Gly Leu Arg Ala Val Met Glu Cys Arg Asn Val Thr
 65 70 75 80

His Leu Leu Gln Gln Glu Leu Thr Glu Ala Gln Lys Gly Phe Gln Asp
 85 90 95

Val Glu Ala Gln Ala Ala Thr Cys Asn His Thr Val Met Ala Leu Met
 100 105 110

Ala Ser Leu Asp Ala Glu Lys Ala Gln Gly Gln Lys Lys Val Glu Glu
 115 120 125

Leu Glu Val Thr Thr Leu Asn His Lys Leu Gln Asp Ala
 130 135 140

<210> 172

<211> 188

<212> PRT

<213> Homo sapien

<400> 172

Met Ala Ser Thr Ser Tyr Asp Tyr Cys Arg Val Pro Met Glu Asp Gly
 1 5 10 15

Asp Lys Arg Cys Lys Leu Leu Leu Gly Ile Gly Ile Leu Val Leu Leu
 20 25 30

Ile Ile Val Ile Leu Gly Val Pro Leu Ile Ile Phe Thr Ile Lys Ala
 35 40 45

Asn Ser Glu Ala Cys Arg Asp Gly Leu Arg Ala Val Met Glu Cys Arg
 50 55 60

Asn Val Thr His Leu Leu Gln Gln Glu Leu Thr Glu Ala Gln Lys Gly
 65 70 75 80

Phe Gln Asp Val Glu Ala Gln Ala Ala Thr Cys Asn His Thr Val Met
 85 90 95

214

Ala Leu Met Ala Ser Leu Asp Ala Glu Lys Ala Gln Gly Gln Lys Lys
 100 105 110

Val Glu Glu Leu Glu Val Thr Thr Leu Asn His Lys Leu Gln Asp Ala
 115 120 125

Ser Arg Pro Gly Phe Leu Phe Ser Val Ala Pro Pro Leu Gln Thr Arg
 130 135 140

Leu Arg Arg Glu Asn Gln Val Leu Ser Val Arg Ile Ala Asp Lys Lys
 145 150 155 160

Tyr Tyr Pro Ser Ser Gln Asp Ser Ser Ser Ala Ala Ala Pro Gln Leu
 165 170 175

Leu Ile Val Leu Leu Gly Leu Ser Ala Leu Leu Gln
 180 185

<210> 173
 <211> 78
 <212> PRT
 <213> Homo sapien

<400> 173

Met Pro Trp Ile Gly Gly Gly Leu Ile Ala Val Trp Gly Gly Ala Ile
 1 5 10 15

Asn Gly Gly Gly Ser Ile Asp Gly Gly Glu Gly Leu Met Asp Gly Trp
 20 25 30

Gly Gly Ser Ser Asp Gly Gly Gly Ala Trp Gly Arg Ala Trp Ser Gly
 35 40 45

Ala Ser Ala Cys Cys Leu Gln Ser Ala Leu Ser Pro Ser Ser Gly Pro
 50 55 60

Leu Gly Thr Ser Trp Lys Val Arg Pro Ala Arg Leu Phe Ala
 65 70 75

<210> 174
 <211> 116
 <212> PRT
 <213> Homo sapien

<400> 174

Met Leu Trp Val Trp Phe His Ile Thr Ala Ile Lys Leu Gln Arg Glu
 1 5 10 15

215

Glu Glu Glu Ala Phe Ala Ser Ser Gln Ser Ser Gln Gly Ala Gln Ser
 20 25 30

Leu Ile Phe Ser Lys Phe Glu Gly Lys Lys Thr Asn Lys Lys Thr Arg
 35 40 45

Lys Val Thr Thr Val Lys Lys Ser Ser Val Arg Leu Pro Gly Ser Asp
 50 55 60

Gln Arg Arg Ile Leu Lys Trp Ile Pro Gly Val Cys Leu Glu Thr Ser
 65 70 75 80

Trp Pro Ala Ser Pro Ser Ala Ala Ser Thr Ser Ser Met Pro Ser Arg
 85 90 95

Ser Pro Arg Thr Ser Trp Arg Gln Gln Met Thr Ser Ser Pro Pro Ser
 100 105 110

Ser Thr Leu Phe
 115

<210> 175

<211> 360

<212> PRT

<213> Homo sapien

<400> 175

Met Ala Thr Lys Gly Gly Thr Val Lys Ala Ala Ser Gly Phe Asn Ala
 1 5 10 15

Met Glu Asp Ala Gln Thr Leu Arg Lys Ala Met Lys Gly Leu Ala Gln
 20 25 30

Thr Thr Arg Lys Gln Lys Ile His Gln Thr Phe Met Asn Ser Gln Leu
 35 40 45

Leu Glu Arg Gln Gly Thr Asn Leu Lys Asn Gln Asn Lys Val Ser Leu
 50 55 60

Leu Lys Leu Leu Gln Glu Thr Gly Thr Asp Glu Asp Ala Ile Ile Ser
 65 70 75 80

Val Leu Ala Tyr Arg Asn Thr Ala Gln Arg Gln Glu Ile Arg Thr Ala
 85 90 95

216

Tyr Lys Ser Thr Ile Gly Arg Asp Leu Ile Asp Asp Leu Lys Ser Glu
 100 105 110

Leu Ser Gly Asn Phe Glu Gln Val Ile Val Gly Met Met Thr Pro Thr
 115 120 125

Val Leu Tyr Asp Val Gln Glu Leu Arg Arg Ala Met Lys Gly Ala Gly
 130 135 140

Thr Asp Glu Gly Cys Leu Ile Glu Ile Leu Ala Ser Arg Thr Pro Glu
 145 150 155 160

Glu Ile Arg Arg Ile Ser Gln Thr Tyr Gln Gln Gln Tyr Gly Arg Ser
 165 170 175

Leu Glu Asp Asp Ile Arg Ser Asp Thr Ser Phe Met Phe Gln Arg Val
 180 185 190

Leu Val Ser Leu Ser Ala Gly Gly Arg Asp Glu Gly Asn Tyr Leu Asp
 195 200 205

Asp Ala Leu Val Arg Gln Asp Ala Gln Asp Leu Tyr Glu Ala Gly Glu
 210 215 220

Lys Lys Trp Gly Thr Asp Glu Val Lys Phe Leu Thr Val Leu Cys Ser
 225 230 235 240

Arg Asn Arg Asn His Leu Leu His Val Phe Asp Glu Tyr Lys Arg Ile
 245 250 255

Ser Gln Lys Asp Ile Glu Gln Ser Ile Lys Ser Glu Thr Ser Gly Ser
 260 265 270

Phe Glu Asp Ala Leu Leu Ala Ile Val Lys Cys Met Arg Asn Lys Ser
 275 280 285

Ala Tyr Phe Ala Glu Lys Leu Tyr Lys Ser Met Lys Gly Leu Gly Thr
 290 295 300

Asp Asp Asn Thr Leu Ile Arg Val Met Val Ser Arg Ala Glu Ile Asp
 305 310 315 320

Met Leu Asp Ile Arg Ala His Phe Lys Arg Leu Tyr Gly Lys Ser Leu
 325 330 335

Tyr Ser Phe Ile Lys Gly Asp Thr Ser Gly Asp Tyr Arg Lys Val Leu

217

340

345

350

Leu Val Leu Cys Gly Gly Asp Asp
 355 360

<210> 176
 <211> 177
 <212> PRT
 <213> Homo sapien

<400> 176

Met Tyr Thr Leu Glu Leu Phe Phe Ile Cys Phe Ser His Pro Gln Gly
 1 5 10 15

Gly Arg Asp Glu Gly Asn Tyr Leu Asp Asp Ala Leu Val Arg Gln Asp
 20 25 30

Ala Gln Asp Leu Tyr Glu Ala Gly Glu Lys Lys Trp Gly Thr Asp Glu
 35 40 45

Val Lys Phe Leu Thr Val Leu Cys Ser Arg Asn Arg Asn His Leu Leu
 50 55 60

His Val Phe Asp Glu Tyr Lys Arg Ile Ser Gln Lys Asp Ile Glu Gln
 65 70 75 80

Ser Ile Lys Ser Glu Thr Ser Gly Ser Phe Glu Asp Ala Leu Leu Ala
 85 90 95

Ile Val Lys Cys Met Arg Asn Lys Ser Ala Tyr Phe Ala Glu Lys Leu
 100 105 110

Tyr Lys Ser Met Lys Gly Leu Gly Thr Asp Asp Asn Thr Leu Ile Arg
 115 120 125

Val Met Val Ser Arg Ala Glu Ile Asp Met Leu Asp Ile Arg Ala His
 130 135 140

Phe Lys Arg Leu Tyr Gly Lys Ser Leu Tyr Ser Phe Ile Lys Gly Asp
 145 150 155 160

Thr Ser Gly Asp Tyr Arg Lys Val Leu Leu Val Leu Cys Gly Gly Asp
 165 170 175

Asp

218

<210> 177
 <211> 380
 <212> PRT
 <213> Homo sapien

<400> 177

Met Tyr Phe Asp Trp Gly Pro Gly Glu Met Leu Val Cys Glu Thr Ser
 1 5 10 15

Phe Asn Lys Lys Glu Lys Ser Glu Met Val Pro Ser Cys Pro Phe Ile
 20 25 30

Tyr Ile Ile Arg Lys Asp Val Asp Val Tyr Ser Gln Ile Leu Arg Lys
 35 40 45

Leu Phe Asn Glu Ser His Gly Ile Phe Leu Gly Leu Gln Arg Ile Asp
 50 55 60

Glu Glu Leu Thr Gly Lys Ser Arg Lys Ser Gln Leu Val Arg Val Ser
 65 70 75 80

Lys Asn Tyr Arg Ser Val Ile Arg Ala Cys Met Glu Glu Met His Gln
 85 90 95

Val Ala Ile Ala Ala Lys Asp Pro Ala Asn Gly Arg Gln Phe Ser Ser
 100 105 110

Gln Val Ser Ile Leu Ser Ala Met Glu Leu Ile Trp Asn Leu Cys Glu
 115 120 125

Ile Leu Phe Ile Glu Val Ala Pro Ala Gly Pro Leu Leu Leu His Leu
 130 135 140

Leu Asp Trp Val Arg Leu His Val Cys Glu Val Asp Ser Leu Ser Ala
 145 150 155 160

Asp Val Leu Gly Ser Glu Asn Pro Ser Lys His Asp Ser Phe Trp Asn
 165 170 175

Leu Val Thr Ile Leu Val Leu Gln Gly Arg Leu Asp Glu Ala Arg Gln
 180 185 190

Met Leu Ser Lys Glu Ala Asp Ala Ser Pro Ala Ser Ala Gly Ile Cys
 195 200 205

Arg Ile Met Gly Asp Leu Met Arg Thr Met Pro Ile Leu Ser Pro Gly

219

210

215

220

Asn Thr Gln Thr Leu Thr Glu Leu Glu Leu Lys Trp Gln His Trp His
 225 230 235 240

Glu Glu Cys Glu Arg Tyr Leu Gln Asp Ser Thr Phe Ala Thr Ser Pro
 245 250 255

His Leu Glu Ser Leu Leu Lys Ile Met Leu Gly Asp Glu Ala Ala Leu
 260 265 270

Leu Glu Gln Lys Glu Leu Leu Ser Asn Trp Tyr His Phe Leu Val Thr
 275 280 285

Arg Leu Leu Tyr Ser Asn Pro Thr Val Lys Pro Ile Asp Leu His Tyr
 290 295 300

Tyr Ala Gln Ser Ser Leu Asp Leu Phe Leu Gly Gly Glu Ser Ser Pro
 305 310 315 320

Glu Pro Leu Asp Asn Ile Leu Leu Ala Ala Phe Glu Phe Asp Ile His
 325 330 335

Gln Val Ile Lys Glu Cys Arg Asn Lys Thr Asp Leu Ser Arg Arg Ser
 340 345 350

Leu Leu Asp Ala Gly Ser Ile Lys Gly Glu Ser Ile Leu Leu Phe Pro
 355 360 365

Val Ala Glu Glu Lys Glu Lys Tyr His Glu Glu Gly
 370 375 380

<210> 178

<211> 394

<212> PRT

<213> Homo sapien

<400> 178

Glu Leu Arg Leu Leu Ser Tyr Phe Arg Leu Val Cys Phe Pro Ser Gly
 1 5 10 15

Arg Glu Ala Leu Val Pro Phe Pro Arg Leu Ser Cys His Phe Ser Gly
 20 25 30

Gly Arg Ser Val Asn Glu Leu Ile Pro Gly Val Asn Ser Lys Lys Asn
 35 40 45

220

Gln Met Tyr Phe Asp Trp Gly Pro Gly Glu Met Leu Val Cys Glu Thr
 50 55 60

Ser Phe Asn Lys Lys Glu Lys Ser Glu Met Val Pro Ser Cys Pro Phe
 65 70 75 80

Ile Tyr Ile Ile Arg Lys Asp Val Asp Val Tyr Ser Gln Ile Leu Arg
 85 90 95

Lys Leu Phe Asn Glu Ser His Gly Ile Phe Leu Gly Leu Gln Arg Ile
 100 105 110

Asp Glu Glu Leu Thr Gly Lys Ser Arg Lys Ser Gln Leu Val Arg Val
 115 120 125

Ser Lys Asn Tyr Arg Ser Val Ile Arg Ala Cys Met Glu Glu Met His
 130 135 140

Gln Val Ala Ile Ala Ala Lys Asp Pro Ala Asn Gly Arg Gln Phe Ser
 145 150 155 160

Ser Gln Val Ser Ile Leu Ser Ala Met Glu Leu Ile Trp Asn Leu Cys
 165 170 175

Glu Ile Leu Phe Ile Glu Val Ala Pro Ala Gly Pro Leu Leu Leu His
 180 185 190

Leu Leu Asp Trp Val Arg Leu His Val Cys Glu Val Asp Ser Leu Ser
 195 200 205

Ala Asp Val Leu Gly Ser Glu Asn Pro Ser Lys His Asp Ser Phe Trp
 210 215 220

Asn Leu Val Thr Ile Leu Val Leu Gln Gly Arg Leu Asp Glu Ala Arg
 225 230 235 240

Gln Met Leu Ser Lys Glu Ala Asp Ala Ser Pro Ala Ser Ala Gly Ile
 245 250 255

Cys Arg Ile Met Gly Asp Leu Met Arg Thr Met Pro Ile Leu Ser Pro
 260 265 270

Gly Asn Thr Gln Thr Leu Thr Glu Leu Glu Leu Lys Trp Gln His Trp
 275 280 285

221

His Glu Glu Cys Glu Arg Tyr Leu Gln Asp Ser Thr Phe Ala Thr Ser
 290 295 300

Pro His Leu Glu Ser Leu Leu Lys Ile Met Leu Gly Asp Glu Ala Ala
 305 310 315 320

Leu Leu Glu Gln Lys Glu Leu Leu Ser Asn Trp Tyr His Phe Leu Val
 325 330 335

Thr Arg Leu Leu Tyr Ser Asn Pro Thr Val Lys Pro Ile Asp Leu His
 340 345 350

Tyr Tyr Ala Gln Ser Ser Leu Asp Leu Phe Leu Gly Gly Glu Ser Ser
 355 360 365

Pro Glu Pro Leu Asp Asn Ile Leu Leu Ala Ala Phe Glu Phe Asp Ile
 370 375 380

His Gln Val Ile Lys Glu Cys Ser Phe Leu
 385 390

<210> 179

<211> 679

<212> PRT

<213> Homo sapien

<400> 179

Met Tyr Phe Asp Trp Gly Pro Gly Glu Met Leu Val Cys Glu Thr Ser
 1 5 10 15

Phe Asn Lys Lys Glu Lys Ser Glu Met Val Pro Ser Cys Pro Phe Ile
 20 25 30

Tyr Ile Ile Arg Lys Asp Val Asp Val Tyr Ser Gln Ile Leu Arg Lys
 35 40 45

Leu Phe Asn Glu Ser His Gly Ile Phe Leu Gly Leu Gln Arg Ile Asp
 50 55 60

Glu Glu Leu Thr Gly Lys Ser Arg Lys Ser Gln Leu Val Arg Val Ser
 65 70 75 80

Lys Asn Tyr Arg Ser Val Ile Arg Ala Cys Met Glu Glu Met His Gln
 85 90 95

Val Ala Ile Ala Ala Lys Asp Pro Ala Asn Gly Arg Gln Phe Ser Ser
 100 105 110

222

Gln Val Ser Ile Leu Ser Ala Met Glu Leu Ile Trp Asn Leu Cys Glu
 115 120 125

Ile Leu Phe Ile Glu Val Ala Pro Ala Gly Pro Leu Leu Leu His Leu
 130 135 140

Leu Asp Trp Val Arg Leu His Val Cys Glu Val Asp Ser Leu Ser Ala
 145 150 155 160

Asp Val Leu Gly Ser Glu Asn Pro Ser Lys His Asp Ser Phe Trp Asn
 165 170 175

Leu Val Thr Ile Leu Val Leu Gln Gly Arg Leu Asp Glu Ala Arg Gln
 180 185 190

Met Leu Ser Lys Glu Ala Asp Ala Ser Pro Ala Ser Ala Gly Ile Cys
 195 200 205

Arg Ile Met Gly Asp Leu Met Arg Thr Met Pro Ile Leu Ser Pro Gly
 210 215 220

Asn Thr Gln Thr Leu Thr Glu Leu Glu Leu Lys Trp Gln His Trp His
 225 230 235 240

Glu Glu Cys Glu Arg Tyr Leu Gln Asp Ser Thr Phe Ala Thr Ser Pro
 245 250 255

His Leu Glu Ser Leu Leu Lys Ile Met Leu Gly Asp Glu Ala Ala Leu
 260 265 270

Leu Glu Gln Lys Glu Leu Leu Ser Asn Trp Tyr His Phe Leu Val Thr
 275 280 285

Arg Leu Leu Tyr Ser Asn Pro Thr Val Lys Pro Ile Asp Leu His Tyr
 290 295 300

Tyr Ala Gln Ser Ser Leu Asp Leu Phe Leu Gly Gly Glu Ser Ser Pro
 305 310 315 320

Glu Pro Leu Asp Asn Ile Leu Leu Ala Ala Phe Glu Phe Asp Ile His
 325 330 335

Gln Val Ile Lys Glu Cys Ser Phe Leu Leu Lys Thr Gly Gln Phe Leu
 340 345 350

223

Ala Val Trp Gln Glu Glu Thr Ala Gly Val His Phe Thr Gly Ser Trp
 355 360 365

Ala Arg Cys Arg Gln Phe Pro Gly Ala Leu Gln Val Leu Gln Lys Tyr
 370 375 380

Arg Ala Lys Ser Ile Ala Leu Ser Asn Trp Trp Phe Val Ala His Leu
 385 390 395 400

Thr Asp Leu Leu Asp His Cys Lys Leu Leu Gln Ser His Asn Leu Tyr
 405 410 415

Phe Gly Ser Asn Met Arg Glu Phe Leu Leu Leu Glu Tyr Ala Ser Gly
 420 425 430

Leu Phe Ala His Pro Ser Leu Trp Gln Leu Gly Val Asp Tyr Phe Asp
 435 440 445

Tyr Cys Pro Glu Leu Gly Arg Val Ser Leu Glu Leu His Ile Glu Arg
 450 455 460

Ile Pro Leu Asn Thr Glu Gln Lys Ala Leu Lys Val Leu Arg Ile Cys
 465 470 475 480

Glu Gln Arg Gln Met Thr Glu Gln Val Arg Ser Ile Cys Lys Ile Leu
 485 490 495

Ala Met Lys Ala Val Arg Asn Asn Arg Leu Gly Ser Ala Leu Ser Trp
 500 505 510

Ser Ile Arg Ala Lys Asp Ala Ala Phe Ala Thr Leu Val Ser Asp Arg
 515 520 525

Phe Leu Arg Asp Tyr Cys Glu Arg Gly Cys Phe Ser Asp Leu Asp Leu
 530 535 540

Ile Asp Asn Leu Gly Pro Ala Met Met Leu Ser Asp Arg Leu Thr Phe
 545 550 555 560

Leu Gly Lys Tyr Arg Glu Phe His Arg Met Tyr Gly Glu Lys Arg Phe
 565 570 575

Ala Asp Ala Ala Ser Leu Leu Leu Ser Leu Met Thr Ser Arg Ile Ala
 580 585 590

224

Pro Arg Ser Phe Trp Met Thr Leu Leu Thr Asp Ala Leu Pro Leu Leu
 595 600 605

Glu Gln Lys Gln Val Ile Phe Ser Ala Glu Gln Thr Tyr Glu Leu Met
 610 615 620

Arg Cys Leu Glu Asp Leu Thr Ser Arg Arg Pro Val His Gly Glu Ser
 625 630 635 640

Asp Thr Glu Gln Leu Gln Asp Asp Asp Ile Glu Thr Thr Lys Val Glu
 645 650 655

Met Leu Arg Leu Ser Leu Ala Arg Asn Leu Ala Arg Ala Ile Ile Arg
 660 665 670

Glu Gly Ser Leu Glu Gly Ser
 675

<210> 180
 <211> 72
 <212> PRT
 <213> Homo sapien

<220>
 <221> MISC_FEATURE
 <222> (45)..(45)
 <223> X=any amino acid

<400> 180

Arg Cys Asn Thr Pro Thr Ser Ser Gln Ile Lys Phe Gln His Ile Leu
 1 5 10 15

Tyr Ala Ser Val Thr Lys Gln Pro His Asn Leu Val Phe Ile Val Asp
 20 25 30

Leu Tyr Arg Met Lys Glu Glu Asn Pro Leu Trp His Xaa Asn Glu Ser
 35 40 45

Phe Trp Trp Gly Gln Leu Thr Arg Pro Arg Gly Gln Arg Ser Arg Ser
 50 55 60

Glu Ser Arg Pro Thr Arg Pro Trp
 65 70

<210> 181
 <211> 77
 <212> PRT
 <213> Homo sapien

225

<400> 181

Arg Cys Asn Thr Pro Thr Ser Ser Gln Ile Lys Phe Gln His Ile Leu
 1 5 10 15

Tyr Ala Ser Val Thr Lys Gln Pro His Asn Leu Val Phe Ile Val Asp
 20 25 30

Leu Tyr Arg Met Lys Glu Glu Asn Pro Leu Trp His Ala Asn Glu Ile
 35 40 45

Phe Leu Val Gly Thr Ala Asp Glu Ala Thr Arg Ala Glu Ile Gln Ile
 50 55 60

Arg Ile Glu Ala Asn Glu Ala Leu Val Lys Ala Leu Glu
 65 70 75

<210> 182

<211> 174

<212> PRT

<213> Homo sapien

<400> 182

Ser Lys Cys His Val Tyr Thr Leu Asn Ile Leu Lys Ile Cys Phe Phe
 1 5 10 15

Tyr Phe Arg Lys Phe Ile Glu Met Gly Phe Ile Asp Glu Lys Arg Ile
 20 25 30

Ala Ile Trp Gly Trp Ser Tyr Gly Gly Tyr Val Ser Ser Leu Ala Leu
 35 40 45

Ala Ser Gly Thr Gly Leu Phe Lys Cys Gly Ile Ala Val Ala Pro Val
 50 55 60

Ser Ser Trp Glu Tyr Tyr Ala Ser Val Tyr Thr Glu Arg Phe Met Gly
 65 70 75 80

Leu Pro Thr Lys Asp Asp Asn Leu Glu His Tyr Lys Asn Ser Thr Val
 85 90 95

Met Ala Arg Ala Glu Tyr Phe Arg Asn Val Asp Tyr Leu Leu Ile His
 100 105 110

Gly Thr Ala Asp Asp Asn Val His Phe Gln Asn Ser Ala Gln Ile Ala
 115 120 125

226

Lys Ala Leu Val Asn Ala Gln Val Asp Phe Gln Ala Met Trp Tyr Ser
 130 135 140

Asp Gln Asn His Gly Leu Ser Gly Leu Ser Thr Asn His Leu Tyr Thr
 145 150 155 160

His Met Thr His Phe Leu Lys Gln Cys Phe Ser Leu Ser Asp
 165 170

<210> 183
 <211> 36
 <212> PRT
 <213> Homo sapien

<400> 183

Met Gln Glu Arg Asn Gly Cys Cys Glu Ile Pro Leu Arg Asn Tyr Ile
 1 5 10 15

Ile Gln Val Met Lys Ile Thr Gln Phe Tyr Phe Gln Arg Arg Thr Asp
 20 25 30

Glu Lys Gly Leu
 35

<210> 184
 <211> 215
 <212> PRT
 <213> Homo sapien

<220>
 <221> MISC_FEATURE
 <222> (207)..(207)
 <223> X=any amino acid

<220>
 <221> MISC_FEATURE
 <222> (211)..(211)
 <223> X=any amino acid

<400> 184

Met Leu Pro Ala Val Gly Ser Ala Asp Glu Glu Glu Asp Pro Ala Glu
 1 5 10 15

Glu Asp Cys Pro Glu Leu Val Pro Ile Glu Thr Thr Gln Ser Glu Glu
 20 25 30

Glu Glu Lys Ser Gly Leu Gly Ala Lys Ile Pro Val Thr Ile Ile Thr
 35 40 45

227

Gly Tyr Leu Gly Ala Gly Lys Thr Thr Leu Leu Asn Tyr Ile Leu Thr
 50 55 60

Glu Gln His Ser Lys Arg Val Ala Val Ile Leu Asn Glu Phe Gly Glu
 65 70 75 80

Gly Ser Ala Leu Glu Lys Ser Leu Ala Val Ser Gln Gly Gly Glu Leu
 85 90 95

Tyr Glu Glu Trp Leu Glu Leu Arg Asn Gly Cys Leu Cys Cys Ser Val
 100 105 110

Lys Asp Ser Gly Leu Arg Ala Ile Glu Asn Leu Met Gln Lys Lys Gly
 115 120 125

Lys Phe Asp Tyr Ile Leu Leu Glu Thr Thr Gly Leu Ala Asp Pro Gly
 130 135 140

Ala Val Ala Ser Met Phe Trp Val Asp Ala Glu Leu Gly Ser Asp Ile
 145 150 155 160

Tyr Leu Asp Gly Ile Ile Thr Ile Val Asp Ser Lys Tyr Gly Leu Lys
 165 170 175

His Leu Thr Glu Glu Lys Pro Asp Gly Leu Ile Asn Glu Ala Thr Arg
 180 185 190

Gln Val Ala Leu Ala Glu Ile Gly Pro Pro Pro Asn Phe Phe Xaa Pro
 195 200 205

Phe Ser Xaa Lys Phe Phe Phe
 210 215

<210> 185
 <211> 133
 <212> PRT
 <213> Homo sapien

<400> 185

Ile Leu Cys Ile Lys Phe Phe Lys Ser Gln Ser Phe Phe Phe Leu Ile
 1 5 10 15

Asn Trp Met Tyr Phe Thr Glu Phe Pro Thr Ala His Val Ser Phe Leu
 20 25 30

228

Pro Phe Arg Val Asp Leu Ser Asn Val Leu Asp Leu His Ala Phe Asp
 35 40 45

Ser Leu Ser Gly Ile Ser Leu Gln Lys Lys Leu Gln His Val Pro Gly
 50 55 60

Thr Gln Pro His Leu Asp Gln Ser Ile Val Thr Ile Thr Phe Asp Val
 65 70 75 80

Pro Gly Asn Ala Lys Glu Glu His Leu Asn Met Phe Ile Gln Asn Leu
 85 90 95

Leu Trp Glu Lys Asn Val Arg Asn Lys Asp Asn His Cys Met Glu Val
 100 105 110

Ile Arg Leu Lys Val Gln Phe Thr Val Ala Asp Phe Trp Thr Lys Ser
 115 120 125

Phe Ser Trp Leu Leu
 130

<210> 186

<211> 953

<212> PRT

<213> Homo sapien

<400> 186

Met Ser His Arg Gln Val His Asp Asp Leu Asn Lys Leu Leu Lys Ile
 1 5 10 15

Met Leu Ile Asn Ser Phe Gly Ser Val Ile Ile Phe Val Phe Ile Asn
 20 25 30

Ile Leu Ser Gln Phe Ser Ser Phe Ile Phe Ile Ser Glu Ile Ser Met
 35 40 45

Ser Trp Asn Lys Ser Cys Val Leu Ile Ser Leu Leu Cys Asn Asn Leu
 50 55 60

Val Cys Leu Thr Phe Leu Thr Phe Ile Ser Asn Ile Cys Phe Ile Lys
 65 70 75 80

Asn Asn Lys His Ala Val Ile Asp Phe Ser Tyr Phe Lys Trp Met Ser
 85 90 95

Glu Gln Val Thr Lys Ile Phe Cys Glu Phe Phe Ser Val Trp Cys Leu
 100 105 110

229

Pro Met His Leu Arg Ile Trp Gly Leu Ser Glu Ile Val Leu Pro Cys
 115 120 125

Tyr Gly Thr Glu Val Gly Leu Glu Ser Phe Ser Met Lys Ile Arg Cys
 130 135 140

Pro Glu Tyr Glu Phe Leu Leu Leu Gly Pro Glu Ser Tyr Ile Lys Tyr
 145 150 155 160

Ser Leu Lys Phe Leu Glu Ala Thr Ala Pro Ser Leu Ser Ser Val Ile
 165 170 175

Phe Trp Ala Tyr Val Lys Ile Ile Thr Gln Ser Pro Val Phe Ile Asn
 180 185 190

Cys Phe Phe Ile Phe Lys Pro Asn Leu Met Leu Ile Val Ile Cys Tyr
 195 200 205

Leu Phe Ser Pro Asp Leu Asn His Trp Ile Gln Leu Asn Glu Phe Glu
 210 215 220

Leu Ser Leu Asn Asn Ser Lys Arg Asn Asn Val Tyr Ser Asp Gly Gly
 225 230 235 240

Asn Phe Leu Ser Thr Cys Ser Pro Ile Leu Asn Glu Val Lys Ser Asn
 245 250 255

His Val Thr Ile Arg Val Leu Glu Lys Leu Asn Ile Leu Tyr Ile Gly
 260 265 270

Tyr Leu Thr Pro His Phe Tyr Ile Thr Cys Tyr Ile Lys Gly Gly Gly
 275 280 285

Ile Lys Glu Ile Gln Lys Leu Gln Arg Tyr Leu Glu Cys Thr Tyr Leu
 290 295 300

Leu Ile Leu Phe Val Ile Ser Leu Phe His Leu Leu Ser Asn Lys Leu
 305 310 315 320

Leu Glu Lys Phe Leu Phe Phe Ser Cys Phe Phe Ser Tyr Lys Asn Val
 325 330 335

Phe Glu Lys Leu Ile Asn Phe Arg Ile Glu Lys Ile Ile Glu Ser Leu
 340 345 350

230

Lys Lys Thr Tyr Phe Ile Glu Val Ile Thr Lys Ile Ile Phe Asn Leu
 355 360 365

Asp Ser Thr Val Ile Gln Ile Leu His His Leu Pro Thr Ser Met Asn
 370 375 380

Phe Met Tyr Lys Phe Phe Lys Ser Gln Ser Phe Phe Phe Leu Ile Asn
 385 390 395 400

Trp Met Tyr Phe Thr Glu Phe Pro Thr Ala His Val Ser Phe Leu Pro
 405 410 415

Phe Arg Val Asp Leu Ser Asn Val Leu Asp Leu His Ala Phe Asp Ser
 420 425 430

Leu Ser Gly Ile Ser Leu Gln Lys Lys Leu Gln His Val Pro Gly Thr
 435 440 445

Gln Pro His Leu Asp Gln Ser Ile Val Thr Ile Thr Phe Asp Val Pro
 450 455 460

Gly Asn Ala Lys Glu Glu His Leu Asn Met Phe Ile Gln Asn Leu Leu
 465 470 475 480

Trp Glu Lys Asn Val Arg Asn Lys Asp Asn His Cys Met Glu Val Ile
 485 490 495

Arg Leu Lys Val Gln Phe Thr Val Ala Asp Phe Trp Thr Lys Ser Phe
 500 505 510

Ser Trp Leu Leu Glu Lys Leu Tyr Leu Val Leu Asn Arg Asn Thr Gly
 515 520 525

Phe Ser Thr Asn His Leu Cys Leu Leu Ser Phe Phe Phe Ile Ile Phe
 530 535 540

Met Thr Glu Lys Glu Leu Trp Lys Ser Leu His Lys Ala Gly Phe Ile
 545 550 555 560

Cys Thr Thr Phe Phe Arg Val Ala Ala Arg Thr Asn Leu Cys Ala Leu
 565 570 575

Lys Cys Tyr Leu Leu Leu Ser Val Pro Lys Tyr Arg Glu Ile Met Leu
 580 585 590

231

Gln Ile Ser Leu Leu Leu Asn Ile Met Leu Pro Asp Ala Phe Glu Gln
 595 600 605

Thr Leu Asn Ile Cys Cys Thr Leu Asn Lys Val Gln Arg Thr Arg Arg
 610 615 620

Ile Leu Val Leu Tyr Leu Glu Thr His Ser His Tyr Leu Ile Phe Gly
 625 630 635 640

Tyr Leu Ser His Glu Arg Tyr Phe Phe Tyr Gly Ser Ser Asp Ser Gln
 645 650 655

Ser Val Cys Leu Thr Ser Gln Leu Ser Val Tyr Ser Cys Val Phe Thr
 660 665 670

Ser Val His Lys Val Phe Gly Glu Ile Lys Asn Ile Ile Ser Asn Glu
 675 680 685

Ile Asn Phe Ile Pro Ile Gly Ala Ser Leu Ser Asp Asn Ser Phe Leu
 690 695 700

Ile Ser Ala Asn Gln Tyr Thr Met Ser Ser Tyr Ser Asp Lys Tyr Asn
 705 710 715 720

Ser Phe Ser Leu Phe Gln His Cys Ser Leu Ile Ala Thr His Phe Tyr
 725 730 735

Asn Lys Leu Phe Asn Ile Thr Asn Ser Phe Asn Phe Ser Thr Phe Pro
 740 745 750

Thr Lys Thr Val Lys His Tyr Ile Lys Ser Leu Ser Ile Gly Tyr Asp
 755 760 765

Thr Tyr Phe Ile Ile Leu Phe Gln Val Leu Val Val Ile Asn Asn Thr
 770 775 780

Glu Lys Pro Ser Ile Ile Tyr Val Leu Thr Leu Ser Leu Glu Lys Gly
 785 790 795 800

Ile Val Gln Lys Lys Ile Asn Thr Gln Lys Pro Phe Leu Lys Ile Lys
 805 810 815

Asn Ile Lys Lys Leu Leu Val Ile His Lys Tyr Leu Glu Leu Ser Asn
 820 825 830

Phe Leu Ser Phe Lys Ser Leu Tyr Phe Leu Ser Glu Tyr Gln Tyr Ile

232

835

840

845

Asn Pro Leu Thr Leu Met Leu Ile Ser Ala Phe Lys Phe Glu Leu Arg
 850 855 860

Leu Ile Asn Val Gln Ser Ile Leu Leu Gly Ala Gly Leu Val Ser Ile
 865 870 875 880

Lys Asp Lys Ser Gln Gln Val Ile Val Gln Gly Val His Glu Leu Tyr
 885 890 895

Asp Leu Glu Glu Thr Pro Val Ser Trp Lys Asp Asp Thr Glu Arg Thr
 900 905 910

Asn Arg Leu Val Leu Ile Gly Arg Asn Leu Asp Lys Asp Ile Leu Lys
 915 920 925

Gln Leu Phe Ile Ala Thr Val Thr Glu Thr Glu Lys Gln Trp Thr Thr
 930 935 940

His Phe Lys Glu Asp Gln Val Cys Thr
 945 950

<210> 187

<211> 194

<212> PRT

<213> Homo sapien

<400> 187

Ile Leu Cys Ile Lys Phe Phe Lys Ser Gln Ser Phe Phe Phe Leu Ile
 1 5 10 15

Asn Trp Met Tyr Phe Thr Glu Phe Pro Thr Ala His Val Ser Phe Leu
 20 25 30

Pro Phe Arg Val Asp Leu Ser Asn Val Leu Asp Leu His Ala Phe Asp
 35 40 45

Ser Leu Ser Gly Ile Ser Leu Gln Lys Lys Leu Gln His Val Pro Gly
 50 55 60

Thr Gln Pro His Leu Asp Gln Ser Ile Val Thr Ile Thr Phe Asp Val
 65 70 75 80

Pro Gly Asn Ala Lys Glu Glu His Leu Asn Met Phe Ile Gln Asn Leu
 85 90 95

233

Leu Trp Glu Lys Asn Val Arg Asn Lys Asp Asn His Cys Met Glu Val
 100 105 110

Ile Arg Leu Lys Gly Leu Val Ser Ile Lys Asp Lys Ser Gln Gln Val
 115 120 125

Ile Val Gln Gly Val His Glu Leu Tyr Asp Leu Glu Glu Thr Pro Val
 130 135 140

Ser Trp Lys Asp Asp Thr Glu Arg Thr Asn Arg Leu Val Leu Ile Gly
 145 150 155 160

Arg Asn Leu Asp Lys Asp Ile Leu Lys Gln Leu Phe Ile Ala Thr Val
 165 170 175

Thr Glu Thr Glu Lys Gln Trp Thr Thr His Phe Lys Glu Asp Gln Val
 180 185 190

Cys Thr

<210> 188

<211> 728

<212> PRT

<213> Homo sapien

<400> 188

Met Arg Leu Ser Asn Arg Gln Pro Gly Ala Leu Arg Leu Thr Ala Gly
 1 5 10 15

Ser Leu Val Pro Leu Ser Leu Tyr Leu Arg Asn Ser Phe Phe Gly Ser
 20 25 30

Thr Ala Glu Ala Leu Gly Glu Trp Leu Cys Leu Leu Trp Gln Arg Leu
 35 40 45

Glu Val Leu Thr Asp Cys His Lys Tyr Tyr Ala Val Thr Ala Ala Ala
 50 55 60

Ala Tyr Met His Val Asn Ser Trp Gly Ile Asn Leu Val Cys Ile Leu
 65 70 75 80

Arg Ser His Ser Ser Ala Gly Arg Gly Ser Arg Arg Met Pro Phe Ser
 85 90 95

Val Ser Pro Leu Gln Pro Tyr Thr Lys Cys Ala Pro Cys Val Ser Asn

234

100	105	110
Ser Ile Val Glu Val Ser Asp 115	Asn Leu Thr Tyr Thr 120	Met Ser His Ser 125
Ser Val Ser Val Leu Phe 130	Leu Val Phe Tyr Asn Ser 135 140	Phe Leu Leu
Asn Phe Ser Pro Leu Tyr 145	Lys Met Ser His Arg Gln Val 150 155	His Asp Thr 160
Tyr Asn Lys Leu Leu Lys 165	Ile Met Leu Ile Asn Ser 170	Phe Gly Ser Val 175
Ile Ile Phe Val Phe Ile 180	Asn Ile Leu Ser Gln Phe 185	Ser Ser Phe Ile 190
Phe Ile Ser Glu Ile Ser 195	Met Ser Trp Asn Lys Ser 200	Cys Val Leu Ile 205
Ser Leu Leu Cys Asn Asn 210	Leu Val Cys Leu Thr 215	Phe Leu Thr Phe Ile 220
Ser Asn Ile Cys Phe Ile 225	Ile Ile Glu Gln Lys His 230 235	Ala Val Ile Asp Phe 240
Ser Tyr Phe Lys Trp Met 245	Ser Glu Gln Val Thr 250	Lys Ile Phe Cys Glu 255
Phe Phe Ser Val Trp Cys 260	Leu Pro Met His Leu Arg 265	Ile Gln Gly Leu 270
Ser Glu Ile Val Leu Pro 275	Cys Tyr Gly Thr Glu Val 280	Gly Leu Glu Ser 285
Phe Ser Met Lys Ile Arg 290	Cys Pro Glu Tyr Glu 295	Phe Leu Leu Leu Gly 300
Pro Glu Ser Tyr Ile Lys 305	Tyr Ser Leu Lys Phe 310 315	Leu Glu Ala Thr Ala 320
Pro Ser Leu Ser Ser Val 325	Ile Phe Trp Ala Tyr Val 330	Lys Ile Ile Thr 335
Gln Ser Pro Val Phe Ile 340	Asn Cys Phe Phe Ile 345	Phe Lys Pro Asn Leu 350

235

Met Leu Ile Val Ile Cys Tyr Leu Phe Ser Pro Asp Leu Asn His Trp
 355 360 365

Ile Gln Leu Asn Glu Phe Glu Leu Ser Leu Asn Asn Ser Lys Arg Asn
 370 375 380

Asn Val Tyr Ser Asp Gly Gly Asn Phe Leu Ser Thr Cys Ser Pro Ile
 385 390 395 400

Leu Asn Glu Val Lys Ser Asn His Val Thr Ile Arg Val Leu Glu Lys
 405 410 415

Leu Asn Ile Leu Tyr Ile Gly Tyr Leu Thr Pro His Phe Tyr Ile Thr
 420 425 430

Cys Tyr Ile Lys Gly Gly Gly Ile Lys Glu Ile Gln Lys Leu Gln Arg
 435 440 445

Tyr Leu Glu Cys Thr Tyr Leu Leu Ile Leu Phe Val Ile Ser Leu Phe
 450 455 460

His Leu Leu Ser Asn Lys Leu Leu Glu Lys Phe Leu Phe Phe Ser Cys
 465 470 475 480

Phe Phe Ser Tyr Lys Asn Val Phe Glu Lys Leu Ile Asn Phe Arg Ile
 485 490 495

Glu Lys Ile Ile Glu Ser Leu Lys Lys Thr Tyr Phe Ile Glu Val Ile
 500 505 510

Thr Lys Ile Ile Phe Asn Leu Asp Ser Thr Val Ile Gln Ile Leu His
 515 520 525

His Leu Pro Thr Ser Met Asn Phe Met Tyr Lys Ile Phe Lys Ser Gln
 530 535 540

Ser Phe Phe Phe Leu Ile Asn Trp Met Tyr Phe Thr Glu Phe Pro Thr
 545 550 555 560

Ala His Val Ser Phe Leu Pro Phe Arg Val Asp Leu Ser Asn Val Leu
 565 570 575

Asp Leu His Ala Phe Asp Ser Leu Ser Gly Ile Ser Leu Gln Lys Lys
 580 585 590

236

Leu Gln His Val Pro Gly Thr Gln Pro His Leu Asp Gln Ser Ile Val
 595 600 605

Thr Ile Thr Phe Asp Val Pro Gly Asn Ala Lys Glu Glu His Leu Asn
 610 615 620

Met Phe Ile Gln Asn Leu Leu Trp Glu Lys Asn Val Arg Asn Lys Asp
 625 630 635 640

Asn His Cys Met Glu Val Ile Arg Leu Lys Gly Leu Val Ser Ile Lys
 645 650 655

Asp Lys Ser Gln Gln Val Ile Val Gln Gly Val His Glu Leu Tyr Asp
 660 665 670

Leu Glu Glu Thr Pro Val Ser Trp Lys Asp Asp Thr Glu Arg Thr Asn
 675 680 685

Arg Leu Val Leu Ile Gly Arg Asn Leu Asp Lys Asp Ile Leu Lys Gln
 690 695 700

Leu Phe Ile Ala Thr Val Thr Glu Thr Glu Lys Gln Trp Thr Thr His
 705 710 715 720

Phe Lys Glu Asp Gln Val Cys Thr
 725

<210> 189
 <211> 312
 <212> PRT
 <213> Homo sapien

<400> 189

Met Ala Glu Ile Ser Asp Leu Asp Arg Gln Ile Glu Gln Leu Arg Arg
 1 5 10 15

Cys Glu Leu Ile Lys Glu Ser Glu Val Lys Ala Leu Cys Ala Lys Ala
 20 25 30

Arg Glu Ile Leu Val Glu Glu Ser Asn Val Gln Arg Val Asp Ser Pro
 35 40 45

Val Thr Val Cys Gly Asp Ile His Gly Gln Phe Tyr Asp Leu Lys Glu
 50 55 60

Leu Phe Arg Val Gly Gly Asp Val Pro Glu Thr Asn Tyr Leu Phe Met

237

65		70		75		80
Gly Asp Phe Val Asp Arg Gly Phe Tyr Ser Val Glu Thr Phe Leu Leu	85		90		95	
Leu Leu Ala Leu Lys Val Arg Tyr Pro Asp Arg Ile Thr Leu Ile Arg	100		105		110	
Gly Asn His Glu Ser Arg Gln Ile Thr Gln Val Tyr Gly Phe Tyr Asp	115		120		125	
Glu Cys Leu Arg Lys Tyr Gly Ser Val Thr Val Trp Arg Tyr Cys Thr	130		135		140	
Glu Ile Phe Asp Tyr Leu Ser Leu Ser Ala Ile Ile Asp Gly Lys Ile	145		150		155	160
Phe Cys Val His Gly Gly Leu Ser Pro Ser Ile Gln Thr Leu Asp Gln	165		170		175	
Ile Arg Thr Ile Asp Arg Lys Gln Glu Val Pro His Asp Gly Pro Met	180		185		190	
Cys Asp Leu Leu Trp Ser Asp Pro Glu Asp Thr Thr Gly Trp Gly Val	195		200		205	
Ser Pro Arg Gly Ala Gly Tyr Leu Phe Gly Ser Asp Val Val Ala Gln	210		215		220	
Phe Asn Ala Ala Asn Asp Ile Asp Met Ile Cys Arg Ala His Gln Leu	225		230		235	240
Val Met Glu Gly Tyr Lys Trp His Phe Asn Glu Thr Val Leu Thr Val	245		250		255	
Trp Ser Ala Pro Asn Tyr Cys Tyr Arg Cys Gly Asn Val Ala Ala Ile	260		265		270	
Leu Glu Leu Asp Glu His Leu Gln Lys Asp Phe Ile Ile Phe Glu Ala	275		280		285	
Ala Pro Gln Glu Thr Arg Gly Asn Pro Ala Arg Pro Leu Pro Pro Pro	290		295		300	
Thr Leu Leu Ala Leu Ala Pro Leu	305		310			

238

<210> 190
 <211> 182
 <212> PRT
 <213> Homo sapien

<400> 190

Met Gln Pro Leu Leu His Ser His Ser Gly Pro Pro Cys Asp Asn Thr
 1 5 10 15

Gly Cys Pro Ser Val Ser Gly Ser Ala Pro Phe Thr Leu Met Cys Cys
 20 25 30

Leu Asp Gly Asp Cys Met Ile Thr Val Ile Met Arg Gly Pro Gln Ala
 35 40 45

Leu Gly Val Leu Ser Pro Leu Glu Leu Ile Cys Pro Tyr Ile Cys Cys
 50 55 60

Pro Gly Pro Arg His Pro Thr Asp His Ile Gln Ala Pro Cys Ser Gly
 65 70 75 80

Pro Thr Gly Leu Trp Trp Thr Trp Gly Gly Ala Arg Leu Leu Thr Leu
 85 90 95

Lys Gly Gln Arg Trp Gln Pro Glu Lys Pro Glu Asp Ile Pro Leu His
 100 105 110

Pro Ser Leu Ser Ala Ser Asp Thr Thr Gly Trp Gly Val Ser Pro Arg
 115 120 125

Gly Ala Gly Tyr Leu Phe Gly Ser Asp Val Val Ala Gln Phe Asn Ala
 130 135 140

Ala Asn Asp Ile Asp Met Ile Cys Arg Ala His Gln Leu Val Met Glu
 145 150 155 160

Gly Tyr Lys Trp His Phe Asn Glu Thr Val Leu Thr Val Trp Ser Ala
 165 170 175

Pro Asn Tyr Cys Tyr Arg
 180

<210> 191
 <211> 293
 <212> PRT
 <213> Homo sapien

239

<400> 191

Val Pro Ser Gln Ala Leu Gly Ser Gly Ser Arg Arg His Arg Cys Pro
 1 5 10 15

Gly Arg Arg Ala Ser Cys Leu Pro Pro Arg Pro Pro Arg Cys Trp Pro
 20 25 30

Pro Gly Arg Val Ala Ala Met Leu Leu Pro Trp Ala Thr Ser Ala Pro
 35 40 45

Gly Leu Ala Trp Gly Pro Leu Val Leu Gly Leu Phe Gly Leu Leu Ala
 50 55 60

Ala Ser Gln Pro Gln Ala Val Pro Pro Tyr Ala Ser Glu Asn Gln Thr
 65 70 75 80

Cys Arg Asp Gln Glu Lys Glu Tyr Tyr Glu Pro Gln His Arg Ile Cys
 85 90 95

Cys Ser Arg Cys Pro Pro Gly Thr Tyr Val Ser Ala Lys Cys Ser Arg
 100 105 110

Ile Arg Asp Thr Val Cys Ala Thr Cys Ala Glu Asn Ser Tyr Asn Glu
 115 120 125

His Trp Asn Tyr Leu Thr Ile Cys Gln Leu Cys Arg Pro Cys Asp Pro
 130 135 140

Val Met Gly Leu Glu Glu Ile Ala Pro Cys Thr Ser Lys Arg Lys Thr
 145 150 155 160

Gln Cys Arg Cys Gln Pro Gly Met Phe Cys Ala Ala Trp Ala Leu Glu
 165 170 175

Cys Thr His Cys Glu Leu Leu Ser Asp Cys Pro Pro Gly Thr Glu Ala
 180 185 190

Glu Leu Lys Asp Glu Val Gly Lys Gly Asn Asn His Cys Val Pro Cys
 195 200 205

Lys Ala Gly His Phe Gln Asn Thr Ser Ser Pro Ser Ala Arg Cys Gln
 210 215 220

Pro His Thr Arg Cys Glu Asn Gln Gly Leu Val Glu Ala Ala Pro Gly
 225 230 235 240

240

Thr Ala Gln Ser Asp Thr Thr Cys Lys Asn Pro Leu Glu Pro Leu Pro
 245 250 255

Pro Glu Met Ser Glu Pro Ala Leu Ser Lys Gly Val Glu Asn Leu Gln
 260 265 270

Ala Leu Leu Tyr Gln Ala Ala Thr Gly Ser Ser Glu Ala Ser Phe Pro
 275 280 285

Thr Leu Ser Pro Leu
 290

<210> 192
 <211> 635
 <212> PRT
 <213> Homo sapien

<400> 192

Met Leu Leu Pro Trp Ala Thr Ser Ala Pro Gly Leu Ala Trp Gly Pro
 1 5 10 15

Leu Val Leu Gly Leu Phe Gly Leu Leu Ala Ala Ser Gln Pro Gln Ala
 20 25 30

Val Pro Pro Tyr Ala Ser Glu Asn Gln Thr Cys Arg Asp Gln Glu Lys
 35 40 45

Glu Tyr Tyr Glu Pro Gln His Arg Ile Cys Cys Ser Arg Cys Pro Pro
 50 55 60

Gly Thr Tyr Val Ser Ala Lys Cys Ser Arg Ile Arg Asp Thr Val Cys
 65 70 75 80

Ala Thr Cys Ala Glu Asn Ser Tyr Asn Glu His Trp Asn Tyr Leu Thr
 85 90 95

Ile Cys Gln Leu Cys Arg Pro Cys Asp Pro Val Met Gly Leu Glu Glu
 100 105 110

Ile Ala Pro Cys Thr Ser Lys Arg Lys Thr Gln Cys Arg Cys Gln Pro
 115 120 125

Gly Met Phe Cys Ala Ala Trp Ala Leu Glu Cys Thr His Cys Glu Leu
 130 135 140

241

Leu Ser Asp Cys Pro Pro Gly Thr Glu Ala Glu Leu Lys Asp Glu Val
 145 150 155 160

Gly Lys Gly Asn Asn His Cys Val Pro Cys Lys Ala Gly His Phe Gln
 165 170 175

Asn Thr Ser Ser Pro Ser Ala Arg Cys Gln Pro His Thr Arg Cys Glu
 180 185 190

Asn Gln Gly Leu Val Glu Ala Ala Pro Gly Thr Ala Gln Ser Asp Thr
 195 200 205

Thr Cys Lys Asn Pro Leu Glu Pro Leu Pro Pro Glu Met Ser Glu Pro
 210 215 220

Ala Leu Ser Lys Gly Val Glu Asn Leu Gln Ala Leu Leu Tyr Gln Ala
 225 230 235 240

Ala Thr Gly Ser Ser Glu Ala Ser Phe Pro Thr Leu Ser Pro Leu Tyr
 245 250 255

Thr Pro Pro Gln Val Gln Val Gln Gln Gly Asn Pro Glu Leu Leu Tyr
 260 265 270

Ser Ser Pro Ser Val Gln Trp Leu Arg Pro Gln Lys Cys Gly Ser Ser
 275 280 285

Leu Cys Leu Phe Thr Thr Pro Ser Pro Thr Leu Pro Tyr Cys Leu Pro
 290 295 300

Ile Pro Leu Pro Asp Leu Glu Asn Gln Leu Pro Lys Leu Pro Ser Cys
 305 310 315 320

Thr His Lys Pro Ala Gln Ser Trp Ser Leu Ser Arg Arg Ala Pro Thr
 325 330 335

Pro Pro Pro Asn Met Pro Ile His Asp Thr Val Ser Pro Gly Cys Gln
 340 345 350

Glu Val Leu Lys Ser Asn Leu Val Pro Leu Leu Tyr Asn Pro Arg Glu
 355 360 365

Val Ser Leu Ile Leu Pro Leu Gly Ala Ala Leu Cys Leu Glu Gly Lys
 370 375 380

Lys Leu Leu Pro Phe Leu Cys Leu Gly Cys Pro Gly Ile Trp Lys Ala

242															
385	390										395			400	
Leu	Pro	Ser	Pro	Pro	Pro	Ser	Ala	Leu	Leu	Gly	Ala	Val	Ile	Thr	Leu
				405					410					415	
Leu	Ser	Ala	Val	Leu	Ala	Gly	Thr	Met	Leu	Met	Leu	Ala	Val	Leu	Leu
			420					425					430		
Pro	Leu	Ala	Phe	Phe	Leu	Leu	Leu	Ala	Thr	Val	Phe	Ser	Cys	Ile	Trp
		435					440					445			
Lys	Ser	His	Pro	Ser	Leu	Cys	Arg	Lys	Leu	Gly	Ser	Leu	Leu	Lys	Arg
	450					455					460				
Arg	Pro	Gln	Gly	Glu	Gly	Pro	Asn	Pro	Val	Ala	Gly	Ser	Trp	Glu	Pro
465					470					475					480
Pro	Lys	Ala	His	Pro	Tyr	Phe	Pro	Asp	Leu	Val	Gln	Pro	Leu	Leu	Pro
				485					490					495	
Ile	Ser	Gly	Asp	Val	Ser	Pro	Val	Ser	Thr	Gly	Leu	Pro	Ala	Ala	Pro
			500					505					510		
Val	Leu	Glu	Ala	Gly	Val	Pro	Gln	Gln	Gln	Ser	Pro	Leu	Asp	Leu	Thr
		515					520					525			
Arg	Glu	Pro	Gln	Leu	Glu	Pro	Gly	Glu	Gln	Ser	Gln	Val	Ala	His	Gly
	530					535					540				
Thr	Asn	Gly	Ile	His	Val	Thr	Gly	Gly	Ser	Met	Thr	Ile	Thr	Gly	Asn
545					550					555					560
Ile	Tyr	Ile	Tyr	Asn	Gly	Pro	Val	Leu	Gly	Gly	Pro	Pro	Gly	Pro	Gly
				565					570					575	
Asp	Leu	Pro	Ala	Thr	Pro	Glu	Pro	Pro	Tyr	Pro	Ile	Pro	Glu	Glu	Gly
			580					585					590		
Asp	Pro	Gly	Pro	Pro	Gly	Leu	Ser	Thr	Pro	His	Gln	Glu	Asp	Gly	Lys
		595					600					605			
Ala	Trp	His	Leu	Ala	Glu	Thr	Glu	His	Cys	Gly	Ala	Thr	Pro	Ser	Asn
	610					615					620				
Arg	Gly	Pro	Arg	Asn	Gln	Phe	Ile	Thr	His	Asp					
625					630					635					

243

<210> 193
 <211> 166
 <212> PRT
 <213> Homo sapien

<400> 193

Met Leu Leu Pro Trp Ala Thr Ser Ala Pro Gly Leu Ala Trp Gly Pro
 1 5 10 15

Leu Val Leu Gly Leu Phe Gly Leu Leu Ala Ala Ser Gln Pro Gln Ala
 20 25 30

Val Pro Pro Tyr Ala Ser Glu Asn Gln Thr Cys Arg Asp Gln Glu Lys
 35 40 45

Glu Tyr Tyr Glu Pro Gln His Arg Ile Cys Cys Ser Arg Cys Pro Pro
 50 55 60

Gly Thr Tyr Val Ser Ala Lys Cys Ser Arg Ile Arg Asp Thr Val Cys
 65 70 75 80

Ala Thr Cys Ala Glu Asn Ser Tyr Asn Glu His Trp Asn Tyr Leu Thr
 85 90 95

Ile Cys Gln Leu Cys Arg Pro Cys Asp Pro Val Met Gly Leu Glu Glu
 100 105 110

Ile Ala Pro Cys Thr Ser Lys Arg Lys Thr Gln Cys Arg Cys Gln Pro
 115 120 125

Gly Met Phe Cys Ala Ala Trp Ala Leu Glu Cys Thr His Cys Glu Leu
 130 135 140

Leu Ser Asp Cys Pro Pro Gly Thr Glu Ala Glu Leu Lys Gly Gln Arg
 145 150 155 160

Ser Leu Arg Gly Trp Met
 165

<210> 194
 <211> 305
 <212> PRT
 <213> Homo sapien

<400> 194

Gly Leu Lys Glu Thr His Arg Pro Ala Lys Gly Pro Ser Leu Leu Pro

244

1		5						10					15				
Ile	His	Pro	Gly	Trp	Pro	Ala	Phe	Leu	Leu	Pro	Asp	Glu	Val	Gly	Lys		
			20					25					30				
Gly	Asn	Asn	His	Cys	Val	Pro	Cys	Lys	Ala	Gly	His	Phe	Gln	Asn	Thr		
		35					40					45					
Ser	Ser	Pro	Ser	Ala	Arg	Cys	Gln	Pro	His	Thr	Arg	Cys	Glu	Asn	Gln		
	50					55					60						
Gly	Leu	Val	Glu	Ala	Ala	Pro	Gly	Thr	Ala	Gln	Ser	Asp	Thr	Thr	Cys		
65					70					75					80		
Lys	Asn	Pro	Leu	Glu	Pro	Leu	Pro	Pro	Glu	Met	Ser	Gly	Thr	Met	Leu		
				85					90					95			
Met	Leu	Ala	Val	Leu	Leu	Pro	Leu	Ala	Phe	Phe	Leu	Leu	Leu	Ala	Thr		
			100					105						110			
Val	Phe	Ser	Cys	Ile	Trp	Lys	Ser	His	Pro	Ser	Leu	Cys	Arg	Lys	Leu		
		115					120					125					
Gly	Ser	Leu	Leu	Lys	Arg	Arg	Pro	Gln	Gly	Glu	Gly	Pro	Asn	Pro	Val		
	130					135					140						
Ala	Gly	Ser	Trp	Glu	Pro	Pro	Lys	Ala	His	Pro	Tyr	Phe	Pro	Asp	Leu		
145					150					155					160		
Val	Gln	Pro	Leu	Leu	Pro	Ile	Ser	Gly	Asp	Val	Ser	Pro	Val	Ser	Thr		
				165					170					175			
Gly	Leu	Pro	Ala	Ala	Pro	Val	Leu	Glu	Ala	Gly	Val	Pro	Gln	Gln	Gln		
			180					185					190				
Ser	Pro	Leu	Asp	Leu	Thr	Arg	Glu	Pro	Gln	Leu	Glu	Pro	Gly	Glu	Gln		
		195					200					205					
Ser	Gln	Val	Ala	His	Gly	Thr	Asn	Gly	Ile	His	Val	Thr	Gly	Gly	Ser		
	210					215					220						
Met	Thr	Ile	Thr	Gly	Asn	Ile	Tyr	Ile	Tyr	Asn	Gly	Pro	Val	Leu	Gly		
225					230				235						240		
Gly	Pro	Pro	Gly	Pro	Gly	Asp	Leu	Pro	Ala	Thr	Pro	Glu	Pro	Pro	Tyr		
				245					250					255			

245

Pro Ile Pro Glu Glu Gly Asp Pro Gly Pro Pro Gly Leu Ser Thr Pro
 260 265 270

His Gln Glu Asp Gly Lys Ala Trp His Leu Ala Glu Thr Glu His Cys
 275 280 285

Gly Ala Thr Pro Ser Asn Arg Gly Pro Arg Asn Gln Phe Ile Thr His
 290 295 300

Asp
 305

<210> 195
 <211> 194
 <212> PRT
 <213> Homo sapien

<400> 195

Lys Lys Arg Glu Gly Gly Arg Glu Lys Lys Gly Ser Gly Ala Leu Ile
 1 5 10 15

Ile Val Trp Val Ser Ile Ser Phe Leu Gln Gly Glu Gly Pro Asn Pro
 20 25 30

Val Ala Gly Ser Trp Glu Pro Pro Lys Ala His Pro Tyr Phe Pro Asp
 35 40 45

Leu Val Gln Pro Leu Leu Pro Ile Ser Gly Asp Val Ser Pro Val Ser
 50 55 60

Thr Gly Leu Pro Ala Ala Pro Val Leu Glu Ala Gly Val Pro Gln Gln
 65 70 75 80

Gln Ser Pro Leu Asp Leu Thr Arg Glu Pro Gln Leu Glu Pro Gly Glu
 85 90 95

Gln Ser Gln Val Ala His Gly Thr Asn Gly Ile His Val Thr Gly Gly
 100 105 110

Ser Met Thr Ile Thr Gly Asn Ile Tyr Ile Tyr Asn Gly Pro Val Leu
 115 120 125

Gly Gly Pro Pro Gly Pro Gly Asp Leu Pro Ala Thr Pro Glu Pro Pro
 130 135 140

246

Tyr Pro Ile Pro Glu Glu Gly Asp Pro Gly Pro Pro Gly Leu Ser Thr
 145 150 155 160

Pro His Gln Glu Asp Gly Lys Ala Trp His Leu Ala Glu Thr Glu His
 165 170 175

Cys Gly Ala Thr Pro Ser Asn Arg Gly Pro Arg Asn Gln Phe Ile Thr
 180 185 190

His Asp

<210> 196

<211> 241

<212> PRT

<213> Homo sapien

<400> 196

Met Ala Thr Gly Leu Ser Glu His His Asn Met Val Trp Glu Val Lys
 1 5 10 15

Thr Asn Gln Met Pro Asn Ala Val Gln Lys Leu Leu Leu Val Met Asp
 20 25 30

Lys Arg Ala Ser Gly Met Asn Asp Ser Leu Glu Leu Leu Gln Cys Asn
 35 40 45

Glu Asn Leu Pro Ser Ser Pro Gly Tyr Asn Ser Cys Asp Glu His Met
 50 55 60

Glu Leu Asp Asp Leu Pro Glu Leu Gln Ala Val Gln Ser Asp Pro Thr
 65 70 75 80

Gln Ser Gly Met Tyr Gln Leu Ser Ser Asp Val Ser His Gln Glu Tyr
 85 90 95

Pro Arg Ser Ser Trp Asn Gln Asn Thr Ser Asp Ile Pro Glu Thr Thr
 100 105 110

Tyr Arg Glu Asn Glu Val Asp Trp Leu Thr Glu Leu Ala Asn Ile Ala
 115 120 125

Thr Ser Pro Gln Ser Pro Leu Met Gln Cys Ser Phe Tyr Asn Arg Ser
 130 135 140

Ser Pro Val His Ile Ile Ala Thr Ser Lys Ser Leu His Ser Tyr Ala
 145 150 155 160

Arg Pro Pro Pro Val Ser Ser Ser Ser Lys Ser Glu Pro Ala Phe Pro
165 170 175

His His His Trp Lys Glu Glu Thr Pro Val Arg His Glu Arg Ala Asn
180 185 190

Ser Glu Ser Glu Ser Gly Ile Phe Cys Met Ser Ser Leu Ser Asp Asp
195 200 205

Asp Asp Leu Gly Trp Cys Asn Ser Trp Pro Ser Thr Val Trp His Cys
210 215 220

Phe Leu Lys Ala Met Thr Ser His Leu Trp Ile Leu Leu Gln Phe Met
225 230 235 240

<210>	197
<211>	261
<212>	PRT
<213>	Homo sapien

Met Thr Gly Leu Ala Leu Leu Tyr Ser Gly Val Phe Val Ala Phe Trp
1 5 10 15

Ala Cys Ala Leu Ala Val Gly Val Cys Tyr Thr Ile Phe Asp Leu Gly
20 25 30

Phe Arg Phe Asp Val Ala Trp Phe Leu Thr Glu Thr Ser Pro Phe Met
35 40 45

Trp Ser Asn Leu Gly Ile Gly Leu Ala Ile Ser Leu Ser Val Val Gly
50 55 60

Ala Ala Trp Gly Ile Tyr Ile Thr Gly Ser Ser Ile Ile Gly Gly Gly
65 70 75 80

Val Lys Ala Pro Arg Ile Lys Thr Lys Asn Leu Val Ser Ile Ile Phe
85 90 95

Cys Glu Ala Val Ala Ile Tyr Gly Ile Ile Met Ala Ile Val Ile Ser
100 105 110

248

Asn Met Ala Glu Pro Phe Ser Ala Thr Asp Pro Lys Ala Ile Gly His
 115 120 125

Arg Asn Tyr His Ala Gly Tyr Ser Met Phe Gly Ala Gly Leu Thr Val
 130 135 140

Gly Leu Ser Asn Leu Phe Cys Gly Val Cys Val Gly Ile Val Gly Ser
 145 150 155 160

Gly Ala Ala Leu Ala Asp Ala Gln Asn Pro Ser Leu Phe Val Lys Ile
 165 170 175

Leu Ile Val Glu Ile Phe Gly Ser Ala Ile Gly Leu Phe Gly Val Ile
 180 185 190

Val Ala Ile Leu Gln Val Met Asn Pro Leu Gly Lys Pro Leu Cys Pro
 195 200 205

Cys Pro Gln Pro Ser Leu Thr Leu Leu Leu Glu Lys Leu Lys Cys Ser
 210 215 220

Pro Ser Leu Pro Ile Thr Ile Asp Ser Pro Lys Gln Leu Pro Pro Pro
 225 230 235 240

His Phe His Leu Leu Val Phe Ser Tyr Arg Gly Ser Leu Phe Leu Ser
 245 250 255

Leu Ile Trp Cys His
 260

<210> 198

<211> 499

<212> PRT

<213> Homo sapien

<400> 198

Met Ala Pro Ala Arg Thr Met Ala Arg Ala Arg Leu Ala Pro Ala Gly
 1 5 10 15

Ile Pro Ala Val Ala Leu Trp Leu Leu Cys Thr Leu Gly Leu Gln Gly
 20 25 30

Thr Gln Ala Gly Pro Pro Pro Ala Pro Pro Gly Leu Pro Ala Gly Ala
 35 40 45

Asp Cys Leu Asn Ser Phe Thr Ala Gly Val Pro Gly Phe Val Leu Asp
 50 55 60

249

Thr Asn Ala Ser Val Ser Asn Gly Ala Thr Phe Leu Glu Ser Pro Thr
65 70 75 80

Val Arg Arg Gly Trp Asp Cys Val Arg Ala Cys Cys Thr Thr Gln Asn
85 90 95

Cys Asn Leu Ala Leu Val Glu Leu Gln Pro Asp Arg Gly Glu Asp Ala
100 105 110

Ile Ala Ala Cys Phe Leu Ile Asn Cys Leu Tyr Glu Gln Asn Phe Val
115 120 125

Cys Lys Phe Ala Pro Arg Glu Gly Phe Ile Asn Tyr Leu Thr Arg Glu
130 135 140

Val Tyr Arg Ser Tyr Arg Gln Leu Arg Thr Gln Gly Phe Gly Gly Ser
145 150 155 160

Gly Ile Pro Lys Ala Trp Ala Gly Ile Asp Leu Lys Val Gln Pro Gln
165 170 175

Glu Pro Leu Val Leu Lys Asp Val Glu Asn Thr Asp Trp Arg Leu Leu
180 185 190

Arg Gly Asp Thr Asp Val Arg Val Glu Arg Lys Asp Pro Asn Gln Val
195 200 205

Glu Leu Trp Gly Leu Lys Glu Gly Thr Tyr Leu Phe Gln Leu Thr Val
210 215 220

Thr Ser Ser Asp His Pro Glu Asp Thr Ala Asn Val Thr Val Thr Val
225 230 235 240

Leu Ser Thr Lys Gln Thr Glu Asp Tyr Cys Leu Ala Ser Asn Lys Val
245 250 255

Gly Arg Cys Arg Gly Ser Phe Pro Arg Trp Tyr Tyr Asp Pro Thr Glu
260 265 270

Gln Ile Cys Lys Ser Phe Val Tyr Gly Gly Cys Leu Gly Asn Lys Asn
275 280 285

Asn Tyr Leu Arg Glu Glu Glu Cys Ile Leu Ala Cys Arg Gly Val Gln
290 295 300

250

Gly Gly Pro Leu Arg Gly Ser Ser Gly Ala Gln Ala Thr Phe Pro Gln
 305 310 315 320

Gly Pro Ser Met Glu Arg Arg His Pro Val Cys Ser Gly Thr Cys Gln
 325 330 335

Pro Thr Gln Phe Arg Cys Ser Asn Gly Cys Cys Ile Asp Ser Phe Leu
 340 345 350

Glu Cys Asp Asp Thr Pro Asn Cys Pro Asp Ala Ser Asp Glu Ala Ala
 355 360 365

Cys Glu Lys Tyr Thr Ser Gly Phe Asp Glu Leu Gln Arg Ile His Phe
 370 375 380

Pro Ser Asp Lys Gly His Cys Val Asp Leu Pro Asp Thr Gly Leu Cys
 385 390 395 400

Lys Glu Ser Ile Pro Arg Trp Tyr Tyr Asn Pro Phe Ser Glu His Cys
 405 410 415

Ala Arg Phe Thr Tyr Gly Gly Cys Tyr Gly Asn Lys Asn Asn Phe Glu
 420 425 430

Glu Glu Gln Gln Cys Leu Glu Ser Cys Arg Gly Ile Ser Ser Glu Trp
 435 440 445

Ala Ser Glu Arg Val Gly Met Tyr Gly Gly Arg Leu Ser Gln Trp Pro
 450 455 460

Pro Leu Cys Pro Gln Ala Phe Gly Ser His Pro Ser Ile Leu Arg Ala
 465 470 475 480

Pro Gly Val Gly Val Gly Glu Asp Ala Ser Val Arg Ser Gly Ala Leu
 485 490 495

Gly Ser Ser

<210> 199

<211> 344

<212> PRT

<213> Homo sapien

<400> 199

Met Ala Pro Ala Arg Thr Met Ala Arg Ala Arg Leu Ala Pro Ala Gly

251

1		5						10					15				
Ile	Pro	Ala	Val	Ala	Leu	Trp	Leu	Leu	Cys	Thr	Leu	Gly	Leu	Gln	Gly		
			20					25					30				
Thr	Gln	Ala	Gly	Pro	Pro	Pro	Ala	Pro	Pro	Gly	Leu	Pro	Ala	Gly	Ala		
		35					40					45					
Asp	Cys	Leu	Asn	Ser	Phe	Thr	Ala	Gly	Val	Pro	Gly	Phe	Val	Leu	Asp		
	50					55					60						
Thr	Asn	Ala	Ser	Val	Ser	Asn	Gly	Ala	Thr	Phe	Leu	Glu	Ser	Pro	Thr		
65					70					75					80		
Val	Arg	Arg	Gly	Trp	Asp	Cys	Val	Arg	Ala	Cys	Cys	Thr	Thr	Gln	Asn		
				85					90					95			
Cys	Asn	Leu	Ala	Leu	Val	Glu	Leu	Gln	Pro	Asp	Arg	Gly	Glu	Asp	Ala		
			100					105					110				
Ile	Ala	Ala	Cys	Phe	Leu	Ile	Asn	Cys	Leu	Tyr	Glu	Gln	Asn	Phe	Val		
		115					120					125					
Cys	Lys	Phe	Ala	Pro	Arg	Glu	Gly	Phe	Ile	Asn	Tyr	Leu	Thr	Arg	Glu		
	130					135					140						
Val	Tyr	Arg	Ser	Tyr	Arg	Gln	Leu	Arg	Thr	Gln	Gly	Phe	Gly	Gly	Ser		
145					150					155					160		
Gly	Ile	Pro	Lys	Ala	Trp	Ala	Gly	Ile	Asp	Leu	Lys	Val	Gln	Pro	Gln		
				165					170					175			
Glu	Pro	Leu	Val	Leu	Lys	Asp	Val	Glu	Asn	Thr	Asp	Trp	Arg	Leu	Leu		
			180					185					190				
Arg	Gly	Asp	Thr	Asp	Val	Arg	Val	Glu	Arg	Lys	Asp	Pro	Asn	Gln	Val		
		195					200					205					
Glu	Leu	Trp	Gly	Leu	Lys	Glu	Gly	Thr	Tyr	Leu	Phe	Gln	Leu	Thr	Val		
	210					215					220						
Thr	Ser	Ser	Asp	His	Pro	Glu	Asp	Thr	Ala	Asn	Val	Thr	Val	Thr	Val		
225					230					235					240		
Leu	Ser	Thr	Lys	Gln	Thr	Glu	Asp	Tyr	Cys	Leu	Ala	Ser	Asn	Lys	Val		
			245						250					255			

252

Gly Arg Cys Arg Gly Ser Phe Pro Arg Trp Tyr Tyr Asp Pro Thr Glu
 260 265 270

Gln Ile Cys Lys Ser Phe Val Tyr Gly Gly Cys Leu Gly Asn Lys Asn
 275 280 285

Asn Tyr Leu Arg Glu Glu Glu Cys Ile Leu Ala Cys Arg Gly Val Gln
 290 295 300

Gly Gly Pro Leu Arg Gly Ser Ser Gly Ala Gln Ala Thr Phe Pro Gln
 305 310 315 320

Gly Pro Ser Met Glu Arg Arg His Pro Gly Gly Leu Tyr Ser Pro Pro
 325 330 335

His Pro Pro Ser Pro Pro His Leu
 340

<210> 200
 <211> 479
 <212> PRT
 <213> Homo sapien

<400> 200

Arg Asn Gln Gly Glu Lys Ala Ala Glu Pro Gln Leu Ser Glu His Arg
 1 5 10 15

Val Gly Ser Arg Asp Pro Ser Arg Ala Gly Ser Trp Asp Arg Asn Leu
 20 25 30

Gly Gly Pro Gly Pro Thr Gln Leu Thr Cys Ala Gly His Gln His Pro
 35 40 45

Arg Asn Pro Glu Ala Arg Ala Leu Lys Val Thr Pro Leu Gly Arg Lys
 50 55 60

Ala Met Ala Pro Ala Arg Thr Met Ala Arg Ala Arg Leu Ala Pro Ala
 65 70 75 80

Gly Ile Pro Ala Val Ala Leu Trp Leu Leu Cys Thr Leu Gly Leu Gln
 85 90 95

Gly Thr Gln Ala Gly Pro Pro Pro Ala Pro Pro Gly Leu Pro Ala Gly
 100 105 110

253

Ala Asp Cys Leu Asn Ser Phe Thr Ala Gly Val Pro Gly Phe Val Leu
 115 120 125

Asp Thr Asn Ala Ser Val Ser Asn Gly Ala Thr Phe Leu Glu Ser Pro
 130 135 140

Thr Val Arg Arg Gly Trp Asp Cys Val Arg Ala Cys Cys Thr Thr Gln
 145 150 155 160

Asn Cys Asn Leu Ala Leu Val Glu Leu Gln Pro Asp Arg Gly Glu Asp
 165 170 175

Ala Ile Ala Ala Cys Phe Leu Ile Asn Cys Leu Tyr Glu Gln Asn Phe
 180 185 190

Val Cys Lys Phe Ala Pro Arg Glu Gly Phe Ile Asn Tyr Leu Thr Arg
 195 200 205

Glu Val Tyr Arg Ser Tyr Arg Gln Leu Arg Thr Gln Gly Phe Gly Gly
 210 215 220

Ser Gly Ile Pro Lys Ala Trp Ala Gly Ile Asp Leu Lys Val Gln Pro
 225 230 235 240

Gln Glu Pro Leu Val Leu Lys Asp Val Glu Asn Thr Asp Trp Arg Leu
 245 250 255

Leu Arg Gly Asp Thr Asp Val Arg Val Glu Arg Lys Asp Pro Asn Gln
 260 265 270

Val Glu Leu Trp Gly Leu Lys Glu Gly Thr Tyr Leu Phe Gln Leu Thr
 275 280 285

Val Thr Ser Ser Asp His Pro Glu Asp Thr Ala Asn Val Thr Val Thr
 290 295 300

Val Leu Ser Thr Lys Gln Thr Glu Asp Tyr Cys Leu Ala Ser Asn Lys
 305 310 315 320

Val Gly Arg Cys Arg Gly Ser Phe Pro Arg Trp Tyr Tyr Asp Pro Thr
 325 330 335

Glu Gln Ile Cys Lys Ser Phe Val Tyr Gly Gly Cys Leu Gly Asn Lys
 340 345 350

Asn Asn Tyr Leu Arg Glu Glu Glu Cys Ile Leu Ala Cys Arg Gly Val

254

355

360

365

Gln Gly Gly Pro Leu Arg Gly Ser Ser Gly Ala Gln Ala Thr Phe Pro
 370 375 380

Gln Gly Pro Ser Met Glu Arg Arg His Pro Val Cys Ser Gly Thr Cys
 385 390 395 400

Gln Pro Thr Gln Phe Arg Cys Ser Asn Gly Cys Cys Ile Asp Ser Phe
 405 410 415

Leu Glu Cys Asp Asp Thr Pro Asn Cys Pro Asp Ala Ser Asp Glu Ala
 420 425 430

Ala Cys Glu Lys Tyr Thr Ser Gly Phe Asp Glu Leu Gln Arg Ile His
 435 440 445

Phe Pro Ser Asp Lys Gly Glu Ile Leu Pro Arg Cys Pro Gly Ser Gly
 450 455 460

Gln Thr Leu Thr Leu Pro Ser Ser Leu Phe Pro Ser Ser Ser Ala
 465 470 475

<210> 201
 <211> 121
 <212> PRT
 <213> Homo sapien

<400> 201

Met Val Arg Ile Leu Ala Asn Gly Glu Ile Val Gln Asp Asp Asp Pro
 1 5 10 15

Arg Val Arg Thr Thr Thr Gln Pro Pro Arg Gly Ser Ile Pro Arg Gln
 20 25 30

Ser Phe Phe Asn Arg Gly His Gly Ala Pro Pro Gly Gly Pro Gly Pro
 35 40 45

Arg Gln Gln Gln Ala Gly Ala Arg Leu Gly Ala Ala Gln Ser Pro Phe
 50 55 60

Asn Asp Leu Asn Arg Gln Leu Val Asn Met Gly Phe Pro Gln Trp His
 65 70 75 80

Leu Gly Asn His Ala Val Glu Pro Val Thr Ser Ile Leu Leu Leu Phe
 85 90 95

255

Leu Leu Met Met Leu Gly Val Arg Gly Leu Leu Leu Val Gly Leu Val
 100 105 110

Tyr Leu Val Ser His Leu Ser Gln Arg
 115 120

<210> 202
 <211> 149
 <212> PRT
 <213> Homo sapien

<400> 202

Glu Gln Ala Tyr Leu Glu Gly Ile Trp Trp Cys Leu Glu Gly Met Ile
 1 5 10 15

Arg Glu Gly Thr Thr Gly Val Cys Phe Pro Phe Val Leu Ser Val Arg
 20 25 30

Gln Arg Glu Thr Leu Val Gln His Phe Gln Ser Val Gly Gly Ser Val
 35 40 45

Gly Ser Arg Asp Thr Phe Arg Trp Tyr Gly Ala Cys Ile Lys Trp His
 50 55 60

Lys Ile Arg Ala Arg Lys Arg Cys Pro Ser Gln Phe Ser Gln Ser Phe
 65 70 75 80

Tyr Ala Glu Lys Ile Ser Ala Gly Cys Gln His Val Pro Met Pro Val
 85 90 95

Glu Asp Met Pro Thr Ser Pro Leu Pro Arg Glu Gln Asp Leu Gly Leu
 100 105 110

Gly Gln Val Glu Lys Ile Pro Asp Phe Phe Ser Thr Val Phe Val Leu
 115 120 125

Met Val Tyr Phe Tyr Trp Leu Leu Tyr Cys Leu Gly Gln Val Val Val
 130 135 140

Ala Phe Tyr Leu Leu
 145

<210> 203
 <211> 121
 <212> PRT
 <213> Homo sapien

256

<400> 203

Met Val Arg Ile Leu Ala Asn Gly Glu Ile Val Gln Asp Asp Asp Pro
 1 5 10 15

Arg Val Arg Thr Thr Thr Gln Pro Pro Arg Gly Ser Ile Pro Arg Gln
 20 25 30

Ser Phe Phe Asn Arg Gly His Gly Ala Pro Pro Gly Gly Pro Gly Pro
 35 40 45

Arg Gln Gln Gln Ala Gly Ala Arg Leu Gly Ala Ala Gln Ser Pro Phe
 50 55 60

Asn Asp Leu Asn Arg Gln Leu Val Asn Met Gly Phe Pro Gln Trp His
 65 70 75 80

Leu Gly Asn His Ala Val Glu Pro Val Thr Ser Ile Leu Leu Leu Phe
 85 90 95

Leu Leu Met Met Leu Gly Val Arg Gly Leu Leu Leu Val Gly Leu Val
 100 105 110

Tyr Leu Val Ser His Leu Ser Gln Arg
 115 120

<210> 204

<211> 149

<212> PRT

<213> Homo sapien

<400> 204

Glu Gln Ala Tyr Leu Glu Gly Ile Trp Trp Cys Leu Glu Gly Met Ile
 1 5 10 15

Arg Glu Gly Thr Thr Gly Val Cys Phe Pro Phe Val Leu Ser Val Arg
 20 25 30

Gln Arg Glu Thr Leu Val Gln His Phe Gln Ser Val Gly Gly Ser Val
 35 40 45

Gly Ser Arg Asp Thr Phe Arg Trp Tyr Gly Ala Cys Ile Lys Trp His
 50 55 60

Lys Ile Arg Ala Arg Lys Arg Cys Pro Ser Gln Phe Ser Gln Ser Phe
 65 70 75 80

<400> 206

258

Trp Ile Ala Arg Ala Gly Thr Gln Leu Gln Asn Phe Thr Leu Asp Arg
 1 5 10 15

Ser Ser Val Leu Val Asp Gly Tyr Ser Pro Asn Arg Asn Glu Pro Leu
 20 25 30

Thr Gly Asn Ser Asp Leu Pro Phe Trp Ala Val Ile Leu Ile Gly Leu
 35 40 45

Ala Gly Leu Leu Gly Leu Ile Thr Cys Leu Ile Cys Gly Val Leu Val
 50 55 60

Thr Thr Arg Arg Arg Lys Lys Glu Gly Glu Tyr Asn Val Gln Gln Gln
 65 70 75 80

Cys Pro Gly Tyr Tyr Gln Ser His Leu Asp Leu Glu Asp Leu Gln
 85 90 95

<210> 207

<211> 109

<212> PRT

<213> Homo sapien

<400> 207

Met His Ala Arg Ala Ala Gln Cys Asp Gly Ser Val Val Ala Ala Asp
 1 5 10 15

Pro Gly Asp Gly Thr Gln Leu Gln Asn Phe Thr Leu Asp Arg Ser Ser
 20 25 30

Val Leu Val Asp Gly Tyr Ser Pro Asn Arg Asn Glu Pro Leu Thr Gly
 35 40 45

Asn Ser Asp Leu Pro Phe Trp Ala Val Ile Leu Ile Gly Leu Ala Gly
 50 55 60

Leu Leu Gly Leu Ile Thr Cys Leu Ile Cys Gly Val Leu Val Thr Thr
 65 70 75 80

Arg Arg Arg Lys Lys Glu Gly Glu Tyr Asn Val Gln Gln Gln Cys Pro
 85 90 95

Gly Tyr Tyr Gln Ser His Leu Asp Leu Glu Asp Leu Gln
 100 105

<210> 208

259

<211> 1485

<212> PRT

<213> Homo sapien

<400> 208

Met Gln His Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu
 1 5 10 15

Gln Gly Leu Leu Lys Pro Leu Phe Lys Ser Thr Ser Val Gly Pro Leu
 20 25 30

Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro Glu Lys His Gly Ala
 35 40 45

Ala Thr Gly Val Asp Ala Ile Cys Thr Leu Arg Leu Asp Pro Thr Gly
 50 55 60

Pro Gly Leu Asp Arg Glu Arg Leu Tyr Trp Glu Leu Ser Gln Leu Thr
 65 70 75 80

Asn Ser Val Thr Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asp Ser Leu
 85 90 95

Tyr Val Asn Gly Phe Thr His Arg Ser Ser Val Pro Thr Thr Ser Ile
 100 105 110

Pro Gly Thr Ser Ala Val His Leu Glu Thr Ser Gly Thr Pro Ala Ser
 115 120 125

Leu Pro Gly His Thr Ala Pro Gly Pro Leu Leu Val Pro Phe Thr Leu
 130 135 140

Asn Phe Thr Ile Thr Asn Leu Gln Tyr Glu Glu Asp Met Arg His Pro
 145 150 155 160

Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu
 165 170 175

Lys Pro Leu Phe Lys Ser Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys
 180 185 190

Arg Leu Thr Leu Leu Arg Pro Glu Lys Arg Gly Ala Ala Thr Gly Val
 195 200 205

Asp Thr Ile Cys Thr His Arg Leu Asp Pro Leu Asn Pro Gly Leu Asp
 210 215 220

260

Arg Glu Gln Leu Tyr Trp Glu Leu Ser Lys Leu Thr Arg Gly Ile Ile
 225 230 235 240

Glu Leu Gly Pro Tyr Leu Leu Asp Arg Gly Ser Leu Tyr Val Asn Gly
 245 250 255

Phe Thr His Arg Asn Phe Val Pro Ile Thr Ser Thr Pro Gly Thr Ser
 260 265 270

Thr Val His Leu Gly Thr Ser Glu Thr Pro Ser Ser Leu Pro Arg Pro
 275 280 285

Ile Val Pro Gly Pro Leu Leu Val Pro Phe Thr Leu Asn Phe Thr Ile
 290 295 300

Thr Asn Leu Gln Tyr Glu Glu Ala Met Arg His Pro Gly Ser Arg Lys
 305 310 315 320

Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu Arg Pro Leu Phe
 325 330 335

Lys Asn Thr Ser Ile Gly Pro Leu Tyr Ser Ser Cys Arg Leu Thr Leu
 340 345 350

Leu Arg Pro Glu Lys Asp Lys Ala Ala Thr Arg Val Asp Ala Ile Cys
 355 360 365

Thr His His Pro Asp Pro Gln Ser Pro Gly Leu Asn Arg Glu Gln Leu
 370 375 380

Tyr Trp Glu Leu Ser Gln Leu Thr His Gly Ile Thr Glu Leu Gly Pro
 385 390 395 400

Tyr Thr Leu Asp Arg Asp Ser Leu Tyr Val Asp Gly Phe Thr His Trp
 405 410 415

Ser Pro Ile Pro Thr Thr Ser Thr Pro Gly Thr Ser Ile Val Asn Leu
 420 425 430

Gly Thr Ser Gly Ile Pro Pro Ser Leu Pro Glu Thr Thr Ala Thr Gly
 435 440 445

Pro Leu Leu Val Pro Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Gln
 450 455 460

261

Tyr Glu Glu Asn Met Gly His Pro Gly Ser Arg Lys Phe Asn Ile Thr
 465 470 475 480

Glu Ser Val Leu Gln Gly Leu Leu Lys Pro Leu Phe Lys Ser Thr Ser
 485 490 495

Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro Glu
 500 505 510

Lys Asp Gly Val Ala Thr Arg Val Asp Ala Ile Cys Thr His Arg Pro
 515 520 525

Asp Pro Lys Ile Pro Gly Leu Asp Arg Gln Gln Leu Tyr Trp Glu Leu
 530 535 540

Ser Gln Leu Thr His Ser Ile Thr Glu Leu Gly Pro Tyr Thr Leu Asp
 545 550 555 560

Arg Asp Ser Leu Tyr Val Asn Gly Phe Thr Gln Arg Ser Ser Val Pro
 565 570 575

Thr Thr Ser Thr Pro Gly Thr Phe Thr Val Gln Pro Glu Thr Ser Glu
 580 585 590

Thr Pro Ser Ser Leu Pro Gly Pro Thr Ala Thr Gly Pro Val Leu Leu
 595 600 605

Pro Phe Thr Leu Asn Phe Thr Ile Ile Asn Leu Gln Tyr Glu Glu Asp
 610 615 620

Met His Arg Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu
 625 630 635 640

Gln Gly Leu Leu Met Pro Leu Phe Lys Asn Thr Ser Val Ser Ser Leu
 645 650 655

Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro Glu Lys Asp Gly Ala
 660 665 670

Ala Thr Arg Val Asp Ala Val Cys Thr His Arg Pro Asp Pro Lys Ser
 675 680 685

Pro Gly Leu Asp Arg Glu Arg Leu Tyr Trp Lys Leu Ser Gln Leu Thr
 690 695 700

His Gly Ile Thr Glu Leu Gly Pro Tyr Thr Leu Asp Arg His Ser Leu

262

705					710						715				720
Tyr	Val	Asn	Gly	Phe	Thr	His	Gln	Ser	Ser	Met	Thr	Thr	Thr	Arg	Thr
				725					730					735	
Pro	Asp	Thr	Ser	Thr	Met	His	Leu	Ala	Thr	Ser	Arg	Thr	Pro	Ala	Ser
			740					745					750		
Leu	Ser	Gly	Pro	Thr	Thr	Ala	Ser	Pro	Leu	Leu	Val	Leu	Phe	Thr	Ile
		755					760					765			
Asn	Phe	Thr	Ile	Thr	Asn	Leu	Arg	Tyr	Glu	Glu	Asn	Met	His	His	Pro
	770					775					780				
Gly	Ser	Arg	Lys	Phe	Asn	Thr	Thr	Glu	Arg	Val	Leu	Gln	Gly	Leu	Leu
785					790					795					800
Arg	Pro	Val	Phe	Lys	Asn	Thr	Ser	Val	Gly	Pro	Leu	Tyr	Ser	Gly	Cys
				805					810					815	
Arg	Leu	Thr	Leu	Leu	Arg	Pro	Lys	Lys	Asp	Gly	Ala	Ala	Thr	Lys	Val
			820					825					830		
Asp	Ala	Ile	Cys	Thr	Tyr	Arg	Pro	Asp	Pro	Lys	Ser	Pro	Gly	Leu	Asp
		835					840					845			
Arg	Glu	Gln	Leu	Tyr	Trp	Glu	Leu	Ser	Gln	Leu	Thr	His	Ser	Ile	Thr
	850					855					860				
Glu	Leu	Gly	Pro	Tyr	Thr	Leu	Asp	Arg	Asp	Ser	Leu	Tyr	Val	Asn	Gly
865					870					875					880
Phe	Thr	Gln	Arg	Ser	Ser	Val	Pro	Thr	Thr	Ser	Ile	Pro	Gly	Thr	Pro
				885					890					895	
Thr	Val	Asp	Leu	Gly	Thr	Ser	Gly	Thr	Pro	Val	Ser	Lys	Pro	Gly	Pro
			900					905					910		
Ser	Ala	Ala	Ser	Pro	Leu	Leu	Val	Leu	Phe	Thr	Leu	Asn	Phe	Thr	Ile
		915					920					925			
Thr	Asn	Leu	Arg	Tyr	Glu	Glu	Asn	Met	Gln	His	Pro	Gly	Ser	Arg	Lys
	930					935					940				
Phe	Asn	Thr	Thr	Glu	Arg	Val	Leu	Gln	Gly	Leu	Leu	Arg	Ser	Leu	Phe
945					950					955					960

264

Val	Asn	Gly	Phe	Thr	His	Arg	Ser	Ser	Val	Pro	Thr	Thr	Ser	Thr
1190						1195					1200			
Gly	Val	Val	Ser	Glu	Glu	Pro	Phe	Thr	Leu	Asn	Phe	Thr	Ile	Asn
1205						1210					1215			
Asn	Leu	Arg	Tyr	Met	Ala	Asp	Met	Gly	Gln	Pro	Gly	Ser	Leu	Lys
1220						1225					1230			
Phe	Asn	Ile	Thr	Asp	Asn	Val	Met	Lys	His	Leu	Leu	Ser	Pro	Leu
1235						1240					1245			
Phe	Gln	Arg	Ser	Ser	Leu	Gly	Ala	Arg	Tyr	Thr	Gly	Cys	Arg	Val
1250						1255					1260			
Ile	Ala	Leu	Arg	Ser	Val	Lys	Asn	Gly	Ala	Glu	Thr	Arg	Val	Asp
1265						1270					1275			
Leu	Leu	Cys	Thr	Tyr	Leu	Gln	Pro	Leu	Ser	Gly	Pro	Gly	Leu	Pro
1280						1285					1290			
Ile	Lys	Gln	Val	Phe	His	Glu	Leu	Ser	Gln	Gln	Thr	His	Gly	Ile
1295						1300					1305			
Thr	Arg	Leu	Gly	Pro	Tyr	Ser	Leu	Asp	Lys	Asp	Ser	Leu	Tyr	Leu
1310						1315					1320			
Asn	Gly	Tyr	Asn	Glu	Pro	Gly	Pro	Asp	Glu	Pro	Pro	Thr	Thr	Pro
1325						1330					1335			
Lys	Pro	Ala	Thr	Thr	Phe	Leu	Pro	Pro	Leu	Ser	Glu	Ala	Thr	Thr
1340						1345					1350			
Ala	Met	Gly	Tyr	His	Leu	Lys	Thr	Leu	Thr	Leu	Asn	Phe	Thr	Ile
1355						1360					1365			
Ser	Asn	Leu	Gln	Tyr	Ser	Pro	Asp	Met	Gly	Lys	Gly	Ser	Ala	Thr
1370						1375					1380			
Phe	Asn	Ser	Thr	Glu	Gly	Val	Leu	Gln	His	Leu	Leu	Arg	Pro	Leu
1385						1390					1395			
Phe	Gln	Lys	Ser	Ser	Met	Gly	Pro	Phe	Tyr	Leu	Gly	Cys	Gln	Leu
1400						1405					1410			

265

Ile Ser Leu Arg Pro Glu Lys Asp Gly Ala Ala Thr Gly Val Asp
 1415 1420 1425

Thr Thr Cys Thr Tyr His Pro Asp Pro Val Gly Pro Gly Leu Asp
 1430 1435 1440

Ile Gln Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Gly Val
 1445 1450 1455

Thr Gln Leu Gly Phe Tyr Val Leu Asp Arg Asp Ser Leu Phe Ile
 1460 1465 1470

Asn Gly His His Thr Leu Gln Arg Gln Ser Thr Thr
 1475 1480 1485

<210> 209
 <211> 111
 <212> PRT
 <213> Homo sapien
 <220>
 <221> MISC_FEATURE
 <222> (11)..(12)
 <223> X=any amino acid

<400> 209

Lys Lys Arg Lys Glu Arg Lys Arg Glu Asn Xaa Xaa Thr Ile Gly Thr
 1 5 10 15

Gly Ser Leu Met His Ala Arg Ala Ala Gln Cys Asp Gly Ser Pro Gly
 20 25 30

Arg Cys Val Leu Val Asp Gly Tyr Ser Pro Asn Arg Asn Glu Pro Leu
 35 40 45

Thr Gly Asn Ser Asp Leu Pro Phe Trp Ala Val Ile Leu Ile Gly Leu
 50 55 60

Ala Gly Leu Leu Gly Leu Ile Thr Cys Leu Ile Cys Gly Val Leu Val
 65 70 75 80

Thr Thr Arg Arg Arg Lys Lys Glu Gly Glu Tyr Asn Val Gln Gln Gln
 85 90 95

Cys Pro Gly Tyr Tyr Gln Ser His Leu Asp Leu Glu Asp Leu Gln
 100 105 110

266

<210> 210
 <211> 87
 <212> PRT
 <213> Homo sapien

<400> 210

Met Arg Gly Arg Gly Arg Pro Gly Arg Cys Val Leu Val Asp Gly Tyr
 1 5 10 15

Ser Pro Asn Arg Asn Glu Pro Leu Thr Gly Asn Ser Asp Leu Pro Phe
 20 25 30

Trp Ala Val Ile Leu Ile Gly Leu Ala Gly Leu Leu Gly Leu Ile Thr
 35 40 45

Cys Leu Ile Cys Gly Val Leu Val Thr Thr Arg Arg Arg Lys Lys Glu
 50 55 60

Gly Glu Tyr Asn Val Gln Gln Gln Cys Pro Gly Tyr Tyr Gln Ser His
 65 70 75 80

Leu Asp Leu Glu Asp Leu Gln
 85

<210> 211
 <211> 92
 <212> PRT
 <213> Homo sapien

<400> 211

Pro Ser Leu Leu Gly Cys His Pro His Arg Leu Gly Arg Thr Pro Gly
 1 5 10 15

Thr His His Met Pro Asp Leu Arg Cys Pro Gly Asp His Pro Pro Ala
 20 25 30

Glu Glu Gly Arg Arg Ile Gln Arg Pro Ala Thr Val Pro Arg Leu Leu
 35 40 45

Pro Val Thr Pro Arg Pro Gly Gly Ser Ala Met Thr Gly Thr Cys Arg
 50 55 60

Cys Leu Gly Cys Leu Ser Pro Ser Gln Gly Pro Lys Lys Leu Gly Trp
 65 70 75 80

Gly Arg Asn Lys Pro Tyr Trp Ser Val Lys Lys Leu
 85 90

267

<210> 212
 <211> 83
 <212> PRT
 <213> Homo sapien

<400> 212

Met His Pro Pro Gly Phe Leu Ser Phe Leu Gly Tyr Ser Pro Asn Arg
 1 5 10 15

Asn Glu Pro Leu Thr Gly Asn Ser Asp Leu Pro Phe Trp Ala Val Ile
 20 25 30

Leu Ile Gly Leu Ala Gly Leu Leu Gly Leu Ile Thr Cys Leu Ile Cys
 35 40 45

Gly Val Leu Val Thr Thr Arg Arg Arg Lys Lys Glu Gly Glu Tyr Asn
 50 55 60

Val Gln Gln Gln Cys Pro Gly Tyr Tyr Gln Ser His Leu Asp Leu Glu
 65 70 75 80

Asp Leu Gln

<210> 213
 <211> 225
 <212> PRT
 <213> Homo sapien

<400> 213

Met Ala Thr His His Thr Leu Trp Met Gly Leu Ala Leu Leu Gly Val
 1 5 10 15

Leu Gly Asp Leu Gln Ala Ala Pro Glu Ala Gln Val Ser Val Gln Pro
 20 25 30

Asn Phe Gln Gln Asp Lys Phe Leu Gly Arg Trp Phe Ser Ala Gly Leu
 35 40 45

Ala Ser Asn Ser Ser Trp Leu Arg Glu Lys Lys Ala Ala Leu Ser Met
 50 55 60

Cys Lys Ser Val Val Ala Pro Ala Thr Asp Gly Gly Leu Asn Leu Thr
 65 70 75 80

Ser Thr Phe Leu Arg Lys Asn Gln Cys Glu Thr Arg Thr Met Leu Leu
 85 90 95

268

Gln Pro Ala Gly Ser Leu Gly Ser Tyr Ser Tyr Arg Ser Pro Arg Glu
 100 105 110

Trp Gly Leu His Arg Pro Pro Gly Pro Ser Leu Gly Ala Thr Leu Ala
 115 120 125

Gly Thr Thr Leu Gly Gln Pro Pro Ala Ala Glu Ile His Gly Val Gly
 130 135 140

Gly Asp Trp Gly Ser Thr Tyr Ser Val Ser Val Val Glu Thr Asp Tyr
 145 150 155 160

Asp Gln Tyr Ala Leu Leu Tyr Ser Gln Gly Ser Lys Gly Pro Gly Glu
 165 170 175

Asp Phe Arg Met Ala Thr Leu Tyr Ser Arg Thr Gln Thr Pro Arg Ala
 180 185 190

Glu Leu Lys Glu Lys Phe Thr Ala Phe Cys Lys Ala Gln Gly Phe Thr
 195 200 205

Glu Asp Thr Ile Val Phe Leu Pro Gln Thr Asp Lys Cys Met Thr Glu
 210 215 220

Gln
 225

<210> 214
 <211> 349
 <212> PRT
 <213> Homo sapien

<400> 214

Arg Arg His Ser Ser Arg Ser Ser Cys Ser Gly Pro Pro Arg Pro Gly
 1 5 10 15

His Leu Pro Arg Ser Pro Thr Pro Leu Ala Pro Gly Pro Gly His Pro
 20 25 30

Leu Cys Cys Arg Arg Met Ala Thr His His Thr Leu Trp Met Gly Leu
 35 40 45

Ala Leu Leu Gly Val Leu Gly Asp Leu Gln Ala Ala Pro Glu Ala Gln
 50 55 60

269

Val Ser Val Gln Pro Asn Phe Gln Gln Asp Lys Val Arg Gly Phe Pro
 65 70 75 80

Ala Ser Ser Pro Arg Ala Thr Gly Pro Cys Gln Gly Lys Gly Thr Phe
 85 90 95

Arg Leu Gly Leu Pro Pro Gly Arg Ser Glu Arg Ser Pro Ala Val Pro
 100 105 110

Gly Ser Ala Gly Gln Gly Leu Ser Gly Arg Ala Gly Arg Arg Leu Gly
 115 120 125

Ser Arg Pro Arg Arg Leu Pro Ala Arg Ser Pro Pro Trp Ala Pro Arg
 130 135 140

Pro Val Ser Pro Asp Gly Pro Arg Arg His Arg Ala Thr His Ala Pro
 145 150 155 160

Thr Pro Ala Arg His Val His Pro Cys Gly His Ala Thr Pro Arg Gly
 165 170 175

His Thr Ser Ala Arg Ser Thr Pro Gly Cys Gln Asp Thr Gly Gly Trp
 180 185 190

Gly Thr Gly Met Ala Thr Asn Thr Pro Cys Ala Val Gly Val Gly Arg
 195 200 205

Asp Ala His Arg Thr Asp Ser Arg Arg Arg Ala Leu Ser Pro Gly Ser
 210 215 220

Cys Ser Gly Lys Arg Arg Ser Ala Gly Pro Arg Ala Ala Arg Pro Ser
 225 230 235 240

Leu Ala Ser Arg Arg Thr Pro Ala Val Arg Arg Ala Glu Pro Lys Thr
 245 250 255

Arg Pro Asp Pro Arg Gln Glu Cys Asp Val Leu Cys Arg Pro Leu Tyr
 260 265 270

Gly Pro Gly Ala Gln Pro Gly His Arg Ile Gly Thr Gly Gly Gly Gly
 275 280 285

Ala Glu Ala Gly Trp Trp Ala Ala Cys Glu Val Pro Gly Ala Leu Val
 290 295 300

Gln Arg Gly Pro Arg Leu Gln Leu Glu Leu Ala Pro Gly Glu Glu Gly

270																
305	310										315				320	
Gly	Val	Val	His	Val	Gln	Val	Cys	Gly	Gly	Pro	Cys	His	Gly	Trp	Trp	
			325						330					335		
Pro	Gln	Pro	Asp	Leu	His	Leu	Pro	Gln	Glu	Lys	Pro	Val				
			340					345								
<210>	215															
<211>	413															
<212>	PRT															
<213>	Homo sapien															
<400>	215															
Met	Ala	Thr	His	His	Thr	Leu	Trp	Met	Gly	Leu	Ala	Leu	Leu	Gly	Val	
1				5					10					15		
Leu	Gly	Asp	Leu	Gln	Ala	Ala	Pro	Glu	Ala	Gln	Val	Ser	Val	Gln	Pro	
			20					25					30			
Asn	Phe	Gln	Gln	Asp	Lys	Val	Arg	Gly	Phe	Pro	Ala	Ser	Ser	Pro	Arg	
		35					40					45				
Ala	Thr	Gly	Pro	Cys	Gln	Gly	Lys	Gly	Thr	Phe	Arg	Leu	Gly	Leu	Pro	
	50					55					60					
Pro	Gly	Arg	Ser	Glu	Arg	Ser	Pro	Ala	Val	Pro	Gly	Ser	Ala	Gly	Gln	
65					70					75					80	
Gly	Leu	Ser	Gly	Arg	Ala	Gly	Arg	Arg	Leu	Gly	Ser	Arg	Pro	Arg	Arg	
				85					90					95		
Leu	Pro	Ala	Arg	Ala	Leu	Pro	Gly	His	Arg	Val	Pro	Ser	Pro	Leu	Met	
			100					105					110			
Gly	His	Ala	Asp	Thr	Gly	Pro	His	Thr	Arg	Pro	Arg	Gln	Pro	Asp	Thr	
		115					120					125				
Ser	Thr	Pro	Val	Gly	Thr	Arg	Pro	Pro	Glu	Asp	Thr	Arg	Ala	His	Val	
	130					135					140					
Pro	His	Leu	Gly	Ala	Arg	Thr	Arg	Ala	Gly	Gly	Ala	Gln	Gly	Trp	Arg	
145					150					155					160	
Gln	Thr	Leu	Arg	Ala	Arg	Trp	Gly	Leu	Gly	Gly	Thr	Arg	Thr	Ala	Gln	
				165					170					175		

271

Thr Ala Gly Asp Ala Arg Ser Arg Pro Gly Ala Ala Arg Gly Ser Ala
 180 185 190

Gly Ala Arg Val Pro Ala Pro Arg Ala Pro Pro Trp Arg Arg Gly Glu
 195 200 205

Pro Gln Arg Ser Ala Glu Leu Ser Arg Arg Pro Ala Pro Ile Pro Ala
 210 215 220

Arg Asn Ala Thr Ser Ser Ala Ala Arg Cys Met Gly Gln Ala Leu Ser
 225 230 235 240

Gln Gly Thr Glu Ser Gly Pro Gly Ala Glu Gly Pro Lys Leu Ala Gly
 245 250 255

Gly Arg Arg Ala Arg Phe Leu Gly Arg Trp Phe Ser Ala Gly Leu Ala
 260 265 270

Ser Asn Ser Ser Trp Leu Arg Glu Lys Lys Ala Ala Leu Ser Met Cys
 275 280 285

Lys Ser Val Val Ala Pro Ala Thr Asp Gly Gly Leu Asn Leu Thr Ser
 290 295 300

Thr Phe Leu Arg Lys Asn Gln Cys Glu Thr Arg Thr Met Leu Leu Gln
 305 310 315 320

Pro Ala Gly Ser Leu Gly Ser Tyr Ser Tyr Arg Ser Pro His Trp Gly
 325 330 335

Ser Thr Tyr Ser Val Ser Val Val Glu Thr Asp Tyr Asp Gln Tyr Ala
 340 345 350

Leu Leu Tyr Ser Gln Gly Ser Lys Gly Pro Gly Glu Asp Phe Arg Met
 355 360 365

Ala Thr Leu Tyr Ser Arg Thr Gln Thr Pro Arg Ala Glu Leu Lys Glu
 370 375 380

Lys Phe Thr Ala Phe Cys Lys Ala Gln Gly Phe Thr Glu Asp Thr Ile
 385 390 395 400

Val Phe Leu Pro Gln Thr Asp Lys Cys Met Thr Glu Gln
 405 410

272

<210> 216
 <211> 410
 <212> PRT
 <213> Homo sapien

<400> 216

Met Ala Thr His His Thr Leu Trp Met Gly Leu Ala Leu Leu Gly Val
 1 5 10 15

Leu Gly Asp Leu Gln Ala Ala Pro Glu Ala Gln Val Ser Val Gln Pro
 20 25 30

Asn Phe Gln Gln Asp Lys Val Arg Gly Phe Pro Ala Ser Ser Pro Arg
 35 40 45

Ala Thr Gly Pro Cys Gln Gly Lys Gly Thr Phe Arg Leu Gly Leu Pro
 50 55 60

Pro Gly Arg Ser Glu Arg Ser Pro Ala Val Pro Gly Ser Ala Gly Gln
 65 70 75 80

Gly Leu Ser Gly Arg Ala Gly Arg Arg Leu Gly Ser Arg Pro Arg Arg
 85 90 95

Leu Pro Ala Arg Ser Pro Pro Trp Ala Pro Arg Pro Val Ser Pro Asp
 100 105 110

Gly Pro Arg Arg His Arg Ala Thr His Ala Pro Thr Pro Ala Arg His
 115 120 125

Val His Pro Cys Gly His Ala Thr Pro Arg Gly His Thr Ser Ala Arg
 130 135 140

Ser Thr Pro Gly Cys Gln Asp Thr Gly Gly Trp Gly Thr Gly Met Ala
 145 150 155 160

Thr Asn Thr Pro Cys Ala Val Gly Val Gly Arg Asp Ala His Arg Thr
 165 170 175

Asp Ser Arg Arg Arg Ala Leu Ser Pro Gly Ser Cys Ser Gly Lys Arg
 180 185 190

Arg Ser Ala Gly Pro Arg Ala Ala Arg Pro Ser Leu Ala Ser Arg Arg
 195 200 205

Thr Pro Ala Val Arg Arg Ala Glu Pro Lys Thr Arg Pro Asp Pro Arg
 210 215 220

273

Gln Glu Cys Asp Val Leu Cys Arg Pro Leu Tyr Gly Pro Gly Ala Gln
 225 230 235 240

Pro Gly His Arg Ile Gly Thr Gly Gly Gly Gly Ala Glu Ala Gly Trp
 245 250 255

Trp Ala Ala Cys Glu Gly Glu Gly Leu Ser Ser Gly Gly Ala Trp Pro
 260 265 270

Asp Gly Gly Ala Gly Cys Gln Gly Arg Gly Gln Leu Leu Gly Arg Arg
 275 280 285

Cys Glu Gly Arg Gly His Leu Leu Gly Arg Gly Leu Arg Gly Gly Gly
 290 295 300

Gln Phe Leu Gly Arg Gly Val Arg Gly Val Ala Ala Arg Gly Ile Gly
 305 310 315 320

Arg Gly Gly Gly Ala Gly Leu Glu Thr Gly Gly Val Asp Gly Arg Gly
 325 330 335

Ala Pro Ala Gly Arg Arg Arg Trp Val Arg Arg Val Leu Ala Asp Ala
 340 345 350

Gly Gly Gly Arg Ser Pro Gln Phe Pro Gly Ala Leu Val Gln Arg Gly
 355 360 365

Pro Arg Leu Gln Leu Glu Leu Ala Pro Gly Glu Glu Gly Gly Val Val
 370 375 380

His Val Gln Val Cys Gly Gly Pro Cys His Gly Trp Trp Pro Gln Pro
 385 390 395 400

Asp Leu His Leu Pro Gln Glu Lys Pro Val
 405 410

<210> 217

<211> 135

<212> PRT

<213> Homo sapien

<400> 217

Met Ala Ala Gly Pro Met Ala Ala Glu Pro Cys Gly Pro His Ala Leu
 1 5 10 15

274

Val Ala Leu Ala Gly Leu Val Thr Gly Ile Pro Thr His His Pro Arg
 20 25 30

Val Tyr Asn Ile His Ser Arg Thr Val Thr Arg Tyr Pro Ala Asn Ser
 35 40 45

Ile Val Val Val Gly Gly Cys Pro Val Cys Arg Val Gly Val Leu Glu
 50 55 60

Asp Cys Phe Thr Phe Leu Gly Ile Phe Leu Ala Ile Ile Leu Phe Arg
 65 70 75 80

Ile Gly Pro Ala Ala Ile Gly Gln Trp Gln Pro Pro Asn Gly Ser Arg
 85 90 95

Thr Gln Thr Pro Arg Ala Glu Leu Lys Glu Lys Phe Thr Ala Phe Cys
 100 105 110

Lys Ala Gln Gly Phe Thr Glu Asp Thr Ile Val Phe Leu Pro Gln Thr
 115 120 125

Asp Lys Cys Met Thr Glu Gln
 130 135

<210> 218
 <211> 150
 <212> PRT
 <213> Homo sapien

<400> 218

Ala Leu Leu Glu Ala Trp Ala Arg Asp Arg Gly Val Ser Val Gln Val
 1 5 10 15

Arg Thr Ser Leu Pro Gln Pro Leu His Glu Glu Pro Pro Pro Trp Gly
 20 25 30

Thr Trp Arg Pro Gly Ala His Ser Val Pro Gly Pro Ser Ser Ser Gln
 35 40 45

Asp Val Gly Leu Gln Pro Gly Gly Gly His Arg Val Glu Gly Ala His
 50 55 60

Gly Gly Tyr Arg Gly Thr Asn His Thr Gly Leu Arg His Ser Leu Leu
 65 70 75 80

Gly Val Asp Ser Leu Leu Leu Ala Glu Val Glu Lys Asp Pro Leu Phe
 85 90 95

275

Val Ser Ser Ala Gln Gly Glu Val Gly Gly Asp Gly Gly Ser Val Gln
 100 105 110

Phe Gly Gly Ser Val Lys Thr Ser Ser Ala Leu Arg Glu Glu Gln Glu
 115 120 125

Ala Gln Trp Glu Asn Trp Pro Lys Ser Gly Val Leu Thr Thr Ala Pro
 130 135 140

Gly Phe Phe Leu Gly Arg
 145 150

<210> 219
 <211> 224
 <212> PRT
 <213> Homo sapien

<400> 219

Met Ala Thr His His Thr Leu Trp Met Gly Leu Ala Leu Leu Gly Val
 1 5 10 15

Leu Gly Asp Leu Gln Ala Ala Pro Glu Ala Gln Val Ser Val Gln Pro
 20 25 30

Asn Phe Gln Gln Asp Lys Phe Leu Gly Arg Trp Phe Ser Ala Gly Leu
 35 40 45

Ala Ser Asn Ser Ser Trp Leu Arg Glu Lys Lys Ala Ala Leu Ser Met
 50 55 60

Cys Lys Ser Val Val Ala Pro Ala Thr Asp Gly Gly Leu Asn Leu Thr
 65 70 75 80

Ser Thr Phe Leu Arg Lys Asn Gln Cys Glu Thr Arg Thr Met Leu Leu
 85 90 95

Gln Pro Ala Gly Ser Leu Gly Ser Tyr Ser Tyr Arg Ser Pro Arg Glu
 100 105 110

Trp Gly Leu His Arg Pro Pro Gly Pro Ser Leu Gly Ala Thr Leu Ala
 115 120 125

Gly Thr Thr Leu Gly Gln Pro Pro Ala Ala Glu Ile His Gly Val Gly
 130 135 140

276

Asp Trp Gly Ser Thr Tyr Ser Val Ser Val Val Glu Thr Asp Tyr Asp
 145 150 155 160

Gln Tyr Ala Leu Leu Tyr Ser Gln Gly Ser Lys Gly Pro Gly Glu Asp
 165 170 175

Phe Arg Met Ala Thr Leu Tyr Ser Arg Thr Gln Thr Pro Arg Ala Glu
 180 185 190

Leu Lys Glu Lys Phe Thr Ala Phe Cys Lys Ala Gln Gly Phe Thr Glu
 195 200 205

Asp Thr Ile Val Phe Leu Pro Gln Thr Asp Lys Cys Met Thr Glu Gln
 210 215 220

<210> 220

<211> 481

<212> PRT

<213> Homo sapien

<400> 220

Met Ala Thr His His Thr Leu Trp Met Gly Leu Ala Leu Leu Gly Val
 1 5 10 15

Leu Gly Asp Leu Gln Ala Ala Pro Glu Ala Gln Val Ser Val Gln Pro
 20 25 30

Asn Phe Gln Gln Asp Lys Val Arg Gly Phe Pro Ala Ser Ser Pro Arg
 35 40 45

Ala Thr Gly Pro Cys Gln Gly Lys Gly Thr Phe Arg Leu Gly Leu Pro
 50 55 60

Pro Gly Arg Ser Glu Arg Ser Pro Ala Val Pro Gly Ser Ala Gly Gln
 65 70 75 80

Gly Leu Ser Gly Arg Ala Gly Arg Arg Leu Gly Ser Arg Pro Arg Arg
 85 90 95

Leu Pro Ala Arg Ser Pro Pro Trp Ala Pro Arg Pro Val Ser Pro Asp
 100 105 110

Gly Pro Arg Arg His Arg Ala Thr His Ala Pro Thr Pro Ala Arg His
 115 120 125

Val His Pro Cys Gly His Ala Thr Pro Arg Gly His Thr Ser Ala Arg
 130 135 140

277

Ser Thr Pro Gly Cys Gln Asp Thr Gly Gly Trp Gly Thr Gly Met Ala
 145 150 155 160

Thr Asn Thr Pro Cys Ala Val Gly Val Gly Arg Asp Ala His Arg Thr
 165 170 175

Asp Ser Arg Arg Arg Ala Leu Ser Pro Gly Ser Cys Ser Gly Lys Arg
 180 185 190

Arg Ser Ala Gly Pro Arg Ala Ala Arg Pro Ser Leu Ala Ser Arg Arg
 195 200 205

Thr Pro Ala Val Arg Arg Ala Glu Pro Lys Thr Arg Pro Asp Pro Arg
 210 215 220

Gln Glu Cys Asp Val Leu Cys Arg Pro Leu Tyr Gly Pro Gly Ala Gln
 225 230 235 240

Pro Gly His Arg Ile Gly Thr Gly Gly Gly Gly Ala Glu Ala Gly Trp
 245 250 255

Trp Ala Ala Cys Glu Gly Glu Gly Leu Ser Ser Gly Gly Ala Trp Pro
 260 265 270

Asp Gly Gly Ala Gly Cys Gln Gly Arg Gly Gln Leu Leu Gly Arg Arg
 275 280 285

Cys Glu Gly Arg Gly His Leu Leu Gly Arg Gly Leu Arg Gly Gly Gly
 290 295 300

Gln Phe Leu Gly Arg Gly Val Arg Gly Val Ala Ala Arg Gly Ile Gly
 305 310 315 320

Arg Gly Gly Gly Ala Gly Leu Glu Thr Gly Gly Val Asp Gly Arg Gly
 325 330 335

Ala Pro Ala Gly Arg Arg Arg Trp Val Arg Arg Val Leu Ala Asp Ala
 340 345 350

Gly Gly Gly Arg Ser Pro Gln Phe Leu Gly Arg Trp Phe Ser Ala Gly
 355 360 365

Leu Ala Ser Asn Ser Ser Trp Leu Arg Glu Lys Lys Ala Ala Leu Ser
 370 375 380

278

Met Cys Lys Ser Val Val Ala Pro Ala Thr Asp Gly Gly Leu Asn Leu
 385 390 395 400

Thr Ser Thr Phe Leu Arg Lys Asn Gln Cys Glu Thr Arg Thr Met Leu
 405 410 415

Leu Gln Pro Ala Gly Ser Leu Gly Ser Tyr Ser Tyr Arg Ser Pro Arg
 420 425 430

Glu Trp Gly Leu His Arg Pro Pro Gly Pro Ser Leu Gly Ala Thr Leu
 435 440 445

Ala Gly Thr Thr Leu Gly Gln Pro Pro Ala Ala Glu Ile His Gly Val
 450 455 460

Gly Gly Asp Gly Cys Pro Thr Ser Val Arg Gly Lys Gly Gln Ala Trp
 465 470 475 480

Ala

<210> 221
 <211> 1088
 <212> PRT
 <213> Homo sapien

<400> 221

Met Asp Ile Tyr Asp Thr Gln Thr Leu Gly Val Val Val Phe Gly Gly
 1 5 10 15

Phe Met Val Val Ser Ala Ile Gly Ile Phe Leu Val Ser Thr Phe Ser
 20 25 30

Met Lys Glu Thr Ser Tyr Glu Glu Ala Leu Ala Asn Gln Arg Lys Glu
 35 40 45

Met Ala Lys Thr His His Gln Lys Val Glu Lys Lys Lys Lys Glu Lys
 50 55 60

Thr Val Glu Lys Lys Gly Lys Thr Lys Lys Lys Glu Glu Lys Pro Asn
 65 70 75 80

Gly Lys Ile Pro Asp His Asp Pro Ala Pro Asn Val Thr Val Leu Leu
 85 90 95

Arg Glu Pro Val Arg Ala Pro Ala Val Ala Val Ala Pro Thr Pro Val

279

100	105	110
Gln Pro Pro Ile Ile Val Ala Pro Val Ala Thr Val Pro Ala Met Pro		
115	120	125
Gln Glu Lys Leu Ala Ser Ser Pro Lys Asp Lys Lys Lys Lys Glu Lys		
130	135	140
Lys Val Ala Lys Val Glu Pro Ala Val Ser Ser Val Val Asn Ser Ile		
145	150	155
Gln Val Leu Thr Ser Lys Ala Ala Ile Leu Glu Thr Ala Pro Lys Glu		
165	170	175
Val Pro Met Val Val Val Pro Pro Val Gly Ala Lys Gly Asn Thr Pro		
180	185	190
Ala Thr Gly Thr Thr Gln Gly Lys Lys Ala Glu Gly Thr Gln Asn Gln		
195	200	205
Ser Lys Lys Ala Glu Gly Ala Pro Asn Gln Gly Arg Lys Ala Glu Gly		
210	215	220
Thr Pro Asn Gln Gly Lys Lys Thr Glu Gly Thr Pro Asn Gln Gly Lys		
225	230	235
Lys Ala Glu Gly Thr Pro Asn Gln Gly Lys Lys Ala Glu Gly Thr Pro		
245	250	255
Asn Gln Gly Lys Lys Ala Glu Gly Ala Gln Asn Gln Gly Lys Lys Val		
260	265	270
Asp Thr Thr Pro Asn Gln Gly Lys Lys Val Glu Gly Ala Pro Thr Gln		
275	280	285
Gly Arg Lys Ala Glu Gly Ala Gln Asn Gln Ala Lys Lys Val Glu Gly		
290	295	300
Ala Gln Asn Gln Gly Lys Lys Ala Glu Gly Ala Gln Asn Gln Gly Lys		
305	310	315
Lys Gly Glu Gly Ala Gln Asn Gln Gly Lys Lys Ala Glu Gly Ala Gln		
325	330	335
Asn Gln Gly Lys Lys Ala Glu Gly Ala Gln Asn Gln Gly Lys Lys Ala		
340	345	350

280

Glu Gly Ala Gln Asn Gln Gly Gln Lys Gly Glu Gly Ala Gln Asn Gln
 355 360 365

Gly Lys Lys Thr Glu Gly Ala Gln Gly Lys Lys Ala Glu Arg Ser Pro
 370 375 380

Asn Gln Gly Lys Lys Gly Glu Gly Ala Pro Ile Gln Gly Lys Lys Ala
 385 390 395 400

Asp Ser Val Ala Asn Gln Gly Thr Lys Val Glu Gly Ile Thr Asn Gln
 405 410 415

Gly Lys Lys Ala Glu Gly Ser Pro Ser Glu Gly Lys Lys Ala Glu Gly
 420 425 430

Ser Pro Asn Gln Gly Lys Lys Ala Asp Ala Ala Ala Asn Gln Gly Lys
 435 440 445

Lys Thr Glu Ser Ala Ser Val Gln Gly Arg Asn Thr Asp Val Ala Gln
 450 455 460

Ser Pro Glu Ala Pro Lys Gln Glu Ala Pro Ala Lys Lys Lys Ser Gly
 465 470 475 480

Ser Lys Lys Lys Gly Glu Pro Gly Pro Pro Asp Ala Asp Gly Pro Leu
 485 490 495

Tyr Leu Pro Tyr Lys Thr Leu Val Ser Thr Val Gly Ser Met Val Phe
 500 505 510

Asn Glu Gly Glu Ala Gln Arg Leu Ile Glu Ile Leu Ser Glu Lys Ala
 515 520 525

Gly Ile Ile Gln Asp Thr Trp His Lys Ala Thr Gln Lys Gly Asp Pro
 530 535 540

Val Ala Ile Leu Lys Arg Gln Leu Glu Glu Lys Glu Lys Leu Leu Ala
 545 550 555 560

Thr Glu Gln Glu Asp Ala Ala Val Ala Lys Ser Lys Leu Arg Glu Leu
 565 570 575

Asn Lys Glu Met Ala Ala Glu Lys Ala Lys Ala Ala Ala Gly Glu Ala
 580 585 590

281

Lys Val Lys Lys Gln Leu Val Ala Arg Glu Gln Glu Ile Thr Ala Val
 595 600 605

Gln Ala Arg Met Gln Ala Ser Tyr Arg Glu His Val Lys Glu Val Gln
 610 615 620

Gln Leu Gln Gly Lys Ile Arg Thr Leu Gln Glu Gln Leu Glu Asn Gly
 625 630 635 640

Pro Asn Thr Gln Leu Ala Arg Leu Gln Gln Glu Asn Ser Ile Leu Arg
 645 650 655

Asp Ala Leu Asn Gln Ala Thr Ser Gln Val Glu Ser Lys Gln Asn Ala
 660 665 670

Glu Leu Ala Lys Leu Arg Gln Glu Leu Ser Lys Val Ser Lys Glu Leu
 675 680 685

Val Glu Lys Ser Glu Ala Val Arg Gln Asp Glu Gln Gln Arg Lys Ala
 690 695 700

Leu Glu Ala Lys Ala Ala Ala Phe Glu Lys Gln Val Leu Gln Leu Gln
 705 710 715 720

Ala Ser His Arg Glu Ser Glu Glu Ala Leu Gln Lys Arg Leu Asp Glu
 725 730 735

Val Ser Arg Glu Leu Cys His Thr Gln Ser Ser His Ala Ser Leu Arg
 740 745 750

Ala Asp Ala Glu Lys Ala Gln Glu Gln Gln Gln Met Ala Glu Leu
 755 760 765

His Ser Lys Leu Gln Ser Ser Glu Ala Glu Val Arg Ser Lys Cys Glu
 770 775 780

Glu Leu Ser Gly Leu His Gly Gln Leu Gln Glu Ala Arg Ala Glu Asn
 785 790 795 800

Ser Gln Leu Thr Glu Arg Ile Arg Ser Ile Glu Ala Leu Leu Glu Ala
 805 810 815

Gly Gln Ala Arg Asp Ala Gln Asp Val Gln Ala Ser Gln Ala Glu Ala
 820 825 830

282

Asp Gln Gln Gln Thr Arg Leu Lys Glu Leu Glu Ser Gln Val Ser Gly
 835 840 845

Leu Glu Lys Glu Ala Ile Glu Leu Arg Glu Ala Val Glu Gln Gln Lys
 850 855 860

Val Lys Asn Asn Asp Leu Arg Glu Lys Asn Trp Lys Ala Met Glu Ala
 865 870 875 880

Leu Ala Thr Ala Glu Gln Ala Cys Lys Glu Lys Leu His Ser Leu Thr
 885 890 895

Gln Ala Lys Glu Glu Ser Glu Lys Gln Leu Cys Leu Ile Glu Ala Gln
 900 905 910

Thr Met Glu Ala Leu Leu Ala Leu Leu Pro Glu Leu Ser Val Leu Ala
 915 920 925

Gln Gln Asn Tyr Thr Glu Trp Leu Gln Asp Leu Lys Glu Lys Gly Pro
 930 935 940

Thr Leu Leu Lys His Pro Pro Ala Pro Ala Glu Pro Ser Ser Asp Leu
 945 950 955 960

Ala Ser Lys Leu Arg Glu Ala Glu Glu Thr Gln Ser Thr Leu Gln Ala
 965 970 975

Glu Cys Asp Gln Tyr Arg Ser Ile Leu Ala Glu Thr Glu Gly Met Leu
 980 985 990

Arg Asp Leu Gln Lys Ser Val Glu Glu Glu Glu Gln Val Trp Arg Ala
 995 1000 1005

Lys Val Gly Ala Ala Glu Glu Glu Leu Gln Lys Val Tyr Ala Ala
 1010 1015 1020

Leu Pro Ala Ser Arg Arg Arg Gly Ala His Glu Ala Gln Gly Arg
 1025 1030 1035

Val Asp Arg Ile Val Ser Val Thr Cys Glu Thr Arg Val Ser Arg
 1040 1045 1050

Trp Gly Phe Ser Thr Thr Pro Tyr Glu Ala Gln Leu Arg Asp Asp
 1055 1060 1065

Ser Ser Val Arg Pro Pro Gly Gly Pro Arg Leu Gly Arg His Cys

283

1070

1075

1080

Gln Met Ala Pro Gly
1085

<210> 222
<211> 440
<212> PRT
<213> Homo sapien

<400> 222

Arg Val Gly Lys Ala Gly Gly Gly Asp Pro Gly Gly Gly Gly Arg Ser
1 5 10 15

Pro Ala Leu Arg Gln Lys Val Pro Arg Leu His Thr Arg Ala Arg Ser
20 25 30

Gln Arg Ala Ala Gly Ala Asp Gly Arg Arg Gly Gly Arg Arg Gln Gly
35 40 45

Arg Ser Val Tyr Ser Cys Ser Gly Ala Val Ser Trp Arg Arg Leu Gly
50 55 60

Arg Leu Leu Ser Pro Gly Ser Ala Ala Ala Lys Ala Ala Ala Pro
65 70 75 80

Ala Leu Ser Leu Ser Leu Ser Arg Leu Trp Leu Gln Val Lys Gly Lys
85 90 95

Gln Ala Arg Met Asp Ile Tyr Asp Thr Gln Thr Leu Gly Val Val Val
100 105 110

Phe Gly Gly Phe Met Val Val Ser Ala Ile Gly Ile Phe Leu Val Ser
115 120 125

Thr Phe Ser Met Lys Glu Thr Ser Tyr Glu Glu Ala Leu Ala Asn Gln
130 135 140

Arg Lys Glu Met Ala Lys Thr His His Gln Lys Val Glu Lys Lys Lys
145 150 155 160

Lys Glu Lys Thr Val Glu Lys Lys Gly Lys Thr Lys Lys Lys Glu Glu
165 170 175

Lys Pro Asn Gly Lys Ile Pro Asp His Asp Pro Ala Pro Asn Val Thr
180 185 190

284

Val	Leu	Leu	Arg	Glu	Pro	Val	Arg	Ala	Pro	Ala	Val	Ala	Val	Ala	Pro
		195						200				205			
Thr	Pro	Val	Gln	Pro	Pro	Ile	Ile	Val	Ala	Pro	Val	Ala	Thr	Val	Pro
	210					215					220				
Ala	Met	Pro	Gln	Glu	Lys	Leu	Ala	Ser	Ser	Pro	Lys	Asp	Lys	Lys	Lys
225					230					235					240
Lys	Glu	Lys	Lys	Val	Ala	Lys	Val	Glu	Pro	Ala	Val	Ser	Ser	Val	Val
				245					250					255	
Asn	Ser	Ile	Gln	Val	Leu	Thr	Ser	Lys	Ala	Ala	Ile	Leu	Glu	Thr	Ala
			260					265					270		
Pro	Lys	Glu	Val	Pro	Met	Val	Val	Val	Pro	Pro	Val	Gly	Ala	Lys	Gly
		275					280					285			
Asn	Thr	Pro	Ala	Thr	Gly	Thr	Thr	Gln	Gly	Lys	Lys	Ala	Glu	Gly	Thr
	290					295					300				
Gln	Asn	Gln	Ser	Lys	Lys	Ala	Glu	Gly	Ala	Pro	Asn	Gln	Gly	Arg	Lys
305					310					315					320
Ala	Glu	Gly	Thr	Pro	Asn	Gln	Gly	Lys	Lys	Thr	Glu	Gly	Thr	Pro	Asn
				325					330					335	
Gln	Gly	Lys	Lys	Ala	Glu	Gly	Thr	Pro	Asn	Gln	Gly	Lys	Lys	Ala	Glu
			340					345					350		
Gly	Thr	Pro	Asn	Gln	Gly	Lys	Lys	Ala	Glu	Gly	Ala	Gln	Asn	Gln	Gly
		355					360					365			
Lys	Lys	Val	Asp	Thr	Thr	Pro	Asn	Gln	Gly	Lys	Lys	Val	Glu	Gly	Ala
	370					375					380				
Pro	Thr	Gln	Gly	Arg	Lys	Ala	Glu	Gly	Ala	Gln	Asn	Gln	Ala	Lys	Lys
385					390					395					400
Val	Glu	Gly	Ala	Gln	Asn	Gln	Gly	Lys	Lys	Ala	Glu	Gly	Ala	Gln	Asn
				405					410					415	
Gln	Gly	Lys	Lys	Gly	Glu	Gly	Ala	Gln	Asn	Gln	Gly	Lys	Lys	Ala	Glu
			420					425					430		

285

Gly Ala Gln Asn Gln Pro Pro Met
 435 440

<210> 223
 <211> 521
 <212> PRT
 <213> Homo sapien
 <400> 223

Met Asp Ile Tyr Asp Thr Gln Thr Leu Gly Val Val Val Phe Gly Gly
 1 5 10 15

Phe Met Val Val Ser Ala Ile Gly Ile Phe Leu Val Ser Thr Phe Ser
 20 25 30

Met Lys Glu Thr Ser Tyr Glu Glu Ala Leu Ala Asn Gln Arg Lys Glu
 35 40 45

Met Ala Lys Thr His His Gln Lys Val Glu Lys Lys Lys Lys Glu Lys
 50 55 60

Thr Val Glu Lys Lys Gly Lys Thr Lys Lys Lys Glu Glu Lys Pro Asn
 65 70 75 80

Gly Lys Ile Pro Asp His Asp Pro Ala Pro Asn Val Thr Val Leu Leu
 85 90 95

Arg Glu Pro Val Arg Ala Pro Ala Val Ala Val Ala Pro Thr Pro Val
 100 105 110

Gln Pro Pro Ile Ile Val Ala Pro Val Ala Thr Val Pro Ala Met Pro
 115 120 125

Gln Glu Lys Leu Ala Ser Ser Pro Lys Asp Lys Lys Lys Lys Glu Lys
 130 135 140

Lys Val Ala Lys Val Glu Pro Ala Val Ser Ser Val Val Asn Ser Ile
 145 150 155 160

Gln Val Leu Thr Ser Lys Ala Ala Ile Leu Glu Thr Ala Pro Lys Glu
 165 170 175

Val Pro Met Val Val Val Pro Pro Val Gly Ala Lys Gly Asn Thr Pro
 180 185 190

Ala Thr Gly Thr Thr Gln Gly Lys Lys Ala Glu Gly Thr Gln Asn Gln
 195 200 205

286

Ser Lys Lys Ala Glu Gly Ala Pro Asn Gln Gly Arg Lys Ala Glu Gly
 210 215 220
 Thr Pro Asn Gln Gly Lys Lys Thr Glu Gly Thr Pro Asn Gln Gly Lys
 225 230 235 240
 Lys Ala Glu Gly Thr Pro Asn Gln Gly Lys Lys Ala Glu Gly Thr Pro
 245 250 255
 Asn Gln Gly Lys Lys Ala Glu Gly Ala Gln Asn Gln Gly Lys Lys Val
 260 265 270
 Asp Thr Thr Pro Asn Gln Gly Lys Lys Val Glu Gly Ala Pro Thr Gln
 275 280 285
 Gly Arg Lys Ala Glu Gly Ala Gln Asn Gln Ala Lys Lys Val Glu Gly
 290 295 300
 Ala Gln Asn Gln Gly Lys Lys Ala Glu Gly Ala Gln Asn Gln Gly Lys
 305 310 315 320
 Lys Gly Glu Gly Ala Gln Asn Gln Gly Lys Lys Ala Glu Gly Ala Gln
 325 330 335
 Asn Gln Pro Pro Asp Val Thr Val Leu Leu Arg Glu Pro Val Arg Ala
 340 345 350
 Pro Ala Val Ala Val Ala Pro Thr Pro Val Gln Pro Pro Ile Ile Val
 355 360 365
 Ala Pro Val Ala Thr Val Pro Ala Met Pro Gln Glu Lys Leu Ala Ser
 370 375 380
 Ser Pro Lys Asp Lys Lys Lys Lys Glu Lys Asn Val Ala Lys Val Glu
 385 390 395 400
 Pro Ala Val Ser Ser Val Val Asn Ser Ile Gln Ser Ser His Phe Glu
 405 410 415
 Gly Cys Gln Val Gly Ser Met Val Phe Asn Glu Gly Glu Ala Gln Arg
 420 425 430
 Leu Ile Glu Ile Leu Ser Glu Lys Ala Gly Ile Ile Gln Asp Thr Trp
 435 440 445

287

His Lys Ala Thr Gln Lys Gly Asp Pro Val Ala Ile Leu Lys Arg Gln
 450 455 460

Leu Glu Glu Lys Glu Lys Leu Leu Ala Thr Glu Gln Glu Asp Ala Ala
 465 470 475 480

Val Ala Lys Ser Lys Leu Arg Glu Leu Asn Lys Glu Met Ala Ala Glu
 485 490 495

Lys Ala Lys Ala Ala Ala Gly Glu Ala Lys Val Lys Lys Gln Leu Val
 500 505 510

Ala Arg Glu Gln Glu Ile Thr Ala Arg
 515 520

<210> 224
 <211> 165
 <212> PRT
 <213> Homo sapien

<400> 224

Gly Arg Ser Gln Arg Ser Ser Pro Cys Ser Ala Pro Leu Gln Gly Pro
 1 5 10 15

Gly Ala Leu Gly Leu Arg Thr Gln Leu Leu Leu Pro Pro Trp Ser Ser
 20 25 30

Thr Trp Glu Gln Val Ser Ser Trp Gly Val Trp Thr Gly Gly Ala Gly
 35 40 45

Gly Arg Thr Gln Ala Gln Lys Leu Pro Ala Pro Thr Thr Gln Leu Leu
 50 55 60

Ser Thr Ala Leu Glu Pro Thr Ser Gln Lys Pro Gly Val Gly Ala Gly
 65 70 75 80

His Gly Gly Asp Pro Lys Leu Ser Pro His Lys Val Gln Gly Arg Ser
 85 90 95

Glu Ala Gly Ala Gly Pro Gly Pro Lys Gln Gly His His Ser Ser Ser
 100 105 110

Asp Ser Ser Ser Ser Ser Ser Asp Ser Asp Thr Asp Val Lys Ser His
 115 120 125

Ala Ala Gly Ser Lys Gln His Glu Ser Ile Pro Gly Lys Ala Lys Lys

288

130

135

140

Pro Lys Val Lys Lys Lys Glu Lys Gly Lys Lys Glu Lys Gly Lys Lys
 145 150 155 160

Lys Glu Ala Pro His
 165

<210> 225

<211> 262

<212> PRT

<213> Homo sapien

<400> 225

Gly Arg Ser Gln Arg Ser Ser Pro Cys Ser Ala Pro Leu Gln Gly Pro
 1 5 10 15

Gly Ala Leu Gly Leu Arg Thr Gln Leu Leu Leu Pro Pro Trp Ser Ser
 20 25 30

Thr Trp Glu Gln Val Ser Ser Trp Gly Val Trp Thr Gly Gly Ala Gly
 35 40 45

Gly Arg Thr Gln Ala Gln Lys Leu Pro Ala Pro Thr Thr Gln Leu Leu
 50 55 60

Ser Thr Ala Leu Glu Pro Thr Ser Gln Lys Pro Gly Val Gly Ala Gly
 65 70 75 80

His Gly Gly Asp Pro Lys Leu Ser Pro His Lys Val Gln Gly Arg Ser
 85 90 95

Glu Ala Gly Ala Gly Pro Gly Pro Lys Val Ser Arg Leu Ile Thr Gly
 100 105 110

Cys Gly Gly Ala Gly Arg Leu Gly Leu Pro Leu Thr Pro Gly Ser Cys
 115 120 125

Leu Arg Pro Pro Thr Ser Gly Gly Trp Val Arg Gly Ala Ala Ser Leu
 130 135 140

Pro His Leu His Pro Ala Arg Thr Pro Gln Leu Phe Arg Leu Gln Gln
 145 150 155 160

Gln Leu Gln Arg Phe Gly His Gly Cys Glu Gly Lys Gly Leu Ser Pro
 165 170 175

289

Ala Ser Pro Ser Thr Cys Pro Ala Pro Gln Arg Gly Val Pro Ala Leu
 180 185 190

Gly Leu Ala Gly Arg Val Arg Gly Val Val Pro Leu Ser Arg Phe Gln
 195 200 205

Pro Arg Thr Ile Ser Ser Leu Pro Ser Leu Pro Ser Ala Pro Gln Ser
 210 215 220

His Ala Ala Gly Ser Lys Gln His Glu Ser Ile Pro Gly Lys Ala Lys
 225 230 235 240

Lys Pro Lys Val Lys Lys Lys Glu Lys Gly Lys Lys Glu Lys Gly Lys
 245 250 255

Lys Lys Glu Ala Pro His
 260

<210> 226
 <211> 231
 <212> PRT
 <213> Homo sapien

<220>
 <221> MISC_FEATURE
 <222> (206)..(206)
 <223> X=any amino acid

<220>
 <221> MISC_FEATURE
 <222> (210)..(210)
 <223> X=any amino acid

<400> 226

Ser Arg Asp Pro Asn Gly Trp Trp Arg Arg Leu Arg Val Ser Ala Glu
 1 5 10 15

Leu Ala Met Ala Gln Leu Cys Gly Leu Arg Arg Ser Arg Ala Phe Leu
 20 25 30

Ala Leu Leu Gly Ser Leu Leu Leu Ser Gly Val Leu Ala Ala Asp Arg
 35 40 45

Glu Arg Ser Ile His Asp Phe Cys Leu Val Ser Lys Val Val Gly Arg
 50 55 60

Cys Arg Ala Ser Met Pro Arg Trp Trp Tyr Asn Val Thr Asp Gly Ser

290																
65	70							75							80	
Cys	Gln	Leu	Phe	Val	Tyr	Gly	Gly	Cys	Asp	Gly	Asn	Ser	Asn	Asn	Tyr	
				85					90					95		
Leu	Thr	Lys	Glu	Glu	Cys	Leu	Lys	Lys	Cys	Ala	Thr	Val	Thr	Glu	Asn	
			100					105						110		
Ala	Thr	Gly	Asp	Leu	Ala	Thr	Ser	Arg	Asn	Ala	Ala	Asp	Ser	Ser	Val	
		115					120					125				
Pro	Ser	Ala	Pro	Arg	Arg	Gln	Asp	Ser	Glu	Asp	His	Ser	Ser	Asp	Met	
	130					135					140					
Phe	Asn	Tyr	Glu	Glu	Tyr	Cys	Thr	Ala	Asn	Ala	Val	Thr	Gly	Pro	Cys	
145					150					155					160	
Arg	Ala	Ser	Phe	Pro	Arg	Trp	Tyr	Phe	Asp	Val	Glu	Arg	Asn	Ser	Cys	
				165					170					175		
Asn	Asn	Phe	Ile	Tyr	Gly	Gly	Cys	Arg	Gly	Asn	Lys	Asn	Ser	Tyr	Arg	
			180					185					190			
Ser	Glu	Glu	Ala	Cys	Met	Leu	Arg	Cys	Phe	Gln	Gly	Asn	Xaa	Pro	Ala	
		195					200					205				
Leu	Xaa	Gln	Gly	Gly	Pro	Gly	Gly	Gly	Pro	Arg	Gly	Asp	Pro	Ser	Gly	
	210					215					220					
Arg	Pro	Gly	Asp	Arg	Thr	Gly										
225					230											
<210>	227															
<211>	213															
<212>	PRT															
<213>	Homo sapien															
<400>	227															
Met	Ala	Gln	Leu	Cys	Gly	Leu	Arg	Arg	Ser	Arg	Ala	Phe	Leu	Ala	Leu	
1				5					10					15		
Leu	Gly	Ser	Leu	Leu	Leu	Ser	Gly	Val	Leu	Ala	Ala	Asp	Arg	Glu	Arg	
			20					25					30			
Ser	Ile	His	Asp	Phe	Cys	Leu	Val	Ser	Lys	Val	Val	Gly	Arg	Cys	Arg	
	35						40					45				

291

Ala Ser Met Pro Arg Trp Trp Tyr Asn Val Thr Asp Gly Ser Cys Gln
50 55 60

Leu Phe Val Tyr Gly Gly Cys Asp Gly Asn Ser Asn Asn Tyr Leu Thr
65 70 75 80

Lys Glu Glu Cys Leu Lys Lys Cys Ala Thr Val Thr Glu Asn Ala Thr
85 90 95

Gly Asp Leu Ala Thr Ser Arg Asn Ala Ala Asp Ser Ser Val Pro Ser
100 105 110

Ala Pro Arg Arg Gln Asp Ser Glu Asp His Ser Ser Asp Met Phe Asn
115 120 125

Tyr Glu Glu Tyr Cys Thr Ala Asn Ala Val Thr Gly Pro Cys Arg Ala
130 135 140

Ser Phe Pro Arg Trp Tyr Phe Asp Val Glu Arg Asn Ser Cys Asn Asn
145 150 155 160

Phe Ile Tyr Gly Gly Cys Arg Gly Asn Lys Asn Ser Tyr Arg Ser Glu
165 170 175

Glu Ala Cys Met Leu Arg Cys Phe Gln Arg Glu Leu Pro Trp Pro Trp
180 185 190

Ala Lys Gly Gly Arg Gly Ala Ala Arg Gly Gly Thr Pro Arg Gly Ala
195 200 205

Gln Gly Thr Glu Pro
210

<210> 228

<211> 242

<212> PRT

<213> Homo sapien

<400> 228

Met Ala Gln Leu Cys Gly Leu Arg Arg Ser Arg Ala Phe Leu Ala Leu
1 5 10 15

Leu Gly Ser Leu Leu Leu Ser Gly Val Leu Ala Ala Asp Arg Glu Arg
20 25 30

Ser Ile His Asp Phe Cys Leu Val Ser Lys Val Val Gly Arg Cys Arg

292

35

40

45

Ala Ser Met Pro Arg Trp Trp Tyr Asn Val Thr Asp Gly Ser Cys Gln
 50 55 60

Leu Phe Val Tyr Gly Gly Cys Asp Gly Asn Ser Asn Asn Tyr Leu Thr
 65 70 75 80

Lys Glu Glu Cys Leu Lys Lys Cys Ala Thr Val Thr Glu Asn Ala Thr
 85 90 95

Gly Asp Leu Ala Thr Ser Arg Asn Ala Ala Asp Ser Ser Val Pro Ser
 100 105 110

Ala Pro Arg Arg Gln Asp Ser Glu Asp His Ser Ser Asp Met Phe Asn
 115 120 125

Tyr Glu Glu Tyr Cys Thr Ala Asn Ala Val Thr Gly Pro Cys Arg Ala
 130 135 140

Ser Phe Pro Arg Trp Tyr Phe Asp Val Glu Arg Asn Ser Cys Asn Asn
 145 150 155 160

Phe Ile Tyr Gly Gly Cys Arg Gly Asn Lys Asn Ser Tyr Arg Ser Glu
 165 170 175

Glu Ala Cys Met Leu Arg Cys Phe Arg Gln Gln Glu Asn Pro Pro Leu
 180 185 190

Pro Leu Gly Ser Lys Gly Lys Trp Pro Leu Thr Leu Leu Leu Pro Ser
 195 200 205

Ala Cys Leu Leu Pro Ser Leu Thr Glu Leu Ser Pro Ala Gln Leu Trp
 210 215 220

Phe Thr Leu Ser Phe Thr Val Asn Ile Ile Leu Ala Glu Ser His Val
 225 230 235 240

Ser Ala

<210> 229

<211> 53

<212> PRT

<213> Homo sapien

<400> 229

293

Arg Phe Trp Leu Ala Ile Gly Cys Trp Pro Ser Arg Gln Ser Arg Glu
 1 5 10 15

Gln His Ile Ser Ser Arg Arg Lys Met Glu Ile Leu Lys Thr Glu Cys
 20 25 30

Gln Glu Lys Glu Ser Arg Thr Ile His Ser Met Arg Arg Lys Met Glu
 35 40 45

Lys Lys Asn Phe Ile
 50

<210> 230
 <211> 43
 <212> PRT
 <213> Homo sapien

<400> 230

Met Asp Arg Pro Pro Gly Gln Val Pro Gly His Leu Gly Gln Cys Asp
 1 5 10 15

Val Ser Gly Trp Gln Ser Asp Ala Gly Pro Ala Gly Ser Gln Glu Asn
 20 25 30

Ser Thr Leu Val Pro Glu Glu Arg Trp Lys Phe
 35 40

<210> 231
 <211> 66
 <212> PRT
 <213> Homo sapien

<400> 231

Val Ala Ala Glu Val Pro Gly His Leu Gly Gln Cys Asp Val Ser Gly
 1 5 10 15

Trp Gln Ser Asp Ala Gly Pro Ala Gly Ser Gln Glu Asn Ser Thr Leu
 20 25 30

Val Pro Glu Glu Arg Trp Glu Ile Leu Lys Thr Glu Cys Gln Glu Lys
 35 40 45

Glu Ser Arg Thr Ile His Ser Met Arg Arg Lys Met Glu Lys Lys Asn
 50 55 60

Phe Ile
 65

294

<210> 232
<211> 34
<212> PRT
<213> Homo sapien

<400> 232

Met Asp Arg Ser Arg Pro Arg Tyr Leu Ala Ile Leu Gly Ser Val Thr
1 5 10 15

Phe Leu Ala Gly Asn Arg Met Leu Ala Gln Gln Ala Val Lys Arg Thr
20 25 30

Ala His

<210> 233
<211> 116
<212> PRT
<213> Homo sapien

<220>
<221> MISC_FEATURE
<222> (3)..(4)
<223> X=any amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(11)
<223> X=any amino acid

<220>
<221> MISC_FEATURE
<222> (31)..(31)
<223> X=any amino acid

<220>
<221> MISC_FEATURE
<222> (34)..(34)
<223> X=any amino acid

<220>
<221> MISC_FEATURE
<222> (39)..(39)
<223> X=any amino acid

<220>
<221> MISC_FEATURE
<222> (41)..(41)
<223> X=any amino acid

295

<220>
<221> MISC_FEATURE
<222> (44)..(44)
<223> X=any amino acid

<220>
<221> MISC_FEATURE
<222> (57)..(57)
<223> X=any amino acid

<220>
<221> MISC_FEATURE
<222> (59)..(60)
<223> X=any amino acid

<220>
<221> MISC_FEATURE
<222> (65)..(66)
<223> X=any amino acid

<220>
<221> MISC_FEATURE
<222> (69)..(69)
<223> X=any amino acid

<220>
<221> MISC_FEATURE
<222> (71)..(71)
<223> X=any amino acid

<220>
<221> MISC_FEATURE
<222> (75)..(76)
<223> X=any amino acid

<220>
<221> MISC_FEATURE
<222> (80)..(81)
<223> X=any amino acid

<220>
<221> MISC_FEATURE
<222> (83)..(83)
<223> X=any amino acid

<220>
<221> MISC_FEATURE
<222> (97)..(97)
<223> X=any amino acid

296

<220>
 <221> MISC_FEATURE
 <222> (115)..(115)
 <223> X=any amino acid

<400> 233

Met Val Xaa Xaa Arg Pro Ser Pro Leu Xaa Xaa Asp Leu Asn Ala Pro
 1 5 10 15

Ser Asp Trp Asp Ser Arg Gly Lys Asp Ser Tyr Glu Thr Arg Xaa Leu
 20 25 30

Asp Xaa Lys Ser Ala Glu Xaa Lys Xaa Lys Lys Xaa Ser Arg Leu Tyr
 35 40 45

Lys Arg Lys Ala Asn Asp Glu Ser Xaa Glu Xaa Xaa Asp Val Ile Asp
 50 55 60

Xaa Xaa Glu Leu Xaa Lys Xaa Ser Arg Glu Xaa Xaa Ser His Glu Xaa
 65 70 75 80

Xaa Ser Xaa Glu Asp Met Leu Val Val Asp Ala Lys Ser Lys Glu Glu
 85 90 95

Xaa Lys His Leu Lys Phe Arg Ile Ser His Glu Leu Asp Ser Ala Ser
 100 105 110

Ser Glu Xaa Asn
 115

<210> 234
 <211> 122
 <212> PRT
 <213> Homo sapien

<220>
 <221> MISC_FEATURE
 <222> (9)..(10)
 <223> X=any amino acid

<220>
 <221> MISC_FEATURE
 <222> (16)..(17)
 <223> X=any amino acid

<220>
 <221> MISC_FEATURE
 <222> (37)..(37)
 <223> X=any amino acid

297

<220>
 <221> MISC_FEATURE
 <222> (40)..(40)
 <223> X=any amino acid

<220>
 <221> MISC_FEATURE
 <222> (45)..(45)
 <223> X=any amino acid

<220>
 <221> MISC_FEATURE
 <222> (47)..(47)
 <223> X=any amino acid

<220>
 <221> MISC_FEATURE
 <222> (87)..(87)
 <223> X=any amino acid

<400> 234

Met Glu Ser Glu Glu Leu Asn Gly Xaa Xaa Lys Ala Ile Pro Val Xaa
 1 5 10 15

Xaa Asp Leu Asn Ala Pro Ser Asp Trp Asp Ser Arg Gly Lys Asp Ser
 20 25 30

Tyr Glu Thr Arg Xaa Leu Asp Xaa Lys Ser Ala Glu Xaa Lys Xaa Lys
 35 40 45

Lys Lys Ser Arg Leu Tyr Lys Arg Lys Ala Asn Asp Glu Ser Lys Glu
 50 55 60

Gln Ala Asp Val Ile Asp Arg Lys Glu Leu Ala Lys Asp Ser Arg Glu
 65 70 75 80

Ala Asn Ser His Glu Phe Xaa Ser Lys Glu Asp Met Leu Val Val Asp
 85 90 95

Ala Lys Ser Lys Glu Glu Glu Lys His Leu Lys Phe Arg Ile Ser His
 100 105 110

Glu Leu Asp Ser Ala Ser Ser Glu Phe Asn
 115 120

<210> 235

298

<211> 86
<212> PRT
<213> Homo sapien

<400> 235

Leu Ser Gly Leu Phe Arg Ser Leu Glu Val Ile Phe Val Ile Phe Phe
1 5 10 15

Leu Asn Tyr Phe Arg Glu Leu Gly Met Gln Met Phe Ser Val Arg Lys
20 25 30

Pro Leu Phe Thr Leu Trp Lys Leu Asn Lys Lys Cys Ile Cys Leu Arg
35 40 45

Asn Trp Arg Leu Leu Met Leu Gly Asn Thr Cys Asn Gly Ser Arg Gly
50 55 60

Asn Cys Val Ser Val Phe Gly Asn Glu Ile Tyr Gly Lys Pro Phe Phe
65 70 75 80

Lys Leu Val Met Leu Leu
85

<210> 236
<211> 30
<212> PRT
<213> Homo sapien

<400> 236

Lys Ser Gly Ile Asn Ala Glu Gly Pro Leu Arg Pro Gly Ala Ala Ile
1 5 10 15

Leu Gly Leu Leu Gly Leu Ala Ser Val Gly Asp Ser Arg Thr
20 25 30

<210> 237
<211> 125
<212> PRT
<213> Homo sapien

<220>
<221> MISC_FEATURE
<222> (70)..(70)
<223> X=any amino acid

<220>
<221> MISC_FEATURE
<222> (84)..(84)
<223> X=any amino acid

299

<220>
 <221> MISC_FEATURE
 <222> (92)..(92)
 <223> X=any amino acid

<400> 237

Gln Arg Leu Gln Arg Val Ala Gly Ile Thr Gly Thr Cys His His Thr
 1 5 10 15

Gln Leu Ile Phe Ile Phe Leu Val Glu Thr Gly Phe His His Val Gly
 20 25 30

Gln Ala Gly Phe Glu Leu Leu Ile Trp Trp Ser Ala Cys Leu Gly Leu
 35 40 45

Pro Glu Cys Trp Asp Tyr Arg Arg Lys Pro Pro Arg Leu Ala Lys Lys
 50 55 60

Ile Lys Ile Tyr Leu Xaa Tyr Val Leu Thr Ser Tyr Thr Gln Arg Ile
 65 70 75 80

Leu Asp Phe Xaa Leu Lys Ile Ile Ile Lys Pro Xaa Ile Ser Pro Val
 85 90 95

Glu Lys Glu Ile Leu Arg Phe Leu Cys Phe Phe Phe Gln His Asn Ser
 100 105 110

Val Thr Tyr Gly Trp Glu Lys Ile Cys Arg Glu Ile Ile
 115 120 125

<210> 238
 <211> 104
 <212> PRT
 <213> Homo sapien

<400> 238

Thr Arg Thr Gln Arg Gly Thr Ile Gly Gln Asn Ile Ser His Thr His
 1 5 10 15

Gln Arg His Thr Lys Pro Pro Thr His Ala Ile Thr Arg Pro Leu Ile
 20 25 30

Arg Thr Leu Ala Glu Pro Asp Trp Lys Ser Thr Arg Ser Thr Lys Tyr
 35 40 45

Ile Gly Asn Pro Pro His Arg Asn Pro Lys Leu Asp Lys Ala Lys Ile

300

50

55

60

Thr Ala Thr Thr Pro Ile Asn Lys Lys Pro Asn Thr Arg His Thr Arg
 65 70 75 80

Asn Pro Pro Pro Asn Arg Arg Pro Met Pro Ile His Gln Gln Thr His
 85 90 95

Thr Lys Asp Lys Lys Arg His Glu
 100

<210> 239
 <211> 61
 <212> PRT
 <213> Homo sapien

<400> 239

Met His Gln Gly Arg Glu His Ser Ala Gln Thr Ile Asp Ser Asp Tyr
 1 5 10 15

Leu Leu Thr Val Cys Arg Arg His Ala Gly Gly Leu Lys Arg Gly Cys
 20 25 30

Ile Leu Leu Pro Ser Leu Ala Gly Tyr Gly Ile Ser Ser Phe Pro Phe
 35 40 45

Ile Gly Tyr Glu Val Tyr Ser Ser Ile Tyr Gln Asn Leu
 50 55 60

<210> 240
 <211> 193
 <212> PRT
 <213> Homo sapien

<400> 240

Ser Gly Gly Phe Thr Leu Arg Ser Thr Gly Ser Ala Ala Gly Arg Gly
 1 5 10 15

Leu Arg Lys Leu Arg Pro Thr Leu Ser Arg Gly Ala Cys Asp Val Gly
 20 25 30

Arg Ser Val Trp Lys Leu Arg Pro Ser His Cys Arg Val Gly Arg Gly
 35 40 45

Ala Arg Gly Ile Phe His Ala Pro Pro Leu Cys Arg Leu Lys Cys Val
 50 55 60

301

Gly Gly Lys Arg Trp Ala Gly Cys His Leu Ala Pro Pro Phe Ser Cys
 65 70 75 80

Gly Val Gly Gln Ala Ala Ala Ser Ser Ser Cys Ser Ser His Arg Leu
 85 90 95

His Ser Asp Pro Ser Pro Ala Ala Trp Ile Leu Leu Pro Arg Arg Gly
 100 105 110

Ser Phe Ser Arg Asn Leu Arg Ala Arg Pro Gln Ser Val Pro Ala Ala
 115 120 125

Ser Arg Arg Thr Arg Trp Leu Gln Ala Ser Leu Pro Gln Val Ser Trp
 130 135 140

Leu Arg Glu Arg Gln Arg Glu Arg Gly Gly Lys Thr Arg Glu Gln Ala
 145 150 155 160

Met Gly Gly Asp Gly Glu Ser Leu Leu Glu Gln Thr Arg Gly Arg Lys
 165 170 175

Pro Thr Phe Leu His Ser Pro Ser Ile His Leu Trp Pro Tyr Val Phe
 180 185 190

His

<210> 241
 <211> 163
 <212> PRT
 <213> Homo sapien

<400> 241

Ser Gly Gly Phe Thr Leu Arg Ser Thr Gly Ser Ala Ala Gly Arg Gly
 1 5 10 15

Leu Arg Lys Leu Arg Pro Thr Leu Ser Arg Gly Ala Cys Asp Val Gly
 20 25 30

Arg Ser Val Trp Lys Leu Arg Pro Ser His Cys Arg Val Gly Arg Gly
 35 40 45

Ala Arg Gly Ile Phe His Ala Pro Pro Leu Cys Arg Leu Lys Cys Val
 50 55 60

Gly Gly Lys Arg Trp Ala Gly Cys His Leu Ala Pro Pro Phe Ser Cys
 65 70 75 80

302

Gly Val Gly Gln Ala Ala Ala Ser Ser Ser Cys Ser Ser His Arg Leu
85 90 95

His Ser Asp Pro Ser Pro Ala Ala Trp Ile Leu Leu Pro Arg Arg Gly
100 105 110

Ser Phe Ser Arg Asn Leu Arg Ala Arg Pro Gln Ser Val Pro Ala Ala
115 120 125

Ser Arg Arg Thr Arg Trp Leu Gln Ala Ser Leu Thr Pro Gly Phe Leu
130 135 140

Ala Lys Arg Glu Thr Glu Gly Glu Arg Gly Glu Asp Glu Arg Thr Gly
145 150 155 160

Asn Gly Arg

<210> 242
<211> 227
<212> PRT
<213> Homo sapien

<220>
<221> MISC_FEATURE
<222> (3)..(4)
<223> X=any amino acid

<400> 242

Phe Phe Xaa Xaa Lys Glu Ala Gly Pro Pro Gly Leu Lys Thr His Ala
1 5 10 15

Gly Val Gly Pro Phe Trp Pro Val Gly Phe Leu Lys Pro Gln Trp Arg
20 25 30

Ala Leu Ser Ser Ser Phe Ser Gln Asn Pro Pro Gly Gly Leu Pro Leu
35 40 45

His Ser Phe Pro Asn Ser Gly Leu Pro Arg Arg His Arg Glu Thr Leu
50 55 60

Phe Gly Leu Pro Ser Lys Ser Arg Ala Met Leu Lys His Pro Trp Gly
65 70 75 80

Pro Gln Pro Phe Ser Pro Ser Val Pro Ala Lys Glu Pro Gln Gly Pro
85 90 95

303

Gly Gly His Gly Ala Arg Phe Arg Val Ala Lys Lys Ser Leu Val Pro
 100 105 110

Asn Gln Gly Ala Ser Gln Gly Ala Leu Leu Lys Thr Leu Ser Pro Thr
 115 120 125

Val Ile Trp Arg Gly Val Asn Ala Gly Gly Lys Pro Pro Arg Pro His
 130 135 140

Gln Arg Gly Phe Gln Lys Glu Gln Pro Ala Arg Gly Pro Arg Leu Arg
 145 150 155 160

Asn Asn Arg Arg Glu Thr Thr Gly Trp Ala Glu Pro Arg Val Lys Tyr
 165 170 175

Pro Trp Leu Pro Ala Arg Asp Gly Asp Arg Arg Arg Ala Trp Cys Cys
 180 185 190

Thr Trp Cys Tyr Trp Cys Ala Arg Lys Lys Tyr Pro Gly Leu Val Leu
 195 200 205

Glu Val Pro Arg Asp Lys Leu Thr Ala Ala Gly Met Lys Thr Asp Glu
 210 215 220

Gly Pro His
 225

<210> 243
 <211> 198
 <212> PRT
 <213> Homo sapien
 <400> 243

Met Ala Cys Pro Phe Glu Leu Leu Phe Ser Lys Pro Pro Trp Gly Pro
 1 5 10 15

Ser Pro Pro Leu Leu Pro Lys Phe Trp Ser Pro Gln Lys Thr Gln Gly
 20 25 30

Asn Ile Val Trp Ser Ala Gln Gln Ile Lys Gly Asn Ala Gln Thr Pro
 35 40 45

Met Gly Ala Pro Thr Leu Gln Pro Val Arg Ala Arg Gln Arg Thr Pro
 50 55 60

304

Arg Pro Trp Gly Thr Trp Gly Ser Leu Gln Ser Cys Gln Lys Lys Pro
65 70 75 80

Cys Ala Lys Ser Gly Gly Leu Pro Arg Gly Ser Val Glu Asn Ile Val
85 90 95

Pro Tyr Gly Asp Met Glu Gly Gly Gln Cys Arg Gly Glu Ala Thr Lys
100 105 110

Ala Thr Ile Asn Gly Asp Ser Arg Arg Ser Ser Gln Gln Gly Ala His
115 120 125

Gly Tyr Glu Ile Thr Ala Glu Lys Pro Pro Val Gly Arg Asn Arg Val
130 135 140_A

Ser Asn Thr Leu Gly Cys Pro Gln Gly Thr Gly Thr Gly Ala Glu His
145 150 155 160

Gly Ala Val Leu Gly Val Thr Gly Val Leu Arg Lys Lys Tyr Pro Gly
165 170 175

Leu Val Leu Glu Val Pro Arg Asp Lys Leu Thr Ala Ala Gly Met Lys
180 185 190

Thr Asp Glu Gly Pro His
195

<210> 244
<211> 103
<212> PRT
<213> Homo sapien

<400> 244

Pro Lys Asp Ala Pro Glu Lys Leu Glu Asn Leu Phe Gln Val Gly Arg
1 5 10 15

Arg Val Gly Asp Thr Lys Ile Thr Leu Leu Tyr Arg Thr Leu Gln Leu
20 25 30

Ser Met Gln Glu Ile Pro Phe Ser Leu Ser Ala Pro Gly Lys Thr Gln
35 40 45

Gln Pro Thr Glu Ala Ile Gly Asp Ser Leu Ser Thr Arg Gly Met Phe
50 55 60

Ser Lys Gln Gly Val Pro Cys Leu Ser Asn Lys Cys Pro Pro Ser Leu
65 70 75 80

305

Leu Gly Phe Leu Phe Leu Gln Leu Val Val Ser Lys Pro Leu Pro Gly
 85 90 95

Ile Val Lys Ala Leu Pro Lys
 100

<210> 245
 <211> 65
 <212> PRT
 <213> Homo sapien

<400> 245

Met Leu Pro Pro Ala Thr Ala Gln Leu Cys Leu Phe Asp Pro Arg Ala
 1 5 10 15

Val Ala Gly Leu Tyr Ile Ser Leu Tyr Asp His Lys Leu Pro Ala Asn
 20 25 30

Glu Ser Ile Cys Val Asp Asn Leu Thr Tyr Asn Ile Leu Ser Lys Ile
 35 40 45

Met His Phe Arg Gln Thr Asp Ile Ser Leu Phe Ser Ile Tyr Ser Phe
 50 55 60

Phe
 65

<210> 246
 <211> 103
 <212> PRT
 <213> Homo sapien

<400> 246

Pro Lys Asp Ala Pro Glu Lys Leu Glu Asn Leu Phe Gln Val Gly Arg
 1 5 10 15

Arg Val Gly Asp Thr Lys Ile Thr Leu Leu Tyr Arg Thr Leu Gln Leu
 20 25 30

Ser Met Gln Glu Ile Pro Phe Ser Leu Ser Ala Pro Gly Lys Thr Gln
 35 40 45

Gln Pro Thr Glu Ala Ile Gly Asp Ser Leu Ser Thr Arg Gly Met Phe
 50 55 60

Ser Lys Gln Gly Val Pro Cys Leu Ser Asn Lys Cys Pro Pro Ser Leu

306

65

70

75

80

Leu Gly Phe Leu Phe Leu Gln Leu Val Val Ser Lys Pro Leu Pro Gly
 85 90 95

Ile Val Lys Ala Leu Pro Lys
 100

<210> 247
 <211> 27
 <212> PRT
 <213> Homo sapien

<400> 247

Met Lys Leu Leu Thr Pro Pro Gly Ala Asp Ser His Leu Asn Ser Thr
 1 5 10 15

Pro Ser Lys Leu Arg Arg Ser Pro Ala Lys Asn
 20 25

<210> 248
 <211> 154
 <212> PRT
 <213> Homo sapien

<400> 248

Met Ala Ala Met Ala Ser Leu Gly Ala Leu Ala Leu Leu Leu Ser
 1 5 10 15

Ser Leu Ser Arg Cys Ser Ala Glu Ala Cys Leu Glu Pro Gln Ile Thr
 20 25 30

Pro Ser Tyr Tyr Thr Thr Ser Asp Ala Val Ile Ser Thr Glu Thr Val
 35 40 45

Phe Ile Val Glu Ile Ser Leu Thr Cys Lys Asn Arg Val Gln Asn Met
 50 55 60

Ala Leu Tyr Ala Asp Val Gly Gly Lys Gln Phe Pro Val Thr Arg Gly
 65 70 75 80

Gln Asp Val Gly Arg Tyr Gln Val Ser Trp Ser Leu Asp His Lys Ser
 85 90 95

Ala His Ala Gly Thr Tyr Glu Val Arg Phe Phe Asp Glu Glu Ser Tyr
 100 105 110

307

Ser Leu Leu Arg Lys Ala Gln Arg Asn Asn Glu Asp Ile Ser Ile Ile
 115 120 125

Pro Pro Leu Phe Thr Val Ser Val Asp His Arg Val Ser Gly Leu Val
 130 135 140

Pro Pro Pro Phe Trp Gly Cys Trp Ala Glu
 145 150

<210> 249
 <211> 176
 <212> PRT
 <213> Homo sapien

<400> 249

Leu Val Gln Ala Val Cys Gly Ser Glu Leu Arg Leu Ala Trp Pro Pro
 1 5 10 15

Gly Leu Arg Val Ile Gly Pro Ser Val Ala Glu Ala Cys Leu Glu Pro
 20 25 30

Gln Ile Thr Pro Ser Tyr Tyr Thr Thr Ser Asp Ala Val Ile Ser Thr
 35 40 45

Glu Thr Val Phe Ile Val Glu Ile Ser Leu Thr Cys Lys Asn Arg Val
 50 55 60

Gln Asn Met Ala Leu Tyr Ala Asp Val Gly Gly Lys Gln Phe Pro Val
 65 70 75 80

Thr Arg Gly Gln Asp Val Gly Arg Tyr Gln Val Ser Trp Ser Leu Asp
 85 90 95

His Lys Ser Ala His Ala Gly Thr Tyr Glu Val Arg Phe Phe Asp Glu
 100 105 110

Glu Ser Tyr Ser Leu Leu Arg Lys Ala Gln Arg Asn Asn Glu Asp Ile
 115 120 125

Ser Ile Ile Pro Pro Leu Phe Thr Val Ser Val Asp His Arg Gly Thr
 130 135 140

Trp Asn Gly Pro Trp Val Ser Thr Glu Val Leu Ala Ala Ala Ile Gly
 145 150 155 160

Leu Val Ile Tyr Tyr Leu Ala Phe Ser Ala Lys Ser His Ile Gln Ala
 165 170 175

308

<210> 250

<211> 271

<212> PRT

<213> Homo sapien

<400> 250

Ala Thr Tyr Ala Ser Leu Phe Leu Val Cys Pro Ser Cys Ser Trp Glu
 1 5 10 15

Leu Val Phe Phe Ser Ser Arg Gln Arg Arg Gly Asp Gly Gly Asp Gly
 20 25 30

Ile Ser Arg Arg Pro Gly Ala Ala Pro Ala Val Gln Pro Leu Pro Leu
 35 40 45

Leu Arg Lys Arg Trp Gly Gln Ser Ser Pro Ser Val Asn Trp Pro Gly
 50 55 60

Ala Glu Thr Leu Ser Leu Ile Leu Lys Ala Pro Val His Cys Leu Pro
 65 70 75 80

Ala Ala Pro Thr Pro Asp Val Ser Ala Glu Asp Ala Phe Ser Asn Ser
 85 90 95

Ser Arg Pro Phe Val Ala Leu Asn Val Arg Leu Ala Trp Pro Pro Gly
 100 105 110

Leu Arg Val Ile Gly Pro Ser Val Ala Glu Ala Cys Leu Glu Pro Gln
 115 120 125

Ile Thr Pro Ser Tyr Tyr Thr Thr Ser Asp Ala Val Ile Ser Thr Glu
 130 135 140

Thr Val Phe Ile Val Glu Ile Ser Leu Thr Cys Lys Asn Arg Val Gln
 145 150 155 160

Asn Met Ala Leu Tyr Ala Asp Val Gly Gly Lys Gln Phe Pro Val Thr
 165 170 175

Arg Gly Gln Asp Val Gly Arg Tyr Gln Val Ser Trp Ser Leu Asp His
 180 185 190

Lys Ser Ala His Ala Gly Thr Tyr Glu Val Arg Phe Phe Asp Glu Glu
 195 200 205

309

Ser Tyr Ser Leu Leu Arg Lys Ala Gln Arg Asn Asn Glu Asp Ile Ser
 210 215 220

Ile Ile Pro Pro Leu Phe Thr Val Ser Val Asp His Arg Gly Thr Trp
 225 230 235 240

Asn Gly Pro Trp Val Ser Thr Glu Val Leu Ala Ala Ala Ile Gly Leu
 245 250 255

Val Ile Tyr Tyr Leu Ala Phe Ser Ala Lys Ser His Ile Gln Ala
 260 265 270

<210> 251

<211> 268

<212> PRT

<213> Homo sapien

<400> 251

Met Lys Ser Val Ile Phe Gln Phe Gly Ile Lys Val Ser Phe Ser Val
 1 5 10 15

Ala Ala Lys Cys Leu Val Met Lys Ala Glu Met Asn Gly Ser Lys Leu
 20 25 30

Gly Arg Arg Ala Lys Pro Glu Gly Ala Leu Gln Asn Asn Asp Gly Leu
 35 40 45

Tyr Asp Pro Asp Cys Asp Glu Ser Gly Leu Phe Lys Ala Lys Gln Cys
 50 55 60

Asn Gly Thr Ser Met Cys Trp Cys Val Asn Thr Ala Gly Val Arg Arg
 65 70 75 80

Thr Asp Lys Asp Thr Glu Ile Thr Cys Ser Glu Arg Val Arg Thr Tyr
 85 90 95

Trp Ile Ile Ile Glu Leu Lys His Lys Ala Arg Glu Lys Pro Tyr Asp
 100 105 110

Ser Lys Ser Leu Arg Thr Ala Leu Gln Lys Glu Ile Thr Thr Arg Tyr
 115 120 125

Gln Leu Asp Pro Lys Phe Ile Thr Ser Ile Leu Tyr Glu Asn Asn Val
 130 135 140

Ile Thr Ile Asp Leu Val Gln Asn Ser Ser Gln Lys Thr Gln Asn Asp
 145 150 155 160

Val	Asp	Ile	Ala	Asp	Val	Ala	Tyr	Tyr	Phe	Glu	Lys	Asp	Val	Lys	Gly
				165						170					175
Glu	Ser	Leu	Phe	His	Ser	Lys	Lys	Met	Asp	Leu	Thr	Val	Asn	Gly	Glu
			180					185					190		
Gln	Leu	Asp	Leu	Asp	Pro	Gly	Gln	Thr	Leu	Ile	Tyr	Tyr	Val	Asp	Glu
		195					200					205			
Lys	Ala	Pro	Glu	Phe	Ser	Met	Gln	Gly	Leu	Lys	Ala	Gly	Val	Ile	Ala
	210					215					220				
Val	Ile	Val	Val	Val	Val	Ile	Ala	Val	Val	Ala	Gly	Ile	Val	Val	Leu
225					230					235					240
Val	Ile	Ser	Arg	Lys	Lys	Arg	Met	Ala	Lys	Tyr	Glu	Lys	Ala	Glu	Ile
				245					250					255	
Lys	Glu	Met	Gly	Glu	Met	His	Arg	Glu	Leu	Asn	Ala				
			260					265							
<210>	252														
<211>	342														
<212>	PRT														
<213>	Homo sapien														
<400>	252														
Met	Glu	Thr	Lys	His	Leu	Gly	Arg	Gly	Gly	Ala	Gly	Arg	Ala	Gly	Pro
1				5					10					15	
His	Leu	Trp	Arg	Gly	Pro	Arg	Pro	Asn	Cys	Ser	Ala	Gly	Ala	Gly	Gly
			20					25					30		
Gly	Glu	Pro	Thr	His	Ser	Pro	Asn	Ser	Arg	Ala	Val	Thr	His	Gln	Arg
		35					40					45			
Ala	Pro	Ala	Ala	Arg	Glu	Cys	Val	Cys	Glu	Asn	Tyr	Lys	Leu	Ala	Val
	50					55					60				
Asn	Cys	Phe	Val	Asn	Asn	Asn	Arg	Gln	Cys	Gln	Cys	Thr	Ser	Val	Gly
65					70					75					80
Ala	Gln	Asn	Thr	Val	Ile	Cys	Ser	Lys	Leu	Ala	Ala	Lys	Cys	Leu	Val
				85					90					95	

311

Met Lys Ala Glu Met Asn Gly Ser Lys Leu Gly Arg Arg Ala Lys Pro
 100 105 110

Glu Gly Ala Leu Gln Asn Asn Asp Gly Leu Tyr Asp Pro Asp Cys Asp
 115 120 125

Glu Ser Gly Leu Phe Lys Ala Lys Gln Cys Asn Gly Thr Ser Met Cys
 130 135 140

Trp Cys Val Asn Thr Ala Gly Val Arg Arg Thr Asp Lys Asp Thr Glu
 145 150 155 160

Ile Thr Cys Ser Glu Arg Val Arg Thr Tyr Trp Ile Ile Ile Glu Leu
 165 170 175

Lys His Lys Ala Arg Glu Lys Pro Tyr Asp Ser Lys Ser Leu Arg Thr
 180 185 190

Ala Leu Gln Lys Glu Ile Thr Thr Arg Tyr Gln Leu Asp Pro Lys Phe
 195 200 205

Ile Thr Ser Ile Leu Tyr Glu Asn Asn Val Ile Thr Ile Asp Leu Val
 210 215 220

Gln Asn Ser Ser Gln Lys Thr Gln Asn Asp Val Asp Ile Ala Asp Val
 225 230 235 240

Ala Tyr Tyr Phe Glu Lys Asp Val Lys Gly Glu Ser Leu Phe His Ser
 245 250 255

Lys Lys Met Asp Leu Thr Val Asn Gly Glu Gln Leu Asp Leu Asp Pro
 260 265 270

Gly Gln Thr Leu Ile Tyr Tyr Val Asp Glu Lys Ala Pro Glu Phe Ser
 275 280 285

Met Gln Gly Leu Lys Ala Gly Val Ile Ala Val Ile Val Val Val Val
 290 295 300

Ile Ala Val Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys
 305 310 315 320

Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met
 325 330 335

His Arg Glu Leu Asn Ala

312

340

<210> 253

<211> 240

<212> PRT

<213> Homo sapien

<400> 253

Met Ala Pro Pro Gln Val Leu Ala Phe Gly Leu Leu Leu Ala Ala Ala
 1 5 10 15

Thr Ala Thr Phe Ala Ala Ala Gln Glu Glu Cys Val Cys Glu Asn Tyr
 20 25 30

Lys Leu Ala Val Asn Cys Phe Val Asn Asn Asn Arg Gln Cys Gln Cys
 35 40 45

Thr Ser Val Gly Ala Gln Asn Thr Val Ile Cys Ser Lys Leu Ala Ala
 50 55 60

Lys Cys Leu Val Met Lys Ala Glu Met Asn Gly Ser Lys Leu Gly Arg
 65 70 75 80

Arg Ala Lys Pro Glu Gly Ala Leu Gln Asn Asn Asp Gly Leu Tyr Asp
 85 90 95

Pro Asp Cys Asp Glu Ser Gly Leu Phe Lys Ala Lys Gln Cys Asn Gly
 100 105 110

Thr Ser Met Cys Trp Cys Val Asn Thr Ala Gly Val Arg Arg Thr Asp
 115 120 125

Lys Asp Thr Glu Ile Thr Cys Ser Glu Arg Val Arg Thr Tyr Trp Ile
 130 135 140

Ile Ile Glu Leu Lys His Lys Ala Arg Glu Lys Pro Tyr Asp Ser Lys
 145 150 155 160

Ser Leu Arg Thr Ala Leu Gln Lys Glu Ile Thr Thr Arg Tyr Gln Leu
 165 170 175

Asp Pro Lys Phe Ile Thr Ser Ile Leu Tyr Glu Asn Asn Val Ile Thr
 180 185 190

Ile Asp Leu Val Gln Asn Ser Ser Gln Lys Thr Gln Asn Asp Val Asp
 195 200 205

313

Ile Ala Asp Val Ala Tyr Tyr Phe Glu Lys Asp Asp Val Ser Ile Ile
 210 215 220

Phe Phe Ile Pro Val Phe Arg Asn Val Val Tyr His Ala Ser Met Asn
 225 230 235 240

<210> 254
 <211> 390
 <212> PRT
 <213> Homo sapien

<400> 254

Met Ala Pro Pro Gln Val Leu Ala Phe Gly Leu Leu Leu Ala Ala Ala
 1 5 10 15

Thr Ala Thr Phe Ala Ala Ala Gln Glu Gly Glu Ala Arg Ile Gly Ala
 20 25 30

Glu Leu Trp Ser Trp Ala Gly Leu Gly Gly Ser Gly Pro Arg Pro Ser
 35 40 45

Ala Pro Glu Thr Gly Ile Ile Gly Arg Gly Pro Arg Gly Arg Ala Phe
 50 55 60

Gln Arg Gly Asp Arg Thr Val Arg Pro Cys Ser Gly Ser Gly Pro Pro
 65 70 75 80

Arg Gly Arg Lys Arg Arg Gly Pro Ser Arg Gly Ala Ala Ser Leu Arg
 85 90 95

Ser Phe Ala Arg Leu Glu Cys Val Cys Glu Asn Tyr Lys Leu Ala Val
 100 105 110

Asn Cys Phe Val Asn Asn Asn Arg Gln Cys Gln Cys Thr Ser Val Gly
 115 120 125

Ala Gln Asn Thr Val Ile Cys Ser Lys Leu Ala Ala Lys Cys Leu Val
 130 135 140

Met Lys Ala Glu Met Asn Gly Ser Lys Leu Gly Arg Arg Ala Lys Pro
 145 150 155 160

Glu Gly Ala Leu Gln Asn Asn Asp Gly Leu Tyr Asp Pro Asp Cys Asp
 165 170 175

Glu Ser Gly Leu Phe Lys Ala Lys Gln Cys Asn Gly Thr Ser Met Cys

314

	180		185		190
Trp Cys Val Asn Thr Ala Gly Val Arg Arg Thr Asp Lys Asp Thr Glu	195		200		205
Ile Thr Cys Ser Glu Arg Val Arg Thr Tyr Trp Ile Ile Ile Glu Leu	210		215		220
Lys His Lys Ala Arg Glu Lys Pro Tyr Asp Ser Lys Ser Leu Arg Thr	225		230		235
Ala Leu Gln Lys Glu Ile Thr Thr Arg Tyr Gln Leu Asp Pro Lys Phe		245		250	255
Ile Thr Ser Ile Leu Tyr Glu Asn Asn Val Ile Thr Ile Asp Leu Val		260		265	270
Gln Asn Ser Ser Gln Lys Thr Gln Asn Asp Val Asp Ile Ala Asp Val		275		280	285
Ala Tyr Tyr Phe Glu Lys Asp Val Lys Gly Glu Ser Leu Phe His Ser		290		295	300
Lys Lys Met Asp Leu Thr Val Asn Gly Glu Gln Leu Asp Leu Asp Pro	305		310		315
Gly Gln Thr Leu Ile Tyr Tyr Val Asp Glu Lys Ala Pro Glu Phe Ser		325		330	335
Met Gln Gly Leu Lys Ala Gly Val Ile Ala Val Ile Val Val Val Val		340		345	350
Ile Ala Val Val Ala Gly Ile Val Val Leu Val Ile Ser Arg Lys Lys		355		360	365
Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu Met Gly Glu Met		370		375	380
His Arg Glu Leu Asn Ala	385		390		

<210> 255

<211> 314

<212> PRT

<213> Homo sapien

<400> 255

315

Met	Ala	Pro	Pro	Gln	Val	Leu	Ala	Phe	Gly	Leu	Leu	Leu	Ala	Ala	Ala	1	5	10	15
Thr	Ala	Thr	Phe	Ala	Ala	Ala	Gln	Glu	Glu	Cys	Val	Cys	Glu	Asn	Tyr	20	25	30	
Lys	Leu	Ala	Val	Asn	Cys	Phe	Val	Asn	Asn	Asn	Arg	Gln	Cys	Gln	Cys	35	40	45	
Thr	Ser	Val	Gly	Ala	Gln	Asn	Thr	Val	Ile	Cys	Ser	Lys	Leu	Ala	Ala	50	55	60	
Lys	Cys	Leu	Val	Met	Lys	Ala	Glu	Met	Asn	Gly	Ser	Lys	Leu	Gly	Arg	65	70	75	80
Arg	Ala	Lys	Pro	Glu	Gly	Ala	Leu	Gln	Asn	Asn	Asp	Gly	Leu	Tyr	Asp	85	90	95	
Pro	Asp	Cys	Asp	Glu	Ser	Gly	Leu	Phe	Lys	Ala	Lys	Gln	Cys	Asn	Gly	100	105	110	
Thr	Ser	Thr	Cys	Trp	Cys	Val	Asn	Thr	Ala	Gly	Val	Arg	Arg	Thr	Asp	115	120	125	
Lys	Asp	Thr	Glu	Ile	Thr	Cys	Ser	Glu	Arg	Val	Arg	Thr	Tyr	Trp	Ile	130	135	140	
Ile	Ile	Glu	Leu	Lys	His	Lys	Ala	Arg	Glu	Lys	Pro	Tyr	Asp	Ser	Lys	145	150	155	160
Ser	Leu	Arg	Thr	Ala	Leu	Gln	Lys	Glu	Ile	Thr	Thr	Arg	Tyr	Gln	Leu	165	170	175	
Asp	Pro	Lys	Phe	Ile	Thr	Ser	Ile	Leu	Tyr	Glu	Asn	Asn	Val	Ile	Thr	180	185	190	
Ile	Asp	Leu	Val	Gln	Asn	Ser	Ser	Gln	Lys	Thr	Gln	Asn	Asp	Val	Asp	195	200	205	
Ile	Ala	Asp	Val	Ala	Tyr	Tyr	Phe	Glu	Lys	Asp	Val	Lys	Gly	Glu	Ser	210	215	220	
Leu	Phe	His	Ser	Lys	Lys	Met	Asp	Leu	Thr	Val	Asn	Gly	Glu	Gln	Leu	225	230	235	240

$\langle 210 \rangle$	257
$\langle 211 \rangle$	48

317

<212> PRT

<213> Homo sapien

<400> 257

Ala	Leu	Ser	Ser	Gly	Arg	Pro	Gly	Arg	Tyr	Ser	Val	Trp	Ile	Gly	Gly
1				5					10					15	

Ser	Ile	Leu	Ala	Ser	Leu	Ser	Thr	Phe	Gln	Gln	Met	Trp	Ile	Ser	Lys
			20					25					30		

Gln	Glu	Tyr	Asp	Glu	Ser	Gly	Pro	Ser	Ile	Val	His	Arg	Lys	Cys	Phe
		35					40					45			

<210> 258

<211> 596

<212> PRT

<213> Homo sapien

<400> 258

Met	Asn	Arg	Thr	Trp	Pro	Arg	Arg	Ile	Trp	Gly	Ser	Ser	Gln	Asp	Glu
1				5					10					15	

Ala	Glu	Leu	Ile	Arg	Glu	Asp	Ile	Gln	Gly	Ala	Leu	His	Asn	Tyr	Arg
			20					25					30		

Ser	Gly	Arg	Gly	Glu	Arg	Arg	Ala	Ala	Ala	Leu	Arg	Ala	Thr	Gln	Glu
		35					40					45			

Glu	Leu	Gln	Arg	Asp	Arg	Ser	Pro	Ala	Ala	Glu	Thr	Pro	Pro	Leu	Gln
	50					55					60				

Arg	Arg	Pro	Ser	Val	Arg	Ala	Val	Ile	Ser	Thr	Val	Glu	Arg	Gly	Ala
65					70					75				80	

Gly	Arg	Gly	Arg	Pro	Gln	Ala	Lys	Pro	Ile	Pro	Glu	Ala	Glu	Glu	Ala
				85					90					95	

Gln	Arg	Pro	Glu	Pro	Val	Gly	Thr	Ser	Ser	Asn	Ala	Asp	Ser	Ala	Ser
		100						105					110		

Pro	Asp	Leu	Gly	Pro	Arg	Gly	Pro	Asp	Leu	Ala	Val	Leu	Gln	Ala	Glu
		115					120					125			

Arg	Glu	Val	Asp	Ile	Leu	Asn	His	Val	Phe	Asp	Asp	Val	Glu	Ser	Phe
	130					135					140				

Val	Ser	Arg	Leu	Gln	Lys	Ser	Ala	Glu	Ala	Ala	Arg	Val	Leu	Glu	His
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

318

145		150		155		160									
Arg	Glu	Arg	Gly	Arg	Arg	Ser	Arg	Arg	Arg	Ala	Ala	Gly	Glu	Gly	Leu
			165						170					175	
Leu	Thr	Leu	Arg	Ala	Lys	Pro	Pro	Ser	Glu	Ala	Glu	Tyr	Thr	Asp	Val
			180					185					190		
Leu	Gln	Lys	Ile	Lys	Tyr	Ala	Phe	Ser	Leu	Leu	Ala	Arg	Leu	Arg	Gly
		195					200					205			
Asn	Ile	Ala	Asp	Pro	Ser	Ser	Pro	Glu	Leu	Leu	His	Phe	Leu	Phe	Gly
	210					215					220				
Pro	Leu	Gln	Met	Ile	Val	Asn	Thr	Ser	Gly	Gly	Pro	Glu	Phe	Ala	Ser
225					230					235					240
Ser	Val	Arg	Arg	Pro	His	Leu	Thr	Ser	Asp	Ala	Val	Ala	Leu	Leu	Arg
				245					250						255
Asp	Asn	Val	Thr	Pro	Arg	Glu	Asn	Glu	Leu	Trp	Thr	Ser	Leu	Gly	Asp
			260					265						270	
Ser	Trp	Thr	Arg	Pro	Gly	Leu	Glu	Leu	Ser	Pro	Glu	Glu	Gly	Pro	Pro
		275					280					285			
Tyr	Arg	Pro	Glu	Phe	Phe	Ser	Gly	Trp	Glu	Pro	Pro	Val	Thr	Asp	Pro
	290					295					300				
Gln	Ser	Arg	Ala	Trp	Glu	Asp	Pro	Val	Glu	Lys	Gln	Leu	Gln	His	Glu
305					310					315					320
Arg	Arg	Arg	Arg	Gln	Gln	Ser	Ala	Pro	Gln	Val	Ala	Val	Asn	Gly	His
				325					330					335	
Arg	Asp	Leu	Glu	Pro	Glu	Ser	Glu	Pro	Gln	Leu	Glu	Ser	Glu	Thr	Ala
			340					345					350		
Gly	Lys	Trp	Val	Leu	Cys	Asn	Tyr	Asp	Phe	Gln	Ala	Arg	Asn	Ser	Ser
		355					360					365			
Glu	Leu	Ser	Val	Lys	Gln	Arg	Asp	Val	Leu	Glu	Val	Leu	Asp	Asp	Ser
	370					375					380				
Arg	Lys	Trp	Trp	Lys	Val	Arg	Asp	Pro	Ala	Gly	Gln	Glu	Gly	Tyr	Val
385					390					395					400

319

Pro Tyr Asn Ile Leu Thr Pro Tyr Pro Gly Pro Arg Leu His His Ser
 405 410 415

Gln Ser Pro Ala Arg Ser Leu Asn Ser Thr Pro Pro Pro Pro Pro Ala
 420 425 430

Pro Ala Pro Ala Pro Pro Pro Ala Leu Ala Arg Pro Arg Trp Asp Arg
 435 440 445

Pro Arg Trp Asp Ser Cys Asp Ser Leu Asn Gly Leu Asp Pro Ser Glu
 450 455 460

Lys Glu Lys Phe Ser Gln Met Leu Ile Val Asn Glu Glu Leu Gln Ala
 465 470 475 480

Arg Leu Ala Gln Gly Arg Ser Gly Pro Ser Arg Ala Val Pro Gly Pro
 485 490 495

Arg Ala Pro Glu Pro Gln Leu Ser Pro Gly Ser Asp Ala Ser Glu Val
 500 505 510

Arg Ala Trp Leu Gln Ala Lys Gly Phe Ser Ser Gly Thr Val Asp Ala
 515 520 525

Leu Gly Val Leu Thr Gly Ala Gln Leu Phe Ser Leu Gln Arg Glu Glu
 530 535 540

Leu Arg Ala Val Ser Pro Glu Glu Gly Ala Arg Val Tyr Ser Gln Val
 545 550 555 560

Thr Val Gln Arg Ser Leu Leu Glu Asp Lys Glu Lys Val Ser Glu Leu
 565 570 575

Glu Ala Val Met Glu Lys Gln Lys Lys Lys Val Glu Gly Glu Val Glu
 580 585 590

Met Glu Val Ile
 595

<210> 259
 <211> 408
 <212> PRT
 <213> Homo sapien
 <400> 259

320

Asp Leu Phe Gln Met Ser Pro Leu Ser Pro Gly Ser Pro Leu Pro Pro
 1 5 10 15
 Leu Ala Arg Ala Asp Leu Thr Ala Ile Leu Thr Gly Cys Pro Pro Leu
 20 25 30
 Ser Ala Cys Leu Val Leu Ala Pro Arg Pro His Arg Arg Ala Arg Leu
 35 40 45
 Leu Pro Ser Glu Gly Leu Leu Thr Leu Arg Ala Lys Pro Pro Ser Glu
 50 55 60
 Ala Glu Tyr Thr Asp Val Leu Gln Lys Ile Lys Tyr Ala Phe Ser Leu
 65 70 75 80
 Leu Ala Arg Leu Arg Gly Asn Ile Ala Asp Pro Ser Ser Pro Glu Leu
 85 90 95
 Leu His Phe Leu Phe Gly Pro Leu Gln Met Ile Val Asn Thr Ser Gly
 100 105 110
 Gly Pro Glu Phe Ala Ser Ser Val Arg Arg Pro His Leu Thr Ser Asp
 115 120 125
 Ala Val Ala Leu Leu Arg Asp Asn Val Thr Pro Arg Glu Asn Glu Leu
 130 135 140
 Trp Thr Ser Leu Gly Asp Ser Trp Thr Arg Pro Gly Leu Glu Leu Ser
 145 150 155 160
 Pro Glu Glu Gly Pro Pro Tyr Arg Pro Glu Phe Phe Ser Gly Trp Glu
 165 170 175
 Pro Pro Val Thr Asp Pro Gln Ser Arg Ala Trp Glu Asp Pro Val Glu
 180 185 190
 Lys Gln Leu Gln His Glu Arg Arg Arg Arg Gln Gln Ser Ala Pro Gln
 195 200 205
 Val Ala Val Asn Gly His Arg Asp Leu Glu Pro Glu Ser Glu Pro Gln
 210 215 220
 Leu Glu Ser Glu Thr Ala Gly Lys Trp Val Leu Cys Asn Tyr Asp Phe
 225 230 235 240
 Gln Ala Arg Asn Ser Ser Glu Leu Ser Val Lys Gln Arg Asp Val Leu

Val Leu Ala Pro Arg Pro His Arg Arg Ala Arg Leu Leu Pro Ser Glu
35 40 45

322

Gly	Leu	Leu	Thr	Leu	Arg	Ala	Lys	Pro	Pro	Ser	Glu	Ala	Glu	Tyr	Thr	50	55	60	
Asp	Val	Leu	Gln	Lys	Ile	Lys	Tyr	Ala	Phe	Ser	Leu	Leu	Ala	Arg	Leu	65	70	75	80
Arg	Gly	Asn	Ile	Ala	Asp	Pro	Ser	Ser	Pro	Glu	Leu	Leu	His	Phe	Leu	85	90	95	
Phe	Gly	Pro	Leu	Gln	Met	Ile	Val	Asn	Thr	Ser	Gly	Gly	Pro	Glu	Phe	100	105	110	
Ala	Ser	Ser	Val	Arg	Arg	Pro	His	Leu	Thr	Ser	Asp	Ala	Val	Ala	Leu	115	120	125	
Leu	Arg	Asp	Asn	Val	Thr	Pro	Arg	Glu	Asn	Glu	Leu	Trp	Thr	Ser	Leu	130	135	140	
Gly	Asp	Ser	Trp	Thr	Arg	Pro	Gly	Leu	Glu	Leu	Ser	Pro	Glu	Glu	Gly	145	150	155	160
Pro	Pro	Tyr	Arg	Pro	Glu	Phe	Phe	Ser	Gly	Trp	Glu	Pro	Pro	Val	Thr	165	170	175	
Asp	Pro	Gln	Ser	Arg	Ala	Trp	Glu	Asp	Pro	Val	Glu	Lys	Gln	Leu	Gln	180	185	190	
His	Glu	Arg	Arg	Arg	Arg	Gln	Gln	Ser	Ala	Pro	Gln	Val	Ala	Val	Asn	195	200	205	
Gly	His	Arg	Asp	Leu	Glu	Pro	Glu	Ser	Glu	Pro	Gln	Leu	Glu	Ser	Glu	210	215	220	
Thr	Ala	Gly	Lys	Trp	Val	Leu	Cys	Asn	Tyr	Asp	Phe	Gln	Ala	Arg	Asn	225	230	235	240
Ser	Ser	Glu	Leu	Ser	Val	Lys	Gln	Arg	Asp	Val	Leu	Glu	Val	Leu	Asp	245	250	255	
Asp	Ser	Arg	Lys	Trp	Trp	Lys	Val	Arg	Asp	Pro	Ala	Gly	Gln	Glu	Gly	260	265	270	
Tyr	Val	Pro	Tyr	Asn	Ile	Leu	Thr	Pro	Tyr	Pro	Gly	Pro	Arg	Leu	His	275	280	285	

323

His Ser Gln Ser Pro Ala Arg Ser Leu Asn Ser Thr Pro Pro Pro Pro
 290 295 300

Pro Ala Pro Ala Pro Ala Pro Pro Pro Ala Leu Ala Arg Pro Arg Trp
 305 310 315 320

Asp Arg Pro Arg Trp Asp Ser Cys Asp Ser Leu Asn Gly Leu Asp Pro
 325 330 335

Ser Glu Lys Glu Lys Phe Ser Gln Met Leu Ile Val Asn Glu Glu Leu
 340 345 350

Gln Ala Arg Leu Ala Gln Gly Arg Ser Gly Pro Ser Arg Ala Val Pro
 355 360 365

Gly Pro Arg Ala Pro Glu Pro Gln Leu Ser Pro Gly Ser Asp Ala Ser
 370 375 380

Glu Val Arg Ala Trp Leu Gln Ala Lys Gly Phe Ser Ser Gly Thr Val
 385 390 395 400

Asp Ala Leu Gly Val Leu Thr Gly Ala Gln Leu Phe Ser Leu Gln Lys
 405 410 415

Glu Glu Leu Arg Ala Val Ser Pro Glu Glu Gly Ala Arg Val Tyr Ser
 420 425 430

Gln Val Thr Val Gln Arg Ser Leu Leu Glu Asp Lys Glu Lys Val Ser
 435 440 445

Glu Leu Glu Ala Val Met Glu Lys Gln Lys Lys Lys Val Glu Gly Glu
 450 455 460

Val Glu Met Glu Val Ile
 465 470

<210> 261

<211> 474

<212> PRT

<213> Homo sapien

<400> 261

Asp Leu Phe Gln Met Ser Pro Leu Ser Pro Gly Ser Pro Leu Pro Pro
 1 5 10 15

Leu Ala Arg Ala Asp Leu Thr Ala Ile Leu Thr Gly Cys Pro Pro Leu
 20 25 30

324

Ser Ala Cys Leu Val Leu Ala Pro Arg Pro His Arg Arg Ala Arg Leu
 35 40 45

Leu Pro Ser Glu Gly Leu Leu Thr Leu Arg Ala Lys Pro Pro Ser Glu
 50 55 60

Ala Glu Tyr Thr Asp Val Leu Gln Lys Ile Lys Tyr Ala Phe Ser Leu
 65 70 75 80

Leu Ala Arg Leu Arg Gly Asn Ile Ala Asp Pro Ser Ser Pro Glu Leu
 85 90 95

Leu His Phe Leu Phe Gly Pro Leu Gln Met Ile Val Asn Thr Ser Gly
 100 105 110

Gly Pro Glu Phe Ala Ser Ser Val Arg Arg Pro His Leu Thr Ser Asp
 115 120 125

Ala Val Ala Leu Leu Arg Asp Asn Val Thr Pro Arg Glu Asn Glu Leu
 130 135 140

Trp Thr Ser Leu Gly Asp Ser Trp Thr Arg Pro Gly Leu Glu Leu Ser
 145 150 155 160

Pro Glu Glu Gly Pro Pro Tyr Arg Pro Glu Phe Phe Ser Gly Trp Glu
 165 170 175

Pro Pro Val Thr Asp Pro Gln Ser Arg Ala Trp Glu Asp Pro Val Glu
 180 185 190

Lys Gln Leu Gln His Glu Arg Arg Arg Arg Gln Gln Ser Ala Pro Gln
 195 200 205

Val Ala Val Asn Gly His Arg Asp Leu Glu Pro Glu Ser Glu Pro Gln
 210 215 220

Leu Glu Ser Glu Thr Ala Gly Lys Trp Val Leu Cys Asn Tyr Asp Phe
 225 230 235 240

Gln Ala Arg Asn Ser Ser Glu Leu Ser Val Lys Gln Arg Asp Val Leu
 245 250 255

Glu Val Leu Asp Asp Ser Arg Lys Trp Trp Lys Val Arg Asp Pro Ala
 260 265 270

325

Gly Gln Glu Gly Tyr Val Pro Tyr Asn Ile Leu Thr Pro Tyr Pro Gly
 275 280 285

Pro Arg Leu His His Ser Gln Ser Pro Ala Arg Ser Leu Asn Ser Thr
 290 295 300

Pro Pro Pro Pro Pro Ala Pro Ala Pro Ala Pro Pro Pro Ala Leu Ala
 305 310 315 320

Arg Pro Arg Trp Asp Arg Pro Arg Trp Asp Ser Cys Asp Ser Leu Asn
 325 330 335

Gly Leu Asp Pro Ser Glu Lys Glu Lys Phe Ser Gln Met Leu Ile Val
 340 345 350

Asn Glu Glu Leu Gln Ala Arg Leu Ala Gln Gly Arg Ser Gly Pro Ser
 355 360 365

Arg Ala Val Pro Gly Pro Arg Ala Pro Glu Pro Gln Leu Ser Pro Gly
 370 375 380

Ser Asp Ala Ser Glu Val Arg Ala Trp Leu Gln Ala Lys Gly Phe Ser
 385 390 395 400

Ser Gly Thr Val Asp Ala Leu Gly Val Leu Thr Gly Ala Gln Leu Phe
 405 410 415

Ser Leu Gln Lys Glu Glu Leu Arg Ala Val Ser Pro Glu Glu Gly Ala
 420 425 430

Arg Val Tyr Ser Gln Val Thr Val Gln Arg Ser Leu Leu Glu Asp Lys
 435 440 445

Glu Lys Val Ser Glu Leu Glu Ala Val Met Glu Lys Gln Lys Lys Lys
 450 455 460

Val Glu Gly Glu Val Glu Met Glu Val Ile
 465 470

<210> 262

<211> 474

<212> PRT

<213> Homo sapien

<400> 262

Asp Leu Phe Gln Met Ser Pro Leu Ser Pro Gly Ser Pro Leu Pro Pro

326

1		5							10					15			
Leu	Ala	Arg	Ala	Asp	Leu	Thr	Ala	Ile	Leu	Thr	Gly	Cys	Pro	Pro	Leu		
			20					25					30				
Ser	Ala	Cys	Leu	Val	Leu	Ala	Pro	Arg	Pro	His	Arg	Arg	Ala	Arg	Leu		
		35					40					45					
Leu	Pro	Ser	Glu	Gly	Leu	Leu	Thr	Leu	Arg	Ala	Lys	Pro	Pro	Ser	Glu		
	50					55					60						
Ala	Glu	Tyr	Thr	Asp	Val	Leu	Gln	Lys	Ile	Lys	Tyr	Ala	Phe	Ser	Leu		
65					70					75					80		
Leu	Ala	Arg	Leu	Arg	Gly	Asn	Ile	Ala	Asp	Pro	Ser	Ser	Pro	Glu	Leu		
			85						90					95			
Leu	His	Phe	Leu	Phe	Gly	Pro	Leu	Gln	Met	Ile	Val	Asn	Thr	Ser	Gly		
			100					105						110			
Gly	Pro	Glu	Phe	Ala	Ser	Ser	Val	Arg	Arg	Pro	His	Leu	Thr	Ser	Asp		
		115					120					125					
Ala	Val	Ala	Leu	Leu	Arg	Asp	Asn	Val	Thr	Pro	Arg	Glu	Asn	Glu	Leu		
	130					135					140						
Trp	Thr	Ser	Leu	Gly	Asp	Ser	Trp	Thr	Arg	Pro	Gly	Leu	Glu	Leu	Ser		
145					150					155					160		
Pro	Glu	Glu	Gly	Pro	Pro	Tyr	Arg	Pro	Glu	Phe	Phe	Ser	Gly	Trp	Glu		
				165					170					175			
Pro	Pro	Val	Thr	Asp	Pro	Gln	Ser	Arg	Ala	Trp	Glu	Asp	Pro	Val	Glu		
			180					185					190				
Lys	Gln	Leu	Gln	His	Glu	Arg	Arg	Arg	Arg	Gln	Gln	Ser	Ala	Pro	Gln		
		195					200					205					
Val	Ala	Val	Asn	Gly	His	Arg	Asp	Leu	Glu	Pro	Glu	Ser	Glu	Pro	Gln		
	210					215					220						
Leu	Glu	Ser	Glu	Thr	Ala	Gly	Lys	Trp	Val	Leu	Cys	Asn	Tyr	Asp	Phe		
225					230					235					240		
Gln	Ala	Arg	Asn	Ser	Ser	Glu	Leu	Ser	Val	Lys	Gln	Arg	Asp	Val	Leu		
			245						250					255			

327

Glu Val Leu Asp Asp Ser Arg Lys Trp Trp Lys Val Arg Asp Pro Ala
 260 265 270

Gly Gln Glu Gly Tyr Val Pro Tyr Asn Ile Leu Thr Pro Tyr Pro Gly
 275 280 285

Pro Arg Leu His His Ser Gln Ser Pro Ala Arg Ser Leu Asn Ser Thr
 290 295 300

Pro Pro Pro Pro Pro Ala Pro Ala Pro Ala Pro Pro Pro Ala Leu Ala
 305 310 315 320

Arg Pro Arg Trp Asp Arg Pro Arg Trp Asp Ser Cys Asp Ser Leu Asn
 325 330 335

Gly Leu Asp Pro Ser Glu Lys Glu Lys Phe Ser Gln Met Leu Ile Val
 340 345 350

Asn Glu Glu Leu Gln Ala Arg Leu Ala Gln Gly Arg Ser Gly Pro Ser
 355 360 365

Arg Ala Val Pro Gly Pro Arg Ala Pro Glu Pro Gln Leu Ser Pro Gly
 370 375 380

Ser Asp Ala Ser Glu Val Arg Ala Trp Leu Gln Ala Lys Gly Phe Ser
 385 390 395 400

Ser Gly Thr Val Asp Ala Leu Gly Val Leu Thr Gly Ala Gln Leu Phe
 405 410 415

Ser Leu Gln Lys Glu Glu Leu Arg Ala Val Ser Pro Glu Glu Gly Ala
 420 425 430

Arg Val Tyr Ser Gln Val Thr Val Gln Arg Ser Leu Leu Glu Asp Lys
 435 440 445

Glu Lys Val Ser Glu Leu Glu Ala Val Met Glu Lys Gln Lys Lys Lys
 450 455 460

Val Glu Gly Glu Val Glu Met Glu Val Ile
 465 470

<210> 263

<211> 474

<212> PRT

328

<213> Homo sapien

<400> 263

Asp Leu Phe Gln Met Ser Pro Leu Ser Pro Gly Ser Pro Leu Pro Pro
 1 5 10 15

Leu Ala Arg Ala Asp Leu Thr Ala Ile Leu Thr Gly Cys Pro Pro Leu
 20 25 30

Ser Ala Cys Leu Val Leu Ala Pro Arg Pro His Arg Arg Ala Arg Leu
 35 40 45

Leu Pro Ser Glu Gly Leu Leu Thr Leu Arg Ala Lys Pro Pro Ser Glu
 50 55 60

Ala Glu Tyr Thr Asp Val Leu Gln Lys Ile Lys Tyr Ala Phe Ser Leu
 65 70 75 80

Leu Ala Arg Leu Arg Gly Asn Ile Ala Asp Pro Ser Ser Pro Glu Leu
 85 90 95

Leu His Phe Leu Phe Gly Pro Leu Gln Met Ile Val Asn Thr Ser Gly
 100 105 110

Gly Pro Glu Phe Ala Ser Ser Val Arg Arg Pro His Leu Thr Ser Asp
 115 120 125

Ala Val Ala Leu Leu Arg Asp Asn Val Thr Pro Arg Glu Asn Glu Leu
 130 135 140

Trp Thr Ser Leu Gly Asp Ser Trp Thr Arg Pro Gly Leu Glu Leu Ser
 145 150 155 160

Pro Glu Glu Gly Pro Pro Tyr Arg Pro Glu Phe Phe Ser Gly Trp Glu
 165 170 175

Pro Pro Val Thr Asp Pro Gln Ser Arg Ala Trp Glu Asp Pro Val Glu
 180 185 190

Lys Gln Leu Gln His Glu Arg Arg Arg Arg Gln Gln Ser Ala Pro Gln
 195 200 205

Val Ala Val Asn Gly His Arg Asp Leu Glu Pro Glu Ser Glu Pro Gln
 210 215 220

Leu Glu Ser Glu Thr Ala Gly Lys Trp Val Leu Cys Asn Tyr Asp Phe

	329																			
225									230				235				240			
Gln	Ala	Arg	Asn	Ser 245	Ser	Glu	Leu	Ser	Val 250	Lys	Gln	Arg	Asp	Val 255	Leu					
Glu	Val	Leu	Asp 260	Asp	Ser	Arg	Lys	Trp 265	Trp	Lys	Val	Arg	Asp 270	Pro	Ala					
Gly	Gln	Glu 275	Gly	Tyr	Val	Pro	Tyr 280	Asn	Ile	Leu	Thr	Pro 285	Tyr	Pro	Gly					
Pro	Arg 290	Leu	His	His	Ser	Gln 295	Ser	Pro	Ala	Arg	Ser 300	Leu	Asn	Ser	Thr					
Pro 305	Pro	Pro	Pro	Pro	Ala 310	Pro	Ala	Pro	Ala	Pro 315	Pro	Pro	Ala	Leu	Ala 320					
Arg	Pro	Arg	Trp	Asp 325	Arg	Pro	Arg	Trp	Asp 330	Ser	Cys	Asp	Ser	Leu 335	Asn					
Gly	Leu	Asp	Pro 340	Ser	Glu	Lys	Glu	Lys 345	Phe	Ser	Gln	Met	Leu 350	Ile	Val					
Asn	Glu	Glu 355	Leu	Gln	Ala	Arg	Leu 360	Ala	Gln	Gly	Arg	Ser 365	Gly	Pro	Ser					
Arg	Ala 370	Val	Pro	Gly	Pro	Arg 375	Ala	Pro	Glu	Pro	Gln 380	Leu	Ser	Pro	Gly					
Ser 385	Asp	Ala	Ser	Glu	Val 390	Arg	Ala	Trp	Leu	Gln 395	Ala	Lys	Gly	Phe	Ser 400					
Ser	Gly	Thr	Val	Asp 405	Ala	Leu	Gly	Val	Leu 410	Thr	Gly	Ala	Gln	Leu 415	Phe					
Ser	Leu	Gln	Lys 420	Glu	Glu	Leu	Arg	Ala 425	Val	Ser	Pro	Glu	Glu 430	Gly	Ala					
Arg	Val	Tyr 435	Ser	Gln	Val	Thr	Val 440	Gln	Arg	Ser	Leu	Leu 445	Glu	Asp	Lys					
Glu	Lys 450	Val	Ser	Glu	Leu	Glu 455	Ala	Val	Met	Glu	Lys 460	Gln	Lys	Lys	Lys					
Val 465	Glu	Gly	Glu	Val	Glu 470	Met	Glu	Val	Ile											

330

<210> 264
 <211> 470
 <212> PRT
 <213> Homo sapien

<400> 264

Met Ser Pro Leu Ser Pro Gly Ser Pro Leu Pro Pro Leu Ala Arg Ala
 1 5 10 15

Asp Leu Thr Ala Ile Leu Thr Gly Cys Pro Pro Leu Ser Ala Cys Leu
 20 25 30

Val Leu Ala Pro Arg Pro His Arg Arg Ala Arg Leu Leu Pro Ser Glu
 35 40 45

Gly Leu Leu Thr Leu Arg Ala Lys Pro Pro Ser Glu Ala Glu Tyr Thr
 50 55 60

Asp Val Leu Gln Lys Ile Lys Tyr Ala Phe Ser Leu Leu Ala Arg Leu
 65 70 75 80

Arg Gly Asn Ile Ala Asp Pro Ser Ser Pro Glu Leu Leu His Phe Leu
 85 90 95

Phe Gly Pro Leu Gln Met Ile Val Asn Thr Ser Gly Gly Pro Glu Phe
 100 105 110

Ala Ser Ser Val Arg Arg Pro His Leu Thr Ser Asp Ala Val Ala Leu
 115 120 125

Leu Arg Asp Asn Val Thr Pro Arg Glu Asn Glu Leu Trp Thr Ser Leu
 130 135 140

Gly Asp Ser Trp Thr Arg Pro Gly Leu Glu Leu Ser Pro Glu Glu Gly
 145 150 155 160

Pro Pro Tyr Arg Pro Glu Phe Phe Ser Gly Trp Glu Pro Pro Val Thr
 165 170 175

Asp Pro Gln Ser Arg Ala Trp Glu Asp Pro Val Glu Lys Gln Leu Gln
 180 185 190

His Glu Arg Arg Arg Arg Gln Gln Ser Ala Pro Gln Val Ala Val Asn
 195 200 205

331

Gly His Arg Asp Leu Glu Pro Glu Ser Glu Pro Gln Leu Glu Ser Glu
 210 215 220

Thr Ala Gly Lys Trp Val Leu Cys Asn Tyr Asp Phe Gln Ala Arg Asn
 225 230 235 240

Ser Ser Glu Leu Ser Val Lys Gln Arg Asp Val Leu Glu Val Leu Asp
 245 250 255

Asp Ser Arg Lys Trp Trp Lys Val Arg Asp Pro Ala Gly Gln Glu Gly
 260 265 270

Tyr Val Pro Tyr Asn Ile Leu Thr Pro Tyr Pro Gly Pro Arg Leu His
 275 280 285

His Ser Gln Ser Pro Ala Arg Ser Leu Asn Ser Thr Pro Pro Pro Pro
 290 295 300

Pro Ala Pro Ala Pro Ala Pro Pro Pro Ala Leu Ala Arg Pro Arg Trp
 305 310 315 320

Asp Arg Pro Arg Trp Asp Ser Cys Asp Ser Leu Asn Gly Leu Asp Pro
 325 330 335

Ser Glu Lys Glu Lys Phe Ser Gln Met Leu Ile Val Asn Glu Glu Leu
 340 345 350

Gln Ala Arg Leu Ala Gln Gly Arg Ser Gly Pro Ser Arg Ala Val Pro
 355 360 365

Gly Pro Arg Ala Pro Glu Pro Gln Leu Ser Pro Gly Ser Asp Ala Ser
 370 375 380

Glu Val Arg Ala Trp Leu Gln Ala Lys Gly Phe Ser Ser Gly Thr Val
 385 390 395 400

Asp Ala Leu Gly Val Leu Thr Gly Ala Gln Leu Phe Ser Leu Gln Lys
 405 410 415

Glu Glu Leu Arg Ala Val Ser Pro Glu Glu Gly Ala Arg Val Tyr Ser
 420 425 430

Gln Val Thr Val Gln Arg Ser Leu Leu Glu Asp Lys Glu Lys Val Ser
 435 440 445

Glu Leu Glu Ala Val Met Glu Lys Gln Lys Lys Lys Val Glu Gly Glu

332

450

455

460

Val Glu Met Glu Val Ile
465 470

<210> 265
<211> 502
<212> PRT
<213> Homo sapien

<400> 265

Met Ser Pro Leu Ser Pro Gly Ser Pro Leu Pro Pro Leu Ala Arg Ala
1 5 10 15

Asp Leu Thr Ala Ile Leu Thr Gly Cys Pro Pro Leu Ser Ala Cys Leu
20 25 30

Val Leu Ala Pro Arg Pro His Arg Arg Ala Arg Leu Leu Pro Ser Glu
35 40 45

Gly Leu Leu Thr Leu Arg Ala Lys Pro Pro Ser Glu Ala Glu Tyr Thr
50 55 60

Asp Val Leu Gln Lys Ile Lys Tyr Ala Phe Ser Leu Leu Ala Arg Leu
65 70 75 80

Arg Gly Asn Ile Ala Asp Pro Ser Ser Pro Glu Leu Leu His Phe Leu
85 90 95

Phe Gly Pro Leu Gln Met Ile Val Asn Thr Ser Gly Gly Pro Glu Phe
100 105 110

Ala Ser Ser Val Arg Arg Pro His Leu Thr Ser Asp Ala Val Ala Leu
115 120 125

Leu Arg Asp Asn Val Thr Pro Arg Glu Asn Glu Leu Trp Thr Ser Leu
130 135 140

Gly Asp Ser Trp Thr Arg Pro Gly Leu Glu Leu Ser Pro Glu Glu Gly
145 150 155 160

Pro Pro Tyr Arg Pro Glu Phe Phe Ser Gly Trp Glu Pro Pro Val Thr
165 170 175

Asp Pro Gln Ser Arg Ala Trp Glu Asp Pro Val Glu Lys Gln Leu Gln
180 185 190

333

His Glu Arg Arg Arg Arg Gln Val Thr Gln Ala Thr Gln Gln Gly Arg
 195 200 205

Gly Trp Glu Val Arg Gly Arg Gly Arg Ser Ala Trp Pro Arg Leu Thr
 210 215 220

Arg Leu Ser Tyr Phe Leu Gln Gln Ser Ala Pro Gln Val Ala Val Asn
 225 230 235 240

Gly His Arg Asp Leu Glu Pro Glu Ser Glu Pro Gln Leu Glu Ser Glu
 245 250 255

Thr Ala Gly Lys Trp Val Leu Cys Asn Tyr Asp Phe Gln Ala Arg Asn
 260 265 270

Ser Ser Glu Leu Ser Val Lys Gln Arg Asp Val Leu Glu Val Leu Asp
 275 280 285

Asp Ser Arg Lys Trp Trp Lys Val Arg Asp Pro Ala Gly Gln Glu Gly
 290 295 300

Tyr Val Pro Tyr Asn Ile Leu Thr Pro Tyr Pro Gly Pro Arg Leu His
 305 310 315 320

His Ser Gln Ser Pro Ala Arg Ser Leu Asn Ser Thr Pro Pro Pro Pro
 325 330 335

Pro Ala Pro Ala Pro Ala Pro Pro Pro Ala Leu Ala Arg Pro Arg Trp
 340 345 350

Asp Arg Pro Arg Trp Asp Ser Cys Asp Ser Leu Asn Gly Leu Asp Pro
 355 360 365

Ser Glu Lys Glu Lys Phe Ser Gln Met Leu Ile Val Asn Glu Glu Leu
 370 375 380

Gln Ala Arg Leu Ala Gln Gly Arg Ser Gly Pro Ser Arg Ala Val Pro
 385 390 395 400

Gly Pro Arg Ala Pro Glu Pro Gln Leu Ser Pro Gly Ser Asp Ala Ser
 405 410 415

Glu Val Arg Ala Trp Leu Gln Ala Lys Gly Phe Ser Ser Gly Thr Val
 420 425 430

334

Asp Ala Leu Gly Val Leu Thr Gly Ala Gln Leu Phe Ser Leu Gln Lys
 435 440 445

Glu Glu Leu Arg Ala Val Ser Pro Glu Glu Gly Ala Arg Val Tyr Ser
 450 455 460

Gln Val Thr Val Gln Arg Ser Leu Leu Glu Asp Lys Glu Lys Val Ser
 465 470 475 480

Glu Leu Glu Ala Val Met Glu Lys Gln Lys Lys Lys Val Glu Gly Glu
 485 490 495

Val Glu Met Glu Val Ile
 500

<210> 266
 <211> 548
 <212> PRT
 <213> Homo sapien

<400> 266

Met Gly Arg Lys Ala Ile Val Leu Ala Ile Ala Asn Thr Ser Leu Ala
 1 5 10 15

Phe Pro Leu Cys Gln His Leu Val Thr Phe Cys Leu Gly Glu Asp Asp
 20 25 30

Gly Val His Thr Val Glu Asp Ala Ser Arg Lys Leu Ala Val Met Asp
 35 40 45

Ser Gln Gly Arg Val Trp Ala Gln Glu Met Leu Leu Arg Val Ser Pro
 50 55 60

Asp His Val Thr Leu Leu Asp Pro Ala Ser Lys Glu Glu Leu Glu Ser
 65 70 75 80

Tyr Pro Leu Gly Ala Ile Val Arg Cys Asp Ala Val Met Pro Pro Gly
 85 90 95

Arg Ser Arg Ser Leu Leu Leu Leu Val Cys Gln Glu Pro Glu Arg Ala
 100 105 110

Gln Pro Asp Val His Phe Phe Gln Gly Leu Arg Leu Gly Ala Glu Leu
 115 120 125

Ile Arg Glu Asp Ile Gln Gly Ala Leu His Asn Tyr Arg Ser Gly Arg
 130 135 140

335

Gly	Glu	Arg	Arg	Ala	Ala	Ala	Leu	Arg	Ala	Thr	Gln	Glu	Glu	Leu	Gln	145	150	155	160
Arg	Asp	Arg	Ser	Pro	Ala	Ala	Glu	Thr	Pro	Pro	Leu	Gln	Arg	Arg	Pro	165	170	175	
Ser	Val	Arg	Ala	Val	Ile	Ser	Thr	Val	Glu	Arg	Gly	Ala	Gly	Arg	Gly	180	185	190	
Arg	Pro	Gln	Ala	Lys	Pro	Ile	Pro	Glu	Ala	Glu	Glu	Ala	Gln	Arg	Pro	195	200	205	
Glu	Pro	Val	Gly	Thr	Ser	Ser	Asn	Ala	Asp	Ser	Ala	Ser	Pro	Asp	Leu	210	215	220	
Gly	Pro	Arg	Gly	Pro	Asp	Leu	Ala	Val	Leu	Gln	Ala	Glu	Arg	Glu	Val	225	230	235	240
Asp	Ile	Leu	Asn	His	Val	Phe	Asp	Asp	Val	Glu	Ser	Phe	Val	Ser	Arg	245	250	255	
Leu	Gln	Lys	Ser	Ala	Glu	Ala	Ala	Arg	Val	Leu	Glu	His	Arg	Glu	Arg	260	265	270	
Gly	Arg	Arg	Ser	Arg	Arg	Arg	Ala	Ala	Gly	Glu	Gly	Leu	Leu	Thr	Leu	275	280	285	
Arg	Ala	Lys	Pro	Pro	Ser	Glu	Ala	Glu	Tyr	Thr	Asp	Val	Leu	Gln	Lys	290	295	300	
Ile	Lys	Tyr	Ala	Phe	Ser	Leu	Leu	Ala	Arg	Leu	Arg	Gly	Asn	Ile	Ala	305	310	315	320
Asp	Pro	Ser	Ser	Pro	Glu	Leu	Leu	His	Phe	Leu	Phe	Gly	Pro	Leu	Gln	325	330	335	
Met	Ile	Val	Asn	Thr	Ser	Gly	Gly	Pro	Glu	Phe	Ala	Ser	Ser	Val	Arg	340	345	350	
Arg	Pro	His	Leu	Thr	Ser	Asp	Ala	Val	Ala	Leu	Leu	Arg	Asp	Asn	Val	355	360	365	
Thr	Pro	Arg	Glu	Asn	Glu	Leu	Trp	Thr	Ser	Leu	Gly	Asp	Ser	Trp	Thr	370	375	380	

336

Arg Pro Gly Leu Glu Leu Ser Pro Glu Glu Gly Pro Pro Tyr Arg Pro
 385 390 395 400

Glu Phe Phe Ser Gly Trp Glu Pro Pro Val Thr Asp Pro Gln Ser Arg
 405 410 415

Ala Trp Glu Asp Pro Val Glu Lys Gln Leu Gln His Glu Arg Arg Arg
 420 425 430

Arg Gln Val Thr Gln Ala Thr Gln Gln Gly Arg Gly Trp Glu Val Arg
 435 440 445

Gly Arg Gly Arg Ser Ala Trp Pro Arg Leu Thr Arg Leu Ser Tyr Phe
 450 455 460

Leu Gln Gln Ser Ala Pro Gln Val Ala Val Asn Gly His Arg Asp Leu
 465 470 475 480

Glu Pro Glu Ser Glu Pro Gln Leu Glu Ser Glu Thr Ala Gly Lys Trp
 485 490 495

Val Leu Cys Asn Tyr Asp Phe Gln Ala Arg Asn Ser Ser Glu Leu Ser
 500 505 510

Val Lys Gln Arg Asp Val Leu Glu Asp Lys Glu Lys Val Ser Glu Leu
 515 520 525

Glu Ala Val Met Glu Lys Gln Lys Lys Lys Val Glu Gly Glu Val Glu
 530 535 540

Met Glu Val Ile
 545

<210> 267
 <211> 277.
 <212> PRT
 <213> Homo sapien

<400> 267

Met Gly Leu Ala Ala Ser Leu Ser Pro Thr Leu Pro Leu Leu Ser
 1 5 10 15

His Arg Asp Leu Glu Pro Glu Ser Glu Pro Gln Leu Glu Ser Glu Thr
 20 25 30

Ala Gly Lys Trp Val Leu Cys Asn Tyr Asp Phe Gln Ala Arg Asn Ser

337

35

40

45

Ser Glu Leu Ser Val Lys Gln Arg Asp Val Leu Glu Val Leu Asp Asp
 50 55 60

Ser Arg Lys Trp Trp Lys Val Arg Asp Pro Ala Gly Gln Glu Gly Tyr
 65 70 75 80

Val Pro Tyr Asn Ile Leu Thr Pro Tyr Pro Gly Pro Arg Leu His His
 85 90 95

Ser Gln Ser Pro Ala Arg Ser Leu Asn Ser Thr Pro Pro Pro Pro Pro
 100 105 110

Ala Pro Ala Pro Ala Pro Pro Pro Ala Leu Ala Arg Pro Arg Trp Asp
 115 120 125

Arg Pro Arg Trp Asp Ser Cys Asp Ser Leu Asn Gly Leu Asp Pro Ser
 130 135 140

Glu Lys Glu Lys Phe Ser Gln Met Leu Ile Val Asn Glu Glu Leu Gln
 145 150 155 160

Ala Arg Leu Ala Gln Gly Arg Ser Gly Pro Ser Arg Ala Val Pro Gly
 165 170 175

Pro Arg Ala Pro Glu Pro Gln Leu Ser Pro Gly Ser Asp Ala Ser Glu
 180 185 190

Val Arg Ala Trp Leu Gln Ala Lys Gly Phe Ser Ser Gly Thr Val Asp
 195 200 205

Ala Leu Gly Val Leu Thr Gly Ala Gln Leu Phe Ser Leu Gln Lys Glu
 210 215 220

Glu Leu Arg Ala Val Ser Pro Glu Glu Gly Ala Arg Val Tyr Ser Gln
 225 230 235 240

Val Thr Val Gln Arg Ser Leu Leu Glu Asp Lys Glu Lys Val Ser Glu
 245 250 255

Leu Glu Ala Val Met Glu Lys Gln Lys Lys Lys Val Glu Gly Glu Val
 260 265 270

Glu Met Glu Val Ile
 275

338

<210> 268
 <211> 282
 <212> PRT
 <213> Homo sapien

<400> 268

Met Ala Ser Leu Gly Gln Ile Leu Phe Trp Ser Ile Ile Ser Ile Ile
 1 5 10 15

Ile Ile Leu Ala Gly Ala Ile Ala Leu Ile Ile Gly Phe Gly Ile Ser
 20 25 30

Gly Arg His Ser Ile Thr Val Thr Thr Val Ala Ser Ala Gly Asn Ile
 35 40 45

Gly Glu Asp Gly Ile Gln Ser Cys Thr Phe Glu Pro Asp Ile Lys Leu
 50 55 60

Ser Asp Ile Val Ile Gln Trp Leu Lys Glu Gly Val Leu Gly Leu Val
 65 70 75 80

His Glu Phe Lys Glu Gly Lys Asp Glu Leu Ser Glu Gln Asp Glu Met
 85 90 95

Phe Arg Gly Arg Thr Ala Val Phe Ala Asp Gln Val Ile Val Gly Asn
 100 105 110

Ala Ser Leu Arg Leu Lys Asn Val Gln Leu Thr Asp Ala Gly Thr Tyr
 115 120 125

Lys Cys Tyr Ile Ile Thr Ser Lys Gly Lys Gly Asn Ala Asn Leu Glu
 130 135 140

Tyr Lys Thr Gly Ala Phe Ser Met Pro Glu Val Asn Val Asp Tyr Asn
 145 150 155 160

Ala Ser Ser Glu Thr Leu Arg Cys Glu Ala Pro Arg Trp Phe Pro Gln
 165 170 175

Pro Thr Val Val Trp Ala Ser Gln Val Asp Gln Gly Ala Asn Phe Ser
 180 185 190

Glu Val Ser Asn Thr Ser Phe Glu Leu Asn Ser Glu Asn Val Thr Met
 195 200 205

339

Lys Val Val Ser Val Leu Tyr Asn Val Thr Ile Asn Asn Thr Tyr Ser
 210 215 220

Cys Met Ile Glu Asn Asp Ile Ala Lys Ala Thr Gly Asp Ile Lys Val
 225 230 235 240

Thr Glu Ser Glu Ile Lys Arg Arg Ser His Leu Gln Leu Leu Asn Ser
 245 250 255

Lys Ala Ser Leu Cys Val Ser Ser Phe Phe Ala Ile Ser Trp Ala Leu
 260 265 270

Leu Pro Leu Ser Pro Tyr Leu Met Leu Lys
 275 280

<210> 269
 <211> 59
 <212> PRT
 <213> Homo sapien

<400> 269

Met Ala Ser Leu Gly Gln Ile Leu Phe Trp Ser Ile Ile Ser Ile Ile
 1 5 10 15

Ile Ile Leu Ala Gly Ala Ile Ala Leu Ile Ile Gly Phe Gly Ile Ser
 20 25 30

Glu Val Ser Val Trp Leu Ser Ala Met Lys Gly Leu Val Val Glu Val
 35 40 45

Pro Arg Leu Pro Leu Ala Leu Ile Phe Ala Ser
 50 55

<210> 270
 <211> 252
 <212> PRT
 <213> Homo sapien

<400> 270

Thr Ala Gly Arg His Ser Ile Thr Val Thr Thr Val Ala Ser Ala Gly
 1 5 10 15

Asn Ile Gly Glu Asp Gly Ile Leu Ser Cys Thr Phe Glu Pro Asp Ile
 20 25 30

Lys Leu Ser Asp Ile Val Ile Gln Trp Leu Lys Glu Gly Val Leu Gly
 35 40 45

340

Leu Val His Glu Phe Lys Glu Gly Lys Asp Glu Leu Ser Glu Gln Asp
 50 55 60

Glu Met Phe Arg Gly Arg Thr Ala Val Phe Ala Asp Gln Val Ile Val
 65 70 75 80

Gly Asn Ala Ser Leu Arg Leu Lys Asn Val Gln Leu Thr Asp Ala Gly
 85 90 95

Thr Tyr Lys Cys Tyr Ile Ile Thr Ser Lys Gly Lys Gly Asn Ala Asn
 100 105 110

Leu Glu Tyr Lys Thr Gly Ala Phe Ser Met Pro Glu Val Asn Val Asp
 115 120 125

Tyr Asn Ala Ser Ser Glu Thr Leu Arg Cys Glu Ala Pro Arg Trp Phe
 130 135 140

Pro Gln Pro Thr Val Val Trp Ala Ser Gln Val Asp Gln Gly Ala Asn
 145 150 155 160

Phe Ser Glu Val Ser Asn Thr Ser Phe Glu Leu Asn Ser Glu Asn Val
 165 170 175

Thr Met Lys Val Val Ser Val Leu Tyr Asn Val Thr Ile Asn Asn Thr
 180 185 190

Tyr Ser Cys Met Ile Glu Asn Asp Ile Ala Lys Ala Thr Gly Asp Ile
 195 200 205

Lys Val Thr Glu Ser Glu Ile Lys Arg Arg Ser His Leu Gln Leu Leu
 210 215 220

Asn Ser Lys Ala Ser Leu Cys Val Ser Ser Phe Phe Ala Ile Ser Trp
 225 230 235 240

Ala Leu Leu Pro Leu Ser Pro Tyr Leu Met Leu Lys
 245 250

<210> 271

<211> 155

<212> PRT

<213> Homo sapien

<400> 271

Gly Arg Gly Pro Pro Gly Glu Leu Cys His Glu Cys Trp Gln Gly Pro

Leu Cys Lys Asp Pro Val Gln Glu Ala Trp Ala Glu Asp Val Asp Leu
50 55 60

342

Arg Val Asn Phe Ala Met Asn Val Gly Lys Ala Arg Gly Phe Phe Lys
 65 70 75 80

Lys Gly Asp Val Val Ile Val Leu Thr Gly Trp Arg Pro Gly Ser Gly
 85 90 95

Phe Thr Asn Thr Met Arg Val Val Pro Val Pro
 100 105

<210> 273
 <211> 155
 <212> PRT
 <213> Homo sapien

<400> 273

Gly Arg Gly Pro Pro Gly Glu Leu Cys His Glu Cys Trp Gln Gly Pro
 1 5 10 15

Arg Leu Leu Gln Glu Gly Arg Cys Gly His Cys Ala Asp Arg Met Ala
 20 25 30

Pro Trp Leu Arg Leu His Gln His His Ala Cys Cys Ser Cys Ala Val
 35 40 45

Met Asp Pro Arg Ala Pro Pro Pro Ala Pro Val Pro Pro Pro Ser Pro
 50 55 60

Ser Pro Ser Ile Arg Pro Ala Thr Leu Val Glu Leu Thr Leu Gly Cys
 65 70 75 80

Asn Val Ala Leu Val Gly Trp Asp Thr Arg Glu Glu Asp Gln Arg Leu
 85 90 95

Thr Glu Thr Trp Leu Cys Leu Gln Pro Ala Leu Val Gly Gln Pro Arg
 100 105 110

Ala Trp Leu Pro Ile Met Trp Pro His Pro Ile Lys Gly Arg Arg Arg
 115 120 125

Asn Ala Gly Leu Glu Ala Pro Gly Ala Arg Trp Gln Glu Gly Asp Ser
 130 135 140

Phe Leu Ser Cys Val Tyr Ser Val Gln Phe Leu
 145 150 155

<210> 274

343

<211> 143
 <212> PRT
 <213> Homo sapien

<400> 274

Met Phe His Arg Lys Leu Phe Glu Glu Leu Val Arg Ala Ser Ser His
 1 5 10 15

Ser Thr Asp Leu Met Glu Ala Met Ala Met Gly Ser Val Glu Ala Ser
 20 25 30

Tyr Lys Cys Leu Ala Ala Ala Leu Ile Val Leu Thr Glu Ser Gly Arg
 35 40 45

Ser Ala His Gln Val Ala Arg Tyr Arg Pro Arg Ala Pro Ile Ile Ala
 50 55 60

Val Thr Arg Asn Pro Gln Thr Ala Arg Gln Ala His Leu Tyr Arg Gly
 65 70 75 80

Ile Phe Pro Val Leu Cys Lys Asp Pro Val Gln Glu Ala Trp Ala Glu
 85 90 95

Asp Val Asp Leu Arg Val Asn Phe Ala Met Asn Val Gly Lys Ala Arg
 100 105 110

Gly Phe Phe Lys Lys Gly Asp Val Val Ile Val Leu Thr Gly Trp Arg
 115 120 125

Pro Gly Ser Gly Phe Thr Asn Thr Met Arg Val Val Pro Val Pro
 130 135 140

<210> 275
 <211> 253
 <212> PRT
 <213> Homo sapien

<220>
 <221> MISC_FEATURE
 <222> (243)..(243)
 <223> X=any amino acid

<220>
 <221> MISC_FEATURE
 <222> (245)..(245)
 <223> X=any amino acid

<400> 275

344

Met Asp Thr Pro Pro Leu Ser Asp Ser Glu Ser Glu Ser Asp Glu Ser
 1 5 10 15

Leu Val Thr Asp Arg Glu Leu Gln Asp Ala Phe Ser Arg Gly Leu Leu
 20 25 30

Lys Pro Gly Leu Asn Val Val Leu Glu Gly Pro Lys Lys Ala Val Asn
 35 40 45

Asp Val Asn Gly Leu Lys Gln Cys Leu Ala Glu Phe Lys Arg Asp Leu
 50 55 60

Glu Trp Val Glu Arg Leu Asp Val Thr Leu Gly Pro Val Pro Glu Ile
 65 70 75 80

Gly Gly Ser Glu Ala Pro Ala Pro Gln Asn Lys Asp Gln Lys Ala Val
 85 90 95

Asp Pro Glu Asp Asp Phe Gln Arg Glu Met Ser Phe Tyr Arg Gln Ala
 100 105 110

Gln Ala Ala Val Leu Ala Val Leu Pro Arg Leu His Gln Leu Lys Val
 115 120 125

Pro Thr Lys Arg Pro Thr Asp Tyr Phe Ala Glu Met Ala Lys Ser Asp
 130 135 140

Leu Gln Met Gln Lys Ile Arg Gln Lys Leu Gln Thr Lys Gln Ala Ala
 145 150 155 160

Met Glu Arg Ser Glu Lys Ala Lys Gln Leu Arg Ala Leu Arg Lys Tyr
 165 170 175

Gly Lys Lys Val Gln Thr Glu Val Leu Gln Lys Arg Gln Gln Glu Lys
 180 185 190

Ala His Met Met Asn Ala Ile Lys Lys Tyr Gln Lys Gly Phe Ser Asp
 195 200 205

Lys Leu Asp Phe Leu Glu Gly Asp Gln Lys Pro Leu Ala Gln Arg Lys
 210 215 220

Lys Ala Gly Ala Lys Gly Gln Gln Met Arg Lys Gly Pro Thr Gly Pro
 225 230 235 240

Gln Arg Xaa Ile Xaa Glu Lys Gly Lys Gly Ala Gln Cys

345

245

250

<210> 276
 <211> 361
 <212> PRT
 <213> Homo sapien

<400> 276

Met Tyr Pro Glu Ala Leu Pro Val Gly Ile Leu Ser Asn Pro Asp Thr
 1 5 10 15

Phe Lys Arg Arg Ser Gly Ser Tyr Ser Asn Asp Lys Pro Glu Val Trp
 20 25 30

Phe Ala Ala Gly Ser Gly Ser Pro Asn Gln Lys Leu Ser Ser Ser Cys
 35 40 45

Val Gly Arg Ala Cys Gly Glu Met Asp Thr Pro Pro Leu Ser Asp Ser
 50 55 60

Glu Ser Glu Ser Asp Glu Ser Leu Val Thr Asp Arg Glu Leu Gln Asp
 65 70 75 80

Ala Phe Ser Arg Gly Leu Leu Lys Pro Gly Leu Asn Val Val Leu Glu
 85 90 95

Gly Pro Lys Lys Ala Val Asn Asp Val Asn Gly Leu Lys Gln Cys Leu
 100 105 110

Ala Glu Phe Lys Arg Asp Leu Glu Trp Val Glu Arg Leu Asp Val Thr
 115 120 125

Leu Gly Pro Val Pro Glu Ile Gly Gly Ser Glu Ala Pro Ala Pro Gln
 130 135 140

Asn Lys Asp Gln Lys Ala Val Asp Pro Glu Asp Asp Phe Gln Arg Glu
 145 150 155 160

Met Ser Phe Tyr Arg Gln Ala Gln Ala Ala Val Leu Ala Val Leu Pro
 165 170 175

Arg Leu His Gln Leu Lys Val Pro Thr Lys Arg Pro Thr Asp Tyr Phe
 180 185 190

Ala Glu Met Ala Lys Ser Asp Leu Gln Met Gln Lys Ile Arg Gln Lys
 195 200 205

346

Leu Gln Thr Lys Gln Ala Ala Met Glu Arg Ser Glu Lys Ala Lys Gln
 210 215 220

Leu Arg Ala Leu Arg Lys Tyr Gly Lys Lys Val Gln Thr Glu Val Leu
 225 230 235 240

Gln Lys Arg Gln Gln Glu Lys Ala His Met Met Asn Ala Ile Lys Lys
 245 250 255

Tyr Gln Lys Gly Phe Ser Asp Lys Leu Asp Phe Leu Glu Gly Asp Gln
 260 265 270

Lys Pro Leu Ala Gln Arg Lys Lys Ala Gly Ala Lys Gly Gln Gln Met
 275 280 285

Arg Lys Gly Pro Ser Ala Lys Arg Arg Tyr Lys Asn Gln Lys Phe Gly
 290 295 300

Phe Gly Gly Lys Lys Lys Gly Ser Lys Trp Asn Thr Arg Glu Ser Tyr
 305 310 315 320

Asp Asp Val Ser Ser Phe Arg Ala Lys Thr Ala His Gly Arg Gly Leu
 325 330 335

Lys Arg Pro Gly Lys Lys Gly Ser Asn Lys Arg Pro Gly Lys Arg Thr
 340 345 350

Arg Glu Lys Met Lys Asn Arg Thr His
 355 360

<210> 277

<211> 167

<212> PRT

<213> Homo sapien

<400> 277

Met Ala Lys Ser Asp Leu Gln Met Gln Lys Ile Arg Gln Lys Leu Gln
 1 5 10 15

Thr Lys Gln Ala Ala Met Glu Arg Ser Glu Lys Ala Lys Gln Leu Arg
 20 25 30

Ala Leu Arg Lys Tyr Gly Lys Lys Val Gln Thr Glu Val Leu Gln Lys
 35 40 45

Arg Gln Gln Glu Lys Ala His Met Met Asn Ala Ile Lys Lys Tyr Gln

347

50

55

60

Lys Gly Phe Ser Asp Lys Leu Asp Phe Leu Glu Gly Asp Gln Lys Pro
 65 70 75 80

Leu Ala Gln Arg Lys Lys Ala Gly Ala Lys Gly Gln Gln Met Arg Lys
 85 90 95

Gly Pro Ser Ala Lys Arg Arg Tyr Lys Asn Gln Lys Phe Gly Phe Gly
 100 105 110

Gly Lys Lys Lys Gly Ser Lys Trp Asn Thr Arg Glu Ser Tyr Asp Asp
 115 120 125

Val Ser Ser Phe Arg Ala Lys Thr Ala His Gly Arg Gly Leu Lys Arg
 130 135 140

Pro Gly Lys Lys Gly Ser Asn Lys Arg Pro Gly Lys Arg Thr Arg Glu
 145 150 155 160

Lys Met Lys Asn Arg Thr His
 165

<210> 278

<211> 636

<212> PRT

<213> Homo sapien

<400> 278

Pro Arg Arg Gly Leu Arg Val Ser Ser Pro Gly Gly Pro Gly Ala Met
 1 5 10 15

Gly Trp Val Gly Gly Arg Arg Arg Asp Ser Ala Ser Pro Pro Gly Arg
 20 25 30

Ser Arg Ser Ala Ala Asp Asp Ile Asn Pro Ala Pro Ala Asn Met Glu
 35 40 45

Gly Gly Gly Gly Ser Val Ala Val Ala Gly Leu Gly Ala Arg Gly Ser
 50 55 60

Gly Ala Ala Ala Ala Thr Val Arg Glu Leu Leu Gln Asp Gly Cys Tyr
 65 70 75 80

Ser Asp Phe Leu Asn Glu Asp Phe Asp Val Lys Thr Tyr Thr Ser Gln
 85 90 95

348

Ser Ile His Gln Ala Val Ile Ala Glu Gln Leu Ala Lys Leu Ala Gln
 100 105 110

Gly Ile Ser Gln Leu Asp Arg Glu Leu His Leu Gln Val Val Ala Arg
 115 120 125

His Glu Asp Leu Leu Ala Gln Ala Thr Gly Ile Glu Ser Leu Glu Gly
 130 135 140

Val Leu Gln Met Met Gln Thr Arg Ile Gly Ala Leu Gln Gly Ala Val
 145 150 155 160

Asp Arg Ile Lys Ala Lys Ile Val Glu Pro Tyr Asn Lys Ile Val Ala
 165 170 175

Arg Thr Ala Gln Leu Ala Arg Leu Gln Val Ala Cys Asp Leu Leu Arg
 180 185 190

Arg Ile Ile Arg Ile Leu Asn Leu Ser Lys Arg Leu Gln Gly Gln Leu
 195 200 205

Gln Gly Gly Ser Arg Glu Ile Thr Lys Ala Ala Gln Ser Leu Asn Glu
 210 215 220

Leu Asp Tyr Leu Ser Gln Gly Ile Asp Leu Ser Gly Ile Glu Val Ile
 225 230 235 240

Glu Asn Asp Leu Leu Phe Ile Ala Arg Ala Arg Leu Glu Val Glu Asn
 245 250 255

Gln Ala Lys Arg Leu Leu Glu Gln Gly Leu Glu Thr Gln Asn Pro Thr
 260 265 270

Gln Val Gly Thr Ala Leu Gln Val Phe Tyr Asn Leu Gly Thr Leu Lys
 275 280 285

Asp Thr Ile Thr Ser Val Val Asp Gly Tyr Cys Ala Thr Leu Glu Glu
 290 295 300

Asn Ile Asn Ser Ala Leu Asp Ile Lys Val Leu Thr Gln Pro Ser Gln
 305 310 315 320

Ser Ala Val Arg Gly Gly Pro Gly Arg Ser Thr Met Pro Thr Pro Gly
 325 330 335

349

Asn Thr Ala Ala Leu Arg Ala Ser Leu Trp Thr Asn Met Glu Lys Leu
 340 345 350

Met Asp His Ile Tyr Ala Val Cys Gly Gln Val Gln His Leu Gln Lys
 355 360 365

Val Leu Ala Lys Lys Arg Asp Pro Val Ser His Ile Cys Phe Ile Glu
 370 375 380

Glu Ile Val Lys Asp Gly Gln Pro Glu Ile Phe Tyr Thr Phe Trp Asn
 385 390 395 400

Ser Val Thr Gln Ala Leu Ser Ser Gln Phe His Met Ala Thr Asn Ser
 405 410 415

Ser Met Phe Leu Lys Gln Ala Phe Glu Gly Glu Tyr Pro Lys Leu Leu
 420 425 430

Arg Leu Tyr Asn Asp Leu Trp Lys Arg Leu Gln Gln Tyr Ser Gln His
 435 440 445

Ile Gln Gly Asn Phe Asn Ala Ser Gly Thr Thr Asp Leu Tyr Val Asp
 450 455 460

Leu Gln His Met Glu Asp Asp Ala Gln Asp Ile Phe Ile Pro Lys Lys
 465 470 475 480

Pro Asp Tyr Asp Pro Glu Lys Ala Leu Lys Asp Ser Leu Gln Pro Tyr
 485 490 495

Glu Ala Ala Tyr Leu Ser Lys Ser Leu Ser Arg Leu Phe Asp Pro Ile
 500 505 510

Asn Leu Val Phe Pro Pro Gly Gly Arg Asn Pro Pro Ser Ser Asp Glu
 515 520 525

Leu Asp Gly Ile Ile Lys Thr Ile Ala Ser Glu Leu Asn Val Ala Ala
 530 535 540

Val Asp Thr Asn Leu Thr Leu Ala Val Ser Lys Asn Val Ala Lys Thr
 545 550 555 560

Ile Gln Leu Tyr Ser Val Lys Ser Glu Gln Leu Leu Ser Thr Gln Gly
 565 570 575

Asp Ala Ser Gln Val Ile Gly Pro Leu Thr Glu Gly Gln Arg Arg Asn

```

350
580                               585                               590
Val Ala Val Val Asn Ser Leu Tyr Lys Leu His Gln Ser Val Thr Lys
    595                                600                                605

Val Val Ser Ser Gln Ser Ser Phe Pro Leu Ala Ala Glu Gln Thr Ile
    610                                615                                620

Ile Ser Ala Leu Lys Asp Leu Gln Tyr Ser Val Glu
    625                                630                                635

<210> 279
<211> 870
<212> PRT
<213> Homo sapien

<400> 279

Met Gly Trp Val Gly Gly Arg Arg Arg Asp Ser Ala Ser Pro Pro Gly
 1      5      10      15

Arg Ser Arg Ser Ala Ala Asp Asp Ile Asn Pro Ala Pro Ala Asn Met
    20      25      30

Glu Gly Gly Gly Gly Ser Val Ala Val Ala Gly Leu Gly Ala Arg Gly
    35      40      45

Ser Gly Ala Ala Ala Ala Thr Val Arg Glu Leu Leu Gln Asp Gly Cys
 50      55      60

Tyr Ser Asp Phe Leu Asn Glu Asp Phe Asp Val Lys Thr Tyr Thr Ser
65      70      75      80

Gln Ser Ile His Gln Ala Val Ile Ala Glu Gln Leu Ala Lys Leu Ala
    85      90      95

Gln Gly Ile Ser Gln Leu Asp Arg Glu Leu His Leu Gln Val Val Ala
    100     105     110

Arg His Glu Asp Leu Leu Ala Gln Ala Thr Gly Ile Glu Ser Leu Glu
    115     120     125

Gly Val Leu Gln Met Met Gln Thr Arg Ile Gly Ala Leu Gln Gly Ala
    130     135     140

Val Asp Arg Ile Lys Ala Lys Ile Val Glu Pro Tyr Asn Lys Ile Val
145      150      155      160

```

351

Ala Arg Thr Ala Gln Leu Ala Arg Leu Gln Val Ala Cys Asp Leu Leu
 165 170 175

Arg Arg Ile Ile Arg Ile Leu Asn Leu Ser Lys Arg Leu Gln Gly Gln
 180 185 190

Leu Gln Gly Gly Ser Arg Glu Ile Thr Lys Ala Ala Gln Ser Leu Asn
 195 200 205

Glu Leu Asp Tyr Leu Ser Gln Gly Ile Asp Leu Ser Gly Ile Glu Val
 210 215 220

Ile Glu Asn Asp Leu Leu Phe Ile Ala Arg Ala Arg Leu Glu Val Glu
 225 230 235 240

Asn Gln Ala Lys Arg Leu Leu Glu Gln Gly Leu Glu Thr Gln Asn Pro
 245 250 255

Thr Gln Val Gly Thr Ala Leu Gln Val Phe Tyr Asn Leu Gly Thr Leu
 260 265 270

Lys Asp Thr Ile Thr Ser Val Val Asp Gly Tyr Cys Ala Thr Leu Glu
 275 280 285

Glu Asn Ile Asn Ser Ala Leu Asp Ile Lys Val Leu Thr Gln Pro Ser
 290 295 300

Gln Ser Ala Val Arg Gly Gly Pro Gly Arg Ser Thr Met Pro Thr Pro
 305 310 315 320

Gly Asn Thr Ala Ala Leu Arg Ala Ser Leu Trp Thr Asn Met Glu Lys
 325 330 335

Leu Met Asp His Ile Tyr Ala Val Cys Gly Gln Val Gln His Leu Gln
 340 345 350

Lys Val Leu Ala Lys Lys Arg Asp Pro Val Ser His Ile Cys Phe Ile
 355 360 365

Glu Glu Ile Val Lys Asp Gly Gln Pro Glu Ile Phe Tyr Thr Phe Trp
 370 375 380

Asn Ser Val Thr Gln Ala Leu Ser Ser Gln Phe His Met Ala Thr Asn
 385 390 395 400

352

Ser Ser Met Phe Leu Lys Gln Ala Phe Glu Gly Glu Tyr Pro Lys Leu
 405 410 415

Leu Arg Leu Tyr Asn Asp Leu Trp Lys Arg Leu Gln Gln Tyr Ser Gln
 420 425 430

His Ile Gln Gly Asn Phe Asn Ala Ser Gly Thr Thr Asp Leu Tyr Val
 435 440 445

Asp Leu Gln His Met Glu Asp Asp Ala Gln Asp Ile Phe Ile Pro Lys
 450 455 460

Lys Pro Asp Tyr Asp Pro Glu Lys Ala Leu Lys Asp Ser Leu Gln Pro
 465 470 475 480

Tyr Glu Ala Ala Tyr Leu Ser Lys Ser Leu Ser Arg Leu Phe Asp Pro
 485 490 495

Ile Asn Leu Val Phe Pro Pro Gly Gly Arg Asn Pro Pro Ser Ser Asp
 500 505 510

Glu Leu Asp Gly Ile Ile Lys Thr Ile Ala Ser Glu Leu Asn Val Ala
 515 520 525

Ala Val Asp Thr Asn Leu Thr Leu Ala Val Ser Lys Asn Val Ala Lys
 530 535 540

Thr Ile Gln Leu Tyr Ser Val Lys Ser Glu Gln Leu Leu Ser Thr Gln
 545 550 555 560

Gly Asp Ala Ser Gln Val Ile Gly Pro Leu Thr Glu Gly Gln Arg Arg
 565 570 575

Asn Val Ala Val Val Asn Ser Leu Tyr Lys Leu His Gln Ser Val Thr
 580 585 590

Lys Val Val Ser Ser Gln Ser Ser Phe Pro Leu Ala Ala Glu Gln Thr
 595 600 605

Ile Ile Ser Ala Leu Lys Asp Leu Gln Tyr Ser Val Glu Tyr Glu Leu
 610 615 620

Ala Ile His Ala Leu Met Glu Asn Ala Val Gln Pro Leu Leu Thr Ser
 625 630 635 640

Val Gly Asp Ala Ile Glu Ala Ile Ile Ile Thr Met His Gln Glu Asp

353

645

650

655

Phe Ser Gly Ser Leu Ser Ser Ser Gly Lys Pro Asp Val Pro Cys Ser
 660 665 670

Leu Tyr Met Lys Glu Leu Gln Gly Phe Ile Ala Arg Val Met Ser Asp
 675 680 685

Tyr Phe Lys His Phe Glu Cys Leu Asp Phe Val Phe Asp Asn Thr Glu
 690 695 700

Ala Ile Ala Gln Arg Ala Val Glu Leu Phe Ile Arg His Ala Ser Leu
 705 710 715 720

Ile Arg Pro Leu Gly Glu Gly Gly Lys Met Arg Leu Ala Ala Asp Phe
 725 730 735

Ala Gln Met Glu Leu Ala Val Gly Pro Phe Cys Arg Arg Val Ser Asp
 740 745 750

Leu Gly Lys Ser Tyr Arg Met Leu Arg Ser Phe Arg Pro Leu Leu Phe
 755 760 765

Gln Ala Ser Glu His Val Ala Ser Ser Pro Ala Leu Gly Asp Val Ile
 770 775 780

Pro Phe Ser Ile Ile Ile Gln Phe Leu Phe Thr Arg Ala Pro Ala Glu
 785 790 795 800

Leu Lys Ser Pro Phe Gln Arg Ala Glu Trp Ser His Thr Arg Phe Ser
 805 810 815

Gln Trp Leu Asp Asp His Pro Ser Glu Lys Asp Arg Leu Leu Leu Ile
 820 825 830

Arg Gly Ala Leu Glu Ala Tyr Val Gln Ser Val Arg Ser Arg Glu Gly
 835 840 845

Lys Glu Phe Ala Pro Val Tyr Pro Ile Met Val Gln Leu Leu Gln Lys
 850 855 860

Ala Met Ser Ala Leu Gln
 865 870

<210> 280

<211> 791

354

<212> PRT

<213> Homo sapien

<400> 280

Met Gly Trp Val Gly Gly Arg Arg Arg Asp Ser Ala Ser Pro Pro Gly
 1 5 10 15

Arg Ser Arg Ser Ala Ala Asp Asp Ile Asn Pro Ala Pro Ala Asn Met
 20 25 30

Glu Gly Gly Gly Gly Ser Val Ala Val Ala Gly Leu Gly Ala Arg Gly
 35 40 45

Ser Gly Ala Ala Ala Ala Thr Val Arg Glu Leu Leu Gln Asp Gly Cys
 50 55 60

Tyr Ser Asp Phe Leu Asn Glu Asp Phe Asp Val Lys Thr Tyr Thr Ser
 65 70 75 80

Gln Ser Ile His Gln Ala Val Ile Ala Glu Gln Leu Ala Lys Leu Ala
 85 90 95

Gln Gly Ile Ser Gln Leu Asp Arg Glu Leu His Leu Gln Val Val Ala
 100 105 110

Arg His Glu Asp Leu Leu Ala Gln Ala Thr Gly Ile Glu Ser Leu Glu
 115 120 125

Gly Val Leu Gln Met Met Gln Thr Arg Ile Gly Ala Leu Gln Gly Ala
 130 135 140

Val Asp Arg Ile Lys Ala Lys Ile Val Glu Pro Tyr Asn Lys Ile Val
 145 150 155 160

Ala Arg Thr Ala Gln Leu Ala Arg Leu Gln Val Ala Cys Asp Leu Leu
 165 170 175

Arg Arg Ile Ile Arg Ile Leu Asn Leu Ser Lys Arg Leu Gln Gly Gln
 180 185 190

Leu Gln Gly Gly Ser Arg Glu Ile Thr Lys Ala Ala Gln Ser Leu Asn
 195 200 205

Glu Leu Asp Tyr Leu Ser Gln Gly Ile Asp Leu Ser Gly Ile Glu Val
 210 215 220

355

Ile Glu Asn Asp Leu Leu Phe Ile Ala Arg Ala Arg Leu Glu Val Glu
 225 230 235 240

Asn Gln Ala Lys Arg Leu Leu Glu Gln Gly Leu Glu Thr Gln Asn Pro
 245 250 255

Thr Gln Val Gly Thr Ala Leu Gln Val Phe Tyr Asn Leu Gly Thr Leu
 260 265 270

Lys Asp Thr Ile Thr Ser Val Val Asp Gly Tyr Cys Ala Thr Leu Glu
 275 280 285

Glu Asn Ile Asn Ser Ala Leu Asp Ile Lys Val Leu Thr Gln Pro Ser
 290 295 300

Gln Ser Ala Val Arg Gly Gly Pro Gly Arg Ser Thr Met Pro Thr Pro
 305 310 315 320

Gly Asn Thr Ala Ala Leu Arg Ala Ser Leu Trp Thr Asn Met Glu Lys
 325 330 335

Leu Met Asp His Ile Tyr Ala Val Cys Gly Gln Val Gln His Leu Gln
 340 345 350

Lys Val Leu Ala Lys Lys Arg Asp Pro Val Ser His Ile Cys Phe Ile
 355 360 365

Glu Glu Ile Val Lys Asp Gly Gln Pro Glu Ile Phe Tyr Thr Phe Trp
 370 375 380

Asn Ser Val Thr Gln Ala Leu Ser Ser Gln Phe His Met Ala Thr Asn
 385 390 395 400

Ser Ser Met Phe Leu Lys Gln Ala Phe Glu Gly Glu Tyr Pro Lys Leu
 405 410 415

Leu Arg Leu Tyr Asn Asp Leu Trp Lys Arg Leu Gln Gln Tyr Ser Gln
 420 425 430

His Ile Gln Gly Asn Phe Asn Ala Ser Gly Thr Thr Asp Leu Tyr Val
 435 440 445

Asp Leu Gln His Met Glu Asp Asp Ala Gln Asp Ile Phe Ile Pro Lys
 450 455 460

Lys Pro Asp Tyr Asp Pro Glu Lys Ala Leu Lys Asp Ser Leu Gln Pro

356

465		470						475				480			
Tyr	Glu	Ala	Ala	Tyr	Leu	Ser	Lys	Ser	Leu	Ser	Arg	Leu	Phe	Asp	Pro
				485					490					495	
Ile	Asn	Leu	Val	Phe	Pro	Pro	Gly	Gly	Arg	Asn	Pro	Pro	Ser	Ser	Asp
			500					505					510		
Glu	Leu	Asp	Gly	Ile	Ile	Lys	Thr	Ile	Ala	Ser	Glu	Leu	Asn	Val	Ala
		515					520					525			
Ala	Val	Asp	Thr	Asn	Leu	Thr	Leu	Ala	Val	Ser	Lys	Asn	Val	Ala	Lys
		530				535					540				
Thr	Ile	Gln	Leu	Tyr	Ser	Val	Lys	Ser	Glu	Gln	Leu	Leu	Ser	Thr	Gln
545					550					555					560
Gly	Asp	Ala	Ser	Gln	Val	Ile	Gly	Pro	Leu	Thr	Glu	Gly	Gln	Arg	Arg
				565					570					575	
Asn	Val	Ala	Val	Val	Asn	Ser	Leu	Tyr	Lys	Leu	His	Gln	Ser	Val	Thr
			580					585					590		
Lys	Val	Val	Ser	Ser	Gln	Ser	Ser	Phe	Pro	Leu	Ala	Ala	Glu	Gln	Thr
		595					600					605			
Ile	Ile	Ser	Ala	Leu	Lys	Ala	Ile	His	Ala	Leu	Met	Glu	Asn	Ala	Val
	610					615					620				
Gln	Pro	Leu	Leu	Thr	Ser	Val	Gly	Asp	Ala	Ile	Glu	Ala	Ile	Ile	Ile
625					630					635					640
Thr	Met	His	Gln	Glu	Asp	Phe	Ser	Gly	Ser	Leu	Ser	Ser	Ser	Gly	Lys
				645					650					655	
Pro	Asp	Val	Pro	Cys	Ser	Leu	Tyr	Met	Lys	Glu	Leu	Gln	Gly	Phe	Ile
			660					665					670		
Ala	Arg	Val	Met	Ser	Asp	Tyr	Phe	Lys	His	Phe	Glu	Cys	Leu	Asp	Phe
		675					680					685			
Val	Phe	Asp	Asn	Thr	Glu	Ala	Ile	Ala	Gln	Arg	Ala	Val	Glu	Leu	Phe
	690					695					700				
Ile	Arg	His	Ala	Ser	Leu	Ile	Arg	Pro	Leu	Gly	Glu	Gly	Gly	Lys	Met
705					710					715					720

Arg Leu Ala Ala Asp Phe Ala Gln Met Glu Leu Ala Val Gly Pro Phe
725 730 735

Cys Arg Arg Val Ser Asp Leu Gly Lys Ser Tyr Arg Met Leu Arg Ser
740 745 750

Phe Arg Gly Ala Leu Glu Ala Tyr Val Gln Ser Val Arg Ser Arg Glu
755 760 765

Gly Lys Glu Phe Ala Pro Val Tyr Pro Ile Met Val Gln Leu Leu Gln
770 775 780

Lys Ala Met Ser Ala Leu Gln
785 790

<210>	281
<211>	122
<212>	PRT
<213>	Homo sapien

<400> 281

Lys Val Thr Gly Lys Ser Gln Thr Val Leu Ala Ser Gly Val Asp Glu
1 5 10 15

Lys Gln Ala Lys Ile Ser Ser Pro Thr Glu Thr Glu Arg Cys Ile Glu
20 25 30

Ser Leu Ile Ala Val Phe Gln Lys Tyr Ala Gly Lys Asp Gly Tyr Asn
35 40 45

Tyr Thr Leu Ser Lys Thr Glu Phe Leu Ser Phe Met Asn Thr Glu Leu
50 55 60

Ala Ala Phe Thr Lys Asn Gln Lys Asp Pro Gly Val Leu Asp Arg Met
65 70 75 80

Met Lys Lys Leu Asp Thr Asn Ser Asp Gly Gln Leu Asp Phe Ser Glu
85 90 95

Phe Leu Asn Leu Ile Gly Gly Leu Ala Met Ala Cys His Asp Ser Phe
100 105 110

Leu Lys Ala Val Pro Ser Gln Lys Arg Thr
115 120

358

<210> 282
 <211> 170
 <212> PRT
 <213> Homo sapien

<400> 282

His Arg Pro Ser Ser Thr His Cys Asp Leu Gln Pro Ala Leu Phe Val
 1 5 10 15

Ser Ser Leu Pro Phe Lys Arg Gln Leu Ala Leu Glu Gly His Leu Leu
 20 25 30

Ser Ser Leu Pro Leu Asp Thr Pro Thr Lys Thr Gln Gly Glu Ala Leu
 35 40 45

Lys Ser Asn Trp Lys Val Thr Asp Arg Ser Gly Lys Trp Ile Asp Glu
 50 55 60

Lys Gln Ala Lys Ile Ser Ser Pro Thr Glu Thr Glu Arg Cys Ile Glu
 65 70 75 80

Ser Leu Ile Ala Val Phe Gln Lys Tyr Ala Gly Lys Asp Gly Tyr Asn
 85 90 95

Tyr Thr Leu Ser Lys Thr Glu Phe Leu Ser Phe Met Asn Thr Glu Leu
 100 105 110

Ala Ala Phe Thr Lys Asn Gln Lys Asp Pro Gly Val Leu Asp Arg Met
 115 120 125

Met Lys Lys Leu Asp Thr Asn Ser Asp Gly Gln Leu Asp Phe Ser Glu
 130 135 140

Phe Leu Asn Leu Ile Gly Gly Leu Ala Met Ala Cys His Asp Ser Phe
 145 150 155 160

Leu Lys Ala Val Pro Ser Gln Lys Arg Thr
 165 170

<210> 283
 <211> 91
 <212> PRT
 <213> Homo sapien

<400> 283

Met Lys Leu Glu Glu Leu Cys Leu Lys Tyr Ala Gly Lys Asp Gly Tyr
 1 5 10 15

359

Asn Tyr Thr Leu Ser Lys Thr Glu Phe Leu Ser Phe Met Asn Thr Glu
 20 25 30

Leu Ala Ala Phe Thr Lys Asn Gln Lys Asp Pro Gly Val Leu Asp Arg
 35 40 45

Met Met Lys Lys Leu Asp Thr Asn Ser Asp Gly Gln Leu Asp Phe Ser
 50 55 60

Glu Phe Leu Asn Leu Ile Gly Gly Leu Ala Met Ala Cys His Asp Ser
 65 70 75 80

Phe Leu Lys Ala Val Pro Ser Gln Lys Arg Thr
 85 90

<210> 284
 <211> 66
 <212> PRT
 <213> Homo sapien

<400> 284

Ser Leu Cys Tyr Asn Val Leu Lys Pro Pro Tyr Tyr Arg Asn Ile Tyr
 1 5 10 15

Tyr Ile Phe Ser Ile Cys Ser Phe Ser Glu Gly Leu Trp Ile Ser Leu
 20 25 30

Asn Cys Gln Ile Leu Ala Tyr Phe Cys Asp Thr Pro Ala His Phe Leu
 35 40 45

Ser Leu Ile Asn Gln Gly Val Arg Cys Asp Cys His Asn Cys Tyr Val
 50 55 60

Phe Gln
 65

<210> 285
 <211> 65
 <212> PRT
 <213> Homo sapien

<400> 285

Met Pro Gln Tyr Gln Thr Trp Glu Glu Phe Ser Arg Ala Ala Glu Lys
 1 5 10 15

Leu Tyr Leu Ala Asp Pro Met Lys Ala Arg Val Val Leu Lys Tyr Arg
 20 25 30

His Ser Asp Gly Asn Leu Cys Val Lys Val Thr Asp Asp Leu Val Leu
35 40 45

Met Arg Leu Met Val Ala Lys Glu Ala Arg Asn Val Thr Met Glu Thr
50 55 60

<210>	286
<211>	363
<212>	PRT
<213>	Homo sapien

Ser Arg Thr Thr Ser Ser Ser Ser Ser Arg Ala Thr Trp Cys Pro Leu
1 5 10 15

Thr Leu Ser Glu Gly Arg Leu Pro Gly Thr Gln Thr Leu Arg Glu Gln
20 25 30

Asn Gly Gln Pro Glu Leu Gly Lys Pro Arg Thr Asp Phe Lys Gly Ser
35 40 45

Phe Trp Thr Gly Gly Gly Arg Gly Pro Phe Pro Arg Gly Thr Asn Lys
50 55 60

Pro Ser Val Gln Asn Glu Gly Leu Cys Cys Ala Ser Arg Arg Ala Ser
65 70 75 80

Trp Arg Arg Gln Pro Leu Glu Val Ser His Leu Leu Pro Lys His Pro
85 90 95

Gln Val Val Asp Asp His Thr Ala Lys Lys Val Ser Gly Ile Leu Lys
100 105 110

Arg His Leu Gln Pro Val His Phe Ser Ser Trp Tyr Gly Glu Ser Val
115 120 125

Ser Val Gly Ser Gln Gly Lys Leu Val Ile Ser Gly Phe Pro Pro Ala
130 135 140

Gly Pro His Pro Phe Gln Thr Gln Leu Thr Leu His Arg Cys Gly Gln
145 150 155 160

361

Pro Gly Glu Ala Ala Gly Pro Ser Lys Pro Leu Thr Gln Asn Arg Trp
 165 170 175

Ser Ser Ala Pro Phe Tyr Arg Lys Ser Gly Val Leu Glu Val Thr Cys
 180 185 190

Ser Arg Ser His Ile Arg Val Pro Ile Arg Val Trp Val Ser Pro Lys
 195 200 205

Leu Pro Glu Ala Gln Thr Thr His Pro Arg Ser Arg Gly Arg Ile Ser
 210 215 220

Glu Ala Ser Cys Cys Pro Gln Gly Arg Asn Leu Gln Ser Cys Gly Glu
 225 230 235 240

Pro Glu Cys Pro Val Asn Leu Gln Gln Arg Lys Ala Met Ser Val Trp
 245 250 255

Gly Asp Pro Trp Asn Pro Cys His Pro Gly Pro Ser Ser Thr Phe Gln
 260 265 270

Ala Ala Pro Ala Thr Gly Glu Ala Thr Leu Lys Leu Asp Leu Gln Leu
 275 280 285

Gly Asp Thr Asp Glu Leu Gly Lys Leu Gln Arg His Pro Leu Gly Gly
 290 295 300

Ala Leu Glu Ala Asp Arg Glu Thr Glu Ala Gln Ala His Cys Arg His
 305 310 315 320

Arg Ala Leu Leu Cys Leu Ser His Ser His Ser Ser Trp Asn Gly Gly
 325 330 335

Glu Glu Gly Asn Ser Ala His Val Pro Phe Leu Val Glu Lys Met Phe
 340 345 350

Phe Ser Lys Leu Pro Ser Val Ala Ile Gln His
 355 360

<210> 287

<211> 116

<212> PRT

<213> Homo sapien

<400> 287

Cys Pro Gly Ser Ser Phe His Glu Ser His Asn Ser His Phe Leu Leu
 1 5 10 15

362

Gly Arg Lys Tyr Phe Tyr Ile Asn Ser Glu Lys Leu Gln Lys Cys Ile
 20 25 30

Phe Thr Asn Leu Gly Glu Val Glu Val Pro Gly Val Ser Pro Arg Phe
 35 40 45

Ser Gln Leu Cys Ser Val Met Gln Val Ser Ala Arg Val Pro Val Cys
 50 55 60

Pro Leu Arg Gly Glu Arg Arg Leu Ala Cys Ala Ser Thr Pro Leu Pro
 65 70 75 80

Ile Gln Ala His Ser Pro Pro Phe Pro Cys Pro Ile Ser Val Gln Gln
 85 90 95

Val Ile Glu Asn His Ile Leu Lys Leu Phe Gln Ser Asn Leu Val Pro
 100 105 110

Ala Asp Pro Glu
 115

<210> 288
 <211> 166
 <212> PRT
 <213> Homo sapien

<400> 288

Pro His Gly Gln Lys Ser Gln Trp His Pro Gln Thr Ser Pro Ser Ala
 1 5 10 15

Gly Pro Leu Gln Gln Leu Val Trp Gly Lys Ser Glu Ala Ser Cys Cys
 20 25 30

Pro Gln Gly Arg Asn Leu Gln Ser Cys Gly Glu Pro Glu Cys Pro Val
 35 40 45

Asn Leu Gln Gln Arg Lys Ala Met Ser Val Trp Gly Asp Pro Trp Asn
 50 55 60

Pro Cys His Pro Gly Pro Ser Ser Thr Phe Gln Ala Ala Pro Ala Thr
 65 70 75 80

Gly Glu Ala Thr Leu Lys Leu Asp Leu Gln Leu Gly Asp Thr Asp Glu
 85 90 95

363

Leu Gly Lys Leu Gln Arg His Pro Leu Gly Gly Ala Leu Glu Ala Asp
 100 105 110

Arg Glu Thr Glu Ala Gln Ala His Cys Arg His Arg Ala Leu Leu Cys
 115 120 125

Leu Ser His Ser His Ser Ser Trp Asn Gly Gly Glu Glu Gly Asn Ser
 130 135 140

Ala His Val Pro Phe Leu Val Glu Lys Met Phe Phe Ser Lys Leu Pro
 145 150 155 160

Ser Val Ala Ile Gln His
 165

<210> 289
 <211> 207
 <212> PRT
 <213> Homo sapien

<400> 289

Ala Ser Pro Leu Arg Ala Ala Leu Gly Leu Arg Ser Leu Val Cys Ala
 1 5 10 15

Leu Val Arg Pro Pro Val Leu Ser Thr Arg Ala Trp Pro Pro Asp Asp
 20 25 30

Ala Gly Ala Ala Arg Ala Gly Arg Gly Ser Leu Arg Ser Leu Leu Pro
 35 40 45

Ser Ala Gly Pro Leu Arg Arg Ser Pro Gln Phe Pro Ala Arg Thr Arg
 50 55 60

Ser Gly Pro Pro Asn Leu Arg Pro Lys Ser Gly Gly Gly Ser Gly Gly
 65 70 75 80

Lys Lys Met Lys Asn Glu Ile Ala Ala Val Val Phe Phe Phe Thr Arg
 85 90 95

Leu Val Arg Lys His Asp Lys Leu Lys Lys Glu Ala Val Glu Arg Phe
 100 105 110

Ala Glu Lys Leu Thr Leu Ile Leu Gln Glu Lys Tyr Lys Asn His Trp
 115 120 125

Tyr Pro Glu Lys Pro Ser Lys Gly Gln Ala Tyr Arg Cys Ile Arg Val
 130 135 140

364

Asn Lys Phe Gln Arg Val Asp Pro Asp Val Leu Lys Ala Cys Glu Asn
 145 150 155 160

Ser Cys Ile Leu Tyr Ser Asp Leu Gly Leu Pro Lys Glu Leu Thr Leu
 165 170 175

Trp Val Asp Pro Cys Glu Val Cys Cys Arg Tyr Gly Glu Lys Asn Asn
 180 185 190

Ala Phe Ile Val Ala Ser Phe Glu Asn Lys Asp Glu Gly Tyr Leu
 195 200 205

<210> 290
 <211> 352
 <212> PRT
 <213> Homo sapien

<400> 290

Met Ala Val Trp Ser Pro Leu Val Met Pro Gly Arg Arg Glu Gly Cys
 1 5 10 15

Cys His Thr Pro Val Thr Asn Glu Glu Thr Glu Ala Arg Glu Ala Lys
 20 25 30

Gly Gln Lys Leu Arg Pro Cys His Thr Leu Gly Val His Val Cys Leu
 35 40 45

Ser Leu Phe Arg Ser Glu Leu Leu Gly Leu Leu Lys Thr Tyr Asn Cys
 50 55 60

Tyr His Glu Gly Lys Ser Phe Gln Leu Arg His Arg Glu Glu Glu Gly
 65 70 75 80

Thr Leu Ile Ile Glu Gly Leu Leu Asn Ile Ala Trp Gly Leu Arg Arg
 85 90 95

Pro Ile Arg Leu Gln Met Gln Asp Asp Arg Glu Gln Val His Leu Pro
 100 105 110

Ser Thr Ser Trp Met Pro Arg Arg Pro Ser Cys Pro Leu Lys Glu Pro
 115 120 125

Ser Pro Gln Asn Gly Asn Ile Thr Ala Gln Gly Pro Ser Ile Gln Pro
 130 135 140

365

Val His Lys Ala Glu Ser Ser Thr Asp Ser Ser Gly Pro Leu Glu Glu
 145 150 155 160

Ala Glu Glu Ala Pro Gln Leu Met Arg Thr Lys Ser Asp Ala Ser Cys
 165 170 175

Met Ser Gln Arg Arg Pro Lys Cys Arg Ala Pro Gly Glu Ala Gln Arg
 180 185 190

Ile Arg Arg His Arg Phe Ser Ile Asn Gly His Phe Tyr Asn His Lys
 195 200 205

Thr Ser Val Phe Thr Pro Ala Tyr Gly Ser Val Thr Asn Val Arg Val
 210 215 220

Asn Ser Thr Met Thr Thr Leu Gln Val Leu Thr Leu Leu Leu Asn Lys
 225 230 235 240

Phe Arg Val Glu Asp Gly Pro Ser Glu Phe Ala Leu Tyr Ile Val His
 245 250 255

Glu Ser Gly Glu Arg Thr Lys Leu Lys Asp Cys Glu Tyr Pro Leu Ile
 260 265 270

Ser Arg Ile Leu His Gly Pro Cys Glu Lys Ile Ala Arg Ile Phe Leu
 275 280 285

Met Glu Ala Asp Leu Gly Val Glu Val Pro His Glu Val Ala Gln Tyr
 290 295 300

Ile Lys Phe Glu Met Pro Val Leu Asp Ser Phe Val Glu Lys Leu Lys
 305 310 315 320

Glu Glu Glu Glu Arg Glu Ile Ile Lys Leu Thr Met Lys Phe Gln Ala
 325 330 335

Leu Arg Leu Thr Met Leu Gln Arg Leu Glu Gln Leu Val Glu Ala Lys
 340 345 350

<210> 291
 <211> 261
 <212> PRT
 <213> Homo sapien

<400> 291

Met Ala Val Trp Ser Pro Leu Val Met Pro Gly Arg Arg Glu Gly Cys
 1 5 10 15

366

Cys His Thr Pro Val Thr Asn Glu Glu Thr Glu Ala Arg Glu Ala Lys
 20 25 30

Gly Gln Lys Leu Arg Pro Cys His Thr Leu Gly Val His Val Cys Leu
 35 40 45

Ser Leu Phe Arg Ser Glu Leu Leu Gly Leu Leu Lys Thr Tyr Asn Cys
 50 55 60

Tyr His Glu Gly Lys Ser Phe Gln Leu Arg His Arg Glu Glu Glu Gly
 65 70 75 80

Thr Leu Ile Ile Glu Gly Leu Leu Asn Ile Ala Trp Gly Leu Arg Arg
 85 90 95

Pro Ile Arg Leu Gln Met Gln Asp Asp Arg Glu Gln Val His Leu Pro
 100 105 110

Ser Thr Ser Trp Met Pro Arg Arg Pro Ser Cys Pro Leu Lys Glu Pro
 115 120 125

Ser Pro Gln Asn Gly Asn Ile Thr Ala Gln Gly Pro Ser Ile Gln Pro
 130 135 140

Val His Lys Ala Glu Ser Ser Thr Asp Ser Ser Gly Pro Leu Glu Glu
 145 150 155 160

Ala Glu Glu Ala Pro Gln Leu Met Arg Thr Lys Ser Asp Ala Ser Cys
 165 170 175

Met Ser Gln Arg Arg Pro Lys Cys Arg Ala Pro Gly Glu Ala Gln Arg
 180 185 190

Ile Arg Arg His Arg Phe Ser Ile Asn Gly His Phe Tyr Asn His Lys
 195 200 205

Thr Ser Val Phe Thr Pro Ala Tyr Gly Ser Val Thr Asn Val Arg Val
 210 215 220

Asn Ser Thr Met Thr Thr Leu Gln Val Leu Thr Leu Leu Leu Asn Lys
 225 230 235 240

Phe Arg Val Glu Asp Gly Pro Ser Glu Phe Ala Leu Tyr Ile Val His
 245 250 255

367

Glu Ser Gly Gly Phe
260

<210> 292

<211> 269

<212> PRT

<213> Homo sapien

<400> 292

Met Ala Val Trp Ser Pro Leu Val Met Pro Gly Arg Arg Glu Gly Cys
1 5 10 15

Cys His Thr Pro Val Thr Asn Glu Glu Thr Glu Ala Arg Glu Ala Lys
20 25 30

Gly Gln Lys Leu Arg Pro Cys His Thr Leu Gly Val His Val Cys Leu
35 40 45

Ser Leu Phe Arg Ser Glu Leu Leu Gly Leu Leu Lys Thr Tyr Asn Cys
50 55 60

Tyr His Glu Gly Lys Ser Phe Gln Leu Arg His Arg Glu Glu Glu Gly
65 70 75 80

Thr Leu Ile Ile Glu Gly Leu Leu Asn Ile Ala Trp Gly Leu Arg Arg
85 90 95

Pro Ile Arg Leu Gln Met Gln Asp Asp Arg Glu Gln Val His Leu Pro
100 105 110

Ser Thr Ser Trp Met Pro Arg Arg Pro Ser Cys Pro Leu Lys Glu Pro
115 120 125

Ser Pro Gln Asn Gly Asn Ile Thr Ala Gln Gly Pro Ser Ile Gln Pro
130 135 140

Val His Lys Ala Glu Ser Ser Thr Asp Ser Ser Gly Pro Leu Glu Glu
145 150 155 160

Ala Glu Glu Ala Pro Gln Leu Met Arg Thr Lys Ser Asp Ala Ser Cys
165 170 175

Met Ser Gln Arg Arg Pro Lys Cys Arg Ala Pro Gly Glu Ala Gln Arg
180 185 190

Ile Arg Arg His Arg Phe Ser Ile Asn Gly His Phe Tyr Asn His Lys

368

195

200

205

Thr Ser Val Phe Thr Pro Ala Tyr Gly Ser Val Thr Asn Val Arg Val
 210 215 220

Asn Ser Thr Met Thr Thr Leu Gln Val Leu Thr Leu Leu Leu Asn Lys
 225 230 235 240

Phe Arg Val Glu Asp Gly Pro Ser Glu Phe Ala Leu Tyr Ile Val His
 245 250 255

Glu Ser Gly Glu Asp Arg Gln Asp Leu Pro Asp Gly Ser
 260 265

<210> 293
 <211> 133
 <212> PRT
 <213> Homo sapien
 <400> 293

Met Arg Ser Ser Leu Leu Ser Ala Ile Thr Leu Pro Gln Cys Pro Arg
 1 5 10 15

Leu Leu Ser Leu Gln Tyr His Pro Val Ser Leu Ala Gln Leu Ser Pro
 20 25 30

Asn Thr Glu Val Arg Pro Gly Ile Arg Pro Gln Val Ser His Phe Leu
 35 40 45

Cys Arg Asn Gln Ser Leu Leu His Gln Arg Asp Leu Lys Arg Phe Leu
 50 55 60

Gln Gly Ala Cys Cys Lys Lys His Gly His Ser Ile Thr Leu Arg Arg
 65 70 75 80

Val His Met Ala Leu Arg Gly Cys Cys Pro Leu Asn Ala Gln Gln Gln
 85 90 95

Leu Trp Lys Ala Val Leu Ser Pro Ile Thr Thr Val Pro Trp Met Pro
 100 105 110

Val Tyr Leu Leu Pro Phe Leu Gly Leu Arg Phe Ser Pro Leu Val Gly
 115 120 125

Gly Asp Asp Phe Gln
 130

369

<210> 294
 <211> 163
 <212> PRT
 <213> Homo sapien

<400> 294

Trp Val His Ser Thr Tyr Arg Val Asp Ala Glu Ala Gln His Lys Glu
 1 5 10 15

Gly Cys Arg Ile Gly Tyr Gly Arg Ile Trp Ala Glu Thr Trp Ala Ser
 20 25 30

Arg Ser Leu Leu Tyr Arg Pro Val His Ser Ser Val Leu Leu Ser Val
 35 40 45

Leu Glu Ser Ala Ile Glu Met Thr Thr Leu Cys Ser Asp Ala Leu Cys
 50 55 60

Ser Pro Gln Pro Gly Leu Thr Ala Pro His Glu Ala Gln Ala Thr Ala
 65 70 75 80

Phe Pro Leu Leu Gly Arg Gly Glu Met Arg Leu Leu Gln Gly Ser Pro
 85 90 95

Glu Leu Ala Ile Cys Arg Ser Leu Ala Leu Leu Pro Thr Ser Leu Pro
 100 105 110

Cys Leu Ala Ser Val Ser Pro Leu Gly Asp Val Ser Leu Gln Val Pro
 115 120 125

Ser Pro Ala Ser Asp Asp Ala Ala Ala Pro Gly Ala Ala Gly Gly Gly
 130 135 140

Gln Val Thr Gly Gln His Leu Pro Leu Pro Lys Ser Pro Ala Val Ala
 145 150 155 160

Gly Val His

<210> 295
 <211> 491
 <212> PRT
 <213> Homo sapien

<400> 295

Met Ala Leu Leu Val Leu Gly Leu Val Ser Cys Thr Phe Phe Leu Ala
 1 5 10 15

370

Val Asn Gly Leu Tyr Ser Ser Ser Asp Asp Val Ile Glu Leu Thr Pro
 20 25 30

Ser Asn Phe Asn Arg Glu Val Ile Gln Ser Asp Ser Leu Trp Leu Val
 35 40 45

Glu Phe Tyr Ala Pro Trp Cys Gly His Cys Gln Arg Leu Thr Pro Glu
 50 55 60

Trp Lys Lys Ala Ala Thr Ala Leu Lys Asp Val Val Lys Val Gly Ala
 65 70 75 80

Val Asp Ala Asp Lys His His Ser Leu Gly Gly Gln Tyr Gly Val Gln
 85 90 95

Gly Phe Pro Thr Ile Lys Ile Phe Gly Ser Asn Lys Asn Arg Pro Glu
 100 105 110

Asp Tyr Gln Gly Gly Arg Thr Gly Glu Ala Ile Val Asp Ala Ala Leu
 115 120 125

Ser Ala Leu Arg Gln Leu Val Lys Asp Arg Leu Gly Gly Arg Ser Gly
 130 135 140

Gly Tyr Ser Ser Gly Lys Gln Gly Arg Ser Asp Ser Ser Ser Lys Lys
 145 150 155 160

Asp Val Ile Glu Leu Thr Asp Asp Ser Phe Asp Lys Asn Val Leu Asp
 165 170 175

Ser Glu Asp Val Trp Met Val Glu Phe Tyr Ala Pro Trp Cys Gly His
 180 185 190

Cys Lys Asn Leu Glu Pro Glu Trp Ala Ala Ala Ala Ser Glu Val Lys
 195 200 205

Glu Gln Thr Lys Gly Lys Val Lys Leu Ala Ala Val Asp Ala Thr Val
 210 215 220

Asn Gln Val Leu Ala Ser Arg Tyr Gly Ile Arg Gly Phe Pro Thr Ile
 225 230 235 240

Lys Ile Phe Gln Lys Gly Glu Ser Pro Val Asp Tyr Asp Gly Gly Arg
 245 250 255

371

Thr Arg Ser Asp Ile Val Ser Arg Ala Leu Asp Leu Phe Ser Asp Asn
 260 265 270

Ala Pro Pro Pro Glu Leu Leu Glu Ile Ile Asn Glu Asp Ile Ala Lys
 275 280 285

Arg Thr Cys Glu Glu His Gln Leu Cys Val Val Ala Val Leu Pro His
 290 295 300

Ile Leu Asp Thr Gly Ala Ala Gly Arg Asn Ser Tyr Leu Glu Val Leu
 305 310 315 320

Leu Lys Leu Ala Asp Lys Tyr Lys Lys Lys Met Trp Gly Trp Leu Trp
 325 330 335

Thr Glu Ala Gly Ala Gln Ser Glu Leu Glu Thr Ala Leu Gly Ile Gly
 340 345 350

Gly Phe Gly Tyr Pro Ala Met Ala Ala Ile Asn Ala Arg Lys Met Lys
 355 360 365

Phe Ala Leu Leu Lys Gly Ser Phe Ser Glu Gln Gly Ile Asn Glu Phe
 370 375 380

Leu Arg Glu Leu Ser Phe Gly Arg Gly Ser Thr Ala Pro Val Gly Gly
 385 390 395 400

Gly Ala Phe Pro Thr Ile Val Glu Arg Glu Pro Trp Asp Gly Arg Asp
 405 410 415

Gly Glu Glu Cys Pro Gly Gly Lys Leu Cys Gly Gln Gln Ser Trp Phe
 420 425 430

Thr Leu Leu Ser Leu Cys Ile Ser Ala Pro Gly Val Lys Ser Phe Pro
 435 440 445

Ser Asp Leu Ser Pro Gly Ala Pro Val Gly Leu Leu Arg Gly Ser Ser
 450 455 460

Leu Lys Thr Leu His Leu Pro Tyr His Lys Phe Lys Cys Cys Met Ala
 465 470 475 480

Phe Asp Thr Leu Asp Ser Gln Asp Thr Phe Gln
 485 490

372

<210> 296
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 296
tcctcaaggg ccctccccag

20

<210> 297
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 297
ccacagccat ctctccata ttctg

25

<210> 298
<211> 27
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 298
aagtgttcct ctggatgacc tacctgg

27

<210> 299
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 299
ctgaagccga gctcaaaggt

20

<210> 300
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 300
ccctgctccc aottgagatc

20

<210> 301

373

<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 301
tgtgaaaagg aggctgggtg ccag

24

<210> 302
<211> 22
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 302
agtgagaggg tgggcatgta tg

22

<210> 303
<211> 21
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 303
tactccaggc gctctgagga t

21

<210> 304
<211> 26
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 304
ttagccagtg gcctccactc tgtccc

26

<210> 305
<211> 21
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 305
tccagatggc tcagcttctt c

21

<210> 306
<211> 23

374

<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 306
gaaggtgttc ggagaatgag tga

23

<210> 307
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 307
tttcttctgt ggctctgtgt tttccaggc

29

<210> 308
<211> 18
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 308
cctgccgcgg agatccat

18

<210> 309
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 309
gcagcgcgta ctggtcgta

19

<210> 310
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 310
cctactccgt gtcagtgggtg gag

23

<210> 311
<211> 19
<212> DNA

375

<213> Artificial sequence

<220>
<223> Synthetic

<400> 311
agaggcgccc ccgcaggta 19

<210> 312
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 312
cccggagcca gctcgagtt 19

<210> 313
<211> 22
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 313
caggaactgc ggcgagcgac cc 22

<210> 314
<211> 22
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 314
tgcccagctg tggtttacat ta 22

<210> 315
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 315
caccacctcg ccattctca 19

<210> 316
<211> 24
<212> DNA
<213> Artificial sequence

376

<220>
<223> Synthetic

<400> 316
ttcactgtga acatcatctt ggca 24

<210> 317
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 317
gctcaaagcg tgagtaaaat atcct 25

<210> 318
<211> 28
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 318
ccacacttac tttgtaacat gattcaga 28

<210> 319
<211> 40
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 319
tttgacttaa tacttcttta attgatgtgc cttgagttgg 40

<210> 320
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 320
ggcggtgact catcaacga 19

<210> 321
<211> 26
<212> DNA
<213> Artificial sequence

377

<220>
<223> Synthetic

<400> 321
cattgacgat tattattcac aaagca 26

<210> 322
<211> 28
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 322
gcggccagag aatgtgtctg tgaaaact 28

<210> 323
<211> 27
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 323
cctttttatc cacttacaga tcaacca 27

<210> 324
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 324
acaagcaaga tgcattgtgag tga 23

<210> 325
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 325
atggttcgct gctgccgtt 19

<210> 326
<211> 20
<212> DNA
<213> Artificial sequence

<220>

378

<223> Synthetic

<400> 326

cctcacttcg cagctttgct

20

<210> 327

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic

<400> 327

ctggcattga cgattattat tcaca

25

<210> 328

<211> 32

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic

<400> 328

ctgtgaaaac tacaagctgg ccgtaaactg ct

32

<210> 329

<211> 23

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic

<400> 329

ggagccctga gcattgtaat atg

23

<210> 330

<211> 19

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic

<400> 330

ccctggtagc cgggtagag

19

<210> 331

<211> 22

<212> DNA

<213> Artificial sequence

<220>

<223> Synthetic

379

<400> 331
cagatggtgt gccaaactgct gt

22

<210> 332
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 332
cgctgaccc gactgtctta

20

<210> 333
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 333
gctcagattc tggctccaag tct

23

<210> 334
<211> 21
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 334
cctacagcaa agcgccccc a

21

<210> 335
<211> 18
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 335
cctgcagccc agagcaat

18

<210> 336
<211> 22
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

380

<400> 336
gctcagattc tggctccaag tc 22

<210> 337
<211> 21
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 337
atctccaacc ctcccgttc t 21

<210> 338
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 338
tcattggctt tggatattca gaag 24

<210> 339
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 339
gttcaggaag caaagatcaa tgc 23

<210> 340
<211> 26
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic

<400> 340
agcaatgaag ggtttggttg tagaag 26

RAW SEQUENCE LISTING

PATENT APPLICATION: PCT/US03/38855

Input Set : N:\FANTU\0338855.txt

Output Set: N:\CRF4\12292003\PU38855.raw

3 <110> APPLICANT: diaDexus, Inc.
 4 Macina, Roberto
 5 Turner, Leah
 6 Sun, Yongming
 7 Liu, Shu-Hui
 8 Chen, Huei-Mei
 10 <120> TITLE OF INVENTION: Compositions, Splice Variants and Methods Relat:
 Ovarian Specific
 11 Genes and Proteins
 13 <130> FILE REFERENCE: DEX-0455
 C--> 15 <140> CURRENT APPLICATION NUMBER: PCT/US03/38855
 C--> 15 <141> CURRENT FILING DATE: 2003-12-08
 15 <150> PRIOR APPLICATION NUMBER: US 60/431,321
 16 <151> PRIOR FILING DATE: 2002-12-06
 18 <150> PRIOR APPLICATION NUMBER: US 60/431,301
 19 <151> PRIOR FILING DATE: 2002-12-06
 21 <150> PRIOR APPLICATION NUMBER: US 60/484,584
 22 <151> PRIOR FILING DATE: 2003-06-30
 24 <150> PRIOR APPLICATION NUMBER: US 60/518,607
 25 <151> PRIOR FILING DATE: 2003-11-07
 27 <160> NUMBER OF SEQ ID NOS: 340
 29 <170> SOFTWARE: PatentIn version 3.1
 31 <210> SEQ ID NO: 1
 32 <211> LENGTH: 4798
 33 <212> TYPE: DNA
 34 <213> ORGANISM: Homo sapien
 36 <400> SEQUENCE: 1
 37 ggsasgwggc caagggcatct gccactgctg ctgactgcca ctaccagccg gagccagggc 60
 39 ctggctcgaga caactatctt tgaggatatct gaggctaccc cacagcactc tctggcattg 120
 41 gcaagactcg tggctgtgac ccatgggcct ctgaggagggc gttgtaagtc cgcccagctc 180
 43 cccacttgct gtgctctcac tcaatgcgaa gggaaccaag gtaccagggc caagtgggtc 240
 45 cagacatcca cacggattct gaaagggcag gtcaagcaga ctttgtccag ccatcagcca 300
 47 cggcctctcg acagcaccaa gatggaagtc aaaggtcagc tgatcagctc tcctaccttc 360
 49 aatgccccag ctgccctgtt cggagaggct gccccccagg tgaagtcaga gcgtctgcgg 420
 51 gggctgcttg accggcagcg gaccctgcag gaggccctga gcctgaaact tcaggagctc 480
 53 cgcaaagtgt gtctccagga ggcgagctg actggccagc tgccccctga gtgcccacta 540
 55 gagcctggtg aacggcccca gttggtccgc cggcgggccc ccacagcccg cgcctaccct 600
 57 ccaccgcacc ccaaccaagc acaccactcc ttgtgcccctg ctgaggagct ggctcttgag 660
 59 gccctggaac gcgaggtgtc agtgaacac agatcgccg cggccgccc cgcctggcc 720
 61 ttggcccctg atctgagcac cgagcagcgc cggcgccggc gccaggtcca ggcagatgca 780
 63 ctgaggagggc tgcattgagct agaggagcag ctgaggggatg tccggggccc ccttggcctc 840
 65 ccagtgtctc cgctgcccga gccactgcca ctgtccacgg ggtcagtgat caccacccag 900
 67 ggagtctgcc tgggcatgcg tcttgctcag ctgagccaag gtgagcatcc cctgggtgagg 960
 69 gtgggagagt ggacactggc aaatggacgt ggtagggctg ggatgggtga ctggccgggtg 1020

RAW SEQUENCE LISTING

PATENT APPLICATION: PCT/US03/38855

Input Set : N:\FANTU\0338855.txt

Output Set: N:\CRF4\12292003\PU38855.raw

71	aaaaccggga	ggtaggcaca	actcaagtgg	cccaaccgt	gagaagagtt	gcgacaaact	1080
73	ggcttaccgg	aaaggacaaa	ctgtggggga	ctgatgaata	tctgccagga	cagtcaggaa	1140
75	ccaaactggg	gtggtcttgg	gctctggtaa	aagcagattc	ttgggacagg	aacaggatga	1200
77	ggcggaaact	ggccagaagg	tggcccaagt	agaggtgccc	accagtggt	gtaagggggc	1260
79	agcaccacag	cctgggagtg	agaggcccac	ttctccccct	ctcacctgta	gaggacgtag	1320
81	ttctgcactc	agagagcagc	tccctctcag	agtctggggc	cagccatgac	aacgggtgagg	1380
83	actcctatcc	cccaaacctg	cccccgactc	ctacgtccct	ttagcccac	ccctttattc	1440
85	atccgaccac	atcctgcatg	atcagcccat	cctttgatgc	ccagcccctc	ctgtgctgct	1500
87	tcagcttctc	ccttagccatg	ctccatcttc	ctatgggtcc	cccatcttct	tagcctcacc	1560
89	ccaccccagc	cccacagccc	cagaacctac	ttgtcagcct	tagttcctcc	tcagcctgct	1620
91	taacctgtcc	cagcactttg	cccctcccc	tggccttgcc	cccagcctg	tcctgcccc	1680
93	tctgggcccc	cctcattgaa	ttctatccca	cttgctctct	tccactcaga	ggagcccat	1740
95	ggctgcttct	ctctggccga	gcgcccctca	ccaccaaacg	cttgggacca	gctgcgggca	1800
97	gtatctgggg	ggagccctga	gcggcgaaac	ccatggaaac	cacctccatc	agatctttat	1860
99	ggggatctga	agagccggcg	gaactctgtg	gccagcccca	ccagccccc	acgctcgctg	1920
101	cccaggagtg	cctccagttt	tgagggggga	agtgtgcctg	ccaccctgt	cctcaccocg	1980
103	ggcgctggcc	cccagctctg	caaacctgaa	ggccttcatt	ctcgtcagtg	gtccggcagc	2040
105	caggactccc	agatgggctt	ccccggggcg	gaccctgcct	ccgatcgcg	ctccctcttc	2100
107	gtagctcgca	cccgcgcag	caacagttct	gaggccctgc	tggtggaccg	ggccgctggt	2160
109	gggggagctg	gctccccgcc	tgccccctctg	gtccccctctg	cctctggccc	ctccctctgc	2220
111	aagagcagtg	aggtgctgta	tgagcgcccc	caaccaaccc	ctgccttctc	ctcccgcaac	2280
113	gcaggccccc	cagaccctcc	ccgggcgcgc	cggcctagct	cagctgcccc	tgctcccgga	2340
115	ggtgcccccc	ggctcccacc	tgtgtgtgga	gacttccctc	tggtactatc	cttggaccgg	2400
117	ggcctgcccc	gcagtggcgg	tggaacaggc	tggggggagc	tgccgcctgc	agctgaggtc	2460
119	ccaggacccc	tctcccgccg	ggatgggctc	ctcaccatgc	tccccggccc	accacctgtg	2520
121	tatgcagctg	acagcaacag	ccccctcctc	cgcaccaagg	acccccacac	ccgtgccacc	2580
123	cgcactaagc	cctgtggcct	gccccagag	gctgccgaag	gccctgaggt	gcacccaaac	2640
125	cctctgctgt	ggatgcccc	accacccctg	atccccctcg	ctggtgaacg	cagtggccac	2700
127	aagaacctgg	ctctggaggg	gctgcgggac	tggtacatcc	ggaactcggg	actggctgcg	2760
129	gggccccagc	gcccgcctgt	gctcccttcc	gtgggcccgc	cacacccacc	cttccctcat	2820
131	gcccgtgct	atgaggtggg	ccaggcgctg	tacggggccc	ccagccaggc	gccactccca	2880
133	cactcgagga	gtttcacggc	gccccctgtc	tctggcaggt	atgggggggtg	cttttactga	2940
135	tgggtagggg	tctcgtaagg	cagatggcga	agatatccag	gccagggagt	ggctagtcat	3000
137	gatagcta	gaattggacc	atgaggaaac	tagctgctgt	gatggcacag	ggtcactcta	3060
139	ctgcacatga	cctgcattag	tccatggggt	cctgggtggag	gggatcttgg	gcactggtag	3120
141	cagcaattct	ttatcaagtt	ataggctgaa	gatgagcctt	gaagccaggg	tgccgggagg	3180
143	aagggacatc	tcatgcccct	tgctgttttc	ttcctttttt	ctccatgcc	cagagcctga	3240
145	aagtgtgtgc	ctgtgcctgc	ctccacctct	ttaacgagcc	tcttttctct	tctttttctg	3300
147	tgtcttgtct	gtcttttctt	cttcttgtct	tccccgccct	gtcctccgga	ttcctgctac	3360
149	cccttctaaa	gatactacgc	ggacttctct	tatcccccg	agctgagcgc	tcgtttaagt	3420
151	gacctgacgc	tagaggggga	gcagtcctcc	agttctgaca	cccagacccc	ggggacactg	3480
153	gtctgacccc	ttctgatatg	tcccttgttg	gcctgggcac	gattccaatc	tggggagcac	3540
155	acagctgacc	tcgctgggcc	ctgggggtgtg	gttgcctctca	gtcctgagca	gagtgcgcca	3600
157	acctaattct	ccaaggcccc	tggtcccccg	tagggccagg	aagggtgtctg	acaccctgct	3660
159	tcttctctca	cactgtgctg	gggactgggg	gccctcagct	agcttaaaag	aggggggatg	3720
161	atgtcatggg	gaccccaagc	ccctcctctc	atttatgttt	acagttgtga	cttaggtatt	3780
163	cactgtcttc	ctccaacact	aggcgtttta	caaaagggaa	actgtgatct	catctggttg	3840
165	ggttcattcc	tgttcccatg	cccaaccagg	ttccattcag	gaacccccctc	cataaaatgg	3900
167	accatatacgg	gtctcagggc	catttagggc	agccaggaga	ctccgggtgtg	aacagaaatc	3960

RAW SEQUENCE LISTING

PATENT APPLICATION: PCT/US03/38855

Input Set : N:\FANTU\0338855.txt

Output Set: N:\CRF4\12292003\PU38855.raw

```

169 cctgccacgc atcgccaggg cagttggggc agtgggctct ctgcccacac ttggaaggac 4020
171 tgcagtcctg gtgggatgcc tgaaagagcc caaccccctc tgtgcccatt gcctctgccc 4080
173 tgaccacccc cagtcaggag gccccacagg aggggacccc gtagatgcc agtgaaatcc 4140
175 tcaggggagg tctgcctgaa agagcccaac cccctctgtg cccatggcct ctgccctgac 4200
177 cacccccagt caggaggccc cacaggaggg gcacccgcta gatgccagt aaatcctcag 4260
179 gtgaggtctg cctacgggcc acgggccact caccactcac accttccttg gctttccttc 4320
181 cacccttttt tttttctcga gacggagtct tgcctgtca ccaggctgga gtgcagcggc 4380
183 gcaatctcag ctcaactgcaa cctctgcctc ctgggttctc ctgcctcacc ctcccagta 4440
185 gctgggatta caggcacacg ccaccatgcc cggctaattt ttgtattctt agtagagaca 4500
187 aggtttcacc atattggcca ggctggtctt gaactcttga cctcgtgatc tgcccgcctt 4560
189 ggccctccaa agtgctggga ttacagccgt gagccactgc acccagcccc aatccaccac 4620
191 tttttaagca aaccacaca agttgtgttt tctatgatac ctgtctgtga ttttcggagc 4680
193 tgggggttcc cctaccccct tttcctggcg ttaagctttt ctttttatac cagtggatct 4740
195 ggacccaaga cattaccac actggaaggg gatttgtata ataatgtgt aaactgaa 4798
198 <210> SEQ ID NO: 2
199 <211> LENGTH: 1494
200 <212> TYPE: DNA
201 <213> ORGANISM: Homo sapien
203 <400> SEQUENCE: 2
204 aggcgcaggc gccctcctgt gcctgtcact ggcaataatc catgccacag aagactatatt 60
206 gctttccctg ggccataggt tgcctgtgaa tttcagactg gcttcagtgg aaatgacatt 120
208 gccttccact tcaaccctcg gtttgaagat ggagggtacg tgggtgtgca cacgaggcag 180
210 aacggaagct gggggcccga ggagagggaag acacacatgc ctttccagaa ggggatgcc 240
212 tttagacctc gcttcctggt gcagagctca gatttcaagg tgatggtgaa cgggatcctc 300
214 ttogtgcagt acttccaccg cgtgcccttc caccgtgtgg acaccatctc cgtcaatggc 360
216 tctgtgcagc tgcctacat cagcttccag cctcccgcg tgtggcctgc caaccggct 420
218 ccattaccc agacagtcac ccacacagtg cagagcgccc ctggacagat gttctctact 480
220 ccgccatcc cacctatgat gtaacccccc cccgcctatc cgatgccttt catcaccacc 540
222 attctgggag ggctgtaccc atccaagtc atcctcctgt caggcaactgt cctgccaggt 600
224 gctcagaggt tccacatcaa cctgtgctct ggaaccaca tcgccttcca cctgaacccc 660
226 cgttttgatg agaatgctgt ggtccgcaac accagatcg acaactcctg ggggtctgag 720
228 gagcgaagtc tgcccgaata aatgccttc gtccgtggcc agagcttctc agtgtggatc 780
230 ttgtgtgaag ctcaactgct caaggtggcc gtggatggtc agcacctgtt tgaatactac 840
232 catgcctga ggaacctgcc caccatcaac agactggaag tggggggcga catccagctg 900
234 acccatgtgc agacataggc ggcttccctg ccctggggcc gggggctggg gtgtggggca 960
236 gtctgggtcc tctcatcacc cccacttccc aggccagcc tttccaaccc tgcctgggat 1020
238 ctgggcttta atgcagaggc catgtccttg tctggctctg cttctggcta cagccaccct 1080
240 ggaacggaga aggcagctga cggggattgc cttcctcagc cgcagcagca cctggggctc 1140
242 cagctgctgg aatcctacca tcccaggagg caggcacagc caggagagg ggaggagtgg 1200
244 gcagtgaaga tgaagccca tgctcagtc cctcccatcc cccacgcagc tccaccccag 1260
246 tcccagcca ccagctgtct gctcctggtg ggaggtggcc tctcagccc ctctctctg 1320
248 acctttaacc tcaactcac cttgcaccgt gcaccaaccc ttcacccctc ctggaaagca 1380
250 ggctgatgg cttcccactg gcctccacca cctgaccaga gtgttctctt cagaggactg 1440
252 gctcctttcc cagtgtcctt aaaataaaga aatgaaaatg cttgttggca catt 1494
255 <210> SEQ ID NO: 3
256 <211> LENGTH: 1691
257 <212> TYPE: DNA
258 <213> ORGANISM: Homo sapien
260 <400> SEQUENCE: 3

```

RAW SEQUENCE LISTING

PATENT APPLICATION: PCT/US03/38855

Input Set : N:\FANTU\0338855.txt

Output Set: N:\CRF4\12292003\PU38855.raw

261	cgggcgccca	gaggggcaaat	gagggggcggc	gggggtggcgg	gtgggggggga	gacgcggaat	60
263	ttcccagcgc	gggggctctg	gcttaccctg	caaccgggca	gtctctttct	gtttacggag	120
265	agaaagggga	aatggaaaag	tcgggggagc	ggtggctggc	gtccgctgcg	ccgcccctgg	180
267	gcaggctcag	acgccgtgag	tcaggggcag	agcagggcgg	totgagcgtg	cgggcgcagc	240
269	gggtctcact	cgtccgctcc	gctctggact	gcgcgccacg	ctctgggggtc	cggcgccctg	300
271	gttcctgctt	ctgccgctgc	cgccgcggga	tcccagtggc	ccggcgtgct	cggctcccac	360
273	aggcctgcag	ccagcatcgc	accgaacctt	cgggggggcg	cggctggagc	gctcggccgg	420
275	cgtgggagcg	ccaaggccgc	agatgcaatc	ttcttaccgc	gaagaagcca	ggggaatagg	480
277	tagccacatc	ttgtttgcag	ataagaaagg	aagctaacgc	agtatctgca	aagccaggag	540
279	tctgactcag	tacttttctc	actcatgcat	acaaagcagc	taaaaatgac	acagcttatt	600
281	taccatgccc	ctgacactgc	actgagcact	ttatgagctt	gaactctggt	aatcctcacg	660
283	accacctcat	gagactctcc	agaaagagca	acagtaatgg	agtacatgag	cactggaagt	720
285	gacaataaag	aagagattga	tttattaatt	aaacatttaa	atgtgtctga	tgtaatagac	780
287	attatggaaa	atctttatgc	aagtgaagag	ccagcagttt	atgaaccacg	tctaatagacc	840
289	atgtgtcaag	acagtaatca	aaacgatgag	cgttctaagt	ctctgctgct	tagtggccaa	900
291	gaggtaccat	ggttgtcatc	agtcagatat	ggaactgtgg	aggatttgct	tgcttttgca	960
293	aaccatatac	ccaacactgc	aaagcatttt	tatggacaac	gaccacagga	atctggaatt	1020
295	ttattaaaca	tggtacgttt	ctttccgatac	agttgggtgc	tatgtgctca	gctttcctac	1080
297	tcgagcttca	tttaaatgcag	agtggtgttt	gaattttggt	tagatgggct	ggcaggcatg	1140
299	attttaaaaa	atgtaatcat	cagtaagaag	tacttccatg	ttaaagatgc	aaaaaaaaaa	1200
301	gtcttcattt	aaattttctat	ttaaagattc	ttgatcatat	tttagtagta	tttctacaaa	1260
303	taggtaattt	agaagaatgt	atgtgggccc	ggcgcagggg	ctcacgcctg	taatccgcgc	1320
305	acttgagag	gocgaggtgg	gtggatcact	tgaggtcagc	aattagagac	cagtctggcc	1380
307	aacatggtga	aaccccgctc	ctactaaaaa	tacaaaatta	gcctggcatg	gtggcggggc	1440
309	cctgtaattc	cagctacctg	ggaggctgag	gcacgagaat	cccttgaaac	tgggaggtgg	1500
311	aggttgtgat	gagccgagat	cacaccactg	cactccagcc	tgtgtgactg	agtgagactc	1560
313	tgtctcaaca	acaacaaaaga	agaatgtatt	ttaatttaac	agttcactaa	aaagtttatt	1620
315	catcagttat	gcagaaaaga	aaggcttaat	gagactcctt	cgtctgagag	gggaataaac	1680
317	actttgtcac	t					1691
320	<210> SEQ ID NO: 4						
321	<211> LENGTH: 8772						
322	<212> TYPE: DNA						
323	<213> ORGANISM: Homo sapien						
325	<400> SEQUENCE: 4						
326	accaaactga	agtgtaaagg	taagacctct	cctgctgcta	gtactaggag	aggtcttatac	60
328	cttacacttc	agtttggtca	ccagattatg	taaggataag	acctctccta	gtactagcag	120
330	caggaattgt	gtgttccagt	aagtggctct	ttgcacggca	cttttttggg	atcaaattgtt	180
332	aacgttaactc	cccagactct	tcggggcaag	gaatggctag	attcagagta	agaacaaccc	240
334	tccctttttt	gtaagtcccc	gtgttttagca	gggagaagaa	attctctaac	atgggttttg	300
336	ttttgttgtg	ttcttcatgt	ggaaatgtcg	cttaacaaaa	tatccaggct	tttgtttacg	360
338	tggaaaaagc	atcccttgta	atgattgctc	atcatactta	aaaacctttt	tcaaaggatt	420
340	ttcatgttcc	cagctataag	gactatttcc	atgacatgtg	ttattggcag	aatgagtgtt	480
342	aaatatggag	catatagcat	ggggtgactt	tcattgtcct	aacctgagac	agttttcctt	540
344	attactctgt	attgatcctg	ctagtcgaag	aatggacatg	aagtgaacct	atcgtggtga	600
346	ctgggatag	aagggtgctt	ctatttttgc	cagcacagca	tattagtctc	tttggagccc	660
348	tccattgtct	gagtctgcag	tgatctgtag	gaaggcagct	ggtcaataat	catgtagtac	720
350	aatggccttg	aattgttaacc	actatggtta	ttgattgtcc	tgtgtgtgtt	caggcatact	780
352	taggtatgtc	cctggggaaa	aagaaaacca	ttcagctgag	agttgctaac	catgttcttt	840
354	tggttagaaa	taatggttca	ttttttgccc	ctgggttgaa	tagtctctaa	aaggctctgg	900

RAW SEQUENCE LISTING

PATENT APPLICATION: PCT/US03/38855

Input Set : N:\FANTU\0338855.txt

Output Set : N:\CRF4\12292003\PU38855.raw

356	tgactgaatt	gaacatgagt	ccgcatgctg	ttttctttca	aaaggatatca	aaacggaaaag	960
358	cctctctaag	gggaagacct	ttcaactcca	ttcagaagac	aacatttagt	aaggaggatg	1020
360	gcggagggtta	ctagtaattt	tcagatgtct	tgggcttttt	ctgccaacaa	aacccaaaat	1080
362	caaattagag	ttgggtgaaag	ctttcttcag	tgttttttaga	agaggccatc	ttgaatctgt	1140
364	agaataccat	ttacacatca	acttcaccct	atgctcattt	cgtattttga	gcttaaattg	1200
366	agtcctctga	agggggggta	gtcgtgattc	tgggtggcaa	actagaactt	ttactttgta	1260
368	aaatgaaaaa	tattaaatgg	acctttttgt	cagttgagga	tttagattga	ttcttttatc	1320
370	tgaggagcgt	atgttcctca	gatgttgctg	agagaccttt	aggttttcat	ctactttaag	1380
372	attgctctct	tggcaattag	gggatttggg	aaaagaagaa	aaaaagatgc	catgtgttgc	1440
374	tagtacacag	ttataggata	tggtttctaa	tggttgaatt	ttgaggaact	ctccctaaag	1500
376	aatgagtttt	atatctcctc	aaggaaatca	tggaaaaatc	tgtttattct	tcagtgagtc	1560
378	cttttgaaatt	aatgttctta	aatttttttc	taagtctgtg	taagtgccta	tgtataagta	1620
380	tataattgta	taaatattta	taaatatatt	tatataatta	cggtttcatt	tctaccttga	1680
382	gtcaaagttc	tgtcttttaga	ttgggtgactg	agtaatactt	acactttggg	gttttttctt	1740
384	aggttcttga	ggcttactta	actagcagct	tctgatttat	tgagtgaag	atgggtttca	1800
386	tgttaattcc	tcagttgcat	ctctgaactt	ggataacata	cttgccgttt	gaaaaataga	1860
388	gctgtatact	gtcaaaggtg	cactggagg	taaaacattt	gttggtagta	gacaagctca	1920
390	gaaatccaaa	aattcmggga	gggcacagg	taagaagaga	ggtttgctca	gctttgtgct	1980
392	ctgatggcac	ccatctgtac	tcagcaaaag	tcatagctga	agcccaaatc	gctcaaacgt	2040
394	gtgaagtcaa	tcatttttcc	tatagggtct	tgtttccttt	tctttacctt	ctagcttctc	2100
396	ttgataaaaac	agttgggaga	actgccaacg	tgttcctcag	tgagagggtg	tggttctttc	2160
398	cgatatgttc	agcacgtgca	tattcattta	tgagaaacca	aagtaacttc	ttcaactcgg	2220
400	gttactgtgg	gatgattaag	tagatataaa	gtgatttaaa	agacagcatg	gtactttcac	2280
402	tcagcttaac	atgcagctgg	gatgtctaca	atacaagatg	tgggtgggtt	tattttat	2340
404	tatttttgagg	caggagtgtg	attatcttag	ggttgatata	aaggcccatg	ggaagagtta	2400
406	cggattgtac	atgggaagaa	tcataagga	gtattgcctt	gctcaagaat	ttaatccgct	2460
408	gacagtatgc	ttcttccagt	ttgccttact	tcctctgcaa	gtttctttgc	tccttagggc	2520
410	agagggtttta	ttgaatagat	taaatgaggt	cagtaagatt	agttaaaaat	agtcattcct	2580
412	tgtgggtgtt	ggacacagct	tgaaaggagt	gtttaaaaaa	aaaaagctag	ggaggaaaag	2640
414	aacaagaaaag	atagacttcg	agagtgataa	gagaaaaata	caggagagatg	gaatggaaac	2700
416	taccaggaag	gccgggocg	gtggctcatg	cctgtaatcc	caacactttg	ggaggcggag	2760
418	gtgggcagat	cacctaaagt	caggagatcg	aggccagcct	gagcaacatg	gtgaaacccc	2820
420	gtctctacta	aaaatacaaa	aattacctgg	gtgtggtggc	gtgcacctgt	aatcccagct	2880
422	actcagaggc	tgaggcagg	gaatggcttg	aacctgggag	gcagagggtt	cagtgaacca	2940
424	agatcgcacc	attacactcc	agcctggg	acaaagcgac	actccatctc	aaatttaaaa	3000
426	aaaaaaaaaa	agaagaagaa	gaaaactagt	gggaaaaaag	tgagaggaat	acttttttga	3060
428	aattggtatc	ggaagggaact	ggagaagaga	aaacaacagt	gccaaatgag	aaaagaacag	3120
430	gaaacttaat	actaattggc	atgcaccaga	tacttttgtg	tacatttgcc	tcttcaatct	3180
432	cccgaagaat	cgtacaaaat	gtatactttc	ttcccatgtt	aagaaaacag	gtatagagaa	3240
434	cttatttcagg	actcatagct	agtgaagtgg	aaatcagaat	tgggaatccag	agtccatgct	3300
436	gtggtctcct	tcagcaagag	aatcaagcta	cccagatgat	tctcttctca	ttgtttggct	3360
438	ttgtaaagtg	tcacttagtt	ttgttcccat	aaatatagag	gaagttagtt	ggttaaagtt	3420
440	gtgggatttg	cactatgcct	atacattttt	atztatgcca	ttatttttgag	aggctgatta	3480
442	ttgctttttt	aaaatgatgc	actggtgaag	atgtgaaagt	aaaattgcca	cgtggcatta	3540
444	tttgccaaga	ataaatgaaa	agggtaaaaa	aacaattttt	tctttttttt	aacatttttc	3600
446	agaaaagata	caattacctt	ttttaatagg	tgagcgccac	cacgcccggc	taattttttg	3660
448	attttttagta	gagacagggt	ttcaccatgt	tggccaggat	ggtctcgatc	tcttgatctc	3720
450	gtgttccgcc	cacctcgcc	tcctaaagt	ctgggattac	aggcatgagc	cactgcgccc	3780
452	gatctacaat	tctgttttct	gtgtcccatc	cataccagat	tattgaaccc	tctgtgtgta	3840

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: PCT/US03/38855

Input Set : N:\FANTU\0338855.txt
Output Set: N:\CRF4\12292003\PU38855.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:44; N Pos. 760,772,803
Seq#:81; N Pos. 6,66,96,100,118,120,180,191,205,206,211,212,330,844
Seq#:112; N Pos. 1528,1538,1545
Seq#:180; Xaa Pos. 45
Seq#:184; Xaa Pos. 207,211
Seq#:209; Xaa Pos. 11,12
Seq#:226; Xaa Pos. 206,210
Seq#:233; Xaa Pos. 3,4,10,11,31,34,39,41,44,57,59,60,65,66,69,71,75,76,80
Seq#:233; Xaa Pos. 81,83,97,115
Seq#:234; Xaa Pos. 9,10,16,17,37,40,45,47,87
Seq#:237; Xaa Pos. 70,84,92
Seq#:242; Xaa Pos. 3,4
Seq#:275; Xaa Pos. 243,245

VERIFICATION SUMMARY

PATENT APPLICATION: PCT/US03/38855

Input Set : N:\FANTU\0338855.txt

Output Set: N:\CRF4\12292003\PU38855.raw

L:15 M:270 C: Current Application Number differs, Replaced Current Application No
L:15 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:3362 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:44 after pos.:720
M:341 Repeated in SeqNo=44
L:6295 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:81 after pos.:0
M:341 Repeated in SeqNo=81
L:8370 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:112 after pos.:1500
L:13649 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:180 after pos.:32
L:13825 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:184 after pos.:192
M:341 Repeated in SeqNo=184
L:16138 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:209 after pos.:0
L:17661 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:226 after pos.:192
M:341 Repeated in SeqNo=226
L:18004 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:233 after pos.:0
M:341 Repeated in SeqNo=233
L:18085 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:234 after pos.:0
M:341 Repeated in SeqNo=234
L:18204 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:237 after pos.:64
M:341 Repeated in SeqNo=237
L:18401 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:242 after pos.:0
L:20984 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:275 after pos.:240

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number
WO 2004/053079 A3

(51) International Patent Classification⁷: **C12N 15/12**,
15/11, 15/00, C12Q 1/68, C12P 21/02, A61K 31/7088,
31/711

(74) Agents: **LICATA, Jane, Massey et al.**; Licata & Tyrrell
P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(21) International Application Number:
PCT/US2003/038855

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 8 December 2003 (08.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/431,321 6 December 2002 (06.12.2002) US
60/431,301 6 December 2002 (06.12.2002) US
60/484,584 30 June 2003 (30.06.2003) US
60/518,607 7 November 2003 (07.11.2003) US

(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **DI-
ADEXUS, INC.** [US/US]; 343 Oyster Point Boulevard,
South San Francisco, CA 94080 (US).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MACINA, Roberto**,
A. [AR/US]; 4118 Crescendo Avenue, San Jose, CA 95136
(US). **TURNER, Leah, R.** [US/US]; 939 Rosette Court,
Sunnyvale, CA 94086 (US). **SUN, Yongming** [CN/US];
551 Shoal Circle, Redwood City, CA 94065 (US). **LIU**,
Shu-Hui [—/US]; 441 Cork Harbour Circle, #H, Redwood
City, CA 94539 (US). **CHEN, Huei-Mei** [US/US]; 101
Lockwood Lane, Pleasant Hill, CA 94523 (US).

(88) Date of publication of the international search report:
7 April 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS, SPLICE VARIANTS AND METHODS RELATING TO OVARIAN SPECIFIC GENES AND PROTEINS

(57) Abstract: The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic ovarian cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and non-cancerous disease states in ovarian, identifying ovarian tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered ovarian tissue for treatment and research.



WO 2004/053079 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/38855

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 15/12, 15/11, 15/00; C12Q 1/68; C12P 21/02; A61K 31/7088, 31/711
US CL : 536/23.1, 23.5; 435/6, 320.1, 69.1; 514/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 23.5; 435/6, 320.1, 69.1; 514/44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Compugen, SEQ ID NOs: 1 and 129

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NETO, E.D. et al, Shotgun sequencing of the human transcriptome with ORF expressed sequence Tags. Proceedings of the National Academy of Science, USA. 28 March 2000, Vol. 97, No. 7, pages 3491-3496, see especially the alignment attached to the reference (compare SEQ ID NO: 1, nucleotides 221-522 to BX281918, nucleotides 1-302).	1-6, 8, and 9
---		-----
Y		10

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

11 January 2005 (11.01.2005)

Date of mailing of the international search report

31 JAN 2005

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

James Martinell

Telephone No. 571-272-1600

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/38855

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-10 and 15-18 as they pertain to nucleic acids encoding SEQ ID NO: 129

Remark on Protest

☐
☐

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-10 and 15-18, drawn to nucleic acids, nucleic acid molecular hybridization assays, vectors, host cells, methods for producing polypeptides, kits, vaccines, and methods of treatment using nucleic acids.

Group II, claim(s) 11, 12, and 16-18, drawn to polypeptides, kits, vaccines, and methods of treatment using polypeptides.

Group III, claim(s) 13-15, drawn to antibodies and protein binding assays.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The nucleic acids, vectors, host cells, nucleic acid containing kits, nucleic acid vaccines, and methods of treatment using nucleic acids of Group I all have the special technical features of the properties of SEQ ID NOs: 129-295 or nucleic acid sequences that encode SEQ ID NOs: 1-128, which are not shared by either of Groups II or III. Group II is directed to polypeptide, polypeptide vaccines, and methods of treatment using polypeptides that all have the special technical features of SEQ ID NOs: 1-128 or sequences that are encoded by SEQ ID NOs: 129-295, which are not shared by Groups I or III. Since each of the three Groups mentions or requires the use of 295 separate and unrelated nucleic acids and/or polypeptides, the total number of inventions is $3 \times 295 = 885$.

Each of the Groups mentions or requires the use of a large number (295) of separate and unrelated nucleic acids and/or polypeptides. No matter which additional Group(s) applicant elects, applicant is further required to select for search one SEQ ID NO within the Group(s) for search. In any event, the first mentioned SEQ ID NO in Group I will be searched. Any additional SEQ ID NO to be searched requires one additional search fee per SEQ ID NO. In the absence of payment of additional search fee(s) only the first mentioned SEQ ID NO in Group I will be searched. Should applicant pay fee(s) for additional Groups to be searched, the first mentioned SEQ ID NO within the selected Group will be searched unless applicant directs otherwise.